<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001886.pub3" GROUP_ID="INJ" ID="453999101310342995" MERGED_FROM="" MODIFIED="2011-02-16 18:32:29 +0100" MODIFIED_BY="Emma Sydenham" REVIEW_NO="001" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2011-02-16 15:49:18 +0000" MODIFIED_BY="Emma M Sydenham">
<TITLE>Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion</TITLE>
<CONTACT>
<PERSON ID="19692" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>David</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Henry</LAST_NAME>
<SUFFIX/>
<POSITION>CEO</POSITION>
<EMAIL_1>david.henry@ices.on.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Institute of Clinical Evaluative Sciences</ORGANISATION>
<ADDRESS_1>2075 Bayview Avenue</ADDRESS_1>
<ADDRESS_2>G1 06</ADDRESS_2>
<CITY>Toronto</CITY>
<ZIP>M4N 3M5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 416 480 4297</PHONE_1>
<PHONE_2/>
<FAX_1>+1 (416) 480-6048</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2011-02-16 15:47:26 +0000" MODIFIED_BY="Emma Sydenham">
<PERSON ID="19692" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>David</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Henry</LAST_NAME>
<SUFFIX/>
<POSITION>CEO</POSITION>
<EMAIL_1>david.henry@ices.on.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Institute of Clinical Evaluative Sciences</ORGANISATION>
<ADDRESS_1>2075 Bayview Avenue</ADDRESS_1>
<ADDRESS_2>G1 06</ADDRESS_2>
<CITY>Toronto</CITY>
<ZIP>M4N 3M5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 416 480 4297</PHONE_1>
<PHONE_2/>
<FAX_1>+1 (416) 480-6048</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14388" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Paul</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Carless</LAST_NAME>
<SUFFIX>BHSc, MMedSc (ClinEpid)</SUFFIX>
<POSITION>Research Academic</POSITION>
<EMAIL_1>Paul.Carless@newcastle.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Discipline of Clinical Pharmacology</DEPARTMENT>
<ORGANISATION>Faculty of Health, University of Newcastle</ORGANISATION>
<ADDRESS_1>Level 5, Clinical Sciences Building, Newcastle Mater Hospital</ADDRESS_1>
<ADDRESS_2>Edith Street, Waratah</ADDRESS_2>
<CITY>Newcastle</CITY>
<ZIP>2298</ZIP>
<REGION>New South Wales</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>61-2-49-211726</PHONE_1>
<PHONE_2>61-2-49-211856</PHONE_2>
<FAX_1>61-2-49-602088</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14443" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Annette</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Moxey</LAST_NAME>
<SUFFIX>BA, Grad. Dip. H. Soc. Sci., PhD</SUFFIX>
<POSITION>Post-doctoral Research Fellow</POSITION>
<EMAIL_1>annette.moxey@newcastle.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Research Centre for Gender, Health &amp; Ageing</DEPARTMENT>
<ORGANISATION>Faculty of Health, University of Newcastle</ORGANISATION>
<ADDRESS_1>Level 2, David Maddison Building</ADDRESS_1>
<ADDRESS_2>Cnr King &amp; Watt Streets</ADDRESS_2>
<CITY>Newcastle</CITY>
<ZIP>2300</ZIP>
<REGION>New South Wales</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>61-2-4913 8322</PHONE_1>
<PHONE_2/>
<FAX_1>61-2-4913 8323</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="4881" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Dianne</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>O'Connell</LAST_NAME>
<SUFFIX>PhD</SUFFIX>
<POSITION>Senior Epidemiologist</POSITION>
<EMAIL_1>dianneo@nswcc.org.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cancer Epidemiology Research Unit</DEPARTMENT>
<ORGANISATION>Cancer Council</ORGANISATION>
<ADDRESS_1>PO Box 572</ADDRESS_1>
<ADDRESS_2>Kings Cross</ADDRESS_2>
<CITY>Sydney</CITY>
<ZIP>1340</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>61-2-93341768</PHONE_1>
<PHONE_2/>
<FAX_1>61-2-93341778</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="AF402CC382E26AA200F0756DC29B361E" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Barrie</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Stokes</LAST_NAME>
<SUFFIX>BSc, M Math</SUFFIX>
<POSITION>Statistician</POSITION>
<EMAIL_1>Barrie.Stokes@newcastle.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Discipline of Clinical Pharmacology</DEPARTMENT>
<ORGANISATION>Faculty of Health, University of Newcastle</ORGANISATION>
<ADDRESS_1>Level 5, Clinical Sciences Building, Newcastle Mater Hospital</ADDRESS_1>
<ADDRESS_2>Edith Street, Waratah</ADDRESS_2>
<CITY>Newcastle</CITY>
<ZIP>2298</ZIP>
<REGION>New South Wales</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>61-2-49-211832</PHONE_1>
<PHONE_2/>
<FAX_1>61-2-49-602088</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14404" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Dean</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Fergusson</LAST_NAME>
<SUFFIX>MHA, PhD</SUFFIX>
<POSITION>Epidemiologist</POSITION>
<EMAIL_1>dafergusson@ottawahospital.on.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Ottawa Health Research Institute</DEPARTMENT>
<ORGANISATION>University of Ottawa Centre for Transfusion Research</ORGANISATION>
<ADDRESS_1>501 Smyth Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1H 8L6</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>613-737-8480</PHONE_1>
<PHONE_2/>
<FAX_1>613-739-6266</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11125" ROLE="AUTHOR">
<PREFIX>Miss</PREFIX>
<FIRST_NAME>Katharine</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Ker</LAST_NAME>
<SUFFIX/>
<POSITION>Research Fellow</POSITION>
<EMAIL_1>katharine.ker@lshtm.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL>http://injuries.cochrane.org</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Injuries Group</DEPARTMENT>
<ORGANISATION>London School of Hygiene &amp; Tropical Medicine</ORGANISATION>
<ADDRESS_1>Room 135</ADDRESS_1>
<ADDRESS_2>Keppel Street</ADDRESS_2>
<CITY>London</CITY>
<ZIP>WC1E 7HT</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 (0) 20 7958 8135</PHONE_1>
<PHONE_2/>
<FAX_1>+44 (0) 20 7958 8111</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2011-02-10 16:47:16 +0000" MODIFIED_BY="Emma Sydenham">
<UP_TO_DATE>
<DATE DAY="1" MONTH="2" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="2" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="5" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1999"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2011"/>
</DATES>
<WHATS_NEW MODIFIED="2011-02-16 15:49:18 +0000" MODIFIED_BY="Emma M Sydenham">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2011-02-16 15:49:18 +0000" MODIFIED_BY="Emma M Sydenham">
<DATE DAY="10" MONTH="2" YEAR="2011"/>
<DESCRIPTION>
<P>The editorial group is aware that a clinical trial by Prof. Joachim Boldt has been found to have been fabricated (<A HREF="http://archie.cochrane.org/sections/documents/view?document=540099072011521412&amp;format=REVMAN#REF-Boldt-2009">Boldt 2009</A>). As the editors who revealed this fabrication point out (<A HREF="http://archie.cochrane.org/sections/documents/view?document=540099072011521412&amp;format=REVMAN#REF-Reinhart-2011">Reinhart 2011</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?document=540099072011521412&amp;format=REVMAN#REF-Shafer-2011">Shafer 2011</A>), this casts some doubt on the veracity of other studies by the same author. All Cochrane Injuries Group reviews which include studies by this author have therefore been edited to show the results with this author's trials included and excluded. Readers can now judge the potential impact of trials by this author (
<LINK REF="STD-Boldt-1991" TYPE="STUDY">Boldt 1991</LINK>, <LINK REF="STD-Boldt-1994" TYPE="STUDY">Boldt 1994</LINK>, <LINK REF="STD-Mengistu-2008" TYPE="STUDY">Mengistu 2008</LINK>) on the conclusions of the review.
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-02-10 16:48:17 +0000" MODIFIED_BY="Emma M Sydenham">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2011-02-10 16:48:17 +0000" MODIFIED_BY="Emma M Sydenham">
<DATE DAY="31" MONTH="5" YEAR="2010"/>
<DESCRIPTION>
<P>The searches were updated to February 2010. An additional 40 trials have been included. The updated data show a lower rate of death with the lysine analogues than aprotinin, which has been withdrawn from world markets.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-06-11 15:22:01 +0100" MODIFIED_BY="Katharine Ker">
<DATE DAY="10" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>The text of 'Type of surgery' under 'Aprotinin' in the 'Effects of interventions' section was amended.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-09-10 10:20:18 +0100" MODIFIED_BY="Emma M Sydenham">
<DATE DAY="8" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Special purpose grant, Hunter Area Pathology Service</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Australian Health Ministers' Advisory Committee. National Health and Medical Research Council of Australia</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-02-16 15:50:08 +0000" MODIFIED_BY="Emma M Sydenham">
<SUMMARY MODIFIED="2011-02-11 13:52:33 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2011-02-11 13:52:33 +0000" MODIFIED_BY="[Empty name]">Anti-fibrinolytic drugs for reducing blood loss and the need for red blood cell transfusions during and after surgery.</TITLE>
<SUMMARY_BODY MODIFIED="2010-11-30 17:40:29 +0000" MODIFIED_BY="[Empty name]">
<P>Aprotinin, although effective in reducing bleeding, had a higher rate of death than tranexamic acid and aminocaproic acid, which appeared free of serious side-effects. Aprotinin has been withdrawn from world markets because of safety concerns. This review of over 250 clinical trials found that anti-fibrinolytic drugs used at the time of major surgery reduce bleeding, the need for transfusions of red blood cells and the need for repeat surgery because of bleeding. With the exception of aprotinin the drugs appear safe.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-02-16 14:53:49 +0000" MODIFIED_BY="Emma M Sydenham">
<ABS_BACKGROUND MODIFIED="2010-12-07 16:15:27 +0000" MODIFIED_BY="Emma M Sydenham">
<P>Concerns regarding the safety of transfused blood have led to the development of a range of interventions to minimise blood loss during major surgery. Anti-fibrinolytic drugs are widely used, particularly in cardiac surgery, and previous reviews have found them to be effective in reducing blood loss, the need for transfusion, and the need for re-operation due to continued or recurrent bleeding. In the last few years questions have been raised regarding the comparative performance of the drugs. The safety of the most popular agent, aprotinin, has been challenged, and it was withdrawn from world markets in May 2008 because of concerns that it increased the risk of cardiovascular complications and death.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-12-07 16:16:37 +0000" MODIFIED_BY="Emma M Sydenham">
<P>To assess the comparative effects of the anti-fibrinolytic drugs aprotinin, tranexamic acid (TXA), and epsilon aminocaproic acid (EACA) on blood loss during surgery, the need for red blood cell (RBC) transfusion, and adverse events, particularly vascular occlusion, renal dysfunction, and death.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-12-07 16:17:08 +0000" MODIFIED_BY="Emma M Sydenham">
<P>We searched: the Cochrane Injuries Group's Specialised Register (July 2010), Cochrane Central Register of Controlled Trials (<I>The Cochrane Library 2010</I>, Issue 3), MEDLINE (Ovid SP) 1950 to July 2010, EMBASE (Ovid SP) 1980 to July 2010. References in identified trials and review articles were checked and trial authors were contacted to identify any additional studies. The searches were last updated in July 2010.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials (RCTs) of anti-fibrinolytic drugs in adults scheduled for non-urgent surgery. Eligible trials compared anti-fibrinolytic drugs with placebo (or no treatment), or with each other.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-02-16 14:53:49 +0000" MODIFIED_BY="Emma M Sydenham">
<P>Two authors independently assessed trial quality and extracted data. This version of the review includes a sensitivity analysis excluding trials authored by Prof. Joachim Boldt.
</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-02-11 19:29:08 +0000" MODIFIED_BY="[Empty name]">
<P>This review summarises data from 252 RCTs that recruited over 25,000 participants. Data from the head-to-head trials suggest an advantage of aprotinin over the lysine analogues TXA and EACA in terms of reducing perioperative blood loss, but the differences were small. Compared to control, aprotinin reduced the probability of requiring RBC transfusion by a relative 34% (relative risk [RR] 0.66, 95% confidence interval [CI] 0.60 to 0.72). The RR for RBC transfusion with TXA was 0.61 (95% CI 0.53 to 0.70) and was 0.81 (95% CI 0.67 to 0.99) with EACA. When the pooled estimates from the head-to-head trials of the two lysine analogues were combined and compared to aprotinin alone, aprotinin appeared more effective in reducing the need for RBC transfusion (RR 0.90; 95% CI 0.81 to 0.99).</P>
<P>Aprotinin reduced the need for re-operation due to bleeding by a relative 54% (RR 0.46, 95% CI 0.34 to 0.62). This translates into an absolute risk reduction of 2% and a number needed-to-treat (NNT) of 50 (95% CI 33 to 100). A similar trend was seen with EACA (RR 0.32, 95% CI 0.11 to 0.99) but not TXA (RR 0.80, 95% CI 0.55 to 1.17). The blood transfusion data were heterogeneous and funnel plots indicate that trials of aprotinin and the lysine analogues may be subject to publication bias.</P>
<P>When compared with no treatment aprotinin did not increase the risk of myocardial infarction (RR 0.87, 95% CI 0.69 to 1.11), stroke (RR 0.82, 95% CI 0.44 to 1.52), renal dysfunction (RR 1.10, 95% CI 0.79 to 1.54) or overall mortality (RR 0.81, 95% CI 0.63 to 1.06). Similar trends were seen with the lysine analogues, but data were sparse. These data conflict with the results of recently published non-randomised studies, which found increased risk of cardiovascular complications and death with aprotinin. There are concerns about the adequacy of reporting of uncommon events in the small clinical trials included in this review.</P>
<P>When aprotinin was compared directly with either, or both, of the two lysine analogues it resulted in a significant increase in the risk of death (RR 1.39, 95% CI 1.02, 1.89), and a non-significant increase in the risk of myocardial infarction (RR 1.11 95% CI 0.82, 1.50). Most of the data contributing to this added risk came from a single study &#8211; the BART trial (2008).<BR/>
</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-11-28 12:56:45 +0000" MODIFIED_BY="[Empty name]">
<P>Anti-fibrinolytic drugs provide worthwhile reductions in blood loss and the receipt of allogeneic red cell transfusion. Aprotinin appears to be slightly more effective than the lysine analogues in reducing blood loss and the receipt of blood transfusion. However, head to head comparisons show a lower risk of death with lysine analogues when compared with aprotinin. The lysine analogues are effective in reducing blood loss during and after surgery, and appear to be free of serious adverse effects.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-02-16 14:22:58 +0000" MODIFIED_BY="Emma M Sydenham">
<BACKGROUND MODIFIED="2010-12-03 15:08:32 +0000" MODIFIED_BY="Katharine Ker">
<P>Public concern regarding the safety of transfused blood has prompted a reconsideration of the role of allogeneic blood transfusion (whole blood or packed red cells from an unrelated donor). The risks associated with receiving transfusion of allogeneic blood that has been screened by a competent blood transfusion program are considered minimal, with very low risks of transmission of HIV, and hepatitis C (<LINK REF="REF-Whyte-1997" TYPE="REFERENCE">Whyte 1997</LINK>). However, this only applies where there is a safe, plentiful, well-regulated supply. The majority of the world's population does not have access to such a system, and the risks of transfusion in developing countries may be much higher (<LINK REF="REF-McFarland-1997" TYPE="REFERENCE">McFarland 1997</LINK>). Concerns of patients and clinicians regarding blood safety have generated enthusiasm for the use of technologies intended to reduce the use of allogeneic blood (<LINK REF="REF-Bryson-1998" TYPE="REFERENCE">Bryson 1998</LINK>; <LINK REF="REF-Forgie-1998" TYPE="REFERENCE">Forgie 1998</LINK>; <LINK REF="REF-Huet-1999" TYPE="REFERENCE">Huet 1999</LINK>; <LINK REF="REF-Laupacis-1997" TYPE="REFERENCE">Laupacis 1997</LINK>). Although allogeneic blood transfusion has had a unique place in medical practice, we are obliged to examine the evidence on the benefits, harms and costs of a range of techniques designed to minimise the use of this resource. Some of the alternatives to allogeneic blood have their own risks, and are expensive (<LINK REF="REF-Coyle-1999" TYPE="REFERENCE">Coyle 1999</LINK>; <LINK REF="REF-Fergusson-1999" TYPE="REFERENCE">Fergusson 1999</LINK>).</P>
<P>Perioperative bleeding is one of the major indications for allogeneic blood transfusions worldwide (<LINK REF="REF-Levy-2006" TYPE="REFERENCE">Levy 2006</LINK>). However, massive surgical blood loss is a serious problem that affects many cardiac surgery patients in particular and has been shown to have a strong, independent association with in-hospital mortality (<LINK REF="REF-Karkouti-2004" TYPE="REFERENCE">Karkouti 2004</LINK>). There is also considerable evidence that blood loss that leads to the transfusion of blood products is harmful, and that the degree of harm is directly related to the amount of blood loss (<LINK REF="REF-Karkouti-2006" TYPE="REFERENCE">Karkouti 2006</LINK>). To reduce perioperative blood loss a number of pharmacological agents have been used, these include the anti-fibrinolytic drugs aprotinin, tranexamic acid (TXA), and epsilon aminocaproic acid (EACA).</P>
<P>Aprotinin is a non-specific, serine protease inhibitor, derived from bovine lung, with anti-fibrinolytic properties. It acts as an inhibitor of several serine proteases, including trypsin, plasmin, plasma-kallikrein and tissue kallikrein. Aprotinin also inhibits the contact phase activation of coagulation that both initiates coagulation and promotes fibrinolysis (<LINK REF="REF-Fritz-1983" TYPE="REFERENCE">Fritz 1983</LINK>; <LINK REF="REF-Royston-1998" TYPE="REFERENCE">Royston 1998</LINK>). During cardiopulmonary bypass (CPB) the negatively charged surface of the CPB circuit activates factor XII, converting prekallikrein to kallikrein which further activates factor XII. This positive feedback loop acts to intensify the intrinsic coagulation cascade. By inhibiting plasma kallikrein, aprotinin minimises derangements in coagulation and fibrinolysis (<LINK REF="REF-Smith-1998" TYPE="REFERENCE">Smith 1998</LINK>). There is also evidence that aprotinin exerts an indirect preservative effect on platelet function during extracorporeal circulation (ECC) (<LINK REF="STD-Mohr-1992" TYPE="STUDY">Mohr 1992</LINK>). In many countries aprotinin is specifically indicated for the reduction of blood loss during cardiopulmonary bypass.</P>
<P>TXA and EACA are synthetic lysine analogues (synthetic derivatives of the amino acid lysine) that act as effective inhibitors of fibrinolysis. TXA and EACA act principally by blocking the lysine binding sites on plasminogen molecules, inhibiting the formation of plasmin and therefore inhibiting fibrinolysis (<LINK REF="REF-Faught-1998" TYPE="REFERENCE">Faught 1998</LINK>). Tranexamic acid is about ten times more potent than aminocaproic acid and binds much more strongly to both the strong and weak sites of the plasminogen molecule than EACA (<LINK REF="REF-Faught-1998" TYPE="REFERENCE">Faught 1998</LINK>; <LINK REF="REF-Mannucci-1998" TYPE="REFERENCE">Mannucci 1998</LINK>).</P>
<IMPORTANCE MODIFIED="2010-11-28 14:03:28 +0000" MODIFIED_BY="[Empty name]">
<P>The efficacy of these three anti-fibrinolytic drugs to reduce perioperative blood loss and allogeneic blood transfusion has been studied extensively. Systematic reviews of these drugs (<LINK REF="REF-Henry-1999" TYPE="REFERENCE">Henry 1999</LINK>; <LINK REF="REF-Laupacis-1997" TYPE="REFERENCE">Laupacis 1997</LINK>; <LINK REF="REF-Levi-1999" TYPE="REFERENCE">Levi 1999</LINK>; <LINK REF="REF-Munoz-1999" TYPE="REFERENCE">Munoz 1999</LINK>; <LINK REF="REF-Sedrakyan-2004" TYPE="REFERENCE">Sedrakyan 2004</LINK>) have shown that the use of aprotinin is associated with statistically significant reductions in allogeneic blood transfusion requirements and re-operation due to bleeding. Systematic reviews have also shown TXA to be effective in reducing exposure to allogeneic blood transfusion without significant increases in adverse effects (<LINK REF="REF-Henry-1999" TYPE="REFERENCE">Henry 1999</LINK>; <LINK REF="REF-Laupacis-1997" TYPE="REFERENCE">Laupacis 1997</LINK>). In the case of EACA, the evidence of effect is equivocal with most systematic reviews severely hampered by the small number of trials of this agent.</P>
<P>Based on the evidence of efficacy anti-fibrinolytic drugs have become widely used, particularly in cardiac surgery. Because of their mode of actions there have been longstanding concerns about the possibility of adverse effects, with most attention directed at the risk of thrombosis and renal failure. However meta-analyses of randomised trials, including previous versions of this Cochrane review (<LINK REF="REF-Henry-1999" TYPE="REFERENCE">Henry 1999</LINK>;<LINK REF="REF-Henry-2007" TYPE="REFERENCE">Henry 2007</LINK>), have been reassuring in providing no convincing evidence of an increased risk of these events in treated subjects. However, in the case of aprotinin, this view of an attractive benefit to harm ratio was thrown into doubt by the publication of several large non-randomised studies (<LINK REF="REF-Mangano-2006" TYPE="REFERENCE">Mangano 2006</LINK>; <LINK REF="REF-Mangano-2007" TYPE="REFERENCE">Mangano 2007</LINK>;<LINK REF="REF-Schneeweiss-2008" TYPE="REFERENCE">Schneeweiss 2008</LINK>). The serious safety concerns raised by these and other studies prompted the United States Food and Drug Administration (FDA) to re-evaluate its position regarding the use of aprotinin in cardiac surgery, some thirteen years after it was initially approved for prophylactic treatment to reduce perioperative blood loss and blood transfusion (<LINK REF="REF-Ferguson-2007" TYPE="REFERENCE">Ferguson 2007</LINK>). Aprotinin was finally removed from world markets in May 2008. The other drugs reviewed here are still in use.</P>
<P>In the light of these developments and in order to inform decisions about the use of the two lysine analogues as an alternative to aprotinin in cardiac surgery we have updated the Cochrane systematic review of the three anti-fibrinolytic drugs used as blood-sparing agents in surgery. This review updates previous estimates of the efficacy of aprotinin, tranexamic acid, and epsilon aminocaproic acid in reducing perioperative allogeneic blood transfusion in elective surgery. In light of the adverse findings from pharmaco-epidemiological studies we also provide updated estimates of the effects of these drugs on clinical outcomes such as all-cause mortality, thrombosis and renal failure.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-11-28 13:05:36 +0000" MODIFIED_BY="[Empty name]">
<P>To examine the evidence for the efficacy of aprotinin, tranexamic acid, and epsilon aminocaproic acid in reducing allogeneic blood transfusion, and the evidence for any effect on clinical outcomes such as mortality and re-operation rates and complications such as thrombosis and renal failure.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-02-16 13:24:04 +0000" MODIFIED_BY="Emma M Sydenham">
<SELECTION_CRITERIA MODIFIED="2010-10-19 09:57:12 +0100" MODIFIED_BY="Katharine Ker">
<CRIT_STUDIES>
<P>Randomised controlled trials (RCTs) with a concurrent control group, or randomised head-to-head comparative trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>The study participants were adults (over 18 years). Trials were included if participants aged less than 18 years were enrolled, but the type of surgery was predominantly carried out in adult patients. The surgery performed was primarily elective but trials were included if urgent cases were proportionately similar across trial arms.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>The interventions considered are the anti-fibrinolytic agents: aprotinin, tranexamic acid (TXA), and epsilon-aminocaproic acid (EACA).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-10-19 09:57:12 +0100" MODIFIED_BY="Katharine Ker">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-07-02 02:34:41 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>the proportion of patients who were transfused with allogeneic blood, autologous blood, or with both;</LI>
<LI>the amounts of allogeneic and autologous blood transfused.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2010-10-19 09:57:12 +0100" MODIFIED_BY="Katharine Ker">
<UL>
<LI>perioperative blood loss,</LI>
<LI>re-operation due to bleeding,</LI>
<LI>mortality,</LI>
<LI>post-operative complications (myocardial infarction, stroke, deep vein thrombosis, pulmonary embolism, any thrombosis, renal failure),</LI>
<LI>length of hospital stay.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-12-07 16:18:13 +0000" MODIFIED_BY="Emma M Sydenham">
<P>We did not limit the searches by date language or publication status</P>
<ELECTRONIC_SEARCHES MODIFIED="2010-12-07 16:18:13 +0000" MODIFIED_BY="Emma M Sydenham">
<P>The original review drew on the literature search that was constructed as part of the International Study on Perioperative Transfusion (ISPOT) (<LINK REF="REF-Laupacis-1997" TYPE="REFERENCE">Laupacis 1997</LINK>). The original search is listed in full in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">July 2006 update</HEADING>
<P>To maximise the sensitivity for the retrieval of all potentially relevant studies, the electronic searches of MEDLINE were initially unrestricted and updated to July 2006. In MEDLINE, two search filters were then used to restrict the electronic searches and improve the specificity of the updated searches. Firstly, the ISPOT filter, which identifies blood transfusion trials, and secondly, a modified version of the Cochrane Collaboration filter, which primarily identifies randomised controlled trials. These search filters were coupled with the specified MeSH headings and the relevant text-word terms. These restricted searches were updated in MEDLINE to July 2006. Electronic database searches of Excerpta Medica (EMBASE) were updated to July 2006 using similar search strategies to those used in MEDLINE.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">July 2010 update</HEADING>
<P>Searches were carried out in July 2010 as part of a larger project to identify trials in the use of antifibrinolytics.</P>
<P>We searched the following databases;<BR/>
</P>
<UL>
<LI>the Cochrane Injuries Group's Specialised Register (searched July 2010),</LI>
<LI>Cochrane Central Register of Controlled Trials (<I>The Cochrane Library 2010</I>, Issue 3),</LI>
<LI>MEDLINE (Ovid SP) 1950 to July 2010,</LI>
<LI>EMBASE (Ovid SP) 1980 to July 2010.</LI>
</UL>
<P>Full details of the search strategies are presented in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-09-10 10:59:08 +0100" MODIFIED_BY="Emma M Sydenham">
<P>The web sites of International Health Technology Assessment Agencies were also searched through the International Network of Agencies of Health Technology Assessment (INAHTA), and the International Society of Technology Assessment in Health Care (ISTAHC). The Internet was widely searched using Google&#8482; and Google&#8482; Scholar. Contact was also made with experts in the field to identify reports or projects in progress relevant to the review.</P>
<P>The reference lists of related reviews and identified articles were checked for relevant trials. In addition references in the identified trials were checked and authors contacted, where possible, to identify any additional published or unpublished data.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-02-16 13:24:04 +0000" MODIFIED_BY="Emma M Sydenham">
<P>Electronic database searches were carried out by the Cochrane Injuries Group Trials Search Co-ordinator, who then collated the results and passed them on to the author (KK).<BR/>
</P>
<STUDY_SELECTION MODIFIED="2008-09-08 22:15:35 +0100" MODIFIED_BY="[Empty name]">
<P>The titles and abstracts identified in the electronic searches were independently screened by two authors to identify trials in which adult patients, scheduled for elective or urgent surgery, were randomised to either/or aprotinin, TXA, EACA or to a control group, who did not receive the intervention. From the results of the screened electronic searches, bibliographic searches, and contacts with experts, two of the authors independently selected trials that met previously defined inclusion criteria.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-11-12 12:59:33 +0000" MODIFIED_BY="Emma M Sydenham">
<P>At least two authors independently extracted study characteristics and outcomes using an article extraction form. The extraction form was used to record information regarding randomisation criteria, methodology descriptions, the presence of a transfusion protocol, the type of surgery involved, treatment outcomes, and general comments.</P>
<P>Data on the following outcomes were recorded on the data extraction form: the number of patients exposed to allogeneic blood, the amount of allogeneic blood transfused, the number of patients receiving any transfusion (allogeneic blood, autologous blood, or both), the number of patients experiencing post-operative complications (thrombosis, myocardial infarction, renal failure), and mortality. Data were also recorded on blood loss, and the proportion of patients requiring re-operation for bleeding. Information regarding demographics (age, sex), type of surgery, and the presence or absence of a transfusion protocol was also recorded. Data were extracted for allogeneic blood transfusion if they were expressed as whole blood or packed red cells. Data were extracted regarding dose size for each drug regimen.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-10-19 09:58:21 +0100" MODIFIED_BY="Katharine Ker">
<P>Articles that met the inclusion criteria were independently assessed for methodological quality by two authors using criteria proposed by <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>. Disagreements were resolved by consensus. Methodological quality scores obtained for each trial using the criteria proposed by <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK> were then entered into <LINK REF="REF-Review-Manager" TYPE="REFERENCE">Review Manager</LINK> using the Cochrane Collaboration's tool for assessing risk of bias presented in <LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>.</P>
<P>The following domains were assessed for each study:</P>
<UL>
<LI>sequence generation,</LI>
<LI>allocation concealment,</LI>
<LI>blinding.</LI>
</UL>
<P>We completed a risk of bias table for each study, incorporating a description of the study's performance against each of the above domains and our overall judgement of the risk of bias for each entry is as follows; 'Yes' indicates low risk of bias, 'Unclear' indicates unknown risk of bias (not enough information was reported to assess methodological quality); and 'No' indicates a high risk of bias.</P>
</QUALITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2008-09-08 22:13:49 +0100" MODIFIED_BY="[Empty name]">
<P>Funnel plots were inspected for evidence of publication bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-07-02 04:30:42 +0100" MODIFIED_BY="[Empty name]">
<P>Extraction of trial data was performed by one author and checked by the review team's statistician if necessary. Data were checked and entered into <LINK REF="REF-Review-Manager" TYPE="REFERENCE">Review Manager</LINK> by one author. Articles identified as duplicate publications were combined to obtain one set of data. The study report with the greatest number of patients was then represented in the analysis. Studies that did not report data for the number or proportion of patients transfused with allogeneic blood, or the amounts of allogeneic blood transfused, were not included for review. However, trials not reporting blood transfusion data that could be used in the meta-analysis were still included if they reported adverse event data. For dichotomous outcome data to be included in the analysis, trial reports had to provide either numeric data, that is the numbers of events that occurred in the treatment and control groups, or where there were no events recorded numerically, the trial report had to provide a clear statement qualifying and/or quantifying specific events had or had not occurred.</P>
<P>All analyses were performed using <LINK REF="REF-Review-Manager" TYPE="REFERENCE">Review Manager</LINK> software. Data on the numbers of patients exposed to allogeneic blood, and the numbers of patients in each treatment arm, were entered into <LINK REF="REF-Review-Manager" TYPE="REFERENCE">Review Manager</LINK>. The relative risks (RR) for allogeneic blood transfusion in the intervention group as compared with the control group, and the corresponding 95% confidence intervals (CI), were calculated for each trial using the random effects model. The presence of heterogeneity of treatment effect was assessed using the Q statistic, which has an approximate chi-square distribution with degrees of freedom equal to the number of studies minus one (<LINK REF="REF-Der-Simonian-1986" TYPE="REFERENCE">Der Simonian 1986</LINK>). A P-value less than or equal to 0.1 was used to define statistically significant heterogeneity. Statistical heterogeneity was also assessed using the I² test. The I² test describes the percentage of total variation across studies due to heterogeneity rather than chance. A value of 0% indicates no observed heterogeneity and larger values show increasing heterogeneity. Substantial heterogeneity is considered to exist when I² &gt; 50% (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>).</P>
<P>The mean number of units of allogeneic blood transfused to each group, and the corresponding standard deviations, were also entered. As the majority of trials reported the means and standard deviations for the amount of blood transfused in all patients in each comparison group, the data included a number of zero values for those patients not receiving transfusion. The data are therefore likely to be highly skewed. Wherever possible, the mean and standard deviation for the numbers of units of blood transfused in those receiving transfusion were recalculated. The new mean was calculated by dividing the total number of units transfused in the group by the number of patients transfused. The reported standard deviation and mean were used to calculate the sum of squares of the numbers of units transfused for the group. As this is equal to the sum of squares of the numbers of units transfused in those receiving transfusion, the new standard deviation was calculated using this, the new mean and the number of patients transfused. Thus the new values estimate the average amount of blood received by those transfused in each group. The new values were then entered into <LINK REF="REF-Review-Manager" TYPE="REFERENCE">Review Manager</LINK> to obtain the mean difference (MD) and 95% CIs to express the average reduction in the number of units of allogeneic blood given to those patients transfused. Data in millilitres (mls) were converted to units by dividing by 300.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-02-16 13:24:04 +0000" MODIFIED_BY="Emma M Sydenham">
<P>Analysis of <I>a-priori </I>subgroups was performed to determine whether effect sizes varied according to factors such as;<BR/>
</P>
<UL>
<LI>the type of surgery,</LI>
<LI>the use of transfusion protocols,</LI>
<LI>dose regimen, and</LI>
<LI>trial methodological quality.</LI>
</UL>
<P>The editorial group is aware that a clinical trial by Prof. Joachim Boldt has been found to have been fabricated (<A HREF="http://archie.cochrane.org/sections/documents/view?document=540099072011521412&amp;format=REVMAN#REF-Boldt-2009">Boldt 2009</A>). As the editors who revealed this fabrication point out (<A HREF="http://archie.cochrane.org/sections/documents/view?document=540099072011521412&amp;format=REVMAN#REF-Reinhart-2011">Reinhart 2011</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?document=540099072011521412&amp;format=REVMAN#REF-Shafer-2011">Shafer 2011</A>), this casts some doubt on the veracity of other studies by the same author. All Cochrane Injuries Group reviews which include studies by this author have therefore been edited to show the results with this author's trials included and excluded. Readers can now judge the potential impact of trials by this author on the conclusions of the review.
</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-02-16 14:22:58 +0000" MODIFIED_BY="Emma M Sydenham">
<STUDY_DESCRIPTION MODIFIED="2010-12-07 16:20:46 +0000" MODIFIED_BY="Emma M Sydenham">
<P>Two hundred and fifty-two trials met the inclusion criteria. Four trials were excluded (refer to 'Characteristics of excluded studies' section of this review). Of the 252 included trials, 131 evaluated aprotinin, 60 evaluated tranexamic acid (TXA), and 12 evaluated epsilon aminocaproic acid (EACA) versus control. Forty-nine trials studied head-to-head comparisons of aprotinin, TXA, and EACA with or without an untreated control. Of these 49 trials, 25 compared aprotinin with TXA, 12 compared aprotinin with EACA, seven compared TXA with EACA, and five compared aprotinin with TXA and EACA. Trials were conducted in many countries including:</P>
<P>United States (n = 45), Germany (n = 24), UK (n = 17), Canada (n = 17), Italy (n = 16), Spain (n = 14), Belgium (n = 12), France (n = 10), Turkey (n = 9), Australia (n = 8), Sweden (n = 8),The Netherlands (n = 8), Japan (n = 7), China (n = 6), Austria (n = 5), Israel (n = 5), Switzerland (n = 5), Finland (n = 5), Czech Republic (n = 3), Denmark (n = 3), Taiwan (n = 2), Ireland (n = 2), Greece (n = 2), Poland (n = 2), Brazil (n = 1), Chile (n = 1), Dubai (n=1), Egypt (n = 1), India (n = 1), Norway (n = 1), Oman (n=1), Saudi Arabia (n=1) and South Africa (n = 1). Three studies were multicentre trials, one conducted across sites in the UK and the United States, one in sites in Australia, New Zealand, Asia and Europe and one in sites in the United States and Canada. The majority of included trials were published in English. Thirteen trials required translation (<LINK REF="STD-Carrera-1994" TYPE="STUDY">Carrera 1994</LINK>; <LINK REF="STD-Corbeau-1995" TYPE="STUDY">Corbeau 1995</LINK>; <LINK REF="STD-Cvachovec-2001" TYPE="STUDY">Cvachovec 2001</LINK>; <LINK REF="STD-Deleuze-1991" TYPE="STUDY">Deleuze 1991</LINK>; <LINK REF="STD-Gherli-1992" TYPE="STUDY">Gherli 1992</LINK>; <LINK REF="STD-Hei-2005" TYPE="STUDY">Hei 2005</LINK>; <LINK REF="STD-Kahveci-1996" TYPE="STUDY">Kahveci 1996</LINK>; <LINK REF="STD-Katzel-1998" TYPE="STUDY">Katzel 1998</LINK>; <LINK REF="STD-Kratzer-1997" TYPE="STUDY">Kratzer 1997</LINK>; <LINK REF="STD-Locatelli-1990" TYPE="STUDY">Locatelli 1990</LINK>; <LINK REF="STD-Maccario-1994" TYPE="STUDY">Maccario 1994</LINK>; <LINK REF="STD-Trinh_x002d_Duc-1992" TYPE="STUDY">Trinh-Duc 1992</LINK>; <LINK REF="STD-Utada-1997" TYPE="STUDY">Utada 1997</LINK>). The data from these trials were included in the analysis.</P>
<P>Of the 252 included trials, 173 were conducted in cardiac surgery, 53 trials were in orthopaedic surgery, 14 involved liver surgery, five were conducted in vascular surgery, four involved thoracic surgery, one involved gynaecological surgery, one involved neurosurgery, and one trial was in orthognathic surgery.</P>
<P>The trial conducted by <LINK REF="STD-Lemmer-1994" TYPE="STUDY">Lemmer 1994</LINK> stratified patients according to the type of procedure being performed, that is, either primary CABG or redo CABG surgery. Patients from each group were then randomised to either aprotinin or placebo. The data obtained from each of these two groups (primary CABG and redo CABG) have been analysed separately by the authors. Therefore from this single trial (<LINK REF="STD-Lemmer-1994" TYPE="STUDY">Lemmer 1994</LINK>), two comparisons of aprotinin versus control have been obtained. This review presents the data from this trial as follows:<BR/>(1) <LINK REF="STD-Lemmer_x005f_1-1994" TYPE="STUDY">Lemmer_1 1994</LINK>: represents those patients who underwent primary CABG and were randomised to either aprotinin or placebo.<BR/>(2) <LINK REF="STD-Lemmer_x005f_2-1994" TYPE="STUDY">Lemmer_2 1994</LINK>: represents those patients who underwent redo CABG and were randomised to either aprotinin or placebo.</P>
<SUBSECTION>
<HEADING LEVEL="3">Description of Dose Regimens</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Aprotinin dose range</HEADING>
<P>Three dose stratifications were used: (1) high-dose aprotinin, (2) low-dose aprotinin, and, (3) cardiopulmonary bypass (CPB) pump prime aprotinin. For the purposes of this review, any aprotinin regimen that did not follow the 'full Hammersmith' regimen, including those studies that described their regimens as 'half Hammersmith', were classified as low-dose aprotinin. For those trials that did not involve cardiac surgery, classification of the dose-regimen was based on the total quantity of aprotinin administered. Trials were classified as 'high-dose' where participants received a total dose equal to or exceeding five million kallikrein inactivator units (KIU) or 700mg of aprotinin.</P>
<P>High-dose aprotinin, described as the 'full Hammersmith' regimen, entails an initial loading dose of two million kallikrein inactivator units (KIU) of aprotinin given intravenously (IV) (280mg) over a 20 to 30 minute period commencing at the induction of anaesthesia, followed by a continuous infusion of 500,000 KIU per hour (70mg/hr) until the end of the operation. In addition, two million KIU of aprotinin (280mg) is added to the oxygenator prime or pump prime of the CPB. A 'half Hammersmith' regimen is described as follows: a loading dose of one million KIU (140mg) of aprotinin infused over a 20 to 30 minute period followed by a continuous IV infusion of 250,000 KIU of aprotinin per hour, until the end of the operation. An additional dose of one million KIU is added to the pump prime.</P>
<P>'Prime' dose aprotinin, for the purposes of this review, included those regimens that added aprotinin to the pump prime solution of the CPB exclusively. The dose of aprotinin used in the 'prime' regimen varied between trials. Sixteen trials studied the efficacy of 'prime' dose aprotinin and reported data on the proportion of participants exposed to allogeneic blood transfusion. Of these trials 12 studied a 'prime' dose of two million KIU of aprotinin, two studied a 'prime' dose of one million KIU of aprotinin, one studied a 'prime' dose of 500,000 KIU of aprotinin, and one trial studied a 'prime' dose of 25,000 KIU/kg (range 1.375 to 2.3 million KIU in total) of aprotinin.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tranexamic acid (TXA) dose range</HEADING>
<P>Of the 65 trials that studied the efficacy of TXA versus placebo or control (current standard practice) and were included in the meta-analysis of allogeneic blood transfusion exposure; 34 involved cardiac surgery, 27 involved orthopaedic surgery, two involved liver surgery, one trial involved gynaecological surgery and one trial involved vascular surgery. Dose regimens for TXA varied significantly between trials with varying dose sizes and time frames for drug delivery. Of the 34 trials involving cardiac surgery, the TXA loading or bolus dose ranged from 2.5mg/kg to 100mg/kg. The maintenance dose of TXA for the cardiac trials, ranged from 0.25mg/kg/hr to 4.0mg/kg/hr delivered over 1 to 12 hours. Similar variation was observed in trials not involving cardiac surgery. More detailed information regarding dose regimens is provided in the 'Characteristics of included studies' section of this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Epsilon aminocaproic acid (EACA) dose range</HEADING>
<P>Of the 16 trials that studied the efficacy of EACA versus placebo or control (current standard practice) and were included in the meta-analysis of allogeneic blood transfusion exposure; 11 involved cardiac surgery, four involved orthopaedic surgery, and one involved liver surgery. Dose regimens for EACA also varied significantly between trials. Generally trials used different dose sizes and time frames for drug delivery. The EACA loading or bolus dose ranged from 80mg to 15g or 75 to 150mg/kg. The maintenance dose of EACA ranged from 1g/hr to 2g/hr or 12.5mg/kg/hr to 30mg/kg/hr infused over varying time periods. More detailed information regarding dose regimens is provided in the 'Characteristics of included studies' section of this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Transfusion 'triggers' / thresholds</HEADING>
<P>Of the 189 trials of aprotinin, TXA, and EACA versus control included in the analysis of allogeneic blood transfusion exposure, 158 trials (84%) reported the use of a transfusion protocol, the remainder did not report the use of a transfusion protocol. Of those trials that reported the use of a transfusion protocol, all included a transfusion "trigger" value, that being the haemoglobin or haematocrit value, at which point a transfusion of allogeneic and/or autologous blood, was considered necessary. There was significant variation between trials in the type and value of transfusion threshold used. The lowest transfusion threshold level for haemoglobin was 5.0g/dL with blood being transfused if the haemoglobin level during CPB fell below 5.0g/dL (<LINK REF="STD-Green-1995" TYPE="STUDY">Green 1995</LINK>). The transfusion protocol used by <LINK REF="STD-Brown-1997" TYPE="STUDY">Brown 1997</LINK> advocated a haemoglobin threshold level of 6.0g/dL during CPB, whereas other trials involving CPB advocated a haemoglobin threshold level of 7.0g/dL, or haematocrit levels (Hct) between 18% to 20% during CPB. In general, post-operative transfusion threshold levels ranged from Hb 7.0g/dL to 10.0g/dL, or Hct 20% to 30%.</P>
</SUBSECTION>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-08-25 04:04:20 +0100" MODIFIED_BY="[Empty name]">
<P>For further details regarding the performance of the studies against each domain, please see the 'Risk of bias' tables (<LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>; <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>). A summary of the information in the tables is given below. Additionally, a visual summary of judgements about each methodological quality item for each included trial is shown in <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Generation of allocation sequences</HEADING>
<P>The method used to generate allocation sequences was judged to be adequate in only 78 trials. For all but two of the remaining trials the method used to generate allocation sequences was judged to be unclear. For two trials the method of randomisation that was judged to be inadequate. Refer to results presented in the 'Risk of bias' tables.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Allocation concealment</HEADING>
<P>Only 79 trials were judged to have adequately concealed treatment allocation. For 31 trials the method used to conceal treatment allocation was judged to be inadequate. For the remaining trials allocation concealment was judged to be unclear. Refer to results presented in the 'Risk of bias' tables.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<P>For 170 trials blinding was judged to be adequate (double blinded), and unclear for 61 trials. Refer to results presented in the 'Risk of bias' tables.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Inclusion of all randomised participants</HEADING>
<P>Of those trials able to be assessed for methodological quality, 124 trials either reported there were no exclusions, or used intention-to-treat analysis. In 80 trials, where exclusions were reported, these exclusions were judged unlikely to cause bias. For 37 trials exclusions were either judged to be excessive and likely to cause bias, or were not reported.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-02-16 14:22:58 +0000" MODIFIED_BY="Emma M Sydenham">
<SUBSECTION>
<HEADING LEVEL="3">Aprotinin</HEADING>
<P>There were 108 trials of aprotinin versus control that reported data on the proportion of patients exposed to allogeneic blood transfusion. These trials included a total of 11,172 patients, of whom 6259 were randomised to receive aprotinin and 4913 patients were randomised to a control group who did not receive aprotinin. The apparent imbalance between the aprotinin and control groups resulted from pooling data across different aprotinin dose groups within trials. Overall, the use of aprotinin significantly reduced the rate of allogeneic blood transfusion by a relative 34% (RR 0.66, 95% CI 0.60 to 0.72) compared to control. Heterogeneity between these trials was statistically significant (Chi² = 961.52, df = 107, P &lt;0.00001; I² = 89%). The absolute risk reduction (ARR) was 20% (RD -0.20, 95% CI -0.24 to -0.17).</P>
<SUBSECTION>
<HEADING LEVEL="4">Type of surgery</HEADING>
<P>There were 84 trials of aprotinin versus control that involved cardiac surgery and provided data on the number of patients exposed to allogeneic blood transfusion. These trials included a total of 9497 patients, of whom 5329 were randomised to receive aprotinin and 4168 patients were randomised to a control group who did not receive aprotinin. Overall, the use of aprotinin in cardiac surgery significantly reduced the need for allogeneic blood transfusion by a relative 32% (RR 0.68, 95% CI 0.63 to 0.73) compared to control. (The effect with the 
<LINK REF="STD-Boldt-1991" TYPE="STUDY">Boldt 1991</LINK>
 trial excluded was unchanged (RR 0.68 (95% CI 0.63 to 0.73).) Heterogeneity between these trials was statistically significant (Chi² = 329.48, df = 83, P &lt;0.00001; I² = 75%). The ARR was 21% (RD -0.21, 95% CI -0.24 to -0.18).</P>
<P>There were 15 trials of aprotinin versus control that involved orthopaedic surgery and provided data on the number of patients exposed to allogeneic blood transfusion. These trials included a total of 1146 patients, of whom 655 were randomised to receive aprotinin and 491 patients were randomised to a control group who did not receive aprotinin. Overall, the use of aprotinin in orthopaedic surgery significantly reduced the need for allogeneic blood transfusion by a relative 32% (RR 0.68, 95% CI 0.52 to 0.89) compared to control. Heterogeneity between these trials was statistically significant (Chi² = 45.47, df = 14, P &lt;0.0001; I² = 69%). The ARR was 13% (RD -0.13, 95% CI -0.20 to -0.05).</P>
<P>There were three trials of aprotinin versus control that involved thoracic surgery and provided data on the number of patients exposed to allogeneic blood transfusion. These trials included a total of 78 patients, of whom 38 were randomised to receive aprotinin and 40 patients were randomised to a control group who did not receive aprotinin. The use of aprotinin in thoracic surgery significantly reduced the need for allogeneic blood transfusion by a relative 71% (RR 0.29, 95% CI 0.14 to 0.59). Heterogeneity between these trials was not statistically significant (Chi² = 0.37, df = 2, P = 0.83; I² = 0%).</P>
<P>There were two trials of aprotinin versus control that involved vascular surgery and provided data on the number of patients exposed to allogeneic blood transfusion. These trials included a total of 188 patients, of whom 105 were randomised to aprotinin and 83 patients were randomised to a control group who did not receive aprotinin. The use of aprotinin in vascular surgery had no effect on the need for allogeneic blood transfusion (RR 1.00, 95% CI 0.97 to 1.03). Heterogeneity between these trials was not statistically significant (Chi² = 0.01, df = 1, P = 0.84; I² = 0%).</P>
<P>There were two trials of aprotinin versus control that involved liver surgery and provided data on the number of patients exposed to allogeneic blood transfusion. These trials included a total of 177 patients, of whom 87 were randomised to aprotinin and 90 patients were randomised to a control group who did not receive aprotinin. The use of aprotinin in liver surgery reduced the need for allogeneic blood transfusion by a relative 42% (RR 0.58, 95% CI 0.37 to 0.90). Heterogeneity between these trials was not statistically significant (Chi² = 1.03, df = 1, P = 0.31; I² = 3%).</P>
<P>Data from the trials involving neurosurgery, and orthognathic surgery could not be analysed due to the small number of trials in each of these surgical subgroups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Effect of transfusion protocols</HEADING>
<P>There were 87 trials that compared aprotinin with control and reported the use of transfusion protocols. These trials included a total of 9974 patients, of whom 5599 were randomised to aprotinin and 4375 were randomised to a control group who did not receive aprotinin. In those trials where a transfusion protocol was used, aprotinin significantly reduced the need for allogeneic blood transfusion by a relative 35% (RR 0.65, 95% CI 0.59 to 0.71). Heterogeneity between these trials was statistical significant (Chi² = 924.12, df = 86, P &lt; 0.00001; I² = 91%). (The effect was unchanged with the <LINK REF="STD-Boldt-1991" TYPE="STUDY">Boldt 1991</LINK> trial excluded (RR 0.65 (95% CI 0.59 to 0.71).)
</P>
<P>There were 21 trials of aprotinin versus control that reported data on the number of patients exposed to allogeneic blood transfusion but did not report the use of a transfusion protocol. These trials included a total of 1198 patients, of whom 660 were randomised to aprotinin and 538 were randomised to a control group who did not receive aprotinin. The use of aprotinin statistically significantly reduced the need for allogeneic blood transfusion by a relative 29% (RR 0.71, 95% CI 0.61 to 0.84) compared to control. Heterogeneity between these trials was statistically significant (Chi² = 49.74, df = 20, P = 0.0002; I² = 60%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Effect of dose</HEADING>
<P>In those trials that used a low-dose aprotinin regimen the RR of requiring an allogeneic blood transfusion was 0.65 (95% CI 0.55 to 0.77) compared to control. Whereas in those trials that used a high-dose aprotinin regimen the RR of receiving an allogeneic blood transfusion was 0.66 (95% CI 0.61 to 0.71) compared to control. Therefore there was little difference in effect between high-dose and low-dose aprotinin. In cardiac surgery when aprotinin was given as a prime-dose only, the RR of requiring allogeneic blood transfusion was 0.83 (95% CI 0.71 to 0.96). There was statistically significant heterogeneity present in all three subgroups (P &gt;0.0001; I² &gt;74%).</P>
<P>The study conducted by <LINK REF="STD-Green-1995" TYPE="STUDY">Green 1995</LINK> was not included in this analysis as it only provided aggregate data for the number of patients exposed to allogeneic blood transfusion, without stratifying allogeneic blood transfusion exposure by dose.</P>
<P>When the high-dose analysis excludes the <LINK REF="STD-Boldt-1991" TYPE="STUDY">Boldt 1991</LINK> trial, the effect remains 0.66 (95% CI 0.61 to 0.71).
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Volume of blood transfused</HEADING>
<P>Seventy-four trials of aprotinin versus control provided data on the volume of allogeneic blood transfused in all patients. These trials included a total of 7820 patients, of whom 4198 were randomised to aprotinin and 3622 were randomised to a control group who did not receive aprotinin. The use of aprotinin resulted in a significant saving of 1.02 units of allogeneic blood (MD -1.02 units, 95% CI -1.26 to -0.79 units). Heterogeneity between these trials was statistically significant (Chi² = 1627.35, df = 69, P &lt;0.00001; I² = 96%).</P>
<P>Forty trials of aprotinin versus control provided data on the volume of allogeneic blood transfused in those patients transfused. These trials provided data for a total of 3563 patients, of whom 1680 were treated with aprotinin and 1883 did not receive aprotinin treatment. In those patients transfused the use of aprotinin resulted in a significant saving of 0.98 units of allogeneic blood per patient (MD -0.98 units, 95% CI -1.29 to -0.66 units). Heterogeneity between these trials was statistically significant (Chi² = 197.82, df = 36, P &lt; 0.00001; I² = 82%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blood loss - all surgery combined</HEADING>
<P>A total of 16 trials of aprotinin versus control reported intra-operative blood loss data. These trials included a total of 883 patients, of whom 449 were randomised to aprotinin and 434 were randomised to a control group. These trials involved cardiac surgery (n = 7), orthopaedic surgery (n = 5), thoracic surgery (n = 2), liver surgery (n = 2) and vascular surgery (n = 1). In aggregate, aprotinin treatment reduced intra-operative blood loss on average by around 192 mls per patient (MD -191.87 mls, 95% CI -280.45 to -103.28 mls). Heterogeneity between these trials was statistically significant (Chi² = 40.04, df = 16, P = 0.0008; I² = 60%).</P>
<P>A total of 87 trials of aprotinin versus control reported post-operative blood loss data. These trials included a total of 7896 patients, of whom 4394 were randomised to aprotinin and 3502 were randomised to a control group. These trials involved cardiac surgery (n = 75), orthopaedic surgery (n = 7), thoracic surgery (n = 2), orthognathic surgery (n = 1), liver surgery (n = 1), and vascular surgery (n = 1). In aggregate, aprotinin treatment significantly reduced post-operative blood loss on average by around 346 mls per patient (MD -345.88 mls, 95% CI -383.47 to -308.29 mls). Heterogeneity between these trials was statistically significant (Chi² = 620.49, df = 86, P &lt;0.00001; I² = 86%).</P>
<P>A total of 17 trials of aprotinin versus control reported total blood loss data (intra-operative and post-operative blood loss combined). These trials included a total of 1789 patients, of whom 932 patients were randomised to aprotinin and 857 were randomised to a control group. These trials involved cardiac surgery (n = 7) and orthopaedic surgery (n = 10). In aggregate, the use of aprotinin significantly reduced perioperative blood loss by around 416 mls per patient (MD -415.95 mls, 95% CI -520.38 to -311.51 mls). Heterogeneity between these trials was statistically significant (Chi² = 66.96, df = 16, P &lt;0.0001; I² = 76%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blood loss - cardiac surgery</HEADING>
<P>Seven trials of aprotinin versus control involving cardiac surgery reported intra-operative blood loss data. These trials included a total of 470 patients, of whom 242 were randomised to aprotinin and 228 were randomised to a control group. Aprotinin treatment in cardiac surgery appeared to be only marginally effective in reducing intra-operative blood loss (MD -148.18 mls, 95% CI -240.21 to -56.14 mls). Heterogeneity between these trials was statistically significant (Chi² = 13.63, df = 6, P = 0.03; I² = 56%).</P>
<P>Seventy-five trials of aprotinin versus control involving cardiac surgery reported post-operative blood loss data. These trials included a total of 7371 patients, of whom 4132 were randomised to aprotinin and 3239 were randomised to a control group. The use aprotinin in cardiac surgery reduced post-operative blood loss on average by 370 mls per patient (MD -369.62 mls, 95% CI -408.95 to -330.29 mls). Heterogeneity between these trials was statistically significant (Chi² = 513.91, df = 74, P &lt;0.00001; I² = 86%). The effect excluding the trials <LINK REF="STD-Boldt-1991" TYPE="STUDY">Boldt 1991</LINK> and <LINK REF="STD-Boldt-1994" TYPE="STUDY">Boldt 1994</LINK> is MD -378.45 (95% CI -417.99 to -338.92).
</P>
<P>Seven trials of aprotinin versus control involving cardiac surgery reported total blood loss data (intra-operative and post-operative blood loss combined). These trials included a total of 1359 patients, of whom 716 were randomised to aprotinin and 643 were randomised to a control group. The use of aprotinin in cardiac surgery significantly reduced the total volume of blood lost during the perioperative period (MD -448.86 mls, 95% CI -612.82 to -284.91 mls). Heterogeneity between these trials was statistically significant (Chi² = 42.60, df = 6, P&lt;0.00001; I² = 86%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blood loss - orthopaedic surgery</HEADING>
<P>Five trials of aprotinin versus control involving orthopaedic surgery reported intra-operative blood loss data. These trials included a total of 201 patients, of whom 103 were randomised to aprotinin and 98 were randomised to a control group. The use of aprotinin in orthopaedic surgery did not reduce the volume of blood lost during the intra-operative period (MD -151.05 mls, 95% CI -317.63 to 15.52 mls). Heterogeneity between these trials was not statistically significant (Chi² = 6.62, df = 4, P = 0.16; I² = 40%).</P>
<P>Seven trials of aprotinin versus control involving orthopaedic surgery reported post-operative blood loss data. These trials included a total of 318 patients, of whom 160 were randomised to aprotinin and 158 were randomised to a control group. The use of aprotinin in orthopaedic surgery was only marginally effective in reducing post-operative blood loss (MD -113.58 mls, 95% CI -223.69 to -3.46 mls). Heterogeneity between these trials was statistically significant (Chi² = 18.56, df = 6, P = 0.005; I² = 68%).</P>
<P>Ten trials of aprotinin versus control involving orthopaedic surgery reported total blood loss data (intra-operative and post-operative blood loss combined). These trials included a total of 430 patients, of whom 216 were randomised to aprotinin and 214 were randomised to a control group. Aprotinin reduced the total volume of blood lost during the perioperative period on average by around 399 mls per patient (MD -399.09 mls, 95% CI -562.81 to -235.37 mls). Heterogeneity between these trials was statistically significant (Chi² = 22.67, df = 9, P = 0.007; I² = 60%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Re-operation for bleeding</HEADING>
<P>Sixty-one trials of aprotinin versus control reported data on re-operation for bleeding. These trials included a total of 6117 patients, of whom 3392 were randomised to aprotinin and 2725 were randomised to a control group who did not receive aprotinin. The use of aprotinin significantly reduced the need for re-operation for bleeding by a relative 54% (RR 0.46, 95% CI 0.34 to 0.62). Heterogeneity between these trials was not significant (Chi² = 35.44, df = 42, P = 0.75; I² = 0%). The 
<LINK REF="STD-Boldt-1994" TYPE="STUDY">Boldt 1994</LINK> trial had no events, and therefore provided no data to this analysis. When aprotinin was used in cardiac surgery, the RR of requiring re-operation due to bleeding was 0.46 (95% CI 0.34 to 0.63). Again heterogeneity between these trials was not significant (Chi² = 34.56, df = 39, P = 0.67; I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mortality</HEADING>
<P>Sixty-three trials of aprotinin versus control reported data on mortality. These trials included a total of 8876 patients, of whom 4889 were randomised to aprotinin and 3987 were randomised to a control group who did not receive aprotinin. The use of aprotinin was not associated with an increased risk of death (RR 0.81, 95% CI 0.63 to 1.06). Heterogeneity between these trials was not significant (Chi² = 29.54, df = 43, P = 0.94; I² = 0%). In the case of cardiac surgery, the use of aprotinin was not associated with an increased risk of death (RR 0.84, 95% CI 0.64 to 1.10).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Myocardial infarction</HEADING>
<P>Forty-nine trials of aprotinin versus control reported data for myocardial infarction. These trials included a total of 7137 patients, of whom 4032 were randomised to aprotinin and 3105 were randomised to a control group who did not receive aprotinin. The use aprotinin did not increase the risk of myocardial infarction (RR 0.87, 95% CI 0.69 to 1.11). Heterogeneity between these trials was not statistically significant (Chi² = 27.71, df = 38, P = 0.89; I² = 0%). When aprotinin was used in cardiac surgery, the relative risk of myocardial infarction was not statistically significant (RR 0.90, 95% CI 0.71 to 1.14).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Stroke</HEADING>
<P>Twenty-three trials of aprotinin versus control reported data for stroke. These trials included a total of 3122 patients, of whom 1862 were randomised to aprotinin and 1260 were randomised to a control group who did not receive aprotinin. The use aprotinin did not increase the risk of stroke (RR 0.82, 95% CI 0.44 to 1.52). Heterogeneity between these trials was not statistically significant (Chi² = 11.97, df = 19, P = 0.89; I² = 0%). The use of aprotinin in cardiac surgery was not associated with an increased risk of stroke (RR 0.81, 95% CI 0.40 to 1.67).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Deep vein thrombosis</HEADING>
<P>Sixteen trials of aprotinin versus control reported data for deep vein thrombosis (DVT). These trials included a total of 1456 patients, of whom 854 were randomised to aprotinin and 602 were randomised to a control group who did not receive aprotinin. The use aprotinin did not increase the risk of deep vein thrombosis (RR 0.78, 95% CI 0.47 to 1.29). Heterogeneity between these trials was not statistically significant (Chi² = 6.22, df = 11, P = 0.86; I² = 0%). Three cardiac trials reported data for DVT. The use of aprotinin was not associated with a statistically significant increased risk of DVT (RR 1.29, 95% CI 0.36 to 4.58).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Pulmonary embolus</HEADING>
<P>Four trials of aprotinin versus control reported data for pulmonary embolus (PE). These trials included a total of 585 patients, of whom 304 were randomised to aprotinin and 281 were randomised to a control group who did not receive aprotinin. The use of aprotinin did not statistically significantly increase the risk of PE (RR 1.49, 95% CI 0.42 to 5.29).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Renal failure / dysfunction</HEADING>
<P>Twenty-seven trials of aprotinin versus control reported data for renal failure / dysfunction. These trials included a total of 5185 patients, of whom 2904 were randomised to aprotinin and 2281 were randomised to a control group who did not receive aprotinin. The use aprotinin did not statistically significantly increase the risk of renal failure / dysfunction (RR 1.10, 95% CI 0.79 to 1.54). Heterogeneity between these trials was not statistically significant (Chi² = 7.64, df = 16, P = 0.96; I² = 0%). Although there appeared to be a trend toward an increased risk of renal failure/dysfunction when aprotinin was used in cardiac surgery, the result was not statistically significant (RR 1.07, 95% CI 0.76 to 1.51).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Length of hospital stay</HEADING>
<P>Twenty-three trials of aprotinin versus control reported data for hospital length of stay. These trials included a total of 2017 patients, of whom 1011 were randomised to aprotinin and 1006 were randomised to a control group who did not receive aprotinin. Aprotinin treatment did not reduce the length of hospital stay (MD -0.25 days, 95% CI -0.71 to 0.20 days). Heterogeneity between these trials was statistically significant (Chi² = 50.13, df = 22, P = 0.0006; I² = 56%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Tranexamic acid</HEADING>
<P>Sixty-five trials compared TXA with control, and reported data on the number of patients exposed to allogeneic blood transfusion. These trials included a total of 4842 patients, of whom 2528 were randomised to TXA and 2314 were randomised to a control group who did not receive TXA. The use of TXA significantly reduced the need for allogeneic blood transfusion by a relative 39% (RR 0.61, 95% CI 0.53 to 0.70). Heterogeneity between these trials was statistically significant (Chi² = 249.33, df = 63, P &lt;0.0001; I² = 75%). This represents an absolute risk reduction of 18% (RD -0.18, 95% CI -0.22 to -0.14).</P>
<SUBSECTION>
<HEADING LEVEL="4">Type of surgery</HEADING>
<P>Thirty-four trials of TXA versus control involved cardiac surgery. These trials included a total of 3006 patients, of whom 1578 were randomised to TXA, and 1428 were randomised to a control group who did not receive TXA. There was a significant 32% relative reduction in the rate of exposure to allogeneic blood transfusion in those patients treated with TXA (RR 0.68, 95% CI 0.57 to 0.81). Heterogeneity between these trials was statistically significant (Chi² = 137.35, df = 33, P &lt;0.00001; I² = 76%).</P>
<P>Twenty-seven trials of TXA versus control involved orthopaedic surgery. These trials included a total of 1381 patients of whom of whom 722 were randomised to TXA and 659 were randomised to a control group who did not receive TXA. Again there was a significant RR reduction of 51% in those participants treated with TXA (RR 0.49, 95% CI 0.39 to 0.62). Heterogeneity between these trials was statistically significant (Chi² = 53.86, df = 25, P = 0.0007; I² = 54%).</P>
<P>Two trials of TXA versus control involved liver surgery. These trials included a total of 296 patients of whom 148 were randomised to TXA and 148 were randomised to a control group who did not receive TXA. In liver surgery treatment with TXA did not reduce the risk of receiving an allogeneic blood transfusion (RR 0.16, 95% CI 0.00 to 32.47). Heterogeneity between these trials was statistically significant (Chi² = 14.23, df = 1, P = 0.0002; I² = 93%).</P>
<P>One trial of TXA versus control involved vascular surgery. This trial included 59 patients of whom 30 were randomised to TXA and 29 were randomised to a control group who did not receive TXA. In vascular surgery treatment with TXA reduced the risk of receiving an allogeneic blood transfusion (RR 0.56, 95% CI 0.33 to 0.96).</P>
<P>One trial of TXA versus control involved gynaecological surgery. This trial included 100 patients of whom 50 were randomised to TXA and 50 were randomised to a control group who did not receive TXA. In gynaecological surgery treatment with TXA did not reduce the risk of receiving an allogeneic blood transfusion (RR 1.50, 95% CI 0.75 to 3.01).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Effect of transfusion protocols</HEADING>
<P>Fifty-six trials of TXA versus control reported the use of transfusion protocols and provided data on the number of patients exposed to allogeneic blood transfusion. These trials included a total of 4125 patients, of whom 2156 were randomised to TXA and 1969 were randomised to a control group who did not receive TXA. The use of TXA reduced the need for allogeneic blood transfusion by a relative 43% (RR 0.57, 95% CI 0.48 to 0.67). Heterogeneity between these trials was statistically significant (Chi² = 248.97, df = 55, P &lt;0.00001; I² = 78%). There were nine trials that did not report the use of transfusion protocols. These trials included a total of 717 patients of whom 372 were randomised to TXA and 345 were randomised to a control group. The use of TXA reduced the need for allogeneic blood transfusion compared to control (RR 0.76, 95% CI 0.61 to 0.96). Heterogeneity between these trials was statistically significant (Chi² = 15.48, df = 7, P = 0.03; I² = 55%).</P>
<P>Although the baseline rate of transfusion remained relatively constant across both subgroups (transfusion protocol 44% versus no transfusion protocol 45%) transfusion rates in the intervention arms was collectively greater in those trials that did not report the use of a transfusion protocol compared to those trials that did use a transfusion protocol to guide transfusion practice (37% versus 26%, respectively).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Volume of blood transfused</HEADING>
<P>Twenty-three trials of TXA versus control reported data on the volume of blood transfused in all patients. These trials included a total of 1814 patients, of whom 943 were randomised to TXA and 871 were randomised to a control group. The use of TXA resulted in a saving of 0.87 units of allogeneic blood per patient (MD -0.87 units, 95% CI -1.20 to -0.53 units). Heterogeneity between these trials was statistically significant (Chi² = 154.24, df = 20, P &lt;0.00001; I² = 87%).</P>
<P>Thirteen trials of TXA versus control provided data on the volume of blood transfused in those patients transfused. All 481 patients received allogeneic blood transfusion. The use of TXA did not statistically significantly reduce the volume of blood transfused compared to control (MD -0.34 units, 95% CI -0.80 to 0.11 units). Heterogeneity between these trials was statistically significant (Chi² = 45.89, df = 12, P &lt; 0.0001; I² = 74%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blood loss - all surgery combined</HEADING>
<P>A total of 17 trials of TXA versus control reported intra-operative blood loss data. These trials included a total of 1173 patients, of whom 599 were randomised to TXA and 574 were randomised to a control group. These trials involved cardiac surgery (n = 4), orthopaedic surgery (n = 12) and gynaecological surgery (n = 1). In aggregate, TXA treatment reduced intra-operative blood loss (MD -121.41 mls, 95% CI -180.19 to -62.63 mls). Heterogeneity between these trials was statistically significant (Chi² = 49.05, df = 16, P &lt;0.0001; I² = 67%).</P>
<P>A total of 35 trials of TXA versus control reported post-operative blood loss data. These trials included a total of 2501 patients, of whom 1285 were randomised to TXA and 1216 were randomised to a control group. These trials involved cardiac surgery (n = 22) orthopaedic surgery (n = 12) and gynaecological surgery (n = 1). In aggregate, TXA treatment significantly reduced post-operative blood loss on average by around 247 mls per patient (MD -247.17 mls, 95% CI -294.76 to -199.58 mls). Heterogeneity between these trials was statistically significant (Chi² = 248.36, df = 34, P &lt;0.00001; I² = 86%).</P>
<P>A total of 28 trials of TXA versus control reported total blood loss data (intra-operative and post-operative blood loss combined). These trials included a total of 1712 patients, of whom 875 patients were randomised to TXA and 837 were randomised to a control group. These trials involved cardiac surgery (n = 6), orthopaedic surgery (n = 20), gynaecological surgery (n = 1) and liver surgery (n = 1). In aggregate, the use of TXA significantly reduced perioperative blood loss by around 414 mls per patient (MD -414.06 mls, 95% CI -525.19 to -302.92 mls). Heterogeneity between these trials was statistically significant (Chi² = 249.58, df = 27, P &lt;0.00001; I² = 89%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blood loss - cardiac surgery</HEADING>
<P>Four trials of TXA versus control involving cardiac surgery reported intra-operative blood loss data. These trials included a total of 244 patients, of whom 138 were randomised to TXA and 106 randomised to a control group. The use of TXA in cardiac surgery reduced intra-operative blood loss on average by around 167 mls per patient (MD -166.76 mls, 95% CI -331.24 to -2.27 mls). There is some evidence of statistical heterogeneity between these trials (Chi² = 5.36, df = 3, P = 0.15; I² = 44%).</P>
<P>Twenty-two trials of TXA versus control involving cardiac surgery reported post-operative blood loss data. These trials included a total of 1597 patients, of whom 827 were randomised to TXA and 770 were randomised to a control group. On average, TXA treatment reduced post-operative blood loss by around 273 mls per patient compared to control (MD -272.87 mls, 95% CI -328.85 to -216.89 mls). Heterogeneity between these trials was statistically significant (Chi² = 83.41, df = 21, P &lt;0.00001; I² = 75%).</P>
<P>Six trials of TXA versus control involving cardiac surgery reported total blood loss data (intra-operative and post-operative blood loss combined). These trials included a total of 391 patients, of whom 210 were randomised to TXA and 181 were randomised to a control group. TXA treatment reduced the total amount of blood lost during the perioperative period by around 300 mls per patient (MD -300.47 mls, 95% CI -470.74 to -130.21 mls). Heterogeneity between these trials was statistically significant (Chi² = 12.19, df = 5, P = 0.03; I² = 59%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blood loss - orthopaedic surgery</HEADING>
<P>Twelve trials of TXA versus control involving orthopaedic surgery reported intra-operative blood loss data. These trials included a total of 829 patients, of whom 411 were randomised to TXA and 418 were randomised to a control group. The use of TXA in orthopaedic surgery reduced intra-operative blood loss by around 116 mls per patient (MD -115.52 mls, 95% CI -187.88 to -43.16 mls). Heterogeneity between these trials was statistically significant (Chi² = 42.52, df = 11, P &lt;0.0001; I² = 74%).</P>
<P>Twelve trials of TXA versus control involving orthopaedic surgery reported post-operative blood loss data. These trials included a total of 804 patients, of whom 408 were randomised to TXA and 396 were randomised to a control group. On average, TXA treatment in orthopaedic surgery reduced post-operative blood loss by around 229 mls per patient (MD -228.52 mls, 95% CI -321.76 to -135.27 mls). Heterogeneity between these trials was statistically significant (Chi² = 125.01, df = 11, P &lt;0.00001; I² = 91%).</P>
<P>Twenty trials of TXA versus control involving orthopaedic surgery reported total blood loss data (intra-operative and post-operative blood loss combined). These trials included a total of 1201 patients, of whom 605 were randomised to TXA and 596 were randomised to a control group. The use of TXA in orthopaedic surgery significantly reduced the total amount of blood lost during the perioperative period (MD -446.19 mls, 95% CI -554.61 to -337.78 mls). Heterogeneity between these trials was statistically significant (Chi² = 85.30, df = 19, P &lt;0.00001; I² = 78%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Re-operation for bleeding</HEADING>
<P>Twenty-seven trials of TXA versus control reported data on re-operation for bleeding. These trials included a total of 2386 patients, of whom 1224 were randomised to TXA and 1162 were randomised to a control group. The use of TXA did not statistically significantly decrease the risk of re-operation for bleeding (RR 0.80, 95% CI 0.55 to 1.17). Heterogeneity between these trials was not statistically significant (Chi² = 12.66, df = 23, P = 0.96; I² = 0%). Of the 27 trials of TXA that reported data for this outcome 26 involved cardiac surgery. Therefore in the context of cardiac surgery the use of TXA did not statistically significantly reduce the risk of re-operation for bleeding (RR 0.79, 95% CI 0.54 to 1.17).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mortality</HEADING>
<P>Thirty trials of TXA versus control reported mortality data. These trials included a total of 2917 patients, of whom 1478 were randomised to TXA and 1439 were randomised to a control group. The use of TXA was not associated with an increased risk of death (RR 0.60, 95% CI 0.33 to 1.10). Heterogeneity between these trials was not statistically significant (Chi² = 10.00, df = 17, P = 0.90; I² = 0%). Of the 30 trials of TXA that reported data for mortality 23 involved cardiac surgery. The use of TXA in cardiac surgery was not associated with an increased risk of death (RR 0.58, 95% CI 0.26 to 1.28).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Myocardial infarction</HEADING>
<P>Twenty-one trials of TXA versus control reported data for myocardial infarction. These trials included a total of 2186 patients, of whom 1117 were randomised to TXA and 1069 were randomised to a control group who did not receive TXA. The use of TXA was not associated with an increased risk of myocardial infarction (RR 0.79, 95% CI 0.41 to 1.52). Heterogeneity between these trials was not statistically significant (Chi² = 7.84, df = 12, P = 0.80; I² = 0%). Of the 21 trials of TXA that reported data for myocardial infarction 19 involved cardiac surgery. The use of TXA in cardiac surgery did not increase the risk of myocardial infarction (RR 0.74, 95% CI 0.37 to 1.47).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Stroke</HEADING>
<P>Eighteen trials of TXA versus control reported data for stroke. These trials included a total of 2027 patients, of whom 1050 were randomised to TXA and 977 were randomised to a control group. The use of TXA was not associated with a statistically significant increase in the risk of stroke (RR 1.23, 95% CI 0.49 to 3.07). Heterogeneity between these trials was not statistically significant (Chi² = 3.18, df = 7, P = 0.87; I² = 0%). Of the 18 trials of TXA that reported data for this outcome 17 involved cardiac surgery. In this surgical setting the risk of stroke was not statistically significantly increased with the use of TXA (RR 1.44, 95% CI 0.53 to 3.91).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Deep vein thrombosis</HEADING>
<P>Twenty-three trials of TXA versus control reported data for deep vein thrombosis. These trials included a total of 1472, of whom 746 were randomised to TXA and 726 were randomised to a control group. TXA treatment did not appear to be associated with an increase in the risk of developing a DVT (RR 0.71, 95% CI 0.35 to 1.43). Heterogeneity between these trials was not statistically significant (Chi² = 5.71, df = 11, P = 0.89; I² = 0%). Of the 23 trials of TXA that reported data for DVT four involved cardiac surgery. Of the 422 patients that underwent cardiac surgical procedures two patients developed a DVT. These were single events occurring in the control arms of two separate trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Pulmonary embolism</HEADING>
<P>Fourteen trials of TXA versus control reported data for pulmonary embolism. These trials included a total of 1006 patients, of whom 527 were randomised to TXA and 479 were randomised to a control group who did not receive TXA. The use of TXA did not increase the risk of developing a pulmonary embolus (RR 0.67, 95% CI 0.23 to 1.99). Heterogeneity between these trials was not statistically significant (Chi² = 2.81, df = 7, P = 0.90; I² = 0%). Of the 16 trials that reported data for pulmonary embolism six involved cardiac surgery. Of the 569 patients that underwent cardiac surgical procedures only two patients developed a pulmonary embolus. As was the case with deep vein thrombosis these were single events occurring in the control arms of two separate trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Renal failure / dysfunction</HEADING>
<P>Nine trials of TXA versus control provided data for renal failure / dysfunction. These nine cardiac surgery trials included a total of 912 patients, of whom 454 were randomised to TXA and 458 were randomised to a control group. Treatment with TXA did not appear to increase the risk of developing renal failure or renal dysfunction (RR 0.89, 95% CI 0.33 to 2.37). Heterogeneity between these trials was not statistically significant (Chi² = 2.52, df = 6, P = 0.87; I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Hospital length of stay</HEADING>
<P>Ten trials of TXA versus control provided data for hospital length of stay. These trials included a total of 772 patients, of whom 379 were randomised to TXA and 393 were randomised to a control group. The use of TXA did not significantly impact on the length of hospital stay (MD -0.34 days, 95% CI -0.82 to 0.13 days). Heterogeneity between these trials was statistically significant (Chi² = 18.42, df = 9, P = 0.03; I² = 51%). For the five trials that involved cardiac surgery the use of TXA did not significantly reduce the length of hospital stay (MD -0.08 days, 95% CI -0.34 to 0.18 days).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Epsilon aminocaproic acid</HEADING>
<P>Sixteen trials of EACA versus control provided data on the number of patients exposed to allogeneic blood transfusion. These trials included a total of 1035 patients, of whom 530 were randomised to EACA and 505 were randomised to a control who did not receive EACA. The use of EACA significantly reduced the need for allogeneic blood transfusion by a relative 19% (RR 0.81, 95% CI 0.67 to 0.99). Heterogeneity between these trials was statistically significant (Chi² = 41.12, df = 15, P = 0.0003; I² = 64%). This represents an absolute risk reduction of 10% (RD -0.10, 95% CI -0.18 to -0.03).</P>
<SUBSECTION>
<HEADING LEVEL="4">Type of surgery</HEADING>
<P>Eleven trials of EACA versus control involved cardiac surgery. These trials included a total of 649 patients, of whom 338 were randomised to EACA and 311 were randomised to a control group. When used in cardiac surgery EACA reduced the need for allogeneic blood transfusion by a relative 30% (RR 0.70, 95% CI 0.52 to 0.93). There is some evidence of statistical heterogeneity between these trials (Chi² = 16.38, df = 10, P = 0.09; I² = 39%). Four trials of EACA versus control involved orthopaedic surgery. These trials included a total of 304 patients, of whom 150 were randomised to EACA and 154 patients were randomised to a control group. The use of EACA in orthopaedic surgery did not reduce the need for allogeneic blood transfusion compared to control (RR 1.00, 95% CI 0.93 to 1.08). Heterogeneity between these trials was not statistically significant (Chi² = 1.01, df = 3, P = 0.80; I² = 0%). One trial of EACA involved liver surgery. For this single trial the relative risk of requiring an allogeneic blood transfusion was 0.93 (95% CI 0.80 to 1.08).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Effect of transfusion protocols</HEADING>
<P>Of the 16 trials of EACA versus control that provided data for the number of patients exposed to allogeneic blood transfusion, 15 reported the use of a transfusion protocol to guide transfusion practice. Therefore stratification of the data by the presence or absence of a transfusion protocol was uninformative.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Volume of blood transfused</HEADING>
<P>Six trials of EACA versus control provided data for the volume of blood transfused in all patients. These trials included a total of 432 patients, of whom 215 were randomised to EACA and 217 were randomised to a control group who did not receive EACA. On average, the use of EACA reduced the volume of allogeneic blood transfused by 1.3 units per patient (MD -1.30 units, 95% CI -2.14 to -0.45 units). Heterogeneity between these trials was statistically significant (Chi² = 23.45, df = 5, P = 0.0003; I² = 79%). Three trials of EACA versus control provided data for the volume of blood transfused in those patients transfused. When the volume of allogeneic blood transfused was assessed in only those patients that actually received a blood transfusion the use of EACA did not reduce the amount of blood transfused (MD 0.22 units, 95% CI -0.34 to 0.79 units). Heterogeneity between these trials was not statistically significant (Chi² = 0.56, df = 2, P = 0.76; I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blood loss - all surgery combined</HEADING>
<P>Five trials of EACA versus control reported intra-operative blood loss data. These trials included a total of 353 patients, of whom 175 were randomised to EACA and 178 were randomised to a control group. These trials involved cardiac surgery (n = 2) and orthopaedic surgery (n = 3). In aggregate, EACA treatment reduced the amount of blood lost during the intra-operative period by around 157 mls per patient (MD -156.63 mls, 95% CI -276.92 to -36.33 mls). Heterogeneity between these trials was not statistically significant (Chi² = 5.01, df = 4, P = 0.29; I² = 20%).</P>
<P>Fourteen trials of EACA versus control reported post-operative blood loss data. These trials included a total of 1174 patients, of whom 580 were randomised to EACA and 594 were randomised to a control group. These trials involved cardiac surgery (n = 12) and orthopaedic surgery (n = 2). In aggregate, EACA treatment reduced post-operative blood loss on average by 207 mls per patient (MD -207.49 mls, 95% CI -276.43 to -138.54 mls). Heterogeneity between these trials was statistically significant (Chi² = 97.46, df = 13, P &lt; 0.00001; I² = 87%).</P>
<P>Two trials of EACA versus control reported total blood loss data (intra-operative and post-operative blood loss combined). These orthopaedic trials included a total of 92 patients, of whom 44 were randomised to EACA and 48 were randomised to a control group. The use of EACA in orthopaedic surgery was only marginally effective in reducing blood loss during the perioperative period (MD -299.69 mls, 95% CI -522.54 to -76.84 mls). Heterogeneity between these trials was not statistically significant (Chi² = 0.73, df = 1, P = 0.39; I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blood loss - cardiac surgery</HEADING>
<P>Two trials of EACA versus control involving cardiac surgery reported intra-operative blood loss data. These trials included a total of 79 patients, of whom 40 patients were randomised to EACA and 39 were randomised to a control group. On average, the use of EACA in cardiac surgery reduced the amount of blood lost during the intra-operative period by around 214 mls per patient (MD -213.58, 95% CI -310.03 to -117.13 mls). Heterogeneity between these trials was not statistically significant (Chi² = 0.12, df = 1, P = 0.73; I² = 0%).</P>
<P>Twelve trials of EACA versus control involving cardiac surgery reported post-operative blood loss data. These trials included a total of 946 patients, of whom 467 were randomised to EACA and 479 were randomised to control group who did not receive EACA treatment. The use of EACA in cardiac surgery reduced the amount of blood lost during the post-operative period on average by around 200 mls per patient (MD -200.27 mls, 95% CI -273.44 to -127.09 mls). Heterogeneity between these trials was statistically significant (Chi² = 97.18, df = 11, P &lt;0.00001, I² = 89%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blood loss - orthopaedic surgery</HEADING>
<P>Three trials of EACA versus control involving orthopaedic surgery provided intra-operative blood loss data. These trials included a total of 274 patients, of whom 135 were randomised to EACA and 139 were randomised to a control group. EACA treatment in orthopaedic surgery did not reduce the amount of blood lost during the intra-operative period (MD -40.66 mls, 95% CI -236.71 to 155.38 mls). Heterogeneity between these trials was not statistically significant (Chi² = 2.10, df = 2, P = 0.35; I² = 5%).</P>
<P>Two trials of EACA versus control involving orthopaedic surgery reported post-operative blood loss. These trials included a total of 228 patients, of whom 113 were randomised to EACA and 115 were randomised to a control group. The use of EACA in orthopaedic surgery reduced blood loss during the post-operative period by around 285 mls per patient (MD -285.06 mls, 95% CI -452.73 to -117.39 mls). Heterogeneity between these trials was not statistically significant (Chi² = 0.18, df = 1, P = 0.67; I² = 0%).</P>
<P>Two trials of EACA versus control involving orthopaedic surgery reported total blood loss data (intra-operative and post-operative blood loss combined). These trials included a total of 92 patients, of whom 44 were randomised to EACA and 48 were randomised to a control group. The use of EACA in orthopaedic surgery reduced blood loss during the perioperative period by around 300 mls per patient (MD -299.69 mls, 95% CI -522.54 to -76.84 mls). Heterogeneity between these trials was not statistically significant (Chi² = 0.73, df = 1, P = 0.39; I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Re-operation for bleeding</HEADING>
<P>Eight trials of EACA versus control reported data on the number of patients requiring re-operation for bleeding. These trials included a total of 922 patients, of whom 470 were randomised to EACA and 452 were randomised to a control group. The use of EACA was not associated with an increased risk of re-operation compared to control (RR 0.32, 95% CI 0.11 to 0.99). Heterogeneity between these trials was not statistically significant (Chi² = 1.84, df = 5, P = 0.87, I² = 0%). Of the eight trials of EACA that reported data on re-operations, seven involved cardiac surgery. In this surgical setting the use of EACA did not increase the risk of re-operation (RR 0.35, 95% CI 0.11 to 1.17).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mortality</HEADING>
<P>Eight trials of EACA versus control reported data on mortality. These trials included a total of 988 patients, of whom 504 were randomised to EACA and 484 were randomised to a control group. The use of EACA was not associated with a statistically significant increased risk of death compared to control (RR 1.07, 95% CI 0.44 to 2.57). Heterogeneity between these trials was not statistically significant (Chi² = 2.30, df = 5, P = 0.81; I² = 0%). Of the eight trials of EACA that reported data on mortality six involved cardiac surgery. In this surgical setting the use of EACA did not statistically significantly increase the risk of death (RR 1.65, 95% CI 0.50 to 5.43).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Myocardial infarction</HEADING>
<P>Seven trials of EACA versus control reported data for myocardial infarction. These trials included a total of 896 patients, of whom 456 were randomised to EACA and 440 were randomised to a control group. The use of EACA was not associated with an increased risk of myocardial infarction compared to control (RR 0.88, 95% CI 0.48 to 1.63). Heterogeneity between these trials was not statistically significant (Chi² = 3.44, df = 4, P = 0.49; I² = 0%). Of the seven trials of EACA that reported data on myocardial infarction six involved cardiac surgery. In this surgical setting the use of EACA did not increase the risk of myocardial infarction (RR 0.88, 95% CI 0.48 to 1.63).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Stroke</HEADING>
<P>Eight trials of EACA versus control reported data for stroke. These trials included a total of 936 patients, of whom 477 were randomised to EACA and 459 were randomised to a control group. The use of EACA was not associated with an increased risk of stroke compared to control (RR 0.62 95% CI 0.16 to 2.36). Heterogeneity between these trials was not statistically significant (Chi² = 1.84, df = 4, P = 0.77; I² = 0%). Of the eight trials of EACA that reported data on stroke, seven involved cardiac surgery. In this surgical setting the use of EACA did not increase the risk of stroke (RR 0.70, 95% CI 0.16 to 3.10).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Deep vein thrombosis</HEADING>
<P>Four trials of EACA versus control reported data for DVT. These trials included a total of 304 patients, of whom 150 were randomised to EACA and 154 were randomised to a control group. The use of EACA was not associated with an increased risk of DVT compared to control (RR 0.78, 95% CI 0.20 to 3.03). Heterogeneity between these trials was not statistically significant (Chi² = 1.02, df = 1, P = 0.31; I² = 2%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Pulmonary embolism</HEADING>
<P>Three trials of EACA versus control provided data for pulmonary embolism. These trials included a total of 274 patients, of whom 135 were randomised to EACA and 139 were randomised to a control group. The use of EACA was not associated with an increased risk of pulmonary embolism compared to control (RR 0.34, 95% CI 0.06 to 2.13). Heterogeneity between these trials was not statistically significant (Chi² = 0.00, df = 1, P = 0.97; I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Renal failure / dysfunction</HEADING>
<P>Two trials of EACA versus control reported data for renal failure / dysfunction. These trials included a total of 235 patients, of whom 117 were randomised to EACA and 118 were randomised to a control group. The use of EACA was not associated with an increased risk of renal failure / dysfunction (RR 0.41, 95% CI 0.14 to 1.22). Heterogeneity between these trials was not statistically significant (Chi² = 0.48, df = 1, P = 0.49; I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Hospital length of stay</HEADING>
<P>Two trials of EACA versus control reported data for hospital length of stay. These trial included a total of 228 patients, of whom 113 were randomised to EACA and 115 were randomised to a control group. The use of EACA did not impact of the length of hospital stay (MD 0.58 days, 95% CI -3.17 to 4.33 days). Heterogeneity between these trials was statistically significant (Chi² = 3.13, df = 1, P = 0.08; I² = 68%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Aprotinin versus tranexamic acid</HEADING>
<P>Twenty-one trials of aprotinin versus TXA reported data on the number of patients exposed to allogeneic blood transfusion. These trials included a total of 4185 patients, of whom 2124 were randomised to aprotinin and 2061 were randomised to TXA. There was no statistically significant difference in the rates of allogeneic blood transfusion between those patients treated with aprotinin compared to those treated with TXA (RR 0.90, 95% CI 0.81 to 1.01). Heterogeneity between these trials was statistically significant (Chi² = 60.78, df = 20, P &lt;0.0001; I² = 67%). The effect with 
<LINK REF="STD-Mengistu-2008" TYPE="STUDY">Mengistu 2008</LINK> excluded was RR 0.92 (95% CI 0.82 to 1.02).
</P>
<SUBSECTION>
<HEADING LEVEL="4">Type of surgery</HEADING>
<P>Eighteen of the 21 trials of aprotinin versus TXA that reported data on the number patients exposed to allogeneic blood transfusion involved cardiac surgery. These trials included a total of 3983 patients, of whom 2025 were randomised to aprotinin and 1958 were randomised to TXA. Compared to TXA, aprotinin reduced the rate of allogeneic blood transfusion (RR 0.87, 95% CI 0.76 to 0.99). Heterogeneity between these trials was statistically significant (Chi² = 45.01, df = 17, P = 0.0002; I² = 62%). When data from 
<LINK REF="STD-Mengistu-2008" TYPE="STUDY">Mengistu 2008</LINK> were excluded, RR was 0.88 (95% CI 0.78 to 1.01).
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Effect of transfusion protocols</HEADING>
<P>Of the 21 trials of aprotinin versus TXA that reported data on the number patients exposed to allogeneic blood transfusion, all but one reported the use of a transfusion protocol to guide transfusion practice. Therefore stratification of the data by the presence or absence of a transfusion protocol proved uninformative.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Volume of blood transfused</HEADING>
<P>Ten trials of aprotinin versus TXA provided data on the volume of allogeneic blood transfused in all patients. These trials included a total of 992 patients, of whom 496 were randomised to aprotinin and 496 were randomised to TXA. There was a small but statistically significant difference between aprotinin and TXA in the volume of allogeneic blood transfused (MD -0.24 units, 95% CI -0.45 to -0.04 units). Heterogeneity between these trials was not statistically significant (Chi² = 10.87, df = 9; P = 0.28; I² = 17%). (When data from 
<LINK REF="STD-Mengistu-2008" TYPE="STUDY">Mengistu 2008</LINK> were removed, MD was -0.21 units, 95% CI -0.39 to -0.02 units). Six trials of aprotinin versus TXA provided data on the volume of allogeneic blood transfused in those patients transfused. These trials provided data for 207 transfused patients, of whom 97 were treated with aprotinin and 110 were treated with TXA. There was no statistically significant difference between aprotinin and TXA in the volume of allogeneic blood transfused in those patients transfused (MD -0.07 units, 95% CI -0.44 to 0.30 units). Heterogeneity between these trials was not statistically significant (Chi² = 0.97, df = 5, P = 0.97; I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blood loss</HEADING>
<P>Thirteen trials of aprotinin versus TXA involving cardiac surgery provided data for post-operative blood loss. These trials included a total of 831 patients, of whom 412 were randomised to aprotinin and 419 were randomised to TXA. On average, aprotinin appeared to be more effective in reducing post-operative blood loss than TXA (MD -145.81 mls, 95% CI -209.99 to -81.62 mls). Heterogeneity between these trials was statistically significant (Chi² = 33.86, df = 12, P = 0.0007; I² = 65%). (When data from 
<LINK REF="STD-Mengistu-2008" TYPE="STUDY">Mengistu 2008</LINK> were removed, MD was -131.54 mls, 95% CI -192.15 to -70.94 mls.) 
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Re-operation for bleeding</HEADING>
<P>Seventeen trials of aprotinin versus TXA provided data on the number of patients requiring re-operation for bleeding. These trials included a total of 4010 patients, of whom 2005 were randomised to aprotinin and 2005 were randomised to TXA. Aprotinin appeared to reduce the need for re-operation compared to TXA (RR 0.69, 95% CI 0.51 to 0.93). Heterogeneity between these trials was not statistically significant (Chi² = 8.90, df = 13, P = 0.78; I² = 0%). The BART study (<LINK REF="STD-Fergusson-2008" TYPE="STUDY">Fergusson 2008</LINK>) provided 61.4% (weight) of the information for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mortality</HEADING>
<P>Seventeen trials of aprotinin versus TXA reported mortality data. These trials included a total of 4130 patients, of whom 2060 were randomised to aprotinin and 2070 were randomised to TXA. There was no statistically significant difference between aprotinin and TXA (RR 1.35, 95% CI 0.94 to 1.93). Heterogeneity between these trials was not statistically significant (Chi² = 6.78, df = 9, P = 0.66, I² = 0%). BART study data (<LINK REF="STD-Fergusson-2008" TYPE="STUDY">Fergusson 2008</LINK>) dominated the analysis of this outcome (65.5% weight).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Myocardial infarction</HEADING>
<P>Thirteen trials of aprotinin versus TXA reported data for myocardial infarction. These trials included a total of 3574 patients, of whom 1778 were randomised to aprotinin and 1796 were randomised to TXA. There was statistically significant difference between aprotinin and TXA (RR 1.00, 95% CI 0.71 to 1.42). Heterogeneity between these trials was not statistically significant (Chi² = 6.18, df = 10, P = 0.80; I² = 0%). The BART study (<LINK REF="STD-Fergusson-2008" TYPE="STUDY">Fergusson 2008</LINK>) provided 49.6% (weight) of the information for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Stroke</HEADING>
<P>Six trials of aprotinin versus TXA reported data for stroke. These trials include a total of 2030 patients of whom 1017 were randomised to aprotinin and 1013 were randomised to TXA. There was no statistically significant difference between aprotinin and TXA (RR 0.88, 95% CI 0.52 to 1.47). Heterogeneity between these trials was not statistically significant (Chi² = 1.91, df = 4, P = 0.75; I² = 0%). BART study data (<LINK REF="STD-Fergusson-2008" TYPE="STUDY">Fergusson 2008</LINK>) dominated the analysis of this outcome (88.5% weight).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Renal failure / dysfunction</HEADING>
<P>Six trials of aprotinin versus TXA reported data for renal failure / dysfunction. These trials included a total of 2238 patients, of whom 1119 were randomised to aprotinin and 1119 were randomised to TXA. There was no statistically significant difference between aprotinin and TXA (RR 1.02, 95% CI 0.79 to 1.31). Heterogeneity between these trials was not statistically significant (Chi² = 1.20, df = 3, P = 0.75; I² = 0%). BART study data (<LINK REF="STD-Fergusson-2008" TYPE="STUDY">Fergusson 2008</LINK>) dominated the analysis of this outcome (94.5% weight).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Hospital length of stay</HEADING>
<P>Six trials of aprotinin versus TXA reported data for hospital length of stay. These trials include a total of 2174 patients, of whom 1090 were randomised to aprotinin and 1084 were randomised to TXA. There was no statistically significant difference between aprotinin and TXA (MD -0.05, 95% CI -0.92 to 0.83 days). There was some evidence of statistical heterogeneity between these trials (Chi² = 9.14, df = 5, P = 0.10; I² = 45%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Aprotinin versus epsilon aminocaproic acid</HEADING>
<P>Twelve trials of aprotinin versus EACA reported data on the number of patients exposed to allogeneic blood transfusion. These trials included a total of 2200 patients, of whom 1102 were randomised to aprotinin and 1098 were randomised to EACA. The use of aprotinin significantly reduced the rate of allogeneic blood transfusion compared to EACA (RR 0.82, 95% CI 0.76 to 0.89). Heterogeneity between these trials was not statistically significant (Chi² = 9.33, df = 11, P = 0.59; I² = 0%).</P>
<SUBSECTION>
<HEADING LEVEL="4">Type of surgery</HEADING>
<P>Of the 12 trials of aprotinin versus EACA that reported data on the number of patients exposed to allogeneic blood transfusion, 10 involved cardiac surgery and two involved orthopaedic surgery. Compared to EACA, aprotinin reduced the rate of allogenic blood transfusion in cardiac surgery (RR 0.82, 95% CI 0.76 to 0.89) but not in orthopaedic surgery (RR 0.82, 95% CI 0.48 to 1.40).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Effect of transfusion protocols</HEADING>
<P>Of the 12 trials of aprotinin versus EACA that reported data on the number of patients exposed to allogeneic blood transfusion, nine reported the use of a transfusion protocol to guide transfusion practice and three did not. For the nine trials that reported the use of a transfusion protocol, aprotinin reduced the rate of allogeneic blood transfusions compared to EACA by a relative 18% (RR 0.82, 95% CI 0.76 to 0.89). Heterogeneity between these trials was not statistically significant (Chi² = 6.45, df = 8, P = 0.60; I² = 0%). For those trials that did not report the use of a transfusion protocol there was no statistically significant difference aprotinin and EACA (RR 0.78, 95% CI 0.47 to 1.31). Heterogeneity between these trials was not statistically significant (Chi² = 2.86, df = 2, P = 0.24; I² = 30%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Volume of blood transfused</HEADING>
<P>Five trials of aprotinin versus EACA reported data for the volume of allogeneic blood transfused in all patients. These trials included a total of 329 patients, of whom 166 were randomised to aprotinin and 163 were randomised to EACA. There was no statistically significant difference between aprotinin and EACA (MD -0.21 units, 95% CI -0.55 to 0.14 units). Heterogeneity between these trials was not statistically significant (Chi² = 5.14, df = 4, P = 0.27; I² = 22%). Two trials of aprotinin versus EACA provided data for the volume of allogeneic blood transfused in those patients transfused. These trials included a total of 63 transfused patients, of whom 28 were treated with aprotinin and 35 were treated with EACA. There was no statistically significant difference between aprotinin and EACA treatment (MD -0.18 units, 95% CI -0.63 to 0.28 units). Heterogeneity between these trials was not statistically significant (Chi² = 0.66, df = 1, P = 0.41; I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blood loss</HEADING>
<P>There were seven trials of aprotinin versus EACA involving cardiac surgery that reported post-operative blood loss data. These trials included a total of 454 patients, of whom 230 were randomised to aprotinin and 224 were randomised to EACA. Aprotinin appeared to be marginally more effective in reducing post-operative blood loss than EACA (MD -111.43 mls, 95% CI -220.64 to -2.21 mls). Heterogeneity between these trials was statistically significant (Chi² = 25.74, df = 6, P = 0.0002; I² = 77%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Re-operation for bleeding</HEADING>
<P>Six trials of aprotinin versus EACA reported data on the number of patients requiring re-operation for bleeding. These trials included a total of 2075 patients, of whom 1034 were randomised to aprotinin and 1041 were randomised to EACA. Although aprotinin appeared to be more effective than EACA in reducing the number patients requiring re-operation due to bleeding the difference did not reach statistical significance (RR 0.70, 95% CI 0.49 to 1.00). Heterogeneity between these trials was not statistically significant (Chi² = 0.93, df = 2, P = 0.63; I² = 0%). However, the data from the BART study (<LINK REF="STD-Fergusson-2008" TYPE="STUDY">Fergusson 2008</LINK>) provided 90.1% of the information (weight) for this outcome. The results of this one trial showed that aprotinin was statistically significantly more effective than EACA in reducing the risk of re-operation for bleeding (RR 0.67, 95% CI 0.46 to 0.98).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mortality</HEADING>
<P>There were five trials of aprotinin versus EACA that reported mortality data. These trials included a total of 1891 patients, of whom 949 were randomised to aprotinin and 942 were randomised to EACA. Although the result failed to reach statistical significance, there appeared to be a trend toward an increased risk of death in the aprotinin group compared to EACA (RR 1.51, 95% CI 0.99 to 2.30). Again, the results of the BART study (<LINK REF="STD-Fergusson-2008" TYPE="STUDY">Fergusson 2008</LINK>) provided most of the information for this outcome (89.9% weight). Heterogeneity between these trials was not statistically significant (Chi² = 0.26, df = 3, P = 0.97; I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Myocardial infarction</HEADING>
<P>Four trials of aprotinin versus EACA reported data for myocardial infarction. These trials included a total of 1676 patients, of whom 830 were randomised to aprotinin and 846 were randomised to EACA. There was no statistically significant difference in the risk of myocardial infarction between aprotinin and EACA (RR 1.42, 95% CI 0.90 to 2.22). Heterogeneity between these trials was not statistically significant (Chi² = 1.27, df = 3, P = 0.74; I² = 0%). Data from the BART study (<LINK REF="STD-Fergusson-2008" TYPE="STUDY">Fergusson 2008</LINK>) dominated this outcome (68.2% weight).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Stroke</HEADING>
<P>Two trials of aprotinin versus EACA reported data for stroke (cerebrovascular accident). These trials included a total of 1578 patients, of whom 785 were randomised to aprotinin and 793 were randomised to EACA. There was no difference in the risk of stroke between aprotinin and EACA (RR 1.05, 95% CI 0.60 to 1.85). Heterogeneity between these trials was not statistically significant (Chi² = 0.27, df = 1, P = 0.60; I² = 0%). The BART study (<LINK REF="STD-Fergusson-2008" TYPE="STUDY">Fergusson 2008</LINK>) results provided 94.2% of the information for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Deep vein thrombosis</HEADING>
<P>Four trials of aprotinin versus EACA reported data for deep vein thrombosis. These trials included a total of 300 patients, of whom 153 were randomised to aprotinin and 147 were randomised to EACA. One trial reported three cases of DVT all of which occurred in EACA treated patients (RR 0.14, 95% CI 0.01 to 2.51). There were no reported cases of DVT in the three remaining trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Pulmonary embolism</HEADING>
<P>Three trials of aprotinin versus EACA reported data for pulmonary embolism. These trials included a total of 270 patients, of whom 138 were randomised to aprotinin and 132 were randomised to EACA. Three events of pulmonary embolism were reported; two in aprotinin treated patients and one in EACA treated patients. There was no statistically significant difference between aprotinin and EACA treatment (RR 1.33, 95% CI 0.10 to 18.42). Heterogeneity between these trials was not statistically significant (Chi² = 1.45, df = 1, P = 0.23; I² = 31%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Renal failure / dysfunction</HEADING>
<P>Two trials of aprotinin versus EACA reported data for renal failure / dysfunction. These trials included a total of 1595 patients, of whom796 were randomised to aprotinin and 799 were randomised to EACA. Although the analysis was dominated by the data from the BART study (71.6% weight) there was no statistically significant difference between aprotinin and EACA in the number patients experiencing renal failure / dysfunction (RR 1.33, 95% CI 0.59 to 2.99). Heterogeneity between these trials was moderate (Chi² = 2.12, df = 1, P = 0.15; I² = 53%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Hospital length of stay</HEADING>
<P>Two trials of aprotinin versus EACA reported data for hospital length of stay. These trials included a total of 1605 patients, of whom 803 were randomised to aprotinin and 802 patients were randomised to EACA. There was no statistically significant difference between aprotinin and EACA (MD -0.49 days, 95% CI -1.74 to 0.77 days).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Tranexamic acid versus epsilon aminocaproic acid</HEADING>
<P>Eight trials provided direct 'head-to-head' comparisons of TXA and EACA and reported data on the number of patients exposed to allogeneic blood transfusion. These trials included a total of 2003 patients, of whom 1000 were randomised to TXA and 1003 were randomised to EACA. There was no statistically significant difference between TXA and EACA in the rates of allogeneic blood transfusion (RR 0.97, 95% CI 0.77 to 1.21). Heterogeneity between these trials was statistically significant (Chi² = 14.01, df = 7, P = 0.05; I² = 50%). All eight trials included in this analysis reported the use of a transfusion protocol to guide transfusion practice. Six of the eight trials included in this analysis involved cardiac surgery. A subgroup analysis of the data from these cardiac trials showed that the relative risk of receiving an allogeneic blood transfusion in patients treated with TXA compared to patients treated with EACA was 1.07 (95% CI 0.79 to 1.46).</P>
<SUBSECTION>
<HEADING LEVEL="4">Volume of blood transfused</HEADING>
<P>Three trials of TXA versus EACA provided data for the volume of allogeneic blood transfused in all patients. These trials included a total of 268 patients, of whom 136 were randomised to TXA and 132 were randomised to EACA. There was no statistically significant difference between TXA and EACA (MD -0.28 units, 95% CI -0.59 to 0.03 units). Heterogeneity between these trials was not statistically significant (Chi² = 0.96, df = 2, P = 0.62; I² = 0%). Four trials of TXA versus EACA provided data for the volume of allogeneic blood transfused to those patients transfused. These trials included a total of 133 patients, of whom 59 were randomised to TXA and 74 were randomised to EACA. Again there was no statistically significant difference between TXA and EACA treatment (MD -0.34 units, 95% CI -0.74 to 0.07 units). Heterogeneity between these trials was not statistically significant (Chi² = 0.12, df = 2, P = 0.94; I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blood loss</HEADING>
<P>Six trials of TXA versus EACA involving cardiac surgery reported post-operative blood loss data. These trials included a total of 402 patients, of whom 209 were randomised to TXA and 193 were randomised to EACA. There was no difference between TXA and EACA in the volume of blood lost during the post-operative period (MD -4.36 mls, 95% CI -163.35 to 154.63 mls). Heterogeneity between these trials was statistically significant (Chi² = 33.81, df = 5, P &lt;0.00001; I² = 85%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Re-operation for bleeding</HEADING>
<P>Five trials of TXA versus EACA provided data on re-operation for bleeding. These trials included a total of 1853 patients, of whom 922 were randomised to TXA and 931 were randomised to EACA. There was no statistically significant difference between TXA and EACA (RR 1.00, 95% CI 0.73 to 1.39). Heterogeneity between these trials was not statistically significant (Chi² = 1.81, df = 3, P = 0.61; I² = 0%). The data of the BART study (<LINK REF="STD-Fergusson-2008" TYPE="STUDY">Fergusson 2008</LINK>) dominated the results of this analysis (93.4% weight).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mortality</HEADING>
<P>Five trials of TXA versus EACA provided mortality data. These trials included a total of 1958 patients, of whom 980 were randomised to TXA and 978 were randomised to EACA. There was no statistically significant difference between TXA and EACA (RR 0.93, 95% CI 0.59 to 1.47). Heterogeneity between these trials was not statistically significant (Chi² = 1.43, df = 3, P = 0.70; I² = 0%).The data of the BART study (<LINK REF="STD-Fergusson-2008" TYPE="STUDY">Fergusson 2008</LINK>) dominated the results of this analysis (86.8% weight).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Myocardial infarction</HEADING>
<P>Three trials of TXA versus EACA reported data for myocardial infarction. These trials included a total of 1687 patients, of whom 840 were randomised to TXA and 847 were randomised to EACA. There was no statistically significant difference between TXA and EACA (RR 1.33, 95% CI 0.80 to 2.23). Heterogeneity between these trials was not statistically significant (Chi² = 0.62, df = 2, P = 0.73; I² = 0%). The data of the BART study (<LINK REF="STD-Fergusson-2008" TYPE="STUDY">Fergusson 2008</LINK>) dominated the results of this analysis (82.9% weight).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Stroke</HEADING>
<P>Three trials of TXA versus EACA reported data for stroke (cerebrovascular accident). These trials included a total of 1658 patients, of whom 820 were randomised to TXA and 838 were randomised to EACA. There was no statistically significant difference between TXA and EACA (RR 1.33, 95% CI 0.78 to 2.29). Heterogeneity between these trials was not statistically significant (Chi² = 0.30, df = 1, P = 0.58; I² = 0%). The data of the BART study (<LINK REF="STD-Fergusson-2008" TYPE="STUDY">Fergusson 2008</LINK>) provided 97.1% (weight) of the information for this analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Pulmonary embolism</HEADING>
<P>Three trials of TXA versus EACA reported data for pulmonary embolism. These trials included a total of 284 patients, of whom 150 were randomised to TXA and 134 were randomised to EACA. There was only one reported case of pulmonary embolism, this occurred in EACA treated patients.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Renal failure / dysfunction</HEADING>
<P>Only the BART study (<LINK REF="STD-Fergusson-2008" TYPE="STUDY">Fergusson 2008</LINK>) provided data on renal failure / dysfunction in patients treated with either TXA or EACA. The results of the BART study showed that there was no statistically significant difference between TXA and EACA in the rates of patients experiencing renal failure / dysfunction (RR 0.98, 95% CI 0.76 to 1.27).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Hospital length of stay</HEADING>
<P>Only the BART study (<LINK REF="STD-Fergusson-2008" TYPE="STUDY">Fergusson 2008</LINK>) hospital length of stay data in patients treated with either TXA or EACA. The results of the BART study showed that there was no statistically significant difference between TXA and EACA in the length of hospital stay (MD -0.64 days, 95% CI -1.82 to 0.54 days).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Aprotinin versus either lysine analogue</HEADING>
<P>Thirty trials of aprotinin versus either TXA or EACA provided data on the number of patients exposed to allogeneic blood transfusion. These trials included a total of 5566 patients, of whom 2407 were randomised to aprotinin and 3159 were randomised to a lysine analogue. The use of aprotinin reduced the need for allogeneic blood transfusion by a relative 10% (RR 0.90, 95% CI 0.81 to 0.99). Heterogeneity between these trials was statistically significant (Chi² = 70.06, df = 29 (P &lt; 0.0001; I² = 59%). (When data from 
<LINK REF="STD-Mengistu-2008" TYPE="STUDY">Mengistu 2008</LINK> were removed, RR was 0.91 (95% CI 0.82 to 1.00).)
</P>
<P>In view of the importance of the data on death and myocardial infarction we compared aprotinin with either tranexamic acid or aminocaproic acid. There were nineteen trials that reported on mortality. Of 2115 subjects randomised to aprotinin 71 died, compared with 85 of 3012 randomised to either lysine analogue. The increase in mortality with aprotinin was statistically significant (RR 1.39, 95% CI 1.02 to 1.89). Seventy percent of the statistical weight came from the Bart trial (<LINK REF="STD-Fergusson-2008" TYPE="STUDY">Fergusson 2008</LINK>). In contrast, there was no significant increase in the risk of myocardial infarction with aprotinin compared with either lysine analogue (RR 1.11, 95% CI 0.82 to 1.50).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Impact of trial quality</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Aprotinin</HEADING>
<P>Of the 108 trials of aprotinin that provided data on the number of patients exposed to allogeneic blood transfusion, 33 trials were assessed as having adequate allocation concealment of treatment schedule. For these 33 trials the use of aprotinin reduced the rate of allogeneic blood transfusion by a relative 36% (RR 0.64, 95% CI 0.53 to 0.79). Heterogeneity between these trials was statistically significant (Chi² = 665.70, df = 32, P &lt;0.00001; I² = 95%). In the 63 trials where there was uncertainty regarding the method of allocation concealment (Unclear), the use of aprotinin reduced the rate of allogeneic blood transfusion by a relative 31% (RR 0.69, 95% CI 0.64 to 0.75). Heterogeneity between these trials was statistically significant (Chi² = 179.31, df = 62, P &lt;0.00001; I² = 65%). In the remaining 12 trials where the method of allocation concealment was assessed as being inadequate (No), the use of aprotinin reduced the rate of allogeneic blood transfusion by a relative 37% (RR 0.63, 95% CI 0.54 to 0.75). Heterogeneity between these trials was not statistically significant (Chi² = 15.50, df = 11, P = 0.16; I² = 29%). These data indicate the effects of aprotinin were not significantly greater in those studies that reported inferior techniques for concealing the randomisation sequence.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tranexamic acid</HEADING>
<P>Of the 65 trials of TXA that provided data on the number of patients exposed to allogeneic blood transfusion, 28 were assessed as having adequate allocation concealment of treatment schedule. For these 28 trials the use of TXA reduced the rate of allogeneic blood transfusion by a relative 41% (RR 0.59, 95% CI 0.51 to 0.69). Heterogeneity between these trials was statistically significant (Chi² = 41.35, df = 27, P = 0.04; I² = 35%). In the 24 trials where there was uncertainty regarding the method of allocation concealment (Unclear), the use of TXA reduced the rate of allogeneic blood transfusion by a relative 47% (RR 0.53, 95% CI 0.37 to 0.76). Heterogeneity between these trials was statistically significant (Chi² = 209.62, df = 23, P &lt;0.00001; I² = 89%). In the remaining 13 trials where the method of allocation concealment was assessed as being inadequate (No), the use of TXA reduced the rate of allogeneic blood transfusion by a relative 27% (RR 0.73, 95% CI 0.62 to 0.86). Heterogeneity between these trials was not statistically significant (Chi² = 16.38, df = 11 (P = 0.13), I² = 33%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Epsilon aminocaproic acid</HEADING>
<P>Of the 16 trials that provided data on the number of patients exposed to allogeneic blood transfusion, five were assessed as having adequate allocation concealment of treatment schedule. For these trials the use of EACA did not statistically significantly reduce the rate of allogeneic blood transfusion (RR 0.82, 95% CI 0.58 to 1.16). Heterogeneity between trials was statistically significant (Chi² = 14.35, df = 4, P = 0.006; I² = 72%). In the nine trials where there was uncertainty regarding the method of allocation concealment (Unclear), the use of EACA did not statistically significantly reduce the rate of allogeneic blood transfusion (RR 0.68, 95% CI 0.46 to 1.03). Heterogeneity between trials was not statistically significant (Chi² = 12.54, df = 8, P = 0.13; I² = 36%). In the remaining two trials where the method of allocation concealment was assessed as being inadequate (No), the use of EACA did not statistically significantly reduce the rate of allogeneic blood transfusion (RR 0.93, 95% CI 0.81 to 1.08). Heterogeneity between these trials was not statistically significant (Chi² = 0.13, df = 1, P = 0.72; I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aprotinin versus tranexamic acid</HEADING>
<P>Of the 21 trials that compared aprotinin to TXA, four were assessed as having adequate allocation concealment of treatment schedule. For these trials the RR of receiving an allogeneic blood transfusion in those patients treated with aprotinin compared to those patients treated with TXA was 0.80 (95% CI 0.69 to 0.92). Heterogeneity between these trials was not statistically significant (Chi² = 3.60, df = 3, P = 0.31; I² = 17%). In the 13 trials where there was uncertainty regarding the method of allocation concealment (Unclear), the RR of receiving an allogeneic blood transfusion was statistically significantly different between aprotinin and TXA (RR 0.97, 95% CI 0.88 to 1.07). Heterogeneity between these trials was not statistically significant (Chi² = 19.25, df = 12, P = 0.08; I² = 38%). (When 
<LINK REF="STD-Mengistu-2008" TYPE="STUDY">Mengistu 2008</LINK> was removed from the analysis RR was 0.99 (95% CI 0.91 to 1.08). In the remaining four trials where the method of allocation concealment was assessed as being inadequate (No), the RR of receiving an allogeneic blood transfusion was not statistically significantly different between aprotinin treated patients and TXA treated patients (RR 0.93, 95% CI 0.62 to 1.39). Heterogeneity between these trials was statistically significant (Chi² = 10.29, df = 3, P = 0.02; I² = 71%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aprotinin versus epsilon aminocaproic acid</HEADING>
<P>Of the 12 trials of aprotinin versus EACA that were assessed for methodological quality, three were assessed as having adequate allocation concealment. For these trials the RR of receiving an allogeneic blood transfusion in those patients treated with aprotinin compared to those patients treated with EACA was 0.86 (95%CI 0.71 to 1.05). Heterogeneity between these trials was not statistically significant (Chi² = 2.75, df = 2, P = 0.25; I² = 27%). For eight trials there was uncertainty regarding the method of allocation concealment (Unclear), the RR of receiving an allogeneic blood transfusion was not statistically significantly different between aprotinin and EACA (RR 0.76, 95% CI 0.58 to 0.99). Heterogeneity between these trials was not statistically significant (Chi² = 6.19, df = 7, P = 0.52; I² = 0%). For one trial the method of allocation concealment was assessed as being inadequate (No).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tranexamic acid versus epsilon aminocaproic acid</HEADING>
<P>Of the eight trials of TXA versus EACA that were assessed for methodological quality, one trial was assessed as having adequate allocation concealment (Yes). For five trials there was uncertainty regarding the method of allocation concealment (Unclear), and for two trials the method of allocation concealment was assessed as being inadequate (No). There were too few trials to formally assess the impact that methodological quality had on treatment effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aprotinin versus lysine analogues (TXA and EACA combined)</HEADING>
<P>Of the 29 trials that compared aprotinin to the lysine analogues, six were assessed as having adequate allocation concealment of treatment schedule. For these trials the RR of receiving an allogeneic blood transfusion in those patients treated with aprotinin compared to those patients treated with a lysine analogue was 0.82 (95% CI 0.71 to 0.95). Heterogeneity between these trials was not statistically significant (Chi² = 6.44, df = 3, P = 0.27; I² = 22%). In the 18 trials where there was uncertainty regarding the method of allocation concealment (Unclear), the RR of receiving an allogeneic blood transfusion was not statistically significantly different between aprotinin and the lysine analogues (RR 0.95, 95% CI 0.86 to 1.04). Heterogeneity between these trials was not statistically significant (Chi² = 26.77, df = 18, P = 0.08; I² = 33%). (When data from 
<LINK REF="STD-Mengistu-2008" TYPE="STUDY">Mengistu 2008</LINK> were removed, RR was 0.97 (95% CI 0.89 to 1.06).) In the remaining five trials where the method of allocation concealment was assessed as being inadequate (No), the RR of receiving an allogeneic blood transfusion was not statistically significantly different between aprotinin treated patients and lysine analogue treated patients (RR 0.92, 95% CI 0.67 to 1.28). Heterogeneity between these trials was statistically significant (Chi² = 10.34, df = 4, P = 0.04; I² = 61%).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-12-07 16:25:15 +0000" MODIFIED_BY="Emma M Sydenham">
<P>This systematic review of the three anti-fibrinolytic drugs, aprotinin, tranexamic acid (TXA), and epsilon aminocaproic acid (EACA), includes a total of 252 randomised controlled trials (RCTs), which recruited over 25,000 participants. The previous versions of this Cochrane review (<LINK REF="REF-Henry-1999" TYPE="REFERENCE">Henry 1999</LINK>; <LINK REF="REF-Henry-2007" TYPE="REFERENCE">Henry 2007</LINK>), included a total of 89 trials with 9876 participants and 211 trials with 20,781 participants, respectively. Although the three drugs differ somewhat in their modes of action, the results of this review confirm and strengthen previous findings that they reduce surgical blood loss and exposure to allogeneic red blood cell transfusion to a degree that is both statistically and clinically significant. Importantly, the risk of re-operation necessitated by recurrent or continued bleeding after cardiac surgery was lowered by treatment with aprotinin and a clear trend was also seen with TXA for that outcome. These findings are not new, but this updated review provides additional information regarding two significant questions: how do the drugs compare with each other and to what extent are the clinical benefits offset by adverse effects, in particular vascular occlusion? In addressing these questions the updated review includes data from 49 active comparisons between aprotinin and the lysine analogues, compared with 29 in the previous review (<LINK REF="REF-Henry-2007" TYPE="REFERENCE">Henry 2007</LINK>). This updated review also adds to the information about vascular events - capturing 54 more episodes of myocardial infarction than the earlier version.<BR/>
<BR/>The analyses of active comparator trials (direct head-to-head comparisons) indicate that aprotinin was slightly more effective than TXA in reducing the need for red cell transfusion in patients undergoing cardiac surgery (RR 0.87, 95% CI 0.76 to 0.99). However, the results of the head-to-head comparison showed that aprotinin was marginally more effective than TXA in reducing post-operative blood loss. In the context of cardiac surgery, aprotinin appeared to be more effective than EACA in reducing the need for red cell transfusion and post-operative blood loss. Our confidence in ascribing an advantage to aprotinin needs to be moderated by evidence of possible publication bias and uncertainty over the comparative dose response relationships.</P>
<P>Mortality appeared to be unaffected by treatment with any of the drugs and there was no evidence that aprotinin, or the lysine analogues, increased the risks of myocardial infarction or other serious thrombosis. These latter results conflict with the findings of recently published observational studies by Mangano et al (<LINK REF="REF-Mangano-2006" TYPE="REFERENCE">Mangano 2006</LINK>; <LINK REF="REF-Mangano-2007" TYPE="REFERENCE">Mangano 2007</LINK>) and Karkouti et al (<LINK REF="REF-Karkouti-2006" TYPE="REFERENCE">Karkouti 2006</LINK>), which showed that the use of aprotinin in cardiac surgery was associated with an increase in the incidence of renal failure, myocardial infarction, and all-cause mortality (over five years).</P>
<SUBSECTION>
<HEADING LEVEL="2">Measures of efficacy: blood loss and need for transfusion</HEADING>
<P>Aprotinin appeared to be the most efficacious of the three drugs in reducing perioperative blood loss, the confidence interval (CI) for the average reduction in blood loss with aprotinin seen in placebo/inactive controlled trials does not overlap with those of either TXA or EACA. This conclusion was supported by the sparser literature from active comparator trials, which found that aprotinin reduced post-operative blood loss to a greater extent than TXA; a similar result was seen in the comparison of aprotinin and EACA. It was notable that the apparent differences between the drugs were only seen in the context of cardiac surgery. There was no advantage of aprotinin over TXA when the drugs were used as an adjunct to orthopaedic procedures.</P>
<P>The three drugs were effective in reducing the proportions of patients who required transfusion with red blood cells. The pooled relative risk (RR) values from placebo/inactive controlled trials were similar. When considering these results it may be relevant that the baseline rates of transfusion differed considerably between the trials of aprotinin and the trials of TXA and EACA. The control-arms of the aprotinin trials had an average transfusion rate of 62%, compared with 44% for the control-arm of the TXA trials and 54% for the control-arms of the EACA trials. A possible explanation for this difference is that aprotinin has been studied more extensively and for a longer period of time than TXA and EACA. It is generally accepted that improvements in surgical technique, advancements in cardiopulmonary bypass technology, the introduction of auto-transfusion procedures and acceptance of lower transfusion thresholds have been responsible for a reduction in the rates of perioperative blood transfusion over time. This time dependant trend was observed in the trials of aprotinin in cardiac surgery. It is also possible that trials of aprotinin included more high-risk patients than trials of the lysine analogues. Such high-risk patients tend to have a greater propensity for blood loss and hence transfusion. Thus, comparisons between drugs based on the placebo/inactive controlled trials of anti-fibrinolytic drugs may be confounded at trial level by differences in patient populations. Publication bias is a further consideration when considering the placebo/inactive controlled studies of these drugs. As in the previous versions of this review, an examination of the generated funnel plots suggested a degree of publication bias (favouring active treatment) in the aprotinin trials (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>), and a similar pattern was also seen with the trials of TXA (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>) and EACA (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<P>In the case of cardiac surgery, when aprotinin was included in pairwise comparisons of blood transfusion requirements with TXA and EACA a small trend in favour of aprotinin was seen in each comparison. When we pooled data on blood transfusions for head-to-head comparisons of aprotinin with either of the lysine analogues the advantage of aprotinin was borderline significant - pooled RR 0.90 (95% CI 0.81 to 0.99). We have previously published a meta-analysis of the comparative trials of aprotinin and lysine analogues in cardiac surgery (<LINK REF="REF-Carless-2005" TYPE="REFERENCE">Carless 2005</LINK>). In that study we used a Bayesian meta-analytic approach to determine if TXA and EACA could be considered equivalent (non-inferior) to aprotinin in reducing the rate of allogeneic blood transfusion. Although hampered by the small number and size of the trials, our results showed that for blood transfusion, using a non-inferiority boundary of 20%, the posterior probability that TXA is equivalent to aprotinin was 0.82.</P>
<P>In other words, the updated analyses make us less sure about the equivalence of the lysine analogues and aprotinin when used to reduce the need for red cell transfusion in cardiac surgery. But these conclusions do not take account of two additional factors, dose effects and the possibility of publication bias. As the funnel plots generated from the head-to-head trials of aprotinin and the lysine analogues show there appears to be a gap that should be occupied by small trials favouring the latter drugs (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>; <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>). The data are sparse but if this represents non-publication of such trials it could explain some of the apparent advantages of aprotinin seen in the overall analyses. This suggestion was made originally by <LINK REF="REF-Beattie-2006" TYPE="REFERENCE">Beattie 2006</LINK> and our updated analysis supports their conclusions. To find evidence of publication bias in the placebo-controlled trials of these drugs is perhaps not surprising, but we thought it less likely to affect the active comparison studies. The commercial interests in the role of aprotinin (an expensive and popular drug) as an adjunct to cardiac surgery may lie behind this. However, it should be noted that none of the reports of the comparative trials mentions commercial sponsorship.</P>
<P>In making comparisons between the average efficacy of the drugs it is important to consider the possible role of dose as a treatment effect modifier. When the pooled RR values for aprotinin were stratified, both low and high doses reduced the incidence of allogeneic red cell transfusion by around 35%. This was greater than the effect of aprotinin when given only as a priming dose - a RR reduction of 17%. So extending duration of treatment beyond the priming dose may be important. TXA in doses of 2 to 10g and in doses below 2g had a similar effect, reducing allogeneic red cell transfusion by around 30%. There were insufficient data to explore dose effects in the head-to-head trials of aprotinin and TXA.</P>
<P>Analyses of the comparative trials of aprotinin and the lysine analogues in orthopaedic surgery were hampered by sparse data. When the results of placebo/inactive controlled trials were combined TXA appeared to be as effective as aprotinin in reducing the number of patients exposed to allogeneic blood transfusion. Conclusions about the relative efficacy of EACA and aprotinin in orthopaedic surgery were hampered by the small number of trials. Of the fourteen trials of aprotinin eight (57.1%) were published between 2000 and 2006. In comparison, of the 21 trials that compared TXA to placebo-control 16 (76.2%) were published in this time period. As with cardiac surgery, conclusions about the relative efficacy of the drugs may be confounded by changes in surgical technique and transfusion practices that have occurred over time. However, as with the data on blood loss, the apparent advantage of aprotinin over the lysine analogues on the need for blood transfusion observed in cardiac surgery was not seen in orthopaedic surgery.</P>
<P>The analyses of the volumes of red cells transfused were difficult to interpret because of incomplete data in many trials. When all randomised subjects were included in the analyses (which included some who did not receive a transfusion) the average volumes of blood transfused were reduced modestly by all three drugs. When the analysis was confined to individuals who received red cell transfusions the reductions in volume were less marked and a statistically significant treatment effect was observed only for aprotinin. There were insufficient data from head-to-head trials to assess the comparative effectiveness of the three drugs in reducing the volumes of blood transfused.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Clinical significance of avoiding red cell transfusion</HEADING>
<P>The true value of avoiding allogeneic red cell transfusion remains unclear (<LINK REF="REF-Vamvakas-2001" TYPE="REFERENCE">Vamvakas 2001</LINK>). Patients who are concerned about the risks of contracting illness as a result of blood transfusion (or object to transfusion on religious grounds) will be more interested in avoiding it completely, rather than just reducing the volume of transfused blood. The importance of avoiding the need for transfusion depends on the probability of avoiding disease transmission or other adverse effects, in particular immunomodulation thought to be due to transfused white blood cells (<LINK REF="REF-Blumberg-1997" TYPE="REFERENCE">Blumberg 1997</LINK>; <LINK REF="REF-Vamvakas-2001" TYPE="REFERENCE">Vamvakas 2001</LINK>). The significance of the latter remains although a number of countries now perform leukocyte depletion, either selectively, or universally, before administering red cell transfusions, despite a lack of convincing evidence that this provides clinical benefits (<LINK REF="REF-Vamvakas-2004" TYPE="REFERENCE">Vamvakas 2004</LINK>). The rate of transmission of HIV or viral hepatitis in most developed countries is very low, because of the quality of screening of donated blood (<LINK REF="REF-Coyle-1999" TYPE="REFERENCE">Coyle 1999</LINK>; <LINK REF="REF-Whyte-1997" TYPE="REFERENCE">Whyte 1997</LINK>). These broad assumptions do not apply equally in developing countries. Allogeneic red cell transfusion is administered frequently and blood products may be inadequately screened; the prevalence of viral pathogens amongst donors is high (<LINK REF="REF-Kimball-1995" TYPE="REFERENCE">Kimball 1995</LINK>; <LINK REF="REF-McFarland-1997" TYPE="REFERENCE">McFarland 1997</LINK>). In these settings there may be much greater clinical value in a range of interventions that diminish or avoid the need for allogeneic blood. However, the costs of the drugs reviewed here are likely to be prohibitive in developing countries.</P>
<P>Most of the red cell transfusion data reviewed here have been collected in the context of major cardiac surgery, where blood loss may be substantial. The applicability of the efficacy data to clinical settings where blood loss is minor is questionable. Anti-fibrinolytic drugs may be used alongside other interventions designed to minimise the need for allogeneic red cell transfusion. A variety of techniques have been employed; most involve the re-infusion of autologous blood either from pre-operative deposit, acute normovolemic haemodilution, or cell salvage. The latter, in most instances involves the re-infusion of red blood cells that have been shed into the operative field. The evidence on the efficacy and safety of these techniques was reviewed extensively by the International Study on Perioperative Transfusion (ISPOT) (<LINK REF="REF-Bryson-1998" TYPE="REFERENCE">Bryson 1998</LINK>; <LINK REF="REF-Forgie-1998" TYPE="REFERENCE">Forgie 1998</LINK>; <LINK REF="REF-Huet-1999" TYPE="REFERENCE">Huet 1999</LINK>). The literature on re-infusion techniques is generally viewed as being of indifferent quality, because of inadequate randomisation and lack of blinding of outcomes assessment. However, these techniques probably have a modest blood sparing effect. Significantly, the efficacy of autologous re-infusion techniques appears lower when they are used in the context of a rigorous transfusion protocol. This and the growing evidence on the efficacy of transfusion triggers indicates that a more conservative approach to blood transfusion decisions is desirable (<LINK REF="REF-Carson-1998" TYPE="REFERENCE">Carson 1998</LINK>; <LINK REF="REF-Hebert-1999" TYPE="REFERENCE">Hebert 1999</LINK>). This conservative approach, combined with the selective use of anti-fibrinolytic drugs, may offer the best approach for managing the transfusion requirements of participants in high-risk settings such as cardiac surgery.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Other measures of efficacy: need for re-operation due to bleeding</HEADING>
<P>If the significance of avoiding red cell transfusion is unclear the importance of avoiding re-operation is not. Going back to theatre because of continued or recurrent bleeding is a serious development after cardiac surgery and any reduction in the incidence of this event is clinically significant (<LINK REF="REF-O_x0027_Brien-2002" TYPE="REFERENCE">O'Brien 2002</LINK>). The updated meta-analysis confirmed that aprotinin reduces the rate of re-operation due to bleeding by about half. This translates into an absolute risk reduction of 2% and a number needed-to-treat of 50 (95% CI 33 to 100). Similar trends were seen with TXA and EACA, but the data were sparse and the differences failed to reach statistical significance. We did not see evidence of publication bias in the data relating to re-operation rates (<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>). When aprotinin was compared directly with TXA in head-to-head comparative trials the analysis suggested that aprotinin reduced re-operations by 31%.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Effects of treatment on all cause mortality</HEADING>
<P>Regardless of the type of surgery, when aprotinin was compared with no treatment there was no apparent effect on all-cause mortality (RR 0.81, 95% CI 0.63 to 1.06). In the subset of cardiac surgery trials the result was similar: RR 0.84 (95% CI 0.64 to 1.10). Likewise, when TXA was compared to no treatment the effect on mortality rate in cardiac surgery was not statistically significant and the CI was fairly wide (RR 0.60, 95% CI 0.33 to 1.10). In head to head comparisons there was a trend to higher mortality with aprotinin than either tranexamic acid or aminocaproic acid but the analyses were constrained by the relatively small numbers of outcomes. As there were no qualitative differences between tranexamic acid and aminocaproic acid, and any quantitative differences between these drugs were small, we compared aprotinin with either lysine analogue for the outcomes of mortality and myocardial infarction. The risk of death was higher with aprotinin than with either lysine analogue, although this result was very dependent on the results of the BART trial (<LINK REF="STD-Fergusson-2008" TYPE="STUDY">Fergusson 2008</LINK>). There was no significant increase in the risk of myocardial infarction that could explain the higher mortality and indeed there were no other outcome analyses from the head to head trials that could provide an explanation. It is also possible that the difference was due to a benefit of the lysine analogues rather than an adverse effect of aprotinin. In any event this distinction is academic as aprotinin has been withdrawn from world markets and the lysine analogues appear almost equally effective in reducing the need for transfusion with allogeneic blood.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Adverse events and other outcomes</HEADING>
<P>Neither aprotinin nor the lysine analogues appeared to increase the risk of myocardial infarction. In each case the pooled relative risk was close to one. Most data have been collected for aprotinin, which is more often used in cardiac surgery that the lysine analogues. This probably explains the higher rates of myocardial infarction in the placebo-treated subjects in the aprotinin trials (4.5%) than the TXA trials (2.3%). Similarly, the risk of stroke was not increased by any of these drugs; nor was there any apparent increase in the risk of developing other thrombotic events (deep vein thrombosis, pulmonary embolism, 'other thrombosis').</P>
<P>Data aggregated from 28 randomised trials of aprotinin and nine trials of TXA showed that neither drug increased the risk of renal dysfunction compared to control. Although the event rate was slightly higher in aprotinin-treated patients compared to the control group (2.4% versus 1.5%) the difference was not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Potential sources of bias in this review</HEADING>
<P>In our review we found a large number of small trials. These continue to be published in the literature, even though individually they contribute very little additional information. In the case of aprotinin, redundancy in terms of new information has long since been reached and there is no justification for continuing to perform placebo-controlled trials. Future investigation should involve large trials of the relative efficacy and safety of the different drugs (<LINK REF="REF-Hebert-2005" TYPE="REFERENCE">Hebert 2005</LINK>). The small size of most of the existing trials raises concerns about the effects of publication bias. The funnel plot of the aprotinin trials reveals possible evidence of this - in the form of a 'missing' population of small negative trials (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
<P>The main study outcome used in these trials was a practice variable - the decision to transfuse a patient with allogeneic red cells. Although this requires a degree of subjectivity on the part of clinicians it is probably not a major source of bias in this meta-analysis as around 70% of the trials were assessed as being double-blind, involving the use of an identical placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Sources of heterogeneity</HEADING>
<P>Substantial heterogeneity in trial outcomes was seen. This was seen in the case of aprotinin for blood loss and blood transfusion outcomes. However, it was not apparent in the analyses of more significant clinical outcomes, such as re-operation, myocardial infarction and death. It is therefore possible that the subjective nature of the intermediate outcomes, which require judgement about the degree of blood loss, and the need for transfusion, contributed to the between study heterogeneity. Despite this heterogeneity we have little doubt about the existence of a treatment benefit with these drugs. The variation for blood transfusion variables was in terms of the size, not the direction, of effect.</P>
<P>We considered a number of other factors that might explain variation in the size of the treatment effect for blood loss and rates of transfusion. In the case of transfusion, we stratified the data by the clinical setting, operation type, the concomitant use of clinical transfusion thresholds (transfusion triggers), and trial methodological quality. In the case of blood loss, we stratified the data by the type surgery performed and the period in which blood loss was assessed (that is, intra-operative and/or post-operative blood loss). Basically, none of these provided an adequate explanation for the degree of heterogeneity seen in these studies. Although effect size varied somewhat with dose, considerable heterogeneity was seen within dose strata. Likewise, there was substantial heterogeneity within the trials of aprotinin in cardiac surgery (that is, for intra-and-post-operative blood loss, and the rates of transfusion). For the rates of exposure to allogeneic blood transfusion the adequacy of concealment of treatment allocation was associated with a small variation in treatment effect size, but once again there was heterogeneity within the different strata of methodological quality.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">How do the results compare with the observational studies?</HEADING>
<P>The most controversial aspect of this review is the lack of evidence of an increase in the risks of myocardial infarction, stroke, renal dysfunction and death with aprotinin when compared with no treatment. This is in keeping with previous published meta-analyses of the randomised controlled trials of anti-fibrinolytic drugs. In the case of aprotinin this review includes 77% more myocardial infarctions, but only 7% more deaths, than the previous version of this review. The updated data-sets comparing aprotinin with no treatment conflict with those from four recent observational studies (<LINK REF="REF-Karkouti-2006" TYPE="REFERENCE">Karkouti 2006</LINK>; <LINK REF="REF-Mangano-2006" TYPE="REFERENCE">Mangano 2006</LINK>; <LINK REF="REF-Mangano-2007" TYPE="REFERENCE">Mangano 2007</LINK>; <LINK REF="REF-Schneeweiss-2008" TYPE="REFERENCE">Schneeweiss 2008</LINK>). Mangano and colleagues (2007) showed that during five years of follow-up aprotinin-treated patients had a death rate around 1.6 times higher than that of the untreated control group. The adjusted hazard ratio (HR) for all-cause mortality was 1.48 (95% confidence interval 1.19 to 1.85). This study generated considerable scientific debate with calls for the use of aprotinin in cardiac surgery to be abandoned. In 2008 a large pharmaco-epidemiological study by <LINK REF="REF-Schneeweiss-2008" TYPE="REFERENCE">Schneeweiss 2008</LINK> confirmed the increased risk of death with aprotinin. These investigators studied the use of aprotinin (33,517 patients) or aminocaproic acid (44,682 patients) on the day coronary bypass surgery was performed. In this non-randomised study they found that 1512 of the 33,517 aprotinin recipients (4.5%) and 1101 of the 44,682 aminocaproic acid recipients (2.5%) died. After adjustment, the estimated risk of death was 64% higher in the aprotinin group than in the aminocaproic acid group (relative risk, 1.64; 95% confidence interval [CI], 1.50 to 1.78). This difference remained statistically significant after a range of analytical procedures including a propensity score matched analysis and an instrumental variable analysis.</P>
<P>The first large observational study to find and adverse effect of aprotinin (<LINK REF="REF-Mangano-2006" TYPE="REFERENCE">Mangano 2006</LINK>, <LINK REF="REF-Mangano-2007" TYPE="REFERENCE">Mangano 2007</LINK>) was criticized on several grounds, including the fact that it was based on a multi-centre patient registry, not a true population based cohort, that there were important differences between centres and that a range of selection biases may have influenced the between-drug comparisons. These arguments will not be repeated here as full details are available in the relevant publications (<LINK REF="REF-Bidstrup-2006" TYPE="REFERENCE">Bidstrup 2006</LINK>; <LINK REF="REF-Body-2006" TYPE="REFERENCE">Body 2006</LINK>; <LINK REF="REF-Ferguson-2007" TYPE="REFERENCE">Ferguson 2007</LINK>; <LINK REF="REF-Levy-2006" TYPE="REFERENCE">Levy 2006</LINK>). Our view is not that the studies of <LINK REF="REF-Karkouti-2006" TYPE="REFERENCE">Karkouti 2006</LINK>; <LINK REF="REF-Mangano-2006" TYPE="REFERENCE">Mangano 2006</LINK> and <LINK REF="REF-Mangano-2007" TYPE="REFERENCE">Mangano 2007</LINK> were badly done, but that they have inherent limitations, mainly due to their observational nature and selection biases that probably cannot be completely overcome through statistical adjustments by propensity scores and co-variates. These weaknesses were addressed in the larger study performed by Schneeweiss and colleagues (2008), described above. The agreement between these studies adds weight to the claim that aprotinin does indeed increase the chances of death.<BR/>
</P>
<P>In considering the apparently conflicting results of the different study types it is also important to acknowledge weaknesses in the database of randomised trials, in particular under-recording of infrequent events that were not the primary outcomes of the trials. It is important to note that for dichotomous data to be included in our analyses, trial reports had to provide either numeric data, that is the numbers of events that occurred in the treatment and control groups, or where there were no events recorded, the trial report had to clearly state this. So, we have some confidence in the data included in the meta-analyses. However, we acknowledge that under-reporting of uncommon events that were not the primary outcomes of these generally small trials is a potential problem with this literature. In the case of aprotinin our analyses of myocardial infarction were based on data from 37 (49%) out of a total of 76 trials included in the analyses of blood transfusions. These trials were larger than average and included 64% of all participants. Nevertheless, the incomplete data are a potential source of bias in this and the analyses of other vascular outcomes. We are more confident of our analyses of mortality in cardiac surgery where, in the case of aprotinin, data were reported for 60% of all trials and 80% of participants. The most likely effect of under-reporting is to make estimates imprecise, meaning that fairly small changes in mortality or occurrence of thrombotic events might have been missed.</P>
<P>There was a disappointing lack of information in the randomised trials regarding this putative adverse effect of the drug. Only 18 out of 76 trials of aprotinin documented this outcome, so there is a potential for bias due to under-reporting. Based on analysis of 107 events in 4174 individuals the point estimate of the pooled RR with aprotinin (compared with placebo or no treatment) was 1.16 (95% CI 0.79 to 1.70), so we are not confident that we have ruled out a modest increase in risk. On the other hand the suggestion of an increase in risk from <LINK REF="REF-Mangano-2006" TYPE="REFERENCE">Mangano 2006</LINK> was based on a total of only 18 events, of which eight occurred in patients treated with aprotinin. <LINK REF="REF-Karkouti-2006" TYPE="REFERENCE">Karkouti 2006</LINK> carried out a closely matched analysis of 898 individuals who received either aprotinin or TXA. Using a very sensitive measure of renal dysfunction they documented 182 instances, with a higher incidence in aprotinin treated subjects (RR 1.43, 95% CI 1.10 to 1.86).</P>
<P>There was greater agreement when we consider the results of the summary analyses of the head to head trials of aprotinin and lysine analogues and the observational studies described above. The comparison of aprotinin with the combined results of the lysine analogues found a significantly increased risk of death; similar in magnitude to what was found in the observational studies, but no apparent increase in the risk of major thrombotic events. The absence of a no treatment control group from these analyses means that we are unable to say whether the differences in mortality were due to an adverse effect of aprotinin or a protective effect of the lysine analogues. In addition, the meta-analyses for death and myocardial infarction were heavily weighted by the results of the BART trial (<LINK REF="STD-Fergusson-2008" TYPE="STUDY">Fergusson 2008</LINK>). These factors limit our ability to draw firm conclusions about the true effects of the drugs. But the summary data now available, and the regulatory action taken against aprotinin, enable us to make some pragmatic recommendations. Despite the possibility that they are inferior to aprotinin in minimising perioperative blood loss and the need for allogeneic red cell transfusion both tranexamic acid and aminocaproic acid appear effective and safe. The experience is greatest with tranexamic acid and confidence in the use of this drug has been strengthened by the recent publication of the CRASH-2 trial (<LINK REF="REF-CRASH_x002d_2-2010" TYPE="REFERENCE">CRASH-2 2010</LINK>), which found that two doses of tranexamic acid reduced overall mortality when administered soon after major trauma.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Conclusions</HEADING>
<P>Antifibrinolytic drugs are effective in reducing blood loss, the need for allogeneic red cell transfusion, and the need for re-operation due to continued post-operative bleeding (in cardiac surgery). Aprotinin appears more effective than the lysine analogues in minimising peri and post operative blood loss when used as adjunctive therapy in cardiac surgery. Strictly speaking, based on their average effects on the need for red cell transfusion, the lysine analogues do not meet the criteria for being considered equivalent to aprotinin. However, comparisons between the drugs need to take account of the clinical significance of any small advantage of aprotinin, the dose response relationships for each of the drugs, and the possible effects of publication bias, which appears to favour aprotinin. Taking these factors into consideration it may reasonably be concluded that tranexamic acid is as effective as aprotinin, particularly when it is used as an adjunct to non-cardiac surgical procedures. The data for epsilon aminocaproic acid are sparser and as a consequence not so convincing.</P>
<P>The updated meta-analyses of the randomised trials comparing aprotinin with no treatment do not confirm the evidence from observational studies that aprotinin increases the risks of vascular occlusive events and mortality. However, there has been a degree of under-reporting of these adverse events in trials of anti-fibrinolytic drugs. The head to head comparisons of aprotinin and the lysine analogues have yielded results that are closer to those seen in the observational studies and indicate that aprotinin carries an increased risk of death. Consequently, the balance of benefit and harm favours the use of the lysine analogues over aprotinin, and justifies the regulatory action that resulted in the withdrawal of aprotinin from international markets in 2008.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-11-28 13:24:39 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2010-11-28 13:24:23 +0000" MODIFIED_BY="[Empty name]">
<P>Tranexamic acid and epsilon aminocaproic acid provide worthwhile reductions in blood loss and the need for allogeneic red cell transfusion. Based on the results of randomised trials their efficacy does not appear to be offset by serious adverse effects. The evidence is stronger for tranexamic acid than for epsilon aminocaproic acid.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-11-28 13:24:39 +0000" MODIFIED_BY="[Empty name]">
<P>There is no need for further placebo-controlled trials of anti-fibrinolytic drugs in cardiac surgery. The principal need is for large comparative trials to assess the relative efficacy, safety and cost-effectiveness of the lysine analogues in different surgical procedures.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors wish to thank Sonya Murray, Kim Henderson, Ann Wilkinson, Ketrina Sly, June McLeod, Jayne Fryer, Rosemary Aldrich, and Patricia McGettigan for their assistance at various stages during the development of this review. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-11-30 17:36:53 +0000" MODIFIED_BY="[Empty name]">
<P>Contributors (names are listed alphabetically)</P>
<P>Paul Carless (University of Newcastle) obtained relevant papers, applied inclusion/ exclusion criteria to retrieved papers, quality assessed trials, extracted data from the trials, entered data into RevMan Analyses, entered study details into Review Manager 4.2.8, and co-wrote review; Dean Fergusson (ISPOT Coordinator*) co-conceived the review, performed the original literature searches, data extraction, and analyses; David Henry (University of Newcastle) obtained funding for the study, was involved in study design, screened abstracts and titles for relevant articles, and co-wrote review; Katharine Ker (London School of Hygiene &amp; Tropical Medicine) performed updated literature searches extracted data and co-wrote the updated review; Annette Moxey (University of Newcastle) obtained relevant papers, applied inclusion/ exclusion criteria to retrieved papers, quality assessed trials, extracted data from the trials and entered data into MetaView 3.1; Dianne O'Connell (University of Newcastle) provided statistical consultancy for the review, checked data for consistency, analysed and interpreted the results, provided methodological content, and co-wrote review, Barrie Stokes (University of Newcastle) provided statistical consultancy for the review and performed Bayesian analyses.<BR/>* ISPOT - International Study of Peri-Operative Transfusion<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2011-02-16 15:50:08 +0000" MODIFIED_BY="Emma M Sydenham">
<P>The editorial group is aware that a clinical trial by Prof. Joachim Boldt has been found to have been fabricated (<A HREF="http://archie.cochrane.org/sections/documents/view?document=540099072011521412&amp;format=REVMAN#REF-Boldt-2009">Boldt 2009</A>). As the editors who revealed this fabrication point out (<A HREF="http://archie.cochrane.org/sections/documents/view?document=540099072011521412&amp;format=REVMAN#REF-Reinhart-2011">Reinhart 2011</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?document=540099072011521412&amp;format=REVMAN#REF-Shafer-2011">Shafer 2011</A>), this casts some doubt on the veracity of other studies by the same author. All Cochrane Injuries Group reviews which include studies by this author have therefore been edited to show the results with this author's trials included and excluded. Readers can now judge the potential impact of trials by this author (
<LINK REF="STD-Boldt-1991" TYPE="STUDY">Boldt 1991</LINK>, <LINK REF="STD-Boldt-1994" TYPE="STUDY">Boldt 1994</LINK>, <LINK REF="STD-Mengistu-2008" TYPE="STUDY">Mengistu 2008</LINK>) on the conclusions of the review.
</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-02-16 13:23:34 +0000" MODIFIED_BY="Emma M Sydenham">
<STUDIES MODIFIED="2010-12-03 15:14:35 +0000" MODIFIED_BY="Katharine Ker">
<INCLUDED_STUDIES MODIFIED="2010-12-03 15:14:35 +0000" MODIFIED_BY="Katharine Ker">
<STUDY DATA_SOURCE="PUB" ID="STD-Alajmo-1989" MODIFIED="2008-10-13 16:45:44 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Alajmo 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-10-13 16:45:44 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alajmo F, Calamai G, Perna AM, Melissano G, Pretelli P, Palmarini MF, et al</AU>
<TI>High-dose aprotinin: hemostatic effects in open heart operations</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1989</YR>
<VL>48</VL>
<NO>4</NO>
<PG>536-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alderman-1998" NAME="Alderman 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alderman EL, Levy JH, Rich JB, Nili M, Vidne B, Schaff H, et al</AU>
<TI>Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1998</YR>
<VL>116</VL>
<NO>5</NO>
<PG>716-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alvarez-1995" NAME="Alvarez 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alvarez JM, Quiney NF, McMillan D, Joscelyne K, Connelly T, Brady P, et al</AU>
<TI>The use of ultra-low-dose aprotinin to reduce blood loss in cardiac surgery</TI>
<SO>Journal of Cardiothoracic &amp; Vascular Anesthesia</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>1</NO>
<PG>29-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alvarez-2001" NAME="Alvarez 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alvarez JM, Jackson LR, Chatwin C, Smolich JJ</AU>
<TI>Low-dose postoperative aprotinin reduces mediastinal drainage and blood product use in patients undergoing primary coronary artery bypass grafting who are taking aspirin: a prospective, randomized, double-blind, placebo-controlled trial</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>2001</YR>
<VL>122</VL>
<NO>3</NO>
<PG>457-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alvarez-2008" MODIFIED="2010-05-28 10:32:22 +0100" MODIFIED_BY="Katharine Ker" NAME="Alvarez 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-28 10:32:22 +0100" MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Álvarez JC, Santiveri FX, Ramos I, Vela E, Puig L, Escolano F</AU>
<TI>Tranexamic acid reduce blood transfusion in total knee arthroplasty event when a blood conservation program is applied</TI>
<SO>Blood Conservation &amp; Transfusion Alternatives</SO>
<YR>2008</YR>
<VL>48</VL>
<NO>3</NO>
<PG>519-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Amar-2003" NAME="Amar 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amar D, Grant FM, Zhang H, Boland PJ, Leung DH, Healey JA</AU>
<TI>Antifibrinolytic therapy and perioperative blood loss in cancer patients undergoing major orthopedic surgery</TI>
<SO>Anesthesiology</SO>
<YR>2003</YR>
<VL>98</VL>
<NO>2</NO>
<PG>337-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andreasen-2004" NAME="Andreasen 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andreasen JJ, Nielsen C</AU>
<TI>Prophylactic tranexamic acid in elective, primary coronary artery bypass surgery using cardiopulmonary bypass</TI>
<SO>European Journal of Cardio-Thoracic Surgery</SO>
<YR>2004</YR>
<VL>26</VL>
<NO>2</NO>
<PG>311-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Apostolakis-2008" MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NAME="Apostolakis 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NOTES="&lt;p&gt;Connective Phrase: PUBMED 18361800Notes: Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial&lt;br&gt;ER  -&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 15:02:44 +0100" NOTES_MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Apostolakis E, Panagopoulos N, Koletsis E N, Crockett J, Stamou-Kouki H, Sourgiadaki E, et al</AU>
<TI>Influence of ultra-low dose Aprotinin on thoracic surgical operations: a prospective randomized trial</TI>
<SO>Journal of cardiothoracic surgery</SO>
<YR>2008</YR>
<VL>3</VL>
<PG>14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Armellin-2001" NAME="Armellin 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Armellin G, Casella S, Guzzinati S, Pasini L, Marcassa A, Giron G</AU>
<TI>Tranexamic acid in aortic valve replacement</TI>
<SO>Journal of Cardiothoracic &amp; Vascular Anesthesia</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>3</NO>
<PG>331-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arom-1994" NAME="Arom 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arom KV, Emery RW</AU>
<TI>Decreased postoperative drainage with addition of epsilon-aminocaproic acid before cardiopulmonary bypass</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1994</YR>
<VL>57</VL>
<NO>5</NO>
<PG>1108-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ashraf-1997" NAME="Ashraf 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ashraf S, Tian Y, Cowan D, Nair U, Chatrath R, Saunders NR, et al</AU>
<TI>"Low-dose" aprotinin modifies hemostasis but not proinflammatory cytokine release</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1997</YR>
<VL>63</VL>
<NO>1</NO>
<PG>68-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asimakopoulos-2000" MODIFIED="2010-01-11 10:56:01 +0000" MODIFIED_BY="Katharine Ker" NAME="Asimakopoulos 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-11 10:56:00 +0000" MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asimakopoulos G, Kohn A, Stefanou DC, Haskard DO, Landis RC, Talyor KM</AU>
<TI>Leukocyte integrin expression in patients undergoing cardiopulmonary bypass</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2000</YR>
<VL>69</VL>
<PG>1192-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baele-1992" NAME="Baele 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baele PL, Ruiz-Gomez J, Londot C, Sauvage M, Van Dyck MJ, Robert A</AU>
<TI>Systematic use of aprotinin in cardiac surgery: influence on total homologous exposure and hospital cost</TI>
<SO>Acta Anaesthesiologica Belgica</SO>
<YR>1992</YR>
<VL>43</VL>
<NO>2</NO>
<PG>103-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bailey-1994" NAME="Bailey 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bailey CR, Kelleher A, Wielogorski AK</AU>
<TI>Randomised placebo-controlled double blind study of three aprotinin regimes in primary cardiac surgery</TI>
<SO>British Journal of Surgery</SO>
<YR>1994</YR>
<VL>81</VL>
<PG>969-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Basora-1999" MODIFIED="2008-10-13 16:46:18 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Basora 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-10-13 16:46:18 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Basora M, Gomar C, Escolar G, Pacheco M, Fita G, Rodriguez E, Ordinas A</AU>
<TI>Platelet function during cardiac surgery and cardiopulmonary bypass with low-dose aprotinin</TI>
<SO>Journal of Cardiothoracic &amp; Vascular Anesthesia</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>4</NO>
<PG>382-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bennett_x002d_Guerrero-1997" MODIFIED="2008-09-10 10:33:20 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Bennett-Guerrero 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bennett-Guerrero E, Sorohan JG, Gurevich ML, Kazanjian PE, Levy RR, Barbera AV, et al</AU>
<TI>Cost-benefit and efficacy of aprotinin compared with epsilon-aminocaproic acid in patients having repeated cardiac operations: a randomized, blinded clinical trial</TI>
<SO>Anesthesiology</SO>
<YR>1997</YR>
<VL>87</VL>
<NO>6</NO>
<PG>1373-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benoni-1996" NAME="Benoni 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benoni G, Fredin H</AU>
<TI>Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients</TI>
<SO>Journal of Bone &amp; Joint Surgery - British Volume</SO>
<YR>1996</YR>
<VL>78</VL>
<NO>3</NO>
<PG>434-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benoni-2000" NAME="Benoni 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benoni G, Lethagen S, Nilsson P, Fredin H</AU>
<TI>Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty</TI>
<SO>Acta Orthopaedica Scandinavica</SO>
<YR>2000</YR>
<VL>71</VL>
<NO>3</NO>
<PG>250-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benoni-2001" NAME="Benoni 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benoni G, Fredin H, Knebel R, Nilsson P</AU>
<TI>Blood conservation with tranexamic acid in total hip arthroplasty: a randomized, double-blind study in 40 primary operations</TI>
<SO>Acta Orthopaedica Scandinavica</SO>
<YR>2001</YR>
<VL>72</VL>
<NO>5</NO>
<PG>442-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berenholtz-2009" MODIFIED="2010-05-28 10:35:06 +0100" MODIFIED_BY="Katharine Ker" NAME="Berenholtz 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-05-28 10:35:06 +0100" MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berenholtz SM, Cuong Pham J, Garrett-Mayer E, Atchison CW, Kostuik JP, Cohen DB et al</AU>
<TI>Effect of Epsilon Aminocaproic Acid on red-cell transfusion requirements in major spinal surgery</TI>
<SO>Spine</SO>
<YR>2009</YR>
<VL>34</VL>
<NO>19</NO>
<PG>2096-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bernet-1999" NAME="Bernet 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernet F, Carrel T, Marbet G, Skarvan K, Stulz P</AU>
<TI>Reduction of blood loss and transfusion requirements after coronary artery bypass grafting: similar efficacy of tranexamic acid and aprotinin in aspirin-treated patients</TI>
<SO>Journal of Cardiac Surgery</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>2</NO>
<PG>92-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bert-2008" MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NAME="Bert 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NOTES="&lt;p&gt;Connective Phrase: PUBMED 18249325Notes: Publication Type: Journal Article; Randomized Controlled Trial&lt;br&gt;ER  -&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 15:02:44 +0100" NOTES_MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bert C, De Buck F, Sergeant P, Van Hemelrijck J, Kasran A, Van Duppen V, et al</AU>
<TI>Aprotinin reduces cardiac troponin I release and inhibits apoptosis of polymorphonuclear cells during off-pump coronary artery bypass surgery</TI>
<SO>Journal of cardiothoracic and vascular anesthesia</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>1</NO>
<PG>16-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bidstrup-1989" NAME="Bidstrup 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bidstrup BP, Royston D, Sapsford RN, Taylor KM</AU>
<TI>Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol)</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1989</YR>
<VL>97</VL>
<NO>3</NO>
<PG>364-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bidstrup-1990" NAME="Bidstrup 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bidstrup BP, Royston D, McGuinness C, Sapsford RN</AU>
<TI>Aprotinin in aspirin-pretreated patients</TI>
<SO>Perfusion</SO>
<YR>1990</YR>
<VL>5</VL>
<PG>77-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bidstrup-1993" NAME="Bidstrup 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bidstrup BP, Underwood SR, Sapsford RN, Streets EM</AU>
<TI>Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1993</YR>
<VL>105</VL>
<NO>1</NO>
<PG>147-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bidstrup-2000" NAME="Bidstrup 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bidstrup BP, Hunt BJ, Sheikh S, Parratt RN, Bidstrup JM, Sapsford RN</AU>
<TI>Amelioration of the bleeding tendency of preoperative aspirin after aortocoronary bypass grafting</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2000</YR>
<VL>69</VL>
<NO>2</NO>
<PG>541-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blauhut-1994" NAME="Blauhut 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blauhut B, Harringer W, Bettelheim P, Doran JE, Spath P, Lundsgaard-Hansen P</AU>
<TI>Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1994</YR>
<VL>108</VL>
<NO>6</NO>
<PG>1083-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boldt-1991" NAME="Boldt 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boldt J, Zickmann B, Czeke A, Herold C, Dapper F, Hempelmann G</AU>
<TI>Blood conservation techniques and platelet function in cardiac surgery</TI>
<SO>Anesthesiology</SO>
<YR>1991</YR>
<VL>75</VL>
<PG>426-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boldt-1994" NAME="Boldt 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boldt J, Schindler E, Knothe C, Hammermann H, Stertmann WA, Hempelmann G</AU>
<TI>Does aprotinin influence endothelial-associated coagulation in cardiac surgery?</TI>
<SO>Journal of Cardiothoracic &amp; Vascular Anesthesia</SO>
<YR>1994</YR>
<VL>8</VL>
<NO>5</NO>
<PG>527-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boylan-1996" MODIFIED="2008-09-08 22:32:35 +0100" MODIFIED_BY="[Empty name]" NAME="Boylan 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-09-08 22:32:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boylan JF, Klinck JR, Sandler AN, Arellano R, Greig PD, Nierenberg H, et al</AU>
<TI>Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation</TI>
<SO>Anesthesiology</SO>
<YR>1996</YR>
<VL>85</VL>
<NO>5</NO>
<PG>1043-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-1997" MODIFIED="2008-09-08 22:32:41 +0100" MODIFIED_BY="[Empty name]" NAME="Brown 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-09-08 22:32:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown RS, Thwaites BK, Mongan PD</AU>
<TI>Tranexamic acid is effective in decreasing postoperative bleeding and transfusions in primary coronary artery bypass operations: A double-blind, randomized, placebo-controlled trial</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>1997</YR>
<VL>85</VL>
<NO>5</NO>
<PG>963-970</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caglar-2008" MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NAME="Caglar 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NOTES="&lt;p&gt;Connective Phrase: PUBMED 17499419Notes: Publication Type: Journal Article; Randomized Controlled Trial&lt;br&gt;ER  -&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 15:02:44 +0100" NOTES_MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caglar G S, Tasci Y, Kayikcioglu F, Haberal A</AU>
<TI>Intravenous tranexamic acid use in myomectomy: a prospective randomized double-blind placebo controlled study</TI>
<SO>European journal of obstetrics, gynecology, and reproductive biology</SO>
<YR>2008</YR>
<VL>137</VL>
<NO>2</NO>
<PG>227-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Camarasa-2006" NAME="Camarasa 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Camarasa MA, Olle G, Serra-Prat M, Martin A, Sanchez M, Ricos P, et al</AU>
<TI>Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>2006</YR>
<VL>96</VL>
<NO>5</NO>
<PG>576-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Capdevila-1998" NAME="Capdevila 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Capdevila X, Calvet Y, Biboulet P, Biron C, Rubenovitch J, d'Athis F</AU>
<TI>Aprotinin decreases blood loss and homologous transfusions in patients undergoing major orthopedic surgery</TI>
<SO>Anesthesiology</SO>
<YR>1998</YR>
<VL>88</VL>
<NO>1</NO>
<PG>50-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carrera-1994" NAME="Carrera 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carrera A, Martinez MV, Garcia Guiral M, Herrero E, Peral A, Planas A</AU>
<TI>Utilizacion de altas dosis de aprotinina en cirugia cardiaca - High doses of aprotinin in cardiac surgery</TI>
<SO>Revista Espanola de Anestesiologia y Reanimacion</SO>
<YR>1994</YR>
<VL>41</VL>
<PG>13-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casas-1995" NAME="Casas 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casas JI, Zuazu-Jausoro I, Mateo J, Oliver A, Litvan H, Muniz-Diaz E, et al</AU>
<TI>Aprotinin versus desmopressin for patients undergoing operations with cardiopulmonary bypass. A double-blind placebo-controlled study</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1995</YR>
<VL>110</VL>
<NO>4 Pt 1</NO>
<PG>1107-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casati-1999" NAME="Casati 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casati V, Guzzon D, Oppizzi M, Cossolini M, Torri G, Calori G, Alfieri O</AU>
<TI>Hemostatic effects of aprotinin, tranexamic acid and epsilon-aminocaproic acid in primary cardiac surgery</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1999</YR>
<VL>68</VL>
<NO>6</NO>
<PG>2252-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casati-2000" NAME="Casati 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casati V, Guzzon D, Oppizzi M, Bellotti F, Franco A, Gerli C, et al</AU>
<TI>Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>2000</YR>
<VL>120</VL>
<NO>3</NO>
<PG>520-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casati-2001" NAME="Casati 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casati V, Gerli C, Franco A, Torri G, D'Angelo A, Benussi S, Alfieri O</AU>
<TI>Tranexamic acid in off-pump coronary surgery: a preliminary, randomized, double-blind, placebo-controlled study</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2001</YR>
<VL>72</VL>
<NO>2</NO>
<PG>470-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casati-2002" NAME="Casati 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casati V, Sandrelli L, Speziali G, Calori G, Grasso MA, Spagnolo S</AU>
<TI>Hemostatic effects of tranexamic acid in elective thoracic aortic surgery: a prospective, randomized, double-blind, placebo-controlled study</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>2002</YR>
<VL>123</VL>
<NO>6</NO>
<PG>1084-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casati-2004" NAME="Casati 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casati V, Della VP, Benussi S, Franco A, Gerli C, Baili P, et al</AU>
<TI>Effects of tranexamic acid on postoperative bleeding and related hematochemical variables in coronary surgery: Comparison between on-pump and off-pump techniques</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>2004</YR>
<VL>128</VL>
<NO>1</NO>
<PG>83-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cicek-1996a" NAME="Cicek 1996a" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cicek S, Demirkilic U, Kuralay E, Ozal E, Tatar H</AU>
<TI>Postoperative Aprotinin: Effect on blood loss and transfusion requirements in cardiac operations</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1996</YR>
<VL>61</VL>
<PG>1372-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cicek-1996b" NAME="Cicek 1996b" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cicek S, Demirkilic U, Ozal E, Kuralay E, Bingol H, Tatar H, Ozturk OY</AU>
<TI>Postoperative use of aprotinin in cardiac operations: An alternative to its prophylactic use</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1996</YR>
<VL>112</VL>
<NO>6</NO>
<PG>1462-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cicekcioglu-2006" MODIFIED="2010-01-13 14:50:15 +0000" MODIFIED_BY="Katharine Ker" NAME="Cicekcioglu 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-13 14:50:15 +0000" MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cicekcioglu F, Cagli K, Emir M, Topbas M, Catav Z, Sener E et al</AU>
<TI>Effects if minimal dose aprotinin on blood loss and fibrinolytic system-complement activation in coronary artery bypass grafting</TI>
<SO>Journal of Cardiac Surgery</SO>
<YR>2006</YR>
<VL>21</VL>
<PG>336-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Claeys-2007" MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NAME="Claeys 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NOTES="&lt;p&gt;Connective Phrase: PUBMED 17966532Notes: Publication Type: Journal Article; Randomized Controlled Trial&lt;br&gt;ER  -&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 15:02:44 +0100" NOTES_MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Claeys M A, Vermeersch N, Haentjens P</AU>
<TI>Reduction of blood loss with tranexamic acid in primary total hip replacement surgery</TI>
<SO>Acta chirurgica Belgica</SO>
<YR>2007</YR>
<VL>107</VL>
<NO>4</NO>
<PG>397-401</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coffey-1995" NAME="Coffey 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coffey A, Pittmam J, Halbrook H, Fehrenbacher J, Beckman D, Hormuth D, et al</AU>
<TI>The use of tranexamic acid to reduce postoperative bleeding following cardiac surgery: A double-blind randomized trial</TI>
<SO>American Surgeon</SO>
<YR>1995</YR>
<VL>61</VL>
<NO>7</NO>
<PG>566-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-1998" NAME="Cohen 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen G, Ivanov J, Weisel RD, Rao V, Mohabeer MK, Mickle DA</AU>
<TI>Aprotinin and dipyridamole for the safe reduction of postoperative blood loss</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1998</YR>
<VL>65</VL>
<NO>3</NO>
<PG>674-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colwell-2007" MODIFIED="2010-12-03 15:14:04 +0000" MODIFIED_BY="Katharine Ker" NAME="Colwell 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-12-03 15:14:04 +0000" MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colwell CW, Chelly JE, Murkin JM, Stevens D, O'Keefe TJ, Hall R et al</AU>
<TI>Randomized study of Aprotinin effect in transfusions and blood loss in primary THA</TI>
<SO>Clinical Orthopaedics &amp; Relation Research</SO>
<YR>2007</YR>
<VL>465</VL>
<PG>189-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corbeau-1995" NAME="Corbeau 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corbeau JJ, Monrigal JP, Jacob JP, Cottineau C, Moreau X, Bukowski JG, et al</AU>
<TI>Comparaison des effets de l'aprotinine et de l'acide tranexamique sur le saignment en chirurgie cardiaque - Comparative effects of aprotinin and tranexamic acid on blood loss in cardiac surgery</TI>
<SO>Annales Francaises d'Anesthesie et de Reanimation</SO>
<YR>1995</YR>
<VL>14</VL>
<PG>154-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cosgrove-1992" MODIFIED="2008-10-13 17:00:26 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Cosgrove 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-10-13 17:00:26 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cosgrove DM, 3d, Heric B, Lytle BW, Taylor PC, Novoa R, Golding LA, et al</AU>
<TI>Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1992</YR>
<VL>54</VL>
<NO>6</NO>
<PG>1031-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cvachovec-2001" NAME="Cvachovec 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cvachovec K, Sechovska H, Berousek J, Popelka S, Hladikova M</AU>
<TI>Aprotinin (Antilysin Spofa)--its effect on decreasing hemorrhage in the postoperative period in hip arthroplasty [Czech]</TI>
<SO>Acta Chirurgiae Orthopaedicae et Traumatologiae Cechoslovaca</SO>
<YR>2000</YR>
<VL>68</VL>
<NO>5</NO>
<PG>311-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-D_x0027_Ambra-1996" MODIFIED="2008-10-13 16:47:07 +0100" MODIFIED_BY="Emma M Sydenham" NAME="D'Ambra 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>D'Ambra MN, Akins CW, Blackstone EH, Bonney SL, Cohn LH, Cosgrove DM, et al</AU>
<TI>Aprotinin in primary valve replacement and reconstruction: a multicenter, double-blind, placebo-controlled trial</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1996</YR>
<VL>112</VL>
<NO>4</NO>
<PG>1081-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-13 16:47:07 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>D'Ambra MN, Lynch KE, Boccagno J, et al</AU>
<TI>The effect of perioperative administration of recombinant human erythropoietin (R-HuEPO) in CABG patients: A double blind, placebo-controlled trial</TI>
<SO>Anesthesiology: ASA Abstracts</SO>
<YR>1992</YR>
<VL>77</VL>
<NO>3A</NO>
<PG>A159</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-D_x0027_Ambrosio-1999" NAME="D'Ambrosio 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>D'Ambrosio A, Borghi B, Damato A, D'Amato G, Antonacci D, Valeri F</AU>
<TI>Reducing perioperative blood loss in patients undergoing total hip arthroplasty</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>1999</YR>
<VL>22</VL>
<NO>1</NO>
<PG>47-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daily-1994" NAME="Daily 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daily PO, Lamphere JA, Dembitsky WP, Adamson RM, Dans NF</AU>
<TI>Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting. A randomized, prospective, double-blind study</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1994</YR>
<VL>108</VL>
<NO>1</NO>
<PG>99-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dalmau-1999" NAME="Dalmau 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dalmau A, Sabate A, Acosta F, Garcia-Huete L, Koo M, Reche M, et al</AU>
<TI>Comparative study of antifibrinolytic drugs in orthotopic liver transplantation</TI>
<SO>Transplantation Proceedings</SO>
<YR>1999</YR>
<VL>31</VL>
<NO>6</NO>
<PG>2361-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dalmau-2000" NAME="Dalmau 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dalmau A, Sabate A, Acosta F, Garcia-Huete L, Koo M, Sansano T, et al</AU>
<TI>Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>2000</YR>
<VL>91</VL>
<NO>1</NO>
<PG>29-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dalmau-2004" MODIFIED="2008-10-13 16:47:28 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Dalmau 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-10-13 16:47:28 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dalmau A, Sabate A, Koo M, Bartolome C, Rafecas A, Figueras J, et al</AU>
<TI>The prophylactic use of tranexamic acid and aprotinin in orthotopic liver transplantation: a comparative study</TI>
<SO>Liver Transplantation</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>2</NO>
<PG>279-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Defraigne-2000" NAME="Defraigne 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Defraigne JO, Pincemail J, Larbuisson R, Blaffart F, Limet R</AU>
<TI>Cytokine release and neutrophil activation are not prevented by heparin- coated circuits and aprotinin administration</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2000</YR>
<VL>69</VL>
<NO>4</NO>
<PG>1084-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Del-Rossi-1989" NAME="Del Rossi 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DelRossi AJ, Cernaianu AC, Botros S, Lemole GM, Moore R</AU>
<TI>Prophylactic treatment of postperfusion bleeding using EACA</TI>
<SO>Chest</SO>
<YR>1989</YR>
<VL>96</VL>
<NO>1</NO>
<PG>27-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deleuze-1991" NAME="Deleuze 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deleuze P, Loisance DY, Feliz A, Hillion ML, Castanie JB, Richemond J, et al</AU>
<TI>Reduction of per- and postoperative blood loss with aprotinin (Trasylol) during extracorporeal circulation [French]</TI>
<SO>Archives des Maladies du Coeur et des Vaisseaux</SO>
<YR>1991</YR>
<VL>84</VL>
<NO>12</NO>
<PG>1797-802</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Demeyere-2006" MODIFIED="2010-05-28 10:38:41 +0100" MODIFIED_BY="Katharine Ker" NAME="Demeyere 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-05-28 10:38:41 +0100" MODIFIED_BY="Katharine Ker" NOTES="&lt;p&gt;CODEN: RCT&lt;/p&gt;" NOTES_MODIFIED="2010-05-28 10:38:41 +0100" NOTES_MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Demeyere R, Bosteels A, Arnout J, Gasthuisberg UV</AU>
<TI>Comparison of the effects of tranexamic acid, aprotinin and placebo on blood conservation, fibrinolysis and platelet function with extensive heart surgery</TI>
<SO>Critical Care</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>Suppl 1</NO>
<PG>S67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Desai-2009" MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NAME="Desai 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NOTES="&lt;p&gt;Connective Phrase: PUBMED 19843776Notes: Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't&lt;br&gt;ER  -&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 15:02:44 +0100" NOTES_MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Desai P H, Kurian D, Thirumavalavan N, Desai S P, Ziu P, Grant M, et al</AU>
<TI>A randomized clinical trial investigating the relationship between aprotinin and hypercoagulability in off-pump coronary surgery</TI>
<SO>Anesthesia and analgesia</SO>
<YR>2009</YR>
<VL>109</VL>
<NO>5</NO>
<PG>1387-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dietrich-1990" NAME="Dietrich 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dietrich W, Spannagl M, Jochum M, Wendt P, Schramm W, Barankay A, Sebening F, Richter JA</AU>
<TI>Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization</TI>
<SO>Anesthesiology</SO>
<YR>1990</YR>
<VL>73</VL>
<NO>6</NO>
<PG>1119-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dietrich-1992" NAME="Dietrich 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dietrich W, Barankay A, Hahnel C, Richter JA</AU>
<TI>High-dose aprotinin in cardiac surgery: three years' experience in 1,784 patients</TI>
<SO>Journal of Cardiothoracic &amp; Vascular Anesthesia</SO>
<YR>1992</YR>
<VL>6</VL>
<NO>3</NO>
<PG>324-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dietrich-1995" NAME="Dietrich 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dietrich W, Dilthey G, Spannagl M, Jochum M, Braun SL, Richter JA</AU>
<TI>Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study</TI>
<SO>Anesthesiology</SO>
<YR>1995</YR>
<VL>83</VL>
<NO>4</NO>
<PG>679-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dietrich-2008" MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NAME="Dietrich 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NOTES="&lt;p&gt;Connective Phrase: PUBMED 18931201Notes: Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't&lt;br&gt;ER  -&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 15:02:44 +0100" NOTES_MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dietrich W, Spannagl M, Boehm J, Hauner K, Braun S, Schuster T, et al</AU>
<TI>Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin</TI>
<SO>Anesthesia and analgesia</SO>
<YR>2008</YR>
<VL>107</VL>
<NO>5</NO>
<PG>1469-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dignan-2001" NAME="Dignan 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dignan RJ, Law DW, Seah PW, Manganas CW, Newman DC, Grant PW, et al</AU>
<TI>Ultra-low dose aprotinin decreases transfusion requirements and is cost effective in coronary operations</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2001</YR>
<VL>71</VL>
<NO>1</NO>
<PG>158-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diprose-2005" NAME="Diprose 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diprose P, Herbertson MJ, O'Shaughnessy D, Deakin CD, Gill RS</AU>
<TI>Reducing allogeneic transfusion in cardiac surgery: a randomized double-blind placebo-controlled trial of antifibrinolytic therapies used in addition to intra-operative cell salvage</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>2005</YR>
<VL>94</VL>
<NO>3</NO>
<PG>271-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dorman-2008" MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NAME="Dorman 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NOTES="&lt;p&gt;Connective Phrase: PUBMED 18427286Notes: Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.&lt;br&gt;ER  -&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 15:02:44 +0100" NOTES_MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dorman B H, Stroud R E, Wyckoff M M, Zellner J L, Botta D, Leonardi A H, et al</AU>
<TI>Differential effects of epsilon-aminocaproic acid and aprotinin on matrix metalloproteinase release in patients following cardiopulmonary bypass</TI>
<SO>Journal of cardiovascular pharmacology</SO>
<YR>2008</YR>
<VL>51</VL>
<NO>4</NO>
<PG>418-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dryden-1997" MODIFIED="2008-09-08 22:32:56 +0100" MODIFIED_BY="[Empty name]" NAME="Dryden 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-09-08 22:32:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dryden PJ, O'Connor JP, Jamieson WR, Reid I, Ansley D, Sadeghi H, et al</AU>
<TI>Tranexamic acid reduces blood loss and transfusion in reoperative cardiac surgery</TI>
<SO>Canadian Journal of Anaesthesia</SO>
<YR>1997</YR>
<VL>44</VL>
<NO>9</NO>
<PG>934-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eberle-1998" NAME="Eberle 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eberle B, Mayer E, Hafner G, Heinermann J, Dahm M, Prellwitz W, et al</AU>
<TI>High-dose epsilon-aminocaproic acid versus aprotinin: antifibrinolytic efficacy in first-time coronary operations</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1998</YR>
<VL>65</VL>
<NO>3</NO>
<PG>667-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ehrlich-1998" NAME="Ehrlich 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ehrlich M, Grabenwoger M, Cartes-Zumelzu F, Luckner D, Kovarik J, Laufer G, et al</AU>
<TI>Operations on the thoracic aorta and hypothermic circulatory arrest: is aprotinin safe?</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1998</YR>
<VL>115</VL>
<NO>1</NO>
<PG>220-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ekback-2000" NAME="Ekback 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ekback G, Axelsson K, Ryttberg L, Edlund B, Kjellberg J, Weckstrom J, et al</AU>
<TI>Tranexamic acid reduces blood loss in total hip replacement surgery</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>2000</YR>
<VL>91</VL>
<NO>5</NO>
<PG>1124-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ellis-2001" NAME="Ellis 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ellis MH, Fredman B, Zohar E, Ifrach N, Jedeikin R</AU>
<TI>The effect of tourniquet application, tranexamic acid, and desmopressin on the procoagulant and fibrinolytic systems during total knee replacement</TI>
<SO>Journal of Clinical Anesthesia</SO>
<YR>2001</YR>
<VL>13</VL>
<NO>7</NO>
<PG>509-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Engel-2001" NAME="Engel 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Engel JM, Hohaus T, Ruwoldt R, Menges T, Jurgensen I, Hempelmann G</AU>
<TI>Regional hemostatic status and blood requirements after total knee arthroplasty with and without tranexamic acid or aprotinin</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>2001</YR>
<VL>92</VL>
<NO>3</NO>
<PG>775-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Englberger-2002a" NAME="Englberger 2002a" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Englberger L, Markart P, Eckstein FS, Immer FF, Berdat PA, Carrel TP</AU>
<TI>Aprotinin reduces blood loss in off-pump coronary artery bypass (OPCAB) surgery</TI>
<SO>European Journal of Cardio-Thoracic Surgery</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>4</NO>
<PG>545-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Englberger-2002b" NAME="Englberger 2002b" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Englberger L, Kipfer B, Berdat PA, Nydegger UE, Carrel TP</AU>
<TI>Aprotinin in coronary operation with cardiopulmonary bypass: does "low-dose" aprotinin inhibit the inflammatory response?</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2002</YR>
<VL>73</VL>
<NO>6</NO>
<PG>1897-904</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fauli-2005" NAME="Fauli 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fauli A, Gomar C, Campistol JM, Alvarez L, Manig AM, Matute P</AU>
<TI>Kidney-specific proteins in patients receiving aprotinin at high- and low-dose regimens during coronary artery bypass graft with cardiopulmonary bypass</TI>
<SO>European Journal of Anaesthesiology</SO>
<YR>2005</YR>
<VL>22</VL>
<NO>9</NO>
<PG>666-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feindt-1994" MODIFIED="2010-01-13 14:52:50 +0000" MODIFIED_BY="Katharine Ker" NAME="Feindt 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-01-13 14:52:50 +0000" MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feindt P, Seyfert U, Volkmer I, Huwer H, Kalweit G, Gams E</AU>
<TI>Is there a phase of hypercoagulability when aprotinin is used in cardiac surgery?</TI>
<SO>European Journal of Cardio-thoracic Surgery</SO>
<YR>1994</YR>
<VL>8</VL>
<PG>308-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fergusson-2008" MODIFIED="2010-06-24 03:22:45 +0100" MODIFIED_BY="[Empty name]" NAME="Fergusson 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-01-13 14:55:15 +0000" MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM et al</AU>
<TI>A comparison of aprotinin and lysine analogues in high-risk cardiac surgery</TI>
<SO>The New England Journal of Medicine</SO>
<YR>2008</YR>
<VL>358</VL>
<NO>22</NO>
<PG>2319-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Findlay-2001" NAME="Findlay 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Findlay JY, Rettke SR, Ereth MH, Plevak DJ, Krom RA, Kufner RP</AU>
<TI>Aprotinin reduces red blood cell transfusion in orthotopic liver transplantation: a prospective, randomized, double-blind study</TI>
<SO>Liver Transplantation</SO>
<YR>2001</YR>
<VL>7</VL>
<NO>9</NO>
<PG>802-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fraedrich-1989" NAME="Fraedrich 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fraedrich G, Weber C, Bernard C, Hettwer A, Schlosser V</AU>
<TI>Reduction of blood transfusion requirement in open heart surgery by administration of high doses of aprotinin - preliminary results</TI>
<SO>Thoracic &amp; Cardiovascular Surgeon</SO>
<YR>1989</YR>
<VL>37</VL>
<NO>2</NO>
<PG>89-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia_x002d_Enguita-1998" NAME="Garcia-Enguita 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Enguita MA, Ortega JP, Gomez C, Rasal S, Pascual A, Urieta SA</AU>
<TI>High dose aprotinin in complex total hip arthroplasty [abstract]</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1998</YR>
<VL>80</VL>
<NO>Suppl 1</NO>
<PG>80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia_x002d_Huete-1997" NAME="Garcia-Huete 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Huete L, Domenech P, Sabate A, Martinez-Brotons F, Jaurrieta E, Figueras J</AU>
<TI>The prophylactic effect of aprotinin on intraoperative bleeding in liver transplantation: A randomized clinical study</TI>
<SO>Hepatology</SO>
<YR>1997</YR>
<VL>26</VL>
<NO>5</NO>
<PG>1143-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garneti-2004" NAME="Garneti 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garneti N, Field J</AU>
<TI>Bone bleeding during total hip arthroplasty after administration of tranexamic acid</TI>
<SO>Journal of Arthroplasty</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>4</NO>
<PG>488-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gherli-1992" NAME="Gherli 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gherli T, Porcu A, Padua G, Marongiu GM, Antona C, Alamanni F, Bacciu PP</AU>
<TI>Reducing bleeding during extracorporeal circulation interventions by high doses of aprotinin [Italian]</TI>
<SO>Minerva Cardioangiologica</SO>
<YR>1992</YR>
<VL>40</VL>
<NO>4</NO>
<PG>121-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gill-2009" MODIFIED="2010-05-28 10:40:19 +0100" MODIFIED_BY="Katharine Ker" NAME="Gill 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-05-28 10:40:19 +0100" MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gill JB, Chase E, Rosenstein AD</AU>
<TI>The use of tranexamic acid in revision total hip arthroplasty: a pilot study</TI>
<SO>Current Orthopaedic Practice</SO>
<YR>2009</YR>
<VL>20</VL>
<NO>2</NO>
<PG>152-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Golanski-2000" NAME="Golanski 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Golanski R, Golanski J, Chizynski K, Iwaszkiewicz A, Zaslonka J, Pietrucha T, et al</AU>
<TI>Low doses of aprotinin in aortocoronary bypass surgery - advantages and disadvantages</TI>
<SO>Medical Science Monitor</SO>
<YR>2000</YR>
<VL>6</VL>
<NO>4</NO>
<PG>722-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Good-2003" NAME="Good 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Good L, Peterson E, Lisander B</AU>
<TI>Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>2003</YR>
<VL>90</VL>
<NO>5</NO>
<PG>596-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gott-1998" MODIFIED="2010-01-13 15:08:51 +0000" MODIFIED_BY="Katharine Ker" NAME="Gott 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-01-13 15:08:51 +0000" MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gott JP, Cooper WA, Schmidt FE, Brown WM, Wright CE, Merlino JD et al</AU>
<TI>Modifying risk for extracorporeal circulation: trial of four antiinflammatory strategies</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1998</YR>
<VL>66</VL>
<PG>747-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Green-1995" NAME="Green 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Green D, Sanders J, Eiken M, Wong CA, Frederiksen J, Joob A, et al</AU>
<TI>Recombinant aprotinin in coronary artery bypass graft operations</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1995</YR>
<VL>110</VL>
<NO>4 Pt 1</NO>
<PG>963-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greilich-2001" MODIFIED="2008-10-13 16:48:08 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Greilich 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-10-13 16:48:08 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greilich PE, Okada K, Latham P, Kumar RR, Jessen ME</AU>
<TI>Aprotinin but not epsilon-aminocaproic acid decreases interleukin-10 after cardiac surgery with extracorporeal circulation: randomized, double-blind, placebo-controlled study in patients receiving aprotinin and epsilon-aminocaproic acid</TI>
<SO>Circulation</SO>
<YR>2001</YR>
<VL>104</VL>
<NO>12 Suppl 1</NO>
<PG>265-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greilich-2003" NAME="Greilich 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greilich PE, Brouse CF, Whitten CW, Chi L, Dimaio JM, Jessen ME</AU>
<TI>Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: a randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>2003</YR>
<VL>126</VL>
<NO>5</NO>
<PG>1498-503</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greilich-2004" NAME="Greilich 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greilich PE, Brouse CF, Rinder CS, Smith BR, Sandoval BA, Rinder HM, et al</AU>
<TI>Effects of epsilon-aminocaproic acid and aprotinin on leukocyte-platelet adhesion in patients undergoing cardiac surgery</TI>
<SO>Anesthesiology</SO>
<YR>2004</YR>
<VL>100</VL>
<NO>2</NO>
<PG>225-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greilich-2009" MODIFIED="2010-07-02 06:54:21 +0100" MODIFIED_BY="[Empty name]" NAME="Greilich 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-07-02 06:54:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greilich PE, Jessen ME, Satyanarayana N, Whitten CW, Nuttall GA, Beckham GA et al</AU>
<TI>The effects of Epsilon-Aminocaproic Acid and Aprotinin on fibrinolysis and blood loss in patients undergoing primary, isolated coronary artery bypass surgery: a randomized double-blind, placebo-controlled, noninferiority trial</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>2009</YR>
<VL>109</VL>
<NO>1</NO>
<PG>15-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Groh-1993" NAME="Groh 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Groh J, Welte M, Azad SC, Anthuber M, Haller M, Kratzer MA</AU>
<TI>Does aprotinin really reduce blood loss in orthotopic liver transplantation?</TI>
<SO>Seminars in Thrombosis &amp; Hemostasis</SO>
<YR>1993</YR>
<VL>19</VL>
<NO>3</NO>
<PG>306-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harder-1991" NAME="Harder 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harder MP, Eijsman L, Roozendaal KJ, van Oeveren W, Wildevuur CR</AU>
<TI>Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1991</YR>
<VL>51</VL>
<NO>6</NO>
<PG>936-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hardy-1993" NAME="Hardy 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hardy JF, Desroches J, Belisle S, Perrault J, Carrier M, Robitaille D</AU>
<TI>Low-dose aprotinin infusion is not clinically useful to reduce bleeding and transfusion of homologous blood products in high-risk cardiac surgical patients</TI>
<SO>Canadian Journal of Anaesthesia</SO>
<YR>1993</YR>
<VL>40</VL>
<NO>7</NO>
<PG>625-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hardy-1997" NAME="Hardy 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hardy JF, Belisle S, Couturier A, Robitaille D</AU>
<TI>Randomized, placebo-controlled, double-blind study of an ultra-low-dose aprotinin regimen in reoperative and/or complex cardiac operations</TI>
<SO>Journal of Cardiac Surgery</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>1</NO>
<PG>15-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hardy-1998" NAME="Hardy 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hardy JF, Belisle S, Dupont C, Harel F, Robitaille D, Roy M, et al</AU>
<TI>Prophylactic tranexamic acid and epsilon-aminocaproic acid for primary myocardial revascularization</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1998</YR>
<VL>65</VL>
<NO>2</NO>
<PG>371-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harley-2002" NAME="Harley 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harley BJ, Beaupre LA, Jones CA, Cinats JG, Guenther CR</AU>
<TI>The effect of epsilon aminocaproic acid on blood loss in patients who undergo primary total hip replacement: a pilot study</TI>
<SO>Canadian Journal of Surgery</SO>
<YR>2002</YR>
<VL>45</VL>
<NO>3</NO>
<PG>185-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harmon-2004" NAME="Harmon 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harmon DC, Ghori KG, Eustace NP, O'Callaghan SJ, O'Donnell AP, Shorten GD</AU>
<TI>Aprotinin decreases the incidence of cognitive deficit following CABG and cardiopulmonary bypass: a pilot randomized controlled study</TI>
<SO>Canadian Journal of Anaesthesia</SO>
<YR>2004</YR>
<VL>51</VL>
<NO>10</NO>
<PG>1002-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Havel-1992" NAME="Havel 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Havel M, Owen AN, Simon P, Teufelsbauer H, Zwoelfer W, Laczkovics A, et al</AU>
<TI>Decreasing use of donated blood and reduction of bleeding after orthotopic heart transplantation by use of aprotinin</TI>
<SO>Journal of Heart &amp; Lung Transplantation</SO>
<YR>1992</YR>
<VL>11</VL>
<NO>2 Pt 1</NO>
<PG>348-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Havel-1994" NAME="Havel 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Havel M, Grabenwoger F, Schneider J, Laufer G, Wollenek, G, Owen A, et al</AU>
<TI>Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1994</YR>
<VL>107</VL>
<NO>3</NO>
<PG>807-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayashida-1997" NAME="Hayashida 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hayashida N, Isomura T, Sato T, Maruyama H, Kosuga K, Aoyagi S</AU>
<TI>Effects of minimal-dose aprotinin on coronary artery bypass grafting</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1997</YR>
<VL>114</VL>
<NO>2</NO>
<PG>261-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayes-1996" NAME="Hayes 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hayes A, Murphy DB, McCarroll M</AU>
<TI>The efficacy of single-dose aprotinin 2 million KIU in reducing blood loss and its impact on the incidence of deep venous thrombosis in patients undergoing total hip replacement surgery</TI>
<SO>Journal of Clinical Anesthesia</SO>
<YR>1996</YR>
<VL>8</VL>
<NO>5</NO>
<PG>357-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hei-2005" NAME="Hei 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hei ZQ, Luo CF, Li SR, Ma WH, Luo GJ, Chi XJ</AU>
<TI>Effect of aprotinin on perioperative requirements of blood and liquid in severe hepatisis patients undergoing liver transplantation</TI>
<SO>Chinese Pharmaceutical Journal</SO>
<YR>2005</YR>
<VL>40</VL>
<NO>18</NO>
<PG>1432-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hekmat-2004" NAME="Hekmat 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hekmat K, Zimmermann T, Kampe S, Kasper SM, Weber HJ, Geissler HJ, et al</AU>
<TI>Impact of tranexamic acid vs. aprotinin on blood loss and transfusion requirements after cardiopulmonary bypass: a prospective, randomised, double-blind trial</TI>
<SO>Current Medical Research &amp; Opinion</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>1</NO>
<PG>121-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hendrice-1995" NAME="Hendrice 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hendrice C, Schmartz D, Pradier O, Coron T, Kucharcezwski C, d'Hollander A, et al</AU>
<TI>Effects of aprotinin on blood loss, heparin monitoring tests, and heparin doses in patients undergoing coronary artery bypass surgery</TI>
<SO>Journal of Cardiothoracic &amp; Vascular Anesthesia</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>3</NO>
<PG>245-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hiipala-1995" MODIFIED="2008-09-08 22:33:08 +0100" MODIFIED_BY="[Empty name]" NAME="Hiipala 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-09-08 22:33:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hiippala S, Strid L, Wennerstrand M, Arvela V, Mantyla S, Ylinen J, et al</AU>
<TI>Tranexamic acid (Cyklokapron) reduces perioperative blood loss associated with total knee arthroplasty</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1995</YR>
<VL>74</VL>
<NO>5</NO>
<PG>534-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hiipala-1997" NAME="Hiipala 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hiippala ST, Strid LJ, Wennerstrand MI, Arvela JVV, Niemela HM, Mantyla SK, et al</AU>
<TI>Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>1997</YR>
<VL>84</VL>
<NO>4</NO>
<PG>839-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hill-1998" NAME="Hill 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hill GE, Diego RP, Stammers AH, Huffman SM, Pohorecki R</AU>
<TI>Aprotinin enhances the endogenous release of interleukin-10 after cardiac operations</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1998</YR>
<VL>65</VL>
<NO>1</NO>
<PG>66-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horrow-1990" NAME="Horrow 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horrow JC, Hlavacek J, Strong MD, Collier W, Brodsky I, Goldman SM, Goel IP</AU>
<TI>Prophylactic tranexamic acid decreases bleeding after cardiac operations</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1990</YR>
<VL>99</VL>
<NO>1</NO>
<PG>70-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horrow-1991" NAME="Horrow 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horrow JC, Van Riper DF, Strong MD, Brodsky I, Parmet JL</AU>
<TI>Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery</TI>
<SO>Circulation</SO>
<YR>1991</YR>
<VL>84</VL>
<NO>5</NO>
<PG>2063-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horrow-1995" NAME="Horrow 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horrow JC, Van Riper DF, Strong MD, Grunewald KE, Parmet JL</AU>
<TI>The dose-response relationship of tranexamic acid</TI>
<SO>Anesthesiology</SO>
<YR>1995</YR>
<VL>82</VL>
<NO>2</NO>
<PG>383-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Husted-2003" NAME="Husted 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Husted H, Blond L, Sonne-Holm S, Holm G, Jacobsen TW, Gebuhr P</AU>
<TI>Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients</TI>
<SO>Acta Orthopaedica Scandinavica</SO>
<YR>2003</YR>
<VL>74</VL>
<NO>6</NO>
<PG>665-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ickx-2006" NAME="Ickx 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ickx BE, Van Der Linden PJ, Melot C, Wijns W, De Pauw L, Vandestadt J, et al</AU>
<TI>Comparison of the effects of aprotinin and tranexamic acid on blood loss and red blood cell transfusion requirements during the late stages of liver transplantation</TI>
<SO>Transfusion</SO>
<YR>2006</YR>
<VL>46</VL>
<NO>4</NO>
<PG>595-605</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Isetta-1993" NAME="Isetta 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Isetta C, Gunness TK, Samat C, Paolini G, Lugrin D, Sanchez B, et al</AU>
<TI>Antifibrinolytic Treatment and Homologeous Transfusion in Cardiac Surgery</TI>
<SO>European Heart Journal</SO>
<YR>1993</YR>
<VL>14</VL>
<NO>Suppl</NO>
<PG>424</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jamieson-1997" MODIFIED="2008-09-08 22:33:16 +0100" MODIFIED_BY="[Empty name]" NAME="Jamieson 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-09-08 22:33:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jamieson WRE, Dryden PJ, O'Connor JP, Sadeghi H, Ansley DM, Merrick PM, et al</AU>
<TI>Beneficial effect of both tranexamic acid and aprotinin on blood loss reduction in reoperative valve replacement surgery</TI>
<SO>Circulation</SO>
<YR>1997</YR>
<VL>96</VL>
<NO>9 SUPPL</NO>
<PG>II96-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jansen-1999" NAME="Jansen 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jansen AJ, Andreica S, Claeys M, D'Haese J, Camu F, Jochmans K</AU>
<TI>Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1999</YR>
<VL>83</VL>
<NO>4</NO>
<PG>596-601</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janssens-1994" NAME="Janssens 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Janssens M, Joris J, David JL, Lemaire R, Lamy M</AU>
<TI>High-dose aprotinin reduces blood loss in patients undergoing total hip replacement surgery. [see comments]</TI>
<SO>Anesthesiology</SO>
<YR>1994</YR>
<VL>80</VL>
<NO>1</NO>
<PG>23-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jares-2003" NAME="Jares 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jares M, Vanek T, Straka Z, Brucek P</AU>
<TI>Tranexamic acid reduces bleeding after off-pump coronary artery bypass grafting</TI>
<SO>Journal of Cardiovascular Surgery</SO>
<YR>2003</YR>
<VL>44</VL>
<NO>2</NO>
<PG>205-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jeserschek-2003" NAME="Jeserschek 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jeserschek R, Clar H, Aigner C, Rehak P, Primus B, Windhager R</AU>
<TI>Reduction of blood loss using high-dose aprotinin in major orthopaedic surgery: a prospective, double-blind, randomised and placebo-controlled study</TI>
<SO>Journal of Bone &amp; Joint Surgery - British Volume</SO>
<YR>2003</YR>
<VL>85</VL>
<NO>2</NO>
<PG>174-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jimenez-2007" MODIFIED="2010-05-28 10:43:37 +0100" MODIFIED_BY="Katharine Ker" NAME="Jimenez 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-05-17 14:35:49 +0100" MODIFIED_BY="Katharine Ker" NOTES="&lt;p&gt;Connective Phrase: PUBMED 17988379Notes: Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't&lt;br&gt;ER  -&lt;/p&gt;" NOTES_MODIFIED="2010-05-17 14:35:49 +0100" NOTES_MODIFIED_BY="Katharine Ker" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jimenez J J, Iribarren J L, Lorente L, Rodriguez J M, Hernandez D, Nassar I, et al</AU>
<TI>Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial</TI>
<SO>Critical care (London, England)</SO>
<YR>2007</YR>
<VL>11</VL>
<NO>6</NO>
<PG>R117</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-28 10:43:37 +0100" MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jimenez Rivera J, Iribarren Sarrias J, Nassar I, Rodriguez J, Raya J, Garrido P et al</AU>
<TI>Tranexamic acid decreased postoperative bleeding and systemic inflammatory response syndrome associated with cardiopulmonary bypass: a prospective, randomized, double-blind controlled study</TI>
<SO>Critical Care</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>Suppl 1</NO>
<PG>S95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johansson-2005" NAME="Johansson 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johansson T, Pettersson LG, Lisander B</AU>
<TI>Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients</TI>
<SO>Acta Orthopaedica</SO>
<YR>2005</YR>
<VL>76</VL>
<NO>3</NO>
<PG>314-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kahveci-1996" NAME="Kahveci 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kahveci SF, Ozkan U, Korfali G, Sahin S</AU>
<TI>Effects of intraoperative aprotinin administration on hemostatic parameters in patients undergoing cardiac surgery [Turkish]</TI>
<SO>Turk Anesteziyoloji Ve Reanimasyon</SO>
<YR>1996</YR>
<VL>24</VL>
<NO>9</NO>
<PG>404-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalangos-1994" NAME="Kalangos 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalangos A, Tayyareci G, Pretre R, Di Dio P, Sezerman O</AU>
<TI>Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization</TI>
<SO>European Journal of Cardiothoracic Surgery</SO>
<YR>1994</YR>
<VL>8</VL>
<NO>12</NO>
<PG>651-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karski-1995" NAME="Karski 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karski JM, Teasdale SJ, Norman P, Carroll J, VanKessel K, Wong P, et al</AU>
<TI>Prevention of bleeding after cardiopulmonary bypass with high-dose tranexamic acid. Double-blind, randomized clinical trial</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1995</YR>
<VL>110</VL>
<NO>3</NO>
<PG>835-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karski-2005" NAME="Karski 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karski J, Djaiani G, Carroll J, Iwanochko M, Seneviratne P, Liu P, et al</AU>
<TI>Tranexamic acid and early saphenous vein graft patency in conventional coronary artery bypass graft surgery: a prospective randomized controlled clinical trial</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>2005</YR>
<VL>130</VL>
<NO>2</NO>
<PG>309-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaspar-1997" MODIFIED="2008-09-08 22:33:28 +0100" MODIFIED_BY="[Empty name]" NAME="Kaspar 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-09-08 22:33:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaspar M, Ramsay MAE, Nguyen AT, Cogswell M, Hurst G, Ramsay KJ</AU>
<TI>Continuous small-dose tranexamic acid reduces fibrinolysis but not transfusion requirements during orthotopic liver transplantation</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>1997</YR>
<VL>85</VL>
<NO>2</NO>
<PG>281-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katoh-1997" NAME="Katoh 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Katoh J, Tsuchiya K, Sato W, Nakajima M, Iida Y</AU>
<TI>Additional postbypass administration of tranexamic acid reduces blood loss after cardiac operations</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1997</YR>
<VL>113</VL>
<NO>4</NO>
<PG>802-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katsaros-1996" MODIFIED="2008-09-08 22:33:33 +0100" MODIFIED_BY="[Empty name]" NAME="Katsaros 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-09-08 22:33:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Katsaros D, Petricevic M, Snow NJ, Woodhall DD, Van Bergen R</AU>
<TI>Tranexamic acid reduces postbypass blood use: a double-blinded, prospective, randomized study of 210 patients</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1996</YR>
<VL>61</VL>
<NO>4</NO>
<PG>1131-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katzel-1998" NAME="Katzel 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Katzel R, Keuper H, Wiedemann B, Brethner L, Voigt B</AU>
<TI>Effects of aprotinin application on perioperative changes in hemostasis and fibrinolysis and its consequence for blood loss and transfusion requirement in lung surgery. [German]</TI>
<SO>Infusionstherapie und Transfusionsmedizin</SO>
<YR>1998</YR>
<VL>25</VL>
<NO>4</NO>
<PG>236-245</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kazemi-2010" MODIFIED="2010-12-03 15:14:35 +0000" MODIFIED_BY="Katharine Ker" NAME="Kazemi 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-12-03 15:14:35 +0000" MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kazemi SM, Mosaffa F, Eajazi A, Kaffashi M, Daftari Besheli L, Reza Bigdeli M et al</AU>
<TI>The effects of tranexamic acid on reducing blood loss in cementless total hip arthroplasty under epidural anesthesia</TI>
<SO>Orthopedics</SO>
<YR>2010</YR>
<VL>33</VL>
<NO>1</NO>
<PG>17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kikura-2006" NAME="Kikura 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kikura M, Levy JH, Tanaka KA, Ramsay JG</AU>
<TI>A double-blind, placebo-controlled trial of epsilon-aminocaproic acid for reducing blood loss in coronary artery bypass grafting surgery</TI>
<SO>Journal of the American College of Surgeons</SO>
<YR>2006</YR>
<VL>202</VL>
<NO>2</NO>
<PG>216-222</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kipfer-2003" NAME="Kipfer 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kipfer B, Englberger L, Gygax E, Nydegger U, Carrel T</AU>
<TI>Is reduced systemic heparinization justified with heparin-bonded bypass circuits in cardiac surgery? - Experience with and without aprotinin</TI>
<SO>Transfusion &amp; Apheresis Science</SO>
<YR>2003</YR>
<VL>29</VL>
<NO>1</NO>
<PG>17-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klein-1998" MODIFIED="2008-09-10 10:38:54 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Klein 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-09-10 10:38:54 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klein M, Keith PR, Dauben HP, Schulte HD, Beckmann H, Mayer G, Elert O, Gams E</AU>
<TI>Aprotinin counterbalances an increased risk of peri-operative hemorrhage in CABG patients pre-treated with Aspirin</TI>
<SO>European Journal of Cardio-Thoracic Surgery</SO>
<YR>1998</YR>
<VL>14</VL>
<NO>4</NO>
<PG>360-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kluger-2003" MODIFIED="2008-09-10 10:39:06 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Kluger 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-09-10 10:39:06 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kluger R, Olive DJ, Stewart AB, Blyth CM</AU>
<TI>Epsilon-aminocaproic acid in coronary artery bypass graft surgery: preincision or postheparin?</TI>
<SO>Anesthesiology</SO>
<YR>2003</YR>
<VL>99</VL>
<NO>6</NO>
<PG>1263-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koster-2004" MODIFIED="2008-09-10 10:39:15 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Koster 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-09-10 10:39:15 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koster A, Huebler S, Merkle F, Hentschel T, Grundel M, Krabatsch T, Tambeur L, Praus M, Habazettl H, Kuebler WM, Kuppe H</AU>
<TI>Heparin-level-based anticoagulation management during cardiopulmonary bypass: a pilot investigation on the effects of a half-dose aprotinin protocol on postoperative blood loss and hemostatic activation and inflammatory response</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>2004</YR>
<VL>98</VL>
<NO>2</NO>
<PG>285-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kratzer-1997" NAME="Kratzer 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kratzer MAA, Azad SC, Groh J, Welte M, Haller M, Pratschke E</AU>
<TI>Effect of aprotinin on blood loss and coagulation parameters in orthotopic liver transplantation. [German]</TI>
<SO>Anaesthesist</SO>
<YR>1997</YR>
<VL>46</VL>
<NO>4</NO>
<PG>294-302</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kreisler-2005" MODIFIED="2008-09-10 10:39:24 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Kreisler 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-09-10 10:39:24 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kreisler KR, Vance RA, Cruzzavala J, Mahnken JD</AU>
<TI>Heparin-bonded cardiopulmonary bypass circuits reduce the rate of red blood cell transfusion during elective coronary artery bypass surgery</TI>
<SO>Journal of Cardiothoracic &amp; Vascular Anesthesia</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>5</NO>
<PG>608-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuepper-2003" MODIFIED="2008-09-10 10:39:31 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Kuepper 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-09-10 10:39:31 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuepper F, Dangas G, Mueller-Chorus A, Kulka PM, Zenz M, Wiebalck A</AU>
<TI>Fibrinolytic activity and bleeding after cardiac surgery with cardiopulmonary bypass and low-dose aprotinin therapy</TI>
<SO>Blood Coagulation &amp; Fibrinolysis</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>2</NO>
<PG>147-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuitunen-2005" MODIFIED="2008-09-10 10:39:37 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Kuitunen 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-09-10 10:39:37 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuitunen A, Hiippala S, Vahtera E, Rasi V, Salmenpera M</AU>
<TI>The effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic response after cardiac surgery</TI>
<SO>Acta Anaesthesiologica Scandinavica</SO>
<YR>2005</YR>
<VL>49</VL>
<NO>9</NO>
<PG>1272-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuitunen-2006" MODIFIED="2010-01-13 15:19:51 +0000" MODIFIED_BY="Katharine Ker" NAME="Kuitunen 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-13 15:19:51 +0000" MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuitunen AH, Suojaranta-Ylinen RT, Kukkonen SI, Niemi TT</AU>
<TI>Tranexamic acid does not correct the haemostatic impairment caused by hydroxyethyl starch (200 kDa/0.5) after cardiac surgery</TI>
<SO>Blood Coagulation and Fibrinolysis</SO>
<YR>2006</YR>
<VL>17</VL>
<PG>639-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kunt-2005" NAME="Kunt 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kunt AS, Darcin OT, Aydin S, Demir D, Selli C, Andac MH</AU>
<TI>Mini-dose pump-prime aprotinin inhibited enhanced fibrinolytic activity and reduced blood loss and transfusion requirements after coronary artery bypass surgery</TI>
<SO>Journal of Thrombosis &amp; Thrombolysis</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>3</NO>
<PG>197-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kyriss-2001" NAME="Kyriss 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kyriss T, Wurst H, Friedel G, Jaki R, Toomes H</AU>
<TI>Reduced blood loss by aprotinin in thoracic surgical operations associated with high risk of bleeding. A placebo-controlled, randomized phase IV study</TI>
<SO>European Journal of Cardio-Thoracic Surgery</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>1</NO>
<PG>38-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Landymore-1997" MODIFIED="2008-09-08 22:33:47 +0100" MODIFIED_BY="[Empty name]" NAME="Landymore 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-09-08 22:33:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Landymore RW, Murphy JT, Lummis H, Carter C</AU>
<TI>The use of low-dose aprotinin, epsilon-aminocaproic acid or tranexamic acid for prevention of mediastinal bleeding in patients receiving aspirin before coronary artery bypass operations.</TI>
<SO>European Journal of Cardio-Thoracic Surgery</SO>
<YR>1997</YR>
<VL>11</VL>
<PG>798-800</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lass-1995" MODIFIED="2010-06-11 15:33:30 +0100" MODIFIED_BY="Katharine Ker" NAME="Lass 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-06-11 15:33:22 +0100" MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lass M, Simic O, Ostermeyer J</AU>
<TI>Re-Graft patency and clinical efficacy of aprotinin in elective bypass surgery</TI>
<SO>Cardiovascular Surgery</SO>
<YR>1997</YR>
<VL>5</VL>
<NO>6</NO>
<PG>604-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-06-11 15:33:30 +0100" MODIFIED_BY="Katharine Ker" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lass M, Welz A, Kochs M, Mayer G, Schwandt M, Hannekum A</AU>
<TI>Aprotinin in elective primary bypass surgery</TI>
<SO>European Journal of Cardio-thoracic Surgery</SO>
<YR>1995</YR>
<VL>9</VL>
<PG>206-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-02-09 12:14:43 +0000" MODIFIED_BY="Karen Blackhall"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Later-2009" MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NAME="Later 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NOTES="&lt;p&gt;Connective Phrase: PUBMED 19250838Notes: Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial&lt;br&gt;ER  -&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 15:02:44 +0100" NOTES_MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Later A F, Maas J J, Engbers F H, Versteegh M I, Bruggemans E F, Dion R A, et al</AU>
<TI>Tranexamic acid and aprotinin in low- and intermediate-risk cardiac surgery: a non-sponsored, double-blind, randomised, placebo-controlled trial</TI>
<SO>European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery</SO>
<YR>2009</YR>
<VL>36</VL>
<NO>2</NO>
<PG>322-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laub-1994" MODIFIED="2008-09-08 22:33:51 +0100" MODIFIED_BY="[Empty name]" NAME="Laub 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-09-08 22:33:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laub GW, Riebman JB, Chen C, Adkins MS, Anderson WA, Fernandez J, McGrath LB</AU>
<TI>The impact of aprotinin on coronary artery bypass graft patency</TI>
<SO>Chest</SO>
<YR>1994</YR>
<VL>106</VL>
<NO>5</NO>
<PG>1370-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lavee-1993" MODIFIED="2008-09-08 22:33:59 +0100" MODIFIED_BY="[Empty name]" NAME="Lavee 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-09-08 22:33:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lavee J, Raviv Z, Smolinsky A, Savion N, Varon D, Goor DA, Mohr R</AU>
<TI>Platelet protection by low-dose aprotinin in cardiopulmonary bypass: electron microscopic study</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1993</YR>
<VL>55</VL>
<NO>1</NO>
<PG>114-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leijdekkers-2006" MODIFIED="2010-05-06 17:03:18 +0100" MODIFIED_BY="Katharine Ker" NAME="Leijdekkers 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-05-06 17:03:15 +0100" MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leijdekkers VJ, Vahl AC, Mackaay AJC, Huijgens PC, Rauwerda JA</AU>
<TI>Aprotinin does not diminish blood loss in elective operations for infrarenal abdominal aneurysms: a randomized double-blind controlled trial</TI>
<SO>Annals of Vascular Surgery</SO>
<YR>2006</YR>
<VL>20</VL>
<PG>322-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lemay-2004" MODIFIED="2008-09-10 10:39:52 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Lemay 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-09-10 10:39:52 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lemay E, Guay J, Cote C, Roy A</AU>
<TI>Tranexamic acid reduces the need for allogenic red blood cell transfusions in patients undergoing total hip replacement</TI>
<SO>Canadian Journal of Anaesthesia</SO>
<YR>2004</YR>
<VL>51</VL>
<NO>1</NO>
<PG>31-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lemmer-1994" NAME="Lemmer 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lemmer JH, Jr., Stanford W, Bonney SL, Breen JF, Chomka EV, Eldredge WJ, Holt WW, Karp RB, Laub GW, Lipton MJ, et al</AU>
<TI>Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1994</YR>
<VL>107</VL>
<NO>2</NO>
<PG>543-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lemmer-1996" MODIFIED="2008-10-13 16:49:00 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Lemmer 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-10-13 16:49:00 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lemmer JH, Jr., Dilling EW, Morton JR, Rich JB, Robicsek F, Bricker DL, Hantler CB, Copeland JG, 3rd, Ochsner JL, Daily PO, et al</AU>
<TI>Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1996</YR>
<VL>62</VL>
<NO>6</NO>
<PG>1659-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lemmer_x005f_1-1994" MODIFIED="2010-06-11 15:35:28 +0100" MODIFIED_BY="Katharine Ker" NAME="Lemmer_1 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-06-11 15:35:07 +0100" MODIFIED_BY="Katharine Ker" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lemmer JH, Jr., Stanford W, Bonney SL, Breen JF, Chomka EV, Eldredge WJ, Holt WW, Karp RB, Laub GW, Lipton MJ, et al</AU>
<TI>Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1994</YR>
<VL>107</VL>
<NO>2</NO>
<PG>543-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-06-11 15:35:28 +0100" MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lemmer JH, Jr., Stanford W, Bonney SL, Chomka EV, Karp RB, Laub GW, Rumberger JA, Schaff HV</AU>
<TI>Aprotinin for coronary artery bypass grafting: effect on postoperative renal function</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1995</YR>
<VL>59</VL>
<NO>1</NO>
<PG>132-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lemmer_x005f_2-1994" MODIFIED="2010-06-11 15:35:55 +0100" MODIFIED_BY="Katharine Ker" NAME="Lemmer_2 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-06-11 15:35:55 +0100" MODIFIED_BY="Katharine Ker" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lemmer JH, Jr., Stanford W, Bonney SL, Breen JF, Chomka EV, Eldredge WJ, Holt WW, Karp RB, Laub GW, Lipton MJ, et al</AU>
<TI>Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1994</YR>
<VL>107</VL>
<NO>2</NO>
<PG>543-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-06-11 15:35:49 +0100" MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lemmer JH, Jr., Stanford W, Bonney SL, Chomka EV, Karp RB, Laub GW, Rumberger JA, Schaff HV</AU>
<TI>Aprotinin for coronary artery bypass grafting: effect on postoperative renal function</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1995</YR>
<VL>59</VL>
<NO>1</NO>
<PG>132-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lentschener-1997" MODIFIED="2008-09-08 22:34:20 +0100" MODIFIED_BY="[Empty name]" NAME="Lentschener 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-09-08 22:34:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lentschener C, Benhamou D, Mercier FJ, Boyer-Neumann C, Naveau S, Smadja C, Wolf M, Franco D</AU>
<TI>Aprotinin reduces blood loss in patients undergoing elective liver resection</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>1997</YR>
<VL>84</VL>
<NO>4</NO>
<PG>875-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lentschener-1999" NAME="Lentschener 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lentschener C, Cottin P, Bouaziz H, Mercier FJ, Wolf M, Aljabi Y, et al</AU>
<TI>Reduction of blood loss and transfusion requirement by aprotinin in posterior lumbar spine fusion</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>1999</YR>
<VL>89</VL>
<NO>3</NO>
<PG>590-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levy-1995" MODIFIED="2008-10-13 16:49:39 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Levy 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-10-13 16:49:39 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levy JH, Pifarre R, Schaff HV, Horrow JC, Albus R, Spiess B, Rosengart TK, Murray J, Clark RE, Smith P</AU>
<TI>A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting</TI>
<SO>Circulation</SO>
<YR>1995</YR>
<VL>92</VL>
<NO>8</NO>
<PG>2236-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2005" MODIFIED="2008-10-13 16:49:26 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Li 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-10-13 16:49:26 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li S, Ji H, Lin J, Lenehan E, Ji B, Liu J, et al</AU>
<TI>Combination of acute preoperative plateletpheresis, cell salvage, and aprotinin minimizes blood loss and requirement during cardiac surgery</TI>
<SO>Journal of Extra-Corporeal Technology</SO>
<YR>2005</YR>
<VL>37</VL>
<NO>1</NO>
<PG>9-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-1993" MODIFIED="2010-06-11 15:37:18 +0100" MODIFIED_BY="Katharine Ker" NAME="Liu 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-06-11 15:37:18 +0100" MODIFIED_BY="Katharine Ker" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Liu B, Belboul A, Radberg G, Tengborn L, Dernevik L, Roberts D, William-Olsson G</AU>
<TI>Effect of reduced aprotinin dosage on blood loss and use of blood products in patients undergoing cardiopulmonary bypass</TI>
<SO>Scandinavian Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1993</YR>
<VL>27</VL>
<NO>3-4</NO>
<PG>149-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-06-11 15:37:11 +0100" MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu B, Tengborn L, Larson G, Radberg LO, Belboul A, Dernevik L, Roberts D</AU>
<TI>Half-dose aprotinin preserves hemostatic function in patients undergoing bypass operations</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1995</YR>
<VL>59</VL>
<NO>6</NO>
<PG>1534-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-1998" NAME="Liu 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu YC, Tsai TP</AU>
<TI>The effect of coagulation protection with combination of epsilon aminocaproic acid and plasma saver in open-heart surgery</TI>
<SO>Acta Anaesthesiologica Sinica</SO>
<YR>1998</YR>
<VL>36</VL>
<NO>3</NO>
<PG>149-154</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Llau-1998" NAME="Llau 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Llau JV, Aguilar G, Soliveres J, Minguez MF, Saz T, Belda FJ</AU>
<TI>Aprotinin administration reduces blood loss and transfusion requirements in patients undergoing total hip arthroplasty. [abstract]</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1998</YR>
<VL>80</VL>
<NO>Suppl 1</NO>
<PG>80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Locatelli-1990" MODIFIED="2008-09-08 22:34:38 +0100" MODIFIED_BY="[Empty name]" NAME="Locatelli 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-09-08 22:34:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Locatelli A, Bertollo D, Bianchi T, et al</AU>
<TI>Aprotinin in cardiosurgery: a randomized prospective study with different protocols for use. [Italian]</TI>
<SO>Minerva Anestesiologica</SO>
<YR>1990</YR>
<VL>56</VL>
<PG>973-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luo-1998" MODIFIED="2010-05-28 10:54:03 +0100" MODIFIED_BY="Katharine Ker" NAME="Luo 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-05-28 10:54:03 +0100" MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luo J, Huang Y, Lan H</AU>
<TI>Effect of Aprotinin on the red cell immunity in cardiopulmonary bypass</TI>
<SO>Journal of Tongi Medical University</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>2</NO>
<PG>97-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maccario-1994" MODIFIED="2008-09-08 22:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Maccario 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-09-08 22:34:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maccario M, Fumagalli C, Deangelis R, Delfino R, Pergolo A, Dottori V, Barberis L</AU>
<TI>Comparison between low and high doses of aprotinin in heart surgery. [Italian]</TI>
<SO>Minerva Anestesiologica</SO>
<YR>1994</YR>
<VL>60</VL>
<NO>6</NO>
<PG>315-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MacGillivray-2010" MODIFIED="2010-05-28 10:55:23 +0100" MODIFIED_BY="Katharine Ker" NAME="MacGillivray 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-05-28 10:55:23 +0100" MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>MacGillivray RG, Tarabichi SB, Hawari MF, Raoof NT</AU>
<TI>Tranexamic acid to reduce blood loss after bilateral total knee arthroplasty</TI>
<SO>The Journal of Arthroplasty</SO>
<YR>2010</YR>
<VL>[In press]</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maddali-2007" MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NAME="Maddali 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NOTES="&lt;p&gt;Connective Phrase: PUBMED 17664205Notes: Publication Type: Journal Article; Randomized Controlled Trial&lt;br&gt;ER  -&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 15:02:44 +0100" NOTES_MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maddali M M, Rajakumar M C</AU>
<TI>Tranexamic acid and primary coronary artery bypass surgery: a prospective study</TI>
<SO>Asian cardiovascular &amp; thoracic annals</SO>
<YR>2007</YR>
<VL>15</VL>
<NO>4</NO>
<PG>313-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maineri-2000" MODIFIED="2008-09-10 10:40:29 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Maineri 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-09-10 10:40:29 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maineri P, Covaia G, Realini M, Caccia G, Ucussich E, Luraschi M, Crosta A, Foresti B, Chiaranda M</AU>
<TI>Postoperative bleeding after coronary revascularization. Comparison between tranexamic acid and epsilon-aminocaproic acid</TI>
<SO>Minerva Cardioangiologica</SO>
<YR>2000</YR>
<VL>48</VL>
<NO>6</NO>
<PG>155-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mansour-2004" MODIFIED="2008-09-10 10:40:24 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Mansour 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-09-10 10:40:24 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mansour EE, Mustafa B</AU>
<TI>Aprotinin versus tranexamic acid in patients receiving aspirin and undergoing off-pump coronary artery bypass</TI>
<SO>Egyptian Journal of Anaesthesia</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>3</NO>
<PG>229-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marcel-1996" MODIFIED="2008-09-08 22:34:48 +0100" MODIFIED_BY="[Empty name]" NAME="Marcel 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-09-08 22:34:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marcel RJ, Stegall WC, Suit CT, Arnold JC, Vera RL, Ramsay MA, O'Donnell MB, Swygert TH, Hein HA, Whitten CW</AU>
<TI>Continuous small-dose aprotinin controls fibrinolysis during orthotopic liver transplantation</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>1996</YR>
<VL>82</VL>
<NO>6</NO>
<PG>1122-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mehr_x002d_Aein-2007" MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NAME="Mehr-Aein 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NOTES="&lt;p&gt;Connective Phrase: PUBMED 17664199Notes: Publication Type: Journal Article; Randomized Controlled Trial&lt;br&gt;ER  -&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 15:02:44 +0100" NOTES_MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mehr-Aein A, Sadeghi M, Madani-civi M</AU>
<TI>Does tranexamic acid reduce blood loss in off-pump coronary artery bypass?</TI>
<SO>Asian cardiovascular &amp; thoracic annals</SO>
<YR>2007</YR>
<VL>15</VL>
<NO>4</NO>
<PG>285-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mengistu-2008" MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NAME="Mengistu 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NOTES="&lt;p&gt;Connective Phrase: PUBMED 18633013Notes: Publication Type: Journal Article; Randomized Controlled Trial&lt;br&gt;ER  -&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 15:02:44 +0100" NOTES_MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mengistu A M, Röhm K D, Boldt J, Mayer J, Suttner S W, Piper S N</AU>
<TI>The influence of aprotinin and tranexamic acid on platelet function and postoperative blood loss in cardiac surgery</TI>
<SO>Anesthesia and analgesia</SO>
<YR>2008</YR>
<VL>107</VL>
<NO>2</NO>
<PG>391-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Menichetti-1996" MODIFIED="2008-09-08 22:34:51 +0100" MODIFIED_BY="[Empty name]" NAME="Menichetti 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-09-08 22:34:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Menichetti A, Tritapepe L, Ruvolo G, Speziale G, Cogliati A, Di Giovann C, Pacilli M, Criniti A</AU>
<TI>Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid</TI>
<SO>Journal of Cardiovascular Surgery</SO>
<YR>1996</YR>
<VL>37</VL>
<NO>4</NO>
<PG>401-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Misfeld-1998" MODIFIED="2008-09-10 10:40:40 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Misfeld 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-09-10 10:40:40 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Misfeld M, Dubbert S, Eleftheriadis S, Siemens HJ, Wagner T, Sievers HH</AU>
<TI>Fibrinolysis-adjusted perioperative low-dose aprotinin reduces blood loss in bypass operations</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1998</YR>
<VL>66</VL>
<NO>3</NO>
<PG>792-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mohr-1992" MODIFIED="2008-09-08 22:34:55 +0100" MODIFIED_BY="[Empty name]" NAME="Mohr 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-09-08 22:34:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohr R, Goor DA, Lusky A, Lavee J</AU>
<TI>Aprotinin prevents cardiopulmonary bypass-induced platelet dysfunction. A scanning electron microscope study</TI>
<SO>Circulation</SO>
<YR>1992</YR>
<VL>86</VL>
<NO>5:Suppl</NO>
<PG>II405-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mongan-1998" MODIFIED="2008-09-10 10:40:50 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Mongan 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-09-10 10:40:50 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mongan PD, Brown RS, Thwaites BK</AU>
<TI>Tranexamic acid and aprotinin reduce postoperative bleeding and transfusions during primary coronary revascularization</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>1998</YR>
<VL>87</VL>
<NO>2</NO>
<PG>258-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moran-2000" MODIFIED="2008-09-10 10:40:58 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Moran 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-09-10 10:40:58 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moran SV, Lema G, Medel J, Irarrazaval MJ, Zalaquett R, Garayar B, Flaskamp R</AU>
<TI>Comparison of two doses of aprotinin in patients receiving aspirin before coronary bypass surgery</TI>
<SO>Perfusion</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>2</NO>
<PG>105-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murkin-1994" MODIFIED="2008-09-08 22:35:02 +0100" MODIFIED_BY="[Empty name]" NAME="Murkin 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-09-08 22:35:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murkin JM, Lux J, Shannon NA, Guiraudon GM, Menkis AH, McKenzie FN, Novick RJ</AU>
<TI>Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1994</YR>
<VL>107</VL>
<NO>2</NO>
<PG>554-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murkin-1995" MODIFIED="2008-09-08 22:35:07 +0100" MODIFIED_BY="[Empty name]" NAME="Murkin 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-09-08 22:35:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murkin JM, Shannon NA, Bourne RB, Rorabeck CH, Cruickshank M, Wyile G</AU>
<TI>Aprotinin decreases blood loss in patients undergoing revision or bilateral total hip arthroplasty</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>1995</YR>
<VL>80</VL>
<NO>2</NO>
<PG>343-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murkin-2000" MODIFIED="2008-09-10 10:41:07 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Murkin 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-09-10 10:41:07 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murkin JM, Haig GM, Beer KJ, Cicutti N, McCutchen J, Comunale ME, Hall R, Ruzicka BB</AU>
<TI>Aprotinin decreases exposure to allogeneic blood during primary unilateral total hip replacement</TI>
<SO>Journal of Bone &amp; Joint Surgery</SO>
<YR>2000</YR>
<VL>82</VL>
<NO>5</NO>
<PG>675-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murphy-2006" MODIFIED="2010-05-28 10:57:57 +0100" MODIFIED_BY="Katharine Ker" NAME="Murphy 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-05-28 10:57:57 +0100" MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murphy GJ, Mango E, Lucchetti V, Battaglia F, Catapano D, Rogers CA et al</AU>
<TI>A randomized trial of tranexamic acid in combination with cell salvage plus a meta-analysis of randomized trials evaluating tranexamic acid in off-pump coronary artery bypass grafting</TI>
<SO>Cardiopulmonary &amp; Physiology</SO>
<YR>2006</YR>
<VL>132</VL>
<NO>3</NO>
<PG>475-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niskanen-2005" MODIFIED="2008-09-10 10:41:14 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Niskanen 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-09-10 10:41:14 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niskanen RO, Korkala OL</AU>
<TI>Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis</TI>
<SO>Acta Orthopaedica</SO>
<YR>2005</YR>
<VL>76</VL>
<NO>6</NO>
<PG>829-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Norman-2009" MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NAME="Norman 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NOTES="&lt;p&gt;Connective Phrase: PUBMED 19130460Notes: Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't&lt;br&gt;ER  -&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 15:02:44 +0100" NOTES_MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Norman P H, Thall P F, Purugganan R V, Riedel B J, Thakar D R, Rice D C, et al</AU>
<TI>A possible association between aprotinin and improved survival after radical surgery for mesothelioma</TI>
<SO>Cancer</SO>
<YR>2009</YR>
<VL>115</VL>
<NO>4</NO>
<PG>833-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nur_x00f6_zler-2008" MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NAME="Nurözler 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NOTES="&lt;p&gt;Connective Phrase: PUBMED 18984759Notes: Publication Type: Journal Article; Randomized Controlled Trial&lt;br&gt;ER  -&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 15:02:44 +0100" NOTES_MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nurözler F, Kutlu T, Küçük G</AU>
<TI>Aprotinin for patients exposed to clopidogrel before off-pump coronary bypass</TI>
<SO>Asian cardiovascular &amp; thoracic annals</SO>
<YR>2008</YR>
<VL>16</VL>
<NO>6</NO>
<PG>483-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nuttall-2000" MODIFIED="2008-09-10 10:41:23 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Nuttall 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-09-10 10:41:23 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nuttall GA, Oliver WC, Ereth MH, Santrach PJ, Bryant SC, Orszulak TA, Schaff HV</AU>
<TI>Comparison of blood-conservation strategies in cardiac surgery patients at high risk for bleeding</TI>
<SO>Anesthesiology</SO>
<YR>2000</YR>
<VL>92</VL>
<NO>3</NO>
<PG>674-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Okita-1996" MODIFIED="2008-09-08 22:35:13 +0100" MODIFIED_BY="[Empty name]" NAME="Okita 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-09-08 22:35:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okita Y, Takamoto S, Ando M, Morota T, Yamaki F, Kawashima Y</AU>
<TI>Is use of aprotinin safe with deep hypothermic circulatory arrest in aortic surgery? Investigations on blood coagulation</TI>
<SO>Circulation</SO>
<YR>1996</YR>
<VL>94</VL>
<NO>Suppl</NO>
<PG>II177-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Orpen-2006" MODIFIED="2008-09-10 10:41:32 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Orpen 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-09-10 10:41:32 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Orpen NM, Little C, Walker G, Crawfurd EJP</AU>
<TI>Tranexamic acid reduces early post-operative blood loss after total knee arthroplasty: A prospective randomised controlled trial of 29 patients</TI>
<SO>Knee</SO>
<YR>2006</YR>
<VL>13</VL>
<NO>2</NO>
<PG>106-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Palmer-2003" MODIFIED="2008-09-10 10:41:38 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Palmer 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-09-10 10:41:38 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palmer JD, Francis JL, Pickard JD, Iannotti F</AU>
<TI>The efficacy and safety of aprotinin for hemostasis during intracranial surgery</TI>
<SO>Journal of Neurosurgery</SO>
<YR>2003</YR>
<VL>98</VL>
<NO>6</NO>
<PG>1208-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parvizi-2007" MODIFIED="2010-04-08 15:05:29 +0100" MODIFIED_BY="Katharine Ker" NAME="Parvizi 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-04-08 15:05:29 +0100" MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parvizi R, Azarfarin R, Hassanzadeh S</AU>
<TI>Ultra-low dose aprotinin effects on reducing the need for blood transfusion in cardiac surgery</TI>
<SO>Saudi Medical Journal</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>1</NO>
<PG>49-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Penta-de-Peppo-1995" MODIFIED="2008-09-08 22:35:19 +0100" MODIFIED_BY="[Empty name]" NAME="Penta de Peppo 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-09-08 22:35:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Penta de Peppo A, Pierri MD, Scafuri A, De Paulis R, Colantuono G, Caprara E, Tomai F, Chiariello L</AU>
<TI>Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. Prospective trial of 3 antifibrinolytic drugs</TI>
<SO>Texas Heart Institute Journal</SO>
<YR>1995</YR>
<VL>22</VL>
<NO>3</NO>
<PG>231-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petsatodis-2006" MODIFIED="2008-09-10 10:41:48 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Petsatodis 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-09-10 10:41:48 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petsatodis G, Samoladas E, Christodoulou A, Hatzokos I, Pournaras I</AU>
<TI>Does aprotinin reduce blood loss in total hip arthroplasty?</TI>
<SO>Orthopedics</SO>
<YR>2006</YR>
<VL>29</VL>
<NO>1</NO>
<PG>75-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pinosky-1997" MODIFIED="2008-09-10 10:41:54 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Pinosky 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-09-10 10:41:54 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pinosky ML, Kennedy DJ, Fishman RL, Reeves ST, Alpert CC, Ecklund J, Kribbs S, Spinale FG, Kratz JM, Crawford R, Gravlee GP, Dorman BH</AU>
<TI>Tranexamic acid reduces bleeding after cardiopulmonary bypass when compared to epsilon aminocaproic acid and placebo</TI>
<SO>Journal of Cardiac Surgery</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>5</NO>
<PG>330-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pleym-2003" MODIFIED="2008-09-10 10:42:01 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Pleym 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-09-10 10:42:01 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pleym H, Stenseth R, Wahba A, Bjella L, Karevold A, Dale O</AU>
<TI>Single-dose tranexamic acid reduces postoperative bleeding after coronary surgery in patients treated with aspirin until surgery</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>2003</YR>
<VL>96</VL>
<NO>4</NO>
<PG>923-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Porte-2000" MODIFIED="2008-09-10 10:42:07 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Porte 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-09-10 10:42:07 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Porte RJ, Molenaar IQ, Begliomini B, Groenland THN, Januszkiewicz A, Lindgren L, Palareti G, Hermans J, Terpstra OT</AU>
<TI>Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<NO>9212</NO>
<PG>1303-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poston-2006" NAME="Poston 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poston RS, White C, Gu J, Brown J, Gammie J, Pierson RN, et al</AU>
<TI>Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2006</YR>
<VL>81</VL>
<NO>1</NO>
<PG>104-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prendergast_x005f_1-1996" MODIFIED="2008-09-08 22:35:26 +0100" MODIFIED_BY="[Empty name]" NAME="Prendergast_1 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-09-08 22:35:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prendergast TW, Furukawa S, Beyer AJ, 3rd, Eisen HJ, McClurken JB, Jeevanandam V</AU>
<TI>Defining the role of aprotinin in heart transplantation</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1996</YR>
<VL>62</VL>
<NO>3</NO>
<PG>670-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prendergast_x005f_2-1996" MODIFIED="2008-09-08 22:35:29 +0100" MODIFIED_BY="[Empty name]" NAME="Prendergast_2 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-09-08 22:35:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prendergast TW, Furukawa S, Beyer AJ, 3rd, Eisen HJ, McClurken JB, Jeevanandam V</AU>
<TI>Defining the role of aprotinin in heart transplantation</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1996</YR>
<VL>62</VL>
<NO>3</NO>
<PG>670-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pugh-1995" MODIFIED="2008-09-08 22:35:32 +0100" MODIFIED_BY="[Empty name]" NAME="Pugh 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-09-08 22:35:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pugh SC, Wielogorski AK</AU>
<TI>A comparison of the effects of tranexamic acid and low-dose aprotinin on blood loss and homologous blood usage in patients undergoing cardiac surgery</TI>
<SO>Journal of Cardiothoracic &amp; Vascular Anesthesia</SO>
<YR>1995</YR>
<VL>9</VL>
<PG>240-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ranaboldo-1997" MODIFIED="2008-09-10 10:42:21 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Ranaboldo 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-09-10 10:42:21 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ranaboldo CJ, Thompson JF, Davies JN, Shutt AM, Francis JN, Roath OS, Webster JHH, Chant ADB</AU>
<TI>Prospective randomized placebo-controlled trial of aprotinin for elective aortic reconstruction</TI>
<SO>British Journal of Surgery</SO>
<YR>1997</YR>
<VL>84</VL>
<NO>8</NO>
<PG>1110-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rao-1999" MODIFIED="2008-09-10 10:42:28 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Rao 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-09-10 10:42:28 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rao BH, Saxena N, Chauhan S, Sashikanth M</AU>
<TI>Use of E-Aminocaproic acid in the management of aspirin related postoperative bleeding in patients undergoing coronary revascularization</TI>
<SO>Journal of Anaesthesiology Clinical Pharmacology</SO>
<YR>1999</YR>
<VL>15</VL>
<NO>3</NO>
<PG>261-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ray-1997" MODIFIED="2008-09-08 22:35:42 +0100" MODIFIED_BY="[Empty name]" NAME="Ray 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-09-08 22:35:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ray MJ, Marsh NA, Just SJ, Perrin EJ, O'Brien MF, Hawson GA</AU>
<TI>Preoperative platelet dysfunction increases the benefit of aprotinin in cardiopulmonary bypass</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1997</YR>
<VL>63</VL>
<NO>1</NO>
<PG>57-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ray-1999" MODIFIED="2008-09-10 10:42:35 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Ray 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-09-10 10:42:35 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ray MJ, Brown KF, Burrows CA, O'Brien MF</AU>
<TI>Economic evaluation of high-dose and low-dose aprotinin therapy during cardiopulmonary bypass</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1999</YR>
<VL>68</VL>
<NO>3</NO>
<PG>940-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ray-2001" MODIFIED="2008-09-10 10:42:58 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Ray 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-09-10 10:42:58 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ray MJ, O'Brien MF</AU>
<TI>Comparison of epsilon aminocaproic acid and low-dose aprotinin in cardiopulmonary bypass: efficiency, safety and cost</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2001</YR>
<VL>71</VL>
<NO>3</NO>
<PG>838-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ray-2005" MODIFIED="2008-09-10 10:35:55 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Ray 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-09-10 10:35:55 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ray M, Hatcher S, Whitehouse SL, Crawford S, Crawford R</AU>
<TI>Aprotinin and epsilon aminocaproic acid are effective in reducing blood loss after primary total hip arthroplasty--a prospective randomized double-blind placebo-controlled study</TI>
<SO>Journal of Thrombosis &amp; Haemostasis</SO>
<YR>2005</YR>
<VL>3</VL>
<NO>7</NO>
<PG>1421-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rhydderch-1993" MODIFIED="2010-05-28 11:00:30 +0100" MODIFIED_BY="Katharine Ker" NAME="Rhydderch 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-05-28 11:00:30 +0100" MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rhydderch RD, Khan B, Saleh A</AU>
<TI>Single dose Aprotinin in routine cardiac surgery</TI>
<SO>Middle East Journal of Anesthesiology</SO>
<YR>1993</YR>
<VL>12</VL>
<NO>3</NO>
<PG>287-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rocha-1994" MODIFIED="2008-09-08 22:35:54 +0100" MODIFIED_BY="[Empty name]" NAME="Rocha 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-09-08 22:35:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rocha E, Hidalgo F, Llorens R, Melero JM, Arroyo JL, Paramo JA</AU>
<TI>Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery</TI>
<SO>Circulation</SO>
<YR>1994</YR>
<VL>90</VL>
<NO>2</NO>
<PG>921-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodrigus-1996" MODIFIED="2008-09-08 22:36:01 +0100" MODIFIED_BY="[Empty name]" NAME="Rodrigus 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-09-08 22:36:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodrigus IE, Vermeyen KM, De Hert SG, Amsel BJ, Walter PJ</AU>
<TI>Efficacy and safety of aprotinin in aortocoronary bypass and valve replacement operations: a placebo-controlled randomized double-blind study</TI>
<SO>Perfusion</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>4</NO>
<PG>313-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rossi-1997" MODIFIED="2008-09-08 22:36:05 +0100" MODIFIED_BY="[Empty name]" NAME="Rossi 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-09-08 22:36:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rossi M, Storti S, Martinelli L, Varano C, Marra R, Zamparelli R, Possati G, Schiavello R</AU>
<TI>A pump-prime aprotinin dose in cardiac surgery: appraisal of its effects on the hemostatic system</TI>
<SO>Journal of Cardiothoracic &amp; Vascular Anesthesia</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>7</NO>
<PG>835-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Royston-1987" MODIFIED="2008-09-08 22:36:08 +0100" MODIFIED_BY="[Empty name]" NAME="Royston 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-09-08 22:36:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Royston D, Bidstrup BP, Taylor KM, Sapsford RN</AU>
<TI>Effect of aprotinin on need for blood transfusion after repeat open-heart surgery</TI>
<SO>Lancet</SO>
<YR>1987</YR>
<VL>2</VL>
<NO>8571</NO>
<PG>1289-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sadeghi-2007" MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NAME="Sadeghi 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NOTES="&lt;p&gt;CODEN: RCTNotes: Publication Type: Journal: Article&lt;br&gt;ER  -&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 15:02:44 +0100" NOTES_MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sadeghi M, Mehr-Aein A</AU>
<TI>Does a single bolus dose of tranexamic acid reduce blood loss and transfusion requirements during hip fracture surgery? A prospective randomized double blind study in 67 patients</TI>
<SO>Acta Medica Iranica</SO>
<YR>2007</YR>
<VL>45</VL>
<NO>6</NO>
<PG>437-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Samama-2002" MODIFIED="2008-10-13 16:50:40 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Samama 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-10-13 16:50:40 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Samama CM, Langeron O, Rosencher N, Capdevila X, Rouche P, Pegoix M, Berniere J, Coriat P</AU>
<TI>Aprotinin versus placebo in major orthopedic surgery: a randomized, double-blinded, dose-ranging study</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>2002</YR>
<VL>95</VL>
<NO>2</NO>
<PG>287-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santamaria-2000" MODIFIED="2008-09-10 10:43:42 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Santamaria 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-09-10 10:43:42 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santamaria A, Mateo J, Oliver A, Litvan H, Murillo J, Souto JC, Fontcuberta J</AU>
<TI>The effect of two different doses of aprotinin on hemostasis in cardiopulmonary bypass surgery: similar transfusion requirements and blood loss</TI>
<SO>Haematologica</SO>
<YR>2000</YR>
<VL>85</VL>
<NO>12</NO>
<PG>1277-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santos-2006" NAME="Santos 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santos ATL, Kalil RAK, Bauemann C, Pereira JB, Nesralla IA</AU>
<TI>A randomized, double-blind, and placebo-controlled study with tranexamic acid of bleeding and fibrinolytic activity after primary coronary artery bypass grafting</TI>
<SO>Brazilian Journal of Medical &amp; Biological Research</SO>
<YR>2006</YR>
<VL>39</VL>
<NO>1</NO>
<PG>63-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmartz-2003" MODIFIED="2008-10-13 16:50:53 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Schmartz 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-10-13 16:50:53 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmartz D, Tabardel Y, Preiser JC, Barvais L, d'Hollander A, Duchateau J, Vincent JL</AU>
<TI>Does aprotinin influence the inflammatory response to cardiopulmonary bypass in patients?</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>2003</YR>
<VL>125</VL>
<NO>1</NO>
<PG>184-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schweizer-2000" NAME="Schweizer 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schweizer A, Hohn L, Morel DR, Kalangos A, Licker M</AU>
<TI>Aprotinin does not impair renal haemodynamics and function after cardiac surgery</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>2000</YR>
<VL>84</VL>
<NO>1</NO>
<PG>16-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shore_x002d_Lesserson-1996" MODIFIED="2008-10-13 16:50:59 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Shore-Lesserson 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-10-13 16:50:59 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shore-Lesserson L, Reich DL, Vela-Cantos F, Ammar T, Ergin MA</AU>
<TI>Tranexamic acid reduces transfusions and mediastinal drainage in repeat cardiac surgery</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>1996</YR>
<VL>83</VL>
<NO>1</NO>
<PG>18-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sorin-1999" NAME="Sorin 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Sorin A, Claeys MA, Jansen A, D'Haese J, Camu F</AU>
<TI>Reduction of blood loss by tranexamic acid in total knee replacement</TI>
<SO>Journal of Bone &amp; Joint Surgery - British Volume</SO>
<YR>1999</YR>
<VL>81-B</VL>
<NO>Suppl.II</NO>
<PG>234</PG>
<EN>81-B</EN>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Speekenbrink-1995" MODIFIED="2008-09-08 22:36:30 +0100" MODIFIED_BY="[Empty name]" NAME="Speekenbrink 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-09-08 22:36:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Speekenbrink RG, Vonk AB, Wildevuur CR, Eijsman L</AU>
<TI>Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1995</YR>
<VL>59</VL>
<NO>2</NO>
<PG>438-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Speekenbrink-1996" MODIFIED="2008-09-10 10:44:40 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Speekenbrink 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-09-10 10:44:40 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Speekenbrink RGH, Wildevuur CRH, Sturk A, Eijsman L</AU>
<TI>Low-dose and high-dose aprotinin improve hemostasis in coronary operations</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1996</YR>
<VL>112</VL>
<NO>2</NO>
<PG>523-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stammers-1997" MODIFIED="2008-09-10 10:44:48 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Stammers 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-09-10 10:44:48 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stammers AH, Huffman S, Alonso A, Fristoe LW, Hill G, Casebeer D, Diego RP, Song Z</AU>
<TI>The antiinflammatory effects of aprotinin in patients undergoing cardiac surgery with cardiopulmonary bypass</TI>
<SO>Journal of Extra-Corporeal Technology</SO>
<YR>1997</YR>
<VL>29</VL>
<NO>3</NO>
<PG>114-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stewart-2001" MODIFIED="2008-09-10 10:44:54 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Stewart 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-09-10 10:44:54 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stewart A, Newman L, Sneddon K, Harris M</AU>
<TI>Aprotinin reduces blood loss and the need for transfusion in orthognathic surgery</TI>
<SO>British Journal of Oral &amp; Maxillofacial Surgery</SO>
<YR>2001</YR>
<VL>39</VL>
<NO>5</NO>
<PG>365-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swart-1994" MODIFIED="2008-09-08 22:36:43 +0100" MODIFIED_BY="[Empty name]" NAME="Swart 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-09-08 22:36:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swart MJ, Gordon PC, Hayse-Gregson PB, Dyer RA, Swanepoel AL, Buckels NJ, Schall R, Odell JA</AU>
<TI>High-dose aprotinin in cardiac surgery--a prospective, randomized study</TI>
<SO>Anaesthesia &amp; Intensive Care</SO>
<YR>1994</YR>
<VL>22</VL>
<NO>5</NO>
<PG>529-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tabuchi-1994" MODIFIED="2008-09-08 22:36:46 +0100" MODIFIED_BY="[Empty name]" NAME="Tabuchi 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-09-08 22:36:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tabuchi N, Huet RC, Sturk A, Eijsman L, Wildevuur CR</AU>
<TI>Aprotinin preserves hemostasis in aspirin-treated patients undergoing cardiopulmonary bypass</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1994</YR>
<VL>58</VL>
<NO>4</NO>
<PG>1036-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taggart-2003" MODIFIED="2008-09-10 10:45:02 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Taggart 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-09-10 10:45:02 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taggart DP, Djapardy V, Naik M, Davies A</AU>
<TI>A randomized trial of aprotinin (Trasylol) on blood loss, blood product requirement, and myocardial injury in total arterial grafting</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>2003</YR>
<VL>126</VL>
<NO>4</NO>
<PG>1087-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taghaddomi-2009" MODIFIED="2010-07-08 10:59:12 +0100" MODIFIED_BY="Katharine Ker" NAME="Taghaddomi 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-04-08 15:02:44 +0100" MODIFIED_BY="Katharine Ker" NOTES="&lt;p&gt;Author Affiliation: R.J. Taghaddomi, Department of Anesthesiology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashad, Iran, Islamic Republic of. E-mail: r-jalaeian@mums.ac.irAuthor Role: EnglishNotes: Publication Type: Journal: Article&lt;br&gt;ER  -&lt;/p&gt;" NOTES_MODIFIED="2010-04-08 15:02:44 +0100" NOTES_MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taghaddomi RJ Mirzaee A Attar AS Shirdel A</AU>
<TI>Tranexamic Acid Reduces Blood Loss in Off-Pump Coronary Artery Bypass Surgery</TI>
<SO>Journal of Cardiothoracic and Vascular Anesthesia</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>3</NO>
<PG>312-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tanaka-2001" MODIFIED="2008-09-10 10:45:09 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Tanaka 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-09-10 10:45:09 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tanaka N, Sakahashi H, Sato E, Hirose K, Ishima T, Ishii S</AU>
<TI>Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee</TI>
<SO>Journal of Bone &amp; Joint Surgery - British Volume</SO>
<YR>2001</YR>
<VL>83</VL>
<NO>5</NO>
<PG>702-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tassani-2000" MODIFIED="2008-09-10 10:45:16 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Tassani 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-09-10 10:45:16 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tassani P, Augustin N, Barankay A, Braun SL, Zaccaria F, Richter JA</AU>
<TI>High-dose aprotinin modulates the balance between proinflammatory and anti-inflammatory responses during coronary artery bypass graft surgery</TI>
<SO>Journal of Cardiothoracic &amp; Vascular Anesthesia</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>6</NO>
<PG>682-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thorpe-1994" MODIFIED="2008-10-13 16:51:17 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Thorpe 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-10-13 16:51:17 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thorpe CM, Murphy WG, Logan M</AU>
<TI>Use of aprotinin in knee replacement surgery</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1994</YR>
<VL>73</VL>
<NO>3</NO>
<PG>408-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trinh_x002d_Duc-1992" NAME="Trinh-Duc 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trinh-Duc P, Wintrebert P, Boulfroy D, Albat B, Thevenet A, Roquefeuil B</AU>
<TI>Comparison of the effects of epsilon-aminocaproic acid and aprotinin on intra- and postoperative bleeding in heart surgery. [French]</TI>
<SO>Annales de Chirurgie</SO>
<YR>1992</YR>
<VL>46</VL>
<NO>8</NO>
<PG>677-683</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Troianos-1999" MODIFIED="2008-09-10 10:45:29 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Troianos 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-09-10 10:45:29 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Troianos CA, Sypula RW, Lucas DM, D'Amico F, Mathie TB, Desai M, Pasqual RT, Pellegrini RV, Newfeld ML</AU>
<TI>The effect of prophylactic epsilon-aminocaproic acid on bleeding, transfusions, platelet function and fibrinolysis during coronary artery bypass grafting</TI>
<SO>Anesthesiology</SO>
<YR>1999</YR>
<VL>91</VL>
<NO>2</NO>
<PG>430-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turkoz-2001" MODIFIED="2008-09-10 10:45:36 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Turkoz 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-09-10 10:45:36 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turkoz A, Cigli A, But K, Sezgin N, Turkoz R, Gulcan O, Ersoy MO</AU>
<TI>The effects of aprotinin and steroids on generation of cytokines during coronary artery surgery</TI>
<SO>Journal of Cardiothoracic &amp; Vascular Anesthesia</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>5</NO>
<PG>603-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uozaki-2001" MODIFIED="2008-09-10 10:45:41 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Uozaki 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-09-10 10:45:41 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uozaki Y, Watanabe G, Kotou K, Ueyama K, Doi Y, Misaki T</AU>
<TI>Effect of tranexamic acid on blood loss reduction after cardiopulmonary bypass</TI>
<SO>Japanese Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>5</NO>
<PG>273-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Urban-2001" MODIFIED="2008-09-10 10:45:47 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Urban 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-09-10 10:45:47 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Urban MK, Beckman J, Gordon M, Urquhart B, Boachie-Adjei O</AU>
<TI>The efficacy of antifibrinolytics in the reduction of blood loss during complex adult reconstructive spine surgery</TI>
<SO>Spine</SO>
<YR>2001</YR>
<VL>26</VL>
<NO>10</NO>
<PG>1152-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Utada-1997" NAME="Utada 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Utada K, Matayoshi Y, Sumi C, Itaya M, Miyawaki H, Ito M, Tamura H, Mitsukuji T</AU>
<TI>Aprotinin 2 million KIU reduces perioperative blood loss in patients undergoing primary total hip replacement. [Japanese]</TI>
<SO>Masui - Japanese Journal of Anesthesiology</SO>
<YR>1997</YR>
<VL>46</VL>
<NO>1</NO>
<PG>77-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-der-Linden-2005" MODIFIED="2008-09-10 10:46:01 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Van der Linden 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-09-10 10:46:01 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van der Linden J, Lindvall G, Sartipy U</AU>
<TI>Aprotinin decreases postoperative bleeding and number of transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery: A double-blind, placebo-controlled, randomized clinical trial</TI>
<SO>Circulation</SO>
<YR>2005</YR>
<VL>112</VL>
<NO>Suppl I</NO>
<PG>I-276-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Oeveren-1987" MODIFIED="2008-09-08 22:36:58 +0100" MODIFIED_BY="[Empty name]" NAME="Van Oeveren 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-09-08 22:36:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Oeveren W, Jansen NJ, Bidstrup BP, Royston D, Westaby S, Neuhof H, Wildevuur CR</AU>
<TI>Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1987</YR>
<VL>44</VL>
<NO>6</NO>
<PG>640-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vander_x002d_Salm-1996" MODIFIED="2008-09-10 10:46:15 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Vander-Salm 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-09-10 10:46:15 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vander Salm TJ, Kaur S, Lancey RA, Okike ON, Pezzella AT, Stahl RF, Leone L, Li J-M, Valeri CR, Michelson AD</AU>
<TI>Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1996</YR>
<VL>112</VL>
<NO>4</NO>
<PG>1098-107</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vanek-2005" MODIFIED="2008-09-10 10:46:22 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Vanek 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-09-10 10:46:22 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vanek T, Jares M, Fajt R, Straka Z, Jirasek K, Kolesar M, Brucek P, Maly M</AU>
<TI>Fibrinolytic inhibitors in off-pump coronary surgery: A prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo)</TI>
<SO>European Journal of Cardio-Thoracic Surgery</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>4</NO>
<PG>563-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vedrinne-1992" MODIFIED="2008-09-08 22:37:10 +0100" MODIFIED_BY="[Empty name]" NAME="Vedrinne 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-09-08 22:37:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vedrinne C, Girard C, Jegaden O, Blanc P, Bouvier H, Ffrench P, Mikaeloff P, Estanove S</AU>
<TI>Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin versus autologous fresh whole blood transfusion</TI>
<SO>Journal of Cardiothoracic &amp; Vascular Anesthesia</SO>
<YR>1992</YR>
<VL>6</VL>
<NO>3</NO>
<PG>319-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Veien-2002" MODIFIED="2008-09-10 10:50:14 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Veien 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-09-10 10:50:14 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Veien M, Sorensen JV, Madsen F, Juelsgaard P</AU>
<TI>Tranexamic acid given intraoperatively reduces blood loss after total knee replacement: a randomized, controlled study</TI>
<SO>Acta Anaesthesiologica Scandinavica</SO>
<YR>2002</YR>
<VL>46</VL>
<NO>10</NO>
<PG>1206-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wei-2006" MODIFIED="2010-05-26 12:30:12 +0100" MODIFIED_BY="Katharine Ker" NAME="Wei 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-09-10 10:50:21 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wei M, Jian K, Guo Z, Wang L, Jiang D, Zhang L, Tarkka M</AU>
<TI>Tranexamic acid reduces postoperative bleeding in off-pump coronary artery bypass grafting</TI>
<SO>Scandinavian Cardiovascular Journal</SO>
<YR>2006</YR>
<VL>40</VL>
<NO>2</NO>
<PG>105-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wendel-1995" MODIFIED="2008-09-08 22:37:14 +0100" MODIFIED_BY="[Empty name]" NAME="Wendel 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-09-08 22:37:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wendel HP, Heller W, Michel J, Mayer G, Ochsenfahrt C, Graeter U, Schulze J, Hoffmeister HM, Hoffmeister HE</AU>
<TI>Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1995</YR>
<VL>109</VL>
<NO>6</NO>
<PG>1164-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wong-2000" MODIFIED="2008-09-10 10:50:30 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Wong 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-09-10 10:50:30 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wong BI, McLean RF, Fremes SE, Deemar KA, Harrington EM, Christakis GT, Goldman BS</AU>
<TI>Aprotinin and tranexamic acid for high transfusion risk cardiac surgery</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2000</YR>
<VL>69</VL>
<NO>3</NO>
<PG>808-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wong-2008" MODIFIED="2010-05-17 11:34:42 +0100" MODIFIED_BY="Katharine Ker" NAME="Wong 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-17 11:34:42 +0100" MODIFIED_BY="Katharine Ker" NOTES="&lt;p&gt;Connective Phrase: PUBMED 18931202Notes: Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't&lt;br&gt;ER  -&lt;/p&gt;" NOTES_MODIFIED="2010-05-17 11:34:42 +0100" NOTES_MODIFIED_BY="Katharine Ker" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wong J, El Beheiry H, Rampersaud Y R, Lewis S, Ahn H, De Silva Y, et al</AU>
<TI>Tranexamic Acid reduces perioperative blood loss in adult patients having spinal fusion surgery</TI>
<SO>Anesthesia and analgesia</SO>
<YR>2008</YR>
<VL>107</VL>
<NO>5</NO>
<PG>1479-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-17 11:34:27 +0100" MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wong J, El-Beheiry H, Rampersaud R, Lewis S, Fehlings M, Chung F</AU>
<TI>Tranexamic acid reduces blood loss and transfusion in adult patients having spinal fusion surgery</TI>
<SO>Canadian Journal of Surgery</SO>
<YR>2007</YR>
<VL>50</VL>
<NO>3 Suppl</NO>
<PG>S12-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2006" MODIFIED="2008-10-13 16:51:48 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Wu 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-10-13 16:51:48 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu CC, Ho WM, Cheng SB, Yeh DC, Wen MC, Liu TJ, et al</AU>
<TI>Perioperative parenteral tranexamic acid in liver tumor resection: a prospective randomized trial toward a "blood transfusion"-free hepatectomy</TI>
<SO>Annals of Surgery</SO>
<YR>2006</YR>
<VL>243</VL>
<NO>2</NO>
<PG>173-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamasaki-2004" NAME="Yamasaki 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamasaki S, Masuhara K, Fuji T</AU>
<TI>Tranexamic acid reduces blood loss after cementless total hip arthroplasty-prospective randomized study in 40 cases</TI>
<SO>International Orthopaedics</SO>
<YR>2004</YR>
<VL>28</VL>
<NO>2</NO>
<PG>69-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yassen-1993" MODIFIED="2008-09-10 10:50:44 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Yassen 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-09-10 10:50:44 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yassen K, Bellamy MC, Sadek SA, Webster NR</AU>
<TI>Tranexamic acid reduces blood loss during orthotopic liver transplantation</TI>
<SO>Clinical Transplantation</SO>
<YR>1993</YR>
<VL>7</VL>
<NO>5</NO>
<PG>453-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zabeeda-2002" MODIFIED="2008-09-10 10:50:51 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Zabeeda 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-09-10 10:50:51 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zabeeda D, Medalion B, Sverdlov M, Ezra S, Schachner A, Ezri T, Cohen AJ</AU>
<TI>Tranexamic acid reduces bleeding and the need for blood transfusion in primary myocardial revascularization</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2002</YR>
<VL>74</VL>
<NO>3</NO>
<PG>733-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2007" MODIFIED="2010-05-28 11:03:12 +0100" MODIFIED_BY="Katharine Ker" NAME="Zhang 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-05-28 11:03:12 +0100" MODIFIED_BY="Katharine Ker" NOTES="&lt;p&gt;Author Affiliation: Department of Joint Surgery, Tianjin Hospital, Tianjin Medical University, Tianjin, 300211, PR China. zhang656696@yahoo.com.cn&lt;/p&gt;" NOTES_MODIFIED="2010-05-28 11:03:12 +0100" NOTES_MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang F, Gao Z, Yu J</AU>
<TI>[Clinical comparative studies on effect of tranexamic acid on blood loss associated with total knee arthroplasty]. [Chinese]</TI>
<SO>Chinese Journal of Reparative &amp; Reconstructive Surgery</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>12</NO>
<PG>1302-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zohar-2004" MODIFIED="2008-09-10 10:50:57 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Zohar 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-09-10 10:50:57 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zohar E, Ellis M, Ifrach N, Stern A, Sapir O, Fredman B</AU>
<TI>The postoperative blood-sparing efficacy of oral versus intravenous tranexamic acid after total knee replacement</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>2004</YR>
<VL>99</VL>
<NO>6</NO>
<PG>1679-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-07-08 11:33:54 +0100" MODIFIED_BY="Katharine Ker">
<STUDY DATA_SOURCE="PUB" ID="STD-Fejer-1998" NAME="Fejer 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fejer C, Mezofi M, Varga PP</AU>
<TI>Use of high-dose aprotinin during spinal surgery results in a reduction in both blood loss and the amount of blood transfused. [abstract]</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1998</YR>
<VL>80</VL>
<NO>Suppl 1</NO>
<PG>80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Langdown-2000" MODIFIED="2008-09-10 10:51:08 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Langdown 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-09-10 10:51:08 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Langdown AJ, Field J, Grote J, Himayat H</AU>
<TI>Aprotinin (Trasylol) does not reduce bleeding in primary total hip arthroplasty</TI>
<SO>Journal of Arthroplasty</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>8</NO>
<PG>1009-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Montesano-1996" MODIFIED="2008-09-10 10:51:24 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Montesano 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-09-10 10:51:24 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Montesano RM, Gustafson PA, Palanzo DA, Manley NJ, Sadr FS</AU>
<TI>The effect of low-dose epsilon-aminocaproic acid on patients following coronary artery bypass surgery</TI>
<SO>Perfusion</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>1</NO>
<PG>53-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zufferey-2010" MODIFIED="2010-06-11 15:37:51 +0100" MODIFIED_BY="Katharine Ker" NAME="Zufferey 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-06-11 15:37:51 +0100" MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="OTHER">
<AU>Zufferey P J, Miquet M, Quenet S, Laporte S, Martin P, Chambefort V, et al</AU>
<TI>Does tranexamic acid decrease erythrocyte transfusion in patients undergoing hip fracture surgery with fondaaparinux for prevention of venous thromboembolism?</TI>
<SO>http://www isth2007 com/</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-25 13:45:33 +0100" MODIFIED_BY="Katharine Ker" NOTES="&lt;p&gt;Author Affiliation: P. J. Zufferey, Department of Anaesthesiology and Intensive Care, University Hospital of Saint-Etienne, 42055 Saint-Etienne Cedex 02, France. E-mail: paul.zufferey@chu-st-etienne.frAuthor Role: EnglishNotes: Publication Type: Journal: Article&lt;br&gt;ER  -&lt;/p&gt;" NOTES_MODIFIED="2010-05-25 13:45:33 +0100" NOTES_MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zufferey PJ Miquet M Quenet S Martin P Adam P Albaladejo P Mismetti P Molliex S</AU>
<TI>Tranexamic acid in hip fracture surgery: A randomized controlled trial</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>2010</YR>
<VL>104</VL>
<NO>1</NO>
<PG>23-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-05-25 13:45:33 +0100" MODIFIED_BY="Katharine Ker"/>
<ONGOING_STUDIES MODIFIED="2010-05-14 13:51:55 +0100" MODIFIED_BY="Katharine Ker">
<STUDY DATA_SOURCE="PUB" ID="STD-Myles-2008" MODIFIED="2010-05-07 14:23:48 +0100" MODIFIED_BY="Katharine Ker" NAME="Myles 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-07 14:23:48 +0100" MODIFIED_BY="Katharine Ker" NOTES="&lt;p&gt;Connective Phrase: PUBMED 18215590Notes: Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial&lt;br&gt;ER  -&lt;/p&gt;" NOTES_MODIFIED="2010-05-07 14:23:48 +0100" NOTES_MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Myles P S, Smith J, Knight J, Cooper D J, Silbert B, McNeil J, et al</AU>
<TI>Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) Trial: rationale and design</TI>
<SO>American heart journal</SO>
<YR>2008</YR>
<VL>155</VL>
<NO>2</NO>
<PG>224-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verma-2010" MODIFIED="2010-05-14 13:51:55 +0100" MODIFIED_BY="Katharine Ker" NAME="Verma 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-05-14 13:51:25 +0100" MODIFIED_BY="Katharine Ker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verma K, Errico TJ, Vaz KM, Lonner BS</AU>
<TI>A prospective, randomized, double-blinded single-site control study comparing blood loss prevention of tranexamic acid (TXA) to epsilon aminocaproic acid (EACA) for corrective spinal surgery</TI>
<SO>BMC Surgery</SO>
<YR>2010</YR>
<VL>10</VL>
<NO>13</NO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-02-16 13:23:34 +0000" MODIFIED_BY="Emma M Sydenham">
<ADDITIONAL_REFERENCES MODIFIED="2011-02-16 13:23:34 +0000" MODIFIED_BY="Emma M Sydenham">
<REFERENCE ID="REF-Beattie-2006" MODIFIED="2008-09-10 10:51:32 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Beattie 2006" TYPE="JOURNAL_ARTICLE">
<AU>Beattie WS, Karkouti K</AU>
<TI>Con: Aprotinin has a good efficacy and safety profile relative to other alternatives for prevention of bleeding in cardiac surgery.[comment]</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>2006</YR>
<VL>103</VL>
<NO>6</NO>
<PG>1360-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bidstrup-2006" MODIFIED="2008-10-13 16:52:11 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Bidstrup 2006" TYPE="JOURNAL_ARTICLE">
<AU>Bidstrup BP</AU>
<TI>Aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery</TI>
<SO>Transfusion</SO>
<YR>2006</YR>
<VL>46</VL>
<NO>12</NO>
<PG>2208-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blumberg-1997" NAME="Blumberg 1997" TYPE="JOURNAL_ARTICLE">
<AU>Blumberg N</AU>
<TI>Allogeneic transfusion and infection: economic and clinical implications</TI>
<SO>Seminars in Hematology</SO>
<YR>1997</YR>
<VL>34</VL>
<NO>3 Suppl 2</NO>
<PG>34-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Body-2006" MODIFIED="2008-10-13 16:52:20 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Body 2006" TYPE="JOURNAL_ARTICLE">
<AU>Body SC, Mazer CD</AU>
<TI>Pro: Aprotinin has a good efficacy and safety profile relative to other alternatives for prevention of bleeding in cardiac surgery</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>2006</YR>
<VL>103</VL>
<NO>6</NO>
<PG>1354-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boldt-2009" MODIFIED="2011-02-16 13:23:34 +0000" MODIFIED_BY="Emma M Sydenham" NAME="Boldt 2009" TYPE="JOURNAL_ARTICLE">
<AU>Boldt J, Suttner S, Brosch C, Lehmann A, Roehm K, Mengitsu A</AU>
<TI>Cardiopulminary bypass priming using a high dose of a balanced hydroxyethyl starch versus an albumin-based priming strategy</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>2009</YR>
<VL>109</VL>
<PG>1752-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bryson-1998" NAME="Bryson 1998" TYPE="JOURNAL_ARTICLE">
<AU>Bryson GL, Laupacis A, Wells GA</AU>
<TI>Does acute normovolemic hemodilution reduce perioperative allogeneic transfusion? A meta-analysis. The International Study of Perioperative Transfusion</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>1998</YR>
<VL>86</VL>
<NO>1</NO>
<PG>9-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carless-2005" NAME="Carless 2005" TYPE="JOURNAL_ARTICLE">
<AU>Carless PA, Moxey AJ, Stokes BJ, Henry DA</AU>
<TI>Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials</TI>
<SO>BMC Cardiovascular Disorders</SO>
<YR>2005</YR>
<VL>5</VL>
<PG>19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carson-1998" NAME="Carson 1998" TYPE="JOURNAL_ARTICLE">
<AU>Carson JL, Terrin ML, Barton FB, Aaron R, Greenburg AG, Heck DA, Magaziner J, Merlino FE, Bunce G, McClelland B, et al</AU>
<TI>A pilot randomized trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following hip fracture</TI>
<SO>Transfusion</SO>
<YR>1998</YR>
<VL>38</VL>
<NO>6</NO>
<PG>522-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coyle-1999" NAME="Coyle 1999" TYPE="JOURNAL_ARTICLE">
<AU>Coyle D, Lee KM, Fergusson DA, Laupacis A</AU>
<TI>Economic analysis of erythropoietin use in orthopaedic surgery</TI>
<SO>Transfusion Medicine</SO>
<YR>1999</YR>
<VL>9</VL>
<NO>1</NO>
<PG>21-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CRASH_x002d_2-2010" MODIFIED="2010-11-28 13:57:31 +0000" MODIFIED_BY="[Empty name]" NAME="CRASH-2 2010" TYPE="JOURNAL_ARTICLE">
<AU>Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, et al</AU>
<TI>Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>2010</YR>
<VL>376</VL>
<NO>9734</NO>
<PG>23-32</PG>
<IDENTIFIERS MODIFIED="2010-11-28 13:56:46 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="20554319"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Der-Simonian-1986" NAME="Der Simonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>Der Simonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Faught-1998" MODIFIED="2008-10-13 16:53:02 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Faught 1998" TYPE="JOURNAL_ARTICLE">
<AU>Faught C, Wells P, Fergusson D, Laupacis A</AU>
<TI>Adverse effects of methods for minimizing perioperative allogeneic transfusion: a critical review of the literature</TI>
<SO>Transfusion Medicine Reviews</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>3</NO>
<PG>206-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ferguson-2007" MODIFIED="2008-10-13 16:52:47 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Ferguson 2007" TYPE="JOURNAL_ARTICLE">
<AU>Ferguson TB, Jr</AU>
<TI>Aprotinin--are there lessons learned?</TI>
<SO>JAMA</SO>
<YR>2007</YR>
<VL>297</VL>
<NO>5</NO>
<PG>527-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fergusson-1999" NAME="Fergusson 1999" TYPE="JOURNAL_ARTICLE">
<AU>Fergusson D, van Walraven C, Coyle D, Laupacis A</AU>
<TI>Economic evaluations of technologies to minimize perioperative transfusion: a systematic review of published studies. International Study of Peri-operative Transfusion (ISPOT) investigators</TI>
<SO>Transfusion Medicine Reviews</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>2</NO>
<PG>106-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Forgie-1998" MODIFIED="2008-09-10 10:52:19 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Forgie 1998" TYPE="JOURNAL_ARTICLE">
<AU>Forgie MA, Wells PS, Laupacis A, Fergusson D</AU>
<TI>Pre-operative Autologous Donation deceases allogeneic transfusion but increases exposure to all red cell transfusion. Results of a Meta-Analysis</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1998</YR>
<VL>158</VL>
<NO>6</NO>
<PG>610-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fritz-1983" NAME="Fritz 1983" TYPE="JOURNAL_ARTICLE">
<AU>Fritz H, Wunderer G</AU>
<TI>Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs</TI>
<SO>Arzneimittel-Forschung</SO>
<YR>1983</YR>
<VL>33</VL>
<NO>4</NO>
<PG>479-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hebert-1999" MODIFIED="2008-10-13 16:53:37 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Hebert 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al</AU>
<TI>A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>340</VL>
<NO>6</NO>
<PG>409-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hebert-2005" NAME="Hebert 2005" TYPE="UNPUBLISHED">
<AU>Hebert P, Fergusson DA, BART Investigators</AU>
<TI>Blood conservation using antifibrinolytics: A randomized trial in a cardiac surgery population - the BART study</TI>
<SO>(http://www.controlled-trials.com/ISRCTN15166455/BART)</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Henry-1999" MODIFIED="2008-10-13 16:54:50 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Henry 1999" TYPE="COCHRANE_REVIEW">
<AU>Henry DA, Moxey AJ, Carless PA, O'Connell D, McClelland B, Henderson KM, et al</AU>
<TI>Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>4</NO>
<PG>CD001886</PG>
<IDENTIFIERS MODIFIED="2008-10-13 16:54:50 +0100" MODIFIED_BY="Emma M Sydenham">
<IDENTIFIER MODIFIED="2008-10-13 16:54:50 +0100" MODIFIED_BY="Emma M Sydenham" TYPE="DOI" VALUE=" 10.1002/14651858.CD001886.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Henry-2007" MODIFIED="2010-12-03 15:22:03 +0000" MODIFIED_BY="Katharine Ker" NAME="Henry 2007" TYPE="COCHRANE_REVIEW">
<AU>Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, McClelland B, et al</AU>
<TI>Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>4. Art. No.: CD001886. DOI: 10.1002/14651858.CD001886.pub2.</NO>
<PG>CD001886</PG>
<IDENTIFIERS MODIFIED="2010-11-28 14:02:56 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17943760"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2010-07-02 04:28:37 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2010-12-03 15:22:59 +0000" MODIFIED_BY="Katharine Ker" NAME="Higgins 2009" TYPE="BOOK">
<AU>Higgins JPT, Green S</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions</TI>
<SO>The Cochrane Collaboration</SO>
<YR>2009</YR>
<PB>Wiley &amp; Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Huet-1999" NAME="Huet 1999" TYPE="JOURNAL_ARTICLE">
<AU>Huet C, Salmi LR, Fergusson D, Koopman-van Gemert AW, Rubens F, Laupacis A</AU>
<TI>A meta-analysis of the effectiveness of cell salvage to minimize perioperative allogeneic blood transfusion in cardiac and orthopedic surgery. International Study of Perioperative Transfusion (ISPOT) Investigators</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>1999</YR>
<VL>89</VL>
<NO>4</NO>
<PG>861-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Karkouti-2004" MODIFIED="2008-10-13 16:56:00 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Karkouti 2004" TYPE="JOURNAL_ARTICLE">
<AU>Karkouti K, Wijeysundera DN, Yau TM, Beattie WS, Abdelnaem E, McCluskey SA, et al</AU>
<TI>The independent association of massive blood loss with mortality in cardiac surgery</TI>
<SO>Transfusion</SO>
<YR>2004</YR>
<VL>44</VL>
<NO>10</NO>
<PG>1453-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Karkouti-2006" MODIFIED="2008-10-13 16:56:29 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Karkouti 2006" TYPE="JOURNAL_ARTICLE">
<AU>Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A, et al</AU>
<TI>A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery</TI>
<SO>Transfusion</SO>
<YR>2006</YR>
<VL>46</VL>
<NO>3</NO>
<PG>327-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kimball-1995" MODIFIED="2008-10-13 16:56:43 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Kimball 1995" TYPE="JOURNAL_ARTICLE">
<AU>Kimball AM, Berkley S, Ngugi E, Gayle H</AU>
<TI>International aspects of the AIDS/HIV epidemic</TI>
<SO>Annual Review of Public Health</SO>
<YR>1995</YR>
<VL>16</VL>
<PG>253-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Laupacis-1997" NAME="Laupacis 1997" TYPE="JOURNAL_ARTICLE">
<AU>Laupacis A, Fergusson D</AU>
<TI>Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>1997</YR>
<VL>85</VL>
<NO>6</NO>
<PG>1258-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Levi-1999" MODIFIED="2008-10-13 16:57:11 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Levi 1999" TYPE="JOURNAL_ARTICLE">
<AU>Levi M, Cromheecke ME, de Jonge E, Prins MH, de Mol BJM, Briet E, et al</AU>
<TI>Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9194</NO>
<PG>1940-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Levy-2006" NAME="Levy 2006" TYPE="OTHER">
<AU>Levy JH, Ramsay JG, Guyton RA</AU>
<TI>Aprotinin in cardiac surgery</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>354</VL>
<NO>18</NO>
<PG>1953-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mangano-2006" MODIFIED="2008-10-13 16:57:21 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Mangano 2006" TYPE="JOURNAL_ARTICLE">
<AU>Mangano DT, Tudor IC, Dietzel C, Multicenter Study of Perioperative Ischemia Research Group, Ischemia Research and Education Foundation</AU>
<TI>The risk associated with aprotinin in cardiac surgery</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>354</VL>
<NO>4</NO>
<PG>353-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mangano-2007" MODIFIED="2008-10-13 16:57:31 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Mangano 2007" TYPE="JOURNAL_ARTICLE">
<AU>Mangano DT, Miao Y, Vuylsteke A, Tudor IC, Juneja R, Filipescu D, et al. Investigators of The Multicenter Study of Perioperative Ischemia Research Group, Ischemia Research and Education Foundation</AU>
<TI>Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery</TI>
<SO>JAMA</SO>
<YR>2007</YR>
<VL>297</VL>
<NO>5</NO>
<PG>471-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mannucci-1998" NAME="Mannucci 1998" TYPE="JOURNAL_ARTICLE">
<AU>Mannucci PM</AU>
<TI>Hemostatic drugs</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>339</VL>
<NO>4</NO>
<PG>245-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McFarland-1997" MODIFIED="2008-10-13 16:57:44 +0100" MODIFIED_BY="Emma M Sydenham" NAME="McFarland 1997" TYPE="JOURNAL_ARTICLE">
<AU>McFarland W, Mvere D, Shandera W, Reingold A</AU>
<TI>Epidemiology and prevention of transfusion-associated human immunodeficiency virus transmission in sub-Saharan Africa</TI>
<SO>Vox Sanguinis</SO>
<YR>1997</YR>
<VL>72</VL>
<NO>2</NO>
<PG>85-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Munoz-1999" NAME="Munoz 1999" TYPE="JOURNAL_ARTICLE">
<AU>Munoz JJ, Birkmeyer NJ, Birkmeyer JD, O'Connor GT, Dacey LJ</AU>
<TI>Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery?: a meta-analysis</TI>
<SO>Circulation</SO>
<YR>1999</YR>
<VL>99</VL>
<NO>1</NO>
<PG>81-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Brien-2002" NAME="O'Brien 2002" TYPE="JOURNAL_ARTICLE">
<AU>O'Brien MF, Harrocks S, Clarke A, Garlick B, Barnett AG</AU>
<TI>How to do safe sternal reentry and the risk factors of redo cardiac surgery: a 21-year review with zero major cardiac injury</TI>
<SO>Journal of Cardiac Surgery</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>1</NO>
<PG>4-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reinhart-2011" MODIFIED="2011-02-11 13:49:09 +0000" MODIFIED_BY="[Empty name]" NAME="Reinhart 2011" TYPE="JOURNAL_ARTICLE">
<AU>Reinhart K, Takala J</AU>
<TI>Hydroxyethyl Starches: What Do We Still Know?</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2011</YR>
<VL>112</VL>
<NO>3</NO>
<PG>507-511</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager" MODIFIED="2008-10-13 16:41:27 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Review Manager" TYPE="COMPUTER_PROGRAM">
<AU>The Nordic Cochrane Centre</AU>
<TI>Review Manager</TI>
<YR>2003</YR>
<EN>4.2.8</EN>
<PB>The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Royston-1998" NAME="Royston 1998" TYPE="JOURNAL_ARTICLE">
<AU>Royston D</AU>
<TI>Aprotinin versus lysine analogues: the debate continues</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1998</YR>
<VL>65</VL>
<NO>4</NO>
<PG>S9-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schneeweiss-2008" MODIFIED="2010-11-28 13:52:58 +0000" MODIFIED_BY="[Empty name]" NAME="Schneeweiss 2008" TYPE="JOURNAL_ARTICLE">
<AU>Schneeweiss S, Seeger JD, Landon J, Walker AM</AU>
<TI>Aprotinin during coronary-artery bypass grafting and risk of death</TI>
<SO>The New England journal of medicine</SO>
<YR>2008</YR>
<VL>358</VL>
<NO>8</NO>
<PG>771-83</PG>
<IDENTIFIERS MODIFIED="2010-11-28 13:52:53 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="18287600"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2008-09-10 10:54:39 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DJ</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sedrakyan-2004" MODIFIED="2008-10-13 16:58:06 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Sedrakyan 2004" TYPE="JOURNAL_ARTICLE">
<AU>Sedrakyan A, Treasure T, Elefteriades JA</AU>
<TI>Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>2004</YR>
<VL>128</VL>
<NO>3</NO>
<PG>442-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shafer-2011" MODIFIED="2011-02-11 13:47:12 +0000" MODIFIED_BY="[Empty name]" NAME="Shafer 2011" TYPE="JOURNAL_ARTICLE">
<AU>Shafer SL</AU>
<TI>Shadow of Doubt</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2011</YR>
<VL>112</VL>
<NO>3</NO>
<PG>498-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-1998" NAME="Smith 1998" TYPE="JOURNAL_ARTICLE">
<AU>Smith CR</AU>
<TI>Management of bleeding complications in redo cardiac operations</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1998</YR>
<VL>65</VL>
<NO>4</NO>
<PG>S2-8; discussion S27-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vamvakas-2001" MODIFIED="2008-10-13 16:58:16 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Vamvakas 2001" TYPE="JOURNAL_ARTICLE">
<AU>Vamvakas EC, Blajchman MA</AU>
<TI>Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?</TI>
<SO>Blood</SO>
<YR>2001</YR>
<VL>97</VL>
<NO>5</NO>
<PG>1180-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vamvakas-2004" MODIFIED="2008-09-10 10:55:00 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Vamvakas 2004" TYPE="JOURNAL_ARTICLE">
<AU>Vamvakas EC</AU>
<TI>White-blood-cell-containing allogeneic blood transfusion, postoperative infection and mortality: a meta-analysis of observational 'before-and-after' studies</TI>
<SO>Vox Sanguinis</SO>
<YR>2004</YR>
<VL>86</VL>
<NO>2</NO>
<PG>111-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whyte-1997" NAME="Whyte 1997" TYPE="JOURNAL_ARTICLE">
<AU>Whyte GS, Savoia HF</AU>
<TI>The risk of transmitting HCV, HBV or HIV by blood transfusion in Victoria</TI>
<SO>Medical Journal of Australia</SO>
<YR>1997</YR>
<VL>166</VL>
<NO>11</NO>
<PG>584-6</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2011-02-16 13:23:34 +0000" MODIFIED_BY="Emma M Sydenham"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-08-19 11:08:50 +0100" MODIFIED_BY="Katharine Ker">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-08-19 11:08:50 +0100" MODIFIED_BY="Katharine Ker" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-06-28 01:56:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alajmo-1989">
<CHAR_METHODS MODIFIED="2010-06-28 01:56:44 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomly divided into two groups according to birth date until an appropriate number of treated patients was reached. Method of blinding and generation of allocation sequences were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-25 04:52:45 +0100" MODIFIED_BY="[Empty name]">
<P>34 consecutive patients undergoing cardiac operations were randomly divided into two groups:</P>
<UL>
<LI>Aprotinin group: n = 22, M/F = 12/8, mean (sd) age = 62 (6.6) years</LI>
<LI>Control group: n = 12, M/F = 7/5, mean (sd) age = 57.8 (16.3) years</LI>
</UL>
<P>NB: Possible error in the gender data provided for the aprotinin group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-25 04:45:33 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 2 million kallikrein inactivation units (KIU) of aprotinin (280 mg) at the start of anaesthesia (Trasylol, Bayer Leverkusen, FRG; 10,000 KIU/ml pure aprotinin with no additives) infused over 20 to 30 minutes. Subsequently, 500,000 KIU/hr (70 mg/hr) of aprotinin was given until the end of the operation. Additionally, 1 million KIU of aprotinin (140 mg) was given via the priming solution of the extracorporeal circuit.</LI>
<LI>Control group did not receive aprotinin.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 07:01:33 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, blood loss, haemoglobin levels, platelet counts</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-25 04:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-29 06:17:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alderman-1998">
<CHAR_METHODS MODIFIED="2010-06-28 01:57:09 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomly divided into two groups by random code, generated in blocks with clinical center and stratum. Allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-28 02:00:06 +0100" MODIFIED_BY="[Empty name]">
<P>870 patients were randomised into two groups:</P>
<UL>
<LI>Aprotonin group n = 436, M = 87.4%, mean (sd) age = 61.8 (9.1) years</LI>
<LI>Control group (Placebo) n = 434, M = 86.9%, mean (sd) age = 62.3 (9.1) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-25 04:53:32 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotonin group received a loading dose of 2 million KIU (280 mg), a maintenance dose of 500,000 KIU and a prime dose of 2 million KIU.</LI>
<LI>No details were described on the placebo used.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 07:01:27 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, blood loss, deaths, myocardial infarction, CABG thrombosis, re-operation for bleeding.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-29 06:17:32 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 3/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-28 02:00:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alvarez-1995">
<CHAR_METHODS MODIFIED="2010-06-28 01:58:05 +0100" MODIFIED_BY="[Empty name]">
<P>The hospital pharmacy made up identical infusions of the study drugs identifiable only by random number. Patients were prospectively randomised into two groups by sealed envelopes. The method used to generate allocation sequences was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-28 02:00:01 +0100" MODIFIED_BY="[Empty name]">
<P>100 patients undergoing primary elective cardiac surgery were randomised into one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 49, M/F = 38/11, mean (sd) age = 63.3 (11.0) years</LI>
<LI>Control group (Placebo): n = 51, M/F = 34/17, mean (sd) age = 62.7 (8.2) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-25 05:00:03 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 250,000 kallikrein inactivation units (KIU) of aprotinin added to the prime solution of the cardiopulmonary bypass (CPB) system. Before the start of CPB a further 250,000 KIU of aprotinin, made up to 100 ml with 0.9% saline, was infused intravenously over 30 minutes.</LI>
<LI>Control group received a placebo of equal volumes of 0.9% saline administered at identical times.</LI>
</UL>
<P>NB: Both the intervention and control group were combined with cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 07:01:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, patients receiving autotransfusion, blood loss, mortality, myocardial infarctions, re-operation, patients receiving cell salvage.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-25 04:59:52 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used<BR/>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-28 01:59:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alvarez-2001">
<CHAR_METHODS>
<P>Patients were randomised by a computer-generated random number sequence into either treatment group. All clinical participants were double blinded until the completion of the trial. Placebo and treatment solutions were identical in their appearance and packaging.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-28 01:59:56 +0100" MODIFIED_BY="[Empty name]">
<P>55 patients undergoing either elective or urgent cardiac surgery were randomised into one of two groups:</P>
<UL>
<LI>Aprotonin group: n = 26, M/F = 23/3, mean (sd) age = 63 (8) years</LI>
<LI>Control group (Placebo): n = 29, M/F = 22/7, mean (sd) age = 64 (8) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-25 05:03:17 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 250,000 kallikrein inactivation units (KIU) of aprotinin 280mg IV at the time of sternal skin closure.</LI>
<LI>Control group received a placebo of an equal volume of normal saline solution infused over 20 mins.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 07:01:14 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, patients receiving autotransfusion, blood loss, mortality, myocardial infarctions, re-operation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-25 05:04:19 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 7/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-29 06:16:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alvarez-2008">
<CHAR_METHODS MODIFIED="2010-05-21 17:24:27 +0100" MODIFIED_BY="Katharine Ker">
<P>Patients were allocated according to a computer-generated randomisation sequence. Allocation was concealed using sealed, numbered envelopes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-28 01:59:53 +0100" MODIFIED_BY="[Empty name]">
<P>95 patients undergoing orthopaedic (knee arthroplasty) surgery. Patients were randomly allocated to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 46, M/F = 7/39, mean (sd) age = 71 (9) years</LI>
<LI>Control group (Placebo): n = 49, M/F = 10/39, mean (sd) age = 72 (7) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-25 05:11:22 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received bolus of 10mg/kg before deflation of tourniquet then infusion of 1mg/kg/hr starting at the end of operation for six hours post-operation.</LI>
<LI>Control group received saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 07:01:06 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients requiring blood transfusion, blood loss, volume of blood transfused, thrombosis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-29 06:16:53 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7</P>
<P>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-28 01:59:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Amar-2003">
<CHAR_METHODS>
<P>Randomisation of patients in blocks of 20 were done by the Biostatistics Department and the hospital pharmacy using sealed, opaque treatment code envelopes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-28 01:59:49 +0100" MODIFIED_BY="[Empty name]">
<P>69 patients undergoing elective orthopaedic surgery were randomised into one of three groups:</P>
<UL>
<LI>Epsilon aminocaproic acid group: n = 22, M/F = 11/11, mean (sd) age = 53 (18) years</LI>
<LI>Aprotinin group: n = 23, M/F = 13/10, mean (sd) age = 48 (17) years</LI>
<LI>Control group (Placebo): n = 24, M/F = 13/11, mean (sd) age = 55 (16) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-25 05:39:28 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Epsilon aminocaproic acid (EACA) group received 150 mg/kg EACA bolus in an equal volume given over 30 minutes followed by an infusion of 15 mg/kg/hr until the end of surgery.</LI>
<LI>Aprotinin group received a bolus of 2 million KIU (280mg) given over 30 minutes followed by an infusion of 500,000 KIU/hour (70mg/hr) until the end of surgery.</LI>
<LI>Control group received a placebo of an equal volume of normal saline bolus and infusion.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 07:00:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood units - total includes intra-operative &amp; 48 hours post-operative, blood loss - total blood loss = intra-operative &amp; 48 hours post-operative, deep venous thrombosis, pulmonary embolus, hospital length of stay (days), wound infection, thrombocytopenia, Haemoglobin levels (pre-operative &amp; post-operative).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-25 05:41:37 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-29 06:16:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Andreasen-2004">
<CHAR_METHODS>
<P>Patients were randomised by a random number sequence. The randomisation schedule was provided in sealed envelopes and preparation of the drug or placebo was carried out just prior to anaesthesia by a staff member not involved in the treatment of the patient.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-28 01:59:44 +0100" MODIFIED_BY="[Empty name]">
<P>46 patients undergoing elective coronary surgery. Patients were randomly allocated to one of two groups:</P>
<UL>
<LI>Tranexamic acid group (n = 21), M/F = 18/3, mean age (+/-SD) = 62.3 (9.5) years</LI>
<LI>Control group (Placebo) (n = 23), M/F = 19/4, mean age (+/-SD) = 63.8 (7.6) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-25 05:45:19 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group (TXA) group (Cyklokapron, Phizer Consumer Healthcare) received 1.5g TXA as an IV bolus beginning at the induction of anesthesia, followed by a constant infusion of 200mg/hr until additional 1.5g was given.</LI>
<LI>Control group received a placebo of 0.9% normal saline solution.</LI>
</UL>
<P>NB: Cell salvage - postoperatively shed mediastinal blood was returned in all patients using a closed autotransfusion system.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 07:00:31 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, blood loss, deaths, myocardial Infarctions, CABG thrombosis, renal insufficiency, re-operation for bleeding, cell salvage - autotransfusion 6 hrs, transient ischemic attack (30 day), stroke 30 day.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-29 06:16:44 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-29 06:16:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Apostolakis-2008">
<CHAR_METHODS MODIFIED="2010-06-28 02:00:42 +0100" MODIFIED_BY="[Empty name]">
<P>A randomisation table was used to generate the allocation sequence. No information was provided regarding allocation concealment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-28 02:00:55 +0100" MODIFIED_BY="[Empty name]">
<P>59 patients undergoing elective thoracic surgery. Patients were randomly allocated to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 29, M/F = 26/3, mean (sd) age = 57.5 (16.3) years</LI>
<LI>Control group (Placebo): n = 30, M/F = 27/3, mean (sd) age = 58.5 (9.8) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-25 05:52:11 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group, administered immediately after intubation, received a test dose of 1ml then 500,000 KIU intravenously in 50ml of solution over 15 minutes, received the same dose again after thoracotomy closure.</LI>
<LI>Control group received a placebo of an equal volume of normal saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 05:50:37 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Blood loss, volume of transfused blood (units), mortality, re-operation for bleeding, length of hospital stay (days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-29 06:16:40 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7</P>
<P>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-28 02:01:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Armellin-2001">
<CHAR_METHODS MODIFIED="2010-06-28 02:01:08 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-28 02:01:17 +0100" MODIFIED_BY="[Empty name]">
<P>300 patients undergoing elective cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 150, M/F = 71/72, mean (sd) age = 65.7(11.7) years</LI>
<LI>Control group (Placebo): n = 150, M/F = 90/50, mean (sd) age = 65.9 (12.8) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-25 05:54:19 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group (TXA) received 2.5g of TXA before the skin incision with a further 2.5g of TXA added to the CPB prime solution.</LI>
<LI>Control group received a placebo of an equal dose of saline at the same times as TXA.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 07:00:22 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, mortality, myocardial infarction, re-operation for bleeding, hospital length of stay (days), fresh frozen plasma (FFP), platelets (units).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-25 05:55:25 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 3/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-28 02:02:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arom-1994">
<CHAR_METHODS MODIFIED="2010-06-28 02:02:00 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-25 05:57:45 +0100" MODIFIED_BY="[Empty name]">
<P>200 patients undergoing cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Epsilon aminocaproic acid group: n = 100, M/F = 70/30, mean age = 60 years</LI>
<LI>Control group: n = 100, M/F = 71/29, mean age = 55 years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-25 05:57:56 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Epsilon aminocaproic acid group received 5g of intravenous EACA just before going on CPB.</LI>
<LI>Control group did not receive EACA treatment.</LI>
</UL>
<P>NB: Both groups received 0.03ug/kg of intravenous desmopressin (DDAVP) after CPB.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 05:58:35 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage (units), cryoprecipitate (units), blood loss (ml).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-25 05:58:40 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-28 02:02:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ashraf-1997">
<CHAR_METHODS MODIFIED="2010-06-28 02:02:43 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-25 06:00:58 +0100" MODIFIED_BY="[Empty name]">
<P>38 patients undergoing coronary artery bypass graft surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 19, M/F = 16/3, median (range) age = 61 (49-72) years</LI>
<LI>Control group: n = 19, M/F = 15/4, median (range) age = 65 (50-79) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-25 06:01:08 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 2 million KIU (280mg) of aprotinin added to the pump prime solution of the extracorporeal circuit.</LI>
<LI>Control group did not receive aprotinin.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 07:00:15 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss 24hrs, mortality, re-exploration for bleeding, pro-inflammatory cytokine levels.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-25 06:02:04 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-25 06:16:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Asimakopoulos-2000">
<CHAR_METHODS MODIFIED="2010-01-11 11:44:42 +0000" MODIFIED_BY="Katharine Ker">
<P>Method of randomisation and allocation concealment not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-25 06:16:43 +0100" MODIFIED_BY="[Empty name]">
<P>18 adults undergoing elective coronary artery bypass grafting were randomly allocated to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 8, M/F = 7/1, mean (sd) age = 59 (3.9) years</LI>
<LI>Control group: n=10, M/F = 10/0, mean (sd) age = 65 (1.9) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-25 06:14:05 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received full-dose aprotinin.</LI>
<LI>Control group did not receive aprotinin.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 06:15:11 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood (units), blood loss, myocardial infarction, renal failure, re-operation for bleeding, cerebrovascular accident (stroke), hospital length of stay (days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-25 06:16:15 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-25 06:59:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baele-1992">
<CHAR_METHODS MODIFIED="2010-06-25 06:19:52 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation was not described. Allocation concealment was inadequately concealed (sealed envelopes).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-25 06:20:31 +0100" MODIFIED_BY="[Empty name]">
<P>115 consecutive adults undergoing cardiac surgery were randomly allocated to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 58, M/F = 45/13, mean (sd) age = 61.6 (9.6) years</LI>
<LI>Control group: n=57, M/F = 41/16, mean (sd) age = 62.9 (10.5) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-25 06:49:12 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 2 million kallikrein inactivator units (KIU) before incision, 2 million (KIU) prior to bypass and a continuous infusion of 500,000 KIU/hr for 5 hours.</LI>
<LI>Control group did not receive aprotinin.</LI>
</UL>
<P>NB: Both the intervention and control groups were exposed to pre-operative autologous donation (7 control and 4 intervention patients), acute normovolemic haemodilution (13 patients in each group), and/or cell salvage (data not presented).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 06:59:58 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood (units) blood loss, mortality, myocardial infarction, myocardial ischemia, pericarditis, cardiac failure, pneumonia, renal insufficiency, hemiplegia, re-operation, allogeneic + autologous blood usage (units), intensive care unit (ICU) length of stay (hrs), hospital length of stay (days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-25 06:49:00 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 3/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-25 06:59:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bailey-1994">
<CHAR_METHODS>
<P>Generation of allocation sequences was by a computer generated random number table. One investigator made up all the test solutions; a known volume of sterile 0.9% saline was discarded from 500ml bags and replaced with the same volume of test solution so that all bags contained the same equal volume (500ml). Each set of bags was given a consecutive number. A separate investigator performed all the patient measurements.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-25 06:59:31 +0100" MODIFIED_BY="[Empty name]">
<P>100 patients scheduled to undergo primary elective cardiac surgery employing cardiopulmonary bypass were consecutively allocated to one of four groups.</P>
<UL>
<LI>Control group (Placebo): n = 25, M/F = 17/8, mean (sd) age = 63 (10) years</LI>
<LI>Aprotinin group (High dose): n = 25, M/F = 18/7, mean (sd) age = 64 (13) years</LI>
<LI>Aprotinin group (Prime dose): n = 24, M/F = 17/7, mean (sd) age = 59 (11) years</LI>
<LI>Aprotinin group (Low dose): n = 26, M/F = 20/6, mean (sd) age = 63 (10) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-25 06:55:42 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Control group received a placebo of an intravenous bolus of 500ml of 0.9% saline at induction of anaesthesia, followed by 500ml of 0.9% saline every hour; a further 500ml of 0.9% saline was added to the pump prime.</LI>
<LI>Aprotinin (High dose) group received an intravenous bolus of 300ml of 0.9% saline with 200ml of aprotinin (2 million kallikrein inactivator units) at induction of anaesthesia, followed by 450ml of 0.9% saline with 50ml aprotinin (500,000KIU) every hour; a further 300ml of 0.9% saline with 200ml aprotinin (2 million KIU) was added to the pump prime.</LI>
<LI>Aprotinin (Prime dose) group received an intravenous bolus of 500ml of 0.9% saline at induction of anaesthesia, followed by 500ml of 0.9% saline every hour; a further 300ml of 0.9% saline with 200ml of aprotinin (2 million KIU) was added to the prime pump.</LI>
<LI>Aprotinin (Low dose) group received an intravenous bolus of 400ml of 0.9% saline with 100ml of aprotinin (1 million KIU) at induction of anaesthesia, followed by 500ml of 0.9% saline every hour; a further 400ml of 0.9% saline with 100ml of aprotinin 1 million KIU) was added to the pump prime.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 06:59:45 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood (units), fresh frozen plasma usage (units), blood loss.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-25 06:56:39 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 7/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-28 02:04:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Basora-1999">
<CHAR_METHODS MODIFIED="2010-06-28 02:03:49 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-25 07:03:48 +0100" MODIFIED_BY="[Empty name]">
<P>59 patients undergoing elective cardiac surgery were randomised to one of three groups:</P>
<UL>
<LI>Control group: n = 21, M/F = 16/5, mean (sd) age = 59.8 (10.3) years</LI>
<LI>Aprotinin group (Low dose - A2): n = 17, M/F = 12/5, mean (sd) age = 61.2 (13.1) years</LI>
<LI>Aprotinin group (Low dose - A4): n = 19, M/F = 14/5, mean (sd) age = 60.9 (7.6) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-25 07:04:03 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Control group did not receive aprotinin.</LI>
<LI>Aprotinin group (Low dose - A2) received 14,286 KIU/kg (2mg/kg) 15 mins before surgery, then a continuous dose of 7,143 KIU/kg/hr (1mg/kg/hr) until the end of surgery.</LI>
<LI>Aprotinin group (Low dose - A4) received 28,572 KIU/kg (4mg/kg) 15 mins before surgery, then a continuous dose of 7,143 KIU/kg/hr (1mg/kg/hr) until the end of surgery.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 07:05:09 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, blood loss, platelet function.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-28 02:04:01 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-25 07:12:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bennett_x002d_Guerrero-1997">
<CHAR_METHODS>
<P>Patients were randomised by means of a computer-generated schedule. Study drug was prepared according to a protocol by hospital pharmacies.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-25 07:10:45 +0100" MODIFIED_BY="[Empty name]">
<P>204 patients undergoing repeat cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 99, M/F = 66/33, mean (sd) age = 62 (14) years</LI>
<LI>Epsilon aminocaproic acid group: n = 105, M/F = 68/37, mean (sd) age = 63 (12) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-25 07:10:57 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received 2 million KIU (280mg) of aprotinin on skin incision, 500,000 KIU/hr as a continuous infusion for 4 hours on initiation of CPB. An additional 2 million KIU (280mg) was added to the CPB prime solution. Patients received 1ml of the study drug in a blinded manner before the loading dose to test for possible allergy.</LI>
<LI>Epsilon aminocaproic acid group received 150mg/kg on skin incision, 30mg/kg over 4 hours as a continuous infusion on initiation of CPB. In addition, normal saline solution was added to the CPB prime solution. Patients received 1ml of the study drug in a blinded manner before the loading dose to test for possible allergy.</LI>
</UL>
<P>NB: Both groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 07:11:54 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of participants exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage (units), blood loss, re-operation for bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-25 07:12:00 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 7/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-25 07:16:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Benoni-1996">
<CHAR_METHODS MODIFIED="2010-06-25 07:14:31 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation into blocks of 12 was done by an independent pharmacologist who was not otherwise engaged in the study. Pairs of ampoules, each containing 10ml of either the active substance or the placebo were numbered and packed into envelopes which were opened by the anaesthetist before administration. These ampoules could be identified only by their numbers, and the randomisation code was known only to the independent pharmacologist. The code was not broken until the end of the study and until all data had been corrected and included in the database. Ten patients were excluded from the study after randomisation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-25 07:15:06 +0100" MODIFIED_BY="[Empty name]">
<P>96 patients undergoing total knee arthroplasty were randomly allocated to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 43, M/F = 13/30, mean (sd) age = 76 (7) years</LI>
<LI>Control group (placebo): n = 43, M/F = 10/33, mean (sd) age = 74 (7) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-25 07:16:49 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>TXA group received 10mg/kg of TXA as a slow intravenous injection towards the end of the operation (median time 12 minutes - range 1-40 minutes) before deflation of the limb tourniquet. This dose was repeated after 3 hours from the other ampoule of the pair provided in the envelope.</LI>
<LI>Control group received a placebo of equal volumes of normal saline solution (0.9%).</LI>
</UL>
<P>NB: 15 patients from the placebo group received an extra dose of TXA for severe post-operative bleeding, these patients represented the 'placebo-extra' group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 07:16:17 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of participants exposed to allogeneic blood, allogeneic blood usage (units), blood loss, deep venous thrombosis, pulmonary embolus, wound haematomas, chest pain, haemoglobin concentrations.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-25 07:16:47 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-28 02:05:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Benoni-2000">
<CHAR_METHODS>
<P>Medication was administered using numbered ampoules and the randomisation was performed by a pharmacist not otherwise engaged in the study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-28 02:05:02 +0100" MODIFIED_BY="[Empty name]">
<P>40 patients undergoing total hip arthroplasty were randomly assigned to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 20, M/F = 6/14, mean (sd) age = 69.5 (10) years</LI>
<LI>Control group (Placebo): n=20, M/F = 11/8, mean (sd) age = 68 (10) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-28 02:05:31 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 10mg/kg IV of TXA (Cyklokapron) at the end of the operation and received another 10mg/kg IV 3 hours later.</LI>
<LI>Control group received corresponding volumes of normal saline (placebo).</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 07:19:16 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of participants exposed to allogeneic blood, allogeneic blood usage (units), blood loss, amount of pre-operative autologous donated blood (2 units), infection.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-25 07:19:21 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-29 06:18:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Benoni-2001">
<CHAR_METHODS>
<P>Method of randomisation was not described. Medication was concealed by a code only known by the hospitals chief pharmacist who was not involved in the study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-28 02:05:44 +0100" MODIFIED_BY="[Empty name]">
<P>40 patients undergoing total hip arthroplasty were randomly assigned to one of two treatments groups:</P>
<UL>
<LI>Tranexamic acid group: n = 20, M/F = 9/9, mean (sd) age = 66 (9.5) years</LI>
<LI>Control group (Placebo): n = 20, M/F = 10/10, mean (sd) age = 68 (9.4) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-28 02:05:54 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 100mg/ml of TXA (Cyklokapron), 10mg/kg (maximum 1g) in a slow (5-10 minutes) IV injection immediately before the operation.</LI>
<LI>Control group received a similar volume of saline as the same times as TXA.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-28 02:06:04 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of participants exposed to allogeneic blood, allogeneic blood usage (units), pulmonary embolus.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-29 06:18:14 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-29 06:18:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berenholtz-2009">
<CHAR_METHODS MODIFIED="2010-05-21 17:30:59 +0100" MODIFIED_BY="Katharine Ker">
<P>Patients were randomised according to a computer-generated randomisation schedule. Allocation was concealed through central (pharmacy) allocation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-25 07:27:11 +0100" MODIFIED_BY="[Empty name]">
<P>182 patients undergoing orthopaedic surgery were randomly allocated to one of two groups:</P>
<UL>
<LI>EACA group: n = 91, M/F = 26/65, mean (sd) age = 55.5 (14.0) years</LI>
<LI>Control group: n=91, M/F = 29/62, mean (sd) age = 55.4 (15.5) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-25 07:27:21 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>EACA group, received 100mg/kg administered immediately after anaesthesia followed by infusion of 10mg/kg/hr continued for 8 hours after surgery.</LI>
<LI>Control group received saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 07:28:56 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients receiving blood transfusion, volume of blood transfused (units), blood loss, mortality, pulmonary embolism, myocardial infarction, renal failure, stroke, thrombosis, deep vein thrombosis, length of hospital stay (days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-29 06:18:21 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7</P>
<P>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-29 06:18:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bernet-1999">
<CHAR_METHODS>
<P>Random code used for randomisation. Drug solutions were prepared by the hospital pharmacy.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-25 07:31:15 +0100" MODIFIED_BY="[Empty name]">
<P>70 patients were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 28, M/F = 25/3, mean (sd) age = 61.3 (2.86) years</LI>
<LI>Aprotinin group: n = 28, M/F = 24/4, mean (sd) age = 58.4 (3.76) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-25 07:31:27 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic group received 200mL (10g) of TXA administered 20 minutes before sternotomy. Normal saline placebo was given at the same time as aprotinin doses for the purpose of blinding.</LI>
<LI>Aprotinin group received 200ml (2 million KIU=280mg) of aprotinin administered 20 minutes before sternotomy and 200mL (2 million KIU = 280mg) administered as a continuous infusion of 50ml/hr (500,000 KIU) until closure of the chest.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 07:33:05 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma (units), platelets (units), blood loss, mortality, myocardial Infarctions, haematocrit levels, stroke, thrombotic complications, re-exploration for bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-29 06:18:44 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used. All patients received ASA until the day of the operation (100mg/day). All patients received cell salvage (Imed 960) - 8 hours post-operatively.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-29 06:19:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bert-2008">
<CHAR_METHODS MODIFIED="2010-06-28 01:53:14 +0100" MODIFIED_BY="[Empty name]">
<P>A computer-generated randomisation list was used to generate the allocation sequence. No information was provided regarding allocation concealment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-25 07:34:47 +0100" MODIFIED_BY="[Empty name]">
<P>50 patients undergoing elective cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 25, M/F = 20/5, mean (sd) age = 65.7 (10.2) years</LI>
<LI>Control group: n = 25, M/F = 20/5, mean (sd) age = 67.8 (8.3) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-25 07:34:59 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received loading dose of 2,000,000 KIU before sternotomy, then continuous infusion of 500,000 KIU until wound closure.</LI>
<LI>Control group did not receive aprotinin.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 07:35:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Blood loss, volume of blood transfused (units), re-operation for bleeding, inflammatory cytokines.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-29 06:19:05 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7</P>
<P>Transfusion protocol was not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-28 02:07:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bidstrup-1989">
<CHAR_METHODS MODIFIED="2010-06-28 01:53:05 +0100" MODIFIED_BY="[Empty name]">
<P>The trial drug was provided by the manufacturer (Bayer AG, Leverkusen) in identical case packs, each of 12 bottles identifiable only by the random number. Method of generating allocation sequences was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-28 01:48:59 +0100" MODIFIED_BY="[Empty name]">
<P>80 patients undergoing primary aorto-coronary bypass grafting were randomised to either one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 40, M/F = 37/3, mean (sd) age = 58.1 (8.6) years</LI>
<LI>Control group (Placebo): n = 37, M/F = 32/5; mean (sd) age = 57.7 (8.3) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-28 02:07:02 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received after induction of anaesthesia, a loading dose of 280mg of aprotinin given intravenously through a central venous cannula over 20 mins, then a continuous infusion of 70mg/hr was begun and maintained until the patient left the operating theatre. In addition to the intravenous infusion, another 280mg of aprotinin was added to the priming volume of the heart lung machine by replacement of an aliquot of the priming volume.</LI>
<LI>Control group received an equal volume of saline.</LI>
</UL>
<P>NB: Both intervention and control received preoperative autologous donation (PAD)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-28 01:32:40 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of participants exposed to allogeneic blood, allogeneic blood usage (units), blood loss (18 -24hrs), mortality.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-28 01:34:01 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used<BR/>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-28 01:52:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bidstrup-1990">
<CHAR_METHODS MODIFIED="2010-06-28 01:52:52 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-28 01:39:24 +0100" MODIFIED_BY="[Empty name]">
<P>44 patients undergoing aortocoronary artery bypass graft surgery were randomly allocated to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 26, M/F = 21/5, mean (sd) age = 59 (8) years</LI>
<LI>Control group: n = 18, M/F = 15/3, mean (sd) age = 58 (8) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-28 01:37:26 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a loading dose of 280mg (2 million KIU) of aprotinin after induction of anaesthesia and a constant infusion of 70mg/hr during the operation. A further 280mg was added to the pump prime.</LI>
<LI>Control group did not receive aprotinin.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-28 01:50:11 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of participants exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma usage (units), platelets (units), blood loss (18-24hrs), re-operation for bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-28 01:38:33 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-28 01:52:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bidstrup-1993">
<CHAR_METHODS MODIFIED="2010-06-28 01:52:44 +0100" MODIFIED_BY="[Empty name]">
<P>Patients received aprotinin or placebo (normal saline) from identical bottles supplied by the manufacturer, identifiable only by their random number. Method of randomisation was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-28 01:48:51 +0100" MODIFIED_BY="[Empty name]">
<P>96 adult male patients undergoing first-time isolated coronary bypass grafting were randomised to either one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 47, mean (sd) age = 59.1 (7.4) years</LI>
<LI>Control group (Placebo): n = 49, mean (sd) age = 58.8 (8.5) years</LI>
</UL>
<P>NB: Six patients withdrew from the study, four in the aprotinin group and two in the placebo group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-28 01:41:40 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 280mg of aprotinin (contained in 200ml) as a loading dose before the commencement of bypass. An additional 280mg of aprotinin was added to the prime of the heart-lung machine. A constant infusion of 70mg/hr was maintained during the procedure until skin closure.</LI>
<LI>Control group (placebo) received identical volumes of normal saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-28 01:50:05 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Allogeneic blood usage (units), blood loss, haemoglobin levels, platelet counts, haemoglobin loss, activated clotting times, adverse events, graft patency, re-operation for bleeding, wound infection.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-28 01:43:15 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-28 01:50:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bidstrup-2000">
<CHAR_METHODS MODIFIED="2010-05-26 13:35:56 +0100" MODIFIED_BY="Katharine Ker">
<P>Patients were allocated to receive either placebo or active treatment in accordance with a previously determined randomization schedule in a double blind fashion. Allocation concealment was adequate, active drug and placebo were contained in identical bottles, identifiable only by a random number.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-28 01:48:26 +0100" MODIFIED_BY="[Empty name]">
<P>60 patients undergoing aortocoronary bypass were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 30, M/F = 24/6, mean (sd) age = 63.0 (7.8) years</LI>
<LI>Control group (Placebo): n = 30, M/F = 27/3, mean (sd) age = 61.7 (6.8) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-28 01:48:37 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received a loading dose 280mg (2 million KIU) of aprotinin over 20 minutes after anaesthesia, 280mg of aprotinin added to the pump prime and a continuous infusion of 70mg/hr until the end of the procedure.</LI>
<LI>Control group received a placebo of 0.9% normal saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-28 01:50:01 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of participants exposed to allogeneic blood, mortality, myocardial infarction, re-operation for bleeding, wound infection, neurologic disturbance,<BR/>atrial fibrillation/flutter.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-28 01:50:27 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-28 01:55:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blauhut-1994">
<CHAR_METHODS MODIFIED="2010-06-28 01:52:23 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described. No exclusions or loss to follow-up reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-28 01:54:20 +0100" MODIFIED_BY="[Empty name]">
<P>45 patients undergoing cardiopulmonary bypass for coronary surgery were allocated at random to one of three groups:</P>
<UL>
<LI>Aprotinin group: n = 15, M/F = 13/2, mean (sd) age = 64.1 (2.2) years</LI>
<LI>Tranexamic group: n = 16, M/F = 13/3, mean (sd) age = 62.5 (2.2) years</LI>
<LI>Control group: n = 14, M/F = 11/3, mean (sd) age = 62.7 (2.6) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-28 01:54:37 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a loading dose of 2 million kallikrein inactivator units (KIU) plus a maintenance dose of 500,000 KIU/hr until the patient was transferred to the recovery area of the intensive care unit. In addition, 1 million KIU was added to the oxygenator priming fluid, giving an average total dose of 4.2 million KIU of aprotinin.</LI>
<LI>Tranexamic (TXA) group received 10mg/kg of TXA beginning 30 minutes before incision of the skin and followed by 1mg/kg/hr for 10 hours after the beginning of the surgical procedures.</LI>
<LI>Control group did not receive aprotinin or TXA treatment.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-28 01:55:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of participants exposed to allogeneic blood, allogeneic blood usage (units), blood loss (24 hrs), mortality, platelet function, coagulation, haematocrit levels.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-28 01:55:54 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 1/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-29 06:19:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boldt-1991">
<CHAR_METHODS MODIFIED="2010-06-28 02:09:11 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described. No exclusions or loss to follow-up reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-28 02:10:36 +0100" MODIFIED_BY="[Empty name]">
<P>30 male patients undergoing elective aortocoronary bypass grafting were randomised to one of three groups:</P>
<UL>
<LI>Cell Salvage group: n = 10, mean (sd) age = 60.4 (7.1) years</LI>
<LI>Hemofiltration group: n = 10, mean (sd) age = 62.4 (8.6) years</LI>
<LI>Aprotinin group: n = 10, mean (sd) age = 62.7 (7.8) years</LI>
<LI>Control group: n = 10, mean (sd) age = 46.6 (16.2) years</LI>
</UL>
<P>NB: Control group did not appear to be part of the randomised schedule. Possibly a non-concurrent or historical control group.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-28 02:11:08 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Cell Salvage group - a cell separator (Cell Saver IV, Hemonetics) was used during and after CPB.</LI>
<LI>Haemofiltration group had blood concentrated during and after CPB by means of a hemofiltration device (HF-80, Fresenius, Bad Homburg, FRG).</LI>
<LI>Aprotinin group received an infusion of 2 million kallikrein inactivator units (KIU) before the operation (loading dose) and then as a continuous infusion of 500,000 units/hr until the end of the operation. In addition, 2 million KIU of aprotinin was added to the priming of the heart-lung machine. In addition blood concentration during and after CPB was performed with a hemofiltration device (HF-80, Fresenius, Bad Homburg, FRG) the same as for Group 2.</LI>
<LI>Control group underwent neurosurgery operations.</LI>
</UL>
<P>NB: Only Group 2 and Group 3 were compared.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-28 02:11:37 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of participants exposed to allogeneic blood, allogeneic blood usage (units), blood loss (24hrs).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-29 06:19:27 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used. Study used neurosurgical patients as a control group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-28 02:14:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boldt-1994">
<CHAR_METHODS MODIFIED="2010-06-28 02:12:23 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-28 02:13:21 +0100" MODIFIED_BY="[Empty name]">
<P>40 patients undergoing cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 20, mean (sd) age = 64 (4) years</LI>
<LI>Control group: n = 20, mean (sd) age = 63 (5) years</LI>
</UL>
<P>NB: Gender data were not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-28 02:13:33 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received 2 million KIU of aprotinin after the induction of anaesthesia, 500,000 KIU/hr of aprotinin as a continuous infusion until the end of the operation, and 2 million KIU was added to the CPB pump prime.</LI>
<LI>Control group received the same amount of saline solution as aprotinin was administered.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-28 02:14:12 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage (units), fresh frozen plasma usage (units), blood loss (24hrs), re-operation for bleeding, haemoglobin levels.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-28 02:14:18 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-28 02:21:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boylan-1996">
<CHAR_METHODS MODIFIED="2010-06-28 02:17:02 +0100" MODIFIED_BY="[Empty name]">
<P>Study agents were prepared by the hospital pharmacy using a randomisation schedule provided in sealed envelopes. The method used to generate allocation sequences was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-28 02:17:45 +0100" MODIFIED_BY="[Empty name]">
<P>45 patients undergoing primary, isolated orthotopic liver transplantation were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 25, mean (sd) age = 49.5 (9.1) years</LI>
<LI>Control group (Placebo): n = 20, mean (sd) age = 48.8 (9.6) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-28 02:18:05 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid (TXA) group received a continuous infusion of TXA in normal saline (40mg/kg/hr to a maximum dose of 20g).</LI>
<LI>Control group (placebo) received an equivalent volume of 0.9% normal saline alone.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-28 02:20:01 +0100" MODIFIED_BY="[Empty name]">
<P>Outcomes reported: Allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage (units), blood loss, mortality, portal vein thrombosis, hepatic thrombosis, hospital length of stay, intensive care unit (ICU) length of stay, overall donor exposure.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-28 02:21:39 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria):5/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-28 02:26:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brown-1997">
<CHAR_METHODS MODIFIED="2010-06-28 02:23:22 +0100" MODIFIED_BY="[Empty name]">
<P>Method of allocation concealment was not described. Patients were randomised using a computer-generated random number sequence.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-28 02:24:27 +0100" MODIFIED_BY="[Empty name]">
<P>91 patients scheduled for elective coronary revascularisation were randomly allocated to one of three groups:</P>
<UL>
<LI>Control group (Placebo): n = 30, M/F = 24/6, mean (sd) age = 59 (7) years</LI>
<LI>Tranexamic acid group (TXA before CPB): n = 30, M/F = 25/5, mean (sd) age = 61 (9) years</LI>
<LI>Tranexamic acid group (TXA after CPB): n = 30, M/F = 24/6, mean (sd) age = 62 (10) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-28 02:24:49 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Control group received equivalent volumes of normal saline solution.</LI>
<LI>Tranexamic acid group received 15mg/kg of TXA before CPB, followed by a TXA infusion of 1mg/kg/hr for 5hrs.</LI>
<LI>Tranexamic acid group received 15mg/kg of TXA after CPB, followed by a TXA infusion of 1mg/kg/hr for 5hrs.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-28 02:26:09 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of participants exposed to allogeneic blood, haematologic/thromboelastographic/coagulation characteristics, mortality, myocardial infarction, stroke, re-exploration for bleeding, infection.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-28 02:26:16 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-29 06:19:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Caglar-2008">
<CHAR_METHODS MODIFIED="2010-06-28 04:08:46 +0100" MODIFIED_BY="[Empty name]">
<P>A computer-generated randomisation list was used to generate the allocation sequence. No information was provided regarding allocation concealment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-28 04:09:56 +0100" MODIFIED_BY="[Empty name]">
<P>100 female patients undergoing myomectomy were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 50, mean (sd) age = 34.2 (5.5) years</LI>
<LI>Control group: n = 50, mean (sd) age = 36.5 (4.5) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-28 04:10:07 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received bolus of 10mg/kg over 10 minutes 15 minutes before incision, then continuous infusion of 1mg/kg/hr for 10 hours.</LI>
<LI>Control group received saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-28 04:10:47 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>number of patients exposed to allogeneic blood, blood loss, volume of blood transfused.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-29 06:19:37 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7</P>
<P>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-28 04:19:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Camarasa-2006">
<CHAR_METHODS>
<P>Randomisation was achieved by computer-generated random numbers. The randomised assignment was sealed in an opaque, numbered envelope which was opened only by the nurse who prepared the solutions. This nurse was the only person who knew the patients study groups and did not participate in any other phase of the trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-28 04:18:14 +0100" MODIFIED_BY="[Empty name]">
<P>68 patients undergoing total knee replacement were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 35, M/F = 9/26, mean (range) age = 73 (61-84) years</LI>
<LI>Epsilon aminocaproic acid group: n = 32, M/F = 4/28, mean (range) age = 73 (59-80) years</LI>
</UL>
<P>NB: One patient was excluded from the final analysis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-28 04:18:28 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 10mg/kg of TXA administered over 30 minutes immediately before releasing the tourniquet followed by a continuous intravenous infusion of 10mg/kg for 3 hours.</LI>
<LI>Epsilon aminocaproic acid group received 100mg/kg of EACA administered over 30 minutes immediately before releasing the tourniquet followed by a continuous intravenous infusion of 1g/hr for 3 hours.</LI>
</UL>
<P>NB: Both groups were exposed to cell salvage and pre-operative autologous blood donation (PAD).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-28 04:19:22 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of participants exposed to allogeneic blood, allogeneic blood usage (units), blood loss, deep vein thrombosis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-28 04:19:27 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-29 00:57:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Capdevila-1998">
<CHAR_METHODS MODIFIED="2010-06-11 11:11:13 +0100" MODIFIED_BY="Katharine Ker">
<P>Randomisation was performed using a random number list generated by computer programme. Allocation was adequately concealed (administered fluids were prepared by the hospitals central pharmacy in identical 100-ml bottles).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-29 00:56:21 +0100" MODIFIED_BY="[Empty name]">
<P>23 patients scheduled for orthopaedic surgery of the hip, femur or pelvis for sepsis or malignant tumours were randomly allocated to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 12, M/F = 7/5, mean (sd) age = 48.6 (17.3) years</LI>
<LI>Control group (Placebo): n = 11, M/F = 6/5, mean (sd) age = 48.5 (16.3) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-29 00:56:30 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group was administered a bolus of 1 million kallikrein inactivation units (KIU) during a 30 minute injection period, followed by a continuous infusion of 500,000 KIU/hr throughout the duration of surgery.</LI>
<LI>Control group received identical volumes of saline over the same time periods.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-29 00:57:46 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage (units), blood loss, haemoglobin and haematocrit levels, coagulation and fibrinolytic pathway explorations, allergic reactions.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-29 00:57:54 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 7/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-29 01:01:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carrera-1994">
<CHAR_METHODS>
<P>Randomisation and allocation concealment not specified. No exclusions or loss to follow-up reported. [Spanish language]</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-29 01:00:05 +0100" MODIFIED_BY="[Empty name]">
<P>102 patients undergoing cardiac surgery were randomly assigned to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 51, M/F = 20/31, mean (sd) age = 54 (13.1) years</LI>
<LI>Control group: n = 51, M/F = 21/30, mean (sd) age = 55 (13.0) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-29 01:01:27 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 2 million kallikrein inhibiting units (KIU) of aprotinin upon anaesthesia induction, a similar dose in the extracorporeal circulation priming pump, and a maintenance dose of 500,000 KIU/hr until the removal from the operating theatre.</LI>
<LI>Control group did not receive aprotinin.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-29 01:01:16 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of participants exposed to allogeneic blood, allogeneic blood usage, fresh frozen plasma usage, platelet usage, blood loss, myocardial infarction.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-29 01:01:43 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-29 06:35:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Casas-1995">
<CHAR_METHODS>
<P>Generation of allocation sequences was not specified. Allocation concealment was by sealed envelopes. The pharmacy prepared the encoded infusions.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-29 06:35:45 +0100" MODIFIED_BY="[Empty name]">
<P>149 patients scheduled to undergo either coronary artery bypass grafting (CABG), heart valve replacement or annuloplasty, combined valve replacement and CABG, or closure of atrial septal defects, were randomised to one of three groups:</P>
<UL>
<LI>Aprotinin group: n = 48, M/F = 31/17, mean (sd) age = 57 (10) years</LI>
<LI>Desmopressin group: n = 50, M/F = 33/17, mean (sd) age = 58 (12) years</LI>
<LI>Control group (Placebo): n = 51, M/F = 31/20, mean (sd) age = 54 (12) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-29 06:07:15 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 2 million kallikrein inactivator units (KIU) of aprotinin before anaesthesia (time stage 1) given over 20 to 30 minutes. A dose of 2 million KIU was added to the prime solution of the heart-lung machine (time stage 2). Aprotinin was administered continuously (time stage 3) at 500,000 KIU/hr (50ml/hr) until the end of the operation (from skin incision to skin closure), then patients received 50ml of saline (time stage 4).</LI>
<LI>Desmopressin group received desmopressin infusions corresponding to 0.3 to 0.4 ug/kg body weight. Desmopressin was infused in 50ml of physiologic saline solution for 20 to 30 minutes, 15 minutes after protamine administration (time stage 4). In other time phases (1-3) patients received saline solution only.</LI>
<LI>Control group received a placebo of saline solution during all four stages.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-29 06:08:34 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), number of patients exposed to fresh frozen plasma, number of patients exposed to platelets, blood loss (24hrs), re-operation for bleeding, femoral embolism, stroke.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-29 06:08:39 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-29 06:23:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Casati-1999">
<CHAR_METHODS MODIFIED="2010-06-29 06:20:46 +0100" MODIFIED_BY="[Empty name]">
<P>Method ofrandomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-29 06:21:35 +0100" MODIFIED_BY="[Empty name]">
<P>210 patients undergoing cardiac surgery were randomly assigned to one of three groups:</P>
<UL>
<LI>Epsilon aminocaproic group: n = 68, M/F = 54/12, mean (sd) age = 58.7 (10) years</LI>
<LI>Tranexamic acid group: n = 72, M/F = 57/13, mean (sd) age = 61.9 (9.6) years</LI>
<LI>Aprotinin group: n= 70, M/F = 54/13, mean (sd) age = 63.6 (9.6) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-29 06:21:49 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>EACA group received 5g during 20 minutes after induction of anaesthesia before sternotomy followed by a continuous infusion of 2g/hr until the end of the operation + 2.5g added to the pump prime.</LI>
<LI>TXA group received 1g over 20 minutes before sternotomy, followed by a continuous infusion of 400mg/hour during operative period and 500mg added to the pump prime.</LI>
<LI>Aprotinin group received 280mg throughout 20 minutes before sternotomy, followed by a constant infusion of 70mg throughout the operation and 280mg added to the pump prime.</LI>
</UL>
<P>NB: All groups were exposed to cell salvage. Pre-operative autologous blood donation use was evenly distributed between groups.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-29 06:23:17 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units) blood loss, mortality, myocardial infarction, deep venous thrombosis, pulmonary embolus, pre-operative autologous donation of blood, neurological complications, re-operation for surgical bleeding.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-29 06:23:25 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 1/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-29 06:26:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Casati-2000">
<CHAR_METHODS>
<P>Patients were randomised into treatment groups by means of a computer generated random number sequence. Allocation concealment was not described. Trial was unblinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-29 06:24:54 +0100" MODIFIED_BY="[Empty name]">
<P>1040 patients undergoing primary elective cardiac operations were randomly assigned to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 522, M/F = 415/107, mean (sd) age = 61 (10) years</LI>
<LI>Aprotinin group: n = 518, M/F = 412/106, mean (sd) age = 62 (10) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-29 06:25:07 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 1g over 20 minutes before surgical incision followed by a constant infusion of 400mg/hr during the entire operative period and 500mg was added to the pump prime.</LI>
<LI>Aprotinin group received 280mg for 20 minutes before surgical incision followed by a constant infusion of 70mg/hr until the end of the operation and 280mg was added to the pump prime.</LI>
</UL>
<P>NB: Both groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-29 06:26:14 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, mortality, myocardial infarction, fresh frozen plasma usage, (units), platelet usage (units), pulmonary embolus.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-29 06:26:21 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 3/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-29 06:35:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Casati-2001">
<CHAR_METHODS MODIFIED="2010-06-29 06:29:28 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation was not described. Coded infusion syringes were used and prepared by a staff member not directly involved with perioperative clinical treatment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-29 06:35:33 +0100" MODIFIED_BY="[Empty name]">
<P>40 patients undergoing elective cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 20, M/F = 15/5, mean (sd) age = 64 (13) years</LI>
<LI>Control group (Placebo): n = 20, M/F = 17/3, mean (sd) age = 62 (11) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-29 06:28:14 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>TXA group (off-pump surgery) received a bolus of 1g of TXA over 20 minutes after the induction of anaesthesia but before skin incision and a continuous infusion of 400mg/hr during the whole surgical period.</LI>
<LI>Control group received an infusion of saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-29 06:28:52 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-29 06:28:57 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-29 06:35:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Casati-2002">
<CHAR_METHODS MODIFIED="2010-06-29 06:30:48 +0100" MODIFIED_BY="[Empty name]">
<P>Coded infusion syringes were used to conceal which medication was placebo and which was TXA. Method of randomisation was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-29 06:35:26 +0100" MODIFIED_BY="[Empty name]">
<P>60 patients undergoing elective thoracic-aorto surgery were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 30, M/F = 23/6, mean (sd) age = 59 (13) years</LI>
<LI>Control group (Placebo): n = 30, M/F = 19/10, mean (sd) age = 63 (11) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-29 06:31:21 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received a bolus of TXA 1g in 20 minutes after the induction of anaesthesia but before skin incision and a continuous infusion of 400mg/hr during the whole surgical period and an additional 500mg of TXA was added to the pump prime of CPB.</LI>
<LI>Control group received an infusion of saline solution.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-29 06:33:06 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), number of patients exposed to fresh frozen plasma, number of patients exposed to platelets, blood loss (24hrs), re-operation for bleeding, mortality, myocardial infarction, pulmonary embolus, pre-operative aspirin, pre-operative anticoagulant, stroke, hospital length of stay (days).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-29 06:33:11 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-29 06:39:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Casati-2004">
<CHAR_METHODS>
<P>Randomisation was by means of two seperate computer-generated random number sequences. Coded syringes were used to administer medication.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-29 06:36:45 +0100" MODIFIED_BY="[Empty name]">
<P>102 patients scheduled for cardiac surgery with either 'on-pump' or 'off-pump' procedures were randomised to one of four groups:</P>
<UL>
<LI>Control group (Placebo) ('Off-pump' surgery): n = 25, M/F = 21/4, mean (sd) age =61 (11) years</LI>
<LI>Tranexamic acid group ('Off-pump' surgery): n = 26, M/F = 20/6, mean (sd) age = 64 (12) years</LI>
<LI>Control group (placebo) ('On-pump' surgery): n = 25, M/F = 21/4, mean (sd) age = 60 (9) years</LI>
<LI>Tranexamic acid group ('On-pump' surgery): n = 26, M/F = 24/2, mean (sd) age = 64 (9) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-29 06:37:31 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Control group ('Off-pump' surgery) received an equivalent volume of saline solution administered as a bolus injection in 20 minutes before skin incision, followed by a continuous infusion of saline until the completion of surgery.</LI>
<LI>Tranexamic acid group ('Off-pump' surgery) received a bolus injection of 1g of TXA in 20 minutes before skin incision followed by a continuous infusion of 400mg/hr until completion of surgery.</LI>
<LI>Control group ('On-pump' surgery) received the same treatment as Group 1 plus received an equivalent volume of saline solution added to the CPB pump.</LI>
<LI>Tranexamic acid ('On-pump' surgery) received the same treatment as Group 2 plus received 500mg of TXA added to the pump prime.</LI>
</UL>
<P>NB: 'On-pump' surgery patients (Groups 3 &amp; 4) the remaining blood in the cardiopulmonary bypass (CPB) circuit and that blood aspirated from the surgical field was concentrated with a cell separator and reinfused. For 'Off-pump' surgery patients only in cases of significant intra-operative bleeding was the shed blood concentrated in a cell separator and reinfused. No autotransfusion of shed mediastinal blood was performed during the post-operative period for any group.</P>
<P>ONCAB-Cell Salvage. Only in cases of significant intra-operative bleeding was the shed blood concentrated in a cell separator and reinfused. No autotransfusion of shed mediastinal blood was performed during the post-operative period.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-29 06:39:23 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), number of patients exposed to fresh frozen plasma, number of participants exposed to platelets, blood loss (24hrs), re-exploration for bleeding, stroke, intra-operative resternotomy, fresh frozen plasma usage (units), platelet usage (units).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-29 06:39:28 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 7/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-30 02:07:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cicek-1996a">
<CHAR_METHODS MODIFIED="2010-06-30 02:04:55 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-30 02:05:53 +0100" MODIFIED_BY="[Empty name]">
<P>75 patients scheduled for elective cardiac operations with cardiopulmonary bypass were randomly assigned to one of three groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 25, M/F = 22/3, mean (sd) age = 44.9 (18.6) years</LI>
<LI>Aprotinin group (Post-operative low dose): n = 25, M/F = 19/6, mean (sd) age = 52.9 (12.4) years</LI>
<LI>Control group: n = 25, M/F = 21/4, mean (sd) age = 46.7 (15) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-30 02:06:25 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received a bolus of 2 million kallikrein inhibiting units (KIU) of aprotinin (280mg), plus a maintenance dose of 500,000 KIU/hr (70mg/hr) until the end of the operation. In addition 2 million KIU (280mg) was added to the oxygenator priming fluid.</LI>
<LI>Aprotinin group (Post-operative low dose) received a bolus of 2 million KIU (280mg) at the end of the procedure before transfer to the intensive care unit.</LI>
<LI>Control group did not receive aprotinin.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-30 02:06:59 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, myocardial infarction.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-30 02:07:06 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-30 07:04:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cicek-1996b">
<CHAR_METHODS MODIFIED="2010-06-30 06:56:52 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomised to receive aprotinin or placebo by means of a random numbers table. Method of allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-30 07:04:36 +0100" MODIFIED_BY="[Empty name]">
<P>57 patients undergoing cardiac operations with cardiopulmonary bypass (CPB) were randomly assigned to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 29, M/F = 21/8, mean (sd) age = 51.6 (15.4) years</LI>
<LI>Control group (Placebo): n = 28, M/F = 19/9, mean (sd) age = 48.2 (14.2) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-30 06:57:32 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a bolus of 2 million kallikrein inhibiting units (KIU) of aprotinin (280mg) infused over 15 minutes when they arrived in intensive care.</LI>
<LI>Control group received an equal volume of normal saline solution at corresponding times to the aprotinin treated group.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-30 06:58:02 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-30 06:58:08 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-30 07:07:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cicekcioglu-2006">
<CHAR_METHODS MODIFIED="2010-06-30 07:03:52 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described. Data were collected in a blinded fashion.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-30 07:04:32 +0100" MODIFIED_BY="[Empty name]">
<P>44 patients undergoing coronary artery bypass grafting were randomly assigned to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 24, M/F = 19/5, mean (sd) age = 48.6 (12.1) years</LI>
<LI>Control group (Placebo): n = 20, M/F = 18/2, mean (sd) age = 48.3 (9.0) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-30 07:00:43 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (low-dose) administered in two equal doses - bolus of 250,000 KIU 5 minutes before skin incision just after induction of anaesthesia, second dose of 250,000 KIU was added to the prime pump.</LI>
<LI>Control group received saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-30 07:07:11 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, amount of allogeneic blood transfused (units), blood loss, mortality, length of hospital stay, post-operative morbidity.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-30 07:04:01 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7</P>
<P>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-30 07:26:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Claeys-2007">
<CHAR_METHODS MODIFIED="2010-06-30 07:05:19 +0100" MODIFIED_BY="[Empty name]">
<P>Methods of sequence generation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-30 07:06:21 +0100" MODIFIED_BY="[Empty name]">
<P>40 patients undergoing orthopaedic (hip) surgery were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 20, M/F = 5/15, mean (sd) age = 73 (8) years</LI>
<LI>Control group (Placebo): n = 20, all females, M/F = 7/13, mean (sd) age = 68 (11) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-30 07:05:47 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received single pre-operative dose of 15mg/kg.</LI>
<LI>Control group received a placebo of saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-30 07:07:08 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients receiving blood transfusions, blood loss, deep vein thrombosis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-30 07:26:04 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7</P>
<P>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-30 07:36:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coffey-1995">
<CHAR_METHODS MODIFIED="2010-06-30 07:27:11 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation was not described. Pharmacy controlled the randomisation process. Method of allocation concealment was not clear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-30 07:27:39 +0100" MODIFIED_BY="[Empty name]">
<P>30 patients undergoing cardiac surgery were randomised to either one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 16, M/F = 5/11, mean age = 63.94 years</LI>
<LI>Control group (Placebo): n = 14, M/F = 5/9, mean age = 64.75 years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-30 07:27:49 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received a loading dose of 10mg/kg of TXA over a period of 30 minutes at the time of skin incision followed by a 1mg/kg/hr infusion over 12 hours.</LI>
<LI>Control group received an equal volume of saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-30 07:36:03 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, blood loss, mortality.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-30 07:28:23 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7<BR/>Transfusion protocol not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 05:13:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cohen-1998">
<CHAR_METHODS>
<P>Patients were randomised by the hospital pharmacy after stratification and blocking in groups of six. The pharmacy supplied bags that contained dipyridamole (DIP), aprotinin (APR) or a saline placebo.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 05:13:52 +0100" MODIFIED_BY="[Empty name]">
<P>115 patients undergoing cardiac operations for valve replacement or myocardial revascularization, or a combined procedure were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 56, M/F = 44/12, mean (sd) age = 63 (9) years</LI>
<LI>Control group (Placebo): n = 59, M/F = 47/12, mean (sd) age = 61 (8) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-30 07:31:36 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a high dose of aprotinin (Full Hammersmith) with a loading dose of 280mg (2 million KIU) plus a pump prime dose of 280mg and a maintenance dose 70mg/hr intra-operatively and continued for 1 hour post-operatively.</LI>
<LI>Control group received a saline placebo.</LI>
</UL>
<P>NB: All patients were administered dipyridamole (DIP) orally (100mg four times daily for three or more doses pre-operatively) and intravenously (at a rate of 0.24mg/kghr beginning before anaesthesia induction and continuing for 1 hour post-operatively). Autologous blood shed into sterile cardiotomy reservoirs from chest drains was autotransfused to the patient when drainage exceeded 150ml during the first 4 hours post-operatively.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-30 07:35:57 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, blood loss, mortality, myocardial infarction, autologous shed blood transfused, blood loss (24 hrs),<BR/>renal failure, stroke, intensive care unit length of stay (days), hospital length of stay (days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-30 07:33:04 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-30 07:44:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Colwell-2007">
<CHAR_METHODS MODIFIED="2010-06-30 07:44:53 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomly assigned on the day of surgery to a treatment group in a 1:1 ration from a computer-generated list managed by an interactive voice response system. Aprotinin and placebo were provided to the pharmacy in the same packaging and were dispensed by the randomisation assignment, blinding the patient and staff to the actual treatment group. The primary efficacy analysis was performed on the intention-to-treat population.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-30 07:35:26 +0100" MODIFIED_BY="[Empty name]">
<P>359 patients undergoing orthopaedic surgery (hip arthroplasty) were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 180, M/F = 61/84, mean (sd) age = 63.4 (12.1) years</LI>
<LI>Control group: n = 179, M/F = 81/96, mean (sd) age = 64.4 (12.7) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-30 07:35:37 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group - received a test dose of 10,000 KIU, loading dose of 2 million KIU, then 0.5 million KIU per hour until end of surgery.</LI>
<LI>Control group received saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-30 07:37:27 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients receiving blood transfusions, volume of blood transfused (units), blood loss, deep vein thrombosis, renal failure, myocardial infarction, stroke, mortality, pulmonary embolism.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-30 07:38:07 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7</P>
<P>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 04:57:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Corbeau-1995">
<CHAR_METHODS MODIFIED="2010-07-01 04:57:08 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described. Two patients were excluded after randomisation. [French language]</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 04:55:45 +0100" MODIFIED_BY="[Empty name]">
<P>104 adults undergoing either coronary artery bypass grafting (CABG) or aortic valve replacement (AVR) were randomised to one of three groups:</P>
<UL>
<LI>Aprotinin group: n = 43 [AVR: n = 20, M/F = 13/7, mean (sd) age = 64 (16) years; CABG: n = 23, M/F = 20/3, mean (sd) age = 68 (8) years]</LI>
<LI>Tranexamic acid group: n = 41 [AVR: n = 19, M/F = 7/12, mean (sd) age = 63 (19) years; CABG: n = 22, M/F = 19/3, mean (sd) age = 62 (9) years</LI>
<LI>Control group: n = 20 [AVR: n = 10, M/F = 7/3, mean (sd) age = 60 (22) years; CABG: n = 10, M/F = 9/1, mean (sd) age = 66 (3) years]</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 04:56:16 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 2 million kallikrien inactivator units (KIU) of aprotinin (280mg) after induction of anaesthesia, followed by an infusion of 500,000 KIU/hr (70mg/hr) until chest closure, with a supplement to the oxygenator prime of 2 million KIU of aprotinin.</LI>
<LI>Tranexamic acid group received 15mg/kg of TXA between the injection of heparin (400IU/kg) and the beginning of extracorporeal circulation, plus 15mg/kg after protamine injection (1.3mg/100IU of heparin).</LI>
<LI>Control group did not receive any antifibrinolytic therapy.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 04:56:46 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 04:56:53 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 1/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 05:01:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cosgrove-1992">
<CHAR_METHODS MODIFIED="2010-07-01 04:57:56 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described. All subjects were included in the final analysis.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 04:58:51 +0100" MODIFIED_BY="[Empty name]">
<P>169 patients undergoing isolated re-operative myocardial revascularisation were randomised to either one of three groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 57, males (87.7%), mean (sd) age = 60.8 (7.8) years</LI>
<LI>Aprotinin group (Low dose): n = 56, males (80.4%), mean (sd) age = 61.1 (8.3) years</LI>
<LI>Control group (Placebo): n = 56, males (87.5%), mean (sd) age = 63.0 (8.8) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 05:01:01 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received 70mg of aprotinin in 50ml of 0.9% saline. After induction of anaesthesia, a loading dose of 200ml of aprotinin solution was given intravenously over 20 minutes. Immediately after this, a continuous infusion of 50ml/hr was begun and maintained until the patient left the operating room. An additional 200ml of aprotinin was added to the prime volume of the cardiopulmonary bypass machine.</LI>
<LI>Aprotinin group (Low dose) received 35mg of aprotinin in 50ml of 0.9% saline solution at corresponding times as Group 1.</LI>
<LI>Control group received 50ml of saline solution at corresponding times as Group 1.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 04:59:56 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), mortality, myocardial infarction, re-operation for bleeding, fresh frozen plasma usage (units), platelet usage (units).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 05:00:37 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 05:05:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cvachovec-2001">
<CHAR_METHODS MODIFIED="2010-07-01 05:02:54 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described in the abstract. [Czech Republic]</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 05:03:33 +0100" MODIFIED_BY="[Empty name]">
<P>42 patients undergoing total hip arthroplasty were randomly allocated to one of two groups:</P>
<UL>
<LI>Aprotinin group (Low dose): n = 20, M/F = 10/10</LI>
<LI>Control group: n = 22, M/F = 8/14</LI>
</UL>
<P>NB: No age data were reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 05:03:45 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (Low dose) received 2 million KIU (280mg) of aprotinin started pre-operatively and continued in the course of the first hour of surgery.</LI>
<LI>Control group did not receive aprotinin.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 05:04:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 05:05:04 +0100" MODIFIED_BY="[Empty name]">
<P>Foreign language paper</P>
<P>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 05:11:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-D_x0027_Ambra-1996">
<CHAR_METHODS>
<P>A separate random code, using blocks of six, was generated for each site by the statistical department of Bayer Incorporated. The study medication for each patient was supplied for each patient in a case pack containing 14 vials. The loading dose vials, pump prime vials, and constant infusion vials were separately identified and packaged within the pack for each patient. Investigators were blinded to the identity and lot number of each case pack.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 05:07:24 +0100" MODIFIED_BY="[Empty name]">
<P>213 patients undergoing cardiac surgery were enrolled and randomised at the five sites to one of three groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 65, M/F = 31/34, mean (sd) age = 59.8 (3.1) years</LI>
<LI>Aprotinin group (Low dose): n = 62, M/F = 33/29, mean (sd) age = 59.2 (3.2) years</LI>
<LI>Control group (Placebo): n = 64, M/F = 30/34, mean (sd) age = 60.0 (3.1) years</LI>
</UL>
<P>NB: Of the 213 patients enrolled and randomised, 212 were included in the safety analysis and 191 were included in a primary analysis of efficacy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 05:09:46 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received an intravenous loading dose of 280mg of aprotinin (2 million KIU) infused over 20-30 minutes followed by a continuous infusion of 70mg/hr (500,000 KIU/hr) infused until chest closure. An additional dose of aprotinin equivalent to the loading dose was added to the pump prime.</LI>
<LI>Aprotinin group (Low dose) received a loading dose of 140mg of aprotinin (1 million KIU) infused over 20-30 minutes followed by a continuous infusion of 35mg (250,000 KIU/hr) of aprotinin, infused until chest closure. An additional dose of aprotinin, equivalent to the loading dose, was added to the pump prime.</LI>
<LI>Control group received equivalent volumes of normal saline solution at corresponding times to the active treatments.</LI>
</UL>
<P>NB: Blood conservation measures were used for all groups. These measures included the reinfusion of post-operative mediastinal shed blood (cell salvage) and the pre-operative donation of autologous blood (PAD). Epsilon aminocaproic acid (EACA) and desmopressin (DDAVP) were used to treat active bleeding after the reversal of heparin.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 05:11:29 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage (units), mortality, myocardial infarction, re-operation, renal dysfunction, deep vein thrombosis, cardiovascular complications, cerebrovascular accident.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 05:11:36 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 05:18:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-D_x0027_Ambrosio-1999">
<CHAR_METHODS MODIFIED="2010-07-01 05:15:14 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 05:17:01 +0100" MODIFIED_BY="[Empty name]">
<P>60 patients undergoing total hip arthroplasty were randomised into one of four groups:</P>
<P>
<I>Comparison 1:</I>
</P>
<UL>
<LI>Aprotinin group: n = 15, M/F = 8/7, mean (sd) age = 61.5 (9.2) years</LI>
<LI>Control group (Placebo): n = 15, M/F = 9/6, mean (sd) age = 66.7 (7.3) years</LI>
</UL>
<P>
<I>Comparison 2:</I>
</P>
<UL>
<LI>Aprotinin group: n = 15, M/F = 7/8, mean (sd) age = 66.6 (9.2) years</LI>
<LI>Control group (Placebo): n = 15, M/F = 7/8, mean (sd) age = 60.5 (12.9) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 05:17:55 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Comparison 1:</I>
</P>
<UL>
<LI>Aprotinin group (epidural + general anaesthesia) received 500,000 KIU of aprotinin administered as a bolus before skin incision and 500,000 KIU continuous infusion until the skin was sutured.</LI>
<LI>Control group (epidural + general anaesthesia) received saline solution 0.9% in same manner as aprotinin.</LI>
</UL>
<P>
<I>Comparison 2:</I>
</P>
<UL>
<LI>Aprotinin group (general anaesthesia) 500,000 KIU was administered as a bolus before skin incision and 500,000 KIU continuous until the skin was sutured.</LI>
<LI>Control group (placebo) (general anaesthesia) saline solution 0.9% in the same manner as aprotinin.</LI>
</UL>
<P>NB: All subjects were exposed to pre-operative autologous blood donation and cell savage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 05:18:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, blood loss, allogeneic &amp; autologous blood usage (units).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 05:18:42 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>No transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 05:23:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Daily-1994">
<CHAR_METHODS MODIFIED="2010-07-01 05:21:16 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation was not described. Epsilon-aminocaproic acid (EACA) and placebo were delivered to the operating room in numbered, but otherwise identical vials labelled "study drug".</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 05:22:04 +0100" MODIFIED_BY="[Empty name]">
<P>40 patients undergoing first-time coronary artery bypass grafting without prior sternotomy were randomised to one of two groups:</P>
<UL>
<LI>Epsilon aminocaproic acid group: n = 21, M/F 14/7, mean (sd) age = 63 (9) years</LI>
<LI>Control group (Placebo): n = 19, M/F = 18/1, mean (sd) age = 67 (10) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 05:22:17 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Epsilon aminocaproic acid group (EACA) received 10g of EACA in 40ml of saline solution given after induction of anaesthesia but before the skin incision. Another 40ml was given after heparin administration in the pump, and a third 40ml dose was given after the administration of protamine.</LI>
<LI>Control group (Placebo) received equivalent volumes of saline solution.</LI>
</UL>
<P>NB: Both groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 05:23:31 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, blood loss (12/24hrs), myocardial infarction, stroke (cerebrovascular accident), use of shed mediastinal blood.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 05:23:36 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 05:27:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dalmau-1999">
<CHAR_METHODS MODIFIED="2010-07-01 05:25:54 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 05:26:32 +0100" MODIFIED_BY="[Empty name]">
<P>124 patients undergoing orthotopic liver transplantation were randomised to one of three groups:</P>
<UL>
<LI>Epsilon aminocaproic acid group: n = 42</LI>
<LI>Tranexamic acid group: n = 42</LI>
<LI>Control group (Placebo) group: n = 40</LI>
</UL>
<P>NB: No age or gender data were reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 05:26:50 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Epsilon aminocaproic acid (EACA) group received a continuous infusion of EACA (8g in 480mL normal saline) at 16mg/kg per hour. EACA was infused from induction of anaesthesia to graft reperfusion.</LI>
<LI>Tranexamic acid group (TXA) received a continuous infusion of TXA (5g in 450mL normal saline) at 10mg/kg per hour. TXA was infused from induction of anaesthesia to graft reperfusion.</LI>
<LI>Control group received an equal volume infusion of normal saline. Placebo was infused from the induction of anaesthesia to graft reperfusion.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 05:27:40 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage (units), thrombotic events, cryoprecipitate (units).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 05:27:46 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 05:37:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dalmau-2000">
<CHAR_METHODS>
<P>Drugs were prepared then randomised to patients using a randomisation schedule provided in sealed envelopes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 05:36:08 +0100" MODIFIED_BY="[Empty name]">
<P>132 patients undergoing orthotopic liver transplantation (OLT) were randomly assigned to one of three groups:</P>
<UL>
<LI>Epsilon aminocaproic acid group: n = 42, M/F = 26/16, median (range) age = 56 (32-69) years</LI>
<LI>Tranexamic acid group: n = 42, M/F = 31/11, median (range) age = 58 (22-69) years</LI>
<LI>Control group (Placebo): n = 40, M/F = 22/18, median (range) age = 60 (18-67) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 05:36:23 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Epsilon aminocaproic acid (EACA) group received a continuous infusion of EACA (8g in 480ml of normal saline) at a rate of 16mg/kg/hr from the induction of anesthesia until the portal vein was unclamped.</LI>
<LI>Tranexamic acid (TXA) group received a continuous dose infusion of TXA (5g in 450ml of normal saline) at a rate of 16mg/kg/hour from the induction of anaesthesia until the portal vein was unclamped.</LI>
<LI>Control group received isotonic saline at an equal volume (10ml/kg/hour) from the induction of anaesthesia until the portal vein was unclamped.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 05:37:44 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma (units), platelets (units), other arterial thrombosis,<BR/>prophylactic DDAVP treatment, DDAVP treatment for bleeding, EACA treatment (clinical fibrolysis).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 05:37:49 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 05:42:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dalmau-2004">
<CHAR_METHODS>
<P>Drugs were prepared and then randomised to patients using a randomisation schedule provided in sealed envelopes. Method of randomisation was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 05:40:49 +0100" MODIFIED_BY="[Empty name]">
<P>127 patients undergoing orthotopic liver transplantation were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (Low dose): n = 63, M/F = 45/19, mean (sd) age = 54 (9) years</LI>
<LI>Tranexamic acid group: n = 64, M/F = 44/19, mean (sd) age = 53 (10) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 05:41:01 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (Low dose) received a bolus of 2 million KIU in 250ml of IV solution in 30 minutes followed by a continuous infusion of 500, 000 KIU/hr. Diluted in normal saline to be administered at a rate of 100ml/hr after the bolus dose.</LI>
<LI>Tranexamic acid (TXA) group received a bolus of 250ml of normal saline in 30 minutes followed by a continuous infusion of TXA at a dose of 10mg/kg/hr. Diluted in normal saline to be administered at a rate of 100ml/hour after the bolus dose.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 05:42:20 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage (units), fresh frozen plasma (units), platelets (units), mortality, myocardial infarction, DDAVP pre-operative administration, EACA intra-operative administration, any thrombosis, re-operation for bleeding, renal failure.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 05:42:26 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 05:47:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Defraigne-2000">
<CHAR_METHODS MODIFIED="2010-07-01 05:44:46 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation was accomplished using a random number table. Sealed envelopes were used to conceal treatment allocation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 05:47:03 +0100" MODIFIED_BY="[Empty name]">
<P>200 patients undergoing cardiac surgery were randomly allocated to one of four groups:</P>
<UL>
<LI>Aprotinin group: n = 50, M/F = 34/16, mean (sd) age = 62.8 (13.4) years</LI>
<LI>Control group: n = 50, M/F = 36/14, mean (sd) age = 64.2 (11.3) years</LI>
<LI>Aprotinin group: n = 50, M/F = 35/15, mean (sd) age = 64 (13.4) years</LI>
<LI>Control group: n = 50, M/F = 34/16, mean (sd) age = 60.1 (12.7) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 05:47:24 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (Heparin coated CPB circuit with aprotinin administration - HCO-A) received a loading dose of 280mg (2 million KIU) before surgery and 280mg in the pump prime and a continuous infusion of 500, 000 KIU/hour IV.</LI>
<LI>Control group (Heparin coated CPB circuit without aprotinin - HCO).</LI>
<LI>Aprotinin group (Uncoated CPB circuit with aprotinin) received a loading dose of 280mg (2 million KIU) of aprotinin before surgery and 280mg in the prime solution and continuous infusion of 500,000 KIU/hour IV.</LI>
<LI>Control group (Uncoated CPB circuit without aprotinin administration).</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 05:47:56 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage (units), blood loss.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 05:45:52 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 05:59:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Del-Rossi-1989">
<CHAR_METHODS MODIFIED="2010-07-01 05:57:13 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 05:58:31 +0100" MODIFIED_BY="[Empty name]">
<P>350 patients undergoing elective coronary artery bypass surgery, repair of myocardial aneurysms, valve replacement or combined procedures were randomly assigned to one of two groups:</P>
<UL>
<LI>Epsilon aminocaproic acid group: n = 170, M/F = 132/38, mean (sd) age males = 58.9 (2.1) years; mean (sd) age females = 61.6 (2.8) years</LI>
<LI>Control group (Placebo): n = 180, M/F = 144/66, mean (sd) age males = 59.8 (5.6) years; mean (sd) age females = 60.2 (4.2) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 05:58:47 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Epsilon aminocaproic acid group received an initial priming dose of 5g of EACA prior to skin incision, followed by a continuous infusion of 1g/hr over the next 6 to 8 hours.</LI>
<LI>Control group received saline solution in the same fashion.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 05:59:34 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage (units), blood loss (24hrs), mortality, myocardial infarction, re-operation for bleeding, stroke, graft failure.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 05:59:39 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 06:03:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Deleuze-1991">
<CHAR_METHODS MODIFIED="2010-07-01 06:01:19 +0100" MODIFIED_BY="[Empty name]">
<P>Pharmaceutical company supplied the study drugs in identical bottles, identifiable only by number. The method of generating allocation sequences was not described. [French]</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 06:01:57 +0100" MODIFIED_BY="[Empty name]">
<P>60 coronary patients undergoing at least two aorto-coronary bypass grafts for the first time were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 30, M/F = 24/6, mean (sd) age = 60.3 (8.0) years</LI>
<LI>Control group (Placebo): n = 30, M/F = 25/5, mean (sd) age = 61.3 (8.0) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 06:02:09 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 4 flasks (200ml) of aprotinin intravenously, after the induction of anaesthesia, over 30 minutes via a central venous catheter, then a continuous infusion of aprotinin at 50ml/hr until the end of surgery. A further 4 flasks were administered via the extracorporeal circulation circuit.</LI>
<LI>Control group received the equivalent volume of physiological serum over the same time periods.</LI>
</UL>
<P>NB: One active flask contained 70mg (500,000 KIU) of aprotinin in 50mls of physiological serum. One placebo flask contained an equivalent quantity of physiological serum.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 06:02:52 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss (48 hrs), re-operation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 06:03:01 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used<BR/>French article - translated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 06:32:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Demeyere-2006">
<CHAR_METHODS MODIFIED="2010-07-01 06:32:24 +0100" MODIFIED_BY="[Empty name]">
<P>Method of sequence generation and allocation concealment were not described. [Poster presentation]</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 06:30:24 +0100" MODIFIED_BY="[Empty name]">
<P>60 patients undergoing cardiac surgery were randomised to one of three groups:</P>
<UL>
<LI>Aprotinin group: n=20</LI>
<LI>Tranexamic acid group: n = 20</LI>
<LI>Control group: n = 20</LI>
</UL>
<P>NB: Demographic data were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 06:30:45 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received 280mg loading dose, 70mg/hr infusion rate and 280mg in the pump prime.</LI>
<LI>Tranexamic acid group received 100mg loading dose then 1mg/kg/hr infusion.</LI>
<LI>Control group received saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 06:31:33 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Transfusion of blood products, blood loss, re-operation for bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 06:31:48 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7</P>
<P>Transfusion protocol not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 06:55:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Desai-2009">
<CHAR_METHODS MODIFIED="2010-07-01 06:33:32 +0100" MODIFIED_BY="[Empty name]">
<P>Methods of sequence generation and allocation concealment were unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 06:33:57 +0100" MODIFIED_BY="[Empty name]">
<P>75 patients undergoing cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 38</LI>
<LI>Control group: n = 37</LI>
</UL>
<P>NB: Demographic data were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 06:34:27 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (full-dose) 10,000 KIU test dose, 2 million KIU via central line and 500,000 KIU/hr IV until the end of surgery.</LI>
<LI>Control group received saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 06:35:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients receiving blood transfusion, blood loss, myocardial infarction, renal failure, mortality, re-operation for bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 06:55:32 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 3/7</P>
<P>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 06:59:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dietrich-1990">
<CHAR_METHODS MODIFIED="2010-07-01 06:58:00 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation was not described. Aprotinin and placebo were provided by the manufacturer (Bayer AG, Leverkusen, FRG) in identical packages, each containing 12 bottles that could only be identified by the random number. One patient from the aprotinin trial arm was excluded from the final analysis.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 06:58:53 +0100" MODIFIED_BY="[Empty name]">
<P>40 patients scheduled for elective primary myocardial revascularisation were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 20, mean (sd) age = 58 (10) years</LI>
<LI>Control group (Placebo): n = 20, mean (sd) age = 55 (8) years</LI>
</UL>
<P>NB: Gender data were not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 06:59:03 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a loading dose of 2 million KIU (280mg) of aprotinin after induction of anaesthesia and before surgery, over a 15 minute period followed by a continuous infusion of 500,000 KIU/hr administered by infusion pump for the entire duration of surgery. An additional bolus of 2 million KIU of aprotinin was added to the pump prime of the heart-lung machine.</LI>
<LI>Control group received an equal volume of saline solution.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 06:59:51 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic whole blood usage (ml/units), fresh frozen plasma usage (units), platelet usage (units), blood loss, re-operation for bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 06:59:56 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 07:04:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dietrich-1992">
<CHAR_METHODS MODIFIED="2010-07-01 07:01:58 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described. No exclusions reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 07:02:29 +0100" MODIFIED_BY="[Empty name]">
<P>1784 adult patients undergoing primary coronary artery bypass grafting, valve replacement (or combined procedures), and cardiac reoperations, were randomly assigned to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 902, M/F = 667/239, mean (sd) age = 60 (10) years</LI>
<LI>Control group: n = 882, M/F = 653/229, mean (sd) age = 59 (11) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 07:02:41 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a loading dose of 2 million KIU of aprotinin after induction of anaesthesia and before surgery, over a 15-minute period, followed by a continuous infusion of 500,000 KIU/hr administered by an infusion pump during the entire course of surgery. An additional bolus of 2 million KIU of aprotinin was added to the pump prime of the heart-lung machine.</LI>
<LI>Control group received no aprotinin.</LI>
</UL>
<P>NB: Both groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 07:04:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage, blood loss (36 hrs), mortality, intensive care unit length of stay (days), re-operation, renal failure, hypotension.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 07:03:46 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 07:07:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dietrich-1995">
<CHAR_METHODS>
<P>Patients were independently randomised, using a table of random numbers, to either aprotinin or control group. Aprotinin and placebo were provided by the manufacturer (Bayer AG, Leverkusen, Germany) in identical packages each containing 14 bottles, that could only be identified by the random number. No loss to follow-up reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 07:07:28 +0100" MODIFIED_BY="[Empty name]">
<P>30 male patients scheduled for elective primary coronary revascularisation were randomly assigned to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 15, mean (sd) age = 62.93 (6.77) years</LI>
<LI>Control group (Placebo): n = 15, mean (sd) age = 62.07 (10.01) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 07:07:37 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a loading dose of 2 million KIU (280mg) of aprotinin over a 15-minute period at the start of surgery, followed by a continuous infusion of 500,000 KIU/hr throughout the course of surgery. An additional bolus of 2 million KIU was added to the prime of the heart-lung machine.</LI>
<LI>Control group received an equal volume of saline.</LI>
</UL>
<P>NB: Both groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 07:06:51 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, complications, re-operation, mortality.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 07:05:49 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 7/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 07:18:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dietrich-2008">
<CHAR_METHODS MODIFIED="2010-07-01 07:18:57 +0100" MODIFIED_BY="[Empty name]">
<P>Computer-generated randomisation list and central allocation were used. </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 07:16:46 +0100" MODIFIED_BY="[Empty name]">
<P>220 patients undergoing cardiac surgery were randomly allocated to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 110, M/F = 82/28, mean (sd) age= 67.3 (10.6) years</LI>
<LI>Tranexamic acid group (n = 110), M/F = 72/38, mean (sd) age = 69.8 (10.3) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 07:17:35 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotonin group received a 1ml test dose, then 1 million KIU IV over 10 minutes, then continuous infusion of 500,000 KIU/hr for the duration of surgery, additional 2 million KIU added to CPB circuit priming fluid.</LI>
<LI>Tranexamic acid group received a 2g bolus dose, followed by a continuous infusion of 1g/hr, additional bolus added to CPB circuit priming fluid.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 07:18:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients receiving blood transfusion, volume of blood transfused (units), mortality, renal failure, length of hospital stay (days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 07:16:16 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 7/7</P>
<P>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 07:30:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dignan-2001">
<CHAR_METHODS MODIFIED="2010-07-01 07:28:00 +0100" MODIFIED_BY="[Empty name]">
<P>Study drug was administered by the anesthesiologist as an infusion in a blinded fashion. Allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 07:28:40 +0100" MODIFIED_BY="[Empty name]">
<P>200 participants undergoing elective cardiac surgery were randomly assigned to one of two groups:</P>
<UL>
<LI>Aprotinin group (Low dose): n = 101, M/F = 75/26, mean (range) age = 62.8 (35-80) years</LI>
<LI>Control group (Placebo): n = 99, M/F = 77/22, mean (range) age = 65.2 (40-81) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 07:28:49 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 1 million KIU of aprotinin in total (140mg) - 500,000KIU before skin incision and 500,000 KIU during the initiation of CPB.</LI>
<LI>Control group received the same volume of normal saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 07:30:04 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic whole blood usage (units/mls), fresh frozen plasma usage (units), platelet usage (units),<BR/>blood loss, re-operation for bleeding, acute renal failure, stroke.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 07:29:57 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 3/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 07:34:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Diprose-2005">
<CHAR_METHODS MODIFIED="2010-07-01 07:31:37 +0100" MODIFIED_BY="[Empty name]">
<P>Computer generated random numbers determined patient allocation to one of three treatment groups. Sealed envelopes were used to conceal treatment allocation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 07:33:00 +0100" MODIFIED_BY="[Empty name]">
<P>186 patients undergoing elective cardiac surgery were randomly assigned to one of three groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 63, M/F = 52/8, median (interquartile range) age = 62 (55-69) years</LI>
<LI>Tranexamic acid group: n = 62, M/F = 49/11, median (interquartile range) age = 65 (58.5-73.5) years</LI>
<LI>Control group (Placebo): n = 61, M/F = 52/8, median (interquartile range) age = 65(60-70) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 07:33:16 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 2 million KIU (280mg) in 200ml volume at the start of surgery, 2 million KIU of aprotinin was added to the pump prime, and a continuous infusion of 500,000 KIU/hr was given throughout the operation.</LI>
<LI>Tranexamic acid group received 5g in 200ml normal saline, 200ml of normal saline added to the pump prime, and a continuous infusion of 50ml/hour of normal saline throughout the operation.</LI>
<LI>Control group received normal saline as an IV bolus into the pump prime and a continuous infusion of 50ml/hour of normal saline per hour throughout the operation.</LI>
</UL>
<P>NB: All groups received intra-operative cell salvage (Compact A; Dideco, Sorin Biomedica, Italy) and each group received a test dose of 5ml of study solution.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 07:34:27 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, mortality, myocardial infarction, re-operation for bleeding, renal failure, respiratory failure.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 07:34:36 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 07:50:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dorman-2008">
<CHAR_METHODS MODIFIED="2010-07-01 07:36:01 +0100" MODIFIED_BY="[Empty name]">
<P>Method of sequence generation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 07:45:13 +0100" MODIFIED_BY="[Empty name]">
<P>60 patients undergoing cardiac surgery were randomly allocated to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 30, M/F = 25/5, mean (SEM) age = 62.0 (2.0) years </LI>
<LI>Epsilon aminocaproic acid group: n = 30, M/F = 20/10, mean (SEM) age = 60.0 (2.0) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 07:50:11 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotonin group received 1 million KIU IV at the start of surgery with an additional 1 million KIU in the CPB circuit, and a continuous infusion of 250,000 KIU per hour until the end of surgery.</LI>
<LI>Epsilon aminocaproic acid group received 5g IV concurrent with systemic heparinization and an additional 5g in the CPB circuit, and another 5g administered IV immediately after discontinuation of CPB.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 07:38:04 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients receiving blood transfusion, volume blood transfused (units), blood loss.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 07:49:08 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7</P>
<P>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 07:52:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dryden-1997">
<CHAR_METHODS MODIFIED="2010-07-01 07:50:41 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation was not described. The "study drug" was mixed by independent Intensive Care Unit (ICU) personnel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 07:51:25 +0100" MODIFIED_BY="[Empty name]">
<P>41 patients undergoing re-operative cardiac valve surgery were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 22, M/F = 9/13, mean (sd) age = 63 (12.6) years</LI>
<LI>Control group (Placebo): n = 19, M/F = 8/11, mean (sd) age = 64 (18) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 07:51:33 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 10g of TXA in 500ml of normal saline infused after the induction of anaesthesia as an intravenous bolus over 30 minutes prior to skin incision.</LI>
<LI>Control group received normal saline solution in the same volume.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 07:52:33 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage (mls), blood loss, total platelets transfused, total plasma transfused, mortality, hospital length of stay (days), hospital complications, re-operation for active bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 07:52:28 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 07:58:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eberle-1998">
<CHAR_METHODS MODIFIED="2010-07-01 07:55:16 +0100" MODIFIED_BY="[Empty name]">
<P>Different treatment solutions were identical in appearance. Method of randomisation was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 07:58:44 +0100" MODIFIED_BY="[Empty name]">
<P>40 patients undergoing cardiac surgery were randomised to one of three groups:</P>
<UL>
<LI>Epsilon aminocaproic acid group: n = 20, mean (sd) age = 61(10) years</LI>
<LI>Aprotinin group: n = 20, mean (sd) age = 60 (10) years</LI>
<LI>Non-randomised historical control group: n = 10, mean (sd) age = 57 (14) years</LI>
</UL>
<P>NB: No gender data were reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 07:56:36 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Epsilon aminocaproic acid group received a test dose of 1 mL followed after 10 minutes by a loading dose of 200mL of solution given over 30 minutes. EACA was infused continuously at a rate of 50ml/hour until the start of CPB. EACA-10g both as loading and pump prime dose at 2.5g/hour as an infusion.</LI>
<LI>Aprotinin group received the same volume regimen as EACA. 2 million KIU (280mg) for loading and pump prime followed by an infusion of 500,000 KIU/hour (70mg/hr) from CPB weaning until 4 hours after heparin reversal.</LI>
<LI>Control group did not receive either EACA or aprotinin treatment.</LI>
</UL>
<P>NB: Both EACA and aprotinin groups received cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 07:57:18 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, myocardial Infarction.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 07:57:26 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 08:12:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ehrlich-1998">
<CHAR_METHODS MODIFIED="2010-07-01 08:10:59 +0100" MODIFIED_BY="[Empty name]">
<P>Each bottle of aprotinin provided by the pharmaceutical company was placed in a box with bottles of normal saline solution. These bottles were indistinguishable from one another. An assistant, who was only involved in randomisation of the medication, arranged these bottles into 50 pairs. Each pair consisted of two bottles of aprotinin or two bottles of saline solution. Each of these pairs was randomly assigned a number from 1 to 50. Each patient was randomly assigned a number and then given the corresponding bottles. After the study was completed, the randomisation code was broken and the data were analysed. </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 07:59:39 +0100" MODIFIED_BY="[Empty name]">
<P>50 patients undergoing thoracic aortic operations with the use of profound hypothermic circulatory arrest were randomly assigned to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 25, M/F = 9/16, mean (range) age = 70 (58-80) years</LI>
<LI>Control group (Placebo): n = 25, M/F = 7/18, mean (range) age = 70 (60-78) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 07:59:58 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 1 million KIU of aprotinin (140mg) before the onset of cardiopulmonary bypass.</LI>
<LI>Control group received an equal volume of 0.9% saline solution as a placebo.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 08:01:05 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage (units), blood loss, mortality (30-day), myocardial infarction, renal dysfunction/renal failure, re-operation for bleeding, neurological deficit, stroke.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 08:12:35 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 08:14:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ekback-2000">
<CHAR_METHODS MODIFIED="2010-07-01 08:13:51 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 08:14:49 +0100" MODIFIED_BY="[Empty name]">
<P>40 patients undergoing elective adult surgery and were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 20, M/F = 9/11, mean (sd) age = 66.4 (9.0) years</LI>
<LI>Control group (Placebo): n = 20, M/F = 11/9, mean (sd) age = 65.6 (8.8) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 08:14:38 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received a bolus dose of 10mg/kg before surgical incision. A continuous infusion of 1.0mg/kg/hr during 10 hours was then started immediately after the first bolus dose. A second bolus dose of 1.0mg/kg was given three hours later to counteract potential dilutive effects of intra-operative autotransfusion.</LI>
<LI>Control group received physiological saline as a placebo.</LI>
</UL>
<P>NB: All study participants underwent pre-operative autologous blood donation (2 units autologous blood donated) on two occasions within a four week period. Both trial arms were equally exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 08:13:38 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, blood loss, deep vein thrombosis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 08:13:09 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 08:18:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ellis-2001">
<CHAR_METHODS MODIFIED="2010-07-01 08:16:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation was carried out using a computer generated randomisation table. Allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 08:17:45 +0100" MODIFIED_BY="[Empty name]">
<P>30 patients were randomly assigned to one of three groups:</P>
<UL>
<LI>Tranexamic acid group: n = 10, M/F = 4/6, mean (sd) age = 71(5) years</LI>
<LI>Desmopressin group: n = 10, M/F = 2/8, mean (sd) age = 72 (6) years</LI>
<LI>Control group (Placebo): n = 10, M/F = 3/7, mean (sd) age = 72 (8) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 08:17:59 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received TXA 30 minutes before deflating the limb tourniquet an IV bolus dose (15mg/kg) administered over a 30 minute period, thereafter a constant IV infusion of TXA (10mg/kg/hr) was administered until 12 hours after final deflation of the limb tourniquet.</LI>
<LI>Desmopressin group 30 minutes before deflating the limb tourniquet an IV bolus dose of DDAVP (0.3micrograms/kg) was infused over a 30 minute period, thereafter a constant IV infusion of saline was administered until 12 hours after final deflation of the limb tourniquet.</LI>
<LI>Control group received an equal volume of saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 08:18:29 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogenic blood usage (units), hospital length of stay (days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 08:18:33 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 3/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-01 08:21:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Engel-2001">
<CHAR_METHODS MODIFIED="2010-07-01 08:19:53 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-01 08:20:45 +0100" MODIFIED_BY="[Empty name]">
<P>36 patients were randomised to one of three groups:</P>
<UL>
<LI>Tranexamic acid group: n = 12, M/F = 4/8, mean (sd) age = 71 (9) years</LI>
<LI>Aprotinin group: n = 12, M/F = 3/9, mean (sd) age = 71 (9) years</LI>
<LI>Control group: n = 12, M/F = 4/8, mean (sd) age = 66 (11) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-01 08:20:58 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 15mg/kg of TXA followed by a repeat dose of 10mg/kg after 3 hours.</LI>
<LI>Aprotinin group received 1 million KIU (140mg) of aprotinin immediately before deflating the tourniquet followed by an infusion of 500,000 KIU per hour for 4 hours.</LI>
<LI>Control group received no antifibrinolytic treatment.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-01 08:21:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, deep vein thrombosis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-01 08:21:40 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-02 01:09:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Englberger-2002a">
<CHAR_METHODS MODIFIED="2010-07-02 01:06:15 +0100" MODIFIED_BY="[Empty name]">
<P>Bottles of aprotinin and saline (placebo solution) were numbered continuously. Blinding of bottles was performed by personal otherwise not involved in the study. Method of randomisation was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-02 01:06:59 +0100" MODIFIED_BY="[Empty name]">
<P>47 patients undergoing elective 'off-pump' cardiac surgery were randomly allocated to one of two groups:</P>
<UL>
<LI>Aprotonin group (Low dose): n = 22, M/F = 16/6, mean (sd) age = 63.9 (10.8) years</LI>
<LI>Control group (Placebo): n = 25, M/F = 19/6, mean (sd) age = 66.4 (9.0) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-02 01:07:07 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotonin group received a loading dose of 2 million KIU (280mg) of aprotinin at the beginning of surgery followed by a continuous infusion of 500,000 KIU/hr throughout surgery (70mg/hr).</LI>
<LI>Control group received the same volume of saline solution.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-02 01:09:57 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, number of patients exposed to fresh frozen plasma, blood loss, mortality, myocardial infarction, re-operation for bleeding, number of patients exposed to autotransfusion, volume of blood autotransfused, hospital length of stay (days), neurological deficit, renal dysfunction.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 01:04:29 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-02 01:13:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Englberger-2002b">
<CHAR_METHODS MODIFIED="2010-07-02 01:10:15 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-02 01:10:55 +0100" MODIFIED_BY="[Empty name]">
<P>29 patients undergoing elective cardiac surgery were randomly allocated to one of two groups:</P>
<UL>
<LI>Aprotinin group (Low dose - pump prime): n = 15, M/F = 13/2, mean (sd) age = 60.3 (10) years</LI>
<LI>Control group: n = 14, M/F = 10/4, mean (sd) age = 61.5 (7.5) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-02 01:11:04 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotonin group received 2 million KIU of aprotinin (280mg) added to the pump prime only.</LI>
<LI>Control group - treatment details were not reported.</LI>
</UL>
<P>NB: Both groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-02 01:12:58 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), number of patients exposed to fresh frozen plasma, fresh frozen plasma usage (units), blood loss, mortality, myocardial infarction, re-operation for bleeding, neurological deficit, renal dysfunction, hospital length of stay (days), number of patients exposed to autotransfusion, volume of blood autotransfused.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 01:13:03 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-02 01:16:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fauli-2005">
<CHAR_METHODS MODIFIED="2010-07-02 01:14:06 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation was not described. All patients received pre-prepared infusions of similar volume and appearance provided by the pharmaceutical company.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-02 01:15:06 +0100" MODIFIED_BY="[Empty name]">
<P>60 patients undergoing cardiac surgery were randomised to one of three groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 20, M/F = 15/5, mean (sd) age = 52.5 (10.1) years</LI>
<LI>Aprotinin group (Low dose): n = 20, M/F = 17/3, mean (sd) age = 57.7 (4.6) years</LI>
<LI>Control group (Placebo): n = 20, M/F = 14/6, mean (sd) age = 56.5 (6.5) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-02 01:15:27 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received a loading dose of 280mg of aprotinin, followed by a continuous infusion of 70mg/hr of aprotinin until closure of sternotomy, and 280mg of aprotinin was added to the pump prime.</LI>
<LI>Aprotinin group (Low dose) received 280mg of aprotinin added to the pump prime.</LI>
<LI>Control group (Placebo) received the same volume of saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-02 01:16:16 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage (units), blood loss (24hrs), hospital length of stay (days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 01:16:21 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-02 01:22:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feindt-1994">
<CHAR_METHODS MODIFIED="2010-07-02 01:17:37 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-02 01:22:54 +0100" MODIFIED_BY="[Empty name]">
<P>20 patients undergoing aortocoronary bypass surgery were randomly allocated to one of two groups:</P>
<UL>
<LI>Aprotinin group (High-dose): n = 10, M/F = NR, mean (sd) age = 62.3 (1.2) years</LI>
<LI>Control group (Placebo): n = 10, M/F = NR, mean (sd) age = 66.4 (2.4) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-02 01:18:30 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotonin group received high-dose (2 million units kallikrein inhibitor at the induction of anaesthesia, 2 million units added to the priming volume of the heart-lung machine and 500,000 U/h during the operation).</LI>
<LI>Control group - treatment details were not reported.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-02 01:21:11 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood transfusion, post-operative blood loss, mortality, parameters of thrombin activation and fibrinolysis.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 01:21:40 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-02 01:35:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fergusson-2008">
<CHAR_METHODS MODIFIED="2010-07-02 01:34:45 +0100" MODIFIED_BY="[Empty name]">
<P>The research pharmacist at each centre randomly assigned patients to receive one of three antifibrinolytic agents with the use of a voice-activated automated centralised program. An independent biostatistician generated the randomisation scheme using a computer-generated randomisation list. Researchers, patients, members of the clinical teams, and members of the data and safety monitoring committee were all unaware of study-group assignment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-02 01:25:45 +0100" MODIFIED_BY="[Empty name]">
<P>2331 high-risk cardiac surgical patients were randomly allocated to one of three groups:</P>
<UL>
<LI>Aprotinin group: n = 781, M/F = 543/238, mean (sd) age = 67.0 (10.8) years</LI>
<LI>Tranexamic acid group: n = 770, M/F = 562/208, mean (sd) age = 66.9 (11.4) years</LI>
<LI>Epsilon aminocaproic acid: n = 780, M/F = 569/211, mean (sd) age = 66.6 (10.8) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-02 01:27:02 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotonin group received high-dose aprotinin with a test dose of 40,000 KIU administered during a 10 minute period after the insertion of a central venous line and induction of anaesthesia. In the absence of of anaphylaxis, the remainder of the loading dose (1.96 million KIU), after which a maintenance infusion of 500,000 KIU per hour was initiated and maintained during surgery. An additional dose of 2 million KIU was added to the cardiopulmonary-bypass circuit.</LI>
<LI>Tranexamic acid group received a 30mg/kg loading dose, a 16mg/kg maintenance dose, then 2 mg/kg added to the bypass circuit.</LI>
<LI>Epsilon aminocaproic acid group received a 10g loading dose, then a 2g maintenance infusion.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-02 01:28:20 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients transfused allogeneic blood, massive post-operative bleeding, re-operation for bleeding, myocardial infarction, stroke, mortality,<BR/>renal failure, length of stay (days).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 01:35:00 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 7/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-02 01:38:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Findlay-2001">
<CHAR_METHODS MODIFIED="2010-07-02 01:36:20 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-02 01:37:21 +0100" MODIFIED_BY="[Empty name]">
<P>63 patients undergoing orthotopic liver transplantation were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 33, mean (sd) age = 50 (9) years</LI>
<LI>Control group (Placebo): n = 30, mean (sd) age = 52 (10) years</LI>
</UL>
<P>NB: Gender data were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-02 01:37:07 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a loading dose of 1 million KIU over 30 minutes (after a test dose of 10,000 KIU) followed by an infusion of 250,000 KIU/hr until skin closure.</LI>
<LI>Control group received an equivalent infusion of normal saline.</LI>
</UL>
<P>NB: Both groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-02 01:38:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage (units), mortality, re-operation for bleeding, hepatic artery thrombosis, hospital length of stay (days), intensive care unit length of stay (hours).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 01:38:31 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-02 01:41:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fraedrich-1989">
<CHAR_METHODS MODIFIED="2010-07-02 01:40:10 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-02 01:41:45 +0100" MODIFIED_BY="[Empty name]">
<P>80 male patients undergoing primary coronary bypass surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n =40, mean age = 60.6 years</LI>
<LI>Control group: n = 40, mean age = 58.2 years</LI>
</UL>
<P>NB: Four patients, two from the intervention and two from the control group were excluded. Aprotinin group excluded two patients: one allergic reaction, one severe cardiac failure. Control group excluded two patients: one surgical bleeding, one lethal cardiac failure.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-02 01:40:44 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a loading dose of 280mg of aprotinin prior to sternotomy, followed by a continuous intravenous infusion of 70mg/hr until skin closure. An additional 280mg of aprotinin was added to the prime volume of the membrane oxygenator.</LI>
<LI>Control group was not treated with aprotinin.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-02 01:41:23 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage, plasma usage, blood loss, volume of re-transfused mediastinal blood.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 01:41:36 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol not specified<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-02 01:44:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garcia_x002d_Enguita-1998">
<CHAR_METHODS MODIFIED="2010-07-02 01:43:03 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described. [Abstract only]</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-02 01:43:34 +0100" MODIFIED_BY="[Empty name]">
<P>30 patients undergoing elective orthopaedic surgery were randomly allocated to one of two groups:</P>
<UL>
<LI>Aprotinin group (Low dose): n = 15</LI>
<LI>Control group (Placebo): n = 15</LI>
</UL>
<P>NB: Gender and age data were reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-02 01:43:48 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a loading dose of 2 million KIU (280mg) of aprotinin before the induction of anaesthesia administered over 30 minutes followed by 500,000 KIU/hr for the duration of surgery.</LI>
<LI>Control group received 200ml of normal saline over 30 minutes followed by 50mL/hr of saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-02 01:44:11 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogenic blood usage (units), blood loss.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 01:44:26 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol was not used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-02 01:47:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garcia_x002d_Huete-1997">
<CHAR_METHODS MODIFIED="2010-07-02 01:46:01 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-02 01:46:40 +0100" MODIFIED_BY="[Empty name]">
<P>80 consecutive patients undergoing elective orthotopic liver transplantation were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 39, M/F = 24/15, mean (range) age = 50 (15-64) years</LI>
<LI>Control group (Placebo): n = 41, M/F = 27/14, mean (range) age = 50 (17-65) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-02 01:46:48 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received an initial dose of 2 million kallikrein inactivator units (KIU) of aprotinin in the induction phase of anaesthesia followed by an infusion of 500,000 KIU/hr of aprotinin until the end of the procedure.</LI>
<LI>Control group received an equal volume of saline solution.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-02 01:47:37 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), mortality, allergic reactions, re-operation for bleeding, re-transplantation.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 01:47:42 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-02 01:50:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garneti-2004">
<CHAR_METHODS MODIFIED="2010-07-02 01:48:54 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomised using a list of random numbers. Allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-02 01:49:30 +0100" MODIFIED_BY="[Empty name]">
<P>50 patients undergoing total hip arthroplasty were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 25), mean (sd) age = 69.6 (11.99) years</LI>
<LI>Control group (Placebo): n = 25, mean (sd) age = 67.6 (11.4) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-02 01:49:42 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 10mg/kg of intravenous TXA as a bolus at time of anaesthesia.</LI>
<LI>Control group received a similar volume of normal saline as a bolus at time of anaesthesia.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-02 01:50:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss (48hrs), deep vein thrombosis, pulmonary embolus.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 01:50:30 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-02 06:57:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gherli-1992">
<CHAR_METHODS MODIFIED="2010-07-02 02:07:50 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.[Italian]</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-02 02:04:53 +0100" MODIFIED_BY="[Empty name]">
<P>31 patients undergoing cardiopulmonary bypass were randomly divided into one of three groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 9, M/F = 7/2, mean (range) age = 61.5 (44-71) years</LI>
<LI>Aprotinin group (Low dose): n = 9, M/F = 8/1, mean (range) age = 58.2 (47-71) years</LI>
<LI>Control group: n = 13, M/F = 10/3, mean (range) age = 60.4 (52-66) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-02 02:05:33 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received 2 million kallikrein inactivator units (KIU) of aprotinin over 15 minutes, followed by a continuous infusion of 1 million KIU/hr of aprotinin. An additional 2 million KIU of aprotinin was added to the pump prime.</LI>
<LI>Aprotinin group (Low dose) received 1 million kallikrein inactivator units (KIU) of aprotinin over 15 minutes, followed by a continuous infusion of 500,000 KIU/hr of aprotinin. An additional 1 million KIU of aprotinin was added to the pump prime.</LI>
<LI>Control group did not receive aprotinin.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-02 06:57:44 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, myocardial infarction, renal failure, blood products used, haemoglobin levels.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:06:34 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-02 05:19:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gill-2009">
<CHAR_METHODS MODIFIED="2010-05-21 17:43:41 +0100" MODIFIED_BY="Katharine Ker">
<P>Patients were allocated according to a computer-generated randomisation schedule. </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-02 05:14:45 +0100" MODIFIED_BY="[Empty name]">
<P>10 patients undergoing orthopaedic (hip) surgery were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 5, mean (range) age = 66.6 (53-83) years</LI>
<LI>Control group (Placebo): n = 5, mean (range) age = 61.4 (36-73) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-02 05:14:55 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 10mg/kg bolus before anaesthesia then 1mg/kg/hr at start of surgery until wound closure.</LI>
<LI>Control group (placebo) received saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-02 05:16:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients receiving blood transfusion, blood loss, volume blood transfused (units).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 05:19:41 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7</P>
<P>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-02 05:32:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Golanski-2000">
<CHAR_METHODS MODIFIED="2010-07-02 05:31:23 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described. [Polish]</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-02 05:32:04 +0100" MODIFIED_BY="[Empty name]">
<P>54 patients undergoing elective cardiac surgery were randomly allocated to one of two groups:</P>
<UL>
<LI>Aprotinin group (Low dose): n = 30, M/F = 29/1, mean (sd) age = 56.2 (10.5) years</LI>
<LI>Control group: n = 24, M/F = 22/2, mean (sd) age = 54.7 (8.1) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-02 05:32:15 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received an infusion of 3 million kallikrein inactivator units (KIU) of aprotinin intra-operatively.</LI>
<LI>Control did not receive aprotinin.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-02 05:32:51 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Allogeneic blood usage (units), blood loss, mortality, myocardial infarction.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:08:56 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 0/7<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-02 05:36:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Good-2003">
<CHAR_METHODS>
<P>Coded ampoules of TXA or saline placebo prepared by the drug company were randomised in blocks of 10 (five saline, five TXA) by means of computer generated numbers. Four patients were withdrawn from the final analysis before the randomisation code was broken.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-02 05:35:34 +0100" MODIFIED_BY="[Empty name]">
<P>55 patients undergoing total knee replacement surgery were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 27, M/F = 9/18, median (IQR) age = 72 (46-83) years</LI>
<LI>Control group (Placebo): n = 24, M/F = 6/18, median (IQR) age = 72 (50-84) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-02 05:35:42 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 10mg/kg of intravenous TXA at the end of the surgical procedure, just before the release of the tourniquet (maximum dose of 1000mg). The dose of TXA was repeated after 3 hours.</LI>
<LI>Control group received saline placebo solution at corresponding times as the TXA group.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-02 05:36:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, deep vein thrombosis, infection.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:09:06 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-02 05:40:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gott-1998">
<CHAR_METHODS MODIFIED="2010-07-02 05:37:14 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-02 05:37:53 +0100" MODIFIED_BY="[Empty name]">
<P>400 cardiac surgery patients were randomly allocated to one of three groups:</P>
<UL>
<LI>Aprotinin group: n = 109</LI>
<LI>Control/standard: n = 112</LI>
<LI>Leukocyte depletion: n= 112</LI>
<LI>Heparin-bonded circuitry: n = 67</LI>
</UL>
<P>NB: No demographic data were reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-02 05:38:15 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotonin group received low-dose - standard treatment plus a half-Hammersmith aprotonin protocol.</LI>
<LI>Control - standard treatment.</LI>
<LI>Leukocyte depletion - based on the standard CPB protocol with addition of leukocyte filtration of arterial line and cardioplegia delivery line.</LI>
<LI>Heparin-bonded circuitry, membrane oxygenator and a centrifugal pump.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-02 05:39:44 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Total amount of allogeneic blood transfused (units), mortality, length of hospital stay, renal dysfunction, lung function.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 05:40:49 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 0/7<BR/>Transfusion protocol not used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-02 06:03:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Green-1995">
<CHAR_METHODS>
<P>Study was described as an open label randomised controlled trial conducted in two phases. Patients were assigned to groups by means of computer generated table of random numbers.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-02 06:01:13 +0100" MODIFIED_BY="[Empty name]">
<P>84 consecutive patients undergoing primary coronary artery bypass graft surgery or re-operations were randomly assigned to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 48, M/F = 39/9, mean (sd) age = 62 (9) years</LI>
<LI>Control group: n = 36, M/F = 31/5, mean (sd) age = 63 (8) years</LI>
</UL>
<P>Two aprotinin dose regimens were studied:</P>
<UL>
<LI>Dosage level 1 - Aprotinin group: n = 24, M/F = 20/4, mean (sd) age = 64 (8) years</LI>
<LI>Dosage level 1 - Control group: n = 18, M/F 16/2, mean (sd) age = 63 (8) years</LI>
<LI>Dosage level 2 - Aprotinin group: n = 24, M/F=19/5, mean (sd) age = 60 (9) years</LI>
<LI>Dosage level 2 - Control group: n = 18, M/F=15/3, mean (sd) age = 64 (8) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-02 06:01:51 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Phase 1, patients assigned to recombinant (r) aprotinin (treatment group) received 2mg/kg (14,300 kallikrein inactivation units/kg) as an intravenous bolus given in 20 minutes after the induction of anaesthesia, an intravenous infusion of 0.5mg/kg/hr until the patient left the operating room, and 1 mg/kg added to each litre of lactated Ringers solution for priming of the membrane oxygenator.</LI>
</UL>
<UL>
<LI>Phase 2, each dose was doubled. Studies of dosage level 1 were performed in Chicago (42 patients) and studies of dosage level 2 were conducted both in Chicago (26 patients) and in Temple, Texas (16 patients). Patients were stratified according to centre, surgeon, and type of surgery.</LI>
</UL>
<P>The study also compared patients who underwent primary operations (n = 60) with those patients who underwent re-operations (n = 24).<BR/>
</P>
<P>NB: Both groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-02 06:03:13 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, blood loss, overall erythrocyte loss, autotransfusion device erythrocytes, myocardial infarction, mortality, renal function (BUN + creatinine levels), pre-operative and post-operative haemoglobin levels.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:09:21 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 3/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-02 06:06:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greilich-2001">
<CHAR_METHODS MODIFIED="2010-07-02 06:04:33 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-02 06:05:23 +0100" MODIFIED_BY="[Empty name]">
<P>72 patients undergoing elective cardiac surgery were randomised to one of three groups:</P>
<UL>
<LI>Epsilon aminocaproic acid group: n = 23, mean (sd) age = 63 (8) years</LI>
<LI>Aprotinin group: n =24, mean (sd) age = 64 (9) years</LI>
<LI>Control group (Placebo) (n = 25), mean (sd) age = 62 (7) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-02 06:05:40 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Epsilon aminocaproic acid group received 100mg/kg loading dose, 5g added to the pump prime, and 30mg/kg/hr as a continuous infusion.</LI>
<LI>Aprotinin group received 2 million KIU of aprotinin added to the pump prime, and 500,000 KIU/hr (70mg/hour) as a continuous infusion.</LI>
<LI>Control group received 200ml normal saline as a loading dose, 200ml of normal saline added to the pump prime, and 50ml/hr of saline as a continuous infusion.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-02 06:06:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, blood loss, intensive care unit length of stay (days), mechanical ventilation (hours).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:09:30 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-02 06:08:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greilich-2003">
<CHAR_METHODS MODIFIED="2010-07-02 06:07:08 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-02 06:07:51 +0100" MODIFIED_BY="[Empty name]">
<P>60 male patients undergoing cardiac surgery were randomised to one of three groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 20, mean (sd) age = 64 (9) years</LI>
<LI>Epsilon aminocaproic acid (n = 20), mean (sd) age = 62 (9) years</LI>
<LI>Control group (Placebo) (n = 20), mean (sd) age = 63 (8) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-02 06:08:12 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received 2 million KIU (280mg) of aprotinin as a loading dose and a continuous infusion of 500,000 KIU/hr of aprotinin. An additional 2 million KIU (280mg) of aprotinin was added to the pump prime solution.</LI>
<LI>Epsilon aminocaproic acid group received 100mg/kg of EACA as a loading dose and a continuous infusion of 30mg/kg/hr. An additional 5g of EACA was added to the pump prime.</LI>
<LI>Control group (placebo) received normal saline in equivalent volumes.</LI>
</UL>
<P>NB: All groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-02 06:08:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Allogeneic blood usage (units), platelet usage (units), blood loss, plasma levels of Interleukin-6 and Interleukin-8 during and after CPB.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:09:41 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-02 06:12:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greilich-2004">
<CHAR_METHODS MODIFIED="2010-07-02 06:09:57 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-02 06:11:07 +0100" MODIFIED_BY="[Empty name]">
<P>36 male patients undergoing cardiac surgery were randomised to one of three groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 12, mean (sd) age = 62 (8) years</LI>
<LI>Epsilon aminocaproic acid group: n = 12, mean (sd) age = 64 (9) years</LI>
<LI>Control group (Placebo): n = 12, mean (sd) age = 65 (8) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-02 06:10:58 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received a loading dose of 2 million KIU (280mg) of aprotinin and a continuous infusion of 500,000 KIU/hr. An additional 2 million KIU of aprotinin was added to the pump prime.</LI>
<LI>Epsilon aminocaproic acid group received a loading dose of 100mg/kg of EACA and a continuous infusion of 30mg/kg/hr. An additional 5g of EACA was added to the pump prime.</LI>
<LI>Control group received normal saline solution using similar volumes as aprotinin and EACA treatments.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-02 06:12:04 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage (units), blood loss (24hrs), biochemical markers of plasmin activity (D-dimer), biochemical markers of platelet (CD62P), activation, biochemical markers of leukocyte (CD11b) activation, biochemical markers of leukocyte-platelet conjugate formation.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:09:49 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria):3/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-11 06:57:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greilich-2009">
<CHAR_METHODS MODIFIED="2010-05-17 12:34:27 +0100" MODIFIED_BY="Katharine Ker">
<P>A table of random numbers was used to generate the allocation sequence. Central (pharmacy) allocation was used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-02 06:14:42 +0100" MODIFIED_BY="[Empty name]">
<P>78 male patients undergoing cardiac surgery were randomised to one of three groups:</P>
<UL>
<LI>Aprotonin group: n = 26, mean (sd) age = 65 (9) years</LI>
<LI>EACA group: n = 25, mean (sd) age = 62 (8) years</LI>
<LI>Control group (Placebo): n = 27, mean (sd) age = 62 (7) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-02 06:15:04 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotonin group received full-dose - loading dose 2 million KIU over 15 minutes plus 2 million added to pump prime and infusion of 500,000 KIU/hr until patient arrival at ICU.</LI>
<LI>EACA group - high dose - 100mg/kg initial loading dose, 5g in pump prime solution, 30mg/kg/hr.</LI>
<LI>Control group received saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-02 06:49:34 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients transfused allogeneic blood, mortality, stroke, myocardial infarction, renal failure, length of hospital stay (days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-11 06:57:46 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria):7/7</P>
<P>Transfusion protocol was used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-11 06:58:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Groh-1993">
<CHAR_METHODS MODIFIED="2010-08-11 06:55:35 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-11 06:58:12 +0100" MODIFIED_BY="[Empty name]">
<P>20 patients undergoing orthotopic liver transplantation were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 9, mean (range) age = 51 (28-66) years</LI>
<LI>Control group (Placebo): n = 9, mean (range) age = 49 (31-59) years</LI>
</UL>
<P>NB: Two patients were excluded from the final analysis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-11 06:58:22 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a loading dose of 2 million KIU of aprotinin after the induction of anaesthesia, followed by a continuous infusion of 500,000 KIU/hr of aprotinin until the end of the procedure.</LI>
<LI>Control group received an unspecified placebo.</LI>
</UL>
<P>NB: Both groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-11 06:57:05 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage (units)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:13:27 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria):3/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-11 07:02:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harder-1991">
<CHAR_METHODS MODIFIED="2010-08-11 07:00:46 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation was not described. The randomisation code was only known by the hospital pharmacy. Allocation concealment was by means of coded vials collected from the hospital pharmacy in the morning before the operation. No exclusions were reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-11 07:01:29 +0100" MODIFIED_BY="[Empty name]">
<P>80 male patients scheduled for elective coronary artery bypass grafting with cardiopulmonary bypass were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group:n = 40, mean (sd) age = 57.6 (8.8) years</LI>
<LI>Control group (Placebo): n = 40, mean (sd) age = 57.0 (8.8) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-11 07:01:44 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a bolus of 200ml (2 million KIU) of aprotinin just after the Swan-Ganz pulmonary artery catheter was introduced, followed by a continuous infusion of 500,000 KIU/hr (50ml) via an infusion pump. An additional 2 million KIU of aprotinin was added to the pump prime. The total amount of aprotinin delivered by infusion was 4 million KIU before and during bypass.</LI>
<LI>Control group received saline solution in equivalent volumes.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-11 07:02:23 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:13:36 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-11 07:06:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hardy-1993">
<CHAR_METHODS MODIFIED="2010-08-11 07:04:38 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation was performed by the pharmacy department with each successive block of four patients being randomised (random allocation of two patients to Group A and two patients to Group C). Method used to generate allocation sequences was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-11 07:05:21 +0100" MODIFIED_BY="[Empty name]">
<P>44 patients scheduled for repeat myocardial revascularisation, repeat value surgery, or a combined procedure (primary or repeat) were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 22, M/F = 16/6, mean (sd) age = 62 (9) years</LI>
<LI>Control group (Placebo): n = 19, M/F = 12/12, mean (sd) age = 58 (11) years</LI>
</UL>
<P>NB: Three patients in the control group were excluded: one patient died in the operating room and one died upon arrival in the ICU. The third patient was excluded when the surgeon proceeded to a single valve replacement instead of the planned combined procedure.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-11 07:05:34 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a bolus of 200,000 KIU of aprotinin after the induction of anaesthesia, but before skin incision, over a period of 20 minutes, followed by an infusion of 100,000 KIU/hr during the entire surgical procedure and in the intensive care unit (ICU), for a total dose of 1 million KIU.</LI>
<LI>Control group received an equal volume of sodium chloride 0.9% throughout surgery and recovery.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-11 07:06:29 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage (units), mortality, re-exploration for bleeding.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:13:44 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-11 07:09:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hardy-1997">
<CHAR_METHODS MODIFIED="2010-08-11 07:07:53 +0100" MODIFIED_BY="[Empty name]">
<P>Each successive block of four patients was randomised by the Department of Pharmacy (random allocation of two patients to the treatment group and two patients to the control group). Method used to generate allocation sequences was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-11 07:08:24 +0100" MODIFIED_BY="[Empty name]">
<P>52 patients undergoing primary or repeat myocardial revascularisation, or repeat valve surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 26, M/F = 15/11, mean (sd) age = 59 (11) years</LI>
<LI>Control group (placebo) (n = 26), M/F = 19/7, mean (sd) age = 59 (10) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-11 07:08:33 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 1 million KIU of aprotinin added to the priming solution of the cardiopulmonary bypass circuit.</LI>
<LI>Control group (placebo) received an equal volume of sodium chloride 0.9% added to the priming solution of the cardiopulmonary bypass circuit.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-11 07:09:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), re-operation, blood loss, haemoglobin concentrations, coagulation factors.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:14:00 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-11 07:12:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hardy-1998">
<CHAR_METHODS>
<P>Study participants were randomised by the pharmacy department. Each successive block of nine patients were randomised to ensure a comparable number of patients in all groups and a similar distribution of patients over time. All bags were coded by the Department of Pharmacy and identical volumes of solution were infused.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-11 07:11:38 +0100" MODIFIED_BY="[Empty name]">
<P>134 patients undergoing scheduled elective coronary artery bypass graft surgery were randomised to one of three groups:</P>
<UL>
<LI>Control group (Placebo): n = 45, M/F = 38/7</LI>
<LI>Tranexamic acid group: n = 43, M/F = 27/16</LI>
<LI>Epsilon aminocaproic acid group: n = 46, M/F = 35/11</LI>
</UL>
<P>NB: Age data were not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-11 07:11:54 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Control group (placebo) received a bolus plus an infusion of placebo solution (0.9% normal saline solution).</LI>
<LI>Tranexamic acid group received a 10g bolus of TXA over 20 minutes, followed by a placebo infusion. The placebo consisted of 0.9% normal saline solution.</LI>
<LI>Epsilon aminocaproic acid group received a 15g bolus over 20 minutes, followed by an infusion of 1g/hr.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-11 07:12:56 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage (units), blood loss, mortality, myocardial infarction, cerebrovascular accident, re-operation for bleeding.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:14:07 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-11 07:18:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harley-2002">
<CHAR_METHODS MODIFIED="2010-08-11 07:16:31 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-11 07:17:16 +0100" MODIFIED_BY="[Empty name]">
<P>35 patients undergoing elective orthopaedic surgery were randomised to one of two groups:</P>
<UL>
<LI>Epsilon aminocaproic acid group: n = 26, M/F = 10/16, mean (sd) age = 69 (11) years</LI>
<LI>Control group (Placebo): n = 29, M/F = 11/18, mean (sd) age = 69 (10) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-11 07:17:27 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Epsilon aminocaproic acid group received a loading dose of 150mg/kg administered as a bolus dose over 20 minutes on the patients arrival in OR. An hourly EACA infusion of 12.5mg/kg was subsequently administered for an additional 5 hours.</LI>
<LI>Control group received a placebo of saline solution</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-11 07:18:09 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, deep vein thrombosis, pulmonary embolus.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:14:15 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 3/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-11 07:21:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harmon-2004">
<CHAR_METHODS>
<P>A computer-generated randomisation sequence was used to allocate patients. The sequence was concealed (numbered containers) until treatment was assigned.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-11 07:20:04 +0100" MODIFIED_BY="[Empty name]">
<P>36 patients undergoing cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 17, M/F = 17/3, mean (sd) age = 63.4 (5.4) years</LI>
<LI>Control group (Placebo): n = 18, M/F = 14/4, mean (sd) age = 60.1 (9.5) years</LI>
</UL>
<P>NB: One patient was excluded from the final analysis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-11 07:20:15 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received a loading dose of 2 million KIU (280mg) of aprotinin after the induction of anaesthesia and a continuous infusion of 500,000 KIU/hr of aprotinin during surgery. An additional 2 million KIU was added to the CPB circuit prime.</LI>
<LI>Control group (placebo) receive an unspecified solution.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-11 07:21:06 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Cognitive deficit, number of patients exposed to allogeneic blood, blood loss, hospital length of stay (days), serious adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:14:23 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-11 07:25:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Havel-1992">
<CHAR_METHODS MODIFIED="2010-08-11 07:23:02 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomly allocated to receive the test compound or a placebo by use of sealed envelopes. Method of randomisation was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-11 07:23:28 +0100" MODIFIED_BY="[Empty name]">
<P>20 male patients undergoing orthotopic heart transplantation were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (Low dose): n = 10</LI>
<LI>Control group (Placebo): n = 10</LI>
</UL>
<P>NB: Demographic data not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-11 07:23:36 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 280mg of aprotinin over 20 minutes after anaesthesia prior to surgery. In addition 280mg was added to the priming volume of the heart lung machine.</LI>
<LI>Control group received a corresponding volume of normal saline solution.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-11 07:25:05 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss (24hrs)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:14:30 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-11 07:27:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Havel-1994">
<CHAR_METHODS>
<P>Method used to generate random sequences was not described. Bottles of aprotinin and placebo were indistinguishable from each other. The preparation of each patient was individually packaged with 12 bottles each; each individual bottle, as well as the carton, was marked with a label carrying the patient number (the randomisation number). Each study package contained a total of 12 bottles, of which eight carried the label "Infusion" and four the label "Pump".</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-11 07:26:48 +0100" MODIFIED_BY="[Empty name]">
<P>45 male patients undergoing cardiac surgery were randomised to one of three groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 15, mean (sd) age = 60 (8) years</LI>
<LI>Aprotinin group (Low dose): n = 15, mean (sd) age = 59 (8) years</LI>
<LI>Control group (Placebo): n = 15, mean (sd) age = 60 (9) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-11 07:27:10 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received 2 million KIU of aprotinin as a bolus over 30 minutes after the institution of anaesthesia but before skin incision, followed by a continuous infusion of 2 million KIU/hr of aprotinin over 4 hours, and an additional 2 million KIU of aprotinin was added to the pump prime.</LI>
<LI>Aprotinin group (Low dose) received 2 million KIU of aprotinin added to the pump prime only.</LI>
<LI>Control group received 0.9% saline solution.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-11 07:27:45 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage (units), blood loss, graft patency rates.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:14:37 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7<BR/>Transfusion protocol not used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-11 07:32:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hayashida-1997">
<CHAR_METHODS MODIFIED="2010-08-11 07:29:45 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomised by means of computer-generated randomisation table. Method of allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-11 07:30:41 +0100" MODIFIED_BY="[Empty name]">
<P>167 patients undergoing primary isolated coronary artery bypass graft surgery were randomised to one of three groups:</P>
<UL>
<LI>Aprotinin group (Minimal dose): n = 55, M/F = 43/12, mean (sd) age = 64.4 (8.8) years</LI>
<LI>Aprotinin group (Low dose): n = 55, M/F = 35/20, mean (sd) age = 63.2 (8.2) years</LI>
<LI>Control group: n = 57, M/F = 41/16, mean (sd) age = 61.2 (9.8) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-11 07:30:57 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (Minimal dose) received 1 million KIU of aprotinin in the cardiopulmonary bypass priming solution.</LI>
<LI>Aprotinin group (Low dose) received 30,000 KIU/kg of aprotinin in the priming solution and a continuous infusion of aprotinin at a rate of 7,500 KIU/kg every hour during cardiopulmonary bypass. The mean dose of aprotinin in the low dose group was 2.7 million KIU (range 1.4 million KIU to 4.0 million KIU).</LI>
<LI>Control group received no aprotinin treatment.</LI>
</UL>
<P>NB: All groups were exposed to pre-operative autologous blood donation (PAD).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-11 07:32:19 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma usage (units), all blood product requirements (units), blood loss, mortality, myocardial infarction, allergic reaction, parameters of clotting and fibrinolysis, renal function, early graft pattency rates.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:14:43 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-11 07:35:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hayes-1996">
<CHAR_METHODS MODIFIED="2010-08-11 07:34:17 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-11 07:34:53 +0100" MODIFIED_BY="[Empty name]">
<P>40 patients scheduled for total hip replacement surgery were randomly allocated to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 20, M/F = 8/12, mean (sd) age = 70.0 (7.9) years</LI>
<LI>Control group: n = 20, M/F = 7/13, mean (sd) age = 72.9 (10.3) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-11 07:35:02 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 2 million KIU of aprotinin intravenously over 20 minutes prior to surgical incision.</LI>
<LI>Control group received an equal volume of infusion consisting of 0.9% normal saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-11 07:35:37 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage (units), blood loss, haemoglobin levels, coagulation parameters, complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:14:50 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-11 07:38:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hei-2005">
<CHAR_METHODS MODIFIED="2010-08-11 07:37:24 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described. [Chinese language]</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-11 07:37:55 +0100" MODIFIED_BY="[Empty name]">
<P>40 patients with severe hepatitis undergoing liver transplantation were randomly assigned to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 20</LI>
<LI>Control group (Placebo): n = 20</LI>
</UL>
<P>Demographic data: M/F = 38/2, age range = 31-67 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-11 07:38:11 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a continuous infusion of 400,000 KIU of aprotinin commenced at the induction of anaesthesia and ceased at the end of surgery.</LI>
<LI>Control group received normal saline at the same volumes as the aprotinin regimen.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-11 07:38:43 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage (units), fresh frozen plasma usage, platelet usage, blood loss.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-11 07:43:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hekmat-2004">
<CHAR_METHODS>
<P>Randomisation was based on a computer-generated code and sealed in sequentially numbered, opaque envelopes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-11 07:43:13 +0100" MODIFIED_BY="[Empty name]">
<P>120 patients undergoing elective cardiac surgery were randomly assigned to one of two groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 60, M/F = 51/9, mean (sd) age = 63 (8) years</LI>
<LI>Tranexamic acid group: n = 60, M/F = 51/7, mean (sd) age = 63 (8) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-11 07:41:33 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose - "Full Hammersmith" regimen) received a loading dose of 2 million kallikrein inactivation units (KIU) of aprotinin, 2 million KIU of aprotinin added to the CPB pump prime, and a continuous infusion of 500,000 KIU/hr during CPB.</LI>
<LI>Tranexamic acid group received 500mg of TXA as a loading dose, 500mg added to the CPB pump prime, and 1g was given post CPB (a total of 2g of TXA).</LI>
</UL>
<P>NB: Cell Salvage was used during surgery in both groups using a cell saver (Brat2, Cobe Cardiovascular Inc, Arvada, CO.).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-11 07:42:58 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage (units), blood loss, mortality, myocardial Infarction, hospital length of stay (days), intensive care unit length of stay (days), intubation time (hours), number of patients requiring Intra-aortic balloon pump (IABP) therapy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:15:00 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-11 07:47:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hendrice-1995">
<CHAR_METHODS MODIFIED="2010-08-11 07:45:39 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-11 07:46:10 +0100" MODIFIED_BY="[Empty name]">
<P>26 patients undergoing primary coronary artery bypass surgery were randomly allocated to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 12, mean (sd) age = 59.8 (7.9) years</LI>
<LI>Control group: n = 14, mean (sd) age = 58.1 (17.3) years</LI>
</UL>
<P>Nb: Gender data not provided.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-11 07:46:20 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a loading dose of 2 million kallikrein inactivation units (KIU) of aprotinin over a period of 30 minutes, followed by an infusion of 500,000 KIU until the end of surgery. A supplement of 2 million KIU of aprotinin was administered to the priming of the extracorporeal circuit.</LI>
<LI>Control group did not receive aprotinin.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-11 07:47:06 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Allogeneic blood usage, blood loss (24 hrs), haemoglobin levels, coagulation factors.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:15:07 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-12 00:25:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hiipala-1995">
<CHAR_METHODS MODIFIED="2010-08-12 00:23:44 +0100" MODIFIED_BY="[Empty name]">
<P>Concealment of treatment allocation was by means of a ticket drawn from an envelope containing an equal number of treatment and placebo tickets. The method used to generate allocation sequences was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-12 00:24:20 +0100" MODIFIED_BY="[Empty name]">
<P>29 patients undergoing total knee arthroplasty were randomly allocated to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 15, M/F = 2/13, mean (range) age = 70 (56-82) years</LI>
<LI>Control group (Placebo): n = 13, M/F = 3/10, mean (range) age = 70 (63-78) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-12 00:24:28 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received a bolus of 15mg/kg of TXA 2-5 minutes before deflation of limb tourniquet.</LI>
<LI>Control group received an equal volume of sodium chloride solution (0.9%).</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-12 00:25:17 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, myocardial infarction, deep vein thrombosis, pulmonary embolus, minor non-thromboembolic complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:15:14 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-12 00:29:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hiipala-1997">
<CHAR_METHODS>
<P>A ticket indicating the group was drawn and enclosed in an envelope. The envelopes were opened after the study was completed. Injection syringes were prepared by a person outside the surgical team.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-12 00:29:53 +0100" MODIFIED_BY="[Empty name]">
<P>75 patients scheduled for 77 total knee arthroplasties were randomly allocated to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 39, M/F = 4/35, mean (sd) age = 70 (7) years</LI>
<LI>Control group (Placebo): n = 38, M/F = 8/30, mean (sd) age = 69 (5) years</LI>
</UL>
<P>NB: Three patients were excluded from the final analysis for miscellaneous reasons.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-12 00:27:57 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 15mg/kg of TXA before the removal of the limb tourniquet, followed by two 10mg/kg additional doses.</LI>
<LI>Control group received equal volumes of normal saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-12 00:28:53 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, mortality, deep vein thrombosis, pulmonary embolus,<BR/>non-thrombotic complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-12 00:29:43 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-12 00:33:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hill-1998">
<CHAR_METHODS MODIFIED="2010-08-12 00:31:27 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomised according to a computer-generated sequence. Method of allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-12 00:32:30 +0100" MODIFIED_BY="[Empty name]">
<P>20 adult patients scheduled for first-time myocardial revascularisation were randomly assigned to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 10, mean (sd) age = 64 (7.9) years</LI>
<LI>Control group: n = 10, mean (sd) age = 62 (7.9) years</LI>
</UL>
<P>NB: Gender data not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-12 00:32:49 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 280mg of aprotinin (2 million KIU) intravenously as a loading dose followed by 70mg (500,000 KIU) of aprotinin per hour as a constant intravenous infusion until chest closure. In addition 280mg of aprotinin (2 million KIU) was added to the "pump prime".</LI>
<LI>Control group did not receive aprotinin.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-12 00:33:11 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Allogeneic blood usage (units), interleukin-10 (IL-10) levels.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:15:28 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 3/7<BR/>Transfusion protocol not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-12 00:36:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Horrow-1990">
<CHAR_METHODS>
<P>Patients were randomised using a random number table. Sealed envelopes ensured that only the pharmacist, who prepared the encoded infusions, knew whether a patient received drug or placebo.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-12 00:35:26 +0100" MODIFIED_BY="[Empty name]">
<P>49 patients undergoing cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 18, mean (sd) age = 66 (10)</LI>
<LI>Control group (Placebo): n = 20, mean (sd) age = 62 (9) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-12 00:35:41 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received a 10mg/kg infusion of TXA over a 20-minute period followed by an infusion of 1mg/kg for 10 hours.</LI>
<LI>Control group received equivalent infusions of saline (100ml total volume).</LI>
</UL>
<P>NB: Both groups received cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-12 00:36:56 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage (units), number of participants exposed to fresh frozen plasma, number of participants exposed to platelets, blood loss (12 hrs), deep vein thrombosis, pulmonary embolus, stroke, number of patients receiving cell salvage, volume of cell salvage autotransfused.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:15:35 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-12 00:42:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Horrow-1991">
<CHAR_METHODS>
<P>A table of random numbers determined patient allocation to one of four groups. Coded infusion bags and sealed envelopes prepared by a pharmacist not involved in the study provided double blinded conditions.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-12 00:39:59 +0100" MODIFIED_BY="[Empty name]">
<P>163 adult patients undergoing coronary revascularisation, valve replacement, both procedures, or repair of atrial septal defect, were randomly allocated to one of four groups:</P>
<UL>
<LI>Control group (Placebo): n = 44, mean (sd) age = 64 (10) years</LI>
<LI>Tranexamic acid group: n = 37, mean (sd) age = 65 (11) years</LI>
<LI>Desmopressin group: n = 38, mean (sd) age = 63 (11) years</LI>
<LI>Tranexamic acid + Desmopressin group: n = 40, mean (sd) age = 63 (9) years</LI>
</UL>
<P>NB: Gender data were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-12 00:40:41 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Control group received saline solutions.</LI>
<LI>Tranexamic acid group received tranexamic acid beginning after induction of anaesthesia but before skin incision (loading dose - 10mg/kg over 30 minutes) followed by a 12 hour infusion of 1mg/kg/hr.</LI>
<LI>Desmopressin group received desmopressin acetate (0.3ug/kg over 20 minutes) beginning after extracorporeal circulation following completion of protamine infusion.</LI>
<LI>Tranexamic acid + Desmopressin group received both tranexamic acid and desmopressin in an identical fashion to groups 2 and 3.</LI>
</UL>
<P>NB: All patients received cell salvaged autologous blood if available.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-12 00:42:20 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage (units), blood loss (12hrs), myocardial infarction, stroke, deep venous thrombosis, re-operation for bleeding, rash, ventricular dysfunction, pulmonary oedema, ventricular tachycardia.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:15:43 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-12 00:50:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Horrow-1995">
<CHAR_METHODS>
<P>Coded infusion bags for both loading and infusion doses and sealed envelopes prepared by a pharmacist provided allocation concealment. Randomisation was determined by a table of random numbers.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-12 00:47:33 +0100" MODIFIED_BY="[Empty name]">
<P>148 patients undergoing elective cardiac operations were randomised to one of six groups:</P>
<UL>
<LI>Control group (Placebo): n = 27, M/F = 23/4, mean (sd) age = 63 (10.4) years</LI>
<LI>Tranexamic acid group (Quarter dose): n = 24; M/F = 18/6; mean (sd) age = 67 (9.8) years</LI>
<LI>Tranexamic acid group (Half dose): n = 22, M/F = 19/3, mean (sd) age = 61 (9.4) years</LI>
<LI>Tranexamic acid group (Whole dose): n = 21, M/F = 18/3, mean (sd) age = 66 (9.2) years</LI>
<LI>Tranexamic acid group (Double dose): n = 27, M/F = 22/5, mean (sd) age = 63 (10.4) years</LI>
<LI>Tranexamic acid group (Fourfold dose): n = 27, M/F = 21/6, mean (sd) age = 65 (10.4) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-12 00:48:32 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Control group received saline infusions.</LI>
<LI>Tranexamic acid group (Quarter dose) received a loading dose of 2.5mg/kg of TXA after the induction of anaesthesia over a period of 30 minutes followed by a 12 hour continuous infusion of 0.25mg/kg/hr of TXA.</LI>
<LI>Tranexamic acid group (Half dose) received a loading dose of 5.0mg/kg of TXA after the induction of anaesthesia over a period of 30 minutes followed by a 12 hour continuous infusion of 0.5mg/kg/hr of TXA.</LI>
<LI>Tranexamic acid group (Whole dose) received a loading dose of 10mg/kg of TXA after the induction of anaesthesia over a period of 30 minutes followed by a 12 hour continuous infusion of 1.0mg/kg/hr of TXA.</LI>
<LI>Tranexamic acid group (Double dose) received a loading dose of 20mg/kg of TXA after the induction of anaesthesia over a period of 30 minutes followed by a 12 hour continuous infusion of 2.0mg/kg/hr of TXA.</LI>
<LI>Tranexamic acid group (Fourfold dose) received a loading dose of 40mg/kg of TXA after the induction of anaesthesia over a period of 30 minutes followed by a 12 hour continuous infusion of 4.0mg/kg/hr of TXA.</LI>
</UL>
<P>NB: All groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-12 00:50:07 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), number of patients exposed to fresh frozen plasma, number of patients exposed to platelets, blood loss (12 hrs), mortality, hypotension.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:15:51 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-12 00:55:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Husted-2003">
<CHAR_METHODS>
<P>Randomisation was performed by computer. The drugs were packed in numbered envelopes by a person not connected with the surgical procedure and handled by the anaesthetist. The randomisation code was not broken until the study was completed.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-12 00:54:02 +0100" MODIFIED_BY="[Empty name]">
<P>40 patients undergoing primary total hip arthroplasty were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 20, M/F = 7/13, mean age = 65 years</LI>
<LI>Control group (Placebo): n = 20, M/F = 6/14, mean age = 67 years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-12 00:54:16 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received a bolus dose of 10mg/kg of TXA (maximum 1g) during 10 minutes about 15 minutes before the incision, followed by a continuous infusion of 1mg/kg/hr dissolved in 1 litre of saline for 10 hours (maximum 1g over 10 hours).</LI>
<LI>Control group received saline as a bolus injection of 20ml about 15 minutes before the operation followed by a continuous infusion of 1 litre of saline during 10 hours.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-12 00:55:12 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, deep vein thrombosis, pulmonary embolus, infection, haemoglobin levels.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-12 00:53:17 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-12 00:57:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ickx-2006">
<CHAR_METHODS MODIFIED="2010-08-12 00:56:01 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-12 00:56:37 +0100" MODIFIED_BY="[Empty name]">
<P>51 patients undergoing primary liver transplantation were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (Low dose): n = 24, M/F = 20/4, mean (sd) age = 50 (10) years</LI>
<LI>Tranexamic acid group (n = 27), M/F = 25/2, mean (sd) age = 53 (7) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-12 00:56:50 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (Low dose) received 280mg of aprotinin as a slow bolus over 30 minutes followed by a continuous infusion of 70mg/hr. The infusion was initiated during the anhepatic phase, 30 minutes before the expected reperfusion time, and maintained until 2 hours after reperfusion.</LI>
<LI>Tranexamic acid group received a slow bolus of 40mg/kg of TXA over 30 minutes followed by a continuous infusion at a rate of 40mg/kg/hr. The infusion was initiated during the anhepatic phase, 30 minutes before the expected reperfusion time, and maintained until 2 hours after reperfusion.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-12 00:57:56 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, number of patients exposed to fresh frozen plasma, number of patients exposed to platelets, allogeneic blood usage (units), mortality, hospital length of stay (days), intensive care unit length of stay (days).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:16:09 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-12 01:01:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Isetta-1993">
<CHAR_METHODS MODIFIED="2010-08-12 01:00:03 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described. Exclusions or loss to follow-up were not reported. [Abstract]</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-12 01:00:43 +0100" MODIFIED_BY="[Empty name]">
<P>240 patients undergoing cardiac surgery were randomised to one of four groups:</P>
<UL>
<LI>Tranexamic acid group: n = 70</LI>
<LI>Aprotinin group (Low dose): n = 70</LI>
<LI>Aprotinin group (High dose): n = 70</LI>
<LI>Control group: n = 70</LI>
</UL>
<P>NB: Demographic data were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-12 01:01:11 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 15mg/kg of TXA before the injection of heparin prior to cardiopulmonary bypass (CPB).</LI>
<LI>Aprotinin group (Low dose) received 500,000 KIU of aprotinin during 20 minutes after induction, followed by a continuous infusion of 500,000 KIU/hr until the end of CPB.</LI>
<LI>Aprotinin group (High dose) received 2 million KIU of aprotinin over a 45 minute period after induction followed by a continuous infusion of 500,000 KIU/hr until the end of CPB, the priming volume of the CPB circuit included 2 million KIU of aprotinin.</LI>
<LI>Control group received no antifibrinolytic treatment.</LI>
</UL>
<P>NB: All groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-12 01:01:46 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, blood loss, haematocrit values.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:16:16 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 0/7 (Abstract)<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-12 01:05:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jamieson-1997">
<CHAR_METHODS MODIFIED="2010-08-12 01:03:06 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-12 01:03:46 +0100" MODIFIED_BY="[Empty name]">
<P>50 patients undergoing re-operative cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 24, M/F = 11/13, median (range) age = 54 (34-77) years</LI>
<LI>Control group (Placebo): n = 36, M/F = 12/12, median (range) age = 53 (28-78) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-12 01:03:59 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received a loading dose of 280mg of aprotinin infused after induction of anaesthesia, 280mg in the cardiopulmonary prime solution, and 70mg/hr of aprotinin for a period of 6 hours.</LI>
<LI>Control group received a placebo of normal saline.</LI>
</UL>
<P>NB: Both groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-12 01:05:09 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage (units), blood loss, mortality, hospital length of stay (days), total blood products transfused.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:16:24 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-12 01:10:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jansen-1999">
<CHAR_METHODS MODIFIED="2010-08-12 01:10:03 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation was performed using a computer-generated random number list. Method of allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-12 01:07:37 +0100" MODIFIED_BY="[Empty name]">
<P>42 patients undergoing unilateral bicondylar cemented total knee arthroplasty were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 21, M/F = 5/16, mean (range) age = 70.7 (62-80) years</LI>
<LI>Control group (Placebo) (n = 21), M/F = 3/18, mean (range) age = 71.0 (64-84) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-12 01:07:46 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 15mg/kg of intravenous TXA before inflation of the tourniquet and surgery and repeated every 8 hours for 3 days.</LI>
<LI>Control group received an equivalent volume of normal saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-12 01:08:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, deep venous thrombosis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:16:30 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-12 01:13:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Janssens-1994">
<CHAR_METHODS MODIFIED="2010-08-12 01:12:10 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-12 01:12:50 +0100" MODIFIED_BY="[Empty name]">
<P>40 patients undergoing primary total hip replacement were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 20, M/F = 10/10, mean (sd) age = 64.9 (13.2) years</LI>
<LI>Control group (Placebo): n = 20, mean (sd) age = 65.3 (15.3) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-12 01:13:01 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a bolus injection of 2 million KIU of aprotinin over 30 minutes after the induction of anaesthesia, followed by an infusion of 500,000 KIU/hr until the end of surgery with a maximum dose of 3.5 million KIU of aprotinin.</LI>
<LI>Control group received the same volume of normal saline according to the same protocol as aprotinin.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-12 01:13:45 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Blood loss, number of patients exposed to allogeneic/autologous blood, allogeneic blood usage (units), autologous blood usage (units), hospital length of stay (days), deep vein thrombosis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:16:38 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-12 01:16:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jares-2003">
<CHAR_METHODS MODIFIED="2010-08-12 01:15:14 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-12 01:15:39 +0100" MODIFIED_BY="[Empty name]">
<P>47 patients undergoing 'off pump' coronary artery bypass graft surgery were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 22, M/F = 20/2</LI>
<LI>Control group: n = 25, M/F = 15/10</LI>
</UL>
<P>NB: No age data were reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-12 01:15:50 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 1g of TXA 10 minutes before surgical incision followed by a continuous infusion at a rate of 200mg/hr until the end of the procedure.</LI>
<LI>Control group did not receive antifibrinolytic treatment.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-12 01:16:37 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, blood loss, pulmonary embolus, aspirin use &lt;5 days, re-operation for bleeding, stroke.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:16:45 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 1/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-12 01:29:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jeserschek-2003">
<CHAR_METHODS MODIFIED="2010-08-12 01:27:47 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-12 01:28:24 +0100" MODIFIED_BY="[Empty name]">
<P>18 patients undergoing elective orthopaedic surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (Low dose): n = 9, M/F = 3/6, mean (sd) age = 67 (12.0) years</LI>
<LI>Control group (Placebo): n = 9, M/F = 5/4, mean (sd) age = 72.7 (7.8) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-12 01:28:34 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (Low dose) received at the begining of the operation 1 million KIU of aprotinin (140mg) as a loading dose followed by a continuous infusion of 500,000 KIU/hr. </LI>
<LI>Control group received the same volume of normal saline.</LI>
</UL>
<P>NB: Both groups were exposed to intra-operative cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-12 01:29:05 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:16:51 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol not used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-12 01:58:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jimenez-2007">
<CHAR_METHODS MODIFIED="2010-08-12 01:54:29 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were assigned to treatment group by independent pharmacists using a list of pseudo-randomised numbers to receive coded infusions of either TXA or placebo. The cose was revealed once recruitment, data collection, and laboratory analyses were completed.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-12 01:55:56 +0100" MODIFIED_BY="[Empty name]">
<P>50 patients undergoing cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 24, M/F = 12/12, mean (95%CI) age = 66 (63-70) years</LI>
<LI>Control group (Placebo): n = 26, M/F = 15/11, mean (95% CI) age = 67 (62-71) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-12 01:56:02 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 2g before and after surgery.</LI>
<LI>Control group received saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-12 01:57:54 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients receiving blood transfusion, volume of blood transfused (units), blood loss, mortality, hospital length of stay, mechanical ventilation hours, inflammatory response, d-dimer levels.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-12 01:58:02 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 7/7</P>
<P>Use of a transfusion protocol was not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-12 02:05:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johansson-2005">
<CHAR_METHODS>
<P>Patients were randomised by computer in blocks of 10. Coded ampoules were prepared by the pharmaceutical company. All personnel and patients were blinded as to the treatment until the randomisation code was broken which took place after all patients had been evaluated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-12 02:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>119 patients undergoing total hip arthroplasty were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 47, M/F = 25/22, mean (sd) age = 69 (7) years</LI>
<LI>Control group (Placebo): n = 53, M/F = 28/25, mean (sd) age = 68 (8) years</LI>
</UL>
<P>NB: Before the randomisation code was broken 19 patients were excluded due to violation of the study protocol.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-12 02:04:48 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received a bolus infusion of 15mg/kg of TXA mixed in 100ml of normal saline immediately before the start of the operation.</LI>
<LI>Control group received normal saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-12 02:05:22 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, deep vein thrombosis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:17:00 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-12 02:08:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kahveci-1996">
<CHAR_METHODS MODIFIED="2010-08-12 02:07:04 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described. [Turkish language]</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-12 02:07:42 +0100" MODIFIED_BY="[Empty name]">
<P>28 patients undergoing coronary artery bypass surgery or cardiac valvular surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (Low dose): n = 14, M/F = 6/8, mean (sd) age = 45.5 (12.8) years</LI>
<LI>Control group: n = 14, M/F = 8/6, mean (sd) age = 48 (10.5) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-12 02:07:51 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (Low dose) received a bolus of 2 million KIU of aprotinin (280 mg) before the induction of anaesthesia followed by a continuous infusion of 500,000 KIU/hr.</LI>
<LI>Control group did not receive aprotinin.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-12 02:08:17 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Allogeneic blood usage (units), fresh frozen plasma usage (units), blood loss.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Transfusion protocol not used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-12 02:11:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kalangos-1994">
<CHAR_METHODS MODIFIED="2010-08-12 02:09:17 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described. No exclusions were reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-12 02:10:17 +0100" MODIFIED_BY="[Empty name]">
<P>165 adult patients undergoing elective primary aortocoronary bypass operations were randomised to one of three groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 55, M/F = 47/8, mean (sd) age = 58.2 (5.6) years</LI>
<LI>Aprotinin group (Low dose): n = 55, M/F = 44/11, mean (sd) age = 57.7 (6.6) years</LI>
<LI>Control (Placebo): n = 55, M/F = 49/6, mean (sd) age = 60.5 (6.8) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-12 02:10:34 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received an intravenous bolus of 2 million KIU of aprotinin at induction of anaesthesia. Another 2 million KIU of aprotinin was added to the pump prime volume. A continuous infusion of 500,000 KIU/hr of aprotinin was maintained until the end of the operation.</LI>
<LI>Aprotinin group (Low dose) received 25,000 KIU/kg added to the pump prime solution (mean dosage 1.78 million KIU; range 1.375 million KIU to 2.3 million KIU) and saline was administered at all other corresponding times.</LI>
<LI>Control group received identical volumes of saline at all corresponding times.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-12 02:11:20 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, myocardial infarction, creatine phosphokinase - myocardial band (CK-MB) levels.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:17:10 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-12 02:18:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karski-1995">
<CHAR_METHODS MODIFIED="2010-08-12 02:16:56 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation was performed by the pharmacy department. The method used to generate allocation sequences was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-12 02:18:01 +0100" MODIFIED_BY="[Empty name]">
<P>150 patients undergoing cardiac operations were randomised to one of three groups:</P>
<UL>
<LI>Tranexamic acid group (TA-10): n = 50, mean (sd) age = 59 (21.2) years</LI>
<LI>Tranexamic acid group (TA-20): n = 50, mean (sd) age = 63 (7.0) years</LI>
<LI>Control group (Placebo): n = 50, mean (sd) age = 58 (14.1) years</LI>
</UL>
<P>NB: Gender data were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-12 02:18:18 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group (TA-10) received an infusion of 10g of TXA intravenously over 20 minutes after induction of anaesthesia and a placebo infusion (0.9% normal saline) over the subsequent 5 hours.</LI>
<LI>Tranexamic acid group (TA-20) received 10g of TXA over 20 minutes and then a further 10g infused over 5 hours.</LI>
<LI>Control group received a placebo bolus (0.9% normal saline) and a placebo infusion (0.9% normal saline) over 5 hours.</LI>
</UL>
<P>NB: All groups were exposed to cell salvage (autotransfusion). Patients with defined 'excessive bleeding' were treated with 10-40g of intravenous epsilon aminocaproic acid (EACA) or desmopressin (DDAVP).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-12 02:18:42 +0100" MODIFIED_BY="[Empty name]">
<P>Outcomes reported: Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:17:47 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-12 02:22:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karski-2005">
<CHAR_METHODS MODIFIED="2010-08-12 02:20:08 +0100" MODIFIED_BY="[Empty name]">
<P>A computer-generated randomisation code in blocks of four was used to assign patients to treatment or control in a double-blinded fashion. The hospital pharmacy prepared identical bags of solution.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-12 02:21:37 +0100" MODIFIED_BY="[Empty name]">
<P>312 patients undergoing cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 147, M/F = 128/19, mean (sd) age = 59.9 (8.9) years</LI>
<LI>Control group (Placebo): n = 165, M/F = 147/18, mean (sd) age = 60 (8.3) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-12 02:21:48 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 100mg/kg of TXA in 100ml solution over 20 minutes after the induction of anaesthesia.</LI>
<LI>Control group received 5% dextrose.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-12 02:22:57 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patinets exposed to allogeneic blood, number of patients exposed to fresh frozen plasma, number of patients exposed to platelets, mortality, myocardial infarction, stroke, cardiac arrest, atrial fibrillation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:17:55 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 7/7<BR/>Transfusion protocol not specified<BR/>NB: Open-labeled tranexamic acid was administered to 4 patients in the TXA group and 24 patients in the control group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-13 04:22:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaspar-1997">
<CHAR_METHODS>
<P>Study infusions were prepared by the hospital pharmacy using a computer generated randomisation schedule.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-13 04:20:15 +0100" MODIFIED_BY="[Empty name]">
<P>32 consecutive patients undergoing orthotopic liver transplantation were randomly allocated to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 16</LI>
<LI>Control group (Placebo): n = 16</LI>
</UL>
<P>NB: Demographic data were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-13 04:20:25 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received a continuous small dose infusion of TXA (1g in 500ml of normal saline) at a dose of 2mg/kg/hr.</LI>
<LI>Control group received an equal volume of normal saline.</LI>
</UL>
<P>NB: Both groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-13 04:22:11 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage (units), fresh frozen plasma (units), platelets (units), mortality, hepatic arterial thrombosis, epsilon aminocaproic acid 'rescue', cryoprecipitate.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:18:22 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 7/7<BR/>Transfusion protocol not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-13 04:31:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Katoh-1997">
<CHAR_METHODS MODIFIED="2010-08-13 04:28:40 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-13 04:29:43 +0100" MODIFIED_BY="[Empty name]">
<P>93 patients undergoing either coronary artery bypass grafting or heart valve operations were randomly divided into one of three groups:</P>
<UL>
<LI>Tranexamic acid group (TA-1): n = 31, M/F = 22/9, mean (sd) age = 63.7 (8.3) years</LI>
<LI>Tranexamic acid group (TA-2): n = 31, M/F = 21/10, mean (sd) age = 62.9 (9.5) years</LI>
<LI>Control group: n = 31, M/F = 22/9, mean (sd) age = 64.7 (11.7) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-13 04:30:03 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group (TA-1) received an infusion of tranexamic acid (TXA) of 100mg/kg intravenously (IV) over 20 minutes soon after induction of anaesthesia and before cardiopulmonary bypass (CPB).</LI>
<LI>Tranexamic acid group (TA-2) received a 100mg/kg dose of TXA intravenously (IV) over 20 minutes soon after induction of anaesthesia and before CPB, and an additional dose of 50mg/kg infused IV over 20 minutes soon after being weaned from CPB.</LI>
<LI>Control group did not receive tranexamic acid.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-13 04:31:08 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, mortality, myocardial infarction, stroke, pulmonary embolism, deep vein thrombosis.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:18:30 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-13 04:34:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Katsaros-1996">
<CHAR_METHODS MODIFIED="2010-08-13 04:32:30 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation was not described. Allocation concealment was by coded infusions. One patient was eliminated from the study due to improper data collection.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-13 04:33:09 +0100" MODIFIED_BY="[Empty name]">
<P>211 patients scheduled for open heart operations were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 104, M/F = 68/36, mean (sd) age = 65 (9.3) years</LI>
<LI>Control group (Placebo): n = 106, M/F = 80/26, mean (sd) age = 63 (12.3) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-13 04:33:20 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 10g of TXA (diluted to 250ml with normal saline solution) intravenously over 20 minutes. No incision was made until the completion of the infusions.</LI>
<LI>Control group received 250ml of normal saline solution.</LI>
</UL>
<P>NB: Both groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-13 04:34:39 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, bood loss (24hrs), mortality, myocardial infarctions, deep vein thrombosis, pulmonary embolus,<BR/>re-operation for bleeding, cerebrovascular accident, renal failure, central nervous system complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:18:36 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-13 04:36:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Katzel-1998">
<CHAR_METHODS MODIFIED="2010-08-13 04:35:12 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described. [German language]</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-13 04:35:53 +0100" MODIFIED_BY="[Empty name]">
<P>24 male patients undergoing thoracic surgery for malignant lung disease were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (Low dose): n = 12, mean (sd) age = 57.1 (8.2) years</LI>
<LI>Control group (Placebo): n = 12, mean (sd) age = 59.4 (9.0) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-13 04:36:04 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (Low dose) received a bolus of 280mg of aprotinin (2 million KIU) followed by 500,000 KIU of aprotinin during surgery until 1 hour after surgery.</LI>
<LI>Control group was infused with isotonic saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-13 04:36:37 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, blood loss, transient ischaemic attack.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:18:44 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-13 04:40:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kazemi-2010">
<CHAR_METHODS MODIFIED="2010-08-13 04:38:54 +0100" MODIFIED_BY="[Empty name]">
<P>Methods of sequence generation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-13 04:39:29 +0100" MODIFIED_BY="[Empty name]">
<P>64 patients undergoing orthopaedic surgery were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 32, M/F = 23/9, mean (sd) age = 46.6 (16.2) years</LI>
<LI>Control group: n = 32, M/F = 20/12, mean (sd) age = 45.4 (17.2) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-13 04:39:51 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 15mg/kg given five minutes pre-operatively.</LI>
<LI>Control group received saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-13 04:40:33 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Volume of blood transfused (units), blood loss, deep vein thrombosis, length of stay (days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-21 17:48:21 +0100" MODIFIED_BY="Katharine Ker">
<P>Transfusion protocol was used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-13 04:55:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kikura-2006">
<CHAR_METHODS MODIFIED="2010-08-13 04:53:41 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-13 04:54:18 +0100" MODIFIED_BY="[Empty name]">
<P>100 patients undergoing cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Epsilon aminocaproic acid: n = 50, M/F = 38/12, mean (sd) age = 63 (10) years</LI>
<LI>Control group (Placebo): n = 50, M/F = 40/10, mean (sd) age = 62 (11) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-13 04:54:30 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Epsilon aminocaproic acid group received 100mg/kg of EACA as a loading dose over 20-30 minutes, after endotracheal intubation, followed by a continuous infusion of 1g/hr of EACA during the operation, and a loading dose of 10g given into the CPB circuit prime solution. The infusion was discontinued on completion of surgery.</LI>
<LI>Control group (placebo) received identical appearing normal saline in identical volumes at the same times as EACA treatment.</LI>
</UL>
<P>NB: Both groups were exposed to intra-operative cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-13 04:55:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), number of patients exposed to fresh frozen plasma, number of patients exposed to platelets, blood loss (24hrs).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:18:54 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-13 05:00:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kipfer-2003">
<CHAR_METHODS MODIFIED="2010-08-13 04:57:46 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-13 04:58:19 +0100" MODIFIED_BY="[Empty name]">
<P>30 adult patients undergoing elective cardiac surgery were randomised into one of two groups:</P>
<UL>
<LI>Aprotinin group (Low dose): n = 15, M/F = 12/3, mean (sd) age = 62.3 (7) years</LI>
<LI>Control group: n = 15, M/F = 12/3, mean (sd) age = 61.3 (7) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-13 04:58:28 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (Low dose - pump prime) received 2 million KIU (280mg) of aprotinin added to the prime volume of the CPB.</LI>
<LI>Control group did not receive aprotonin.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-13 05:00:07 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, fresh frozen plasma, myocardial infarction, mortality, myocardial infarction, retransfused mediastinal shed blood, re-operation for bleeding, renal dysfunction, neurological deficit, hospital length of stay (days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:19:00 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-13 05:04:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klein-1998">
<CHAR_METHODS MODIFIED="2010-08-13 05:01:04 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-13 05:02:13 +0100" MODIFIED_BY="[Empty name]">
<P>109 patients undergoing elective cardiac surgery were randomised to one of three groups:</P>
<UL>
<LI>Aprotinin group (High dose + ASA): n = 40), M/F = 33/7, mean (sd) age = 64.0 (6.3) years</LI>
<LI>Aprotinin group (High dose): n = 38, M/F = 34/4, mean (sd) age = 62.1 (7.3) years</LI>
<LI>Control group (Placebo): n = 31, M/F = 28/3, mean (sd) age = 63.0 (9.3) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-13 05:02:30 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose + ASA) received a loading dose of 2 million KIU (280mg) followed by a continuous infusion of 500,000 KIU/hr until chest closure for a 6 hour maximum period. In addition, 2 million KIU of aprotinin was added to the pump prime. Patients underwent a minimum 10-day run-in period on ASA (100mg/day) until surgery.</LI>
<LI>Aprotinin group (High dose) received a loading dose of 2 million KIU (280mg) followed by a continuous infusion of 500,000 KIU/hr until chest closure for a 6 hour maximum period. In addition, 2 million KIU of aprotinin was added to the pump prime.</LI>
<LI>Control group received an unspecified placebo.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-13 05:03:09 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage (units), blood loss, fresh frozen plasma, myocardial infarction.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-13 05:04:22 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-13 05:08:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kluger-2003">
<CHAR_METHODS MODIFIED="2010-05-26 14:07:24 +0100" MODIFIED_BY="Katharine Ker">
<P>Patients underwent permuted block randomisation using random number tables. All patients received four syringes, labelled A,B,C,and D. Patients, clinicians, and investigators were all blinded to group allocation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-13 05:06:29 +0100" MODIFIED_BY="[Empty name]">
<P>90 patients undergoing cardiac surgery were randomised to one of three groups:</P>
<UL>
<LI>Epsilon aminocaproic acid group (Post-heparin): n = 30, M/F = 24/6, mean (sd) age = 65 (8.1) years</LI>
<LI>Epsilon aminocaproic acid group (Pre-incision): n = 28, M/F = 23/5, mean (sd) age = 66 (8.1) years</LI>
<LI>Control group (Placebo): n = 30, M/F = 22/8, mean (sd) age = 67 (6.5) years</LI>
</UL>
<P>NB: Two patients were excluded from the final analysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-13 05:06:50 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Epsilon aminocaproic acid group (Post-heparin) received an initial bolus of normal saline prior to skin incision, followed by a normal saline infusion. Three minutes after heparin administration patients received a bolus of 150mg/kg of EACA over 10 minutes and then an infusion of 15mg/kg/hr.</LI>
<LI>Epsilon aminocaproic acid group (Pre-incision) received a bolus of 150mg/kg of EACA over 10 minutes after the induction of anaesthesia but before skin incision, followed by an infusion of 15mg/kg/hr. Three minutes after heparin administration, to maintain blinding, this group received a bolus of normal saline over 10 minutes, followed by a resumption of the EACA infusion until the termination of CPB.</LI>
<LI>Control group received normal saline boluses and infusions throughout.</LI>
</UL>
<P>NB: All groups were exposed to acute normovolaemic haemodilution (ANH).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-13 05:08:23 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, number of patients exposed to fresh frozen plasma and platelets, mortality, myocardial infarction,<BR/>re-operation for bleeding, stroke.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:19:21 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-13 05:14:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koster-2004">
<CHAR_METHODS MODIFIED="2010-08-13 05:12:33 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation of patients was blinded to the surgeon. Method of randomisation was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-13 05:13:20 +0100" MODIFIED_BY="[Empty name]">
<P>200 patients undergoing elective cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (Low dose + heparin): n = 100, M/F = 56/44, mean (sd) age = 64 (15) years</LI>
<LI>Control group (Heparin alone): n = 100, M/F = 57/43, mean (sd) age = 66 (17) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-13 05:13:30 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (Low dose + heparin) received a bolus of 1 million KIU of aprotinin immediately before initiation of CPB and a continuous infusion of 250,000 KIU/hr during the period of CPB. In addition, 1 million KIU of aprotinin was added to the CPB pump prime.</LI>
<LI>Control group received standard care without aprotinin treatment.</LI>
</UL>
<P>NB: Both groups were exposed to cell salvage.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-13 05:14:06 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage (units), fresh frozen plasma, blood loss, duration of ventilation (hours).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:19:36 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 0/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-13 05:19:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kratzer-1997">
<CHAR_METHODS MODIFIED="2010-08-13 05:18:09 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation was by means of a random number generator. Method used to conceal treatment allocation was not described. [German language]</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-13 05:18:43 +0100" MODIFIED_BY="[Empty name]">
<P>18 patients undergoing orthotopic liver transplantation were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 9, mean age 47.9 years</LI>
<LI>Control group (Placebo): n = 9, mean age 49.4 years</LI>
</UL>
<P>NB: Gender data were not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-13 05:18:55 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received an intravenous bolus of 2 million KIU (280mg) of aprotinin at induction of anaesthesia and a continuous infusion of 500,000 KIU/hr of aprotinin until the end of the operation.</LI>
<LI>Control group received physiological saline solution.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-13 05:19:29 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage (units), coagulation parameters, blood loss.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-13 05:34:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kreisler-2005">
<CHAR_METHODS MODIFIED="2010-08-13 05:32:44 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation was accomplished through the use of a computer-generated table of random numbers. Method used to conceal treatment allocation was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-13 05:33:44 +0100" MODIFIED_BY="[Empty name]">
<P>71 patients undergoing cardiac surgery were randomised to one of three groups:</P>
<UL>
<LI>Epsilon aminocaproic acid: n = 22, M/F = 17/5, mean (sd) age = 63.4 (7.2) years</LI>
<LI>Heparin-coated CPB circuit: n = 20, 17/3, mean (sd) age = 59.6 (10.4) years</LI>
<LI>Control group (Placebo): n = 25, M/F = 17/8, mean (sd) age = 61.4 (8.8) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-13 05:34:04 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Epsilon aminocaproic acid group received non-heparin coated circuits and EACA. A loading dose of 75mg/kg of EACA was given over 10 minutes after the induction of anaesthesia and prior to skin incision followed by a maintenance infusion of EACA of 12.5mg/kg/hr continued for 2 hours after the arrival of the patient in the intensive care unit. An additional 5g of EACA was added to the CPB priming fluid.</LI>
<LI>Heparin coated (bonded) CPB circuit group were treated with tip-to-tip heparin-coated CPB circuits, including the cardiotomy reservoir, arterial filter, aortic and venous cannulas, and a placebo infusion of normal saline.</LI>
<LI>Control group received non-heparin coated circuits and a 0.9% normal saline load and maintenance infusion given in the same manner as EACA-treated patients.</LI>
</UL>
<P>NB: All groups were exposed to cell savage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-13 05:34:58 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, number of patients exposed to platelets, hospital length of stay (days), intensive care length of stay (hours), cell saver volume autotransfused.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:19:47 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-13 05:37:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuepper-2003">
<CHAR_METHODS>
<P>Group assignment was by sealed envelopes. Sealed envelopes were opened after induction of anaesthesia by the unblinded investigator who was not part of the operating team.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-13 05:36:57 +0100" MODIFIED_BY="[Empty name]">
<P>120 patients undergoing elective cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (Low dose): n = 60, M/F = 40/20, mean (sd) age = 65.5 (7.8) years</LI>
<LI>Control group: n = 59, M/F = 40/19, mean (sd) age = 65.6 (8.8) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-13 05:37:04 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotonin group (Low dose) received a single loading dose of 2 million KIU (280mg) of aprotinin given after the induction of anaesthesia but before skin incision.</LI>
<LI>Control group did not receive aprotinin.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-13 05:37:40 +0100" MODIFIED_BY="[Empty name]">
<P>Outcomes reported: Allogeneic blood usage (units), blood loss, fresh frozen plasma, platelets (units), mortality.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:19:54 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 3/7<BR/>Transfusion threshold for RBC not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-13 05:41:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuitunen-2005">
<CHAR_METHODS>
<P>Study drugs were prepared by the hospital pharmacy. Randomisation was carried out using closed envelopes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-13 05:39:59 +0100" MODIFIED_BY="[Empty name]">
<P>60 patients undergoing primary coronary artery bypass graft surgery were randomised to one of three groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 20, mean (sd) age = 61 (8.9) years</LI>
<LI>Tranexamic acid group: n = 20, mean (sd) age = 63 (8.9) years</LI>
<LI>Control group (Placebo): n = 20, mean (sd) age = 65 (8.9) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-13 05:40:17 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received 2 million KIU (280mg) of aprotinin after the induction of anaesthesia, followed by an infusion of 500,000 KIU/hr (70mg/hr) until the end of surgery. In addition, 2 million KIU (280mg) of aprotinin was added to the pump prime of the CPB circuit.</LI>
<LI>Tranexamic acid group received 15mg/kg after the induction of anaesthesia, followed by an infusion of 15mg/kg until the end of surgery. In addition, 15mg/kg was added to the pump prime of the CPB circuit.</LI>
<LI>Control group received normal saline.</LI>
</UL>
<P>NB: All groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-13 05:41:27 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, number of patients exposed to fresh frozen plasma, number of participants exposed to platelets,<BR/>blood loss (16hrs), mortality, myocardial infarction, re-operation for bleeding, stroke.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:20:08 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-13 05:46:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuitunen-2006">
<CHAR_METHODS MODIFIED="2010-08-13 05:44:08 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-13 05:44:43 +0100" MODIFIED_BY="[Empty name]">
<P>30 patients undergoing elective primary cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 15, M/F = 12/3, mean (sd) age = 57 (16) years</LI>
<LI>Control group: n = 15, M/F = 11/4, mean (sd) age = 61 (11) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-13 05:44:58 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 1g after administration of 15ml/kg of 6% HES in the immediate post-operative period.</LI>
<LI>Control group received saline after administration of 15ml/kg of 6% HES in the immediate post-operative period.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-13 05:46:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood transfusion, number of patients exposed to fresh frozen plasma and platelets, blood loss (24hrs), re-operation for bleeding</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-26 14:09:13 +0100" MODIFIED_BY="Katharine Ker">
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-13 05:50:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kunt-2005">
<CHAR_METHODS MODIFIED="2010-08-13 05:48:31 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-13 05:49:06 +0100" MODIFIED_BY="[Empty name]">
<P>86 patients undergoing routine cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 40, M/F = 30/10, mean (sd) age = 63 (12) years</LI>
<LI>Control group: n = 46, mean (sd) age = 60 (7) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-13 05:49:16 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 500,000 KIU (70mg) of aprotinin in the pump prime only.</LI>
<LI>Control group received "no aprotinin."</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-13 05:50:02 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Allogeneic blood usage (units), blood loss (24 hrs), mortality, hospital length of stay (days), intensive care unit length of stay (hours), re-operation for bleeding.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:20:27 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol not used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-13 05:53:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kyriss-2001">
<CHAR_METHODS>
<P>Randomisation carried out using a computer-generated random list. Allocation concealment not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-13 05:52:13 +0100" MODIFIED_BY="[Empty name]">
<P>38 patients undergoing elective thoracic surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (Low dose): n = 18, M/F = 12/6, mean age = 51.8 years</LI>
<LI>Control group (Placebo): n =20, M/F = 12/8, mean age = 50.8 years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-13 05:52:23 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotonin group (Low dose) received a test dose of 10,000 KIU during induction of anaesthesia followed by an initial bolus dose of 2 million KIU (280mg) of aprotinin over 20 minutes and a continuous infusion of 500,000 KIU/hr during the surgical procedure.</LI>
<LI>Control group received a corresponding volume of saline solution.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-13 05:53:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, fresh frozen plasma, blood loss, mortality, blood loss, re-operation for bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:20:35 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>No transfusion protocol</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-13 05:56:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Landymore-1997">
<CHAR_METHODS MODIFIED="2010-08-13 05:54:25 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation was not described. The study drugs were prepared by pharmacy, given an identification number, and then sent to the operating room.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-13 05:55:12 +0100" MODIFIED_BY="[Empty name]">
<P>148 patients undergoing primary myocardial revascularisation were randomised to one of three groups:</P>
<UL>
<LI>Aprotinin group (Low dose): n = 48</LI>
<LI>Epsilon-aminocaproic acid group: n = 44</LI>
<LI>Tranexamic acid group: n = 56</LI>
<LI>Control group: n = 50 (not included in randomisation process)</LI>
</UL>
<P>NB: Demographic data were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-13 05:55:36 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (Low dose) received a loading dose of 200,000 KIU of aprotinin administered before cardiopulmonary bypass (CPB), followed by a maintenance dose of 200,000 KIU/hr of aprotinin continued until the termination of CPB.</LI>
<LI>Epsilon-aminocaproic acid group received a loading dose of 5g administered before CPB, followed by a maintenance dose of 1g/hr of EACA continued until the termination of CPB.</LI>
<LI>Tranexamic acid group received a loading dose of 10mg/kg of TXA administered before CPB, followed by a maintenance dose of 1mg/kg/hr of TXA continued until the termination of CPB.</LI>
<LI>Control group did not receive antifibrinolytic treatment.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-13 05:56:20 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage (units), blood loss, thrombosis, deep vein thrombosis, pulmonary embolus.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:20:44 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria):2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-13 05:59:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lass-1995">
<CHAR_METHODS MODIFIED="2010-08-13 05:57:56 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described. Four aprotinin (7.8%) and eight control (14.5%) patients were excluded from the final analysis.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-13 05:58:25 +0100" MODIFIED_BY="[Empty name]">
<P>110 male patients undergoing elective primary coronary bypass surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 55</LI>
<LI>Control (Placebo): n = 55</LI>
</UL>
<P>NB: Demographic data were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-13 05:58:34 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received 2 million KIU of aprotinin as a loading dose before sternotomy followed by an infusion of 500,000 KIU/hr until the end of surgery. An additional 2 million KIU was added to the priming volume.</LI>
<LI>Control group received saline solution as a matching placebo in identical form by the same administration scheme.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-13 05:59:39 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), graft patency, blood loss, mortality, myocardial infarction, acute heart failure, post-operative complications, re-operation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:20:51 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 3/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-13 06:14:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Later-2009">
<CHAR_METHODS MODIFIED="2010-05-06 15:41:28 +0100" MODIFIED_BY="Katharine Ker">
<P>Allocated according to a computer-generated randomisation sequence, allocation concealed by use of sealed, opaque envelopes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-13 06:12:04 +0100" MODIFIED_BY="[Empty name]">
<P>298 patients undergoing cardiac surgery were randomised to one of three groups:</P>
<UL>
<LI>Aprotonin group: n = 96, M/F = 73/23, mean (sd) age = 66.5 (10.7) years</LI>
<LI>Tranexamic acid group: n = 99, M/F = 73/26, mean (sd) age = 64.1 (13.0) years</LI>
<LI>Control group: n = 103, M/F = 68/35, mean (sd) age = 65 (11.2) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-13 06:13:21 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aporinin group (high dose) received 2 million KIU pre-CPB, 2 million KIU at pump prime, and 500,000 KIU/hr during CPB.</LI>
<LI>Tranexamic acid group received 1g loading dose, 500mg added to CBP system prime, and a continuous infusion of 400mg/hr.</LI>
<LI>Control group received saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-13 06:14:01 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patienst exposed to allogeneic blood, myocardial infarction, renal failure, hospital length of stay (days), re-operation for bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-13 06:11:10 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-13 06:18:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Laub-1994">
<CHAR_METHODS MODIFIED="2010-08-13 06:15:19 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-13 06:15:54 +0100" MODIFIED_BY="[Empty name]">
<P>47 patients undergoing isolated coronary revascularisation were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 16, M/F = 12/4, mean (sd) age = 65.3 (11.2) years</LI>
<LI>Control group (Placebo): n = 16, M/F = 13/3, mean (sd) age = 63.6 (10) years</LI>
</UL>
<P>NB: The study group consisted of 32 patients in total. Fifteen of the originally enrolled patients were not included in the final analysis due to: adverse reactions while receiving the study medication (n = 2), inability to obtain or a technically inadequate CT scan (n = 7), refusal to come for follow-up examinations (n = 4), or died (n = 2).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-13 06:16:10 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 500 KIU of aprotinin as a test dose after the induction of anaesthesia, followed by 2 million KIU (280mg) of aprotinin as a bolus. An infusion of 0.5 million KIU of aprotinin was commenced after the bolus was given and 2 million KIU of aprotinin was added to the pump prime.</LI>
<LI>Control group received an identical volume of placebo.</LI>
</UL>
<P>NB: Autologous blood salvage with reinfusion of washed RBCs was used for all patients. Shed mediastinal and pleural blood was filtered and reinfused using an autotransfusion system.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-13 06:18:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, volume of allogeneic blood transfused, blood loss, volume of platelets and fresh frozen plasma, re-operation for bleeding, post-operative Hb levels, graft occlusions, any blood product usage, haematologic variables, coagulation profiles, renal function.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:21:00 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-13 06:21:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lavee-1993">
<CHAR_METHODS MODIFIED="2010-08-13 06:19:51 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-13 06:20:26 +0100" MODIFIED_BY="[Empty name]">
<P>30 patients undergoing various cardiopulmonary bypass procedures were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (Low dose): n = 15, M/F = 13/2, mean (sd) age = 62 (11) years</LI>
<LI>Control group (Placebo): n = 11, M/F = 11/4, mean (sd) age = 60 (9) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-13 06:20:39 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 2 million KIU of aprotinin added to the priming volume of the oxygenator. No additional aprotinin doses were given to the patients.</LI>
<LI>Control group received an equivalent volume of placebo solution (saline solution 0.9%) added to the priming volume of the oxygenator.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-13 06:21:10 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Allogeneic blood usage (units), blood loss (24hrs), platelets (units), platelet aggregation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:21:08 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-13 06:41:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leijdekkers-2006">
<CHAR_METHODS MODIFIED="2010-08-13 06:41:26 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomised to receive either placebo or aprotinin using a standard randomisation list stored in the pharmacy department, only to be opened after the study was closed for inclusion. </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-13 06:22:32 +0100" MODIFIED_BY="[Empty name]">
<P>35 patients undergoing cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotonin group: n = 16, M/F = 14/2, mean (sd) age = 68 (9.5) years</LI>
<LI>Control group: n = 19, M/F = 14/5, mean (sd) age = 68 (6.8) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-13 06:22:51 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aporinin group received 2 million KIU starting dose followed by 500,000 KIU/hr during surgery.</LI>
<LI>Control group received saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-13 06:23:34 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outocmes reported:</I>
</B> Volume blood transfused (units), blood loss, mortality, re-operation for bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-13 06:39:15 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 7/7</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-13 06:45:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lemay-2004">
<CHAR_METHODS MODIFIED="2010-08-13 06:43:43 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation was not described. Study drugs were prepared by the hospital pharmacist. Patient caregivers and the investigator collecting the data were blinded to the solution used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-13 06:44:29 +0100" MODIFIED_BY="[Empty name]">
<P>40 patients undergoing total hip replacement were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 20, M/F = 12/8, mean (sd) age = 59.7 (10.3) years</LI>
<LI>Control group (Placebo): n = 19, M/F = 13/6, mean (sd) age = 53.6 (12.8) years</LI>
</UL>
<P>NB: One patient was excluded from the final analysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-13 06:44:41 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received TXA immediately before surgery. After a test dose of 1ml of TXA, patients received a dose of 10mg/kg of intravenous TXA followed by an infusion of TXA of 1mg/kg/hr until skin closure.</LI>
<LI>Control group received an equivalent volume of physiologic saline.</LI>
</UL>
<P>NB: Pre-operative autologous donation of 3 units was offered to all patients.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-13 06:45:26 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, deep vein thrombosis, changes in haemoglobin levels.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:21:18 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-16 06:54:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lemmer-1994">
<CHAR_METHODS MODIFIED="2010-08-16 06:51:25 +0100" MODIFIED_BY="[Empty name]">
<P>Metho used to generate allocation sequences was not described. Aprotinin and an identically appearing placebo was supplied by Bayer AG, Leverkusen, Germany. Enrolled patients were stratified as to whether they were undergoing primary procedures (n = 151 patients: Lemmer_1) or repeat procedures (n = 65 patients: Lemmer_2).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-16 06:52:33 +0100" MODIFIED_BY="[Empty name]">
<P>151 patients undergoing isolated primary coronary artery bypass graft operations were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 74, M/F = 51/16, mean age = 64 years</LI>
<LI>Control group (Placebo): n = 74, M/F = 61/13, mean age = 62 years</LI>
</UL>
<P>65 patients undergoing repeat coronary artery bypass graft operations were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 29, M/F = 21/2, mean age = 66 years</LI>
<LI>Control group (Placebo): n = 36, M/F = 29/3, mean age = 65 years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-16 06:52:49 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a loading dose of 280mg of aprotinin followed by a continuous infusion of 70mg/hr, and 280mg of aprotinin was added to the oxygenator prime solution. The continuous infusion was discontinued on the patients' arrival to the intensive care unit.</LI>
<LI>Control group received identical volumes of 0.9% sodium chloride solution.</LI>
</UL>
<P>NB: Both groups were exposed to cell salvage.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-16 06:54:18 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma (units), platelets (units), blood loss, mortality,<BR/>myocardial infarction, re-operation for bleeding, allergic reactions, renal failure, renal failure + dialysis.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:21:24 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used.<BR/>Of the 151 patients undergoing primary CABG, 141 (74 in the aprotinin treated group and 67 in the placebo treated group) fulfilled the criteria for efficacy analysis. Patients were eliminated from efficacy analysis before the random code was broken.<BR/>Of the 65 patients undergoing repeat CABG surgery 55 (23 in the aprotinin treated group and 32 in the placebo treated group) fulfilled the criteria for efficacy analysis. Patients were eliminated from efficacy analysis before the random code was broken.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-16 07:04:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lemmer-1996">
<CHAR_METHODS MODIFIED="2010-08-16 07:00:45 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-16 07:02:01 +0100" MODIFIED_BY="[Empty name]">
<P>704 first time coronary artery bypass grafting patients were randomised to one of four groups:</P>
<UL>
<LI>Control group (Placebo): n = 178, M/F = 151/27, mean (sd) age = 62.5 (10.67) years</LI>
<LI>Aprotinin group (High dose): n = 173, M/F = 145/28, mean (sd) age = 61.3 (10.5) years</LI>
<LI>Aprotinin group (Low dose): n = 180, M/F = 155/25, mean (sd) age = 61.7 (10.7) years</LI>
<LI>Aprotinin group (Pump prime dose): n = 173, M/F = 151/22, mean (sd) age = 62.1 (10.5) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-16 07:02:23 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Control group received equivalent volumes of 0.9% sodium chloride at the same time periods.</LI>
<LI>Aprotinin group (High dose) received a loading dose of 280mg of aprotinin, a continuous infusion dose of 70mg/hr until the end of the operation, and 280mg of aprotinin was added to the pump prime solution.</LI>
<LI>Aprotinin group (Low dose) received a loading dose of 140mg of aprotinin, a continuous infusion dose of 35mg/hr until the end of the operation, and 140mg of aprotinin was added to the pump prime solution.</LI>
<LI>Aprotinin group (Pump prime dose) received a loading dose of placebo (0.9% sodium chloride), a continuous infusion of placebo until the end of the operation, and 280mg of aprotinin was added to the pump prime.</LI>
</UL>
<P>NB: All groups were exposed to cell salvage autotransfusion.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-16 07:04:16 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Total blood product exposures per patient, number of patients exposed to allogeneic blood, allogeneic blood usage (units), platelet (units), fresh frozen plasma (units), cryoprecipitate (units), blood loss, re-operation for diffuse bleeding, myocardial infarction.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:21:33 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-16 06:57:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lemmer_x005f_1-1994">
<CHAR_METHODS MODIFIED="2010-08-16 06:55:10 +0100" MODIFIED_BY="[Empty name]">
<P>Refer to Lemmer 1994</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-16 06:55:37 +0100" MODIFIED_BY="[Empty name]">
<P>151 patients undergoing isolated primary coronary artery bypass graft operations were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 74, M/F = 51/16, mean age = 64 years</LI>
<LI>Control group (Placebo): n = 74, M/F = 61/13, mean age = 62 years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-16 06:55:51 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a loading dose of 280mg of aprotinin followed by a continuous infusion of 70mg/hr, and 280mg of aprotinin was added to the oxygenator prime solution. The continuous infusion was discontinued on the patients' arrival to the intensive care unit.</LI>
<LI>Control group received identical volumes of 0.9% sodium chloride solution.</LI>
</UL>
<P>NB: Both groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-16 06:57:09 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma (units), platelets (units), blood loss, mortality,<BR/>myocardial infarction, re-operation for bleeding, allergic reactions, renal failure, renal failure + dialysis.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:21:42 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used.<BR/>Of the 151 patients undergoing primary CABG, 141 (74 in the aprotinin treated group and 67 in the placebo treated group) fulfilled the criteria for efficacy analysis. Patients were eliminated from efficacy analysis before the random code was broken.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-16 06:59:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lemmer_x005f_2-1994">
<CHAR_METHODS MODIFIED="2010-08-16 06:57:43 +0100" MODIFIED_BY="[Empty name]">
<P>Refer to Lemmer 1994</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-16 06:58:08 +0100" MODIFIED_BY="[Empty name]">
<P>65 patients undergoing repeat coronary artery bypass graft operations were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 29, M/F = 21/2, mean age = 66 years</LI>
<LI>Control group (Placebo): n = 36, M/F = 29/3, mean age = 65 years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-16 06:58:21 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received a loading dose of 280mg of aprotinin followed by a continuous infusion of 70mg/hr, and 280mg of aprotinin was added to the oxygenator prime solution. The continuous infusion was discontinued on the patients arrival to the intensive care unit.</LI>
<LI>Control group received an identical volume of 0.9% sodium chloride solution.</LI>
</UL>
<P>NB: Both groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-16 06:59:17 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma (units), platelets (units), blood loss, mortality,<BR/>myocardial infarction, re-operation for bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used.<BR/>Of the 65 patients undergoing repeat CABG surgery 55 (23 in the aprotinin treated group and 32 in the placebo treated group) fulfilled the criteria for efficacy analysis. Patients were eliminated from efficacy analysis before the random code was broken.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-16 07:08:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lentschener-1997">
<CHAR_METHODS MODIFIED="2010-08-16 07:06:26 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequences was by means of computer-generated random codes. Method of allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-16 07:06:59 +0100" MODIFIED_BY="[Empty name]">
<P>97 patients scheduled for elective liver resection performed through subcostal incision were randomly assigned to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 48, M/F = 23/24, mean (sd) age = 53 (15) years</LI>
<LI>Control group (Placebo): n = 49, M/F = 26/21, mean (sd) age = 54 (15) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-16 07:07:15 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a loading dose of 2 million KIU over 20 minutes after the induction of anaesthesia, followed by a continuous infusion of 500,000 KIU/hr administered by infusion pump until skin closure. An additional bolus of 500,000 KIU of aprotinin was infused for every three units of RBC transfused.</LI>
<LI>Control group received equivalent volumes of the placebo (0.9% saline solution) at the respective times.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-16 07:08:51 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Blood loss, number of patients exposed to allogeneic blood transfusion, fresh frozen plasma transfused, platelet units transfused.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:21:56 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 3/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-16 07:12:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lentschener-1999">
<CHAR_METHODS MODIFIED="2010-08-16 07:10:25 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomised in a double blind fashion by using a computer generated random code. Randomisation was both stratified by the number of fused levels and blocked in groups of four before the induction of anesthesia. Allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-16 07:11:26 +0100" MODIFIED_BY="[Empty name]">
<P>72 patients undergoing posterior lumbar spine fusion were randomly assigned to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 35, M/F = 18/17, mean (sd) age = 46 (9) years</LI>
<LI>Control group (Placebo): n = 37, M/F = 19/18, mean (sd) age = 51 (11) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-16 07:11:40 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a loading dose of 2 million KIU (280mg) over 20 minutes after induction of anaesthesia, followed by a continuous infusion of 500,000 KIU/hr administered by infusion pump until skin closure. An additional bolus of 500,000 KIU of aprotinin was infused every three units of RBC transfused.</LI>
<LI>Control group received equivalent volumes of the placebo (0.9% saline solution) at the respective times.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-16 07:12:43 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood (units), autologous transfusion, blood loss (24hrs), post-operative total autologous units (total).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:22:04 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-16 07:16:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levy-1995">
<CHAR_METHODS MODIFIED="2010-08-16 07:13:46 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described. Eleven medical centres participated. Study performed efficacy and safety analysis. Exclusions defined by protocol.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-16 07:15:44 +0100" MODIFIED_BY="[Empty name]">
<P>287 patients undergoing repeat coronary artery bypass graft surgery were randomly assigned to one of four groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 73 (safety analysis), n = 61 (efficacy analysis), M/F = 55/6; mean (sd) age = 64 (7.8) years</LI>
<LI>Aprotinin group (Low dose): n = 70 (safety analysis), n = 59 (efficacy analysis), M/F = 52/7; mean (sd) age = 65+/-7.7 years</LI>
<LI>Aprotinin group (Pump-prime): n = 72 (safety analysis), n = 68 (efficacy analysis), M/F = 62/6; mean (sd) age = 66 (8.2) years</LI>
<LI>Control group (Placebo): n = 72 (safety analysis), n = 65 (efficacy analysis), M/F = 59/6; mean (sd) age = 64 (8.0) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-16 07:16:08 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received a loading dose of 2 million KIU of aprotinin, plus an additional 2 million KIU was added to the cardiopulmonary bypass (CPB) circuit prime, followed by a continuous infusion of 500,000 KIU/hr during surgery.</LI>
<LI>Aprotinin group (Low dose) received a loading dose of 1 million KIU of aprotinin, plus 1 million KIU was added to the CPB circuit prime, followed by a continuous infusion of 250,000 KIU/hr during surgery.</LI>
<LI>Aprotinin group (Pump-prime) received 2 million KIU of aprotinin added to the CPB circuit prime.</LI>
<LI>Control group received equivalent volumes of 0.9% sodium chloride.</LI>
</UL>
<P>NB: All groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-16 07:16:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage (units), blood loss.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:22:16 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-16 07:20:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2005">
<CHAR_METHODS MODIFIED="2010-08-16 07:18:08 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-16 07:19:24 +0100" MODIFIED_BY="[Empty name]">
<P>70 patients undergoing elective cardiac surgery were randomised to one of four groups:</P>
<UL>
<LI>Control group: n = 10, M/F = 9/1, mean (sd) age = 59 (9) years</LI>
<LI>Platelet-rich plasmapheresis + acute normovolaemic haemodilution + cell salvage group: n = 20, M/F = 17/3, mean (sd) age = 59 (6) years</LI>
<LI>Aprotinin group: n = 22, M/F = 9/1, mean (sd) age = 61 (7) years</LI>
<LI>Combined group: n = 18, M/F = 16/2, mean (sd) age 62 (8) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-16 07:19:59 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Control received standard care with no active intervention.</LI>
<LI>PRP+ ANH + CS group: After the induction of anaesthesia, blood was withdrawn via the 9-French central venous catheter at a rate of 35-45ml/min and collected in the 125mL centrifugal bowl of an autotransfusion unit (Cell Saver 5, Haemonetics Corp., Braintree, MA). No systemic heparin was administered at this time but calcium in the blood was sequested with citrate by mixing the blood and ACD (adenosine, citrate, dextrose) agent (Perfect, Beijing, China) at a volume ratio of 8:1. The withdrawn blood volume was replaced with a mixing (1:2) of plasma substitute (Gelofusion) and crystalloid (Lactate Ringer Injection) at a volume ratio of 1:2-3 to maintain a steady PCWP. The withdrawn blood was centrifuged at 2400 rpm to separate the RBC's from the plasma and platelets. After removing the RBC's the plasma was continuously centrifuged at 2400 rpm to separate the PRP from the platelet-poor plasma. An average of 30 minutes and three to four passes were required to complete blood withdrawal and separation of the PRP and PPP. A volume of blood was withdrawn to obtain approximately 300ml of PRP from each study patient. In addition, the autotransfusion device at the same machine (Cell saver 5, Haemonetics Corp., Braintree, MA) was also used to retrieve RBC's that were lost throughout the course of the operation. Saline (0.9% NaCl) was used to irrigate all the sponges with blood in the surgical field and then suctioned to the cell saver for further washing. Autologous RBC's both obtained during initial blood withdrawal and obtained via the autotransfusion device during the operation were reinfused as necessary. After reversal of heparin, the autologous PPP and PRP were reinfused back to the patients as were any remaining autologous RBC's.</LI>
<LI>Aprotinin group (High dose) received a loading dose of 2 million KIU before CPB and 2 million KIU added to the pump prime and a continuous infusion of 1 million KIU/hr administered until skin closure or until a total dose of 5 million KIU was achieved.</LI>
<LI>Combined group (PRP + ANH +CS + Aprotinin) received treatment combining interventions of Group 2 and Group 3.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-16 07:20:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), number of patients receiving fresh frozen plasma, number of patients receiving platelets, blood loss.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:22:28 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-16 07:25:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-1993">
<CHAR_METHODS MODIFIED="2010-08-16 07:25:01 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation sequences were generated by a computer generated random list. The trial drug and placebo were supplied in identical packs. Exclusions or loss to follow-up were reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-16 07:23:08 +0100" MODIFIED_BY="[Empty name]">
<P>40 patients undergoing elective myocardial revascularisation were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 20, M/F = 13/7, mean (sd) age = 64.7 (2.0) years</LI>
<LI>Control group (Placebo): n = 20, M/F = 17/3, mean (sd) age = 66.7 (1.3) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-16 07:23:20 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a loading dose of 1 million KIU of aprotinin intravenously after the induction of anaesthesia, 1 million KIU in the priming volume of the heart-lung machine and 250,000 KIU/hr after the loading dose to the end of skin closure, or up to 1 million KIU of aprotinin if the operation exceeded 4 hours in duration.</LI>
<LI>Control group received a corresponding volume of placebo (substance used was not specified).</LI>
</UL>
<P>NB: Both groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-16 07:24:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma, blood loss, total post-operative autotransfusion from the chest drainage, mortality, re-operation for bleeding, allergic reaction, hospital length of stay (days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:22:34 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol not specified<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-16 07:28:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-1998">
<CHAR_METHODS MODIFIED="2010-08-16 07:25:52 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-16 07:28:27 +0100" MODIFIED_BY="[Empty name]">
<P>60 patients undergoing open heart surgery were randomly assigned to one of three groups:</P>
<UL>
<LI>Epsilon aminocaproic group: n = 20, mean (sd) age = 65 (9) years</LI>
<LI>Epsilon aminocaproic + platelet-rich plasmapheresis group: n = 20, mean (sd) age = 67 (12) years</LI>
<LI>Control group: n = 20, mean (sd) age = 64 (11) years</LI>
</UL>
<P>NB: Gender data were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-16 07:27:30 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Epsilon aminocaproic acid group received 150mg/kg before CPB.</LI>
<LI>Epsilon aminocaproic + platelet-rich plasmapheresis group received 150mg/kg of EACA before CPB and platelet-rich plasma (PRP) at 10ml/kg salvaged from each patient with a plasma saver before CPB which was then reinfused. PRP was reinfused at the end of CPB after protamine administration.</LI>
<LI>Control group received standard care.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-16 07:28:02 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Allogeneic blood usage (units), fresh frozen plasma usage (units), platelets usage (units), blood loss.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:22:41 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 0/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-16 07:31:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Llau-1998">
<CHAR_METHODS MODIFIED="2010-08-16 07:29:19 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described. [Abstract]</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-16 07:29:53 +0100" MODIFIED_BY="[Empty name]">
<P>20 patients undergoing elective orthopaedic surgery were randomly allocated to one of two groups:</P>
<UL>
<LI>Aprotinin group (Low dose): n = 10, mean (sd) age = 68 (8) years</LI>
<LI>Control group (Placebo): n = 10, mean (sd) age = 67 (7) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-16 07:30:04 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (Low dose) received 2 million KIU of aprotinin 30 minutes immediately after the induction of anaesthesia.</LI>
<LI>Control group received normal saline in the same volume and time as aprotinin, immediately after the induction of anaesthesia.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-16 07:30:53 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, deep vein thrombosis, change in haematocrit levels - baseline to 24 hrs post-operative, change in haemoglobin levels - baseline to 24 hrs post-operative.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-16 07:31:29 +0100" MODIFIED_BY="[Empty name]">
<P>Transfusion protocol used.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-17 01:50:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Locatelli-1990">
<CHAR_METHODS MODIFIED="2010-08-17 01:49:01 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described. [Italian language]</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-17 01:49:57 +0100" MODIFIED_BY="[Empty name]">
<P>38 patients undergoing myocardial revascularisation were randomly allocated to one of three groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 12</LI>
<LI>Aprotinin group (Low dose): n = 13</LI>
<LI>Control group: n = 13</LI>
</UL>
<P>NB: Demographic data were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 01:50:11 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received a loading dose of 2 million KIU of aprotinin previous to median sternotomy, followed by a continuous infusion of 500,000 KIU/hr until the end of the operation. An additional 2 million KIU of aprotinin was added to the pump prime.</LI>
<LI>Aprotinin group (Low dose) received a continuous infusion of 500,000 KIU/hr of aprotinin until the end of the operation.</LI>
<LI>Control group did not receive aprotinin.</LI>
</UL>
<P>NB: All groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-17 01:50:52 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss (28 hrs), adverse reactions.</P>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:22:51 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-17 01:59:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Luo-1998">
<CHAR_METHODS MODIFIED="2010-08-17 01:52:07 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-17 01:52:45 +0100" MODIFIED_BY="[Empty name]">
<P>20 patients undergoing cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotonin group: n = 10, M/F = 7/3, mean (sd) age = 36.9 (15.97) years</LI>
<LI>Control group: n = 10, M/F = 7/3, mean (sd) age = 42.8 (13.31) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 01:54:10 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 3 million KIU of aprotinin.</LI>
<LI>Control group did not receive aprotinin. no intervention.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-17 01:59:23 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>volume of blood transfused, duration of CPB.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-17 01:59:56 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7</P>
<P>Transfusion protocol not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-17 02:27:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maccario-1994">
<CHAR_METHODS MODIFIED="2010-08-17 02:25:16 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described. [Italian language]</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-17 02:26:18 +0100" MODIFIED_BY="[Empty name]">
<P>99 patients undergoing coronary artery bypass graft surgery and valvular cardiac surgery were randomised to one of three groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 33, mean (sd) age = 64.0 (8.51) years</LI>
<LI>Aprotinin group (Low dose): n = 33, mean (sd) age = 63.5 (8.37) years</LI>
<LI>Control group: n = 33, mean (sd) age = 62.9 (9.7) years</LI>
</UL>
<P>NB: Gender data were not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 02:26:34 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received a loading dose of 2 million KIU of aprotinin intravenously (IV) over a period of 30 minutes, followed by 500,000 KIU/hr until the termination of the operation. An additional 2 million KIU was added to pump prime.</LI>
<LI>Aprotinin group (Low dose) received 2 million KIU added to the pump prime.</LI>
<LI>Control group did not receive aprotinin.</LI>
</UL>
<P>NB: All groups were exposed to acute normovolemic haemodilution and cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-17 02:27:32 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss (24hrs), allergic reactions.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-17 02:27:40 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used.<BR/>Four patients were excluded from the study due to surgical bleeding (one from the control group, one from the high-dose aprotinin group, and two from the low-dose aprotinin group). One patient from the low-dose aprotinin group died and was excluded from analysis.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-17 05:29:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-MacGillivray-2010">
<CHAR_METHODS MODIFIED="2010-08-17 05:22:43 +0100" MODIFIED_BY="[Empty name]">
<P>Tranexamic acid or placebo for infusion was prepared by the institution's pharmacy in two identical 50mL bags (identified only by random number) with the constituents unknown to the administering anesthesiologist or surgeon. Method of randomisation was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-17 02:30:33 +0100" MODIFIED_BY="[Empty name]">
<P>60 patients undergoing orthopaedic (knee) surgery were randomised to one of three groups:</P>
<UL>
<LI>Tranexamic acid group #1: n = 20, M/F = 7/13, mean (sd) age = 62 (4.3) years</LI>
<LI>Tranexamic acid group #2: n = 20, M/F = 8/12, mean (sd) age = 65 (4.3) years</LI>
<LI>Control group: n = 20, M/F = 5/15, mean (sd) age = 66 (7.3) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 05:28:09 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group #1 received two doses of 10mg/kg. Patients received the first infusion over 10 minutes before deflation of the first tourniquet and the second (over 10 minutes) 3 hours after the first.</LI>
<LI>Tranexamic acid group #2 received two doses of 15mg/kg. Patients received the first infusion over 10 minutes before deflation of the first tourniquet and the second (over 10 minutes) 3 hours after the first.</LI>
<LI>Control group received normal saline. Patients received the first infusion of saline over 10 minutes before deflation of the first tourniquet and the second (over 10 minutes) 3 hours after the first.</LI>
</UL>
<P>NB: Patients received re-infusion of autotransfused blood from the intra-articular drains.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-17 05:29:13 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>number of patients exposed to allogeneic blood transfusion, blood loss, number of allogeneic units transfused, adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-17 05:24:49 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-17 05:43:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maddali-2007">
<CHAR_METHODS MODIFIED="2010-05-07 11:49:34 +0100" MODIFIED_BY="Katharine Ker">
<P>A computer-generated randomisation code was used to allocate participants. Allocation was concealed by using sequentially-numbered, sealed opaque envelopes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-17 05:41:51 +0100" MODIFIED_BY="[Empty name]">
<P>222 patients undergoing cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 111, M/F = 80/31, mean (sd) age = 57.1 (8.9) years</LI>
<LI>Control group: n = 111, M/F = 72/38, mean (sd) age = 58.2 (8.3) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 05:42:11 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received loading dose of 10mg/kg before incision, then a continuous infusion of 1mg/kg/hr until end of CPB.</LI>
<LI>Control group received saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-17 05:43:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Volume blood transfused, blood loss, mortality, stroke, re-operation for bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-17 05:43:37 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7</P>
<P>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-17 05:52:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maineri-2000">
<CHAR_METHODS MODIFIED="2010-08-17 05:50:15 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-17 05:50:50 +0100" MODIFIED_BY="[Empty name]">
<P>48 patients undergoing elective cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Epsilon aminocaproic acid group: n = 24, mean (sd) age = 59.9 (10) years</LI>
<LI>Tranexamic acid group (n = 24), mean (sd) age = 64.2 (9) years</LI>
</UL>
<P>NB: Gender data were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 05:50:58 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Epsilon aminocaproic acid group received 10g of EACA as a standard dose in 30 minutes following the induction of anaesthesia, and a maintenance infusion of 2g/hr was given throughout the operation.</LI>
<LI>Tranexamic acid group received a loading dose of 20mg/kg of TXA given in 60 minutes, followed by a maintenance infusion of 2mg/kg/hr.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-17 05:52:13 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, pulmonary embolus, post -operative Hct, stroke.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:23:27 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 0/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-17 06:23:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mansour-2004">
<CHAR_METHODS>
<P>Randomisation of patients was performed with the help of a computer -generated random number sequence programme. To ensure proper blinding the three studied solutions were prepared by the pharmacy as bottles.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-17 06:21:41 +0100" MODIFIED_BY="[Empty name]">
<P>60 patients undergoing elective cardiac surgery (off pump CABG) were randomly assigned to one of three groups:</P>
<UL>
<LI>Aprotinin group: n = 20, M/F = 1/5, mean (sd) age = 56.4 (9.1) years</LI>
<LI>Tranexamic acid group: n = 20, M/F = 17/3, mean (sd) age = 57.5 (8.4) years</LI>
<LI>Control group (Placebo): n = 20, M/F = 19/1, mean (sd) age = 57.7 (8.4) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 06:22:09 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 2 million KIU of aprotinin after skin incision, followed by a continuous infusion of 3 million KIU throughout surgery at a rate of 500,000 KIU/hr.</LI>
<LI>Tranexamic acid group received 1.5g of TXA (15mg/kg) after skin incision followed by a continuous infusion of 1g throughout surgery at a rate of 2mg/kg/hr.</LI>
<LI>Control group received normal saline at the same time and volumes as aprotinin and TXA.</LI>
</UL>
<P>NB: Loading dose was administered over 20 minutes in all groups. Infusion dose was infused at a rate of 50ml/hr in all groups.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-17 06:23:52 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage (units), blood loss (24hrs), myocardial infarction, number of patients exposed to fresh frozen plasma, number of patients exposed to platelets, re-operation for bleeding, renal dysfunction, hospital length of stay (days), renal dysfunction, neurological deficit.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:23:33 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 7/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-17 06:26:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marcel-1996">
<CHAR_METHODS MODIFIED="2010-08-17 06:25:28 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomised by a computer program. Method of allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-17 06:25:55 +0100" MODIFIED_BY="[Empty name]">
<P>44 consecutive patients undergoing orthotopic liver transplantation were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 21</LI>
<LI>Control group (Placebo): n = 23</LI>
</UL>
<P>NB: Demographic data were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 06:26:06 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 200,000 KIU per hour via an intravenous infusion which was started immediately after the induction of anaesthesia.</LI>
<LI>Control group received normal saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-17 06:26:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage (units), blood loss (24hrs).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:23:40 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-17 06:30:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mehr_x002d_Aein-2007">
<CHAR_METHODS MODIFIED="2010-08-17 06:27:32 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation was not reported. Concealment of allocation was achieved by using pharmacy prepared coded infusion syringes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-17 06:28:42 +0100" MODIFIED_BY="[Empty name]">
<P>66 patients undergoing cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 33, mean (sd) age = 44 (10) years</LI>
<LI>Control group: n = 33, mean (sd) age = 45 (10) years</LI>
</UL>
<P>NDB: Gender data were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 06:28:59 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received loading dose of 15mg/kg at beginning of surgery, same dose before infusion of heparin at end of surgery, and again after protamine infusion.</LI>
<LI>Control group received saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-17 06:30:20 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patient exposed to allogeneic blood transfusion, volume of blood transfused (units), blood loss, re-operation for bleeding, mortality, myocardial infarction, renal failure, length of hospital stay (days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-17 06:30:41 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7</P>
<P>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-17 06:48:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mengistu-2008">
<CHAR_METHODS MODIFIED="2010-08-17 06:32:40 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-17 06:33:13 +0100" MODIFIED_BY="[Empty name]">
<P>50 patients undergoing cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 25, M/F = 20/5, mean (sd) age = 69 (9) years</LI>
<LI>Tranexamic acid group: n = 25, M/F = 18/7, mean (sd) age = 70 (9) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 06:48:59 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 2 million KIU pre-CPB, 2 million KIU at pump prime, and 500,000 KIU/hr until arrival at ICU.</LI>
<LI>Tranexamic group received 2g administered after induction of anaesthesia and 6mg/kg/hr given continuously until arrival at ICU, and 1g added to CBP system prime.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-17 06:47:07 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> number of patients exposed to allogeneic blood transfusion, volume of allogeneic blood transfused, blood loss.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-17 06:47:23 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 3/7</P>
<P>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-17 06:54:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Menichetti-1996">
<CHAR_METHODS MODIFIED="2010-08-17 06:51:16 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-17 06:52:35 +0100" MODIFIED_BY="[Empty name]">
<P>96 consecutive patients undergoing coronary artery bypass surgery were randomised to one of four groups:</P>
<UL>
<LI>Aprotinin group: n = 24, M/F = 12/12, mean (sd) age = 60.4 (5.1) years</LI>
<LI>Epsilon aminocaproic acid group: n = 24, M/F = 14/10, mean (sd) age = 56.6 (6.7) years</LI>
<LI>Tranexamic acid group: n = 24, M/F = 12/12, mean (sd) age = 55.2 (8.6) years</LI>
<LI>Control group: n = 24, M/F = 13/11, mean (sd) age = 61.0 (9.7) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 06:52:59 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a loading dose of 2 million KIU of aprotinin followed by a continuous infusion of 500,000 KIU/hr. An additional 2 million KIU of aprotinin was added to the CPB prime solution.</LI>
<LI>Epsilon aminocaproic acid group received 80mg bolus of EACA intravenously and after 30 minutes a continuous infusion of 30 mg/kg of EACA. An additional 80mg/kg of EACA was added to the CPB prime solution.</LI>
<LI>Tranexamic acid group received a 10mg/kg bolus of TXA followed by a continuous infusion of 3mg/kg/hr. An additional 10mg/kg of TXA was added to the CPB prime solution.</LI>
<LI>Control group received usual care.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-17 06:54:16 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, blood loss (24hrs), re-operation for bleeding, haemoglobin levels, activated clotting times (ACT),<BR/>prothrombin times, activated partial thromboplastin times (APTT), plasminogen levels, factor VIII levels, TAT complex/values.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:23:53 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-17 06:58:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Misfeld-1998">
<CHAR_METHODS MODIFIED="2010-08-17 06:56:15 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-17 06:57:05 +0100" MODIFIED_BY="[Empty name]">
<P>42 patients undergoing elective cardiac surgery were randomised to one of three groups:</P>
<UL>
<LI>Aprotinin group: n = 14, M/F = 14/0, mean (sd) age = 63 (6) years</LI>
<LI>Tranexamic acid group: n = 14, M/F = 14/0, mean (sd) age = 56 (7) years</LI>
<LI>Control group: n = 14, M/F = 11/3, mean (sd) age = 59 (10) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 06:57:24 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a test dose of 30,000 KIU at anesthesia induction and 1 million KIU of aprotinin was added to the pump prime. After protamine administration further aprotinin was administered in a dose of 200,000 KIU/hr for another 5 hours.</LI>
<LI>Tranexamic acid group received 10mg/kg as a bolus after heparinization followed by a continuous intravenous infusion of 1mg/kg/hr over 10 hours.</LI>
<LI>Control treatment was not specified.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-17 06:58:11 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss (6 hrs), mortality, change in haemoglobin levels - baseline to 24 hrs post-operative.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:24:01 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 1/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-17 07:02:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mohr-1992">
<CHAR_METHODS MODIFIED="2010-08-17 07:00:00 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described. No loss to follow-up reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-17 07:01:11 +0100" MODIFIED_BY="[Empty name]">
<P>50 patients undergoing primary coronary artery bypass graft surgery (CABG), repeat CABG, valve replacement, or valve replacement + CABG surgery were randomised to one of three groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 17, M/F = 14/3, mean (sd) age = 58 (10) years</LI>
<LI>Aprotinin group (Low dose): n = 17, M/F = 14/3, mean (sd) age = 62 (10) years</LI>
<LI>Control group (Placebo): n = 16, M/F = 11/5, mean (sd) age = 63 (11) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 07:01:29 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received a loading dose of 2 million KIU of aprotinin for 20 minutes before sternotomy. An additional 2 million KIU of aprotinin was added to the priming volume of the bubble oxygenator, and a continuous infusion of 500,000 KIU/hr was given after the loading dose throughout surgery until skin closure or a total of 6 million KIU of aprotinin was achieved.</LI>
<LI>Aprotinin group (Low dose) received placebo (saline 0.9%) as a loading dose, 2 million KIU of aprotinin in the pump prime, and placebo in the continuous infusion phase.</LI>
<LI>Control group received equal volumes of placebo solution (0.9% saline) at the respective times.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-17 07:02:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss (24hrs), re-operation for bleeding, post-operative platelet counts, platelet aggregation evaluation by scanning electron microscopy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:24:10 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-17 07:06:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mongan-1998">
<CHAR_METHODS MODIFIED="2010-08-17 07:04:39 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomised using a computer-generated random sequence. Method used to conceal treatment allocation was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-17 07:05:09 +0100" MODIFIED_BY="[Empty name]">
<P>150 patients undergoing primary coronary artery bypass graft surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 75, M/F = 61/14, mean (sd) age = 62 (10) years</LI>
<LI>Tranexamic acid (n = 75), M/F = 59/16, mean (sd) age = 61 (11) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 07:05:22 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received a loading dose of 2 million KIU (280mg in 200ml) administered before skin incision and a continuous infusion of 500,000 KIU/hr (3 million KIU in 300ml) limited to the subsequent 6 hours. An additional 2 million KIU (280mg in 200ml) was added to the pump prime.</LI>
<LI>Tranexamic acid group received a loading dose of 1g (15mg/kg) administered before skin incision and a continuous infusion of 1g infused at 50ml/hr (2mg/kg/hr in 300ml) limited to the subsequent 6 hours. Normal saline solution (300ml) was added to the pump prime.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-17 07:06:12 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), mortality, myocardial infarction, re-operation for bleeding, stroke.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:24:16 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-17 07:10:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moran-2000">
<CHAR_METHODS MODIFIED="2010-08-17 07:08:06 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomly assigned by a computer-generated code. Method used to conceal treatment allocation was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-17 07:08:51 +0100" MODIFIED_BY="[Empty name]">
<P>42 patients undergoing coronary artery bypass surgery were randomised to one of three groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 12, M/F = 11/1, mean (sd) age = 58.0 (8.4) years</LI>
<LI>Aprotinin group (Low dose): n = 12, M/F = 12/4, mean (sd) age = 59.6 (10.7) years</LI>
<LI>Control group (placebo) (n = 14), M/F = 11/3, mean (sd) age = 59.7 (8.6) years</LI>
</UL>
<P>NB: Four patients were excluded from the final efficacy analysis. All 42 patients were included in the safety analysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 07:09:19 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received a total dose of 6 million KIU (840mg) of aprotinin. Prior to anaesthesia 2 million KIU (280mg) of aprotinin was administered and another 2 million KIU (280mg) was added to the pump prime. An additional 2 million KIU (280mg) was administered after the completion of CPB.</LI>
<LI>Aprotinin group (Low dose) received a total dose of 4 million KIU (560mg) of aprotinin. Prior to anaesthesia 2 million KIU (280mg) of aprotinin was administered and another 2 million KIU (280mg) was added to the pump prime.</LI>
<LI>Control group received 600ml of normal saline solution.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-17 07:10:12 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, blood loss (24hrs), mortality, myocardial infarction, re-operation for bleeding, stroke.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:24:23 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-17 07:14:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Murkin-1994">
<CHAR_METHODS MODIFIED="2010-08-17 07:11:39 +0100" MODIFIED_BY="[Empty name]">
<P>Method of allocation concealment was not described. Randomisation was by means of computer-generated random code.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-17 07:12:50 +0100" MODIFIED_BY="[Empty name]">
<P>54 patients undergoing first-time coronary artery bypass or valvular heart operations requiring cardiopulmonary bypass (CPB) were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 29, M/F = 22/7, mean (sd) age = 62 (9.7) years</LI>
<LI>Control group (Placebo): n = 25, M/F = 16/9, mean (sd) age = 65.8 (7.5) years</LI>
</UL>
<P>NB: Three of the 57 enrolled patients were deemed ineligible because of cancellation of the operation (n = 2) and non-use of CPB (n = 1). All 54 remaining patients were included for analysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 07:13:12 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 2 million KIU of aprotinin (200ml) as a loading dose including an initial 5 ml dose given after establishment of full monitoring and anaesthesia, 2 million KIU of aprotinin was added to the CPB pump prime, and a continuous infusion of 500,000 KIU/hr of aprotinin was given throughout the operation and for 1 hour after the patient had returned to the intensive care unit (ICU). The maximum dose of aprotinin was 7 million KIU.</LI>
<LI>Control group received equal volumes of placebo (substance not specified).</LI>
</UL>
<P>NB: Both groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-17 07:14:22 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage (units), blood loss (36hrs), myocardial infarction, pulmonary embolic events, hospital length of stay (days).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:24:30 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-17 07:17:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Murkin-1995">
<CHAR_METHODS MODIFIED="2010-08-17 07:15:58 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation was by means of computer generated codes. Method of allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-17 07:16:35 +0100" MODIFIED_BY="[Empty name]">
<P>53 consecutive patients undergoing revision total hip arthroplasty or primary bilateral total hip arthroplasty were randomly assigned to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 29, M/F = 9/20, mean (sd) age = 66.9 (15) years</LI>
<LI>Control group (Placebo): n = 24, M/F = 11/13, mean (sd) age = 65.5 (16.6) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 07:16:47 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 2 million KIU (200ml) of aprotinin over 15 minutes followed by an infusion of 500,000 KIU (50ml) per hour. Those patients weighing less than 60kg and more than 80kg received a loading dose of 2.8ml/kg (10,000 KIU/ml) and an infusion of 0.7ml/kg/hr.</LI>
<LI>Control group received an equivalent volume of 0.9% saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-17 07:17:39 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, cerebrovascular accident, deep vein thrombosis,<BR/>hospital length of stay (days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:24:37 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-17 07:20:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Murkin-2000">
<CHAR_METHODS>
<P>Labels on all medication vials were the same except for the patient executive number. Patients were stratified on the basis of whether or not pre-operative autologous blood donations had been made. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-17 07:19:14 +0100" MODIFIED_BY="[Empty name]">
<P>301 undergoing elective primary unilateral total hip replacement were randomised to one of four groups:</P>
<UL>
<LI>Aprotinin group (Low dose): n = 69, M/F = 34/35, mean age = 63.7 years</LI>
<LI>Aprotinin group (Medium dose): n = 68, M/F = 27/41, mean age = 65.5 years</LI>
<LI>Aprotinin group (High dose): n = 75, M/F = 46/29, mean age = 63.4 years</LI>
<LI>Control group (Placebo): n = 68, M/F = 32/36, mean age = 63.2 years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 07:19:40 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (Low dose) received a loading dose of 500,000 KIU (70mg) of aprotinin.</LI>
<LI>Aprotinin group (Medium dose) received a loading dose of 1 million KIU (140mg) of aprotinin and a continuous infusion of 250,000 KIU/hr.</LI>
<LI>Aprotinin group (High dose) received a loading dose of 2 million KIU (280mg) of aprotinin and a continuous infusion of 500,000 KIU/hr.</LI>
<LI>Control group received an unspecified placebo.</LI>
</UL>
<P>NB: Epsilon aminocaproic acid and desmopressin were used if deemed necessary. Data regarding the use of these two drugs to minimise blood loss were not reported. All groups used pre-operative autologous donation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-17 07:20:45 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, blood loss, myocardial infarction, mortality, deep venous thrombosis, pre-operative autologous blood donation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:24:44 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-17 07:27:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Murphy-2006">
<CHAR_METHODS MODIFIED="2010-01-11 15:13:38 +0000" MODIFIED_BY="Katharine Ker">
<P>Allocation was generated by a card system and concealed in sealed, opaque envelopes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-17 07:23:34 +0100" MODIFIED_BY="[Empty name]">
<P>100 off-pump coronary artery bypass grafting surgical patients were randomly allocated to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 50, M/F = 42/8, mean (sd) age = 64.9 (7.0) years</LI>
<LI>Control group (Placebo): n = 50, M/F = 37/13, mean (sd) age = 65.8 (8.7) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 07:25:49 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 2g as an intravenous bolus before sternotomy.</LI>
<LI>Control group received a bolus of normal saline.</LI>
</UL>
<P>NB: All patients underwent peri-operative cell salvage with autotransfusion of washed salvaged red blood cells at the completion of the operative procedure.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-17 07:27:19 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>number of patients exposed to allogeneic blood transfusion, blood loss, mortality, stroke, renal dysfunction, myocardial infarction, length of stay.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-17 07:27:38 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7</P>
<P>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-17 07:29:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Niskanen-2005">
<CHAR_METHODS>
<P>Patients were randomised into two groups by an envelope method in a double-blind manner. The randomisation and preparation of the drug were done in the absence of other personnel by two anaesthesia nurses not engaged in the study. The code was broken after the last patient had been treated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-17 07:28:52 +0100" MODIFIED_BY="[Empty name]">
<P>40 patients undergoing cemented hip arthroplasty were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 19, M/F = 6/13, mean (sd) age = 66 (9.1) years</LI>
<LI>Control group (Placebo): n = 20, M/F = 7/13, mean (sd) age = 65 (8.2) years</LI>
</UL>
<P>NB: One patient was excluded from the final analysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-17 07:29:05 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 10mg/kg of intravenous TXA over 5-10 minutes, immediately before the operation. The next two doses were given 8 hours and 16 hours after the first injection.</LI>
<LI>Control group received corresponding doses of saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-17 07:29:39 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), deep vein thrombosis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:24:58 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 03:43:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Norman-2009">
<CHAR_METHODS MODIFIED="2010-05-07 14:36:36 +0100" MODIFIED_BY="Katharine Ker">
<P>Patients were allocated according to a randomisation schedule based on study accession number. Pharmacy controlled allocation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 03:42:07 +0100" MODIFIED_BY="[Empty name]">
<P>20 undergoing extrapleural pneumonectomy for mesothelioma were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 11, M/F = 0/9, mean (sd) age = 63.5 (6.2) years</LI>
<LI>Control group (Placebo): n = 9, M/F = 8/3, mean (sd) age = 62 (7.6) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 03:42:20 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received a loading dose of 2 million KIU infused over 1 hour, followed by maintenance infusion of 500,000 KIU/hr until ICU admission.</LI>
<LI>Control group received a saline placebo.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 03:43:11 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood transfusion, blood loss, mortality.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-18 03:43:14 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 7/7</P>
<P>Use of transfusion protocol not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 03:51:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nur_x00f6_zler-2008">
<CHAR_METHODS MODIFIED="2010-08-18 03:45:35 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were allocated according to a list of random treatment codes. Method used to conceal treatment allocation was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 03:46:23 +0100" MODIFIED_BY="[Empty name]">
<P>51 undergoing cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 25, M/F = 19/6, mean (sd) age = 63.1 (8.8) years</LI>
<LI>Control group (Placebo): n = 26, M/F = 18/8, mean (sd) age = 64.6 (6.7) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 03:46:33 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (low dose) received bolus 1 million KIU infused over 30 minutes, then continuous infusion of 500,000 KIU/hr until end of surgery.</LI>
<LI>Control group received a saline placebo.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 03:47:35 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood transfusion, volume blood transfused (units), blood loss, re-operation for bleeding, myocardial infarction, stroke, length of hospital stay (days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-18 03:51:32 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 3/7</P>
<P>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 03:56:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nuttall-2000">
<CHAR_METHODS MODIFIED="2010-08-18 03:53:52 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomly assigned by a computer-generated random number sequence. Method used to conceal treatment allocation was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 03:55:25 +0100" MODIFIED_BY="[Empty name]">
<P>168 patients undergoing cardiac surgery were randomised to one of four groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 40, M/F = 28/12, median (range) age = 70.5 (45-86) years</LI>
<LI>Tranexamic acid group: n = 45, M/F = 31/14, median (range) age = 71 (43-83) years</LI>
<LI>Tranexamic acid + acute normovolaemic haemodilution (ANH) group: n = 32, M/F = 28/4, median (range) age = 67.5 (42-91) years</LI>
<LI>Control group (Placebo): n = 43, M/F = 35/8, median (range) age = 63 (29-83) years</LI>
</UL>
<P>NB: Eight patients were excluded from the final analysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 03:55:52 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received a test dose of 1.4mg (1ml) followed by a loading dose of 280mg of aprotinin over 20-30 minutes. In addition, patients received a continuous infusion of 70mg/hr (50ml/hr) of aprotinin and 280mg (200ml) was added to the pump prime.</LI>
<LI>Tranexamic acid group received a loading dose of 10mg/kg and a continuous infusion of 1mg/kg/hr commenced after central venous cannulation and continued for 2 hours into treatment in intensive care.</LI>
<LI>Tranexamic acid + ANH group received a loading dose of 10mg/kg and a continuous infusion of 1mg/kg/hr commenced after central venous cannulation and continued for 2 hours into treatment in intensive care. In addition, patients received intra-operative autologous blood (12.5% of whole blood volume withdrawn before CPB and within 10 mins after central venous cannulation).</LI>
<LI>Control group received a normal saline infusion.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 03:56:29 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), mortality, re-operation for bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:25:27 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 03:59:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Okita-1996">
<CHAR_METHODS MODIFIED="2010-08-18 03:57:40 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 03:58:13 +0100" MODIFIED_BY="[Empty name]">
<P>60 patients undergoing aortic surgery under deep hypothermic circulatory arrest were randomly allocated to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 39, M/F = 26/13, mean (sd) age = 63.5 (8.9) years</LI>
<LI>Control group: n = 21, M/F = 16/5, mean (sd) age = 67.9 (9.4) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 03:58:24 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 2 million KIU of aprotinin administered in the pump prime only.</LI>
<LI>Control group did not receive aprotinin.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 03:59:26 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage, blood loss (24 hrs), mortality, myocardial infarction, stroke, renal failure,<BR/>respiratory failure + pneumonia.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:25:34 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 04:02:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Orpen-2006">
<CHAR_METHODS>
<P>A pharmacist not involved with the study carried out randomisation in the pharmacy by a sealed envelope method and prepared the contents of the administered solution. The operating team was blinded to the contents of the administered solution for every patient although allowance was made for the code to be broken should an adverse drug reaction occur.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 04:02:00 +0100" MODIFIED_BY="[Empty name]">
<P>30 patients undergoing total knee arthroplasty were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 15, M/F = 8/7, mean (95%CI) age = 73 (70-78) years</LI>
<LI>Control group: n = 14, M/F = 3/11, mean (95%CI) age = 69 (63-74) years</LI>
</UL>
<P>NB: One patient was excluded from the final analysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 04:01:50 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 15mg/kg of TXA intravenously at the time that cement mixing commenced.</LI>
<LI>Control group received an equivalent volume of normal saline given intravenously at the time that cement mixing commenced.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 04:02:40 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, blood loss, deep vein thrombosis, change in haemoglobin levels.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:25:45 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 04:07:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Palmer-2003">
<CHAR_METHODS>
<P>A computer generated randomisation schedule was used to randomly assign patients into the treatment groups. The vials used for each group were only identifiable by the patient study number.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 04:06:37 +0100" MODIFIED_BY="[Empty name]">
<P>95 patients undergoing elective neurological surgery were divided into two subsets:</P>
<P>Meningioma subset: n = 56</P>
<UL>
<LI>Aprotinin group: n = 30, M/F = 7/23, mean (sd) age = 58.4 (13.0) years</LI>
<LI>Control group (Placebo): n = 26, M/F = 9/17, mean (sd) age = 58.5 (2.8) years</LI>
</UL>
<P>Vestibular Schwannoma subset: n = 39</P>
<UL>
<LI>Aprotinin group: n = 17, M/F =11/6, mean (sd) age = 48.6 (10.9) years</LI>
<LI>Control group (Placebo): n = 17, M/F = 11/16, mean (sd) age = 54.1 (12.0) years</LI>
</UL>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 04:06:52 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (Low dose) received a loading dose of 30,000 KIU/kg of aprotinin infused over 15-20 minutes administered before the start of surgery and followed by a continuous infusion of 10,000 KIU/kg/hr until the patient was transferred to the Intensive Care Unit.</LI>
<LI>Control group received 0.9% sodium chloride solution.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 04:07:39 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, mortality (7-day &amp; 30-day).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:25:51 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 04:12:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Parvizi-2007">
<CHAR_METHODS MODIFIED="2010-05-07 15:28:53 +0100" MODIFIED_BY="Katharine Ker">
<P>Patients were allocated according to a computer-generated randomisation list. Adequacy of allocation concealment was unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 04:10:56 +0100" MODIFIED_BY="[Empty name]">
<P>162 undergoing cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 81), M/F = 49/32, mean (sd) age = 52.6 (13.8) years</LI>
<LI>Control group (Placebo): n = 81, M/F = 49/32, mean (sd) age = 54.1 (11.4) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 04:11:06 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 500,000 KIU infused before and 500,000 KIU during CPB.</LI>
<LI>Control group received a saline placebo.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 04:11:56 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood transfusion, volume of blood transfused, blood loss, myocardial infarction, re-operation for bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-18 04:12:29 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7</P>
<P>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 04:15:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Penta-de-Peppo-1995">
<CHAR_METHODS MODIFIED="2010-08-18 04:13:43 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 04:14:53 +0100" MODIFIED_BY="[Empty name]">
<P>60 consecutive patients undergoing elective open-heart surgery were randomised to one of four groups:</P>
<UL>
<LI>Control group: n = 15, M/F = 13/2, mean (sd) age = 63 (7) years</LI>
<LI>Epsilon aminocaproic acid group: n = 15, M/F = 13/2, mean (sd) age = 62 (7) years</LI>
<LI>Tranexamic acid group: n = 15, M/F = 12/3, mean (sd) age = 60 (12) years</LI>
<LI>Aprotinin group (High dose): n = 15, M/F = 12/3, mean (sd) age = 64 (10) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 04:15:13 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Control group received no antifibrinolytic treatment.</LI>
<LI>Epsilon aminocaproic acid group received 10g of EACA intravenously (IV) at the induction of anaesthesia followed by an infusion of 2g/hr for 5 hours.</LI>
<LI>Tranexamic acid group received 10mg/kg of TXA IV within 30 minutes after the induction of anaesthesia, followed by an infusion of 1mg/kg per hour for 10 hours.</LI>
<LI>Aprotinin group (High dose) received 2 million KIU of aprotinin IV at the induction of anaesthesia followed by an infusion of 500,000 KIU/hr during surgery and 2 million KIU of aprotinin added to the extracorporeal circuit.</LI>
</UL>
<P>NB: All groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 04:15:48 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, re-operation for bleeding,</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:26:05 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 04:18:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Petsatodis-2006">
<CHAR_METHODS MODIFIED="2010-08-18 04:17:16 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomised using an envelope technique. Method of allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 04:17:53 +0100" MODIFIED_BY="[Empty name]">
<P>50 patients undergoing total hip arthroplasty were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 25, mean (sd) age = 58.4 (12.5) years</LI>
<LI>Control group (Placebo): n = 25, mean (sd) age = 59.6 (10.9) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 04:18:04 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a bolus of 20,000 KIU/kg of aprotinin at the time of anaesthesia followed by an infusion of 50,000 KIU/hr.</LI>
<LI>Control group received normal saline in the same volumes.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 04:18:39 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, deep vein thrombosis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:26:12 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol not used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 04:22:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pinosky-1997">
<CHAR_METHODS MODIFIED="2010-08-18 04:20:03 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 04:20:57 +0100" MODIFIED_BY="[Empty name]">
<P>59 patients undergoing cardiac surgery were randomly assigned to one of three groups:</P>
<UL>
<LI>Epsilon aminocaproic acid group: n = 20, M/F = 12/8, mean (sd) age = 62.6 (9.4) years</LI>
<LI>Tranexamic acid group: n = 20, M/F = 12/18, mean (sd) age = 62.6 (9.4) years</LI>
<LI>Control group (Placebo): n = 19, M/F = 15/4, mean (sd) age = 60.6 (10.9) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 04:21:13 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Epsilon aminocaproic acid group received an intravenous loading dose of 150mg/kg and a continuous infusion of 10mg/kg/hr for 6 hours. EACA was given immediately following the induction of anaesthesia.</LI>
<LI>Tranexamic acid group received a loading dose of 15mg/kg followed by a continuous infusion of 1mg/kg/hr for 6 hours. TXA was given immediately following the induction of anaesthesia.</LI>
<LI>Control group received a bolus of normal saline and a continuous infusion of normal saline for 6 hours.</LI>
</UL>
<P>NB: Both groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 04:22:01 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, blood loss, aspirin use, number of patients exposed to platelets and fresh frozen plasma.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:26:18 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 04:25:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pleym-2003">
<CHAR_METHODS>
<P>Randomisation was by mean of a computer programme. Study medications were delivered in identical 50mL syringes. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 04:23:46 +0100" MODIFIED_BY="[Empty name]">
<P>79 patients undergoing elective cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 40, M/F = 34/6, mean (sd) age = 63.6 (9.9) years</LI>
<LI>Control group (Placebo): n = 39, M/F = 32/7, mean (sd) age = 62 (9.2) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 04:24:00 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 30mg/kg of TXA as a bolus injection given over 5 minutes immediately before the start of CPB.</LI>
<LI>Control group received a bolus injection of the corresponding volume of 0.9% sodium chloride solution given 5 minutes immediately before the start of CPB.</LI>
</UL>
<P>NB: Both groups were exposed to post-operative cell salvage, tranexamic acid, and desmopressin.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 04:25:27 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, re-operation for bleeding, fresh frozen plasma usage (units), platelet usage (units), pulmonary embolus, retransfused mediastinal shed blood, post-operative TXA, post-operative DDAVP, ASA 75mg/day, ASA 160mg/day.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:26:27 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 04:30:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Porte-2000">
<CHAR_METHODS>
<P>The trial drug was provided double-blind by the manufacturer in blocks of 12 identical case packs. Each case pack contained all bottles for one patient, identifiable only by the sequence number. Each block of 12 case packs contained four packs of each dosage group, randomly assigned to the sequence numbers 1 to 12. Patients received the next available case pack of each block. Centres were provided with sealed cards with the randomisation codes to enable an individual patient's code to be broken in an emergency. A separate set of the sealed randomisation cards was kept at the Central Data Centre. At the end of the study all cards with randomisation codes were sent to the Central Data Centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 04:28:44 +0100" MODIFIED_BY="[Empty name]">
<P>141 patients undergoing orthotopic liver transplantation were randomised to one of three groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 46, M/F = 34/12, median (range) age = 52 (18-66) years</LI>
<LI>Aprotinin group (Low dose): n = 43, M/F = 34/19, median (range) age = 49 (18-69) years</LI>
<LI>Control group (Placebo): n = 48, M/F = 36/12, median (range) age = 53 (19-68) years</LI>
</UL>
<P>NB: Four patients were excluded from the final analysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 04:29:02 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received a loading dose of 2 million KIU (280mg) of aprotinin over 20 minutes before and during the induction of anaesthesia, followed by a continuous infusion of 1 million KIU/hr (140mg/hr) until 2 hours after graft reperfusion. An additional dose of 1 million KIU was administered 30 minutes before graft reperfusion.</LI>
<LI>Aprotinin group (Low dose) received a loading dose of 2 million KIU (280mg) of aprotinin over 20 minutes before and during the induction of anaesthesia, followed by a continuous infusion of 500,000 KIU/hr until 2 hours after graft reperfusion.</LI>
<LI>Control group received 0.9% normal saline in an identical time schedule and volume.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 04:30:19 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Allogeneic blood usage (units), blood loss, number of patients exposed to platelets and cryoprecipitate.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:26:33 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 04:32:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Poston-2006">
<CHAR_METHODS>
<P>Study drug or placebo was delivered to the operating room in unlabeled bottles to maintain blinding. Method of randomisation was not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 04:31:03 +0100" MODIFIED_BY="[Empty name]">
<P>70 patients undergoing 'off-pump' coronary artery bypass graft surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (Low dose): n = 29</LI>
<LI>Control group (Placebo): n = 31</LI>
</UL>
<P>NB: Demographic data were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 04:31:14 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (Low dose) received 10,000 KIU of aprotinin as a test dose followed by 2 million KIU (280mg) of aprotinin as a bolus before sternotomy, and 500,000 KIU/hr (70mg/hr) of aprotinin as a continuous infusion until the end of surgery.</LI>
<LI>Control group received normal saline.</LI>
</UL>
<P>NB: Both groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 04:32:20 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage (units), myocardial infarction, deep vein thrombosis, stroke, hospital length of stay (days), Intensive Care Unit length of stay (days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:26:44 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 04:35:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prendergast_x005f_1-1996">
<CHAR_METHODS MODIFIED="2010-08-18 04:33:45 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 04:34:40 +0100" MODIFIED_BY="[Empty name]">
<P>38 patients undergoing primary sternotomy for heart transplantation were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 18, M/F = 15/3, mean (sd) age = 45.4 (10.2) years</LI>
<LI>Control group: n = 20, M/F = 14/6, mean (sd) age = 49.3 (6.7) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 04:34:58 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 200ml of aprotinin as a loading dose intravenously followed by a continuous infusion of aprotinin of 50ml/hr until the end of the operation. In addition, 200ml of aprotinin was added to the cardiopulmonary bypass circuit.</LI>
<LI>Control group did not receive aprotinin.</LI>
</UL>
<P>NB: Precise dose of aprotinin (KIU or mg) was not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 04:35:34 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Allogeneic blood usage (units), blood loss (24hrs), haemoglobin levels, creatinine levels.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:26:51 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol not specified<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 04:38:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prendergast_x005f_2-1996">
<CHAR_METHODS MODIFIED="2010-08-18 04:37:04 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 04:37:44 +0100" MODIFIED_BY="[Empty name]">
<P>32 patients undergoing re-operative heart transplantation were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 16, M/F = 14/2, mean (sd) age = 54.4 (6.9) years</LI>
<LI>Control group: n = 16, M/F = 13/3, mean (sd) age = 55 (10.6) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 04:38:03 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin received a 200ml loading dose of aprotinin intravenously followed by a continuous infusion of 50ml/hr until the end of the operation. In addition, 200ml of aprotinin was added to the cardiopulmonary bypass circuit.</LI>
<LI>Control group received no aprotinin.</LI>
</UL>
<P>NB: Precise dose of aprotinin (KIU or mg) was not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 04:38:38 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage (units), blood loss (24 hrs), haemoglobin levels, creatinine levels.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:26:56 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 04:41:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pugh-1995">
<CHAR_METHODS MODIFIED="2010-08-18 04:39:47 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 04:40:35 +0100" MODIFIED_BY="[Empty name]">
<P>75 patients scheduled for routine primary cardiac surgery were randomly allocated to one of three groups:</P>
<UL>
<LI>Control group: n = 23, M/F = 16/7, mean (sd) age (+/-SD) = 66 (9.3) years</LI>
<LI>Tranexamic acid group: n = 22, M/F = 17/5, mean (sd) age = 58 (10) years</LI>
<LI>Aprotinin group: n = 21, M/F = 15/6, mean (sd) age = 62 (9.7) years</LI>
</UL>
<P>NB: Nine patients were withdrawn from the trial: two from the control group, three from the tranexamic acid group, and four from the aprotinin group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 04:40:49 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Control group received neither trial drug nor placebo preparation.</LI>
<LI>Tranexamic acid group received 2.5g of TXA before skin incision, with a further 2.5g of TXA added to the cardiopulmonary bypass (CPB) solution.</LI>
<LI>Aprotinin group received 1 million KIU of aprotinin before skin incision, with a further 1 million KIU added to the priming solution.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 04:41:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), number of patinets exposed to fresh frozen plasma, blood loss,<BR/>re-operation for bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:27:04 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 1/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 04:45:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ranaboldo-1997">
<CHAR_METHODS MODIFIED="2010-08-18 04:42:59 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation concealment was by the use of identical coded bottles containing active drug or placebo. The method of randomisation was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 04:43:21 +0100" MODIFIED_BY="[Empty name]">
<P>136 patients undergoing elective aortic surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 66, M/F = 55/11, median age = 68 years</LI>
<LI>Control group (Placebo) group: n = 62, M/F = 45/17, median age = 70 years</LI>
</UL>
<P>NB: Eight patients were excluded from the final analysis. Four deaths occurred within 7 days of surgery (two in each group). Four patients were found at operation not to be suitable for the planned reconstructive surgery.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 04:43:35 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 2 million KIU of aprotinin as a loading dose over a 20 minute period, followed by a maintenance infusion of 500,000 KIU/hr.</LI>
<LI>Control group received equal volumes of 0.9% normal saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 04:45:08 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss (24hrs), mortality (30 day), myocardial infarction, stroke, pulmonary embolus, deep vein thrombosis, chest infection, hepatitis, sepsis, renal failure, urinary tract infection.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:27:10 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 04:47:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rao-1999">
<CHAR_METHODS MODIFIED="2010-08-18 04:46:21 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 04:46:42 +0100" MODIFIED_BY="[Empty name]">
<P>30 patients undergoing elective cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Epsilon aminocaproic acid group: n = 15, M/F = 13/2, mean age = 53 years</LI>
<LI>Control group: n = 15, M/F = 13/2, mean age = 55 years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 04:46:50 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Epsilon aminocaproic acid group received 100mg/kg of EACA as a loading dose slowly after the induction of anaesthesia and a continuous infusion of EACA at 1g/hr for a further 6 hours.</LI>
<LI>Control group received no EACA treatment.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 04:47:53 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage (units), blood loss (24 hrs), myocardial infarction, fresh frozen plasma usage (units), platelet usage (units), ASA treatment until surgery (185mg), ASA treatment until surgery (375mg), stroke, re-operation for bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:27:17 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 0/7<BR/>Transfusion protocol not used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 04:50:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ray-1997">
<CHAR_METHODS MODIFIED="2010-08-18 04:49:02 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 04:49:25 +0100" MODIFIED_BY="[Empty name]">
<P>106 patients undergoing aortic or mitral valve replacement or both were randomly assigned to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 54, M/F = 35/19, median age = 54 years</LI>
<LI>Control group (Placebo): n = 52, M/F = 28/24, median age = 58 years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 04:49:39 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 2 million KIU of aprotinin (280mg) over 20 minutes after the induction of anaesthesia followed by 500,000 KIU/hr (70mg/hr) until the patient was returned to the post-operative ward. In addition, 2 million KIU (280mg) was added to the oxygenator prime.</LI>
<LI>Control group received an equivalent volume of normal saline.</LI>
</UL>
<P>NB: Both groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 04:50:11 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, re-operation, platelet usage (units), fresh frozen plasma usage (units).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:27:23 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 3/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 05:13:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ray-1999">
<CHAR_METHODS MODIFIED="2010-08-18 05:11:52 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 05:12:23 +0100" MODIFIED_BY="[Empty name]">
<P>150 patients in elective adult cardiac surgery were randomly assigned to one of three groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 50</LI>
<LI>Aprotinin group (Low dose): n = 50</LI>
<LI>Control group (Placebo): n = 50</LI>
</UL>
<P>NB: Gender or age data were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 05:12:43 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received a loading dose of 2 million KIU over 20 minutes after the induction of anaesthesia followed by 500,000 KIU/hr (70mg/hr) until the patient was returned to the post-operative ward. In addition, 2 million KIU (280mg) was added to the pump prime.</LI>
<LI>Aprotinin group (Low dose) received a loading dose of 140mg (1 million KIU) infused over 20 minutes after the induction of anaesthesia and a pump prime dose of 140mg (1 million KIU).</LI>
<LI>Control group received a volume of saline solution equivalent to the volume admitted in the low dose aprotinin.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 05:13:07 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, re-operation for bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:27:31 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol not used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 05:15:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ray-2001">
<CHAR_METHODS MODIFIED="2010-08-18 05:14:13 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 05:14:35 +0100" MODIFIED_BY="[Empty name]">
<P>100 patients undergoing elective cardiac surgery were randomly assigned to one of two groups:</P>
<UL>
<LI>Epsilon aminocaproic acid group: n = 51</LI>
<LI>Aprotinin group: n = 49</LI>
</UL>
<P>NB: Gender or age data were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 05:14:45 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Epsilon aminocaproic acid group received a test dose of 250mg at least 10 minutes before the loading dose of 5g given over a 20 minute period after the induction of anaesthesia and 1.25g/hr continuous infusion until 4 hours after bypass. In addition, 5g of EACA was added to the pump prime before cross clamping.</LI>
<LI>Aprotinin group received a test dose of 10,000 KIU before the loading dose (1 million KIU) given over a 20 minute period after the induction of anaesthesia and 1 million KIU was added to the pump prime.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 05:15:32 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, re-operation for bleeding, aspirin use within 10 days, Intensive Care Unit length of stay (hours), neurologic events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:27:49 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 1/7<BR/>Transfusion protocol was not used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 05:19:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ray-2005">
<CHAR_METHODS MODIFIED="2010-08-18 05:16:49 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described. Allocation of the randomised drug was performed by a nurse not otherwise connected with the study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 05:18:15 +0100" MODIFIED_BY="[Empty name]">
<P>45 patients undergoing elective primary total hip arthroplasty were randomly allocated to one of three groups:</P>
<UL>
<LI>Aprotinin group: n = 15, mean (interquartile range) age = 69 (58-74) years</LI>
<LI>Epsilon aminocaproic acid group: n = 15, mean (interquartile range) age = 72 (59-77) years</LI>
<LI>Control group (Placebo): n = 15, mean (interquartile range) age = 72 (59-77) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 05:18:47 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a 10,000 KIU test dose of aprotinin followed by a bolus of 2 million KIU given over 30 minutes after the induction of anaesthesia followed by a continuous infusion of 500,000 KIU/hr for 3 hours.</LI>
<LI>Epsilon aminocaproic acid group received 10g of EACA in 250mL of IV saline given over 30 minutes after the induction of anaesthesia followed by 5g in 250mL of IV saline over 3 hours.</LI>
<LI>Control group received normal saline in the same manner as the other trial arms.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 05:19:48 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss (24hrs), deep vein thrombosis, pre-operative apirin use.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:28:00 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol not used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 05:22:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rhydderch-1993">
<CHAR_METHODS MODIFIED="2010-05-07 15:13:02 +0100" MODIFIED_BY="Katharine Ker">
<P>Methods of sequence generation and allocation concealment were unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 05:20:28 +0100" MODIFIED_BY="[Empty name]">
<P>43 undergoing cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (n = 20), M/F = 14/6, mean (SD) age = 42 (15) years</LI>
<LI>Control group (placebo) (n = 23), M/F = 15/8, mean (SD) age = 37 (17) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 05:20:52 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 2 million KIU added to the pump prime.</LI>
<LI>Control group received a saline placebo.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 05:21:11 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Volume blood transfused, re-operation for bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-18 05:22:14 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 3/7</P>
<P>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 05:25:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rocha-1994">
<CHAR_METHODS MODIFIED="2010-08-18 05:22:45 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 05:24:07 +0100" MODIFIED_BY="[Empty name]">
<P>109 of 122 eligible patients scheduled for coronary artery bypass graft surgery, valvular surgery, or mixed cardiac surgery were randomised to one of four groups:</P>
<UL>
<LI>Aprotinin group: n = 28, M/F = 16/12, mean (sd) age = 58.9 (10.0) years</LI>
<LI>Desmopressin group: n = 25, M/F = 14/11, mean (sd) age = 56.6 (8.8) years</LI>
<LI>Desmopressin group: n = 28, M/F = 20/8, mean (sd) age = 57.3 (7.6) years</LI>
<LI>Control group: n = 28, M/F = 22/6, mean (sd) age = 56.3 (10.1) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 05:24:28 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a bolus infusion of 2 million KIU of aprotinin within 30 minutes after the induction of anaesthesia followed by a continuous infusion of 500,000 KIU/hr of aprotinin until the patient left the operating room. In addition, a bolus of 2 million KIU of aprotinin was added to the pump prime by replacement of crystalloid.</LI>
<LI>Desmopressin group received 0.3ug/kg of desmopressin (DDAVP) in 50ml of saline solution over a period of 20 minutes, given intravenously on completion of cardiopulmonary bypass (CPB) and immediately after administration of protamine.</LI>
<LI>Desmopressin group received two doses of DDAVP (2 x 0.3ug/ml) and an additional dose 6 hours after surgery.</LI>
<LI>Control group did not receive aprotinin or DDAVP.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 05:25:13 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage, blood loss (72hrs), mortality, thrombosis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:28:15 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 1/7<BR/>Transfusion protocol not used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 05:28:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rodrigus-1996">
<CHAR_METHODS MODIFIED="2010-08-18 05:27:04 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 05:27:43 +0100" MODIFIED_BY="[Empty name]">
<P>99 adult patients undergoing elective primary coronary artery bypass graft, or valvular surgery, with cardiopulmonary bypass were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 46, M/F = 39/7, mean (sd) age = 60.4 (8.8) years</LI>
<LI>Control group (Placebo): n = 47, M/F = 34/13, mean (sd) age = 59 (7.8) years</LI>
</UL>
<P>NB: Six of the 99 patients randomised were excluded from the study. Ninety-three patients remained in the study for analysis.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 05:27:53 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received aprotinin as an infusion of 2 million KIU in 200ml of normal saline after induction, followed by a continuous infusion of 500,000 KIU/hr and 2 million KIU in the priming volume of the extracorporeal circuit.</LI>
<LI>Control group received the same volume of normal saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 05:28:59 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage (units), blood loss (24hrs), mortality, myocardial infarction [definite &amp; possible], re-operation for bleeding, atrial fibrillation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:28:21 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 3/7<BR/>Transfusion protocol not specified<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 05:32:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rossi-1997">
<CHAR_METHODS MODIFIED="2010-08-18 05:30:32 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 05:31:06 +0100" MODIFIED_BY="[Empty name]">
<P>43 patients scheduled for elective primary myocardial revascularisation were randomly allocated to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 21, mean (sd) age = 58 (8) years</LI>
<LI>Control group (n = 22), mean (sd) age = 56 (12) years</LI>
</UL>
<P>NB: Gender data were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 05:31:14 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 2 million KIU of aprotinin in the cardiopulmonary bypass prime.</LI>
<LI>Control group did not receive aprotinin.</LI>
</UL>
<P>NB: Both groups were exposed to acute normovolaemic haemodilution (ANH).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 05:32:00 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, blood loss (24hrs), re-operation for bleeding, side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:28:28 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 05:34:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Royston-1987">
<CHAR_METHODS MODIFIED="2010-08-18 05:32:38 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomly allocated to receive test compound by means of sealed envelopes. Method of randomisation was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 05:33:18 +0100" MODIFIED_BY="[Empty name]">
<P>22 patients undergoing repeat cardiac surgery through previous median sternotomy wound were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 11, mean (sd) age = 53 (15) years</LI>
<LI>Control group: n = 11, mean (sd) age = 57 (13) years</LI>
</UL>
<P>NB: Gender data were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 05:33:26 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a loading dose of 280mg of aprotinin via central venous access over 20 minutes before the opening of the previous median sternotomy wound, followed by a continuous infusion of 70mg/hr until skin closure at the end of the operation. An additional 280mg of aprotinin was added to the prime volume of the oxygenator.</LI>
<LI>Control group did not receive aprotinin.</LI>
</UL>
<P>NB: Both groups were exposed to acute normovolaemic haemodilution (ANH).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 05:34:26 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss (24hrs), mortality, total haemoglobin loss,<BR/>time for wound closure (mins), platelet counts.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:28:35 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria):3/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 06:06:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sadeghi-2007">
<CHAR_METHODS MODIFIED="2010-08-18 06:06:06 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomised using a random number technique. The correct treatment option was assured by means of coded infusion syringes prepared by hospital pharmacy not involved otherwise in the study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 06:01:40 +0100" MODIFIED_BY="[Empty name]">
<P>67 undergoing orthopaedic surgery for hip fractures were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 32, M/F = 17/15, mean (sd) age = 51.81 (25.7) years</LI>
<LI>Control group (Placebo): n = 35, M/F = 24/11, mean (sd) age = 44.4 (26.16) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 06:02:14 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received a bolus of 15mg/kg at the beginning of surgery.</LI>
<LI>Control group received saline solution.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 05:38:22 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood transfusion, mortality, blood loss, volume blood transfused (units), length of hospital stay (days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-18 06:03:16 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria):7/7</P>
<P>Transfusion protocol not used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 06:09:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Samama-2002">
<CHAR_METHODS>
<P>Centres were provided with sealed envelopes with the randomisation codes to enable an individual patient's code to be broken in an emergency. A separate set of sealed randomisation tables were kept at the central data centre. To maintain masking, all patients received identical volumes of solution and an identical number of bottles for the identical dose and for the continuous infusion, regardless of treatment group.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 06:07:59 +0100" MODIFIED_BY="[Empty name]">
<P>58 patients undergoing elective orthopaedic surgery were randomised to one of three groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 18, mean (sd) age = 44 (17) years</LI>
<LI>Aprotinin group (Low dose): n = 22, mean (sd) age = 48 (19) years</LI>
<LI>Control group (Placebo): n = 18, mean (sd) age = 44 (22) years</LI>
</UL>
<P>NB: Gender data were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 06:08:18 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received a loading dose of 4 million KIU (560mg) given over 20 minutes before and during the induction of anaesthesia followed by a continuous infusion of 1 million KIU until skin closure.</LI>
<LI>Aprotinin group (Low dose) received a loading dose of 2 million KIU (280mg) given over 20 minutes before and during the induction of anaesthesia followed by a continuous infusion of 500,000 KIU until skin closure.</LI>
<LI>Control group received saline in an identical time schedule and volume.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 06:09:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, deep vein thrombosis, pulmonary embolus, trauma cases, cell salvage used, autologous transfusion.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:28:57 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria):6/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 06:13:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Santamaria-2000">
<CHAR_METHODS MODIFIED="2010-08-18 06:11:15 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 06:12:20 +0100" MODIFIED_BY="[Empty name]">
<P>84 patients undergoing elective coronary artery bypass graft surgery were randomly allocated to one of two groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 28, M/F = 27/1, mean (range) age = 58 (38-78) years</LI>
<LI>Aprotinin group (Low dose): n = 28, M/F = 24/4, mean (range) age = 61 (40-75) years</LI>
<LI>Control group (Placebo): n = 28, M/F = 24/4, mean (range) age = 59 (41-76) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 06:12:42 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received a bolus of 2 million KIU as a loading dose followed by a continuous infusion of 500,000 KIU/hr during CPB. In addition, 2 million KIU (280mg) of aprotinin was added to the pump prime.</LI>
<LI>Aprotonin group (Low dose - pump prime only) received a bolus of saline as a loading dose followed by a continuous infusion of saline during CPB. Two million KIU (280mg) of aprotinin was added to the prime solution.</LI>
<LI>Control group received a bolus of saline. Saline was added to the priming solution and a continuous infusion of saline was administered during CPB.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 06:13:43 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, myocardial infarction, stroke, hypertension, A-V block.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:29:03 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria):4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 06:16:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Santos-2006">
<CHAR_METHODS>
<P>Groups were randomised by means of sequentially numbered sealed envelopes opened by a nurse in the operating room. Only the nurse, who prepared the infusions, knew whether a patient received drug or placebo. Study drugs were delivered in identical volumes. Staff in the operating room and in the intensive care unit were not aware of the treatment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 06:15:56 +0100" MODIFIED_BY="[Empty name]">
<P>65 patients undergoing primary coronary artery bypass graft surgery were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 29, M/F = 18/11, mean (sd) age = 62 (9.2) years</LI>
<LI>Control group (placebo) (n = 31), M/F = 25/6, mean (sd) age = 59 (8.7) years</LI>
</UL>
<P>NB: Five patients were excluded from the final analysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 06:16:10 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received a loading dose of 10mg/kg of TXA before skin incision, followed by a continuous infusion of 1mg/kg/hr for 5 hours.</LI>
<LI>Control group received a bolus of normal saline solution in an identical syringe and a continuous infusion of normal saline for 5 hours.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 06:16:52 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma usage (units), blood loss, mortality, re-operation for bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:29:10 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 06:21:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmartz-2003">
<CHAR_METHODS MODIFIED="2010-08-18 06:19:24 +0100" MODIFIED_BY="[Empty name]">
<P>Sixty patients were divided into three groups by means of computerised randomisation. Allocation concealment was not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 06:20:48 +0100" MODIFIED_BY="[Empty name]">
<P>60 male patients undergoing primary elective cardiac surgery were randomised to one of three groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 20, mean (sd) age = 62 (9) years</LI>
<LI>Aprotinin group (Low dose): n = 20, mean (sd) age = 59 (11) years</LI>
<LI>Control group (Placebo): n = 20, mean (sd) age = 61 (11) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 06:21:12 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotonin group (High dose) received a loading dose of 2 million KIU (280mg) followed by a continuous infusion of 500,000 KIU/hr. In addition, 2 million KIU (280mg) of aprotinin was added to the pump prime.</LI>
<LI>Aprotinin group (Low dose) received a loading dose of 1 million KIU (140mg) followed by a continuous infusion of 250,000 KIU/hr. In addition, 1 million KIU (140mg) of aprotinin was added to the pump prime.</LI>
<LI>Control group received an unspecified placebo.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 06:21:31 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage (units), blood markers of inflammation during and after CPB.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:29:16 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol not used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 06:25:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schweizer-2000">
<CHAR_METHODS MODIFIED="2010-08-18 06:23:57 +0100" MODIFIED_BY="[Empty name]">
<P>Concealment of treatment allocation was not described. Patients were allocated randomly in a double-blind manner. Method of randomisation was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 06:24:42 +0100" MODIFIED_BY="[Empty name]">
<P>60 patients undergoing elective coronary artery bypass graft surgery, aortic valve replacement and mitral valve replacement and repair were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (Low dose): n = 28), M/F = 21/7, mean (range) age = 66 (35-85) years</LI>
<LI>Control group (Placebo): n = 29, M/F = 21/8, mean (range) age = 64 (33-81) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 06:24:56 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (Low dose) received a mean dose of 4.1 million KIU of aprotinin, consisting of a loading dose of 280mg (2 million KIU) over 30 minutes, 140mg (1 million KIU) added to the pump prime and a continuous infusion of 500,000 KIU/hr from the start of surgery until skin closure.</LI>
<LI>Control group received a similar volume of normal saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 06:25:35 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Allogeneic blood usage (units), blood loss, mortality, myocardial infarction, re-operation for bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:29:24 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria):3/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 06:30:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shore_x002d_Lesserson-1996">
<CHAR_METHODS>
<P>Patients were randomly assigned to treatment or placebo by computer generated table. The pharmacist who prepared the infusions knew whether the patient received active treatment or placebo in the event of an adverse response.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 06:29:05 +0100" MODIFIED_BY="[Empty name]">
<P>31 patients undergoing repeat open heart surgery were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 17, M/F = 10/7, mean (sd) age = 68 (13) years</LI>
<LI>Control group (Placebo): n = 13, M/F = 10/3, mean (sd) age = 63 (6) years</LI>
</UL>
<P>NB: One patient from the placebo group was withdrawn from the study due to excessive post-operative bleeding and requiring intra-aortic balloon counter pulsation.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 06:29:19 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received an initial dose of TXA, 20mg/kg over 20 minutes, followed by a continuous infusion of 2mg/kg/hr. This infusion was terminated at the completion of the surgical procedure.</LI>
<LI>Control group received an equal volume of saline.</LI>
</UL>
<P>NB: Both groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 06:30:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage, fresh frozen plasma usage, platelet usage, blood loss, mortality, myocardial infarction, pulmonary complications, re-operation, renal impairment, cerebral ischemia, embolic stroke.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:29:43 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 06:35:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sorin-1999">
<CHAR_METHODS MODIFIED="2010-08-18 06:34:18 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described. [Abstract]</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 06:34:43 +0100" MODIFIED_BY="[Empty name]">
<P>42 patients undergoing total knee replacement were randomly assigned to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 21</LI>
<LI>Control group (Placebo): n = 21</LI>
</UL>
<P>NB: Demographic data were not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 06:34:54 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 15mg/kg of TXA 30 minutes before surgery and subsequently every 8 hours over the following 3 days.</LI>
<LI>Control group received an equal volume of saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 06:35:32 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, deep vein thrombosis.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 06:38:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Speekenbrink-1995">
<CHAR_METHODS MODIFIED="2010-08-18 06:36:25 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 06:37:23 +0100" MODIFIED_BY="[Empty name]">
<P>60 patients scheduled for elective primary coronary artery bypass grafting were randomly assigned to one of four groups:</P>
<UL>
<LI>Aprotinin group: n = 15, M/F = 13/2, mean (sd) age = 62 (10) years</LI>
<LI>Tranexamic acid group: n = 15, M/F = 14/1, mean (sd) age = 61 (11) years</LI>
<LI>Dipyridamole group: n = 15, M/F = 13/2, mean (sd) age = 60 (9) years</LI>
<LI>Control group: n = 15, M/F = 14/1, mean (sd) age = 57 (12) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 06:37:49 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received single dose of 2 million KIU of aprotinin added to the pump prime.</LI>
<LI>Tranexamic acid group received a bolus of 10mg/kg over 20 minutes and continued at a rate of 1mg/kg up to total dose of 1,000 mg.</LI>
<LI>Dipyridamole (Persantin) group received 100mg four times a day (oral), 36 hours before the operation. After induction of anaesthesia treatment was continued with intravenous dipyridamole at a rate of 0.24mg/kg/hr for 24 hours.</LI>
<LI>Control group received usual care.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 06:38:32 +0100" MODIFIED_BY="[Empty name]">
<P>Outcomes reported: Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma usage (units), blood loss (6hrs), myocardial infarction, haemorrhage from chest.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:29:56 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 1/7<BR/>Transfusion protocol not specified<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 06:42:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Speekenbrink-1996">
<CHAR_METHODS MODIFIED="2010-08-18 06:39:59 +0100" MODIFIED_BY="[Empty name]">
<P>Study medications were supplied in boxes containing 12 bottles with 50mL solution. The randomisation code was kept by supplied. The codes were broken after data acquisition were complete and verified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 06:40:52 +0100" MODIFIED_BY="[Empty name]">
<P>115 patients scheduled for elective coronary artery bypass graft surgery were randomised to one of three groups:</P>
<UL>
<LI>Control group (Placebo): n = 37, M/F = 29/8, mean (sd) age = 57 (8) years</LI>
<LI>Aprotinin group (Low dose): n = 37, M/F = 33/4, mean (sd) age = 62 (9) years</LI>
<LI>Aprotinin group (High dose): n = 38, M/F = 30/8, mean (sd) age = 62 (9) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 06:41:13 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Control group received equivalent volumes of normal saline.</LI>
<LI>Aprotinin group (Low dose) received 500,000 KIU of aprotinin in the prime solution.</LI>
<LI>Aprotinin group (High dose) received 2 million KIU of aprotinin over 30 minutes followed by an infusion of 500,000 KIU/hr. In addition, 500,000 KIU of aprotinin was added to the prime solution.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 06:42:11 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss (24hrs), mortality, myocardial infarction, renal failure, re-operation for bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:30:03 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used<BR/>Three patients were excluded from the final analysis: Two from the placebo group (one for excessive postoperative bleeding caused by a broken suture and one for a small left ventricular aneurysm requiring resection), one from the high dose aprotinin group who had dense pericardial adhesions resembling those found in reoperation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 06:46:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stammers-1997">
<CHAR_METHODS MODIFIED="2010-08-18 06:45:04 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation was not described. All drugs were drawn up by a pharmacist and placed in a 500mL glass bottle which was labelled with the patient's name, registration number and date. No other clinician knew of the treatment received by the patient.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 06:45:44 +0100" MODIFIED_BY="[Empty name]">
<P>20 patients undergoing first time coronary artery bypass grafting were randomly assigned to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 8, M/F = 6/2, mean (sd) age = 66.3 (5.8) years</LI>
<LI>Control group (Placebo): n = 12, M/F = 10/2, mean (sd) age = 63.9 (9.2) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 06:45:58 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a loading dose of 2 million KIU (280mg) of aprotinin administered intravenously immediately following the induction of anaesthesia, 2 million KIU of aprotinin placed in the priming volume of the extracorporeal circuit, and a constant infusion of 500,000 KIU/hr (70mg/hr) until chest closure.</LI>
<LI>Control group received an equal volume of saline administered in the same manner.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 06:46:45 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage, Intensive care ventilator time (hrs), renal failure, neurological injury, hospital length of stay (days), blood loss (24hrs).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:30:09 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-18 06:50:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stewart-2001">
<CHAR_METHODS>
<P>Randomisation using numbers chosen randomly from a computer generated table. Study drug and placebo bottles were identifiable only by the random number. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-18 06:50:02 +0100" MODIFIED_BY="[Empty name]">
<P>30 patients undergoing elective orthognathic surgery (maxillary Le Fort I and mandibular sagittal split osteotomies) were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (Low dose): n = 15</LI>
<LI>Control group (Placebo): n = 15</LI>
</UL>
<P>NB: Gender and age data were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-18 06:50:16 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (Low dose) received a loading dose of 280mg (2 million KIU) given after the induction of anaesthesia and before the operation started for over 20 minutes, followed by a continuous infusion at a rate of 500,000 KIU/hr was infused until the end of the procedure.</LI>
<LI>Control group received normal saline at the same time and volumes as aprotinin.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-18 06:50:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:30:15 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 01:01:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Swart-1994">
<CHAR_METHODS MODIFIED="2010-08-19 00:59:06 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation was not described. Intervention and placebo solutions were supplied by Bayer AG (Germany).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 01:00:44 +0100" MODIFIED_BY="[Empty name]">
<P>50 patients undergoing primary coronary artery bypass surgery and 50 patients undergoing valve surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 49, M/F = 33/16, mean (range) age = 53.1 (18-78) years</LI>
<LI>Control group (Placebo) (n = 49), M/F = 32/17, mean (range) age = 51.6 (18-76) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 01:00:56 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 2 million KIU of aprotinin at the start of the operation, infused over a period of 30 minutes followed by a continuous infusion of aprotinin at 500,000 KIU/hr for 4 hours or until the end of the operation. In addition, 2 million KIU was added to the priming solution of the extracorporeal circuit.</LI>
<LI>Control group received similar volumes of saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 01:01:32 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, blood loss (48hrs), mortality, biochemistry and haematology values.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:30:22 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 01:04:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tabuchi-1994">
<CHAR_METHODS MODIFIED="2010-08-19 01:03:11 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation was not described. The study solution was prepared by the pharmacy department according to a randomised code, which was kept blind to all clinicians and investigators until all data were obtained.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 01:03:56 +0100" MODIFIED_BY="[Empty name]">
<P>40 patients undergoing elective coronary artery bypass grafting were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 19, mean (sd) age = 60.9 (8.7) years</LI>
<LI>Control group (Placebo): n = 17, mean (sd) age = 60.2 (8.6) years</LI>
</UL>
<P>NB: Gender data were not reported. Four patients were excluded from the final analysis; three from the placebo group for surgical bleeding requiring repeat thoracotomy, and one from the aprotinin group for haemothorax.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 01:04:13 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 325mg of aspirin orally 10 hours before operation and 2 million KIU of aprotinin (280mg) added to the pump prime solution.</LI>
<LI>Control group received 325mg of aspirin orally 10 hours before operation and 200ml of placebo solution.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 01:04:59 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage (units), re-operation for bleeding, haemothorax.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:30:27 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 01:09:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taggart-2003">
<CHAR_METHODS>
<P>A pre-determined randomisation scheme was generated by the pharmaceutical company supplying the trial drug. Sealed code break cards were available if necessary. The study was analysed on an intention-to-treat (ITT) basis and included those patients who received open-label aprotinin.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 01:08:08 +0100" MODIFIED_BY="[Empty name]">
<P>74 patients undergoing cardiac surgery with total arterial grafting were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 37, M/F = 33/3, mean (sd) age = 60 (8) years</LI>
<LI>Control group (Placebo): n = 34, M/F = 32/2, mean (sd) age = 61 (8) years</LI>
</UL>
<P>NB: Four patients were excluded from the final analysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 01:09:59 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received a 5mL (1.4mg/mL) test dose of aprotinin after the induction of anaesthesia and before sternotomy. The remaining 195mL of the loading dose was administered over 20-30 minutes using an infusion pump. After the completion of the loading dose, a maintenance infusion of 50ml/hr was continued for 4 hours. A further 200mL was added to the pump prime of the bypass circuit.</LI>
<LI>Control group received an unspecified solution.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 01:09:22 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), number of participants exposed to fresh frozen plasma and platelets, blood loss, myocardial infarction, re-operation for bleeding, hospital length of stay.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:30:34 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 3/7<BR/>Transfusion protocol used<BR/>NB: Nine patients in the control group (placebo) received open-label aprotinin whilst two patients in the aprotinin group received open-label aprotinin.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 01:31:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taghaddomi-2009">
<CHAR_METHODS MODIFIED="2010-08-19 01:27:58 +0100" MODIFIED_BY="[Empty name]">
<P>Table of random numbers was used to generate the allocation sequence. An independent anesthesiologist prepared coded infusions with tranexamic acid and placebo and was not directly involved in the clinical treatment of randomised patients. Both operating room staff and the intensive care unit staff were blinded regarding the study group.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 01:28:47 +0100" MODIFIED_BY="[Empty name]">
<P>100 patients undergoing cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 50, M/F = 38/12, mean (sd) age = 54.7 (10.9) years</LI>
<LI>Control group (Placebo): n = 50, M/F = 34/16, mean (sd) age = 60.3 (10.2) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 01:30:32 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received a bolus of 1g was given 20 minutes before incision then a maintenance dose of 400mg/hr during the entire surgical procedure. </LI>
<LI>Control group received normal saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 01:31:43 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood transfusion, blood loss, stroke, renal failure, myocardial infarction.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-19 01:31:58 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7</P>
<P>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 01:39:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tanaka-2001">
<CHAR_METHODS>
<P>Ampoules containing either tranexamic acid or placebo were numbered and placed in envelopes at random by a pharmacologist.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 01:38:23 +0100" MODIFIED_BY="[Empty name]">
<P>99 patients undergoing elective knee arthroplasty were randomised to one of four groups:</P>
<UL>
<LI>Control group (Placebo): n = 26, M/F = 9/17, mean (range) age = 65 (58-70) years</LI>
<LI>Tranexamic acid group (Pre-operative TXA): n = 24, M/F = 7/17, mean (range) age = 65 (59-70) years</LI>
<LI>Tranexamic acid group (Intra-operative TXA): n = 22, M/F = 7/15, mean (range) age = 65 (60-71) years</LI>
<LI>Tranexamic acid group (Pre-and-intra-operative TXA): n = 27, M/F = 8/19, mean (range) age = 65 (59-69) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 01:38:46 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Control group received saline twice, 10 minutes before surgery and on deflation of the tourniquet.</LI>
<LI>Tranexamic acid group (Pre-operative TXA) received 20mg/kg of TXA 10 minutes before surgery and saline 10 minutes before the deflation of the tourniquet.</LI>
<LI>Tranexamic acid group (Intra-operative TXA) received saline 10 minutes before surgery and 20mg/kg of TXA 10 minutes before deflation of the tourniquet.</LI>
<LI>Tranexamic acid group (Pre-and-intra-operative TXA) received 10mg of TXA 10 minutes before surgery and 10mg/kg 10 minutes before deflation of the tourniquet.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 01:39:26 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:31:12 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7<BR/>Transfusion protocol not used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 01:42:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tassani-2000">
<CHAR_METHODS MODIFIED="2010-08-19 01:41:09 +0100" MODIFIED_BY="[Empty name]">
<P>Study performed in a double blind, placebo controlled manner. Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 01:41:43 +0100" MODIFIED_BY="[Empty name]">
<P>20 patients undergoing elective cardiac surgery were randomly assigned to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 10</LI>
<LI>Control group (Placebo): n = 10</LI>
</UL>
<P>NB: Gender and age data were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 01:41:52 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received a loading dose of 2 million KIU of aprotinin, a priming dose of 2 million KIU, and a continuous infusion of 500,000 KIU/hr during surgery.</LI>
<LI>Control group received an unspecified placebo.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 01:42:20 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:31:19 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol not used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 01:46:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thorpe-1994">
<CHAR_METHODS MODIFIED="2010-08-19 01:45:41 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 01:46:02 +0100" MODIFIED_BY="[Empty name]">
<P>17 patients undergoing elective knee replacement surgery were randomly allocated to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 8</LI>
<LI>Control group: n = 9</LI>
</UL>
<P>NB: Demographic data were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 01:46:12 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 0.5 million KIU of aprotinin over 20 minutes immediately before inflation of the tourniquet, another 0.5 million KIU of aprotinin over 20 minutes before deflation of the tourniquet followed by an infusion of 1 million KIU over the next 2 hours.</LI>
<LI>Control group did not receive aprotinin.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 01:46:45 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, femoral thrombosis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:31:27 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 1/7<BR/>Transfusion protocol not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 01:49:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trinh_x002d_Duc-1992">
<CHAR_METHODS MODIFIED="2010-08-19 01:47:10 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described. [French language]</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 01:47:47 +0100" MODIFIED_BY="[Empty name]">
<P>60 patients undergoing cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 29, M/F = 19/10, mean (sd) age = 54.89 (14.92) years</LI>
<LI>Epsilon aminocaproic acid group (n = 27), M/F = 20/7, mean (sd) age = 61.07 (10.65) years</LI>
</UL>
<P>NB: Four patients were excluded from the final analysis.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 01:47:55 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 2 million KIU (280mg) of aprotinin after the induction of anaesthesia followed by a continuous infusion of 500,000 KIU/hr of aprotinin until skin closure. In addition, 2 million KIU (280mg) of aprotinin was added to the pump prime.</LI>
<LI>Epsilon aminocaproic acid group received 5g of EACA as a bolus after the induction of anaesthesia followed by a continuous infusion of 2g/hr until skin closure. In addition, 5g of EACA was added to the pump prime.</LI>
</UL>
<P>NB: Both groups received cell salvage and acute normovolaemic haemodilution (ANH).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 01:49:02 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma usage (units), blood loss (48hrs), mortality,<BR/>minor stroke, respiratory problems, severe hypotension.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-19 01:49:47 +0100" MODIFIED_BY="[Empty name]">
<P>Transfusion protocol not used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 01:52:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Troianos-1999">
<CHAR_METHODS MODIFIED="2010-08-19 01:50:57 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 01:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>72 patients undergoing primary coronary artery bypass surgery were randomised to one of two groups:</P>
<UL>
<LI>Epsilon aminocaproic acid group: n = 38, M/F = 27/11, mean (sd) age = 66 (9) years</LI>
<LI>Control group (Placebo): n = 36, M/F = 24/12, mean (sd) age = 65 (9) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 01:51:51 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Epsilon aminocaproic acid group received a bolus dose of 0.5ml/kg of EACA administered immediately after systemic heparization (125mg/kg), and an infusion of EACA commenced at 0.05ml/kg/hr (12.5mg/kg/hr) and continued until after the administration of protamine and before the patient left the operating room.</LI>
<LI>Control group received saline solution.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 01:52:55 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), number of patients exposed to fresh frozen plasma and platelets, blood loss (6hrs &amp; 48hrs), re-exploration for bleeding, haemoglobin loss.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:31:39 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 3/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 01:57:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Turkoz-2001">
<CHAR_METHODS MODIFIED="2010-08-19 01:54:32 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 01:55:24 +0100" MODIFIED_BY="[Empty name]">
<P>30 patients undergoing elective cardiac surgery were allocated randomly to one of three groups:</P>
<UL>
<LI>Aprotonin group (High dose): n = 10, M/F = 9/1, mean (sd) age = 60.2 (3.4) years</LI>
<LI>Methylprednisolone group: n = 10, M/F = 8/2, mean (sd) age = 58.3 (3.0) years</LI>
<LI>Control group: n = 10, M/F = 9/1, mean (sd) age = 63.8 (1.9) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 01:55:40 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received a loading dose of 280mg (2 million KIU) of aprotinin followed by a continuous infusion of 70mg/hr (500,000 KIU/hr) administered during the operation. In addition, 280mg (2million KIU) of aprotinin was added to the pump prime.</LI>
<LI>Methylprednisolone group received 30mg/kg of methylprednisolone intravenously 5 minutes before surgery.</LI>
<LI>Control group received standard care.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 01:57:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage (units), blood loss.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:31:44 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 02:00:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Uozaki-2001">
<CHAR_METHODS MODIFIED="2010-08-19 01:59:06 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 01:59:38 +0100" MODIFIED_BY="[Empty name]">
<P>14 patients undergoing elective cardiac surgery were allocated to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 14, M/F = 5/1, mean (sd) age = 72.3 (4.1) years</LI>
<LI>Control group: n = 7, M/F = 3/3, mean (sd) age = 63.3 (5.3) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 01:59:49 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 50mg/kg of intravenous TXA before skin incision and after the start of CPB.</LI>
<LI>Control group did not receive TXA treatment.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 02:00:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage (units), blood loss (24hrs), re-operation for bleeding.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:31:51 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 0/7<BR/>Transfusion protocol not used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 02:05:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Urban-2001">
<CHAR_METHODS MODIFIED="2010-08-19 02:01:11 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomised by means of a random number generator. Method used to conceal treatment allocation was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 02:04:33 +0100" MODIFIED_BY="[Empty name]">
<P>60 patients undergoing complex reconstructive spinal surgery were randomised to one of three groups:</P>
<UL>
<LI>Aprotinin group: n = 20, mean (sd) age = 47.2 years</LI>
<LI>Epsilon aminocaproic acid group: n = 17, mean (sd) age = 46.6 years</LI>
<LI>Control group: n = 18, mean (sd) age = 47.3 years</LI>
</UL>
<P>NB: Gender data were not reported. Five patients were excluded from the final analysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 02:04:48 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 1 million KIU of aprotinin as a loading dose over 30 minutes followed by 250,000 KIU/hr.</LI>
<LI>Epsilon aminocaproic acid group received a 5g loading dose over 30 minutes followed by 15mg/kg/hr.</LI>
<LI>Control group received no antifibrinolytic treatment.</LI>
</UL>
<P>NB: All groups were exposed to cell salvage and pre-operative autologous blood donation (PAD).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 02:05:16 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic &amp; autologous blood usage (units), blood loss, respiratory complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:31:57 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 02:07:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Utada-1997">
<CHAR_METHODS MODIFIED="2010-08-19 02:06:20 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described. [Japanese language]</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 02:07:00 +0100" MODIFIED_BY="[Empty name]">
<P>21 patients undergoing primary total hip replacement were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (Low dose): n = 11, M/F = 1/10, mean (sd) age = 63 (11) years</LI>
<LI>Control group (Placebo): n = 10, M/F = 2/8, mean (sd) age = 64 (5) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 02:07:11 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (Low dose) received 2 million KIU (280mg) of aprotinin as a continuous infusion throughout the surgical procedure.</LI>
<LI>Control group received normal saline solution.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 02:07:33 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Allogeneic blood usage (units), blood loss, changes in haemoglobin levels.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Transfusion protocol not used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 02:09:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-der-Linden-2005">
<CHAR_METHODS>
<P>Random assignment was conducted using unmasked envelopes, each containing a card indicating treatment with aprotinin or placebo. A nurse, assigned to another department of the hospital was responsible for the preparation of placebo and treatment solutions, which were identical in appearance and packing.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 02:08:38 +0100" MODIFIED_BY="[Empty name]">
<P>75 patients scheduled for urgent or acute isolated coronary artery bypass graft surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group (High dose): n = 37, M/F = 31/6, mean (sd) age = 66.4 (10) years</LI>
<LI>Control group (Placebo): n = 38, M/F = 25/13, mean (sd) age = 68.3 (10) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 02:08:51 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group (High dose) received a 1 ml test dose of aprotinin after the induction of anaesthesia then received 2 million KIU (280 mg) of aprotinin as a bolus before the start of surgery. Another 2 million KIU of aprotinin was added to the pump prime and a continuous infusion of 500,000 KIU/hr was infused during surgery.</LI>
<LI>Control group received an equal volume of saline solution at the same time periods as the aprotinin regimen.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 02:09:56 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma usage (units), platelets usage (units), mortality, myocardial infarction, stroke, atrial fibrillation, number of patients receiving TXA treatment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:32:06 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 02:13:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Oeveren-1987">
<CHAR_METHODS>
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 02:11:55 +0100" MODIFIED_BY="[Empty name]">
<P>22 patients undergoing coronary artery bypass graft surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 11, mean (sd) age = 56.2 (3.9) years</LI>
<LI>Control group: n = 11, mean (sd) age = 57.5 (5.1) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 02:12:05 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received an infusion of 2 million KIU (280mg) of aprotinin over 20-30 minutes and a continuous infusion of 500,000 KIU/hr until the end of the operation. In addition, for each litre of transfused whole blood given during the operation, an additional 500,000 KIU of aprotinin was administered by a separate bolus infusion.</LI>
<LI>Control group did not receive aprotinin.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 02:13:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage, blood loss, biochemical markers.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:32:19 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 0/7<BR/>Transfusion protocol not used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 02:17:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vander_x002d_Salm-1996">
<CHAR_METHODS>
<P>Random assignment was by means of a random number table and drug preparation was performed by the hospital pharmacy.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 02:15:58 +0100" MODIFIED_BY="[Empty name]">
<P>103 patients undergoing coronary artery bypass graft surgery or valvular surgery were randomly assigned to one of two groups:</P>
<UL>
<LI>Epsilon aminocaproic acid group: n = 51, M/F = 35/16, mean (sd) age = 64.7 (12.1) years</LI>
<LI>Control group (Placebo): n = 52, M/F = 40/12, mean (sd) age = 64.2 (12.4) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 02:16:10 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Epsilon aminocaproic acid group received 10mg of EACA intravenously before skin incision, 10g of EACA after heparin administration, and 10g of EACA at discontinuation of cardiopulmonary bypass (CPB) but before protamine administration.</LI>
<LI>Control group received saline solution in the same volumes and with the same timing as the EACA treated group.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 02:17:08 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), number of patients exposed to fresh frozen plasma, blood loss (12hrs &amp; 24hrs), mortality, cerebrovascular accident, re-operation for bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:32:26 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 7/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 02:25:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vanek-2005">
<CHAR_METHODS>
<P>An envelope method with random numbers was used to randomise patients. An independent pharmacologist not directly involved in the clinical treatment of randomised patients prepared coded infusions with the study drug and placebo.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 02:24:02 +0100" MODIFIED_BY="[Empty name]">
<P>91 patients undergoing cardiac surgery were randomised to one of three groups:</P>
<UL>
<LI>Tranexamic acid group: n = 32, M/F = 16/16, mean (95% CI) age = 68.4 (64.6-72.2) years</LI>
<LI>Aprotinin group: n = 29, M/F = 20/9, mean (95% CI) age = 67.3 (64.2-70.4) years</LI>
<LI>Control group: n = 30, M/F = 22/8, mean (95% CI) age = 68.9 (65.8-72.0) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 02:24:23 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 1g TXA before skin incision and a continuous infusion of 200mg/hr during the whole surgical procedure.</LI>
<LI>Aprotinin group received 1 million KIU of aprotinin before skin incision and a continuous infusion of 250,000 KIU/hr during the whole surgical procedure.</LI>
<LI>Control group received normal saline 0.9% before skin incision and a continuous infusion during the whole surgical procedure.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 02:25:08 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, blood loss, number of patients exposed to fresh frozen plasma.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:32:32 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 6/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 02:28:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vedrinne-1992">
<CHAR_METHODS MODIFIED="2010-08-19 02:26:20 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 02:27:08 +0100" MODIFIED_BY="[Empty name]">
<P>90 consecutive patients undergoing cardiac surgery were randomly allocated to one of three groups:</P>
<UL>
<LI>Aprotinin group: n = 30, M/F = 23/7, mean (sd) age = 58 (8) years</LI>
<LI>Auto-transfusion group: n = 30, M/F = 20/10, mean (sd) age = 57 (7) years</LI>
<LI>Control group: n = 30, M/F = 24/6, mean (sd) age = 59 (10) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 02:27:27 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 2 million KIU of aprotinin at the induction of anaesthesia infused over 20-30 minutes (10,000 KIU/ml of pure aprotinin without additives) followed by a continuous infusion of 500,000 KIU/hr of aprotinin administered throughout the operation. In addition, 2 million KIU of aprotinin was added to the priming solution of the extracorporeal circuit.</LI>
<LI>Auto-transfusion group had 400 ml of autologous blood withdrawn into citrate-phosphate-dextrose during electrocardiographic and haemodynamic monitoring. Blood was withdrawn after the induction of anaesthesia and before skin incision. Withdrawn blood was concomitantly replaced by 500ml of 4% albumin. Autologous blood was kept at room temperature (18-20 degrees) and was transfused after the completion of cardiopulmonary bypass, but before the patients were transferred to the Intensive Care Unit (ICU). </LI>
<LI>Control group patients underwent routine management without autologous transfusion or aprotinin treatment.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 02:28:40 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), number of patients exposed to fresh frozen plasma and platelets,<BR/>blood loss (6hrs &amp; 48hrs), re-operation for bleeding, haemoglobin loss.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:32:39 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 02:31:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Veien-2002">
<CHAR_METHODS MODIFIED="2010-08-19 02:29:59 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomised using a computer generated randomisation table to treatment groups. Method of allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 02:30:37 +0100" MODIFIED_BY="[Empty name]">
<P>30 patients undergoing elective orthopaedic surgery were randomly assigned to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 15, M/F = 4/11, mean (sd) age = 70.5 (9.5) years</LI>
<LI>Control group: n = 15, M/F = 1/14, mean (sd) age = 69.5 (9.0) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 02:30:45 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 10mg/kg of TXA administered just before the release of the tourniquet, and 10mg/kg of TXA given 3 hours later in the recovery room. Although a maximum of 1g was given each time.</LI>
<LI>Control group received standard care without TXA treatment.</LI>
</UL>
<P>NB: All groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 02:31:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), cell salvage autologous blood returned, thrombo-embolic events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:32:45 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria):3/7<BR/>Transfusion protocol used<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 02:35:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wei-2006">
<CHAR_METHODS MODIFIED="2010-08-19 02:32:18 +0100" MODIFIED_BY="[Empty name]">
<P>Method of allocation concealment and randomisation were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 02:33:05 +0100" MODIFIED_BY="[Empty name]">
<P>112 patients undergoing 'off-pump' coronary artery bypass graft surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 36, M/F = 28/8, mean (sd) age = 61.4 (7.5) years</LI>
<LI>Tranexamic acid group: n = 36, M/F = 28/8, mean (sd) age = 62.8 (7.9) years</LI>
<LI>Control group (Placebo): n = 40, M/F = 32/8, mean (sd) age = 60.7 (8.0) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 02:33:25 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprontinin group received 1 million KIU loading dose at beginning of surgery, followed by continuous infusion of 500000 KIU per hour during surgery.</LI>
<LI>Tranexamic acid group received a loading dose of 0.75g of TXA over 20 minutes at the beginning of surgery followed by a continuous infusion of 0.25g/hr throughout surgery.</LI>
<LI>Control group received the same volume of saline solution.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 02:35:52 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma usage (units), number of patients exposed to fresh frozen plasma, blood loss (24hrs), hospital length of stay (days), Intensive Care Unit length of stay (days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:32:52 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used<BR/>Results for aprotinin versus control and TXA versus control - reported in separate publications.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 03:20:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wendel-1995">
<CHAR_METHODS MODIFIED="2010-08-19 03:18:32 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation was not described. Aprotinin and placebo were provided by the manufacturer in identical bottles that differed only in the random numbers on their labels.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 03:19:27 +0100" MODIFIED_BY="[Empty name]">
<P>40 patients undergoing aorto-coronary artery bypass graft surgery were randomised to one of two groups:</P>
<UL>
<LI>Aprotinin group: n = 20, mean (sd) age = 62.4 (7.4) years</LI>
<LI>Control group (Placebo): n = 20, mean (sd) age = 60.6 (7.7) years</LI>
</UL>
<P>NB: Gender data were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 03:19:41 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Aprotinin group received 30,000 KIU/kg of aprotinin as a loading dose over 20 minutes, followed by a continuous infusion of 7,000 KIU/kg/per/hr. In addition, 30,000 KIU/kg of aprotinin was added to the priming solution after 5 minutes of extracorporeal circulation (ECC).</LI>
<LI>Control group received physiologic saline solution.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 03:20:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss, myocardial infarction, infarctional biomarkers.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:32:58 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 03:24:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wong-2000">
<CHAR_METHODS>
<P>The randomisation and preparation of study drugs was performed by the hospitals department of pharmacy. There was no attempt to stratify the randomisation process.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 03:22:28 +0100" MODIFIED_BY="[Empty name]">
<P>80 patients undergoing elective cardiac surgery were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 40, mean (sd) age = 66.0 (10.9) years</LI>
<LI>Aprotinin group (High dose): n = 40, mean (sd) age = 65.4 (8.6) years</LI>
</UL>
<P>NB: Gender data were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 03:22:40 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received a bolus of 10g of TXA over 20 minutes after the induction of anaesthesia and before skin incision. Normal saline 0.9% was used during the other time periods similar to the aprotinin regimen. A test dose of 1mL was given.</LI>
<LI>Aprotinin group (High dose) received an infusion of 2 million KIU (280mg) of aprotinin infused over 20 minutes after the induction of anaesthesia and before skin incision, followed by a continuous infusion of 500,000 KIU/hr administered throughout the operation until skin closure. In addition, 2 million KIU (280mg) was added to the pump prime.</LI>
</UL>
<P>NB: Both groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 03:24:17 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss (24hrs), myocardial infarction, mortality, fresh frozen plasma usage, platelet usage (units), re-operation for bleeding, stroke.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:33:04 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 5/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 03:48:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wong-2008">
<CHAR_METHODS MODIFIED="2010-08-19 03:48:37 +0100" MODIFIED_BY="[Empty name]">
<P>A computer-generated randomisation list was used for sequence generation. The randomisation schedule was kept inaccessible throughout the study period. Patient assignments were placed into sequentially numbered opaque sealed envelopes. A research pharmacist, not involved with care of the patient prepared the placebo and treatment medications that were identical in appearance. The research personnel, anaesthesiologists, surgeons, and operating room staff were blinded to the randomisation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 03:27:41 +0100" MODIFIED_BY="[Empty name]">
<P>151 patients undergoing orthopaedic (spinal) surgery were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 73, M/F = 21/52, mean (sds) age = 56.8 (16.2) years</LI>
<LI>Control group (Placebo): n = 74, M/F = 26/48, mean (sd) age = 50.0 (16.2) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 03:27:53 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received a bolus of 10mg/kg IV, then maintenance infusion of 1mg/kg/hr until skin closure.</LI>
<LI>Control group received the same volume of saline solution.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 03:28:59 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> number of patients exposed to allogeneic blood transfusion, blood loss, volume blood transfused (units), deep vein thrombosis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:33:09 +0100" MODIFIED_BY="[Empty name]">
<P>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 03:52:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2006">
<CHAR_METHODS MODIFIED="2010-08-19 03:50:41 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation was not described. Sealed envelopes were used to conceal treatment allocation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 03:51:32 +0100" MODIFIED_BY="[Empty name]">
<P>217 patients undergoing liver tumor resection were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 106, M/F = 77/29, mean (range) age = 62 (22-88) years</LI>
<LI>Control group (Placebo): n = 108, M/F = 80/28, mean (range) age = 57 (28-84) years</LI>
</UL>
<P>NB: Three patients were excluded from the final analysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 03:51:43 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 500mg of intravenous TXA administered just before the operation, then received 250mg of intravenous TXA every 6 hours for 3 days.</LI>
<LI>Control group group received a similar volume of normal saline at the same time intervals as the TXA drug regimen.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 03:52:22 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, blood loss, hospital length of stay (days), wound infection.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:33:16 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 04:17:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yamasaki-2004">
<CHAR_METHODS>
<P>Randomisation was carried out by a person not involved in the operation using a ticket drawn from an envelope containing an equal number of tranexamic acid and placebo tickets.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 04:16:31 +0100" MODIFIED_BY="[Empty name]">
<P>40 patients undergoing cementless total hip arthroplasty were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 20, M/F = 19/1, mean (sd) age = 55.5 (14.2) years</LI>
<LI>Control group: n = 20, M/F = 18/2, mean (sd) age = 61.2 (6.9) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 04:16:43 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 1,000mg of TXA administered intravenously 5 minutes before the start of the operation.</LI>
<LI>Control group did not receive TXA treatment.</LI>
</UL>
<P>NB: Both groups received pre-operatively donated autologous blood (PAD).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 04:17:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, blood loss (24hrs), thrombo-embolic events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:33:21 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol not used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 04:30:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yassen-1993">
<CHAR_METHODS MODIFIED="2010-08-19 04:21:57 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 04:29:24 +0100" MODIFIED_BY="[Empty name]">
<P>20 patients undergoing orthotopic liver transplantation were randomly allocated to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 10, M/F = 5/5, mean (sd) age = 44.8 (12.2) years</LI>
<LI>Control group (Placebo): n = 10, M/F = 4/6, mean (sd) age = 49.6 (14.2) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 04:29:36 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 10mg/kg loading dose of TXA at the start of the anhepatic phase of the operation, followed by an infusion of 3mg/kg/hr until the patient was transferred to the Intensive Care Unit (ICU).</LI>
<LI>Control group received a similar volume of normal saline as a bolus followed by an infusion.</LI>
</UL>
<P>NB: Both groups were exposed to cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 04:30:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Allogeneic blood usage (units), fresh frozen plasma usage (units), platelets usage (units), blood loss, any thrombosis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:33:27 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 04:33:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zabeeda-2002">
<CHAR_METHODS MODIFIED="2010-08-19 04:31:50 +0100" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment were not described. The surgeon was blinded with respect to whether tranexamic acid or placebo was infused.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 04:32:33 +0100" MODIFIED_BY="[Empty name]">
<P>50 patients undergoing coronary artery bypass graft surgery were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 25, M/F = 20/5, mean (sd) age = 65.6 (9) years</LI>
<LI>Control group (Placebo): n = 25, M/F = 18/7, mean (sd) age = 65 (13) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 04:32:47 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 10mg/kg of TXA for more than 15 minutes in a volume of 10ml after the induction of anaesthesia followed by a continuous infusion of 1mg/kg/hr in a volume of 10ml for the duration of the procedure.</LI>
<LI>Control group received a 10ml bolus of 0.9% saline solution followed by a continuous infusion of saline (10ml/hr).</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 04:33:53 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage (units), blood loss (24hrs), stroke, mediastinal infection, pre-operative aspirin use.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:33:32 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 04:57:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2007">
<CHAR_METHODS MODIFIED="2010-08-19 04:56:56 +0100" MODIFIED_BY="[Empty name]">
<P>Methods of sequence generation and allocation concealment were not described. [Chinese language]</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 04:57:05 +0100" MODIFIED_BY="[Empty name]">
<P>102 patients undergoing orthopaedic knee surgery were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 51</LI>
<LI>Control group (Placebo): n = 51</LI>
</UL>
<P>NB: Randomised subjects were aged between 59-77 years of age. Gender: M/F = 43/59</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 04:40:44 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 1g in 250ml saline IV infused before deflation of tourniquet, then IV administration of 1g 3 hours later.</LI>
<LI>Control group received saline.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 04:41:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported: </I>
</B>Volume blood transfused (units), blood loss, deep vein thrombosis.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:33:41 +0100" MODIFIED_BY="[Empty name]">
<P>Use of transfusion protocol is not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-19 04:37:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zohar-2004">
<CHAR_METHODS>
<P>Patients were randomly allocated to treatment groups using a computer generated randomisation table. Method used to conceal treatment allocation was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-19 04:36:39 +0100" MODIFIED_BY="[Empty name]">
<P>40 patients undergoing total knee replacement were randomised to one of two groups:</P>
<UL>
<LI>Tranexamic acid group: n = 20, M/F = 6/14, mean (sd) age = 73 (8) years</LI>
<LI>Control group: n = 20, M/F = 7/13, mean (sd) age = 73 (7) years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-19 04:36:49 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Tranexamic acid group received 15mg/kg of TXA as an intravenous bolus 30 minutes before the limb tourniquet was deflated administered over 30 minutes. Thereafter a constant infusion of 10mg/kg/hr was administered until 12 hours after final deflation of the limb tourniquet.</LI>
<LI>Control group received usual care with no TXA treatment.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-19 04:37:39 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Outcomes reported:</I>
</B> Number of patients exposed to allogeneic blood, allogeneic blood usage, blood loss (12hrs), thrombo-embolic events (30-day), hospital length of stay (days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-02 02:33:48 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 1/7<BR/>Transfusion protocol used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-07-08 11:33:54 +0100" MODIFIED_BY="Katharine Ker" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Fejer-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study was excluded on the basis there was uncertainty regarding the age of study participants. As the study involved thoracolumbar transpedicular (TLT) fixation of the spine for spondylolisthesis subjects less than 18 years of age may have been included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Langdown-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study did not report the number of patients randomised to each trial arm rather reported the total number of patients randomised. Study was excluded on the basis there was uncertainty regarding the number of patients in each trial arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Montesano-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract refers to patients as being randomly selected but methods section of paper states study was retrospective. Study was excluded on the basis there was uncertainty regarding trial design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-25 15:37:00 +0100" MODIFIED_BY="Katharine Ker" STUDY_ID="STD-Zufferey-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-25 15:37:00 +0100" MODIFIED_BY="Katharine Ker">
<P>Patients undergoing surgery for hip fractures - not elective.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-05-25 13:45:33 +0100" MODIFIED_BY="Katharine Ker" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-05-14 13:59:48 +0100" MODIFIED_BY="Katharine Ker" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2010-05-14 13:59:48 +0100" MODIFIED_BY="Katharine Ker" STUDY_ID="STD-Myles-2008">
<CHAR_STUDY_NAME MODIFIED="2010-05-07 14:24:11 +0100" MODIFIED_BY="Katharine Ker">
<P>ATACAS trial </P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-05-07 14:24:59 +0100" MODIFIED_BY="Katharine Ker">
<P>Multi-centre, randomised, blinded 2x2 factorial trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-07 14:25:34 +0100" MODIFIED_BY="Katharine Ker">
<P>N=4600, patients undergoing elective CABG surgery.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-07 14:28:01 +0100" MODIFIED_BY="Katharine Ker">
<P>Patients will be allocated to one of four groups<BR/>(1) Aspirin<BR/>(2) Tranexamic acid<BR/>(3) Tranexamic acid plus aspirin<BR/>(4) Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-14 13:59:48 +0100" MODIFIED_BY="Katharine Ker">
<P>Mortality<BR/>Myocardial infarction<BR/>Stroke<BR/>Pulmonary embolism<BR/>Renal failure<BR/>Bowel infarction<BR/>Re-operation for bleeding<BR/>Blood transfusion</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES MODIFIED="2010-05-07 14:23:48 +0100" MODIFIED_BY="Katharine Ker"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-05-14 13:58:26 +0100" MODIFIED_BY="Katharine Ker" STUDY_ID="STD-Verma-2010">
<CHAR_STUDY_NAME/>
<CHAR_METHODS MODIFIED="2010-05-14 13:53:43 +0100" MODIFIED_BY="Katharine Ker">
<P>Single-centre, randomised, double-blinded control study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-14 13:55:39 +0100" MODIFIED_BY="Katharine Ker">
<P>Patient undergoing corrective spinal surgery.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-14 13:58:01 +0100" MODIFIED_BY="Katharine Ker">
<P>Patients will be allocated to one of three groups<BR/>(1) Tranexamic acid<BR/>(2) EACA<BR/>(3) Saline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-14 13:57:25 +0100" MODIFIED_BY="Katharine Ker">
<P>Perioperative blood loss<BR/>Renal failure</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES MODIFIED="2010-05-14 13:58:26 +0100" MODIFIED_BY="Katharine Ker">
<P>ClinicalTrials.gov ID: NCT00958581</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-08-19 11:08:50 +0100" MODIFIED_BY="Katharine Ker">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-08-19 11:08:50 +0100" MODIFIED_BY="Katharine Ker" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:17:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Alajmo-1989">
<DESCRIPTION>
<P>Patients were randomly allocated into two groups according to birth date until an appropriate number of treated patients was reached</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:17:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alderman-1998">
<DESCRIPTION>
<P>Random code generated in blocks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:17:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alvarez-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:17:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alvarez-2001">
<DESCRIPTION>
<P>Computer-generated random number sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:16:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alvarez-2008">
<DESCRIPTION>
<P>Computer-generated random number sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:15:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Amar-2003">
<DESCRIPTION>
<P>Computer-generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:16:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Andreasen-2004">
<DESCRIPTION>
<P>Random number sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:16:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Apostolakis-2008">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:16:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Armellin-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:16:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Arom-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:16:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ashraf-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:16:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asimakopoulos-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:16:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baele-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:16:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bailey-1994">
<DESCRIPTION>
<P>Generation of allocation sequences was by a computer generated random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:15:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Basora-1999">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:15:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bennett_x002d_Guerrero-1997">
<DESCRIPTION>
<P>Patients were randomised by means of a computer-generated schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:15:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benoni-1996">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:15:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Benoni-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:15:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Benoni-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:14:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berenholtz-2009">
<DESCRIPTION>
<P>Patients were randomised according to a computer-generated randomisation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:14:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bernet-1999">
<DESCRIPTION>
<P>Random code used for randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:14:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bert-2008">
<DESCRIPTION>
<P>A computer-generated randomisation list was used to generate the allocation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:14:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bidstrup-1989">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:14:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bidstrup-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:14:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bidstrup-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:14:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bidstrup-2000">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:14:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blauhut-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:13:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boldt-1991">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:13:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boldt-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:13:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boylan-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:13:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brown-1997">
<DESCRIPTION>
<P>Adequate - computer-generated random number sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:13:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Caglar-2008">
<DESCRIPTION>
<P>Computer-generated randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 05:42:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Camarasa-2006">
<DESCRIPTION>
<P>Computer-generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 05:42:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Capdevila-1998">
<DESCRIPTION>
<P>Randomisation was performed using a random number list generated by computer programme</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 05:42:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carrera-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:12:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casas-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:23:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casati-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:26:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casati-2000">
<DESCRIPTION>
<P>Computer generated random number sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:29:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casati-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:33:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casati-2002">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:39:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casati-2004">
<DESCRIPTION>
<P>Computer-generated random number sequences</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-30 02:07:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cicek-1996a">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-30 06:59:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cicek-1996b">
<DESCRIPTION>
<P>Random numbers table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-30 07:04:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cicekcioglu-2006">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-30 07:08:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Claeys-2007">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-30 07:29:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Coffey-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 05:14:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cohen-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-30 07:39:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colwell-2007">
<DESCRIPTION>
<P>Computer-generated list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 04:57:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Corbeau-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 05:01:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cosgrove-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 05:04:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cvachovec-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 05:12:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-D_x0027_Ambra-1996">
<DESCRIPTION>
<P>Random code generated for each site by the statistical department of Bayer</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 05:19:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Ambrosio-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 05:24:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daily-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 05:27:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dalmau-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 05:38:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dalmau-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 05:43:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dalmau-2004">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 05:45:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Defraigne-2000">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 05:59:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Del-Rossi-1989">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 06:03:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Deleuze-1991">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 06:31:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Demeyere-2006">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 06:55:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Desai-2009">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 07:00:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dietrich-1990">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 07:04:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dietrich-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 07:06:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dietrich-1995">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 07:19:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dietrich-2008">
<DESCRIPTION>
<P>Computer-generated randomisation list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 07:30:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dignan-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 07:35:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Diprose-2005">
<DESCRIPTION>
<P>Computer generated random numbers determined patient allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 07:48:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dorman-2008">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 07:52:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dryden-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 07:58:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eberle-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 08:02:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ehrlich-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 08:15:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ekback-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 08:19:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ellis-2001">
<DESCRIPTION>
<P>Randomisation was carried out using a computer generated randomisation table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 08:22:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Engel-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 01:04:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Englberger-2002a">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 01:13:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Englberger-2002b">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 01:17:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fauli-2005">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 01:21:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feindt-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 01:28:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fergusson-2008">
<DESCRIPTION>
<P>Computer-generated randomisation list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 01:39:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Findlay-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 01:42:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fraedrich-1989">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 01:44:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garcia_x002d_Enguita-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 01:48:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garcia_x002d_Huete-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 01:50:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garneti-2004">
<DESCRIPTION>
<P>List of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 02:07:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gherli-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 05:19:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gill-2009">
<DESCRIPTION>
<P>Computer-generated randomisation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 05:33:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Golanski-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 05:34:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Good-2003">
<DESCRIPTION>
<P>Computer generated numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 05:40:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gott-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 05:58:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Green-1995">
<DESCRIPTION>
<P>Patients were assigned to groups by means of computer generated table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 06:06:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greilich-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 06:09:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greilich-2003">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 06:12:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greilich-2004">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 06:13:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greilich-2009">
<DESCRIPTION>
<P>A table of random numbers was used to generate the allocation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 06:58:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Groh-1993">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:02:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harder-1991">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:06:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hardy-1993">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:10:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hardy-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:15:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hardy-1998">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:18:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harley-2002">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:21:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harmon-2004">
<DESCRIPTION>
<P>Computer-generated randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:24:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Havel-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:27:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Havel-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:33:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hayashida-1997">
<DESCRIPTION>
<P>Computer-generated randomisation table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:36:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hayes-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:39:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hei-2005">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:40:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hekmat-2004">
<DESCRIPTION>
<P>Computer-generated code</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:47:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hendrice-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 00:25:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hiipala-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 00:30:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hiipala-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 00:33:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hill-1998">
<DESCRIPTION>
<P>Computer-generated sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 00:37:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horrow-1990">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 00:43:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horrow-1991">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 00:50:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horrow-1995">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 00:51:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Husted-2003">
<DESCRIPTION>
<P>Randomisation was performed by computer</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 00:58:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ickx-2006">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 01:01:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Isetta-1993">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 01:05:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jamieson-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 01:10:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jansen-1999">
<DESCRIPTION>
<P>Randomisation was performed using a computer-generated random number list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 01:14:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Janssens-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 01:16:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jares-2003">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 01:29:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jeserschek-2003">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 01:32:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jimenez-2007">
<DESCRIPTION>
<P>Randomised number list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 02:06:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johansson-2005">
<DESCRIPTION>
<P>Computer randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 02:08:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kahveci-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 02:11:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kalangos-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 02:19:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karski-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 02:19:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karski-2005">
<DESCRIPTION>
<P>Computer-generated randomisation code</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 04:22:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaspar-1997">
<DESCRIPTION>
<P>Computer generated randomisation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 04:31:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Katoh-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 04:34:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Katsaros-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 04:37:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Katzel-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 04:51:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kazemi-2010">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 04:56:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kikura-2006">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:00:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kipfer-2003">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:03:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klein-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:09:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kluger-2003">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:14:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koster-2004">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:20:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kratzer-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:35:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kreisler-2005">
<DESCRIPTION>
<P>Computer-generated table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:38:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuepper-2003">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:43:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kuitunen-2005">
<DESCRIPTION>
<P>Closed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:47:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuitunen-2006">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:50:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kunt-2005">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:51:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kyriss-2001">
<DESCRIPTION>
<P>Computer-generated random list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:56:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Landymore-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:59:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lass-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 06:10:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Later-2009">
<DESCRIPTION>
<P>Computer-generated randomisation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 06:18:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laub-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 06:21:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lavee-1993">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 06:39:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leijdekkers-2006">
<DESCRIPTION>
<P>Randomisation list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 06:45:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lemay-2004">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-16 06:54:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lemmer-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-16 07:04:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lemmer-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-16 06:57:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lemmer_x005f_1-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-16 06:59:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lemmer_x005f_2-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-16 07:06:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lentschener-1997">
<DESCRIPTION>
<P>Computer-generated random codes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-16 07:10:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lentschener-1999">
<DESCRIPTION>
<P>Computer generated random code</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-16 07:17:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levy-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-16 07:20:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2005">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-16 07:22:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-1993">
<DESCRIPTION>
<P>Allocation sequences were generated by a computer generated random list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-16 07:28:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-16 07:31:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Llau-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 01:51:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Locatelli-1990">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 01:57:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Luo-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 02:31:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-MacGillivray-2010">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 02:27:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maccario-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 05:40:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maddali-2007">
<DESCRIPTION>
<P>Computer-generated randomisation code</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 05:52:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maineri-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 06:19:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mansour-2004">
<DESCRIPTION>
<P>Computer -generated random number sequence programme</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 06:25:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marcel-1996">
<DESCRIPTION>
<P>Randomised by a computer program</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 06:30:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mehr_x002d_Aein-2007">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 06:47:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mengistu-2008">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 06:55:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Menichetti-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 06:58:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Misfeld-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 07:03:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mohr-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 07:03:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mongan-1998">
<DESCRIPTION>
<P>Computer-generated random sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 07:07:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moran-2000">
<DESCRIPTION>
<P>Computer-generated code</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 07:11:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Murkin-1994">
<DESCRIPTION>
<P>Computer-generated random code</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 07:15:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Murkin-1995">
<DESCRIPTION>
<P>Computer generated codes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 07:21:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Murkin-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 07:22:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Murphy-2006">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 07:30:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Niskanen-2005">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 03:41:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Norman-2009">
<DESCRIPTION>
<P>Randomisation schedule based on study accession number</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 03:44:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nur_x00f6_zler-2008">
<DESCRIPTION>
<P>List of random treatment codes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 03:53:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nuttall-2000">
<DESCRIPTION>
<P>Computer-generated random number sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 03:59:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Okita-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:02:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Orpen-2006">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:04:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Palmer-2003">
<DESCRIPTION>
<P>Computer generated randomisation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:12:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parvizi-2007">
<DESCRIPTION>
<P>Computer-generated randomisation list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:16:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Penta-de-Peppo-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:19:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Petsatodis-2006">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:22:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pinosky-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:22:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pleym-2003">
<DESCRIPTION>
<P>Computer programme</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:27:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Porte-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:33:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poston-2006">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:36:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prendergast_x005f_1-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:38:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prendergast_x005f_2-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:41:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pugh-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:45:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ranaboldo-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:48:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rao-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:50:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ray-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 05:13:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ray-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 05:15:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ray-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 05:20:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ray-2005">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 05:21:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rhydderch-1993">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 05:25:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rocha-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 05:29:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rodrigus-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 05:32:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rossi-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 05:36:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Royston-1987">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 06:03:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sadeghi-2007">
<DESCRIPTION>
<P>Random number technique</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 06:10:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Samama-2002">
<DESCRIPTION>
<P>Randomisation codes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 06:14:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Santamaria-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 06:17:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Santos-2006">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 06:19:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmartz-2003">
<DESCRIPTION>
<P>Computerised randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 06:26:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schweizer-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 06:28:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shore_x002d_Lesserson-1996">
<DESCRIPTION>
<P>Computer generated table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 06:35:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sorin-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 06:39:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Speekenbrink-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 06:44:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Speekenbrink-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 06:47:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stammers-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 06:48:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stewart-2001">
<DESCRIPTION>
<P>Computer generated table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 00:59:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Swart-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 01:05:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tabuchi-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 01:07:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Taggart-2003">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 01:33:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taghaddomi-2009">
<DESCRIPTION>
<P>Table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 01:39:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tanaka-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 01:42:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tassani-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 01:46:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thorpe-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 01:49:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Trinh_x002d_Duc-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 01:53:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Troianos-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 01:58:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Turkoz-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 02:00:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Uozaki-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 02:01:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Urban-2001">
<DESCRIPTION>
<P>Random number generator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 02:07:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Utada-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 02:13:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Oeveren-1987">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 02:11:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-der-Linden-2005">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 02:15:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vander_x002d_Salm-1996">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 02:22:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vanek-2005">
<DESCRIPTION>
<P>Random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 02:28:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vedrinne-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 02:31:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Veien-2002">
<DESCRIPTION>
<P>Computer generated randomisation table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 02:38:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wei-2006">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 03:21:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wendel-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 03:24:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wong-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 03:25:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wong-2008">
<DESCRIPTION>
<P>Computer-generated randomisation list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 03:53:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wu-2006">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 04:20:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yamasaki-2004">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 04:31:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yassen-1993">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 04:34:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zabeeda-2002">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 04:41:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 04:35:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zohar-2004">
<DESCRIPTION>
<P>Computer generated randomisation table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-08-19 11:08:50 +0100" MODIFIED_BY="Katharine Ker" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:17:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Alajmo-1989">
<DESCRIPTION>
<P>Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:17:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alderman-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:17:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Alvarez-1995">
<DESCRIPTION>
<P>Inadequate - sealed envelopes were used to conceal treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:17:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alvarez-2001">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:16:55 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Alvarez-2008">
<DESCRIPTION>
<P>Inadequate - randomised assignment was sealed in a numbered envelope</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:15:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Amar-2003">
<DESCRIPTION>
<P>Inadequate - sealed opaque treatment coded envelopes were used to conceal treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:16:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Andreasen-2004">
<DESCRIPTION>
<P>Inadequate - used sealed envelopes to conceal treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:16:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Apostolakis-2008">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:16:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Armellin-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:16:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Arom-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:16:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ashraf-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:16:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Asimakopoulos-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:16:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Baele-1992">
<DESCRIPTION>
<P>Inadequate - sealed envelopes were used to conceal treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:16:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bailey-1994">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:15:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Basora-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:15:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bennett_x002d_Guerrero-1997">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:15:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benoni-1996">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:15:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benoni-2000">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:15:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benoni-2001">
<DESCRIPTION>
<P>Adequate - medication was concealed by a code only known by the hospitals chief pharmacist who was not involved in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:14:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berenholtz-2009">
<DESCRIPTION>
<P>Adequate - allocation was concealed through central (pharmacy) allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:14:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bernet-1999">
<DESCRIPTION>
<P>Adequate - drug solutions were prepared by the hospital pharmacy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:14:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bert-2008">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:14:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bidstrup-1989">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:14:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bidstrup-1990">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:14:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bidstrup-1993">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:14:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bidstrup-2000">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:14:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blauhut-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:13:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boldt-1991">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:13:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boldt-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:13:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Boylan-1996">
<DESCRIPTION>
<P>Inadequate - randomisation schedule was provided in sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:13:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:13:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Caglar-2008">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 05:42:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Camarasa-2006">
<DESCRIPTION>
<P>Inadequate - randomised assignment was sealed in an opaque, numbered envelope</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 05:42:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Capdevila-1998">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 05:42:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carrera-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:12:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Casas-1995">
<DESCRIPTION>
<P>Inadequate - allocation concealment was by sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:23:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casati-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:26:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casati-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:29:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casati-2001">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:33:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casati-2002">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 06:39:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casati-2004">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-30 02:07:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cicek-1996a">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-30 06:59:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cicek-1996b">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-30 07:04:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cicekcioglu-2006">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-30 07:07:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Claeys-2007">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-30 07:30:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coffey-1995">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-30 07:34:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-1998">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-30 07:45:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colwell-2007">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 04:56:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Corbeau-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 05:00:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cosgrove-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 05:04:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cvachovec-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 05:11:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-D_x0027_Ambra-1996">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 05:19:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Ambrosio-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 05:24:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Daily-1994">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 05:27:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dalmau-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 05:38:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dalmau-2000">
<DESCRIPTION>
<P>Inadequate - sealed envelopes were used to conceal treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 05:42:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dalmau-2004">
<DESCRIPTION>
<P>Inadequate - sealed envelopes were used to conceal treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 05:45:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Defraigne-2000">
<DESCRIPTION>
<P>Inadequate - sealed envelopes were used to conceal treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 05:59:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Del-Rossi-1989">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 06:03:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Deleuze-1991">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 06:32:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Demeyere-2006">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 06:35:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Desai-2009">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 07:00:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dietrich-1990">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 07:03:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dietrich-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 07:05:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dietrich-1995">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 07:18:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dietrich-2008">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 07:30:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dignan-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 07:34:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Diprose-2005">
<DESCRIPTION>
<P>Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 07:38:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dorman-2008">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 07:52:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dryden-1997">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 07:57:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eberle-1998">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 08:01:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ehrlich-1998">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 08:14:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ekback-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 08:18:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ellis-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-01 08:22:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Engel-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 01:04:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Englberger-2002a">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 01:13:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Englberger-2002b">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 01:16:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fauli-2005">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 01:21:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feindt-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 01:28:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fergusson-2008">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 01:38:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Findlay-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 01:41:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fraedrich-1989">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 01:44:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garcia_x002d_Enguita-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 01:47:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garcia_x002d_Huete-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 01:50:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garneti-2004">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 02:07:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gherli-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 05:18:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gill-2009">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 05:33:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Golanski-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 05:34:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Good-2003">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 05:40:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gott-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 05:56:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Green-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 06:06:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greilich-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 06:09:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greilich-2003">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 06:12:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greilich-2004">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 06:13:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greilich-2009">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 06:58:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Groh-1993">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:02:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harder-1991">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:06:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hardy-1993">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:09:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hardy-1997">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:15:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hardy-1998">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:18:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harley-2002">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:21:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harmon-2004">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:24:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Havel-1992">
<DESCRIPTION>
<P>Inadequate - used sealed envelopes to conceal treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:28:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Havel-1994">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:32:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hayashida-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:35:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hayes-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:38:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hei-2005">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:40:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hekmat-2004">
<DESCRIPTION>
<P>Inadequate - sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-11 07:47:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hendrice-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 00:25:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hiipala-1995">
<DESCRIPTION>
<P>Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 00:30:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hiipala-1997">
<DESCRIPTION>
<P>Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 00:33:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hill-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 00:37:09 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Horrow-1990">
<DESCRIPTION>
<P>Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 00:42:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Horrow-1991">
<DESCRIPTION>
<P>Inadequate </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 00:50:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Horrow-1995">
<DESCRIPTION>
<P>Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 00:51:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Husted-2003">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 00:57:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ickx-2006">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 01:01:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Isetta-1993">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 01:05:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jamieson-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 01:08:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jansen-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 01:13:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Janssens-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 01:16:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jares-2003">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 01:29:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jeserschek-2003">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 01:31:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jimenez-2007">
<DESCRIPTION>
<P>Adeaquate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 02:05:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johansson-2005">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 02:08:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kahveci-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 02:11:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kalangos-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 02:18:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karski-1995">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-12 02:19:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karski-2005">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 04:22:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaspar-1997">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 04:31:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Katoh-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 04:34:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Katsaros-1996">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 04:36:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Katzel-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 04:40:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kazemi-2010">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 04:55:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kikura-2006">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:00:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kipfer-2003">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:03:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klein-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:08:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kluger-2003">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:12:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koster-2004">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:19:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kratzer-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:35:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kreisler-2005">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:36:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kuepper-2003">
<DESCRIPTION>
<P>Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:41:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kuitunen-2005">
<DESCRIPTION>
<P>Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:47:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuitunen-2006">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:50:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kunt-2005">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:51:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kyriss-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:56:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Landymore-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 05:59:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lass-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 06:10:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Later-2009">
<DESCRIPTION>
<P>Inadequate - sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 06:18:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laub-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 06:21:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lavee-1993">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 06:23:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leijdekkers-2006">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-13 06:45:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lemay-2004">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-16 06:54:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lemmer-1994">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-16 07:04:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lemmer-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-16 06:57:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lemmer_x005f_1-1994">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-16 06:59:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lemmer_x005f_2-1994">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-16 07:06:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lentschener-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-16 07:10:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lentschener-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-16 07:16:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levy-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-16 07:20:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2005">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-16 07:22:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-1993">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-16 07:28:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-16 07:30:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Llau-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 01:51:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Locatelli-1990">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 01:57:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Luo-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 05:23:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacGillivray-2010">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 02:27:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maccario-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 05:44:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Maddali-2007">
<DESCRIPTION>
<P>Inadequate - sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 05:52:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maineri-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 06:20:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mansour-2004">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 06:25:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marcel-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 06:30:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mehr_x002d_Aein-2007">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 06:47:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mengistu-2008">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 06:55:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Menichetti-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 06:58:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Misfeld-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 07:02:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mohr-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 07:03:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mongan-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 07:07:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moran-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 07:11:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Murkin-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 07:15:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Murkin-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 07:20:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Murkin-2000">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 07:22:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Murphy-2006">
<DESCRIPTION>
<P>Inadequate - sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-17 07:29:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Niskanen-2005">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 03:40:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Norman-2009">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 03:45:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nur_x00f6_zler-2008">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 03:53:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nuttall-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 03:59:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Okita-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:02:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Orpen-2006">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:08:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Palmer-2003">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:12:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Parvizi-2007">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:15:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Penta-de-Peppo-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:18:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Petsatodis-2006">
<DESCRIPTION>
<P>Inadequate - sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:22:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pinosky-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:23:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pleym-2003">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:27:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Porte-2000">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:33:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poston-2006">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:36:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prendergast_x005f_1-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:38:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prendergast_x005f_2-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:41:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pugh-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:45:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ranaboldo-1997">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:47:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rao-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 04:50:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ray-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 05:13:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ray-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 05:15:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ray-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 05:19:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ray-2005">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 05:21:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rhydderch-1993">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 05:25:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rocha-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 05:29:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rodrigus-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 05:32:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rossi-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 05:35:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Royston-1987">
<DESCRIPTION>
<P>Inadequate - sealed envelopes </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 05:38:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sadeghi-2007">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 06:10:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Samama-2002">
<DESCRIPTION>
<P>Inadequate - sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 06:13:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Santamaria-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 06:17:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Santos-2006">
<DESCRIPTION>
<P>Inadequate - sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 06:19:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmartz-2003">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 06:25:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schweizer-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 06:28:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shore_x002d_Lesserson-1996">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 06:35:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sorin-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 06:38:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Speekenbrink-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 06:43:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Speekenbrink-1996">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 06:46:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stammers-1997">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-18 06:49:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stewart-2001">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 00:59:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Swart-1994">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 01:05:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tabuchi-1994">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 01:07:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taggart-2003">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 01:33:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taghaddomi-2009">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 01:39:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tanaka-2001">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 01:42:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tassani-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 01:46:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thorpe-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 01:49:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Trinh_x002d_Duc-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 01:53:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Troianos-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 01:57:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Turkoz-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 02:00:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Uozaki-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 02:01:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Urban-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 02:07:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Utada-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 02:13:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Oeveren-1987">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 02:10:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Van-der-Linden-2005">
<DESCRIPTION>
<P>Inadequate - sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 02:15:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vander_x002d_Salm-1996">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 02:22:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vanek-2005">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 02:28:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vedrinne-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 02:31:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Veien-2002">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 02:37:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wei-2006">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 03:20:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wendel-1995">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 03:24:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wong-2000">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 03:27:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wong-2008">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 03:52:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wu-2006">
<DESCRIPTION>
<P>Inadequate - sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 04:17:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yamasaki-2004">
<DESCRIPTION>
<P>Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 04:31:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yassen-1993">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 04:33:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zabeeda-2002">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 04:41:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-19 04:35:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zohar-2004">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-08-19 11:08:50 +0100" MODIFIED_BY="Katharine Ker" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-25 04:51:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Alajmo-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:17:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alderman-1998">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:17:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alvarez-1995">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:17:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alvarez-2001">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:16:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alvarez-2008">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:15:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Amar-2003">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:16:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Andreasen-2004">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:16:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Apostolakis-2008">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:16:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Armellin-2001">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:16:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Arom-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:16:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ashraf-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:16:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Asimakopoulos-2000">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:16:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baele-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:16:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bailey-1994">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:15:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Basora-1999">
<DESCRIPTION>
<P>Single blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:15:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bennett_x002d_Guerrero-1997">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:15:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benoni-1996">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:15:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benoni-2000">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:15:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benoni-2001">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-25 07:25:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berenholtz-2009">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-25 07:30:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bernet-1999">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:14:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bert-2008">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:14:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bidstrup-1989">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:14:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bidstrup-1990">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:14:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bidstrup-1993">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:14:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bidstrup-2000">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:14:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blauhut-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:13:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boldt-1991">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:13:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boldt-1994">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:13:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boylan-1996">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:13:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brown-1997">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:13:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Caglar-2008">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 05:42:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Camarasa-2006">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 05:42:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Capdevila-1998">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 05:42:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carrera-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:13:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casas-1995">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:23:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casati-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:26:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Casati-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:29:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casati-2001">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:33:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casati-2002">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-29 06:39:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casati-2004">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-30 02:07:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cicek-1996a">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-30 06:59:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cicek-1996b">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-30 07:04:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cicekcioglu-2006">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-30 07:26:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Claeys-2007">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-30 07:29:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coffey-1995">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-30 07:33:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-1998">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-30 07:45:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colwell-2007">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 04:57:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Corbeau-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 05:01:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cosgrove-1992">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 05:04:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cvachovec-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 05:12:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-D_x0027_Ambra-1996">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 05:19:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-D_x0027_Ambrosio-1999">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 05:24:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Daily-1994">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 05:35:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dalmau-1999">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 05:38:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dalmau-2000">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 05:43:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dalmau-2004">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 05:45:45 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Defraigne-2000">
<DESCRIPTION>
<P>Single blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 05:59:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Del-Rossi-1989">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 06:03:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Deleuze-1991">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 06:32:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Demeyere-2006">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 06:55:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Desai-2009">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 07:00:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dietrich-1990">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 07:04:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dietrich-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 07:05:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dietrich-1995">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 07:18:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dietrich-2008">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 07:30:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dignan-2001">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 07:35:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Diprose-2005">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 07:48:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dorman-2008">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 07:54:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dryden-1997">
<DESCRIPTION>
<P>Single blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 07:58:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eberle-1998">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 08:12:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ehrlich-1998">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 08:15:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ekback-2000">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 08:18:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ellis-2001">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-01 08:22:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Engel-2001">
<DESCRIPTION>
<P>Unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-02 01:04:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Englberger-2002a">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-02 01:13:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Englberger-2002b">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-02 01:17:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fauli-2005">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-02 01:23:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Feindt-1994">
<DESCRIPTION>
<P>Double blind - study was described as being double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-02 01:29:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fergusson-2008">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-02 01:38:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Findlay-2001">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-02 01:42:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fraedrich-1989">
<DESCRIPTION>
<P>Single blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-02 01:44:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garcia_x002d_Enguita-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-02 01:47:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garcia_x002d_Huete-1997">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-02 01:51:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garneti-2004">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-02 02:07:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gherli-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-02 05:19:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gill-2009">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-02 05:33:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Golanski-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-02 05:34:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Good-2003">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-02 05:40:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gott-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-02 05:58:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Green-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-02 06:06:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greilich-2001">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-02 06:09:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greilich-2003">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-02 06:12:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greilich-2004">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-02 06:53:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greilich-2009">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-11 06:59:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Groh-1993">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-11 07:02:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harder-1991">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-11 07:06:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hardy-1993">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-11 07:10:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hardy-1997">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-11 07:13:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hardy-1998">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-11 07:18:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harley-2002">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-11 07:21:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Harmon-2004">
<DESCRIPTION>
<P>Single blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-11 07:25:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Havel-1992">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-11 07:28:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Havel-1994">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-11 07:32:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hayashida-1997">
<DESCRIPTION>
<P>Single blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-11 07:35:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hayes-1996">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-11 07:39:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hei-2005">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-11 07:40:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hekmat-2004">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-11 07:47:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hendrice-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-12 00:25:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hiipala-1995">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-12 00:30:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hiipala-1997">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-12 00:33:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hill-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-12 00:37:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horrow-1990">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-12 00:43:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Horrow-1991">
<DESCRIPTION>
<P>Single blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-12 00:50:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horrow-1995">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-12 00:53:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Husted-2003">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-12 00:58:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ickx-2006">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-12 01:02:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Isetta-1993">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-12 01:05:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jamieson-1997">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-12 01:08:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jansen-1999">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-12 01:14:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Janssens-1994">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-12 01:17:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jares-2003">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-12 01:29:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jeserschek-2003">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-12 01:54:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jimenez-2007">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-12 02:05:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johansson-2005">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-12 02:08:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kahveci-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-12 02:11:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kalangos-1994">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-12 02:19:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Karski-1995">
<DESCRIPTION>
<P>Single blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-12 02:20:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karski-2005">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-13 04:22:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaspar-1997">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-13 04:31:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Katoh-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-13 04:34:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Katsaros-1996">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-13 04:37:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Katzel-1998">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-13 04:53:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kazemi-2010">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-13 04:56:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kikura-2006">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-13 05:00:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kipfer-2003">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-13 05:04:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klein-1998">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-13 05:08:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kluger-2003">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-13 05:17:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Koster-2004">
<DESCRIPTION>
<P>Single blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-13 05:20:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kratzer-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-13 05:35:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kreisler-2005">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-13 05:38:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kuepper-2003">
<DESCRIPTION>
<P>Single blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-13 05:42:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuitunen-2005">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-13 05:47:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuitunen-2006">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-13 05:50:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kunt-2005">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-13 05:51:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kyriss-2001">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-13 05:56:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Landymore-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-13 06:01:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lass-1995">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-13 06:10:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Later-2009">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-13 06:19:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laub-1994">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-13 06:21:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lavee-1993">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-13 06:39:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leijdekkers-2006">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-13 06:45:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lemay-2004">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-16 06:54:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lemmer-1994">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-16 07:04:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lemmer-1996">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-16 06:57:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lemmer_x005f_1-1994">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-16 06:59:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lemmer_x005f_2-1994">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-16 07:06:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lentschener-1997">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-16 07:10:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lentschener-1999">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-16 07:17:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Levy-1995">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-16 07:21:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2005">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-16 07:22:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-1993">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-16 07:28:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-16 07:31:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Llau-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-17 01:51:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Locatelli-1990">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-17 01:58:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Luo-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-17 05:22:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacGillivray-2010">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-17 02:28:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Maccario-1994">
<DESCRIPTION>
<P>Single blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-17 05:41:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maddali-2007">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-17 05:52:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maineri-2000">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-17 06:20:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mansour-2004">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-17 06:25:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marcel-1996">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-17 06:31:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mehr_x002d_Aein-2007">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-17 06:47:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mengistu-2008">
<DESCRIPTION>
<P>Single blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-17 06:55:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Menichetti-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-17 06:58:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Misfeld-1998">
<DESCRIPTION>
<P>Single blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-17 07:03:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mohr-1992">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-17 07:06:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mongan-1998">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-17 07:10:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moran-2000">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-17 07:12:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Murkin-1994">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-17 07:15:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Murkin-1995">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-17 07:21:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Murkin-2000">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-17 07:22:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Murphy-2006">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-17 07:30:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Niskanen-2005">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 03:41:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Norman-2009">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 03:45:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nur_x00f6_zler-2008">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 03:53:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nuttall-2000">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 03:59:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Okita-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 04:03:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Orpen-2006">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 04:07:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Palmer-2003">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 04:12:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parvizi-2007">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 04:16:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Penta-de-Peppo-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 04:19:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Petsatodis-2006">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 04:22:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pinosky-1997">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 04:26:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pleym-2003">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 04:27:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Porte-2000">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 04:33:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poston-2006">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 04:36:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prendergast_x005f_1-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 04:38:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prendergast_x005f_2-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 04:41:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pugh-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 04:45:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ranaboldo-1997">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 04:48:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rao-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 04:50:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ray-1997">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 05:13:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ray-1999">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 05:15:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ray-2001">
<DESCRIPTION>
<P>Single blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 05:20:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ray-2005">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 05:22:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rhydderch-1993">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 05:25:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rocha-1994">
<DESCRIPTION>
<P>Single blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 05:29:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rodrigus-1996">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 05:32:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rossi-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 05:35:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Royston-1987">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 06:02:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sadeghi-2007">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 06:10:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Samama-2002">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 06:14:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Santamaria-2000">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 06:17:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Santos-2006">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 06:19:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmartz-2003">
<DESCRIPTION>
<P>Double blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 06:26:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schweizer-2000">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 06:28:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shore_x002d_Lesserson-1996">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 06:35:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sorin-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 06:39:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Speekenbrink-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 06:43:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Speekenbrink-1996">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 06:47:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stammers-1997">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-18 06:49:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stewart-2001">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 00:59:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Swart-1994">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 01:05:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tabuchi-1994">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 01:07:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Taggart-2003">
<DESCRIPTION>
<P>Single blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 01:33:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taghaddomi-2009">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 01:39:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tanaka-2001">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 01:42:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tassani-2000">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 01:46:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thorpe-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 01:49:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Trinh_x002d_Duc-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 01:54:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Troianos-1999">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 01:58:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Turkoz-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 02:00:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Uozaki-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 02:02:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Urban-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 02:07:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Utada-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 02:13:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Oeveren-1987">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 02:11:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-der-Linden-2005">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 02:15:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vander_x002d_Salm-1996">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 02:23:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vanek-2005">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 02:28:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vedrinne-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 02:31:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Veien-2002">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 02:38:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wei-2006">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 03:20:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wendel-1995">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 03:24:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wong-2000">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 03:44:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wong-2008">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 03:53:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wu-2006">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 04:21:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamasaki-2004">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 04:31:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yassen-1993">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 04:34:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zabeeda-2002">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 04:57:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-19 04:36:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zohar-2004">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-02-16 14:10:33 +0000" MODIFIED_BY="Emma M Sydenham">
<COMPARISON ID="CMP-001" MODIFIED="2011-02-16 14:07:30 +0000" MODIFIED_BY="Emma M Sydenham" NO="1">
<NAME>Aprotinin versus Control (Blood Transfusion &amp; Blood Loss)</NAME>
<DICH_OUTCOME CHI2="961.5207601301836" CI_END="0.7170808096922968" CI_START="0.6037823987386717" CI_STUDY="95" CI_TOTAL="95" DF="107" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6579975466257332" ESTIMABLE="YES" EVENTS_1="2695" EVENTS_2="3067" I2="88.87179513570639" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.1444318998051568" LOG_CI_START="-0.21911955153499446" LOG_EFFECT_SIZE="-0.18177572567007563" METHOD="MH" MODIFIED="2010-10-19 10:09:37 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="-1.5543122344752192E-15" P_Q="0.0" P_Z="1.423251039856203E-21" Q="0.0" RANDOM="YES" SCALE="10.93" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="108" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.11851430400953715" TOTALS="YES" TOTAL_1="6259" TOTAL_2="4913" WEIGHT="99.99999999999999" Z="9.540368918431277">
<NAME>No. Exposed to Allogeneic Blood</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0093613198140765" CI_START="0.8702995983750681" EFFECT_SIZE="0.9372549019607843" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="25" LOG_CI_END="0.004046657923747294" LOG_CI_START="-0.060331216895382254" LOG_EFFECT_SIZE="-0.028142279485817483" ORDER="66234" O_E="0.0" SE="0.03781588234437657" STUDY_ID="STD-Bailey-1994" TOTAL_1="129" TOTAL_2="25" VAR="0.0014300409574837317" WEIGHT="1.6046969856237427"/>
<DICH_DATA CI_END="1.3454053931997747" CI_START="0.022094839371514755" EFFECT_SIZE="0.1724137931034483" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.1288531642656234" LOG_CI_START="-1.6557091513914979" LOG_EFFECT_SIZE="-0.7634279935629372" ORDER="66322" O_E="0.0" SE="1.048260737942924" STUDY_ID="STD-Vanek-2005" TOTAL_1="29" TOTAL_2="30" VAR="1.0988505747126436" WEIGHT="0.1581073449508625"/>
<DICH_DATA CI_END="0.581965375170908" CI_START="0.011932745040725218" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.23510285352801047" LOG_CI_START="-1.9232596385672394" LOG_EFFECT_SIZE="-1.0791812460476249" ORDER="66320" O_E="0.0" SE="0.991631652042901" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.9833333333333332" WEIGHT="0.17468325228281908"/>
<DICH_DATA CI_END="0.9323483780122118" CI_START="0.25881421861080883" EFFECT_SIZE="0.49122807017543857" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.030421780373552382" LOG_CI_START="-0.587011868286992" LOG_EFFECT_SIZE="-0.3087168243302722" ORDER="66249" O_E="0.0" SE="0.32694377280572434" STUDY_ID="STD-Dietrich-1990" TOTAL_1="19" TOTAL_2="20" VAR="0.10689223057644108" WEIGHT="0.8538986199522803"/>
<DICH_DATA CI_END="0.7537424083054954" CI_START="0.31088474574670794" EFFECT_SIZE="0.4840733590733591" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="37" LOG_CI_END="-0.12277704904434342" LOG_CI_START="-0.507400587061211" LOG_EFFECT_SIZE="-0.3150888180527773" ORDER="66296" O_E="0.0" SE="0.22592977014832727" STUDY_ID="STD-Cohen-1998" TOTAL_1="56" TOTAL_2="59" VAR="0.05104426103927599" WEIGHT="1.1351495499845883"/>
<DICH_DATA CI_END="1.26102060903135" CI_START="0.4408653477494194" EFFECT_SIZE="0.7456140350877193" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.10072218436487669" LOG_CI_START="-0.3556940356092364" LOG_EFFECT_SIZE="-0.12748592562217986" ORDER="66289" O_E="0.0" SE="0.26810114690952036" STUDY_ID="STD-Tabuchi-1994" TOTAL_1="19" TOTAL_2="17" VAR="0.07187822497420022" WEIGHT="1.0109342516671607"/>
<DICH_DATA CI_END="3.0394125886228682" CI_START="0.20748181399616164" EFFECT_SIZE="0.7941176470588235" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.48278965789495476" LOG_CI_START="-0.6830199636614904" LOG_EFFECT_SIZE="-0.10011515288326783" ORDER="66327" O_E="0.0" SE="0.6848023425529537" STUDY_ID="STD-Harmon-2004" TOTAL_1="17" TOTAL_2="18" VAR="0.46895424836601296" WEIGHT="0.32763341634694004"/>
<DICH_DATA CI_END="1.3461324819232787" CI_START="0.39949840375995604" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.12908780382323215" LOG_CI_START="-0.39848495161814457" LOG_EFFECT_SIZE="-0.13469857389745624" ORDER="66310" O_E="0.0" SE="0.3098988480735223" STUDY_ID="STD-Palmer-2003" TOTAL_1="30" TOTAL_2="26" VAR="0.09603729603729605" WEIGHT="0.8971004120648769"/>
<DICH_DATA CI_END="1.0650367118693163" CI_START="0.331144696158032" EFFECT_SIZE="0.5938697318007663" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" LOG_CI_END="0.027364578185526574" LOG_CI_START="-0.4799821965215054" LOG_EFFECT_SIZE="-0.22630880916798943" ORDER="66328" O_E="0.0" SE="0.29801800686994884" STUDY_ID="STD-Poston-2006" TOTAL_1="29" TOTAL_2="31" VAR="0.08881473241873687" WEIGHT="0.9283520153617253"/>
<DICH_DATA CI_END="0.8902876187799331" CI_START="0.3588398767925144" EFFECT_SIZE="0.5652173913043478" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="23" LOG_CI_END="-0.05046966631041668" LOG_CI_START="-0.4450993011110956" LOG_EFFECT_SIZE="-0.24778448371075615" ORDER="66295" O_E="0.0" SE="0.23180740093011587" STUDY_ID="STD-Bidstrup-2000" TOTAL_1="30" TOTAL_2="30" VAR="0.053734671125975485" WEIGHT="1.117419297617117"/>
<DICH_DATA CI_END="0.7716992950035634" CI_START="0.015998043658039977" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.11255189650552387" LOG_CI_START="-1.7959331223731259" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="66303" O_E="0.0" SE="0.9888264649460884" STUDY_ID="STD-Stewart-2001" TOTAL_1="15" TOTAL_2="15" VAR="0.9777777777777779" WEIGHT="0.1755684748697597"/>
<DICH_DATA CI_END="1.1628512108432862" CI_START="0.7528113445654874" EFFECT_SIZE="0.9356321839080459" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="29" LOG_CI_END="0.06552414942872957" LOG_CI_START="-0.12331384488756425" LOG_EFFECT_SIZE="-0.028894847729417316" ORDER="66287" O_E="0.0" SE="0.11092437262453853" STUDY_ID="STD-Speekenbrink-1996" TOTAL_1="75" TOTAL_2="37" VAR="0.012304216442147471" WEIGHT="1.4713079474269053"/>
<DICH_DATA CI_END="1.2371304328257535" CI_START="0.6806192486246042" EFFECT_SIZE="0.9176136363636364" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.09241549047004377" LOG_CI_START="-0.1670957727641001" LOG_EFFECT_SIZE="-0.03734014114702813" ORDER="66257" O_E="0.0" SE="0.1524382006252069" STUDY_ID="STD-Hardy-1993" TOTAL_1="22" TOTAL_2="19" VAR="0.02323740500985083" WEIGHT="1.3578272187523834"/>
<DICH_DATA CI_END="0.851080315601441" CI_START="0.17407565969356745" EFFECT_SIZE="0.3849056603773585" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="-0.07002945404391975" LOG_CI_START="-0.7592619503058609" LOG_EFFECT_SIZE="-0.4146457021748903" ORDER="66300" O_E="0.0" SE="0.4048585800601448" STUDY_ID="STD-Murkin-2000" TOTAL_1="212" TOTAL_2="68" VAR="0.1639104698483167" WEIGHT="0.6815065342251678"/>
<DICH_DATA CI_END="0.7811089758395658" CI_START="0.21508479595057134" EFFECT_SIZE="0.40988372093023256" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="24" LOG_CI_END="-0.10728837162309306" LOG_CI_START="-0.6673902882092073" LOG_EFFECT_SIZE="-0.3873393299161502" ORDER="66237" O_E="0.0" SE="0.3290066383518857" STUDY_ID="STD-Bidstrup-1993" TOTAL_1="43" TOTAL_2="47" VAR="0.10824536807960852" WEIGHT="0.8488031713836914"/>
<DICH_DATA CI_END="1.6182854246331981" CI_START="0.7470899207455475" EFFECT_SIZE="1.0995475113122173" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.20905512259825326" LOG_CI_START="-0.1266271227718502" LOG_EFFECT_SIZE="0.04121399991320153" MODIFIED="2010-05-17 13:57:08 +0100" MODIFIED_BY="Katharine Ker" ORDER="2590" O_E="0.0" SE="0.1971814125843122" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="27" VAR="0.03888050946874476" WEIGHT="1.2228759293758513"/>
<DICH_DATA CI_END="0.8150022791529388" CI_START="0.22000161521551823" EFFECT_SIZE="0.42344045368620037" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="23" LOG_CI_END="-0.08884117675430474" LOG_CI_START="-0.6575741306477412" LOG_EFFECT_SIZE="-0.37320765370102293" ORDER="66267" O_E="0.0" SE="0.33407655239053047" STUDY_ID="STD-Lemmer_x005f_2-1994" TOTAL_1="23" TOTAL_2="32" VAR="0.11160714285714285" WEIGHT="0.8364032619814963"/>
<DICH_DATA CI_END="1.3438135911295888" CI_START="0.7963564179938953" EFFECT_SIZE="1.0344827586206897" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="29" LOG_CI_END="0.12833902916533568" LOG_CI_START="-0.09889251552392286" LOG_EFFECT_SIZE="0.014723256820706378" ORDER="66256" O_E="0.0" SE="0.13347693416475745" STUDY_ID="STD-Harder-1991" TOTAL_1="40" TOTAL_2="40" VAR="0.01781609195402299" WEIGHT="1.411822561291756"/>
<DICH_DATA CI_END="1.020610877852942" CI_START="0.5393517492042281" EFFECT_SIZE="0.7419354838709677" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.008860192809001107" LOG_CI_START="-0.26812790844236073" LOG_EFFECT_SIZE="-0.1296338578166798" ORDER="66251" O_E="0.0" SE="0.16270418178826412" STUDY_ID="STD-Dietrich-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.026472650771388495" WEIGHT="1.3275285980178024"/>
<DICH_DATA CI_END="1.0307774244809154" CI_START="0.970141541956631" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="62" LOG_CI_END="0.013164898304624488" LOG_CI_START="-0.01316489830462447" LOG_EFFECT_SIZE="0.0" ORDER="66280" O_E="0.0" SE="0.015466252862868035" STUDY_ID="STD-Ranaboldo-1997" TOTAL_1="66" TOTAL_2="62" VAR="2.3920497761817372E-4" WEIGHT="1.6207885598733025"/>
<DICH_DATA CI_END="0.7975135540067488" CI_START="0.32428296497632014" EFFECT_SIZE="0.5085470085470085" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="26" LOG_CI_END="-0.09826192722963079" LOG_CI_START="-0.48907586480559345" LOG_EFFECT_SIZE="-0.2936688960176121" ORDER="66318" O_E="0.0" SE="0.22956604149231166" STUDY_ID="STD-Taggart-2003" TOTAL_1="36" TOTAL_2="34" VAR="0.05270056740644976" WEIGHT="1.1241682875989987"/>
<DICH_DATA CI_END="0.8534432320457009" CI_START="0.10136021596195216" EFFECT_SIZE="0.29411764705882354" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.06882536128531151" LOG_CI_START="-0.9941324727991987" LOG_EFFECT_SIZE="-0.5314789170422551" MODIFIED="2010-05-07 14:42:16 +0100" MODIFIED_BY="Katharine Ker" ORDER="2457" O_E="0.0" SE="0.5435299776473301" STUDY_ID="STD-Norman-2009" TOTAL_1="8" TOTAL_2="8" VAR="0.29542483660130725" WEIGHT="0.4649821916505914"/>
<DICH_DATA CI_END="2.314529531862027" CI_START="0.432053247208086" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.3644627264637834" LOG_CI_START="-0.3644627264637834" LOG_EFFECT_SIZE="0.0" ORDER="66248" O_E="0.0" SE="0.42817441928883765" STUDY_ID="STD-Deleuze-1991" TOTAL_1="30" TOTAL_2="30" VAR="0.18333333333333335" WEIGHT="0.6376539187303958"/>
<DICH_DATA CI_END="0.7532478029295167" CI_START="0.08297402230305383" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.12306212640134118" LOG_CI_START="-1.0810578562545836" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="66270" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Liu-1993" TOTAL_1="20" TOTAL_2="20" VAR="0.31666666666666665" WEIGHT="0.4422857196906323"/>
<DICH_DATA CI_END="1.0497678264256392" CI_START="0.4997731056344701" EFFECT_SIZE="0.7243243243243244" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="35" LOG_CI_END="0.021093258258824937" LOG_CI_START="-0.30122711833523724" LOG_EFFECT_SIZE="-0.14006693003820614" ORDER="66266" O_E="0.0" SE="0.18933258472294834" STUDY_ID="STD-Lemmer_x005f_1-1994" TOTAL_1="74" TOTAL_2="67" VAR="0.035846827637872405" WEIGHT="1.2469092883488382"/>
<DICH_DATA CI_END="1.174017116620848" CI_START="0.8517763377064567" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.06967442876831904" LOG_CI_START="-0.06967442876831907" LOG_EFFECT_SIZE="0.0" ORDER="66240" O_E="0.0" SE="0.0818542087049908" STUDY_ID="STD-Capdevila-1998" TOTAL_1="12" TOTAL_2="11" VAR="0.006700111482720192" WEIGHT="1.5371579067355423"/>
<DICH_DATA CI_END="1.5918330412997033" CI_START="0.8846618996705448" EFFECT_SIZE="1.1866903733807468" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="31" LOG_CI_END="0.20189751500676237" LOG_CI_START="-0.05322267637853529" LOG_EFFECT_SIZE="0.07433741931411353" ORDER="66247" O_E="0.0" SE="0.14985886328503842" STUDY_ID="STD-D_x0027_Ambra-1996" TOTAL_1="127" TOTAL_2="64" VAR="0.022457678905083836" WEIGHT="1.365337458066146"/>
<DICH_DATA CI_END="0.9849542929885672" CI_START="0.6267772455738472" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="42" LOG_CI_END="-0.006583922561699111" LOG_CI_START="-0.20288677847832687" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="66288" O_E="0.0" SE="0.11530926928023555" STUDY_ID="STD-Swart-1994" TOTAL_1="49" TOTAL_2="49" VAR="0.013296227581941874" WEIGHT="1.4602348271208656"/>
<DICH_DATA CI_END="0.8525208268207006" CI_START="0.3155703671806873" EFFECT_SIZE="0.5186813186813187" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="39" LOG_CI_END="-0.06929500252570277" LOG_CI_START="-0.5009037848483089" LOG_EFFECT_SIZE="-0.2850993936870058" MODIFIED="2010-05-20 12:02:46 +0100" MODIFIED_BY="Katharine Ker" ORDER="5334" O_E="0.0" SE="0.2535291352342283" STUDY_ID="STD-Colwell-2007" TOTAL_1="175" TOTAL_2="177" VAR="0.06427702241261564" WEIGHT="1.052972986074171"/>
<DICH_DATA CI_END="0.39482790023923114" CI_START="0.11321905262835025" EFFECT_SIZE="0.21142857142857144" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="35" LOG_CI_END="-0.40359216580023544" LOG_CI_START="-0.9460804834383635" LOG_EFFECT_SIZE="-0.6748363246192994" ORDER="66235" O_E="0.0" SE="0.3186603231411177" STUDY_ID="STD-Bidstrup-1989" TOTAL_1="40" TOTAL_2="37" VAR="0.10154440154440156" WEIGHT="0.8746499181965572"/>
<DICH_DATA CI_END="1.216920975501839" CI_START="0.8217460460714104" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" LOG_CI_END="0.08526237690073346" LOG_CI_START="-0.08526237690073346" LOG_EFFECT_SIZE="0.0" ORDER="66258" O_E="0.0" SE="0.10016708449412663" STUDY_ID="STD-Hardy-1997" TOTAL_1="26" TOTAL_2="26" VAR="0.010033444816053505" WEIGHT="1.497298323538404"/>
<DICH_DATA CI_END="1.1465948472003975" CI_START="0.06538635291433063" EFFECT_SIZE="0.27380952380952384" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.05940998572274674" LOG_CI_START="-1.1845128858113243" LOG_EFFECT_SIZE="-0.5625514500442887" ORDER="66312" O_E="0.0" SE="0.7306864522566346" STUDY_ID="STD-Englberger-2002a" TOTAL_1="21" TOTAL_2="23" VAR="0.5339026915113871" WEIGHT="0.2950173434055179"/>
<DICH_DATA CI_END="0.9740335218944856" CI_START="0.3695971359382001" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="-0.011426096382906073" LOG_CI_START="-0.4322714028498067" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="66292" O_E="0.0" SE="0.24720661623652213" STUDY_ID="STD-Wendel-1995" TOTAL_1="20" TOTAL_2="18" VAR="0.06111111111111113" WEIGHT="1.0715317132707212"/>
<DICH_DATA CI_END="1.3299782792134183" CI_START="0.575667296200363" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.12384454826424007" LOG_CI_START="-0.23982844221961358" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="66311" O_E="0.0" SE="0.2136233148205519" STUDY_ID="STD-Jeserschek-2003" TOTAL_1="9" TOTAL_2="9" VAR="0.04563492063492064" WEIGHT="1.1725570390483797"/>
<DICH_DATA CI_END="1.3225611225787064" CI_START="0.14449806862033407" EFFECT_SIZE="0.4371584699453552" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.12141575222725745" LOG_CI_START="-0.8401379577042294" LOG_EFFECT_SIZE="-0.3593611027384859" ORDER="66272" O_E="0.0" SE="0.564821408981384" STUDY_ID="STD-Maccario-1994" TOTAL_1="61" TOTAL_2="32" VAR="0.31902322404371586" WEIGHT="0.4399035887677423"/>
<DICH_DATA CI_END="1.1769979621462765" CI_START="0.7239358378865783" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="52" LOG_CI_END="0.07077571090682193" LOG_CI_START="-0.14029992342524575" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2010-05-21 15:24:02 +0100" MODIFIED_BY="Katharine Ker" ORDER="2328" O_E="0.0" SE="0.1239868724478975" STUDY_ID="STD-Parvizi-2007" TOTAL_1="81" TOTAL_2="81" VAR="0.015372744539411204" WEIGHT="1.4375873611167493"/>
<DICH_DATA CI_END="2.5475015595668227" CI_START="0.008011050351928473" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.40611445855130324" LOG_CI_START="-2.0963105385798166" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="66278" O_E="0.0" SE="1.469936830518334" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="2.1607142857142856" WEIGHT="0.08444713693000627"/>
<DICH_DATA CI_END="0.7708713825665181" CI_START="0.5331054961218116" EFFECT_SIZE="0.6410583209421983" ESTIMABLE="YES" EVENTS_1="173" EVENTS_2="87" LOG_CI_END="-0.11301807655504825" LOG_CI_START="-0.2731868400353992" LOG_EFFECT_SIZE="-0.1931024582952237" ORDER="66265" O_E="0.0" SE="0.09408392451652427" STUDY_ID="STD-Lemmer-1996" TOTAL_1="487" TOTAL_2="157" VAR="0.008851784852431035" WEIGHT="1.5111897564805106"/>
<DICH_DATA CI_END="0.9019134165859846" CI_START="0.5221928115776203" EFFECT_SIZE="0.6862745098039216" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="25" LOG_CI_END="-0.04483515259530587" LOG_CI_START="-0.2821691109000156" LOG_EFFECT_SIZE="-0.16350213174766073" ORDER="66326" O_E="0.0" SE="0.1394111419302274" STUDY_ID="STD-Petsatodis-2006" TOTAL_1="25" TOTAL_2="25" VAR="0.01943546649429001" WEIGHT="1.3952493585761558"/>
<DICH_DATA CI_END="0.9468374527500885" CI_START="0.399961179980938" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="26" LOG_CI_END="-0.02372457161220413" LOG_CI_START="-0.3979821590175822" LOG_EFFECT_SIZE="-0.21085336531489315" ORDER="66252" O_E="0.0" SE="0.2198407594468552" STUDY_ID="STD-Fraedrich-1989" TOTAL_1="38" TOTAL_2="38" VAR="0.048329959514170046" WEIGHT="1.1536167006655507"/>
<DICH_DATA CI_END="0.8864387002945626" CI_START="0.20841729216507215" EFFECT_SIZE="0.4298245614035088" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" LOG_CI_END="-0.052351291697907774" LOG_CI_START="-0.6810662509180101" LOG_EFFECT_SIZE="-0.3667087713079589" ORDER="66268" O_E="0.0" SE="0.369310279235129" STUDY_ID="STD-Lentschener-1997" TOTAL_1="48" TOTAL_2="49" VAR="0.13639008234872896" WEIGHT="0.7550844124772007"/>
<DICH_DATA CI_END="0.7866183929057147" CI_START="0.16610386164783042" EFFECT_SIZE="0.3614697120158888" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="19" LOG_CI_END="-0.10423590302661616" LOG_CI_START="-0.779620270782508" LOG_EFFECT_SIZE="-0.441928086904562" ORDER="66281" O_E="0.0" SE="0.3967241208263498" STUDY_ID="STD-Ray-1997" TOTAL_1="53" TOTAL_2="52" VAR="0.15739002804544017" WEIGHT="0.697612565114925"/>
<DICH_DATA CI_END="2.410392969374453" CI_START="0.26551687136977226" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.38208785191856476" LOG_CI_START="-0.5759078779346776" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="66316" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Kipfer-2003" TOTAL_1="15" TOTAL_2="15" VAR="0.3166666666666667" WEIGHT="0.4422857196906322"/>
<DICH_DATA CI_END="0.7620123531650056" CI_START="0.5126229232079317" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="48" LOG_CI_END="-0.11803798815133151" LOG_CI_START="-0.29020197716051804" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="66262" O_E="0.0" SE="0.10112997936948631" STUDY_ID="STD-Kalangos-1994" TOTAL_1="110" TOTAL_2="55" VAR="0.010227272727272727" WEIGHT="1.4950440540640073"/>
<DICH_DATA CI_END="0.8207319356942484" CI_START="0.6020493368181332" EFFECT_SIZE="0.702937491950874" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="213" LOG_CI_END="-0.08579866731277815" LOG_CI_START="-0.22036791766259636" LOG_EFFECT_SIZE="-0.1530832924876873" ORDER="66293" O_E="0.0" SE="0.07904664378401566" STUDY_ID="STD-Alderman-1998" TOTAL_1="401" TOTAL_2="395" VAR="0.0062483718935170615" WEIGHT="1.5427236344365787"/>
<DICH_DATA CI_END="1.1223523647028855" CI_START="0.17286841501668593" EFFECT_SIZE="0.44047619047619047" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.05012922592328552" LOG_CI_START="-0.7622843499130588" LOG_EFFECT_SIZE="-0.35607756199488666" ORDER="66297" O_E="0.0" SE="0.4772157559583272" STUDY_ID="STD-Lentschener-1999" TOTAL_1="35" TOTAL_2="37" VAR="0.22773487773487772" WEIGHT="0.5558838517437087"/>
<DICH_DATA CI_END="1.0732934239859022" CI_START="0.06625505152824374" EFFECT_SIZE="0.26666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.030718468468461112" LOG_CI_START="-1.1787810039238988" LOG_EFFECT_SIZE="-0.5740312677277188" ORDER="66315" O_E="0.0" SE="0.7104659772022196" STUDY_ID="STD-Englberger-2002b" TOTAL_1="15" TOTAL_2="14" VAR="0.5047619047619047" WEIGHT="0.30881064623112214"/>
<DICH_DATA CI_END="0.7917906433240165" CI_START="0.12333594849015803" EFFECT_SIZE="0.3125" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.10138963465852775" LOG_CI_START="-0.9089103219812843" LOG_EFFECT_SIZE="-0.505149978319906" ORDER="66319" O_E="0.0" SE="0.4743416490252569" STUDY_ID="STD-Li-2005" TOTAL_1="40" TOTAL_2="30" VAR="0.22499999999999998" WEIGHT="0.5603095025872605"/>
<DICH_DATA CI_END="0.8548579066310278" CI_START="0.4535633977347247" EFFECT_SIZE="0.6226815050344462" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="37" LOG_CI_END="-0.06810606713672084" LOG_CI_START="-0.34336199997763184" LOG_EFFECT_SIZE="-0.2057340335571763" ORDER="66263" O_E="0.0" SE="0.16168669748959338" STUDY_ID="STD-Lass-1995" TOTAL_1="51" TOTAL_2="47" VAR="0.026142588145091284" WEIGHT="1.3305576108012243"/>
<DICH_DATA CI_END="0.9372502510926616" CI_START="0.4494540535626551" EFFECT_SIZE="0.6490384615384616" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="-0.028144434557366343" LOG_CI_START="-0.3473146983781445" LOG_EFFECT_SIZE="-0.1877295664677554" ORDER="66236" O_E="0.0" SE="0.1874821928866116" STUDY_ID="STD-Bidstrup-1990" TOTAL_1="26" TOTAL_2="18" VAR="0.035149572649572636" WEIGHT="1.2525671810179606"/>
<DICH_DATA CI_END="0.720649865502474" CI_START="0.1158076815365343" EFFECT_SIZE="0.28888888888888886" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.14227569008565652" LOG_CI_START="-0.9362626328513574" LOG_EFFECT_SIZE="-0.539269161468507" ORDER="66254" O_E="0.0" SE="0.4663918604793264" STUDY_ID="STD-Gherli-1992" TOTAL_1="18" TOTAL_2="13" VAR="0.21752136752136747" WEIGHT="0.5727794550332173"/>
<DICH_DATA CI_END="0.7804173827907901" CI_START="0.45795498425174797" EFFECT_SIZE="0.5978260869565217" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="46" LOG_CI_END="-0.10767306582026084" LOG_CI_START="-0.33917720988236205" LOG_EFFECT_SIZE="-0.22342513785131143" ORDER="66261" O_E="0.0" SE="0.13598668018607324" STUDY_ID="STD-Isetta-1993" TOTAL_1="140" TOTAL_2="70" VAR="0.01849237718802936" WEIGHT="1.4048535963997313"/>
<DICH_DATA CI_END="0.8973650634832809" CI_START="0.4380356604107999" EFFECT_SIZE="0.6269592476489029" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" LOG_CI_END="-0.04703084257180927" LOG_CI_START="-0.3584905322145905" LOG_EFFECT_SIZE="-0.2027606873931999" ORDER="66275" O_E="0.0" SE="0.18295296344649845" STUDY_ID="STD-Murkin-1994" TOTAL_1="29" TOTAL_2="25" VAR="0.0334717868338558" WEIGHT="1.2663943637416073"/>
<DICH_DATA CI_END="1.0138017822726142" CI_START="0.3434056028344289" EFFECT_SIZE="0.5900383141762452" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" LOG_CI_END="0.005953050381643381" LOG_CI_START="-0.4641926233852791" LOG_EFFECT_SIZE="-0.2291197865018179" ORDER="66243" O_E="0.0" SE="0.27616589602930897" STUDY_ID="STD-Cicek-1996b" TOTAL_1="29" TOTAL_2="28" VAR="0.0762676021296711" WEIGHT="0.9881530200943495"/>
<DICH_DATA CI_END="1.6216329114793497" CI_START="0.733879188195826" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.20995254989858633" LOG_CI_START="-0.13437542811978684" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="66286" O_E="0.0" SE="0.20225995873897265" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.04090909090909092" WEIGHT="1.2073154564888946"/>
<DICH_DATA CI_END="0.7824570437156144" CI_START="0.4904318747402467" EFFECT_SIZE="0.6194690265486725" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="44" LOG_CI_END="-0.10653949555704548" LOG_CI_START="-0.3094213113812804" LOG_EFFECT_SIZE="-0.2079804034691629" ORDER="66246" O_E="0.0" SE="0.11917378289634074" STUDY_ID="STD-Cosgrove-1992" TOTAL_1="113" TOTAL_2="56" VAR="0.014202390529824159" WEIGHT="1.4502646368585412"/>
<DICH_DATA CI_END="2.156255130476228" CI_START="0.031811682828664346" EFFECT_SIZE="0.2619047619047619" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3337001457552575" LOG_CI_START="-1.4974133562346084" LOG_EFFECT_SIZE="-0.5818566052396754" ORDER="66284" O_E="0.0" SE="1.075605135226867" STUDY_ID="STD-Rossi-1997" TOTAL_1="21" TOTAL_2="22" VAR="1.156926406926407" WEIGHT="0.15090809565734437"/>
<DICH_DATA CI_END="0.9067145062236663" CI_START="0.6096295146835113" EFFECT_SIZE="0.7434782608695653" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="46" LOG_CI_END="-0.04252943608158775" LOG_CI_START="-0.21493401516929028" LOG_EFFECT_SIZE="-0.12873172562543903" ORDER="66260" O_E="0.0" SE="0.10127130317254668" STUDY_ID="STD-Hayashida-1997" TOTAL_1="110" TOTAL_2="57" VAR="0.010255876846265864" WEIGHT="1.4947119552990742"/>
<DICH_DATA CI_END="1.3254060928964186" CI_START="0.40235538574672136" EFFECT_SIZE="0.7302631578947368" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.12234896271291117" LOG_CI_START="-0.3953901810291414" LOG_EFFECT_SIZE="-0.13652060915811512" MODIFIED="2010-05-17 10:45:03 +0100" MODIFIED_BY="Katharine Ker" ORDER="2546" O_E="0.0" SE="0.30412253588417626" STUDY_ID="STD-Desai-2009" TOTAL_1="38" TOTAL_2="37" VAR="0.09249051683262208" WEIGHT="0.9121797693673165"/>
<DICH_DATA CI_END="0.7811464089683755" CI_START="0.6922940885893394" EFFECT_SIZE="0.7353795219147709" ESTIMABLE="YES" EVENTS_1="549" EVENTS_2="730" LOG_CI_END="-0.10726755940321708" LOG_CI_START="-0.1597093767577549" LOG_EFFECT_SIZE="-0.13348846808048598" ORDER="66250" O_E="0.0" SE="0.03080458310523803" STUDY_ID="STD-Dietrich-1992" TOTAL_1="902" TOTAL_2="882" VAR="9.489223402875163E-4" WEIGHT="1.6111596404367095"/>
<DICH_DATA CI_END="1.4043574036065283" CI_START="0.7193914498899935" EFFECT_SIZE="1.005128205128205" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="15" LOG_CI_END="0.14747764815076966" LOG_CI_START="-0.14303472816285362" LOG_EFFECT_SIZE="0.0022214599939580325" ORDER="66277" O_E="0.0" SE="0.17064840790607783" STUDY_ID="STD-Okita-1996" TOTAL_1="39" TOTAL_2="21" VAR="0.02912087912087913" WEIGHT="1.303715853701126"/>
<DICH_DATA CI_END="0.9357484130358864" CI_START="0.3431596641124053" EFFECT_SIZE="0.5666666666666667" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="-0.028840900746099345" LOG_CI_START="-0.46450376593667775" LOG_EFFECT_SIZE="-0.2466723333413885" ORDER="66244" O_E="0.0" SE="0.2559105235789091" STUDY_ID="STD-Cicek-1996a" TOTAL_1="50" TOTAL_2="25" VAR="0.06549019607843137" WEIGHT="1.0460305520744055"/>
<DICH_DATA CI_END="1.1620394238299383" CI_START="0.27073602422146403" EFFECT_SIZE="0.5608974358974359" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.06522086235840659" LOG_CI_START="-0.5674539530227032" LOG_EFFECT_SIZE="-0.25111654533214833" ORDER="66302" O_E="0.0" SE="0.3716363183457089" STUDY_ID="STD-Greilich-2001" TOTAL_1="24" TOTAL_2="25" VAR="0.1381135531135531" WEIGHT="0.7500133889162056"/>
<DICH_DATA CI_END="1.0403570180709536" CI_START="0.56797137464091" EFFECT_SIZE="0.768695652173913" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="23" LOG_CI_END="0.01718240119376299" LOG_CI_START="-0.24567355187484013" LOG_EFFECT_SIZE="-0.11424557534053863" MODIFIED="2010-05-07 14:56:17 +0100" MODIFIED_BY="Katharine Ker" ORDER="2462" O_E="0.0" SE="0.15440288799045002" STUDY_ID="STD-Nur_x00f6_zler-2008" TOTAL_1="25" TOTAL_2="26" VAR="0.023840251819791457" WEIGHT="1.3520770564024214"/>
<DICH_DATA CI_END="0.9361707678459628" CI_START="0.3957722348326828" EFFECT_SIZE="0.6086956521739131" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="23" LOG_CI_END="-0.028644923944956005" LOG_CI_START="-0.40255467673375367" LOG_EFFECT_SIZE="-0.21559980033935483" ORDER="66291" O_E="0.0" SE="0.21963643967126673" STUDY_ID="STD-Vedrinne-1992" TOTAL_1="30" TOTAL_2="30" VAR="0.04824016563146998" WEIGHT="1.154237899742993"/>
<DICH_DATA CI_END="0.8485647549882042" CI_START="0.46077627889680506" EFFECT_SIZE="0.6252987367702287" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="58" LOG_CI_END="-0.07131501055197918" LOG_CI_START="-0.33650988681009075" LOG_EFFECT_SIZE="-0.20391244868103495" ORDER="66329" O_E="0.0" SE="0.15577678304982373" STUDY_ID="STD-Dignan-2001" TOTAL_1="101" TOTAL_2="99" VAR="0.02426640613735185" WEIGHT="1.3480415429589911"/>
<DICH_DATA CI_END="1.0237823367364247" CI_START="0.10853001377744706" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.010207632418683592" LOG_CI_START="-0.9644501418580085" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="66307" O_E="0.0" SE="0.5725188012439223" STUDY_ID="STD-Kyriss-2001" TOTAL_1="18" TOTAL_2="20" VAR="0.3277777777777778" WEIGHT="0.4312743529761264"/>
<DICH_DATA CI_END="0.8731188140017339" CI_START="0.5154136572187269" EFFECT_SIZE="0.6708333333333333" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="-0.05892665348310755" LOG_CI_START="-0.28784407787640515" LOG_EFFECT_SIZE="-0.17338536567975632" ORDER="66294" O_E="0.0" SE="0.1344672282481491" STUDY_ID="STD-Basora-1999" TOTAL_1="36" TOTAL_2="21" VAR="0.018081435472739826" WEIGHT="1.4090800309051066"/>
<DICH_DATA CI_END="1.1831785640385561" CI_START="0.023477249015536238" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.07305029283121232" LOG_CI_START="-1.6293527935984997" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="66298" O_E="0.0" SE="1.0" STUDY_ID="STD-Katzel-1998" TOTAL_1="12" TOTAL_2="12" VAR="1.0000000000000002" WEIGHT="0.17208034633194244"/>
<DICH_DATA CI_END="0.8847859245407694" CI_START="0.540868121448187" EFFECT_SIZE="0.6917748917748918" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="16" LOG_CI_END="-0.05316179488080641" LOG_CI_START="-0.266908614947537" LOG_EFFECT_SIZE="-0.1600352049141717" ORDER="66274" O_E="0.0" SE="0.12555594017102115" STUDY_ID="STD-Mohr-1992" TOTAL_1="34" TOTAL_2="16" VAR="0.015764294112229044" WEIGHT="1.4333954293792497"/>
<DICH_DATA CI_END="1.9071560686454936" CI_START="1.0494267347438109" EFFECT_SIZE="1.414715719063545" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="26" LOG_CI_END="0.28038623419867686" LOG_CI_START="0.02095212390254852" LOG_EFFECT_SIZE="0.15066917905061267" ORDER="66283" O_E="0.0" SE="0.1523928806075034" STUDY_ID="STD-Rodrigus-1996" TOTAL_1="46" TOTAL_2="47" VAR="0.02322359005985278" WEIGHT="1.3579595638479292"/>
<DICH_DATA CI_END="2.4521888362810533" CI_START="0.008322427279400224" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3895539109512145" LOG_CI_START="-2.079749990979728" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="66317" O_E="0.0" SE="1.4504813352456845" STUDY_ID="STD-Llau-1998" TOTAL_1="10" TOTAL_2="10" VAR="2.103896103896104" WEIGHT="0.08660611385121122"/>
<DICH_DATA CI_END="3.436173203095408" CI_START="0.1293428526955729" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5360750466763062" LOG_CI_START="-0.8882575647876688" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="66324" O_E="0.0" SE="0.8366600265340756" STUDY_ID="STD-Ray-2005" TOTAL_1="15" TOTAL_2="15" VAR="0.7" WEIGHT="0.23515084326363844"/>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516804" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="66239" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Boldt-1991" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="0.07393296456220094"/>
<DICH_DATA CI_END="5.461059148182932" CI_START="0.5086518388474208" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7372768803609144" LOG_CI_START="-0.2935793811282016" LOG_EFFECT_SIZE="0.22184874961635637" ORDER="66305" O_E="0.0" SE="0.6055300708194984" STUDY_ID="STD-Engel-2001" TOTAL_1="12" TOTAL_2="12" VAR="0.3666666666666667" WEIGHT="0.3967062610533518"/>
<DICH_DATA CI_END="1.0006396605496894" CI_START="0.3378044714556414" EFFECT_SIZE="0.5813953488372093" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="2.7771223570681805E-4" LOG_CI_START="-0.4713346060508047" LOG_EFFECT_SIZE="-0.23552844690754887" ORDER="66245" O_E="0.0" SE="0.277027410280123" STUDY_ID="STD-Corbeau-1995" TOTAL_1="43" TOTAL_2="20" VAR="0.0767441860465116" WEIGHT="0.985741151413919"/>
<DICH_DATA CI_END="1.0533410525445912" CI_START="0.6797193839842649" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="26" LOG_CI_END="0.02256901055561178" LOG_CI_START="-0.16767034485283525" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="66282" O_E="0.0" SE="0.11174753906691859" STUDY_ID="STD-Rocha-1994" TOTAL_1="28" TOTAL_2="28" VAR="0.012487512487512495" WEIGHT="1.4692493123981036"/>
<DICH_DATA CI_END="2.4702082767769804" CI_START="0.15813443897519056" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.392733572547735" LOG_CI_START="-0.8009735378595846" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2010-04-21 11:10:16 +0100" MODIFIED_BY="Katharine Ker" ORDER="2363" O_E="0.0" SE="0.7011894655987543" STUDY_ID="STD-Cicekcioglu-2006" TOTAL_1="24" TOTAL_2="20" VAR="0.49166666666666664" WEIGHT="0.3154381045313365"/>
<DICH_DATA CI_END="70.82882080128427" CI_START="0.12706691849706478" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8502100114756685" LOG_CI_START="-0.895967502036344" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="66299" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-D_x0027_Ambrosio-1999" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="0.07074532881267774"/>
<DICH_DATA CI_END="1.5757982109905528" CI_START="0.20721600644516502" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.19750060308743156" LOG_CI_START="-0.6835767004600205" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="66264" O_E="0.0" SE="0.5175491695067657" STUDY_ID="STD-Laub-1994" TOTAL_1="16" TOTAL_2="16" VAR="0.26785714285714285" WEIGHT="0.49815878055193674"/>
<DICH_DATA CI_END="1.0902507120596947" CI_START="0.9172202218614527" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.037526378990036593" LOG_CI_START="-0.037526378990036614" LOG_EFFECT_SIZE="0.0" ORDER="66279" O_E="0.0" SE="0.04408636155463877" STUDY_ID="STD-Pugh-1995" TOTAL_1="21" TOTAL_2="23" VAR="0.0019436072751263314" WEIGHT="1.5978554397837903"/>
<DICH_DATA CI_END="1.2854855901578142" CI_START="0.5973191554248912" EFFECT_SIZE="0.8762677484787018" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.10906721271748547" LOG_CI_START="-0.22379355764212133" LOG_EFFECT_SIZE="-0.05736317246231793" ORDER="66276" O_E="0.0" SE="0.19552406419661988" STUDY_ID="STD-Murkin-1995" TOTAL_1="29" TOTAL_2="24" VAR="0.03822965967996394" WEIGHT="1.227953691361736"/>
<DICH_DATA CI_END="0.9968014774159336" CI_START="0.30347065775242266" EFFECT_SIZE="0.55" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="-0.0013913269919762872" LOG_CI_START="-0.5178832940195359" LOG_EFFECT_SIZE="-0.2596373105057561" ORDER="66309" O_E="0.0" SE="0.30338993810845893" STUDY_ID="STD-Cvachovec-2001" TOTAL_1="20" TOTAL_2="22" VAR="0.09204545454545456" WEIGHT="0.9141078529538891"/>
<DICH_DATA CI_END="1.2419824481161656" CI_START="0.02830655944721672" EFFECT_SIZE="0.1875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.09411545836861414" LOG_CI_START="-1.5481129142411387" LOG_EFFECT_SIZE="-0.7269987279362623" ORDER="66290" O_E="0.0" SE="0.9646530752325188" STUDY_ID="STD-Thorpe-1994" TOTAL_1="8" TOTAL_2="9" VAR="0.9305555555555556" WEIGHT="0.18347141237189465"/>
<DICH_DATA CI_END="1.7248117563970482" CI_START="0.1672117424292004" EFFECT_SIZE="0.5370370370370371" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.23674170368809447" LOG_CI_START="-0.7767332275361192" LOG_EFFECT_SIZE="-0.26999576192401237" ORDER="66306" O_E="0.0" SE="0.5953201913829222" STUDY_ID="STD-Klein-1998" TOTAL_1="36" TOTAL_2="29" VAR="0.35440613026819917" WEIGHT="0.4069909330628682"/>
<DICH_DATA CI_END="0.925107108046671" CI_START="0.6394106016052801" EFFECT_SIZE="0.769105514546244" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="49" LOG_CI_END="-0.03380798213586703" LOG_CI_START="-0.19422016728156163" LOG_EFFECT_SIZE="-0.11401407470871433" ORDER="66269" O_E="0.0" SE="0.09422691160770381" STUDY_ID="STD-Levy-1995" TOTAL_1="188" TOTAL_2="65" VAR="0.008878710871126027" WEIGHT="1.510870348672533"/>
<DICH_DATA CI_END="0.8889502048802845" CI_START="0.3373491784678522" EFFECT_SIZE="0.5476190476190477" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" LOG_CI_END="-0.05112256563428223" LOG_CI_START="-0.47192034312633274" LOG_EFFECT_SIZE="-0.26152145438030755" ORDER="66304" O_E="0.0" SE="0.24717869748142302" STUDY_ID="STD-Ray-1999" TOTAL_1="100" TOTAL_2="50" VAR="0.061097308488612834" WEIGHT="1.071614057321462"/>
<DICH_DATA CI_END="0.6609816379241117" CI_START="0.11252985109065299" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="-0.1798106050514249" LOG_CI_START="-0.9487322558257003" LOG_EFFECT_SIZE="-0.5642714304385626" ORDER="66308" O_E="0.0" SE="0.4516683838883667" STUDY_ID="STD-Santamaria-2000" TOTAL_1="56" TOTAL_2="28" VAR="0.20400432900432902" WEIGHT="0.5967851438925007"/>
<DICH_DATA CI_END="0.4272576057276957" CI_START="0.028895164993771816" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="18" LOG_CI_END="-0.3693101975453905" LOG_CI_START="-1.5391748213332594" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="66273" O_E="0.0" SE="0.6871842709362768" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.47222222222222227" WEIGHT="0.325820937531939"/>
<DICH_DATA CI_END="1.1257994302155443" CI_START="0.3587946958901859" EFFECT_SIZE="0.6355555555555555" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.05146102452110328" LOG_CI_START="-0.4451539858137047" LOG_EFFECT_SIZE="-0.1968464806463007" ORDER="66271" O_E="0.0" SE="0.29171411535461406" STUDY_ID="STD-Locatelli-1990" TOTAL_1="25" TOTAL_2="13" VAR="0.08509712509712508" WEIGHT="0.9453021849297305"/>
<DICH_DATA CI_END="2.1315266092423184" CI_START="0.3002542859305412" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3286907585993715" LOG_CI_START="-0.5225107846154844" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="66301" O_E="0.0" SE="0.49999999999999994" STUDY_ID="STD-Tassani-2000" TOTAL_1="10" TOTAL_2="10" VAR="0.24999999999999997" WEIGHT="0.5222981217201585"/>
<DICH_DATA CI_END="0.9593385583155755" CI_START="0.7355067654519231" EFFECT_SIZE="0.84" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="50" LOG_CI_END="-0.018028099752735213" LOG_CI_START="-0.13341332812350148" LOG_EFFECT_SIZE="-0.07572071393811836" ORDER="66241" O_E="0.0" SE="0.06777785431108017" STUDY_ID="STD-Carrera-1994" TOTAL_1="51" TOTAL_2="51" VAR="0.004593837535014009" WEIGHT="1.5634573505566156"/>
<DICH_DATA CI_END="0.9779863575014763" CI_START="0.11361212787770752" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="-0.009667203395581254" LOG_CI_START="-0.9445753060437436" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="66238" O_E="0.0" SE="0.5491696473652761" STUDY_ID="STD-Blauhut-1994" TOTAL_1="14" TOTAL_2="14" VAR="0.3015873015873016" WEIGHT="0.45816137393177603"/>
<DICH_DATA CI_END="0.9036903622073366" CI_START="0.15561192846686125" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="-0.04398034941401264" LOG_CI_START="-0.8079571151305497" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="66255" O_E="0.0" SE="0.44876373392787533" STUDY_ID="STD-Green-1995" TOTAL_1="48" TOTAL_2="36" VAR="0.2013888888888889" WEIGHT="0.6016642943364"/>
<DICH_DATA CI_END="2.1719720978715733" CI_START="0.319729910492389" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3368542418108039" LOG_CI_START="-0.49521673390605353" LOG_EFFECT_SIZE="-0.07918124604762482" MODIFIED="2010-05-26 12:15:17 +0100" MODIFIED_BY="Katharine Ker" ORDER="2764" O_E="0.0" SE="0.4887626099538393" STUDY_ID="STD-Wei-2006" TOTAL_1="36" TOTAL_2="40" VAR="0.23888888888888885" WEIGHT="0.5385355604976197"/>
<DICH_DATA CI_END="1.176699175298307" CI_START="0.3968256749445487" EFFECT_SIZE="0.6833333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" LOG_CI_END="0.07066544907408982" LOG_CI_START="-0.4014002364019061" LOG_EFFECT_SIZE="-0.16536739366390812" ORDER="66253" O_E="0.0" SE="0.2772937204114299" STUDY_ID="STD-Garcia_x002d_Huete-1997" TOTAL_1="39" TOTAL_2="41" VAR="0.07689180737961226" WEIGHT="0.9849964642501992"/>
<DICH_DATA CI_END="1.2005001082166866" CI_START="0.15299746175000142" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.07936220354165731" LOG_CI_START="-0.8153157741308461" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="66259" O_E="0.0" SE="0.5255382728122436" STUDY_ID="STD-Havel-1992" TOTAL_1="10" TOTAL_2="10" VAR="0.2761904761904762" WEIGHT="0.4876412409134188"/>
<DICH_DATA CI_END="0.8925895825655312" CI_START="0.5575925005095984" EFFECT_SIZE="0.7054794520547946" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="73" LOG_CI_END="-0.0493481861272466" LOG_CI_START="-0.25368307603128315" LOG_EFFECT_SIZE="-0.15151563107926486" MODIFIED="2010-05-06 16:06:06 +0100" MODIFIED_BY="Katharine Ker" ORDER="2368" O_E="0.0" SE="0.12002732580364896" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="103" VAR="0.014406558939575296" WEIGHT="1.448037008944787"/>
<DICH_DATA CI_END="1.1661827845720796" CI_START="0.3228907095511885" EFFECT_SIZE="0.6136363636363636" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.06676662598870041" LOG_CI_START="-0.49094445064310055" LOG_EFFECT_SIZE="-0.2120889123272001" ORDER="66231" O_E="0.0" SE="0.3276022471278735" STUDY_ID="STD-Alajmo-1989" TOTAL_1="22" TOTAL_2="12" VAR="0.1073232323232323" WEIGHT="0.8522689891886868"/>
<DICH_DATA CI_END="0.9794902492496453" CI_START="0.5964920617890417" EFFECT_SIZE="0.764367816091954" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="45" LOG_CI_END="-0.008999883016004835" LOG_CI_START="-0.22439533161502298" LOG_EFFECT_SIZE="-0.11669760731551393" ORDER="66233" O_E="0.0" SE="0.1265243527317297" STUDY_ID="STD-Baele-1992" TOTAL_1="58" TOTAL_2="57" VAR="0.01600841183418316" WEIGHT="1.4307942536247695"/>
<DICH_DATA CI_END="1.55131165165505" CI_START="0.5025351252755366" EFFECT_SIZE="0.882943143812709" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.1906990544207529" LOG_CI_START="-0.29883357732995014" LOG_EFFECT_SIZE="-0.0540672614545986" ORDER="66313" O_E="0.0" SE="0.28755389111597146" STUDY_ID="STD-Amar-2003" TOTAL_1="23" TOTAL_2="24" VAR="0.08268724029593597" WEIGHT="0.9566245103912805"/>
<DICH_DATA CI_END="0.968686759662337" CI_START="0.43166883561525266" EFFECT_SIZE="0.6466466466466466" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="27" LOG_CI_END="-0.013816636306206052" LOG_CI_START="-0.36484930415559036" LOG_EFFECT_SIZE="-0.18933297023089823" ORDER="66321" O_E="0.0" SE="0.2061983267344585" STUDY_ID="STD-Van-der-Linden-2005" TOTAL_1="37" TOTAL_2="38" VAR="0.0425177499480905" WEIGHT="1.1952547587937896"/>
<DICH_DATA CI_END="0.5985457020816825" CI_START="0.1466746731178129" EFFECT_SIZE="0.2962962962962963" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="27" LOG_CI_END="-0.22290268334593874" LOG_CI_START="-0.8336448709881488" LOG_EFFECT_SIZE="-0.5282737771670437" ORDER="66323" O_E="0.0" SE="0.3587529842436209" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.1287037037037037" WEIGHT="0.7785611193600924"/>
<DICH_DATA CI_END="2.1861039695791042" CI_START="0.25282575215333275" EFFECT_SIZE="0.7434402332361516" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.3396708128473259" LOG_CI_START="-0.5971786920649566" LOG_EFFECT_SIZE="-0.12875393960881534" ORDER="66232" O_E="0.0" SE="0.5503100366653163" STUDY_ID="STD-Alvarez-1995" TOTAL_1="49" TOTAL_2="51" VAR="0.3028411364545818" WEIGHT="0.45679801499461864"/>
<DICH_DATA CI_END="0.8944158527519801" CI_START="0.26944036691176204" EFFECT_SIZE="0.4909090909090909" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="-0.04846051189314574" LOG_CI_START="-0.5695373387773675" LOG_EFFECT_SIZE="-0.3089989253352565" ORDER="66314" O_E="0.0" SE="0.3060831074836844" STUDY_ID="STD-Samama-2002" TOTAL_1="40" TOTAL_2="18" VAR="0.09368686868686871" WEIGHT="0.9070370647129452"/>
<DICH_DATA CI_END="1.5636597783045803" CI_START="0.5373789039255461" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.19414226504209867" LOG_CI_START="-0.26971938682089824" LOG_EFFECT_SIZE="-0.0377885608893998" ORDER="66325" O_E="0.0" SE="0.27247463045653303" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.07424242424242425" WEIGHT="0.9985349437950644"/>
<DICH_DATA CI_END="0.8200679247854159" CI_START="0.18671513419777433" EFFECT_SIZE="0.391304347826087" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="-0.0861501742775433" LOG_CI_START="-0.7288204788789927" LOG_EFFECT_SIZE="-0.40748532657826797" ORDER="66285" O_E="0.0" SE="0.37750771819220597" STUDY_ID="STD-Royston-1987" TOTAL_1="11" TOTAL_2="11" VAR="0.142512077294686" WEIGHT="0.7373750034364005"/>
<DICH_DATA CI_END="0.7733027556602502" CI_START="0.2607123323246595" EFFECT_SIZE="0.44900953778429936" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="29" LOG_CI_END="-0.11165044221312088" LOG_CI_START="-0.5838384251651039" LOG_EFFECT_SIZE="-0.34774443368911234" ORDER="66242" O_E="0.0" SE="0.27736555855420697" STUDY_ID="STD-Casas-1995" TOTAL_1="47" TOTAL_2="51" VAR="0.07693165307208723" WEIGHT="0.9847956523900333"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="961.5207601301885" CI_END="0.7170808096922966" CI_START="0.6037823987386712" CI_STUDY="95" CI_TOTAL="95" DF="107" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6579975466257328" ESTIMABLE="YES" EVENTS_1="2695" EVENTS_2="3067" I2="88.87179513570644" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.14443189980515697" LOG_CI_START="-0.21911955153499474" LOG_EFFECT_SIZE="-0.18177572567007586" METHOD="MH" MODIFIED="2011-02-10 16:52:45 +0000" MODIFIED_BY="Emma M Sydenham" NO="2" P_CHI2="-1.1102230246251565E-15" P_Q="0.0" P_Z="1.4232510398563765E-21" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="108" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.11851430400953793" TOTALS="YES" TOTAL_1="6259" TOTAL_2="4913" WEIGHT="99.99999999999997" Z="9.540368918431264">
<NAME>No. Exposed to Allogeneic Blood - Type of Surgery</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="329.475316051408" CI_END="0.732832084409905" CI_START="0.631884758787737" DF="83" EFFECT_SIZE="0.6804891071055197" ESTIMABLE="YES" EVENTS_1="2431" EVENTS_2="2728" I2="74.80843147987162" ID="CMP-001.02.01" LOG_CI_END="-0.13499552490632824" LOG_CI_START="-0.1993621197969721" LOG_EFFECT_SIZE="-0.16717882235165013" MODIFIED="2011-02-10 16:52:45 +0000" MODIFIED_BY="Emma M Sydenham" NO="1" P_CHI2="1.2212453270876722E-15" P_Z="2.4058512146977536E-24" STUDIES="84" TAU2="0.0572107669565992" TOTAL_1="5329" TOTAL_2="4168" WEIGHT="81.82067817662909" Z="10.181196359501138">
<NAME>Cardiac surgery</NAME>
<DICH_DATA CI_END="1.1661827845720796" CI_START="0.3228907095511885" EFFECT_SIZE="0.6136363636363636" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.06676662598870041" LOG_CI_START="-0.49094445064310055" LOG_EFFECT_SIZE="-0.2120889123272001" ORDER="66330" O_E="0.0" SE="0.3276022471278735" STUDY_ID="STD-Alajmo-1989" TOTAL_1="22" TOTAL_2="12" VAR="0.1073232323232323" WEIGHT="0.8522689891886879"/>
<DICH_DATA CI_END="0.8207319356942484" CI_START="0.6020493368181332" EFFECT_SIZE="0.702937491950874" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="213" LOG_CI_END="-0.08579866731277815" LOG_CI_START="-0.22036791766259636" LOG_EFFECT_SIZE="-0.1530832924876873" ORDER="66385" O_E="0.0" SE="0.07904664378401566" STUDY_ID="STD-Alderman-1998" TOTAL_1="401" TOTAL_2="395" VAR="0.0062483718935170615" WEIGHT="1.5427236344365765"/>
<DICH_DATA CI_END="2.1861039695791042" CI_START="0.25282575215333275" EFFECT_SIZE="0.7434402332361516" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.3396708128473259" LOG_CI_START="-0.5971786920649566" LOG_EFFECT_SIZE="-0.12875393960881534" ORDER="66331" O_E="0.0" SE="0.5503100366653163" STUDY_ID="STD-Alvarez-1995" TOTAL_1="49" TOTAL_2="51" VAR="0.3028411364545818" WEIGHT="0.4567980149946199"/>
<DICH_DATA CI_END="0.9794902492496453" CI_START="0.5964920617890417" EFFECT_SIZE="0.764367816091954" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="45" LOG_CI_END="-0.008999883016004835" LOG_CI_START="-0.22439533161502298" LOG_EFFECT_SIZE="-0.11669760731551393" ORDER="66332" O_E="0.0" SE="0.1265243527317297" STUDY_ID="STD-Baele-1992" TOTAL_1="58" TOTAL_2="57" VAR="0.01600841183418316" WEIGHT="1.430794253624768"/>
<DICH_DATA CI_END="1.0093613198140765" CI_START="0.8702995983750681" EFFECT_SIZE="0.9372549019607843" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="25" LOG_CI_END="0.004046657923747294" LOG_CI_START="-0.060331216895382254" LOG_EFFECT_SIZE="-0.028142279485817483" ORDER="66333" O_E="0.0" SE="0.03781588234437657" STUDY_ID="STD-Bailey-1994" TOTAL_1="129" TOTAL_2="25" VAR="0.0014300409574837317" WEIGHT="1.6046969856237399"/>
<DICH_DATA CI_END="0.8731188140017339" CI_START="0.5154136572187269" EFFECT_SIZE="0.6708333333333333" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="-0.05892665348310755" LOG_CI_START="-0.28784407787640515" LOG_EFFECT_SIZE="-0.17338536567975632" ORDER="66386" O_E="0.0" SE="0.1344672282481491" STUDY_ID="STD-Basora-1999" TOTAL_1="36" TOTAL_2="21" VAR="0.018081435472739826" WEIGHT="1.4090800309051053"/>
<DICH_DATA CI_END="0.39482790023923114" CI_START="0.11321905262835025" EFFECT_SIZE="0.21142857142857144" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="35" LOG_CI_END="-0.40359216580023544" LOG_CI_START="-0.9460804834383635" LOG_EFFECT_SIZE="-0.6748363246192994" ORDER="66334" O_E="0.0" SE="0.3186603231411177" STUDY_ID="STD-Bidstrup-1989" TOTAL_1="40" TOTAL_2="37" VAR="0.10154440154440156" WEIGHT="0.8746499181965582"/>
<DICH_DATA CI_END="0.9372502510926616" CI_START="0.4494540535626551" EFFECT_SIZE="0.6490384615384616" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="-0.028144434557366343" LOG_CI_START="-0.3473146983781445" LOG_EFFECT_SIZE="-0.1877295664677554" ORDER="66335" O_E="0.0" SE="0.1874821928866116" STUDY_ID="STD-Bidstrup-1990" TOTAL_1="26" TOTAL_2="18" VAR="0.035149572649572636" WEIGHT="1.2525671810179602"/>
<DICH_DATA CI_END="0.7811089758395658" CI_START="0.21508479595057134" EFFECT_SIZE="0.40988372093023256" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="24" LOG_CI_END="-0.10728837162309306" LOG_CI_START="-0.6673902882092073" LOG_EFFECT_SIZE="-0.3873393299161502" ORDER="66336" O_E="0.0" SE="0.3290066383518857" STUDY_ID="STD-Bidstrup-1993" TOTAL_1="43" TOTAL_2="47" VAR="0.10824536807960852" WEIGHT="0.8488031713836925"/>
<DICH_DATA CI_END="0.8902876187799331" CI_START="0.3588398767925144" EFFECT_SIZE="0.5652173913043478" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="23" LOG_CI_END="-0.05046966631041668" LOG_CI_START="-0.4450993011110956" LOG_EFFECT_SIZE="-0.24778448371075615" ORDER="66387" O_E="0.0" SE="0.23180740093011587" STUDY_ID="STD-Bidstrup-2000" TOTAL_1="30" TOTAL_2="30" VAR="0.053734671125975485" WEIGHT="1.1174192976171171"/>
<DICH_DATA CI_END="0.9779863575014763" CI_START="0.11361212787770752" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="-0.009667203395581254" LOG_CI_START="-0.9445753060437436" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="66337" O_E="0.0" SE="0.5491696473652761" STUDY_ID="STD-Blauhut-1994" TOTAL_1="14" TOTAL_2="14" VAR="0.3015873015873016" WEIGHT="0.45816137393177736"/>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516804" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-02-10 16:52:45 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="66338" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Boldt-1991" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="0.07393296456220128"/>
<DICH_DATA CI_END="0.9593385583155755" CI_START="0.7355067654519231" EFFECT_SIZE="0.84" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="50" LOG_CI_END="-0.018028099752735213" LOG_CI_START="-0.13341332812350148" LOG_EFFECT_SIZE="-0.07572071393811836" ORDER="66339" O_E="0.0" SE="0.06777785431108017" STUDY_ID="STD-Carrera-1994" TOTAL_1="51" TOTAL_2="51" VAR="0.004593837535014009" WEIGHT="1.5634573505566132"/>
<DICH_DATA CI_END="0.7733027556602502" CI_START="0.2607123323246595" EFFECT_SIZE="0.44900953778429936" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="29" LOG_CI_END="-0.11165044221312088" LOG_CI_START="-0.5838384251651039" LOG_EFFECT_SIZE="-0.34774443368911234" ORDER="66340" O_E="0.0" SE="0.27736555855420697" STUDY_ID="STD-Casas-1995" TOTAL_1="47" TOTAL_2="51" VAR="0.07693165307208723" WEIGHT="0.9847956523900343"/>
<DICH_DATA CI_END="0.9357484130358864" CI_START="0.3431596641124053" EFFECT_SIZE="0.5666666666666667" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="-0.028840900746099345" LOG_CI_START="-0.46450376593667775" LOG_EFFECT_SIZE="-0.2466723333413885" ORDER="66342" O_E="0.0" SE="0.2559105235789091" STUDY_ID="STD-Cicek-1996a" TOTAL_1="50" TOTAL_2="25" VAR="0.06549019607843137" WEIGHT="1.0460305520744062"/>
<DICH_DATA CI_END="1.0138017822726142" CI_START="0.3434056028344289" EFFECT_SIZE="0.5900383141762452" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" LOG_CI_END="0.005953050381643381" LOG_CI_START="-0.4641926233852791" LOG_EFFECT_SIZE="-0.2291197865018179" ORDER="66341" O_E="0.0" SE="0.27616589602930897" STUDY_ID="STD-Cicek-1996b" TOTAL_1="29" TOTAL_2="28" VAR="0.0762676021296711" WEIGHT="0.9881530200943502"/>
<DICH_DATA CI_END="2.4702082767769804" CI_START="0.15813443897519056" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.392733572547735" LOG_CI_START="-0.8009735378595846" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2010-04-21 11:10:52 +0100" MODIFIED_BY="Katharine Ker" ORDER="2364" O_E="0.0" SE="0.7011894655987543" STUDY_ID="STD-Cicekcioglu-2006" TOTAL_1="24" TOTAL_2="20" VAR="0.49166666666666664" WEIGHT="0.3154381045313376"/>
<DICH_DATA CI_END="0.7537424083054954" CI_START="0.31088474574670794" EFFECT_SIZE="0.4840733590733591" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="37" LOG_CI_END="-0.12277704904434342" LOG_CI_START="-0.507400587061211" LOG_EFFECT_SIZE="-0.3150888180527773" ORDER="66388" O_E="0.0" SE="0.22592977014832727" STUDY_ID="STD-Cohen-1998" TOTAL_1="56" TOTAL_2="59" VAR="0.05104426103927599" WEIGHT="1.1351495499845883"/>
<DICH_DATA CI_END="1.0006396605496894" CI_START="0.3378044714556414" EFFECT_SIZE="0.5813953488372093" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="2.7771223570681805E-4" LOG_CI_START="-0.4713346060508047" LOG_EFFECT_SIZE="-0.23552844690754887" ORDER="66343" O_E="0.0" SE="0.277027410280123" STUDY_ID="STD-Corbeau-1995" TOTAL_1="43" TOTAL_2="20" VAR="0.0767441860465116" WEIGHT="0.9857411514139198"/>
<DICH_DATA CI_END="0.7824570437156144" CI_START="0.4904318747402467" EFFECT_SIZE="0.6194690265486725" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="44" LOG_CI_END="-0.10653949555704548" LOG_CI_START="-0.3094213113812804" LOG_EFFECT_SIZE="-0.2079804034691629" ORDER="66344" O_E="0.0" SE="0.11917378289634074" STUDY_ID="STD-Cosgrove-1992" TOTAL_1="113" TOTAL_2="56" VAR="0.014202390529824159" WEIGHT="1.4502646368585397"/>
<DICH_DATA CI_END="1.5918330412997033" CI_START="0.8846618996705448" EFFECT_SIZE="1.1866903733807468" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="31" LOG_CI_END="0.20189751500676237" LOG_CI_START="-0.05322267637853529" LOG_EFFECT_SIZE="0.07433741931411353" ORDER="66345" O_E="0.0" SE="0.14985886328503842" STUDY_ID="STD-D_x0027_Ambra-1996" TOTAL_1="127" TOTAL_2="64" VAR="0.022457678905083836" WEIGHT="1.3653374580661448"/>
<DICH_DATA CI_END="2.314529531862027" CI_START="0.432053247208086" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.3644627264637834" LOG_CI_START="-0.3644627264637834" LOG_EFFECT_SIZE="0.0" ORDER="66346" O_E="0.0" SE="0.42817441928883765" STUDY_ID="STD-Deleuze-1991" TOTAL_1="30" TOTAL_2="30" VAR="0.18333333333333335" WEIGHT="0.6376539187303972"/>
<DICH_DATA CI_END="1.3254060928964186" CI_START="0.40235538574672136" EFFECT_SIZE="0.7302631578947368" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.12234896271291117" LOG_CI_START="-0.3953901810291414" LOG_EFFECT_SIZE="-0.13652060915811512" MODIFIED="2010-05-17 10:46:59 +0100" MODIFIED_BY="Katharine Ker" ORDER="2547" O_E="0.0" SE="0.30412253588417626" STUDY_ID="STD-Desai-2009" TOTAL_1="38" TOTAL_2="37" VAR="0.09249051683262208" WEIGHT="0.9121797693673176"/>
<DICH_DATA CI_END="0.9323483780122118" CI_START="0.25881421861080883" EFFECT_SIZE="0.49122807017543857" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.030421780373552382" LOG_CI_START="-0.587011868286992" LOG_EFFECT_SIZE="-0.3087168243302722" ORDER="66347" O_E="0.0" SE="0.32694377280572434" STUDY_ID="STD-Dietrich-1990" TOTAL_1="19" TOTAL_2="20" VAR="0.10689223057644108" WEIGHT="0.8538986199522813"/>
<DICH_DATA CI_END="0.7811464089683755" CI_START="0.6922940885893394" EFFECT_SIZE="0.7353795219147709" ESTIMABLE="YES" EVENTS_1="549" EVENTS_2="730" LOG_CI_END="-0.10726755940321708" LOG_CI_START="-0.1597093767577549" LOG_EFFECT_SIZE="-0.13348846808048598" ORDER="66348" O_E="0.0" SE="0.03080458310523803" STUDY_ID="STD-Dietrich-1992" TOTAL_1="902" TOTAL_2="882" VAR="9.489223402875163E-4" WEIGHT="1.6111596404367066"/>
<DICH_DATA CI_END="1.020610877852942" CI_START="0.5393517492042281" EFFECT_SIZE="0.7419354838709677" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.008860192809001107" LOG_CI_START="-0.26812790844236073" LOG_EFFECT_SIZE="-0.1296338578166798" ORDER="66349" O_E="0.0" SE="0.16270418178826412" STUDY_ID="STD-Dietrich-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.026472650771388495" WEIGHT="1.3275285980178015"/>
<DICH_DATA CI_END="0.8485647549882042" CI_START="0.46077627889680506" EFFECT_SIZE="0.6252987367702287" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="58" LOG_CI_END="-0.07131501055197918" LOG_CI_START="-0.33650988681009075" LOG_EFFECT_SIZE="-0.20391244868103495" ORDER="66406" O_E="0.0" SE="0.15577678304982373" STUDY_ID="STD-Dignan-2001" TOTAL_1="101" TOTAL_2="99" VAR="0.02426640613735185" WEIGHT="1.3480415429589903"/>
<DICH_DATA CI_END="0.5985457020816825" CI_START="0.1466746731178129" EFFECT_SIZE="0.2962962962962963" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="27" LOG_CI_END="-0.22290268334593874" LOG_CI_START="-0.8336448709881488" LOG_EFFECT_SIZE="-0.5282737771670437" ORDER="66402" O_E="0.0" SE="0.3587529842436209" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.1287037037037037" WEIGHT="0.7785611193600935"/>
<DICH_DATA CI_END="1.1465948472003975" CI_START="0.06538635291433063" EFFECT_SIZE="0.27380952380952384" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.05940998572274674" LOG_CI_START="-1.1845128858113243" LOG_EFFECT_SIZE="-0.5625514500442887" ORDER="66394" O_E="0.0" SE="0.7306864522566346" STUDY_ID="STD-Englberger-2002a" TOTAL_1="21" TOTAL_2="23" VAR="0.5339026915113871" WEIGHT="0.295017343405519"/>
<DICH_DATA CI_END="1.0732934239859022" CI_START="0.06625505152824374" EFFECT_SIZE="0.26666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.030718468468461112" LOG_CI_START="-1.1787810039238988" LOG_EFFECT_SIZE="-0.5740312677277188" ORDER="66395" O_E="0.0" SE="0.7104659772022196" STUDY_ID="STD-Englberger-2002b" TOTAL_1="15" TOTAL_2="14" VAR="0.5047619047619047" WEIGHT="0.30881064623112325"/>
<DICH_DATA CI_END="0.9468374527500885" CI_START="0.399961179980938" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="26" LOG_CI_END="-0.02372457161220413" LOG_CI_START="-0.3979821590175822" LOG_EFFECT_SIZE="-0.21085336531489315" ORDER="66350" O_E="0.0" SE="0.2198407594468552" STUDY_ID="STD-Fraedrich-1989" TOTAL_1="38" TOTAL_2="38" VAR="0.048329959514170046" WEIGHT="1.1536167006655507"/>
<DICH_DATA CI_END="0.720649865502474" CI_START="0.1158076815365343" EFFECT_SIZE="0.28888888888888886" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.14227569008565652" LOG_CI_START="-0.9362626328513574" LOG_EFFECT_SIZE="-0.539269161468507" ORDER="66351" O_E="0.0" SE="0.4663918604793264" STUDY_ID="STD-Gherli-1992" TOTAL_1="18" TOTAL_2="13" VAR="0.21752136752136747" WEIGHT="0.5727794550332186"/>
<DICH_DATA CI_END="0.9036903622073366" CI_START="0.15561192846686125" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="-0.04398034941401264" LOG_CI_START="-0.8079571151305497" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="66352" O_E="0.0" SE="0.44876373392787533" STUDY_ID="STD-Green-1995" TOTAL_1="48" TOTAL_2="36" VAR="0.2013888888888889" WEIGHT="0.6016642943364013"/>
<DICH_DATA CI_END="1.1620394238299383" CI_START="0.27073602422146403" EFFECT_SIZE="0.5608974358974359" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.06522086235840659" LOG_CI_START="-0.5674539530227032" LOG_EFFECT_SIZE="-0.25111654533214833" ORDER="66390" O_E="0.0" SE="0.3716363183457089" STUDY_ID="STD-Greilich-2001" TOTAL_1="24" TOTAL_2="25" VAR="0.1381135531135531" WEIGHT="0.750013388916207"/>
<DICH_DATA CI_END="1.6182854246331981" CI_START="0.7470899207455475" EFFECT_SIZE="1.0995475113122173" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.20905512259825326" LOG_CI_START="-0.1266271227718502" LOG_EFFECT_SIZE="0.04121399991320153" MODIFIED="2010-05-17 13:57:35 +0100" MODIFIED_BY="Katharine Ker" ORDER="2591" O_E="0.0" SE="0.1971814125843122" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="27" VAR="0.03888050946874476" WEIGHT="1.222875929375851"/>
<DICH_DATA CI_END="1.3438135911295888" CI_START="0.7963564179938953" EFFECT_SIZE="1.0344827586206897" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="29" LOG_CI_END="0.12833902916533568" LOG_CI_START="-0.09889251552392286" LOG_EFFECT_SIZE="0.014723256820706378" ORDER="66353" O_E="0.0" SE="0.13347693416475745" STUDY_ID="STD-Harder-1991" TOTAL_1="40" TOTAL_2="40" VAR="0.01781609195402299" WEIGHT="1.4118225612917548"/>
<DICH_DATA CI_END="1.2371304328257535" CI_START="0.6806192486246042" EFFECT_SIZE="0.9176136363636364" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.09241549047004377" LOG_CI_START="-0.1670957727641001" LOG_EFFECT_SIZE="-0.03734014114702813" ORDER="66354" O_E="0.0" SE="0.1524382006252069" STUDY_ID="STD-Hardy-1993" TOTAL_1="22" TOTAL_2="19" VAR="0.02323740500985083" WEIGHT="1.3578272187523825"/>
<DICH_DATA CI_END="1.216920975501839" CI_START="0.8217460460714104" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" LOG_CI_END="0.08526237690073346" LOG_CI_START="-0.08526237690073346" LOG_EFFECT_SIZE="0.0" ORDER="66355" O_E="0.0" SE="0.10016708449412663" STUDY_ID="STD-Hardy-1997" TOTAL_1="26" TOTAL_2="26" VAR="0.010033444816053505" WEIGHT="1.497298323538402"/>
<DICH_DATA CI_END="3.0394125886228682" CI_START="0.20748181399616164" EFFECT_SIZE="0.7941176470588235" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.48278965789495476" LOG_CI_START="-0.6830199636614904" LOG_EFFECT_SIZE="-0.10011515288326783" ORDER="66404" O_E="0.0" SE="0.6848023425529537" STUDY_ID="STD-Harmon-2004" TOTAL_1="17" TOTAL_2="18" VAR="0.46895424836601296" WEIGHT="0.3276334163469412"/>
<DICH_DATA CI_END="1.2005001082166866" CI_START="0.15299746175000142" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.07936220354165731" LOG_CI_START="-0.8153157741308461" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="66356" O_E="0.0" SE="0.5255382728122436" STUDY_ID="STD-Havel-1992" TOTAL_1="10" TOTAL_2="10" VAR="0.2761904761904762" WEIGHT="0.4876412409134202"/>
<DICH_DATA CI_END="0.9067145062236663" CI_START="0.6096295146835113" EFFECT_SIZE="0.7434782608695653" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="46" LOG_CI_END="-0.04252943608158775" LOG_CI_START="-0.21493401516929028" LOG_EFFECT_SIZE="-0.12873172562543903" ORDER="66357" O_E="0.0" SE="0.10127130317254668" STUDY_ID="STD-Hayashida-1997" TOTAL_1="110" TOTAL_2="57" VAR="0.010255876846265864" WEIGHT="1.4947119552990724"/>
<DICH_DATA CI_END="0.7804173827907901" CI_START="0.45795498425174797" EFFECT_SIZE="0.5978260869565217" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="46" LOG_CI_END="-0.10767306582026084" LOG_CI_START="-0.33917720988236205" LOG_EFFECT_SIZE="-0.22342513785131143" ORDER="66358" O_E="0.0" SE="0.13598668018607324" STUDY_ID="STD-Isetta-1993" TOTAL_1="140" TOTAL_2="70" VAR="0.01849237718802936" WEIGHT="1.40485359639973"/>
<DICH_DATA CI_END="0.7620123531650056" CI_START="0.5126229232079317" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="48" LOG_CI_END="-0.11803798815133151" LOG_CI_START="-0.29020197716051804" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="66359" O_E="0.0" SE="0.10112997936948631" STUDY_ID="STD-Kalangos-1994" TOTAL_1="110" TOTAL_2="55" VAR="0.010227272727272727" WEIGHT="1.4950440540640055"/>
<DICH_DATA CI_END="2.410392969374453" CI_START="0.26551687136977226" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.38208785191856476" LOG_CI_START="-0.5759078779346776" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="66396" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Kipfer-2003" TOTAL_1="15" TOTAL_2="15" VAR="0.3166666666666667" WEIGHT="0.4422857196906335"/>
<DICH_DATA CI_END="1.7248117563970482" CI_START="0.1672117424292004" EFFECT_SIZE="0.5370370370370371" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.23674170368809447" LOG_CI_START="-0.7767332275361192" LOG_EFFECT_SIZE="-0.26999576192401237" ORDER="66392" O_E="0.0" SE="0.5953201913829222" STUDY_ID="STD-Klein-1998" TOTAL_1="36" TOTAL_2="29" VAR="0.35440613026819917" WEIGHT="0.4069909330628695"/>
<DICH_DATA CI_END="1.5636597783045803" CI_START="0.5373789039255461" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.19414226504209867" LOG_CI_START="-0.26971938682089824" LOG_EFFECT_SIZE="-0.0377885608893998" ORDER="66403" O_E="0.0" SE="0.27247463045653303" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.07424242424242425" WEIGHT="0.998534943795065"/>
<DICH_DATA CI_END="0.8548579066310278" CI_START="0.4535633977347247" EFFECT_SIZE="0.6226815050344462" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="37" LOG_CI_END="-0.06810606713672084" LOG_CI_START="-0.34336199997763184" LOG_EFFECT_SIZE="-0.2057340335571763" ORDER="66360" O_E="0.0" SE="0.16168669748959338" STUDY_ID="STD-Lass-1995" TOTAL_1="51" TOTAL_2="47" VAR="0.026142588145091284" WEIGHT="1.3305576108012234"/>
<DICH_DATA CI_END="0.8925895825655312" CI_START="0.5575925005095984" EFFECT_SIZE="0.7054794520547946" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="73" LOG_CI_END="-0.0493481861272466" LOG_CI_START="-0.25368307603128315" LOG_EFFECT_SIZE="-0.15151563107926486" MODIFIED="2010-05-06 16:06:38 +0100" MODIFIED_BY="Katharine Ker" ORDER="2369" O_E="0.0" SE="0.12002732580364896" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="103" VAR="0.014406558939575296" WEIGHT="1.4480370089447854"/>
<DICH_DATA CI_END="1.5757982109905528" CI_START="0.20721600644516502" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.19750060308743156" LOG_CI_START="-0.6835767004600205" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="66361" O_E="0.0" SE="0.5175491695067657" STUDY_ID="STD-Laub-1994" TOTAL_1="16" TOTAL_2="16" VAR="0.26785714285714285" WEIGHT="0.4981587805519382"/>
<DICH_DATA CI_END="0.7708713825665181" CI_START="0.5331054961218116" EFFECT_SIZE="0.6410583209421983" ESTIMABLE="YES" EVENTS_1="173" EVENTS_2="87" LOG_CI_END="-0.11301807655504825" LOG_CI_START="-0.2731868400353992" LOG_EFFECT_SIZE="-0.1931024582952237" ORDER="66362" O_E="0.0" SE="0.09408392451652427" STUDY_ID="STD-Lemmer-1996" TOTAL_1="487" TOTAL_2="157" VAR="0.008851784852431035" WEIGHT="1.5111897564805086"/>
<DICH_DATA CI_END="1.0497678264256392" CI_START="0.4997731056344701" EFFECT_SIZE="0.7243243243243244" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="35" LOG_CI_END="0.021093258258824937" LOG_CI_START="-0.30122711833523724" LOG_EFFECT_SIZE="-0.14006693003820614" ORDER="66363" O_E="0.0" SE="0.18933258472294834" STUDY_ID="STD-Lemmer_x005f_1-1994" TOTAL_1="74" TOTAL_2="67" VAR="0.035846827637872405" WEIGHT="1.2469092883488377"/>
<DICH_DATA CI_END="0.8150022791529388" CI_START="0.22000161521551823" EFFECT_SIZE="0.42344045368620037" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="23" LOG_CI_END="-0.08884117675430474" LOG_CI_START="-0.6575741306477412" LOG_EFFECT_SIZE="-0.37320765370102293" ORDER="66364" O_E="0.0" SE="0.33407655239053047" STUDY_ID="STD-Lemmer_x005f_2-1994" TOTAL_1="23" TOTAL_2="32" VAR="0.11160714285714285" WEIGHT="0.8364032619814976"/>
<DICH_DATA CI_END="0.925107108046671" CI_START="0.6394106016052801" EFFECT_SIZE="0.769105514546244" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="49" LOG_CI_END="-0.03380798213586703" LOG_CI_START="-0.19422016728156163" LOG_EFFECT_SIZE="-0.11401407470871433" ORDER="66365" O_E="0.0" SE="0.09422691160770381" STUDY_ID="STD-Levy-1995" TOTAL_1="188" TOTAL_2="65" VAR="0.008878710871126027" WEIGHT="1.510870348672531"/>
<DICH_DATA CI_END="0.7917906433240165" CI_START="0.12333594849015803" EFFECT_SIZE="0.3125" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.10138963465852775" LOG_CI_START="-0.9089103219812843" LOG_EFFECT_SIZE="-0.505149978319906" ORDER="66398" O_E="0.0" SE="0.4743416490252569" STUDY_ID="STD-Li-2005" TOTAL_1="40" TOTAL_2="30" VAR="0.22499999999999998" WEIGHT="0.560309502587262"/>
<DICH_DATA CI_END="0.7532478029295167" CI_START="0.08297402230305383" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.12306212640134118" LOG_CI_START="-1.0810578562545836" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="66366" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Liu-1993" TOTAL_1="20" TOTAL_2="20" VAR="0.31666666666666665" WEIGHT="0.4422857196906336"/>
<DICH_DATA CI_END="1.1257994302155443" CI_START="0.3587946958901859" EFFECT_SIZE="0.6355555555555555" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.05146102452110328" LOG_CI_START="-0.4451539858137047" LOG_EFFECT_SIZE="-0.1968464806463007" ORDER="66367" O_E="0.0" SE="0.29171411535461406" STUDY_ID="STD-Locatelli-1990" TOTAL_1="25" TOTAL_2="13" VAR="0.08509712509712508" WEIGHT="0.9453021849297314"/>
<DICH_DATA CI_END="1.3225611225787064" CI_START="0.14449806862033407" EFFECT_SIZE="0.4371584699453552" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.12141575222725745" LOG_CI_START="-0.8401379577042294" LOG_EFFECT_SIZE="-0.3593611027384859" ORDER="66368" O_E="0.0" SE="0.564821408981384" STUDY_ID="STD-Maccario-1994" TOTAL_1="61" TOTAL_2="32" VAR="0.31902322404371586" WEIGHT="0.43990358876774366"/>
<DICH_DATA CI_END="0.581965375170908" CI_START="0.011932745040725218" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.23510285352801047" LOG_CI_START="-1.9232596385672394" LOG_EFFECT_SIZE="-1.0791812460476249" ORDER="66399" O_E="0.0" SE="0.991631652042901" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.9833333333333332" WEIGHT="0.17468325228281978"/>
<DICH_DATA CI_END="0.4272576057276957" CI_START="0.028895164993771816" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="18" LOG_CI_END="-0.3693101975453905" LOG_CI_START="-1.5391748213332594" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="66369" O_E="0.0" SE="0.6871842709362768" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.47222222222222227" WEIGHT="0.3258209375319402"/>
<DICH_DATA CI_END="0.8847859245407694" CI_START="0.540868121448187" EFFECT_SIZE="0.6917748917748918" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="16" LOG_CI_END="-0.05316179488080641" LOG_CI_START="-0.266908614947537" LOG_EFFECT_SIZE="-0.1600352049141717" ORDER="66370" O_E="0.0" SE="0.12555594017102115" STUDY_ID="STD-Mohr-1992" TOTAL_1="34" TOTAL_2="16" VAR="0.015764294112229044" WEIGHT="1.4333954293792481"/>
<DICH_DATA CI_END="0.8973650634832809" CI_START="0.4380356604107999" EFFECT_SIZE="0.6269592476489029" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" LOG_CI_END="-0.04703084257180927" LOG_CI_START="-0.3584905322145905" LOG_EFFECT_SIZE="-0.2027606873931999" ORDER="66371" O_E="0.0" SE="0.18295296344649845" STUDY_ID="STD-Murkin-1994" TOTAL_1="29" TOTAL_2="25" VAR="0.0334717868338558" WEIGHT="1.2663943637416069"/>
<DICH_DATA CI_END="1.0403570180709536" CI_START="0.56797137464091" EFFECT_SIZE="0.768695652173913" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="23" LOG_CI_END="0.01718240119376299" LOG_CI_START="-0.24567355187484013" LOG_EFFECT_SIZE="-0.11424557534053863" MODIFIED="2010-05-07 14:56:47 +0100" MODIFIED_BY="Katharine Ker" ORDER="2463" O_E="0.0" SE="0.15440288799045002" STUDY_ID="STD-Nur_x00f6_zler-2008" TOTAL_1="25" TOTAL_2="26" VAR="0.023840251819791457" WEIGHT="1.3520770564024205"/>
<DICH_DATA CI_END="1.1769979621462765" CI_START="0.7239358378865783" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="52" LOG_CI_END="0.07077571090682193" LOG_CI_START="-0.14029992342524575" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2010-05-21 15:24:27 +0100" MODIFIED_BY="Katharine Ker" ORDER="2329" O_E="0.0" SE="0.1239868724478975" STUDY_ID="STD-Parvizi-2007" TOTAL_1="81" TOTAL_2="81" VAR="0.015372744539411204" WEIGHT="1.4375873611167478"/>
<DICH_DATA CI_END="2.5475015595668227" CI_START="0.008011050351928473" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.40611445855130324" LOG_CI_START="-2.0963105385798166" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="66372" O_E="0.0" SE="1.469936830518334" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="2.1607142857142856" WEIGHT="0.08444713693000665"/>
<DICH_DATA CI_END="1.0650367118693163" CI_START="0.331144696158032" EFFECT_SIZE="0.5938697318007663" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" LOG_CI_END="0.027364578185526574" LOG_CI_START="-0.4799821965215054" LOG_EFFECT_SIZE="-0.22630880916798943" ORDER="66405" O_E="0.0" SE="0.29801800686994884" STUDY_ID="STD-Poston-2006" TOTAL_1="29" TOTAL_2="31" VAR="0.08881473241873687" WEIGHT="0.9283520153617263"/>
<DICH_DATA CI_END="1.0902507120596947" CI_START="0.9172202218614527" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.037526378990036593" LOG_CI_START="-0.037526378990036614" LOG_EFFECT_SIZE="0.0" ORDER="66373" O_E="0.0" SE="0.04408636155463877" STUDY_ID="STD-Pugh-1995" TOTAL_1="21" TOTAL_2="23" VAR="0.0019436072751263314" WEIGHT="1.5978554397837872"/>
<DICH_DATA CI_END="0.7866183929057147" CI_START="0.16610386164783042" EFFECT_SIZE="0.3614697120158888" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="19" LOG_CI_END="-0.10423590302661616" LOG_CI_START="-0.779620270782508" LOG_EFFECT_SIZE="-0.441928086904562" ORDER="66374" O_E="0.0" SE="0.3967241208263498" STUDY_ID="STD-Ray-1997" TOTAL_1="53" TOTAL_2="52" VAR="0.15739002804544017" WEIGHT="0.6976125651149263"/>
<DICH_DATA CI_END="0.8889502048802845" CI_START="0.3373491784678522" EFFECT_SIZE="0.5476190476190477" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" LOG_CI_END="-0.05112256563428223" LOG_CI_START="-0.47192034312633274" LOG_EFFECT_SIZE="-0.26152145438030755" ORDER="66391" O_E="0.0" SE="0.24717869748142302" STUDY_ID="STD-Ray-1999" TOTAL_1="100" TOTAL_2="50" VAR="0.061097308488612834" WEIGHT="1.0716140573214625"/>
<DICH_DATA CI_END="1.0533410525445912" CI_START="0.6797193839842649" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="26" LOG_CI_END="0.02256901055561178" LOG_CI_START="-0.16767034485283525" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="66375" O_E="0.0" SE="0.11174753906691859" STUDY_ID="STD-Rocha-1994" TOTAL_1="28" TOTAL_2="28" VAR="0.012487512487512495" WEIGHT="1.4692493123981019"/>
<DICH_DATA CI_END="1.9071560686454936" CI_START="1.0494267347438109" EFFECT_SIZE="1.414715719063545" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="26" LOG_CI_END="0.28038623419867686" LOG_CI_START="0.02095212390254852" LOG_EFFECT_SIZE="0.15066917905061267" ORDER="66376" O_E="0.0" SE="0.1523928806075034" STUDY_ID="STD-Rodrigus-1996" TOTAL_1="46" TOTAL_2="47" VAR="0.02322359005985278" WEIGHT="1.3579595638479283"/>
<DICH_DATA CI_END="2.156255130476228" CI_START="0.031811682828664346" EFFECT_SIZE="0.2619047619047619" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3337001457552575" LOG_CI_START="-1.4974133562346084" LOG_EFFECT_SIZE="-0.5818566052396754" ORDER="66377" O_E="0.0" SE="1.075605135226867" STUDY_ID="STD-Rossi-1997" TOTAL_1="21" TOTAL_2="22" VAR="1.156926406926407" WEIGHT="0.150908095657345"/>
<DICH_DATA CI_END="0.8200679247854159" CI_START="0.18671513419777433" EFFECT_SIZE="0.391304347826087" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="-0.0861501742775433" LOG_CI_START="-0.7288204788789927" LOG_EFFECT_SIZE="-0.40748532657826797" ORDER="66378" O_E="0.0" SE="0.37750771819220597" STUDY_ID="STD-Royston-1987" TOTAL_1="11" TOTAL_2="11" VAR="0.142512077294686" WEIGHT="0.7373750034364018"/>
<DICH_DATA CI_END="0.6609816379241117" CI_START="0.11252985109065299" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="-0.1798106050514249" LOG_CI_START="-0.9487322558257003" LOG_EFFECT_SIZE="-0.5642714304385626" ORDER="66393" O_E="0.0" SE="0.4516683838883667" STUDY_ID="STD-Santamaria-2000" TOTAL_1="56" TOTAL_2="28" VAR="0.20400432900432902" WEIGHT="0.5967851438925021"/>
<DICH_DATA CI_END="1.6216329114793497" CI_START="0.733879188195826" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.20995254989858633" LOG_CI_START="-0.13437542811978684" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="66379" O_E="0.0" SE="0.20225995873897265" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.04090909090909092" WEIGHT="1.2073154564888944"/>
<DICH_DATA CI_END="1.1628512108432862" CI_START="0.7528113445654874" EFFECT_SIZE="0.9356321839080459" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="29" LOG_CI_END="0.06552414942872957" LOG_CI_START="-0.12331384488756425" LOG_EFFECT_SIZE="-0.028894847729417316" ORDER="66380" O_E="0.0" SE="0.11092437262453853" STUDY_ID="STD-Speekenbrink-1996" TOTAL_1="75" TOTAL_2="37" VAR="0.012304216442147471" WEIGHT="1.4713079474269037"/>
<DICH_DATA CI_END="0.9849542929885672" CI_START="0.6267772455738472" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="42" LOG_CI_END="-0.006583922561699111" LOG_CI_START="-0.20288677847832687" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="66381" O_E="0.0" SE="0.11530926928023555" STUDY_ID="STD-Swart-1994" TOTAL_1="49" TOTAL_2="49" VAR="0.013296227581941874" WEIGHT="1.460234827120864"/>
<DICH_DATA CI_END="1.26102060903135" CI_START="0.4408653477494194" EFFECT_SIZE="0.7456140350877193" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.10072218436487669" LOG_CI_START="-0.3556940356092364" LOG_EFFECT_SIZE="-0.12748592562217986" ORDER="66382" O_E="0.0" SE="0.26810114690952036" STUDY_ID="STD-Tabuchi-1994" TOTAL_1="19" TOTAL_2="17" VAR="0.07187822497420022" WEIGHT="1.0109342516671613"/>
<DICH_DATA CI_END="0.7975135540067488" CI_START="0.32428296497632014" EFFECT_SIZE="0.5085470085470085" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="26" LOG_CI_END="-0.09826192722963079" LOG_CI_START="-0.48907586480559345" LOG_EFFECT_SIZE="-0.2936688960176121" ORDER="66397" O_E="0.0" SE="0.22956604149231166" STUDY_ID="STD-Taggart-2003" TOTAL_1="36" TOTAL_2="34" VAR="0.05270056740644976" WEIGHT="1.124168287598999"/>
<DICH_DATA CI_END="2.1315266092423184" CI_START="0.3002542859305412" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3286907585993715" LOG_CI_START="-0.5225107846154844" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="66389" O_E="0.0" SE="0.49999999999999994" STUDY_ID="STD-Tassani-2000" TOTAL_1="10" TOTAL_2="10" VAR="0.24999999999999997" WEIGHT="0.52229812172016"/>
<DICH_DATA CI_END="0.968686759662337" CI_START="0.43166883561525266" EFFECT_SIZE="0.6466466466466466" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="27" LOG_CI_END="-0.013816636306206052" LOG_CI_START="-0.36484930415559036" LOG_EFFECT_SIZE="-0.18933297023089823" ORDER="66400" O_E="0.0" SE="0.2061983267344585" STUDY_ID="STD-Van-der-Linden-2005" TOTAL_1="37" TOTAL_2="38" VAR="0.0425177499480905" WEIGHT="1.1952547587937896"/>
<DICH_DATA CI_END="1.3454053931997747" CI_START="0.022094839371514755" EFFECT_SIZE="0.1724137931034483" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.1288531642656234" LOG_CI_START="-1.6557091513914979" LOG_EFFECT_SIZE="-0.7634279935629372" ORDER="66401" O_E="0.0" SE="1.048260737942924" STUDY_ID="STD-Vanek-2005" TOTAL_1="29" TOTAL_2="30" VAR="1.0988505747126436" WEIGHT="0.15810734495086318"/>
<DICH_DATA CI_END="0.9361707678459628" CI_START="0.3957722348326828" EFFECT_SIZE="0.6086956521739131" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="23" LOG_CI_END="-0.028644923944956005" LOG_CI_START="-0.40255467673375367" LOG_EFFECT_SIZE="-0.21559980033935483" ORDER="66383" O_E="0.0" SE="0.21963643967126673" STUDY_ID="STD-Vedrinne-1992" TOTAL_1="30" TOTAL_2="30" VAR="0.04824016563146998" WEIGHT="1.1542378997429932"/>
<DICH_DATA CI_END="2.1719720978715733" CI_START="0.319729910492389" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3368542418108039" LOG_CI_START="-0.49521673390605353" LOG_EFFECT_SIZE="-0.07918124604762482" MODIFIED="2010-05-26 12:15:55 +0100" MODIFIED_BY="Katharine Ker" ORDER="2765" O_E="0.0" SE="0.4887626099538393" STUDY_ID="STD-Wei-2006" TOTAL_1="36" TOTAL_2="40" VAR="0.23888888888888885" WEIGHT="0.5385355604976211"/>
<DICH_DATA CI_END="0.9740335218944856" CI_START="0.3695971359382001" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="-0.011426096382906073" LOG_CI_START="-0.4322714028498067" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="66384" O_E="0.0" SE="0.24720661623652213" STUDY_ID="STD-Wendel-1995" TOTAL_1="20" TOTAL_2="18" VAR="0.06111111111111113" WEIGHT="1.0715317132707216"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="45.467936192309125" CI_END="0.894904408306561" CI_START="0.5241733457353391" DF="14" EFFECT_SIZE="0.684897830201961" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="177" I2="69.20907089165817" ID="CMP-001.02.02" LOG_CI_END="-0.048223352574774406" LOG_CI_START="-0.28052506674380917" LOG_EFFECT_SIZE="-0.16437420965929175" MODIFIED="2010-06-01 17:14:11 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="3.423935816793122E-5" P_Z="0.005542291001150189" STUDIES="15" TAU2="0.1371620116498471" TOTAL_1="655" TOTAL_2="491" WEIGHT="11.373730755175755" Z="2.7736991272050795">
<NAME>Orthopaedic surgery</NAME>
<DICH_DATA CI_END="1.55131165165505" CI_START="0.5025351252755366" EFFECT_SIZE="0.882943143812709" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.1906990544207529" LOG_CI_START="-0.29883357732995014" LOG_EFFECT_SIZE="-0.0540672614545986" ORDER="66413" O_E="0.0" SE="0.28755389111597146" STUDY_ID="STD-Amar-2003" TOTAL_1="23" TOTAL_2="24" VAR="0.08268724029593597" WEIGHT="0.9566245103912815"/>
<DICH_DATA CI_END="1.174017116620848" CI_START="0.8517763377064567" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.06967442876831904" LOG_CI_START="-0.06967442876831907" LOG_EFFECT_SIZE="0.0" ORDER="66418" O_E="0.0" SE="0.0818542087049908" STUDY_ID="STD-Capdevila-1998" TOTAL_1="12" TOTAL_2="11" VAR="0.006700111482720192" WEIGHT="1.53715790673554"/>
<DICH_DATA CI_END="0.8525208268207006" CI_START="0.3155703671806873" EFFECT_SIZE="0.5186813186813187" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="39" LOG_CI_END="-0.06929500252570277" LOG_CI_START="-0.5009037848483089" LOG_EFFECT_SIZE="-0.2850993936870058" MODIFIED="2010-06-01 17:14:11 +0100" MODIFIED_BY="Katharine Ker" ORDER="5335" O_E="0.0" SE="0.2535291352342283" STUDY_ID="STD-Colwell-2007" TOTAL_1="175" TOTAL_2="177" VAR="0.06427702241261564" WEIGHT="1.0529729860741717"/>
<DICH_DATA CI_END="0.9968014774159336" CI_START="0.30347065775242266" EFFECT_SIZE="0.55" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="-0.0013913269919762872" LOG_CI_START="-0.5178832940195359" LOG_EFFECT_SIZE="-0.2596373105057561" ORDER="66411" O_E="0.0" SE="0.30338993810845893" STUDY_ID="STD-Cvachovec-2001" TOTAL_1="20" TOTAL_2="22" VAR="0.09204545454545456" WEIGHT="0.9141078529538901"/>
<DICH_DATA CI_END="70.82882080128427" CI_START="0.12706691849706478" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8502100114756685" LOG_CI_START="-0.895967502036344" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="66408" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-D_x0027_Ambrosio-1999" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="0.07074532881267806"/>
<DICH_DATA CI_END="5.461059148182932" CI_START="0.5086518388474208" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7372768803609144" LOG_CI_START="-0.2935793811282016" LOG_EFFECT_SIZE="0.22184874961635637" ORDER="66410" O_E="0.0" SE="0.6055300708194984" STUDY_ID="STD-Engel-2001" TOTAL_1="12" TOTAL_2="12" VAR="0.3666666666666667" WEIGHT="0.396706261053353"/>
<DICH_DATA CI_END="1.3299782792134183" CI_START="0.575667296200363" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.12384454826424007" LOG_CI_START="-0.23982844221961358" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="66412" O_E="0.0" SE="0.2136233148205519" STUDY_ID="STD-Jeserschek-2003" TOTAL_1="9" TOTAL_2="9" VAR="0.04563492063492064" WEIGHT="1.1725570390483797"/>
<DICH_DATA CI_END="1.1223523647028855" CI_START="0.17286841501668593" EFFECT_SIZE="0.44047619047619047" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.05012922592328552" LOG_CI_START="-0.7622843499130588" LOG_EFFECT_SIZE="-0.35607756199488666" ORDER="66407" O_E="0.0" SE="0.4772157559583272" STUDY_ID="STD-Lentschener-1999" TOTAL_1="35" TOTAL_2="37" VAR="0.22773487773487772" WEIGHT="0.55588385174371"/>
<DICH_DATA CI_END="2.4521888362810533" CI_START="0.008322427279400224" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3895539109512145" LOG_CI_START="-2.079749990979728" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="66415" O_E="0.0" SE="1.4504813352456845" STUDY_ID="STD-Llau-1998" TOTAL_1="10" TOTAL_2="10" VAR="2.103896103896104" WEIGHT="0.08660611385121161"/>
<DICH_DATA CI_END="1.2854855901578142" CI_START="0.5973191554248912" EFFECT_SIZE="0.8762677484787018" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.10906721271748547" LOG_CI_START="-0.22379355764212133" LOG_EFFECT_SIZE="-0.05736317246231793" ORDER="66419" O_E="0.0" SE="0.19552406419661988" STUDY_ID="STD-Murkin-1995" TOTAL_1="29" TOTAL_2="24" VAR="0.03822965967996394" WEIGHT="1.2279536913617357"/>
<DICH_DATA CI_END="0.851080315601441" CI_START="0.17407565969356745" EFFECT_SIZE="0.3849056603773585" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="-0.07002945404391975" LOG_CI_START="-0.7592619503058609" LOG_EFFECT_SIZE="-0.4146457021748903" ORDER="66409" O_E="0.0" SE="0.4048585800601448" STUDY_ID="STD-Murkin-2000" TOTAL_1="212" TOTAL_2="68" VAR="0.1639104698483167" WEIGHT="0.6815065342251692"/>
<DICH_DATA CI_END="0.9019134165859846" CI_START="0.5221928115776203" EFFECT_SIZE="0.6862745098039216" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="25" LOG_CI_END="-0.04483515259530587" LOG_CI_START="-0.2821691109000156" LOG_EFFECT_SIZE="-0.16350213174766073" ORDER="66417" O_E="0.0" SE="0.1394111419302274" STUDY_ID="STD-Petsatodis-2006" TOTAL_1="25" TOTAL_2="25" VAR="0.01943546649429001" WEIGHT="1.3952493585761545"/>
<DICH_DATA CI_END="3.436173203095408" CI_START="0.1293428526955729" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5360750466763062" LOG_CI_START="-0.8882575647876688" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="66416" O_E="0.0" SE="0.8366600265340756" STUDY_ID="STD-Ray-2005" TOTAL_1="15" TOTAL_2="15" VAR="0.7" WEIGHT="0.2351508432636393"/>
<DICH_DATA CI_END="0.8944158527519801" CI_START="0.26944036691176204" EFFECT_SIZE="0.4909090909090909" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="-0.04846051189314574" LOG_CI_START="-0.5695373387773675" LOG_EFFECT_SIZE="-0.3089989253352565" ORDER="66414" O_E="0.0" SE="0.3060831074836844" STUDY_ID="STD-Samama-2002" TOTAL_1="40" TOTAL_2="18" VAR="0.09368686868686871" WEIGHT="0.9070370647129461"/>
<DICH_DATA CI_END="1.2419824481161656" CI_START="0.02830655944721672" EFFECT_SIZE="0.1875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.09411545836861414" LOG_CI_START="-1.5481129142411387" LOG_EFFECT_SIZE="-0.7269987279362623" ORDER="66420" O_E="0.0" SE="0.9646530752325188" STUDY_ID="STD-Thorpe-1994" TOTAL_1="8" TOTAL_2="9" VAR="0.9305555555555556" WEIGHT="0.18347141237189538"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3735206923606231" CI_END="0.588577502027123" CI_START="0.13979650002214072" DF="2" EFFECT_SIZE="0.2868467792658064" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="24" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="-0.23019634252898707" LOG_CI_START="-0.8545037015524168" LOG_EFFECT_SIZE="-0.5423500220407019" MODIFIED="2010-05-07 14:46:12 +0100" MODIFIED_BY="Katharine Ker" NO="3" P_CHI2="0.8296425897969251" P_Z="6.608397294644926E-4" STUDIES="3" TAU2="0.0" TOTAL_1="38" TOTAL_2="40" WEIGHT="1.0683368909586637" Z="3.405330707224252">
<NAME>Thoracic surgery</NAME>
<DICH_DATA CI_END="1.1831785640385561" CI_START="0.023477249015536238" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.07305029283121232" LOG_CI_START="-1.6293527935984997" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="66421" O_E="0.0" SE="1.0" STUDY_ID="STD-Katzel-1998" TOTAL_1="12" TOTAL_2="12" VAR="1.0000000000000002" WEIGHT="0.17208034633194313"/>
<DICH_DATA CI_END="1.0237823367364247" CI_START="0.10853001377744706" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.010207632418683592" LOG_CI_START="-0.9644501418580085" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="66422" O_E="0.0" SE="0.5725188012439223" STUDY_ID="STD-Kyriss-2001" TOTAL_1="18" TOTAL_2="20" VAR="0.3277777777777778" WEIGHT="0.43127435297612776"/>
<DICH_DATA CI_END="0.8534432320457009" CI_START="0.10136021596195216" EFFECT_SIZE="0.29411764705882354" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.06882536128531151" LOG_CI_START="-0.9941324727991987" LOG_EFFECT_SIZE="-0.5314789170422551" MODIFIED="2010-05-07 14:46:12 +0100" MODIFIED_BY="Katharine Ker" ORDER="2458" O_E="0.0" SE="0.5435299776473301" STUDY_ID="STD-Norman-2009" TOTAL_1="8" TOTAL_2="8" VAR="0.29542483660130725" WEIGHT="0.46498219165059274"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.006457386542202511" CI_END="1.0306928383279805" CI_START="0.9703020285495483" DF="1" EFFECT_SIZE="1.0000416750521606" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="77" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="0.013129258402222422" LOG_CI_START="-0.013093060666115718" LOG_EFFECT_SIZE="1.8098868053351183E-5" NO="4" P_CHI2="0.9359526371390895" P_Z="0.9978412719495665" STUDIES="2" TAU2="0.0" TOTAL_1="105" TOTAL_2="83" WEIGHT="2.924504413574425" Z="0.0027055676847719703">
<NAME>Vascular surgery</NAME>
<DICH_DATA CI_END="1.4043574036065283" CI_START="0.7193914498899935" EFFECT_SIZE="1.005128205128205" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="15" LOG_CI_END="0.14747764815076966" LOG_CI_START="-0.14303472816285362" LOG_EFFECT_SIZE="0.0022214599939580325" ORDER="66424" O_E="0.0" SE="0.17064840790607783" STUDY_ID="STD-Okita-1996" TOTAL_1="39" TOTAL_2="21" VAR="0.02912087912087913" WEIGHT="1.3037158537011253"/>
<DICH_DATA CI_END="1.0307774244809154" CI_START="0.970141541956631" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="62" LOG_CI_END="0.013164898304624488" LOG_CI_START="-0.01316489830462447" LOG_EFFECT_SIZE="0.0" ORDER="66423" O_E="0.0" SE="0.015466252862868035" STUDY_ID="STD-Ranaboldo-1997" TOTAL_1="66" TOTAL_2="62" VAR="2.3920497761817372E-4" WEIGHT="1.6207885598732996"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.031109819346434" CI_END="0.8981352229332888" CI_START="0.3707274609011344" DF="1" EFFECT_SIZE="0.577029800568335" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="39" I2="3.0171198802231323" ID="CMP-001.02.05" LOG_CI_END="-0.046658271180573405" LOG_CI_START="-0.4309452432768348" LOG_EFFECT_SIZE="-0.2388017572287041" NO="5" P_CHI2="0.3098984602544066" P_Z="0.01485467813412836" STUDIES="2" TAU2="0.003317580529657386" TOTAL_1="87" TOTAL_2="90" WEIGHT="1.7400808767274016" Z="2.4359027372694584">
<NAME>Liver surgery</NAME>
<DICH_DATA CI_END="1.176699175298307" CI_START="0.3968256749445487" EFFECT_SIZE="0.6833333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" LOG_CI_END="0.07066544907408982" LOG_CI_START="-0.4014002364019061" LOG_EFFECT_SIZE="-0.16536739366390812" ORDER="66426" O_E="0.0" SE="0.2772937204114299" STUDY_ID="STD-Garcia_x002d_Huete-1997" TOTAL_1="39" TOTAL_2="41" VAR="0.07689180737961226" WEIGHT="0.9849964642501998"/>
<DICH_DATA CI_END="0.8864387002945626" CI_START="0.20841729216507215" EFFECT_SIZE="0.4298245614035088" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" LOG_CI_END="-0.052351291697907774" LOG_CI_START="-0.6810662509180101" LOG_EFFECT_SIZE="-0.3667087713079589" ORDER="66425" O_E="0.0" SE="0.369310279235129" STUDY_ID="STD-Lentschener-1997" TOTAL_1="48" TOTAL_2="49" VAR="0.13639008234872896" WEIGHT="0.7550844124772019"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3461324819232787" CI_START="0.39949840375995604" DF="0" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" I2="0.0" ID="CMP-001.02.06" LOG_CI_END="0.12908780382323215" LOG_CI_START="-0.39848495161814457" LOG_EFFECT_SIZE="-0.13469857389745624" NO="6" P_CHI2="1.0" P_Z="0.3169107888124305" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="26" WEIGHT="0.897100412064878" Z="1.000826334889301">
<NAME>Neuro surgery</NAME>
<DICH_DATA CI_END="1.3461324819232787" CI_START="0.39949840375995604" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.12908780382323215" LOG_CI_START="-0.39848495161814457" LOG_EFFECT_SIZE="-0.13469857389745624" ORDER="66427" O_E="0.0" SE="0.3098988480735223" STUDY_ID="STD-Palmer-2003" TOTAL_1="30" TOTAL_2="26" VAR="0.09603729603729605" WEIGHT="0.897100412064878"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7716992950035634" CI_START="0.015998043658039977" DF="0" EFFECT_SIZE="0.11111111111111109" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" I2="0.0" ID="CMP-001.02.07" LOG_CI_END="-0.11255189650552387" LOG_CI_START="-1.7959331223731259" LOG_EFFECT_SIZE="-0.954242509439325" NO="7" P_CHI2="1.0" P_Z="0.026279740134539046" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.17556847486976038" Z="2.2220527617614017">
<NAME>Orthognathic surgery</NAME>
<DICH_DATA CI_END="0.7716992950035634" CI_START="0.015998043658039977" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.11255189650552387" LOG_CI_START="-1.7959331223731259" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="66428" O_E="0.0" SE="0.9888264649460884" STUDY_ID="STD-Stewart-2001" TOTAL_1="15" TOTAL_2="15" VAR="0.9777777777777779" WEIGHT="0.17556847486976038"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="961.5207601301856" CI_END="0.7170808096922965" CI_START="0.6037823987386712" CI_STUDY="95" CI_TOTAL="95" DF="107" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6579975466257328" ESTIMABLE="YES" EVENTS_1="2695" EVENTS_2="3067" I2="88.87179513570642" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.14443189980515703" LOG_CI_START="-0.21911955153499474" LOG_EFFECT_SIZE="-0.18177572567007586" METHOD="MH" MODIFIED="2011-02-10 16:54:21 +0000" MODIFIED_BY="Emma M Sydenham" NO="3" P_CHI2="1.1102230246251565E-15" P_Q="0.0" P_Z="1.4232510398562336E-21" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="108" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.1185143040095376" TOTALS="YES" TOTAL_1="6259" TOTAL_2="4913" WEIGHT="100.00000000000004" Z="9.540368918431275">
<NAME>No. Exposed to Allogeneic Blood - Transfusion Protocol</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="924.1235475464861" CI_END="0.7134049713656327" CI_START="0.5865705334532281" DF="86" EFFECT_SIZE="0.646886647429149" ESTIMABLE="YES" EVENTS_1="2394" EVENTS_2="2715" I2="90.69388500830578" ID="CMP-001.03.01" LOG_CI_END="-0.14666386860414196" LOG_CI_START="-0.23167975772112123" LOG_EFFECT_SIZE="-0.18917181316263154" MODIFIED="2011-02-10 16:54:21 +0000" MODIFIED_BY="Emma M Sydenham" NO="1" P_CHI2="2.7755575615628914E-15" P_Z="2.7244289483120424E-18" STUDIES="87" TAU2="0.12689687164306937" TOTAL_1="5599" TOTAL_2="4375" WEIGHT="81.04675569222826" Z="8.722368125297855">
<NAME>Transfusion Protocol</NAME>
<DICH_DATA CI_END="1.1661827845720796" CI_START="0.3228907095511885" EFFECT_SIZE="0.6136363636363636" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.06676662598870041" LOG_CI_START="-0.49094445064310055" LOG_EFFECT_SIZE="-0.2120889123272001" ORDER="66429" O_E="0.0" SE="0.3276022471278735" STUDY_ID="STD-Alajmo-1989" TOTAL_1="22" TOTAL_2="12" VAR="0.1073232323232323" WEIGHT="0.8522689891886877"/>
<DICH_DATA CI_END="0.8207319356942484" CI_START="0.6020493368181332" EFFECT_SIZE="0.702937491950874" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="213" LOG_CI_END="-0.08579866731277815" LOG_CI_START="-0.22036791766259636" LOG_EFFECT_SIZE="-0.1530832924876873" ORDER="66480" O_E="0.0" SE="0.07904664378401566" STUDY_ID="STD-Alderman-1998" TOTAL_1="401" TOTAL_2="395" VAR="0.0062483718935170615" WEIGHT="1.542723634436578"/>
<DICH_DATA CI_END="2.1861039695791042" CI_START="0.25282575215333275" EFFECT_SIZE="0.7434402332361516" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.3396708128473259" LOG_CI_START="-0.5971786920649566" LOG_EFFECT_SIZE="-0.12875393960881534" ORDER="66430" O_E="0.0" SE="0.5503100366653163" STUDY_ID="STD-Alvarez-1995" TOTAL_1="49" TOTAL_2="51" VAR="0.3028411364545818" WEIGHT="0.4567980149946195"/>
<DICH_DATA CI_END="1.55131165165505" CI_START="0.5025351252755366" EFFECT_SIZE="0.882943143812709" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.1906990544207529" LOG_CI_START="-0.29883357732995014" LOG_EFFECT_SIZE="-0.0540672614545986" ORDER="66493" O_E="0.0" SE="0.28755389111597146" STUDY_ID="STD-Amar-2003" TOTAL_1="23" TOTAL_2="24" VAR="0.08268724029593597" WEIGHT="0.9566245103912814"/>
<DICH_DATA CI_END="1.0093613198140765" CI_START="0.8702995983750681" EFFECT_SIZE="0.9372549019607843" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="25" LOG_CI_END="0.004046657923747294" LOG_CI_START="-0.060331216895382254" LOG_EFFECT_SIZE="-0.028142279485817483" ORDER="66431" O_E="0.0" SE="0.03781588234437657" STUDY_ID="STD-Bailey-1994" TOTAL_1="129" TOTAL_2="25" VAR="0.0014300409574837317" WEIGHT="1.6046969856237414"/>
<DICH_DATA CI_END="0.8731188140017339" CI_START="0.5154136572187269" EFFECT_SIZE="0.6708333333333333" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="-0.05892665348310755" LOG_CI_START="-0.28784407787640515" LOG_EFFECT_SIZE="-0.17338536567975632" ORDER="66481" O_E="0.0" SE="0.1344672282481491" STUDY_ID="STD-Basora-1999" TOTAL_1="36" TOTAL_2="21" VAR="0.018081435472739826" WEIGHT="1.4090800309051064"/>
<DICH_DATA CI_END="0.39482790023923114" CI_START="0.11321905262835025" EFFECT_SIZE="0.21142857142857144" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="35" LOG_CI_END="-0.40359216580023544" LOG_CI_START="-0.9460804834383635" LOG_EFFECT_SIZE="-0.6748363246192994" ORDER="66432" O_E="0.0" SE="0.3186603231411177" STUDY_ID="STD-Bidstrup-1989" TOTAL_1="40" TOTAL_2="37" VAR="0.10154440154440156" WEIGHT="0.8746499181965581"/>
<DICH_DATA CI_END="0.9372502510926616" CI_START="0.4494540535626551" EFFECT_SIZE="0.6490384615384616" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="-0.028144434557366343" LOG_CI_START="-0.3473146983781445" LOG_EFFECT_SIZE="-0.1877295664677554" ORDER="66433" O_E="0.0" SE="0.1874821928866116" STUDY_ID="STD-Bidstrup-1990" TOTAL_1="26" TOTAL_2="18" VAR="0.035149572649572636" WEIGHT="1.2525671810179608"/>
<DICH_DATA CI_END="0.7811089758395658" CI_START="0.21508479595057134" EFFECT_SIZE="0.40988372093023256" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="24" LOG_CI_END="-0.10728837162309306" LOG_CI_START="-0.6673902882092073" LOG_EFFECT_SIZE="-0.3873393299161502" ORDER="66434" O_E="0.0" SE="0.3290066383518857" STUDY_ID="STD-Bidstrup-1993" TOTAL_1="43" TOTAL_2="47" VAR="0.10824536807960852" WEIGHT="0.8488031713836922"/>
<DICH_DATA CI_END="0.9779863575014763" CI_START="0.11361212787770752" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="-0.009667203395581254" LOG_CI_START="-0.9445753060437436" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="66435" O_E="0.0" SE="0.5491696473652761" STUDY_ID="STD-Blauhut-1994" TOTAL_1="14" TOTAL_2="14" VAR="0.3015873015873016" WEIGHT="0.4581613739317769"/>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516804" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-02-10 16:54:21 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="66436" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Boldt-1991" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="0.07393296456220115"/>
<DICH_DATA CI_END="1.174017116620848" CI_START="0.8517763377064567" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.06967442876831904" LOG_CI_START="-0.06967442876831907" LOG_EFFECT_SIZE="0.0" ORDER="66437" O_E="0.0" SE="0.0818542087049908" STUDY_ID="STD-Capdevila-1998" TOTAL_1="12" TOTAL_2="11" VAR="0.006700111482720192" WEIGHT="1.5371579067355414"/>
<DICH_DATA CI_END="0.9593385583155755" CI_START="0.7355067654519231" EFFECT_SIZE="0.84" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="50" LOG_CI_END="-0.018028099752735213" LOG_CI_START="-0.13341332812350148" LOG_EFFECT_SIZE="-0.07572071393811836" ORDER="66438" O_E="0.0" SE="0.06777785431108017" STUDY_ID="STD-Carrera-1994" TOTAL_1="51" TOTAL_2="51" VAR="0.004593837535014009" WEIGHT="1.5634573505566145"/>
<DICH_DATA CI_END="0.7733027556602502" CI_START="0.2607123323246595" EFFECT_SIZE="0.44900953778429936" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="29" LOG_CI_END="-0.11165044221312088" LOG_CI_START="-0.5838384251651039" LOG_EFFECT_SIZE="-0.34774443368911234" ORDER="66439" O_E="0.0" SE="0.27736555855420697" STUDY_ID="STD-Casas-1995" TOTAL_1="47" TOTAL_2="51" VAR="0.07693165307208723" WEIGHT="0.9847956523900341"/>
<DICH_DATA CI_END="0.9357484130358864" CI_START="0.3431596641124053" EFFECT_SIZE="0.5666666666666667" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="-0.028840900746099345" LOG_CI_START="-0.46450376593667775" LOG_EFFECT_SIZE="-0.2466723333413885" ORDER="66441" O_E="0.0" SE="0.2559105235789091" STUDY_ID="STD-Cicek-1996a" TOTAL_1="50" TOTAL_2="25" VAR="0.06549019607843137" WEIGHT="1.0460305520744062"/>
<DICH_DATA CI_END="1.0138017822726142" CI_START="0.3434056028344289" EFFECT_SIZE="0.5900383141762452" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" LOG_CI_END="0.005953050381643381" LOG_CI_START="-0.4641926233852791" LOG_EFFECT_SIZE="-0.2291197865018179" ORDER="66440" O_E="0.0" SE="0.27616589602930897" STUDY_ID="STD-Cicek-1996b" TOTAL_1="29" TOTAL_2="28" VAR="0.0762676021296711" WEIGHT="0.9881530200943502"/>
<DICH_DATA CI_END="2.4702082767769804" CI_START="0.15813443897519056" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.392733572547735" LOG_CI_START="-0.8009735378595846" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2010-05-20 11:43:48 +0100" MODIFIED_BY="Katharine Ker" ORDER="2365" O_E="0.0" SE="0.7011894655987543" STUDY_ID="STD-Cicekcioglu-2006" TOTAL_1="24" TOTAL_2="20" VAR="0.49166666666666664" WEIGHT="0.31543810453133725"/>
<DICH_DATA CI_END="0.7537424083054954" CI_START="0.31088474574670794" EFFECT_SIZE="0.4840733590733591" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="37" LOG_CI_END="-0.12277704904434342" LOG_CI_START="-0.507400587061211" LOG_EFFECT_SIZE="-0.3150888180527773" ORDER="66482" O_E="0.0" SE="0.22592977014832727" STUDY_ID="STD-Cohen-1998" TOTAL_1="56" TOTAL_2="59" VAR="0.05104426103927599" WEIGHT="1.1351495499845885"/>
<DICH_DATA CI_END="0.8525208268207006" CI_START="0.3155703671806873" EFFECT_SIZE="0.5186813186813187" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="39" LOG_CI_END="-0.06929500252570277" LOG_CI_START="-0.5009037848483089" LOG_EFFECT_SIZE="-0.2850993936870058" MODIFIED="2010-05-20 12:03:52 +0100" MODIFIED_BY="Katharine Ker" ORDER="5336" O_E="0.0" SE="0.2535291352342283" STUDY_ID="STD-Colwell-2007" TOTAL_1="175" TOTAL_2="177" VAR="0.06427702241261564" WEIGHT="1.0529729860741717"/>
<DICH_DATA CI_END="1.0006396605496894" CI_START="0.3378044714556414" EFFECT_SIZE="0.5813953488372093" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="2.7771223570681805E-4" LOG_CI_START="-0.4713346060508047" LOG_EFFECT_SIZE="-0.23552844690754887" ORDER="66442" O_E="0.0" SE="0.277027410280123" STUDY_ID="STD-Corbeau-1995" TOTAL_1="43" TOTAL_2="20" VAR="0.0767441860465116" WEIGHT="0.9857411514139198"/>
<DICH_DATA CI_END="1.5918330412997033" CI_START="0.8846618996705448" EFFECT_SIZE="1.1866903733807468" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="31" LOG_CI_END="0.20189751500676237" LOG_CI_START="-0.05322267637853529" LOG_EFFECT_SIZE="0.07433741931411353" ORDER="66443" O_E="0.0" SE="0.14985886328503842" STUDY_ID="STD-D_x0027_Ambra-1996" TOTAL_1="127" TOTAL_2="64" VAR="0.022457678905083836" WEIGHT="1.3653374580661455"/>
<DICH_DATA CI_END="2.314529531862027" CI_START="0.432053247208086" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.3644627264637834" LOG_CI_START="-0.3644627264637834" LOG_EFFECT_SIZE="0.0" ORDER="66444" O_E="0.0" SE="0.42817441928883765" STUDY_ID="STD-Deleuze-1991" TOTAL_1="30" TOTAL_2="30" VAR="0.18333333333333335" WEIGHT="0.6376539187303968"/>
<DICH_DATA CI_END="1.3254060928964186" CI_START="0.40235538574672136" EFFECT_SIZE="0.7302631578947368" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.12234896271291117" LOG_CI_START="-0.3953901810291414" LOG_EFFECT_SIZE="-0.13652060915811512" MODIFIED="2010-05-17 10:47:25 +0100" MODIFIED_BY="Katharine Ker" ORDER="2548" O_E="0.0" SE="0.30412253588417626" STUDY_ID="STD-Desai-2009" TOTAL_1="38" TOTAL_2="37" VAR="0.09249051683262208" WEIGHT="0.9121797693673174"/>
<DICH_DATA CI_END="0.9323483780122118" CI_START="0.25881421861080883" EFFECT_SIZE="0.49122807017543857" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.030421780373552382" LOG_CI_START="-0.587011868286992" LOG_EFFECT_SIZE="-0.3087168243302722" ORDER="66445" O_E="0.0" SE="0.32694377280572434" STUDY_ID="STD-Dietrich-1990" TOTAL_1="19" TOTAL_2="20" VAR="0.10689223057644108" WEIGHT="0.8538986199522812"/>
<DICH_DATA CI_END="0.7811464089683755" CI_START="0.6922940885893394" EFFECT_SIZE="0.7353795219147709" ESTIMABLE="YES" EVENTS_1="549" EVENTS_2="730" LOG_CI_END="-0.10726755940321708" LOG_CI_START="-0.1597093767577549" LOG_EFFECT_SIZE="-0.13348846808048598" ORDER="66446" O_E="0.0" SE="0.03080458310523803" STUDY_ID="STD-Dietrich-1992" TOTAL_1="902" TOTAL_2="882" VAR="9.489223402875163E-4" WEIGHT="1.6111596404367086"/>
<DICH_DATA CI_END="1.020610877852942" CI_START="0.5393517492042281" EFFECT_SIZE="0.7419354838709677" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.008860192809001107" LOG_CI_START="-0.26812790844236073" LOG_EFFECT_SIZE="-0.1296338578166798" ORDER="66447" O_E="0.0" SE="0.16270418178826412" STUDY_ID="STD-Dietrich-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.026472650771388495" WEIGHT="1.3275285980178022"/>
<DICH_DATA CI_END="0.8485647549882042" CI_START="0.46077627889680506" EFFECT_SIZE="0.6252987367702287" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="58" LOG_CI_END="-0.07131501055197918" LOG_CI_START="-0.33650988681009075" LOG_EFFECT_SIZE="-0.20391244868103495" ORDER="66507" O_E="0.0" SE="0.15577678304982373" STUDY_ID="STD-Dignan-2001" TOTAL_1="101" TOTAL_2="99" VAR="0.02426640613735185" WEIGHT="1.3480415429589911"/>
<DICH_DATA CI_END="0.5985457020816825" CI_START="0.1466746731178129" EFFECT_SIZE="0.2962962962962963" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="27" LOG_CI_END="-0.22290268334593874" LOG_CI_START="-0.8336448709881488" LOG_EFFECT_SIZE="-0.5282737771670437" ORDER="66503" O_E="0.0" SE="0.3587529842436209" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.1287037037037037" WEIGHT="0.7785611193600932"/>
<DICH_DATA CI_END="5.461059148182932" CI_START="0.5086518388474208" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7372768803609144" LOG_CI_START="-0.2935793811282016" LOG_EFFECT_SIZE="0.22184874961635637" ORDER="66488" O_E="0.0" SE="0.6055300708194984" STUDY_ID="STD-Engel-2001" TOTAL_1="12" TOTAL_2="12" VAR="0.3666666666666667" WEIGHT="0.39670626105335266"/>
<DICH_DATA CI_END="1.1465948472003975" CI_START="0.06538635291433063" EFFECT_SIZE="0.27380952380952384" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.05940998572274674" LOG_CI_START="-1.1845128858113243" LOG_EFFECT_SIZE="-0.5625514500442887" ORDER="66492" O_E="0.0" SE="0.7306864522566346" STUDY_ID="STD-Englberger-2002a" TOTAL_1="21" TOTAL_2="23" VAR="0.5339026915113871" WEIGHT="0.2950173434055186"/>
<DICH_DATA CI_END="1.0732934239859022" CI_START="0.06625505152824374" EFFECT_SIZE="0.26666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.030718468468461112" LOG_CI_START="-1.1787810039238988" LOG_EFFECT_SIZE="-0.5740312677277188" ORDER="66495" O_E="0.0" SE="0.7104659772022196" STUDY_ID="STD-Englberger-2002b" TOTAL_1="15" TOTAL_2="14" VAR="0.5047619047619047" WEIGHT="0.30881064623112287"/>
<DICH_DATA CI_END="1.176699175298307" CI_START="0.3968256749445487" EFFECT_SIZE="0.6833333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" LOG_CI_END="0.07066544907408982" LOG_CI_START="-0.4014002364019061" LOG_EFFECT_SIZE="-0.16536739366390812" ORDER="66448" O_E="0.0" SE="0.2772937204114299" STUDY_ID="STD-Garcia_x002d_Huete-1997" TOTAL_1="39" TOTAL_2="41" VAR="0.07689180737961226" WEIGHT="0.9849964642501999"/>
<DICH_DATA CI_END="0.720649865502474" CI_START="0.1158076815365343" EFFECT_SIZE="0.28888888888888886" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.14227569008565652" LOG_CI_START="-0.9362626328513574" LOG_EFFECT_SIZE="-0.539269161468507" ORDER="66449" O_E="0.0" SE="0.4663918604793264" STUDY_ID="STD-Gherli-1992" TOTAL_1="18" TOTAL_2="13" VAR="0.21752136752136747" WEIGHT="0.5727794550332183"/>
<DICH_DATA CI_END="0.9036903622073366" CI_START="0.15561192846686125" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="-0.04398034941401264" LOG_CI_START="-0.8079571151305497" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="66450" O_E="0.0" SE="0.44876373392787533" STUDY_ID="STD-Green-1995" TOTAL_1="48" TOTAL_2="36" VAR="0.2013888888888889" WEIGHT="0.6016642943364009"/>
<DICH_DATA CI_END="1.1620394238299383" CI_START="0.27073602422146403" EFFECT_SIZE="0.5608974358974359" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.06522086235840659" LOG_CI_START="-0.5674539530227032" LOG_EFFECT_SIZE="-0.25111654533214833" ORDER="66486" O_E="0.0" SE="0.3716363183457089" STUDY_ID="STD-Greilich-2001" TOTAL_1="24" TOTAL_2="25" VAR="0.1381135531135531" WEIGHT="0.7500133889162065"/>
<DICH_DATA CI_END="1.6182854246331981" CI_START="0.7470899207455475" EFFECT_SIZE="1.0995475113122173" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.20905512259825326" LOG_CI_START="-0.1266271227718502" LOG_EFFECT_SIZE="0.04121399991320153" MODIFIED="2010-05-17 13:58:42 +0100" MODIFIED_BY="Katharine Ker" ORDER="2592" O_E="0.0" SE="0.1971814125843122" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="27" VAR="0.03888050946874476" WEIGHT="1.2228759293758515"/>
<DICH_DATA CI_END="1.3438135911295888" CI_START="0.7963564179938953" EFFECT_SIZE="1.0344827586206897" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="29" LOG_CI_END="0.12833902916533568" LOG_CI_START="-0.09889251552392286" LOG_EFFECT_SIZE="0.014723256820706378" ORDER="66451" O_E="0.0" SE="0.13347693416475745" STUDY_ID="STD-Harder-1991" TOTAL_1="40" TOTAL_2="40" VAR="0.01781609195402299" WEIGHT="1.4118225612917557"/>
<DICH_DATA CI_END="1.2371304328257535" CI_START="0.6806192486246042" EFFECT_SIZE="0.9176136363636364" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.09241549047004377" LOG_CI_START="-0.1670957727641001" LOG_EFFECT_SIZE="-0.03734014114702813" ORDER="66452" O_E="0.0" SE="0.1524382006252069" STUDY_ID="STD-Hardy-1993" TOTAL_1="22" TOTAL_2="19" VAR="0.02323740500985083" WEIGHT="1.3578272187523834"/>
<DICH_DATA CI_END="1.216920975501839" CI_START="0.8217460460714104" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" LOG_CI_END="0.08526237690073346" LOG_CI_START="-0.08526237690073346" LOG_EFFECT_SIZE="0.0" ORDER="66453" O_E="0.0" SE="0.10016708449412663" STUDY_ID="STD-Hardy-1997" TOTAL_1="26" TOTAL_2="26" VAR="0.010033444816053505" WEIGHT="1.4972983235384034"/>
<DICH_DATA CI_END="3.0394125886228682" CI_START="0.20748181399616164" EFFECT_SIZE="0.7941176470588235" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.48278965789495476" LOG_CI_START="-0.6830199636614904" LOG_EFFECT_SIZE="-0.10011515288326783" ORDER="66505" O_E="0.0" SE="0.6848023425529537" STUDY_ID="STD-Harmon-2004" TOTAL_1="17" TOTAL_2="18" VAR="0.46895424836601296" WEIGHT="0.3276334163469408"/>
<DICH_DATA CI_END="0.9067145062236663" CI_START="0.6096295146835113" EFFECT_SIZE="0.7434782608695653" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="46" LOG_CI_END="-0.04252943608158775" LOG_CI_START="-0.21493401516929028" LOG_EFFECT_SIZE="-0.12873172562543903" ORDER="66454" O_E="0.0" SE="0.10127130317254668" STUDY_ID="STD-Hayashida-1997" TOTAL_1="110" TOTAL_2="57" VAR="0.010255876846265864" WEIGHT="1.4947119552990735"/>
<DICH_DATA CI_END="0.7804173827907901" CI_START="0.45795498425174797" EFFECT_SIZE="0.5978260869565217" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="46" LOG_CI_END="-0.10767306582026084" LOG_CI_START="-0.33917720988236205" LOG_EFFECT_SIZE="-0.22342513785131143" ORDER="66455" O_E="0.0" SE="0.13598668018607324" STUDY_ID="STD-Isetta-1993" TOTAL_1="140" TOTAL_2="70" VAR="0.01849237718802936" WEIGHT="1.404853596399731"/>
<DICH_DATA CI_END="0.7620123531650056" CI_START="0.5126229232079317" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="48" LOG_CI_END="-0.11803798815133151" LOG_CI_START="-0.29020197716051804" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="66456" O_E="0.0" SE="0.10112997936948631" STUDY_ID="STD-Kalangos-1994" TOTAL_1="110" TOTAL_2="55" VAR="0.010227272727272727" WEIGHT="1.4950440540640066"/>
<DICH_DATA CI_END="1.1831785640385561" CI_START="0.023477249015536238" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.07305029283121232" LOG_CI_START="-1.6293527935984997" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="66484" O_E="0.0" SE="1.0" STUDY_ID="STD-Katzel-1998" TOTAL_1="12" TOTAL_2="12" VAR="1.0000000000000002" WEIGHT="0.1720803463319429"/>
<DICH_DATA CI_END="2.410392969374453" CI_START="0.26551687136977226" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.38208785191856476" LOG_CI_START="-0.5759078779346776" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="66496" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Kipfer-2003" TOTAL_1="15" TOTAL_2="15" VAR="0.3166666666666667" WEIGHT="0.44228571969063313"/>
<DICH_DATA CI_END="1.7248117563970482" CI_START="0.1672117424292004" EFFECT_SIZE="0.5370370370370371" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.23674170368809447" LOG_CI_START="-0.7767332275361192" LOG_EFFECT_SIZE="-0.26999576192401237" ORDER="66489" O_E="0.0" SE="0.5953201913829222" STUDY_ID="STD-Klein-1998" TOTAL_1="36" TOTAL_2="29" VAR="0.35440613026819917" WEIGHT="0.40699093306286904"/>
<DICH_DATA CI_END="1.5636597783045803" CI_START="0.5373789039255461" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.19414226504209867" LOG_CI_START="-0.26971938682089824" LOG_EFFECT_SIZE="-0.0377885608893998" ORDER="66504" O_E="0.0" SE="0.27247463045653303" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.07424242424242425" WEIGHT="0.9985349437950651"/>
<DICH_DATA CI_END="0.8548579066310278" CI_START="0.4535633977347247" EFFECT_SIZE="0.6226815050344462" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="37" LOG_CI_END="-0.06810606713672084" LOG_CI_START="-0.34336199997763184" LOG_EFFECT_SIZE="-0.2057340335571763" ORDER="66457" O_E="0.0" SE="0.16168669748959338" STUDY_ID="STD-Lass-1995" TOTAL_1="51" TOTAL_2="47" VAR="0.026142588145091284" WEIGHT="1.330557610801224"/>
<DICH_DATA CI_END="0.8925895825655312" CI_START="0.5575925005095984" EFFECT_SIZE="0.7054794520547946" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="73" LOG_CI_END="-0.0493481861272466" LOG_CI_START="-0.25368307603128315" LOG_EFFECT_SIZE="-0.15151563107926486" MODIFIED="2010-05-06 16:07:15 +0100" MODIFIED_BY="Katharine Ker" ORDER="2370" O_E="0.0" SE="0.12002732580364896" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="103" VAR="0.014406558939575296" WEIGHT="1.4480370089447865"/>
<DICH_DATA CI_END="1.5757982109905528" CI_START="0.20721600644516502" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.19750060308743156" LOG_CI_START="-0.6835767004600205" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="66458" O_E="0.0" SE="0.5175491695067657" STUDY_ID="STD-Laub-1994" TOTAL_1="16" TOTAL_2="16" VAR="0.26785714285714285" WEIGHT="0.49815878055193774"/>
<DICH_DATA CI_END="0.7708713825665181" CI_START="0.5331054961218116" EFFECT_SIZE="0.6410583209421983" ESTIMABLE="YES" EVENTS_1="173" EVENTS_2="87" LOG_CI_END="-0.11301807655504825" LOG_CI_START="-0.2731868400353992" LOG_EFFECT_SIZE="-0.1931024582952237" ORDER="66459" O_E="0.0" SE="0.09408392451652427" STUDY_ID="STD-Lemmer-1996" TOTAL_1="487" TOTAL_2="157" VAR="0.008851784852431035" WEIGHT="1.51118975648051"/>
<DICH_DATA CI_END="1.0497678264256392" CI_START="0.4997731056344701" EFFECT_SIZE="0.7243243243243244" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="35" LOG_CI_END="0.021093258258824937" LOG_CI_START="-0.30122711833523724" LOG_EFFECT_SIZE="-0.14006693003820614" ORDER="66460" O_E="0.0" SE="0.18933258472294834" STUDY_ID="STD-Lemmer_x005f_1-1994" TOTAL_1="74" TOTAL_2="67" VAR="0.035846827637872405" WEIGHT="1.2469092883488382"/>
<DICH_DATA CI_END="0.8150022791529388" CI_START="0.22000161521551823" EFFECT_SIZE="0.42344045368620037" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="23" LOG_CI_END="-0.08884117675430474" LOG_CI_START="-0.6575741306477412" LOG_EFFECT_SIZE="-0.37320765370102293" ORDER="66461" O_E="0.0" SE="0.33407655239053047" STUDY_ID="STD-Lemmer_x005f_2-1994" TOTAL_1="23" TOTAL_2="32" VAR="0.11160714285714285" WEIGHT="0.8364032619814973"/>
<DICH_DATA CI_END="0.8864387002945626" CI_START="0.20841729216507215" EFFECT_SIZE="0.4298245614035088" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" LOG_CI_END="-0.052351291697907774" LOG_CI_START="-0.6810662509180101" LOG_EFFECT_SIZE="-0.3667087713079589" ORDER="66462" O_E="0.0" SE="0.369310279235129" STUDY_ID="STD-Lentschener-1997" TOTAL_1="48" TOTAL_2="49" VAR="0.13639008234872896" WEIGHT="0.7550844124772017"/>
<DICH_DATA CI_END="1.1223523647028855" CI_START="0.17286841501668593" EFFECT_SIZE="0.44047619047619047" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.05012922592328552" LOG_CI_START="-0.7622843499130588" LOG_EFFECT_SIZE="-0.35607756199488666" ORDER="66483" O_E="0.0" SE="0.4772157559583272" STUDY_ID="STD-Lentschener-1999" TOTAL_1="35" TOTAL_2="37" VAR="0.22773487773487772" WEIGHT="0.5558838517437096"/>
<DICH_DATA CI_END="0.925107108046671" CI_START="0.6394106016052801" EFFECT_SIZE="0.769105514546244" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="49" LOG_CI_END="-0.03380798213586703" LOG_CI_START="-0.19422016728156163" LOG_EFFECT_SIZE="-0.11401407470871433" ORDER="66463" O_E="0.0" SE="0.09422691160770381" STUDY_ID="STD-Levy-1995" TOTAL_1="188" TOTAL_2="65" VAR="0.008878710871126027" WEIGHT="1.5108703486725321"/>
<DICH_DATA CI_END="0.7917906433240165" CI_START="0.12333594849015803" EFFECT_SIZE="0.3125" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.10138963465852775" LOG_CI_START="-0.9089103219812843" LOG_EFFECT_SIZE="-0.505149978319906" ORDER="66499" O_E="0.0" SE="0.4743416490252569" STUDY_ID="STD-Li-2005" TOTAL_1="40" TOTAL_2="30" VAR="0.22499999999999998" WEIGHT="0.5603095025872614"/>
<DICH_DATA CI_END="2.4521888362810533" CI_START="0.008322427279400224" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3895539109512145" LOG_CI_START="-2.079749990979728" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="66497" O_E="0.0" SE="1.4504813352456845" STUDY_ID="STD-Llau-1998" TOTAL_1="10" TOTAL_2="10" VAR="2.103896103896104" WEIGHT="0.08660611385121146"/>
<DICH_DATA CI_END="1.1257994302155443" CI_START="0.3587946958901859" EFFECT_SIZE="0.6355555555555555" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.05146102452110328" LOG_CI_START="-0.4451539858137047" LOG_EFFECT_SIZE="-0.1968464806463007" ORDER="66464" O_E="0.0" SE="0.29171411535461406" STUDY_ID="STD-Locatelli-1990" TOTAL_1="25" TOTAL_2="13" VAR="0.08509712509712508" WEIGHT="0.9453021849297313"/>
<DICH_DATA CI_END="1.3225611225787064" CI_START="0.14449806862033407" EFFECT_SIZE="0.4371584699453552" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.12141575222725745" LOG_CI_START="-0.8401379577042294" LOG_EFFECT_SIZE="-0.3593611027384859" ORDER="66465" O_E="0.0" SE="0.564821408981384" STUDY_ID="STD-Maccario-1994" TOTAL_1="61" TOTAL_2="32" VAR="0.31902322404371586" WEIGHT="0.43990358876774327"/>
<DICH_DATA CI_END="0.581965375170908" CI_START="0.011932745040725218" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.23510285352801047" LOG_CI_START="-1.9232596385672394" LOG_EFFECT_SIZE="-1.0791812460476249" ORDER="66500" O_E="0.0" SE="0.991631652042901" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.9833333333333332" WEIGHT="0.17468325228281953"/>
<DICH_DATA CI_END="0.4272576057276957" CI_START="0.028895164993771816" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="18" LOG_CI_END="-0.3693101975453905" LOG_CI_START="-1.5391748213332594" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="66466" O_E="0.0" SE="0.6871842709362768" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.47222222222222227" WEIGHT="0.3258209375319398"/>
<DICH_DATA CI_END="0.8847859245407694" CI_START="0.540868121448187" EFFECT_SIZE="0.6917748917748918" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="16" LOG_CI_END="-0.05316179488080641" LOG_CI_START="-0.266908614947537" LOG_EFFECT_SIZE="-0.1600352049141717" ORDER="66467" O_E="0.0" SE="0.12555594017102115" STUDY_ID="STD-Mohr-1992" TOTAL_1="34" TOTAL_2="16" VAR="0.015764294112229044" WEIGHT="1.4333954293792492"/>
<DICH_DATA CI_END="0.8973650634832809" CI_START="0.4380356604107999" EFFECT_SIZE="0.6269592476489029" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" LOG_CI_END="-0.04703084257180927" LOG_CI_START="-0.3584905322145905" LOG_EFFECT_SIZE="-0.2027606873931999" ORDER="66468" O_E="0.0" SE="0.18295296344649845" STUDY_ID="STD-Murkin-1994" TOTAL_1="29" TOTAL_2="25" VAR="0.0334717868338558" WEIGHT="1.2663943637416075"/>
<DICH_DATA CI_END="1.2854855901578142" CI_START="0.5973191554248912" EFFECT_SIZE="0.8762677484787018" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.10906721271748547" LOG_CI_START="-0.22379355764212133" LOG_EFFECT_SIZE="-0.05736317246231793" ORDER="66469" O_E="0.0" SE="0.19552406419661988" STUDY_ID="STD-Murkin-1995" TOTAL_1="29" TOTAL_2="24" VAR="0.03822965967996394" WEIGHT="1.2279536913617362"/>
<DICH_DATA CI_END="0.851080315601441" CI_START="0.17407565969356745" EFFECT_SIZE="0.3849056603773585" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="-0.07002945404391975" LOG_CI_START="-0.7592619503058609" LOG_EFFECT_SIZE="-0.4146457021748903" ORDER="66485" O_E="0.0" SE="0.4048585800601448" STUDY_ID="STD-Murkin-2000" TOTAL_1="212" TOTAL_2="68" VAR="0.1639104698483167" WEIGHT="0.6815065342251687"/>
<DICH_DATA CI_END="1.0403570180709536" CI_START="0.56797137464091" EFFECT_SIZE="0.768695652173913" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="23" LOG_CI_END="0.01718240119376299" LOG_CI_START="-0.24567355187484013" LOG_EFFECT_SIZE="-0.11424557534053863" MODIFIED="2010-05-07 14:57:25 +0100" MODIFIED_BY="Katharine Ker" ORDER="2464" O_E="0.0" SE="0.15440288799045002" STUDY_ID="STD-Nur_x00f6_zler-2008" TOTAL_1="25" TOTAL_2="26" VAR="0.023840251819791457" WEIGHT="1.3520770564024212"/>
<DICH_DATA CI_END="1.3461324819232787" CI_START="0.39949840375995604" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.12908780382323215" LOG_CI_START="-0.39848495161814457" LOG_EFFECT_SIZE="-0.13469857389745624" ORDER="66491" O_E="0.0" SE="0.3098988480735223" STUDY_ID="STD-Palmer-2003" TOTAL_1="30" TOTAL_2="26" VAR="0.09603729603729605" WEIGHT="0.8971004120648778"/>
<DICH_DATA CI_END="1.1769979621462765" CI_START="0.7239358378865783" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="52" LOG_CI_END="0.07077571090682193" LOG_CI_START="-0.14029992342524575" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2010-05-21 15:24:56 +0100" MODIFIED_BY="Katharine Ker" ORDER="2330" O_E="0.0" SE="0.1239868724478975" STUDY_ID="STD-Parvizi-2007" TOTAL_1="81" TOTAL_2="81" VAR="0.015372744539411204" WEIGHT="1.437587361116749"/>
<DICH_DATA CI_END="2.5475015595668227" CI_START="0.008011050351928473" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.40611445855130324" LOG_CI_START="-2.0963105385798166" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="66470" O_E="0.0" SE="1.469936830518334" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="2.1607142857142856" WEIGHT="0.08444713693000651"/>
<DICH_DATA CI_END="1.0650367118693163" CI_START="0.331144696158032" EFFECT_SIZE="0.5938697318007663" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" LOG_CI_END="0.027364578185526574" LOG_CI_START="-0.4799821965215054" LOG_EFFECT_SIZE="-0.22630880916798943" ORDER="66506" O_E="0.0" SE="0.29801800686994884" STUDY_ID="STD-Poston-2006" TOTAL_1="29" TOTAL_2="31" VAR="0.08881473241873687" WEIGHT="0.9283520153617262"/>
<DICH_DATA CI_END="1.0902507120596947" CI_START="0.9172202218614527" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.037526378990036593" LOG_CI_START="-0.037526378990036614" LOG_EFFECT_SIZE="0.0" ORDER="66471" O_E="0.0" SE="0.04408636155463877" STUDY_ID="STD-Pugh-1995" TOTAL_1="21" TOTAL_2="23" VAR="0.0019436072751263314" WEIGHT="1.597855439783789"/>
<DICH_DATA CI_END="1.0307774244809154" CI_START="0.970141541956631" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="62" LOG_CI_END="0.013164898304624488" LOG_CI_START="-0.01316489830462447" LOG_EFFECT_SIZE="0.0" ORDER="66472" O_E="0.0" SE="0.015466252862868035" STUDY_ID="STD-Ranaboldo-1997" TOTAL_1="66" TOTAL_2="62" VAR="2.3920497761817372E-4" WEIGHT="1.6207885598733012"/>
<DICH_DATA CI_END="0.7866183929057147" CI_START="0.16610386164783042" EFFECT_SIZE="0.3614697120158888" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="19" LOG_CI_END="-0.10423590302661616" LOG_CI_START="-0.779620270782508" LOG_EFFECT_SIZE="-0.441928086904562" ORDER="66473" O_E="0.0" SE="0.3967241208263498" STUDY_ID="STD-Ray-1997" TOTAL_1="53" TOTAL_2="52" VAR="0.15739002804544017" WEIGHT="0.697612565114926"/>
<DICH_DATA CI_END="2.156255130476228" CI_START="0.031811682828664346" EFFECT_SIZE="0.2619047619047619" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3337001457552575" LOG_CI_START="-1.4974133562346084" LOG_EFFECT_SIZE="-0.5818566052396754" ORDER="66474" O_E="0.0" SE="1.075605135226867" STUDY_ID="STD-Rossi-1997" TOTAL_1="21" TOTAL_2="22" VAR="1.156926406926407" WEIGHT="0.15090809565734478"/>
<DICH_DATA CI_END="0.8200679247854159" CI_START="0.18671513419777433" EFFECT_SIZE="0.391304347826087" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="-0.0861501742775433" LOG_CI_START="-0.7288204788789927" LOG_EFFECT_SIZE="-0.40748532657826797" ORDER="66475" O_E="0.0" SE="0.37750771819220597" STUDY_ID="STD-Royston-1987" TOTAL_1="11" TOTAL_2="11" VAR="0.142512077294686" WEIGHT="0.7373750034364015"/>
<DICH_DATA CI_END="0.8944158527519801" CI_START="0.26944036691176204" EFFECT_SIZE="0.4909090909090909" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="-0.04846051189314574" LOG_CI_START="-0.5695373387773675" LOG_EFFECT_SIZE="-0.3089989253352565" ORDER="66494" O_E="0.0" SE="0.3060831074836844" STUDY_ID="STD-Samama-2002" TOTAL_1="40" TOTAL_2="18" VAR="0.09368686868686871" WEIGHT="0.9070370647129461"/>
<DICH_DATA CI_END="0.6609816379241117" CI_START="0.11252985109065299" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="-0.1798106050514249" LOG_CI_START="-0.9487322558257003" LOG_EFFECT_SIZE="-0.5642714304385626" ORDER="66490" O_E="0.0" SE="0.4516683838883667" STUDY_ID="STD-Santamaria-2000" TOTAL_1="56" TOTAL_2="28" VAR="0.20400432900432902" WEIGHT="0.5967851438925017"/>
<DICH_DATA CI_END="1.1628512108432862" CI_START="0.7528113445654874" EFFECT_SIZE="0.9356321839080459" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="29" LOG_CI_END="0.06552414942872957" LOG_CI_START="-0.12331384488756425" LOG_EFFECT_SIZE="-0.028894847729417316" ORDER="66476" O_E="0.0" SE="0.11092437262453853" STUDY_ID="STD-Speekenbrink-1996" TOTAL_1="75" TOTAL_2="37" VAR="0.012304216442147471" WEIGHT="1.4713079474269048"/>
<DICH_DATA CI_END="0.7716992950035634" CI_START="0.015998043658039977" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.11255189650552387" LOG_CI_START="-1.7959331223731259" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="66487" O_E="0.0" SE="0.9888264649460884" STUDY_ID="STD-Stewart-2001" TOTAL_1="15" TOTAL_2="15" VAR="0.9777777777777779" WEIGHT="0.17556847486976015"/>
<DICH_DATA CI_END="0.9849542929885672" CI_START="0.6267772455738472" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="42" LOG_CI_END="-0.006583922561699111" LOG_CI_START="-0.20288677847832687" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="66477" O_E="0.0" SE="0.11530926928023555" STUDY_ID="STD-Swart-1994" TOTAL_1="49" TOTAL_2="49" VAR="0.013296227581941874" WEIGHT="1.460234827120865"/>
<DICH_DATA CI_END="1.26102060903135" CI_START="0.4408653477494194" EFFECT_SIZE="0.7456140350877193" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.10072218436487669" LOG_CI_START="-0.3556940356092364" LOG_EFFECT_SIZE="-0.12748592562217986" ORDER="66478" O_E="0.0" SE="0.26810114690952036" STUDY_ID="STD-Tabuchi-1994" TOTAL_1="19" TOTAL_2="17" VAR="0.07187822497420022" WEIGHT="1.0109342516671613"/>
<DICH_DATA CI_END="0.7975135540067488" CI_START="0.32428296497632014" EFFECT_SIZE="0.5085470085470085" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="26" LOG_CI_END="-0.09826192722963079" LOG_CI_START="-0.48907586480559345" LOG_EFFECT_SIZE="-0.2936688960176121" ORDER="66498" O_E="0.0" SE="0.22956604149231166" STUDY_ID="STD-Taggart-2003" TOTAL_1="36" TOTAL_2="34" VAR="0.05270056740644976" WEIGHT="1.1241682875989991"/>
<DICH_DATA CI_END="0.968686759662337" CI_START="0.43166883561525266" EFFECT_SIZE="0.6466466466466466" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="27" LOG_CI_END="-0.013816636306206052" LOG_CI_START="-0.36484930415559036" LOG_EFFECT_SIZE="-0.18933297023089823" ORDER="66501" O_E="0.0" SE="0.2061983267344585" STUDY_ID="STD-Van-der-Linden-2005" TOTAL_1="37" TOTAL_2="38" VAR="0.0425177499480905" WEIGHT="1.1952547587937898"/>
<DICH_DATA CI_END="1.3454053931997747" CI_START="0.022094839371514755" EFFECT_SIZE="0.1724137931034483" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.1288531642656234" LOG_CI_START="-1.6557091513914979" LOG_EFFECT_SIZE="-0.7634279935629372" ORDER="66502" O_E="0.0" SE="1.048260737942924" STUDY_ID="STD-Vanek-2005" TOTAL_1="29" TOTAL_2="30" VAR="1.0988505747126436" WEIGHT="0.15810734495086295"/>
<DICH_DATA CI_END="0.9361707678459628" CI_START="0.3957722348326828" EFFECT_SIZE="0.6086956521739131" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="23" LOG_CI_END="-0.028644923944956005" LOG_CI_START="-0.40255467673375367" LOG_EFFECT_SIZE="-0.21559980033935483" ORDER="66479" O_E="0.0" SE="0.21963643967126673" STUDY_ID="STD-Vedrinne-1992" TOTAL_1="30" TOTAL_2="30" VAR="0.04824016563146998" WEIGHT="1.1542378997429934"/>
<DICH_DATA CI_END="2.1719720978715733" CI_START="0.319729910492389" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3368542418108039" LOG_CI_START="-0.49521673390605353" LOG_EFFECT_SIZE="-0.07918124604762482" MODIFIED="2010-05-26 12:16:27 +0100" MODIFIED_BY="Katharine Ker" ORDER="2766" O_E="0.0" SE="0.4887626099538393" STUDY_ID="STD-Wei-2006" TOTAL_1="36" TOTAL_2="40" VAR="0.23888888888888885" WEIGHT="0.5385355604976207"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="49.7359876138311" CI_END="0.8419967553774029" CI_START="0.607035538235417" DF="20" EFFECT_SIZE="0.7149279359438939" ESTIMABLE="YES" EVENTS_1="301" EVENTS_2="352" I2="59.787668930418114" ID="CMP-001.03.02" LOG_CI_END="-0.07468958204477423" LOG_CI_START="-0.21678588288233017" LOG_EFFECT_SIZE="-0.1457377324635522" MODIFIED="2010-05-07 14:46:49 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="2.415856794649729E-4" P_Z="5.810384145621979E-5" STUDIES="21" TAU2="0.06708261448794865" TOTAL_1="660" TOTAL_2="538" WEIGHT="18.953244307771786" Z="4.020382024492528">
<NAME>No Transfusion Protocol</NAME>
<DICH_DATA CI_END="0.9794902492496453" CI_START="0.5964920617890417" EFFECT_SIZE="0.764367816091954" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="45" LOG_CI_END="-0.008999883016004835" LOG_CI_START="-0.22439533161502298" LOG_EFFECT_SIZE="-0.11669760731551393" ORDER="66508" O_E="0.0" SE="0.1265243527317297" STUDY_ID="STD-Baele-1992" TOTAL_1="58" TOTAL_2="57" VAR="0.01600841183418316" WEIGHT="1.430794253624769"/>
<DICH_DATA CI_END="0.8902876187799331" CI_START="0.3588398767925144" EFFECT_SIZE="0.5652173913043478" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="23" LOG_CI_END="-0.05046966631041668" LOG_CI_START="-0.4450993011110956" LOG_EFFECT_SIZE="-0.24778448371075615" ORDER="66519" O_E="0.0" SE="0.23180740093011587" STUDY_ID="STD-Bidstrup-2000" TOTAL_1="30" TOTAL_2="30" VAR="0.053734671125975485" WEIGHT="1.1174192976171173"/>
<DICH_DATA CI_END="0.7824570437156144" CI_START="0.4904318747402467" EFFECT_SIZE="0.6194690265486725" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="44" LOG_CI_END="-0.10653949555704548" LOG_CI_START="-0.3094213113812804" LOG_EFFECT_SIZE="-0.2079804034691629" ORDER="66509" O_E="0.0" SE="0.11917378289634074" STUDY_ID="STD-Cosgrove-1992" TOTAL_1="113" TOTAL_2="56" VAR="0.014202390529824159" WEIGHT="1.4502646368585408"/>
<DICH_DATA CI_END="0.9968014774159336" CI_START="0.30347065775242266" EFFECT_SIZE="0.55" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="-0.0013913269919762872" LOG_CI_START="-0.5178832940195359" LOG_EFFECT_SIZE="-0.2596373105057561" ORDER="66524" O_E="0.0" SE="0.30338993810845893" STUDY_ID="STD-Cvachovec-2001" TOTAL_1="20" TOTAL_2="22" VAR="0.09204545454545456" WEIGHT="0.91410785295389"/>
<DICH_DATA CI_END="70.82882080128427" CI_START="0.12706691849706478" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8502100114756685" LOG_CI_START="-0.895967502036344" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="66520" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-D_x0027_Ambrosio-1999" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="0.07074532881267794"/>
<DICH_DATA CI_END="0.9468374527500885" CI_START="0.399961179980938" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="26" LOG_CI_END="-0.02372457161220413" LOG_CI_START="-0.3979821590175822" LOG_EFFECT_SIZE="-0.21085336531489315" ORDER="66510" O_E="0.0" SE="0.2198407594468552" STUDY_ID="STD-Fraedrich-1989" TOTAL_1="38" TOTAL_2="38" VAR="0.048329959514170046" WEIGHT="1.153616700665551"/>
<DICH_DATA CI_END="1.2005001082166866" CI_START="0.15299746175000142" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.07936220354165731" LOG_CI_START="-0.8153157741308461" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="66511" O_E="0.0" SE="0.5255382728122436" STUDY_ID="STD-Havel-1992" TOTAL_1="10" TOTAL_2="10" VAR="0.2761904761904762" WEIGHT="0.4876412409134198"/>
<DICH_DATA CI_END="1.3299782792134183" CI_START="0.575667296200363" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.12384454826424007" LOG_CI_START="-0.23982844221961358" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="66525" O_E="0.0" SE="0.2136233148205519" STUDY_ID="STD-Jeserschek-2003" TOTAL_1="9" TOTAL_2="9" VAR="0.04563492063492064" WEIGHT="1.17255703904838"/>
<DICH_DATA CI_END="1.0237823367364247" CI_START="0.10853001377744706" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.010207632418683592" LOG_CI_START="-0.9644501418580085" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="66523" O_E="0.0" SE="0.5725188012439223" STUDY_ID="STD-Kyriss-2001" TOTAL_1="18" TOTAL_2="20" VAR="0.3277777777777778" WEIGHT="0.43127435297612726"/>
<DICH_DATA CI_END="0.7532478029295167" CI_START="0.08297402230305383" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.12306212640134118" LOG_CI_START="-1.0810578562545836" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="66512" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Liu-1993" TOTAL_1="20" TOTAL_2="20" VAR="0.31666666666666665" WEIGHT="0.4422857196906332"/>
<DICH_DATA CI_END="0.8534432320457009" CI_START="0.10136021596195216" EFFECT_SIZE="0.29411764705882354" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.06882536128531151" LOG_CI_START="-0.9941324727991987" LOG_EFFECT_SIZE="-0.5314789170422551" MODIFIED="2010-05-07 14:46:49 +0100" MODIFIED_BY="Katharine Ker" ORDER="2459" O_E="0.0" SE="0.5435299776473301" STUDY_ID="STD-Norman-2009" TOTAL_1="8" TOTAL_2="8" VAR="0.29542483660130725" WEIGHT="0.4649821916505923"/>
<DICH_DATA CI_END="1.4043574036065283" CI_START="0.7193914498899935" EFFECT_SIZE="1.005128205128205" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="15" LOG_CI_END="0.14747764815076966" LOG_CI_START="-0.14303472816285362" LOG_EFFECT_SIZE="0.0022214599939580325" ORDER="66513" O_E="0.0" SE="0.17064840790607783" STUDY_ID="STD-Okita-1996" TOTAL_1="39" TOTAL_2="21" VAR="0.02912087912087913" WEIGHT="1.3037158537011262"/>
<DICH_DATA CI_END="0.9019134165859846" CI_START="0.5221928115776203" EFFECT_SIZE="0.6862745098039216" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="25" LOG_CI_END="-0.04483515259530587" LOG_CI_START="-0.2821691109000156" LOG_EFFECT_SIZE="-0.16350213174766073" ORDER="66527" O_E="0.0" SE="0.1394111419302274" STUDY_ID="STD-Petsatodis-2006" TOTAL_1="25" TOTAL_2="25" VAR="0.01943546649429001" WEIGHT="1.3952493585761556"/>
<DICH_DATA CI_END="0.8889502048802845" CI_START="0.3373491784678522" EFFECT_SIZE="0.5476190476190477" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" LOG_CI_END="-0.05112256563428223" LOG_CI_START="-0.47192034312633274" LOG_EFFECT_SIZE="-0.26152145438030755" ORDER="66522" O_E="0.0" SE="0.24717869748142302" STUDY_ID="STD-Ray-1999" TOTAL_1="100" TOTAL_2="50" VAR="0.061097308488612834" WEIGHT="1.0716140573214628"/>
<DICH_DATA CI_END="3.436173203095408" CI_START="0.1293428526955729" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5360750466763062" LOG_CI_START="-0.8882575647876688" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="66526" O_E="0.0" SE="0.8366600265340756" STUDY_ID="STD-Ray-2005" TOTAL_1="15" TOTAL_2="15" VAR="0.7" WEIGHT="0.23515084326363903"/>
<DICH_DATA CI_END="1.0533410525445912" CI_START="0.6797193839842649" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="26" LOG_CI_END="0.02256901055561178" LOG_CI_START="-0.16767034485283525" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="66514" O_E="0.0" SE="0.11174753906691859" STUDY_ID="STD-Rocha-1994" TOTAL_1="28" TOTAL_2="28" VAR="0.012487512487512495" WEIGHT="1.4692493123981032"/>
<DICH_DATA CI_END="1.9071560686454936" CI_START="1.0494267347438109" EFFECT_SIZE="1.414715719063545" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="26" LOG_CI_END="0.28038623419867686" LOG_CI_START="0.02095212390254852" LOG_EFFECT_SIZE="0.15066917905061267" ORDER="66515" O_E="0.0" SE="0.1523928806075034" STUDY_ID="STD-Rodrigus-1996" TOTAL_1="46" TOTAL_2="47" VAR="0.02322359005985278" WEIGHT="1.3579595638479292"/>
<DICH_DATA CI_END="1.6216329114793497" CI_START="0.733879188195826" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.20995254989858633" LOG_CI_START="-0.13437542811978684" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="66516" O_E="0.0" SE="0.20225995873897265" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.04090909090909092" WEIGHT="1.2073154564888948"/>
<DICH_DATA CI_END="2.1315266092423184" CI_START="0.3002542859305412" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3286907585993715" LOG_CI_START="-0.5225107846154844" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="66521" O_E="0.0" SE="0.49999999999999994" STUDY_ID="STD-Tassani-2000" TOTAL_1="10" TOTAL_2="10" VAR="0.24999999999999997" WEIGHT="0.5222981217201595"/>
<DICH_DATA CI_END="1.2419824481161656" CI_START="0.02830655944721672" EFFECT_SIZE="0.1875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.09411545836861414" LOG_CI_START="-1.5481129142411387" LOG_EFFECT_SIZE="-0.7269987279362623" ORDER="66517" O_E="0.0" SE="0.9646530752325188" STUDY_ID="STD-Thorpe-1994" TOTAL_1="8" TOTAL_2="9" VAR="0.9305555555555556" WEIGHT="0.18347141237189515"/>
<DICH_DATA CI_END="0.9740335218944856" CI_START="0.3695971359382001" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="-0.011426096382906073" LOG_CI_START="-0.4322714028498067" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="66518" O_E="0.0" SE="0.24720661623652213" STUDY_ID="STD-Wendel-1995" TOTAL_1="20" TOTAL_2="18" VAR="0.06111111111111113" WEIGHT="1.0715317132707218"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1011.2639665866099" CI_END="0.7256187072413078" CI_START="0.6228537022408434" CI_STUDY="95" CI_TOTAL="95" DF="126" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6722754630510199" ESTIMABLE="YES" EVENTS_1="2689" EVENTS_2="3720" I2="87.54034513606803" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.13929152921843785" LOG_CI_START="-0.20561394976255198" LOG_EFFECT_SIZE="-0.1724527394904949" METHOD="MH" MODIFIED="2011-02-16 14:07:30 +0000" MODIFIED_BY="Emma M Sydenham" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="2.1381747938784226E-24" Q="0.0" RANDOM="YES" SCALE="112.07" SORT_BY="STUDY" STUDIES="107" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.10948598255174043" TOTALS="YES" TOTAL_1="6211" TOTAL_2="5905" WEIGHT="100.00000000000003" Z="10.192666542133146">
<NAME>No. Exposed to Allogeneic Blood - Dose</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="59.490292798044145" CI_END="0.9616408629818571" CI_START="0.7100998476567473" DF="15" EFFECT_SIZE="0.826354058684242" ESTIMABLE="YES" EVENTS_1="345" EVENTS_2="394" I2="74.78580236456132" ID="CMP-001.04.01" LOG_CI_END="-0.01698709048435037" LOG_CI_START="-0.14868058052382363" LOG_EFFECT_SIZE="-0.08283383550408699" MODIFIED="2008-09-16 05:41:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.08527100534306E-7" P_Z="0.013678630899326766" STUDIES="16" TAU2="0.051376200415337206" TOTAL_1="649" TOTAL_2="602" WEIGHT="14.232468851849912" Z="2.4655939217749223">
<NAME>Prime Dose</NAME>
<DICH_DATA CI_END="1.0529122156472872" CI_START="0.8947009147502587" EFFECT_SIZE="0.9705882352941176" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="25" LOG_CI_END="0.02239216430115447" LOG_CI_START="-0.04832211862988974" LOG_EFFECT_SIZE="-0.012964977164367647" ORDER="66528" O_E="0.0" SE="0.04153791983504127" STUDY_ID="STD-Bailey-1994" TOTAL_1="51" TOTAL_2="25" VAR="0.001725398784222315" WEIGHT="1.3647298953687999"/>
<DICH_DATA CI_END="1.0732934239859022" CI_START="0.06625505152824374" EFFECT_SIZE="0.26666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.030718468468461112" LOG_CI_START="-1.1787810039238988" LOG_EFFECT_SIZE="-0.5740312677277188" ORDER="66542" O_E="0.0" SE="0.7104659772022196" STUDY_ID="STD-Englberger-2002b" TOTAL_1="15" TOTAL_2="14" VAR="0.5047619047619047" WEIGHT="0.2470883497511324"/>
<DICH_DATA CI_END="1.216920975501839" CI_START="0.8217460460714104" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" LOG_CI_END="0.08526237690073346" LOG_CI_START="-0.08526237690073346" LOG_EFFECT_SIZE="0.0" ORDER="66529" O_E="0.0" SE="0.10016708449412663" STUDY_ID="STD-Hardy-1997" TOTAL_1="26" TOTAL_2="26" VAR="0.010033444816053505" WEIGHT="1.269864658465938"/>
<DICH_DATA CI_END="0.9102795643744894" CI_START="0.5358673093452336" EFFECT_SIZE="0.6984189723320158" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="46" LOG_CI_END="-0.040825206998584156" LOG_CI_START="-0.27094273633952354" LOG_EFFECT_SIZE="-0.15588397166905388" ORDER="66530" O_E="0.0" SE="0.13517217583500923" STUDY_ID="STD-Hayashida-1997" TOTAL_1="55" TOTAL_2="57" VAR="0.018271517119970652" WEIGHT="1.1879811142551253"/>
<DICH_DATA CI_END="0.8321686094280049" CI_START="0.5012213747537783" EFFECT_SIZE="0.6458333333333334" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="48" LOG_CI_END="-0.07978867043362828" LOG_CI_START="-0.29997041664900065" LOG_EFFECT_SIZE="-0.1898795435413145" ORDER="66531" O_E="0.0" SE="0.1293358476441315" STUDY_ID="STD-Kalangos-1994" TOTAL_1="55" TOTAL_2="55" VAR="0.016727761485825998" WEIGHT="1.202511643813324"/>
<DICH_DATA CI_END="2.410392969374453" CI_START="0.26551687136977226" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.38208785191856476" LOG_CI_START="-0.5759078779346776" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="66543" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Kipfer-2003" TOTAL_1="15" TOTAL_2="15" VAR="0.3166666666666667" WEIGHT="0.35614819500198114"/>
<DICH_DATA CI_END="0.8187411344876563" CI_START="0.493396420643741" EFFECT_SIZE="0.6355815802790429" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="87" LOG_CI_END="-0.08685338961260106" LOG_CI_START="-0.3068040054346707" LOG_EFFECT_SIZE="-0.19682869752363585" ORDER="66532" O_E="0.0" SE="0.12920008050699153" STUDY_ID="STD-Lemmer-1996" TOTAL_1="159" TOTAL_2="157" VAR="0.01669266080301309" WEIGHT="1.202846161435848"/>
<DICH_DATA CI_END="1.1710073557419394" CI_START="0.7802778250572483" EFFECT_SIZE="0.9558823529411765" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="49" LOG_CI_END="0.06855962312368777" LOG_CI_START="-0.10775073525044924" LOG_EFFECT_SIZE="-0.019595556063380724" ORDER="66533" O_E="0.0" SE="0.10356557725931759" STUDY_ID="STD-Levy-1995" TOTAL_1="68" TOTAL_2="65" VAR="0.01072582879305568" WEIGHT="1.262550618916519"/>
<DICH_DATA CI_END="2.0074970509295444" CI_START="0.15163136814312883" EFFECT_SIZE="0.5517241379310345" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.30265491596019983" LOG_CI_START="-0.8192109464462624" LOG_EFFECT_SIZE="-0.2582780152430313" ORDER="66534" O_E="0.0" SE="0.6589895609031378" STUDY_ID="STD-Maccario-1994" TOTAL_1="29" TOTAL_2="32" VAR="0.43426724137931033" WEIGHT="0.27912201736884484"/>
<DICH_DATA CI_END="1.0870519908380398" CI_START="0.724099128395356" EFFECT_SIZE="0.8872053872053872" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.03625031574600616" LOG_CI_START="-0.1402019752833" LOG_EFFECT_SIZE="-0.05197582976864693" ORDER="66535" O_E="0.0" SE="0.10364894920354192" STUDY_ID="STD-Mohr-1992" TOTAL_1="17" TOTAL_2="16" VAR="0.010743104670998413" WEIGHT="1.2623692013336962"/>
<DICH_DATA CI_END="1.4043574036065283" CI_START="0.7193914498899935" EFFECT_SIZE="1.005128205128205" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="15" LOG_CI_END="0.14747764815076966" LOG_CI_START="-0.14303472816285362" LOG_EFFECT_SIZE="0.0022214599939580325" ORDER="66536" O_E="0.0" SE="0.17064840790607783" STUDY_ID="STD-Okita-1996" TOTAL_1="39" TOTAL_2="21" VAR="0.02912087912087913" WEIGHT="1.094992664742149"/>
<DICH_DATA CI_END="2.156255130476228" CI_START="0.031811682828664346" EFFECT_SIZE="0.2619047619047619" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3337001457552575" LOG_CI_START="-1.4974133562346084" LOG_EFFECT_SIZE="-0.5818566052396754" ORDER="66537" O_E="0.0" SE="1.075605135226867" STUDY_ID="STD-Rossi-1997" TOTAL_1="21" TOTAL_2="22" VAR="1.156926406926407" WEIGHT="0.1198452400461667"/>
<DICH_DATA CI_END="0.8736277439213014" CI_START="0.08513942672584873" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.0586735824683168" LOG_CI_START="-1.0698692784088086" LOG_EFFECT_SIZE="-0.5642714304385626" MODIFIED="2008-09-16 05:40:55 +0100" MODIFIED_BY="[Empty name]" ORDER="2266" O_E="0.0" SE="0.5939813572948673" STUDY_ID="STD-Santamaria-2000" TOTAL_1="28" TOTAL_2="28" VAR="0.3528138528138528" WEIGHT="0.32830099689398223"/>
<DICH_DATA CI_END="1.6216329114793497" CI_START="0.733879188195826" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.20995254989858633" LOG_CI_START="-0.13437542811978684" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="66538" O_E="0.0" SE="0.20225995873897265" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.04090909090909092" WEIGHT="1.0091653491161447"/>
<DICH_DATA CI_END="1.2385384775639203" CI_START="0.7526803246632294" EFFECT_SIZE="0.9655172413793104" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="29" LOG_CI_END="0.09290950331920074" LOG_CI_START="-0.12338943643267448" LOG_EFFECT_SIZE="-0.015239966556736848" ORDER="66539" O_E="0.0" SE="0.12705506790727125" STUDY_ID="STD-Speekenbrink-1996" TOTAL_1="37" TOTAL_2="37" VAR="0.01614299028092131" WEIGHT="1.208109032433235"/>
<DICH_DATA CI_END="1.26102060903135" CI_START="0.4408653477494194" EFFECT_SIZE="0.7456140350877193" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.10072218436487669" LOG_CI_START="-0.3556940356092364" LOG_EFFECT_SIZE="-0.12748592562217986" ORDER="66540" O_E="0.0" SE="0.26810114690952036" STUDY_ID="STD-Tabuchi-1994" TOTAL_1="19" TOTAL_2="17" VAR="0.07187822497420022" WEIGHT="0.8368437129070235"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="721.1048975028093" CI_END="0.7716967980070437" CI_START="0.5529903255701962" DF="49" EFFECT_SIZE="0.653254057447325" ESTIMABLE="YES" EVENTS_1="722" EVENTS_2="969" I2="93.20487211088327" ID="CMP-001.04.02" LOG_CI_END="-0.11255330175957982" LOG_CI_START="-0.2572824665040389" LOG_EFFECT_SIZE="-0.18491788413180943" MODIFIED="2010-05-26 12:17:16 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="2.3314683517128287E-15" P_Z="5.487800202479294E-7" STUDIES="50" TAU2="0.22749230778783244" TOTAL_1="1899" TOTAL_2="1702" WEIGHT="35.604992407868984" Z="5.008422367884531">
<NAME>Low Dose</NAME>
<DICH_DATA CI_END="1.1661827845720796" CI_START="0.3228907095511885" EFFECT_SIZE="0.6136363636363636" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.06676662598870041" LOG_CI_START="-0.49094445064310055" LOG_EFFECT_SIZE="-0.2120889123272001" ORDER="66544" O_E="0.0" SE="0.3276022471278735" STUDY_ID="STD-Alajmo-1989" TOTAL_1="22" TOTAL_2="12" VAR="0.1073232323232323" WEIGHT="0.700032500472691"/>
<DICH_DATA CI_END="2.1861039695791042" CI_START="0.25282575215333275" EFFECT_SIZE="0.7434402332361516" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.3396708128473259" LOG_CI_START="-0.5971786920649566" LOG_EFFECT_SIZE="-0.12875393960881534" ORDER="66545" O_E="0.0" SE="0.5503100366653163" STUDY_ID="STD-Alvarez-1995" TOTAL_1="49" TOTAL_2="51" VAR="0.3028411364545818" WEIGHT="0.36809001838203365"/>
<DICH_DATA CI_END="1.55131165165505" CI_START="0.5025351252755366" EFFECT_SIZE="0.882943143812709" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.1906990544207529" LOG_CI_START="-0.29883357732995014" LOG_EFFECT_SIZE="-0.0540672614545986" ORDER="66581" O_E="0.0" SE="0.28755389111597146" STUDY_ID="STD-Amar-2003" TOTAL_1="23" TOTAL_2="24" VAR="0.08268724029593597" WEIGHT="0.7897744262464153"/>
<DICH_DATA CI_END="1.0035609949452269" CI_START="0.8015345758405634" EFFECT_SIZE="0.896877269426289" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="25" LOG_CI_END="0.001543773398606848" LOG_CI_START="-0.09607773872108513" LOG_EFFECT_SIZE="-0.04726698266123917" ORDER="66546" O_E="0.0" SE="0.05734335945338559" STUDY_ID="STD-Bailey-1994" TOTAL_1="53" TOTAL_2="25" VAR="0.0032882608734001867" WEIGHT="1.3458170252784285"/>
<DICH_DATA CI_END="0.8731188140017339" CI_START="0.5154136572187269" EFFECT_SIZE="0.6708333333333333" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="-0.05892665348310755" LOG_CI_START="-0.28784407787640515" LOG_EFFECT_SIZE="-0.17338536567975632" ORDER="66568" O_E="0.0" SE="0.1344672282481491" STUDY_ID="STD-Basora-1999" TOTAL_1="36" TOTAL_2="21" VAR="0.018081435472739826" WEIGHT="1.1897512638009395"/>
<DICH_DATA CI_END="0.9779863575014763" CI_START="0.11361212787770752" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="-0.009667203395581254" LOG_CI_START="-0.9445753060437436" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="66547" O_E="0.0" SE="0.5491696473652761" STUDY_ID="STD-Blauhut-1994" TOTAL_1="14" TOTAL_2="14" VAR="0.3015873015873016" WEIGHT="0.369212747873715"/>
<DICH_DATA CI_END="1.174017116620848" CI_START="0.8517763377064567" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.06967442876831904" LOG_CI_START="-0.06967442876831907" LOG_EFFECT_SIZE="0.0" ORDER="66548" O_E="0.0" SE="0.0818542087049908" STUDY_ID="STD-Capdevila-1998" TOTAL_1="12" TOTAL_2="11" VAR="0.006700111482720192" WEIGHT="1.3062965759863858"/>
<DICH_DATA CI_END="1.107432316188807" CI_START="0.3250763001380784" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.0443171925890425" LOG_CI_START="-0.48801469182175516" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="66550" O_E="0.0" SE="0.3126943839882286" STUDY_ID="STD-Cicek-1996a" TOTAL_1="25" TOTAL_2="25" VAR="0.09777777777777774" WEIGHT="0.7322722340516795"/>
<DICH_DATA CI_END="1.0138017822726142" CI_START="0.3434056028344289" EFFECT_SIZE="0.5900383141762452" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" LOG_CI_END="0.005953050381643381" LOG_CI_START="-0.4641926233852791" LOG_EFFECT_SIZE="-0.2291197865018179" ORDER="66549" O_E="0.0" SE="0.27616589602930897" STUDY_ID="STD-Cicek-1996b" TOTAL_1="29" TOTAL_2="28" VAR="0.0762676021296711" WEIGHT="0.8170690060962049"/>
<DICH_DATA CI_END="2.4702082767769804" CI_START="0.15813443897519056" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.392733572547735" LOG_CI_START="-0.8009735378595846" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2010-04-21 11:11:58 +0100" MODIFIED_BY="Katharine Ker" ORDER="2366" O_E="0.0" SE="0.7011894655987543" STUDY_ID="STD-Cicekcioglu-2006" TOTAL_1="24" TOTAL_2="20" VAR="0.49166666666666664" WEIGHT="0.25247081088601625"/>
<DICH_DATA CI_END="0.8785037477258802" CI_START="0.49447805723172295" EFFECT_SIZE="0.6590909090909091" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="44" LOG_CI_END="-0.056256381450191364" LOG_CI_START="-0.3058529757242714" LOG_EFFECT_SIZE="-0.18105467858723134" ORDER="66551" O_E="0.0" SE="0.14661427499966254" STUDY_ID="STD-Cosgrove-1992" TOTAL_1="56" TOTAL_2="56" VAR="0.02149574563367667" WEIGHT="1.1587379317487576"/>
<DICH_DATA CI_END="0.9968014774159336" CI_START="0.30347065775242266" EFFECT_SIZE="0.55" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="-0.0013913269919762872" LOG_CI_START="-0.5178832940195359" LOG_EFFECT_SIZE="-0.2596373105057561" ORDER="66577" O_E="0.0" SE="0.30338993810845893" STUDY_ID="STD-Cvachovec-2001" TOTAL_1="20" TOTAL_2="22" VAR="0.09204545454545456" WEIGHT="0.753100851165223"/>
<DICH_DATA CI_END="1.51097681167625" CI_START="0.7514417807075171" EFFECT_SIZE="1.065556711758585" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="31" LOG_CI_END="0.1792577994559525" LOG_CI_START="-0.12410466151341919" LOG_EFFECT_SIZE="0.027576568971266632" ORDER="66552" O_E="0.0" SE="0.1781966112418093" STUDY_ID="STD-D_x0027_Ambra-1996" TOTAL_1="62" TOTAL_2="64" VAR="0.031754032258064516" WEIGHT="1.07457859600785"/>
<DICH_DATA CI_END="70.82882080128427" CI_START="0.12706691849706478" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8502100114756685" LOG_CI_START="-0.895967502036344" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="66571" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-D_x0027_Ambrosio-1999" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="0.05597118038667998"/>
<DICH_DATA CI_END="0.8485647549882042" CI_START="0.46077627889680506" EFFECT_SIZE="0.6252987367702287" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="58" LOG_CI_END="-0.07131501055197918" LOG_CI_START="-0.33650988681009075" LOG_EFFECT_SIZE="-0.20391244868103495" ORDER="66589" O_E="0.0" SE="0.15577678304982373" STUDY_ID="STD-Dignan-2001" TOTAL_1="101" TOTAL_2="99" VAR="0.02426640613735185" WEIGHT="1.1347348507341126"/>
<DICH_DATA CI_END="5.461059148182932" CI_START="0.5086518388474208" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7372768803609144" LOG_CI_START="-0.2935793811282016" LOG_EFFECT_SIZE="0.22184874961635637" ORDER="66575" O_E="0.0" SE="0.6055300708194984" STUDY_ID="STD-Engel-2001" TOTAL_1="12" TOTAL_2="12" VAR="0.3666666666666667" WEIGHT="0.3187496637130563"/>
<DICH_DATA CI_END="1.1465948472003975" CI_START="0.06538635291433063" EFFECT_SIZE="0.27380952380952384" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.05940998572274674" LOG_CI_START="-1.1845128858113243" LOG_EFFECT_SIZE="-0.5625514500442887" ORDER="66580" O_E="0.0" SE="0.7306864522566346" STUDY_ID="STD-Englberger-2002a" TOTAL_1="21" TOTAL_2="23" VAR="0.5339026915113871" WEIGHT="0.23589706025747745"/>
<DICH_DATA CI_END="1.176699175298307" CI_START="0.3968256749445487" EFFECT_SIZE="0.6833333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" LOG_CI_END="0.07066544907408982" LOG_CI_START="-0.4014002364019061" LOG_EFFECT_SIZE="-0.16536739366390812" ORDER="66553" O_E="0.0" SE="0.2772937204114299" STUDY_ID="STD-Garcia_x002d_Huete-1997" TOTAL_1="39" TOTAL_2="41" VAR="0.07689180737961226" WEIGHT="0.8143325278744312"/>
<DICH_DATA CI_END="1.0164144456513737" CI_START="0.08210901614053026" EFFECT_SIZE="0.28888888888888886" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="0.007070828773153743" LOG_CI_START="-1.0856091517101678" LOG_EFFECT_SIZE="-0.539269161468507" ORDER="66554" O_E="0.0" SE="0.6418456293890392" STUDY_ID="STD-Gherli-1992" TOTAL_1="9" TOTAL_2="13" VAR="0.41196581196581195" WEIGHT="0.2910594966019229"/>
<DICH_DATA CI_END="1.2371304328257535" CI_START="0.6806192486246042" EFFECT_SIZE="0.9176136363636364" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.09241549047004377" LOG_CI_START="-0.1670957727641001" LOG_EFFECT_SIZE="-0.03734014114702813" ORDER="66555" O_E="0.0" SE="0.1524382006252069" STUDY_ID="STD-Hardy-1993" TOTAL_1="22" TOTAL_2="19" VAR="0.02323740500985083" WEIGHT="1.1435324218500416"/>
<DICH_DATA CI_END="1.2005001082166866" CI_START="0.15299746175000142" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.07936220354165731" LOG_CI_START="-0.8153157741308461" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="66556" O_E="0.0" SE="0.5255382728122436" STUDY_ID="STD-Havel-1992" TOTAL_1="10" TOTAL_2="10" VAR="0.2761904761904762" WEIGHT="0.3935254366040849"/>
<DICH_DATA CI_END="0.9991258279259411" CI_START="0.6223354951355209" EFFECT_SIZE="0.7885375494071146" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="46" LOG_CI_END="-3.798141436542471E-4" LOG_CI_START="-0.2059754281624475" LOG_EFFECT_SIZE="-0.10317762115305087" ORDER="66557" O_E="0.0" SE="0.12076788138934204" STUDY_ID="STD-Hayashida-1997" TOTAL_1="55" TOTAL_2="57" VAR="0.014584881175270188" WEIGHT="1.2232807305056792"/>
<DICH_DATA CI_END="0.8492965507116076" CI_START="0.4362556243340239" EFFECT_SIZE="0.6086956521739131" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="46" LOG_CI_END="-0.07094063973244553" LOG_CI_START="-0.3602589609462642" LOG_EFFECT_SIZE="-0.21559980033935483" ORDER="66558" O_E="0.0" SE="0.16994701402978446" STUDY_ID="STD-Isetta-1993" TOTAL_1="70" TOTAL_2="70" VAR="0.028881987577639753" WEIGHT="1.0968831635857141"/>
<DICH_DATA CI_END="1.3299782792134183" CI_START="0.575667296200363" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.12384454826424007" LOG_CI_START="-0.23982844221961358" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="66579" O_E="0.0" SE="0.2136233148205519" STUDY_ID="STD-Jeserschek-2003" TOTAL_1="9" TOTAL_2="9" VAR="0.04563492063492064" WEIGHT="0.9784206621838393"/>
<DICH_DATA CI_END="1.1831785640385561" CI_START="0.023477249015536238" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.07305029283121232" LOG_CI_START="-1.6293527935984997" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="66570" O_E="0.0" SE="1.0" STUDY_ID="STD-Katzel-1998" TOTAL_1="12" TOTAL_2="12" VAR="1.0000000000000002" WEIGHT="0.13679622744343253"/>
<DICH_DATA CI_END="1.0237823367364247" CI_START="0.10853001377744706" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.010207632418683592" LOG_CI_START="-0.9644501418580085" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="66576" O_E="0.0" SE="0.5725188012439223" STUDY_ID="STD-Kyriss-2001" TOTAL_1="18" TOTAL_2="20" VAR="0.3277777777777778" WEIGHT="0.34709827473484867"/>
<DICH_DATA CI_END="0.8487029408975272" CI_START="0.5226006048576521" EFFECT_SIZE="0.6659824849480022" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="87" LOG_CI_END="-0.0712442929177794" LOG_CI_START="-0.2818300919562082" LOG_EFFECT_SIZE="-0.17653719243699378" ORDER="66559" O_E="0.0" SE="0.12369914077169018" STUDY_ID="STD-Lemmer-1996" TOTAL_1="168" TOTAL_2="157" VAR="0.015301477427654425" WEIGHT="1.2162559991164918"/>
<DICH_DATA CI_END="0.8864387002945626" CI_START="0.20841729216507215" EFFECT_SIZE="0.4298245614035088" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" LOG_CI_END="-0.052351291697907774" LOG_CI_START="-0.6810662509180101" LOG_EFFECT_SIZE="-0.3667087713079589" ORDER="66560" O_E="0.0" SE="0.369310279235129" STUDY_ID="STD-Lentschener-1997" TOTAL_1="48" TOTAL_2="49" VAR="0.13639008234872896" WEIGHT="0.6172764188164718"/>
<DICH_DATA CI_END="1.1223523647028855" CI_START="0.17286841501668593" EFFECT_SIZE="0.44047619047619047" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.05012922592328552" LOG_CI_START="-0.7622843499130588" LOG_EFFECT_SIZE="-0.35607756199488666" ORDER="66569" O_E="0.0" SE="0.4772157559583272" STUDY_ID="STD-Lentschener-1999" TOTAL_1="35" TOTAL_2="37" VAR="0.22773487773487772" WEIGHT="0.4500714952374224"/>
<DICH_DATA CI_END="0.828162236873594" CI_START="0.4449821959596931" EFFECT_SIZE="0.6070563818747838" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="49" LOG_CI_END="-0.08188457664857489" LOG_CI_START="-0.351657365089055" LOG_EFFECT_SIZE="-0.21677097086881492" ORDER="66561" O_E="0.0" SE="0.15846587132677778" STUDY_ID="STD-Levy-1995" TOTAL_1="59" TOTAL_2="65" VAR="0.02511143237535489" WEIGHT="1.1276107858138007"/>
<DICH_DATA CI_END="0.7532478029295167" CI_START="0.08297402230305383" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.12306212640134118" LOG_CI_START="-1.0810578562545836" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="66562" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Liu-1993" TOTAL_1="20" TOTAL_2="20" VAR="0.31666666666666665" WEIGHT="0.3561481950019812"/>
<DICH_DATA CI_END="2.4521888362810533" CI_START="0.008322427279400224" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3895539109512145" LOG_CI_START="-2.079749990979728" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="66583" O_E="0.0" SE="1.4504813352456845" STUDY_ID="STD-Llau-1998" TOTAL_1="10" TOTAL_2="10" VAR="2.103896103896104" WEIGHT="0.06857085260774948"/>
<DICH_DATA CI_END="1.446083509057262" CI_START="0.41832872570361634" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.1601933735086789" LOG_CI_START="-0.37848231235881497" LOG_EFFECT_SIZE="-0.10914446942506803" ORDER="66563" O_E="0.0" SE="0.3164207643662155" STUDY_ID="STD-Locatelli-1990" TOTAL_1="13" TOTAL_2="13" VAR="0.1001221001221001" WEIGHT="0.7240822723931617"/>
<DICH_DATA CI_END="0.581965375170908" CI_START="0.011932745040725218" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.23510285352801047" LOG_CI_START="-1.9232596385672394" LOG_EFFECT_SIZE="-1.0791812460476249" ORDER="66584" O_E="0.0" SE="0.991631652042901" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.9833333333333332" WEIGHT="0.1388825166322457"/>
<DICH_DATA CI_END="1.2854855901578142" CI_START="0.5973191554248912" EFFECT_SIZE="0.8762677484787018" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.10906721271748547" LOG_CI_START="-0.22379355764212133" LOG_EFFECT_SIZE="-0.05736317246231793" ORDER="66564" O_E="0.0" SE="0.19552406419661988" STUDY_ID="STD-Murkin-1995" TOTAL_1="29" TOTAL_2="24" VAR="0.03822965967996394" WEIGHT="1.0274707168546082"/>
<DICH_DATA CI_END="0.851080315601441" CI_START="0.17407565969356745" EFFECT_SIZE="0.3849056603773585" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="-0.07002945404391975" LOG_CI_START="-0.7592619503058609" LOG_EFFECT_SIZE="-0.4146457021748903" ORDER="66572" O_E="0.0" SE="0.4048585800601448" STUDY_ID="STD-Murkin-2000" TOTAL_1="212" TOTAL_2="68" VAR="0.1639104698483167" WEIGHT="0.555140695799374"/>
<DICH_DATA CI_END="1.0403570180709536" CI_START="0.56797137464091" EFFECT_SIZE="0.768695652173913" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="23" LOG_CI_END="0.01718240119376299" LOG_CI_START="-0.24567355187484013" LOG_EFFECT_SIZE="-0.11424557534053863" MODIFIED="2010-05-07 14:58:19 +0100" MODIFIED_BY="Katharine Ker" ORDER="2465" O_E="0.0" SE="0.15440288799045002" STUDY_ID="STD-Nur_x00f6_zler-2008" TOTAL_1="25" TOTAL_2="26" VAR="0.023840251819791457" WEIGHT="1.1383618350122335"/>
<DICH_DATA CI_END="1.3461324819232787" CI_START="0.39949840375995604" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.12908780382323215" LOG_CI_START="-0.39848495161814457" LOG_EFFECT_SIZE="-0.13469857389745624" ORDER="66578" O_E="0.0" SE="0.3098988480735223" STUDY_ID="STD-Palmer-2003" TOTAL_1="30" TOTAL_2="26" VAR="0.09603729603729605" WEIGHT="0.7384735094555095"/>
<DICH_DATA CI_END="1.1769979621462765" CI_START="0.7239358378865783" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="52" LOG_CI_END="0.07077571090682193" LOG_CI_START="-0.14029992342524575" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2010-05-21 15:25:22 +0100" MODIFIED_BY="Katharine Ker" ORDER="2331" O_E="0.0" SE="0.1239868724478975" STUDY_ID="STD-Parvizi-2007" TOTAL_1="81" TOTAL_2="81" VAR="0.015372744539411204" WEIGHT="1.2155617821063296"/>
<DICH_DATA CI_END="0.9019134165859846" CI_START="0.5221928115776203" EFFECT_SIZE="0.6862745098039216" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="25" LOG_CI_END="-0.04483515259530587" LOG_CI_START="-0.2821691109000156" LOG_EFFECT_SIZE="-0.16350213174766073" ORDER="66587" O_E="0.0" SE="0.1394111419302274" STUDY_ID="STD-Petsatodis-2006" TOTAL_1="25" TOTAL_2="25" VAR="0.01943546649429001" WEIGHT="1.1772555919710346"/>
<DICH_DATA CI_END="1.0650367118693163" CI_START="0.331144696158032" EFFECT_SIZE="0.5938697318007663" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" LOG_CI_END="0.027364578185526574" LOG_CI_START="-0.4799821965215054" LOG_EFFECT_SIZE="-0.22630880916798943" ORDER="66588" O_E="0.0" SE="0.29801800686994884" STUDY_ID="STD-Poston-2006" TOTAL_1="29" TOTAL_2="31" VAR="0.08881473241873687" WEIGHT="0.7653703963550709"/>
<DICH_DATA CI_END="1.0902507120596947" CI_START="0.9172202218614527" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.037526378990036593" LOG_CI_START="-0.037526378990036614" LOG_EFFECT_SIZE="0.0" ORDER="66565" O_E="0.0" SE="0.04408636155463877" STUDY_ID="STD-Pugh-1995" TOTAL_1="21" TOTAL_2="23" VAR="0.0019436072751263314" WEIGHT="1.3620573947213261"/>
<DICH_DATA CI_END="1.0307774244809154" CI_START="0.970141541956631" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="62" LOG_CI_END="0.013164898304624488" LOG_CI_START="-0.01316489830462447" LOG_EFFECT_SIZE="0.0" ORDER="66566" O_E="0.0" SE="0.015466252862868035" STUDY_ID="STD-Ranaboldo-1997" TOTAL_1="66" TOTAL_2="62" VAR="2.3920497761817372E-4" WEIGHT="1.3832147406796536"/>
<DICH_DATA CI_END="1.156718099789521" CI_START="0.3842288320078301" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" LOG_CI_END="0.06322753127423315" LOG_CI_START="-0.4154100493855958" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2008-09-16 05:04:42 +0100" MODIFIED_BY="[Empty name]" ORDER="2260" O_E="0.0" SE="0.28115408417381926" STUDY_ID="STD-Ray-1999" TOTAL_1="50" TOTAL_2="50" VAR="0.07904761904761903" WEIGHT="0.8050209380552341"/>
<DICH_DATA CI_END="3.436173203095408" CI_START="0.1293428526955729" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5360750466763062" LOG_CI_START="-0.8882575647876688" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="66586" O_E="0.0" SE="0.8366600265340756" STUDY_ID="STD-Ray-2005" TOTAL_1="15" TOTAL_2="15" VAR="0.7" WEIGHT="0.18749366892804364"/>
<DICH_DATA CI_END="1.156316745805134" CI_START="0.3062086375085" EFFECT_SIZE="0.5950413223140496" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.06307681515096289" LOG_CI_START="-0.5139825629213262" LOG_EFFECT_SIZE="-0.22545287388518162" MODIFIED="2008-09-16 05:34:03 +0100" MODIFIED_BY="[Empty name]" ORDER="2264" O_E="0.0" SE="0.33896753516965294" STUDY_ID="STD-Samama-2002" TOTAL_1="22" TOTAL_2="18" VAR="0.11489898989898992" WEIGHT="0.6763977781434272"/>
<DICH_DATA CI_END="0.7716992950035634" CI_START="0.015998043658039977" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.11255189650552387" LOG_CI_START="-1.7959331223731259" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="66573" O_E="0.0" SE="0.9888264649460884" STUDY_ID="STD-Stewart-2001" TOTAL_1="15" TOTAL_2="15" VAR="0.9777777777777779" WEIGHT="0.13959216001869681"/>
<DICH_DATA CI_END="1.2419824481161656" CI_START="0.02830655944721672" EFFECT_SIZE="0.1875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.09411545836861414" LOG_CI_START="-1.5481129142411387" LOG_EFFECT_SIZE="-0.7269987279362623" ORDER="66567" O_E="0.0" SE="0.9646530752325188" STUDY_ID="STD-Thorpe-1994" TOTAL_1="8" TOTAL_2="9" VAR="0.9305555555555556" WEIGHT="0.1459302261048639"/>
<DICH_DATA CI_END="1.3454053931997747" CI_START="0.022094839371514755" EFFECT_SIZE="0.1724137931034483" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.1288531642656234" LOG_CI_START="-1.6557091513914979" LOG_EFFECT_SIZE="-0.7634279935629372" ORDER="66585" O_E="0.0" SE="1.048260737942924" STUDY_ID="STD-Vanek-2005" TOTAL_1="29" TOTAL_2="30" VAR="1.0988505747126436" WEIGHT="0.1256053174109505"/>
<DICH_DATA CI_END="2.1719720978715733" CI_START="0.319729910492389" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3368542418108039" LOG_CI_START="-0.49521673390605353" LOG_EFFECT_SIZE="-0.07918124604762482" MODIFIED="2010-05-26 12:17:16 +0100" MODIFIED_BY="Katharine Ker" ORDER="2767" O_E="0.0" SE="0.4887626099538393" STUDY_ID="STD-Wei-2006" TOTAL_1="36" TOTAL_2="40" VAR="0.23888888888888885" WEIGHT="0.43566143616163105"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="173.51995118886637" CI_END="0.7145787525875429" CI_START="0.6067849532859758" DF="60" EFFECT_SIZE="0.65847979088806" ESTIMABLE="YES" EVENTS_1="1622" EVENTS_2="2357" I2="65.42184366183143" ID="CMP-001.04.03" LOG_CI_END="-0.145949901331412" LOG_CI_START="-0.21696519714353518" LOG_EFFECT_SIZE="-0.18145754923747354" MODIFIED="2011-02-16 14:07:30 +0000" MODIFIED_BY="Emma M Sydenham" NO="3" P_CHI2="5.726530361016557E-13" P_Z="1.2943527244400681E-23" STUDIES="61" TAU2="0.046366675792665644" TOTAL_1="3663" TOTAL_2="3601" WEIGHT="50.16253874028113" Z="10.016159396681344">
<NAME>High Dose</NAME>
<DICH_DATA CI_END="0.8207319356942484" CI_START="0.6020493368181332" EFFECT_SIZE="0.702937491950874" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="213" LOG_CI_END="-0.08579866731277815" LOG_CI_START="-0.22036791766259636" LOG_EFFECT_SIZE="-0.1530832924876873" ORDER="66631" O_E="0.0" SE="0.07904664378401566" STUDY_ID="STD-Alderman-1998" TOTAL_1="401" TOTAL_2="395" VAR="0.0062483718935170615" WEIGHT="1.311395372116904"/>
<DICH_DATA CI_END="0.9794902492496453" CI_START="0.5964920617890417" EFFECT_SIZE="0.764367816091954" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="45" LOG_CI_END="-0.008999883016004835" LOG_CI_START="-0.22439533161502298" LOG_EFFECT_SIZE="-0.11669760731551393" ORDER="66590" O_E="0.0" SE="0.1265243527317297" STUDY_ID="STD-Baele-1992" TOTAL_1="58" TOTAL_2="57" VAR="0.01600841183418316" WEIGHT="1.209404591791649"/>
<DICH_DATA CI_END="1.056285558232989" CI_START="0.8040332734669017" EFFECT_SIZE="0.9215686274509803" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="25" LOG_CI_END="0.02378134206136279" LOG_CI_START="-0.09472597838580064" LOG_EFFECT_SIZE="-0.03547231816221892" ORDER="66591" O_E="0.0" SE="0.06961178665136088" STUDY_ID="STD-Bailey-1994" TOTAL_1="25" TOTAL_2="25" VAR="0.004845800840794584" WEIGHT="1.3274829825173338"/>
<DICH_DATA CI_END="0.39482790023923114" CI_START="0.11321905262835025" EFFECT_SIZE="0.21142857142857144" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="35" LOG_CI_END="-0.40359216580023544" LOG_CI_START="-0.9460804834383635" LOG_EFFECT_SIZE="-0.6748363246192994" ORDER="66592" O_E="0.0" SE="0.3186603231411177" STUDY_ID="STD-Bidstrup-1989" TOTAL_1="40" TOTAL_2="37" VAR="0.10154440154440156" WEIGHT="0.7192021066753241"/>
<DICH_DATA CI_END="0.9372502510926616" CI_START="0.4494540535626551" EFFECT_SIZE="0.6490384615384616" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="-0.028144434557366343" LOG_CI_START="-0.3473146983781445" LOG_EFFECT_SIZE="-0.1877295664677554" ORDER="66593" O_E="0.0" SE="0.1874821928866116" STUDY_ID="STD-Bidstrup-1990" TOTAL_1="26" TOTAL_2="18" VAR="0.035149572649572636" WEIGHT="1.0493512235162372"/>
<DICH_DATA CI_END="0.7811089758395658" CI_START="0.21508479595057134" EFFECT_SIZE="0.40988372093023256" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="24" LOG_CI_END="-0.10728837162309306" LOG_CI_START="-0.6673902882092073" LOG_EFFECT_SIZE="-0.3873393299161502" ORDER="66594" O_E="0.0" SE="0.3290066383518857" STUDY_ID="STD-Bidstrup-1993" TOTAL_1="43" TOTAL_2="47" VAR="0.10824536807960852" WEIGHT="0.69706772301901"/>
<DICH_DATA CI_END="0.8902876187799331" CI_START="0.3588398767925144" EFFECT_SIZE="0.5652173913043478" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="23" LOG_CI_END="-0.05046966631041668" LOG_CI_START="-0.4450993011110956" LOG_EFFECT_SIZE="-0.24778448371075615" ORDER="66632" O_E="0.0" SE="0.23180740093011587" STUDY_ID="STD-Bidstrup-2000" TOTAL_1="30" TOTAL_2="30" VAR="0.053734671125975485" WEIGHT="0.9298669830971849"/>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516804" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-02-16 14:07:30 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="66595" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Boldt-1991" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="0.05850190047644084"/>
<DICH_DATA CI_END="0.9593385583155755" CI_START="0.7355067654519231" EFFECT_SIZE="0.84" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="50" LOG_CI_END="-0.018028099752735213" LOG_CI_START="-0.13341332812350148" LOG_EFFECT_SIZE="-0.07572071393811836" ORDER="66596" O_E="0.0" SE="0.06777785431108017" STUDY_ID="STD-Carrera-1994" TOTAL_1="51" TOTAL_2="51" VAR="0.004593837535014009" WEIGHT="1.330414938409166"/>
<DICH_DATA CI_END="0.7733027556602502" CI_START="0.2607123323246595" EFFECT_SIZE="0.44900953778429936" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="29" LOG_CI_END="-0.11165044221312088" LOG_CI_START="-0.5838384251651039" LOG_EFFECT_SIZE="-0.34774443368911234" ORDER="66597" O_E="0.0" SE="0.27736555855420697" STUDY_ID="STD-Casas-1995" TOTAL_1="47" TOTAL_2="51" VAR="0.07693165307208723" WEIGHT="0.8141584690018923"/>
<DICH_DATA CI_END="1.0266940043095694" CI_START="0.277048899916122" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.011441025835386942" LOG_CI_START="-0.5574435699628623" LOG_EFFECT_SIZE="-0.27300127206373764" ORDER="66598" O_E="0.0" SE="0.334165627596057" STUDY_ID="STD-Cicek-1996a" TOTAL_1="25" TOTAL_2="25" VAR="0.11166666666666664" WEIGHT="0.6862838738348501"/>
<DICH_DATA CI_END="0.7537424083054954" CI_START="0.31088474574670794" EFFECT_SIZE="0.4840733590733591" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="37" LOG_CI_END="-0.12277704904434342" LOG_CI_START="-0.507400587061211" LOG_EFFECT_SIZE="-0.3150888180527773" ORDER="66633" O_E="0.0" SE="0.22592977014832727" STUDY_ID="STD-Cohen-1998" TOTAL_1="56" TOTAL_2="59" VAR="0.05104426103927599" WEIGHT="0.9454511088958546"/>
<DICH_DATA CI_END="0.8525208268207006" CI_START="0.3155703671806873" EFFECT_SIZE="0.5186813186813187" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="39" LOG_CI_END="-0.06929500252570277" LOG_CI_START="-0.5009037848483089" LOG_EFFECT_SIZE="-0.2850993936870058" MODIFIED="2010-05-20 12:04:26 +0100" MODIFIED_BY="Katharine Ker" ORDER="5337" O_E="0.0" SE="0.2535291352342283" STUDY_ID="STD-Colwell-2007" TOTAL_1="175" TOTAL_2="177" VAR="0.06427702241261564" WEIGHT="0.8734511517315287"/>
<DICH_DATA CI_END="1.0006396605496894" CI_START="0.3378044714556414" EFFECT_SIZE="0.5813953488372093" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="2.7771223570681805E-4" LOG_CI_START="-0.4713346060508047" LOG_EFFECT_SIZE="-0.23552844690754887" ORDER="66599" O_E="0.0" SE="0.277027410280123" STUDY_ID="STD-Corbeau-1995" TOTAL_1="43" TOTAL_2="20" VAR="0.0767441860465116" WEIGHT="0.8149780347450788"/>
<DICH_DATA CI_END="0.7952885847856555" CI_START="0.42378242013260525" EFFECT_SIZE="0.580542264752791" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="44" LOG_CI_END="-0.09947525117000126" LOG_CI_START="-0.37285706319331974" LOG_EFFECT_SIZE="-0.2361661571816605" ORDER="66600" O_E="0.0" SE="0.16058582964429188" STUDY_ID="STD-Cosgrove-1992" TOTAL_1="57" TOTAL_2="56" VAR="0.02578780868254553" WEIGHT="1.1219726706083493"/>
<DICH_DATA CI_END="1.7823127419899514" CI_START="0.9514668212088658" EFFECT_SIZE="1.3022332506203473" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="31" LOG_CI_END="0.25098391193624364" LOG_CI_START="-0.02160635148325482" LOG_EFFECT_SIZE="0.1146887802264944" ORDER="66601" O_E="0.0" SE="0.16012087007617923" STUDY_ID="STD-D_x0027_Ambra-1996" TOTAL_1="65" TOTAL_2="64" VAR="0.02563869303395267" WEIGHT="1.1232108136918093"/>
<DICH_DATA CI_END="2.314529531862027" CI_START="0.432053247208086" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.3644627264637834" LOG_CI_START="-0.3644627264637834" LOG_EFFECT_SIZE="0.0" ORDER="66602" O_E="0.0" SE="0.42817441928883765" STUDY_ID="STD-Deleuze-1991" TOTAL_1="30" TOTAL_2="30" VAR="0.18333333333333335" WEIGHT="0.5183179134057415"/>
<DICH_DATA CI_END="1.3254060928964186" CI_START="0.40235538574672136" EFFECT_SIZE="0.7302631578947368" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.12234896271291117" LOG_CI_START="-0.3953901810291414" LOG_EFFECT_SIZE="-0.13652060915811512" MODIFIED="2010-05-17 10:47:45 +0100" MODIFIED_BY="Katharine Ker" ORDER="2549" O_E="0.0" SE="0.30412253588417626" STUDY_ID="STD-Desai-2009" TOTAL_1="38" TOTAL_2="37" VAR="0.09249051683262208" WEIGHT="0.7514413670751974"/>
<DICH_DATA CI_END="0.9323483780122118" CI_START="0.25881421861080883" EFFECT_SIZE="0.49122807017543857" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.030421780373552382" LOG_CI_START="-0.587011868286992" LOG_EFFECT_SIZE="-0.3087168243302722" ORDER="66603" O_E="0.0" SE="0.32694377280572434" STUDY_ID="STD-Dietrich-1990" TOTAL_1="19" TOTAL_2="20" VAR="0.10689223057644108" WEIGHT="0.7014268886883642"/>
<DICH_DATA CI_END="0.7811464089683755" CI_START="0.6922940885893394" EFFECT_SIZE="0.7353795219147709" ESTIMABLE="YES" EVENTS_1="549" EVENTS_2="730" LOG_CI_END="-0.10726755940321708" LOG_CI_START="-0.1597093767577549" LOG_EFFECT_SIZE="-0.13348846808048598" ORDER="66604" O_E="0.0" SE="0.03080458310523803" STUDY_ID="STD-Dietrich-1992" TOTAL_1="902" TOTAL_2="882" VAR="9.489223402875163E-4" WEIGHT="1.3743254178815736"/>
<DICH_DATA CI_END="1.020610877852942" CI_START="0.5393517492042281" EFFECT_SIZE="0.7419354838709677" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.008860192809001107" LOG_CI_START="-0.26812790844236073" LOG_EFFECT_SIZE="-0.1296338578166798" ORDER="66605" O_E="0.0" SE="0.16270418178826412" STUDY_ID="STD-Dietrich-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.026472650771388495" WEIGHT="1.1163211419883319"/>
<DICH_DATA CI_END="0.5985457020816825" CI_START="0.1466746731178129" EFFECT_SIZE="0.2962962962962963" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="27" LOG_CI_END="-0.22290268334593874" LOG_CI_START="-0.8336448709881488" LOG_EFFECT_SIZE="-0.5282737771670437" ORDER="66643" O_E="0.0" SE="0.3587529842436209" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.1287037037037037" WEIGHT="0.637195922293966"/>
<DICH_DATA CI_END="0.9468374527500885" CI_START="0.399961179980938" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="26" LOG_CI_END="-0.02372457161220413" LOG_CI_START="-0.3979821590175822" LOG_EFFECT_SIZE="-0.21085336531489315" ORDER="66606" O_E="0.0" SE="0.2198407594468552" STUDY_ID="STD-Fraedrich-1989" TOTAL_1="38" TOTAL_2="38" VAR="0.048329959514170046" WEIGHT="0.9617120731127482"/>
<DICH_DATA CI_END="1.0164144456513737" CI_START="0.08210901614053026" EFFECT_SIZE="0.28888888888888886" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="0.007070828773153743" LOG_CI_START="-1.0856091517101678" LOG_EFFECT_SIZE="-0.539269161468507" ORDER="66607" O_E="0.0" SE="0.6418456293890392" STUDY_ID="STD-Gherli-1992" TOTAL_1="9" TOTAL_2="13" VAR="0.41196581196581195" WEIGHT="0.2910594966019229"/>
<DICH_DATA CI_END="1.1620394238299383" CI_START="0.27073602422146403" EFFECT_SIZE="0.5608974358974359" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.06522086235840659" LOG_CI_START="-0.5674539530227032" LOG_EFFECT_SIZE="-0.25111654533214833" ORDER="66635" O_E="0.0" SE="0.3716363183457089" STUDY_ID="STD-Greilich-2001" TOTAL_1="24" TOTAL_2="25" VAR="0.1381135531135531" WEIGHT="0.612979731188254"/>
<DICH_DATA CI_END="1.6182854246331981" CI_START="0.7470899207455475" EFFECT_SIZE="1.0995475113122173" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.20905512259825326" LOG_CI_START="-0.1266271227718502" LOG_EFFECT_SIZE="0.04121399991320153" MODIFIED="2010-05-17 13:59:12 +0100" MODIFIED_BY="Katharine Ker" ORDER="2593" O_E="0.0" SE="0.1971814125843122" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="27" VAR="0.03888050946874476" WEIGHT="1.0229634383583899"/>
<DICH_DATA CI_END="1.3438135911295888" CI_START="0.7963564179938953" EFFECT_SIZE="1.0344827586206897" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="29" LOG_CI_END="0.12833902916533568" LOG_CI_START="-0.09889251552392286" LOG_EFFECT_SIZE="0.014723256820706378" ORDER="66608" O_E="0.0" SE="0.13347693416475745" STUDY_ID="STD-Harder-1991" TOTAL_1="40" TOTAL_2="40" VAR="0.01781609195402299" WEIGHT="1.1922311353031154"/>
<DICH_DATA CI_END="3.0394125886228682" CI_START="0.20748181399616164" EFFECT_SIZE="0.7941176470588235" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.48278965789495476" LOG_CI_START="-0.6830199636614904" LOG_EFFECT_SIZE="-0.10011515288326783" ORDER="66645" O_E="0.0" SE="0.6848023425529537" STUDY_ID="STD-Harmon-2004" TOTAL_1="17" TOTAL_2="18" VAR="0.46895424836601296" WEIGHT="0.2623840609662372"/>
<DICH_DATA CI_END="0.825164612818845" CI_START="0.4175142184481112" EFFECT_SIZE="0.5869565217391305" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="46" LOG_CI_END="-0.08345940501667462" LOG_CI_START="-0.3793287300284988" LOG_EFFECT_SIZE="-0.2313940675225867" ORDER="66609" O_E="0.0" SE="0.1737951060887247" STUDY_ID="STD-Isetta-1993" TOTAL_1="70" TOTAL_2="70" VAR="0.030204738900391076" WEIGHT="1.0864966207970876"/>
<DICH_DATA CI_END="0.7912977021892589" CI_START="0.4612895501923344" EFFECT_SIZE="0.6041666666666666" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="48" LOG_CI_END="-0.10166009539718963" LOG_CI_START="-0.3360263835560727" LOG_EFFECT_SIZE="-0.21884323947663117" ORDER="66610" O_E="0.0" SE="0.13766791779636467" STUDY_ID="STD-Kalangos-1994" TOTAL_1="55" TOTAL_2="55" VAR="0.01895245559038662" WEIGHT="1.181682828052604"/>
<DICH_DATA CI_END="1.7248117563970482" CI_START="0.1672117424292004" EFFECT_SIZE="0.5370370370370371" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.23674170368809447" LOG_CI_START="-0.7767332275361192" LOG_EFFECT_SIZE="-0.26999576192401237" ORDER="66637" O_E="0.0" SE="0.5953201913829222" STUDY_ID="STD-Klein-1998" TOTAL_1="36" TOTAL_2="29" VAR="0.35440613026819917" WEIGHT="0.32717412652661165"/>
<DICH_DATA CI_END="1.5636597783045803" CI_START="0.5373789039255461" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.19414226504209867" LOG_CI_START="-0.26971938682089824" LOG_EFFECT_SIZE="-0.0377885608893998" ORDER="66644" O_E="0.0" SE="0.27247463045653303" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.07424242424242425" WEIGHT="0.826075289405212"/>
<DICH_DATA CI_END="0.8548579066310278" CI_START="0.4535633977347247" EFFECT_SIZE="0.6226815050344462" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="37" LOG_CI_END="-0.06810606713672084" LOG_CI_START="-0.34336199997763184" LOG_EFFECT_SIZE="-0.2057340335571763" ORDER="66611" O_E="0.0" SE="0.16168669748959338" STUDY_ID="STD-Lass-1995" TOTAL_1="51" TOTAL_2="47" VAR="0.026142588145091284" WEIGHT="1.1190377959058855"/>
<DICH_DATA CI_END="0.8925895825655312" CI_START="0.5575925005095984" EFFECT_SIZE="0.7054794520547946" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="73" LOG_CI_END="-0.0493481861272466" LOG_CI_START="-0.25368307603128315" LOG_EFFECT_SIZE="-0.15151563107926486" MODIFIED="2010-05-06 16:07:43 +0100" MODIFIED_BY="Katharine Ker" ORDER="2371" O_E="0.0" SE="0.12002732580364896" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="103" VAR="0.014406558939575296" WEIGHT="1.2250414350010468"/>
<DICH_DATA CI_END="1.5757982109905528" CI_START="0.20721600644516502" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.19750060308743156" LOG_CI_START="-0.6835767004600205" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="66612" O_E="0.0" SE="0.5175491695067657" STUDY_ID="STD-Laub-1994" TOTAL_1="16" TOTAL_2="16" VAR="0.26785714285714285" WEIGHT="0.40221614386107785"/>
<DICH_DATA CI_END="0.8012922727729785" CI_START="0.48023660328947937" EFFECT_SIZE="0.6203304597701149" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="87" LOG_CI_END="-0.09620904533863149" LOG_CI_START="-0.3185447414035" LOG_EFFECT_SIZE="-0.20737689337106574" ORDER="66613" O_E="0.0" SE="0.13060108844794918" STUDY_ID="STD-Lemmer-1996" TOTAL_1="160" TOTAL_2="157" VAR="0.017056644303789045" WEIGHT="1.1993863300129222"/>
<DICH_DATA CI_END="1.0497678264256392" CI_START="0.4997731056344701" EFFECT_SIZE="0.7243243243243244" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="35" LOG_CI_END="0.021093258258824937" LOG_CI_START="-0.30122711833523724" LOG_EFFECT_SIZE="-0.14006693003820614" ORDER="66614" O_E="0.0" SE="0.18933258472294834" STUDY_ID="STD-Lemmer_x005f_1-1994" TOTAL_1="74" TOTAL_2="67" VAR="0.035846827637872405" WEIGHT="1.044316810611673"/>
<DICH_DATA CI_END="0.8150022791529388" CI_START="0.22000161521551823" EFFECT_SIZE="0.42344045368620037" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="23" LOG_CI_END="-0.08884117675430474" LOG_CI_START="-0.6575741306477412" LOG_EFFECT_SIZE="-0.37320765370102293" ORDER="66615" O_E="0.0" SE="0.33407655239053047" STUDY_ID="STD-Lemmer_x005f_2-1994" TOTAL_1="23" TOTAL_2="32" VAR="0.11160714285714285" WEIGHT="0.6864686386506256"/>
<DICH_DATA CI_END="0.939776936082713" CI_START="0.5479967471412873" EFFECT_SIZE="0.7176313148210104" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="49" LOG_CI_END="-0.026975217596659436" LOG_CI_START="-0.2612220194404158" LOG_EFFECT_SIZE="-0.1440986185185376" ORDER="66616" O_E="0.0" SE="0.13759773094339242" STUDY_ID="STD-Levy-1995" TOTAL_1="61" TOTAL_2="65" VAR="0.018933135560770212" WEIGHT="1.1818606064673038"/>
<DICH_DATA CI_END="0.7917906433240165" CI_START="0.12333594849015803" EFFECT_SIZE="0.3125" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.10138963465852775" LOG_CI_START="-0.9089103219812843" LOG_EFFECT_SIZE="-0.505149978319906" ORDER="66641" O_E="0.0" SE="0.4743416490252569" STUDY_ID="STD-Li-2005" TOTAL_1="40" TOTAL_2="30" VAR="0.22499999999999998" WEIGHT="0.453751441709432"/>
<DICH_DATA CI_END="1.1589401767202359" CI_START="0.2000313921859694" EFFECT_SIZE="0.48148148148148145" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.0640610187152497" LOG_CI_START="-0.6989018424195508" LOG_EFFECT_SIZE="-0.3174204118521506" ORDER="66617" O_E="0.0" SE="0.44816816135765475" STUDY_ID="STD-Locatelli-1990" TOTAL_1="12" TOTAL_2="13" VAR="0.20085470085470086" WEIGHT="0.4890544647530991"/>
<DICH_DATA CI_END="1.5293329029537468" CI_START="0.07265331890559054" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.18450203229193085" LOG_CI_START="-1.1387445417312558" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="66618" O_E="0.0" SE="0.7772815877574012" STUDY_ID="STD-Maccario-1994" TOTAL_1="32" TOTAL_2="32" VAR="0.6041666666666666" WEIGHT="0.21267138429412485"/>
<DICH_DATA CI_END="0.4272576057276957" CI_START="0.028895164993771816" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="18" LOG_CI_END="-0.3693101975453905" LOG_CI_START="-1.5391748213332594" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="66619" O_E="0.0" SE="0.6871842709362768" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.47222222222222227" WEIGHT="0.2609100156553981"/>
<DICH_DATA CI_END="0.7984325379789613" CI_START="0.2964726043329143" EFFECT_SIZE="0.48653198653198654" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="-0.09776177285197986" LOG_CI_START="-0.5280154315973115" LOG_EFFECT_SIZE="-0.3128886022246457" ORDER="66620" O_E="0.0" SE="0.25273312893696737" STUDY_ID="STD-Mohr-1992" TOTAL_1="17" TOTAL_2="16" VAR="0.06387403446226976" WEIGHT="0.8754815523707664"/>
<DICH_DATA CI_END="0.8973650634832809" CI_START="0.4380356604107999" EFFECT_SIZE="0.6269592476489029" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" LOG_CI_END="-0.04703084257180927" LOG_CI_START="-0.3584905322145905" LOG_EFFECT_SIZE="-0.2027606873931999" ORDER="66621" O_E="0.0" SE="0.18295296344649845" STUDY_ID="STD-Murkin-1994" TOTAL_1="29" TOTAL_2="25" VAR="0.0334717868338558" WEIGHT="1.0616666548921414"/>
<DICH_DATA CI_END="0.8534432320457009" CI_START="0.10136021596195216" EFFECT_SIZE="0.29411764705882354" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.06882536128531151" LOG_CI_START="-0.9941324727991987" LOG_EFFECT_SIZE="-0.5314789170422551" MODIFIED="2010-05-07 14:47:21 +0100" MODIFIED_BY="Katharine Ker" ORDER="2460" O_E="0.0" SE="0.5435299776473301" STUDY_ID="STD-Norman-2009" TOTAL_1="8" TOTAL_2="8" VAR="0.29542483660130725" WEIGHT="0.3748319126960176"/>
<DICH_DATA CI_END="2.5475015595668227" CI_START="0.008011050351928473" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.40611445855130324" LOG_CI_START="-2.0963105385798166" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="66622" O_E="0.0" SE="1.469936830518334" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="2.1607142857142856" WEIGHT="0.06685467310351981"/>
<DICH_DATA CI_END="0.7866183929057147" CI_START="0.16610386164783042" EFFECT_SIZE="0.3614697120158888" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="19" LOG_CI_END="-0.10423590302661616" LOG_CI_START="-0.779620270782508" LOG_EFFECT_SIZE="-0.441928086904562" ORDER="66623" O_E="0.0" SE="0.3967241208263498" STUDY_ID="STD-Ray-1997" TOTAL_1="53" TOTAL_2="52" VAR="0.15739002804544017" WEIGHT="0.568704157690416"/>
<DICH_DATA CI_END="0.842022696401393" CI_START="0.21813363246944803" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="21" LOG_CI_END="-0.07467620210006774" LOG_CI_START="-0.6612773684891211" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2008-09-16 05:05:53 +0100" MODIFIED_BY="[Empty name]" ORDER="2261" O_E="0.0" SE="0.34457242885953415" STUDY_ID="STD-Ray-1999" TOTAL_1="50" TOTAL_2="50" VAR="0.11873015873015873" WEIGHT="0.6650427790161133"/>
<DICH_DATA CI_END="1.0533410525445912" CI_START="0.6797193839842649" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="26" LOG_CI_END="0.02256901055561178" LOG_CI_START="-0.16767034485283525" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="66624" O_E="0.0" SE="0.11174753906691859" STUDY_ID="STD-Rocha-1994" TOTAL_1="28" TOTAL_2="28" VAR="0.012487512487512495" WEIGHT="1.2443153880734918"/>
<DICH_DATA CI_END="1.9071560686454936" CI_START="1.0494267347438109" EFFECT_SIZE="1.414715719063545" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="26" LOG_CI_END="0.28038623419867686" LOG_CI_START="0.02095212390254852" LOG_EFFECT_SIZE="0.15066917905061267" ORDER="66625" O_E="0.0" SE="0.1523928806075034" STUDY_ID="STD-Rodrigus-1996" TOTAL_1="46" TOTAL_2="47" VAR="0.02322359005985278" WEIGHT="1.143651462571205"/>
<DICH_DATA CI_END="0.8200679247854159" CI_START="0.18671513419777433" EFFECT_SIZE="0.391304347826087" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="-0.0861501742775433" LOG_CI_START="-0.7288204788789927" LOG_EFFECT_SIZE="-0.40748532657826797" ORDER="66626" O_E="0.0" SE="0.37750771819220597" STUDY_ID="STD-Royston-1987" TOTAL_1="11" TOTAL_2="11" VAR="0.142512077294686" WEIGHT="0.6022804179799737"/>
<DICH_DATA CI_END="0.9304861336670401" CI_START="0.14211002203499212" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="-0.03129009444805532" LOG_CI_START="-0.84737529321247" LOG_EFFECT_SIZE="-0.43933269383026263" MODIFIED="2008-09-16 05:34:55 +0100" MODIFIED_BY="[Empty name]" ORDER="2265" O_E="0.0" SE="0.4793724854411023" STUDY_ID="STD-Samama-2002" TOTAL_1="18" TOTAL_2="18" VAR="0.2297979797979798" WEIGHT="0.44733472152157344"/>
<DICH_DATA CI_END="0.8736277439213014" CI_START="0.08513942672584873" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.0586735824683168" LOG_CI_START="-1.0698692784088086" LOG_EFFECT_SIZE="-0.5642714304385626" MODIFIED="2008-09-16 05:43:14 +0100" MODIFIED_BY="[Empty name]" ORDER="2267" O_E="0.0" SE="0.5939813572948673" STUDY_ID="STD-Santamaria-2000" TOTAL_1="28" TOTAL_2="28" VAR="0.3528138528138528" WEIGHT="0.32830099689398223"/>
<DICH_DATA CI_END="1.1807137253011981" CI_START="0.696022334260981" EFFECT_SIZE="0.9065335753176044" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="29" LOG_CI_END="0.07214461176004733" LOG_CI_START="-0.1573768243396152" LOG_EFFECT_SIZE="-0.04261610628978393" ORDER="66627" O_E="0.0" SE="0.13482202771437407" STUDY_ID="STD-Speekenbrink-1996" TOTAL_1="38" TOTAL_2="37" VAR="0.018176979157015452" WEIGHT="1.1888608472103042"/>
<DICH_DATA CI_END="0.9849542929885672" CI_START="0.6267772455738472" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="42" LOG_CI_END="-0.006583922561699111" LOG_CI_START="-0.20288677847832687" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="66628" O_E="0.0" SE="0.11530926928023555" STUDY_ID="STD-Swart-1994" TOTAL_1="49" TOTAL_2="49" VAR="0.013296227581941874" WEIGHT="1.236119602743759"/>
<DICH_DATA CI_END="0.7975135540067488" CI_START="0.32428296497632014" EFFECT_SIZE="0.5085470085470085" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="26" LOG_CI_END="-0.09826192722963079" LOG_CI_START="-0.48907586480559345" LOG_EFFECT_SIZE="-0.2936688960176121" ORDER="66640" O_E="0.0" SE="0.22956604149231166" STUDY_ID="STD-Taggart-2003" TOTAL_1="36" TOTAL_2="34" VAR="0.05270056740644976" WEIGHT="0.9357958280361324"/>
<DICH_DATA CI_END="2.1315266092423184" CI_START="0.3002542859305412" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3286907585993715" LOG_CI_START="-0.5225107846154844" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="66634" O_E="0.0" SE="0.49999999999999994" STUDY_ID="STD-Tassani-2000" TOTAL_1="10" TOTAL_2="10" VAR="0.24999999999999997" WEIGHT="0.42219586904922934"/>
<DICH_DATA CI_END="0.968686759662337" CI_START="0.43166883561525266" EFFECT_SIZE="0.6466466466466466" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="27" LOG_CI_END="-0.013816636306206052" LOG_CI_START="-0.36484930415559036" LOG_EFFECT_SIZE="-0.18933297023089823" ORDER="66642" O_E="0.0" SE="0.2061983267344585" STUDY_ID="STD-Van-der-Linden-2005" TOTAL_1="37" TOTAL_2="38" VAR="0.0425177499480905" WEIGHT="0.9984853287376805"/>
<DICH_DATA CI_END="0.9361707678459628" CI_START="0.3957722348326828" EFFECT_SIZE="0.6086956521739131" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="23" LOG_CI_END="-0.028644923944956005" LOG_CI_START="-0.40255467673375367" LOG_EFFECT_SIZE="-0.21559980033935483" ORDER="66629" O_E="0.0" SE="0.21963643967126673" STUDY_ID="STD-Vedrinne-1992" TOTAL_1="30" TOTAL_2="30" VAR="0.04824016563146998" WEIGHT="0.9622595781528384"/>
<DICH_DATA CI_END="0.9740335218944856" CI_START="0.3695971359382001" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="-0.011426096382906073" LOG_CI_START="-0.4322714028498067" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="66630" O_E="0.0" SE="0.24720661623652213" STUDY_ID="STD-Wendel-1995" TOTAL_1="20" TOTAL_2="18" VAR="0.06111111111111113" WEIGHT="0.8896605068454201"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="392.71575707514035" CI_END="0.7426094266564331" CI_START="0.65017023722622" CI_STUDY="95" CI_TOTAL="95" DF="101" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6948543351635941" ESTIMABLE="YES" EVENTS_1="2425" EVENTS_2="3370" I2="74.28165328729727" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.1292395421568739" LOG_CI_START="-0.18697291503716365" LOG_EFFECT_SIZE="-0.15810622859701878" METHOD="MH" MODIFIED="2010-05-26 12:18:13 +0100" MODIFIED_BY="Katharine Ker" NO="5" P_CHI2="1.4432899320127035E-15" P_Q="0.0" P_Z="6.975467577746992E-27" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="83" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.057323354253677745" TOTALS="YES" TOTAL_1="5281" TOTAL_2="5142" WEIGHT="100.0" Z="10.734952708346201">
<NAME>No. Exposed to Allogeneic Blood - Dose (Cardiac Surgery)</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="62.41762559413711" CI_END="0.9555558710231231" CI_START="0.6860649130097014" DF="14" EFFECT_SIZE="0.8096748455580107" ESTIMABLE="YES" EVENTS_1="317" EVENTS_2="379" I2="77.57043805057042" ID="CMP-001.05.01" LOG_CI_END="-0.01974391481759311" LOG_CI_START="-0.1636347909576914" LOG_EFFECT_SIZE="-0.09168935288764221" MODIFIED="2008-09-16 05:44:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="4.400545738914019E-8" P_Z="0.01249543580043522" STUDIES="15" TAU2="0.058822210248669266" TOTAL_1="610" TOTAL_2="581" WEIGHT="16.410739158008603" Z="2.4978349461239118">
<NAME>Prime Dose</NAME>
<DICH_DATA CI_END="1.0529122156472872" CI_START="0.8947009147502587" EFFECT_SIZE="0.9705882352941176" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="25" LOG_CI_END="0.02239216430115447" LOG_CI_START="-0.04832211862988974" LOG_EFFECT_SIZE="-0.012964977164367647" ORDER="66646" O_E="0.0" SE="0.04153791983504127" STUDY_ID="STD-Bailey-1994" TOTAL_1="51" TOTAL_2="25" VAR="0.001725398784222315" WEIGHT="1.9476832712608614"/>
<DICH_DATA CI_END="1.0732934239859022" CI_START="0.06625505152824374" EFFECT_SIZE="0.26666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.030718468468461112" LOG_CI_START="-1.1787810039238988" LOG_EFFECT_SIZE="-0.5740312677277188" ORDER="66647" O_E="0.0" SE="0.7104659772022196" STUDY_ID="STD-Englberger-2002b" TOTAL_1="15" TOTAL_2="14" VAR="0.5047619047619047" WEIGHT="0.20461000646441715"/>
<DICH_DATA CI_END="1.216920975501839" CI_START="0.8217460460714104" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" LOG_CI_END="0.08526237690073346" LOG_CI_START="-0.08526237690073346" LOG_EFFECT_SIZE="0.0" ORDER="66648" O_E="0.0" SE="0.10016708449412663" STUDY_ID="STD-Hardy-1997" TOTAL_1="26" TOTAL_2="26" VAR="0.010033444816053505" WEIGHT="1.7074485437122597"/>
<DICH_DATA CI_END="0.9102795643744894" CI_START="0.5358673093452336" EFFECT_SIZE="0.6984189723320158" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="46" LOG_CI_END="-0.040825206998584156" LOG_CI_START="-0.27094273633952354" LOG_EFFECT_SIZE="-0.15588397166905388" ORDER="66649" O_E="0.0" SE="0.13517217583500923" STUDY_ID="STD-Hayashida-1997" TOTAL_1="55" TOTAL_2="57" VAR="0.018271517119970652" WEIGHT="1.5213766012283028"/>
<DICH_DATA CI_END="0.8321686094280049" CI_START="0.5012213747537783" EFFECT_SIZE="0.6458333333333334" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="48" LOG_CI_END="-0.07978867043362828" LOG_CI_START="-0.29997041664900065" LOG_EFFECT_SIZE="-0.1898795435413145" ORDER="66650" O_E="0.0" SE="0.1293358476441315" STUDY_ID="STD-Kalangos-1994" TOTAL_1="55" TOTAL_2="55" VAR="0.016727761485825998" WEIGHT="1.5530929862732499"/>
<DICH_DATA CI_END="2.410392969374453" CI_START="0.26551687136977226" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.38208785191856476" LOG_CI_START="-0.5759078779346776" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="66651" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Kipfer-2003" TOTAL_1="15" TOTAL_2="15" VAR="0.3166666666666667" WEIGHT="0.3075169444299888"/>
<DICH_DATA CI_END="0.8187411344876563" CI_START="0.493396420643741" EFFECT_SIZE="0.6355815802790429" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="87" LOG_CI_END="-0.08685338961260106" LOG_CI_START="-0.3068040054346707" LOG_EFFECT_SIZE="-0.19682869752363585" ORDER="66652" O_E="0.0" SE="0.12920008050699153" STUDY_ID="STD-Lemmer-1996" TOTAL_1="159" TOTAL_2="157" VAR="0.01669266080301309" WEIGHT="1.5538295109868319"/>
<DICH_DATA CI_END="1.1710073557419394" CI_START="0.7802778250572483" EFFECT_SIZE="0.9558823529411765" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="49" LOG_CI_END="0.06855962312368777" LOG_CI_START="-0.10775073525044924" LOG_EFFECT_SIZE="-0.019595556063380724" ORDER="66653" O_E="0.0" SE="0.10356557725931759" STUDY_ID="STD-Levy-1995" TOTAL_1="68" TOTAL_2="65" VAR="0.01072582879305568" WEIGHT="1.6900756677967594"/>
<DICH_DATA CI_END="2.0074970509295444" CI_START="0.15163136814312883" EFFECT_SIZE="0.5517241379310345" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.30265491596019983" LOG_CI_START="-0.8192109464462624" LOG_EFFECT_SIZE="-0.2582780152430313" ORDER="66654" O_E="0.0" SE="0.6589895609031378" STUDY_ID="STD-Maccario-1994" TOTAL_1="29" TOTAL_2="32" VAR="0.43426724137931033" WEIGHT="0.23395131945647477"/>
<DICH_DATA CI_END="1.0870519908380398" CI_START="0.724099128395356" EFFECT_SIZE="0.8872053872053872" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.03625031574600616" LOG_CI_START="-0.1402019752833" LOG_EFFECT_SIZE="-0.05197582976864693" ORDER="66655" O_E="0.0" SE="0.10364894920354192" STUDY_ID="STD-Mohr-1992" TOTAL_1="17" TOTAL_2="16" VAR="0.010743104670998413" WEIGHT="1.6896467114295248"/>
<DICH_DATA CI_END="2.156255130476228" CI_START="0.031811682828664346" EFFECT_SIZE="0.2619047619047619" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3337001457552575" LOG_CI_START="-1.4974133562346084" LOG_EFFECT_SIZE="-0.5818566052396754" ORDER="66656" O_E="0.0" SE="1.075605135226867" STUDY_ID="STD-Rossi-1997" TOTAL_1="21" TOTAL_2="22" VAR="1.156926406926407" WEIGHT="0.09471549606809032"/>
<DICH_DATA CI_END="0.8736277439213014" CI_START="0.08513942672584873" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.0586735824683168" LOG_CI_START="-1.0698692784088086" LOG_EFFECT_SIZE="-0.5642714304385626" MODIFIED="2008-09-16 05:44:44 +0100" MODIFIED_BY="[Empty name]" ORDER="2268" O_E="0.0" SE="0.5939813572948673" STUDY_ID="STD-Santamaria-2000" TOTAL_1="28" TOTAL_2="28" VAR="0.3528138528138528" WEIGHT="0.2804141309271543"/>
<DICH_DATA CI_END="1.6216329114793497" CI_START="0.733879188195826" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.20995254989858633" LOG_CI_START="-0.13437542811978684" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="66658" O_E="0.0" SE="0.20225995873897265" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.04090909090909092" WEIGHT="1.1707768068906983"/>
<DICH_DATA CI_END="1.2385384775639203" CI_START="0.7526803246632294" EFFECT_SIZE="0.9655172413793104" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="29" LOG_CI_END="0.09290950331920074" LOG_CI_START="-0.12338943643267448" LOG_EFFECT_SIZE="-0.015239966556736848" ORDER="66659" O_E="0.0" SE="0.12705506790727125" STUDY_ID="STD-Speekenbrink-1996" TOTAL_1="37" TOTAL_2="37" VAR="0.01614299028092131" WEIGHT="1.565455164664803"/>
<DICH_DATA CI_END="1.26102060903135" CI_START="0.4408653477494194" EFFECT_SIZE="0.7456140350877193" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.10072218436487669" LOG_CI_START="-0.3556940356092364" LOG_EFFECT_SIZE="-0.12748592562217986" ORDER="66660" O_E="0.0" SE="0.26810114690952036" STUDY_ID="STD-Tabuchi-1994" TOTAL_1="19" TOTAL_2="17" VAR="0.07187822497420022" WEIGHT="0.8901459964191865"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="125.73583547282448" CI_END="0.7997410492031183" CI_START="0.5988428446627589" DF="28" EFFECT_SIZE="0.6920398867828175" ESTIMABLE="YES" EVENTS_1="512" EVENTS_2="692" I2="77.7310900311696" ID="CMP-001.05.02" LOG_CI_END="-0.0970506118921176" LOG_CI_START="-0.2226871352912995" LOG_EFFECT_SIZE="-0.15986887359170854" MODIFIED="2010-05-26 12:18:13 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="2.375877272697835E-14" P_Z="6.100884972746598E-7" STUDIES="29" TAU2="0.08304293616430246" TOTAL_1="1209" TOTAL_2="1163" WEIGHT="27.0630549745802" Z="4.98799594275904">
<NAME>Low Dose</NAME>
<DICH_DATA CI_END="1.1661827845720796" CI_START="0.3228907095511885" EFFECT_SIZE="0.6136363636363636" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.06676662598870041" LOG_CI_START="-0.49094445064310055" LOG_EFFECT_SIZE="-0.2120889123272001" ORDER="66661" O_E="0.0" SE="0.3276022471278735" STUDY_ID="STD-Alajmo-1989" TOTAL_1="22" TOTAL_2="12" VAR="0.1073232323232323" WEIGHT="0.6985159599832275"/>
<DICH_DATA CI_END="2.1861039695791042" CI_START="0.25282575215333275" EFFECT_SIZE="0.7434402332361516" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.3396708128473259" LOG_CI_START="-0.5971786920649566" LOG_EFFECT_SIZE="-0.12875393960881534" ORDER="66662" O_E="0.0" SE="0.5503100366653163" STUDY_ID="STD-Alvarez-1995" TOTAL_1="49" TOTAL_2="51" VAR="0.3028411364545818" WEIGHT="0.31932150849899"/>
<DICH_DATA CI_END="1.0035609949452269" CI_START="0.8015345758405634" EFFECT_SIZE="0.896877269426289" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="25" LOG_CI_END="0.001543773398606848" LOG_CI_START="-0.09607773872108513" LOG_EFFECT_SIZE="-0.04726698266123917" ORDER="66663" O_E="0.0" SE="0.05734335945338559" STUDY_ID="STD-Bailey-1994" TOTAL_1="53" TOTAL_2="25" VAR="0.0032882608734001867" WEIGHT="1.8974625282564457"/>
<DICH_DATA CI_END="0.8731188140017339" CI_START="0.5154136572187269" EFFECT_SIZE="0.6708333333333333" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="-0.05892665348310755" LOG_CI_START="-0.28784407787640515" LOG_EFFECT_SIZE="-0.17338536567975632" ORDER="66664" O_E="0.0" SE="0.1344672282481491" STUDY_ID="STD-Basora-1999" TOTAL_1="36" TOTAL_2="21" VAR="0.018081435472739826" WEIGHT="1.5252117126511864"/>
<DICH_DATA CI_END="0.9779863575014763" CI_START="0.11361212787770752" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="-0.009667203395581254" LOG_CI_START="-0.9445753060437436" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="66665" O_E="0.0" SE="0.5491696473652761" STUDY_ID="STD-Blauhut-1994" TOTAL_1="14" TOTAL_2="14" VAR="0.3015873015873016" WEIGHT="0.3204370408319335"/>
<DICH_DATA CI_END="1.107432316188807" CI_START="0.3250763001380784" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.0443171925890425" LOG_CI_START="-0.48801469182175516" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="66666" O_E="0.0" SE="0.3126943839882286" STUDY_ID="STD-Cicek-1996a" TOTAL_1="25" TOTAL_2="25" VAR="0.09777777777777774" WEIGHT="0.7415050230414019"/>
<DICH_DATA CI_END="1.0138017822726142" CI_START="0.3434056028344289" EFFECT_SIZE="0.5900383141762452" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" LOG_CI_END="0.005953050381643381" LOG_CI_START="-0.4641926233852791" LOG_EFFECT_SIZE="-0.2291197865018179" ORDER="66667" O_E="0.0" SE="0.27616589602930897" STUDY_ID="STD-Cicek-1996b" TOTAL_1="29" TOTAL_2="28" VAR="0.0762676021296711" WEIGHT="0.8608986086656003"/>
<DICH_DATA CI_END="2.4702082767769804" CI_START="0.15813443897519056" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.392733572547735" LOG_CI_START="-0.8009735378595846" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2010-04-21 11:12:32 +0100" MODIFIED_BY="Katharine Ker" ORDER="2367" O_E="0.0" SE="0.7011894655987543" STUDY_ID="STD-Cicekcioglu-2006" TOTAL_1="24" TOTAL_2="20" VAR="0.49166666666666664" WEIGHT="0.20949063570942214"/>
<DICH_DATA CI_END="0.8785037477258802" CI_START="0.49447805723172295" EFFECT_SIZE="0.6590909090909091" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="44" LOG_CI_END="-0.056256381450191364" LOG_CI_START="-0.3058529757242714" LOG_EFFECT_SIZE="-0.18105467858723134" ORDER="66668" O_E="0.0" SE="0.14661427499966254" STUDY_ID="STD-Cosgrove-1992" TOTAL_1="56" TOTAL_2="56" VAR="0.02149574563367667" WEIGHT="1.4591421196778172"/>
<DICH_DATA CI_END="1.51097681167625" CI_START="0.7514417807075171" EFFECT_SIZE="1.065556711758585" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="31" LOG_CI_END="0.1792577994559525" LOG_CI_START="-0.12410466151341919" LOG_EFFECT_SIZE="0.027576568971266632" ORDER="66669" O_E="0.0" SE="0.1781966112418093" STUDY_ID="STD-D_x0027_Ambra-1996" TOTAL_1="62" TOTAL_2="64" VAR="0.031754032258064516" WEIGHT="1.2911051051724718"/>
<DICH_DATA CI_END="0.8485647549882042" CI_START="0.46077627889680506" EFFECT_SIZE="0.6252987367702287" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="58" LOG_CI_END="-0.07131501055197918" LOG_CI_START="-0.33650988681009075" LOG_EFFECT_SIZE="-0.20391244868103495" ORDER="66670" O_E="0.0" SE="0.15577678304982373" STUDY_ID="STD-Dignan-2001" TOTAL_1="101" TOTAL_2="99" VAR="0.02426640613735185" WEIGHT="1.4095919381248303"/>
<DICH_DATA CI_END="1.1465948472003975" CI_START="0.06538635291433063" EFFECT_SIZE="0.27380952380952384" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.05940998572274674" LOG_CI_START="-1.1845128858113243" LOG_EFFECT_SIZE="-0.5625514500442887" ORDER="66671" O_E="0.0" SE="0.7306864522566346" STUDY_ID="STD-Englberger-2002a" TOTAL_1="21" TOTAL_2="23" VAR="0.5339026915113871" WEIGHT="0.1945250370895072"/>
<DICH_DATA CI_END="1.0164144456513737" CI_START="0.08210901614053026" EFFECT_SIZE="0.28888888888888886" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="0.007070828773153743" LOG_CI_START="-1.0856091517101678" LOG_EFFECT_SIZE="-0.539269161468507" ORDER="66672" O_E="0.0" SE="0.6418456293890392" STUDY_ID="STD-Gherli-1992" TOTAL_1="9" TOTAL_2="13" VAR="0.41196581196581195" WEIGHT="0.24506908908044506"/>
<DICH_DATA CI_END="1.2371304328257535" CI_START="0.6806192486246042" EFFECT_SIZE="0.9176136363636364" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.09241549047004377" LOG_CI_START="-0.1670957727641001" LOG_EFFECT_SIZE="-0.03734014114702813" ORDER="66673" O_E="0.0" SE="0.1524382006252069" STUDY_ID="STD-Hardy-1993" TOTAL_1="22" TOTAL_2="19" VAR="0.02323740500985083" WEIGHT="1.4275966305694738"/>
<DICH_DATA CI_END="1.2005001082166866" CI_START="0.15299746175000142" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.07936220354165731" LOG_CI_START="-0.8153157741308461" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="66674" O_E="0.0" SE="0.5255382728122436" STUDY_ID="STD-Havel-1992" TOTAL_1="10" TOTAL_2="10" VAR="0.2761904761904762" WEIGHT="0.34483807861152477"/>
<DICH_DATA CI_END="0.9991258279259411" CI_START="0.6223354951355209" EFFECT_SIZE="0.7885375494071146" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="46" LOG_CI_END="-3.798141436542471E-4" LOG_CI_START="-0.2059754281624475" LOG_EFFECT_SIZE="-0.10317762115305087" ORDER="66675" O_E="0.0" SE="0.12076788138934204" STUDY_ID="STD-Hayashida-1997" TOTAL_1="55" TOTAL_2="57" VAR="0.014584881175270188" WEIGHT="1.5993754789654215"/>
<DICH_DATA CI_END="0.8492965507116076" CI_START="0.4362556243340239" EFFECT_SIZE="0.6086956521739131" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="46" LOG_CI_END="-0.07094063973244553" LOG_CI_START="-0.3602589609462642" LOG_EFFECT_SIZE="-0.21559980033935483" ORDER="66676" O_E="0.0" SE="0.16994701402978446" STUDY_ID="STD-Isetta-1993" TOTAL_1="70" TOTAL_2="70" VAR="0.028881987577639753" WEIGHT="1.3341199749056687"/>
<DICH_DATA CI_END="0.8487029408975272" CI_START="0.5226006048576521" EFFECT_SIZE="0.6659824849480022" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="87" LOG_CI_END="-0.0712442929177794" LOG_CI_START="-0.2818300919562082" LOG_EFFECT_SIZE="-0.17653719243699378" ORDER="66677" O_E="0.0" SE="0.12369914077169018" STUDY_ID="STD-Lemmer-1996" TOTAL_1="168" TOTAL_2="157" VAR="0.015301477427654425" WEIGHT="1.5835942861165235"/>
<DICH_DATA CI_END="0.828162236873594" CI_START="0.4449821959596931" EFFECT_SIZE="0.6070563818747838" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="49" LOG_CI_END="-0.08188457664857489" LOG_CI_START="-0.351657365089055" LOG_EFFECT_SIZE="-0.21677097086881492" ORDER="66678" O_E="0.0" SE="0.15846587132677778" STUDY_ID="STD-Levy-1995" TOTAL_1="59" TOTAL_2="65" VAR="0.02511143237535489" WEIGHT="1.395142429351873"/>
<DICH_DATA CI_END="0.7532478029295167" CI_START="0.08297402230305383" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.12306212640134118" LOG_CI_START="-1.0810578562545836" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="66679" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Liu-1993" TOTAL_1="20" TOTAL_2="20" VAR="0.31666666666666665" WEIGHT="0.30751694442998884"/>
<DICH_DATA CI_END="1.446083509057262" CI_START="0.41832872570361634" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.1601933735086789" LOG_CI_START="-0.37848231235881497" LOG_EFFECT_SIZE="-0.10914446942506803" ORDER="66680" O_E="0.0" SE="0.3164207643662155" STUDY_ID="STD-Locatelli-1990" TOTAL_1="13" TOTAL_2="13" VAR="0.1001221001221001" WEIGHT="0.7304642038520823"/>
<DICH_DATA CI_END="0.581965375170908" CI_START="0.011932745040725218" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.23510285352801047" LOG_CI_START="-1.9232596385672394" LOG_EFFECT_SIZE="-1.0791812460476249" ORDER="66681" O_E="0.0" SE="0.991631652042901" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.9833333333333332" WEIGHT="0.1105150909541586"/>
<DICH_DATA CI_END="1.0403570180709536" CI_START="0.56797137464091" EFFECT_SIZE="0.768695652173913" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="23" LOG_CI_END="0.01718240119376299" LOG_CI_START="-0.24567355187484013" LOG_EFFECT_SIZE="-0.11424557534053863" MODIFIED="2010-05-07 14:59:32 +0100" MODIFIED_BY="Katharine Ker" ORDER="2466" O_E="0.0" SE="0.15440288799045002" STUDY_ID="STD-Nur_x00f6_zler-2008" TOTAL_1="25" TOTAL_2="26" VAR="0.023840251819791457" WEIGHT="1.4169930840261897"/>
<DICH_DATA CI_END="1.1769979621462765" CI_START="0.7239358378865783" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="52" LOG_CI_END="0.07077571090682193" LOG_CI_START="-0.14029992342524575" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2010-05-21 15:25:45 +0100" MODIFIED_BY="Katharine Ker" ORDER="2332" O_E="0.0" SE="0.1239868724478975" STUDY_ID="STD-Parvizi-2007" TOTAL_1="81" TOTAL_2="81" VAR="0.015372744539411204" WEIGHT="1.5820418205394193"/>
<DICH_DATA CI_END="1.0650367118693163" CI_START="0.331144696158032" EFFECT_SIZE="0.5938697318007663" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" LOG_CI_END="0.027364578185526574" LOG_CI_START="-0.4799821965215054" LOG_EFFECT_SIZE="-0.22630880916798943" ORDER="66682" O_E="0.0" SE="0.29801800686994884" STUDY_ID="STD-Poston-2006" TOTAL_1="29" TOTAL_2="31" VAR="0.08881473241873687" WEIGHT="0.7869835379639"/>
<DICH_DATA CI_END="1.0902507120596947" CI_START="0.9172202218614527" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.037526378990036593" LOG_CI_START="-0.037526378990036614" LOG_EFFECT_SIZE="0.0" ORDER="66683" O_E="0.0" SE="0.04408636155463877" STUDY_ID="STD-Pugh-1995" TOTAL_1="21" TOTAL_2="23" VAR="0.0019436072751263314" WEIGHT="1.9405123109750995"/>
<DICH_DATA CI_END="1.156718099789521" CI_START="0.3842288320078301" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" LOG_CI_END="0.06322753127423315" LOG_CI_START="-0.4154100493855958" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2008-09-16 05:14:56 +0100" MODIFIED_BY="[Empty name]" ORDER="2262" O_E="0.0" SE="0.28115408417381926" STUDY_ID="STD-Ray-1999" TOTAL_1="50" TOTAL_2="50" VAR="0.07904761904761903" WEIGHT="0.843348593154305"/>
<DICH_DATA CI_END="1.3454053931997747" CI_START="0.022094839371514755" EFFECT_SIZE="0.1724137931034483" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.1288531642656234" LOG_CI_START="-1.6557091513914979" LOG_EFFECT_SIZE="-0.7634279935629372" ORDER="66686" O_E="0.0" SE="1.048260737942924" STUDY_ID="STD-Vanek-2005" TOTAL_1="29" TOTAL_2="30" VAR="1.0988505747126436" WEIGHT="0.09947315503261277"/>
<DICH_DATA CI_END="2.1719720978715733" CI_START="0.319729910492389" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3368542418108039" LOG_CI_START="-0.49521673390605353" LOG_EFFECT_SIZE="-0.07918124604762482" MODIFIED="2010-05-26 12:18:13 +0100" MODIFIED_BY="Katharine Ker" ORDER="2768" O_E="0.0" SE="0.4887626099538393" STUDY_ID="STD-Wei-2006" TOTAL_1="36" TOTAL_2="40" VAR="0.23888888888888885" WEIGHT="0.38826304834867537"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="164.59363808799347" CI_END="0.7246245864536901" CI_START="0.6151954927726344" DF="57" EFFECT_SIZE="0.6676719101014692" ESTIMABLE="YES" EVENTS_1="1596" EVENTS_2="2299" I2="65.36925687885507" ID="CMP-001.05.03" LOG_CI_END="-0.13988693447479505" LOG_CI_START="-0.21098685505178827" LOG_EFFECT_SIZE="-0.17543689476329163" MODIFIED="2010-05-17 13:59:32 +0100" MODIFIED_BY="Katharine Ker" NO="3" P_CHI2="2.2194468485281504E-12" P_Z="3.953779719162199E-22" STUDIES="58" TAU2="0.04443235130032819" TOTAL_1="3462" TOTAL_2="3398" WEIGHT="56.5262058674112" Z="9.672303217926787">
<NAME>High Dose</NAME>
<DICH_DATA CI_END="0.8207319356942484" CI_START="0.6020493368181332" EFFECT_SIZE="0.702937491950874" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="213" LOG_CI_END="-0.08579866731277815" LOG_CI_START="-0.22036791766259636" LOG_EFFECT_SIZE="-0.1530832924876873" ORDER="66741" O_E="0.0" SE="0.07904664378401566" STUDY_ID="STD-Alderman-1998" TOTAL_1="401" TOTAL_2="395" VAR="0.0062483718935170615" WEIGHT="1.8091103616478852"/>
<DICH_DATA CI_END="0.9794902492496453" CI_START="0.5964920617890417" EFFECT_SIZE="0.764367816091954" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="45" LOG_CI_END="-0.008999883016004835" LOG_CI_START="-0.22439533161502298" LOG_EFFECT_SIZE="-0.11669760731551393" ORDER="66740" O_E="0.0" SE="0.1265243527317297" STUDY_ID="STD-Baele-1992" TOTAL_1="58" TOTAL_2="57" VAR="0.01600841183418316" WEIGHT="1.5683280877612735"/>
<DICH_DATA CI_END="1.056285558232989" CI_START="0.8040332734669017" EFFECT_SIZE="0.9215686274509803" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="25" LOG_CI_END="0.02378134206136279" LOG_CI_START="-0.09472597838580064" LOG_EFFECT_SIZE="-0.03547231816221892" ORDER="66739" O_E="0.0" SE="0.06961178665136088" STUDY_ID="STD-Bailey-1994" TOTAL_1="25" TOTAL_2="25" VAR="0.004845800840794584" WEIGHT="1.8499249073912167"/>
<DICH_DATA CI_END="0.39482790023923114" CI_START="0.11321905262835025" EFFECT_SIZE="0.21142857142857144" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="35" LOG_CI_END="-0.40359216580023544" LOG_CI_START="-0.9460804834383635" LOG_EFFECT_SIZE="-0.6748363246192994" ORDER="66738" O_E="0.0" SE="0.3186603231411177" STUDY_ID="STD-Bidstrup-1989" TOTAL_1="40" TOTAL_2="37" VAR="0.10154440154440156" WEIGHT="0.7239245490879047"/>
<DICH_DATA CI_END="0.9372502510926616" CI_START="0.4494540535626551" EFFECT_SIZE="0.6490384615384616" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="-0.028144434557366343" LOG_CI_START="-0.3473146983781445" LOG_EFFECT_SIZE="-0.1877295664677554" ORDER="66737" O_E="0.0" SE="0.1874821928866116" STUDY_ID="STD-Bidstrup-1990" TOTAL_1="26" TOTAL_2="18" VAR="0.035149572649572636" WEIGHT="1.243696640002096"/>
<DICH_DATA CI_END="0.7811089758395658" CI_START="0.21508479595057134" EFFECT_SIZE="0.40988372093023256" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="24" LOG_CI_END="-0.10728837162309306" LOG_CI_START="-0.6673902882092073" LOG_EFFECT_SIZE="-0.3873393299161502" ORDER="66736" O_E="0.0" SE="0.3290066383518857" STUDY_ID="STD-Bidstrup-1993" TOTAL_1="43" TOTAL_2="47" VAR="0.10824536807960852" WEIGHT="0.6946255721489639"/>
<DICH_DATA CI_END="0.8902876187799331" CI_START="0.3588398767925144" EFFECT_SIZE="0.5652173913043478" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="23" LOG_CI_END="-0.05046966631041668" LOG_CI_START="-0.4450993011110956" LOG_EFFECT_SIZE="-0.24778448371075615" ORDER="66735" O_E="0.0" SE="0.23180740093011587" STUDY_ID="STD-Bidstrup-2000" TOTAL_1="30" TOTAL_2="30" VAR="0.053734671125975485" WEIGHT="1.035569181854033"/>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516804" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="66734" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Boldt-1991" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="0.04524016304159448"/>
<DICH_DATA CI_END="0.9593385583155755" CI_START="0.7355067654519231" EFFECT_SIZE="0.84" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="50" LOG_CI_END="-0.018028099752735213" LOG_CI_START="-0.13341332812350148" LOG_EFFECT_SIZE="-0.07572071393811836" ORDER="66733" O_E="0.0" SE="0.06777785431108017" STUDY_ID="STD-Carrera-1994" TOTAL_1="51" TOTAL_2="51" VAR="0.004593837535014009" WEIGHT="1.8574529166830922"/>
<DICH_DATA CI_END="0.7733027556602502" CI_START="0.2607123323246595" EFFECT_SIZE="0.44900953778429936" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="29" LOG_CI_END="-0.11165044221312088" LOG_CI_START="-0.5838384251651039" LOG_EFFECT_SIZE="-0.34774443368911234" ORDER="66732" O_E="0.0" SE="0.27736555855420697" STUDY_ID="STD-Casas-1995" TOTAL_1="47" TOTAL_2="51" VAR="0.07693165307208723" WEIGHT="0.8566404395008408"/>
<DICH_DATA CI_END="1.0266940043095694" CI_START="0.277048899916122" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.011441025835386942" LOG_CI_START="-0.5574435699628623" LOG_EFFECT_SIZE="-0.27300127206373764" ORDER="66731" O_E="0.0" SE="0.334165627596057" STUDY_ID="STD-Cicek-1996a" TOTAL_1="25" TOTAL_2="25" VAR="0.11166666666666664" WEIGHT="0.6805624844258853"/>
<DICH_DATA CI_END="0.7537424083054954" CI_START="0.31088474574670794" EFFECT_SIZE="0.4840733590733591" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="37" LOG_CI_END="-0.12277704904434342" LOG_CI_START="-0.507400587061211" LOG_EFFECT_SIZE="-0.3150888180527773" ORDER="66730" O_E="0.0" SE="0.22592977014832727" STUDY_ID="STD-Cohen-1998" TOTAL_1="56" TOTAL_2="59" VAR="0.05104426103927599" WEIGHT="1.061278945465638"/>
<DICH_DATA CI_END="1.0006396605496894" CI_START="0.3378044714556414" EFFECT_SIZE="0.5813953488372093" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="2.7771223570681805E-4" LOG_CI_START="-0.4713346060508047" LOG_EFFECT_SIZE="-0.23552844690754887" ORDER="66729" O_E="0.0" SE="0.277027410280123" STUDY_ID="STD-Corbeau-1995" TOTAL_1="43" TOTAL_2="20" VAR="0.0767441860465116" WEIGHT="0.8578382822808414"/>
<DICH_DATA CI_END="0.7952885847856555" CI_START="0.42378242013260525" EFFECT_SIZE="0.580542264752791" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="44" LOG_CI_END="-0.09947525117000126" LOG_CI_START="-0.37285706319331974" LOG_EFFECT_SIZE="-0.2361661571816605" ORDER="66728" O_E="0.0" SE="0.16058582964429188" STUDY_ID="STD-Cosgrove-1992" TOTAL_1="57" TOTAL_2="56" VAR="0.02578780868254553" WEIGHT="1.3837884637588984"/>
<DICH_DATA CI_END="1.7823127419899514" CI_START="0.9514668212088658" EFFECT_SIZE="1.3022332506203473" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="31" LOG_CI_END="0.25098391193624364" LOG_CI_START="-0.02160635148325482" LOG_EFFECT_SIZE="0.1146887802264944" ORDER="66727" O_E="0.0" SE="0.16012087007617923" STUDY_ID="STD-D_x0027_Ambra-1996" TOTAL_1="65" TOTAL_2="64" VAR="0.02563869303395267" WEIGHT="1.3862756795525653"/>
<DICH_DATA CI_END="2.314529531862027" CI_START="0.432053247208086" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.3644627264637834" LOG_CI_START="-0.3644627264637834" LOG_EFFECT_SIZE="0.0" ORDER="66726" O_E="0.0" SE="0.42817441928883765" STUDY_ID="STD-Deleuze-1991" TOTAL_1="30" TOTAL_2="30" VAR="0.18333333333333335" WEIGHT="0.4778935072774567"/>
<DICH_DATA CI_END="1.3254060928964186" CI_START="0.40235538574672136" EFFECT_SIZE="0.7302631578947368" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.12234896271291117" LOG_CI_START="-0.3953901810291414" LOG_EFFECT_SIZE="-0.13652060915811512" MODIFIED="2010-05-17 10:48:16 +0100" MODIFIED_BY="Katharine Ker" ORDER="2550" O_E="0.0" SE="0.30412253588417626" STUDY_ID="STD-Desai-2009" TOTAL_1="38" TOTAL_2="37" VAR="0.09249051683262208" WEIGHT="0.7676743658434789"/>
<DICH_DATA CI_END="0.9323483780122118" CI_START="0.25881421861080883" EFFECT_SIZE="0.49122807017543857" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.030421780373552382" LOG_CI_START="-0.587011868286992" LOG_EFFECT_SIZE="-0.3087168243302722" ORDER="66725" O_E="0.0" SE="0.32694377280572434" STUDY_ID="STD-Dietrich-1990" TOTAL_1="19" TOTAL_2="20" VAR="0.10689223057644108" WEIGHT="0.700349291449457"/>
<DICH_DATA CI_END="0.7811464089683755" CI_START="0.6922940885893394" EFFECT_SIZE="0.7353795219147709" ESTIMABLE="YES" EVENTS_1="549" EVENTS_2="730" LOG_CI_END="-0.10726755940321708" LOG_CI_START="-0.1597093767577549" LOG_EFFECT_SIZE="-0.13348846808048598" ORDER="66724" O_E="0.0" SE="0.03080458310523803" STUDY_ID="STD-Dietrich-1992" TOTAL_1="902" TOTAL_2="882" VAR="9.489223402875163E-4" WEIGHT="1.973636095979169"/>
<DICH_DATA CI_END="1.020610877852942" CI_START="0.5393517492042281" EFFECT_SIZE="0.7419354838709677" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.008860192809001107" LOG_CI_START="-0.26812790844236073" LOG_EFFECT_SIZE="-0.1296338578166798" ORDER="66723" O_E="0.0" SE="0.16270418178826412" STUDY_ID="STD-Dietrich-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.026472650771388495" WEIGHT="1.3724791348505103"/>
<DICH_DATA CI_END="0.5985457020816825" CI_START="0.1466746731178129" EFFECT_SIZE="0.2962962962962963" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="27" LOG_CI_END="-0.22290268334593874" LOG_CI_START="-0.8336448709881488" LOG_EFFECT_SIZE="-0.5282737771670437" ORDER="66722" O_E="0.0" SE="0.3587529842436209" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.1287037037037037" WEIGHT="0.618234087791036"/>
<DICH_DATA CI_END="0.9468374527500885" CI_START="0.399961179980938" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="26" LOG_CI_END="-0.02372457161220413" LOG_CI_START="-0.3979821590175822" LOG_EFFECT_SIZE="-0.21085336531489315" ORDER="66721" O_E="0.0" SE="0.2198407594468552" STUDY_ID="STD-Fraedrich-1989" TOTAL_1="38" TOTAL_2="38" VAR="0.048329959514170046" WEIGHT="1.0885438835684775"/>
<DICH_DATA CI_END="1.0164144456513737" CI_START="0.08210901614053026" EFFECT_SIZE="0.28888888888888886" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="0.007070828773153743" LOG_CI_START="-1.0856091517101678" LOG_EFFECT_SIZE="-0.539269161468507" ORDER="66720" O_E="0.0" SE="0.6418456293890392" STUDY_ID="STD-Gherli-1992" TOTAL_1="9" TOTAL_2="13" VAR="0.41196581196581195" WEIGHT="0.24506908908044506"/>
<DICH_DATA CI_END="1.1620394238299383" CI_START="0.27073602422146403" EFFECT_SIZE="0.5608974358974359" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.06522086235840659" LOG_CI_START="-0.5674539530227032" LOG_EFFECT_SIZE="-0.25111654533214833" ORDER="66719" O_E="0.0" SE="0.3716363183457089" STUDY_ID="STD-Greilich-2001" TOTAL_1="24" TOTAL_2="25" VAR="0.1381135531135531" WEIGHT="0.5884675009957484"/>
<DICH_DATA CI_END="1.6182854246331981" CI_START="0.7470899207455475" EFFECT_SIZE="1.0995475113122173" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.20905512259825326" LOG_CI_START="-0.1266271227718502" LOG_EFFECT_SIZE="0.04121399991320153" MODIFIED="2010-05-17 13:59:32 +0100" MODIFIED_BY="Katharine Ker" ORDER="2594" O_E="0.0" SE="0.1971814125843122" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="27" VAR="0.03888050946874476" WEIGHT="1.1954641324236814"/>
<DICH_DATA CI_END="1.3438135911295888" CI_START="0.7963564179938953" EFFECT_SIZE="1.0344827586206897" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="29" LOG_CI_END="0.12833902916533568" LOG_CI_START="-0.09889251552392286" LOG_EFFECT_SIZE="0.014723256820706378" ORDER="66718" O_E="0.0" SE="0.13347693416475745" STUDY_ID="STD-Harder-1991" TOTAL_1="40" TOTAL_2="40" VAR="0.01781609195402299" WEIGHT="1.5305977656905485"/>
<DICH_DATA CI_END="3.0394125886228682" CI_START="0.20748181399616164" EFFECT_SIZE="0.7941176470588235" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.48278965789495476" LOG_CI_START="-0.6830199636614904" LOG_EFFECT_SIZE="-0.10011515288326783" ORDER="66717" O_E="0.0" SE="0.6848023425529537" STUDY_ID="STD-Harmon-2004" TOTAL_1="17" TOTAL_2="18" VAR="0.46895424836601296" WEIGHT="0.21853156567607437"/>
<DICH_DATA CI_END="0.825164612818845" CI_START="0.4175142184481112" EFFECT_SIZE="0.5869565217391305" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="46" LOG_CI_END="-0.08345940501667462" LOG_CI_START="-0.3793287300284988" LOG_EFFECT_SIZE="-0.2313940675225867" ORDER="66716" O_E="0.0" SE="0.1737951060887247" STUDY_ID="STD-Isetta-1993" TOTAL_1="70" TOTAL_2="70" VAR="0.030204738900391076" WEIGHT="1.3139583456741357"/>
<DICH_DATA CI_END="0.7912977021892589" CI_START="0.4612895501923344" EFFECT_SIZE="0.6041666666666666" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="48" LOG_CI_END="-0.10166009539718963" LOG_CI_START="-0.3360263835560727" LOG_EFFECT_SIZE="-0.21884323947663117" ORDER="66715" O_E="0.0" SE="0.13766791779636467" STUDY_ID="STD-Kalangos-1994" TOTAL_1="55" TOTAL_2="55" VAR="0.01895245559038662" WEIGHT="1.5077947873100375"/>
<DICH_DATA CI_END="1.7248117563970482" CI_START="0.1672117424292004" EFFECT_SIZE="0.5370370370370371" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.23674170368809447" LOG_CI_START="-0.7767332275361192" LOG_EFFECT_SIZE="-0.26999576192401237" ORDER="66714" O_E="0.0" SE="0.5953201913829222" STUDY_ID="STD-Klein-1998" TOTAL_1="36" TOTAL_2="29" VAR="0.35440613026819917" WEIGHT="0.27932968807003433"/>
<DICH_DATA CI_END="1.5636597783045803" CI_START="0.5373789039255461" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.19414226504209867" LOG_CI_START="-0.26971938682089824" LOG_EFFECT_SIZE="-0.0377885608893998" ORDER="66713" O_E="0.0" SE="0.27247463045653303" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.07424242424242425" WEIGHT="0.8741503284164382"/>
<DICH_DATA CI_END="0.8548579066310278" CI_START="0.4535633977347247" EFFECT_SIZE="0.6226815050344462" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="37" LOG_CI_END="-0.06810606713672084" LOG_CI_START="-0.34336199997763184" LOG_EFFECT_SIZE="-0.2057340335571763" ORDER="66712" O_E="0.0" SE="0.16168669748959338" STUDY_ID="STD-Lass-1995" TOTAL_1="51" TOTAL_2="47" VAR="0.026142588145091284" WEIGHT="1.3779065469753573"/>
<DICH_DATA CI_END="0.8925895825655312" CI_START="0.5575925005095984" EFFECT_SIZE="0.7054794520547946" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="73" LOG_CI_END="-0.0493481861272466" LOG_CI_START="-0.25368307603128315" LOG_EFFECT_SIZE="-0.15151563107926486" MODIFIED="2010-05-06 16:08:19 +0100" MODIFIED_BY="Katharine Ker" ORDER="2372" O_E="0.0" SE="0.12002732580364896" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="103" VAR="0.014406558939575296" WEIGHT="1.6033515636758033"/>
<DICH_DATA CI_END="1.5757982109905528" CI_START="0.20721600644516502" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.19750060308743156" LOG_CI_START="-0.6835767004600205" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="66711" O_E="0.0" SE="0.5175491695067657" STUDY_ID="STD-Laub-1994" TOTAL_1="16" TOTAL_2="16" VAR="0.26785714285714285" WEIGHT="0.35367517271965243"/>
<DICH_DATA CI_END="0.8012922727729785" CI_START="0.48023660328947937" EFFECT_SIZE="0.6203304597701149" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="87" LOG_CI_END="-0.09620904533863149" LOG_CI_START="-0.3185447414035" LOG_EFFECT_SIZE="-0.20737689337106574" ORDER="66710" O_E="0.0" SE="0.13060108844794918" STUDY_ID="STD-Lemmer-1996" TOTAL_1="160" TOTAL_2="157" VAR="0.017056644303789045" WEIGHT="1.5462257422857473"/>
<DICH_DATA CI_END="1.0497678264256392" CI_START="0.4997731056344701" EFFECT_SIZE="0.7243243243243244" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="35" LOG_CI_END="0.021093258258824937" LOG_CI_START="-0.30122711833523724" LOG_EFFECT_SIZE="-0.14006693003820614" ORDER="66709" O_E="0.0" SE="0.18933258472294834" STUDY_ID="STD-Lemmer_x005f_1-1994" TOTAL_1="74" TOTAL_2="67" VAR="0.035846827637872405" WEIGHT="1.2343892235243377"/>
<DICH_DATA CI_END="0.8150022791529388" CI_START="0.22000161521551823" EFFECT_SIZE="0.42344045368620037" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="23" LOG_CI_END="-0.08884117675430474" LOG_CI_START="-0.6575741306477412" LOG_EFFECT_SIZE="-0.37320765370102293" ORDER="66708" O_E="0.0" SE="0.33407655239053047" STUDY_ID="STD-Lemmer_x005f_2-1994" TOTAL_1="23" TOTAL_2="32" VAR="0.11160714285714285" WEIGHT="0.6808022852456594"/>
<DICH_DATA CI_END="0.939776936082713" CI_START="0.5479967471412873" EFFECT_SIZE="0.7176313148210104" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="49" LOG_CI_END="-0.026975217596659436" LOG_CI_START="-0.2612220194404158" LOG_EFFECT_SIZE="-0.1440986185185376" ORDER="66707" O_E="0.0" SE="0.13759773094339242" STUDY_ID="STD-Levy-1995" TOTAL_1="61" TOTAL_2="65" VAR="0.018933135560770212" WEIGHT="1.508176795976017"/>
<DICH_DATA CI_END="0.7917906433240165" CI_START="0.12333594849015803" EFFECT_SIZE="0.3125" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.10138963465852775" LOG_CI_START="-0.9089103219812843" LOG_EFFECT_SIZE="-0.505149978319906" ORDER="66706" O_E="0.0" SE="0.4743416490252569" STUDY_ID="STD-Li-2005" TOTAL_1="40" TOTAL_2="30" VAR="0.22499999999999998" WEIGHT="0.4073636372901437"/>
<DICH_DATA CI_END="1.1589401767202359" CI_START="0.2000313921859694" EFFECT_SIZE="0.48148148148148145" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.0640610187152497" LOG_CI_START="-0.6989018424195508" LOG_EFFECT_SIZE="-0.3174204118521506" ORDER="66705" O_E="0.0" SE="0.44816816135765475" STUDY_ID="STD-Locatelli-1990" TOTAL_1="12" TOTAL_2="13" VAR="0.20085470085470086" WEIGHT="0.4454610537384886"/>
<DICH_DATA CI_END="1.5293329029537468" CI_START="0.07265331890559054" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.18450203229193085" LOG_CI_START="-1.1387445417312558" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="66704" O_E="0.0" SE="0.7772815877574012" STUDY_ID="STD-Maccario-1994" TOTAL_1="32" TOTAL_2="32" VAR="0.6041666666666666" WEIGHT="0.1738624391048539"/>
<DICH_DATA CI_END="0.4272576057276957" CI_START="0.028895164993771816" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="18" LOG_CI_END="-0.3693101975453905" LOG_CI_START="-1.5391748213332594" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="66703" O_E="0.0" SE="0.6871842709362768" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.47222222222222227" WEIGHT="0.21718294626518517"/>
<DICH_DATA CI_END="0.7984325379789613" CI_START="0.2964726043329143" EFFECT_SIZE="0.48653198653198654" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="-0.09776177285197986" LOG_CI_START="-0.5280154315973115" LOG_EFFECT_SIZE="-0.3128886022246457" ORDER="66702" O_E="0.0" SE="0.25273312893696737" STUDY_ID="STD-Mohr-1992" TOTAL_1="17" TOTAL_2="16" VAR="0.06387403446226976" WEIGHT="0.9489335512853238"/>
<DICH_DATA CI_END="0.8973650634832809" CI_START="0.4380356604107999" EFFECT_SIZE="0.6269592476489029" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" LOG_CI_END="-0.04703084257180927" LOG_CI_START="-0.3584905322145905" LOG_EFFECT_SIZE="-0.2027606873931999" ORDER="66701" O_E="0.0" SE="0.18295296344649845" STUDY_ID="STD-Murkin-1994" TOTAL_1="29" TOTAL_2="25" VAR="0.0334717868338558" WEIGHT="1.26667866917961"/>
<DICH_DATA CI_END="2.5475015595668227" CI_START="0.008011050351928473" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.40611445855130324" LOG_CI_START="-2.0963105385798166" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="66700" O_E="0.0" SE="1.469936830518334" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="2.1607142857142856" WEIGHT="0.05185136014301049"/>
<DICH_DATA CI_END="0.7866183929057147" CI_START="0.16610386164783042" EFFECT_SIZE="0.3614697120158888" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="19" LOG_CI_END="-0.10423590302661616" LOG_CI_START="-0.779620270782508" LOG_EFFECT_SIZE="-0.441928086904562" ORDER="66699" O_E="0.0" SE="0.3967241208263498" STUDY_ID="STD-Ray-1997" TOTAL_1="53" TOTAL_2="52" VAR="0.15739002804544017" WEIGHT="0.5356362386416769"/>
<DICH_DATA CI_END="0.842022696401393" CI_START="0.21813363246944803" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="21" LOG_CI_END="-0.07467620210006774" LOG_CI_START="-0.6612773684891211" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2008-09-16 05:15:53 +0100" MODIFIED_BY="[Empty name]" ORDER="2263" O_E="0.0" SE="0.34457242885953415" STUDY_ID="STD-Ray-1999" TOTAL_1="50" TOTAL_2="50" VAR="0.11873015873015873" WEIGHT="0.6532574473040527"/>
<DICH_DATA CI_END="1.0533410525445912" CI_START="0.6797193839842649" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="26" LOG_CI_END="0.02256901055561178" LOG_CI_START="-0.16767034485283525" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="66697" O_E="0.0" SE="0.11174753906691859" STUDY_ID="STD-Rocha-1994" TOTAL_1="28" TOTAL_2="28" VAR="0.012487512487512495" WEIGHT="1.6474264516311183"/>
<DICH_DATA CI_END="1.9071560686454936" CI_START="1.0494267347438109" EFFECT_SIZE="1.414715719063545" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="26" LOG_CI_END="0.28038623419867686" LOG_CI_START="0.02095212390254852" LOG_EFFECT_SIZE="0.15066917905061267" ORDER="66696" O_E="0.0" SE="0.1523928806075034" STUDY_ID="STD-Rodrigus-1996" TOTAL_1="46" TOTAL_2="47" VAR="0.02322359005985278" WEIGHT="1.4278414837570996"/>
<DICH_DATA CI_END="0.8200679247854159" CI_START="0.18671513419777433" EFFECT_SIZE="0.391304347826087" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="-0.0861501742775433" LOG_CI_START="-0.7288204788789927" LOG_EFFECT_SIZE="-0.40748532657826797" ORDER="66695" O_E="0.0" SE="0.37750771819220597" STUDY_ID="STD-Royston-1987" TOTAL_1="11" TOTAL_2="11" VAR="0.142512077294686" WEIGHT="0.5755149003839084"/>
<DICH_DATA CI_END="0.8736277439213014" CI_START="0.08513942672584873" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.0586735824683168" LOG_CI_START="-1.0698692784088086" LOG_EFFECT_SIZE="-0.5642714304385626" MODIFIED="2008-09-16 05:47:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2269" O_E="0.0" SE="0.5939813572948673" STUDY_ID="STD-Santamaria-2000" TOTAL_1="28" TOTAL_2="28" VAR="0.3528138528138528" WEIGHT="0.2804141309271543"/>
<DICH_DATA CI_END="1.1807137253011981" CI_START="0.696022334260981" EFFECT_SIZE="0.9065335753176044" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="29" LOG_CI_END="0.07214461176004733" LOG_CI_START="-0.1573768243396152" LOG_EFFECT_SIZE="-0.04261610628978393" ORDER="66693" O_E="0.0" SE="0.13482202771437407" STUDY_ID="STD-Speekenbrink-1996" TOTAL_1="38" TOTAL_2="37" VAR="0.018176979157015452" WEIGHT="1.5232815973822327"/>
<DICH_DATA CI_END="0.9849542929885672" CI_START="0.6267772455738472" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="42" LOG_CI_END="-0.006583922561699111" LOG_CI_START="-0.20288677847832687" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="66692" O_E="0.0" SE="0.11530926928023555" STUDY_ID="STD-Swart-1994" TOTAL_1="49" TOTAL_2="49" VAR="0.013296227581941874" WEIGHT="1.628560598793056"/>
<DICH_DATA CI_END="0.7975135540067488" CI_START="0.32428296497632014" EFFECT_SIZE="0.5085470085470085" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="26" LOG_CI_END="-0.09826192722963079" LOG_CI_START="-0.48907586480559345" LOG_EFFECT_SIZE="-0.2936688960176121" ORDER="66691" O_E="0.0" SE="0.22956604149231166" STUDY_ID="STD-Taggart-2003" TOTAL_1="36" TOTAL_2="34" VAR="0.05270056740644976" WEIGHT="1.0453023919289248"/>
<DICH_DATA CI_END="2.1315266092423184" CI_START="0.3002542859305412" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3286907585993715" LOG_CI_START="-0.5225107846154844" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="66690" O_E="0.0" SE="0.49999999999999994" STUDY_ID="STD-Tassani-2000" TOTAL_1="10" TOTAL_2="10" VAR="0.24999999999999997" WEIGHT="0.3742256059908783"/>
<DICH_DATA CI_END="0.968686759662337" CI_START="0.43166883561525266" EFFECT_SIZE="0.6466466466466466" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="27" LOG_CI_END="-0.013816636306206052" LOG_CI_START="-0.36484930415559036" LOG_EFFECT_SIZE="-0.18933297023089823" ORDER="66689" O_E="0.0" SE="0.2061983267344585" STUDY_ID="STD-Van-der-Linden-2005" TOTAL_1="37" TOTAL_2="38" VAR="0.0425177499480905" WEIGHT="1.1519130262052433"/>
<DICH_DATA CI_END="0.9361707678459628" CI_START="0.3957722348326828" EFFECT_SIZE="0.6086956521739131" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="23" LOG_CI_END="-0.028644923944956005" LOG_CI_START="-0.40255467673375367" LOG_EFFECT_SIZE="-0.21559980033935483" ORDER="66688" O_E="0.0" SE="0.21963643967126673" STUDY_ID="STD-Vedrinne-1992" TOTAL_1="30" TOTAL_2="30" VAR="0.04824016563146998" WEIGHT="1.089469815006737"/>
<DICH_DATA CI_END="0.9740335218944856" CI_START="0.3695971359382001" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="-0.011426096382906073" LOG_CI_START="-0.4322714028498067" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="66687" O_E="0.0" SE="0.24720661623652213" STUDY_ID="STD-Wendel-1995" TOTAL_1="20" TOTAL_2="18" VAR="0.06111111111111113" WEIGHT="0.9710709473504695"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="961.520760130184" CI_END="0.7170808096922968" CI_START="0.6037823987386717" CI_STUDY="95" CI_TOTAL="95" DF="107" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6579975466257332" ESTIMABLE="YES" EVENTS_1="2695" EVENTS_2="3067" I2="88.87179513570639" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.1444318998051568" LOG_CI_START="-0.21911955153499446" LOG_EFFECT_SIZE="-0.18177572567007563" METHOD="MH" MODIFIED="2011-02-10 17:14:37 +0000" MODIFIED_BY="Emma M Sydenham" NO="6" P_CHI2="-4.440892098500626E-16" P_Q="0.0" P_Z="1.423251039856203E-21" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="108" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.11851430400953716" TOTALS="YES" TOTAL_1="6259" TOTAL_2="4913" WEIGHT="100.0" Z="9.540368918431277">
<NAME>Trial Methodological Quality - Allocation Concealment</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="665.704997263645" CI_END="0.786669322079451" CI_START="0.5264302875644045" DF="32" EFFECT_SIZE="0.6435266563557258" ESTIMABLE="YES" EVENTS_1="654" EVENTS_2="692" I2="95.19306597794296" ID="CMP-001.06.01" LOG_CI_END="-0.10420778578026813" LOG_CI_START="-0.27865913203906345" LOG_EFFECT_SIZE="-0.19143345890966582" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.9984014443252818E-15" P_Z="1.6963302826552324E-5" STUDIES="33" TAU2="0.2485429285603966" TOTAL_1="1553" TOTAL_2="1202" WEIGHT="32.23260728547762" Z="4.30151664570438">
<NAME>Allocation concealment - Yes</NAME>
<DICH_DATA CI_END="1.0093613198140765" CI_START="0.8702995983750681" EFFECT_SIZE="0.9372549019607843" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="25" LOG_CI_END="0.004046657923747294" LOG_CI_START="-0.060331216895382254" LOG_EFFECT_SIZE="-0.028142279485817483" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2839" O_E="0.0" SE="0.03781588234437657" STUDY_ID="STD-Bailey-1994" TOTAL_1="129" TOTAL_2="25" VAR="0.0014300409574837317" WEIGHT="1.604696985623743"/>
<DICH_DATA CI_END="0.39482790023923114" CI_START="0.11321905262835025" EFFECT_SIZE="0.21142857142857144" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="35" LOG_CI_END="-0.40359216580023544" LOG_CI_START="-0.9460804834383635" LOG_EFFECT_SIZE="-0.6748363246192994" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2828" O_E="0.0" SE="0.3186603231411177" STUDY_ID="STD-Bidstrup-1989" TOTAL_1="40" TOTAL_2="37" VAR="0.10154440154440156" WEIGHT="0.8746499181965574"/>
<DICH_DATA CI_END="0.7811089758395658" CI_START="0.21508479595057134" EFFECT_SIZE="0.40988372093023256" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="24" LOG_CI_END="-0.10728837162309306" LOG_CI_START="-0.6673902882092073" LOG_EFFECT_SIZE="-0.3873393299161502" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2829" O_E="0.0" SE="0.3290066383518857" STUDY_ID="STD-Bidstrup-1993" TOTAL_1="43" TOTAL_2="47" VAR="0.10824536807960852" WEIGHT="0.8488031713836913"/>
<DICH_DATA CI_END="0.8902876187799331" CI_START="0.3588398767925144" EFFECT_SIZE="0.5652173913043478" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="23" LOG_CI_END="-0.05046966631041668" LOG_CI_START="-0.4450993011110956" LOG_EFFECT_SIZE="-0.24778448371075615" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2830" O_E="0.0" SE="0.23180740093011587" STUDY_ID="STD-Bidstrup-2000" TOTAL_1="30" TOTAL_2="30" VAR="0.053734671125975485" WEIGHT="1.117419297617117"/>
<DICH_DATA CI_END="1.174017116620848" CI_START="0.8517763377064567" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.06967442876831904" LOG_CI_START="-0.06967442876831907" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2837" O_E="0.0" SE="0.0818542087049908" STUDY_ID="STD-Capdevila-1998" TOTAL_1="12" TOTAL_2="11" VAR="0.006700111482720192" WEIGHT="1.537157906735542"/>
<DICH_DATA CI_END="0.7537424083054954" CI_START="0.31088474574670794" EFFECT_SIZE="0.4840733590733591" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="37" LOG_CI_END="-0.12277704904434342" LOG_CI_START="-0.507400587061211" LOG_EFFECT_SIZE="-0.3150888180527773" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2826" O_E="0.0" SE="0.22592977014832727" STUDY_ID="STD-Cohen-1998" TOTAL_1="56" TOTAL_2="59" VAR="0.05104426103927599" WEIGHT="1.1351495499845883"/>
<DICH_DATA CI_END="0.8525208268207006" CI_START="0.3155703671806873" EFFECT_SIZE="0.5186813186813187" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="39" LOG_CI_END="-0.06929500252570277" LOG_CI_START="-0.5009037848483089" LOG_EFFECT_SIZE="-0.2850993936870058" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2825" O_E="0.0" SE="0.2535291352342283" STUDY_ID="STD-Colwell-2007" TOTAL_1="175" TOTAL_2="177" VAR="0.06427702241261564" WEIGHT="1.0529729860741712"/>
<DICH_DATA CI_END="1.5918330412997033" CI_START="0.8846618996705448" EFFECT_SIZE="1.1866903733807468" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="31" LOG_CI_END="0.20189751500676237" LOG_CI_START="-0.05322267637853529" LOG_EFFECT_SIZE="0.07433741931411353" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2846" O_E="0.0" SE="0.14985886328503842" STUDY_ID="STD-D_x0027_Ambra-1996" TOTAL_1="127" TOTAL_2="64" VAR="0.022457678905083836" WEIGHT="1.3653374580661461"/>
<DICH_DATA CI_END="2.314529531862027" CI_START="0.432053247208086" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.3644627264637834" LOG_CI_START="-0.3644627264637834" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2843" O_E="0.0" SE="0.42817441928883765" STUDY_ID="STD-Deleuze-1991" TOTAL_1="30" TOTAL_2="30" VAR="0.18333333333333335" WEIGHT="0.6376539187303959"/>
<DICH_DATA CI_END="0.9323483780122118" CI_START="0.25881421861080883" EFFECT_SIZE="0.49122807017543857" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.030421780373552382" LOG_CI_START="-0.587011868286992" LOG_EFFECT_SIZE="-0.3087168243302722" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2849" O_E="0.0" SE="0.32694377280572434" STUDY_ID="STD-Dietrich-1990" TOTAL_1="19" TOTAL_2="20" VAR="0.10689223057644108" WEIGHT="0.8538986199522803"/>
<DICH_DATA CI_END="1.020610877852942" CI_START="0.5393517492042281" EFFECT_SIZE="0.7419354838709677" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.008860192809001107" LOG_CI_START="-0.26812790844236073" LOG_EFFECT_SIZE="-0.1296338578166798" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2824" O_E="0.0" SE="0.16270418178826412" STUDY_ID="STD-Dietrich-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.026472650771388495" WEIGHT="1.3275285980178027"/>
<DICH_DATA CI_END="1.1465948472003975" CI_START="0.06538635291433063" EFFECT_SIZE="0.27380952380952384" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.05940998572274674" LOG_CI_START="-1.1845128858113243" LOG_EFFECT_SIZE="-0.5625514500442887" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2852" O_E="0.0" SE="0.7306864522566346" STUDY_ID="STD-Englberger-2002a" TOTAL_1="21" TOTAL_2="23" VAR="0.5339026915113871" WEIGHT="0.29501734340551794"/>
<DICH_DATA CI_END="1.6182854246331981" CI_START="0.7470899207455475" EFFECT_SIZE="1.0995475113122173" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.20905512259825326" LOG_CI_START="-0.1266271227718502" LOG_EFFECT_SIZE="0.04121399991320153" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2832" O_E="0.0" SE="0.1971814125843122" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="27" VAR="0.03888050946874476" WEIGHT="1.2228759293758513"/>
<DICH_DATA CI_END="1.3438135911295888" CI_START="0.7963564179938953" EFFECT_SIZE="1.0344827586206897" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="29" LOG_CI_END="0.12833902916533568" LOG_CI_START="-0.09889251552392286" LOG_EFFECT_SIZE="0.014723256820706378" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2834" O_E="0.0" SE="0.13347693416475745" STUDY_ID="STD-Harder-1991" TOTAL_1="40" TOTAL_2="40" VAR="0.01781609195402299" WEIGHT="1.4118225612917559"/>
<DICH_DATA CI_END="1.2371304328257535" CI_START="0.6806192486246042" EFFECT_SIZE="0.9176136363636364" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.09241549047004377" LOG_CI_START="-0.1670957727641001" LOG_EFFECT_SIZE="-0.03734014114702813" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2835" O_E="0.0" SE="0.1524382006252069" STUDY_ID="STD-Hardy-1993" TOTAL_1="22" TOTAL_2="19" VAR="0.02323740500985083" WEIGHT="1.3578272187523837"/>
<DICH_DATA CI_END="1.216920975501839" CI_START="0.8217460460714104" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" LOG_CI_END="0.08526237690073346" LOG_CI_START="-0.08526237690073346" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2841" O_E="0.0" SE="0.10016708449412663" STUDY_ID="STD-Hardy-1997" TOTAL_1="26" TOTAL_2="26" VAR="0.010033444816053505" WEIGHT="1.4972983235384043"/>
<DICH_DATA CI_END="3.0394125886228682" CI_START="0.20748181399616164" EFFECT_SIZE="0.7941176470588235" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.48278965789495476" LOG_CI_START="-0.6830199636614904" LOG_EFFECT_SIZE="-0.10011515288326783" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2838" O_E="0.0" SE="0.6848023425529537" STUDY_ID="STD-Harmon-2004" TOTAL_1="17" TOTAL_2="18" VAR="0.46895424836601296" WEIGHT="0.3276334163469401"/>
<DICH_DATA CI_END="1.0497678264256392" CI_START="0.4997731056344701" EFFECT_SIZE="0.7243243243243244" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="35" LOG_CI_END="0.021093258258824937" LOG_CI_START="-0.30122711833523724" LOG_EFFECT_SIZE="-0.14006693003820614" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2854" O_E="0.0" SE="0.18933258472294834" STUDY_ID="STD-Lemmer_x005f_1-1994" TOTAL_1="74" TOTAL_2="67" VAR="0.035846827637872405" WEIGHT="1.2469092883488382"/>
<DICH_DATA CI_END="0.8150022791529388" CI_START="0.22000161521551823" EFFECT_SIZE="0.42344045368620037" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="23" LOG_CI_END="-0.08884117675430474" LOG_CI_START="-0.6575741306477412" LOG_EFFECT_SIZE="-0.37320765370102293" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2855" O_E="0.0" SE="0.33407655239053047" STUDY_ID="STD-Lemmer_x005f_2-1994" TOTAL_1="23" TOTAL_2="32" VAR="0.11160714285714285" WEIGHT="0.8364032619814965"/>
<DICH_DATA CI_END="0.7532478029295167" CI_START="0.08297402230305383" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.12306212640134118" LOG_CI_START="-1.0810578562545836" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2844" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Liu-1993" TOTAL_1="20" TOTAL_2="20" VAR="0.31666666666666665" WEIGHT="0.44228571969063235"/>
<DICH_DATA CI_END="0.581965375170908" CI_START="0.011932745040725218" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.23510285352801047" LOG_CI_START="-1.9232596385672394" LOG_EFFECT_SIZE="-1.0791812460476249" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2827" O_E="0.0" SE="0.991631652042901" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.9833333333333332" WEIGHT="0.1746832522828191"/>
<DICH_DATA CI_END="0.851080315601441" CI_START="0.17407565969356745" EFFECT_SIZE="0.3849056603773585" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="-0.07002945404391975" LOG_CI_START="-0.7592619503058609" LOG_EFFECT_SIZE="-0.4146457021748903" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2842" O_E="0.0" SE="0.4048585800601448" STUDY_ID="STD-Murkin-2000" TOTAL_1="212" TOTAL_2="68" VAR="0.1639104698483167" WEIGHT="0.6815065342251679"/>
<DICH_DATA CI_END="0.8534432320457009" CI_START="0.10136021596195216" EFFECT_SIZE="0.29411764705882354" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.06882536128531151" LOG_CI_START="-0.9941324727991987" LOG_EFFECT_SIZE="-0.5314789170422551" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2845" O_E="0.0" SE="0.5435299776473301" STUDY_ID="STD-Norman-2009" TOTAL_1="8" TOTAL_2="8" VAR="0.29542483660130725" WEIGHT="0.46498219165059146"/>
<DICH_DATA CI_END="1.3461324819232787" CI_START="0.39949840375995604" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.12908780382323215" LOG_CI_START="-0.39848495161814457" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2853" O_E="0.0" SE="0.3098988480735223" STUDY_ID="STD-Palmer-2003" TOTAL_1="30" TOTAL_2="26" VAR="0.09603729603729605" WEIGHT="0.8971004120648771"/>
<DICH_DATA CI_END="1.0650367118693163" CI_START="0.331144696158032" EFFECT_SIZE="0.5938697318007663" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" LOG_CI_END="0.027364578185526574" LOG_CI_START="-0.4799821965215054" LOG_EFFECT_SIZE="-0.22630880916798943" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2833" O_E="0.0" SE="0.29801800686994884" STUDY_ID="STD-Poston-2006" TOTAL_1="29" TOTAL_2="31" VAR="0.08881473241873687" WEIGHT="0.9283520153617254"/>
<DICH_DATA CI_END="1.0307774244809154" CI_START="0.970141541956631" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="62" LOG_CI_END="0.013164898304624488" LOG_CI_START="-0.01316489830462447" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2836" O_E="0.0" SE="0.015466252862868035" STUDY_ID="STD-Ranaboldo-1997" TOTAL_1="66" TOTAL_2="62" VAR="2.3920497761817372E-4" WEIGHT="1.6207885598733023"/>
<DICH_DATA CI_END="1.1628512108432862" CI_START="0.7528113445654874" EFFECT_SIZE="0.9356321839080459" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="29" LOG_CI_END="0.06552414942872957" LOG_CI_START="-0.12331384488756425" LOG_EFFECT_SIZE="-0.028894847729417316" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2831" O_E="0.0" SE="0.11092437262453853" STUDY_ID="STD-Speekenbrink-1996" TOTAL_1="75" TOTAL_2="37" VAR="0.012304216442147471" WEIGHT="1.4713079474269055"/>
<DICH_DATA CI_END="0.7716992950035634" CI_START="0.015998043658039977" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.11255189650552387" LOG_CI_START="-1.7959331223731259" LOG_EFFECT_SIZE="-0.9542425094393249" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2847" O_E="0.0" SE="0.9888264649460884" STUDY_ID="STD-Stewart-2001" TOTAL_1="15" TOTAL_2="15" VAR="0.9777777777777779" WEIGHT="0.1755684748697597"/>
<DICH_DATA CI_END="0.9849542929885672" CI_START="0.6267772455738472" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="42" LOG_CI_END="-0.006583922561699111" LOG_CI_START="-0.20288677847832687" LOG_EFFECT_SIZE="-0.104735350520013" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2848" O_E="0.0" SE="0.11530926928023555" STUDY_ID="STD-Swart-1994" TOTAL_1="49" TOTAL_2="49" VAR="0.013296227581941874" WEIGHT="1.4602348271208654"/>
<DICH_DATA CI_END="1.26102060903135" CI_START="0.4408653477494194" EFFECT_SIZE="0.7456140350877193" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.10072218436487669" LOG_CI_START="-0.3556940356092364" LOG_EFFECT_SIZE="-0.12748592562217986" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2856" O_E="0.0" SE="0.26810114690952036" STUDY_ID="STD-Tabuchi-1994" TOTAL_1="19" TOTAL_2="17" VAR="0.07187822497420022" WEIGHT="1.0109342516671609"/>
<DICH_DATA CI_END="0.7975135540067488" CI_START="0.32428296497632014" EFFECT_SIZE="0.5085470085470085" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="26" LOG_CI_END="-0.09826192722963079" LOG_CI_START="-0.48907586480559345" LOG_EFFECT_SIZE="-0.2936688960176121" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2851" O_E="0.0" SE="0.22956604149231166" STUDY_ID="STD-Taggart-2003" TOTAL_1="36" TOTAL_2="34" VAR="0.05270056740644976" WEIGHT="1.1241682875989987"/>
<DICH_DATA CI_END="1.3454053931997747" CI_START="0.022094839371514755" EFFECT_SIZE="0.1724137931034483" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.1288531642656234" LOG_CI_START="-1.6557091513914979" LOG_EFFECT_SIZE="-0.7634279935629372" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2840" O_E="0.0" SE="1.048260737942924" STUDY_ID="STD-Vanek-2005" TOTAL_1="29" TOTAL_2="30" VAR="1.0988505747126436" WEIGHT="0.15810734495086254"/>
<DICH_DATA CI_END="0.9740335218944856" CI_START="0.3695971359382001" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="-0.011426096382906073" LOG_CI_START="-0.4322714028498067" LOG_EFFECT_SIZE="-0.22184874961635637" MODIFIED="2010-08-23 06:37:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2850" O_E="0.0" SE="0.24720661623652213" STUDY_ID="STD-Wendel-1995" TOTAL_1="20" TOTAL_2="18" VAR="0.06111111111111113" WEIGHT="1.0715317132707212"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="179.311753252351" CI_END="0.7459662107795761" CI_START="0.6356912248936071" DF="62" EFFECT_SIZE="0.6886248429004805" ESTIMABLE="YES" EVENTS_1="1866" EVENTS_2="2105" I2="65.42334851149134" ID="CMP-001.06.02" LOG_CI_END="-0.12728084384679456" LOG_CI_START="-0.19675378354608522" LOG_EFFECT_SIZE="-0.16201731369643985" MODIFIED="2011-02-10 17:14:37 +0000" MODIFIED_BY="Emma M Sydenham" NO="2" P_CHI2="2.4702462297909733E-13" P_Z="6.151562252656225E-20" STUDIES="63" TAU2="0.040273059953395876" TOTAL_1="4233" TOTAL_2="3256" WEIGHT="56.53367015397649" Z="9.141634169834687">
<NAME>Allocation concealment - Unclear</NAME>
<DICH_DATA CI_END="0.8207319356942484" CI_START="0.6020493368181332" EFFECT_SIZE="0.702937491950874" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="213" LOG_CI_END="-0.08579866731277815" LOG_CI_START="-0.22036791766259636" LOG_EFFECT_SIZE="-0.1530832924876873" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2890" O_E="0.0" SE="0.07904664378401566" STUDY_ID="STD-Alderman-1998" TOTAL_1="401" TOTAL_2="395" VAR="0.0062483718935170615" WEIGHT="1.5427236344365787"/>
<DICH_DATA CI_END="0.8731188140017339" CI_START="0.5154136572187269" EFFECT_SIZE="0.6708333333333333" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="-0.05892665348310755" LOG_CI_START="-0.28784407787640515" LOG_EFFECT_SIZE="-0.17338536567975632" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2884" O_E="0.0" SE="0.1344672282481491" STUDY_ID="STD-Basora-1999" TOTAL_1="36" TOTAL_2="21" VAR="0.018081435472739826" WEIGHT="1.4090800309051068"/>
<DICH_DATA CI_END="0.9372502510926616" CI_START="0.4494540535626551" EFFECT_SIZE="0.6490384615384616" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="-0.028144434557366343" LOG_CI_START="-0.3473146983781445" LOG_EFFECT_SIZE="-0.1877295664677554" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2858" O_E="0.0" SE="0.1874821928866116" STUDY_ID="STD-Bidstrup-1990" TOTAL_1="26" TOTAL_2="18" VAR="0.035149572649572636" WEIGHT="1.2525671810179608"/>
<DICH_DATA CI_END="0.9779863575014763" CI_START="0.11361212787770752" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="-0.009667203395581254" LOG_CI_START="-0.9445753060437436" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2873" O_E="0.0" SE="0.5491696473652761" STUDY_ID="STD-Blauhut-1994" TOTAL_1="14" TOTAL_2="14" VAR="0.3015873015873016" WEIGHT="0.4581613739317761"/>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516804" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-02-10 17:14:37 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="2876" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Boldt-1991" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="0.07393296456220094"/>
<DICH_DATA CI_END="0.9593385583155755" CI_START="0.7355067654519231" EFFECT_SIZE="0.84" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="50" LOG_CI_END="-0.018028099752735213" LOG_CI_START="-0.13341332812350148" LOG_EFFECT_SIZE="-0.07572071393811836" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2893" O_E="0.0" SE="0.06777785431108017" STUDY_ID="STD-Carrera-1994" TOTAL_1="51" TOTAL_2="51" VAR="0.004593837535014009" WEIGHT="1.5634573505566154"/>
<DICH_DATA CI_END="0.9357484130358864" CI_START="0.3431596641124053" EFFECT_SIZE="0.5666666666666667" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="-0.028840900746099345" LOG_CI_START="-0.46450376593667775" LOG_EFFECT_SIZE="-0.2466723333413885" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2881" O_E="0.0" SE="0.2559105235789091" STUDY_ID="STD-Cicek-1996a" TOTAL_1="50" TOTAL_2="25" VAR="0.06549019607843137" WEIGHT="1.0460305520744058"/>
<DICH_DATA CI_END="1.0138017822726142" CI_START="0.3434056028344289" EFFECT_SIZE="0.5900383141762452" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" LOG_CI_END="0.005953050381643381" LOG_CI_START="-0.4641926233852791" LOG_EFFECT_SIZE="-0.2291197865018179" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2880" O_E="0.0" SE="0.27616589602930897" STUDY_ID="STD-Cicek-1996b" TOTAL_1="29" TOTAL_2="28" VAR="0.0762676021296711" WEIGHT="0.9881530200943497"/>
<DICH_DATA CI_END="2.4702082767769804" CI_START="0.15813443897519056" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.392733572547735" LOG_CI_START="-0.8009735378595846" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2883" O_E="0.0" SE="0.7011894655987543" STUDY_ID="STD-Cicekcioglu-2006" TOTAL_1="24" TOTAL_2="20" VAR="0.49166666666666664" WEIGHT="0.3154381045313366"/>
<DICH_DATA CI_END="1.0006396605496894" CI_START="0.3378044714556414" EFFECT_SIZE="0.5813953488372093" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="2.7771223570681805E-4" LOG_CI_START="-0.4713346060508047" LOG_EFFECT_SIZE="-0.23552844690754887" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2872" O_E="0.0" SE="0.277027410280123" STUDY_ID="STD-Corbeau-1995" TOTAL_1="43" TOTAL_2="20" VAR="0.0767441860465116" WEIGHT="0.985741151413919"/>
<DICH_DATA CI_END="0.7824570437156144" CI_START="0.4904318747402467" EFFECT_SIZE="0.6194690265486725" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="44" LOG_CI_END="-0.10653949555704548" LOG_CI_START="-0.3094213113812804" LOG_EFFECT_SIZE="-0.2079804034691629" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2878" O_E="0.0" SE="0.11917378289634074" STUDY_ID="STD-Cosgrove-1992" TOTAL_1="113" TOTAL_2="56" VAR="0.014202390529824159" WEIGHT="1.450264636858541"/>
<DICH_DATA CI_END="0.9968014774159336" CI_START="0.30347065775242266" EFFECT_SIZE="0.55" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="-0.0013913269919762872" LOG_CI_START="-0.5178832940195359" LOG_EFFECT_SIZE="-0.2596373105057561" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2887" O_E="0.0" SE="0.30338993810845893" STUDY_ID="STD-Cvachovec-2001" TOTAL_1="20" TOTAL_2="22" VAR="0.09204545454545456" WEIGHT="0.9141078529538892"/>
<DICH_DATA CI_END="70.82882080128427" CI_START="0.12706691849706478" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8502100114756685" LOG_CI_START="-0.895967502036344" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2911" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-D_x0027_Ambrosio-1999" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="0.07074532881267774"/>
<DICH_DATA CI_END="1.3254060928964186" CI_START="0.40235538574672136" EFFECT_SIZE="0.7302631578947368" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.12234896271291117" LOG_CI_START="-0.3953901810291414" LOG_EFFECT_SIZE="-0.13652060915811512" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2915" O_E="0.0" SE="0.30412253588417626" STUDY_ID="STD-Desai-2009" TOTAL_1="38" TOTAL_2="37" VAR="0.09249051683262208" WEIGHT="0.9121797693673167"/>
<DICH_DATA CI_END="0.7811464089683755" CI_START="0.6922940885893394" EFFECT_SIZE="0.7353795219147709" ESTIMABLE="YES" EVENTS_1="549" EVENTS_2="730" LOG_CI_END="-0.10726755940321708" LOG_CI_START="-0.1597093767577549" LOG_EFFECT_SIZE="-0.13348846808048598" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2918" O_E="0.0" SE="0.03080458310523803" STUDY_ID="STD-Dietrich-1992" TOTAL_1="902" TOTAL_2="882" VAR="9.489223402875163E-4" WEIGHT="1.61115964043671"/>
<DICH_DATA CI_END="0.8485647549882042" CI_START="0.46077627889680506" EFFECT_SIZE="0.6252987367702287" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="58" LOG_CI_END="-0.07131501055197918" LOG_CI_START="-0.33650988681009075" LOG_EFFECT_SIZE="-0.20391244868103495" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2905" O_E="0.0" SE="0.15577678304982373" STUDY_ID="STD-Dignan-2001" TOTAL_1="101" TOTAL_2="99" VAR="0.02426640613735185" WEIGHT="1.3480415429589914"/>
<DICH_DATA CI_END="5.461059148182932" CI_START="0.5086518388474208" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7372768803609144" LOG_CI_START="-0.2935793811282016" LOG_EFFECT_SIZE="0.22184874961635637" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2892" O_E="0.0" SE="0.6055300708194984" STUDY_ID="STD-Engel-2001" TOTAL_1="12" TOTAL_2="12" VAR="0.3666666666666667" WEIGHT="0.3967062610533519"/>
<DICH_DATA CI_END="1.0732934239859022" CI_START="0.06625505152824374" EFFECT_SIZE="0.26666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.030718468468461112" LOG_CI_START="-1.1787810039238988" LOG_EFFECT_SIZE="-0.5740312677277188" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2896" O_E="0.0" SE="0.7104659772022196" STUDY_ID="STD-Englberger-2002b" TOTAL_1="15" TOTAL_2="14" VAR="0.5047619047619047" WEIGHT="0.3088106462311222"/>
<DICH_DATA CI_END="0.9468374527500885" CI_START="0.399961179980938" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="26" LOG_CI_END="-0.02372457161220413" LOG_CI_START="-0.3979821590175822" LOG_EFFECT_SIZE="-0.21085336531489315" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2895" O_E="0.0" SE="0.2198407594468552" STUDY_ID="STD-Fraedrich-1989" TOTAL_1="38" TOTAL_2="38" VAR="0.048329959514170046" WEIGHT="1.1536167006655507"/>
<DICH_DATA CI_END="1.176699175298307" CI_START="0.3968256749445487" EFFECT_SIZE="0.6833333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" LOG_CI_END="0.07066544907408982" LOG_CI_START="-0.4014002364019061" LOG_EFFECT_SIZE="-0.16536739366390812" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2869" O_E="0.0" SE="0.2772937204114299" STUDY_ID="STD-Garcia_x002d_Huete-1997" TOTAL_1="39" TOTAL_2="41" VAR="0.07689180737961226" WEIGHT="0.9849964642501993"/>
<DICH_DATA CI_END="0.720649865502474" CI_START="0.1158076815365343" EFFECT_SIZE="0.28888888888888886" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.14227569008565652" LOG_CI_START="-0.9362626328513574" LOG_EFFECT_SIZE="-0.539269161468507" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2907" O_E="0.0" SE="0.4663918604793264" STUDY_ID="STD-Gherli-1992" TOTAL_1="18" TOTAL_2="13" VAR="0.21752136752136747" WEIGHT="0.5727794550332174"/>
<DICH_DATA CI_END="0.9036903622073366" CI_START="0.15561192846686125" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="-0.04398034941401264" LOG_CI_START="-0.8079571151305497" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2864" O_E="0.0" SE="0.44876373392787533" STUDY_ID="STD-Green-1995" TOTAL_1="48" TOTAL_2="36" VAR="0.2013888888888889" WEIGHT="0.6016642943364"/>
<DICH_DATA CI_END="1.1620394238299383" CI_START="0.27073602422146403" EFFECT_SIZE="0.5608974358974359" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.06522086235840659" LOG_CI_START="-0.5674539530227032" LOG_EFFECT_SIZE="-0.25111654533214833" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2857" O_E="0.0" SE="0.3716363183457089" STUDY_ID="STD-Greilich-2001" TOTAL_1="24" TOTAL_2="25" VAR="0.1381135531135531" WEIGHT="0.7500133889162057"/>
<DICH_DATA CI_END="0.9067145062236663" CI_START="0.6096295146835113" EFFECT_SIZE="0.7434782608695653" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="46" LOG_CI_END="-0.04252943608158775" LOG_CI_START="-0.21493401516929028" LOG_EFFECT_SIZE="-0.12873172562543903" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2877" O_E="0.0" SE="0.10127130317254668" STUDY_ID="STD-Hayashida-1997" TOTAL_1="110" TOTAL_2="57" VAR="0.010255876846265864" WEIGHT="1.4947119552990744"/>
<DICH_DATA CI_END="0.7804173827907901" CI_START="0.45795498425174797" EFFECT_SIZE="0.5978260869565217" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="46" LOG_CI_END="-0.10767306582026084" LOG_CI_START="-0.33917720988236205" LOG_EFFECT_SIZE="-0.22342513785131143" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2882" O_E="0.0" SE="0.13598668018607324" STUDY_ID="STD-Isetta-1993" TOTAL_1="140" TOTAL_2="70" VAR="0.01849237718802936" WEIGHT="1.404853596399731"/>
<DICH_DATA CI_END="1.3299782792134183" CI_START="0.575667296200363" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.12384454826424007" LOG_CI_START="-0.23982844221961358" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2865" O_E="0.0" SE="0.2136233148205519" STUDY_ID="STD-Jeserschek-2003" TOTAL_1="9" TOTAL_2="9" VAR="0.04563492063492064" WEIGHT="1.17255703904838"/>
<DICH_DATA CI_END="0.7620123531650056" CI_START="0.5126229232079317" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="48" LOG_CI_END="-0.11803798815133151" LOG_CI_START="-0.29020197716051804" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2862" O_E="0.0" SE="0.10112997936948631" STUDY_ID="STD-Kalangos-1994" TOTAL_1="110" TOTAL_2="55" VAR="0.010227272727272727" WEIGHT="1.4950440540640075"/>
<DICH_DATA CI_END="1.1831785640385561" CI_START="0.023477249015536238" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.07305029283121232" LOG_CI_START="-1.6293527935984997" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2868" O_E="0.0" SE="1.0" STUDY_ID="STD-Katzel-1998" TOTAL_1="12" TOTAL_2="12" VAR="1.0000000000000002" WEIGHT="0.17208034633194247"/>
<DICH_DATA CI_END="2.410392969374453" CI_START="0.26551687136977226" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.38208785191856476" LOG_CI_START="-0.5759078779346776" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2874" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Kipfer-2003" TOTAL_1="15" TOTAL_2="15" VAR="0.3166666666666667" WEIGHT="0.4422857196906323"/>
<DICH_DATA CI_END="1.7248117563970482" CI_START="0.1672117424292004" EFFECT_SIZE="0.5370370370370371" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.23674170368809447" LOG_CI_START="-0.7767332275361192" LOG_EFFECT_SIZE="-0.26999576192401237" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2901" O_E="0.0" SE="0.5953201913829222" STUDY_ID="STD-Klein-1998" TOTAL_1="36" TOTAL_2="29" VAR="0.35440613026819917" WEIGHT="0.40699093306286827"/>
<DICH_DATA CI_END="1.0237823367364247" CI_START="0.10853001377744706" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.010207632418683592" LOG_CI_START="-0.9644501418580085" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2888" O_E="0.0" SE="0.5725188012439223" STUDY_ID="STD-Kyriss-2001" TOTAL_1="18" TOTAL_2="20" VAR="0.3277777777777778" WEIGHT="0.4312743529761265"/>
<DICH_DATA CI_END="0.8548579066310278" CI_START="0.4535633977347247" EFFECT_SIZE="0.6226815050344462" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="37" LOG_CI_END="-0.06810606713672084" LOG_CI_START="-0.34336199997763184" LOG_EFFECT_SIZE="-0.2057340335571763" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2909" O_E="0.0" SE="0.16168669748959338" STUDY_ID="STD-Lass-1995" TOTAL_1="51" TOTAL_2="47" VAR="0.026142588145091284" WEIGHT="1.330557610801224"/>
<DICH_DATA CI_END="1.5757982109905528" CI_START="0.20721600644516502" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.19750060308743156" LOG_CI_START="-0.6835767004600205" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2912" O_E="0.0" SE="0.5175491695067657" STUDY_ID="STD-Laub-1994" TOTAL_1="16" TOTAL_2="16" VAR="0.26785714285714285" WEIGHT="0.4981587805519368"/>
<DICH_DATA CI_END="0.7708713825665181" CI_START="0.5331054961218116" EFFECT_SIZE="0.6410583209421983" ESTIMABLE="YES" EVENTS_1="173" EVENTS_2="87" LOG_CI_END="-0.11301807655504825" LOG_CI_START="-0.2731868400353992" LOG_EFFECT_SIZE="-0.1931024582952237" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2860" O_E="0.0" SE="0.09408392451652427" STUDY_ID="STD-Lemmer-1996" TOTAL_1="487" TOTAL_2="157" VAR="0.008851784852431035" WEIGHT="1.5111897564805103"/>
<DICH_DATA CI_END="0.8864387002945626" CI_START="0.20841729216507215" EFFECT_SIZE="0.4298245614035088" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" LOG_CI_END="-0.052351291697907774" LOG_CI_START="-0.6810662509180101" LOG_EFFECT_SIZE="-0.3667087713079589" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2903" O_E="0.0" SE="0.369310279235129" STUDY_ID="STD-Lentschener-1997" TOTAL_1="48" TOTAL_2="49" VAR="0.13639008234872896" WEIGHT="0.7550844124772008"/>
<DICH_DATA CI_END="1.1223523647028855" CI_START="0.17286841501668593" EFFECT_SIZE="0.44047619047619047" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.05012922592328552" LOG_CI_START="-0.7622843499130588" LOG_EFFECT_SIZE="-0.35607756199488666" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2913" O_E="0.0" SE="0.4772157559583272" STUDY_ID="STD-Lentschener-1999" TOTAL_1="35" TOTAL_2="37" VAR="0.22773487773487772" WEIGHT="0.5558838517437088"/>
<DICH_DATA CI_END="0.925107108046671" CI_START="0.6394106016052801" EFFECT_SIZE="0.769105514546244" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="49" LOG_CI_END="-0.03380798213586703" LOG_CI_START="-0.19422016728156163" LOG_EFFECT_SIZE="-0.11401407470871433" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2894" O_E="0.0" SE="0.09422691160770381" STUDY_ID="STD-Levy-1995" TOTAL_1="188" TOTAL_2="65" VAR="0.008878710871126027" WEIGHT="1.5108703486725332"/>
<DICH_DATA CI_END="0.7917906433240165" CI_START="0.12333594849015803" EFFECT_SIZE="0.3125" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.10138963465852775" LOG_CI_START="-0.9089103219812843" LOG_EFFECT_SIZE="-0.505149978319906" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2889" O_E="0.0" SE="0.4743416490252569" STUDY_ID="STD-Li-2005" TOTAL_1="40" TOTAL_2="30" VAR="0.22499999999999998" WEIGHT="0.5603095025872606"/>
<DICH_DATA CI_END="2.4521888362810533" CI_START="0.008322427279400224" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3895539109512145" LOG_CI_START="-2.079749990979728" LOG_EFFECT_SIZE="-0.8450980400142569" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2906" O_E="0.0" SE="1.4504813352456845" STUDY_ID="STD-Llau-1998" TOTAL_1="10" TOTAL_2="10" VAR="2.103896103896104" WEIGHT="0.08660611385121124"/>
<DICH_DATA CI_END="1.1257994302155443" CI_START="0.3587946958901859" EFFECT_SIZE="0.6355555555555555" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.05146102452110328" LOG_CI_START="-0.4451539858137047" LOG_EFFECT_SIZE="-0.1968464806463007" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2871" O_E="0.0" SE="0.29171411535461406" STUDY_ID="STD-Locatelli-1990" TOTAL_1="25" TOTAL_2="13" VAR="0.08509712509712508" WEIGHT="0.9453021849297306"/>
<DICH_DATA CI_END="1.3225611225787064" CI_START="0.14449806862033407" EFFECT_SIZE="0.4371584699453552" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.12141575222725745" LOG_CI_START="-0.8401379577042294" LOG_EFFECT_SIZE="-0.3593611027384859" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2870" O_E="0.0" SE="0.564821408981384" STUDY_ID="STD-Maccario-1994" TOTAL_1="61" TOTAL_2="32" VAR="0.31902322404371586" WEIGHT="0.43990358876774244"/>
<DICH_DATA CI_END="0.4272576057276957" CI_START="0.028895164993771816" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="18" LOG_CI_END="-0.3693101975453905" LOG_CI_START="-1.5391748213332594" LOG_EFFECT_SIZE="-0.9542425094393249" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2910" O_E="0.0" SE="0.6871842709362768" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.47222222222222227" WEIGHT="0.3258209375319391"/>
<DICH_DATA CI_END="0.8847859245407694" CI_START="0.540868121448187" EFFECT_SIZE="0.6917748917748918" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="16" LOG_CI_END="-0.05316179488080641" LOG_CI_START="-0.266908614947537" LOG_EFFECT_SIZE="-0.1600352049141717" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2904" O_E="0.0" SE="0.12555594017102115" STUDY_ID="STD-Mohr-1992" TOTAL_1="34" TOTAL_2="16" VAR="0.015764294112229044" WEIGHT="1.4333954293792497"/>
<DICH_DATA CI_END="0.8973650634832809" CI_START="0.4380356604107999" EFFECT_SIZE="0.6269592476489029" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" LOG_CI_END="-0.04703084257180927" LOG_CI_START="-0.3584905322145905" LOG_EFFECT_SIZE="-0.2027606873931999" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2916" O_E="0.0" SE="0.18295296344649845" STUDY_ID="STD-Murkin-1994" TOTAL_1="29" TOTAL_2="25" VAR="0.0334717868338558" WEIGHT="1.2663943637416075"/>
<DICH_DATA CI_END="1.2854855901578142" CI_START="0.5973191554248912" EFFECT_SIZE="0.8762677484787018" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.10906721271748547" LOG_CI_START="-0.22379355764212133" LOG_EFFECT_SIZE="-0.05736317246231793" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2917" O_E="0.0" SE="0.19552406419661988" STUDY_ID="STD-Murkin-1995" TOTAL_1="29" TOTAL_2="24" VAR="0.03822965967996394" WEIGHT="1.227953691361736"/>
<DICH_DATA CI_END="1.0403570180709536" CI_START="0.56797137464091" EFFECT_SIZE="0.768695652173913" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="23" LOG_CI_END="0.01718240119376299" LOG_CI_START="-0.24567355187484013" LOG_EFFECT_SIZE="-0.11424557534053863" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2899" O_E="0.0" SE="0.15440288799045002" STUDY_ID="STD-Nur_x00f6_zler-2008" TOTAL_1="25" TOTAL_2="26" VAR="0.023840251819791457" WEIGHT="1.3520770564024212"/>
<DICH_DATA CI_END="1.4043574036065283" CI_START="0.7193914498899935" EFFECT_SIZE="1.005128205128205" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="15" LOG_CI_END="0.14747764815076966" LOG_CI_START="-0.14303472816285362" LOG_EFFECT_SIZE="0.0022214599939580325" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2914" O_E="0.0" SE="0.17064840790607783" STUDY_ID="STD-Okita-1996" TOTAL_1="39" TOTAL_2="21" VAR="0.02912087912087913" WEIGHT="1.3037158537011262"/>
<DICH_DATA CI_END="1.1769979621462765" CI_START="0.7239358378865783" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="52" LOG_CI_END="0.07077571090682193" LOG_CI_START="-0.14029992342524575" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2908" O_E="0.0" SE="0.1239868724478975" STUDY_ID="STD-Parvizi-2007" TOTAL_1="81" TOTAL_2="81" VAR="0.015372744539411204" WEIGHT="1.4375873611167491"/>
<DICH_DATA CI_END="2.5475015595668227" CI_START="0.008011050351928473" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.40611445855130324" LOG_CI_START="-2.0963105385798166" LOG_EFFECT_SIZE="-0.8450980400142569" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2902" O_E="0.0" SE="1.469936830518334" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="2.1607142857142856" WEIGHT="0.08444713693000629"/>
<DICH_DATA CI_END="0.9019134165859846" CI_START="0.5221928115776203" EFFECT_SIZE="0.6862745098039216" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="25" LOG_CI_END="-0.04483515259530587" LOG_CI_START="-0.2821691109000156" LOG_EFFECT_SIZE="-0.16350213174766073" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2875" O_E="0.0" SE="0.1394111419302274" STUDY_ID="STD-Petsatodis-2006" TOTAL_1="25" TOTAL_2="25" VAR="0.01943546649429001" WEIGHT="1.3952493585761558"/>
<DICH_DATA CI_END="1.0902507120596947" CI_START="0.9172202218614527" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.037526378990036593" LOG_CI_START="-0.037526378990036614" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2885" O_E="0.0" SE="0.04408636155463877" STUDY_ID="STD-Pugh-1995" TOTAL_1="21" TOTAL_2="23" VAR="0.0019436072751263314" WEIGHT="1.5978554397837905"/>
<DICH_DATA CI_END="0.7866183929057147" CI_START="0.16610386164783042" EFFECT_SIZE="0.3614697120158888" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="19" LOG_CI_END="-0.10423590302661616" LOG_CI_START="-0.779620270782508" LOG_EFFECT_SIZE="-0.441928086904562" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2866" O_E="0.0" SE="0.3967241208263498" STUDY_ID="STD-Ray-1997" TOTAL_1="53" TOTAL_2="52" VAR="0.15739002804544017" WEIGHT="0.6976125651149251"/>
<DICH_DATA CI_END="0.8889502048802845" CI_START="0.3373491784678522" EFFECT_SIZE="0.5476190476190477" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" LOG_CI_END="-0.05112256563428223" LOG_CI_START="-0.47192034312633274" LOG_EFFECT_SIZE="-0.26152145438030755" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2861" O_E="0.0" SE="0.24717869748142302" STUDY_ID="STD-Ray-1999" TOTAL_1="100" TOTAL_2="50" VAR="0.061097308488612834" WEIGHT="1.071614057321462"/>
<DICH_DATA CI_END="3.436173203095408" CI_START="0.1293428526955729" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5360750466763062" LOG_CI_START="-0.8882575647876688" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2859" O_E="0.0" SE="0.8366600265340756" STUDY_ID="STD-Ray-2005" TOTAL_1="15" TOTAL_2="15" VAR="0.7" WEIGHT="0.2351508432636385"/>
<DICH_DATA CI_END="1.0533410525445912" CI_START="0.6797193839842649" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="26" LOG_CI_END="0.02256901055561178" LOG_CI_START="-0.16767034485283525" LOG_EFFECT_SIZE="-0.07255066714861173" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2919" O_E="0.0" SE="0.11174753906691859" STUDY_ID="STD-Rocha-1994" TOTAL_1="28" TOTAL_2="28" VAR="0.012487512487512495" WEIGHT="1.4692493123981036"/>
<DICH_DATA CI_END="1.9071560686454936" CI_START="1.0494267347438109" EFFECT_SIZE="1.414715719063545" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="26" LOG_CI_END="0.28038623419867686" LOG_CI_START="0.02095212390254852" LOG_EFFECT_SIZE="0.15066917905061267" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2863" O_E="0.0" SE="0.1523928806075034" STUDY_ID="STD-Rodrigus-1996" TOTAL_1="46" TOTAL_2="47" VAR="0.02322359005985278" WEIGHT="1.3579595638479294"/>
<DICH_DATA CI_END="2.156255130476228" CI_START="0.031811682828664346" EFFECT_SIZE="0.2619047619047619" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3337001457552575" LOG_CI_START="-1.4974133562346084" LOG_EFFECT_SIZE="-0.5818566052396754" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2867" O_E="0.0" SE="1.075605135226867" STUDY_ID="STD-Rossi-1997" TOTAL_1="21" TOTAL_2="22" VAR="1.156926406926407" WEIGHT="0.1509080956573444"/>
<DICH_DATA CI_END="0.6609816379241117" CI_START="0.11252985109065299" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="-0.1798106050514249" LOG_CI_START="-0.9487322558257003" LOG_EFFECT_SIZE="-0.5642714304385626" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2886" O_E="0.0" SE="0.4516683838883667" STUDY_ID="STD-Santamaria-2000" TOTAL_1="56" TOTAL_2="28" VAR="0.20400432900432902" WEIGHT="0.5967851438925007"/>
<DICH_DATA CI_END="1.6216329114793497" CI_START="0.733879188195826" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.20995254989858633" LOG_CI_START="-0.13437542811978684" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2879" O_E="0.0" SE="0.20225995873897265" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.04090909090909092" WEIGHT="1.2073154564888946"/>
<DICH_DATA CI_END="2.1315266092423184" CI_START="0.3002542859305412" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3286907585993715" LOG_CI_START="-0.5225107846154844" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2898" O_E="0.0" SE="0.49999999999999994" STUDY_ID="STD-Tassani-2000" TOTAL_1="10" TOTAL_2="10" VAR="0.24999999999999997" WEIGHT="0.5222981217201587"/>
<DICH_DATA CI_END="1.2419824481161656" CI_START="0.02830655944721672" EFFECT_SIZE="0.1875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.09411545836861414" LOG_CI_START="-1.5481129142411387" LOG_EFFECT_SIZE="-0.7269987279362623" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2900" O_E="0.0" SE="0.9646530752325188" STUDY_ID="STD-Thorpe-1994" TOTAL_1="8" TOTAL_2="9" VAR="0.9305555555555556" WEIGHT="0.18347141237189468"/>
<DICH_DATA CI_END="0.9361707678459628" CI_START="0.3957722348326828" EFFECT_SIZE="0.6086956521739131" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="23" LOG_CI_END="-0.028644923944956005" LOG_CI_START="-0.40255467673375367" LOG_EFFECT_SIZE="-0.21559980033935483" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2891" O_E="0.0" SE="0.21963643967126673" STUDY_ID="STD-Vedrinne-1992" TOTAL_1="30" TOTAL_2="30" VAR="0.04824016563146998" WEIGHT="1.154237899742993"/>
<DICH_DATA CI_END="2.1719720978715733" CI_START="0.319729910492389" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3368542418108039" LOG_CI_START="-0.49521673390605353" LOG_EFFECT_SIZE="-0.07918124604762482" MODIFIED="2010-08-23 06:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="2897" O_E="0.0" SE="0.4887626099538393" STUDY_ID="STD-Wei-2006" TOTAL_1="36" TOTAL_2="40" VAR="0.23888888888888885" WEIGHT="0.5385355604976197"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="15.495820817181352" CI_END="0.7529561443926109" CI_START="0.5352920916941223" DF="11" EFFECT_SIZE="0.6348633470959418" ESTIMABLE="YES" EVENTS_1="175" EVENTS_2="270" I2="29.013118247963387" ID="CMP-001.06.03" LOG_CI_END="-0.12323031835832876" LOG_CI_START="-0.2714091727551343" LOG_EFFECT_SIZE="-0.1973197455567315" MODIFIED="2010-08-23 06:40:02 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.1609042632917126" P_Z="1.7901723956954624E-7" STUDIES="12" TAU2="0.02332034607773518" TOTAL_1="473" TOTAL_2="455" WEIGHT="11.233722560545889" Z="5.219902614365718">
<NAME>Allocation concealment - No</NAME>
<DICH_DATA CI_END="1.1661827845720796" CI_START="0.3228907095511885" EFFECT_SIZE="0.6136363636363636" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.06676662598870041" LOG_CI_START="-0.49094445064310055" LOG_EFFECT_SIZE="-0.2120889123272001" MODIFIED="2010-08-23 06:40:02 +0100" MODIFIED_BY="[Empty name]" ORDER="2923" O_E="0.0" SE="0.3276022471278735" STUDY_ID="STD-Alajmo-1989" TOTAL_1="22" TOTAL_2="12" VAR="0.1073232323232323" WEIGHT="0.8522689891886868"/>
<DICH_DATA CI_END="2.1861039695791042" CI_START="0.25282575215333275" EFFECT_SIZE="0.7434402332361516" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.3396708128473259" LOG_CI_START="-0.5971786920649566" LOG_EFFECT_SIZE="-0.12875393960881534" MODIFIED="2010-08-23 06:40:02 +0100" MODIFIED_BY="[Empty name]" ORDER="2925" O_E="0.0" SE="0.5503100366653163" STUDY_ID="STD-Alvarez-1995" TOTAL_1="49" TOTAL_2="51" VAR="0.3028411364545818" WEIGHT="0.4567980149946187"/>
<DICH_DATA CI_END="1.55131165165505" CI_START="0.5025351252755366" EFFECT_SIZE="0.882943143812709" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.1906990544207529" LOG_CI_START="-0.29883357732995014" LOG_EFFECT_SIZE="-0.0540672614545986" MODIFIED="2010-08-23 06:40:02 +0100" MODIFIED_BY="[Empty name]" ORDER="2920" O_E="0.0" SE="0.28755389111597146" STUDY_ID="STD-Amar-2003" TOTAL_1="23" TOTAL_2="24" VAR="0.08268724029593597" WEIGHT="0.9566245103912806"/>
<DICH_DATA CI_END="0.9794902492496453" CI_START="0.5964920617890417" EFFECT_SIZE="0.764367816091954" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="45" LOG_CI_END="-0.008999883016004835" LOG_CI_START="-0.22439533161502298" LOG_EFFECT_SIZE="-0.11669760731551393" MODIFIED="2010-08-23 06:40:02 +0100" MODIFIED_BY="[Empty name]" ORDER="2922" O_E="0.0" SE="0.1265243527317297" STUDY_ID="STD-Baele-1992" TOTAL_1="58" TOTAL_2="57" VAR="0.01600841183418316" WEIGHT="1.4307942536247695"/>
<DICH_DATA CI_END="0.7733027556602502" CI_START="0.2607123323246595" EFFECT_SIZE="0.44900953778429936" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="29" LOG_CI_END="-0.11165044221312088" LOG_CI_START="-0.5838384251651039" LOG_EFFECT_SIZE="-0.34774443368911234" MODIFIED="2010-08-23 06:40:02 +0100" MODIFIED_BY="[Empty name]" ORDER="2926" O_E="0.0" SE="0.27736555855420697" STUDY_ID="STD-Casas-1995" TOTAL_1="47" TOTAL_2="51" VAR="0.07693165307208723" WEIGHT="0.9847956523900335"/>
<DICH_DATA CI_END="0.5985457020816825" CI_START="0.1466746731178129" EFFECT_SIZE="0.2962962962962963" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="27" LOG_CI_END="-0.22290268334593874" LOG_CI_START="-0.8336448709881488" LOG_EFFECT_SIZE="-0.5282737771670437" MODIFIED="2010-08-23 06:40:02 +0100" MODIFIED_BY="[Empty name]" ORDER="2931" O_E="0.0" SE="0.3587529842436209" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.1287037037037037" WEIGHT="0.7785611193600925"/>
<DICH_DATA CI_END="1.2005001082166866" CI_START="0.15299746175000142" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.07936220354165731" LOG_CI_START="-0.8153157741308461" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2010-08-23 06:40:02 +0100" MODIFIED_BY="[Empty name]" ORDER="2927" O_E="0.0" SE="0.5255382728122436" STUDY_ID="STD-Havel-1992" TOTAL_1="10" TOTAL_2="10" VAR="0.2761904761904762" WEIGHT="0.48764124091341887"/>
<DICH_DATA CI_END="1.5636597783045803" CI_START="0.5373789039255461" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.19414226504209867" LOG_CI_START="-0.26971938682089824" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2010-08-23 06:40:02 +0100" MODIFIED_BY="[Empty name]" ORDER="2929" O_E="0.0" SE="0.27247463045653303" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.07424242424242425" WEIGHT="0.9985349437950644"/>
<DICH_DATA CI_END="0.8925895825655312" CI_START="0.5575925005095984" EFFECT_SIZE="0.7054794520547946" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="73" LOG_CI_END="-0.0493481861272466" LOG_CI_START="-0.25368307603128315" LOG_EFFECT_SIZE="-0.15151563107926486" MODIFIED="2010-08-23 06:40:02 +0100" MODIFIED_BY="[Empty name]" ORDER="2930" O_E="0.0" SE="0.12002732580364896" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="103" VAR="0.014406558939575296" WEIGHT="1.4480370089447872"/>
<DICH_DATA CI_END="0.8200679247854159" CI_START="0.18671513419777433" EFFECT_SIZE="0.391304347826087" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="-0.0861501742775433" LOG_CI_START="-0.7288204788789927" LOG_EFFECT_SIZE="-0.40748532657826797" MODIFIED="2010-08-23 06:40:02 +0100" MODIFIED_BY="[Empty name]" ORDER="2921" O_E="0.0" SE="0.37750771819220597" STUDY_ID="STD-Royston-1987" TOTAL_1="11" TOTAL_2="11" VAR="0.142512077294686" WEIGHT="0.7373750034364006"/>
<DICH_DATA CI_END="0.8944158527519801" CI_START="0.26944036691176204" EFFECT_SIZE="0.4909090909090909" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="-0.04846051189314574" LOG_CI_START="-0.5695373387773675" LOG_EFFECT_SIZE="-0.3089989253352565" MODIFIED="2010-08-23 06:40:02 +0100" MODIFIED_BY="[Empty name]" ORDER="2924" O_E="0.0" SE="0.3060831074836844" STUDY_ID="STD-Samama-2002" TOTAL_1="40" TOTAL_2="18" VAR="0.09368686868686871" WEIGHT="0.9070370647129453"/>
<DICH_DATA CI_END="0.968686759662337" CI_START="0.43166883561525266" EFFECT_SIZE="0.6466466466466466" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="27" LOG_CI_END="-0.013816636306206052" LOG_CI_START="-0.36484930415559036" LOG_EFFECT_SIZE="-0.18933297023089823" MODIFIED="2010-08-23 06:40:02 +0100" MODIFIED_BY="[Empty name]" ORDER="2928" O_E="0.0" SE="0.2061983267344585" STUDY_ID="STD-Van-der-Linden-2005" TOTAL_1="37" TOTAL_2="38" VAR="0.0425177499480905" WEIGHT="1.1952547587937898"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="197.81823183562594" CI_END="-0.6647245957928595" CI_START="-1.28706331790386" CI_STUDY="95" CI_TOTAL="95" DF="36" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9758939568483598" ESTIMABLE="YES" I2="81.80147518965104" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2010-05-20 12:06:09 +0100" MODIFIED_BY="Katharine Ker" NO="7" P_CHI2="5.551115123125783E-16" P_Q="1.0" P_Z="7.902780966812381E-10" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="40" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.5521249047541587" TOTALS="YES" TOTAL_1="1680" TOTAL_2="1883" UNITS="" WEIGHT="100.00000000000004" Z="6.14686806459688">
<NAME>Units of Allogeneic Blood Transfused - Transfused Patients</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.4881520588423814" CI_START="-1.3718479411576185" EFFECT_SIZE="-0.9299999999999999" ESTIMABLE="YES" MEAN_1="0.99" MEAN_2="1.92" ORDER="66865" SD_1="1.67" SD_2="2.63" SE="0.22543676549306962" STUDY_ID="STD-Alderman-1998" TOTAL_1="152" TOTAL_2="213" WEIGHT="4.180407274757109"/>
<CONT_DATA CI_END="0.592576317419397" CI_START="-1.172576317419397" EFFECT_SIZE="-0.29000000000000004" ESTIMABLE="YES" MEAN_1="2.11" MEAN_2="2.4" ORDER="66866" SD_1="1.75" SD_2="1.18" SE="0.45030231391038117" STUDY_ID="STD-Basora-1999" TOTAL_1="23" TOTAL_2="20" WEIGHT="3.338948568399898"/>
<CONT_DATA CI_END="-0.6447626423500978" CI_START="-2.655237357649902" EFFECT_SIZE="-1.6500000000000001" ESTIMABLE="YES" MEAN_1="1.39" MEAN_2="3.04" ORDER="66841" SD_1="0.52" SD_2="1.98" SE="0.5128856272763613" STUDY_ID="STD-Bidstrup-1990" TOTAL_1="15" TOTAL_2="16" WEIGHT="3.0920448507393483"/>
<CONT_DATA CI_END="1.41170803088754" CI_START="-1.1317080308875398" EFFECT_SIZE="0.14000000000000012" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="2.86" ORDER="66867" SD_1="1.74" SD_2="2.08" SE="0.6488425506379762" STUDY_ID="STD-Bidstrup-2000" TOTAL_1="13" TOTAL_2="23" WEIGHT="2.5901825866432935"/>
<CONT_DATA CI_END="0.21781234216428658" CI_START="-1.7578123421642866" EFFECT_SIZE="-0.77" ESTIMABLE="YES" MEAN_1="1.67" MEAN_2="2.44" ORDER="66842" SD_1="0.58" SD_2="1.13" SE="0.5039951498884797" STUDY_ID="STD-Blauhut-1994" TOTAL_1="3" TOTAL_2="9" WEIGHT="3.126721137002746"/>
<CONT_DATA CI_END="-0.3370306636223588" CI_START="-2.182969336377641" EFFECT_SIZE="-1.2599999999999998" ESTIMABLE="YES" MEAN_1="4.25" MEAN_2="5.51" ORDER="66843" SD_1="1.45" SD_2="2.93" SE="0.4709113757486899" STUDY_ID="STD-Carrera-1994" TOTAL_1="42" TOTAL_2="50" WEIGHT="3.25703547085732"/>
<CONT_DATA CI_END="0.5380482147179926" CI_START="-1.9580482147179925" EFFECT_SIZE="-0.71" ESTIMABLE="YES" MEAN_1="2.54" MEAN_2="3.25" ORDER="66844" SD_1="1.81" SD_2="1.96" SE="0.6367709940399097" STUDY_ID="STD-Casas-1995" TOTAL_1="12" TOTAL_2="29" WEIGHT="2.6321603173184895"/>
<CONT_DATA CI_END="0.0050200683009561375" CI_START="-0.7050200683009559" EFFECT_SIZE="-0.34999999999999987" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="1.95" MODIFIED="2010-05-20 12:06:09 +0100" MODIFIED_BY="Katharine Ker" ORDER="5339" SD_1="0.5" SD_2="0.89" SE="0.1811360163254575" STUDY_ID="STD-Colwell-2007" TOTAL_1="20" TOTAL_2="39" WEIGHT="4.30913148576588"/>
<CONT_DATA CI_END="0.5742787410386379" CI_START="-1.654278741038638" EFFECT_SIZE="-0.54" ESTIMABLE="YES" MEAN_1="2.29" MEAN_2="2.83" ORDER="66845" SD_1="1.49" SD_2="1.45" SE="0.5685200084429747" STUDY_ID="STD-Corbeau-1995" TOTAL_1="15" TOTAL_2="12" WEIGHT="2.87952429269522"/>
<CONT_DATA CI_END="5.48755150252585" CI_START="-1.7875515025258495" EFFECT_SIZE="1.8500000000000005" ESTIMABLE="YES" MEAN_1="7.07" MEAN_2="5.22" ORDER="66846" SD_1="11.64" SD_2="6.57" SE="1.8559277268451828" STUDY_ID="STD-Cosgrove-1992" TOTAL_1="55" TOTAL_2="44" WEIGHT="0.6306778679184042"/>
<CONT_DATA CI_END="2.401256296774309" CI_START="-0.981256296774309" EFFECT_SIZE="0.71" ESTIMABLE="YES" MEAN_1="3.39" MEAN_2="2.68" ORDER="66847" SD_1="3.58" SD_2="4.2" SE="0.8629017217228085" STUDY_ID="STD-D_x0027_Ambra-1996" TOTAL_1="73" TOTAL_2="31" WEIGHT="1.9437921747217168"/>
<CONT_DATA CI_END="-0.3764753583629996" CI_START="-4.123524641637" EFFECT_SIZE="-2.25" ESTIMABLE="YES" MEAN_1="1.47" MEAN_2="3.72" ORDER="66848" SD_1="1.26" SD_2="3.21" SE="0.9558974840431373" STUDY_ID="STD-Dietrich-1990" TOTAL_1="7" TOTAL_2="15" WEIGHT="1.7195053322651486"/>
<CONT_DATA CI_END="-2.131086878875165" CI_START="-3.6489131211248362" EFFECT_SIZE="-2.8900000000000006" ESTIMABLE="YES" MEAN_1="5.16" MEAN_2="8.05" ORDER="66849" SD_1="6.17" SD_2="7.67" SE="0.387207687034581" STUDY_ID="STD-Dietrich-1992" TOTAL_1="549" TOTAL_2="730" WEIGHT="3.5902651581594527"/>
<CONT_DATA CI_END="-1.1975983808767325" CI_START="-6.362401619123268" EFFECT_SIZE="-3.7800000000000002" ESTIMABLE="YES" MEAN_1="2.75" MEAN_2="6.53" ORDER="66850" SD_1="1.86" SD_2="4.66" SE="1.3175760572607058" STUDY_ID="STD-Dietrich-1995" TOTAL_1="12" TOTAL_2="15" WEIGHT="1.101581111675307"/>
<CONT_DATA CI_END="0.3312109353985412" CI_START="-0.9912109353985404" EFFECT_SIZE="-0.3299999999999996" ESTIMABLE="YES" MEAN_1="2.18" MEAN_2="2.51" ORDER="66870" SD_1="1.77" SD_2="1.3" SE="0.3373587171060735" STUDY_ID="STD-Dignan-2001" TOTAL_1="37" TOTAL_2="58" WEIGHT="3.784993218479122"/>
<CONT_DATA CI_END="0.32219037793371097" CI_START="-3.5821903779337108" EFFECT_SIZE="-1.63" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="3.73" ORDER="66877" SD_1="1.42" SD_2="4.47" SE="0.9960338013006051" STUDY_ID="STD-Diprose-2005" TOTAL_1="8" TOTAL_2="27" WEIGHT="1.6322685360277878"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="1.4" MEAN_2="2.0" ORDER="66872" SD_1="0.55" SD_2="0.0" SE="0.0" STUDY_ID="STD-Engel-2001" TOTAL_1="5" TOTAL_2="3" WEIGHT="0.0"/>
<CONT_DATA CI_END="-1.6292207178009381" CI_START="-3.6507792821990614" EFFECT_SIZE="-2.6399999999999997" ESTIMABLE="YES" MEAN_1="1.92" MEAN_2="4.56" ORDER="66851" SD_1="1.13" SD_2="2.2" SE="0.5157131917586035" STUDY_ID="STD-Fraedrich-1989" TOTAL_1="16" TOTAL_2="26" WEIGHT="3.081052112320248"/>
<CONT_DATA CI_END="0.29086637999162634" CI_START="-0.7108663799916263" EFFECT_SIZE="-0.20999999999999996" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.21" ORDER="66852" SD_1="1.05" SD_2="0.91" SE="0.25554876719286496" STUDY_ID="STD-Harder-1991" TOTAL_1="30" TOTAL_2="29" WEIGHT="4.082344889427023"/>
<CONT_DATA CI_END="2.4163898074778243" CI_START="-0.8363898074778242" EFFECT_SIZE="0.79" ESTIMABLE="YES" MEAN_1="3.88" MEAN_2="3.09" ORDER="66853" SD_1="2.58" SD_2="2.18" SE="0.829805965980283" STUDY_ID="STD-Hardy-1993" TOTAL_1="17" TOTAL_2="16" WEIGHT="2.0315601986183007"/>
<CONT_DATA CI_END="0.6719203670119644" CI_START="-3.7519203670119645" EFFECT_SIZE="-1.54" ESTIMABLE="YES" MEAN_1="3.71" MEAN_2="5.25" ORDER="66874" SD_1="1.5" SD_2="2.76" SE="1.1285515368952237" STUDY_ID="STD-Jeserschek-2003" TOTAL_1="7" TOTAL_2="8" WEIGHT="1.3805601648778405"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="1.0" MEAN_2="2.67" ORDER="66868" SD_1="0.0" SD_2="1.03" SE="0.0" STUDY_ID="STD-Katzel-1998" TOTAL_1="1" TOTAL_2="6" WEIGHT="0.0"/>
<CONT_DATA CI_END="2.9431546451876667" CI_START="-2.2831546451876665" EFFECT_SIZE="0.33000000000000007" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="2.67" ORDER="66873" SD_1="2.0" SD_2="2.16" SE="1.3332666649999168" STUDY_ID="STD-Klein-1998" TOTAL_1="4" TOTAL_2="6" WEIGHT="1.0819142272813103"/>
<CONT_DATA CI_END="-0.24836347661811886" CI_START="-1.3516365233818808" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="2.45" MEAN_2="3.25" ORDER="66854" SD_1="0.82" SD_2="2.56" SE="0.2814523775605672" STUDY_ID="STD-Lemmer-1996" TOTAL_1="173" TOTAL_2="87" WEIGHT="3.9923989298592595"/>
<CONT_DATA CI_END="0.3517179605074554" CI_START="-2.5717179605074545" EFFECT_SIZE="-1.1099999999999994" ESTIMABLE="YES" MEAN_1="2.91" MEAN_2="4.02" ORDER="66855" SD_1="3.54" SD_2="1.95" SE="0.7457881736793632" STUDY_ID="STD-Lemmer_x005f_1-1994" TOTAL_1="28" TOTAL_2="35" WEIGHT="2.2742090422160226"/>
<CONT_DATA CI_END="2.339950367569203" CI_START="-8.899950367569202" EFFECT_SIZE="-3.28" ESTIMABLE="YES" MEAN_1="1.31" MEAN_2="4.59" ORDER="66856" SD_1="7.26" SD_2="3.99" SE="2.8673743047824622" STUDY_ID="STD-Lemmer_x005f_2-1994" TOTAL_1="7" TOTAL_2="23" WEIGHT="0.287277629654736"/>
<CONT_DATA CI_END="-0.20160551611082256" CI_START="-2.5983944838891775" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="3.4" ORDER="66857" SD_1="2.15" SD_2="4.03" SE="0.6114369923845336" STUDY_ID="STD-Levy-1995" TOTAL_1="109" TOTAL_2="49" WEIGHT="2.7220482589074897"/>
<CONT_DATA CI_END="-0.20649498808907207" CI_START="-1.3735050119109278" EFFECT_SIZE="-0.7899999999999999" ESTIMABLE="YES" MEAN_1="0.35" MEAN_2="1.14" ORDER="66875" SD_1="0.59" SD_2="0.39" SE="0.29771210925993585" STUDY_ID="STD-Li-2005" TOTAL_1="5" TOTAL_2="8" WEIGHT="3.9337235924291685"/>
<CONT_DATA CI_END="-0.2694189570097898" CI_START="-2.4305810429902106" EFFECT_SIZE="-1.35" ESTIMABLE="YES" MEAN_1="2.09" MEAN_2="3.44" ORDER="66858" SD_1="1.02" SD_2="1.97" SE="0.5513269894312832" STUDY_ID="STD-Mohr-1992" TOTAL_1="23" TOTAL_2="15" WEIGHT="2.9442853612150928"/>
<CONT_DATA CI_END="-0.23817054734055798" CI_START="-3.561829452659442" EFFECT_SIZE="-1.9" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="5.3" ORDER="66859" SD_1="2.4" SD_2="2.81" SE="0.8478877498605794" STUDY_ID="STD-Murkin-1994" TOTAL_1="16" TOTAL_2="22" WEIGHT="1.9830732417354164"/>
<CONT_DATA CI_END="-0.02285108419325299" CI_START="-1.7771489158067468" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.9" ORDER="66860" SD_1="0.85" SD_2="1.65" SE="0.44753318057147257" STUDY_ID="STD-Murkin-1995" TOTAL_1="18" TOTAL_2="17" WEIGHT="3.3499816115651875"/>
<CONT_DATA CI_END="-1.6628978213505001" CI_START="-1.8971021786494995" EFFECT_SIZE="-1.7799999999999998" ESTIMABLE="YES" MEAN_1="2.56" MEAN_2="4.34" MODIFIED="2010-01-11 16:34:31 +0000" MODIFIED_BY="Katharine Ker" ORDER="2337" SD_1="0.27" SD_2="0.37" SE="0.059747107382169665" STUDY_ID="STD-Parvizi-2007" TOTAL_1="55" TOTAL_2="61" WEIGHT="4.535877120551893"/>
<CONT_DATA CI_END="-0.7069480985182203" CI_START="-2.313051901481779" EFFECT_SIZE="-1.5099999999999998" ESTIMABLE="YES" MEAN_1="2.29" MEAN_2="3.8" ORDER="66878" SD_1="0.99" SD_2="1.66" SE="0.4097278867449353" STUDY_ID="STD-Petsatodis-2006" TOTAL_1="17" TOTAL_2="25" WEIGHT="3.5007723026698616"/>
<CONT_DATA CI_END="0.8010136516985993" CI_START="-3.521013651698598" EFFECT_SIZE="-1.3599999999999994" ESTIMABLE="YES" MEAN_1="2.91" MEAN_2="4.27" ORDER="66861" SD_1="1.94" SD_2="3.15" SE="1.1025782456945121" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="12" TOTAL_2="11" WEIGHT="1.4258158474321452"/>
<CONT_DATA CI_END="0.7118843215486376" CI_START="-1.2518843215486375" EFFECT_SIZE="-0.27" ESTIMABLE="YES" MEAN_1="1.64" MEAN_2="1.91" ORDER="66862" SD_1="1.13" SD_2="2.57" SE="0.5009705939974488" STUDY_ID="STD-Speekenbrink-1996" TOTAL_1="55" TOTAL_2="29" WEIGHT="3.138555212099722"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="2.0" MEAN_2="2.33" ORDER="66871" SD_1="0.0" SD_2="1.12" SE="0.0" STUDY_ID="STD-Stewart-2001" TOTAL_1="1" TOTAL_2="9" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.734681268766074" CI_START="-1.9346812687660733" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" MEAN_1="2.66" MEAN_2="3.26" ORDER="66863" SD_1="1.53" SD_2="1.66" SE="0.6809723440297215" STUDY_ID="STD-Tabuchi-1994" TOTAL_1="10" TOTAL_2="12" WEIGHT="2.481239249723472"/>
<CONT_DATA CI_END="2.573980588865341" CI_START="-1.9739805888653408" EFFECT_SIZE="0.30000000000000004" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.2" ORDER="66869" SD_1="1.58" SD_2="1.9" SE="1.1602154972245458" STUDY_ID="STD-Tassani-2000" TOTAL_1="4" TOTAL_2="5" WEIGHT="1.3278524129529115"/>
<CONT_DATA CI_END="-0.037542236755667036" CI_START="-2.6224577632443333" EFFECT_SIZE="-1.33" ESTIMABLE="YES" MEAN_1="2.61" MEAN_2="3.94" ORDER="66876" SD_1="1.07" SD_2="3.15" SE="0.659429343313997" STUDY_ID="STD-Van-der-Linden-2005" TOTAL_1="17" TOTAL_2="27" WEIGHT="2.5538339619783104"/>
<CONT_DATA CI_END="-0.14915702860834212" CI_START="-1.1508429713916581" EFFECT_SIZE="-0.6500000000000001" ESTIMABLE="YES" MEAN_1="1.78" MEAN_2="2.43" ORDER="66864" SD_1="0.53" SD_2="1.02" SE="0.25553682381015336" STUDY_ID="STD-Vedrinne-1992" TOTAL_1="14" TOTAL_2="23" WEIGHT="4.082385249058356"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1627.3462457273586" CI_END="-0.7852350571819222" CI_START="-1.2624081425369222" CI_STUDY="95" CI_TOTAL="95" DF="69" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0238215998594222" ESTIMABLE="YES" I2="95.75996809645389" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2010-05-28 14:45:33 +0100" MODIFIED_BY="Katharine Ker" NO="8" P_CHI2="0.0" P_Q="1.0" P_Z="4.0795525673063665E-17" Q="0.0" RANDOM="YES" SCALE="7.44244513506393" SORT_BY="STUDY" STUDIES="74" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.7676913093646621" TOTALS="YES" TOTAL_1="4198" TOTAL_2="3622" UNITS="" WEIGHT="99.99999999999997" Z="8.410589464935">
<NAME>Units of Allogeneic Blood Transfused - All Patients</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.4569656635470014" CI_START="-1.7569656635470017" EFFECT_SIZE="-0.6500000000000001" ESTIMABLE="YES" MEAN_1="0.71" MEAN_2="1.36" ORDER="66929" SD_1="1.33" SD_2="1.62" SE="0.564788777895209" STUDY_ID="STD-Alajmo-1989" TOTAL_1="22" TOTAL_2="11" WEIGHT="1.363625021819147"/>
<CONT_DATA CI_END="0.10427150586194545" CI_START="-1.9042715058619453" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="1.9" ORDER="66886" SD_1="1.8" SD_2="2.0" SE="0.512392836696751" STUDY_ID="STD-Alvarez-2001" TOTAL_1="26" TOTAL_2="29" WEIGHT="1.4383290619412625"/>
<CONT_DATA CI_END="1.1731047633760379" CI_START="-1.1731047633760379" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="1.8" ORDER="66891" SD_1="1.5" SD_2="2.5" SE="0.5985338366568664" STUDY_ID="STD-Amar-2003" TOTAL_1="23" TOTAL_2="24" WEIGHT="1.3160813890150453"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.03" MODIFIED="2010-05-25 15:30:11 +0100" MODIFIED_BY="Katharine Ker" ORDER="2342" SD_1="0.0" SD_2="0.183" SE="0.0" STUDY_ID="STD-Apostolakis-2008" TOTAL_1="29" TOTAL_2="30" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.555027921860796" CI_START="-0.9150279218607963" EFFECT_SIZE="-0.18000000000000016" ESTIMABLE="YES" MEAN_1="2.11" MEAN_2="2.29" MODIFIED="2010-05-28 11:17:23 +0100" MODIFIED_BY="Katharine Ker" ORDER="66881" SD_1="1.75" SD_2="1.26" SE="0.3750211369487412" STUDY_ID="STD-Basora-1999" TOTAL_1="23" TOTAL_2="212" WEIGHT="1.6313645235686576"/>
<CONT_DATA CI_END="-0.2541840413713776" CI_START="-1.4658159586286226" EFFECT_SIZE="-0.8600000000000001" ESTIMABLE="YES" MEAN_1="0.44" MEAN_2="1.3" MODIFIED="2010-04-21 10:25:53 +0100" MODIFIED_BY="Katharine Ker" ORDER="2348" SD_1="0.77" SD_2="1.34" SE="0.3090954545120326" STUDY_ID="STD-Bert-2008" TOTAL_1="25" TOTAL_2="25" WEIGHT="1.716597683009231"/>
<CONT_DATA CI_END="-0.8822984733107608" CI_START="-2.9177015266892394" EFFECT_SIZE="-1.9000000000000001" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="2.7" ORDER="66930" SD_1="0.8" SD_2="2.1" SE="0.5192450140496148" STUDY_ID="STD-Bidstrup-1990" TOTAL_1="26" TOTAL_2="18" WEIGHT="1.4285272370804805"/>
<CONT_DATA CI_END="0.14281609698584807" CI_START="-1.9228160969858479" EFFECT_SIZE="-0.8899999999999999" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="2.19" ORDER="66882" SD_1="1.88" SD_2="2.19" SE="0.5269566712105781" STUDY_ID="STD-Bidstrup-2000" TOTAL_1="30" TOTAL_2="30" WEIGHT="1.4175022092864136"/>
<CONT_DATA CI_END="-0.3338531924722935" CI_START="-2.0861468075277063" EFFECT_SIZE="-1.21" ESTIMABLE="YES" MEAN_1="0.36" MEAN_2="1.57" ORDER="66931" SD_1="0.74" SD_2="1.5" SE="0.4470218914422105" STUDY_ID="STD-Blauhut-1994" TOTAL_1="14" TOTAL_2="14" WEIGHT="1.5315663222770306"/>
<CONT_DATA CI_END="-0.8949737806024007" CI_START="-2.9050262193976" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="5.4" ORDER="66932" SD_1="2.1" SD_2="3.0" SE="0.5127779016987649" STUDY_ID="STD-Carrera-1994" TOTAL_1="51" TOTAL_2="51" WEIGHT="1.4377781468391218"/>
<CONT_DATA CI_END="-0.7551018121069858" CI_START="-1.8448981878930137" EFFECT_SIZE="-1.2999999999999998" ESTIMABLE="YES" MEAN_1="1.25" MEAN_2="2.55" ORDER="66934" SD_1="1.22" SD_2="1.09" SE="0.2780143881168743" STUDY_ID="STD-Cicek-1996a" TOTAL_1="50" TOTAL_2="25" WEIGHT="1.753668799293297"/>
<CONT_DATA CI_END="-0.8702053973518127" CI_START="-1.6297946026481873" EFFECT_SIZE="-1.25" ESTIMABLE="YES" MEAN_1="0.45" MEAN_2="1.7" ORDER="66933" SD_1="0.5" SD_2="0.9" SE="0.19377631713845694" STUDY_ID="STD-Cicek-1996b" TOTAL_1="29" TOTAL_2="28" WEIGHT="1.840221320109638"/>
<CONT_DATA CI_END="0.44830293535918875" CI_START="-0.44830293535918875" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.91" MEAN_2="0.91" MODIFIED="2010-05-20 11:46:01 +0100" MODIFIED_BY="Katharine Ker" ORDER="5329" SD_1="0.75" SD_2="0.76" SE="0.22873019039908135" STUDY_ID="STD-Cicekcioglu-2006" TOTAL_1="24" TOTAL_2="20" WEIGHT="1.8070792028496738"/>
<CONT_DATA CI_END="-0.09537792163540842" CI_START="-0.4046220783645916" EFFECT_SIZE="-0.25" ESTIMABLE="YES" MEAN_1="0.18" MEAN_2="0.43" MODIFIED="2010-05-20 12:06:50 +0100" MODIFIED_BY="Katharine Ker" ORDER="5340" SD_1="0.52" SD_2="0.91" SE="0.07889026511927301" STUDY_ID="STD-Colwell-2007" TOTAL_1="175" TOTAL_2="177" WEIGHT="1.9147075551463821"/>
<CONT_DATA CI_END="-0.007018823168827626" CI_START="-1.792981176831172" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.7" ORDER="66935" SD_1="1.4" SD_2="1.8" SE="0.45561101319967806" STUDY_ID="STD-Corbeau-1995" TOTAL_1="43" TOTAL_2="20" WEIGHT="1.5193913029604478"/>
<CONT_DATA CI_END="1.6394469513423915" CI_START="-2.959446951342391" EFFECT_SIZE="-0.6599999999999997" ESTIMABLE="YES" MEAN_1="3.44" MEAN_2="4.1" ORDER="66936" SD_1="8.83" SD_2="6.2" SE="1.173208778059258" STUDY_ID="STD-Cosgrove-1992" TOTAL_1="113" TOTAL_2="56" WEIGHT="0.6911122864314455"/>
<CONT_DATA CI_END="0.26313174588433524" CI_START="-0.3631317458843349" EFFECT_SIZE="-0.04999999999999982" ESTIMABLE="YES" MEAN_1="1.58" MEAN_2="1.63" ORDER="66889" SD_1="0.32" SD_2="0.67" SE="0.15976403054049887" STUDY_ID="STD-Cvachovec-2001" TOTAL_1="20" TOTAL_2="22" WEIGHT="1.868118062130951"/>
<CONT_DATA CI_END="1.6104358932554053" CI_START="-0.31043589325540544" EFFECT_SIZE="0.6499999999999999" ESTIMABLE="YES" MEAN_1="1.95" MEAN_2="1.3" ORDER="66937" SD_1="3.19" SD_2="3.2" SE="0.49002731725235826" STUDY_ID="STD-D_x0027_Ambra-1996" TOTAL_1="127" TOTAL_2="64" WEIGHT="1.4703257397994987"/>
<CONT_DATA CI_END="-0.06329685967691823" CI_START="-1.6967031403230814" EFFECT_SIZE="-0.8799999999999999" ESTIMABLE="YES" MEAN_1="2.13" MEAN_2="3.01" ORDER="66888" SD_1="2.57" SD_2="3.28" SE="0.4166929325054602" STUDY_ID="STD-Defraigne-2000" TOTAL_1="100" TOTAL_2="100" WEIGHT="1.574187398343664"/>
<CONT_DATA CI_END="0.053377371261185524" CI_START="-0.5933773712611856" EFFECT_SIZE="-0.27" ESTIMABLE="YES" MEAN_1="0.39" MEAN_2="0.66" MODIFIED="2010-05-17 10:50:11 +0100" MODIFIED_BY="Katharine Ker" ORDER="2553" SD_1="0.64" SD_2="0.78" SE="0.16499148648237671" STUDY_ID="STD-Desai-2009" TOTAL_1="38" TOTAL_2="37" WEIGHT="1.8641284436615235"/>
<CONT_DATA CI_END="-0.7689079294855818" CI_START="-3.731092070514418" EFFECT_SIZE="-2.25" ESTIMABLE="YES" MEAN_1="0.54" MEAN_2="2.79" ORDER="66938" SD_1="1.03" SD_2="3.21" SE="0.7556731053208545" STUDY_ID="STD-Dietrich-1990" TOTAL_1="19" TOTAL_2="20" WEIGHT="1.1068829243000133"/>
<CONT_DATA CI_END="-2.905344743088828" CI_START="-4.134655256911172" EFFECT_SIZE="-3.52" ESTIMABLE="YES" MEAN_1="3.14" MEAN_2="6.66" ORDER="66939" SD_1="5.43" SD_2="7.61" SE="0.31360538344556027" STUDY_ID="STD-Dietrich-1992" TOTAL_1="902" TOTAL_2="882" WEIGHT="1.711031212702035"/>
<CONT_DATA CI_END="-1.7317390975194686" CI_START="-6.868260902480531" EFFECT_SIZE="-4.3" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="6.5" ORDER="66940" SD_1="2.01" SD_2="4.66" SE="1.3103612733390233" STUDY_ID="STD-Dietrich-1995" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.5963690658132077"/>
<CONT_DATA CI_END="-0.2414280197264208" CI_START="-1.098571980273579" EFFECT_SIZE="-0.6699999999999999" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.47" ORDER="66887" SD_1="1.5" SD_2="1.59" SE="0.2186631915964274" STUDY_ID="STD-Dignan-2001" TOTAL_1="101" TOTAL_2="99" WEIGHT="1.8170594244635683"/>
<CONT_DATA CI_END="-0.4849885520004218" CI_START="-2.315011447999578" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="0.28" MEAN_2="1.68" ORDER="66898" SD_1="0.87" SD_2="3.51" SE="0.46685115400949795" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" WEIGHT="1.5034078335369039"/>
<CONT_DATA CI_END="-0.8866498711356248" CI_START="-3.713350128864375" EFFECT_SIZE="-2.3" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="3.5" ORDER="66919" SD_1="2.0" SD_2="3.0" SE="0.7211102550927979" STUDY_ID="STD-Ehrlich-1998" TOTAL_1="25" TOTAL_2="25" WEIGHT="1.1507578367423508"/>
<CONT_DATA CI_END="-0.18198828396725486" CI_START="-3.118011716032745" EFFECT_SIZE="-1.6500000000000001" ESTIMABLE="YES" MEAN_1="1.55" MEAN_2="3.2" ORDER="66900" SD_1="1.4" SD_2="3.2" SE="0.7489993324429604" STUDY_ID="STD-Fauli-2005" TOTAL_1="40" TOTAL_2="20" WEIGHT="1.1152484065429487"/>
<CONT_DATA CI_END="-1.338508421686658" CI_START="-3.281491578313342" EFFECT_SIZE="-2.31" ESTIMABLE="YES" MEAN_1="0.81" MEAN_2="3.12" ORDER="66920" SD_1="1.2" SD_2="2.81" SE="0.49566807654443834" STUDY_ID="STD-Fraedrich-1989" TOTAL_1="38" TOTAL_2="38" WEIGHT="1.4622585491970523"/>
<CONT_DATA CI_END="-0.46685660773326965" CI_START="-3.333143392266731" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="4.2" ORDER="66894" SD_1="2.1" SD_2="1.9" SE="0.731209044437134" STUDY_ID="STD-Garcia_x002d_Enguita-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.137798433938994"/>
<CONT_DATA CI_END="2.4883945204426343" CI_START="-5.288394520442635" EFFECT_SIZE="-1.4000000000000004" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="14.4" ORDER="66921" SD_1="8.0" SD_2="9.7" SE="1.9839112101619185" STUDY_ID="STD-Garcia_x002d_Huete-1997" TOTAL_1="39" TOTAL_2="41" WEIGHT="0.31504006314694144"/>
<CONT_DATA CI_END="-0.5231654537166807" CI_START="-1.8768345462833191" EFFECT_SIZE="-1.2" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="2.9" ORDER="66890" SD_1="1.5" SD_2="1.0" SE="0.345330093625242" STUDY_ID="STD-Golanski-2000" TOTAL_1="29" TOTAL_2="24" WEIGHT="1.67070362947168"/>
<CONT_DATA CI_END="1.9830397361069392" CI_START="-0.5830397361069393" EFFECT_SIZE="0.7" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="1.8" MODIFIED="2010-05-17 14:03:52 +0100" MODIFIED_BY="Katharine Ker" ORDER="2596" SD_1="2.7" SD_2="2.0" SE="0.6546241391308172" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="27" WEIGHT="1.2387485748946867"/>
<CONT_DATA CI_END="0.4522092005632464" CI_START="-0.6522092005632466" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.6" ORDER="66922" SD_1="1.26" SD_2="1.26" SE="0.28174456516497354" STUDY_ID="STD-Harder-1991" TOTAL_1="40" TOTAL_2="40" WEIGHT="1.7493460694210379"/>
<CONT_DATA CI_END="1.9615694806130934" CI_START="-1.1615694806130936" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="2.6" ORDER="66923" SD_1="2.8" SD_2="2.3" SE="0.7967337629316428" STUDY_ID="STD-Hardy-1993" TOTAL_1="22" TOTAL_2="19" WEIGHT="1.0565748485459403"/>
<CONT_DATA CI_END="-0.7314368559074184" CI_START="-2.168563144092581" EFFECT_SIZE="-1.4499999999999997" ESTIMABLE="YES" MEAN_1="2.85" MEAN_2="4.3" ORDER="66924" SD_1="2.22" SD_2="2.26" SE="0.36662058576612416" STUDY_ID="STD-Hayashida-1997" TOTAL_1="110" TOTAL_2="57" WEIGHT="1.6426312389138968"/>
<CONT_DATA CI_END="0.5573919054324363" CI_START="-0.7573919054324361" EFFECT_SIZE="-0.09999999999999987" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="1.2" ORDER="66925" SD_1="0.9" SD_2="1.2" SE="0.33541019662496846" STUDY_ID="STD-Hayes-1996" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.6835213547223145"/>
<CONT_DATA CI_END="-1.666296059891624" CI_START="-6.533703940108375" EFFECT_SIZE="-4.1" ESTIMABLE="YES" MEAN_1="2.94" MEAN_2="7.04" ORDER="66899" SD_1="1.72" SD_2="5.28" SE="1.241708500413845" STUDY_ID="STD-Hei-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.641611074744011"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="1.35" ORDER="66926" SD_1="0.0" SD_2="0.33" SE="0.0" STUDY_ID="STD-Hendrice-1995" TOTAL_1="12" TOTAL_2="14" WEIGHT="0.0"/>
<CONT_DATA CI_END="-1.1978130113408256" CI_START="-2.202186988659174" EFFECT_SIZE="-1.6999999999999997" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="2.8" ORDER="66927" SD_1="0.47" SD_2="0.66" SE="0.2562225595063791" STUDY_ID="STD-Hill-1998" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.778168019399088"/>
<CONT_DATA CI_END="-0.8094636452100231" CI_START="-2.3905363547899765" EFFECT_SIZE="-1.5999999999999999" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="3.4" ORDER="66941" SD_1="1.24" SD_2="1.31" SE="0.4033422864020087" STUDY_ID="STD-Janssens-1994" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.5927113047067087"/>
<CONT_DATA CI_END="0.2698219948209985" CI_START="-0.5498219948209984" EFFECT_SIZE="-0.13999999999999996" ESTIMABLE="YES" MEAN_1="0.28" MEAN_2="0.42" ORDER="66880" SD_1="0.45" SD_2="0.64" SE="0.20909669670137923" STUDY_ID="STD-Kahveci-1996" TOTAL_1="14" TOTAL_2="14" WEIGHT="1.826223321716101"/>
<CONT_DATA CI_END="-1.0008211815373549" CI_START="-1.8591788184626445" EFFECT_SIZE="-1.4299999999999997" ESTIMABLE="YES" MEAN_1="2.87" MEAN_2="4.3" ORDER="66928" SD_1="0.88" SD_2="1.5" SE="0.21897280860666446" STUDY_ID="STD-Kalangos-1994" TOTAL_1="110" TOTAL_2="55" WEIGHT="1.8167575625962875"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="1.0" MEAN_2="1.3" ORDER="66884" SD_1="0.0" SD_2="1.56" SE="0.0" STUDY_ID="STD-Katzel-1998" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0"/>
<CONT_DATA CI_END="-0.07808693648558546" CI_START="-0.12191306351441455" EFFECT_SIZE="-0.1" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.2" ORDER="66897" SD_1="0.05" SD_2="0.1" SE="0.01118033988749895" STUDY_ID="STD-Koster-2004" TOTAL_1="100" TOTAL_2="100" WEIGHT="1.9299158502930893"/>
<CONT_DATA CI_END="-0.25444597638734334" CI_START="-2.145554023612656" EFFECT_SIZE="-1.1999999999999997" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="3.3" ORDER="66893" SD_1="1.7" SD_2="3.3" SE="0.4824343870964292" STUDY_ID="STD-Kuepper-2003" TOTAL_1="60" TOTAL_2="59" WEIGHT="1.4811776682749334"/>
<CONT_DATA CI_END="-1.7658542216475666" CI_START="-2.4941457783524332" EFFECT_SIZE="-2.13" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="3.33" ORDER="66896" SD_1="0.52" SD_2="1.13" SE="0.18579207639771375" STUDY_ID="STD-Kunt-2005" TOTAL_1="40" TOTAL_2="46" WEIGHT="1.847173254246941"/>
<CONT_DATA CI_END="0.2236190413355964" CI_START="-1.3636190413355966" EFFECT_SIZE="-0.5700000000000001" ESTIMABLE="YES" MEAN_1="0.42" MEAN_2="0.99" ORDER="66910" SD_1="0.68" SD_2="1.47" SE="0.4049151145610645" STUDY_ID="STD-Laub-1994" TOTAL_1="16" TOTAL_2="16" WEIGHT="1.590538021230832"/>
<CONT_DATA CI_END="-0.4324641535420972" CI_START="-2.567535846457903" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="3.6" ORDER="66911" SD_1="1.1" SD_2="1.8" SE="0.5446711546122731" STUDY_ID="STD-Lavee-1993" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.3922203797275694"/>
<CONT_DATA CI_END="2.0087289042666145" CI_START="-5.128728904266614" EFFECT_SIZE="-1.56" ESTIMABLE="YES" MEAN_1="0.44" MEAN_2="2.0" MODIFIED="2010-05-25 15:27:39 +0100" MODIFIED_BY="Katharine Ker" ORDER="2408" SD_1="0.7" SD_2="7.9" SE="1.8208135110728016" STUDY_ID="STD-Leijdekkers-2006" TOTAL_1="16" TOTAL_2="19" WEIGHT="0.3629198079439496"/>
<CONT_DATA CI_END="-0.5230026036295576" CI_START="-1.3369973963704425" EFFECT_SIZE="-0.93" ESTIMABLE="YES" MEAN_1="0.87" MEAN_2="1.8" ORDER="66914" SD_1="1.27" SD_2="2.5" SE="0.20765554856149704" STUDY_ID="STD-Lemmer-1996" TOTAL_1="487" TOTAL_2="157" WEIGHT="1.8275760800490288"/>
<CONT_DATA CI_END="-0.16782565144069528" CI_START="-1.8321743485593047" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="2.1" ORDER="66913" SD_1="2.58" SD_2="2.46" SE="0.42458655114246474" STUDY_ID="STD-Lemmer_x005f_1-1994" TOTAL_1="74" TOTAL_2="67" WEIGHT="1.563159810026917"/>
<CONT_DATA CI_END="-0.8154577838257198" CI_START="-4.98454221617428" EFFECT_SIZE="-2.9" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="3.3" ORDER="66912" SD_1="3.84" SD_2="3.96" SE="1.0635614902196586" STUDY_ID="STD-Lemmer_x005f_2-1994" TOTAL_1="23" TOTAL_2="32" WEIGHT="0.7803762638971515"/>
<CONT_DATA CI_END="0.08923754981858906" CI_START="-0.749237549818589" EFFECT_SIZE="-0.32999999999999996" ESTIMABLE="YES" MEAN_1="0.17" MEAN_2="0.5" ORDER="66909" SD_1="0.56" SD_2="1.14" SE="0.2139006395655641" STUDY_ID="STD-Maccario-1994" TOTAL_1="61" TOTAL_2="32" WEIGHT="1.8216612588346017"/>
<CONT_DATA CI_END="1.0912841709231447" CI_START="-2.8912841709231447" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="3.0" ORDER="66915" SD_1="2.0" SD_2="4.4" SE="1.015979980566041" STUDY_ID="STD-Marcel-1996" TOTAL_1="21" TOTAL_2="23" WEIGHT="0.8232765192544903"/>
<CONT_DATA CI_END="-0.9825316988371173" CI_START="-3.077468301162883" EFFECT_SIZE="-2.0300000000000002" ESTIMABLE="YES" MEAN_1="1.41" MEAN_2="3.44" ORDER="66916" SD_1="1.21" SD_2="1.97" SE="0.534432422955309" STUDY_ID="STD-Mohr-1992" TOTAL_1="34" TOTAL_2="16" WEIGHT="1.4068240275609296"/>
<CONT_DATA CI_END="-1.1371981910614883" CI_START="-4.462801808938512" EFFECT_SIZE="-2.8000000000000003" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="4.7" ORDER="66917" SD_1="3.23" SD_2="3.0" SE="0.848383859119086" STUDY_ID="STD-Murkin-1994" TOTAL_1="29" TOTAL_2="25" WEIGHT="0.9962179370545653"/>
<CONT_DATA CI_END="-0.31689454765165226" CI_START="-2.083105452348348" EFFECT_SIZE="-1.2" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="2.9" MODIFIED="2010-05-07 15:00:40 +0100" MODIFIED_BY="Katharine Ker" ORDER="2468" SD_1="1.4" SD_2="1.8" SE="0.4505722856716607" STUDY_ID="STD-Nur_x00f6_zler-2008" TOTAL_1="25" TOTAL_2="26" WEIGHT="1.5265382166890293"/>
<CONT_DATA CI_END="3.987299361906274" CI_START="-5.247299361906272" EFFECT_SIZE="-0.629999999999999" ESTIMABLE="YES" MEAN_1="11.64" MEAN_2="12.27" ORDER="66918" SD_1="9.07" SD_2="8.5" SE="2.355808269094198" STUDY_ID="STD-Okita-1996" TOTAL_1="39" TOTAL_2="21" WEIGHT="0.23455722315320685"/>
<CONT_DATA CI_END="-1.6802510521370113" CI_START="-1.8797489478629883" EFFECT_SIZE="-1.7799999999999998" ESTIMABLE="YES" MEAN_1="2.56" MEAN_2="4.34" MODIFIED="2010-01-11 16:35:08 +0000" MODIFIED_BY="Katharine Ker" ORDER="2338" SD_1="0.27" SD_2="0.37" SE="0.050893255513772384" STUDY_ID="STD-Parvizi-2007" TOTAL_1="81" TOTAL_2="81" WEIGHT="1.9237395611739783"/>
<CONT_DATA CI_END="0.539152912152997" CI_START="-1.5391529121529965" EFFECT_SIZE="-0.4999999999999998" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="2.3" ORDER="66901" SD_1="2.1" SD_2="2.0" SE="0.5301897995829017" STUDY_ID="STD-Poston-2006" TOTAL_1="29" TOTAL_2="31" WEIGHT="1.4128827380125013"/>
<CONT_DATA CI_END="0.23456697745358107" CI_START="-0.8345669774535811" EFFECT_SIZE="-0.3" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.5" ORDER="66902" SD_1="0.5" SD_2="1.1" SE="0.2727432655243551" STUDY_ID="STD-Prendergast_x005f_1-1996" TOTAL_1="18" TOTAL_2="20" WEIGHT="1.7597146550051357"/>
<CONT_DATA CI_END="0.28513011155581114" CI_START="-2.085130111555811" EFFECT_SIZE="-0.9000000000000001" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="2.2" ORDER="66903" SD_1="1.2" SD_2="2.1" SE="0.6046693311223912" STUDY_ID="STD-Prendergast_x005f_2-1996" TOTAL_1="16" TOTAL_2="16" WEIGHT="1.3075086393022206"/>
<CONT_DATA CI_END="-0.1005724997525066" CI_START="-2.499427500247493" EFFECT_SIZE="-1.2999999999999998" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="3.3" MODIFIED="2010-05-07 15:14:22 +0100" MODIFIED_BY="Katharine Ker" ORDER="2479" SD_1="1.7" SD_2="2.3" SE="0.6119640512317697" STUDY_ID="STD-Rhydderch-1993" TOTAL_1="20" TOTAL_2="23" WEIGHT="1.297349098532941"/>
<CONT_DATA CI_END="-0.13893141714583523" CI_START="-1.0410685828541646" EFFECT_SIZE="-0.5899999999999999" ESTIMABLE="YES" MEAN_1="1.62" MEAN_2="2.21" ORDER="66892" SD_1="0.68" SD_2="0.91" SE="0.230141260968128" STUDY_ID="STD-Schmartz-2003" TOTAL_1="40" TOTAL_2="20" WEIGHT="1.8056534125760926"/>
<CONT_DATA CI_END="-0.6157921248587497" CI_START="-1.7842078751412507" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="2.6" ORDER="66883" SD_1="0.7" SD_2="1.4" SE="0.298070719538424" STUDY_ID="STD-Schweizer-2000" TOTAL_1="26" TOTAL_2="28" WEIGHT="1.730012905683834"/>
<CONT_DATA CI_END="1.1794665940874092" CI_START="-2.779466594087409" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="2.33" MEAN_2="3.13" ORDER="66904" SD_1="2.1" SD_2="3.3" SE="1.0099504938362076" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.8289019797735866"/>
<CONT_DATA CI_END="0.5203731441343542" CI_START="-1.1203731441343543" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.5" ORDER="66905" SD_1="1.21" SD_2="2.4" SE="0.41856541783693624" STUDY_ID="STD-Speekenbrink-1996" TOTAL_1="75" TOTAL_2="37" WEIGHT="1.5715762266652147"/>
<CONT_DATA CI_END="-0.4358974238188196" CI_START="-2.94410257618118" EFFECT_SIZE="-1.69" ESTIMABLE="YES" MEAN_1="0.58" MEAN_2="2.27" ORDER="66906" SD_1="1.19" SD_2="1.67" SE="0.6398600107315141" STUDY_ID="STD-Stammers-1997" TOTAL_1="8" TOTAL_2="12" WEIGHT="1.2588612518769895"/>
<CONT_DATA CI_END="0.35341328494917135" CI_START="-2.1534132849491714" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="2.3" ORDER="66907" SD_1="1.74" SD_2="2.06" SE="0.639508325069203" STUDY_ID="STD-Tabuchi-1994" TOTAL_1="19" TOTAL_2="17" WEIGHT="1.2593426188861265"/>
<CONT_DATA CI_END="0.5381180415828856" CI_START="-0.7381180415828857" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="2.0" ORDER="66885" SD_1="0.5" SD_2="0.9" SE="0.32557641192199416" STUDY_ID="STD-Turkoz-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.6960462461666996"/>
<CONT_DATA CI_END="1.5989178645753477" CI_START="-0.798917864575347" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="2.8" ORDER="66879" SD_1="1.4" SD_2="1.4" SE="0.6117040282537121" STUDY_ID="STD-Utada-1997" TOTAL_1="11" TOTAL_2="10" WEIGHT="1.2977106035767407"/>
<CONT_DATA CI_END="-0.47360118664026407" CI_START="-2.7263988133597357" EFFECT_SIZE="-1.5999999999999999" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="2.8" ORDER="66895" SD_1="1.5" SD_2="3.2" SE="0.5747038324400988" STUDY_ID="STD-Van-der-Linden-2005" TOTAL_1="37" TOTAL_2="38" WEIGHT="1.3495933695779891"/>
<CONT_DATA CI_END="-0.42932086588173934" CI_START="-1.6306791341182612" EFFECT_SIZE="-1.0300000000000002" ESTIMABLE="YES" MEAN_1="0.83" MEAN_2="1.86" ORDER="66908" SD_1="0.97" SD_2="1.37" SE="0.3064745775209857" STUDY_ID="STD-Vedrinne-1992" TOTAL_1="30" TOTAL_2="30" WEIGHT="1.7198119198740163"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="1.67" MEAN_2="1.33" MODIFIED="2010-05-26 12:21:25 +0100" MODIFIED_BY="Katharine Ker" ORDER="2770" SD_1="0.56" SD_2="0.0" SE="0.0" STUDY_ID="STD-Wei-2006" TOTAL_1="36" TOTAL_2="40" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="40.0374765100026" CI_END="-103.27685881980236" CI_START="-280.45341084093445" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="MD" EFFECT_SIZE="-191.86513483036842" ESTIMABLE="YES" I2="60.03744143064884" I2_Q="70.19459572451241" ID="CMP-001.09" MODIFIED="2010-12-03 12:22:38 +0000" MODIFIED_BY="Katharine Ker" NO="9" P_CHI2="7.688426102989698E-4" P_Q="0.009394338999051177" P_Z="2.1868672962106293E-5" Q="13.42038498464408" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="13085.010400742813" TOTALS="YES" TOTAL_1="449" TOTAL_2="434" UNITS="" WEIGHT="100.00000000000001" Z="4.244904304397929">
<NAME>Blood loss - Intra-operative</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="13.633790561464778" CI_END="-56.14023974317361" CI_START="-240.21254404610784" DF="6" EFFECT_SIZE="-148.17639189464072" ESTIMABLE="YES" I2="55.99169597808919" ID="CMP-001.09.01" MODIFIED="2010-05-17 10:51:01 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="0.03400551671169383" P_Z="0.001602213962758944" STUDIES="7" TAU2="6875.871594377939" TOTAL_1="242" TOTAL_2="228" WEIGHT="61.10224995979621" Z="3.1555034047341923">
<NAME>Cardiac surgery</NAME>
<CONT_DATA CI_END="18.740901679423246" CI_START="-498.74090167942325" EFFECT_SIZE="-240.0" ESTIMABLE="YES" MEAN_1="794.0" MEAN_2="1034.0" MODIFIED="2010-05-17 10:51:01 +0100" MODIFIED_BY="Katharine Ker" ORDER="2554" SD_1="465.0" SD_2="659.0" SE="132.01308989366052" STUDY_ID="STD-Desai-2009" TOTAL_1="38" TOTAL_2="37" WEIGHT="6.695438192961307"/>
<CONT_DATA CI_END="-114.8031130134325" CI_START="-431.1968869865675" EFFECT_SIZE="-273.0" ESTIMABLE="YES" MEAN_1="363.0" MEAN_2="636.0" ORDER="66946" SD_1="159.0" SD_2="322.0" SE="80.7141805841354" STUDY_ID="STD-Dietrich-1990" TOTAL_1="19" TOTAL_2="20" WEIGHT="10.423292241813344"/>
<CONT_DATA CI_END="349.24321636211664" CI_START="-90.24321636211667" EFFECT_SIZE="129.5" ESTIMABLE="YES" MEAN_1="958.5" MEAN_2="829.0" ORDER="66944" SD_1="385.12" SD_2="421.0" SE="112.11594605585772" STUDY_ID="STD-Fauli-2005" TOTAL_1="40" TOTAL_2="20" WEIGHT="7.9631403629368025"/>
<CONT_DATA CI_END="-54.799280998941384" CI_START="-489.2007190010586" EFFECT_SIZE="-272.0" ESTIMABLE="YES" MEAN_1="568.0" MEAN_2="840.0" ORDER="66943" SD_1="355.0" SD_2="296.0" SE="110.81872968805048" STUDY_ID="STD-Harmon-2004" TOTAL_1="17" TOTAL_2="18" WEIGHT="8.053927815506837"/>
<CONT_DATA CI_END="-47.76492919882983" CI_START="-304.2350708011702" EFFECT_SIZE="-176.0" ESTIMABLE="YES" MEAN_1="225.0" MEAN_2="401.0" ORDER="66945" SD_1="121.0" SD_2="207.0" SE="65.42725877244278" STUDY_ID="STD-Hendrice-1995" TOTAL_1="12" TOTAL_2="14" WEIGHT="11.764219224460955"/>
<CONT_DATA CI_END="-61.45161273471409" CI_START="-126.54838726528591" EFFECT_SIZE="-94.0" ESTIMABLE="YES" MEAN_1="261.0" MEAN_2="355.0" ORDER="66942" SD_1="107.0" SD_2="127.0" SE="16.606625183943905" STUDY_ID="STD-Koster-2004" TOTAL_1="100" TOTAL_2="100" WEIGHT="15.290587317497746"/>
<CONT_DATA CI_END="796.3239378268355" CI_START="-1004.3239378268355" EFFECT_SIZE="-104.0" ESTIMABLE="YES" MEAN_1="2362.0" MEAN_2="2466.0" MODIFIED="2010-05-07 10:31:06 +0100" MODIFIED_BY="Katharine Ker" ORDER="2409" SD_1="1340.0" SD_2="1370.0" SE="459.3573886706469" STUDY_ID="STD-Leijdekkers-2006" TOTAL_1="16" TOTAL_2="19" WEIGHT="0.9116448046192155"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.61983569345049" CI_END="15.524739028083218" CI_START="-317.6298949933238" DF="4" EFFECT_SIZE="-151.05257798262028" ESTIMABLE="YES" I2="39.57553955670673" ID="CMP-001.09.02" NO="2" P_CHI2="0.15739472510543306" P_Z="0.07551914333171696" STUDIES="5" TAU2="13580.137170640217" TOTAL_1="103" TOTAL_2="98" WEIGHT="28.821393374364234" Z="1.777298481754514">
<NAME>Orthopaedic surgery</NAME>
<CONT_DATA CI_END="744.6734654123131" CI_START="-344.67346541231313" EFFECT_SIZE="200.0" ESTIMABLE="YES" MEAN_1="1200.0" MEAN_2="1000.0" ORDER="66949" SD_1="1000.0" SD_2="900.0" SE="277.8997316831472" STUDY_ID="STD-Amar-2003" TOTAL_1="23" TOTAL_2="24" WEIGHT="2.262063253604111"/>
<CONT_DATA CI_END="79.18375236471725" CI_START="-165.18375236471724" EFFECT_SIZE="-43.0" ESTIMABLE="YES" MEAN_1="725.0" MEAN_2="768.0" ORDER="66951" SD_1="150.0" SD_2="235.0" SE="62.33979467402824" STUDY_ID="STD-Hayes-1996" TOTAL_1="20" TOTAL_2="20" WEIGHT="12.037664111523616"/>
<CONT_DATA CI_END="-59.14801114241993" CI_START="-580.8519888575801" EFFECT_SIZE="-320.0" ESTIMABLE="YES" MEAN_1="793.0" MEAN_2="1113.0" ORDER="66948" SD_1="332.0" SD_2="494.0" SE="133.09019498069722" STUDY_ID="STD-Janssens-1994" TOTAL_1="20" TOTAL_2="20" WEIGHT="6.633361363122869"/>
<CONT_DATA CI_END="3.530663995055477" CI_START="-647.5306639950554" EFFECT_SIZE="-322.0" ESTIMABLE="YES" MEAN_1="996.0" MEAN_2="1318.0" ORDER="66950" SD_1="436.2" SD_2="710.35" SE="166.09012541189523" STUDY_ID="STD-Murkin-1995" TOTAL_1="29" TOTAL_2="24" WEIGHT="5.023103263638258"/>
<CONT_DATA CI_END="285.90360964838055" CI_START="-659.9036096483806" EFFECT_SIZE="-187.0" ESTIMABLE="YES" MEAN_1="1573.0" MEAN_2="1760.0" ORDER="66947" SD_1="462.0" SD_2="623.0" SE="241.28178547084735" STUDY_ID="STD-Utada-1997" TOTAL_1="11" TOTAL_2="10" WEIGHT="2.8652013824753757"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.8389240020497095" CI_END="-260.4144229378025" CI_START="-893.7053949220572" DF="1" EFFECT_SIZE="-577.0599089299299" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.03" MODIFIED="2010-05-21 15:11:56 +0100" MODIFIED_BY="Katharine Ker" NO="3" P_CHI2="0.35970476107167704" P_Z="3.5444081049099065E-4" STUDIES="2" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="5.547332359178857" Z="3.571870399102251">
<NAME>Thoracic surgery</NAME>
<CONT_DATA CI_END="-200.9990834123259" CI_START="-863.000916587674" EFFECT_SIZE="-532.0" ESTIMABLE="YES" MEAN_1="324.0" MEAN_2="856.0" ORDER="66952" SD_1="159.0" SD_2="563.0" SE="168.88112189742623" STUDY_ID="STD-Katzel-1998" TOTAL_1="12" TOTAL_2="12" WEIGHT="4.910231686661407"/>
<CONT_DATA CI_END="23.98964516758292" CI_START="-2149.989645167583" EFFECT_SIZE="-1063.0" ESTIMABLE="YES" MEAN_1="769.0" MEAN_2="1832.0" MODIFIED="2010-05-21 15:11:56 +0100" MODIFIED_BY="Katharine Ker" ORDER="2790" SD_1="630.4" SD_2="1436.39" SE="554.5967445022554" STUDY_ID="STD-Norman-2009" TOTAL_1="8" TOTAL_2="8" WEIGHT="0.6371006725174496"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.524541268393539" CI_END="542.5892058116542" CI_START="-2943.3888592472367" DF="1" EFFECT_SIZE="-1200.3998267177913" ESTIMABLE="YES" I2="81.89894958842825" ID="CMP-001.09.04" NO="4" P_CHI2="0.01875161988772156" P_Z="0.17707023569452268" STUDIES="2" TAU2="1325289.2117346944" TOTAL_1="68" TOTAL_2="69" WEIGHT="3.617379502041498" Z="1.3498308844781823">
<NAME>Liver surgery</NAME>
<CONT_DATA CI_END="-800.1289868307495" CI_START="-3669.8710131692505" EFFECT_SIZE="-2235.0" ESTIMABLE="YES" MEAN_1="3107.0" MEAN_2="5342.0" ORDER="66953" SD_1="1281.0" SD_2="3013.0" SE="732.0904998700639" STUDY_ID="STD-Hei-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.37209268950216573"/>
<CONT_DATA CI_END="1.6739420412515074" CI_START="-873.6739420412515" EFFECT_SIZE="-436.0" ESTIMABLE="YES" MEAN_1="1217.0" MEAN_2="1653.0" ORDER="66954" SD_1="966.0" SD_2="1221.0" SE="223.30713497470754" STUDY_ID="STD-Lentschener-1997" TOTAL_1="48" TOTAL_2="49" WEIGHT="3.245286812539332"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.570596052791414E-34" CI_END="796.3239378268355" CI_START="-1004.3239378268355" DF="0" EFFECT_SIZE="-103.99999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-001.09.05" MODIFIED="2010-05-21 10:47:13 +0100" MODIFIED_BY="Katharine Ker" NO="5" P_CHI2="0.0" P_Z="0.8208878102534624" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="19" WEIGHT="0.9116448046192155" Z="0.22640323757710706">
<NAME>Vascular surgery</NAME>
<CONT_DATA CI_END="796.3239378268355" CI_START="-1004.3239378268355" EFFECT_SIZE="-104.0" ESTIMABLE="YES" MEAN_1="2362.0" MEAN_2="2466.0" MODIFIED="2010-05-21 10:47:13 +0100" MODIFIED_BY="Katharine Ker" ORDER="2746" SD_1="1340.0" SD_2="1370.0" SE="459.3573886706469" STUDY_ID="STD-Leijdekkers-2006" TOTAL_1="16" TOTAL_2="19" WEIGHT="0.9116448046192155"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="620.4868787879367" CI_END="-308.2880046289124" CI_START="-383.4655271838225" CI_STUDY="95" CI_TOTAL="95" DF="86" EFFECT_MEASURE="MD" EFFECT_SIZE="-345.87676590636744" ESTIMABLE="YES" I2="86.13991642047402" I2_Q="94.30434778191527" ID="CMP-001.10" MODIFIED="2011-02-10 17:16:09 +0000" MODIFIED_BY="Emma M Sydenham" NO="10" P_CHI2="-4.440892098500626E-16" P_Q="4.440892098500626E-16" P_Z="1.0385994779370092E-72" Q="87.786258861173" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="87" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="21627.054304739035" TOTALS="YES" TOTAL_1="4394" TOTAL_2="3502" UNITS="" WEIGHT="99.99999999999994" Z="18.034805650067167">
<NAME>Blood loss - Post-operative</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="513.9080330425809" CI_END="-330.2879477450993" CI_START="-408.949724164501" DF="74" EFFECT_SIZE="-369.61883595480015" ESTIMABLE="YES" I2="85.60053643024712" ID="CMP-001.10.01" MODIFIED="2011-02-10 17:16:09 +0000" MODIFIED_BY="Emma M Sydenham" NO="1" P_CHI2="-4.440892098500626E-16" P_Z="9.232395760000008E-76" STUDIES="75" TAU2="19799.195749946502" TOTAL_1="4132" TOTAL_2="3239" WEIGHT="85.5080183115787" Z="18.419101104875278">
<NAME>Cardiac surgery</NAME>
<CONT_DATA CI_END="-87.61630555939439" CI_START="-600.3836944406056" EFFECT_SIZE="-344.0" ESTIMABLE="YES" MEAN_1="486.0" MEAN_2="830.0" ORDER="67008" SD_1="220.0" SD_2="405.0" SE="130.81041103965555" STUDY_ID="STD-Alajmo-1989" TOTAL_1="22" TOTAL_2="11" WEIGHT="0.9494628257316701"/>
<CONT_DATA CI_END="-187.58920934118368" CI_START="-712.4107906588163" EFFECT_SIZE="-450.0" ESTIMABLE="YES" MEAN_1="890.0" MEAN_2="1340.0" ORDER="66964" SD_1="430.0" SD_2="560.0" SE="133.88551663636636" STUDY_ID="STD-Alvarez-2001" TOTAL_1="26" TOTAL_2="29" WEIGHT="0.9299233650247755"/>
<CONT_DATA CI_END="-387.8679575737349" CI_START="-566.1320424262651" EFFECT_SIZE="-477.0" ESTIMABLE="YES" MEAN_1="371.0" MEAN_2="848.0" MODIFIED="2010-01-11 11:28:05 +0000" MODIFIED_BY="Katharine Ker" ORDER="2260" SD_1="62.0" SD_2="126.0" SE="45.47636748905963" STUDY_ID="STD-Asimakopoulos-2000" TOTAL_1="8" TOTAL_2="10" WEIGHT="1.5522451252987886"/>
<CONT_DATA CI_END="-187.01699918638087" CI_START="-810.9830008136191" EFFECT_SIZE="-499.0" ESTIMABLE="YES" MEAN_1="699.0" MEAN_2="1198.0" ORDER="67009" SD_1="429.0" SD_2="1124.0" SE="159.17792534684372" STUDY_ID="STD-Baele-1992" TOTAL_1="58" TOTAL_2="57" WEIGHT="0.7831565881573462"/>
<CONT_DATA CI_END="-19.66237153995354" CI_START="-710.2376284600466" EFFECT_SIZE="-364.95000000000005" ESTIMABLE="YES" MEAN_1="498.15" MEAN_2="863.1" ORDER="66956" SD_1="372.58" SD_2="755.5" SE="176.17039454991584" STUDY_ID="STD-Basora-1999" TOTAL_1="36" TOTAL_2="21" WEIGHT="0.6984152879043558"/>
<CONT_DATA CI_END="-196.47414169744857" CI_START="-331.52585830255146" EFFECT_SIZE="-264.0" ESTIMABLE="YES" MEAN_1="309.0" MEAN_2="573.0" ORDER="67010" SD_1="133.0" SD_2="166.0" SE="34.452601596349105" STUDY_ID="STD-Bidstrup-1989" TOTAL_1="40" TOTAL_2="37" WEIGHT="1.612195565203392"/>
<CONT_DATA CI_END="-585.6333218258633" CI_START="-1496.3666781741367" EFFECT_SIZE="-1041.0" ESTIMABLE="YES" MEAN_1="352.0" MEAN_2="1393.0" ORDER="67011" SD_1="138.0" SD_2="979.0" SE="232.33420703952262" STUDY_ID="STD-Bidstrup-1990" TOTAL_1="26" TOTAL_2="18" WEIGHT="0.48647689269907984"/>
<CONT_DATA CI_END="-312.2369198483749" CI_START="-624.963080151625" EFFECT_SIZE="-468.59999999999997" ESTIMABLE="YES" MEAN_1="368.7" MEAN_2="837.3" ORDER="66957" SD_1="164.3" SD_2="404.9" SE="79.77854765954734" STUDY_ID="STD-Bidstrup-2000" TOTAL_1="30" TOTAL_2="30" WEIGHT="1.3139868570299467"/>
<CONT_DATA CI_END="-58.61644974290955" CI_START="-309.38355025709046" EFFECT_SIZE="-184.0" ESTIMABLE="YES" MEAN_1="269.0" MEAN_2="453.0" ORDER="67012" SD_1="142.18" SD_2="192.56" SE="63.972374618156195" STUDY_ID="STD-Blauhut-1994" TOTAL_1="14" TOTAL_2="14" WEIGHT="1.4300690357205772"/>
<CONT_DATA CI_END="43.653251459478554" CI_START="-303.65325145947855" EFFECT_SIZE="-130.0" ESTIMABLE="YES" MEAN_1="260.0" MEAN_2="390.0" MODIFIED="2011-02-10 17:16:09 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="67013" SD_1="160.0" SD_2="230.0" SE="88.60022573334675" STUDY_ID="STD-Boldt-1991" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.2477735184285537"/>
<CONT_DATA CI_END="59.170169878055646" CI_START="-159.17016987805565" EFFECT_SIZE="-50.0" ESTIMABLE="YES" MEAN_1="465.0" MEAN_2="515.0" MODIFIED="2011-02-10 17:16:09 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="66955" SD_1="195.0" SD_2="155.0" SE="55.70008976653449" STUDY_ID="STD-Boldt-1994" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.4873170502585775"/>
<CONT_DATA CI_END="-281.2940946266908" CI_START="-645.5059053733092" EFFECT_SIZE="-463.40000000000003" ESTIMABLE="YES" MEAN_1="431.8" MEAN_2="895.2" ORDER="67014" SD_1="343.0" SD_2="568.0" SE="92.91288350690999" STUDY_ID="STD-Carrera-1994" TOTAL_1="51" TOTAL_2="51" WEIGHT="1.2154943849259994"/>
<CONT_DATA CI_END="-71.08328341623431" CI_START="-220.9167165837657" EFFECT_SIZE="-146.0" ESTIMABLE="YES" MEAN_1="265.0" MEAN_2="411.0" ORDER="67016" SD_1="165.68" SD_2="151.0" SE="38.22351694964764" STUDY_ID="STD-Cicek-1996a" TOTAL_1="50" TOTAL_2="25" WEIGHT="1.5930588147018294"/>
<CONT_DATA CI_END="-174.0528673996087" CI_START="-397.34713260039143" EFFECT_SIZE="-285.70000000000005" ESTIMABLE="YES" MEAN_1="410.5" MEAN_2="696.2" ORDER="67015" SD_1="174.8" SD_2="247.7" SE="56.9638694797709" STUDY_ID="STD-Cicek-1996b" TOTAL_1="29" TOTAL_2="28" WEIGHT="1.4788027229546838"/>
<CONT_DATA CI_END="2.9816216320067497" CI_START="-228.5816216320069" EFFECT_SIZE="-112.80000000000007" ESTIMABLE="YES" MEAN_1="547.8" MEAN_2="660.6" MODIFIED="2010-05-20 11:48:25 +0100" MODIFIED_BY="Katharine Ker" ORDER="5330" SD_1="170.6" SD_2="213.4" SE="59.07334142120849" STUDY_ID="STD-Cicekcioglu-2006" TOTAL_1="24" TOTAL_2="20" WEIGHT="1.4643909153325947"/>
<CONT_DATA CI_END="-602.3396631103705" CI_START="-831.6603368896295" EFFECT_SIZE="-717.0" ESTIMABLE="YES" MEAN_1="780.0" MEAN_2="1497.0" ORDER="66958" SD_1="262.0" SD_2="360.0" SE="58.501246856603316" STUDY_ID="STD-Cohen-1998" TOTAL_1="56" TOTAL_2="59" WEIGHT="1.468323156234207"/>
<CONT_DATA CI_END="-302.80600340008493" CI_START="-861.1939965999151" EFFECT_SIZE="-582.0" ESTIMABLE="YES" MEAN_1="834.0" MEAN_2="1416.0" ORDER="67017" SD_1="448.0" SD_2="559.0" SE="142.44853415785272" STUDY_ID="STD-Corbeau-1995" TOTAL_1="43" TOTAL_2="20" WEIGHT="0.8774303859763498"/>
<CONT_DATA CI_END="-34.017352932379595" CI_START="-623.2826470676204" EFFECT_SIZE="-328.65" ESTIMABLE="YES" MEAN_1="792.35" MEAN_2="1121.0" ORDER="67019" SD_1="1269.74" SD_2="683.0" SE="150.3255413832321" STUDY_ID="STD-Cosgrove-1992" TOTAL_1="113" TOTAL_2="56" WEIGHT="0.8316751887240749"/>
<CONT_DATA CI_END="-355.5796439137212" CI_START="-591.4203560862788" EFFECT_SIZE="-473.5" ESTIMABLE="YES" MEAN_1="587.0" MEAN_2="1060.5" ORDER="66966" SD_1="328.82" SD_2="503.84" SE="60.16455252056646" STUDY_ID="STD-Defraigne-2000" TOTAL_1="100" TOTAL_2="100" WEIGHT="1.4568439339001238"/>
<CONT_DATA CI_END="-279.9271961493625" CI_START="-664.0728038506375" EFFECT_SIZE="-472.0" ESTIMABLE="YES" MEAN_1="380.0" MEAN_2="852.0" ORDER="67018" SD_1="125.0" SD_2="522.0" SE="97.99812923384474" STUDY_ID="STD-Deleuze-1991" TOTAL_1="30" TOTAL_2="30" WEIGHT="1.177709827877615"/>
<CONT_DATA CI_END="-37.030106106540046" CI_START="-376.9698938934599" EFFECT_SIZE="-207.0" ESTIMABLE="YES" MEAN_1="603.0" MEAN_2="810.0" MODIFIED="2010-05-17 10:51:50 +0100" MODIFIED_BY="Katharine Ker" ORDER="2555" SD_1="330.0" SD_2="415.0" SE="86.72092713649883" STUDY_ID="STD-Desai-2009" TOTAL_1="38" TOTAL_2="37" WEIGHT="1.2618782058288902"/>
<CONT_DATA CI_END="-312.08777433627534" CI_START="-1073.9122256637247" EFFECT_SIZE="-693.0" ESTIMABLE="YES" MEAN_1="738.0" MEAN_2="1431.0" ORDER="67020" SD_1="411.0" SD_2="760.0" SE="194.3465434407528" STUDY_ID="STD-Dietrich-1990" TOTAL_1="19" TOTAL_2="20" WEIGHT="0.6192281703653365"/>
<CONT_DATA CI_END="-306.95520259286434" CI_START="-411.04479740713566" EFFECT_SIZE="-359.0" ESTIMABLE="YES" MEAN_1="678.0" MEAN_2="1037.0" ORDER="67021" SD_1="419.0" SD_2="671.0" SE="26.55395600003796" STUDY_ID="STD-Dietrich-1992" TOTAL_1="902" TOTAL_2="882" WEIGHT="1.6469824873599852"/>
<CONT_DATA CI_END="-471.20080822734036" CI_START="-1326.7991917726597" EFFECT_SIZE="-899.0" ESTIMABLE="YES" MEAN_1="597.0" MEAN_2="1496.0" ORDER="67022" SD_1="312.4" SD_2="785.51" SE="218.26890450390164" STUDY_ID="STD-Dietrich-1995" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.530988217354693"/>
<CONT_DATA CI_END="-150.8447206185079" CI_START="-317.1552793814921" EFFECT_SIZE="-234.0" ESTIMABLE="YES" MEAN_1="455.0" MEAN_2="689.0" ORDER="66965" SD_1="298.5" SD_2="298.5" SE="42.42694255476648" STUDY_ID="STD-Dignan-2001" TOTAL_1="99" TOTAL_2="99" WEIGHT="1.5700060246747811"/>
<CONT_DATA CI_END="-50.49110971378269" CI_START="-703.5088902862174" EFFECT_SIZE="-377.0" ESTIMABLE="YES" MEAN_1="850.0" MEAN_2="1227.0" ORDER="66970" SD_1="231.0" SD_2="582.0" SE="166.58922962956348" STUDY_ID="STD-Englberger-2002b" TOTAL_1="15" TOTAL_2="14" WEIGHT="0.7448645901071713"/>
<CONT_DATA CI_END="-228.97748912500515" CI_START="-1033.0225108749949" EFFECT_SIZE="-631.0" ESTIMABLE="YES" MEAN_1="526.0" MEAN_2="1157.0" ORDER="66978" SD_1="675.83" SD_2="783.0" SE="205.11729503506038" STUDY_ID="STD-Fauli-2005" TOTAL_1="40" TOTAL_2="20" WEIGHT="0.5774033899508141"/>
<CONT_DATA CI_END="-315.6909511298993" CI_START="-454.3090488701007" EFFECT_SIZE="-385.0" ESTIMABLE="YES" MEAN_1="279.0" MEAN_2="664.0" MODIFIED="2010-01-11 12:12:10 +0000" MODIFIED_BY="Katharine Ker" ORDER="2267" SD_1="29.0" SD_2="108.0" SE="35.36240942017385" STUDY_ID="STD-Feindt-1994" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.6077193948618331"/>
<CONT_DATA CI_END="-297.0561409939297" CI_START="-806.9438590060703" EFFECT_SIZE="-552.0" ESTIMABLE="YES" MEAN_1="652.0" MEAN_2="1204.0" ORDER="67003" SD_1="382.0" SD_2="705.0" SE="130.07578762519867" STUDY_ID="STD-Fraedrich-1989" TOTAL_1="38" TOTAL_2="38" WEIGHT="0.954183520301599"/>
<CONT_DATA CI_END="-259.14476325597496" CI_START="-500.85523674402504" EFFECT_SIZE="-380.0" ESTIMABLE="YES" MEAN_1="280.0" MEAN_2="660.0" ORDER="66993" SD_1="145.09" SD_2="185.0" SE="61.66196812661646" STUDY_ID="STD-Gherli-1992" TOTAL_1="18" TOTAL_2="13" WEIGHT="1.4463927947578628"/>
<CONT_DATA CI_END="-306.76288890654365" CI_START="-803.2371110934564" EFFECT_SIZE="-555.0" ESTIMABLE="YES" MEAN_1="660.0" MEAN_2="1215.0" ORDER="66969" SD_1="221.0" SD_2="587.0" SE="126.65391458798172" STUDY_ID="STD-Golanski-2000" TOTAL_1="29" TOTAL_2="24" WEIGHT="0.9764369146627988"/>
<CONT_DATA CI_END="-11.038465241097526" CI_START="-622.9615347589024" EFFECT_SIZE="-317.0" ESTIMABLE="YES" MEAN_1="685.0" MEAN_2="1002.0" MODIFIED="2010-05-17 14:12:10 +0100" MODIFIED_BY="Katharine Ker" ORDER="2597" SD_1="505.0" SD_2="627.0" SE="156.10569233531228" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="27" WEIGHT="0.7996489823009499"/>
<CONT_DATA CI_END="245.05099065194304" CI_START="-377.05099065194304" EFFECT_SIZE="-66.0" ESTIMABLE="YES" MEAN_1="565.0" MEAN_2="631.0" ORDER="67004" SD_1="589.0" SD_2="423.0" SE="158.70240122036606" STUDY_ID="STD-Hardy-1993" TOTAL_1="22" TOTAL_2="19" WEIGHT="0.7856853832526116"/>
<CONT_DATA CI_END="-53.5361092838958" CI_START="-444.4638907161042" EFFECT_SIZE="-249.0" ESTIMABLE="YES" MEAN_1="520.0" MEAN_2="769.0" ORDER="66977" SD_1="287.0" SD_2="303.0" SE="99.72830738620628" STUDY_ID="STD-Harmon-2004" TOTAL_1="17" TOTAL_2="18" WEIGHT="1.1649489395788353"/>
<CONT_DATA CI_END="-60.914263743729435" CI_START="-226.08573625627056" EFFECT_SIZE="-143.5" ESTIMABLE="YES" MEAN_1="391.5" MEAN_2="535.0" ORDER="67005" SD_1="167.32" SD_2="294.44" SE="42.13635398797953" STUDY_ID="STD-Hayashida-1997" TOTAL_1="110" TOTAL_2="57" WEIGHT="1.5716545628121112"/>
<CONT_DATA CI_END="-226.25714788522896" CI_START="-515.742852114771" EFFECT_SIZE="-371.0" ESTIMABLE="YES" MEAN_1="328.0" MEAN_2="699.0" ORDER="67006" SD_1="84.0" SD_2="261.0" SE="73.84975094261128" STUDY_ID="STD-Hendrice-1995" TOTAL_1="12" TOTAL_2="14" WEIGHT="1.3581811988437105"/>
<CONT_DATA CI_END="-522.5280214575084" CI_START="-729.4719785424916" EFFECT_SIZE="-626.0" ESTIMABLE="YES" MEAN_1="752.0" MEAN_2="1378.0" ORDER="67007" SD_1="159.15" SD_2="375.0" SE="52.79279586699823" STUDY_ID="STD-Kalangos-1994" TOTAL_1="110" TOTAL_2="55" WEIGHT="1.5065325833410748"/>
<CONT_DATA CI_END="92.1395655632553" CI_START="-550.1395655632552" EFFECT_SIZE="-229.0" ESTIMABLE="YES" MEAN_1="964.0" MEAN_2="1193.0" ORDER="66971" SD_1="355.0" SD_2="526.0" SE="163.84972790131002" STUDY_ID="STD-Kipfer-2003" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.7587747843712014"/>
<CONT_DATA CI_END="-35.74269621556013" CI_START="-314.25730378443984" EFFECT_SIZE="-175.0" ESTIMABLE="YES" MEAN_1="597.0" MEAN_2="772.0" ORDER="66967" SD_1="266.0" SD_2="299.0" SE="71.05095036586576" STUDY_ID="STD-Klein-1998" TOTAL_1="36" TOTAL_2="29" WEIGHT="1.3788298162183004"/>
<CONT_DATA CI_END="-51.830643236040544" CI_START="-308.16935676395946" EFFECT_SIZE="-180.0" ESTIMABLE="YES" MEAN_1="564.0" MEAN_2="744.0" ORDER="66975" SD_1="425.0" SD_2="497.0" SE="65.39373058634902" STUDY_ID="STD-Koster-2004" TOTAL_1="100" TOTAL_2="100" WEIGHT="1.41991768839363"/>
<CONT_DATA CI_END="-212.25886197837525" CI_START="-801.7411380216247" EFFECT_SIZE="-507.0" ESTIMABLE="YES" MEAN_1="608.0" MEAN_2="1115.0" ORDER="66972" SD_1="336.0" SD_2="1106.0" SE="150.3808949279197" STUDY_ID="STD-Kuepper-2003" TOTAL_1="60" TOTAL_2="59" WEIGHT="0.8313622838136444"/>
<CONT_DATA CI_END="-287.1721110470977" CI_START="-622.8278889529023" EFFECT_SIZE="-455.0" ESTIMABLE="YES" MEAN_1="540.0" MEAN_2="995.0" ORDER="66976" SD_1="259.4" SD_2="281.7" SE="85.6280473910272" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.2700857212655967"/>
<CONT_DATA CI_END="-557.7614000031745" CI_START="-702.2385999968255" EFFECT_SIZE="-630.0" ESTIMABLE="YES" MEAN_1="188.0" MEAN_2="818.0" ORDER="66974" SD_1="51.5" SD_2="243.8" SE="36.85710582777764" STUDY_ID="STD-Kunt-2005" TOTAL_1="40" TOTAL_2="46" WEIGHT="1.60016910117498"/>
<CONT_DATA CI_END="-398.659304412159" CI_START="-1237.340695587841" EFFECT_SIZE="-818.0" ESTIMABLE="YES" MEAN_1="722.0" MEAN_2="1540.0" ORDER="66994" SD_1="304.0" SD_2="800.0" SE="213.95326592506132" STUDY_ID="STD-Laub-1994" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.545682805358388"/>
<CONT_DATA CI_END="-51.57861065141648" CI_START="-478.4213893485835" EFFECT_SIZE="-265.0" ESTIMABLE="YES" MEAN_1="487.0" MEAN_2="752.0" ORDER="66995" SD_1="121.0" SD_2="404.0" SE="108.89046484120331" STUDY_ID="STD-Lavee-1993" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.0984494580036694"/>
<CONT_DATA CI_END="-337.3460839779872" CI_START="-571.6139160220129" EFFECT_SIZE="-454.48" ESTIMABLE="YES" MEAN_1="831.52" MEAN_2="1286.0" ORDER="66998" SD_1="650.03" SD_2="651.56" SE="59.76330021671326" STUDY_ID="STD-Lemmer-1996" TOTAL_1="487" TOTAL_2="157" WEIGHT="1.4596260316252232"/>
<CONT_DATA CI_END="-426.1829922474619" CI_START="-869.8170077525381" EFFECT_SIZE="-648.0" ESTIMABLE="YES" MEAN_1="855.0" MEAN_2="1503.0" ORDER="66996" SD_1="671.0" SD_2="671.2" SE="113.1740223301052" STUDY_ID="STD-Lemmer_x005f_1-1994" TOTAL_1="74" TOTAL_2="67" WEIGHT="1.0681064601828414"/>
<CONT_DATA CI_END="92.11415445387058" CI_START="-1600.1141544538705" EFFECT_SIZE="-754.0" ESTIMABLE="YES" MEAN_1="1225.0" MEAN_2="1979.0" ORDER="66997" SD_1="1563.44" SD_2="1600.88" SE="431.69882769678986" STUDY_ID="STD-Lemmer_x005f_2-1994" TOTAL_1="23" TOTAL_2="32" WEIGHT="0.17683793896390176"/>
<CONT_DATA CI_END="-252.91323664025617" CI_START="-883.0467633597439" EFFECT_SIZE="-567.98" ESTIMABLE="YES" MEAN_1="1132.02" MEAN_2="1700.0" ORDER="66999" SD_1="1083.18" SD_2="1128.72" SE="160.7513024958368" STUDY_ID="STD-Levy-1995" TOTAL_1="188" TOTAL_2="65" WEIGHT="0.7748516939812271"/>
<CONT_DATA CI_END="-229.82107785966545" CI_START="-382.9189221403344" EFFECT_SIZE="-306.36999999999995" ESTIMABLE="YES" MEAN_1="304.3" MEAN_2="610.67" ORDER="66973" SD_1="105.64" SD_2="193.37" SE="39.05629018907624" STUDY_ID="STD-Li-2005" TOTAL_1="40" TOTAL_2="30" WEIGHT="1.588630610078325"/>
<CONT_DATA CI_END="-104.68644876043916" CI_START="-297.4135512395609" EFFECT_SIZE="-201.05" ESTIMABLE="YES" MEAN_1="323.55" MEAN_2="524.6" ORDER="66992" SD_1="136.42" SD_2="147.47" SE="49.165980599472356" STUDY_ID="STD-Locatelli-1990" TOTAL_1="25" TOTAL_2="13" WEIGHT="1.5297020253806959"/>
<CONT_DATA CI_END="-135.47181694650973" CI_START="-332.1081830534903" EFFECT_SIZE="-233.79000000000002" ESTIMABLE="YES" MEAN_1="387.21" MEAN_2="621.0" ORDER="66991" SD_1="169.4" SD_2="255.87" SE="50.1632600542722" STUDY_ID="STD-Maccario-1994" TOTAL_1="61" TOTAL_2="32" WEIGHT="1.5234257459007114"/>
<CONT_DATA CI_END="-266.5064429226487" CI_START="-759.4935570773513" EFFECT_SIZE="-513.0" ESTIMABLE="YES" MEAN_1="298.0" MEAN_2="811.0" ORDER="67000" SD_1="140.0" SD_2="600.0" SE="125.76432986608988" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.9822925395374495"/>
<CONT_DATA CI_END="-292.74976627670503" CI_START="-647.250233723295" EFFECT_SIZE="-470.0" ESTIMABLE="YES" MEAN_1="290.0" MEAN_2="760.0" ORDER="66959" SD_1="110.0" SD_2="320.0" SE="90.43545448866517" STUDY_ID="STD-Misfeld-1998" TOTAL_1="14" TOTAL_2="14" WEIGHT="1.2340183055317655"/>
<CONT_DATA CI_END="-133.42534640227265" CI_START="-542.5746535977273" EFFECT_SIZE="-338.0" ESTIMABLE="YES" MEAN_1="442.0" MEAN_2="780.0" ORDER="67001" SD_1="129.14" SD_2="408.0" SE="104.37674121126005" STUDY_ID="STD-Mohr-1992" TOTAL_1="34" TOTAL_2="16" WEIGHT="1.1309632613030427"/>
<CONT_DATA CI_END="-160.73631159983407" CI_START="-415.26368840016596" EFFECT_SIZE="-288.0" ESTIMABLE="YES" MEAN_1="162.0" MEAN_2="450.0" ORDER="66961" SD_1="123.17" SD_2="224.0" SE="64.93164639963064" STUDY_ID="STD-Moran-2000" TOTAL_1="24" TOTAL_2="14" WEIGHT="1.4232264648794843"/>
<CONT_DATA CI_END="-689.9614338716078" CI_START="-2022.2385661283924" EFFECT_SIZE="-1356.1000000000001" ESTIMABLE="YES" MEAN_1="1409.7" MEAN_2="2765.8" ORDER="67002" SD_1="1251.51" SD_2="1240.0" SE="339.8728606151992" STUDY_ID="STD-Murkin-1994" TOTAL_1="29" TOTAL_2="25" WEIGHT="0.2681968983320443"/>
<CONT_DATA CI_END="-217.7203837263889" CI_START="-432.2796162736111" EFFECT_SIZE="-325.0" ESTIMABLE="YES" MEAN_1="423.0" MEAN_2="748.0" MODIFIED="2010-05-07 15:01:34 +0100" MODIFIED_BY="Katharine Ker" ORDER="2469" SD_1="178.0" SD_2="212.0" SE="54.73550387650948" STUDY_ID="STD-Nur_x00f6_zler-2008" TOTAL_1="25" TOTAL_2="26" WEIGHT="1.4937515093293179"/>
<CONT_DATA CI_END="-229.4414173369993" CI_START="-270.5585826630007" EFFECT_SIZE="-250.0" ESTIMABLE="YES" MEAN_1="555.0" MEAN_2="805.0" MODIFIED="2010-05-07 15:32:12 +0100" MODIFIED_BY="Katharine Ker" ORDER="2482" SD_1="56.0" SD_2="76.0" SE="10.489265529960841" STUDY_ID="STD-Parvizi-2007" TOTAL_1="81" TOTAL_2="81" WEIGHT="1.6920713113909107"/>
<CONT_DATA CI_END="-228.48916367649065" CI_START="-531.5108363235094" EFFECT_SIZE="-380.0" ESTIMABLE="YES" MEAN_1="344.0" MEAN_2="724.0" ORDER="66979" SD_1="106.0" SD_2="280.0" SE="77.30286756216313" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.3324990303516437"/>
<CONT_DATA CI_END="32.84371674362035" CI_START="-112.84371674362035" EFFECT_SIZE="-40.0" ESTIMABLE="YES" MEAN_1="510.0" MEAN_2="550.0" ORDER="66980" SD_1="105.0" SD_2="124.0" SE="37.16584453500283" STUDY_ID="STD-Prendergast_x005f_1-1996" TOTAL_1="18" TOTAL_2="20" WEIGHT="1.5985796843869902"/>
<CONT_DATA CI_END="-293.0057615234844" CI_START="-442.9942384765156" EFFECT_SIZE="-368.0" ESTIMABLE="YES" MEAN_1="526.0" MEAN_2="894.0" ORDER="66981" SD_1="95.0" SD_2="120.0" SE="38.26306966253492" STUDY_ID="STD-Prendergast_x005f_2-1996" TOTAL_1="16" TOTAL_2="16" WEIGHT="1.592850102217022"/>
<CONT_DATA CI_END="-441.3955301426539" CI_START="-1322.604469857346" EFFECT_SIZE="-882.0" ESTIMABLE="YES" MEAN_1="1051.0" MEAN_2="1933.0" ORDER="66982" SD_1="944.0" SD_2="1189.0" SE="224.80232970237103" STUDY_ID="STD-Rodrigus-1996" TOTAL_1="45" TOTAL_2="46" WEIGHT="0.5096880051735303"/>
<CONT_DATA CI_END="16.288983012069536" CI_START="-270.28898301206954" EFFECT_SIZE="-127.0" ESTIMABLE="YES" MEAN_1="446.0" MEAN_2="573.0" ORDER="66983" SD_1="155.0" SD_2="304.0" SE="73.107967361806" STUDY_ID="STD-Rossi-1997" TOTAL_1="21" TOTAL_2="22" WEIGHT="1.3636704983838328"/>
<CONT_DATA CI_END="-456.73689568127986" CI_START="-1989.2631043187203" EFFECT_SIZE="-1223.0" ESTIMABLE="YES" MEAN_1="286.0" MEAN_2="1509.0" ORDER="66984" SD_1="159.2" SD_2="1286.85" SE="390.9577473682709" STUDY_ID="STD-Royston-1987" TOTAL_1="11" TOTAL_2="11" WEIGHT="0.21080776443199806"/>
<CONT_DATA CI_END="-66.55699283485086" CI_START="-361.44300716514914" EFFECT_SIZE="-214.0" ESTIMABLE="YES" MEAN_1="558.0" MEAN_2="772.0" ORDER="66968" SD_1="301.64" SD_2="336.1" SE="75.22740638509725" STUDY_ID="STD-Santamaria-2000" TOTAL_1="56" TOTAL_2="28" WEIGHT="1.3479584874245796"/>
<CONT_DATA CI_END="-218.03880924420238" CI_START="-601.9611907557976" EFFECT_SIZE="-410.0" ESTIMABLE="YES" MEAN_1="775.0" MEAN_2="1185.0" ORDER="66960" SD_1="314.0" SD_2="403.0" SE="97.94118273088841" STUDY_ID="STD-Schweizer-2000" TOTAL_1="26" TOTAL_2="28" WEIGHT="1.1781307488671289"/>
<CONT_DATA CI_END="-178.1376418102081" CI_START="-629.8623581897918" EFFECT_SIZE="-404.0" ESTIMABLE="YES" MEAN_1="270.0" MEAN_2="674.0" ORDER="66985" SD_1="174.0" SD_2="411.0" SE="115.23801456116814" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.0536809602388129"/>
<CONT_DATA CI_END="-137.7918512698896" CI_START="-834.3081487301104" EFFECT_SIZE="-486.04999999999995" ESTIMABLE="YES" MEAN_1="581.95" MEAN_2="1068.0" ORDER="66986" SD_1="381.94" SD_2="1047.0" SE="177.68599396576985" STUDY_ID="STD-Speekenbrink-1996" TOTAL_1="75" TOTAL_2="37" WEIGHT="0.6913745408134699"/>
<CONT_DATA CI_END="-157.61222169513178" CI_START="-860.1877783048682" EFFECT_SIZE="-508.9" ESTIMABLE="YES" MEAN_1="435.1" MEAN_2="944.0" ORDER="66987" SD_1="169.6" SD_2="585.1" SE="179.23175174430824" STUDY_ID="STD-Stammers-1997" TOTAL_1="8" TOTAL_2="12" WEIGHT="0.68427817803186"/>
<CONT_DATA CI_END="-344.9577831528487" CI_START="-505.0422168471513" EFFECT_SIZE="-425.0" ESTIMABLE="YES" MEAN_1="416.0" MEAN_2="841.0" ORDER="66988" SD_1="67.0" SD_2="156.0" SE="40.83861615749783" STUDY_ID="STD-Tabuchi-1994" TOTAL_1="19" TOTAL_2="17" WEIGHT="1.5789194906945925"/>
<CONT_DATA CI_END="-256.0199216348648" CI_START="-1015.9800783651352" EFFECT_SIZE="-636.0" ESTIMABLE="YES" MEAN_1="648.0" MEAN_2="1284.0" ORDER="66962" SD_1="202.4" SD_2="578.7" SE="193.87094934517654" STUDY_ID="STD-Tassani-2000" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.6211590055325921"/>
<CONT_DATA CI_END="-27.313588505908456" CI_START="-312.68641149409154" EFFECT_SIZE="-170.0" ESTIMABLE="YES" MEAN_1="510.0" MEAN_2="680.0" ORDER="66963" SD_1="139.14" SD_2="183.41" SE="72.80052726457411" STUDY_ID="STD-Turkoz-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.3659422614093715"/>
<CONT_DATA CI_END="-361.8667609187139" CI_START="-650.1332390812861" EFFECT_SIZE="-506.0" ESTIMABLE="YES" MEAN_1="328.0" MEAN_2="834.0" ORDER="66989" SD_1="153.36" SD_2="372.45" SE="73.5387181694106" STUDY_ID="STD-Vedrinne-1992" TOTAL_1="30" TOTAL_2="30" WEIGHT="1.3604842365215435"/>
<CONT_DATA CI_END="-80.01554593152974" CI_START="-869.3844540684702" EFFECT_SIZE="-474.69999999999993" ESTIMABLE="YES" MEAN_1="878.9" MEAN_2="1353.6" ORDER="66990" SD_1="438.0" SD_2="746.5" SE="201.37331970469396" STUDY_ID="STD-Wendel-1995" TOTAL_1="20" TOTAL_2="18" WEIGHT="0.591536059643795"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="18.557689482013735" CI_END="-3.4593211073370043" CI_START="-223.69370210071338" DF="6" EFFECT_SIZE="-113.57651160402519" ESTIMABLE="YES" I2="67.66838885942538" ID="CMP-001.10.02" NO="2" P_CHI2="0.004979664577877796" P_Z="0.04322430263353849" STUDIES="7" TAU2="13702.502840876155" TOTAL_1="160" TOTAL_2="158" WEIGHT="8.469190184488347" Z="2.0215360674342655">
<NAME>Orthopaedic surgery</NAME>
<CONT_DATA CI_END="0.6549566524372921" CI_START="-252.6549566524373" EFFECT_SIZE="-126.0" ESTIMABLE="YES" MEAN_1="379.0" MEAN_2="505.0" ORDER="67026" SD_1="162.0" SD_2="251.0" SE="64.62106327028222" STUDY_ID="STD-Cvachovec-2001" TOTAL_1="20" TOTAL_2="22" WEIGHT="1.4254458325020358"/>
<CONT_DATA CI_END="137.99594075894015" CI_START="-137.99594075894015" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="432.0" MEAN_2="432.0" ORDER="67029" SD_1="270.0" SD_2="162.0" SE="70.4073859761886" STUDY_ID="STD-Hayes-1996" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.3835516069441551"/>
<CONT_DATA CI_END="21.524131824807284" CI_START="-375.5241318248073" EFFECT_SIZE="-177.0" ESTIMABLE="YES" MEAN_1="653.0" MEAN_2="830.0" ORDER="67024" SD_1="306.0" SD_2="334.0" SE="101.28968358130062" STUDY_ID="STD-Janssens-1994" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.1534821876018322"/>
<CONT_DATA CI_END="-214.27590588597485" CI_START="-751.7240941140251" EFFECT_SIZE="-483.0" ESTIMABLE="YES" MEAN_1="812.0" MEAN_2="1295.0" ORDER="67025" SD_1="411.0" SD_2="719.0" SE="137.1066490168628" STUDY_ID="STD-Lentschener-1999" TOTAL_1="35" TOTAL_2="37" WEIGHT="0.9098435664608815"/>
<CONT_DATA CI_END="-14.743231871619969" CI_START="-537.25676812838" EFFECT_SIZE="-276.0" ESTIMABLE="YES" MEAN_1="502.0" MEAN_2="778.0" ORDER="67028" SD_1="333.88" SD_2="578.08" SE="133.29671881174352" STUDY_ID="STD-Murkin-1995" TOTAL_1="29" TOTAL_2="24" WEIGHT="0.9336368277097061"/>
<CONT_DATA CI_END="109.1385658554097" CI_START="-74.73856585540972" EFFECT_SIZE="17.19999999999999" ESTIMABLE="YES" MEAN_1="451.2" MEAN_2="434.0" ORDER="67027" SD_1="161.9" SD_2="169.7" SE="46.90829350978353" STUDY_ID="STD-Petsatodis-2006" TOTAL_1="25" TOTAL_2="25" WEIGHT="1.543627188026743"/>
<CONT_DATA CI_END="232.64975225250885" CI_START="-182.64975225250885" EFFECT_SIZE="25.0" ESTIMABLE="YES" MEAN_1="412.0" MEAN_2="387.0" ORDER="67023" SD_1="243.0" SD_2="242.0" SE="105.94569792630048" STUDY_ID="STD-Utada-1997" TOTAL_1="11" TOTAL_2="10" WEIGHT="1.1196029752429946"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.23489740216903457" CI_END="-258.47642738591156" CI_START="-460.14537108492976" DF="1" EFFECT_SIZE="-359.31089923542066" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.03" MODIFIED="2010-05-25 15:34:08 +0100" MODIFIED_BY="Katharine Ker" NO="3" P_CHI2="0.6279160418509723" P_Z="2.867204782759055E-12" STUDIES="2" TAU2="0.0" TOTAL_1="41" TOTAL_2="42" WEIGHT="2.1981579402156317" Z="6.984084002593538">
<NAME>Thoracic surgery</NAME>
<CONT_DATA CI_END="-246.27279338727453" CI_START="-457.12720661272533" EFFECT_SIZE="-351.69999999999993" ESTIMABLE="YES" MEAN_1="412.6" MEAN_2="764.3" MODIFIED="2010-05-25 15:34:08 +0100" MODIFIED_BY="Katharine Ker" ORDER="2343" SD_1="199.2" SD_2="213.9" SE="53.79037953978836" STUDY_ID="STD-Apostolakis-2008" TOTAL_1="29" TOTAL_2="30" WEIGHT="1.49999995550954"/>
<CONT_DATA CI_END="-95.60442347288517" CI_START="-786.3955765271148" EFFECT_SIZE="-441.0" ESTIMABLE="YES" MEAN_1="402.0" MEAN_2="843.0" ORDER="67030" SD_1="236.0" SD_2="563.0" SE="176.2254711063831" STUDY_ID="STD-Katzel-1998" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.6981579847060916"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-308.7896854504245" CI_START="-717.2103145495755" DF="0" EFFECT_SIZE="-513.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.04" NO="4" P_CHI2="1.0" P_Z="8.494171235703255E-7" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.1323131552793186" Z="4.923656898951374">
<NAME>Orthognathic surgery</NAME>
<CONT_DATA CI_END="-308.7896854504245" CI_START="-717.2103145495755" EFFECT_SIZE="-513.0" ESTIMABLE="YES" MEAN_1="473.0" MEAN_2="986.0" ORDER="67031" SD_1="190.0" SD_2="356.0" SE="104.19085052600988" STUDY_ID="STD-Stewart-2001" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.1323131552793186"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-15.63765128166402" CI_START="-194.36234871833597" DF="0" EFFECT_SIZE="-105.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.05" MODIFIED="2010-01-11 11:29:34 +0000" MODIFIED_BY="Katharine Ker" NO="5" P_CHI2="1.0" P_Z="0.02128216186678043" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="1.551544414410603" Z="2.302941018541951">
<NAME>Liver surgery</NAME>
<CONT_DATA CI_END="-15.63765128166402" CI_START="-194.36234871833597" EFFECT_SIZE="-105.0" ESTIMABLE="YES" MEAN_1="748.0" MEAN_2="853.0" ORDER="67032" SD_1="120.0" SD_2="179.0" SE="45.593872858488616" STUDY_ID="STD-Marcel-1996" TOTAL_1="21" TOTAL_2="23" WEIGHT="1.551544414410603"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.610097326235507E-32" CI_END="-1.068914152498138" CI_START="-404.9310858475019" DF="0" EFFECT_SIZE="-203.00000000000003" ESTIMABLE="YES" I2="100.0" ID="CMP-001.10.06" NO="6" P_CHI2="0.0" P_Z="0.04879953434146869" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="1.1407759940273459" Z="1.9703389757538572">
<NAME>Vascular surgery</NAME>
<CONT_DATA CI_END="-1.0689141524981096" CI_START="-404.9310858475019" EFFECT_SIZE="-203.0" ESTIMABLE="YES" MEAN_1="717.0" MEAN_2="920.0" ORDER="67033" SD_1="340.0" SD_2="387.0" SE="103.027957370803" STUDY_ID="STD-Ehrlich-1998" TOTAL_1="25" TOTAL_2="25" WEIGHT="1.1407759940273459"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="578.6725765284364" CI_END="-331.87388873650104" CI_START="-403.498526017083" CI_STUDY="95" CI_TOTAL="95" DF="90" EFFECT_MEASURE="MD" EFFECT_SIZE="-367.686207376792" ESTIMABLE="YES" I2="84.4471634477779" I2_Q="97.71415437623553" ID="CMP-001.11" MODIFIED="2011-02-10 17:22:37 +0000" MODIFIED_BY="Emma M Sydenham" NO="11" P_CHI2="-1.5543122344752192E-15" P_Q="4.440892098500626E-16" P_Z="0.0" Q="87.49497250414845" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="75" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="19798.86571466632" TOTALS="YES" TOTAL_1="4132" TOTAL_2="4049" UNITS="" WEIGHT="100.00000000000003" Z="20.123012176593964">
<NAME>Blood loss - Post-operative - Dose (Cardiac Surgery)</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="112.6217282628697" CI_END="-228.0381782880532" CI_START="-458.12883423951183" DF="14" EFFECT_SIZE="-343.0835062637825" ESTIMABLE="YES" I2="87.56900625133129" ID="CMP-001.11.01" NO="1" P_CHI2="8.881784197001252E-16" P_Z="5.067964868392358E-9" STUDIES="15" TAU2="38644.58955437731" TOTAL_1="579" TOTAL_2="579" WEIGHT="16.065371604423213" Z="5.844925020411051">
<NAME>Prime Dose</NAME>
<CONT_DATA CI_END="-50.49110971378269" CI_START="-703.5088902862174" EFFECT_SIZE="-377.0" ESTIMABLE="YES" MEAN_1="850.0" MEAN_2="1227.0" ORDER="67034" SD_1="231.0" SD_2="582.0" SE="166.58922962956348" STUDY_ID="STD-Englberger-2002b" TOTAL_1="15" TOTAL_2="14" WEIGHT="0.7021186849185369"/>
<CONT_DATA CI_END="66.83530645189717" CI_START="-974.8353064518972" EFFECT_SIZE="-454.0" ESTIMABLE="YES" MEAN_1="703.0" MEAN_2="1157.0" ORDER="67035" SD_1="894.0" SD_2="783.0" SE="265.73718219323393" STUDY_ID="STD-Fauli-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.3692560804450752"/>
<CONT_DATA CI_END="-27.03712107033843" CI_START="-212.96287892966157" EFFECT_SIZE="-120.0" ESTIMABLE="YES" MEAN_1="415.0" MEAN_2="535.0" ORDER="67036" SD_1="200.2" SD_2="294.44" SE="47.430911824370696" STUDY_ID="STD-Hayashida-1997" TOTAL_1="55" TOTAL_2="57" WEIGHT="1.5142184168092634"/>
<CONT_DATA CI_END="-485.61848648717734" CI_START="-702.3815135128227" EFFECT_SIZE="-594.0" ESTIMABLE="YES" MEAN_1="784.0" MEAN_2="1378.0" ORDER="67037" SD_1="166.0" SD_2="375.0" SE="55.29770667610334" STUDY_ID="STD-Kalangos-1994" TOTAL_1="55" TOTAL_2="55" WEIGHT="1.4606801596927863"/>
<CONT_DATA CI_END="92.1395655632553" CI_START="-550.1395655632552" EFFECT_SIZE="-229.0" ESTIMABLE="YES" MEAN_1="964.0" MEAN_2="1193.0" ORDER="67038" SD_1="355.0" SD_2="526.0" SE="163.84972790131002" STUDY_ID="STD-Kipfer-2003" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.7157445058735363"/>
<CONT_DATA CI_END="-557.7614000031745" CI_START="-702.2385999968255" EFFECT_SIZE="-630.0" ESTIMABLE="YES" MEAN_1="188.0" MEAN_2="818.0" ORDER="67039" SD_1="51.5" SD_2="243.8" SE="36.85710582777764" STUDY_ID="STD-Kunt-2005" TOTAL_1="40" TOTAL_2="46" WEIGHT="1.578004393825752"/>
<CONT_DATA CI_END="-51.57861065141648" CI_START="-478.4213893485835" EFFECT_SIZE="-265.0" ESTIMABLE="YES" MEAN_1="487.0" MEAN_2="752.0" ORDER="67040" SD_1="121.0" SD_2="404.0" SE="108.89046484120331" STUDY_ID="STD-Lavee-1993" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.054660482872844"/>
<CONT_DATA CI_END="-242.86525177272293" CI_START="-531.1347482272771" EFFECT_SIZE="-387.0" ESTIMABLE="YES" MEAN_1="899.0" MEAN_2="1286.0" ORDER="67041" SD_1="655.7" SD_2="651.56" SE="73.53948815600367" STUDY_ID="STD-Lemmer-1996" TOTAL_1="159" TOTAL_2="157" WEIGHT="1.32449059818538"/>
<CONT_DATA CI_END="97.12956373669556" CI_START="-657.1295637366956" EFFECT_SIZE="-280.0" ESTIMABLE="YES" MEAN_1="1420.0" MEAN_2="1700.0" ORDER="67042" SD_1="1088.5" SD_2="1128.72" SE="192.41657842258604" STUDY_ID="STD-Levy-1995" TOTAL_1="68" TOTAL_2="65" WEIGHT="0.5875495501590606"/>
<CONT_DATA CI_END="-83.03617598631018" CI_START="-502.9638240136898" EFFECT_SIZE="-293.0" ESTIMABLE="YES" MEAN_1="487.0" MEAN_2="780.0" ORDER="67043" SD_1="135.0" SD_2="408.0" SE="107.12636847914435" STUDY_ID="STD-Mohr-1992" TOTAL_1="17" TOTAL_2="16" WEIGHT="1.0675111686044594"/>
<CONT_DATA CI_END="16.288983012069536" CI_START="-270.28898301206954" EFFECT_SIZE="-127.0" ESTIMABLE="YES" MEAN_1="446.0" MEAN_2="573.0" ORDER="67044" SD_1="155.0" SD_2="304.0" SE="73.107967361806" STUDY_ID="STD-Rossi-1997" TOTAL_1="21" TOTAL_2="22" WEIGHT="1.3278240714764593"/>
<CONT_DATA CI_END="33.76528631045497" CI_START="-319.76528631045494" EFFECT_SIZE="-143.0" ESTIMABLE="YES" MEAN_1="629.0" MEAN_2="772.0" ORDER="67045" SD_1="338.8" SD_2="336.1" SE="90.18802779273344" STUDY_ID="STD-Santamaria-2000" TOTAL_1="28" TOTAL_2="28" WEIGHT="1.1952398506024584"/>
<CONT_DATA CI_END="-178.1376418102081" CI_START="-629.8623581897918" EFFECT_SIZE="-404.0" ESTIMABLE="YES" MEAN_1="270.0" MEAN_2="674.0" ORDER="67046" SD_1="174.0" SD_2="411.0" SE="115.23801456116814" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.0093010259172235"/>
<CONT_DATA CI_END="-36.60232938293342" CI_START="-775.3976706170665" EFFECT_SIZE="-406.0" ESTIMABLE="YES" MEAN_1="662.0" MEAN_2="1068.0" ORDER="67047" SD_1="467.0" SD_2="1047.0" SE="188.4716625054482" STUDY_ID="STD-Speekenbrink-1996" TOTAL_1="37" TOTAL_2="37" WEIGHT="0.6035081300150915"/>
<CONT_DATA CI_END="-344.9577831528487" CI_START="-505.0422168471513" EFFECT_SIZE="-425.0" ESTIMABLE="YES" MEAN_1="416.0" MEAN_2="841.0" ORDER="67048" SD_1="67.0" SD_2="156.0" SE="40.83861615749783" STUDY_ID="STD-Tabuchi-1994" TOTAL_1="19" TOTAL_2="17" WEIGHT="1.555264485025282"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="58.71088118035486" CI_END="-232.6746688240284" CI_START="-316.4760905474753" DF="23" EFFECT_SIZE="-274.57537968575184" ESTIMABLE="YES" I2="60.82497905397477" ID="CMP-001.11.02" MODIFIED="2010-05-20 11:49:25 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="5.854946812799966E-5" P_Z="9.337250567166177E-38" STUDIES="24" TAU2="4792.810087946393" TOTAL_1="1033" TOTAL_2="1005" WEIGHT="28.4420564849392" Z="12.843644992121003">
<NAME>Low Dose</NAME>
<CONT_DATA CI_END="-87.61630555939439" CI_START="-600.3836944406056" EFFECT_SIZE="-344.0" ESTIMABLE="YES" MEAN_1="486.0" MEAN_2="830.0" ORDER="67049" SD_1="220.0" SD_2="405.0" SE="130.81041103965555" STUDY_ID="STD-Alajmo-1989" TOTAL_1="22" TOTAL_2="11" WEIGHT="0.9045278728633525"/>
<CONT_DATA CI_END="-187.58920934118368" CI_START="-712.4107906588163" EFFECT_SIZE="-450.0" ESTIMABLE="YES" MEAN_1="890.0" MEAN_2="1340.0" ORDER="67050" SD_1="430.0" SD_2="560.0" SE="133.88551663636636" STUDY_ID="STD-Alvarez-2001" TOTAL_1="26" TOTAL_2="29" WEIGHT="0.8850110446165245"/>
<CONT_DATA CI_END="-19.66237153995354" CI_START="-710.2376284600466" EFFECT_SIZE="-364.95000000000005" ESTIMABLE="YES" MEAN_1="498.15" MEAN_2="863.1" ORDER="67051" SD_1="372.58" SD_2="755.5" SE="176.17039454991584" STUDY_ID="STD-Basora-1999" TOTAL_1="36" TOTAL_2="21" WEIGHT="0.6567603862740514"/>
<CONT_DATA CI_END="-58.61644974290955" CI_START="-309.38355025709046" EFFECT_SIZE="-184.0" ESTIMABLE="YES" MEAN_1="269.0" MEAN_2="453.0" ORDER="67052" SD_1="142.18" SD_2="192.56" SE="63.972374618156195" STUDY_ID="STD-Blauhut-1994" TOTAL_1="14" TOTAL_2="14" WEIGHT="1.3974245319267498"/>
<CONT_DATA CI_END="-60.8133085462124" CI_START="-293.1866914537876" EFFECT_SIZE="-177.0" ESTIMABLE="YES" MEAN_1="325.0" MEAN_2="502.0" ORDER="67053" SD_1="237.0" SD_2="178.0" SE="59.280013495275114" STUDY_ID="STD-Cicek-1996a" TOTAL_1="25" TOTAL_2="25" WEIGHT="1.432091609818218"/>
<CONT_DATA CI_END="-174.0528673996087" CI_START="-397.34713260039143" EFFECT_SIZE="-285.70000000000005" ESTIMABLE="YES" MEAN_1="410.5" MEAN_2="696.2" ORDER="67054" SD_1="174.8" SD_2="247.7" SE="56.9638694797709" STUDY_ID="STD-Cicek-1996b" TOTAL_1="29" TOTAL_2="28" WEIGHT="1.4488238214472695"/>
<CONT_DATA CI_END="2.9816216320067497" CI_START="-228.5816216320069" EFFECT_SIZE="-112.80000000000007" ESTIMABLE="YES" MEAN_1="547.8" MEAN_2="660.6" MODIFIED="2010-05-20 11:49:25 +0100" MODIFIED_BY="Katharine Ker" ORDER="5331" SD_1="170.6" SD_2="213.4" SE="59.07334142120849" STUDY_ID="STD-Cicekcioglu-2006" TOTAL_1="24" TOTAL_2="20" WEIGHT="1.4335957599336264"/>
<CONT_DATA CI_END="209.3283830967839" CI_START="-719.3283830967839" EFFECT_SIZE="-255.0" ESTIMABLE="YES" MEAN_1="866.0" MEAN_2="1121.0" ORDER="67055" SD_1="1636.0" SD_2="683.0" SE="236.90658948804514" STUDY_ID="STD-Cosgrove-1992" TOTAL_1="56" TOTAL_2="56" WEIGHT="0.43973589481939007"/>
<CONT_DATA CI_END="-150.8447206185079" CI_START="-317.1552793814921" EFFECT_SIZE="-234.0" ESTIMABLE="YES" MEAN_1="455.0" MEAN_2="689.0" ORDER="67056" SD_1="298.5" SD_2="298.5" SE="42.42694255476648" STUDY_ID="STD-Dignan-2001" TOTAL_1="99" TOTAL_2="99" WEIGHT="1.5457414024358893"/>
<CONT_DATA CI_END="-249.582671513472" CI_START="-530.417328486528" EFFECT_SIZE="-390.0" ESTIMABLE="YES" MEAN_1="270.0" MEAN_2="660.0" ORDER="67057" SD_1="150.0" SD_2="185.0" SE="71.64281057923613" STUDY_ID="STD-Gherli-1992" TOTAL_1="9" TOTAL_2="13" WEIGHT="1.3391193286775231"/>
<CONT_DATA CI_END="-306.76288890654365" CI_START="-803.2371110934564" EFFECT_SIZE="-555.0" ESTIMABLE="YES" MEAN_1="660.0" MEAN_2="1215.0" ORDER="67058" SD_1="221.0" SD_2="587.0" SE="126.65391458798172" STUDY_ID="STD-Golanski-2000" TOTAL_1="29" TOTAL_2="24" WEIGHT="0.9315361860976054"/>
<CONT_DATA CI_END="245.05099065194304" CI_START="-377.05099065194304" EFFECT_SIZE="-66.0" ESTIMABLE="YES" MEAN_1="565.0" MEAN_2="631.0" ORDER="67059" SD_1="589.0" SD_2="423.0" SE="158.70240122036606" STUDY_ID="STD-Hardy-1993" TOTAL_1="22" TOTAL_2="19" WEIGHT="0.7421606164908467"/>
<CONT_DATA CI_END="-83.61334884882392" CI_START="-250.38665115117607" EFFECT_SIZE="-167.0" ESTIMABLE="YES" MEAN_1="368.0" MEAN_2="535.0" ORDER="67060" SD_1="126.1" SD_2="294.44" SE="42.54499154521172" STUDY_ID="STD-Hayashida-1997" TOTAL_1="55" TOTAL_2="57" WEIGHT="1.5450238706967356"/>
<CONT_DATA CI_END="-51.830643236040544" CI_START="-308.16935676395946" EFFECT_SIZE="-180.0" ESTIMABLE="YES" MEAN_1="564.0" MEAN_2="744.0" ORDER="67061" SD_1="425.0" SD_2="497.0" SE="65.39373058634902" STUDY_ID="STD-Koster-2004" TOTAL_1="100" TOTAL_2="100" WEIGHT="1.3867516497043706"/>
<CONT_DATA CI_END="-212.25886197837525" CI_START="-801.7411380216247" EFFECT_SIZE="-507.0" ESTIMABLE="YES" MEAN_1="608.0" MEAN_2="1115.0" ORDER="67062" SD_1="336.0" SD_2="1106.0" SE="150.3808949279197" STUDY_ID="STD-Kuepper-2003" TOTAL_1="60" TOTAL_2="59" WEIGHT="0.7871669395358711"/>
<CONT_DATA CI_END="-332.24449896243965" CI_START="-617.7555010375604" EFFECT_SIZE="-475.0" ESTIMABLE="YES" MEAN_1="811.0" MEAN_2="1286.0" ORDER="67063" SD_1="661.04" SD_2="651.56" SE="72.83577767938468" STUDY_ID="STD-Lemmer-1996" TOTAL_1="168" TOTAL_2="157" WEIGHT="1.3299252173558265"/>
<CONT_DATA CI_END="-267.7672156360716" CI_START="-1052.2327843639284" EFFECT_SIZE="-660.0" ESTIMABLE="YES" MEAN_1="1040.0" MEAN_2="1700.0" ORDER="67064" SD_1="1098.4" SD_2="1128.72" SE="200.12244482950223" STUDY_ID="STD-Levy-1995" TOTAL_1="59" TOTAL_2="65" WEIGHT="0.557853396945364"/>
<CONT_DATA CI_END="-2.981651139439535" CI_START="-247.81834886056055" EFFECT_SIZE="-125.40000000000003" ESTIMABLE="YES" MEAN_1="399.2" MEAN_2="524.6" ORDER="67065" SD_1="170.2" SD_2="147.47" SE="62.45948896315484" STUDY_ID="STD-Locatelli-1990" TOTAL_1="13" TOTAL_2="13" WEIGHT="1.4087027810003043"/>
<CONT_DATA CI_END="-143.13147633895431" CI_START="-354.8685236610457" EFFECT_SIZE="-249.0" ESTIMABLE="YES" MEAN_1="372.0" MEAN_2="621.0" ORDER="67066" SD_1="159.0" SD_2="255.87" SE="54.01554543661163" STUDY_ID="STD-Maccario-1994" TOTAL_1="29" TOTAL_2="32" WEIGHT="1.4696923076298163"/>
<CONT_DATA CI_END="-292.74976627670503" CI_START="-647.250233723295" EFFECT_SIZE="-470.0" ESTIMABLE="YES" MEAN_1="290.0" MEAN_2="760.0" ORDER="67067" SD_1="110.0" SD_2="320.0" SE="90.43545448866517" STUDY_ID="STD-Misfeld-1998" TOTAL_1="14" TOTAL_2="14" WEIGHT="1.193330578167529"/>
<CONT_DATA CI_END="-125.15102641066264" CI_START="-410.84897358933733" EFFECT_SIZE="-268.0" ESTIMABLE="YES" MEAN_1="182.0" MEAN_2="450.0" ORDER="67068" SD_1="144.0" SD_2="224.0" SE="72.8834686331544" STUDY_ID="STD-Moran-2000" TOTAL_1="12" TOTAL_2="14" WEIGHT="1.329557157493216"/>
<CONT_DATA CI_END="-217.7203837263889" CI_START="-432.2796162736111" EFFECT_SIZE="-325.0" ESTIMABLE="YES" MEAN_1="423.0" MEAN_2="748.0" MODIFIED="2010-05-07 15:02:20 +0100" MODIFIED_BY="Katharine Ker" ORDER="2470" SD_1="178.0" SD_2="212.0" SE="54.73550387650948" STUDY_ID="STD-Nur_x00f6_zler-2008" TOTAL_1="25" TOTAL_2="26" WEIGHT="1.464644175248831"/>
<CONT_DATA CI_END="-229.4414173369993" CI_START="-270.5585826630007" EFFECT_SIZE="-250.0" ESTIMABLE="YES" MEAN_1="555.0" MEAN_2="805.0" MODIFIED="2010-05-07 15:32:49 +0100" MODIFIED_BY="Katharine Ker" ORDER="2483" SD_1="56.0" SD_2="76.0" SE="10.489265529960841" STUDY_ID="STD-Parvizi-2007" TOTAL_1="81" TOTAL_2="81" WEIGHT="1.6769559006504475"/>
<CONT_DATA CI_END="-218.03880924420238" CI_START="-601.9611907557976" EFFECT_SIZE="-410.0" ESTIMABLE="YES" MEAN_1="775.0" MEAN_2="1185.0" ORDER="67069" SD_1="314.0" SD_2="403.0" SE="97.94118273088841" STUDY_ID="STD-Schweizer-2000" TOTAL_1="26" TOTAL_2="28" WEIGHT="1.1359240551098349"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="319.84499458106336" CI_END="-366.22427283760106" CI_START="-470.9614802251728" DF="51" EFFECT_SIZE="-418.59287653138693" ESTIMABLE="YES" I2="84.05477626223278" ID="CMP-001.11.03" MODIFIED="2011-02-10 17:22:37 +0000" MODIFIED_BY="Emma M Sydenham" NO="3" P_CHI2="-8.881784197001252E-16" P_Z="2.5675489069571543E-55" STUDIES="52" TAU2="24914.31994926457" TOTAL_1="2520" TOTAL_2="2465" WEIGHT="55.49257191063761" Z="15.66638986564947">
<NAME>High Dose</NAME>
<CONT_DATA CI_END="-387.8679575737349" CI_START="-566.1320424262651" EFFECT_SIZE="-477.0" ESTIMABLE="YES" MEAN_1="371.0" MEAN_2="848.0" MODIFIED="2010-01-11 14:00:24 +0000" MODIFIED_BY="Katharine Ker" ORDER="2261" SD_1="62.0" SD_2="126.0" SE="45.47636748905963" STUDY_ID="STD-Asimakopoulos-2000" TOTAL_1="8" TOTAL_2="10" WEIGHT="1.5267930483557293"/>
<CONT_DATA CI_END="-187.01699918638087" CI_START="-810.9830008136191" EFFECT_SIZE="-499.0" ESTIMABLE="YES" MEAN_1="699.0" MEAN_2="1198.0" ORDER="67070" SD_1="429.0" SD_2="1124.0" SE="159.17792534684372" STUDY_ID="STD-Baele-1992" TOTAL_1="58" TOTAL_2="57" WEIGHT="0.7396751583873326"/>
<CONT_DATA CI_END="-196.47414169744857" CI_START="-331.52585830255146" EFFECT_SIZE="-264.0" ESTIMABLE="YES" MEAN_1="309.0" MEAN_2="573.0" ORDER="67071" SD_1="133.0" SD_2="166.0" SE="34.452601596349105" STUDY_ID="STD-Bidstrup-1989" TOTAL_1="40" TOTAL_2="37" WEIGHT="1.590897450638987"/>
<CONT_DATA CI_END="-585.6333218258633" CI_START="-1496.3666781741367" EFFECT_SIZE="-1041.0" ESTIMABLE="YES" MEAN_1="352.0" MEAN_2="1393.0" ORDER="67072" SD_1="138.0" SD_2="979.0" SE="232.33420703952262" STUDY_ID="STD-Bidstrup-1990" TOTAL_1="26" TOTAL_2="18" WEIGHT="0.45252390757416655"/>
<CONT_DATA CI_END="-312.2369198483749" CI_START="-624.963080151625" EFFECT_SIZE="-468.59999999999997" ESTIMABLE="YES" MEAN_1="368.7" MEAN_2="837.3" ORDER="67073" SD_1="164.3" SD_2="404.9" SE="79.77854765954734" STUDY_ID="STD-Bidstrup-2000" TOTAL_1="30" TOTAL_2="30" WEIGHT="1.2760660356744389"/>
<CONT_DATA CI_END="43.653251459478554" CI_START="-303.65325145947855" EFFECT_SIZE="-130.0" ESTIMABLE="YES" MEAN_1="260.0" MEAN_2="390.0" MODIFIED="2011-02-10 17:22:37 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="67074" SD_1="160.0" SD_2="230.0" SE="88.60022573334675" STUDY_ID="STD-Boldt-1991" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.2075117867882679"/>
<CONT_DATA CI_END="59.170169878055646" CI_START="-159.17016987805565" EFFECT_SIZE="-50.0" ESTIMABLE="YES" MEAN_1="465.0" MEAN_2="515.0" MODIFIED="2011-02-10 17:22:36 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="67075" SD_1="195.0" SD_2="155.0" SE="55.70008976653449" STUDY_ID="STD-Boldt-1994" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.4578314524013116"/>
<CONT_DATA CI_END="-281.2940946266908" CI_START="-645.5059053733092" EFFECT_SIZE="-463.40000000000003" ESTIMABLE="YES" MEAN_1="431.8" MEAN_2="895.2" ORDER="67076" SD_1="343.0" SD_2="568.0" SE="92.91288350690999" STUDY_ID="STD-Carrera-1994" TOTAL_1="51" TOTAL_2="51" WEIGHT="1.1742655872462782"/>
<CONT_DATA CI_END="-112.9176455723848" CI_START="-301.0823544276152" EFFECT_SIZE="-207.0" ESTIMABLE="YES" MEAN_1="295.0" MEAN_2="502.0" ORDER="67077" SD_1="161.0" SD_2="178.0" SE="48.00208328812407" STUDY_ID="STD-Cicek-1996a" TOTAL_1="25" TOTAL_2="25" WEIGHT="1.5104841867991354"/>
<CONT_DATA CI_END="-602.3396631103705" CI_START="-831.6603368896295" EFFECT_SIZE="-717.0" ESTIMABLE="YES" MEAN_1="780.0" MEAN_2="1497.0" ORDER="67078" SD_1="262.0" SD_2="360.0" SE="58.501246856603316" STUDY_ID="STD-Cohen-1998" TOTAL_1="56" TOTAL_2="59" WEIGHT="1.4377483798737005"/>
<CONT_DATA CI_END="-302.80600340008493" CI_START="-861.1939965999151" EFFECT_SIZE="-582.0" ESTIMABLE="YES" MEAN_1="834.0" MEAN_2="1416.0" ORDER="67079" SD_1="448.0" SD_2="559.0" SE="142.44853415785272" STUDY_ID="STD-Corbeau-1995" TOTAL_1="43" TOTAL_2="20" WEIGHT="0.8327751557656142"/>
<CONT_DATA CI_END="-136.02267632197476" CI_START="-665.9773236780252" EFFECT_SIZE="-401.0" ESTIMABLE="YES" MEAN_1="720.0" MEAN_2="1121.0" ORDER="67080" SD_1="753.0" SD_2="683.0" SE="135.1949963204082" STUDY_ID="STD-Cosgrove-1992" TOTAL_1="57" TOTAL_2="56" WEIGHT="0.8768212675554344"/>
<CONT_DATA CI_END="-355.5796439137212" CI_START="-591.4203560862788" EFFECT_SIZE="-473.5" ESTIMABLE="YES" MEAN_1="587.0" MEAN_2="1060.5" ORDER="67081" SD_1="328.82" SD_2="503.84" SE="60.16455252056646" STUDY_ID="STD-Defraigne-2000" TOTAL_1="100" TOTAL_2="100" WEIGHT="1.4256307169185363"/>
<CONT_DATA CI_END="-279.9271961493625" CI_START="-664.0728038506375" EFFECT_SIZE="-472.0" ESTIMABLE="YES" MEAN_1="380.0" MEAN_2="852.0" ORDER="67082" SD_1="125.0" SD_2="522.0" SE="97.99812923384474" STUDY_ID="STD-Deleuze-1991" TOTAL_1="30" TOTAL_2="30" WEIGHT="1.1354929792628283"/>
<CONT_DATA CI_END="-37.030106106540046" CI_START="-376.9698938934599" EFFECT_SIZE="-207.0" ESTIMABLE="YES" MEAN_1="603.0" MEAN_2="810.0" MODIFIED="2010-05-17 10:52:38 +0100" MODIFIED_BY="Katharine Ker" ORDER="2556" SD_1="330.0" SD_2="415.0" SE="86.72092713649883" STUDY_ID="STD-Desai-2009" TOTAL_1="38" TOTAL_2="37" WEIGHT="1.222074777375027"/>
<CONT_DATA CI_END="-312.08777433627534" CI_START="-1073.9122256637247" EFFECT_SIZE="-693.0" ESTIMABLE="YES" MEAN_1="738.0" MEAN_2="1431.0" ORDER="67083" SD_1="411.0" SD_2="760.0" SE="194.3465434407528" STUDY_ID="STD-Dietrich-1990" TOTAL_1="19" TOTAL_2="20" WEIGHT="0.5799314451925373"/>
<CONT_DATA CI_END="-306.95520259286434" CI_START="-411.04479740713566" EFFECT_SIZE="-359.0" ESTIMABLE="YES" MEAN_1="678.0" MEAN_2="1037.0" ORDER="67084" SD_1="419.0" SD_2="671.0" SE="26.55395600003796" STUDY_ID="STD-Dietrich-1992" TOTAL_1="902" TOTAL_2="882" WEIGHT="1.6282855338219118"/>
<CONT_DATA CI_END="-471.20080822734036" CI_START="-1326.7991917726597" EFFECT_SIZE="-899.0" ESTIMABLE="YES" MEAN_1="597.0" MEAN_2="1496.0" ORDER="67085" SD_1="312.4" SD_2="785.51" SE="218.26890450390164" STUDY_ID="STD-Dietrich-1995" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.4950510370776883"/>
<CONT_DATA CI_END="-434.2340459303495" CI_START="-1181.7659540696504" EFFECT_SIZE="-808.0" ESTIMABLE="YES" MEAN_1="349.0" MEAN_2="1157.0" ORDER="67086" SD_1="338.0" SD_2="783.0" SE="190.70041950661778" STUDY_ID="STD-Fauli-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.5944275738763943"/>
<CONT_DATA CI_END="-315.6909511298993" CI_START="-454.3090488701007" EFFECT_SIZE="-385.0" ESTIMABLE="YES" MEAN_1="279.0" MEAN_2="664.0" MODIFIED="2010-01-11 14:01:08 +0000" MODIFIED_BY="Katharine Ker" ORDER="2268" SD_1="29.0" SD_2="108.0" SE="35.36240942017385" STUDY_ID="STD-Feindt-1994" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.5860967828842178"/>
<CONT_DATA CI_END="-297.0561409939297" CI_START="-806.9438590060703" EFFECT_SIZE="-552.0" ESTIMABLE="YES" MEAN_1="652.0" MEAN_2="1204.0" ORDER="67087" SD_1="382.0" SD_2="705.0" SE="130.07578762519867" STUDY_ID="STD-Fraedrich-1989" TOTAL_1="38" TOTAL_2="38" WEIGHT="0.9092490684462504"/>
<CONT_DATA CI_END="-234.06169509106607" CI_START="-505.9383049089339" EFFECT_SIZE="-370.0" ESTIMABLE="YES" MEAN_1="290.0" MEAN_2="660.0" ORDER="67088" SD_1="140.0" SD_2="185.0" SE="69.35755247606482" STUDY_ID="STD-Gherli-1992" TOTAL_1="9" TOTAL_2="13" WEIGHT="1.356653081291229"/>
<CONT_DATA CI_END="-11.038465241097526" CI_START="-622.9615347589024" EFFECT_SIZE="-317.0" ESTIMABLE="YES" MEAN_1="685.0" MEAN_2="1002.0" MODIFIED="2010-05-17 14:12:42 +0100" MODIFIED_BY="Katharine Ker" ORDER="2598" SD_1="505.0" SD_2="627.0" SE="156.10569233531228" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="27" WEIGHT="0.7558966319190252"/>
<CONT_DATA CI_END="-53.5361092838958" CI_START="-444.4638907161042" EFFECT_SIZE="-249.0" ESTIMABLE="YES" MEAN_1="520.0" MEAN_2="769.0" ORDER="67089" SD_1="287.0" SD_2="303.0" SE="99.72830738620628" STUDY_ID="STD-Harmon-2004" TOTAL_1="17" TOTAL_2="18" WEIGHT="1.1224333193081388"/>
<CONT_DATA CI_END="-226.25714788522896" CI_START="-515.742852114771" EFFECT_SIZE="-371.0" ESTIMABLE="YES" MEAN_1="328.0" MEAN_2="699.0" ORDER="67090" SD_1="84.0" SD_2="261.0" SE="73.84975094261128" STUDY_ID="STD-Hendrice-1995" TOTAL_1="12" TOTAL_2="14" WEIGHT="1.3220921112271147"/>
<CONT_DATA CI_END="-551.0626171959898" CI_START="-764.9373828040102" EFFECT_SIZE="-658.0" ESTIMABLE="YES" MEAN_1="720.0" MEAN_2="1378.0" ORDER="67091" SD_1="152.0" SD_2="375.0" SE="54.560891754909115" STUDY_ID="STD-Kalangos-1994" TOTAL_1="55" TOTAL_2="55" WEIGHT="1.465871443627939"/>
<CONT_DATA CI_END="-35.74269621556013" CI_START="-314.25730378443984" EFFECT_SIZE="-175.0" ESTIMABLE="YES" MEAN_1="597.0" MEAN_2="772.0" ORDER="67092" SD_1="266.0" SD_2="299.0" SE="71.05095036586576" STUDY_ID="STD-Klein-1998" TOTAL_1="36" TOTAL_2="29" WEIGHT="1.3436709659469213"/>
<CONT_DATA CI_END="-287.1721110470977" CI_START="-622.8278889529023" EFFECT_SIZE="-455.0" ESTIMABLE="YES" MEAN_1="540.0" MEAN_2="995.0" ORDER="67093" SD_1="259.4" SD_2="281.7" SE="85.6280473910272" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.2305590107984863"/>
<CONT_DATA CI_END="-398.659304412159" CI_START="-1237.340695587841" EFFECT_SIZE="-818.0" ESTIMABLE="YES" MEAN_1="722.0" MEAN_2="1540.0" ORDER="67094" SD_1="304.0" SD_2="800.0" SE="213.95326592506132" STUDY_ID="STD-Laub-1994" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.5091330478213774"/>
<CONT_DATA CI_END="-358.60994752854805" CI_START="-641.390052471452" EFFECT_SIZE="-500.0" ESTIMABLE="YES" MEAN_1="786.0" MEAN_2="1286.0" ORDER="67095" SD_1="632.46" SD_2="651.56" SE="72.13910744621771" STUDY_ID="STD-Lemmer-1996" TOTAL_1="160" TOTAL_2="157" WEIGHT="1.3352974718492143"/>
<CONT_DATA CI_END="-426.1829922474619" CI_START="-869.8170077525381" EFFECT_SIZE="-648.0" ESTIMABLE="YES" MEAN_1="855.0" MEAN_2="1503.0" ORDER="67096" SD_1="671.0" SD_2="671.2" SE="113.1740223301052" STUDY_ID="STD-Lemmer_x005f_1-1994" TOTAL_1="74" TOTAL_2="67" WEIGHT="1.0238936676048922"/>
<CONT_DATA CI_END="92.11415445387058" CI_START="-1600.1141544538705" EFFECT_SIZE="-754.0" ESTIMABLE="YES" MEAN_1="1225.0" MEAN_2="1979.0" ORDER="67097" SD_1="1563.44" SD_2="1600.88" SE="431.69882769678986" STUDY_ID="STD-Lemmer_x005f_2-1994" TOTAL_1="23" TOTAL_2="32" WEIGHT="0.16194163245493365"/>
<CONT_DATA CI_END="-417.4503844680659" CI_START="-1182.549615531934" EFFECT_SIZE="-800.0" ESTIMABLE="YES" MEAN_1="900.0" MEAN_2="1700.0" ORDER="67098" SD_1="1062.19" SD_2="1128.72" SE="195.18196178574536" STUDY_ID="STD-Levy-1995" TOTAL_1="61" TOTAL_2="65" WEIGHT="0.5766717283804003"/>
<CONT_DATA CI_END="-229.82107785966545" CI_START="-382.9189221403344" EFFECT_SIZE="-306.36999999999995" ESTIMABLE="YES" MEAN_1="304.3" MEAN_2="610.67" ORDER="67099" SD_1="105.64" SD_2="193.37" SE="39.05629018907624" STUDY_ID="STD-Li-2005" TOTAL_1="40" TOTAL_2="30" WEIGHT="1.5656502029345705"/>
<CONT_DATA CI_END="-185.30244035996964" CI_START="-380.69755964003036" EFFECT_SIZE="-283.0" ESTIMABLE="YES" MEAN_1="241.6" MEAN_2="524.6" ORDER="67100" SD_1="98.7" SD_2="147.47" SE="49.84660963704244" STUDY_ID="STD-Locatelli-1990" TOTAL_1="12" TOTAL_2="13" WEIGHT="1.4982500962228535"/>
<CONT_DATA CI_END="-111.95190234298072" CI_START="-328.0480976570193" EFFECT_SIZE="-220.0" ESTIMABLE="YES" MEAN_1="401.0" MEAN_2="621.0" ORDER="67101" SD_1="178.27" SD_2="255.87" SE="55.127593419720405" STUDY_ID="STD-Maccario-1994" TOTAL_1="32" TOTAL_2="32" WEIGHT="1.4618816088060054"/>
<CONT_DATA CI_END="-266.5064429226487" CI_START="-759.4935570773513" EFFECT_SIZE="-513.0" ESTIMABLE="YES" MEAN_1="298.0" MEAN_2="811.0" ORDER="67102" SD_1="140.0" SD_2="600.0" SE="125.76432986608988" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.9374092989631748"/>
<CONT_DATA CI_END="-174.70883371406856" CI_START="-591.2911662859315" EFFECT_SIZE="-383.0" ESTIMABLE="YES" MEAN_1="397.0" MEAN_2="780.0" ORDER="67103" SD_1="123.0" SD_2="408.0" SE="106.272955997613" STUDY_ID="STD-Mohr-1992" TOTAL_1="17" TOTAL_2="16" WEIGHT="1.0737638244973784"/>
<CONT_DATA CI_END="-178.22235956761807" CI_START="-437.77764043238193" EFFECT_SIZE="-308.0" ESTIMABLE="YES" MEAN_1="142.0" MEAN_2="450.0" ORDER="67104" SD_1="98.0" SD_2="224.0" SE="66.21429855653032" STUDY_ID="STD-Moran-2000" TOTAL_1="12" TOTAL_2="14" WEIGHT="1.380558923388062"/>
<CONT_DATA CI_END="-689.9614338716078" CI_START="-2022.2385661283924" EFFECT_SIZE="-1356.1000000000001" ESTIMABLE="YES" MEAN_1="1409.7" MEAN_2="2765.8" ORDER="67105" SD_1="1251.51" SD_2="1240.0" SE="339.8728606151992" STUDY_ID="STD-Murkin-1994" TOTAL_1="29" TOTAL_2="25" WEIGHT="0.2467351444206041"/>
<CONT_DATA CI_END="-228.48916367649065" CI_START="-531.5108363235094" EFFECT_SIZE="-380.0" ESTIMABLE="YES" MEAN_1="344.0" MEAN_2="724.0" ORDER="67106" SD_1="106.0" SD_2="280.0" SE="77.30286756216313" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.2953191310410197"/>
<CONT_DATA CI_END="32.84371674362035" CI_START="-112.84371674362035" EFFECT_SIZE="-40.0" ESTIMABLE="YES" MEAN_1="510.0" MEAN_2="550.0" ORDER="67107" SD_1="105.0" SD_2="124.0" SE="37.16584453500283" STUDY_ID="STD-Prendergast_x005f_1-1996" TOTAL_1="18" TOTAL_2="20" WEIGHT="1.5763017009195097"/>
<CONT_DATA CI_END="-293.0057615234844" CI_START="-442.9942384765156" EFFECT_SIZE="-368.0" ESTIMABLE="YES" MEAN_1="526.0" MEAN_2="894.0" ORDER="67108" SD_1="95.0" SD_2="120.0" SE="38.26306966253492" STUDY_ID="STD-Prendergast_x005f_2-1996" TOTAL_1="16" TOTAL_2="16" WEIGHT="1.5701662021676321"/>
<CONT_DATA CI_END="-441.3955301426539" CI_START="-1322.604469857346" EFFECT_SIZE="-882.0" ESTIMABLE="YES" MEAN_1="1051.0" MEAN_2="1933.0" ORDER="67109" SD_1="944.0" SD_2="1189.0" SE="224.80232970237103" STUDY_ID="STD-Rodrigus-1996" TOTAL_1="45" TOTAL_2="46" WEIGHT="0.4746762419611289"/>
<CONT_DATA CI_END="-456.73689568127986" CI_START="-1989.2631043187203" EFFECT_SIZE="-1223.0" ESTIMABLE="YES" MEAN_1="286.0" MEAN_2="1509.0" ORDER="67110" SD_1="159.2" SD_2="1286.85" SE="390.9577473682709" STUDY_ID="STD-Royston-1987" TOTAL_1="11" TOTAL_2="11" WEIGHT="0.19337935151506"/>
<CONT_DATA CI_END="-127.78875137805562" CI_START="-442.2112486219444" EFFECT_SIZE="-285.0" ESTIMABLE="YES" MEAN_1="487.0" MEAN_2="772.0" ORDER="67111" SD_1="259.2" SD_2="336.1" SE="80.21129462684347" STUDY_ID="STD-Santamaria-2000" TOTAL_1="28" TOTAL_2="28" WEIGHT="1.2726981579892058"/>
<CONT_DATA CI_END="-215.49326086701296" CI_START="-912.506739132987" EFFECT_SIZE="-564.0" ESTIMABLE="YES" MEAN_1="504.0" MEAN_2="1068.0" ORDER="67112" SD_1="275.0" SD_2="1047.0" SE="177.8128281345799" STUDY_ID="STD-Speekenbrink-1996" TOTAL_1="38" TOTAL_2="37" WEIGHT="0.6493340108809645"/>
<CONT_DATA CI_END="-157.61222169513178" CI_START="-860.1877783048682" EFFECT_SIZE="-508.9" ESTIMABLE="YES" MEAN_1="435.1" MEAN_2="944.0" ORDER="67113" SD_1="169.6" SD_2="585.1" SE="179.23175174430824" STUDY_ID="STD-Stammers-1997" TOTAL_1="8" TOTAL_2="12" WEIGHT="0.6429983666436169"/>
<CONT_DATA CI_END="-256.0199216348648" CI_START="-1015.9800783651352" EFFECT_SIZE="-636.0" ESTIMABLE="YES" MEAN_1="648.0" MEAN_2="1284.0" ORDER="67114" SD_1="202.4" SD_2="578.7" SE="193.87094934517654" STUDY_ID="STD-Tassani-2000" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.5817973576281708"/>
<CONT_DATA CI_END="-27.313588505908456" CI_START="-312.68641149409154" EFFECT_SIZE="-170.0" ESTIMABLE="YES" MEAN_1="510.0" MEAN_2="680.0" ORDER="67115" SD_1="139.14" SD_2="183.41" SE="72.80052726457411" STUDY_ID="STD-Turkoz-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.3301972421244905"/>
<CONT_DATA CI_END="-361.8667609187139" CI_START="-650.1332390812861" EFFECT_SIZE="-506.0" ESTIMABLE="YES" MEAN_1="328.0" MEAN_2="834.0" ORDER="67116" SD_1="153.36" SD_2="372.45" SE="73.5387181694106" STUDY_ID="STD-Vedrinne-1992" TOTAL_1="30" TOTAL_2="30" WEIGHT="1.3244965488092648"/>
<CONT_DATA CI_END="-80.01554593152974" CI_START="-869.3844540684702" EFFECT_SIZE="-474.69999999999993" ESTIMABLE="YES" MEAN_1="878.9" MEAN_2="1353.6" ORDER="67117" SD_1="438.0" SD_2="746.5" SE="201.37331970469396" STUDY_ID="STD-Wendel-1995" TOTAL_1="20" TOTAL_2="18" WEIGHT="0.5532110555794334"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="66.95867747022875" CI_END="-311.51056562687313" CI_START="-520.3822655066149" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="MD" EFFECT_SIZE="-415.946415566744" ESTIMABLE="YES" I2="76.10466543770382" I2_Q="40.73574488596507" ID="CMP-001.12" MODIFIED="2010-05-28 16:25:37 +0100" MODIFIED_BY="Katharine Ker" NO="12" P_CHI2="3.380869506575124E-8" P_Q="0.1939497247913453" P_Z="5.896998049208299E-15" Q="1.687357747221867" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="24649.737536001616" TOTALS="YES" TOTAL_1="932" TOTAL_2="857" UNITS="" WEIGHT="100.0" Z="7.806131653821221">
<NAME>Blood loss - Total</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="42.60158010281581" CI_END="-284.91284836249827" CI_START="-612.8163163995656" DF="6" EFFECT_SIZE="-448.86458238103194" ESTIMABLE="YES" I2="85.91601535548814" ID="CMP-001.12.01" MODIFIED="2010-05-28 16:25:37 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="1.3985217306444753E-7" P_Z="8.051987137419706E-8" STUDIES="7" TAU2="32951.29147575818" TOTAL_1="716" TOTAL_2="643" WEIGHT="50.50233698075447" Z="5.365959809263034">
<NAME>Cardiac surgery</NAME>
<CONT_DATA CI_END="-362.8945895181404" CI_START="-645.1054104818596" EFFECT_SIZE="-504.0" ESTIMABLE="YES" MEAN_1="664.0" MEAN_2="1168.0" ORDER="67118" SD_1="1009.0" SD_2="1022.0" SE="71.99387927272187" STUDY_ID="STD-Alderman-1998" TOTAL_1="401" TOTAL_2="395" WEIGHT="9.51717805418331"/>
<CONT_DATA CI_END="-613.9041582621686" CI_START="-1847.8958417378312" EFFECT_SIZE="-1230.8999999999999" ESTIMABLE="YES" MEAN_1="901.3" MEAN_2="2132.2" MODIFIED="2010-05-28 16:25:34 +0100" MODIFIED_BY="Katharine Ker" ORDER="2349" SD_1="514.6" SD_2="1487.5" SE="314.79958132119555" STUDY_ID="STD-Bert-2008" TOTAL_1="25" TOTAL_2="25" WEIGHT="2.2943677882054327"/>
<CONT_DATA CI_END="43.80055845412954" CI_START="-747.8005584541295" EFFECT_SIZE="-352.0" ESTIMABLE="YES" MEAN_1="559.0" MEAN_2="911.0" ORDER="67120" SD_1="689.38" SD_2="1075.17" SE="201.94277118159" STUDY_ID="STD-Harder-1991" TOTAL_1="40" TOTAL_2="40" WEIGHT="4.339323127520504"/>
<CONT_DATA CI_END="-24.434452895297056" CI_START="-699.565547104703" EFFECT_SIZE="-362.0" ESTIMABLE="YES" MEAN_1="1158.0" MEAN_2="1520.0" ORDER="67119" SD_1="385.0" SD_2="614.0" SE="172.23048472695257" STUDY_ID="STD-Harmon-2004" TOTAL_1="17" TOTAL_2="18" WEIGHT="5.227555089438512"/>
<CONT_DATA CI_END="-417.4643210200682" CI_START="-676.5356789799318" EFFECT_SIZE="-547.0" ESTIMABLE="YES" MEAN_1="553.0" MEAN_2="1100.0" ORDER="67121" SD_1="168.0" SD_2="168.0" SE="66.09084656743322" STUDY_ID="STD-Hendrice-1995" TOTAL_1="12" TOTAL_2="14" WEIGHT="9.784518998450334"/>
<CONT_DATA CI_END="-182.5777621439959" CI_START="-601.4222378560041" EFFECT_SIZE="-392.0" ESTIMABLE="YES" MEAN_1="608.0" MEAN_2="1000.0" ORDER="67122" SD_1="717.62" SD_2="736.0" SE="106.85004393340897" STUDY_ID="STD-Isetta-1993" TOTAL_1="140" TOTAL_2="70" WEIGHT="7.872215781022711"/>
<CONT_DATA CI_END="-229.4414173369993" CI_START="-270.5585826630007" EFFECT_SIZE="-250.0" ESTIMABLE="YES" MEAN_1="555.0" MEAN_2="805.0" MODIFIED="2010-05-28 16:25:37 +0100" MODIFIED_BY="Katharine Ker" ORDER="2336" SD_1="56.0" SD_2="76.0" SE="10.489265529960841" STUDY_ID="STD-Parvizi-2007" TOTAL_1="81" TOTAL_2="81" WEIGHT="11.467178141933665"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="22.66973962019108" CI_END="-235.37277988334952" CI_START="-562.8058363888279" DF="9" EFFECT_SIZE="-399.0893081360887" ESTIMABLE="YES" I2="60.299499902574794" ID="CMP-001.12.02" NO="2" P_CHI2="0.006982224684336735" P_Z="1.7724590303971206E-6" STUDIES="10" TAU2="34542.41266622003" TOTAL_1="216" TOTAL_2="214" WEIGHT="49.49766301924552" Z="4.777774601683534">
<NAME>Orthopaedic surgery</NAME>
<CONT_DATA CI_END="793.3535070576806" CI_START="-593.3535070576806" EFFECT_SIZE="100.0" ESTIMABLE="YES" MEAN_1="1700.0" MEAN_2="1600.0" ORDER="67127" SD_1="1000.0" SD_2="1400.0" SE="353.75828970673166" STUDY_ID="STD-Amar-2003" TOTAL_1="23" TOTAL_2="24" WEIGHT="1.8954253415910376"/>
<CONT_DATA CI_END="-119.34495194145865" CI_START="-380.15504805854135" EFFECT_SIZE="-249.75" ESTIMABLE="YES" MEAN_1="715.6" MEAN_2="965.35" ORDER="67125" SD_1="243.48" SD_2="271.15" SE="66.534410370374" STUDY_ID="STD-D_x0027_Ambrosio-1999" TOTAL_1="30" TOTAL_2="30" WEIGHT="9.76472294062694"/>
<CONT_DATA CI_END="-13.501268384582431" CI_START="-876.4987316154176" EFFECT_SIZE="-445.0" ESTIMABLE="YES" MEAN_1="1576.0" MEAN_2="2021.0" ORDER="67129" SD_1="452.0" SD_2="723.0" SE="220.15645951610566" STUDY_ID="STD-Garcia_x002d_Enguita-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="3.8830692586264126"/>
<CONT_DATA CI_END="148.7442598219278" CI_START="-324.7442598219278" EFFECT_SIZE="-88.0" ESTIMABLE="YES" MEAN_1="1186.0" MEAN_2="1274.0" ORDER="67132" SD_1="414.0" SD_2="347.0" SE="120.79010721081424" STUDY_ID="STD-Hayes-1996" TOTAL_1="20" TOTAL_2="20" WEIGHT="7.235593639079528"/>
<CONT_DATA CI_END="-116.39437230039363" CI_START="-877.6056276996064" EFFECT_SIZE="-497.0" ESTIMABLE="YES" MEAN_1="1446.0" MEAN_2="1943.0" ORDER="67123" SD_1="514.0" SD_2="700.0" SE="194.19011303359397" STUDY_ID="STD-Janssens-1994" TOTAL_1="20" TOTAL_2="20" WEIGHT="4.5530261357236155"/>
<CONT_DATA CI_END="-651.4308308758561" CI_START="-3014.7691691241444" EFFECT_SIZE="-1833.1000000000001" ESTIMABLE="YES" MEAN_1="1771.3" MEAN_2="3604.4" ORDER="67126" SD_1="1153.2" SD_2="1393.4" SE="602.903511720113" STUDY_ID="STD-Jeserschek-2003" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.7314960112430002"/>
<CONT_DATA CI_END="-472.69618759769014" CI_START="-1335.3038124023099" EFFECT_SIZE="-904.0" ESTIMABLE="YES" MEAN_1="1935.0" MEAN_2="2839.0" ORDER="67124" SD_1="873.0" SD_2="993.0" SE="220.05700911056493" STUDY_ID="STD-Lentschener-1999" TOTAL_1="35" TOTAL_2="37" WEIGHT="3.8853956203216113"/>
<CONT_DATA CI_END="-138.9198852017223" CI_START="-581.0801147982777" EFFECT_SIZE="-360.0" ESTIMABLE="YES" MEAN_1="817.0" MEAN_2="1177.0" ORDER="67128" SD_1="147.0" SD_2="325.0" SE="112.79804962852859" STUDY_ID="STD-Llau-1998" TOTAL_1="10" TOTAL_2="10" WEIGHT="7.597023502229325"/>
<CONT_DATA CI_END="-110.64694224181494" CI_START="-1085.353057758185" EFFECT_SIZE="-598.0" ESTIMABLE="YES" MEAN_1="1498.0" MEAN_2="2096.0" ORDER="67131" SD_1="592.37" SD_2="1092.47" SE="248.6540883416041" STUDY_ID="STD-Murkin-1995" TOTAL_1="29" TOTAL_2="24" WEIGHT="3.2831778797057773"/>
<CONT_DATA CI_END="-160.586082190949" CI_START="-685.413917809051" EFFECT_SIZE="-423.0" ESTIMABLE="YES" MEAN_1="1073.2" MEAN_2="1496.2" ORDER="67130" SD_1="388.6" SD_2="545.1" SE="133.8871121504979" STUDY_ID="STD-Petsatodis-2006" TOTAL_1="25" TOTAL_2="25" WEIGHT="6.668732690098275"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-12-03 12:38:07 +0000" MODIFIED_BY="Katharine Ker" NO="2">
<NAME>Tranexamic Acid versus Control (Blood Transfusion &amp; Blood Loss)</NAME>
<DICH_OUTCOME CHI2="249.32523222641805" CI_END="0.6986179805908747" CI_START="0.5309156917295179" CI_STUDY="95" CI_TOTAL="95" DF="63" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6090215500457132" ESTIMABLE="YES" EVENTS_1="707" EVENTS_2="1028" I2="74.73179932996584" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.15576024095587643" LOG_CI_START="-0.2749744384734396" LOG_EFFECT_SIZE="-0.215367339714658" METHOD="MH" MODIFIED="2010-12-03 12:34:00 +0000" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="-4.440892098500626E-16" P_Q="0.0" P_Z="1.4252366225430112E-12" Q="0.0" RANDOM="YES" SCALE="953.74" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="65" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.16040430117389037" TOTALS="YES" TOTAL_1="2528" TOTAL_2="2314" WEIGHT="99.99999999999999" Z="7.081576491336029">
<NAME>No. Exposed to Allogeneic Blood</NAME>
<GROUP_LABEL_1>TXA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TXA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7813352588543377" CI_START="0.5474218617451075" EFFECT_SIZE="0.654003059663437" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="26" LOG_CI_END="-0.10716257709786291" LOG_CI_START="-0.2616778626699975" LOG_EFFECT_SIZE="-0.1844202198839302" ORDER="67161" O_E="0.0" SE="0.09076304360807098" STUDY_ID="STD-Tanaka-2001" TOTAL_1="73" TOTAL_2="26" VAR="0.008237930085000594" WEIGHT="2.907801952539239"/>
<DICH_DATA CI_END="1.032554195568666" CI_START="0.4180951534213291" EFFECT_SIZE="0.6570433051269288" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="41" LOG_CI_END="0.01391285569765569" LOG_CI_START="-0.3787248667824544" LOG_EFFECT_SIZE="-0.1824060055423993" ORDER="67183" O_E="0.0" SE="0.23063734177288867" STUDY_ID="STD-Karski-2005" TOTAL_1="147" TOTAL_2="165" VAR="0.05319358342006426" WEIGHT="2.295800870253825"/>
<DICH_DATA CI_END="1.215242085527897" CI_START="0.3476673537161672" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.08466280133863553" LOG_CI_START="-0.4588360880529243" LOG_EFFECT_SIZE="-0.1870866433571444" MODIFIED="2010-05-07 10:54:53 +0100" MODIFIED_BY="Katharine Ker" ORDER="2415" O_E="0.0" SE="0.3192539379914944" STUDY_ID="STD-MacGillivray-2010" TOTAL_1="40" TOTAL_2="20" VAR="0.10192307692307694" WEIGHT="1.8693367535351666"/>
<DICH_DATA CI_END="2.1268041030916094" CI_START="0.34221405937999083" EFFECT_SIZE="0.853125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.32772748949634717" LOG_CI_START="-0.465702152054647" LOG_EFFECT_SIZE="-0.06898733127914992" ORDER="67164" O_E="0.0" SE="0.4660644989871222" STUDY_ID="STD-Pleym-2003" TOTAL_1="40" TOTAL_2="39" VAR="0.21721611721611722" WEIGHT="1.2986008845229149"/>
<DICH_DATA CI_END="1.712227535929018" CI_START="0.2281384873232139" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2335614770655728" LOG_CI_START="-0.6418014423774223" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2010-05-07 12:09:45 +0100" MODIFIED_BY="Katharine Ker" ORDER="2431" O_E="0.0" SE="0.5141925119971501" STUDY_ID="STD-Mehr_x002d_Aein-2007" TOTAL_1="33" TOTAL_2="33" VAR="0.2643939393939394" WEIGHT="1.154379096955972"/>
<DICH_DATA CI_END="0.9597327428757618" CI_START="0.32634829121299347" EFFECT_SIZE="0.5596491228070175" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="-0.017849688266260794" LOG_CI_START="-0.4863186569643599" LOG_EFFECT_SIZE="-0.2520841726153103" ORDER="67165" O_E="0.0" SE="0.27518099117205813" STUDY_ID="STD-Casati-2002" TOTAL_1="30" TOTAL_2="29" VAR="0.07572457790243635" WEIGHT="2.076739665446285"/>
<DICH_DATA CI_END="0.7915384951180039" CI_START="0.19436062386207878" EFFECT_SIZE="0.39222941720629045" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="23" LOG_CI_END="-0.10152795912027116" LOG_CI_START="-0.7113917156008844" LOG_EFFECT_SIZE="-0.4064598373605777" ORDER="67181" O_E="0.0" SE="0.3582369894309945" STUDY_ID="STD-Johansson-2005" TOTAL_1="47" TOTAL_2="53" VAR="0.12833374059658248" WEIGHT="1.6983498479393113"/>
<DICH_DATA CI_END="1.5366307449348802" CI_START="0.20085630612689692" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.1865695183106097" LOG_CI_START="-0.6971145285172219" LOG_EFFECT_SIZE="-0.255272505103306" ORDER="67160" O_E="0.0" SE="0.5190803834132479" STUDY_ID="STD-Benoni-2001" TOTAL_1="18" TOTAL_2="20" VAR="0.26944444444444443" WEIGHT="1.140815727238592"/>
<DICH_DATA CI_END="1.708504253584658" CI_START="0.1286075595299139" EFFECT_SIZE="0.46875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.23261606437917473" LOG_CI_START="-0.8907335029076242" LOG_EFFECT_SIZE="-0.32905871926422475" ORDER="67168" O_E="0.0" SE="0.6598610964943051" STUDY_ID="STD-Vanek-2005" TOTAL_1="32" TOTAL_2="30" VAR="0.4354166666666667" WEIGHT="0.8230294598601694"/>
<DICH_DATA CI_END="1.417807293880328" CI_START="0.31254634853586305" EFFECT_SIZE="0.665680473372781" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.15161720624074812" LOG_CI_START="-0.5050855705733328" LOG_EFFECT_SIZE="-0.17673418216629228" ORDER="67170" O_E="0.0" SE="0.3857504618317635" STUDY_ID="STD-Casati-2004" TOTAL_1="52" TOTAL_2="50" VAR="0.14880341880341882" WEIGHT="1.5859183896545752"/>
<DICH_DATA CI_END="0.904452772551861" CI_START="0.29114955796727204" EFFECT_SIZE="0.5131578947368421" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="19" LOG_CI_END="-0.043614105593121844" LOG_CI_START="-0.5358838649154624" LOG_EFFECT_SIZE="-0.2897489852542921" MODIFIED="2010-05-17 14:40:55 +0100" MODIFIED_BY="Katharine Ker" ORDER="2631" O_E="0.0" SE="0.28916169340055126" STUDY_ID="STD-Jimenez-2007" TOTAL_1="24" TOTAL_2="26" VAR="0.0836144849302744" WEIGHT="2.0095920365977413"/>
<DICH_DATA CI_END="2.427899066052217" CI_START="0.1029696841584531" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.38523062805078434" LOG_CI_START="-0.9872906193787466" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="67155" O_E="0.0" SE="0.8062257748298549" STUDY_ID="STD-Casati-2001" TOTAL_1="20" TOTAL_2="20" VAR="0.6499999999999999" WEIGHT="0.6051031671782249"/>
<DICH_DATA CI_END="1.202502465890051" CI_START="0.5022788672971052" EFFECT_SIZE="0.7771689497716895" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="30" LOG_CI_END="0.08008597562494968" LOG_CI_START="-0.2990550938080483" LOG_EFFECT_SIZE="-0.10948455909154928" MODIFIED="2010-05-14 15:09:02 +0100" MODIFIED_BY="Katharine Ker" ORDER="2516" O_E="0.0" SE="0.222709340963505" STUDY_ID="STD-Wong-2008" TOTAL_1="73" TOTAL_2="74" VAR="0.04959945055239873" WEIGHT="2.3350926128896847"/>
<DICH_DATA CI_END="0.977231691528309" CI_START="0.41555530136149377" EFFECT_SIZE="0.6372549019607843" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="-0.010002457342592376" LOG_CI_START="-0.3813711728955317" LOG_EFFECT_SIZE="-0.19568681511906202" ORDER="67149" O_E="0.0" SE="0.21814382182058634" STUDY_ID="STD-Shore_x002d_Lesserson-1996" TOTAL_1="17" TOTAL_2="13" VAR="0.047586726998491716" WEIGHT="2.357689240945305"/>
<DICH_DATA CI_END="0.7928550646291872" CI_START="0.21747487464892984" EFFECT_SIZE="0.41524216524216523" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="27" LOG_CI_END="-0.10080619526073613" LOG_CI_START="-0.6625909108088087" LOG_EFFECT_SIZE="-0.3816985530347724" ORDER="67145" O_E="0.0" SE="0.32999512279212917" STUDY_ID="STD-Katsaros-1996" TOTAL_1="104" TOTAL_2="106" VAR="0.1088967810665924" WEIGHT="1.8209292189077613"/>
<DICH_DATA CI_END="1.6578630011980628" CI_START="0.2610743375367926" EFFECT_SIZE="0.6578947368421053" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2195486394338172" LOG_CI_START="-0.5832358153233621" LOG_EFFECT_SIZE="-0.1818435879447725" ORDER="67177" O_E="0.0" SE="0.4715595625715076" STUDY_ID="STD-Niskanen-2005" TOTAL_1="19" TOTAL_2="20" VAR="0.2223684210526316" WEIGHT="1.281121095784289"/>
<DICH_DATA CI_END="1.2108417211183848" CI_START="0.06741810398292612" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.08308737672071692" LOG_CI_START="-1.171223465421268" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="67166" O_E="0.0" SE="0.7367883976130072" STUDY_ID="STD-Husted-2003" TOTAL_1="20" TOTAL_2="20" VAR="0.5428571428571427" WEIGHT="0.6972914745963777"/>
<DICH_DATA CI_END="0.9754681459204624" CI_START="0.33307084537693515" EFFECT_SIZE="0.57" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="-0.010786907998672239" LOG_CI_START="-0.477463380656345" LOG_EFFECT_SIZE="-0.24412514432750865" ORDER="67159" O_E="0.0" SE="0.27412807012491325" STUDY_ID="STD-Benoni-2000" TOTAL_1="20" TOTAL_2="19" VAR="0.07514619883040935" WEIGHT="2.0818389658532914"/>
<DICH_DATA CI_END="1.116493663022033" CI_START="0.3857290701805813" EFFECT_SIZE="0.65625" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="20" LOG_CI_END="0.04785626245235314" LOG_CI_START="-0.4137176296243265" LOG_EFFECT_SIZE="-0.1829306835859867" MODIFIED="2010-05-14 11:34:49 +0100" MODIFIED_BY="Katharine Ker" ORDER="2485" O_E="0.0" SE="0.2711307890334566" STUDY_ID="STD-Sadeghi-2007" TOTAL_1="32" TOTAL_2="35" VAR="0.07351190476190476" WEIGHT="2.096384076397747"/>
<DICH_DATA CI_END="0.657557944250512" CI_START="0.16897539157215433" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="24" LOG_CI_END="-0.1820659709607079" LOG_CI_START="-0.772176538478617" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67133" O_E="0.0" SE="0.34663386845443983" STUDY_ID="STD-Benoni-1996" TOTAL_1="43" TOTAL_2="43" VAR="0.1201550387596899" WEIGHT="1.7478591496945686"/>
<DICH_DATA CI_END="1.523032096014423" CI_START="0.04103656131972161" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.18270905565060536" LOG_CI_START="-1.38682903830653" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2010-05-20 14:50:00 +0100" MODIFIED_BY="Katharine Ker" ORDER="5363" O_E="0.0" SE="0.9219544457292888" STUDY_ID="STD-Gill-2009" TOTAL_1="5" TOTAL_2="5" VAR="0.8500000000000001" WEIGHT="0.48532870333732175"/>
<DICH_DATA CI_END="0.9081443087249566" CI_START="0.003455959890878708" EFFECT_SIZE="0.056022408963585436" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.04184513440491924" LOG_CI_START="-2.4614313064915043" LOG_EFFECT_SIZE="-1.251638220448212" ORDER="67180" O_E="0.0" SE="1.421276894628377" STUDY_ID="STD-Lemay-2004" TOTAL_1="20" TOTAL_2="19" VAR="2.020028011204482" WEIGHT="0.22489953324911158"/>
<DICH_DATA CI_END="1.492158128301091" CI_START="0.7910072381137022" EFFECT_SIZE="1.0864197530864197" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="27" LOG_CI_END="0.17381484901444078" LOG_CI_START="-0.10181954247140304" LOG_EFFECT_SIZE="0.035997653271518854" ORDER="67138" O_E="0.0" SE="0.16190900597102748" STUDY_ID="STD-Hardy-1998" TOTAL_1="42" TOTAL_2="44" VAR="0.02621452621452621" WEIGHT="2.627699553135306"/>
<DICH_DATA CI_END="2.6516009553217748" CI_START="0.03650252247138919" EFFECT_SIZE="0.3111111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.42350816681362524" LOG_CI_START="-1.4376771230078367" LOG_EFFECT_SIZE="-0.5070844780971057" ORDER="67179" O_E="0.0" SE="1.0932694522568969" STUDY_ID="STD-Orpen-2006" TOTAL_1="15" TOTAL_2="14" VAR="1.1952380952380952" WEIGHT="0.3617312431604928"/>
<DICH_DATA CI_END="1.8418560833961877" CI_START="0.5260965551870249" EFFECT_SIZE="0.984375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.2652556928376572" LOG_CI_START="-0.2789345418982681" LOG_EFFECT_SIZE="-0.0068394245303054655" ORDER="67136" O_E="0.0" SE="0.3196600376689893" STUDY_ID="STD-Coffey-1995" TOTAL_1="16" TOTAL_2="14" VAR="0.10218253968253968" WEIGHT="1.8674896568914225"/>
<DICH_DATA CI_END="1.1702850633778696" CI_START="0.2907648644131303" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.06829166206472205" LOG_CI_START="-0.536458074131458" LOG_EFFECT_SIZE="-0.23408320603336794" ORDER="67167" O_E="0.0" SE="0.3552329886011098" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.1261904761904762" WEIGHT="1.7110507520230467"/>
<DICH_DATA CI_END="0.5876020010184078" CI_START="0.14940639250163543" EFFECT_SIZE="0.2962962962962963" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="27" LOG_CI_END="-0.23091673393390336" LOG_CI_START="-0.8256308204001841" LOG_EFFECT_SIZE="-0.5282737771670437" MODIFIED="2010-05-21 15:39:45 +0100" MODIFIED_BY="Katharine Ker" ORDER="2498" O_E="0.0" SE="0.34933799827249973" STUDY_ID="STD-Taghaddomi-2009" TOTAL_1="50" TOTAL_2="50" VAR="0.12203703703703704" WEIGHT="1.7362125970702"/>
<DICH_DATA CI_END="0.5832968063338196" CI_START="0.0622002019286873" EFFECT_SIZE="0.19047619047619047" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="14" LOG_CI_END="-0.2341104014122547" LOG_CI_START="-1.206208205399659" LOG_EFFECT_SIZE="-0.7201593034059569" ORDER="67185" O_E="0.0" SE="0.5710150620239374" STUDY_ID="STD-Good-2003" TOTAL_1="27" TOTAL_2="24" VAR="0.32605820105820105" WEIGHT="1.008049350330434"/>
<DICH_DATA CI_END="2.8531415452949767" CI_START="0.03894342756823292" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45532331768430767" LOG_CI_START="-1.4095658271236327" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67147" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="1.2" WEIGHT="0.36046505359622183"/>
<DICH_DATA CI_END="0.9581328580005153" CI_START="0.021299930479260473" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.018574265977916792" LOG_CI_START="-1.6716218140505967" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="67154" O_E="0.0" SE="0.9710083124552245" STUDY_ID="STD-Ellis-2001" TOTAL_1="10" TOTAL_2="10" VAR="0.9428571428571427" WEIGHT="0.4444805100262196"/>
<DICH_DATA CI_END="1.2617285296697793" CI_START="0.022015653228549727" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.10096592325294027" LOG_CI_START="-1.6572684240202276" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2010-05-14 15:54:05 +0100" MODIFIED_BY="Katharine Ker" ORDER="2534" O_E="0.0" SE="1.0327955589886444" STUDY_ID="STD-Claeys-2007" TOTAL_1="20" TOTAL_2="20" VAR="1.0666666666666667" WEIGHT="0.39963312814593116"/>
<DICH_DATA CI_END="1.4146284322310363" CI_START="0.3725136848128532" EFFECT_SIZE="0.725925925925926" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.15064238260049112" LOG_CI_START="-0.4288577682055137" LOG_EFFECT_SIZE="-0.13910769280251123" ORDER="67134" O_E="0.0" SE="0.34040125715545744" STUDY_ID="STD-Blauhut-1994" TOTAL_1="15" TOTAL_2="14" VAR="0.11587301587301588" WEIGHT="1.7749492233990414"/>
<DICH_DATA CI_END="2.153888658301622" CI_START="0.6259279035383108" EFFECT_SIZE="1.1611111111111112" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.3332232494099629" LOG_CI_START="-0.20347568739446692" LOG_EFFECT_SIZE="0.06487378100774796" ORDER="67152" O_E="0.0" SE="0.315259612181506" STUDY_ID="STD-Pinosky-1997" TOTAL_1="20" TOTAL_2="19" VAR="0.09938862307283358" WEIGHT="1.8875733846756637"/>
<DICH_DATA CI_END="1.4026562348128688" CI_START="0.07515317284216183" EFFECT_SIZE="0.3246753246753247" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.14695124649727434" LOG_CI_START="-1.124052679498163" LOG_EFFECT_SIZE="-0.48855071650044424" ORDER="67162" O_E="0.0" SE="0.7465939977006226" STUDY_ID="STD-Jares-2003" TOTAL_1="22" TOTAL_2="25" VAR="0.5574025974025973" WEIGHT="0.6831617393308231"/>
<DICH_DATA CI_END="2.4988165463450835" CI_START="0.008167131474760041" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.39773437303938103" LOG_CI_START="-2.087930453067895" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="67158" O_E="0.0" SE="1.4600918230947433" STUDY_ID="STD-Engel-2001" TOTAL_1="12" TOTAL_2="12" VAR="2.1318681318681314" WEIGHT="0.21392667043698965"/>
<DICH_DATA CI_END="0.8306868840875706" CI_START="0.14746832091198164" EFFECT_SIZE="0.35" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="-0.0805626466593111" LOG_CI_START="-0.8313012646401378" LOG_EFFECT_SIZE="-0.4559319556497244" ORDER="67144" O_E="0.0" SE="0.44098758041803093" STUDY_ID="STD-Katoh-1997" TOTAL_1="62" TOTAL_2="31" VAR="0.1944700460829493" WEIGHT="1.38183617138228"/>
<DICH_DATA CI_END="0.7650824343325807" CI_START="0.3866613431183696" EFFECT_SIZE="0.5439005439005439" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="63" LOG_CI_END="-0.1162917689679506" LOG_CI_START="-0.41266924481230916" LOG_EFFECT_SIZE="-0.26448050689012986" ORDER="67153" O_E="0.0" SE="0.1740935964031426" STUDY_ID="STD-Armellin-2001" TOTAL_1="143" TOTAL_2="140" VAR="0.030308580308580305" WEIGHT="2.5712904420682774"/>
<DICH_DATA CI_END="1.451648645691749" CI_START="0.11959582067352173" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.16186151326336917" LOG_CI_START="-0.9222839966865812" LOG_EFFECT_SIZE="-0.38021124171160603" ORDER="67175" O_E="0.0" SE="0.6368324391514266" STUDY_ID="STD-Wei-2006" TOTAL_1="36" TOTAL_2="40" VAR="0.4055555555555555" WEIGHT="0.8664540488241727"/>
<DICH_DATA CI_END="1.0581296128387647" CI_START="0.42002835857894827" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.02453886873221163" LOG_CI_START="-0.37672138684357415" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="67146" O_E="0.0" SE="0.23570226039551587" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.05555555555555557" WEIGHT="2.270691492213397"/>
<DICH_DATA CI_END="14.903914722906746" CI_START="0.06709646549862758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528004" LOG_EFFECT_SIZE="0.0" ORDER="67156" O_E="0.0" SE="1.378404875209022" STUDY_ID="STD-Ekback-2000" TOTAL_1="20" TOTAL_2="20" VAR="1.9" WEIGHT="0.23800096372143564"/>
<DICH_DATA CI_END="1.8016168986512344" CI_START="0.7249723567520983" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.25566244674838573" LOG_CI_START="-0.13967855279301233" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="67182" O_E="0.0" SE="0.23222526010012653" STUDY_ID="STD-Garneti-2004" TOTAL_1="25" TOTAL_2="25" VAR="0.053928571428571416" WEIGHT="2.2879281343124434"/>
<DICH_DATA CI_END="0.7532478029295167" CI_START="0.08297402230305383" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.12306212640134118" LOG_CI_START="-1.0810578562545836" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="67173" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Zohar-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.31666666666666665" WEIGHT="1.027893630909579"/>
<DICH_DATA CI_END="1.0452326878696259" CI_START="0.3557126588440236" EFFECT_SIZE="0.6097560975609756" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.01921298308688103" LOG_CI_START="-0.44890067918227683" LOG_EFFECT_SIZE="-0.21484384804769788" ORDER="67137" O_E="0.0" SE="0.27497228241690286" STUDY_ID="STD-Corbeau-1995" TOTAL_1="41" TOTAL_2="20" VAR="0.07560975609756097" WEIGHT="2.077750007793684"/>
<DICH_DATA CI_END="0.5995847135813608" CI_START="0.039475054178549726" EFFECT_SIZE="0.15384615384615385" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="13" LOG_CI_END="-0.22214944802504333" LOG_CI_START="-1.403677265260668" LOG_EFFECT_SIZE="-0.8129133566428556" ORDER="67151" O_E="0.0" SE="0.6940352885012271" STUDY_ID="STD-Jansen-1999" TOTAL_1="21" TOTAL_2="21" VAR="0.4816849816849816" WEIGHT="0.7637227756734879"/>
<DICH_DATA CI_END="0.7521793216911061" CI_START="0.3618973725771085" EFFECT_SIZE="0.5217391304347826" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="46" LOG_CI_END="-0.12367861002408044" LOG_CI_START="-0.4414145699158558" LOG_EFFECT_SIZE="-0.28254658996996806" ORDER="67143" O_E="0.0" SE="0.18663967565879638" STUDY_ID="STD-Isetta-1993" TOTAL_1="70" TOTAL_2="70" VAR="0.03483436853002071" WEIGHT="2.511685876977442"/>
<DICH_DATA CI_END="3.0132565450625943" CI_START="0.746700443972075" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.4790361085608422" LOG_CI_START="-0.12685359044947975" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2010-04-21 10:36:09 +0100" MODIFIED_BY="Katharine Ker" ORDER="2351" O_E="0.0" SE="0.35590260840104376" STUDY_ID="STD-Caglar-2008" TOTAL_1="50" TOTAL_2="50" VAR="0.1266666666666667" WEIGHT="1.708212477994429"/>
<DICH_DATA CI_END="1.7007938080196618" CI_START="0.8212013756695701" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.23065166607163218" LOG_CI_START="-0.08555033177440872" LOG_EFFECT_SIZE="0.07255066714861175" ORDER="67150" O_E="0.0" SE="0.1857386187598974" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.03449883449883451" WEIGHT="2.516009850957988"/>
<DICH_DATA CI_END="3.845086034384406" CI_START="0.010402888164868843" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5849060616512035" LOG_CI_START="-1.982846070323241" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="67163" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Veien-2002" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="0.20135392267263783"/>
<DICH_DATA CI_END="1.0228204893606019" CI_START="0.12928114594315548" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.009799419322149849" LOG_CI_START="-0.8884648069826752" LOG_EFFECT_SIZE="-0.43933269383026263" MODIFIED="2010-05-28 14:49:07 +0100" MODIFIED_BY="Katharine Ker" ORDER="5375" O_E="0.0" SE="0.5276448530110863" STUDY_ID="STD-Kazemi-2010" TOTAL_1="32" TOTAL_2="32" VAR="0.27840909090909094" WEIGHT="1.11750967081343"/>
<DICH_DATA CI_END="0.5995847135813608" CI_START="0.039475054178549726" EFFECT_SIZE="0.15384615384615385" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="13" LOG_CI_END="-0.22214944802504333" LOG_CI_START="-1.403677265260668" LOG_EFFECT_SIZE="-0.8129133566428556" ORDER="67184" O_E="0.0" SE="0.6940352885012271" STUDY_ID="STD-Sorin-1999" TOTAL_1="21" TOTAL_2="21" VAR="0.4816849816849816" WEIGHT="0.7637227756734879"/>
<DICH_DATA CI_END="0.7142374886661662" CI_START="0.2835191420407901" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="-0.14615735843676345" LOG_CI_START="-0.5474176140125492" LOG_EFFECT_SIZE="-0.3467874862246563" ORDER="67135" O_E="0.0" SE="0.23570226039551584" STUDY_ID="STD-Brown-1997" TOTAL_1="60" TOTAL_2="30" VAR="0.05555555555555556" WEIGHT="2.270691492213397"/>
<DICH_DATA CI_END="1.0880236925267535" CI_START="0.9190976325870872" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="23" LOG_CI_END="0.03663835255113116" LOG_CI_START="-0.03663835255113116" LOG_EFFECT_SIZE="0.0" ORDER="67148" O_E="0.0" SE="0.043043099302609085" STUDY_ID="STD-Pugh-1995" TOTAL_1="22" TOTAL_2="23" VAR="0.0018527083975742667" WEIGHT="3.0222312775904725"/>
<DICH_DATA CI_END="0.9643873049425113" CI_START="0.18002218633670253" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.01574851524782261" LOG_CI_START="-0.7446739681753893" LOG_EFFECT_SIZE="-0.38021124171160603" ORDER="67174" O_E="0.0" SE="0.42817441928883765" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.18333333333333335" WEIGHT="1.4266061091569875"/>
<DICH_DATA CI_END="2.3557243756307376" CI_START="0.5905268923745671" EFFECT_SIZE="1.179456906729634" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="7" LOG_CI_END="0.37212447578184316" LOG_CI_START="-0.2287603199912923" LOG_EFFECT_SIZE="0.07168207789527543" ORDER="67142" O_E="0.0" SE="0.3529627034648498" STUDY_ID="STD-Horrow-1995" TOTAL_1="121" TOTAL_2="27" VAR="0.12458267003721549" WEIGHT="1.720703957978228"/>
<DICH_DATA CI_END="0.930965325905842" CI_START="0.5985224481530158" EFFECT_SIZE="0.7464607464607464" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="37" LOG_CI_END="-0.03106649415097593" LOG_CI_START="-0.22291955632497804" LOG_EFFECT_SIZE="-0.12699302523797698" ORDER="67157" O_E="0.0" SE="0.11269543840898297" STUDY_ID="STD-Dalmau-2000" TOTAL_1="42" TOTAL_2="40" VAR="0.012700261838192874" WEIGHT="2.832843922785254"/>
<DICH_DATA CI_END="1.0674920186129604" CI_START="0.48862654631305746" EFFECT_SIZE="0.7222222222222222" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.028364636591387042" LOG_CI_START="-0.3110229421843257" LOG_EFFECT_SIZE="-0.1413291527964693" ORDER="67139" O_E="0.0" SE="0.19935794376846325" STUDY_ID="STD-Hiipala-1995" TOTAL_1="15" TOTAL_2="13" VAR="0.039743589743589755" WEIGHT="2.4500793242800505"/>
<DICH_DATA CI_END="1.7701241393504614" CI_START="0.48710984658713274" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.2480037246354673" LOG_CI_START="-0.31237309137826985" LOG_EFFECT_SIZE="-0.03218468337140124" MODIFIED="2010-01-11 14:56:17 +0000" MODIFIED_BY="Katharine Ker" ORDER="2300" O_E="0.0" SE="0.3291681156364455" STUDY_ID="STD-Murphy-2006" TOTAL_1="50" TOTAL_2="50" VAR="0.10835164835164836" WEIGHT="1.8246227114260722"/>
<DICH_DATA CI_END="0.7076468664513917" CI_START="0.3353987193056711" EFFECT_SIZE="0.48717948717948717" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="34" LOG_CI_END="-0.15018341210034744" LOG_CI_START="-0.4744386000469931" LOG_EFFECT_SIZE="-0.31231100607367024" ORDER="67140" O_E="0.0" SE="0.19046910248892657" STUDY_ID="STD-Hiipala-1997" TOTAL_1="39" TOTAL_2="38" VAR="0.03627847900293721" WEIGHT="2.493244242807137"/>
<DICH_DATA CI_END="1.001769718383294" CI_START="0.6587796143846663" EFFECT_SIZE="0.8123702781237028" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="73" LOG_CI_END="7.678996455661966E-4" LOG_CI_START="-0.18125984832625064" LOG_EFFECT_SIZE="-0.09024597434034222" MODIFIED="2010-05-06 16:14:52 +0100" MODIFIED_BY="Katharine Ker" ORDER="2379" O_E="0.0" SE="0.1069240002105296" STUDY_ID="STD-Later-2009" TOTAL_1="99" TOTAL_2="103" VAR="0.011432741821021334" WEIGHT="2.8537398036446526"/>
<DICH_DATA CI_END="1.6374042289645896" CI_START="0.485812319738244" EFFECT_SIZE="0.8918918918918919" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.21415590771813872" LOG_CI_START="-0.3135314760963538" LOG_EFFECT_SIZE="-0.04968778418910752" ORDER="67141" O_E="0.0" SE="0.30996618134731013" STUDY_ID="STD-Horrow-1991" TOTAL_1="37" TOTAL_2="44" VAR="0.09607903357903355" WEIGHT="1.9119301057418376"/>
<DICH_DATA CI_END="1.1666059421800465" CI_START="0.4703360622077637" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="27" LOG_CI_END="0.06692418420563072" LOG_CI_START="-0.32759172119564306" LOG_EFFECT_SIZE="-0.13033376849500614" ORDER="67171" O_E="0.0" SE="0.23174059571793568" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.05370370370370371" WEIGHT="2.2903310393066674"/>
<DICH_DATA CI_END="1.363876456483296" CI_START="0.28509260166605166" EFFECT_SIZE="0.6235632183908046" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.13477503256563717" LOG_CI_START="-0.5450140527617399" LOG_EFFECT_SIZE="-0.20511951009805138" ORDER="67178" O_E="0.0" SE="0.3993114737315439" STUDY_ID="STD-Santos-2006" TOTAL_1="29" TOTAL_2="31" VAR="0.15944965305365746" WEIGHT="1.5331316147691467"/>
<DICH_DATA CI_END="2.7594687360744157" CI_START="0.3770290949119647" EFFECT_SIZE="1.02" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.4408254780072691" LOG_CI_START="-0.423625134483434" LOG_EFFECT_SIZE="0.008600171761917567" ORDER="67169" O_E="0.0" SE="0.5077825688765832" STUDY_ID="STD-Andreasen-2004" TOTAL_1="20" TOTAL_2="17" VAR="0.257843137254902" WEIGHT="1.1724595640737323"/>
<DICH_DATA CI_END="0.47788477395061085" CI_START="0.0017726629114815711" EFFECT_SIZE="0.029105473965287048" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="17" LOG_CI_END="-0.32067680646303687" LOG_CI_START="-2.751373841726686" LOG_EFFECT_SIZE="-1.5360253240948616" ORDER="67176" O_E="0.0" SE="1.4278034706582443" STUDY_ID="STD-Wu-2006" TOTAL_1="106" TOTAL_2="108" VAR="2.038622750823728" WEIGHT="0.22299780663894633"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67172" O_E="0.0" SE="0.0" STUDY_ID="STD-Yamasaki-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="249.32523222641802" CI_END="0.6986179805908748" CI_START="0.530915691729518" CI_STUDY="95" CI_TOTAL="95" DF="63" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6090215500457133" ESTIMABLE="YES" EVENTS_1="707" EVENTS_2="1028" I2="74.73179932996582" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.15576024095587634" LOG_CI_START="-0.27497443847343955" LOG_EFFECT_SIZE="-0.2153673397146579" METHOD="MH" MODIFIED="2010-06-01 10:54:33 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="1.4252366225430217E-12" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="65" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.1604043011738903" TOTALS="YES" TOTAL_1="2528" TOTAL_2="2314" WEIGHT="99.99999999999999" Z="7.081576491336028">
<NAME>No. Exposed to Allogeneic Blood - Type of Surgery</NAME>
<GROUP_LABEL_1>TXA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TXA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="137.35329353184173" CI_END="0.8052151016891327" CI_START="0.570715967441067" DF="33" EFFECT_SIZE="0.6779005205475731" ESTIMABLE="YES" EVENTS_1="459" EVENTS_2="617" I2="75.97436570215929" ID="CMP-002.02.01" LOG_CI_END="-0.09408808857876963" LOG_CI_START="-0.24357997662830275" LOG_EFFECT_SIZE="-0.16883403260353616" MODIFIED="2010-05-28 14:50:54 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="1.0658141036401503E-14" P_Z="9.550340157842066E-6" STUDIES="34" TAU2="0.1498837477948128" TOTAL_1="1578" TOTAL_2="1428" WEIGHT="60.82180989111662" Z="4.427111431731303">
<NAME>Cardiac surgery</NAME>
<DICH_DATA CI_END="2.7594687360744157" CI_START="0.3770290949119647" EFFECT_SIZE="1.02" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.4408254780072691" LOG_CI_START="-0.423625134483434" LOG_EFFECT_SIZE="0.008600171761917567" ORDER="67208" O_E="0.0" SE="0.5077825688765832" STUDY_ID="STD-Andreasen-2004" TOTAL_1="20" TOTAL_2="17" VAR="0.257843137254902" WEIGHT="1.1724595640737316"/>
<DICH_DATA CI_END="0.7650824343325807" CI_START="0.3866613431183696" EFFECT_SIZE="0.5439005439005439" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="63" LOG_CI_END="-0.1162917689679506" LOG_CI_START="-0.41266924481230916" LOG_EFFECT_SIZE="-0.26448050689012986" ORDER="67202" O_E="0.0" SE="0.1740935964031426" STUDY_ID="STD-Armellin-2001" TOTAL_1="143" TOTAL_2="140" VAR="0.030308580308580305" WEIGHT="2.5712904420682774"/>
<DICH_DATA CI_END="1.4146284322310363" CI_START="0.3725136848128532" EFFECT_SIZE="0.725925925925926" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.15064238260049112" LOG_CI_START="-0.4288577682055137" LOG_EFFECT_SIZE="-0.13910769280251123" ORDER="67186" O_E="0.0" SE="0.34040125715545744" STUDY_ID="STD-Blauhut-1994" TOTAL_1="15" TOTAL_2="14" VAR="0.11587301587301588" WEIGHT="1.7749492233990412"/>
<DICH_DATA CI_END="0.7142374886661662" CI_START="0.2835191420407901" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="-0.14615735843676345" LOG_CI_START="-0.5474176140125492" LOG_EFFECT_SIZE="-0.3467874862246563" ORDER="67187" O_E="0.0" SE="0.23570226039551584" STUDY_ID="STD-Brown-1997" TOTAL_1="60" TOTAL_2="30" VAR="0.05555555555555556" WEIGHT="2.270691492213397"/>
<DICH_DATA CI_END="2.427899066052217" CI_START="0.1029696841584531" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.38523062805078434" LOG_CI_START="-0.9872906193787466" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="67203" O_E="0.0" SE="0.8062257748298549" STUDY_ID="STD-Casati-2001" TOTAL_1="20" TOTAL_2="20" VAR="0.6499999999999999" WEIGHT="0.6051031671782247"/>
<DICH_DATA CI_END="1.417807293880328" CI_START="0.31254634853586305" EFFECT_SIZE="0.665680473372781" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.15161720624074812" LOG_CI_START="-0.5050855705733328" LOG_EFFECT_SIZE="-0.17673418216629228" ORDER="67209" O_E="0.0" SE="0.3857504618317635" STUDY_ID="STD-Casati-2004" TOTAL_1="52" TOTAL_2="50" VAR="0.14880341880341882" WEIGHT="1.585918389654575"/>
<DICH_DATA CI_END="1.8418560833961877" CI_START="0.5260965551870249" EFFECT_SIZE="0.984375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.2652556928376572" LOG_CI_START="-0.2789345418982681" LOG_EFFECT_SIZE="-0.0068394245303054655" ORDER="67188" O_E="0.0" SE="0.3196600376689893" STUDY_ID="STD-Coffey-1995" TOTAL_1="16" TOTAL_2="14" VAR="0.10218253968253968" WEIGHT="1.8674896568914219"/>
<DICH_DATA CI_END="1.0452326878696259" CI_START="0.3557126588440236" EFFECT_SIZE="0.6097560975609756" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.01921298308688103" LOG_CI_START="-0.44890067918227683" LOG_EFFECT_SIZE="-0.21484384804769788" ORDER="67189" O_E="0.0" SE="0.27497228241690286" STUDY_ID="STD-Corbeau-1995" TOTAL_1="41" TOTAL_2="20" VAR="0.07560975609756097" WEIGHT="2.077750007793684"/>
<DICH_DATA CI_END="1.1666059421800465" CI_START="0.4703360622077637" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="27" LOG_CI_END="0.06692418420563072" LOG_CI_START="-0.32759172119564306" LOG_EFFECT_SIZE="-0.13033376849500614" ORDER="67210" O_E="0.0" SE="0.23174059571793568" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.05370370370370371" WEIGHT="2.290331039306667"/>
<DICH_DATA CI_END="1.492158128301091" CI_START="0.7910072381137022" EFFECT_SIZE="1.0864197530864197" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="27" LOG_CI_END="0.17381484901444078" LOG_CI_START="-0.10181954247140304" LOG_EFFECT_SIZE="0.035997653271518854" ORDER="67190" O_E="0.0" SE="0.16190900597102748" STUDY_ID="STD-Hardy-1998" TOTAL_1="42" TOTAL_2="44" VAR="0.02621452621452621" WEIGHT="2.6276995531353053"/>
<DICH_DATA CI_END="1.6374042289645896" CI_START="0.485812319738244" EFFECT_SIZE="0.8918918918918919" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.21415590771813872" LOG_CI_START="-0.3135314760963538" LOG_EFFECT_SIZE="-0.04968778418910752" ORDER="67191" O_E="0.0" SE="0.30996618134731013" STUDY_ID="STD-Horrow-1991" TOTAL_1="37" TOTAL_2="44" VAR="0.09607903357903355" WEIGHT="1.9119301057418374"/>
<DICH_DATA CI_END="2.3557243756307376" CI_START="0.5905268923745671" EFFECT_SIZE="1.179456906729634" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="7" LOG_CI_END="0.37212447578184316" LOG_CI_START="-0.2287603199912923" LOG_EFFECT_SIZE="0.07168207789527543" ORDER="67192" O_E="0.0" SE="0.3529627034648498" STUDY_ID="STD-Horrow-1995" TOTAL_1="121" TOTAL_2="27" VAR="0.12458267003721549" WEIGHT="1.720703957978227"/>
<DICH_DATA CI_END="0.7521793216911061" CI_START="0.3618973725771085" EFFECT_SIZE="0.5217391304347826" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="46" LOG_CI_END="-0.12367861002408044" LOG_CI_START="-0.4414145699158558" LOG_EFFECT_SIZE="-0.28254658996996806" ORDER="67193" O_E="0.0" SE="0.18663967565879638" STUDY_ID="STD-Isetta-1993" TOTAL_1="70" TOTAL_2="70" VAR="0.03483436853002071" WEIGHT="2.5116858769774417"/>
<DICH_DATA CI_END="1.4026562348128688" CI_START="0.07515317284216183" EFFECT_SIZE="0.3246753246753247" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.14695124649727434" LOG_CI_START="-1.124052679498163" LOG_EFFECT_SIZE="-0.48855071650044424" ORDER="67204" O_E="0.0" SE="0.7465939977006226" STUDY_ID="STD-Jares-2003" TOTAL_1="22" TOTAL_2="25" VAR="0.5574025974025973" WEIGHT="0.6831617393308228"/>
<DICH_DATA CI_END="0.904452772551861" CI_START="0.29114955796727204" EFFECT_SIZE="0.5131578947368421" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="19" LOG_CI_END="-0.043614105593121844" LOG_CI_START="-0.5358838649154624" LOG_EFFECT_SIZE="-0.2897489852542921" MODIFIED="2010-05-17 14:41:14 +0100" MODIFIED_BY="Katharine Ker" ORDER="2632" O_E="0.0" SE="0.28916169340055126" STUDY_ID="STD-Jimenez-2007" TOTAL_1="24" TOTAL_2="26" VAR="0.0836144849302744" WEIGHT="2.0095920365977404"/>
<DICH_DATA CI_END="1.032554195568666" CI_START="0.4180951534213291" EFFECT_SIZE="0.6570433051269288" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="41" LOG_CI_END="0.01391285569765569" LOG_CI_START="-0.3787248667824544" LOG_EFFECT_SIZE="-0.1824060055423993" ORDER="67214" O_E="0.0" SE="0.23063734177288867" STUDY_ID="STD-Karski-2005" TOTAL_1="147" TOTAL_2="165" VAR="0.05319358342006426" WEIGHT="2.2958008702538244"/>
<DICH_DATA CI_END="0.8306868840875706" CI_START="0.14746832091198164" EFFECT_SIZE="0.35" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="-0.0805626466593111" LOG_CI_START="-0.8313012646401378" LOG_EFFECT_SIZE="-0.4559319556497244" ORDER="67194" O_E="0.0" SE="0.44098758041803093" STUDY_ID="STD-Katoh-1997" TOTAL_1="62" TOTAL_2="31" VAR="0.1944700460829493" WEIGHT="1.3818361713822795"/>
<DICH_DATA CI_END="0.7928550646291872" CI_START="0.21747487464892984" EFFECT_SIZE="0.41524216524216523" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="27" LOG_CI_END="-0.10080619526073613" LOG_CI_START="-0.6625909108088087" LOG_EFFECT_SIZE="-0.3816985530347724" ORDER="67195" O_E="0.0" SE="0.32999512279212917" STUDY_ID="STD-Katsaros-1996" TOTAL_1="104" TOTAL_2="106" VAR="0.1088967810665924" WEIGHT="1.820929218907761"/>
<DICH_DATA CI_END="0.9643873049425113" CI_START="0.18002218633670253" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.01574851524782261" LOG_CI_START="-0.7446739681753893" LOG_EFFECT_SIZE="-0.38021124171160603" ORDER="67211" O_E="0.0" SE="0.42817441928883765" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.18333333333333335" WEIGHT="1.4266061091569873"/>
<DICH_DATA CI_END="1.001769718383294" CI_START="0.6587796143846663" EFFECT_SIZE="0.8123702781237028" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="73" LOG_CI_END="7.678996455661966E-4" LOG_CI_START="-0.18125984832625064" LOG_EFFECT_SIZE="-0.09024597434034222" MODIFIED="2010-05-06 16:15:23 +0100" MODIFIED_BY="Katharine Ker" ORDER="2380" O_E="0.0" SE="0.1069240002105296" STUDY_ID="STD-Later-2009" TOTAL_1="99" TOTAL_2="103" VAR="0.011432741821021334" WEIGHT="2.853739803644652"/>
<DICH_DATA CI_END="1.1702850633778696" CI_START="0.2907648644131303" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.06829166206472205" LOG_CI_START="-0.536458074131458" LOG_EFFECT_SIZE="-0.23408320603336794" ORDER="67206" O_E="0.0" SE="0.3552329886011098" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.1261904761904762" WEIGHT="1.7110507520230465"/>
<DICH_DATA CI_END="1.712227535929018" CI_START="0.2281384873232139" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2335614770655728" LOG_CI_START="-0.6418014423774223" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2010-05-07 12:10:09 +0100" MODIFIED_BY="Katharine Ker" ORDER="2432" O_E="0.0" SE="0.5141925119971501" STUDY_ID="STD-Mehr_x002d_Aein-2007" TOTAL_1="33" TOTAL_2="33" VAR="0.2643939393939394" WEIGHT="1.1543790969559715"/>
<DICH_DATA CI_END="1.0581296128387647" CI_START="0.42002835857894827" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.02453886873221163" LOG_CI_START="-0.37672138684357415" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="67196" O_E="0.0" SE="0.23570226039551587" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.05555555555555557" WEIGHT="2.270691492213397"/>
<DICH_DATA CI_END="1.7701241393504614" CI_START="0.48710984658713274" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.2480037246354673" LOG_CI_START="-0.31237309137826985" LOG_EFFECT_SIZE="-0.03218468337140124" MODIFIED="2010-01-11 14:57:12 +0000" MODIFIED_BY="Katharine Ker" ORDER="2301" O_E="0.0" SE="0.3291681156364455" STUDY_ID="STD-Murphy-2006" TOTAL_1="50" TOTAL_2="50" VAR="0.10835164835164836" WEIGHT="1.8246227114260716"/>
<DICH_DATA CI_END="2.8531415452949767" CI_START="0.03894342756823292" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45532331768430767" LOG_CI_START="-1.4095658271236327" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67197" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="1.2" WEIGHT="0.36046505359622166"/>
<DICH_DATA CI_END="2.153888658301622" CI_START="0.6259279035383108" EFFECT_SIZE="1.1611111111111112" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.3332232494099629" LOG_CI_START="-0.20347568739446692" LOG_EFFECT_SIZE="0.06487378100774796" ORDER="67201" O_E="0.0" SE="0.315259612181506" STUDY_ID="STD-Pinosky-1997" TOTAL_1="20" TOTAL_2="19" VAR="0.09938862307283358" WEIGHT="1.8875733846756635"/>
<DICH_DATA CI_END="2.1268041030916094" CI_START="0.34221405937999083" EFFECT_SIZE="0.853125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.32772748949634717" LOG_CI_START="-0.465702152054647" LOG_EFFECT_SIZE="-0.06898733127914992" ORDER="67205" O_E="0.0" SE="0.4660644989871222" STUDY_ID="STD-Pleym-2003" TOTAL_1="40" TOTAL_2="39" VAR="0.21721611721611722" WEIGHT="1.2986008845229144"/>
<DICH_DATA CI_END="1.0880236925267535" CI_START="0.9190976325870872" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="23" LOG_CI_END="0.03663835255113116" LOG_CI_START="-0.03663835255113116" LOG_EFFECT_SIZE="0.0" ORDER="67198" O_E="0.0" SE="0.043043099302609085" STUDY_ID="STD-Pugh-1995" TOTAL_1="22" TOTAL_2="23" VAR="0.0018527083975742667" WEIGHT="3.0222312775904725"/>
<DICH_DATA CI_END="1.363876456483296" CI_START="0.28509260166605166" EFFECT_SIZE="0.6235632183908046" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.13477503256563717" LOG_CI_START="-0.5450140527617399" LOG_EFFECT_SIZE="-0.20511951009805138" ORDER="67213" O_E="0.0" SE="0.3993114737315439" STUDY_ID="STD-Santos-2006" TOTAL_1="29" TOTAL_2="31" VAR="0.15944965305365746" WEIGHT="1.533131614769146"/>
<DICH_DATA CI_END="0.977231691528309" CI_START="0.41555530136149377" EFFECT_SIZE="0.6372549019607843" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="-0.010002457342592376" LOG_CI_START="-0.3813711728955317" LOG_EFFECT_SIZE="-0.19568681511906202" ORDER="67199" O_E="0.0" SE="0.21814382182058634" STUDY_ID="STD-Shore_x002d_Lesserson-1996" TOTAL_1="17" TOTAL_2="13" VAR="0.047586726998491716" WEIGHT="2.3576892409453043"/>
<DICH_DATA CI_END="1.7007938080196618" CI_START="0.8212013756695701" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.23065166607163218" LOG_CI_START="-0.08555033177440872" LOG_EFFECT_SIZE="0.07255066714861175" ORDER="67200" O_E="0.0" SE="0.1857386187598974" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.03449883449883451" WEIGHT="2.5160098509579876"/>
<DICH_DATA CI_END="0.5876020010184078" CI_START="0.14940639250163543" EFFECT_SIZE="0.2962962962962963" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="27" LOG_CI_END="-0.23091673393390336" LOG_CI_START="-0.8256308204001841" LOG_EFFECT_SIZE="-0.5282737771670437" MODIFIED="2010-05-21 15:40:14 +0100" MODIFIED_BY="Katharine Ker" ORDER="2499" O_E="0.0" SE="0.34933799827249973" STUDY_ID="STD-Taghaddomi-2009" TOTAL_1="50" TOTAL_2="50" VAR="0.12203703703703704" WEIGHT="1.7362125970701998"/>
<DICH_DATA CI_END="1.708504253584658" CI_START="0.1286075595299139" EFFECT_SIZE="0.46875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.23261606437917473" LOG_CI_START="-0.8907335029076242" LOG_EFFECT_SIZE="-0.32905871926422475" ORDER="67207" O_E="0.0" SE="0.6598610964943051" STUDY_ID="STD-Vanek-2005" TOTAL_1="32" TOTAL_2="30" VAR="0.4354166666666667" WEIGHT="0.8230294598601692"/>
<DICH_DATA CI_END="1.451648645691749" CI_START="0.11959582067352173" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.16186151326336917" LOG_CI_START="-0.9222839966865812" LOG_EFFECT_SIZE="-0.38021124171160603" ORDER="67212" O_E="0.0" SE="0.6368324391514266" STUDY_ID="STD-Wei-2006" TOTAL_1="36" TOTAL_2="40" VAR="0.4055555555555555" WEIGHT="0.8664540488241722"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="53.85830474919269" CI_END="0.6171064385391889" CI_START="0.39488059545046955" DF="25" EFFECT_SIZE="0.49364294576816703" ESTIMABLE="YES" EVENTS_1="193" EVENTS_2="328" I2="53.58190326186466" ID="CMP-002.02.02" LOG_CI_END="-0.2096399223792384" LOG_CI_START="-0.40353420709870835" LOG_EFFECT_SIZE="-0.3065870647389734" MODIFIED="2010-05-28 14:51:08 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="6.931575871903517E-4" P_Z="5.710570214252604E-10" STUDIES="27" TAU2="0.12215222186152987" TOTAL_1="722" TOTAL_2="659" WEIGHT="32.33739623601844" Z="6.198218847797718">
<NAME>Orthopaedic surgery</NAME>
<DICH_DATA CI_END="0.657557944250512" CI_START="0.16897539157215433" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="24" LOG_CI_END="-0.1820659709607079" LOG_CI_START="-0.772176538478617" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67215" O_E="0.0" SE="0.34663386845443983" STUDY_ID="STD-Benoni-1996" TOTAL_1="43" TOTAL_2="43" VAR="0.1201550387596899" WEIGHT="1.7478591496945681"/>
<DICH_DATA CI_END="0.9754681459204624" CI_START="0.33307084537693515" EFFECT_SIZE="0.57" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="-0.010786907998672239" LOG_CI_START="-0.477463380656345" LOG_EFFECT_SIZE="-0.24412514432750865" ORDER="67222" O_E="0.0" SE="0.27412807012491325" STUDY_ID="STD-Benoni-2000" TOTAL_1="20" TOTAL_2="19" VAR="0.07514619883040935" WEIGHT="2.081838965853291"/>
<DICH_DATA CI_END="1.5366307449348802" CI_START="0.20085630612689692" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.1865695183106097" LOG_CI_START="-0.6971145285172219" LOG_EFFECT_SIZE="-0.255272505103306" ORDER="67223" O_E="0.0" SE="0.5190803834132479" STUDY_ID="STD-Benoni-2001" TOTAL_1="18" TOTAL_2="20" VAR="0.26944444444444443" WEIGHT="1.1408157272385913"/>
<DICH_DATA CI_END="1.2617285296697793" CI_START="0.022015653228549727" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.10096592325294027" LOG_CI_START="-1.6572684240202276" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2010-05-14 15:54:26 +0100" MODIFIED_BY="Katharine Ker" ORDER="2535" O_E="0.0" SE="1.0327955589886444" STUDY_ID="STD-Claeys-2007" TOTAL_1="20" TOTAL_2="20" VAR="1.0666666666666667" WEIGHT="0.39963312814593094"/>
<DICH_DATA CI_END="14.903914722906746" CI_START="0.06709646549862758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528004" LOG_EFFECT_SIZE="0.0" ORDER="67220" O_E="0.0" SE="1.378404875209022" STUDY_ID="STD-Ekback-2000" TOTAL_1="20" TOTAL_2="20" VAR="1.9" WEIGHT="0.2380009637214355"/>
<DICH_DATA CI_END="0.9581328580005153" CI_START="0.021299930479260473" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.018574265977916792" LOG_CI_START="-1.6716218140505967" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="67219" O_E="0.0" SE="0.9710083124552245" STUDY_ID="STD-Ellis-2001" TOTAL_1="10" TOTAL_2="10" VAR="0.9428571428571427" WEIGHT="0.4444805100262193"/>
<DICH_DATA CI_END="2.4988165463450835" CI_START="0.008167131474760041" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.39773437303938103" LOG_CI_START="-2.087930453067895" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="67221" O_E="0.0" SE="1.4600918230947433" STUDY_ID="STD-Engel-2001" TOTAL_1="12" TOTAL_2="12" VAR="2.1318681318681314" WEIGHT="0.21392667043698954"/>
<DICH_DATA CI_END="1.8016168986512344" CI_START="0.7249723567520983" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.25566244674838573" LOG_CI_START="-0.13967855279301233" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="67233" O_E="0.0" SE="0.23222526010012653" STUDY_ID="STD-Garneti-2004" TOTAL_1="25" TOTAL_2="25" VAR="0.053928571428571416" WEIGHT="2.287928134312443"/>
<DICH_DATA CI_END="1.523032096014423" CI_START="0.04103656131972161" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.18270905565060536" LOG_CI_START="-1.38682903830653" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2010-05-20 14:50:34 +0100" MODIFIED_BY="Katharine Ker" ORDER="5364" O_E="0.0" SE="0.9219544457292888" STUDY_ID="STD-Gill-2009" TOTAL_1="5" TOTAL_2="5" VAR="0.8500000000000001" WEIGHT="0.4853287033373216"/>
<DICH_DATA CI_END="0.5832968063338196" CI_START="0.0622002019286873" EFFECT_SIZE="0.19047619047619047" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="14" LOG_CI_END="-0.2341104014122547" LOG_CI_START="-1.206208205399659" LOG_EFFECT_SIZE="-0.7201593034059569" ORDER="67235" O_E="0.0" SE="0.5710150620239374" STUDY_ID="STD-Good-2003" TOTAL_1="27" TOTAL_2="24" VAR="0.32605820105820105" WEIGHT="1.0080493503304337"/>
<DICH_DATA CI_END="1.0674920186129604" CI_START="0.48862654631305746" EFFECT_SIZE="0.7222222222222222" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.028364636591387042" LOG_CI_START="-0.3110229421843257" LOG_EFFECT_SIZE="-0.1413291527964693" ORDER="67216" O_E="0.0" SE="0.19935794376846325" STUDY_ID="STD-Hiipala-1995" TOTAL_1="15" TOTAL_2="13" VAR="0.039743589743589755" WEIGHT="2.450079324280051"/>
<DICH_DATA CI_END="0.7076468664513917" CI_START="0.3353987193056711" EFFECT_SIZE="0.48717948717948717" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="34" LOG_CI_END="-0.15018341210034744" LOG_CI_START="-0.4744386000469931" LOG_EFFECT_SIZE="-0.31231100607367024" ORDER="67217" O_E="0.0" SE="0.19046910248892657" STUDY_ID="STD-Hiipala-1997" TOTAL_1="39" TOTAL_2="38" VAR="0.03627847900293721" WEIGHT="2.4932442428071364"/>
<DICH_DATA CI_END="1.2108417211183848" CI_START="0.06741810398292612" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.08308737672071692" LOG_CI_START="-1.171223465421268" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="67226" O_E="0.0" SE="0.7367883976130072" STUDY_ID="STD-Husted-2003" TOTAL_1="20" TOTAL_2="20" VAR="0.5428571428571427" WEIGHT="0.6972914745963774"/>
<DICH_DATA CI_END="0.5995847135813608" CI_START="0.039475054178549726" EFFECT_SIZE="0.15384615384615385" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="13" LOG_CI_END="-0.22214944802504333" LOG_CI_START="-1.403677265260668" LOG_EFFECT_SIZE="-0.8129133566428556" ORDER="67218" O_E="0.0" SE="0.6940352885012271" STUDY_ID="STD-Jansen-1999" TOTAL_1="21" TOTAL_2="21" VAR="0.4816849816849816" WEIGHT="0.7637227756734877"/>
<DICH_DATA CI_END="0.7915384951180039" CI_START="0.19436062386207878" EFFECT_SIZE="0.39222941720629045" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="23" LOG_CI_END="-0.10152795912027116" LOG_CI_START="-0.7113917156008844" LOG_EFFECT_SIZE="-0.4064598373605777" ORDER="67232" O_E="0.0" SE="0.3582369894309945" STUDY_ID="STD-Johansson-2005" TOTAL_1="47" TOTAL_2="53" VAR="0.12833374059658248" WEIGHT="1.6983498479393107"/>
<DICH_DATA CI_END="1.0228204893606019" CI_START="0.12928114594315548" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.009799419322149849" LOG_CI_START="-0.8884648069826752" LOG_EFFECT_SIZE="-0.43933269383026263" MODIFIED="2010-05-28 14:51:08 +0100" MODIFIED_BY="Katharine Ker" ORDER="5376" O_E="0.0" SE="0.5276448530110863" STUDY_ID="STD-Kazemi-2010" TOTAL_1="32" TOTAL_2="32" VAR="0.27840909090909094" WEIGHT="1.1175096708134298"/>
<DICH_DATA CI_END="0.9081443087249566" CI_START="0.003455959890878708" EFFECT_SIZE="0.056022408963585436" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.04184513440491924" LOG_CI_START="-2.4614313064915043" LOG_EFFECT_SIZE="-1.251638220448212" ORDER="67231" O_E="0.0" SE="1.421276894628377" STUDY_ID="STD-Lemay-2004" TOTAL_1="20" TOTAL_2="19" VAR="2.020028011204482" WEIGHT="0.22489953324911144"/>
<DICH_DATA CI_END="1.215242085527897" CI_START="0.3476673537161672" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.08466280133863553" LOG_CI_START="-0.4588360880529243" LOG_EFFECT_SIZE="-0.1870866433571444" MODIFIED="2010-05-07 10:55:26 +0100" MODIFIED_BY="Katharine Ker" ORDER="2416" O_E="0.0" SE="0.3192539379914944" STUDY_ID="STD-MacGillivray-2010" TOTAL_1="40" TOTAL_2="20" VAR="0.10192307692307694" WEIGHT="1.8693367535351664"/>
<DICH_DATA CI_END="1.6578630011980628" CI_START="0.2610743375367926" EFFECT_SIZE="0.6578947368421053" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2195486394338172" LOG_CI_START="-0.5832358153233621" LOG_EFFECT_SIZE="-0.1818435879447725" ORDER="67229" O_E="0.0" SE="0.4715595625715076" STUDY_ID="STD-Niskanen-2005" TOTAL_1="19" TOTAL_2="20" VAR="0.2223684210526316" WEIGHT="1.2811210957842885"/>
<DICH_DATA CI_END="2.6516009553217748" CI_START="0.03650252247138919" EFFECT_SIZE="0.3111111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.42350816681362524" LOG_CI_START="-1.4376771230078367" LOG_EFFECT_SIZE="-0.5070844780971057" ORDER="67230" O_E="0.0" SE="1.0932694522568969" STUDY_ID="STD-Orpen-2006" TOTAL_1="15" TOTAL_2="14" VAR="1.1952380952380952" WEIGHT="0.3617312431604926"/>
<DICH_DATA CI_END="1.116493663022033" CI_START="0.3857290701805813" EFFECT_SIZE="0.65625" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="20" LOG_CI_END="0.04785626245235314" LOG_CI_START="-0.4137176296243265" LOG_EFFECT_SIZE="-0.1829306835859867" MODIFIED="2010-05-14 11:35:25 +0100" MODIFIED_BY="Katharine Ker" ORDER="2486" O_E="0.0" SE="0.2711307890334566" STUDY_ID="STD-Sadeghi-2007" TOTAL_1="32" TOTAL_2="35" VAR="0.07351190476190476" WEIGHT="2.0963840763977464"/>
<DICH_DATA CI_END="0.5995847135813608" CI_START="0.039475054178549726" EFFECT_SIZE="0.15384615384615385" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="13" LOG_CI_END="-0.22214944802504333" LOG_CI_START="-1.403677265260668" LOG_EFFECT_SIZE="-0.8129133566428556" ORDER="67234" O_E="0.0" SE="0.6940352885012271" STUDY_ID="STD-Sorin-1999" TOTAL_1="21" TOTAL_2="21" VAR="0.4816849816849816" WEIGHT="0.7637227756734877"/>
<DICH_DATA CI_END="0.7813352588543377" CI_START="0.5474218617451075" EFFECT_SIZE="0.654003059663437" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="26" LOG_CI_END="-0.10716257709786291" LOG_CI_START="-0.2616778626699975" LOG_EFFECT_SIZE="-0.1844202198839302" ORDER="67224" O_E="0.0" SE="0.09076304360807098" STUDY_ID="STD-Tanaka-2001" TOTAL_1="73" TOTAL_2="26" VAR="0.008237930085000594" WEIGHT="2.907801952539239"/>
<DICH_DATA CI_END="3.845086034384406" CI_START="0.010402888164868843" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5849060616512035" LOG_CI_START="-1.982846070323241" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="67225" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Veien-2002" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="0.20135392267263771"/>
<DICH_DATA CI_END="1.202502465890051" CI_START="0.5022788672971052" EFFECT_SIZE="0.7771689497716895" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="30" LOG_CI_END="0.08008597562494968" LOG_CI_START="-0.2990550938080483" LOG_EFFECT_SIZE="-0.10948455909154928" MODIFIED="2010-05-14 15:09:36 +0100" MODIFIED_BY="Katharine Ker" ORDER="2517" O_E="0.0" SE="0.222709340963505" STUDY_ID="STD-Wong-2008" TOTAL_1="73" TOTAL_2="74" VAR="0.04959945055239873" WEIGHT="2.3350926128896843"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67227" O_E="0.0" SE="0.0" STUDY_ID="STD-Yamasaki-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.7532478029295167" CI_START="0.08297402230305383" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.12306212640134118" LOG_CI_START="-1.0810578562545836" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="67228" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Zohar-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.31666666666666665" WEIGHT="1.0278936309095785"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="14.231864890636052" CI_END="32.46583095892078" CI_START="8.38174896573838E-4" DF="1" EFFECT_SIZE="0.16496073625616836" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="54" I2="92.9735139583994" ID="CMP-002.02.03" LOG_CI_END="1.5114265230644839" LOG_CI_START="-3.07666535047273" LOG_EFFECT_SIZE="-0.782619413704123" NO="3" P_CHI2="1.6161190498620304E-4" P_Z="0.5037209853310887" STUDIES="2" TAU2="13.571414475297406" TOTAL_1="148" TOTAL_2="148" WEIGHT="3.0558417294241997" Z="0.6686465340021019">
<NAME>Liver surgery</NAME>
<DICH_DATA CI_END="0.930965325905842" CI_START="0.5985224481530158" EFFECT_SIZE="0.7464607464607464" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="37" LOG_CI_END="-0.03106649415097593" LOG_CI_START="-0.22291955632497804" LOG_EFFECT_SIZE="-0.12699302523797698" ORDER="67236" O_E="0.0" SE="0.11269543840898297" STUDY_ID="STD-Dalmau-2000" TOTAL_1="42" TOTAL_2="40" VAR="0.012700261838192874" WEIGHT="2.8328439227852535"/>
<DICH_DATA CI_END="0.47788477395061085" CI_START="0.0017726629114815711" EFFECT_SIZE="0.029105473965287048" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="17" LOG_CI_END="-0.32067680646303687" LOG_CI_START="-2.751373841726686" LOG_EFFECT_SIZE="-1.5360253240948616" ORDER="67237" O_E="0.0" SE="1.4278034706582443" STUDY_ID="STD-Wu-2006" TOTAL_1="106" TOTAL_2="108" VAR="2.038622750823728" WEIGHT="0.2229978066389462"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9597327428757618" CI_START="0.32634829121299347" DF="0" EFFECT_SIZE="0.5596491228070175" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" I2="0.0" ID="CMP-002.02.04" LOG_CI_END="-0.017849688266260794" LOG_CI_START="-0.4863186569643599" LOG_EFFECT_SIZE="-0.2520841726153103" NO="4" P_CHI2="1.0" P_Z="0.03491681608386236" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="29" WEIGHT="2.0767396654462846" Z="2.1093217797185178">
<NAME>Vascular surgery</NAME>
<DICH_DATA CI_END="0.9597327428757618" CI_START="0.32634829121299347" EFFECT_SIZE="0.5596491228070175" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="-0.017849688266260794" LOG_CI_START="-0.4863186569643599" LOG_EFFECT_SIZE="-0.2520841726153103" ORDER="67238" O_E="0.0" SE="0.27518099117205813" STUDY_ID="STD-Casati-2002" TOTAL_1="30" TOTAL_2="29" VAR="0.07572457790243635" WEIGHT="2.0767396654462846"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.0132565450625943" CI_START="0.746700443972075" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" I2="0.0" ID="CMP-002.02.05" LOG_CI_END="0.4790361085608422" LOG_CI_START="-0.12685359044947975" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2010-04-21 10:37:34 +0100" MODIFIED_BY="Katharine Ker" NO="5" P_CHI2="1.0" P_Z="0.2545953286391597" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="1.7082124779944288" Z="1.139258602036633">
<NAME>Gynaecological surgery</NAME>
<DICH_DATA CI_END="3.0132565450625943" CI_START="0.746700443972075" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.4790361085608422" LOG_CI_START="-0.12685359044947975" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2010-04-21 10:37:34 +0100" MODIFIED_BY="Katharine Ker" ORDER="2352" O_E="0.0" SE="0.35590260840104376" STUDY_ID="STD-Caglar-2008" TOTAL_1="50" TOTAL_2="50" VAR="0.1266666666666667" WEIGHT="1.7082124779944288"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="249.32523222641808" CI_END="0.6986179805908745" CI_START="0.5309156917295179" CI_STUDY="95" CI_TOTAL="95" DF="63" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6090215500457131" ESTIMABLE="YES" EVENTS_1="707" EVENTS_2="1028" I2="74.73179932996584" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.1557602409558765" LOG_CI_START="-0.2749744384734396" LOG_EFFECT_SIZE="-0.21536733971465807" METHOD="MH" MODIFIED="2010-05-28 14:55:54 +0100" MODIFIED_BY="Katharine Ker" NO="3" P_CHI2="-8.881784197001252E-16" P_Q="0.0" P_Z="1.4252366225430062E-12" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="65" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.1604043011738904" TOTALS="YES" TOTAL_1="2528" TOTAL_2="2314" WEIGHT="100.0" Z="7.08157649133603">
<NAME>No. Exposed to Allogeneic Blood - Transfusion Protocol</NAME>
<GROUP_LABEL_1>TXA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TXA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="248.96873349645637" CI_END="0.6714676213040662" CI_START="0.4806402748594178" DF="55" EFFECT_SIZE="0.5680971589990447" ESTIMABLE="YES" EVENTS_1="568" EVENTS_2="874" I2="77.9088726413179" ID="CMP-002.03.01" LOG_CI_END="-0.17297492451128588" LOG_CI_START="-0.3181798406558061" LOG_EFFECT_SIZE="-0.24557738258354603" MODIFIED="2010-05-28 14:55:54 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="7.771561172376096E-16" P_Z="3.3667409064634473E-11" STUDIES="56" TAU2="0.2175340276916331" TOTAL_1="2156" TOTAL_2="1969" WEIGHT="81.93715445619631" Z="6.629566519666742">
<NAME>Transfusion Protocol</NAME>
<DICH_DATA CI_END="2.7594687360744157" CI_START="0.3770290949119647" EFFECT_SIZE="1.02" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.4408254780072691" LOG_CI_START="-0.423625134483434" LOG_EFFECT_SIZE="0.008600171761917567" ORDER="67271" O_E="0.0" SE="0.5077825688765832" STUDY_ID="STD-Andreasen-2004" TOTAL_1="20" TOTAL_2="17" VAR="0.257843137254902" WEIGHT="1.172459564073732"/>
<DICH_DATA CI_END="0.7650824343325807" CI_START="0.3866613431183696" EFFECT_SIZE="0.5439005439005439" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="63" LOG_CI_END="-0.1162917689679506" LOG_CI_START="-0.41266924481230916" LOG_EFFECT_SIZE="-0.26448050689012986" ORDER="67257" O_E="0.0" SE="0.1740935964031426" STUDY_ID="STD-Armellin-2001" TOTAL_1="143" TOTAL_2="140" VAR="0.030308580308580305" WEIGHT="2.571290442068277"/>
<DICH_DATA CI_END="0.657557944250512" CI_START="0.16897539157215433" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="24" LOG_CI_END="-0.1820659709607079" LOG_CI_START="-0.772176538478617" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67239" O_E="0.0" SE="0.34663386845443983" STUDY_ID="STD-Benoni-1996" TOTAL_1="43" TOTAL_2="43" VAR="0.1201550387596899" WEIGHT="1.7478591496945686"/>
<DICH_DATA CI_END="1.5366307449348802" CI_START="0.20085630612689692" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.1865695183106097" LOG_CI_START="-0.6971145285172219" LOG_EFFECT_SIZE="-0.255272505103306" ORDER="67263" O_E="0.0" SE="0.5190803834132479" STUDY_ID="STD-Benoni-2001" TOTAL_1="18" TOTAL_2="20" VAR="0.26944444444444443" WEIGHT="1.1408157272385917"/>
<DICH_DATA CI_END="1.4146284322310363" CI_START="0.3725136848128532" EFFECT_SIZE="0.725925925925926" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.15064238260049112" LOG_CI_START="-0.4288577682055137" LOG_EFFECT_SIZE="-0.13910769280251123" ORDER="67240" O_E="0.0" SE="0.34040125715545744" STUDY_ID="STD-Blauhut-1994" TOTAL_1="15" TOTAL_2="14" VAR="0.11587301587301588" WEIGHT="1.7749492233990414"/>
<DICH_DATA CI_END="0.7142374886661662" CI_START="0.2835191420407901" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="-0.14615735843676345" LOG_CI_START="-0.5474176140125492" LOG_EFFECT_SIZE="-0.3467874862246563" ORDER="67241" O_E="0.0" SE="0.23570226039551584" STUDY_ID="STD-Brown-1997" TOTAL_1="60" TOTAL_2="30" VAR="0.05555555555555556" WEIGHT="2.270691492213397"/>
<DICH_DATA CI_END="3.0132565450625943" CI_START="0.746700443972075" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.4790361085608422" LOG_CI_START="-0.12685359044947975" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2010-04-21 10:38:21 +0100" MODIFIED_BY="Katharine Ker" ORDER="2353" O_E="0.0" SE="0.35590260840104376" STUDY_ID="STD-Caglar-2008" TOTAL_1="50" TOTAL_2="50" VAR="0.1266666666666667" WEIGHT="1.708212477994429"/>
<DICH_DATA CI_END="2.427899066052217" CI_START="0.1029696841584531" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.38523062805078434" LOG_CI_START="-0.9872906193787466" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="67259" O_E="0.0" SE="0.8062257748298549" STUDY_ID="STD-Casati-2001" TOTAL_1="20" TOTAL_2="20" VAR="0.6499999999999999" WEIGHT="0.6051031671782249"/>
<DICH_DATA CI_END="0.9597327428757618" CI_START="0.32634829121299347" EFFECT_SIZE="0.5596491228070175" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="-0.017849688266260794" LOG_CI_START="-0.4863186569643599" LOG_EFFECT_SIZE="-0.2520841726153103" ORDER="67267" O_E="0.0" SE="0.27518099117205813" STUDY_ID="STD-Casati-2002" TOTAL_1="30" TOTAL_2="29" VAR="0.07572457790243635" WEIGHT="2.076739665446285"/>
<DICH_DATA CI_END="1.417807293880328" CI_START="0.31254634853586305" EFFECT_SIZE="0.665680473372781" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.15161720624074812" LOG_CI_START="-0.5050855705733328" LOG_EFFECT_SIZE="-0.17673418216629228" ORDER="67272" O_E="0.0" SE="0.3857504618317635" STUDY_ID="STD-Casati-2004" TOTAL_1="52" TOTAL_2="50" VAR="0.14880341880341882" WEIGHT="1.5859183896545752"/>
<DICH_DATA CI_END="1.2617285296697793" CI_START="0.022015653228549727" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.10096592325294027" LOG_CI_START="-1.6572684240202276" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2010-05-14 15:54:48 +0100" MODIFIED_BY="Katharine Ker" ORDER="2536" O_E="0.0" SE="1.0327955589886444" STUDY_ID="STD-Claeys-2007" TOTAL_1="20" TOTAL_2="20" VAR="1.0666666666666667" WEIGHT="0.39963312814593105"/>
<DICH_DATA CI_END="1.0452326878696259" CI_START="0.3557126588440236" EFFECT_SIZE="0.6097560975609756" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.01921298308688103" LOG_CI_START="-0.44890067918227683" LOG_EFFECT_SIZE="-0.21484384804769788" ORDER="67242" O_E="0.0" SE="0.27497228241690286" STUDY_ID="STD-Corbeau-1995" TOTAL_1="41" TOTAL_2="20" VAR="0.07560975609756097" WEIGHT="2.077750007793684"/>
<DICH_DATA CI_END="0.930965325905842" CI_START="0.5985224481530158" EFFECT_SIZE="0.7464607464607464" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="37" LOG_CI_END="-0.03106649415097593" LOG_CI_START="-0.22291955632497804" LOG_EFFECT_SIZE="-0.12699302523797698" ORDER="67261" O_E="0.0" SE="0.11269543840898297" STUDY_ID="STD-Dalmau-2000" TOTAL_1="42" TOTAL_2="40" VAR="0.012700261838192874" WEIGHT="2.8328439227852535"/>
<DICH_DATA CI_END="1.1666059421800465" CI_START="0.4703360622077637" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="27" LOG_CI_END="0.06692418420563072" LOG_CI_START="-0.32759172119564306" LOG_EFFECT_SIZE="-0.13033376849500614" ORDER="67273" O_E="0.0" SE="0.23174059571793568" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.05370370370370371" WEIGHT="2.290331039306667"/>
<DICH_DATA CI_END="14.903914722906746" CI_START="0.06709646549862758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528004" LOG_EFFECT_SIZE="0.0" ORDER="67260" O_E="0.0" SE="1.378404875209022" STUDY_ID="STD-Ekback-2000" TOTAL_1="20" TOTAL_2="20" VAR="1.9" WEIGHT="0.23800096372143564"/>
<DICH_DATA CI_END="0.9581328580005153" CI_START="0.021299930479260473" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.018574265977916792" LOG_CI_START="-1.6716218140505967" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="67258" O_E="0.0" SE="0.9710083124552245" STUDY_ID="STD-Ellis-2001" TOTAL_1="10" TOTAL_2="10" VAR="0.9428571428571427" WEIGHT="0.4444805100262196"/>
<DICH_DATA CI_END="2.4988165463450835" CI_START="0.008167131474760041" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.39773437303938103" LOG_CI_START="-2.087930453067895" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="67262" O_E="0.0" SE="1.4600918230947433" STUDY_ID="STD-Engel-2001" TOTAL_1="12" TOTAL_2="12" VAR="2.1318681318681314" WEIGHT="0.21392667043698965"/>
<DICH_DATA CI_END="1.523032096014423" CI_START="0.04103656131972161" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.18270905565060536" LOG_CI_START="-1.38682903830653" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2010-05-20 14:51:01 +0100" MODIFIED_BY="Katharine Ker" ORDER="5365" O_E="0.0" SE="0.9219544457292888" STUDY_ID="STD-Gill-2009" TOTAL_1="5" TOTAL_2="5" VAR="0.8500000000000001" WEIGHT="0.48532870333732175"/>
<DICH_DATA CI_END="0.5832968063338196" CI_START="0.0622002019286873" EFFECT_SIZE="0.19047619047619047" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="14" LOG_CI_END="-0.2341104014122547" LOG_CI_START="-1.206208205399659" LOG_EFFECT_SIZE="-0.7201593034059569" ORDER="67284" O_E="0.0" SE="0.5710150620239374" STUDY_ID="STD-Good-2003" TOTAL_1="27" TOTAL_2="24" VAR="0.32605820105820105" WEIGHT="1.008049350330434"/>
<DICH_DATA CI_END="1.492158128301091" CI_START="0.7910072381137022" EFFECT_SIZE="1.0864197530864197" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="27" LOG_CI_END="0.17381484901444078" LOG_CI_START="-0.10181954247140304" LOG_EFFECT_SIZE="0.035997653271518854" ORDER="67243" O_E="0.0" SE="0.16190900597102748" STUDY_ID="STD-Hardy-1998" TOTAL_1="42" TOTAL_2="44" VAR="0.02621452621452621" WEIGHT="2.627699553135306"/>
<DICH_DATA CI_END="1.0674920186129604" CI_START="0.48862654631305746" EFFECT_SIZE="0.7222222222222222" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.028364636591387042" LOG_CI_START="-0.3110229421843257" LOG_EFFECT_SIZE="-0.1413291527964693" ORDER="67244" O_E="0.0" SE="0.19935794376846325" STUDY_ID="STD-Hiipala-1995" TOTAL_1="15" TOTAL_2="13" VAR="0.039743589743589755" WEIGHT="2.4500793242800505"/>
<DICH_DATA CI_END="0.7076468664513917" CI_START="0.3353987193056711" EFFECT_SIZE="0.48717948717948717" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="34" LOG_CI_END="-0.15018341210034744" LOG_CI_START="-0.4744386000469931" LOG_EFFECT_SIZE="-0.31231100607367024" ORDER="67245" O_E="0.0" SE="0.19046910248892657" STUDY_ID="STD-Hiipala-1997" TOTAL_1="39" TOTAL_2="38" VAR="0.03627847900293721" WEIGHT="2.4932442428071364"/>
<DICH_DATA CI_END="1.6374042289645896" CI_START="0.485812319738244" EFFECT_SIZE="0.8918918918918919" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.21415590771813872" LOG_CI_START="-0.3135314760963538" LOG_EFFECT_SIZE="-0.04968778418910752" ORDER="67246" O_E="0.0" SE="0.30996618134731013" STUDY_ID="STD-Horrow-1991" TOTAL_1="37" TOTAL_2="44" VAR="0.09607903357903355" WEIGHT="1.9119301057418376"/>
<DICH_DATA CI_END="2.3557243756307376" CI_START="0.5905268923745671" EFFECT_SIZE="1.179456906729634" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="7" LOG_CI_END="0.37212447578184316" LOG_CI_START="-0.2287603199912923" LOG_EFFECT_SIZE="0.07168207789527543" ORDER="67247" O_E="0.0" SE="0.3529627034648498" STUDY_ID="STD-Horrow-1995" TOTAL_1="121" TOTAL_2="27" VAR="0.12458267003721549" WEIGHT="1.7207039579782275"/>
<DICH_DATA CI_END="1.2108417211183848" CI_START="0.06741810398292612" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.08308737672071692" LOG_CI_START="-1.171223465421268" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="67268" O_E="0.0" SE="0.7367883976130072" STUDY_ID="STD-Husted-2003" TOTAL_1="20" TOTAL_2="20" VAR="0.5428571428571427" WEIGHT="0.6972914745963777"/>
<DICH_DATA CI_END="0.7521793216911061" CI_START="0.3618973725771085" EFFECT_SIZE="0.5217391304347826" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="46" LOG_CI_END="-0.12367861002408044" LOG_CI_START="-0.4414145699158558" LOG_EFFECT_SIZE="-0.28254658996996806" ORDER="67248" O_E="0.0" SE="0.18663967565879638" STUDY_ID="STD-Isetta-1993" TOTAL_1="70" TOTAL_2="70" VAR="0.03483436853002071" WEIGHT="2.5116858769774417"/>
<DICH_DATA CI_END="0.5995847135813608" CI_START="0.039475054178549726" EFFECT_SIZE="0.15384615384615385" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="13" LOG_CI_END="-0.22214944802504333" LOG_CI_START="-1.403677265260668" LOG_EFFECT_SIZE="-0.8129133566428556" ORDER="67255" O_E="0.0" SE="0.6940352885012271" STUDY_ID="STD-Jansen-1999" TOTAL_1="21" TOTAL_2="21" VAR="0.4816849816849816" WEIGHT="0.7637227756734879"/>
<DICH_DATA CI_END="1.4026562348128688" CI_START="0.07515317284216183" EFFECT_SIZE="0.3246753246753247" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.14695124649727434" LOG_CI_START="-1.124052679498163" LOG_EFFECT_SIZE="-0.48855071650044424" ORDER="67264" O_E="0.0" SE="0.7465939977006226" STUDY_ID="STD-Jares-2003" TOTAL_1="22" TOTAL_2="25" VAR="0.5574025974025973" WEIGHT="0.6831617393308231"/>
<DICH_DATA CI_END="0.7915384951180039" CI_START="0.19436062386207878" EFFECT_SIZE="0.39222941720629045" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="23" LOG_CI_END="-0.10152795912027116" LOG_CI_START="-0.7113917156008844" LOG_EFFECT_SIZE="-0.4064598373605777" ORDER="67282" O_E="0.0" SE="0.3582369894309945" STUDY_ID="STD-Johansson-2005" TOTAL_1="47" TOTAL_2="53" VAR="0.12833374059658248" WEIGHT="1.6983498479393109"/>
<DICH_DATA CI_END="0.8306868840875706" CI_START="0.14746832091198164" EFFECT_SIZE="0.35" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="-0.0805626466593111" LOG_CI_START="-0.8313012646401378" LOG_EFFECT_SIZE="-0.4559319556497244" ORDER="67249" O_E="0.0" SE="0.44098758041803093" STUDY_ID="STD-Katoh-1997" TOTAL_1="62" TOTAL_2="31" VAR="0.1944700460829493" WEIGHT="1.3818361713822798"/>
<DICH_DATA CI_END="0.7928550646291872" CI_START="0.21747487464892984" EFFECT_SIZE="0.41524216524216523" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="27" LOG_CI_END="-0.10080619526073613" LOG_CI_START="-0.6625909108088087" LOG_EFFECT_SIZE="-0.3816985530347724" ORDER="67250" O_E="0.0" SE="0.32999512279212917" STUDY_ID="STD-Katsaros-1996" TOTAL_1="104" TOTAL_2="106" VAR="0.1088967810665924" WEIGHT="1.8209292189077613"/>
<DICH_DATA CI_END="1.0228204893606019" CI_START="0.12928114594315548" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.009799419322149849" LOG_CI_START="-0.8884648069826752" LOG_EFFECT_SIZE="-0.43933269383026263" MODIFIED="2010-05-28 14:51:43 +0100" MODIFIED_BY="Katharine Ker" ORDER="5377" O_E="0.0" SE="0.5276448530110863" STUDY_ID="STD-Kazemi-2010" TOTAL_1="32" TOTAL_2="32" VAR="0.27840909090909094" WEIGHT="1.11750967081343"/>
<DICH_DATA CI_END="0.9643873049425113" CI_START="0.18002218633670253" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.01574851524782261" LOG_CI_START="-0.7446739681753893" LOG_EFFECT_SIZE="-0.38021124171160603" ORDER="67275" O_E="0.0" SE="0.42817441928883765" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.18333333333333335" WEIGHT="1.4266061091569875"/>
<DICH_DATA CI_END="1.001769718383294" CI_START="0.6587796143846663" EFFECT_SIZE="0.8123702781237028" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="73" LOG_CI_END="7.678996455661966E-4" LOG_CI_START="-0.18125984832625064" LOG_EFFECT_SIZE="-0.09024597434034222" MODIFIED="2010-05-06 16:15:45 +0100" MODIFIED_BY="Katharine Ker" ORDER="2381" O_E="0.0" SE="0.1069240002105296" STUDY_ID="STD-Later-2009" TOTAL_1="99" TOTAL_2="103" VAR="0.011432741821021334" WEIGHT="2.853739803644652"/>
<DICH_DATA CI_END="0.9081443087249566" CI_START="0.003455959890878708" EFFECT_SIZE="0.056022408963585436" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.04184513440491924" LOG_CI_START="-2.4614313064915043" LOG_EFFECT_SIZE="-1.251638220448212" ORDER="67281" O_E="0.0" SE="1.421276894628377" STUDY_ID="STD-Lemay-2004" TOTAL_1="20" TOTAL_2="19" VAR="2.020028011204482" WEIGHT="0.22489953324911158"/>
<DICH_DATA CI_END="1.215242085527897" CI_START="0.3476673537161672" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.08466280133863553" LOG_CI_START="-0.4588360880529243" LOG_EFFECT_SIZE="-0.1870866433571444" MODIFIED="2010-05-07 10:56:00 +0100" MODIFIED_BY="Katharine Ker" ORDER="2417" O_E="0.0" SE="0.3192539379914944" STUDY_ID="STD-MacGillivray-2010" TOTAL_1="40" TOTAL_2="20" VAR="0.10192307692307694" WEIGHT="1.8693367535351666"/>
<DICH_DATA CI_END="1.1702850633778696" CI_START="0.2907648644131303" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.06829166206472205" LOG_CI_START="-0.536458074131458" LOG_EFFECT_SIZE="-0.23408320603336794" ORDER="67269" O_E="0.0" SE="0.3552329886011098" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.1261904761904762" WEIGHT="1.7110507520230467"/>
<DICH_DATA CI_END="1.712227535929018" CI_START="0.2281384873232139" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2335614770655728" LOG_CI_START="-0.6418014423774223" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2010-05-07 12:10:37 +0100" MODIFIED_BY="Katharine Ker" ORDER="2433" O_E="0.0" SE="0.5141925119971501" STUDY_ID="STD-Mehr_x002d_Aein-2007" TOTAL_1="33" TOTAL_2="33" VAR="0.2643939393939394" WEIGHT="1.154379096955972"/>
<DICH_DATA CI_END="1.0581296128387647" CI_START="0.42002835857894827" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.02453886873221163" LOG_CI_START="-0.37672138684357415" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="67251" O_E="0.0" SE="0.23570226039551587" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.05555555555555557" WEIGHT="2.2706914922133965"/>
<DICH_DATA CI_END="1.7701241393504614" CI_START="0.48710984658713274" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.2480037246354673" LOG_CI_START="-0.31237309137826985" LOG_EFFECT_SIZE="-0.03218468337140124" MODIFIED="2010-01-11 14:59:17 +0000" MODIFIED_BY="Katharine Ker" ORDER="2302" O_E="0.0" SE="0.3291681156364455" STUDY_ID="STD-Murphy-2006" TOTAL_1="50" TOTAL_2="50" VAR="0.10835164835164836" WEIGHT="1.824622711426072"/>
<DICH_DATA CI_END="1.6578630011980628" CI_START="0.2610743375367926" EFFECT_SIZE="0.6578947368421053" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2195486394338172" LOG_CI_START="-0.5832358153233621" LOG_EFFECT_SIZE="-0.1818435879447725" ORDER="67278" O_E="0.0" SE="0.4715595625715076" STUDY_ID="STD-Niskanen-2005" TOTAL_1="19" TOTAL_2="20" VAR="0.2223684210526316" WEIGHT="1.2811210957842887"/>
<DICH_DATA CI_END="2.6516009553217748" CI_START="0.03650252247138919" EFFECT_SIZE="0.3111111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.42350816681362524" LOG_CI_START="-1.4376771230078367" LOG_EFFECT_SIZE="-0.5070844780971057" ORDER="67280" O_E="0.0" SE="1.0932694522568969" STUDY_ID="STD-Orpen-2006" TOTAL_1="15" TOTAL_2="14" VAR="1.1952380952380952" WEIGHT="0.3617312431604927"/>
<DICH_DATA CI_END="2.8531415452949767" CI_START="0.03894342756823292" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45532331768430767" LOG_CI_START="-1.4095658271236327" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67252" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="1.2" WEIGHT="0.3604650535962218"/>
<DICH_DATA CI_END="2.153888658301622" CI_START="0.6259279035383108" EFFECT_SIZE="1.1611111111111112" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.3332232494099629" LOG_CI_START="-0.20347568739446692" LOG_EFFECT_SIZE="0.06487378100774796" ORDER="67256" O_E="0.0" SE="0.315259612181506" STUDY_ID="STD-Pinosky-1997" TOTAL_1="20" TOTAL_2="19" VAR="0.09938862307283358" WEIGHT="1.8875733846756637"/>
<DICH_DATA CI_END="2.1268041030916094" CI_START="0.34221405937999083" EFFECT_SIZE="0.853125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.32772748949634717" LOG_CI_START="-0.465702152054647" LOG_EFFECT_SIZE="-0.06898733127914992" ORDER="67266" O_E="0.0" SE="0.4660644989871222" STUDY_ID="STD-Pleym-2003" TOTAL_1="40" TOTAL_2="39" VAR="0.21721611721611722" WEIGHT="1.2986008845229149"/>
<DICH_DATA CI_END="1.0880236925267535" CI_START="0.9190976325870872" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="23" LOG_CI_END="0.03663835255113116" LOG_CI_START="-0.03663835255113116" LOG_EFFECT_SIZE="0.0" ORDER="67253" O_E="0.0" SE="0.043043099302609085" STUDY_ID="STD-Pugh-1995" TOTAL_1="22" TOTAL_2="23" VAR="0.0018527083975742667" WEIGHT="3.022231277590472"/>
<DICH_DATA CI_END="1.363876456483296" CI_START="0.28509260166605166" EFFECT_SIZE="0.6235632183908046" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.13477503256563717" LOG_CI_START="-0.5450140527617399" LOG_EFFECT_SIZE="-0.20511951009805138" ORDER="67279" O_E="0.0" SE="0.3993114737315439" STUDY_ID="STD-Santos-2006" TOTAL_1="29" TOTAL_2="31" VAR="0.15944965305365746" WEIGHT="1.5331316147691463"/>
<DICH_DATA CI_END="0.977231691528309" CI_START="0.41555530136149377" EFFECT_SIZE="0.6372549019607843" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="-0.010002457342592376" LOG_CI_START="-0.3813711728955317" LOG_EFFECT_SIZE="-0.19568681511906202" ORDER="67254" O_E="0.0" SE="0.21814382182058634" STUDY_ID="STD-Shore_x002d_Lesserson-1996" TOTAL_1="17" TOTAL_2="13" VAR="0.047586726998491716" WEIGHT="2.3576892409453043"/>
<DICH_DATA CI_END="0.5995847135813608" CI_START="0.039475054178549726" EFFECT_SIZE="0.15384615384615385" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="13" LOG_CI_END="-0.22214944802504333" LOG_CI_START="-1.403677265260668" LOG_EFFECT_SIZE="-0.8129133566428556" ORDER="67283" O_E="0.0" SE="0.6940352885012271" STUDY_ID="STD-Sorin-1999" TOTAL_1="21" TOTAL_2="21" VAR="0.4816849816849816" WEIGHT="0.7637227756734879"/>
<DICH_DATA CI_END="0.5876020010184078" CI_START="0.14940639250163543" EFFECT_SIZE="0.2962962962962963" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="27" LOG_CI_END="-0.23091673393390336" LOG_CI_START="-0.8256308204001841" LOG_EFFECT_SIZE="-0.5282737771670437" MODIFIED="2010-05-21 15:40:45 +0100" MODIFIED_BY="Katharine Ker" ORDER="2500" O_E="0.0" SE="0.34933799827249973" STUDY_ID="STD-Taghaddomi-2009" TOTAL_1="50" TOTAL_2="50" VAR="0.12203703703703704" WEIGHT="1.7362125970702"/>
<DICH_DATA CI_END="1.708504253584658" CI_START="0.1286075595299139" EFFECT_SIZE="0.46875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.23261606437917473" LOG_CI_START="-0.8907335029076242" LOG_EFFECT_SIZE="-0.32905871926422475" ORDER="67270" O_E="0.0" SE="0.6598610964943051" STUDY_ID="STD-Vanek-2005" TOTAL_1="32" TOTAL_2="30" VAR="0.4354166666666667" WEIGHT="0.8230294598601694"/>
<DICH_DATA CI_END="3.845086034384406" CI_START="0.010402888164868843" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5849060616512035" LOG_CI_START="-1.982846070323241" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="67265" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Veien-2002" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="0.20135392267263783"/>
<DICH_DATA CI_END="1.451648645691749" CI_START="0.11959582067352173" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.16186151326336917" LOG_CI_START="-0.9222839966865812" LOG_EFFECT_SIZE="-0.38021124171160603" ORDER="67276" O_E="0.0" SE="0.6368324391514266" STUDY_ID="STD-Wei-2006" TOTAL_1="36" TOTAL_2="40" VAR="0.4055555555555555" WEIGHT="0.8664540488241727"/>
<DICH_DATA CI_END="1.202502465890051" CI_START="0.5022788672971052" EFFECT_SIZE="0.7771689497716895" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="30" LOG_CI_END="0.08008597562494968" LOG_CI_START="-0.2990550938080483" LOG_EFFECT_SIZE="-0.10948455909154928" MODIFIED="2010-05-14 15:10:04 +0100" MODIFIED_BY="Katharine Ker" ORDER="2518" O_E="0.0" SE="0.222709340963505" STUDY_ID="STD-Wong-2008" TOTAL_1="73" TOTAL_2="74" VAR="0.04959945055239873" WEIGHT="2.3350926128896843"/>
<DICH_DATA CI_END="0.47788477395061085" CI_START="0.0017726629114815711" EFFECT_SIZE="0.029105473965287048" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="17" LOG_CI_END="-0.32067680646303687" LOG_CI_START="-2.751373841726686" LOG_EFFECT_SIZE="-1.5360253240948616" ORDER="67277" O_E="0.0" SE="1.4278034706582443" STUDY_ID="STD-Wu-2006" TOTAL_1="106" TOTAL_2="108" VAR="2.038622750823728" WEIGHT="0.22299780663894633"/>
<DICH_DATA CI_END="0.7532478029295167" CI_START="0.08297402230305383" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.12306212640134118" LOG_CI_START="-1.0810578562545836" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="67274" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Zohar-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.31666666666666665" WEIGHT="1.027893630909579"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="15.476108897295479" CI_END="0.9550709455275039" CI_START="0.6115334461129753" DF="7" EFFECT_SIZE="0.7642367608279598" ESTIMABLE="YES" EVENTS_1="139" EVENTS_2="154" I2="54.76899234520583" ID="CMP-002.03.02" LOG_CI_END="-0.019964366524414523" LOG_CI_START="-0.2135797854550313" LOG_EFFECT_SIZE="-0.11677207598972293" MODIFIED="2010-05-17 14:41:31 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.030358304372402167" P_Z="0.018070931128825296" STUDIES="9" TAU2="0.051373717549521594" TOTAL_1="372" TOTAL_2="345" WEIGHT="18.062845543803697" Z="2.3641615384139207">
<NAME>No Transfusion Protocol</NAME>
<DICH_DATA CI_END="0.9754681459204624" CI_START="0.33307084537693515" EFFECT_SIZE="0.57" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="-0.010786907998672239" LOG_CI_START="-0.477463380656345" LOG_EFFECT_SIZE="-0.24412514432750865" ORDER="67287" O_E="0.0" SE="0.27412807012491325" STUDY_ID="STD-Benoni-2000" TOTAL_1="20" TOTAL_2="19" VAR="0.07514619883040935" WEIGHT="2.0818389658532914"/>
<DICH_DATA CI_END="1.8418560833961877" CI_START="0.5260965551870249" EFFECT_SIZE="0.984375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.2652556928376572" LOG_CI_START="-0.2789345418982681" LOG_EFFECT_SIZE="-0.0068394245303054655" ORDER="67285" O_E="0.0" SE="0.3196600376689893" STUDY_ID="STD-Coffey-1995" TOTAL_1="16" TOTAL_2="14" VAR="0.10218253968253968" WEIGHT="1.867489656891422"/>
<DICH_DATA CI_END="1.8016168986512344" CI_START="0.7249723567520983" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.25566244674838573" LOG_CI_START="-0.13967855279301233" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="67290" O_E="0.0" SE="0.23222526010012653" STUDY_ID="STD-Garneti-2004" TOTAL_1="25" TOTAL_2="25" VAR="0.053928571428571416" WEIGHT="2.2879281343124434"/>
<DICH_DATA CI_END="0.904452772551861" CI_START="0.29114955796727204" EFFECT_SIZE="0.5131578947368421" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="19" LOG_CI_END="-0.043614105593121844" LOG_CI_START="-0.5358838649154624" LOG_EFFECT_SIZE="-0.2897489852542921" MODIFIED="2010-05-17 14:41:31 +0100" MODIFIED_BY="Katharine Ker" ORDER="2633" O_E="0.0" SE="0.28916169340055126" STUDY_ID="STD-Jimenez-2007" TOTAL_1="24" TOTAL_2="26" VAR="0.0836144849302744" WEIGHT="2.009592036597741"/>
<DICH_DATA CI_END="1.032554195568666" CI_START="0.4180951534213291" EFFECT_SIZE="0.6570433051269288" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="41" LOG_CI_END="0.01391285569765569" LOG_CI_START="-0.3787248667824544" LOG_EFFECT_SIZE="-0.1824060055423993" ORDER="67291" O_E="0.0" SE="0.23063734177288867" STUDY_ID="STD-Karski-2005" TOTAL_1="147" TOTAL_2="165" VAR="0.05319358342006426" WEIGHT="2.2958008702538244"/>
<DICH_DATA CI_END="1.116493663022033" CI_START="0.3857290701805813" EFFECT_SIZE="0.65625" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="20" LOG_CI_END="0.04785626245235314" LOG_CI_START="-0.4137176296243265" LOG_EFFECT_SIZE="-0.1829306835859867" MODIFIED="2010-05-14 11:46:39 +0100" MODIFIED_BY="Katharine Ker" ORDER="2487" O_E="0.0" SE="0.2711307890334566" STUDY_ID="STD-Sadeghi-2007" TOTAL_1="32" TOTAL_2="35" VAR="0.07351190476190476" WEIGHT="2.096384076397747"/>
<DICH_DATA CI_END="1.7007938080196618" CI_START="0.8212013756695701" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.23065166607163218" LOG_CI_START="-0.08555033177440872" LOG_EFFECT_SIZE="0.07255066714861175" ORDER="67286" O_E="0.0" SE="0.1857386187598974" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.03449883449883451" WEIGHT="2.516009850957988"/>
<DICH_DATA CI_END="0.7813352588543377" CI_START="0.5474218617451075" EFFECT_SIZE="0.654003059663437" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="26" LOG_CI_END="-0.10716257709786291" LOG_CI_START="-0.2616778626699975" LOG_EFFECT_SIZE="-0.1844202198839302" ORDER="67288" O_E="0.0" SE="0.09076304360807098" STUDY_ID="STD-Tanaka-2001" TOTAL_1="73" TOTAL_2="26" VAR="0.008237930085000594" WEIGHT="2.9078019525392387"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67289" O_E="0.0" SE="0.0" STUDY_ID="STD-Yamasaki-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="139.40185467603462" CI_END="0.8001840746268866" CI_START="0.5781228721980028" CI_STUDY="95" CI_TOTAL="95" DF="36" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6801505094538978" ESTIMABLE="YES" EVENTS_1="475" EVENTS_2="662" I2="74.175379456993" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-0.09681009625930799" LOG_CI_START="-0.23797984835039104" LOG_EFFECT_SIZE="-0.16739497230484954" METHOD="MH" MODIFIED="2010-05-28 14:52:37 +0100" MODIFIED_BY="Katharine Ker" NO="4" P_CHI2="4.263256414560601E-14" P_Q="0.0" P_Z="3.3494774505757076E-6" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="36" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.14169160287199767" TOTALS="YES" TOTAL_1="1642" TOTAL_2="1549" WEIGHT="100.00000000000001" Z="4.6481361913691215">
<NAME>No. Exposed to Allogeneic Blood - Dose (Cardiac Surgery)</NAME>
<GROUP_LABEL_1>TXA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TXA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="26.932969537811893" CI_END="0.837432030267911" CI_START="0.5835517731010005" DF="18" EFFECT_SIZE="0.699060044713192" ESTIMABLE="YES" EVENTS_1="183" EVENTS_2="243" I2="33.16741410660516" ID="CMP-002.04.01" LOG_CI_END="-0.0770504321448395" LOG_CI_START="-0.2339206070143024" LOG_EFFECT_SIZE="-0.15548551957957102" MODIFIED="2010-05-28 14:52:37 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="0.08026137008230894" P_Z="1.0219194573153002E-4" STUDIES="19" TAU2="0.04794513368186399" TOTAL_1="592" TOTAL_2="531" WEIGHT="47.44800432947568" Z="3.885327708049617">
<NAME>Total dose &lt; 2.0 grams</NAME>
<DICH_DATA CI_END="1.4146284322310363" CI_START="0.3725136848128532" EFFECT_SIZE="0.725925925925926" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.15064238260049112" LOG_CI_START="-0.4288577682055137" LOG_EFFECT_SIZE="-0.13910769280251123" ORDER="67296" O_E="0.0" SE="0.34040125715545744" STUDY_ID="STD-Blauhut-1994" TOTAL_1="15" TOTAL_2="14" VAR="0.11587301587301588" WEIGHT="2.6697605028577858"/>
<DICH_DATA CI_END="0.7142374886661662" CI_START="0.2835191420407901" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="-0.14615735843676345" LOG_CI_START="-0.5474176140125492" LOG_EFFECT_SIZE="-0.3467874862246563" ORDER="67302" O_E="0.0" SE="0.23570226039551584" STUDY_ID="STD-Brown-1997" TOTAL_1="60" TOTAL_2="30" VAR="0.05555555555555556" WEIGHT="3.486163509481545"/>
<DICH_DATA CI_END="1.8418560833961877" CI_START="0.5260965551870249" EFFECT_SIZE="0.984375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.2652556928376572" LOG_CI_START="-0.2789345418982681" LOG_EFFECT_SIZE="-0.0068394245303054655" ORDER="67299" O_E="0.0" SE="0.3196600376689893" STUDY_ID="STD-Coffey-1995" TOTAL_1="16" TOTAL_2="14" VAR="0.10218253968253968" WEIGHT="2.8196340901753696"/>
<DICH_DATA CI_END="1.6374042289645896" CI_START="0.485812319738244" EFFECT_SIZE="0.8918918918918919" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.21415590771813872" LOG_CI_START="-0.3135314760963538" LOG_EFFECT_SIZE="-0.04968778418910752" ORDER="67301" O_E="0.0" SE="0.30996618134731013" STUDY_ID="STD-Horrow-1991" TOTAL_1="37" TOTAL_2="44" VAR="0.09607903357903355" WEIGHT="2.8920133130092354"/>
<DICH_DATA CI_END="2.7160830407393415" CI_START="0.6454973610687358" EFFECT_SIZE="1.32409381663113" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="7" LOG_CI_END="0.43394304380564974" LOG_CI_START="-0.19010552888265594" LOG_EFFECT_SIZE="0.1219187574614969" MODIFIED="2008-09-11 07:21:58 +0100" MODIFIED_BY="[Empty name]" ORDER="2261" O_E="0.0" SE="0.3665692206873658" STUDY_ID="STD-Horrow-1995" TOTAL_1="67" TOTAL_2="27" VAR="0.13437299355534268" WEIGHT="2.490851253503799"/>
<DICH_DATA CI_END="0.7521793216911061" CI_START="0.3618973725771085" EFFECT_SIZE="0.5217391304347826" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="46" LOG_CI_END="-0.12367861002408044" LOG_CI_START="-0.4414145699158558" LOG_EFFECT_SIZE="-0.28254658996996806" ORDER="67292" O_E="0.0" SE="0.18663967565879638" STUDY_ID="STD-Isetta-1993" TOTAL_1="70" TOTAL_2="70" VAR="0.03483436853002071" WEIGHT="3.895380609423452"/>
<DICH_DATA CI_END="1.4026562348128688" CI_START="0.07515317284216183" EFFECT_SIZE="0.3246753246753247" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.14695124649727434" LOG_CI_START="-1.124052679498163" LOG_EFFECT_SIZE="-0.48855071650044424" ORDER="67297" O_E="0.0" SE="0.7465939977006226" STUDY_ID="STD-Jares-2003" TOTAL_1="22" TOTAL_2="25" VAR="0.5574025974025973" WEIGHT="0.9836097135249684"/>
<DICH_DATA CI_END="1.0228204893606019" CI_START="0.12928114594315548" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.009799419322149849" LOG_CI_START="-0.8884648069826752" LOG_EFFECT_SIZE="-0.43933269383026263" MODIFIED="2010-05-28 14:52:37 +0100" MODIFIED_BY="Katharine Ker" ORDER="2764" O_E="0.0" SE="0.5276448530110863" STUDY_ID="STD-Kazemi-2010" TOTAL_1="32" TOTAL_2="32" VAR="0.27840909090909094" WEIGHT="1.636835778275061"/>
<DICH_DATA CI_END="1.1702850633778696" CI_START="0.2907648644131303" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.06829166206472205" LOG_CI_START="-0.536458074131458" LOG_EFFECT_SIZE="-0.23408320603336794" ORDER="67303" O_E="0.0" SE="0.3552329886011098" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.1261904761904762" WEIGHT="2.5669348560591656"/>
<DICH_DATA CI_END="1.712227535929018" CI_START="0.2281384873232139" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2335614770655728" LOG_CI_START="-0.6418014423774223" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2010-05-21 14:48:47 +0100" MODIFIED_BY="Katharine Ker" ORDER="2786" O_E="0.0" SE="0.5141925119971501" STUDY_ID="STD-Mehr_x002d_Aein-2007" TOTAL_1="33" TOTAL_2="33" VAR="0.2643939393939394" WEIGHT="1.693327573845864"/>
<DICH_DATA CI_END="1.0581296128387647" CI_START="0.42002835857894827" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.02453886873221163" LOG_CI_START="-0.37672138684357415" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="67306" O_E="0.0" SE="0.23570226039551587" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.05555555555555557" WEIGHT="3.4861635094815444"/>
<DICH_DATA CI_END="2.8531415452949767" CI_START="0.03894342756823292" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45532331768430767" LOG_CI_START="-1.4095658271236327" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67298" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="1.2" WEIGHT="0.5125140863870072"/>
<DICH_DATA CI_END="2.153888658301622" CI_START="0.6259279035383108" EFFECT_SIZE="1.1611111111111112" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.3332232494099629" LOG_CI_START="-0.20347568739446692" LOG_EFFECT_SIZE="0.06487378100774796" ORDER="67300" O_E="0.0" SE="0.315259612181506" STUDY_ID="STD-Pinosky-1997" TOTAL_1="20" TOTAL_2="19" VAR="0.09938862307283358" WEIGHT="2.8523112725820146"/>
<DICH_DATA CI_END="1.116493663022033" CI_START="0.3857290701805813" EFFECT_SIZE="0.65625" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="20" LOG_CI_END="0.04785626245235314" LOG_CI_START="-0.4137176296243265" LOG_EFFECT_SIZE="-0.1829306835859867" MODIFIED="2010-05-14 11:47:22 +0100" MODIFIED_BY="Katharine Ker" ORDER="2488" O_E="0.0" SE="0.2711307890334566" STUDY_ID="STD-Sadeghi-2007" TOTAL_1="32" TOTAL_2="35" VAR="0.07351190476190476" WEIGHT="3.195281775931116"/>
<DICH_DATA CI_END="1.363876456483296" CI_START="0.28509260166605166" EFFECT_SIZE="0.6235632183908046" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.13477503256563717" LOG_CI_START="-0.5450140527617399" LOG_EFFECT_SIZE="-0.20511951009805138" ORDER="67293" O_E="0.0" SE="0.3993114737315439" STUDY_ID="STD-Santos-2006" TOTAL_1="29" TOTAL_2="31" VAR="0.15944965305365746" WEIGHT="2.2834328825035612"/>
<DICH_DATA CI_END="0.977231691528309" CI_START="0.41555530136149377" EFFECT_SIZE="0.6372549019607843" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="-0.010002457342592376" LOG_CI_START="-0.3813711728955317" LOG_EFFECT_SIZE="-0.19568681511906202" ORDER="67305" O_E="0.0" SE="0.21814382182058634" STUDY_ID="STD-Shore_x002d_Lesserson-1996" TOTAL_1="17" TOTAL_2="13" VAR="0.047586726998491716" WEIGHT="3.6329348770647174"/>
<DICH_DATA CI_END="1.7007938080196618" CI_START="0.8212013756695701" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.23065166607163218" LOG_CI_START="-0.08555033177440872" LOG_EFFECT_SIZE="0.07255066714861175" ORDER="67304" O_E="0.0" SE="0.1857386187598974" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.03449883449883451" WEIGHT="3.9027989050948197"/>
<DICH_DATA CI_END="1.708504253584658" CI_START="0.1286075595299139" EFFECT_SIZE="0.46875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.23261606437917473" LOG_CI_START="-0.8907335029076242" LOG_EFFECT_SIZE="-0.32905871926422475" ORDER="67294" O_E="0.0" SE="0.6598610964943051" STUDY_ID="STD-Vanek-2005" TOTAL_1="32" TOTAL_2="30" VAR="0.4354166666666667" WEIGHT="1.191519654723977"/>
<DICH_DATA CI_END="1.451648645691749" CI_START="0.11959582067352173" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.16186151326336917" LOG_CI_START="-0.9222839966865812" LOG_EFFECT_SIZE="-0.38021124171160603" ORDER="67295" O_E="0.0" SE="0.6368324391514266" STUDY_ID="STD-Wei-2006" TOTAL_1="36" TOTAL_2="40" VAR="0.4055555555555555" WEIGHT="1.2565361655506766"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="107.96934338095942" CI_END="0.8581314724059671" CI_START="0.5179913002783162" DF="17" EFFECT_SIZE="0.6667118097058975" ESTIMABLE="YES" EVENTS_1="292" EVENTS_2="419" I2="84.25478986195448" ID="CMP-002.04.02" LOG_CI_END="-0.06644616976632715" LOG_CI_START="-0.2856775342177963" LOG_EFFECT_SIZE="-0.17606185199206176" MODIFIED="2010-05-21 15:41:46 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="2.4424906541753444E-15" P_Z="0.001643674723566088" STUDIES="18" TAU2="0.1991494932582765" TOTAL_1="1050" TOTAL_2="1018" WEIGHT="52.551995670524335" Z="3.148043071476218">
<NAME>Total dose 2.0 - 10.0 grams</NAME>
<DICH_DATA CI_END="2.7594687360744157" CI_START="0.3770290949119647" EFFECT_SIZE="1.02" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.4408254780072691" LOG_CI_START="-0.423625134483434" LOG_EFFECT_SIZE="0.008600171761917567" ORDER="67312" O_E="0.0" SE="0.5077825688765832" STUDY_ID="STD-Andreasen-2004" TOTAL_1="20" TOTAL_2="17" VAR="0.257843137254902" WEIGHT="1.7210915021824018"/>
<DICH_DATA CI_END="0.7650824343325807" CI_START="0.3866613431183696" EFFECT_SIZE="0.5439005439005439" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="63" LOG_CI_END="-0.1162917689679506" LOG_CI_START="-0.41266924481230916" LOG_EFFECT_SIZE="-0.26448050689012986" ORDER="67314" O_E="0.0" SE="0.1740935964031426" STUDY_ID="STD-Armellin-2001" TOTAL_1="143" TOTAL_2="140" VAR="0.030308580308580305" WEIGHT="3.9978785681706657"/>
<DICH_DATA CI_END="2.427899066052217" CI_START="0.1029696841584531" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.38523062805078434" LOG_CI_START="-0.9872906193787466" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="67308" O_E="0.0" SE="0.8062257748298549" STUDY_ID="STD-Casati-2001" TOTAL_1="20" TOTAL_2="20" VAR="0.6499999999999999" WEIGHT="0.868565289267366"/>
<DICH_DATA CI_END="1.417807293880328" CI_START="0.31254634853586305" EFFECT_SIZE="0.665680473372781" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.15161720624074812" LOG_CI_START="-0.5050855705733328" LOG_EFFECT_SIZE="-0.17673418216629228" ORDER="67309" O_E="0.0" SE="0.3857504618317635" STUDY_ID="STD-Casati-2004" TOTAL_1="52" TOTAL_2="50" VAR="0.14880341880341882" WEIGHT="2.3671174882555768"/>
<DICH_DATA CI_END="1.0452326878696259" CI_START="0.3557126588440236" EFFECT_SIZE="0.6097560975609756" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.01921298308688103" LOG_CI_START="-0.44890067918227683" LOG_EFFECT_SIZE="-0.21484384804769788" ORDER="67310" O_E="0.0" SE="0.27497228241690286" STUDY_ID="STD-Corbeau-1995" TOTAL_1="41" TOTAL_2="20" VAR="0.07560975609756097" WEIGHT="3.1644341725234715"/>
<DICH_DATA CI_END="1.1666059421800465" CI_START="0.4703360622077637" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="27" LOG_CI_END="0.06692418420563072" LOG_CI_START="-0.32759172119564306" LOG_EFFECT_SIZE="-0.13033376849500614" ORDER="67315" O_E="0.0" SE="0.23174059571793568" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.05370370370370371" WEIGHT="3.519203496285888"/>
<DICH_DATA CI_END="1.492158128301091" CI_START="0.7910072381137022" EFFECT_SIZE="1.0864197530864197" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="27" LOG_CI_END="0.17381484901444078" LOG_CI_START="-0.10181954247140304" LOG_EFFECT_SIZE="0.035997653271518854" ORDER="67318" O_E="0.0" SE="0.16190900597102748" STUDY_ID="STD-Hardy-1998" TOTAL_1="42" TOTAL_2="44" VAR="0.02621452621452621" WEIGHT="4.095358816262835"/>
<DICH_DATA CI_END="1.89189000458798" CI_START="0.5285719558615577" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.2768958827057606" LOG_CI_START="-0.2768958827057606" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-09-11 07:21:06 +0100" MODIFIED_BY="[Empty name]" ORDER="2260" O_E="0.0" SE="0.3253000243161777" STUDY_ID="STD-Horrow-1995" TOTAL_1="54" TOTAL_2="54" VAR="0.10582010582010581" WEIGHT="2.778195220309589"/>
<DICH_DATA CI_END="0.904452772551861" CI_START="0.29114955796727204" EFFECT_SIZE="0.5131578947368421" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="19" LOG_CI_END="-0.043614105593121844" LOG_CI_START="-0.5358838649154624" LOG_EFFECT_SIZE="-0.2897489852542921" MODIFIED="2010-05-17 14:42:00 +0100" MODIFIED_BY="Katharine Ker" ORDER="2634" O_E="0.0" SE="0.28916169340055126" STUDY_ID="STD-Jimenez-2007" TOTAL_1="24" TOTAL_2="26" VAR="0.0836144849302744" WEIGHT="3.0520073947692365"/>
<DICH_DATA CI_END="1.032554195568666" CI_START="0.4180951534213291" EFFECT_SIZE="0.6570433051269288" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="41" LOG_CI_END="0.01391285569765569" LOG_CI_START="-0.3787248667824544" LOG_EFFECT_SIZE="-0.1824060055423993" ORDER="67319" O_E="0.0" SE="0.23063734177288867" STUDY_ID="STD-Karski-2005" TOTAL_1="147" TOTAL_2="165" VAR="0.05319358342006426" WEIGHT="3.5284151614712553"/>
<DICH_DATA CI_END="0.8306868840875706" CI_START="0.14746832091198164" EFFECT_SIZE="0.35" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="-0.0805626466593111" LOG_CI_START="-0.8313012646401378" LOG_EFFECT_SIZE="-0.4559319556497244" ORDER="67320" O_E="0.0" SE="0.44098758041803093" STUDY_ID="STD-Katoh-1997" TOTAL_1="62" TOTAL_2="31" VAR="0.1944700460829493" WEIGHT="2.0455511453991577"/>
<DICH_DATA CI_END="0.7928550646291872" CI_START="0.21747487464892984" EFFECT_SIZE="0.41524216524216523" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="27" LOG_CI_END="-0.10080619526073613" LOG_CI_START="-0.6625909108088087" LOG_EFFECT_SIZE="-0.3816985530347724" ORDER="67321" O_E="0.0" SE="0.32999512279212917" STUDY_ID="STD-Katsaros-1996" TOTAL_1="104" TOTAL_2="106" VAR="0.1088967810665924" WEIGHT="2.7440850818830267"/>
<DICH_DATA CI_END="0.9643873049425113" CI_START="0.18002218633670253" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.01574851524782261" LOG_CI_START="-0.7446739681753893" LOG_EFFECT_SIZE="-0.38021124171160603" ORDER="67313" O_E="0.0" SE="0.42817441928883765" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.18333333333333335" WEIGHT="2.1156402769806397"/>
<DICH_DATA CI_END="1.001769718383294" CI_START="0.6587796143846663" EFFECT_SIZE="0.8123702781237028" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="73" LOG_CI_END="7.678996455661966E-4" LOG_CI_START="-0.18125984832625064" LOG_EFFECT_SIZE="-0.09024597434034222" MODIFIED="2010-05-06 16:16:36 +0100" MODIFIED_BY="Katharine Ker" ORDER="2382" O_E="0.0" SE="0.1069240002105296" STUDY_ID="STD-Later-2009" TOTAL_1="99" TOTAL_2="103" VAR="0.011432741821021334" WEIGHT="4.490702294515098"/>
<DICH_DATA CI_END="1.7701241393504614" CI_START="0.48710984658713274" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.2480037246354673" LOG_CI_START="-0.31237309137826985" LOG_EFFECT_SIZE="-0.03218468337140124" MODIFIED="2010-01-11 15:00:48 +0000" MODIFIED_BY="Katharine Ker" ORDER="2303" O_E="0.0" SE="0.3291681156364455" STUDY_ID="STD-Murphy-2006" TOTAL_1="50" TOTAL_2="50" VAR="0.10835164835164836" WEIGHT="2.750067609079437"/>
<DICH_DATA CI_END="2.1268041030916094" CI_START="0.34221405937999083" EFFECT_SIZE="0.853125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.32772748949634717" LOG_CI_START="-0.465702152054647" LOG_EFFECT_SIZE="-0.06898733127914992" ORDER="67311" O_E="0.0" SE="0.4660644989871222" STUDY_ID="STD-Pleym-2003" TOTAL_1="40" TOTAL_2="39" VAR="0.21721611721611722" WEIGHT="1.915912663818546"/>
<DICH_DATA CI_END="1.0880236925267535" CI_START="0.9190976325870872" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="23" LOG_CI_END="0.03663835255113116" LOG_CI_START="-0.03663835255113116" LOG_EFFECT_SIZE="0.0" ORDER="67316" O_E="0.0" SE="0.043043099302609085" STUDY_ID="STD-Pugh-1995" TOTAL_1="22" TOTAL_2="23" VAR="0.0018527083975742667" WEIGHT="4.790408202019944"/>
<DICH_DATA CI_END="0.5876020010184078" CI_START="0.14940639250163543" EFFECT_SIZE="0.2962962962962963" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="27" LOG_CI_END="-0.23091673393390336" LOG_CI_START="-0.8256308204001841" LOG_EFFECT_SIZE="-0.5282737771670437" MODIFIED="2010-05-21 15:41:46 +0100" MODIFIED_BY="Katharine Ker" ORDER="2501" O_E="0.0" SE="0.34933799827249973" STUDY_ID="STD-Taghaddomi-2009" TOTAL_1="50" TOTAL_2="50" VAR="0.12203703703703704" WEIGHT="2.6073612873301917"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="249.325232226418" CI_END="0.6986179805908749" CI_START="0.5309156917295182" CI_STUDY="95" CI_TOTAL="95" DF="63" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6090215500457135" ESTIMABLE="YES" EVENTS_1="707" EVENTS_2="1028" I2="74.73179932996584" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-0.1557602409558763" LOG_CI_START="-0.27497443847343933" LOG_EFFECT_SIZE="-0.21536733971465782" METHOD="MH" MODIFIED="2010-08-23 06:44:04 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="2.220446049250313E-16" P_Q="0.0" P_Z="1.425236622543032E-12" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="65" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.16040430117389023" TOTALS="YES" TOTAL_1="2528" TOTAL_2="2314" WEIGHT="100.0" Z="7.081576491336027">
<NAME>Trial Methodological Quality - Allocation Concealment</NAME>
<GROUP_LABEL_1>TXA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="41.34983753998899" CI_END="0.6900098109367705" CI_START="0.5107541442750109" DF="27" EFFECT_SIZE="0.593654251670425" ESTIMABLE="YES" EVENTS_1="279" EVENTS_2="431" I2="34.7034919450685" ID="CMP-002.05.01" LOG_CI_END="-0.16114473418244013" LOG_CI_START="-0.29178810080228573" LOG_EFFECT_SIZE="-0.22646641749236296" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.03810422816415027" P_Z="1.082529221392977E-11" STUDIES="28" TAU2="0.04539438623709674" TOTAL_1="1079" TOTAL_2="1031" WEIGHT="43.90613507598836" Z="6.7950793595886525">
<NAME>Allocation concealment - Yes</NAME>
<DICH_DATA CI_END="0.657557944250512" CI_START="0.16897539157215433" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="24" LOG_CI_END="-0.1820659709607079" LOG_CI_START="-0.772176538478617" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2948" O_E="0.0" SE="0.34663386845443983" STUDY_ID="STD-Benoni-1996" TOTAL_1="43" TOTAL_2="43" VAR="0.1201550387596899" WEIGHT="1.7478591496945683"/>
<DICH_DATA CI_END="0.9754681459204624" CI_START="0.33307084537693515" EFFECT_SIZE="0.57" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="-0.010786907998672239" LOG_CI_START="-0.477463380656345" LOG_EFFECT_SIZE="-0.24412514432750865" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2958" O_E="0.0" SE="0.27412807012491325" STUDY_ID="STD-Benoni-2000" TOTAL_1="20" TOTAL_2="19" VAR="0.07514619883040935" WEIGHT="2.081838965853291"/>
<DICH_DATA CI_END="1.5366307449348802" CI_START="0.20085630612689692" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.1865695183106097" LOG_CI_START="-0.6971145285172219" LOG_EFFECT_SIZE="-0.255272505103306" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2938" O_E="0.0" SE="0.5190803834132479" STUDY_ID="STD-Benoni-2001" TOTAL_1="18" TOTAL_2="20" VAR="0.26944444444444443" WEIGHT="1.1408157272385915"/>
<DICH_DATA CI_END="2.427899066052217" CI_START="0.1029696841584531" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.38523062805078434" LOG_CI_START="-0.9872906193787466" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2956" O_E="0.0" SE="0.8062257748298549" STUDY_ID="STD-Casati-2001" TOTAL_1="20" TOTAL_2="20" VAR="0.6499999999999999" WEIGHT="0.6051031671782245"/>
<DICH_DATA CI_END="0.9597327428757618" CI_START="0.32634829121299347" EFFECT_SIZE="0.5596491228070175" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="-0.017849688266260794" LOG_CI_START="-0.4863186569643599" LOG_EFFECT_SIZE="-0.2520841726153103" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2937" O_E="0.0" SE="0.27518099117205813" STUDY_ID="STD-Casati-2002" TOTAL_1="30" TOTAL_2="29" VAR="0.07572457790243635" WEIGHT="2.0767396654462846"/>
<DICH_DATA CI_END="1.417807293880328" CI_START="0.31254634853586305" EFFECT_SIZE="0.665680473372781" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.15161720624074812" LOG_CI_START="-0.5050855705733328" LOG_EFFECT_SIZE="-0.17673418216629228" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2935" O_E="0.0" SE="0.3857504618317635" STUDY_ID="STD-Casati-2004" TOTAL_1="52" TOTAL_2="50" VAR="0.14880341880341882" WEIGHT="1.5859183896545748"/>
<DICH_DATA CI_END="1.8418560833961877" CI_START="0.5260965551870249" EFFECT_SIZE="0.984375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.2652556928376572" LOG_CI_START="-0.2789345418982681" LOG_EFFECT_SIZE="-0.0068394245303054655" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2947" O_E="0.0" SE="0.3196600376689893" STUDY_ID="STD-Coffey-1995" TOTAL_1="16" TOTAL_2="14" VAR="0.10218253968253968" WEIGHT="1.8674896568914217"/>
<DICH_DATA CI_END="1.523032096014423" CI_START="0.04103656131972161" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.18270905565060536" LOG_CI_START="-1.38682903830653" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2936" O_E="0.0" SE="0.9219544457292888" STUDY_ID="STD-Gill-2009" TOTAL_1="5" TOTAL_2="5" VAR="0.8500000000000001" WEIGHT="0.4853287033373215"/>
<DICH_DATA CI_END="0.5832968063338196" CI_START="0.0622002019286873" EFFECT_SIZE="0.19047619047619047" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="14" LOG_CI_END="-0.2341104014122547" LOG_CI_START="-1.206208205399659" LOG_EFFECT_SIZE="-0.7201593034059569" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2945" O_E="0.0" SE="0.5710150620239374" STUDY_ID="STD-Good-2003" TOTAL_1="27" TOTAL_2="24" VAR="0.32605820105820105" WEIGHT="1.0080493503304335"/>
<DICH_DATA CI_END="1.492158128301091" CI_START="0.7910072381137022" EFFECT_SIZE="1.0864197530864197" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="27" LOG_CI_END="0.17381484901444078" LOG_CI_START="-0.10181954247140304" LOG_EFFECT_SIZE="0.035997653271518854" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2957" O_E="0.0" SE="0.16190900597102748" STUDY_ID="STD-Hardy-1998" TOTAL_1="42" TOTAL_2="44" VAR="0.02621452621452621" WEIGHT="2.627699553135306"/>
<DICH_DATA CI_END="1.2108417211183848" CI_START="0.06741810398292612" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.08308737672071692" LOG_CI_START="-1.171223465421268" LOG_EFFECT_SIZE="-0.5440680443502757" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2953" O_E="0.0" SE="0.7367883976130072" STUDY_ID="STD-Husted-2003" TOTAL_1="20" TOTAL_2="20" VAR="0.5428571428571427" WEIGHT="0.6972914745963773"/>
<DICH_DATA CI_END="0.904452772551861" CI_START="0.29114955796727204" EFFECT_SIZE="0.5131578947368421" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="19" LOG_CI_END="-0.043614105593121844" LOG_CI_START="-0.5358838649154624" LOG_EFFECT_SIZE="-0.2897489852542921" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2932" O_E="0.0" SE="0.28916169340055126" STUDY_ID="STD-Jimenez-2007" TOTAL_1="24" TOTAL_2="26" VAR="0.0836144849302744" WEIGHT="2.009592036597741"/>
<DICH_DATA CI_END="0.7915384951180039" CI_START="0.19436062386207878" EFFECT_SIZE="0.39222941720629045" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="23" LOG_CI_END="-0.10152795912027116" LOG_CI_START="-0.7113917156008844" LOG_EFFECT_SIZE="-0.4064598373605777" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2940" O_E="0.0" SE="0.3582369894309945" STUDY_ID="STD-Johansson-2005" TOTAL_1="47" TOTAL_2="53" VAR="0.12833374059658248" WEIGHT="1.6983498479393109"/>
<DICH_DATA CI_END="1.032554195568666" CI_START="0.4180951534213291" EFFECT_SIZE="0.6570433051269288" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="41" LOG_CI_END="0.01391285569765569" LOG_CI_START="-0.3787248667824544" LOG_EFFECT_SIZE="-0.1824060055423993" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2941" O_E="0.0" SE="0.23063734177288867" STUDY_ID="STD-Karski-2005" TOTAL_1="147" TOTAL_2="165" VAR="0.05319358342006426" WEIGHT="2.2958008702538244"/>
<DICH_DATA CI_END="0.7928550646291872" CI_START="0.21747487464892984" EFFECT_SIZE="0.41524216524216523" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="27" LOG_CI_END="-0.10080619526073613" LOG_CI_START="-0.6625909108088087" LOG_EFFECT_SIZE="-0.3816985530347724" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2944" O_E="0.0" SE="0.32999512279212917" STUDY_ID="STD-Katsaros-1996" TOTAL_1="104" TOTAL_2="106" VAR="0.1088967810665924" WEIGHT="1.8209292189077606"/>
<DICH_DATA CI_END="0.9081443087249566" CI_START="0.003455959890878708" EFFECT_SIZE="0.056022408963585436" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.04184513440491924" LOG_CI_START="-2.4614313064915043" LOG_EFFECT_SIZE="-1.251638220448212" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2952" O_E="0.0" SE="1.421276894628377" STUDY_ID="STD-Lemay-2004" TOTAL_1="20" TOTAL_2="19" VAR="2.020028011204482" WEIGHT="0.22489953324911144"/>
<DICH_DATA CI_END="1.215242085527897" CI_START="0.3476673537161672" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.08466280133863553" LOG_CI_START="-0.4588360880529243" LOG_EFFECT_SIZE="-0.1870866433571444" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2950" O_E="0.0" SE="0.3192539379914944" STUDY_ID="STD-MacGillivray-2010" TOTAL_1="40" TOTAL_2="20" VAR="0.10192307692307694" WEIGHT="1.8693367535351664"/>
<DICH_DATA CI_END="1.1702850633778696" CI_START="0.2907648644131303" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.06829166206472205" LOG_CI_START="-0.536458074131458" LOG_EFFECT_SIZE="-0.23408320603336794" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2954" O_E="0.0" SE="0.3552329886011098" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.1261904761904762" WEIGHT="1.711050752023046"/>
<DICH_DATA CI_END="1.712227535929018" CI_START="0.2281384873232139" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2335614770655728" LOG_CI_START="-0.6418014423774223" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2933" O_E="0.0" SE="0.5141925119971501" STUDY_ID="STD-Mehr_x002d_Aein-2007" TOTAL_1="33" TOTAL_2="33" VAR="0.2643939393939394" WEIGHT="1.1543790969559713"/>
<DICH_DATA CI_END="1.6578630011980628" CI_START="0.2610743375367926" EFFECT_SIZE="0.6578947368421053" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2195486394338172" LOG_CI_START="-0.5832358153233621" LOG_EFFECT_SIZE="-0.1818435879447725" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2949" O_E="0.0" SE="0.4715595625715076" STUDY_ID="STD-Niskanen-2005" TOTAL_1="19" TOTAL_2="20" VAR="0.2223684210526316" WEIGHT="1.2811210957842882"/>
<DICH_DATA CI_END="2.6516009553217748" CI_START="0.03650252247138919" EFFECT_SIZE="0.3111111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.42350816681362524" LOG_CI_START="-1.4376771230078367" LOG_EFFECT_SIZE="-0.5070844780971057" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2939" O_E="0.0" SE="1.0932694522568969" STUDY_ID="STD-Orpen-2006" TOTAL_1="15" TOTAL_2="14" VAR="1.1952380952380952" WEIGHT="0.3617312431604925"/>
<DICH_DATA CI_END="2.1268041030916094" CI_START="0.34221405937999083" EFFECT_SIZE="0.853125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.32772748949634717" LOG_CI_START="-0.465702152054647" LOG_EFFECT_SIZE="-0.06898733127914992" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2946" O_E="0.0" SE="0.4660644989871222" STUDY_ID="STD-Pleym-2003" TOTAL_1="40" TOTAL_2="39" VAR="0.21721611721611722" WEIGHT="1.2986008845229142"/>
<DICH_DATA CI_END="1.116493663022033" CI_START="0.3857290701805813" EFFECT_SIZE="0.65625" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="20" LOG_CI_END="0.04785626245235314" LOG_CI_START="-0.4137176296243265" LOG_EFFECT_SIZE="-0.1829306835859867" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2943" O_E="0.0" SE="0.2711307890334566" STUDY_ID="STD-Sadeghi-2007" TOTAL_1="32" TOTAL_2="35" VAR="0.07351190476190476" WEIGHT="2.0963840763977464"/>
<DICH_DATA CI_END="0.977231691528309" CI_START="0.41555530136149377" EFFECT_SIZE="0.6372549019607843" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="-0.010002457342592376" LOG_CI_START="-0.3813711728955317" LOG_EFFECT_SIZE="-0.19568681511906202" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2942" O_E="0.0" SE="0.21814382182058634" STUDY_ID="STD-Shore_x002d_Lesserson-1996" TOTAL_1="17" TOTAL_2="13" VAR="0.047586726998491716" WEIGHT="2.3576892409453047"/>
<DICH_DATA CI_END="0.5876020010184078" CI_START="0.14940639250163543" EFFECT_SIZE="0.2962962962962963" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="27" LOG_CI_END="-0.23091673393390336" LOG_CI_START="-0.8256308204001841" LOG_EFFECT_SIZE="-0.5282737771670437" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2955" O_E="0.0" SE="0.34933799827249973" STUDY_ID="STD-Taghaddomi-2009" TOTAL_1="50" TOTAL_2="50" VAR="0.12203703703703704" WEIGHT="1.7362125970701998"/>
<DICH_DATA CI_END="0.7813352588543377" CI_START="0.5474218617451075" EFFECT_SIZE="0.654003059663437" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="26" LOG_CI_END="-0.10716257709786291" LOG_CI_START="-0.2616778626699975" LOG_EFFECT_SIZE="-0.1844202198839302" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2934" O_E="0.0" SE="0.09076304360807098" STUDY_ID="STD-Tanaka-2001" TOTAL_1="73" TOTAL_2="26" VAR="0.008237930085000594" WEIGHT="2.907801952539239"/>
<DICH_DATA CI_END="1.708504253584658" CI_START="0.1286075595299139" EFFECT_SIZE="0.46875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.23261606437917473" LOG_CI_START="-0.8907335029076242" LOG_EFFECT_SIZE="-0.32905871926422475" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2959" O_E="0.0" SE="0.6598610964943051" STUDY_ID="STD-Vanek-2005" TOTAL_1="32" TOTAL_2="30" VAR="0.4354166666666667" WEIGHT="0.823029459860169"/>
<DICH_DATA CI_END="1.202502465890051" CI_START="0.5022788672971052" EFFECT_SIZE="0.7771689497716895" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="30" LOG_CI_END="0.08008597562494968" LOG_CI_START="-0.2990550938080483" LOG_EFFECT_SIZE="-0.10948455909154928" MODIFIED="2010-08-23 06:42:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2951" O_E="0.0" SE="0.222709340963505" STUDY_ID="STD-Wong-2008" TOTAL_1="73" TOTAL_2="74" VAR="0.04959945055239873" WEIGHT="2.3350926128896847"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="209.61571856120892" CI_END="0.762191924795628" CI_START="0.3708915704807927" DF="23" EFFECT_SIZE="0.531686524180582" ESTIMABLE="YES" EVENTS_1="215" EVENTS_2="331" I2="89.02754041640065" ID="CMP-002.05.02" LOG_CI_END="-0.11793565676468713" LOG_CI_START="-0.43075303708195445" LOG_EFFECT_SIZE="-0.2743443469233208" MODIFIED="2010-08-23 06:43:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="3.3306690738754696E-16" P_Z="5.864157638094243E-4" STUDIES="24" TAU2="0.5257515786520119" TOTAL_1="791" TOTAL_2="712" WEIGHT="33.36117472140293" Z="3.43782074248251">
<NAME>Allocation concealment - Unclear</NAME>
<DICH_DATA CI_END="0.7650824343325807" CI_START="0.3866613431183696" EFFECT_SIZE="0.5439005439005439" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="63" LOG_CI_END="-0.1162917689679506" LOG_CI_START="-0.41266924481230916" LOG_EFFECT_SIZE="-0.26448050689012986" MODIFIED="2010-08-23 06:43:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2969" O_E="0.0" SE="0.1740935964031426" STUDY_ID="STD-Armellin-2001" TOTAL_1="143" TOTAL_2="140" VAR="0.030308580308580305" WEIGHT="2.571290442068278"/>
<DICH_DATA CI_END="1.4146284322310363" CI_START="0.3725136848128532" EFFECT_SIZE="0.725925925925926" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.15064238260049112" LOG_CI_START="-0.4288577682055137" LOG_EFFECT_SIZE="-0.13910769280251123" MODIFIED="2010-08-23 06:43:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2978" O_E="0.0" SE="0.34040125715545744" STUDY_ID="STD-Blauhut-1994" TOTAL_1="15" TOTAL_2="14" VAR="0.11587301587301588" WEIGHT="1.7749492233990412"/>
<DICH_DATA CI_END="0.7142374886661662" CI_START="0.2835191420407901" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="-0.14615735843676345" LOG_CI_START="-0.5474176140125492" LOG_EFFECT_SIZE="-0.3467874862246563" MODIFIED="2010-08-23 06:43:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2976" O_E="0.0" SE="0.23570226039551584" STUDY_ID="STD-Brown-1997" TOTAL_1="60" TOTAL_2="30" VAR="0.05555555555555556" WEIGHT="2.270691492213397"/>
<DICH_DATA CI_END="3.0132565450625943" CI_START="0.746700443972075" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.4790361085608422" LOG_CI_START="-0.12685359044947975" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2010-08-23 06:43:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2975" O_E="0.0" SE="0.35590260840104376" STUDY_ID="STD-Caglar-2008" TOTAL_1="50" TOTAL_2="50" VAR="0.1266666666666667" WEIGHT="1.7082124779944283"/>
<DICH_DATA CI_END="1.2617285296697793" CI_START="0.022015653228549727" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.10096592325294027" LOG_CI_START="-1.6572684240202276" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2010-08-23 06:43:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2968" O_E="0.0" SE="1.0327955589886444" STUDY_ID="STD-Claeys-2007" TOTAL_1="20" TOTAL_2="20" VAR="1.0666666666666667" WEIGHT="0.3996331281459309"/>
<DICH_DATA CI_END="1.0452326878696259" CI_START="0.3557126588440236" EFFECT_SIZE="0.6097560975609756" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.01921298308688103" LOG_CI_START="-0.44890067918227683" LOG_EFFECT_SIZE="-0.21484384804769788" MODIFIED="2010-08-23 06:43:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2961" O_E="0.0" SE="0.27497228241690286" STUDY_ID="STD-Corbeau-1995" TOTAL_1="41" TOTAL_2="20" VAR="0.07560975609756097" WEIGHT="2.077750007793684"/>
<DICH_DATA CI_END="14.903914722906746" CI_START="0.06709646549862758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528004" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-23 06:43:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2964" O_E="0.0" SE="1.378404875209022" STUDY_ID="STD-Ekback-2000" TOTAL_1="20" TOTAL_2="20" VAR="1.9" WEIGHT="0.2380009637214355"/>
<DICH_DATA CI_END="0.9581328580005153" CI_START="0.021299930479260473" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.018574265977916792" LOG_CI_START="-1.6716218140505967" LOG_EFFECT_SIZE="-0.8450980400142569" MODIFIED="2010-08-23 06:43:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2979" O_E="0.0" SE="0.9710083124552245" STUDY_ID="STD-Ellis-2001" TOTAL_1="10" TOTAL_2="10" VAR="0.9428571428571427" WEIGHT="0.44448051002621924"/>
<DICH_DATA CI_END="2.4988165463450835" CI_START="0.008167131474760041" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.39773437303938103" LOG_CI_START="-2.087930453067895" LOG_EFFECT_SIZE="-0.8450980400142569" MODIFIED="2010-08-23 06:43:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2971" O_E="0.0" SE="1.4600918230947433" STUDY_ID="STD-Engel-2001" TOTAL_1="12" TOTAL_2="12" VAR="2.1318681318681314" WEIGHT="0.2139266704369895"/>
<DICH_DATA CI_END="1.8016168986512344" CI_START="0.7249723567520983" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.25566244674838573" LOG_CI_START="-0.13967855279301233" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2010-08-23 06:43:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2982" O_E="0.0" SE="0.23222526010012653" STUDY_ID="STD-Garneti-2004" TOTAL_1="25" TOTAL_2="25" VAR="0.053928571428571416" WEIGHT="2.2879281343124434"/>
<DICH_DATA CI_END="0.7521793216911061" CI_START="0.3618973725771085" EFFECT_SIZE="0.5217391304347826" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="46" LOG_CI_END="-0.12367861002408044" LOG_CI_START="-0.4414145699158558" LOG_EFFECT_SIZE="-0.28254658996996806" MODIFIED="2010-08-23 06:43:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2980" O_E="0.0" SE="0.18663967565879638" STUDY_ID="STD-Isetta-1993" TOTAL_1="70" TOTAL_2="70" VAR="0.03483436853002071" WEIGHT="2.5116858769774413"/>
<DICH_DATA CI_END="0.5995847135813608" CI_START="0.039475054178549726" EFFECT_SIZE="0.15384615384615385" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="13" LOG_CI_END="-0.22214944802504333" LOG_CI_START="-1.403677265260668" LOG_EFFECT_SIZE="-0.8129133566428556" MODIFIED="2010-08-23 06:43:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2974" O_E="0.0" SE="0.6940352885012271" STUDY_ID="STD-Jansen-1999" TOTAL_1="21" TOTAL_2="21" VAR="0.4816849816849816" WEIGHT="0.7637227756734877"/>
<DICH_DATA CI_END="1.4026562348128688" CI_START="0.07515317284216183" EFFECT_SIZE="0.3246753246753247" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.14695124649727434" LOG_CI_START="-1.124052679498163" LOG_EFFECT_SIZE="-0.48855071650044424" MODIFIED="2010-08-23 06:43:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2983" O_E="0.0" SE="0.7465939977006226" STUDY_ID="STD-Jares-2003" TOTAL_1="22" TOTAL_2="25" VAR="0.5574025974025973" WEIGHT="0.6831617393308227"/>
<DICH_DATA CI_END="0.8306868840875706" CI_START="0.14746832091198164" EFFECT_SIZE="0.35" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="-0.0805626466593111" LOG_CI_START="-0.8313012646401378" LOG_EFFECT_SIZE="-0.4559319556497244" MODIFIED="2010-08-23 06:43:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2970" O_E="0.0" SE="0.44098758041803093" STUDY_ID="STD-Katoh-1997" TOTAL_1="62" TOTAL_2="31" VAR="0.1944700460829493" WEIGHT="1.3818361713822793"/>
<DICH_DATA CI_END="1.0228204893606019" CI_START="0.12928114594315548" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.009799419322149849" LOG_CI_START="-0.8884648069826752" LOG_EFFECT_SIZE="-0.43933269383026263" MODIFIED="2010-08-23 06:43:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2967" O_E="0.0" SE="0.5276448530110863" STUDY_ID="STD-Kazemi-2010" TOTAL_1="32" TOTAL_2="32" VAR="0.27840909090909094" WEIGHT="1.1175096708134296"/>
<DICH_DATA CI_END="1.0581296128387647" CI_START="0.42002835857894827" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.02453886873221163" LOG_CI_START="-0.37672138684357415" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2010-08-23 06:43:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2977" O_E="0.0" SE="0.23570226039551587" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.05555555555555557" WEIGHT="2.2706914922133965"/>
<DICH_DATA CI_END="2.8531415452949767" CI_START="0.03894342756823292" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45532331768430767" LOG_CI_START="-1.4095658271236327" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2010-08-23 06:43:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2963" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="1.2" WEIGHT="0.36046505359622155"/>
<DICH_DATA CI_END="2.153888658301622" CI_START="0.6259279035383108" EFFECT_SIZE="1.1611111111111112" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.3332232494099629" LOG_CI_START="-0.20347568739446692" LOG_EFFECT_SIZE="0.06487378100774796" MODIFIED="2010-08-23 06:43:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2965" O_E="0.0" SE="0.315259612181506" STUDY_ID="STD-Pinosky-1997" TOTAL_1="20" TOTAL_2="19" VAR="0.09938862307283358" WEIGHT="1.887573384675663"/>
<DICH_DATA CI_END="1.0880236925267535" CI_START="0.9190976325870872" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="23" LOG_CI_END="0.03663835255113116" LOG_CI_START="-0.03663835255113116" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-23 06:43:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2966" O_E="0.0" SE="0.043043099302609085" STUDY_ID="STD-Pugh-1995" TOTAL_1="22" TOTAL_2="23" VAR="0.0018527083975742667" WEIGHT="3.0222312775904725"/>
<DICH_DATA CI_END="0.5995847135813608" CI_START="0.039475054178549726" EFFECT_SIZE="0.15384615384615385" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="13" LOG_CI_END="-0.22214944802504333" LOG_CI_START="-1.403677265260668" LOG_EFFECT_SIZE="-0.8129133566428556" MODIFIED="2010-08-23 06:43:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2973" O_E="0.0" SE="0.6940352885012271" STUDY_ID="STD-Sorin-1999" TOTAL_1="21" TOTAL_2="21" VAR="0.4816849816849816" WEIGHT="0.7637227756734877"/>
<DICH_DATA CI_END="1.7007938080196618" CI_START="0.8212013756695701" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.23065166607163218" LOG_CI_START="-0.08555033177440872" LOG_EFFECT_SIZE="0.07255066714861175" MODIFIED="2010-08-23 06:43:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2972" O_E="0.0" SE="0.1857386187598974" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.03449883449883451" WEIGHT="2.516009850957988"/>
<DICH_DATA CI_END="3.845086034384406" CI_START="0.010402888164868843" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5849060616512035" LOG_CI_START="-1.982846070323241" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2010-08-23 06:43:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2960" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Veien-2002" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="0.2013539226726377"/>
<DICH_DATA CI_END="1.451648645691749" CI_START="0.11959582067352173" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.16186151326336917" LOG_CI_START="-0.9222839966865812" LOG_EFFECT_SIZE="-0.38021124171160603" MODIFIED="2010-08-23 06:43:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2962" O_E="0.0" SE="0.6368324391514266" STUDY_ID="STD-Wei-2006" TOTAL_1="36" TOTAL_2="40" VAR="0.4055555555555555" WEIGHT="0.8664540488241722"/>
<DICH_DATA CI_END="0.7532478029295167" CI_START="0.08297402230305383" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.12306212640134118" LOG_CI_START="-1.0810578562545836" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2010-08-23 06:43:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2981" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Zohar-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.31666666666666665" WEIGHT="1.0278936309095783"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="16.38389339819425" CI_END="0.8609397131405995" CI_START="0.6163957936922952" DF="11" EFFECT_SIZE="0.7284776028146074" ESTIMABLE="YES" EVENTS_1="213" EVENTS_2="266" I2="32.8608912872177" ID="CMP-002.05.03" LOG_CI_END="-0.06502725872874572" LOG_CI_START="-0.2101403335851211" LOG_EFFECT_SIZE="-0.1375837961569334" MODIFIED="2010-08-23 06:44:04 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.1274667792776386" P_Z="2.0196954903479726E-4" STUDIES="13" TAU2="0.023962879174223052" TOTAL_1="658" TOTAL_2="571" WEIGHT="22.73269020260871" Z="3.716540161398731">
<NAME>Allocation concealment - No</NAME>
<DICH_DATA CI_END="2.7594687360744157" CI_START="0.3770290949119647" EFFECT_SIZE="1.02" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.4408254780072691" LOG_CI_START="-0.423625134483434" LOG_EFFECT_SIZE="0.008600171761917567" MODIFIED="2010-08-23 06:44:04 +0100" MODIFIED_BY="[Empty name]" ORDER="2991" O_E="0.0" SE="0.5077825688765832" STUDY_ID="STD-Andreasen-2004" TOTAL_1="20" TOTAL_2="17" VAR="0.257843137254902" WEIGHT="1.1724595640737319"/>
<DICH_DATA CI_END="0.930965325905842" CI_START="0.5985224481530158" EFFECT_SIZE="0.7464607464607464" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="37" LOG_CI_END="-0.03106649415097593" LOG_CI_START="-0.22291955632497804" LOG_EFFECT_SIZE="-0.12699302523797698" MODIFIED="2010-08-23 06:44:04 +0100" MODIFIED_BY="[Empty name]" ORDER="2990" O_E="0.0" SE="0.11269543840898297" STUDY_ID="STD-Dalmau-2000" TOTAL_1="42" TOTAL_2="40" VAR="0.012700261838192874" WEIGHT="2.832843922785254"/>
<DICH_DATA CI_END="1.1666059421800465" CI_START="0.4703360622077637" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="27" LOG_CI_END="0.06692418420563072" LOG_CI_START="-0.32759172119564306" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2010-08-23 06:44:04 +0100" MODIFIED_BY="[Empty name]" ORDER="2994" O_E="0.0" SE="0.23174059571793568" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.05370370370370371" WEIGHT="2.290331039306667"/>
<DICH_DATA CI_END="1.0674920186129604" CI_START="0.48862654631305746" EFFECT_SIZE="0.7222222222222222" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.028364636591387042" LOG_CI_START="-0.3110229421843257" LOG_EFFECT_SIZE="-0.1413291527964693" MODIFIED="2010-08-23 06:44:04 +0100" MODIFIED_BY="[Empty name]" ORDER="2986" O_E="0.0" SE="0.19935794376846325" STUDY_ID="STD-Hiipala-1995" TOTAL_1="15" TOTAL_2="13" VAR="0.039743589743589755" WEIGHT="2.450079324280051"/>
<DICH_DATA CI_END="0.7076468664513917" CI_START="0.3353987193056711" EFFECT_SIZE="0.48717948717948717" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="34" LOG_CI_END="-0.15018341210034744" LOG_CI_START="-0.4744386000469931" LOG_EFFECT_SIZE="-0.31231100607367024" MODIFIED="2010-08-23 06:44:04 +0100" MODIFIED_BY="[Empty name]" ORDER="2995" O_E="0.0" SE="0.19046910248892657" STUDY_ID="STD-Hiipala-1997" TOTAL_1="39" TOTAL_2="38" VAR="0.03627847900293721" WEIGHT="2.493244242807137"/>
<DICH_DATA CI_END="1.6374042289645896" CI_START="0.485812319738244" EFFECT_SIZE="0.8918918918918919" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.21415590771813872" LOG_CI_START="-0.3135314760963538" LOG_EFFECT_SIZE="-0.04968778418910752" MODIFIED="2010-08-23 06:44:04 +0100" MODIFIED_BY="[Empty name]" ORDER="2989" O_E="0.0" SE="0.30996618134731013" STUDY_ID="STD-Horrow-1991" TOTAL_1="37" TOTAL_2="44" VAR="0.09607903357903355" WEIGHT="1.9119301057418374"/>
<DICH_DATA CI_END="2.3557243756307376" CI_START="0.5905268923745671" EFFECT_SIZE="1.179456906729634" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="7" LOG_CI_END="0.37212447578184316" LOG_CI_START="-0.2287603199912923" LOG_EFFECT_SIZE="0.07168207789527543" MODIFIED="2010-08-23 06:44:04 +0100" MODIFIED_BY="[Empty name]" ORDER="2987" O_E="0.0" SE="0.3529627034648498" STUDY_ID="STD-Horrow-1995" TOTAL_1="121" TOTAL_2="27" VAR="0.12458267003721549" WEIGHT="1.720703957978227"/>
<DICH_DATA CI_END="0.9643873049425113" CI_START="0.18002218633670253" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.01574851524782261" LOG_CI_START="-0.7446739681753893" LOG_EFFECT_SIZE="-0.38021124171160603" MODIFIED="2010-08-23 06:44:04 +0100" MODIFIED_BY="[Empty name]" ORDER="2985" O_E="0.0" SE="0.42817441928883765" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.18333333333333335" WEIGHT="1.4266061091569868"/>
<DICH_DATA CI_END="1.001769718383294" CI_START="0.6587796143846663" EFFECT_SIZE="0.8123702781237028" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="73" LOG_CI_END="7.678996455661966E-4" LOG_CI_START="-0.18125984832625064" LOG_EFFECT_SIZE="-0.09024597434034222" MODIFIED="2010-08-23 06:44:04 +0100" MODIFIED_BY="[Empty name]" ORDER="2988" O_E="0.0" SE="0.1069240002105296" STUDY_ID="STD-Later-2009" TOTAL_1="99" TOTAL_2="103" VAR="0.011432741821021334" WEIGHT="2.8537398036446526"/>
<DICH_DATA CI_END="1.7701241393504614" CI_START="0.48710984658713274" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.2480037246354673" LOG_CI_START="-0.31237309137826985" LOG_EFFECT_SIZE="-0.03218468337140124" MODIFIED="2010-08-23 06:44:04 +0100" MODIFIED_BY="[Empty name]" ORDER="2993" O_E="0.0" SE="0.3291681156364455" STUDY_ID="STD-Murphy-2006" TOTAL_1="50" TOTAL_2="50" VAR="0.10835164835164836" WEIGHT="1.8246227114260716"/>
<DICH_DATA CI_END="1.363876456483296" CI_START="0.28509260166605166" EFFECT_SIZE="0.6235632183908046" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.13477503256563717" LOG_CI_START="-0.5450140527617399" LOG_EFFECT_SIZE="-0.20511951009805138" MODIFIED="2010-08-23 06:44:04 +0100" MODIFIED_BY="[Empty name]" ORDER="2984" O_E="0.0" SE="0.3993114737315439" STUDY_ID="STD-Santos-2006" TOTAL_1="29" TOTAL_2="31" VAR="0.15944965305365746" WEIGHT="1.5331316147691458"/>
<DICH_DATA CI_END="0.47788477395061085" CI_START="0.0017726629114815711" EFFECT_SIZE="0.029105473965287048" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="17" LOG_CI_END="-0.32067680646303687" LOG_CI_START="-2.751373841726686" LOG_EFFECT_SIZE="-1.5360253240948616" MODIFIED="2010-08-23 06:44:04 +0100" MODIFIED_BY="[Empty name]" ORDER="2992" O_E="0.0" SE="1.4278034706582443" STUDY_ID="STD-Wu-2006" TOTAL_1="106" TOTAL_2="108" VAR="2.038622750823728" WEIGHT="0.2229978066389462"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-23 06:44:04 +0100" MODIFIED_BY="[Empty name]" ORDER="2996" O_E="0.0" SE="0.0" STUDY_ID="STD-Yamasaki-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="45.89010630603703" CI_END="0.10888318857862345" CI_START="-0.7967573843768092" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3439370978990929" ESTIMABLE="YES" I2="73.8505726703419" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2010-05-28 14:53:32 +0100" MODIFIED_BY="Katharine Ker" NO="6" P_CHI2="7.247381317965207E-6" P_Q="1.0" P_Z="0.13657175830883644" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.4257545643875269" TOTALS="YES" TOTAL_1="201" TOTAL_2="280" UNITS="" WEIGHT="100.0" Z="1.4886796041604071">
<NAME>Units Allogeneic Blood Transfused - Transfused Patients</NAME>
<GROUP_LABEL_1>TXA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TXA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.26097675948474186" CI_START="-0.7609767594847419" EFFECT_SIZE="-0.25" ESTIMABLE="YES" MEAN_1="1.68" MEAN_2="1.93" ORDER="67380" SD_1="1.2" SD_2="1.3" SE="0.2607072188648676" STUDY_ID="STD-Armellin-2001" TOTAL_1="35" TOTAL_2="63" WEIGHT="10.811161842996572"/>
<CONT_DATA CI_END="0.28994678236597426" CI_START="-1.7499467823659742" EFFECT_SIZE="-0.73" ESTIMABLE="YES" MEAN_1="1.71" MEAN_2="2.44" ORDER="67375" SD_1="0.95" SD_2="1.13" SE="0.5203905737101213" STUDY_ID="STD-Blauhut-1994" TOTAL_1="7" TOTAL_2="9" WEIGHT="7.66295838691985"/>
<CONT_DATA CI_END="0.6919470557933343" CI_START="-0.2919470557933343" EFFECT_SIZE="0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="1.6" MODIFIED="2010-05-20 11:33:57 +0100" MODIFIED_BY="Katharine Ker" ORDER="5325" SD_1="0.54" SD_2="0.66" SE="0.25099800796022265" STUDY_ID="STD-Caglar-2008" TOTAL_1="15" TOTAL_2="10" WEIGHT="10.921058714845149"/>
<CONT_DATA CI_END="0.21278706406682102" CI_START="-1.4927870640668213" EFFECT_SIZE="-0.6400000000000001" ESTIMABLE="YES" MEAN_1="2.19" MEAN_2="2.83" ORDER="67376" SD_1="0.46" SD_2="1.45" SE="0.4351034359781591" STUDY_ID="STD-Corbeau-1995" TOTAL_1="15" TOTAL_2="12" WEIGHT="8.67823349402751"/>
<CONT_DATA CI_END="2.136684454879448" CI_START="-3.45668445487945" EFFECT_SIZE="-0.660000000000001" ESTIMABLE="YES" MEAN_1="7.72" MEAN_2="8.38" ORDER="67381" SD_1="5.44" SD_2="6.13" SE="1.426906043651485" STUDY_ID="STD-Dalmau-2000" TOTAL_1="29" TOTAL_2="37" WEIGHT="2.1682036953563397"/>
<CONT_DATA CI_END="0.6977631354983771" CI_START="-2.9377631354983773" EFFECT_SIZE="-1.12" ESTIMABLE="YES" MEAN_1="2.61" MEAN_2="3.73" ORDER="67382" SD_1="1.55" SD_2="4.47" SE="0.9274472132328251" STUDY_ID="STD-Diprose-2005" TOTAL_1="20" TOTAL_2="27" WEIGHT="4.150916678948679"/>
<CONT_DATA CI_END="1.5926669166688658" CI_START="0.4473330833311342" EFFECT_SIZE="1.02" ESTIMABLE="YES" MEAN_1="2.31" MEAN_2="1.29" ORDER="67384" SD_1="0.87" SD_2="0.73" SE="0.29218236722000474" STUDY_ID="STD-Garneti-2004" TOTAL_1="16" TOTAL_2="14" WEIGHT="10.443074100179208"/>
<CONT_DATA CI_END="1.6418955781579558" CI_START="-1.9818955781579557" EFFECT_SIZE="-0.16999999999999993" ESTIMABLE="YES" MEAN_1="2.33" MEAN_2="2.5" ORDER="67385" SD_1="1.53" SD_2="1.02" SE="0.924453506518465" STUDY_ID="STD-Good-2003" TOTAL_1="3" TOTAL_2="14" WEIGHT="4.168890311881845"/>
<CONT_DATA CI_END="-0.2908524300823532" CI_START="-2.369147569917647" EFFECT_SIZE="-1.33" ESTIMABLE="YES" MEAN_1="2.25" MEAN_2="3.58" ORDER="67377" SD_1="0.87" SD_2="1.57" SE="0.5301870739025362" STUDY_ID="STD-Hiipala-1995" TOTAL_1="10" TOTAL_2="12" WEIGHT="7.551383480262165"/>
<CONT_DATA CI_END="-0.6825172601074819" CI_START="-1.6574827398925178" EFFECT_SIZE="-1.17" ESTIMABLE="YES" MEAN_1="2.29" MEAN_2="3.46" ORDER="67378" SD_1="0.52" SD_2="1.25" SE="0.2487202539116635" STUDY_ID="STD-Hiipala-1997" TOTAL_1="17" TOTAL_2="34" WEIGHT="10.946551574162392"/>
<CONT_DATA CI_END="0.5202009295436822" CI_START="-1.2202009295436824" EFFECT_SIZE="-0.3500000000000001" ESTIMABLE="YES" MEAN_1="2.13" MEAN_2="2.48" ORDER="67383" SD_1="0.99" SD_2="1.31" SE="0.44398822448152936" STUDY_ID="STD-Johansson-2005" TOTAL_1="8" TOTAL_2="23" WEIGHT="8.56941364384503"/>
<CONT_DATA CI_END="0.8233826514582433" CI_START="-0.3233826514582433" EFFECT_SIZE="0.25" ESTIMABLE="YES" MEAN_1="1.46" MEAN_2="1.21" MODIFIED="2010-05-21 15:01:48 +0100" MODIFIED_BY="Katharine Ker" ORDER="2788" SD_1="0.97" SD_2="0.43" SE="0.29254754474113426" STUDY_ID="STD-Murphy-2006" TOTAL_1="13" TOTAL_2="14" WEIGHT="10.438713170306984"/>
<CONT_DATA CI_END="1.099289283922761" CI_START="-3.01928928392276" EFFECT_SIZE="-0.9599999999999995" ESTIMABLE="YES" MEAN_1="3.31" MEAN_2="4.27" ORDER="67379" SD_1="1.62" SD_2="3.15" SE="1.0506771043581267" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="13" TOTAL_2="11" WEIGHT="3.4894409062682885"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="154.23900176483818" CI_END="-0.5291933194932474" CI_START="-1.2033363311822043" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8662648253377259" ESTIMABLE="YES" I2="87.03311109955628" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2010-05-28 14:53:38 +0100" MODIFIED_BY="Katharine Ker" NO="7" P_CHI2="6.661338147750939E-16" P_Q="1.0" P_Z="4.7274791346923835E-7" Q="0.0" RANDOM="YES" SCALE="6.409411385665495" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.4048053196553544" TOTALS="YES" TOTAL_1="943" TOTAL_2="871" UNITS="" WEIGHT="100.00000000000003" Z="5.037055429773392">
<NAME>Units of Allogeneic Blood Transfused - All Patients</NAME>
<GROUP_LABEL_1>TXA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TXA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.1961704986317987" CI_START="-0.7238295013682013" EFFECT_SIZE="-0.46" ESTIMABLE="YES" MEAN_1="0.41" MEAN_2="0.87" ORDER="67387" SD_1="0.93" SD_2="1.3" SE="0.1346093619317777" STUDY_ID="STD-Armellin-2001" TOTAL_1="143" TOTAL_2="140" WEIGHT="6.993338378637121"/>
<CONT_DATA CI_END="0.18712546114178474" CI_START="-1.7271254611417848" EFFECT_SIZE="-0.77" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.57" ORDER="67400" SD_1="1.08" SD_2="1.5" SE="0.4883382902397535" STUDY_ID="STD-Blauhut-1994" TOTAL_1="15" TOTAL_2="14" WEIGHT="4.597779268800214"/>
<CONT_DATA CI_END="0.29464719470527334" CI_START="-0.29464719470527334" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.3" MODIFIED="2010-04-21 10:39:23 +0100" MODIFIED_BY="Katharine Ker" ORDER="2355" SD_1="0.8" SD_2="0.7" SE="0.1503329637837291" STUDY_ID="STD-Caglar-2008" TOTAL_1="50" TOTAL_2="50" WEIGHT="6.92002999868011"/>
<CONT_DATA CI_END="-0.042278476880920124" CI_START="-1.7577215231190797" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.7" ORDER="67401" SD_1="1.1" SD_2="1.8" SE="0.43762106338926515" STUDY_ID="STD-Corbeau-1995" TOTAL_1="41" TOTAL_2="20" WEIGHT="4.959870472218226"/>
<CONT_DATA CI_END="0.19854276083957645" CI_START="-5.038542760839576" EFFECT_SIZE="-2.42" ESTIMABLE="YES" MEAN_1="5.33" MEAN_2="7.75" ORDER="67388" SD_1="5.77" SD_2="6.3" SE="1.3360157541129876" STUDY_ID="STD-Dalmau-2000" TOTAL_1="42" TOTAL_2="40" WEIGHT="1.3506868491961788"/>
<CONT_DATA CI_END="0.15783661909922764" CI_START="-1.7778366190992276" EFFECT_SIZE="-0.8099999999999999" ESTIMABLE="YES" MEAN_1="0.87" MEAN_2="1.68" ORDER="67392" SD_1="1.52" SD_2="3.51" SE="0.4938032671688864" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" WEIGHT="4.5597338706237105"/>
<CONT_DATA CI_END="-0.620926593754743" CI_START="-2.9790734062452566" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="3.3" ORDER="67398" SD_1="1.3" SD_2="1.8" SE="0.6015791185683192" STUDY_ID="STD-Hiipala-1995" TOTAL_1="15" TOTAL_2="13" WEIGHT="3.8576327164470046"/>
<CONT_DATA CI_END="-1.4670454243611246" CI_START="-2.7329545756388756" EFFECT_SIZE="-2.1" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="3.1" ORDER="67399" SD_1="1.2" SD_2="1.6" SE="0.32294194211298805" STUDY_ID="STD-Hiipala-1997" TOTAL_1="39" TOTAL_2="38" WEIGHT="5.809617210677396"/>
<CONT_DATA CI_END="0.7605156791761981" CI_START="-0.44051567917619805" EFFECT_SIZE="0.16000000000000003" ESTIMABLE="YES" MEAN_1="0.92" MEAN_2="0.76" ORDER="67394" SD_1="0.8" SD_2="1.08" SE="0.3063911806099444" STUDY_ID="STD-Horrow-1990" TOTAL_1="18" TOTAL_2="20" WEIGHT="5.930962626869568"/>
<CONT_DATA CI_END="-0.8150019768785204" CI_START="-3.2649980231214797" EFFECT_SIZE="-2.04" ESTIMABLE="YES" MEAN_1="0.46" MEAN_2="2.5" ORDER="67386" SD_1="1.45" SD_2="2.47" SE="0.6250104761026772" STUDY_ID="STD-Jansen-1999" TOTAL_1="21" TOTAL_2="21" WEIGHT="3.7182501963470207"/>
<CONT_DATA CI_END="-1.341686819274638" CI_START="-1.9183131807253617" EFFECT_SIZE="-1.63" ESTIMABLE="YES" MEAN_1="1.58" MEAN_2="3.21" MODIFIED="2010-05-20 16:00:30 +0100" MODIFIED_BY="Katharine Ker" ORDER="2636" SD_1="0.49" SD_2="0.55" SE="0.14710126461482936" STUDY_ID="STD-Jimenez-2007" TOTAL_1="24" TOTAL_2="26" WEIGHT="6.935627956334532"/>
<CONT_DATA CI_END="0.13733485024623837" CI_START="-3.357334850246238" EFFECT_SIZE="-1.6099999999999999" ESTIMABLE="YES" MEAN_1="1.42" MEAN_2="3.03" ORDER="67397" SD_1="2.74" SD_2="4.57" SE="0.8915137543490557" STUDY_ID="STD-Katoh-1997" TOTAL_1="62" TOTAL_2="31" WEIGHT="2.4655322367110246"/>
<CONT_DATA CI_END="-0.14736754018548703" CI_START="-0.912632459814513" EFFECT_SIZE="-0.53" ESTIMABLE="YES" MEAN_1="0.31" MEAN_2="0.84" MODIFIED="2010-05-20 16:12:30 +0100" MODIFIED_BY="Katharine Ker" ORDER="5379" SD_1="0.64" SD_2="0.9" SE="0.1952242300535464" STUDY_ID="STD-Kazemi-2010" TOTAL_1="32" TOTAL_2="32" WEIGHT="6.677666831991413"/>
<CONT_DATA CI_END="0.1345017491047542" CI_START="-0.8345017491047544" EFFECT_SIZE="-0.3500000000000001" ESTIMABLE="YES" MEAN_1="0.76" MEAN_2="1.11" MODIFIED="2010-05-07 11:38:18 +0100" MODIFIED_BY="Katharine Ker" ORDER="2420" SD_1="0.75" SD_2="0.97" SE="0.24719931229677802" STUDY_ID="STD-MacGillivray-2010" TOTAL_1="40" TOTAL_2="20" WEIGHT="6.348092408786597"/>
<CONT_DATA CI_END="-0.9084448939771833" CI_START="-1.3715551060228168" EFFECT_SIZE="-1.1400000000000001" ESTIMABLE="YES" MEAN_1="2.03" MEAN_2="3.17" MODIFIED="2010-05-07 11:55:24 +0100" MODIFIED_BY="Katharine Ker" ORDER="2423" SD_1="0.78" SD_2="0.97" SE="0.1181425311124561" STUDY_ID="STD-Maddali-2007" TOTAL_1="111" TOTAL_2="111" WEIGHT="7.06284412387239"/>
<CONT_DATA CI_END="0.3177622345727022" CI_START="-0.23776223457270224" EFFECT_SIZE="0.03999999999999998" ESTIMABLE="YES" MEAN_1="0.38" MEAN_2="0.34" MODIFIED="2010-05-21 15:02:18 +0100" MODIFIED_BY="Katharine Ker" ORDER="2789" SD_1="0.81" SD_2="0.59" SE="0.141718029904455" STUDY_ID="STD-Murphy-2006" TOTAL_1="50" TOTAL_2="50" WEIGHT="6.9610072477453535"/>
<CONT_DATA CI_END="1.667021067175358" CI_START="-2.1870210671753574" EFFECT_SIZE="-0.2599999999999998" ESTIMABLE="YES" MEAN_1="2.87" MEAN_2="3.13" ORDER="67396" SD_1="1.9" SD_2="3.3" SE="0.983192080250175" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" WEIGHT="2.156557088375014"/>
<CONT_DATA CI_END="0.51430319709507" CI_START="-10.634303197095072" EFFECT_SIZE="-5.0600000000000005" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="9.16" ORDER="67389" SD_1="2.23" SD_2="6.6" SE="2.8440845041360263" STUDY_ID="STD-Uozaki-2001" TOTAL_1="6" TOTAL_2="6" WEIGHT="0.3482210108212343"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.27" ORDER="67391" SD_1="0.0" SD_2="0.7" SE="0.0" STUDY_ID="STD-Veien-2002" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="1.27" MEAN_2="1.33" ORDER="67393" SD_1="0.07" SD_2="0.0" SE="0.0" STUDY_ID="STD-Wei-2006" TOTAL_1="36" TOTAL_2="40" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.18241451715752022" CI_START="-1.1024145171575204" EFFECT_SIZE="-0.4600000000000001" ESTIMABLE="YES" MEAN_1="0.89" MEAN_2="1.35" MODIFIED="2010-05-14 15:12:47 +0100" MODIFIED_BY="Katharine Ker" ORDER="2520" SD_1="1.8" SD_2="2.16" SE="0.32776853157752084" STUDY_ID="STD-Wong-2008" TOTAL_1="73" TOTAL_2="74" WEIGHT="5.7739963604613145"/>
<CONT_DATA CI_END="0.8636447596926393" CI_START="-9.86364475969264" EFFECT_SIZE="-4.5" ESTIMABLE="YES" MEAN_1="7.9" MEAN_2="12.4" ORDER="67395" SD_1="3.3" SD_2="8.0" SE="2.736603734558586" STUDY_ID="STD-Yassen-1993" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.37468084324882306"/>
<CONT_DATA CI_END="-0.6326276281238703" CI_START="-1.6873723718761295" EFFECT_SIZE="-1.16" ESTIMABLE="YES" MEAN_1="0.52" MEAN_2="1.68" ORDER="67390" SD_1="0.9" SD_2="1.0" SE="0.26907248094147423" STUDY_ID="STD-Zabeeda-2002" TOTAL_1="25" TOTAL_2="25" WEIGHT="6.197872303155765"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="49.05160904906102" CI_END="-62.63137961702101" CI_START="-180.1855605077647" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="MD" EFFECT_SIZE="-121.40847006239285" ESTIMABLE="YES" I2="67.3812942935329" I2_Q="0.0" ID="CMP-002.08" MODIFIED="2010-07-08 10:59:03 +0100" MODIFIED_BY="Katharine Ker" NO="8" P_CHI2="3.242633850752963E-5" P_Q="0.5567185916369638" P_Z="5.155750724566629E-5" Q="1.1713915107532813" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="7861.985874603809" TOTALS="YES" TOTAL_1="599" TOTAL_2="574" UNITS="" WEIGHT="100.0" Z="4.048451989326672">
<NAME>Blood loss - Intra-operative</NAME>
<GROUP_LABEL_1>TXA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TXA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.362501764787084" CI_END="-2.2732441009006266" CI_START="-331.24284407969367" DF="3" EFFECT_SIZE="-166.75804409029715" ESTIMABLE="YES" I2="44.0559624670051" ID="CMP-002.08.01" MODIFIED="2010-05-14 12:16:16 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="0.14709784333913578" P_Z="0.046916695455565455" STUDIES="4" TAU2="12513.656023682259" TOTAL_1="138" TOTAL_2="106" WEIGHT="17.01005726910153" Z="1.9870514513827084">
<NAME>Cardiac surgery</NAME>
<CONT_DATA CI_END="-99.72618452978583" CI_START="-628.2738154702142" EFFECT_SIZE="-364.0" ESTIMABLE="YES" MEAN_1="197.0" MEAN_2="561.0" ORDER="67404" SD_1="117.8" SD_2="746.1" SE="134.83605696572604" STUDY_ID="STD-Katoh-1997" TOTAL_1="62" TOTAL_2="31" WEIGHT="3.453290987989301"/>
<CONT_DATA CI_END="233.5995134910458" CI_START="-539.5995134910459" EFFECT_SIZE="-153.0" ESTIMABLE="YES" MEAN_1="1318.0" MEAN_2="1471.0" ORDER="67402" SD_1="545.6" SD_2="675.6" SE="197.24827422365584" STUDY_ID="STD-Pinosky-1997" TOTAL_1="20" TOTAL_2="19" WEIGHT="1.9229284804880722"/>
<CONT_DATA CI_END="1.4733589117664678" CI_START="-129.47335891176647" EFFECT_SIZE="-64.0" ESTIMABLE="YES" MEAN_1="467.0" MEAN_2="531.0" MODIFIED="2010-05-14 12:16:16 +0100" MODIFIED_BY="Katharine Ker" ORDER="2503" SD_1="170.0" SD_2="164.0" SE="33.405388786840966" STUDY_ID="STD-Taghaddomi-2009" TOTAL_1="50" TOTAL_2="50" WEIGHT="10.017167553896575"/>
<CONT_DATA CI_END="178.3616264347482" CI_START="-678.3616264347481" EFFECT_SIZE="-250.0" ESTIMABLE="YES" MEAN_1="273.0" MEAN_2="523.0" ORDER="67403" SD_1="290.0" SD_2="450.0" SE="218.55586623714007" STUDY_ID="STD-Uozaki-2001" TOTAL_1="6" TOTAL_2="6" WEIGHT="1.6166702467275833"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="42.517715773520656" CI_END="-43.15894523570289" CI_START="-187.8799819729402" DF="11" EFFECT_SIZE="-115.51946360432154" ESTIMABLE="YES" I2="74.1284314082305" ID="CMP-002.08.02" MODIFIED="2010-07-08 10:59:03 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="1.3173424127765898E-5" P_Z="0.0017541941686914607" STUDIES="12" TAU2="10071.829955665675" TOTAL_1="411" TOTAL_2="418" WEIGHT="78.08126512944078" Z="3.1289713407587634">
<NAME>Orthopaedic surgery</NAME>
<CONT_DATA CI_END="57.10318016544967" CI_START="-57.10318016544967" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="210.0" MEAN_2="210.0" ORDER="67409" SD_1="140.0" SD_2="130.0" SE="29.134810953605406" STUDY_ID="STD-Benoni-1996" TOTAL_1="43" TOTAL_2="43" WEIGHT="10.324304208999115"/>
<CONT_DATA CI_END="12.697316026868393" CI_START="-198.6973160268684" EFFECT_SIZE="-93.0" ESTIMABLE="YES" MEAN_1="423.0" MEAN_2="516.0" MODIFIED="2010-05-14 15:56:11 +0100" MODIFIED_BY="Katharine Ker" ORDER="2538" SD_1="174.0" SD_2="167.0" SE="53.92819299772615" STUDY_ID="STD-Claeys-2007" TOTAL_1="20" TOTAL_2="20" WEIGHT="8.350159502177757"/>
<CONT_DATA CI_END="197.70265265152477" CI_START="-171.70265265152477" EFFECT_SIZE="13.0" ESTIMABLE="YES" MEAN_1="428.0" MEAN_2="415.0" ORDER="67410" SD_1="254.0" SD_2="244.0" SE="94.23777891248804" STUDY_ID="STD-Hiipala-1995" TOTAL_1="15" TOTAL_2="13" WEIGHT="5.37147213556146"/>
<CONT_DATA CI_END="51.570448213529644" CI_START="-121.57044821352964" EFFECT_SIZE="-35.0" ESTIMABLE="YES" MEAN_1="283.0" MEAN_2="318.0" ORDER="67411" SD_1="178.0" SD_2="208.0" SE="44.169407650541686" STUDY_ID="STD-Hiipala-1997" TOTAL_1="39" TOTAL_2="38" WEIGHT="9.164771037023081"/>
<CONT_DATA CI_END="43.901154881413234" CI_START="-199.90115488141322" EFFECT_SIZE="-78.0" ESTIMABLE="YES" MEAN_1="534.0" MEAN_2="612.0" ORDER="67408" SD_1="316.0" SD_2="304.0" SE="62.195609635153495" STUDY_ID="STD-Johansson-2005" TOTAL_1="47" TOTAL_2="53" WEIGHT="7.666755565931555"/>
<CONT_DATA CI_END="-97.70990022019072" CI_START="-652.2900997798092" EFFECT_SIZE="-375.0" ESTIMABLE="YES" MEAN_1="1024.0" MEAN_2="1399.0" MODIFIED="2010-05-20 16:13:15 +0100" MODIFIED_BY="Katharine Ker" ORDER="5380" SD_1="544.0" SD_2="587.0" SE="141.4771403796387" STUDY_ID="STD-Kazemi-2010" TOTAL_1="32" TOTAL_2="32" WEIGHT="3.2259824478427213"/>
<CONT_DATA CI_END="164.52235424869735" CI_START="-345.52235424869735" EFFECT_SIZE="-90.5" ESTIMABLE="YES" MEAN_1="820.5" MEAN_2="911.0" ORDER="67407" SD_1="447.1" SD_2="363.0" SE="130.11583695429158" STUDY_ID="STD-Lemay-2004" TOTAL_1="20" TOTAL_2="19" WEIGHT="3.6274912621795075"/>
<CONT_DATA CI_END="54.48150186326734" CI_START="-382.48150186326734" EFFECT_SIZE="-164.0" ESTIMABLE="YES" MEAN_1="626.0" MEAN_2="790.0" ORDER="67406" SD_1="279.05" SD_2="408.11" SE="111.47220233974784" STUDY_ID="STD-Niskanen-2005" TOTAL_1="19" TOTAL_2="20" WEIGHT="4.432818415100381"/>
<CONT_DATA CI_END="-309.6138001878444" CI_START="-602.3861998121556" EFFECT_SIZE="-456.0" ESTIMABLE="YES" MEAN_1="652.0" MEAN_2="1108.0" MODIFIED="2010-05-14 11:49:16 +0100" MODIFIED_BY="Katharine Ker" ORDER="2491" SD_1="228.0" SD_2="372.0" SE="74.68820905222304" STUDY_ID="STD-Sadeghi-2007" TOTAL_1="32" TOTAL_2="35" WEIGHT="6.69130084642977"/>
<CONT_DATA CI_END="-13.603954247467641" CI_START="-780.3960457525324" EFFECT_SIZE="-397.0" ESTIMABLE="YES" MEAN_1="1203.0" MEAN_2="1600.0" MODIFIED="2010-05-14 15:13:41 +0100" MODIFIED_BY="Katharine Ker" ORDER="2521" SD_1="1060.0" SD_2="1301.0" SE="195.6138218746423" STUDY_ID="STD-Wong-2008" TOTAL_1="73" TOTAL_2="74" WEIGHT="1.9496968943859632"/>
<CONT_DATA CI_END="56.03802863110968" CI_START="-196.03802863110968" EFFECT_SIZE="-70.0" ESTIMABLE="YES" MEAN_1="570.0" MEAN_2="640.0" ORDER="67405" SD_1="191.0" SD_2="215.0" SE="64.30629829184697" STUDY_ID="STD-Yamasaki-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="7.496127738307197"/>
<CONT_DATA CI_END="21.566187030558723" CI_START="-121.56618703055872" EFFECT_SIZE="-50.0" ESTIMABLE="YES" MEAN_1="256.0" MEAN_2="306.0" MODIFIED="2010-05-14 15:33:28 +0100" MODIFIED_BY="Katharine Ker" ORDER="2527" SD_1="149.0" SD_2="214.0" SE="36.514031683777695" STUDY_ID="STD-Zhang-2007" TOTAL_1="51" TOTAL_2="51" WEIGHT="9.78038507550228"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.723223462287234E-32" CI_END="34.446734605754216" CI_START="-366.44673460575416" DF="0" EFFECT_SIZE="-165.99999999999997" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-002.08.03" MODIFIED="2010-07-08 10:58:33 +0100" MODIFIED_BY="Katharine Ker" NO="3" P_CHI2="0.0" P_Z="0.10455851170616445" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="4.9086776014576845" Z="1.6231445330030787">
<NAME>Gynaecological surgery</NAME>
<CONT_DATA CI_END="34.44673460575419" CI_START="-366.44673460575416" EFFECT_SIZE="-166.0" ESTIMABLE="YES" MEAN_1="654.0" MEAN_2="820.0" MODIFIED="2010-04-21 10:40:40 +0100" MODIFIED_BY="Katharine Ker" ORDER="2356" SD_1="460.0" SD_2="558.0" SE="102.2706213924605" STUDY_ID="STD-Caglar-2008" TOTAL_1="50" TOTAL_2="50" WEIGHT="4.9086776014576845"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.08.04" MODIFIED="2010-07-08 10:58:07 +0100" MODIFIED_BY="Katharine Ker" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Head &amp; neck surgery</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="248.3556729490652" CI_END="-199.57955323055614" CI_START="-294.76480028650013" CI_STUDY="95" CI_TOTAL="95" DF="34" EFFECT_MEASURE="MD" EFFECT_SIZE="-247.17217675852814" ESTIMABLE="YES" I2="86.3099563636813" I2_Q="94.99185177808599" ID="CMP-002.09" MODIFIED="2010-12-03 12:37:10 +0000" MODIFIED_BY="Katharine Ker" NO="9" P_CHI2="-1.5543122344752192E-15" P_Q="2.1293676821798613E-9" P_Z="2.459045131055636E-24" Q="39.934920281485546" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="35" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="13588.501932048914" TOTALS="YES" TOTAL_1="1285" TOTAL_2="1216" UNITS="" WEIGHT="100.00000000000003" Z="10.179068278140926">
<NAME>Blood loss - Post-operative</NAME>
<GROUP_LABEL_1>TXA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TXA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="83.4058329294047" CI_END="-216.89227311723127" CI_START="-328.8515382756152" DF="21" EFFECT_SIZE="-272.87190569642325" ESTIMABLE="YES" I2="74.82190482076409" ID="CMP-002.09.01" MODIFIED="2010-05-21 14:50:42 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="2.160183920629777E-9" P_Z="1.2500509905881258E-21" STUDIES="22" TAU2="9687.613010735598" TOTAL_1="827" TOTAL_2="770" WEIGHT="57.52101993813618" Z="9.553815966927152">
<NAME>Cardiac surgery</NAME>
<CONT_DATA CI_END="-199.9173089935403" CI_START="-346.0826910064597" EFFECT_SIZE="-273.0" ESTIMABLE="YES" MEAN_1="447.0" MEAN_2="720.0" ORDER="67414" SD_1="262.0" SD_2="357.0" SE="37.28777241976211" STUDY_ID="STD-Armellin-2001" TOTAL_1="143" TOTAL_2="140" WEIGHT="3.9364412198671244"/>
<CONT_DATA CI_END="93.39098918177007" CI_START="-193.39098918177007" EFFECT_SIZE="-50.0" ESTIMABLE="YES" MEAN_1="403.0" MEAN_2="453.0" ORDER="67420" SD_1="201.39" SD_2="192.56" SE="73.16001228227655" STUDY_ID="STD-Blauhut-1994" TOTAL_1="15" TOTAL_2="14" WEIGHT="3.1130259649937786"/>
<CONT_DATA CI_END="-69.75765525059973" CI_START="-828.2423447494002" EFFECT_SIZE="-449.0" ESTIMABLE="YES" MEAN_1="711.0" MEAN_2="1160.0" ORDER="67427" SD_1="384.0" SD_2="628.6" SE="193.4945477268029" STUDY_ID="STD-Coffey-1995" TOTAL_1="16" TOTAL_2="14" WEIGHT="1.1554977371407396"/>
<CONT_DATA CI_END="-125.87749933890234" CI_START="-676.1225006610977" EFFECT_SIZE="-401.0" ESTIMABLE="YES" MEAN_1="1015.0" MEAN_2="1416.0" ORDER="67421" SD_1="409.0" SD_2="559.0" SE="140.371202140054" STUDY_ID="STD-Corbeau-1995" TOTAL_1="41" TOTAL_2="20" WEIGHT="1.7710699139365023"/>
<CONT_DATA CI_END="-80.7032695968486" CI_START="-427.2967304031514" EFFECT_SIZE="-254.0" ESTIMABLE="YES" MEAN_1="496.0" MEAN_2="750.0" ORDER="67419" SD_1="228.0" SD_2="314.0" SE="88.41832389273165" STUDY_ID="STD-Horrow-1990" TOTAL_1="18" TOTAL_2="20" WEIGHT="2.754491666473652"/>
<CONT_DATA CI_END="-280.10511599854306" CI_START="-865.894884001457" EFFECT_SIZE="-573.0" ESTIMABLE="YES" MEAN_1="464.0" MEAN_2="1037.0" MODIFIED="2010-05-20 16:02:12 +0100" MODIFIED_BY="Katharine Ker" ORDER="5373" SD_1="369.2" SD_2="658.0" SE="149.43891128192885" STUDY_ID="STD-Jimenez-2007" TOTAL_1="24" TOTAL_2="26" WEIGHT="1.6414998808944796"/>
<CONT_DATA CI_END="-41.603888428815154" CI_START="-260.39611157118486" EFFECT_SIZE="-151.0" ESTIMABLE="YES" MEAN_1="241.0" MEAN_2="392.0" ORDER="67426" SD_1="79.27" SD_2="305.67" SE="55.815368258849354" STUDY_ID="STD-Katoh-1997" TOTAL_1="62" TOTAL_2="31" WEIGHT="3.5299319997272764"/>
<CONT_DATA CI_END="-321.52316214282183" CI_START="-542.4768378571782" EFFECT_SIZE="-432.0" ESTIMABLE="YES" MEAN_1="474.0" MEAN_2="906.0" ORDER="67425" SD_1="244.75" SD_2="525.1" SE="56.36676935321535" STUDY_ID="STD-Katsaros-1996" TOTAL_1="104" TOTAL_2="106" WEIGHT="3.5169082631129767"/>
<CONT_DATA CI_END="-37.771978417921844" CI_START="-348.22802158207816" EFFECT_SIZE="-193.0" ESTIMABLE="YES" MEAN_1="802.0" MEAN_2="995.0" ORDER="67418" SD_1="214.7" SD_2="281.7" SE="79.19942550296688" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="2.968799611036734"/>
<CONT_DATA CI_END="283.12319845783696" CI_START="-429.12319845783696" EFFECT_SIZE="-73.0" ESTIMABLE="YES" MEAN_1="1008.0" MEAN_2="1081.0" MODIFIED="2010-05-20 16:22:42 +0100" MODIFIED_BY="Katharine Ker" ORDER="5386" SD_1="251.0" SD_2="654.0" SE="181.69884817623756" STUDY_ID="STD-Kuitunen-2006" TOTAL_1="14" TOTAL_2="15" WEIGHT="1.2652300063684756"/>
<CONT_DATA CI_END="-287.6309230067882" CI_START="-408.1690769932118" EFFECT_SIZE="-347.9" ESTIMABLE="YES" MEAN_1="633.0" MEAN_2="980.9" MODIFIED="2010-05-07 11:56:25 +0100" MODIFIED_BY="Katharine Ker" ORDER="2424" SD_1="183.2" SD_2="267.2" SE="30.750094118364714" STUDY_ID="STD-Maddali-2007" TOTAL_1="111" TOTAL_2="111" WEIGHT="4.05691450419314"/>
<CONT_DATA CI_END="-131.31399221693783" CI_START="-188.68600778306217" EFFECT_SIZE="-160.0" ESTIMABLE="YES" MEAN_1="320.0" MEAN_2="480.0" MODIFIED="2010-05-21 14:50:42 +0100" MODIFIED_BY="Katharine Ker" ORDER="2436" SD_1="38.0" SD_2="75.0" SE="14.635987196363669" STUDY_ID="STD-Mehr_x002d_Aein-2007" TOTAL_1="33" TOTAL_2="33" WEIGHT="4.271875810389394"/>
<CONT_DATA CI_END="214.49888696788082" CI_START="-362.4988869678808" EFFECT_SIZE="-74.0" ESTIMABLE="YES" MEAN_1="737.0" MEAN_2="811.0" ORDER="67422" SD_1="400.0" SD_2="600.0" SE="147.19601443879745" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" WEIGHT="1.6724776146438778"/>
<CONT_DATA CI_END="-190.9783751575817" CI_START="-549.0216248424183" EFFECT_SIZE="-370.0" ESTIMABLE="YES" MEAN_1="390.0" MEAN_2="760.0" ORDER="67412" SD_1="120.0" SD_2="320.0" SE="91.33924207511875" STUDY_ID="STD-Misfeld-1998" TOTAL_1="14" TOTAL_2="14" WEIGHT="2.6885465729898064"/>
<CONT_DATA CI_END="13.272613660583573" CI_START="-393.2726136605836" EFFECT_SIZE="-190.0" ESTIMABLE="YES" MEAN_1="534.0" MEAN_2="724.0" ORDER="67423" SD_1="288.0" SD_2="280.0" SE="103.71242291387597" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" WEIGHT="2.422018514686497"/>
<CONT_DATA CI_END="-193.2391132434248" CI_START="-726.7608867565752" EFFECT_SIZE="-460.0" ESTIMABLE="YES" MEAN_1="600.0" MEAN_2="1060.0" ORDER="67413" SD_1="219.1" SD_2="553.5" SE="136.10499420435835" STUDY_ID="STD-Pinosky-1997" TOTAL_1="20" TOTAL_2="19" WEIGHT="1.836120861352422"/>
<CONT_DATA CI_END="-125.01522582901066" CI_START="-350.98477417098934" EFFECT_SIZE="-238.0" ESTIMABLE="YES" MEAN_1="475.0" MEAN_2="713.0" ORDER="67417" SD_1="269.0" SD_2="243.0" SE="57.64635220963182" STUDY_ID="STD-Pleym-2003" TOTAL_1="40" TOTAL_2="39" WEIGHT="3.486569386733594"/>
<CONT_DATA CI_END="53.480057231959336" CI_START="-601.4800572319593" EFFECT_SIZE="-274.0" ESTIMABLE="YES" MEAN_1="649.0" MEAN_2="923.0" ORDER="67428" SD_1="391.0" SD_2="496.0" SE="167.08473207420147" STUDY_ID="STD-Shore_x002d_Lesserson-1996" TOTAL_1="17" TOTAL_2="13" WEIGHT="1.4206078815348875"/>
<CONT_DATA CI_END="-100.58998985049021" CI_START="-543.4100101495098" EFFECT_SIZE="-322.0" ESTIMABLE="YES" MEAN_1="352.0" MEAN_2="674.0" ORDER="67424" SD_1="150.0" SD_2="411.0" SE="112.96636667610409" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" WEIGHT="2.2377115646920624"/>
<CONT_DATA CI_END="-260.44515387414754" CI_START="-485.55484612585246" EFFECT_SIZE="-373.0" ESTIMABLE="YES" MEAN_1="471.0" MEAN_2="844.0" MODIFIED="2010-05-14 12:18:23 +0100" MODIFIED_BY="Katharine Ker" ORDER="2504" SD_1="182.0" SD_2="363.0" SE="57.426997135493686" STUDY_ID="STD-Taghaddomi-2009" TOTAL_1="50" TOTAL_2="50" WEIGHT="3.491781149730054"/>
<CONT_DATA CI_END="308.89915388853063" CI_START="-708.8991538885307" EFFECT_SIZE="-200.0" ESTIMABLE="YES" MEAN_1="646.0" MEAN_2="846.0" ORDER="67415" SD_1="380.0" SD_2="510.0" SE="259.64719653149865" STUDY_ID="STD-Uozaki-2001" TOTAL_1="6" TOTAL_2="6" WEIGHT="0.7278977539561902"/>
<CONT_DATA CI_END="-186.74214612504153" CI_START="-401.25785387495847" EFFECT_SIZE="-294.0" ESTIMABLE="YES" MEAN_1="194.0" MEAN_2="488.0" ORDER="67416" SD_1="135.0" SD_2="238.0" SE="54.72440040786194" STUDY_ID="STD-Zabeeda-2002" TOTAL_1="25" TOTAL_2="25" WEIGHT="3.5556020596825038"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="125.01491973817495" CI_END="-135.2729749567638" CI_START="-321.7583536804737" DF="11" EFFECT_SIZE="-228.51566431861875" ESTIMABLE="YES" I2="91.20105022421495" ID="CMP-002.09.02" MODIFIED="2010-05-21 11:23:16 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="8.881784197001252E-16" P_Z="1.5598931728164302E-6" STUDIES="12" TAU2="22019.775826741487" TOTAL_1="408" TOTAL_2="396" WEIGHT="38.384766452347534" Z="4.803405768677491">
<NAME>Orthopaedic surgery</NAME>
<CONT_DATA CI_END="-277.5306875836037" CI_START="-484.4693124163963" EFFECT_SIZE="-381.0" ESTIMABLE="YES" MEAN_1="170.0" MEAN_2="551.0" MODIFIED="2010-05-20 10:45:51 +0100" MODIFIED_BY="Katharine Ker" ORDER="5301" SD_1="109.0" SD_2="352.0" SE="52.79143557358657" STUDY_ID="STD-Alvarez-2008" TOTAL_1="46" TOTAL_2="49" WEIGHT="3.600726998267059"/>
<CONT_DATA CI_END="-530.9120994834641" CI_START="-849.0879005165359" EFFECT_SIZE="-690.0" ESTIMABLE="YES" MEAN_1="520.0" MEAN_2="1210.0" ORDER="67434" SD_1="230.0" SD_2="480.0" SE="81.16878767742719" STUDY_ID="STD-Benoni-1996" TOTAL_1="43" TOTAL_2="43" WEIGHT="2.922329802355827"/>
<CONT_DATA CI_END="-75.66969391803212" CI_START="-302.3303060819679" EFFECT_SIZE="-189.0" ESTIMABLE="YES" MEAN_1="199.0" MEAN_2="388.0" ORDER="67429" SD_1="114.62" SD_2="228.63" SE="57.82264724040996" STUDY_ID="STD-Benoni-2001" TOTAL_1="18" TOTAL_2="20" WEIGHT="3.4823776254654626"/>
<CONT_DATA CI_END="-46.01227104551758" CI_START="-297.9877289544824" EFFECT_SIZE="-172.0" ESTIMABLE="YES" MEAN_1="352.0" MEAN_2="524.0" MODIFIED="2010-05-14 15:56:38 +0100" MODIFIED_BY="Katharine Ker" ORDER="2539" SD_1="152.0" SD_2="244.0" SE="64.28063471995279" STUDY_ID="STD-Claeys-2007" TOTAL_1="20" TOTAL_2="20" WEIGHT="3.3274159224128694"/>
<CONT_DATA CI_END="207.3286771545174" CI_START="-91.32867715451741" EFFECT_SIZE="58.0" ESTIMABLE="YES" MEAN_1="411.0" MEAN_2="353.0" ORDER="67433" SD_1="220.0" SD_2="311.0" SE="76.18950058899192" STUDY_ID="STD-Garneti-2004" TOTAL_1="25" TOTAL_2="25" WEIGHT="3.040398116448724"/>
<CONT_DATA CI_END="72.89350738334443" CI_START="-258.8935073833444" EFFECT_SIZE="-93.0" ESTIMABLE="YES" MEAN_1="487.0" MEAN_2="580.0" ORDER="67432" SD_1="234.0" SD_2="290.0" SE="84.64109988341175" STUDY_ID="STD-Lemay-2004" TOTAL_1="20" TOTAL_2="19" WEIGHT="2.8412550683038114"/>
<CONT_DATA CI_END="-91.72196971672946" CI_START="-606.2780302832705" EFFECT_SIZE="-349.0" ESTIMABLE="YES" MEAN_1="569.0" MEAN_2="918.0" MODIFIED="2010-05-21 11:23:16 +0100" MODIFIED_BY="Katharine Ker" ORDER="2748" SD_1="294.0" SD_2="549.0" SE="131.26671322159325" STUDY_ID="STD-MacGillivray-2010" TOTAL_1="40" TOTAL_2="20" WEIGHT="1.9131904231084624"/>
<CONT_DATA CI_END="-61.47331262349787" CI_START="-118.52668737650214" EFFECT_SIZE="-90.0" ESTIMABLE="YES" MEAN_1="300.0" MEAN_2="390.0" MODIFIED="2010-05-14 11:50:00 +0100" MODIFIED_BY="Katharine Ker" ORDER="2492" SD_1="54.0" SD_2="65.0" SE="14.554699780974039" STUDY_ID="STD-Sadeghi-2007" TOTAL_1="32" TOTAL_2="35" WEIGHT="4.272610318210998"/>
<CONT_DATA CI_END="-39.97963277172698" CI_START="-362.020367228273" EFFECT_SIZE="-201.0" ESTIMABLE="YES" MEAN_1="536.0" MEAN_2="737.0" MODIFIED="2010-05-14 15:14:12 +0100" MODIFIED_BY="Katharine Ker" ORDER="2522" SD_1="471.0" SD_2="524.0" SE="82.15475819881442" STUDY_ID="STD-Wong-2008" TOTAL_1="73" TOTAL_2="74" WEIGHT="2.8991912748757263"/>
<CONT_DATA CI_END="4.778584654138257" CI_START="-474.7785846541383" EFFECT_SIZE="-235.0" ESTIMABLE="YES" MEAN_1="655.0" MEAN_2="890.0" ORDER="67430" SD_1="418.0" SD_2="353.0" SE="122.33826057288864" STUDY_ID="STD-Yamasaki-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="2.064898145951373"/>
<CONT_DATA CI_END="-272.2708766037116" CI_START="-399.7291233962884" EFFECT_SIZE="-336.0" ESTIMABLE="YES" MEAN_1="478.0" MEAN_2="814.0" MODIFIED="2010-05-14 15:34:05 +0100" MODIFIED_BY="Katharine Ker" ORDER="2528" SD_1="172.0" SD_2="156.0" SE="32.51545635479816" STUDY_ID="STD-Zhang-2007" TOTAL_1="51" TOTAL_2="51" WEIGHT="4.0259770082298045"/>
<CONT_DATA CI_END="-60.87159118811735" CI_START="-195.12840881188265" EFFECT_SIZE="-128.0" ESTIMABLE="YES" MEAN_1="121.0" MEAN_2="249.0" ORDER="67431" SD_1="81.0" SD_2="130.0" SE="34.24981751776205" STUDY_ID="STD-Zohar-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="3.994395748717418"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-7.109744546695481" CI_START="-118.89025545330452" DF="0" EFFECT_SIZE="-63.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.09.03" MODIFIED="2010-07-08 10:22:08 +0100" MODIFIED_BY="Katharine Ker" NO="3" P_CHI2="1.0" P_Z="0.02715454028294279" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="4.094213609516307" Z="2.2092890795460263">
<NAME>Gynaecological surgery</NAME>
<CONT_DATA CI_END="-7.109744546695481" CI_START="-118.89025545330452" EFFECT_SIZE="-63.0" ESTIMABLE="YES" MEAN_1="150.0" MEAN_2="213.0" MODIFIED="2010-04-21 10:41:29 +0100" MODIFIED_BY="Katharine Ker" ORDER="2357" SD_1="167.0" SD_2="113.0" SE="28.515960443232487" STUDY_ID="STD-Caglar-2008" TOTAL_1="50" TOTAL_2="50" WEIGHT="4.094213609516307"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.09.04" MODIFIED="2010-07-08 10:58:07 +0100" MODIFIED_BY="Katharine Ker" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Head &amp; neck surgery</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="83.4058329294047" CI_END="-216.8922731172312" CI_START="-328.8515382756152" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="MD" EFFECT_SIZE="-272.8719056964232" ESTIMABLE="YES" I2="74.82190482076409" I2_Q="93.49796878143529" ID="CMP-002.10" MODIFIED="2010-05-21 14:51:17 +0100" MODIFIED_BY="Katharine Ker" NO="10" P_CHI2="2.160183920629777E-9" P_Q="8.792449921990464E-5" P_Z="1.2500509905881708E-21" Q="15.379809268598763" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="9687.613010735602" TOTALS="YES" TOTAL_1="827" TOTAL_2="770" UNITS="" WEIGHT="100.0" Z="9.553815966927148">
<NAME>Blood loss - Post-operative - Dose (Cardiac Surgery)</NAME>
<GROUP_LABEL_1>TXA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TXA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="46.5301399423071" CI_END="-160.29308900118286" CI_START="-329.7585198351959" DF="11" EFFECT_SIZE="-245.02580441818938" ESTIMABLE="YES" I2="76.35940916223561" ID="CMP-002.10.01" MODIFIED="2010-05-21 14:51:17 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="2.6053278460169693E-6" P_Z="1.4470574324796055E-8" STUDIES="12" TAU2="11844.383960991976" TOTAL_1="312" TOTAL_2="307" WEIGHT="49.44674627487452" Z="5.667725265018689">
<NAME>Total dose &lt; 2.0 grams</NAME>
<CONT_DATA CI_END="93.39098918177007" CI_START="-193.39098918177007" EFFECT_SIZE="-50.0" ESTIMABLE="YES" MEAN_1="403.0" MEAN_2="453.0" ORDER="67435" SD_1="201.39" SD_2="192.56" SE="73.16001228227655" STUDY_ID="STD-Blauhut-1994" TOTAL_1="15" TOTAL_2="14" WEIGHT="5.423954744070538"/>
<CONT_DATA CI_END="-69.75765525059973" CI_START="-828.2423447494002" EFFECT_SIZE="-449.0" ESTIMABLE="YES" MEAN_1="711.0" MEAN_2="1160.0" ORDER="67436" SD_1="384.0" SD_2="628.6" SE="193.4945477268029" STUDY_ID="STD-Coffey-1995" TOTAL_1="16" TOTAL_2="14" WEIGHT="1.730960556183366"/>
<CONT_DATA CI_END="-80.7032695968486" CI_START="-427.2967304031514" EFFECT_SIZE="-254.0" ESTIMABLE="YES" MEAN_1="496.0" MEAN_2="750.0" ORDER="67437" SD_1="228.0" SD_2="314.0" SE="88.41832389273165" STUDY_ID="STD-Horrow-1990" TOTAL_1="18" TOTAL_2="20" WEIGHT="4.660060377501899"/>
<CONT_DATA CI_END="283.12319845783696" CI_START="-429.12319845783696" EFFECT_SIZE="-73.0" ESTIMABLE="YES" MEAN_1="1008.0" MEAN_2="1081.0" MODIFIED="2010-05-20 16:23:39 +0100" MODIFIED_BY="Katharine Ker" ORDER="5387" SD_1="251.0" SD_2="654.0" SE="181.69884817623756" STUDY_ID="STD-Kuitunen-2006" TOTAL_1="14" TOTAL_2="15" WEIGHT="1.9103583029788749"/>
<CONT_DATA CI_END="-287.6309230067882" CI_START="-408.1690769932118" EFFECT_SIZE="-347.9" ESTIMABLE="YES" MEAN_1="633.0" MEAN_2="980.9" MODIFIED="2010-05-21 14:31:39 +0100" MODIFIED_BY="Katharine Ker" ORDER="2785" SD_1="183.2" SD_2="267.2" SE="30.750094118364714" STUDY_ID="STD-Maddali-2007" TOTAL_1="111" TOTAL_2="111" WEIGHT="7.671860308694612"/>
<CONT_DATA CI_END="-131.31399221693783" CI_START="-188.68600778306217" EFFECT_SIZE="-160.0" ESTIMABLE="YES" MEAN_1="320.0" MEAN_2="480.0" MODIFIED="2010-05-21 14:51:17 +0100" MODIFIED_BY="Katharine Ker" ORDER="2787" SD_1="38.0" SD_2="75.0" SE="14.635987196363669" STUDY_ID="STD-Mehr_x002d_Aein-2007" TOTAL_1="33" TOTAL_2="33" WEIGHT="8.238509615760995"/>
<CONT_DATA CI_END="214.49888696788082" CI_START="-362.4988869678808" EFFECT_SIZE="-74.0" ESTIMABLE="YES" MEAN_1="737.0" MEAN_2="811.0" ORDER="67438" SD_1="400.0" SD_2="600.0" SE="147.19601443879745" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" WEIGHT="2.6017590709292886"/>
<CONT_DATA CI_END="-190.9783751575817" CI_START="-549.0216248424183" EFFECT_SIZE="-370.0" ESTIMABLE="YES" MEAN_1="390.0" MEAN_2="760.0" ORDER="67439" SD_1="120.0" SD_2="320.0" SE="91.33924207511875" STUDY_ID="STD-Misfeld-1998" TOTAL_1="14" TOTAL_2="14" WEIGHT="4.524356873016998"/>
<CONT_DATA CI_END="13.272613660583573" CI_START="-393.2726136605836" EFFECT_SIZE="-190.0" ESTIMABLE="YES" MEAN_1="534.0" MEAN_2="724.0" ORDER="67440" SD_1="288.0" SD_2="280.0" SE="103.71242291387597" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" WEIGHT="3.9902544355759386"/>
<CONT_DATA CI_END="-193.2391132434248" CI_START="-726.7608867565752" EFFECT_SIZE="-460.0" ESTIMABLE="YES" MEAN_1="600.0" MEAN_2="1060.0" ORDER="67441" SD_1="219.1" SD_2="553.5" SE="136.10499420435835" STUDY_ID="STD-Pinosky-1997" TOTAL_1="20" TOTAL_2="19" WEIGHT="2.891526796421317"/>
<CONT_DATA CI_END="53.480057231959336" CI_START="-601.4800572319593" EFFECT_SIZE="-274.0" ESTIMABLE="YES" MEAN_1="649.0" MEAN_2="923.0" ORDER="67442" SD_1="391.0" SD_2="496.0" SE="167.08473207420147" STUDY_ID="STD-Shore_x002d_Lesserson-1996" TOTAL_1="17" TOTAL_2="13" WEIGHT="2.1692980609458745"/>
<CONT_DATA CI_END="-100.58998985049021" CI_START="-543.4100101495098" EFFECT_SIZE="-322.0" ESTIMABLE="YES" MEAN_1="352.0" MEAN_2="674.0" ORDER="67443" SD_1="150.0" SD_2="411.0" SE="112.96636667610409" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" WEIGHT="3.633847132794821"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="21.495883718498835" CI_END="-231.392669729788" CI_START="-364.4902431165928" DF="9" EFFECT_SIZE="-297.9414564231904" ESTIMABLE="YES" I2="58.13151895562768" ID="CMP-002.10.02" MODIFIED="2010-05-20 16:03:03 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.010621624399618779" P_Z="1.7115688332740502E-18" STUDIES="10" TAU2="5796.926779267806" TOTAL_1="515" TOTAL_2="463" WEIGHT="50.55325372512549" Z="8.774833518471281">
<NAME>Total dose 2.0 - 10.0 grams</NAME>
<CONT_DATA CI_END="-199.9173089935403" CI_START="-346.0826910064597" EFFECT_SIZE="-273.0" ESTIMABLE="YES" MEAN_1="447.0" MEAN_2="720.0" ORDER="67444" SD_1="262.0" SD_2="357.0" SE="37.28777241976211" STUDY_ID="STD-Armellin-2001" TOTAL_1="143" TOTAL_2="140" WEIGHT="7.363815486947141"/>
<CONT_DATA CI_END="-125.87749933890234" CI_START="-676.1225006610977" EFFECT_SIZE="-401.0" ESTIMABLE="YES" MEAN_1="1015.0" MEAN_2="1416.0" ORDER="67445" SD_1="409.0" SD_2="559.0" SE="140.371202140054" STUDY_ID="STD-Corbeau-1995" TOTAL_1="41" TOTAL_2="20" WEIGHT="2.7754882001234336"/>
<CONT_DATA CI_END="-280.10511599854306" CI_START="-865.894884001457" EFFECT_SIZE="-573.0" ESTIMABLE="YES" MEAN_1="464.0" MEAN_2="1037.0" MODIFIED="2010-05-20 16:03:03 +0100" MODIFIED_BY="Katharine Ker" ORDER="5374" SD_1="369.2" SD_2="658.0" SE="149.43891128192885" STUDY_ID="STD-Jimenez-2007" TOTAL_1="24" TOTAL_2="26" WEIGHT="2.5476982368761982"/>
<CONT_DATA CI_END="-41.603888428815154" CI_START="-260.39611157118486" EFFECT_SIZE="-151.0" ESTIMABLE="YES" MEAN_1="241.0" MEAN_2="392.0" ORDER="67446" SD_1="79.27" SD_2="305.67" SE="55.815368258849354" STUDY_ID="STD-Katoh-1997" TOTAL_1="62" TOTAL_2="31" WEIGHT="6.371669394738475"/>
<CONT_DATA CI_END="-321.52316214282183" CI_START="-542.4768378571782" EFFECT_SIZE="-432.0" ESTIMABLE="YES" MEAN_1="474.0" MEAN_2="906.0" ORDER="67447" SD_1="244.75" SD_2="525.1" SE="56.36676935321535" STUDY_ID="STD-Katsaros-1996" TOTAL_1="104" TOTAL_2="106" WEIGHT="6.341032787989791"/>
<CONT_DATA CI_END="-37.771978417921844" CI_START="-348.22802158207816" EFFECT_SIZE="-193.0" ESTIMABLE="YES" MEAN_1="802.0" MEAN_2="995.0" ORDER="67448" SD_1="214.7" SD_2="281.7" SE="79.19942550296688" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="5.111243952803419"/>
<CONT_DATA CI_END="-125.01522582901066" CI_START="-350.98477417098934" EFFECT_SIZE="-238.0" ESTIMABLE="YES" MEAN_1="475.0" MEAN_2="713.0" ORDER="67449" SD_1="269.0" SD_2="243.0" SE="57.64635220963182" STUDY_ID="STD-Pleym-2003" TOTAL_1="40" TOTAL_2="39" WEIGHT="6.269930743861969"/>
<CONT_DATA CI_END="-260.44515387414754" CI_START="-485.55484612585246" EFFECT_SIZE="-373.0" ESTIMABLE="YES" MEAN_1="471.0" MEAN_2="844.0" MODIFIED="2010-05-14 12:18:56 +0100" MODIFIED_BY="Katharine Ker" ORDER="2505" SD_1="182.0" SD_2="363.0" SE="57.426997135493686" STUDY_ID="STD-Taghaddomi-2009" TOTAL_1="50" TOTAL_2="50" WEIGHT="6.282118602510119"/>
<CONT_DATA CI_END="308.89915388853063" CI_START="-708.8991538885307" EFFECT_SIZE="-200.0" ESTIMABLE="YES" MEAN_1="646.0" MEAN_2="846.0" ORDER="67450" SD_1="380.0" SD_2="510.0" SE="259.64719653149865" STUDY_ID="STD-Uozaki-2001" TOTAL_1="6" TOTAL_2="6" WEIGHT="1.0579993990533783"/>
<CONT_DATA CI_END="-186.74214612504153" CI_START="-401.25785387495847" EFFECT_SIZE="-294.0" ESTIMABLE="YES" MEAN_1="194.0" MEAN_2="488.0" ORDER="67451" SD_1="135.0" SD_2="238.0" SE="54.72440040786194" STUDY_ID="STD-Zabeeda-2002" TOTAL_1="25" TOTAL_2="25" WEIGHT="6.432256920221558"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="249.576938228594" CI_END="-302.9227001602359" CI_START="-525.1936089081651" CI_STUDY="95" CI_TOTAL="95" DF="27" EFFECT_MEASURE="MD" EFFECT_SIZE="-414.05815453420047" ESTIMABLE="YES" I2="89.18169275108664" I2_Q="98.02741401429954" ID="CMP-002.11" MODIFIED="2010-12-03 12:38:07 +0000" MODIFIED_BY="Katharine Ker" NO="11" P_CHI2="2.220446049250313E-16" P_Q="2.220446049250313E-16" P_Z="2.829910481365808E-13" Q="152.08462504283253" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="28" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="63946.72920941031" TOTALS="YES" TOTAL_1="875" TOTAL_2="837" UNITS="" WEIGHT="100.0" Z="7.302251787817141">
<NAME>Blood loss - Total</NAME>
<GROUP_LABEL_1>TXA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TXA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="12.190421820534104" CI_END="-130.20674886318534" CI_START="-470.74173875927283" DF="5" EFFECT_SIZE="-300.4742438112291" ESTIMABLE="YES" I2="58.98419206808929" ID="CMP-002.11.01" MODIFIED="2010-05-17 14:56:39 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="0.0322697639379137" P_Z="5.426174023233915E-4" STUDIES="6" TAU2="21220.401639548072" TOTAL_1="210" TOTAL_2="181" WEIGHT="19.768385824619614" Z="3.458785226925561">
<NAME>Cardiac surgery</NAME>
<CONT_DATA CI_END="-181.06667920112147" CI_START="-614.9333207988785" EFFECT_SIZE="-398.0" ESTIMABLE="YES" MEAN_1="602.0" MEAN_2="1000.0" ORDER="67453" SD_1="562.0" SD_2="736.0" SE="110.68229952694074" STUDY_ID="STD-Isetta-1993" TOTAL_1="70" TOTAL_2="70" WEIGHT="4.2195825780076"/>
<CONT_DATA CI_END="274.7178018003924" CI_START="-1536.7178018003924" EFFECT_SIZE="-631.0" ESTIMABLE="YES" MEAN_1="835.0" MEAN_2="1466.0" MODIFIED="2010-05-17 14:56:39 +0100" MODIFIED_BY="Katharine Ker" ORDER="2637" SD_1="1013.57" SD_2="2106.95" SE="462.10941065477675" STUDY_ID="STD-Jimenez-2007" TOTAL_1="24" TOTAL_2="26" WEIGHT="1.1586676068514468"/>
<CONT_DATA CI_END="-216.4441231386134" CI_START="-816.5558768613867" EFFECT_SIZE="-516.5" ESTIMABLE="YES" MEAN_1="437.5" MEAN_2="954.0" ORDER="67454" SD_1="143.76" SD_2="846.3" SE="153.0925462040063" STUDY_ID="STD-Katoh-1997" TOTAL_1="62" TOTAL_2="31" WEIGHT="3.679398892920269"/>
<CONT_DATA CI_END="281.501447868652" CI_START="-427.501447868652" EFFECT_SIZE="-73.0" ESTIMABLE="YES" MEAN_1="1008.0" MEAN_2="1081.0" MODIFIED="2010-01-13 14:07:22 +0000" MODIFIED_BY="Katharine Ker" ORDER="2339" SD_1="251.0" SD_2="654.0" SE="180.87140920185993" STUDY_ID="STD-Kuitunen-2006" TOTAL_1="15" TOTAL_2="15" WEIGHT="3.3262655127444933"/>
<CONT_DATA CI_END="-131.31399221693783" CI_START="-188.68600778306217" EFFECT_SIZE="-160.0" ESTIMABLE="YES" MEAN_1="320.0" MEAN_2="480.0" MODIFIED="2010-05-07 12:16:22 +0100" MODIFIED_BY="Katharine Ker" ORDER="2435" SD_1="38.0" SD_2="75.0" SE="14.635987196363669" STUDY_ID="STD-Mehr_x002d_Aein-2007" TOTAL_1="33" TOTAL_2="33" WEIGHT="5.0111609274314235"/>
<CONT_DATA CI_END="74.18258729630838" CI_START="-974.1825872963084" EFFECT_SIZE="-450.0" ESTIMABLE="YES" MEAN_1="919.0" MEAN_2="1369.0" ORDER="67452" SD_1="365.0" SD_2="544.0" SE="267.4450099241587" STUDY_ID="STD-Uozaki-2001" TOTAL_1="6" TOTAL_2="6" WEIGHT="2.373310306664381"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="85.30189136522738" CI_END="-337.77857102832587" CI_START="-554.605086431891" DF="19" EFFECT_SIZE="-446.19182873010845" ESTIMABLE="YES" I2="77.72616797129402" ID="CMP-002.11.02" MODIFIED="2010-05-20 10:46:40 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="2.2299173618733903E-10" P_Z="7.231820610004192E-16" STUDIES="20" TAU2="41720.908380674824" TOTAL_1="605" TOTAL_2="596" WEIGHT="75.99223227752054" Z="8.066540320305288">
<NAME>Orthopaedic surgery</NAME>
<CONT_DATA CI_END="-155.1076208670392" CI_START="-730.8923791329607" EFFECT_SIZE="-443.0" ESTIMABLE="YES" MEAN_1="1301.0" MEAN_2="1744.0" MODIFIED="2010-05-20 10:46:40 +0100" MODIFIED_BY="Katharine Ker" ORDER="5302" SD_1="621.0" SD_2="804.0" SE="146.88656597969103" STUDY_ID="STD-Alvarez-2008" TOTAL_1="46" TOTAL_2="49" WEIGHT="3.7594926072524038"/>
<CONT_DATA CI_END="-513.9065488717798" CI_START="-846.0934511282202" EFFECT_SIZE="-680.0" ESTIMABLE="YES" MEAN_1="730.0" MEAN_2="1410.0" ORDER="67466" SD_1="280.0" SD_2="480.0" SE="84.74311387267528" STUDY_ID="STD-Benoni-1996" TOTAL_1="43" TOTAL_2="43" WEIGHT="4.52030479167124"/>
<CONT_DATA CI_END="-31.43766558095689" CI_START="-442.5623344190431" EFFECT_SIZE="-237.0" ESTIMABLE="YES" MEAN_1="759.0" MEAN_2="996.0" ORDER="67457" SD_1="260.41" SD_2="380.33" SE="104.88066925744175" STUDY_ID="STD-Benoni-2001" TOTAL_1="18" TOTAL_2="20" WEIGHT="4.28999370128212"/>
<CONT_DATA CI_END="-71.23698022296415" CI_START="-402.7630197770359" EFFECT_SIZE="-237.0" ESTIMABLE="YES" MEAN_1="801.0" MEAN_2="1038.0" MODIFIED="2010-05-14 15:57:16 +0100" MODIFIED_BY="Katharine Ker" ORDER="2540" SD_1="244.0" SD_2="289.0" SE="84.57452335071123" STUDY_ID="STD-Claeys-2007" TOTAL_1="20" TOTAL_2="20" WEIGHT="4.522119622062131"/>
<CONT_DATA CI_END="-351.4359862113171" CI_START="-928.5640137886829" EFFECT_SIZE="-640.0" ESTIMABLE="YES" MEAN_1="1130.0" MEAN_2="1770.0" ORDER="67456" SD_1="400.0" SD_2="523.0" SE="147.2292430191774" STUDY_ID="STD-Ekback-2000" TOTAL_1="20" TOTAL_2="20" WEIGHT="3.7550673220961026"/>
<CONT_DATA CI_END="513.5094852696182" CI_START="-307.5094852696182" EFFECT_SIZE="103.0" ESTIMABLE="YES" MEAN_1="1443.0" MEAN_2="1340.0" ORDER="67464" SD_1="809.0" SD_2="665.0" SE="209.4474635797722" STUDY_ID="STD-Garneti-2004" TOTAL_1="25" TOTAL_2="25" WEIGHT="2.9821536343319948"/>
<CONT_DATA CI_END="-341.7003247124683" CI_START="-1062.2996752875317" EFFECT_SIZE="-702.0" ESTIMABLE="YES" MEAN_1="847.0" MEAN_2="1549.0" ORDER="67467" SD_1="356.0" SD_2="574.0" SE="183.82974285728184" STUDY_ID="STD-Hiipala-1995" TOTAL_1="15" TOTAL_2="13" WEIGHT="3.289548409760794"/>
<CONT_DATA CI_END="-596.3424222159615" CI_START="-1043.6575777840385" EFFECT_SIZE="-820.0" ESTIMABLE="YES" MEAN_1="689.0" MEAN_2="1509.0" ORDER="67468" SD_1="289.0" SD_2="643.0" SE="114.11310592858896" STUDY_ID="STD-Hiipala-1997" TOTAL_1="39" TOTAL_2="38" WEIGHT="4.1773020950198445"/>
<CONT_DATA CI_END="482.90224097519956" CI_START="-1316.9022409751997" EFFECT_SIZE="-417.0" ESTIMABLE="YES" MEAN_1="814.0" MEAN_2="1231.0" ORDER="67458" SD_1="1264.92" SD_2="1617.47" SE="459.1422332621995" STUDY_ID="STD-Husted-2003" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.170194965383607"/>
<CONT_DATA CI_END="-440.89257679281263" CI_START="-1041.1074232071874" EFFECT_SIZE="-741.0" ESTIMABLE="YES" MEAN_1="678.0" MEAN_2="1419.0" ORDER="67455" SD_1="352.0" SD_2="607.0" SE="153.11884584328917" STUDY_ID="STD-Jansen-1999" TOTAL_1="21" TOTAL_2="21" WEIGHT="3.679059833524964"/>
<CONT_DATA CI_END="-156.189174249545" CI_START="-553.810825750455" EFFECT_SIZE="-355.0" ESTIMABLE="YES" MEAN_1="969.0" MEAN_2="1324.0" ORDER="67463" SD_1="434.0" SD_2="577.0" SE="101.43595868018464" STUDY_ID="STD-Johansson-2005" TOTAL_1="47" TOTAL_2="53" WEIGHT="4.331064122875381"/>
<CONT_DATA CI_END="111.32283499768772" CI_START="-433.3228349976877" EFFECT_SIZE="-161.0" ESTIMABLE="YES" MEAN_1="1308.0" MEAN_2="1469.0" ORDER="67462" SD_1="462.0" SD_2="405.0" SE="138.94277504369236" STUDY_ID="STD-Lemay-2004" TOTAL_1="20" TOTAL_2="19" WEIGHT="3.8620271247247357"/>
<CONT_DATA CI_END="-91.72196971672946" CI_START="-606.2780302832705" EFFECT_SIZE="-349.0" ESTIMABLE="YES" MEAN_1="569.0" MEAN_2="918.0" MODIFIED="2010-05-07 11:09:17 +0100" MODIFIED_BY="Katharine Ker" ORDER="2419" SD_1="294.0" SD_2="549.0" SE="131.26671322159325" STUDY_ID="STD-MacGillivray-2010" TOTAL_1="40" TOTAL_2="20" WEIGHT="3.9607045359577566"/>
<CONT_DATA CI_END="-50.188774509670964" CI_START="-569.811225490329" EFFECT_SIZE="-310.0" ESTIMABLE="YES" MEAN_1="792.0" MEAN_2="1102.0" ORDER="67460" SD_1="360.0" SD_2="463.7" SE="132.55918350525153" STUDY_ID="STD-Niskanen-2005" TOTAL_1="19" TOTAL_2="20" WEIGHT="3.9441371736667854"/>
<CONT_DATA CI_END="154.31733778144473" CI_START="-286.31733778144473" EFFECT_SIZE="-66.0" ESTIMABLE="YES" MEAN_1="660.0" MEAN_2="726.0" ORDER="67461" SD_1="296.15" SD_2="308.29" SE="112.40887052990757" STUDY_ID="STD-Orpen-2006" TOTAL_1="15" TOTAL_2="14" WEIGHT="4.19835957335492"/>
<CONT_DATA CI_END="-365.77666891221713" CI_START="-682.2233310877829" EFFECT_SIZE="-524.0" ESTIMABLE="YES" MEAN_1="960.0" MEAN_2="1484.0" MODIFIED="2010-05-14 11:50:40 +0100" MODIFIED_BY="Katharine Ker" ORDER="2493" SD_1="284.0" SD_2="374.0" SE="80.72767272043177" STUDY_ID="STD-Sadeghi-2007" TOTAL_1="32" TOTAL_2="35" WEIGHT="4.5629290618697365"/>
<CONT_DATA CI_END="-432.7263477769716" CI_START="-1055.2736522230284" EFFECT_SIZE="-744.0" ESTIMABLE="YES" MEAN_1="678.0" MEAN_2="1422.0" ORDER="67465" SD_1="352.0" SD_2="637.0" SE="158.8160061502738" STUDY_ID="STD-Sorin-1999" TOTAL_1="21" TOTAL_2="21" WEIGHT="3.605736185711499"/>
<CONT_DATA CI_END="-71.59974351072219" CI_START="-1020.4002564892778" EFFECT_SIZE="-546.0" ESTIMABLE="YES" MEAN_1="1592.0" MEAN_2="2138.0" MODIFIED="2010-05-14 15:14:53 +0100" MODIFIED_BY="Katharine Ker" ORDER="2523" SD_1="1315.0" SD_2="1607.0" SE="242.0453948293369" STUDY_ID="STD-Wong-2008" TOTAL_1="73" TOTAL_2="74" WEIGHT="2.6239591231647728"/>
<CONT_DATA CI_END="-43.892539113250336" CI_START="-590.1074608867497" EFFECT_SIZE="-317.0" ESTIMABLE="YES" MEAN_1="1350.0" MEAN_2="1667.0" ORDER="67459" SD_1="477.0" SD_2="401.0" SE="139.34310173094326" STUDY_ID="STD-Yamasaki-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="3.8568659745121865"/>
<CONT_DATA CI_END="-569.3007832905448" CI_START="-728.6992167094552" EFFECT_SIZE="-649.0" ESTIMABLE="YES" MEAN_1="559.0" MEAN_2="1208.0" MODIFIED="2010-05-14 15:34:41 +0100" MODIFIED_BY="Katharine Ker" ORDER="2529" SD_1="159.0" SD_2="243.0" SE="40.66361287151826" STUDY_ID="STD-Zhang-2007" TOTAL_1="51" TOTAL_2="51" WEIGHT="4.901212419297564"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1225.5391988785605" CI_START="-14329.53919887856" DF="0" EFFECT_SIZE="-6552.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.11.03" NO="3" P_CHI2="1.0" P_Z="0.09871319475656902" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.020335776253816613" Z="1.6511243078733788">
<NAME>Liver surgery</NAME>
<CONT_DATA CI_END="1225.5391988785605" CI_START="-14329.53919887856" EFFECT_SIZE="-6552.0" ESTIMABLE="YES" MEAN_1="6042.0" MEAN_2="12594.0" ORDER="67469" SD_1="3949.0" SD_2="11911.0" SE="3968.2051610268336" STUDY_ID="STD-Yassen-1993" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.020335776253816613"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-25.98091346380761" CI_START="-460.0190865361924" DF="0" EFFECT_SIZE="-243.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.11.04" MODIFIED="2010-07-08 10:58:33 +0100" MODIFIED_BY="Katharine Ker" NO="4" P_CHI2="1.0" P_Z="0.02819191948979149" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="4.219046121606029" Z="2.1946053494414888">
<NAME>Gynaecological surgery</NAME>
<CONT_DATA CI_END="-25.98091346380761" CI_START="-460.0190865361924" EFFECT_SIZE="-243.0" ESTIMABLE="YES" MEAN_1="804.0" MEAN_2="1047.0" MODIFIED="2010-04-21 10:42:21 +0100" MODIFIED_BY="Katharine Ker" ORDER="2358" SD_1="482.0" SD_2="617.0" SE="110.72605836026133" STUDY_ID="STD-Caglar-2008" TOTAL_1="50" TOTAL_2="50" WEIGHT="4.219046121606029"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.11.05" MODIFIED="2010-07-08 10:58:07 +0100" MODIFIED_BY="Katharine Ker" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Head &amp; neck surgery</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-12-07 16:30:04 +0000" MODIFIED_BY="Emma M Sydenham" NO="3">
<NAME>Epsilon Aminocaproic Acid versus Control (Blood Transfusion &amp; Blood Loss)</NAME>
<DICH_OUTCOME CHI2="41.11986010547808" CI_END="0.9910051774639433" CI_START="0.6652558832849169" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8119556790082212" ESTIMABLE="YES" EVENTS_1="238" EVENTS_2="275" I2="63.52127667379475" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-0.003924076555948561" LOG_CI_START="-0.1770112760146393" LOG_EFFECT_SIZE="-0.09046767628529392" METHOD="MH" MODIFIED="2010-08-23 06:08:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.066103208769766E-4" P_Q="0.0" P_Z="0.04047844291833682" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="16" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.05902568407183258" TOTALS="YES" TOTAL_1="530" TOTAL_2="505" WEIGHT="100.0" Z="2.048833048760747">
<NAME>No. Exposed to Allogeneic Blood</NAME>
<GROUP_LABEL_1>EACA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EACA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.08025642709969" CI_START="0.9257061332047195" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="85" LOG_CI_END="0.03352685887183662" LOG_CI_START="-0.033526858871836644" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-20 11:16:24 +0100" MODIFIED_BY="Katharine Ker" ORDER="5308" O_E="0.0" SE="0.03938768572388967" STUDY_ID="STD-Berenholtz-2009" TOTAL_1="91" TOTAL_2="91" VAR="0.0015513897866839023" WEIGHT="17.064627599114353"/>
<DICH_DATA CI_END="1.0409651435105327" CI_START="0.33568677269493497" EFFECT_SIZE="0.5911330049261084" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.017436187498550255" LOG_CI_START="-0.4740657712297263" LOG_EFFECT_SIZE="-0.22831479186558803" ORDER="67480" O_E="0.0" SE="0.28871068353092383" STUDY_ID="STD-Kluger-2003" TOTAL_1="58" TOTAL_2="30" VAR="0.08335385878489326" WEIGHT="7.260349244693456"/>
<DICH_DATA CI_END="1.4670105707282939" CI_START="0.6190118216819162" EFFECT_SIZE="0.9529411764705882" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.16643324321780747" LOG_CI_START="-0.20830105688909348" LOG_EFFECT_SIZE="-0.02093390683564301" MODIFIED="2010-05-17 14:13:20 +0100" MODIFIED_BY="Katharine Ker" ORDER="2599" O_E="0.0" SE="0.22012078284749564" STUDY_ID="STD-Greilich-2009" TOTAL_1="25" TOTAL_2="27" VAR="0.04845315904139433" WEIGHT="9.617941322187654"/>
<DICH_DATA CI_END="1.1821502906810388" CI_START="0.561623329686121" EFFECT_SIZE="0.8148148148148148" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="27" LOG_CI_END="0.07267269335087015" LOG_CI_START="-0.25055486002443234" LOG_EFFECT_SIZE="-0.0889410833367811" ORDER="67471" O_E="0.0" SE="0.1898654648548464" STUDY_ID="STD-Hardy-1998" TOTAL_1="46" TOTAL_2="44" VAR="0.036048894744546915" WEIGHT="10.872782391559104"/>
<DICH_DATA CI_END="1.4132217192919043" CI_START="0.02316958742237693" EFFECT_SIZE="0.18095238095238095" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.15021030332843316" LOG_CI_START="-1.6350816995626514" LOG_EFFECT_SIZE="-0.7424356981171092" ORDER="67470" O_E="0.0" SE="1.0486893598361642" STUDY_ID="STD-Daily-1994" TOTAL_1="21" TOTAL_2="19" VAR="1.099749373433584" WEIGHT="0.8920844470582654"/>
<DICH_DATA CI_END="4.965261095458803" CI_START="0.35804316099383415" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6959420905626427" LOG_CI_START="-0.44606461734604286" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="67481" O_E="0.0" SE="0.6708203932499369" STUDY_ID="STD-Ray-2005" TOTAL_1="15" TOTAL_2="15" VAR="0.44999999999999996" WEIGHT="2.0307918417211974"/>
<DICH_DATA CI_END="4.1843664851249125" CI_START="0.23898480296955818" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.62162971493598" LOG_CI_START="-0.6216297149359801" LOG_EFFECT_SIZE="0.0" ORDER="67473" O_E="0.0" SE="0.7302967433402214" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.5333333333333333" WEIGHT="1.7450991308748398"/>
<DICH_DATA CI_END="0.5598191387831571" CI_START="0.08821191100526277" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="18" LOG_CI_END="-0.2519522581995579" LOG_CI_START="-1.0544727693511295" LOG_EFFECT_SIZE="-0.6532125137753437" ORDER="67472" O_E="0.0" SE="0.4714045207910317" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.22222222222222224" WEIGHT="3.6754947621150724"/>
<DICH_DATA CI_END="1.5838486749528184" CI_START="0.3447026213787251" EFFECT_SIZE="0.7388888888888889" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.1997136856042464" LOG_CI_START="-0.46255541387668697" LOG_EFFECT_SIZE="-0.13142086413622026" ORDER="67475" O_E="0.0" SE="0.3890201473200142" STUDY_ID="STD-Pinosky-1997" TOTAL_1="20" TOTAL_2="19" VAR="0.15133667502088555" WEIGHT="4.914021742758695"/>
<DICH_DATA CI_END="1.8425052183949786" CI_START="0.21090763309259541" EFFECT_SIZE="0.6233766233766234" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.26540872655384845" LOG_CI_START="-0.6759077021476378" LOG_EFFECT_SIZE="-0.20524948779689467" ORDER="67478" O_E="0.0" SE="0.5529339298107241" STUDY_ID="STD-Harley-2002" TOTAL_1="22" TOTAL_2="24" VAR="0.3057359307359307" WEIGHT="2.8339747508367163"/>
<DICH_DATA CI_END="0.9899593643560859" CI_START="0.17654697523569457" EFFECT_SIZE="0.4180602006688963" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="-0.004382631865195394" LOG_CI_START="-0.7531397187675511" LOG_EFFECT_SIZE="-0.3787611753163732" ORDER="67476" O_E="0.0" SE="0.4398236192538001" STUDY_ID="STD-Greilich-2001" TOTAL_1="23" TOTAL_2="25" VAR="0.19344481605351171" WEIGHT="4.094439571856572"/>
<DICH_DATA CI_END="3.015921170666856" CI_START="0.42515142499811714" EFFECT_SIZE="1.1323529411764706" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.47941998587419293" LOG_CI_START="-0.37145636094170187" LOG_EFFECT_SIZE="0.05398181246624554" ORDER="67474" O_E="0.0" SE="0.4998089780255021" STUDY_ID="STD-Troianos-1999" TOTAL_1="34" TOTAL_2="33" VAR="0.24980901451489687" WEIGHT="3.34717961152066"/>
<DICH_DATA CI_END="1.413322290141931" CI_START="0.18047972103104282" EFFECT_SIZE="0.5050505050505051" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.15024120846564631" LOG_CI_START="-0.7435715889887086" LOG_EFFECT_SIZE="-0.2966651902615311" ORDER="67482" O_E="0.0" SE="0.525030061669392" STUDY_ID="STD-Kreisler-2005" TOTAL_1="22" TOTAL_2="25" VAR="0.27565656565656566" WEIGHT="3.0886765201277306"/>
<DICH_DATA CI_END="2.880421272405446" CI_START="0.6171936705262393" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.4594560095999913" LOG_CI_START="-0.20957853638339138" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="67483" O_E="0.0" SE="0.3929942040850532" STUDY_ID="STD-Kikura-2006" TOTAL_1="50" TOTAL_2="50" VAR="0.15444444444444444" WEIGHT="4.84248177309177"/>
<DICH_DATA CI_END="1.0784979701866373" CI_START="0.7961659925770292" EFFECT_SIZE="0.9266409266409267" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="37" LOG_CI_END="0.032819332064829704" LOG_CI_START="-0.09899637680412121" LOG_EFFECT_SIZE="-0.03308852236964579" ORDER="67477" O_E="0.0" SE="0.07742919988790402" STUDY_ID="STD-Dalmau-2000" TOTAL_1="42" TOTAL_2="40" VAR="0.005995280995280995" WEIGHT="15.898336872924524"/>
<DICH_DATA CI_END="1.7108869566393983" CI_START="0.5926954508582096" EFFECT_SIZE="1.006993006993007" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.23322131536834406" LOG_CI_START="-0.22716840610796835" LOG_EFFECT_SIZE="0.0030264546301878867" ORDER="67479" O_E="0.0" SE="0.2704352013610619" STUDY_ID="STD-Amar-2003" TOTAL_1="22" TOTAL_2="24" VAR="0.07313519813519812" WEIGHT="7.82171841755939"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="41.1198601054781" CI_END="0.9910051774639435" CI_START="0.6652558832849169" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8119556790082212" ESTIMABLE="YES" EVENTS_1="238" EVENTS_2="275" I2="63.52127667379476" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.0039240765559485115" LOG_CI_START="-0.1770112760146393" LOG_EFFECT_SIZE="-0.09046767628529392" METHOD="MH" MODIFIED="2010-12-07 16:29:40 +0000" MODIFIED_BY="Emma M Sydenham" NO="2" P_CHI2="3.0661032087675455E-4" P_Q="0.0" P_Z="0.04047844291833687" Q="0.0" RANDOM="YES" SCALE="7.386780945759869" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.05902568407183261" TOTALS="YES" TOTAL_1="530" TOTAL_2="505" WEIGHT="99.99999999999999" Z="2.0488330487607467">
<NAME>No. Exposed to Allogeneic Blood - Type of Surgery</NAME>
<GROUP_LABEL_1>EACA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EACA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="16.381349033088476" CI_END="0.9332488548751394" CI_START="0.5229326345928964" DF="10" EFFECT_SIZE="0.6985887791903476" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="130" I2="38.954966530527315" ID="CMP-003.02.01" LOG_CI_END="-0.03000253429393018" LOG_CI_START="-0.28155425436204873" LOG_EFFECT_SIZE="-0.1557783943279895" MODIFIED="2010-05-17 14:13:39 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="0.08922392532294932" P_Z="0.015203572689002433" STUDIES="11" TAU2="0.08239448438886189" TOTAL_1="338" TOTAL_2="311" WEIGHT="54.350550517843814" Z="2.4274931800876525">
<NAME>Cardiac Surgery</NAME>
<DICH_DATA CI_END="1.4132217192919043" CI_START="0.02316958742237693" EFFECT_SIZE="0.18095238095238095" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.15021030332843316" LOG_CI_START="-1.6350816995626514" LOG_EFFECT_SIZE="-0.7424356981171092" ORDER="67484" O_E="0.0" SE="1.0486893598361642" STUDY_ID="STD-Daily-1994" TOTAL_1="21" TOTAL_2="19" VAR="1.099749373433584" WEIGHT="0.8920844470582655"/>
<DICH_DATA CI_END="0.9899593643560859" CI_START="0.17654697523569457" EFFECT_SIZE="0.4180602006688963" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="-0.004382631865195394" LOG_CI_START="-0.7531397187675511" LOG_EFFECT_SIZE="-0.3787611753163732" ORDER="67485" O_E="0.0" SE="0.4398236192538001" STUDY_ID="STD-Greilich-2001" TOTAL_1="23" TOTAL_2="25" VAR="0.19344481605351171" WEIGHT="4.094439571856572"/>
<DICH_DATA CI_END="1.4670105707282939" CI_START="0.6190118216819162" EFFECT_SIZE="0.9529411764705882" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.16643324321780747" LOG_CI_START="-0.20830105688909348" LOG_EFFECT_SIZE="-0.02093390683564301" MODIFIED="2010-05-17 14:13:39 +0100" MODIFIED_BY="Katharine Ker" ORDER="2600" O_E="0.0" SE="0.22012078284749564" STUDY_ID="STD-Greilich-2009" TOTAL_1="25" TOTAL_2="27" VAR="0.04845315904139433" WEIGHT="9.617941322187653"/>
<DICH_DATA CI_END="1.1821502906810388" CI_START="0.561623329686121" EFFECT_SIZE="0.8148148148148148" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="27" LOG_CI_END="0.07267269335087015" LOG_CI_START="-0.25055486002443234" LOG_EFFECT_SIZE="-0.0889410833367811" ORDER="67486" O_E="0.0" SE="0.1898654648548464" STUDY_ID="STD-Hardy-1998" TOTAL_1="46" TOTAL_2="44" VAR="0.036048894744546915" WEIGHT="10.872782391559102"/>
<DICH_DATA CI_END="2.880421272405446" CI_START="0.6171936705262393" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.4594560095999913" LOG_CI_START="-0.20957853638339138" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="67487" O_E="0.0" SE="0.3929942040850532" STUDY_ID="STD-Kikura-2006" TOTAL_1="50" TOTAL_2="50" VAR="0.15444444444444444" WEIGHT="4.84248177309177"/>
<DICH_DATA CI_END="1.0409651435105327" CI_START="0.33568677269493497" EFFECT_SIZE="0.5911330049261084" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.017436187498550255" LOG_CI_START="-0.4740657712297263" LOG_EFFECT_SIZE="-0.22831479186558803" ORDER="67488" O_E="0.0" SE="0.28871068353092383" STUDY_ID="STD-Kluger-2003" TOTAL_1="58" TOTAL_2="30" VAR="0.08335385878489326" WEIGHT="7.260349244693456"/>
<DICH_DATA CI_END="1.413322290141931" CI_START="0.18047972103104282" EFFECT_SIZE="0.5050505050505051" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.15024120846564631" LOG_CI_START="-0.7435715889887086" LOG_EFFECT_SIZE="-0.2966651902615311" ORDER="67489" O_E="0.0" SE="0.525030061669392" STUDY_ID="STD-Kreisler-2005" TOTAL_1="22" TOTAL_2="25" VAR="0.27565656565656566" WEIGHT="3.088676520127731"/>
<DICH_DATA CI_END="0.5598191387831571" CI_START="0.08821191100526277" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="18" LOG_CI_END="-0.2519522581995579" LOG_CI_START="-1.0544727693511295" LOG_EFFECT_SIZE="-0.6532125137753437" ORDER="67490" O_E="0.0" SE="0.4714045207910317" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.22222222222222224" WEIGHT="3.6754947621150733"/>
<DICH_DATA CI_END="4.1843664851249125" CI_START="0.23898480296955818" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.62162971493598" LOG_CI_START="-0.6216297149359801" LOG_EFFECT_SIZE="0.0" ORDER="67491" O_E="0.0" SE="0.7302967433402214" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.5333333333333333" WEIGHT="1.7450991308748403"/>
<DICH_DATA CI_END="1.5838486749528184" CI_START="0.3447026213787251" EFFECT_SIZE="0.7388888888888889" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.1997136856042464" LOG_CI_START="-0.46255541387668697" LOG_EFFECT_SIZE="-0.13142086413622026" ORDER="67492" O_E="0.0" SE="0.3890201473200142" STUDY_ID="STD-Pinosky-1997" TOTAL_1="20" TOTAL_2="19" VAR="0.15133667502088555" WEIGHT="4.914021742758695"/>
<DICH_DATA CI_END="3.015921170666856" CI_START="0.42515142499811714" EFFECT_SIZE="1.1323529411764706" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.47941998587419293" LOG_CI_START="-0.37145636094170187" LOG_EFFECT_SIZE="0.05398181246624554" ORDER="67493" O_E="0.0" SE="0.4998089780255021" STUDY_ID="STD-Troianos-1999" TOTAL_1="34" TOTAL_2="33" VAR="0.24980901451489687" WEIGHT="3.3471796115206605"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0139201929883943" CI_END="1.0777262812291268" CI_START="0.9256141038261161" DF="3" EFFECT_SIZE="0.9987785770478614" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="108" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.03250847360928532" LOG_CI_START="-0.03357003654637822" LOG_EFFECT_SIZE="-5.307814685464717E-4" MODIFIED="2010-05-20 11:17:05 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.7978837482965883" P_Z="0.9748810258415352" STUDIES="4" TAU2="0.0" TOTAL_1="150" TOTAL_2="154" WEIGHT="29.751112609231654" Z="0.03148716759992397">
<NAME>Orthopaedic Surgery</NAME>
<DICH_DATA CI_END="1.7108869566393983" CI_START="0.5926954508582096" EFFECT_SIZE="1.006993006993007" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.23322131536834406" LOG_CI_START="-0.22716840610796835" LOG_EFFECT_SIZE="0.0030264546301878867" ORDER="67494" O_E="0.0" SE="0.2704352013610619" STUDY_ID="STD-Amar-2003" TOTAL_1="22" TOTAL_2="24" VAR="0.07313519813519812" WEIGHT="7.82171841755939"/>
<DICH_DATA CI_END="1.08025642709969" CI_START="0.9257061332047195" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="85" LOG_CI_END="0.03352685887183662" LOG_CI_START="-0.033526858871836644" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-20 11:17:05 +0100" MODIFIED_BY="Katharine Ker" ORDER="5309" O_E="0.0" SE="0.03938768572388967" STUDY_ID="STD-Berenholtz-2009" TOTAL_1="91" TOTAL_2="91" VAR="0.0015513897866839023" WEIGHT="17.06462759911435"/>
<DICH_DATA CI_END="1.8425052183949786" CI_START="0.21090763309259541" EFFECT_SIZE="0.6233766233766234" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.26540872655384845" LOG_CI_START="-0.6759077021476378" LOG_EFFECT_SIZE="-0.20524948779689467" ORDER="67495" O_E="0.0" SE="0.5529339298107241" STUDY_ID="STD-Harley-2002" TOTAL_1="22" TOTAL_2="24" VAR="0.3057359307359307" WEIGHT="2.8339747508367163"/>
<DICH_DATA CI_END="4.965261095458803" CI_START="0.35804316099383415" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6959420905626427" LOG_CI_START="-0.44606461734604286" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="67496" O_E="0.0" SE="0.6708203932499369" STUDY_ID="STD-Ray-2005" TOTAL_1="15" TOTAL_2="15" VAR="0.44999999999999996" WEIGHT="2.030791841721198"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0784979701866373" CI_START="0.7961659925770292" DF="0" EFFECT_SIZE="0.9266409266409267" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="37" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="0.032819332064829704" LOG_CI_START="-0.09899637680412121" LOG_EFFECT_SIZE="-0.03308852236964579" NO="3" P_CHI2="1.0" P_Z="0.3251231099197195" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="40" WEIGHT="15.89833687292452" Z="0.9839845751712162">
<NAME>Liver Surgery</NAME>
<DICH_DATA CI_END="1.0784979701866373" CI_START="0.7961659925770292" EFFECT_SIZE="0.9266409266409267" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="37" LOG_CI_END="0.032819332064829704" LOG_CI_START="-0.09899637680412121" LOG_EFFECT_SIZE="-0.03308852236964579" ORDER="67497" O_E="0.0" SE="0.07742919988790402" STUDY_ID="STD-Dalmau-2000" TOTAL_1="42" TOTAL_2="40" VAR="0.005995280995280995" WEIGHT="15.89833687292452"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="41.11986010547811" CI_END="0.9910051774639435" CI_START="0.6652558832849169" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8119556790082212" ESTIMABLE="YES" EVENTS_1="238" EVENTS_2="275" I2="63.52127667379477" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-0.0039240765559485115" LOG_CI_START="-0.1770112760146393" LOG_EFFECT_SIZE="-0.09046767628529392" METHOD="MH" MODIFIED="2010-12-07 16:30:04 +0000" MODIFIED_BY="Emma M Sydenham" NO="3" P_CHI2="3.066103208775317E-4" P_Q="0.0" P_Z="0.04047844291833691" Q="0.0" RANDOM="YES" SCALE="13.73403615012859" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.05902568407183264" TOTALS="YES" TOTAL_1="530" TOTAL_2="505" WEIGHT="100.0" Z="2.0488330487607462">
<NAME>No. Exposed to Allogeneic Blood - Transfusion Protocol</NAME>
<GROUP_LABEL_1>EACA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EACA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="42.2856063713524" CI_END="0.983253534201388" CI_START="0.6506672686694074" DF="14" EFFECT_SIZE="0.7998567943753174" ESTIMABLE="YES" EVENTS_1="234" EVENTS_2="272" I2="66.89180739882993" ID="CMP-003.03.01" LOG_CI_END="-0.007334483889583866" LOG_CI_START="-0.18664103957595543" LOG_EFFECT_SIZE="-0.09698776173276967" MODIFIED="2010-05-20 11:17:45 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="1.113668415635427E-4" P_Z="0.033980119216039585" STUDIES="15" TAU2="0.06441149210606678" TOTAL_1="515" TOTAL_2="490" WEIGHT="97.9692081582788" Z="2.120307528185138">
<NAME>Transfusion Protocol</NAME>
<DICH_DATA CI_END="1.7108869566393983" CI_START="0.5926954508582096" EFFECT_SIZE="1.006993006993007" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.23322131536834406" LOG_CI_START="-0.22716840610796835" LOG_EFFECT_SIZE="0.0030264546301878867" ORDER="67498" O_E="0.0" SE="0.2704352013610619" STUDY_ID="STD-Amar-2003" TOTAL_1="22" TOTAL_2="24" VAR="0.07313519813519812" WEIGHT="7.821718417559392"/>
<DICH_DATA CI_END="1.08025642709969" CI_START="0.9257061332047195" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="85" LOG_CI_END="0.03352685887183662" LOG_CI_START="-0.033526858871836644" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-20 11:17:45 +0100" MODIFIED_BY="Katharine Ker" ORDER="5310" O_E="0.0" SE="0.03938768572388967" STUDY_ID="STD-Berenholtz-2009" TOTAL_1="91" TOTAL_2="91" VAR="0.0015513897866839023" WEIGHT="17.06462759911435"/>
<DICH_DATA CI_END="1.4132217192919043" CI_START="0.02316958742237693" EFFECT_SIZE="0.18095238095238095" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.15021030332843316" LOG_CI_START="-1.6350816995626514" LOG_EFFECT_SIZE="-0.7424356981171092" ORDER="67499" O_E="0.0" SE="1.0486893598361642" STUDY_ID="STD-Daily-1994" TOTAL_1="21" TOTAL_2="19" VAR="1.099749373433584" WEIGHT="0.892084447058266"/>
<DICH_DATA CI_END="1.0784979701866373" CI_START="0.7961659925770292" EFFECT_SIZE="0.9266409266409267" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="37" LOG_CI_END="0.032819332064829704" LOG_CI_START="-0.09899637680412121" LOG_EFFECT_SIZE="-0.03308852236964579" ORDER="67500" O_E="0.0" SE="0.07742919988790402" STUDY_ID="STD-Dalmau-2000" TOTAL_1="42" TOTAL_2="40" VAR="0.005995280995280995" WEIGHT="15.898336872924519"/>
<DICH_DATA CI_END="0.9899593643560859" CI_START="0.17654697523569457" EFFECT_SIZE="0.4180602006688963" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="-0.004382631865195394" LOG_CI_START="-0.7531397187675511" LOG_EFFECT_SIZE="-0.3787611753163732" ORDER="67501" O_E="0.0" SE="0.4398236192538001" STUDY_ID="STD-Greilich-2001" TOTAL_1="23" TOTAL_2="25" VAR="0.19344481605351171" WEIGHT="4.094439571856574"/>
<DICH_DATA CI_END="1.4670105707282939" CI_START="0.6190118216819162" EFFECT_SIZE="0.9529411764705882" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.16643324321780747" LOG_CI_START="-0.20830105688909348" LOG_EFFECT_SIZE="-0.02093390683564301" MODIFIED="2010-05-17 14:13:58 +0100" MODIFIED_BY="Katharine Ker" ORDER="2601" O_E="0.0" SE="0.22012078284749564" STUDY_ID="STD-Greilich-2009" TOTAL_1="25" TOTAL_2="27" VAR="0.04845315904139433" WEIGHT="9.617941322187656"/>
<DICH_DATA CI_END="1.1821502906810388" CI_START="0.561623329686121" EFFECT_SIZE="0.8148148148148148" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="27" LOG_CI_END="0.07267269335087015" LOG_CI_START="-0.25055486002443234" LOG_EFFECT_SIZE="-0.0889410833367811" ORDER="67502" O_E="0.0" SE="0.1898654648548464" STUDY_ID="STD-Hardy-1998" TOTAL_1="46" TOTAL_2="44" VAR="0.036048894744546915" WEIGHT="10.872782391559104"/>
<DICH_DATA CI_END="1.8425052183949786" CI_START="0.21090763309259541" EFFECT_SIZE="0.6233766233766234" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.26540872655384845" LOG_CI_START="-0.6759077021476378" LOG_EFFECT_SIZE="-0.20524948779689467" ORDER="67503" O_E="0.0" SE="0.5529339298107241" STUDY_ID="STD-Harley-2002" TOTAL_1="22" TOTAL_2="24" VAR="0.3057359307359307" WEIGHT="2.8339747508367177"/>
<DICH_DATA CI_END="2.880421272405446" CI_START="0.6171936705262393" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.4594560095999913" LOG_CI_START="-0.20957853638339138" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="67504" O_E="0.0" SE="0.3929942040850532" STUDY_ID="STD-Kikura-2006" TOTAL_1="50" TOTAL_2="50" VAR="0.15444444444444444" WEIGHT="4.842481773091771"/>
<DICH_DATA CI_END="1.0409651435105327" CI_START="0.33568677269493497" EFFECT_SIZE="0.5911330049261084" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.017436187498550255" LOG_CI_START="-0.4740657712297263" LOG_EFFECT_SIZE="-0.22831479186558803" ORDER="67505" O_E="0.0" SE="0.28871068353092383" STUDY_ID="STD-Kluger-2003" TOTAL_1="58" TOTAL_2="30" VAR="0.08335385878489326" WEIGHT="7.260349244693459"/>
<DICH_DATA CI_END="1.413322290141931" CI_START="0.18047972103104282" EFFECT_SIZE="0.5050505050505051" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.15024120846564631" LOG_CI_START="-0.7435715889887086" LOG_EFFECT_SIZE="-0.2966651902615311" ORDER="67506" O_E="0.0" SE="0.525030061669392" STUDY_ID="STD-Kreisler-2005" TOTAL_1="22" TOTAL_2="25" VAR="0.27565656565656566" WEIGHT="3.0886765201277324"/>
<DICH_DATA CI_END="0.5598191387831571" CI_START="0.08821191100526277" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="18" LOG_CI_END="-0.2519522581995579" LOG_CI_START="-1.0544727693511295" LOG_EFFECT_SIZE="-0.6532125137753437" ORDER="67507" O_E="0.0" SE="0.4714045207910317" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.22222222222222224" WEIGHT="3.6754947621150738"/>
<DICH_DATA CI_END="4.1843664851249125" CI_START="0.23898480296955818" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.62162971493598" LOG_CI_START="-0.6216297149359801" LOG_EFFECT_SIZE="0.0" ORDER="67508" O_E="0.0" SE="0.7302967433402214" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.5333333333333333" WEIGHT="1.745099130874841"/>
<DICH_DATA CI_END="1.5838486749528184" CI_START="0.3447026213787251" EFFECT_SIZE="0.7388888888888889" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.1997136856042464" LOG_CI_START="-0.46255541387668697" LOG_EFFECT_SIZE="-0.13142086413622026" ORDER="67509" O_E="0.0" SE="0.3890201473200142" STUDY_ID="STD-Pinosky-1997" TOTAL_1="20" TOTAL_2="19" VAR="0.15133667502088555" WEIGHT="4.914021742758696"/>
<DICH_DATA CI_END="3.015921170666856" CI_START="0.42515142499811714" EFFECT_SIZE="1.1323529411764706" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.47941998587419293" LOG_CI_START="-0.37145636094170187" LOG_EFFECT_SIZE="0.05398181246624554" ORDER="67510" O_E="0.0" SE="0.4998089780255021" STUDY_ID="STD-Troianos-1999" TOTAL_1="34" TOTAL_2="33" VAR="0.24980901451489687" WEIGHT="3.347179611520661"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.965261095458803" CI_START="0.35804316099383415" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="0.6959420905626427" LOG_CI_START="-0.44606461734604286" LOG_EFFECT_SIZE="0.12493873660829992" NO="2" P_CHI2="1.0" P_Z="0.6680315801223178" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="2.0307918417211988" Z="0.4288511132734677">
<NAME>No Transfusion Protocol</NAME>
<DICH_DATA CI_END="4.965261095458803" CI_START="0.35804316099383415" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6959420905626427" LOG_CI_START="-0.44606461734604286" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="67511" O_E="0.0" SE="0.6708203932499369" STUDY_ID="STD-Ray-2005" TOTAL_1="15" TOTAL_2="15" VAR="0.44999999999999996" WEIGHT="2.0307918417211988"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="41.119860105478004" CI_END="0.9910051774639433" CI_START="0.6652558832849172" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8119556790082214" ESTIMABLE="YES" EVENTS_1="238" EVENTS_2="275" I2="63.52127667379468" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-0.003924076555948561" LOG_CI_START="-0.1770112760146391" LOG_EFFECT_SIZE="-0.0904676762852938" METHOD="MH" MODIFIED="2010-08-23 06:46:59 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="3.0661032087730966E-4" P_Q="0.0" P_Z="0.04047844291833682" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.059025684071832396" TOTALS="YES" TOTAL_1="530" TOTAL_2="505" WEIGHT="99.99999999999999" Z="2.048833048760747">
<NAME>Trial Methodological Quality - Allocation Concealment</NAME>
<GROUP_LABEL_1>EACA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="14.350241753606845" CI_END="1.156615770548229" CI_START="0.5831221242554427" DF="4" EFFECT_SIZE="0.8212479802528765" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="148" I2="72.12590513330812" ID="CMP-003.04.01" LOG_CI_END="0.06318910964782695" LOG_CI_START="-0.23424048068532569" LOG_EFFECT_SIZE="-0.08552568551874938" MODIFIED="2010-08-23 06:46:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.006257193936395455" P_Z="0.25966947147366803" STUDIES="5" TAU2="0.08972877581897352" TOTAL_1="241" TOTAL_2="211" WEIGHT="45.707785004612845" Z="1.1271727415021984">
<NAME>Allocation concealment - Yes</NAME>
<DICH_DATA CI_END="1.08025642709969" CI_START="0.9257061332047195" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="85" LOG_CI_END="0.03352685887183662" LOG_CI_START="-0.033526858871836644" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-23 06:46:11 +0100" MODIFIED_BY="[Empty name]" ORDER="3001" O_E="0.0" SE="0.03938768572388967" STUDY_ID="STD-Berenholtz-2009" TOTAL_1="91" TOTAL_2="91" VAR="0.0015513897866839023" WEIGHT="17.064627599114377"/>
<DICH_DATA CI_END="1.4132217192919043" CI_START="0.02316958742237693" EFFECT_SIZE="0.18095238095238095" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.15021030332843316" LOG_CI_START="-1.6350816995626514" LOG_EFFECT_SIZE="-0.7424356981171092" MODIFIED="2010-08-23 06:46:11 +0100" MODIFIED_BY="[Empty name]" ORDER="2999" O_E="0.0" SE="1.0486893598361642" STUDY_ID="STD-Daily-1994" TOTAL_1="21" TOTAL_2="19" VAR="1.099749373433584" WEIGHT="0.8920844470582638"/>
<DICH_DATA CI_END="1.4670105707282939" CI_START="0.6190118216819162" EFFECT_SIZE="0.9529411764705882" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.16643324321780747" LOG_CI_START="-0.20830105688909348" LOG_EFFECT_SIZE="-0.02093390683564301" MODIFIED="2010-08-23 06:46:11 +0100" MODIFIED_BY="[Empty name]" ORDER="2997" O_E="0.0" SE="0.22012078284749564" STUDY_ID="STD-Greilich-2009" TOTAL_1="25" TOTAL_2="27" VAR="0.04845315904139433" WEIGHT="9.617941322187653"/>
<DICH_DATA CI_END="1.1821502906810388" CI_START="0.561623329686121" EFFECT_SIZE="0.8148148148148148" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="27" LOG_CI_END="0.07267269335087015" LOG_CI_START="-0.25055486002443234" LOG_EFFECT_SIZE="-0.0889410833367811" MODIFIED="2010-08-23 06:46:11 +0100" MODIFIED_BY="[Empty name]" ORDER="2998" O_E="0.0" SE="0.1898654648548464" STUDY_ID="STD-Hardy-1998" TOTAL_1="46" TOTAL_2="44" VAR="0.036048894744546915" WEIGHT="10.872782391559102"/>
<DICH_DATA CI_END="1.0409651435105327" CI_START="0.33568677269493497" EFFECT_SIZE="0.5911330049261084" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.017436187498550255" LOG_CI_START="-0.4740657712297263" LOG_EFFECT_SIZE="-0.22831479186558803" MODIFIED="2010-08-23 06:46:11 +0100" MODIFIED_BY="[Empty name]" ORDER="3000" O_E="0.0" SE="0.28871068353092383" STUDY_ID="STD-Kluger-2003" TOTAL_1="58" TOTAL_2="30" VAR="0.08335385878489326" WEIGHT="7.260349244693453"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.54226401326107" CI_END="1.02825367728724" CI_START="0.45504008137425767" DF="8" EFFECT_SIZE="0.6840297047542346" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="77" I2="36.21566256665053" ID="CMP-003.04.02" LOG_CI_END="0.01210027132753023" LOG_CI_START="-0.34195034762199195" LOG_EFFECT_SIZE="-0.1649250381472308" MODIFIED="2010-08-23 06:46:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.12859957926181398" P_Z="0.06785118097125237" STUDIES="9" TAU2="0.13781568715094147" TOTAL_1="225" TOTAL_2="230" WEIGHT="30.572159704903214" Z="1.8259938981411756">
<NAME>Allocation concealment - Unclear</NAME>
<DICH_DATA CI_END="0.9899593643560859" CI_START="0.17654697523569457" EFFECT_SIZE="0.4180602006688963" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="-0.004382631865195394" LOG_CI_START="-0.7531397187675511" LOG_EFFECT_SIZE="-0.3787611753163732" MODIFIED="2010-08-23 06:46:42 +0100" MODIFIED_BY="[Empty name]" ORDER="3008" O_E="0.0" SE="0.4398236192538001" STUDY_ID="STD-Greilich-2001" TOTAL_1="23" TOTAL_2="25" VAR="0.19344481605351171" WEIGHT="4.094439571856566"/>
<DICH_DATA CI_END="1.8425052183949786" CI_START="0.21090763309259541" EFFECT_SIZE="0.6233766233766234" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.26540872655384845" LOG_CI_START="-0.6759077021476378" LOG_EFFECT_SIZE="-0.20524948779689467" MODIFIED="2010-08-23 06:46:42 +0100" MODIFIED_BY="[Empty name]" ORDER="3010" O_E="0.0" SE="0.5529339298107241" STUDY_ID="STD-Harley-2002" TOTAL_1="22" TOTAL_2="24" VAR="0.3057359307359307" WEIGHT="2.8339747508367124"/>
<DICH_DATA CI_END="2.880421272405446" CI_START="0.6171936705262393" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.4594560095999913" LOG_CI_START="-0.20957853638339138" LOG_EFFECT_SIZE="0.12493873660829992" MODIFIED="2010-08-23 06:46:42 +0100" MODIFIED_BY="[Empty name]" ORDER="3005" O_E="0.0" SE="0.3929942040850532" STUDY_ID="STD-Kikura-2006" TOTAL_1="50" TOTAL_2="50" VAR="0.15444444444444444" WEIGHT="4.842481773091765"/>
<DICH_DATA CI_END="1.413322290141931" CI_START="0.18047972103104282" EFFECT_SIZE="0.5050505050505051" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.15024120846564631" LOG_CI_START="-0.7435715889887086" LOG_EFFECT_SIZE="-0.2966651902615311" MODIFIED="2010-08-23 06:46:42 +0100" MODIFIED_BY="[Empty name]" ORDER="3003" O_E="0.0" SE="0.525030061669392" STUDY_ID="STD-Kreisler-2005" TOTAL_1="22" TOTAL_2="25" VAR="0.27565656565656566" WEIGHT="3.088676520127726"/>
<DICH_DATA CI_END="0.5598191387831571" CI_START="0.08821191100526277" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="18" LOG_CI_END="-0.2519522581995579" LOG_CI_START="-1.0544727693511295" LOG_EFFECT_SIZE="-0.6532125137753437" MODIFIED="2010-08-23 06:46:42 +0100" MODIFIED_BY="[Empty name]" ORDER="3009" O_E="0.0" SE="0.4714045207910317" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.22222222222222224" WEIGHT="3.675494762115068"/>
<DICH_DATA CI_END="4.1843664851249125" CI_START="0.23898480296955818" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.62162971493598" LOG_CI_START="-0.6216297149359801" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-23 06:46:42 +0100" MODIFIED_BY="[Empty name]" ORDER="3006" O_E="0.0" SE="0.7302967433402214" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.5333333333333333" WEIGHT="1.7450991308748371"/>
<DICH_DATA CI_END="1.5838486749528184" CI_START="0.3447026213787251" EFFECT_SIZE="0.7388888888888889" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.1997136856042464" LOG_CI_START="-0.46255541387668697" LOG_EFFECT_SIZE="-0.13142086413622026" MODIFIED="2010-08-23 06:46:42 +0100" MODIFIED_BY="[Empty name]" ORDER="3004" O_E="0.0" SE="0.3890201473200142" STUDY_ID="STD-Pinosky-1997" TOTAL_1="20" TOTAL_2="19" VAR="0.15133667502088555" WEIGHT="4.91402174275869"/>
<DICH_DATA CI_END="4.965261095458803" CI_START="0.35804316099383415" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6959420905626427" LOG_CI_START="-0.44606461734604286" LOG_EFFECT_SIZE="0.12493873660829992" MODIFIED="2010-08-23 06:46:42 +0100" MODIFIED_BY="[Empty name]" ORDER="3007" O_E="0.0" SE="0.6708203932499369" STUDY_ID="STD-Ray-2005" TOTAL_1="15" TOTAL_2="15" VAR="0.44999999999999996" WEIGHT="2.0307918417211943"/>
<DICH_DATA CI_END="3.015921170666856" CI_START="0.42515142499811714" EFFECT_SIZE="1.1323529411764706" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.47941998587419293" LOG_CI_START="-0.37145636094170187" LOG_EFFECT_SIZE="0.05398181246624554" MODIFIED="2010-08-23 06:46:42 +0100" MODIFIED_BY="[Empty name]" ORDER="3002" O_E="0.0" SE="0.4998089780255021" STUDY_ID="STD-Troianos-1999" TOTAL_1="34" TOTAL_2="33" VAR="0.24980901451489687" WEIGHT="3.347179611520655"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1274249855898371" CI_END="1.0789707098019694" CI_START="0.8059085552828628" DF="1" EFFECT_SIZE="0.9324975742215259" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="50" I2="0.0" ID="CMP-003.04.03" LOG_CI_END="0.033009655300115494" LOG_CI_START="-0.09371423386376086" LOG_EFFECT_SIZE="-0.03035228928182266" MODIFIED="2010-08-23 06:46:59 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.721117061506384" P_Z="0.3477913059083588" STUDIES="2" TAU2="0.0" TOTAL_1="64" TOTAL_2="64" WEIGHT="23.720055290483927" Z="0.9388820724051999">
<NAME>Allocation concealment - No</NAME>
<DICH_DATA CI_END="1.7108869566393983" CI_START="0.5926954508582096" EFFECT_SIZE="1.006993006993007" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.23322131536834406" LOG_CI_START="-0.22716840610796835" LOG_EFFECT_SIZE="0.0030264546301878867" MODIFIED="2010-08-23 06:46:59 +0100" MODIFIED_BY="[Empty name]" ORDER="3012" O_E="0.0" SE="0.2704352013610619" STUDY_ID="STD-Amar-2003" TOTAL_1="22" TOTAL_2="24" VAR="0.07313519813519812" WEIGHT="7.821718417559387"/>
<DICH_DATA CI_END="1.0784979701866373" CI_START="0.7961659925770292" EFFECT_SIZE="0.9266409266409267" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="37" LOG_CI_END="0.032819332064829704" LOG_CI_START="-0.09899637680412121" LOG_EFFECT_SIZE="-0.03308852236964579" MODIFIED="2010-08-23 06:46:59 +0100" MODIFIED_BY="[Empty name]" ORDER="3011" O_E="0.0" SE="0.07742919988790402" STUDY_ID="STD-Dalmau-2000" TOTAL_1="42" TOTAL_2="40" VAR="0.005995280995280995" WEIGHT="15.89833687292454"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.5552192282430778" CI_END="0.7908818062794352" CI_START="-0.34385626231058963" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.22351277198442274" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" NO="5" P_CHI2="0.7575925369976402" P_Q="1.0" P_Z="0.44004335964591135" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="59" UNITS="" WEIGHT="100.0" Z="0.7721200077803274">
<NAME>Units of Allogeneic Blood Transfused - Transfused Patients</NAME>
<GROUP_LABEL_1>EACA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EACA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.8502640808763706" CI_START="-2.25026408087637" EFFECT_SIZE="-0.19999999999999973" ESTIMABLE="YES" MEAN_1="3.12" MEAN_2="3.32" ORDER="67527" SD_1="2.67" SD_2="2.55" SE="1.046072324312381" STUDY_ID="STD-Amar-2003" TOTAL_1="12" TOTAL_2="13" WEIGHT="7.657934583205176"/>
<CONT_DATA CI_END="2.137743192159092" CI_START="-3.2777431921590945" EFFECT_SIZE="-0.5700000000000012" ESTIMABLE="YES" MEAN_1="7.81" MEAN_2="8.38" ORDER="67526" SD_1="5.67" SD_2="6.13" SE="1.3815270145356884" STUDY_ID="STD-Dalmau-2000" TOTAL_1="36" TOTAL_2="37" WEIGHT="4.390523574661096"/>
<CONT_DATA CI_END="0.9049840162025601" CI_START="-0.30498401620255955" EFFECT_SIZE="0.30000000000000027" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="1.9" ORDER="67528" SD_1="0.7" SD_2="0.7" SE="0.30867098629086887" STUDY_ID="STD-Kikura-2006" TOTAL_1="12" TOTAL_2="9" WEIGHT="87.95154184213374"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="23.44839697317505" CI_END="-0.45200986060861337" CI_START="-2.138271791936817" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.2951408262727153" ESTIMABLE="YES" I2="78.67658072438812" I2_Q="0.0" ID="CMP-003.06" MODIFIED="2010-05-20 11:19:28 +0100" MODIFIED_BY="Katharine Ker" NO="6" P_CHI2="2.7703646936583226E-4" P_Q="1.0" P_Z="0.002606309868541313" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.7342078306851201" TOTALS="YES" TOTAL_1="215" TOTAL_2="217" UNITS="" WEIGHT="100.0" Z="3.010717762456448">
<NAME>Units of Allogeneic Blood Transfused - All Patients</NAME>
<GROUP_LABEL_1>EACA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EACA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3462722530107236" CI_START="-1.5462722530107238" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="1.8" ORDER="67532" SD_1="2.5" SD_2="2.5" SE="0.737907565862809" STUDY_ID="STD-Amar-2003" TOTAL_1="22" TOTAL_2="24" WEIGHT="14.471714964614574"/>
<CONT_DATA CI_END="0.4708701340414452" CI_START="-2.470870134041445" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="5.9" MEAN_2="6.9" MODIFIED="2010-05-20 11:19:28 +0100" MODIFIED_BY="Katharine Ker" ORDER="5312" SD_1="4.7" SD_2="5.4" SE="0.7504577357765148" STUDY_ID="STD-Berenholtz-2009" TOTAL_1="91" TOTAL_2="91" WEIGHT="14.26335847022861"/>
<CONT_DATA CI_END="1.5889898255956618" CI_START="-3.708989825595661" EFFECT_SIZE="-1.0599999999999996" ESTIMABLE="YES" MEAN_1="6.69" MEAN_2="7.75" ORDER="67530" SD_1="5.92" SD_2="6.3" SE="1.3515502562753985" STUDY_ID="STD-Dalmau-2000" TOTAL_1="42" TOTAL_2="40" WEIGHT="7.226066743117942"/>
<CONT_DATA CI_END="0.9329366261466201" CI_START="-1.1329366261466203" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="1.8" MODIFIED="2010-05-17 14:14:54 +0100" MODIFIED_BY="Katharine Ker" ORDER="2603" SD_1="1.8" SD_2="2.0" SE="0.527018166810356" STUDY_ID="STD-Greilich-2009" TOTAL_1="25" TOTAL_2="27" WEIGHT="18.286571026770844"/>
<CONT_DATA CI_END="-1.8865623406758156" CI_START="-3.3134376593241854" EFFECT_SIZE="-2.6000000000000005" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="9.4" ORDER="67529" SD_1="1.2" SD_2="1.1" SE="0.3640054944640259" STUDY_ID="STD-Liu-1998" TOTAL_1="20" TOTAL_2="20" WEIGHT="21.35114536610552"/>
<CONT_DATA CI_END="-1.6953112164298767" CI_START="-2.304688783570123" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="3.2" ORDER="67531" SD_1="0.4" SD_2="0.45" SE="0.15545631755148026" STUDY_ID="STD-Rao-1999" TOTAL_1="15" TOTAL_2="15" WEIGHT="24.401143429162506"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.012345560251536" CI_END="-36.33195854630878" CI_START="-276.9246596296229" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-156.62830908796585" ESTIMABLE="YES" I2="20.197042444151293" I2_Q="64.16564597096975" ID="CMP-003.07" MODIFIED="2010-05-20 11:21:17 +0100" MODIFIED_BY="Katharine Ker" NO="7" P_CHI2="0.2860331790780274" P_Q="0.09481773702826057" P_Z="0.01071332055176887" Q="2.7906181849681913" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="4186.530827262523" TOTALS="YES" TOTAL_1="175" TOTAL_2="178" UNITS="" WEIGHT="100.0" Z="2.551913199274616">
<NAME>Blood loss - Intra-operative</NAME>
<GROUP_LABEL_1>EACA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EACA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.11862957947216556" CI_END="-117.12533911209903" CI_START="-310.02912548658287" DF="1" EFFECT_SIZE="-213.57723229934095" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.01" NO="1" P_CHI2="0.7305256549638053" P_Z="1.4246613394315888E-5" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="39" WEIGHT="65.26588037229487" Z="4.340025575359297">
<NAME>Cardiac surgery</NAME>
<CONT_DATA CI_END="-108.84315711533704" CI_START="-308.95684288466316" EFFECT_SIZE="-208.9000000000001" ESTIMABLE="YES" MEAN_1="1235.0" MEAN_2="1443.9" ORDER="67534" SD_1="207.6" SD_2="95.0" SE="51.0503476971509" STUDY_ID="STD-Liu-1998" TOTAL_1="20" TOTAL_2="20" WEIGHT="55.45852071272164"/>
<CONT_DATA CI_END="87.59099674577539" CI_START="-637.5909967457753" EFFECT_SIZE="-275.0" ESTIMABLE="YES" MEAN_1="1196.0" MEAN_2="1471.0" ORDER="67533" SD_1="451.7" SD_2="675.6" SE="184.998805899418" STUDY_ID="STD-Pinosky-1997" TOTAL_1="20" TOTAL_2="19" WEIGHT="9.807359659573226"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.1030977958111787" CI_END="155.3835927205077" CI_START="-236.70915836435285" DF="2" EFFECT_SIZE="-40.66278282192256" ESTIMABLE="YES" I2="4.902187431156202" ID="CMP-003.07.02" MODIFIED="2010-05-20 11:21:17 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.3493963266441956" P_Z="0.6843575034661437" STUDIES="3" TAU2="2904.59623580665" TOTAL_1="135" TOTAL_2="139" WEIGHT="34.73411962770512" Z="0.40652416869034785">
<NAME>Orthopaedic surgery</NAME>
<CONT_DATA CI_END="883.8916597594143" CI_START="-283.8916597594143" EFFECT_SIZE="300.0" ESTIMABLE="YES" MEAN_1="1300.0" MEAN_2="1000.0" ORDER="67536" SD_1="1100.0" SD_2="900.0" SE="297.9093821953246" STUDY_ID="STD-Amar-2003" TOTAL_1="22" TOTAL_2="24" WEIGHT="4.053426155443395"/>
<CONT_DATA CI_END="320.45460092833605" CI_START="-990.454600928336" EFFECT_SIZE="-335.0" ESTIMABLE="YES" MEAN_1="2938.0" MEAN_2="3273.0" MODIFIED="2010-05-20 11:21:17 +0100" MODIFIED_BY="Katharine Ker" ORDER="5314" SD_1="2315.0" SD_2="2195.0" SE="334.42175779681577" STUDY_ID="STD-Berenholtz-2009" TOTAL_1="91" TOTAL_2="91" WEIGHT="3.2468276113750503"/>
<CONT_DATA CI_END="136.48644629861982" CI_START="-246.48644629861982" EFFECT_SIZE="-55.0" ESTIMABLE="YES" MEAN_1="552.0" MEAN_2="607.0" ORDER="67535" SD_1="331.0" SD_2="331.0" SE="97.69896172023591" STUDY_ID="STD-Harley-2002" TOTAL_1="22" TOTAL_2="24" WEIGHT="27.433865860886673"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="97.4616368950886" CI_END="-138.54445679675405" CI_START="-276.42686661662515" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="MD" EFFECT_SIZE="-207.4856617066896" ESTIMABLE="YES" I2="86.6614183650602" I2_Q="0.0" ID="CMP-003.08" MODIFIED="2010-05-20 11:20:26 +0100" MODIFIED_BY="Katharine Ker" NO="8" P_CHI2="5.88418203051333E-15" P_Q="0.7529335538848638" P_Z="3.6634644968008606E-9" Q="0.0990824428031516" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="9763.54153224781" TOTALS="YES" TOTAL_1="580" TOTAL_2="594" UNITS="" WEIGHT="100.0" Z="5.8987136181451625">
<NAME>Blood loss - Post-operative</NAME>
<GROUP_LABEL_1>EACA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EACA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="97.18308111259284" CI_END="-127.09353525932457" CI_START="-273.4381881376016" DF="11" EFFECT_SIZE="-200.26586169846308" ESTIMABLE="YES" I2="88.6811573845289" ID="CMP-003.08.01" MODIFIED="2010-05-17 14:15:21 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="1.4432899320127035E-15" P_Z="8.129103064558307E-8" STUDIES="12" TAU2="10265.781054494113" TOTAL_1="467" TOTAL_2="479" WEIGHT="92.02337581262917" Z="5.364239397094237">
<NAME>Cardiac surgery</NAME>
<CONT_DATA CI_END="0.8218237594371658" CI_START="-444.82182375943717" EFFECT_SIZE="-222.0" ESTIMABLE="YES" MEAN_1="623.0" MEAN_2="845.0" ORDER="67545" SD_1="380.0" SD_2="339.0" SE="113.68669297855841" STUDY_ID="STD-Daily-1994" TOTAL_1="21" TOTAL_2="19" WEIGHT="5.453325314559987"/>
<CONT_DATA CI_END="-258.1342373591987" CI_START="-273.8657626408013" EFFECT_SIZE="-266.0" ESTIMABLE="YES" MEAN_1="617.2" MEAN_2="883.2" ORDER="67546" SD_1="43.9" SD_2="29.3" SE="4.013217948312001" STUDY_ID="STD-Del-Rossi-1989" TOTAL_1="170" TOTAL_2="180" WEIGHT="12.651393321824397"/>
<CONT_DATA CI_END="-4.535437664915264" CI_START="-569.4645623350848" EFFECT_SIZE="-287.0" ESTIMABLE="YES" MEAN_1="715.0" MEAN_2="1002.0" MODIFIED="2010-05-17 14:15:21 +0100" MODIFIED_BY="Katharine Ker" ORDER="2604" SD_1="394.0" SD_2="627.0" SE="144.11722080769297" STUDY_ID="STD-Greilich-2009" TOTAL_1="25" TOTAL_2="27" WEIGHT="4.0521694742399825"/>
<CONT_DATA CI_END="-101.75160659144177" CI_START="-478.24839340855823" EFFECT_SIZE="-290.0" ESTIMABLE="YES" MEAN_1="650.0" MEAN_2="940.0" ORDER="67542" SD_1="261.0" SD_2="627.0" SE="96.04686356149273" STUDY_ID="STD-Kikura-2006" TOTAL_1="50" TOTAL_2="50" WEIGHT="6.515833047816994"/>
<CONT_DATA CI_END="53.89960866807509" CI_START="-83.89960866807509" EFFECT_SIZE="-15.0" ESTIMABLE="YES" MEAN_1="269.0" MEAN_2="284.0" ORDER="67541" SD_1="113.0" SD_2="128.0" SE="35.15350751929444" STUDY_ID="STD-Kreisler-2005" TOTAL_1="22" TOTAL_2="25" WEIGHT="11.248538266133199"/>
<CONT_DATA CI_END="-233.61331281027003" CI_START="-388.5866871897298" EFFECT_SIZE="-311.0999999999999" ESTIMABLE="YES" MEAN_1="987.2" MEAN_2="1298.3" ORDER="67539" SD_1="103.7" SD_2="143.2" SE="39.53475053671137" STUDY_ID="STD-Liu-1998" TOTAL_1="20" TOTAL_2="20" WEIGHT="10.923564295939748"/>
<CONT_DATA CI_END="-38.95061753075396" CI_START="-559.049382469246" EFFECT_SIZE="-299.0" ESTIMABLE="YES" MEAN_1="512.0" MEAN_2="811.0" ORDER="67543" SD_1="250.0" SD_2="600.0" SE="132.6806944007555" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" WEIGHT="4.520881527470149"/>
<CONT_DATA CI_END="-54.72654918319469" CI_START="-375.2734508168053" EFFECT_SIZE="-215.0" ESTIMABLE="YES" MEAN_1="509.0" MEAN_2="724.0" ORDER="67544" SD_1="148.0" SD_2="280.0" SE="81.77367139448573" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" WEIGHT="7.521130390256061"/>
<CONT_DATA CI_END="283.2176488557172" CI_START="-481.2176488557172" EFFECT_SIZE="-99.0" ESTIMABLE="YES" MEAN_1="961.0" MEAN_2="1060.0" ORDER="67538" SD_1="661.9" SD_2="553.5" SE="195.01258792028895" STUDY_ID="STD-Pinosky-1997" TOTAL_1="20" TOTAL_2="19" WEIGHT="2.58876820797968"/>
<CONT_DATA CI_END="-79.73861318720594" CI_START="-164.26138681279406" EFFECT_SIZE="-122.0" ESTIMABLE="YES" MEAN_1="372.0" MEAN_2="494.0" ORDER="67540" SD_1="55.5" SD_2="62.4" SE="21.562328260185634" STUDY_ID="STD-Rao-1999" TOTAL_1="15" TOTAL_2="15" WEIGHT="12.096246997471749"/>
<CONT_DATA CI_END="-35.17758694647307" CI_START="-288.82241305352693" EFFECT_SIZE="-162.0" ESTIMABLE="YES" MEAN_1="529.0" MEAN_2="691.0" ORDER="67537" SD_1="241.0" SD_2="286.0" SE="64.70650177956632" STUDY_ID="STD-Troianos-1999" TOTAL_1="34" TOTAL_2="33" WEIGHT="8.868958585850013"/>
<CONT_DATA CI_END="26.24718896014093" CI_START="-410.24718896014093" EFFECT_SIZE="-192.0" ESTIMABLE="YES" MEAN_1="647.0" MEAN_2="839.0" ORDER="67547" SD_1="488.0" SD_2="634.0" SE="111.35265274344167" STUDY_ID="STD-Vander_x002d_Salm-1996" TOTAL_1="51" TOTAL_2="52" WEIGHT="5.582566383087201"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.17947333969260862" CI_END="-117.39310376070475" CI_START="-452.73101957071685" DF="1" EFFECT_SIZE="-285.0620616657108" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.02" MODIFIED="2010-05-20 11:20:26 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.6718262408510777" P_Z="8.615331332181133E-4" STUDIES="2" TAU2="0.0" TOTAL_1="113" TOTAL_2="115" WEIGHT="7.976624187370834" Z="3.332229061386967">
<NAME>Orthopaedic surgery</NAME>
<CONT_DATA CI_END="261.19329881247745" CI_START="-1121.1932988124775" EFFECT_SIZE="-430.0" ESTIMABLE="YES" MEAN_1="3265.0" MEAN_2="3695.0" MODIFIED="2010-05-20 11:20:26 +0100" MODIFIED_BY="Katharine Ker" ORDER="5313" SD_1="2416.0" SD_2="2341.0" SE="352.6561223902694" STUDY_ID="STD-Berenholtz-2009" TOTAL_1="91" TOTAL_2="91" WEIGHT="0.9224355111930821"/>
<CONT_DATA CI_END="-103.16886348084651" CI_START="-448.83113651915346" EFFECT_SIZE="-276.0" ESTIMABLE="YES" MEAN_1="315.0" MEAN_2="591.0" ORDER="67548" SD_1="207.0" SD_2="374.0" SE="88.1807716276541" STUDY_ID="STD-Harley-2002" TOTAL_1="22" TOTAL_2="24" WEIGHT="7.054188676177752"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.7258338401571272" CI_END="-76.84157293428217" CI_START="-522.5378318278974" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-299.68970238108983" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.09" NO="9" P_CHI2="0.3942369712247705" P_Q="1.0" P_Z="0.008394149444073446" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="48" UNITS="" WEIGHT="100.0" Z="2.635790682482115">
<NAME>Blood loss - Total</NAME>
<GROUP_LABEL_1>EACA</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours EACA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.7258338401571272" CI_END="-76.84157293428217" CI_START="-522.5378318278974" DF="1" EFFECT_SIZE="-299.68970238108983" ESTIMABLE="YES" I2="0.0" ID="CMP-003.09.01" NO="1" P_CHI2="0.3942369712247705" P_Z="0.008394149444073446" STUDIES="2" TAU2="0.0" TOTAL_1="44" TOTAL_2="48" WEIGHT="100.0" Z="2.635790682482115">
<NAME>Orthopaedic surgery</NAME>
<CONT_DATA CI_END="724.5684040596378" CI_START="-724.5684040596378" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1600.0" MEAN_2="1600.0" ORDER="67550" SD_1="1100.0" SD_2="1400.0" SE="369.68455021364724" STUDY_ID="STD-Amar-2003" TOTAL_1="22" TOTAL_2="24" WEIGHT="9.459304416589182"/>
<CONT_DATA CI_END="-96.7998980955264" CI_START="-565.2001019044736" EFFECT_SIZE="-331.0" ESTIMABLE="YES" MEAN_1="867.0" MEAN_2="1198.0" ORDER="67549" SD_1="207.0" SD_2="544.0" SE="119.4920436047877" STUDY_ID="STD-Harley-2002" TOTAL_1="22" TOTAL_2="24" WEIGHT="90.54069558341082"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2011-02-16 14:09:32 +0000" MODIFIED_BY="Emma M Sydenham" NO="4">
<NAME>Aprotinin versus Tranexamic Acid (Blood Transfusion &amp; Blood Loss)</NAME>
<DICH_OUTCOME CHI2="60.778881512077746" CI_END="1.0098100865752093" CI_START="0.8086184662656645" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="RR" EFFECT_SIZE="0.903632161571313" ESTIMABLE="YES" EVENTS_1="942" EVENTS_2="1053" I2="67.09383341313105" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.004239704369050479" LOG_CI_START="-0.09225634498885771" LOG_EFFECT_SIZE="-0.04400832030990364" METHOD="MH" MODIFIED="2011-02-16 13:26:13 +0000" MODIFIED_BY="Emma M Sydenham" NO="1" P_CHI2="5.392026053541166E-6" P_Q="0.0" P_Z="0.07381863686616318" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="21" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.024080766447065992" TOTALS="YES" TOTAL_1="2124" TOTAL_2="2061" WEIGHT="100.00000000000003" Z="1.7877358379220487">
<NAME>No. Exposed to Allogeneic Blood</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>TXA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0571879058568519" CI_START="0.01930419668276973" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.024152186194750208" LOG_CI_START="-1.714348266223264" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="67560" O_E="0.0" SE="1.0212037714663722" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="1.0428571428571427" WEIGHT="0.3011307628066008"/>
<DICH_DATA CI_END="0.9942864949565421" CI_START="0.60582269873457" EFFECT_SIZE="0.7761194029850746" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="67" LOG_CI_END="-0.0024884594142842056" LOG_CI_START="-0.21765445871777034" LOG_EFFECT_SIZE="-0.11007145906602726" MODIFIED="2010-05-17 11:08:24 +0100" MODIFIED_BY="Katharine Ker" ORDER="2567" O_E="0.0" SE="0.12638957307974186" STUDY_ID="STD-Dietrich-2008" TOTAL_1="110" TOTAL_2="110" VAR="0.01597432418327941" WEIGHT="8.021148409352275"/>
<DICH_DATA CI_END="3.3417930664224986" CI_START="0.04048385845900427" EFFECT_SIZE="0.367816091954023" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5239795536084553" LOG_CI_START="-1.3927181022058803" LOG_EFFECT_SIZE="-0.4343692742987125" ORDER="67561" O_E="0.0" SE="1.1258776908317545" STUDY_ID="STD-Vanek-2005" TOTAL_1="29" TOTAL_2="32" VAR="1.2676005747126435" WEIGHT="0.24873613658272292"/>
<DICH_DATA CI_END="0.8879606346925294" CI_START="0.7525329912490775" EFFECT_SIZE="0.8174470457079153" ESTIMABLE="YES" EVENTS_1="419" EVENTS_2="506" LOG_CI_END="-0.05160628705333877" LOG_CI_START="-0.12347445572966592" LOG_EFFECT_SIZE="-0.08754037139150234" MODIFIED="2010-01-11 12:46:47 +0000" MODIFIED_BY="Katharine Ker" ORDER="2275" O_E="0.0" SE="0.042215718033647036" STUDY_ID="STD-Fergusson-2008" TOTAL_1="780" TOTAL_2="770" VAR="0.0017821668490963917" WEIGHT="12.422714114323984"/>
<DICH_DATA CI_END="1.0198361669523746" CI_START="0.33929053749849375" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" LOG_CI_END="0.00853040950370991" LOG_CI_START="-0.46942825226025775" LOG_EFFECT_SIZE="-0.2304489213782739" MODIFIED="2011-02-16 13:26:13 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="2447" O_E="0.0" SE="0.2807552838536876" STUDY_ID="STD-Mengistu-2008" TOTAL_1="25" TOTAL_2="25" VAR="0.07882352941176468" WEIGHT="3.122200330069943"/>
<DICH_DATA CI_END="1.435243954367492" CI_START="0.14690857630106668" EFFECT_SIZE="0.45918367346938777" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.15692572617866216" LOG_CI_START="-0.8329528500129644" LOG_EFFECT_SIZE="-0.33801356191715115" ORDER="67551" O_E="0.0" SE="0.5814595756329395" STUDY_ID="STD-Blauhut-1994" TOTAL_1="14" TOTAL_2="15" VAR="0.3380952380952381" WEIGHT="0.8871041219367366"/>
<DICH_DATA CI_END="1.1197841224249232" CI_START="0.3738980690319062" EFFECT_SIZE="0.6470588235294118" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="0.04913430528065808" LOG_CI_START="-0.42724677772075587" LOG_EFFECT_SIZE="-0.18905623622004886" ORDER="67559" O_E="0.0" SE="0.27982860627942274" STUDY_ID="STD-Bernet-1999" TOTAL_1="28" TOTAL_2="28" VAR="0.07830404889228418" WEIGHT="3.138041763626385"/>
<DICH_DATA CI_END="0.666406359652897" CI_START="0.041682942209984405" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.1762608670199649" LOG_CI_START="-1.3800416337473222" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="67554" O_E="0.0" SE="0.7071067811865476" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.5000000000000001" WEIGHT="0.6130502149013844"/>
<DICH_DATA CI_END="179.29256051754408" CI_START="0.6748746275401646" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2535622695219755" LOG_CI_START="-0.17077689920552552" LOG_EFFECT_SIZE="1.041392685158225" ORDER="67567" O_E="0.0" SE="1.424068828382964" STUDY_ID="STD-Engel-2001" TOTAL_1="12" TOTAL_2="12" VAR="2.0279720279720275" WEIGHT="0.15656898661177387"/>
<DICH_DATA CI_END="1.6825402105470073" CI_START="0.7803284697433366" EFFECT_SIZE="1.1458333333333333" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="24" LOG_CI_END="0.22596545209958277" LOG_CI_START="-0.10772254786226959" LOG_EFFECT_SIZE="0.05912145211865659" ORDER="67553" O_E="0.0" SE="0.19600998295983146" STUDY_ID="STD-Isetta-1993" TOTAL_1="140" TOTAL_2="70" VAR="0.038419913419913417" WEIGHT="5.140549305701236"/>
<DICH_DATA CI_END="1.0779225045907352" CI_START="0.9277104761623649" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="27" LOG_CI_END="0.032587539108232075" LOG_CI_START="-0.032587539108232096" LOG_EFFECT_SIZE="0.0" ORDER="67565" O_E="0.0" SE="0.0382841635661914" STUDY_ID="STD-Ickx-2006" TOTAL_1="24" TOTAL_2="27" VAR="0.0014656771799628973" WEIGHT="12.576616580639202"/>
<DICH_DATA CI_END="1.6923197685338265" CI_START="0.5372153021082148" EFFECT_SIZE="0.9534883720930233" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.22848242760880472" LOG_CI_START="-0.2698516253285067" LOG_EFFECT_SIZE="-0.02068459885985102" ORDER="67552" O_E="0.0" SE="0.2927238894887227" STUDY_ID="STD-Corbeau-1995" TOTAL_1="43" TOTAL_2="41" VAR="0.08568727547740593" WEIGHT="2.926970554117424"/>
<DICH_DATA CI_END="2.048506537591385" CI_START="0.6656079177641339" EFFECT_SIZE="1.1676909569798068" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.3114373542961579" LOG_CI_START="-0.176781520520187" LOG_EFFECT_SIZE="0.06732791688798542" ORDER="67558" O_E="0.0" SE="0.28678218378952774" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="70" VAR="0.08224402093909047" WEIGHT="3.021758466623447"/>
<DICH_DATA CI_END="1.2365301946437357" CI_START="0.8871155928252136" EFFECT_SIZE="1.0473515248796148" ESTIMABLE="YES" EVENTS_1="185" EVENTS_2="178" LOG_CI_END="0.09220472579804354" LOG_CI_START="-0.05201978709574561" LOG_EFFECT_SIZE="0.02009246935114897" ORDER="67566" O_E="0.0" SE="0.08471819279666457" STUDY_ID="STD-Casati-2000" TOTAL_1="518" TOTAL_2="522" VAR="0.007177172190732827" WEIGHT="10.278599309409907"/>
<DICH_DATA CI_END="1.2732251164306965" CI_START="0.6692225867377" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.10490519719658377" LOG_CI_START="-0.1744294097150076" LOG_EFFECT_SIZE="-0.03476210625921192" ORDER="67557" O_E="0.0" SE="0.16408253082847335" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.02692307692307691" WEIGHT="6.2992865883541365"/>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67555" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="0.1252219226060566"/>
<DICH_DATA CI_END="1.0921635201498592" CI_START="0.9156138083267851" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.03828766637439782" LOG_CI_START="-0.03828766637439781" LOG_EFFECT_SIZE="0.0" ORDER="67556" O_E="0.0" SE="0.04498072951065294" STUDY_ID="STD-Pugh-1995" TOTAL_1="21" TOTAL_2="22" VAR="0.0020232660273105246" WEIGHT="12.307976815897291"/>
<DICH_DATA CI_END="1.1284556431965513" CI_START="0.6683072827900095" EFFECT_SIZE="0.868421052631579" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="57" LOG_CI_END="0.05248449270613696" LOG_CI_START="-0.17502380618398225" LOG_EFFECT_SIZE="-0.06126965673892266" MODIFIED="2010-05-06 16:44:23 +0100" MODIFIED_BY="Katharine Ker" ORDER="2399" O_E="0.0" SE="0.1336395009522984" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="99" VAR="0.017859516214779367" WEIGHT="7.660602316072221"/>
<DICH_DATA CI_END="1.4091078666036987" CI_START="0.8114978976663392" EFFECT_SIZE="1.0693400167084377" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="38" LOG_CI_END="0.14894423943845972" LOG_CI_START="-0.09071260095554438" LOG_EFFECT_SIZE="0.029115819241457678" ORDER="67562" O_E="0.0" SE="0.1407756143679307" STUDY_ID="STD-Dalmau-2004" TOTAL_1="63" TOTAL_2="64" VAR="0.01981777360066834" WEIGHT="7.318872703891627"/>
<DICH_DATA CI_END="5.1801150354072085" CI_START="0.9343421848583578" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.714339404279566" LOG_CI_START="-0.02949404263515343" LOG_EFFECT_SIZE="0.3424226808222063" MODIFIED="2010-08-23 06:49:17 +0100" MODIFIED_BY="[Empty name]" ORDER="67564" O_E="0.0" SE="0.4369314487526515" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.19090909090909092" WEIGHT="1.4944324836859804"/>
<DICH_DATA CI_END="0.8364512088877062" CI_START="0.19128431915683927" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" LOG_CI_END="-0.07755938683408231" LOG_CI_START="-0.7183206305099928" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="67563" O_E="0.0" SE="0.3763863263545405" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.14166666666666666" WEIGHT="1.938418112789685"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="60.77888151207776" CI_END="1.0098100865752093" CI_START="0.8086184662656645" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="RR" EFFECT_SIZE="0.903632161571313" ESTIMABLE="YES" EVENTS_1="942" EVENTS_2="1053" I2="67.09383341313105" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.004239704369050479" LOG_CI_START="-0.09225634498885771" LOG_EFFECT_SIZE="-0.04400832030990364" METHOD="MH" MODIFIED="2011-02-16 14:09:32 +0000" MODIFIED_BY="Emma M Sydenham" NO="2" P_CHI2="5.392026053874233E-6" P_Q="0.0" P_Z="0.07381863686616318" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="21" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.024080766447066" TOTALS="YES" TOTAL_1="2124" TOTAL_2="2061" WEIGHT="100.00000000000001" Z="1.7877358379220487">
<NAME>No. Exposed to Allogeneic Blood - Type of Surgery</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>TXA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="45.01498010362329" CI_END="0.9881964128233016" CI_START="0.7640242746670873" DF="17" EFFECT_SIZE="0.8689108398080556" ESTIMABLE="YES" EVENTS_1="873" EVENTS_2="988" I2="62.23479392667407" ID="CMP-004.02.01" LOG_CI_END="-0.00515672694313441" LOG_CI_START="-0.11689284275089666" LOG_EFFECT_SIZE="-0.061024784847015574" MODIFIED="2011-02-16 14:09:32 +0000" MODIFIED_BY="Emma M Sydenham" NO="1" P_CHI2="2.4226152412543112E-4" P_Z="0.032284333386493856" STUDIES="18" TAU2="0.026988997505230244" TOTAL_1="2025" TOTAL_2="1958" WEIGHT="79.94794172885742" Z="2.140872350892066">
<NAME>Cardiac surgery</NAME>
<DICH_DATA CI_END="1.1197841224249232" CI_START="0.3738980690319062" EFFECT_SIZE="0.6470588235294118" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="0.04913430528065808" LOG_CI_START="-0.42724677772075587" LOG_EFFECT_SIZE="-0.18905623622004886" ORDER="67581" O_E="0.0" SE="0.27982860627942274" STUDY_ID="STD-Bernet-1999" TOTAL_1="28" TOTAL_2="28" VAR="0.07830404889228418" WEIGHT="3.138041763626385"/>
<DICH_DATA CI_END="1.435243954367492" CI_START="0.14690857630106668" EFFECT_SIZE="0.45918367346938777" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.15692572617866216" LOG_CI_START="-0.8329528500129644" LOG_EFFECT_SIZE="-0.33801356191715115" ORDER="67569" O_E="0.0" SE="0.5814595756329395" STUDY_ID="STD-Blauhut-1994" TOTAL_1="14" TOTAL_2="15" VAR="0.3380952380952381" WEIGHT="0.8871041219367365"/>
<DICH_DATA CI_END="2.048506537591385" CI_START="0.6656079177641339" EFFECT_SIZE="1.1676909569798068" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.3114373542961579" LOG_CI_START="-0.176781520520187" LOG_EFFECT_SIZE="0.06732791688798542" ORDER="67570" O_E="0.0" SE="0.28678218378952774" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="70" VAR="0.08224402093909047" WEIGHT="3.021758466623447"/>
<DICH_DATA CI_END="1.2365301946437357" CI_START="0.8871155928252136" EFFECT_SIZE="1.0473515248796148" ESTIMABLE="YES" EVENTS_1="185" EVENTS_2="178" LOG_CI_END="0.09220472579804354" LOG_CI_START="-0.05201978709574561" LOG_EFFECT_SIZE="0.02009246935114897" ORDER="67580" O_E="0.0" SE="0.08471819279666457" STUDY_ID="STD-Casati-2000" TOTAL_1="518" TOTAL_2="522" VAR="0.007177172190732827" WEIGHT="10.278599309409904"/>
<DICH_DATA CI_END="1.6923197685338265" CI_START="0.5372153021082148" EFFECT_SIZE="0.9534883720930233" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.22848242760880472" LOG_CI_START="-0.2698516253285067" LOG_EFFECT_SIZE="-0.02068459885985102" ORDER="67571" O_E="0.0" SE="0.2927238894887227" STUDY_ID="STD-Corbeau-1995" TOTAL_1="43" TOTAL_2="41" VAR="0.08568727547740593" WEIGHT="2.926970554117424"/>
<DICH_DATA CI_END="0.9942864949565421" CI_START="0.60582269873457" EFFECT_SIZE="0.7761194029850746" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="67" LOG_CI_END="-0.0024884594142842056" LOG_CI_START="-0.21765445871777034" LOG_EFFECT_SIZE="-0.11007145906602726" MODIFIED="2010-05-17 11:08:48 +0100" MODIFIED_BY="Katharine Ker" ORDER="2568" O_E="0.0" SE="0.12638957307974186" STUDY_ID="STD-Dietrich-2008" TOTAL_1="110" TOTAL_2="110" VAR="0.01597432418327941" WEIGHT="8.021148409352271"/>
<DICH_DATA CI_END="0.8364512088877062" CI_START="0.19128431915683927" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" LOG_CI_END="-0.07755938683408231" LOG_CI_START="-0.7183206305099928" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="67572" O_E="0.0" SE="0.3763863263545405" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.14166666666666666" WEIGHT="1.938418112789685"/>
<DICH_DATA CI_END="0.8879606346925294" CI_START="0.7525329912490775" EFFECT_SIZE="0.8174470457079153" ESTIMABLE="YES" EVENTS_1="419" EVENTS_2="506" LOG_CI_END="-0.05160628705333877" LOG_CI_START="-0.12347445572966592" LOG_EFFECT_SIZE="-0.08754037139150234" MODIFIED="2010-01-11 13:53:48 +0000" MODIFIED_BY="Katharine Ker" ORDER="2288" O_E="0.0" SE="0.042215718033647036" STUDY_ID="STD-Fergusson-2008" TOTAL_1="780" TOTAL_2="770" VAR="0.0017821668490963917" WEIGHT="12.422714114323982"/>
<DICH_DATA CI_END="1.6825402105470073" CI_START="0.7803284697433366" EFFECT_SIZE="1.1458333333333333" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="24" LOG_CI_END="0.22596545209958277" LOG_CI_START="-0.10772254786226959" LOG_EFFECT_SIZE="0.05912145211865659" ORDER="67568" O_E="0.0" SE="0.19600998295983146" STUDY_ID="STD-Isetta-1993" TOTAL_1="140" TOTAL_2="70" VAR="0.038419913419913417" WEIGHT="5.140549305701236"/>
<DICH_DATA CI_END="5.1801150354072085" CI_START="0.9343421848583578" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.714339404279566" LOG_CI_START="-0.02949404263515343" LOG_EFFECT_SIZE="0.3424226808222063" ORDER="67573" O_E="0.0" SE="0.4369314487526515" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.19090909090909092" WEIGHT="1.4944324836859804"/>
<DICH_DATA CI_END="1.1284556431965513" CI_START="0.6683072827900095" EFFECT_SIZE="0.868421052631579" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="57" LOG_CI_END="0.05248449270613696" LOG_CI_START="-0.17502380618398225" LOG_EFFECT_SIZE="-0.06126965673892266" MODIFIED="2010-05-06 16:44:51 +0100" MODIFIED_BY="Katharine Ker" ORDER="2400" O_E="0.0" SE="0.1336395009522984" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="99" VAR="0.017859516214779367" WEIGHT="7.66060231607222"/>
<DICH_DATA CI_END="1.0571879058568519" CI_START="0.01930419668276973" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.024152186194750208" LOG_CI_START="-1.714348266223264" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="67574" O_E="0.0" SE="1.0212037714663722" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="1.0428571428571427" WEIGHT="0.3011307628066008"/>
<DICH_DATA CI_END="1.0198361669523746" CI_START="0.33929053749849375" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" LOG_CI_END="0.00853040950370991" LOG_CI_START="-0.46942825226025775" LOG_EFFECT_SIZE="-0.2304489213782739" MODIFIED="2011-02-16 14:09:32 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="2448" O_E="0.0" SE="0.2807552838536876" STUDY_ID="STD-Mengistu-2008" TOTAL_1="25" TOTAL_2="25" VAR="0.07882352941176468" WEIGHT="3.122200330069943"/>
<DICH_DATA CI_END="0.666406359652897" CI_START="0.041682942209984405" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.1762608670199649" LOG_CI_START="-1.3800416337473222" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="67575" O_E="0.0" SE="0.7071067811865476" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.5000000000000001" WEIGHT="0.6130502149013844"/>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67576" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="0.1252219226060566"/>
<DICH_DATA CI_END="1.0921635201498592" CI_START="0.9156138083267851" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.03828766637439782" LOG_CI_START="-0.03828766637439781" LOG_EFFECT_SIZE="0.0" ORDER="67577" O_E="0.0" SE="0.04498072951065294" STUDY_ID="STD-Pugh-1995" TOTAL_1="21" TOTAL_2="22" VAR="0.0020232660273105246" WEIGHT="12.30797681589729"/>
<DICH_DATA CI_END="1.2732251164306965" CI_START="0.6692225867377" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.10490519719658377" LOG_CI_START="-0.1744294097150076" LOG_EFFECT_SIZE="-0.03476210625921192" ORDER="67578" O_E="0.0" SE="0.16408253082847335" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.02692307692307691" WEIGHT="6.299286588354136"/>
<DICH_DATA CI_END="3.3417930664224986" CI_START="0.04048385845900427" EFFECT_SIZE="0.367816091954023" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5239795536084553" LOG_CI_START="-1.3927181022058803" LOG_EFFECT_SIZE="-0.4343692742987125" ORDER="67579" O_E="0.0" SE="1.1258776908317545" STUDY_ID="STD-Vanek-2005" TOTAL_1="29" TOTAL_2="32" VAR="1.2676005747126435" WEIGHT="0.24873613658272292"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1417444413788664" CI_END="1.1144241254911798" CI_START="0.9121712955587973" DF="1" EFFECT_SIZE="1.0082389093618978" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="65" I2="12.414725768901835" ID="CMP-004.02.02" LOG_CI_END="0.04705050529519682" LOG_CI_START="-0.039923598370637275" LOG_EFFECT_SIZE="0.003563453462279761" NO="2" P_CHI2="0.28528406278555196" P_Z="0.8724044716041558" STUDIES="2" TAU2="0.0015084054207575865" TOTAL_1="87" TOTAL_2="91" WEIGHT="19.895489284530825" Z="0.16060505719006393">
<NAME>Liver surgery</NAME>
<DICH_DATA CI_END="1.4091078666036987" CI_START="0.8114978976663392" EFFECT_SIZE="1.0693400167084377" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="38" LOG_CI_END="0.14894423943845972" LOG_CI_START="-0.09071260095554438" LOG_EFFECT_SIZE="0.029115819241457678" ORDER="67582" O_E="0.0" SE="0.1407756143679307" STUDY_ID="STD-Dalmau-2004" TOTAL_1="63" TOTAL_2="64" VAR="0.01981777360066834" WEIGHT="7.318872703891625"/>
<DICH_DATA CI_END="1.0779225045907352" CI_START="0.9277104761623649" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="27" LOG_CI_END="0.032587539108232075" LOG_CI_START="-0.032587539108232096" LOG_EFFECT_SIZE="0.0" ORDER="67583" O_E="0.0" SE="0.0382841635661914" STUDY_ID="STD-Ickx-2006" TOTAL_1="24" TOTAL_2="27" VAR="0.0014656771799628973" WEIGHT="12.576616580639199"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="179.29256051754408" CI_START="0.6748746275401646" DF="0" EFFECT_SIZE="11.000000000000002" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-004.02.03" LOG_CI_END="2.2535622695219755" LOG_CI_START="-0.17077689920552552" LOG_EFFECT_SIZE="1.0413926851582251" NO="3" P_CHI2="1.0" P_Z="0.09221378677662928" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.15656898661177387" Z="1.6838338323304154">
<NAME>Orthopaedic surgery</NAME>
<DICH_DATA CI_END="179.29256051754408" CI_START="0.6748746275401646" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2535622695219755" LOG_CI_START="-0.17077689920552552" LOG_EFFECT_SIZE="1.041392685158225" ORDER="67584" O_E="0.0" SE="1.424068828382964" STUDY_ID="STD-Engel-2001" TOTAL_1="12" TOTAL_2="12" VAR="2.0279720279720275" WEIGHT="0.15656898661177387"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="60.778881512077746" CI_END="1.0098100865752093" CI_START="0.8086184662656646" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9036321615713131" ESTIMABLE="YES" EVENTS_1="942" EVENTS_2="1053" I2="67.09383341313105" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.004239704369050479" LOG_CI_START="-0.09225634498885764" LOG_EFFECT_SIZE="-0.044008320309903586" METHOD="MH" MODIFIED="2011-02-16 14:06:54 +0000" MODIFIED_BY="Emma M Sydenham" NO="3" P_CHI2="5.392026053541166E-6" P_Q="0.0" P_Z="0.0738186368661632" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="21" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.024080766447065974" TOTALS="YES" TOTAL_1="2124" TOTAL_2="2061" WEIGHT="100.0" Z="1.7877358379220485">
<NAME>No. Exposed to Allogeneic Blood - Transfusion Protocol</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>TXA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="60.87298261632398" CI_END="1.0128688179359038" CI_START="0.8018770884012268" DF="19" EFFECT_SIZE="0.9012193399272093" ESTIMABLE="YES" EVENTS_1="930" EVENTS_2="1040" I2="68.78746665042684" ID="CMP-004.03.01" LOG_CI_END="0.005553201198628004" LOG_CI_START="-0.09589219520701622" LOG_EFFECT_SIZE="-0.045169497004194134" MODIFIED="2011-02-16 14:06:54 +0000" MODIFIED_BY="Emma M Sydenham" NO="1" P_CHI2="2.8135459833045218E-6" P_Z="0.080918043916393" STUDIES="20" TAU2="0.02540049553089139" TOTAL_1="2109" TOTAL_2="2046" WEIGHT="93.70071341164586" Z="1.7453840285469022">
<NAME>Transfusion Protocol</NAME>
<DICH_DATA CI_END="1.1197841224249232" CI_START="0.3738980690319062" EFFECT_SIZE="0.6470588235294118" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="0.04913430528065808" LOG_CI_START="-0.42724677772075587" LOG_EFFECT_SIZE="-0.18905623622004886" ORDER="67585" O_E="0.0" SE="0.27982860627942274" STUDY_ID="STD-Bernet-1999" TOTAL_1="28" TOTAL_2="28" VAR="0.07830404889228418" WEIGHT="3.1380417636263838"/>
<DICH_DATA CI_END="1.435243954367492" CI_START="0.14690857630106668" EFFECT_SIZE="0.45918367346938777" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.15692572617866216" LOG_CI_START="-0.8329528500129644" LOG_EFFECT_SIZE="-0.33801356191715115" ORDER="67586" O_E="0.0" SE="0.5814595756329395" STUDY_ID="STD-Blauhut-1994" TOTAL_1="14" TOTAL_2="15" VAR="0.3380952380952381" WEIGHT="0.887104121936736"/>
<DICH_DATA CI_END="2.048506537591385" CI_START="0.6656079177641339" EFFECT_SIZE="1.1676909569798068" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.3114373542961579" LOG_CI_START="-0.176781520520187" LOG_EFFECT_SIZE="0.06732791688798542" ORDER="67587" O_E="0.0" SE="0.28678218378952774" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="70" VAR="0.08224402093909047" WEIGHT="3.0217584666234454"/>
<DICH_DATA CI_END="1.2365301946437357" CI_START="0.8871155928252136" EFFECT_SIZE="1.0473515248796148" ESTIMABLE="YES" EVENTS_1="185" EVENTS_2="178" LOG_CI_END="0.09220472579804354" LOG_CI_START="-0.05201978709574561" LOG_EFFECT_SIZE="0.02009246935114897" ORDER="67599" O_E="0.0" SE="0.08471819279666457" STUDY_ID="STD-Casati-2000" TOTAL_1="518" TOTAL_2="522" VAR="0.007177172190732827" WEIGHT="10.278599309409907"/>
<DICH_DATA CI_END="1.6923197685338265" CI_START="0.5372153021082148" EFFECT_SIZE="0.9534883720930233" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.22848242760880472" LOG_CI_START="-0.2698516253285067" LOG_EFFECT_SIZE="-0.02068459885985102" ORDER="67588" O_E="0.0" SE="0.2927238894887227" STUDY_ID="STD-Corbeau-1995" TOTAL_1="43" TOTAL_2="41" VAR="0.08568727547740593" WEIGHT="2.9269705541174225"/>
<DICH_DATA CI_END="1.4091078666036987" CI_START="0.8114978976663392" EFFECT_SIZE="1.0693400167084377" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="38" LOG_CI_END="0.14894423943845972" LOG_CI_START="-0.09071260095554438" LOG_EFFECT_SIZE="0.029115819241457678" ORDER="67589" O_E="0.0" SE="0.1407756143679307" STUDY_ID="STD-Dalmau-2004" TOTAL_1="63" TOTAL_2="64" VAR="0.01981777360066834" WEIGHT="7.318872703891624"/>
<DICH_DATA CI_END="0.9942864949565421" CI_START="0.60582269873457" EFFECT_SIZE="0.7761194029850746" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="67" LOG_CI_END="-0.0024884594142842056" LOG_CI_START="-0.21765445871777034" LOG_EFFECT_SIZE="-0.11007145906602726" MODIFIED="2010-05-17 11:09:05 +0100" MODIFIED_BY="Katharine Ker" ORDER="2569" O_E="0.0" SE="0.12638957307974186" STUDY_ID="STD-Dietrich-2008" TOTAL_1="110" TOTAL_2="110" VAR="0.01597432418327941" WEIGHT="8.021148409352271"/>
<DICH_DATA CI_END="0.8364512088877062" CI_START="0.19128431915683927" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" LOG_CI_END="-0.07755938683408231" LOG_CI_START="-0.7183206305099928" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="67590" O_E="0.0" SE="0.3763863263545405" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.14166666666666666" WEIGHT="1.938418112789684"/>
<DICH_DATA CI_END="179.29256051754408" CI_START="0.6748746275401646" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2535622695219755" LOG_CI_START="-0.17077689920552552" LOG_EFFECT_SIZE="1.041392685158225" ORDER="67600" O_E="0.0" SE="1.424068828382964" STUDY_ID="STD-Engel-2001" TOTAL_1="12" TOTAL_2="12" VAR="2.0279720279720275" WEIGHT="0.15656898661177376"/>
<DICH_DATA CI_END="0.8879606346925294" CI_START="0.7525329912490775" EFFECT_SIZE="0.8174470457079153" ESTIMABLE="YES" EVENTS_1="419" EVENTS_2="506" LOG_CI_END="-0.05160628705333877" LOG_CI_START="-0.12347445572966592" LOG_EFFECT_SIZE="-0.08754037139150234" MODIFIED="2010-01-11 13:54:20 +0000" MODIFIED_BY="Katharine Ker" ORDER="2289" O_E="0.0" SE="0.042215718033647036" STUDY_ID="STD-Fergusson-2008" TOTAL_1="780" TOTAL_2="770" VAR="0.0017821668490963917" WEIGHT="12.422714114323986"/>
<DICH_DATA CI_END="1.0779225045907352" CI_START="0.9277104761623649" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="27" LOG_CI_END="0.032587539108232075" LOG_CI_START="-0.032587539108232096" LOG_EFFECT_SIZE="0.0" ORDER="67591" O_E="0.0" SE="0.0382841635661914" STUDY_ID="STD-Ickx-2006" TOTAL_1="24" TOTAL_2="27" VAR="0.0014656771799628973" WEIGHT="12.5766165806392"/>
<DICH_DATA CI_END="1.6825402105470073" CI_START="0.7803284697433366" EFFECT_SIZE="1.1458333333333333" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="24" LOG_CI_END="0.22596545209958277" LOG_CI_START="-0.10772254786226959" LOG_EFFECT_SIZE="0.05912145211865659" ORDER="67592" O_E="0.0" SE="0.19600998295983146" STUDY_ID="STD-Isetta-1993" TOTAL_1="140" TOTAL_2="70" VAR="0.038419913419913417" WEIGHT="5.140549305701233"/>
<DICH_DATA CI_END="5.1801150354072085" CI_START="0.9343421848583578" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.714339404279566" LOG_CI_START="-0.02949404263515343" LOG_EFFECT_SIZE="0.3424226808222063" ORDER="67593" O_E="0.0" SE="0.4369314487526515" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.19090909090909092" WEIGHT="1.4944324836859795"/>
<DICH_DATA CI_END="1.1284556431965513" CI_START="0.6683072827900095" EFFECT_SIZE="0.868421052631579" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="57" LOG_CI_END="0.05248449270613696" LOG_CI_START="-0.17502380618398225" LOG_EFFECT_SIZE="-0.06126965673892266" MODIFIED="2010-05-06 16:45:42 +0100" MODIFIED_BY="Katharine Ker" ORDER="2402" O_E="0.0" SE="0.1336395009522984" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="99" VAR="0.017859516214779367" WEIGHT="7.660602316072221"/>
<DICH_DATA CI_END="1.0571879058568519" CI_START="0.01930419668276973" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.024152186194750208" LOG_CI_START="-1.714348266223264" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="67594" O_E="0.0" SE="1.0212037714663722" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="1.0428571428571427" WEIGHT="0.3011307628066006"/>
<DICH_DATA CI_END="1.0198361669523746" CI_START="0.33929053749849375" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" LOG_CI_END="0.00853040950370991" LOG_CI_START="-0.46942825226025775" LOG_EFFECT_SIZE="-0.2304489213782739" MODIFIED="2011-02-16 14:06:54 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="2449" O_E="0.0" SE="0.2807552838536876" STUDY_ID="STD-Mengistu-2008" TOTAL_1="25" TOTAL_2="25" VAR="0.07882352941176468" WEIGHT="3.122200330069941"/>
<DICH_DATA CI_END="0.666406359652897" CI_START="0.041682942209984405" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.1762608670199649" LOG_CI_START="-1.3800416337473222" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="67595" O_E="0.0" SE="0.7071067811865476" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.5000000000000001" WEIGHT="0.613050214901384"/>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67596" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="0.12522192260605652"/>
<DICH_DATA CI_END="1.0921635201498592" CI_START="0.9156138083267851" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.03828766637439782" LOG_CI_START="-0.03828766637439781" LOG_EFFECT_SIZE="0.0" ORDER="67597" O_E="0.0" SE="0.04498072951065294" STUDY_ID="STD-Pugh-1995" TOTAL_1="21" TOTAL_2="22" VAR="0.0020232660273105246" WEIGHT="12.307976815897293"/>
<DICH_DATA CI_END="3.3417930664224986" CI_START="0.04048385845900427" EFFECT_SIZE="0.367816091954023" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5239795536084553" LOG_CI_START="-1.3927181022058803" LOG_EFFECT_SIZE="-0.4343692742987125" ORDER="67598" O_E="0.0" SE="1.1258776908317545" STUDY_ID="STD-Vanek-2005" TOTAL_1="29" TOTAL_2="32" VAR="1.2676005747126435" WEIGHT="0.24873613658272276"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2732251164306965" CI_START="0.6692225867377" DF="0" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="0.10490519719658377" LOG_CI_START="-0.1744294097150076" LOG_EFFECT_SIZE="-0.03476210625921192" NO="2" P_CHI2="1.0" P_Z="0.6256774858658098" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="6.299286588354135" Z="0.48781980183625073">
<NAME>No Transfusion Protocol</NAME>
<DICH_DATA CI_END="1.2732251164306965" CI_START="0.6692225867377" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.10490519719658377" LOG_CI_START="-0.1744294097150076" LOG_EFFECT_SIZE="-0.03476210625921192" ORDER="67601" O_E="0.0" SE="0.16408253082847335" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.02692307692307691" WEIGHT="6.299286588354135"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="60.77888151207775" CI_END="1.0098100865752093" CI_START="0.8086184662656646" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9036321615713131" ESTIMABLE="YES" EVENTS_1="942" EVENTS_2="1053" I2="67.09383341313105" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.004239704369050479" LOG_CI_START="-0.09225634498885764" LOG_EFFECT_SIZE="-0.044008320309903586" METHOD="MH" MODIFIED="2011-02-16 13:37:48 +0000" MODIFIED_BY="Emma M Sydenham" NO="4" P_CHI2="5.392026053319121E-6" P_Q="0.0" P_Z="0.0738186368661632" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="21" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.024080766447065985" TOTALS="YES" TOTAL_1="2124" TOTAL_2="2061" WEIGHT="100.0" Z="1.7877358379220485">
<NAME>Trial Methodological Quality - Allocation Concealment</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>TXA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.5977823392476407" CI_END="0.9184246667627632" CI_START="0.6926621152381232" DF="3" EFFECT_SIZE="0.7975951180685372" ESTIMABLE="YES" EVENTS_1="473" EVENTS_2="583" I2="16.615300284470443" ID="CMP-004.04.01" LOG_CI_END="-0.03695646064395138" LOG_CI_START="-0.1594785652041758" LOG_EFFECT_SIZE="-0.09821751292406364" MODIFIED="2010-08-23 06:48:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.30829993091657615" P_Z="0.0016760578299276842" STUDIES="4" TAU2="0.005161823606831847" TOTAL_1="939" TOTAL_2="932" WEIGHT="20.99372942306558" Z="3.142335640955944">
<NAME>Allocation concealment - Yes</NAME>
<DICH_DATA CI_END="0.9942864949565421" CI_START="0.60582269873457" EFFECT_SIZE="0.7761194029850746" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="67" LOG_CI_END="-0.0024884594142842056" LOG_CI_START="-0.21765445871777034" LOG_EFFECT_SIZE="-0.11007145906602726" MODIFIED="2010-08-23 06:48:38 +0100" MODIFIED_BY="[Empty name]" ORDER="3016" O_E="0.0" SE="0.12638957307974186" STUDY_ID="STD-Dietrich-2008" TOTAL_1="110" TOTAL_2="110" VAR="0.01597432418327941" WEIGHT="8.021148409352273"/>
<DICH_DATA CI_END="0.8879606346925294" CI_START="0.7525329912490775" EFFECT_SIZE="0.8174470457079153" ESTIMABLE="YES" EVENTS_1="419" EVENTS_2="506" LOG_CI_END="-0.05160628705333877" LOG_CI_START="-0.12347445572966592" LOG_EFFECT_SIZE="-0.08754037139150234" MODIFIED="2010-08-23 06:48:38 +0100" MODIFIED_BY="[Empty name]" ORDER="3014" O_E="0.0" SE="0.042215718033647036" STUDY_ID="STD-Fergusson-2008" TOTAL_1="780" TOTAL_2="770" VAR="0.0017821668490963917" WEIGHT="12.422714114323984"/>
<DICH_DATA CI_END="1.0571879058568519" CI_START="0.01930419668276973" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.024152186194750208" LOG_CI_START="-1.714348266223264" LOG_EFFECT_SIZE="-0.8450980400142569" MODIFIED="2010-08-23 06:48:38 +0100" MODIFIED_BY="[Empty name]" ORDER="3013" O_E="0.0" SE="1.0212037714663722" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="1.0428571428571427" WEIGHT="0.30113076280660067"/>
<DICH_DATA CI_END="3.3417930664224986" CI_START="0.04048385845900427" EFFECT_SIZE="0.367816091954023" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5239795536084553" LOG_CI_START="-1.3927181022058803" LOG_EFFECT_SIZE="-0.4343692742987125" MODIFIED="2010-08-23 06:48:38 +0100" MODIFIED_BY="[Empty name]" ORDER="3015" O_E="0.0" SE="1.1258776908317545" STUDY_ID="STD-Vanek-2005" TOTAL_1="29" TOTAL_2="32" VAR="1.2676005747126435" WEIGHT="0.24873613658272284"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="19.2498951651706" CI_END="1.0736609225730478" CI_START="0.8772161306970936" DF="12" EFFECT_SIZE="0.9704806438977548" ESTIMABLE="YES" EVENTS_1="362" EVENTS_2="350" I2="37.66199817175133" ID="CMP-004.04.02" LOG_CI_END="0.030867146627658253" LOG_CI_START="-0.056893390892911316" LOG_EFFECT_SIZE="-0.013013122132626537" MODIFIED="2011-02-16 13:37:48 +0000" MODIFIED_BY="Emma M Sydenham" NO="2" P_CHI2="0.08267361451163968" P_Z="0.5610743647214489" STUDIES="13" TAU2="0.007847538622977001" TOTAL_1="946" TOTAL_2="886" WEIGHT="60.593944960494916" Z="0.5812464560256608">
<NAME>Allocation concealment - Unclear</NAME>
<DICH_DATA CI_END="1.1197841224249232" CI_START="0.3738980690319062" EFFECT_SIZE="0.6470588235294118" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="0.04913430528065808" LOG_CI_START="-0.42724677772075587" LOG_EFFECT_SIZE="-0.18905623622004886" MODIFIED="2010-08-23 06:49:10 +0100" MODIFIED_BY="[Empty name]" ORDER="3024" O_E="0.0" SE="0.27982860627942274" STUDY_ID="STD-Bernet-1999" TOTAL_1="28" TOTAL_2="28" VAR="0.07830404889228418" WEIGHT="3.138041763626384"/>
<DICH_DATA CI_END="1.435243954367492" CI_START="0.14690857630106668" EFFECT_SIZE="0.45918367346938777" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.15692572617866216" LOG_CI_START="-0.8329528500129644" LOG_EFFECT_SIZE="-0.33801356191715115" MODIFIED="2010-08-23 06:49:10 +0100" MODIFIED_BY="[Empty name]" ORDER="3028" O_E="0.0" SE="0.5814595756329395" STUDY_ID="STD-Blauhut-1994" TOTAL_1="14" TOTAL_2="15" VAR="0.3380952380952381" WEIGHT="0.8871041219367363"/>
<DICH_DATA CI_END="2.048506537591385" CI_START="0.6656079177641339" EFFECT_SIZE="1.1676909569798068" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.3114373542961579" LOG_CI_START="-0.176781520520187" LOG_EFFECT_SIZE="0.06732791688798542" MODIFIED="2010-08-23 06:49:10 +0100" MODIFIED_BY="[Empty name]" ORDER="3019" O_E="0.0" SE="0.28678218378952774" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="70" VAR="0.08224402093909047" WEIGHT="3.0217584666234463"/>
<DICH_DATA CI_END="1.2365301946437357" CI_START="0.8871155928252136" EFFECT_SIZE="1.0473515248796148" ESTIMABLE="YES" EVENTS_1="185" EVENTS_2="178" LOG_CI_END="0.09220472579804354" LOG_CI_START="-0.05201978709574561" LOG_EFFECT_SIZE="0.02009246935114897" MODIFIED="2010-08-23 06:49:10 +0100" MODIFIED_BY="[Empty name]" ORDER="3021" O_E="0.0" SE="0.08471819279666457" STUDY_ID="STD-Casati-2000" TOTAL_1="518" TOTAL_2="522" VAR="0.007177172190732827" WEIGHT="10.278599309409906"/>
<DICH_DATA CI_END="1.6923197685338265" CI_START="0.5372153021082148" EFFECT_SIZE="0.9534883720930233" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.22848242760880472" LOG_CI_START="-0.2698516253285067" LOG_EFFECT_SIZE="-0.02068459885985102" MODIFIED="2010-08-23 06:49:10 +0100" MODIFIED_BY="[Empty name]" ORDER="3026" O_E="0.0" SE="0.2927238894887227" STUDY_ID="STD-Corbeau-1995" TOTAL_1="43" TOTAL_2="41" VAR="0.08568727547740593" WEIGHT="2.926970554117423"/>
<DICH_DATA CI_END="179.29256051754408" CI_START="0.6748746275401646" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2535622695219755" LOG_CI_START="-0.17077689920552552" LOG_EFFECT_SIZE="1.041392685158225" MODIFIED="2010-08-23 06:49:10 +0100" MODIFIED_BY="[Empty name]" ORDER="3022" O_E="0.0" SE="1.424068828382964" STUDY_ID="STD-Engel-2001" TOTAL_1="12" TOTAL_2="12" VAR="2.0279720279720275" WEIGHT="0.15656898661177382"/>
<DICH_DATA CI_END="1.0779225045907352" CI_START="0.9277104761623649" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="27" LOG_CI_END="0.032587539108232075" LOG_CI_START="-0.032587539108232096" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-23 06:49:10 +0100" MODIFIED_BY="[Empty name]" ORDER="3027" O_E="0.0" SE="0.0382841635661914" STUDY_ID="STD-Ickx-2006" TOTAL_1="24" TOTAL_2="27" VAR="0.0014656771799628973" WEIGHT="12.5766165806392"/>
<DICH_DATA CI_END="1.6825402105470073" CI_START="0.7803284697433366" EFFECT_SIZE="1.1458333333333333" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="24" LOG_CI_END="0.22596545209958277" LOG_CI_START="-0.10772254786226959" LOG_EFFECT_SIZE="0.05912145211865659" MODIFIED="2010-08-23 06:49:10 +0100" MODIFIED_BY="[Empty name]" ORDER="3025" O_E="0.0" SE="0.19600998295983146" STUDY_ID="STD-Isetta-1993" TOTAL_1="140" TOTAL_2="70" VAR="0.038419913419913417" WEIGHT="5.140549305701234"/>
<DICH_DATA CI_END="1.0198361669523746" CI_START="0.33929053749849375" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" LOG_CI_END="0.00853040950370991" LOG_CI_START="-0.46942825226025775" LOG_EFFECT_SIZE="-0.2304489213782739" MODIFIED="2011-02-16 13:37:48 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="3017" O_E="0.0" SE="0.2807552838536876" STUDY_ID="STD-Mengistu-2008" TOTAL_1="25" TOTAL_2="25" VAR="0.07882352941176468" WEIGHT="3.1222003300699424"/>
<DICH_DATA CI_END="0.666406359652897" CI_START="0.041682942209984405" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.1762608670199649" LOG_CI_START="-1.3800416337473222" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2010-08-23 06:49:10 +0100" MODIFIED_BY="[Empty name]" ORDER="3020" O_E="0.0" SE="0.7071067811865476" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.5000000000000001" WEIGHT="0.6130502149013842"/>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2010-08-23 06:49:10 +0100" MODIFIED_BY="[Empty name]" ORDER="3023" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="0.12522192260605655"/>
<DICH_DATA CI_END="1.0921635201498592" CI_START="0.9156138083267851" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.03828766637439782" LOG_CI_START="-0.03828766637439781" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-23 06:49:10 +0100" MODIFIED_BY="[Empty name]" ORDER="3029" O_E="0.0" SE="0.04498072951065294" STUDY_ID="STD-Pugh-1995" TOTAL_1="21" TOTAL_2="22" VAR="0.0020232660273105246" WEIGHT="12.307976815897291"/>
<DICH_DATA CI_END="1.2732251164306965" CI_START="0.6692225867377" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.10490519719658377" LOG_CI_START="-0.1744294097150076" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2010-08-23 06:49:10 +0100" MODIFIED_BY="[Empty name]" ORDER="3018" O_E="0.0" SE="0.16408253082847335" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.02692307692307691" WEIGHT="6.299286588354134"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.293602501399004" CI_END="1.393108110448162" CI_START="0.623494675983079" DF="3" EFFECT_SIZE="0.9319847047743198" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="120" I2="70.85568439628138" ID="CMP-004.04.03" LOG_CI_END="0.14398482062296447" LOG_CI_START="-0.20516725060731866" LOG_EFFECT_SIZE="-0.030591214992177106" MODIFIED="2010-08-23 06:49:31 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.016228471292395463" P_Z="0.7312619316081391" STUDIES="4" TAU2="0.10381570210097359" TOTAL_1="239" TOTAL_2="243" WEIGHT="18.41232561643951" Z="0.34344736616752763">
<NAME>Allocation concealment - No</NAME>
<DICH_DATA CI_END="1.4091078666036987" CI_START="0.8114978976663392" EFFECT_SIZE="1.0693400167084377" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="38" LOG_CI_END="0.14894423943845972" LOG_CI_START="-0.09071260095554438" LOG_EFFECT_SIZE="0.029115819241457678" MODIFIED="2010-08-23 06:49:31 +0100" MODIFIED_BY="[Empty name]" ORDER="3033" O_E="0.0" SE="0.1407756143679307" STUDY_ID="STD-Dalmau-2004" TOTAL_1="63" TOTAL_2="64" VAR="0.01981777360066834" WEIGHT="7.318872703891625"/>
<DICH_DATA CI_END="0.8364512088877062" CI_START="0.19128431915683927" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" LOG_CI_END="-0.07755938683408231" LOG_CI_START="-0.7183206305099928" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2010-08-23 06:49:31 +0100" MODIFIED_BY="[Empty name]" ORDER="3032" O_E="0.0" SE="0.3763863263545405" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.14166666666666666" WEIGHT="1.9384181127896847"/>
<DICH_DATA CI_END="5.1801150354072085" CI_START="0.9343421848583578" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.714339404279566" LOG_CI_START="-0.02949404263515343" LOG_EFFECT_SIZE="0.3424226808222063" MODIFIED="2010-08-23 06:49:31 +0100" MODIFIED_BY="[Empty name]" ORDER="3030" O_E="0.0" SE="0.4369314487526515" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.19090909090909092" WEIGHT="1.4944324836859801"/>
<DICH_DATA CI_END="1.1284556431965513" CI_START="0.6683072827900095" EFFECT_SIZE="0.868421052631579" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="57" LOG_CI_END="0.05248449270613696" LOG_CI_START="-0.17502380618398225" LOG_EFFECT_SIZE="-0.06126965673892266" MODIFIED="2010-08-23 06:49:31 +0100" MODIFIED_BY="[Empty name]" ORDER="3031" O_E="0.0" SE="0.1336395009522984" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="99" VAR="0.017859516214779367" WEIGHT="7.660602316072221"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.9688321257652881" CI_END="0.29594172083215886" CI_START="-0.43591800672670244" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.0699881429472718" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.05" NO="5" P_CHI2="0.9650403106833113" P_Q="1.0" P_Z="0.7077609905134175" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="97" TOTAL_2="110" UNITS="" WEIGHT="100.0" Z="0.3748648391380744">
<NAME>Units Allogeneic Blood Transfused - Transfused Patients</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>TXA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8589869714360764" CI_START="-0.9189869714360764" EFFECT_SIZE="-0.030000000000000027" ESTIMABLE="YES" MEAN_1="1.68" MEAN_2="1.71" ORDER="67619" SD_1="0.48" SD_2="0.95" SE="0.4535731158573791" STUDY_ID="STD-Blauhut-1994" TOTAL_1="3" TOTAL_2="7" WEIGHT="16.94356977970514"/>
<CONT_DATA CI_END="0.5311948369121703" CI_START="-0.6111948369121704" EFFECT_SIZE="-0.040000000000000036" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="1.94" ORDER="67622" SD_1="1.04" SD_2="0.69" SE="0.2914312923184723" STUDY_ID="STD-Casati-1999" TOTAL_1="19" TOTAL_2="17" WEIGHT="41.04187200988346"/>
<CONT_DATA CI_END="0.8891461805555804" CI_START="-0.6891461805555802" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.29" MEAN_2="2.19" ORDER="67620" SD_1="1.49" SD_2="0.46" SE="0.4026330008001497" STUDY_ID="STD-Corbeau-1995" TOTAL_1="15" TOTAL_2="15" WEIGHT="21.502095688278075"/>
<CONT_DATA CI_END="1.857542465248001" CI_START="-1.6375424652480004" EFFECT_SIZE="0.11000000000000032" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="5.09" ORDER="67623" SD_1="4.17" SD_2="3.7" SE="0.8916196823168143" STUDY_ID="STD-Dalmau-2004" TOTAL_1="40" TOTAL_2="38" WEIGHT="4.384703511394164"/>
<CONT_DATA CI_END="0.6856985140878269" CI_START="-1.7056985140878265" EFFECT_SIZE="-0.5099999999999998" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.61" ORDER="67624" SD_1="1.42" SD_2="1.55" SE="0.610061472312422" STUDY_ID="STD-Diprose-2005" TOTAL_1="8" TOTAL_2="20" WEIGHT="9.365960652056298"/>
<CONT_DATA CI_END="1.007235382459335" CI_START="-1.8072353824593348" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="2.91" MEAN_2="3.31" ORDER="67621" SD_1="1.94" SD_2="1.62" SE="0.7179904291912647" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="12" TOTAL_2="13" WEIGHT="6.76179835868286"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="10.8705447935479" CI_END="-0.04301662738291043" CI_START="-0.4455291311266276" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.24427287925476904" ESTIMABLE="YES" I2="17.207461346906392" I2_Q="0.0" ID="CMP-004.06" MODIFIED="2011-02-16 13:42:34 +0000" MODIFIED_BY="Emma M Sydenham" NO="6" P_CHI2="0.28468711200629004" P_Q="1.0" P_Z="0.017364959790628853" Q="0.0" RANDOM="YES" SCALE="2.928405501592052" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.01756417574914165" TOTALS="YES" TOTAL_1="496" TOTAL_2="496" UNITS="" WEIGHT="100.00000000000001" Z="2.378887817328938">
<NAME>Units Allogeneic Blood Transfused - All Patients</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>TXA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.1594368776521955" CI_START="-1.0394368776521956" EFFECT_SIZE="-0.44000000000000006" ESTIMABLE="YES" MEAN_1="0.36" MEAN_2="0.8" ORDER="67625" SD_1="0.47" SD_2="1.08" SE="0.3058407615550475" STUDY_ID="STD-Blauhut-1994" TOTAL_1="14" TOTAL_2="15" WEIGHT="9.490252791629805"/>
<CONT_DATA CI_END="0.3926495234250865" CI_START="-0.2526495234250864" EFFECT_SIZE="0.07000000000000006" ESTIMABLE="YES" MEAN_1="0.54" MEAN_2="0.47" ORDER="67628" SD_1="1.02" SD_2="0.9" SE="0.16462012872180545" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="70" WEIGHT="23.60724612967373"/>
<CONT_DATA CI_END="0.5370930417456575" CI_START="-0.5370930417456575" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.8" ORDER="67626" SD_1="1.4" SD_2="1.1" SE="0.27403209751922936" STUDY_ID="STD-Corbeau-1995" TOTAL_1="43" TOTAL_2="41" WEIGHT="11.3794363880773"/>
<CONT_DATA CI_END="1.6646991249456335" CI_START="-1.104699124945634" EFFECT_SIZE="0.2799999999999998" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="3.02" ORDER="67630" SD_1="4.16" SD_2="3.79" SE="0.7064921273390551" STUDY_ID="STD-Dalmau-2004" TOTAL_1="63" TOTAL_2="64" WEIGHT="2.0406478499182117"/>
<CONT_DATA CI_END="0.0757066815715326" CI_START="-0.8757066815715324" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="1.7" MODIFIED="2010-05-17 11:10:13 +0100" MODIFIED_BY="Katharine Ker" ORDER="2571" SD_1="1.8" SD_2="1.8" SE="0.24271195048676716" STUDY_ID="STD-Dietrich-2008" TOTAL_1="110" TOTAL_2="110" WEIGHT="13.787735278436985"/>
<CONT_DATA CI_END="-0.1468501637761201" CI_START="-1.0331498362238798" EFFECT_SIZE="-0.59" ESTIMABLE="YES" MEAN_1="0.28" MEAN_2="0.87" ORDER="67631" SD_1="0.87" SD_2="1.52" SE="0.22610100987537995" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" WEIGHT="15.350953260178104"/>
<CONT_DATA CI_END="0.35180435354902223" CI_START="-0.5518043535490225" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.8" ORDER="67632" SD_1="1.2" SD_2="1.3" SE="0.2305166610778552" STUDY_ID="STD-Hekmat-2004" TOTAL_1="60" TOTAL_2="58" WEIGHT="14.913178751347251"/>
<CONT_DATA CI_END="0.03489067983508409" CI_START="-2.034890679835084" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.8" MODIFIED="2011-02-16 13:42:34 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="2451" SD_1="1.1" SD_2="2.4" SE="0.5280151512977634" STUDY_ID="STD-Mengistu-2008" TOTAL_1="25" TOTAL_2="25" WEIGHT="3.5577618445136445"/>
<CONT_DATA CI_END="0.8931433922667307" CI_START="-1.9731433922667307" EFFECT_SIZE="-0.54" ESTIMABLE="YES" MEAN_1="2.33" MEAN_2="2.87" ORDER="67627" SD_1="2.1" SD_2="1.9" SE="0.731209044437134" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.9093340602789353"/>
<CONT_DATA CI_END="0.5169682447707552" CI_START="-1.436968244770756" EFFECT_SIZE="-0.4600000000000004" ESTIMABLE="YES" MEAN_1="2.03" MEAN_2="2.49" ORDER="67629" SD_1="2.12" SD_2="2.25" SE="0.49846234547009866" STUDY_ID="STD-Wong-2000" TOTAL_1="39" TOTAL_2="38" WEIGHT="3.9634536459460428"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="35.67946040528781" CI_END="-74.4654426924843" CI_START="-198.40457799319978" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="MD" EFFECT_SIZE="-136.43501034284205" ESTIMABLE="YES" I2="63.56447140082489" I2_Q="45.00879271788238" ID="CMP-004.07" MODIFIED="2011-02-16 13:45:30 +0000" MODIFIED_BY="Emma M Sydenham" NO="7" P_CHI2="6.652410732550518E-4" P_Q="0.17749536042761427" P_Z="1.5949775092655358E-5" Q="1.8184725330174487" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="8176.673629184758" TOTALS="YES" TOTAL_1="552" TOTAL_2="489" UNITS="" WEIGHT="100.0" Z="4.315145589058769">
<NAME>Blood loss</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>TXA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="33.860987872270364" CI_END="-81.62053645356912" CI_START="-209.9949919407665" DF="12" EFFECT_SIZE="-145.8077641971678" ESTIMABLE="YES" I2="64.56098668690316" ID="CMP-004.07.01" MODIFIED="2011-02-16 13:45:30 +0000" MODIFIED_BY="Emma M Sydenham" NO="1" P_CHI2="7.094385586952079E-4" P_Z="8.497279367670089E-6" STUDIES="13" TAU2="8272.18553523633" TOTAL_1="412" TOTAL_2="419" WEIGHT="93.89215888910861" Z="4.452255947777055">
<NAME>Cardiac surgery - Post-operative</NAME>
<CONT_DATA CI_END="178.29093947915771" CI_START="-248.29093947915771" EFFECT_SIZE="-35.0" ESTIMABLE="YES" MEAN_1="844.0" MEAN_2="879.0" ORDER="67641" SD_1="437.0" SD_2="375.0" SE="108.82390756236819" STUDY_ID="STD-Bernet-1999" TOTAL_1="28" TOTAL_2="28" WEIGHT="4.993574170254097"/>
<CONT_DATA CI_END="-7.771599741446423" CI_START="-260.22840025855356" EFFECT_SIZE="-134.0" ESTIMABLE="YES" MEAN_1="269.0" MEAN_2="403.0" ORDER="67633" SD_1="142.18" SD_2="201.39" SE="64.4034284579855" STUDY_ID="STD-Blauhut-1994" TOTAL_1="14" TOTAL_2="15" WEIGHT="8.111334549865092"/>
<CONT_DATA CI_END="50.18874231591681" CI_START="-105.18874231591681" EFFECT_SIZE="-27.5" ESTIMABLE="YES" MEAN_1="283.4" MEAN_2="310.9" ORDER="67639" SD_1="232.7" SD_2="231.1" SE="39.63784178113256" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="70" WEIGHT="10.255402470671697"/>
<CONT_DATA CI_END="2.312271090936264" CI_START="-364.3122710909363" EFFECT_SIZE="-181.0" ESTIMABLE="YES" MEAN_1="834.0" MEAN_2="1015.0" ORDER="67634" SD_1="448.0" SD_2="409.0" SE="93.52838753001589" STUDY_ID="STD-Corbeau-1995" TOTAL_1="43" TOTAL_2="41" WEIGHT="5.906793075015152"/>
<CONT_DATA CI_END="-13.473168884490178" CI_START="-266.5268311155098" EFFECT_SIZE="-140.0" ESTIMABLE="YES" MEAN_1="756.0" MEAN_2="896.0" ORDER="67643" SD_1="347.0" SD_2="354.0" SE="64.55569189716613" STUDY_ID="STD-Hekmat-2004" TOTAL_1="60" TOTAL_2="58" WEIGHT="8.098431861933305"/>
<CONT_DATA CI_END="-114.42600236117948" CI_START="-409.5739976388205" EFFECT_SIZE="-262.0" ESTIMABLE="YES" MEAN_1="540.0" MEAN_2="802.0" ORDER="67644" SD_1="259.4" SD_2="214.7" SE="75.29423948749333" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="7.220041287291794"/>
<CONT_DATA CI_END="110.39259533449271" CI_START="-150.3925953344927" EFFECT_SIZE="-20.0" ESTIMABLE="YES" MEAN_1="515.0" MEAN_2="535.0" ORDER="67635" SD_1="339.48" SD_2="336.75" SE="66.52805682298903" STUDY_ID="STD-Landymore-1997" TOTAL_1="48" TOTAL_2="56" WEIGHT="7.932291567735766"/>
<CONT_DATA CI_END="-189.0937984495775" CI_START="-726.9062015504226" EFFECT_SIZE="-458.0" ESTIMABLE="YES" MEAN_1="575.0" MEAN_2="1033.0" MODIFIED="2011-02-16 13:45:30 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="2452" SD_1="228.0" SD_2="647.0" SE="137.19956268151878" STUDY_ID="STD-Mengistu-2008" TOTAL_1="25" TOTAL_2="25" WEIGHT="3.7024623820377234"/>
<CONT_DATA CI_END="-269.4508424039573" CI_START="-608.5491575960427" EFFECT_SIZE="-439.0" ESTIMABLE="YES" MEAN_1="298.0" MEAN_2="737.0" ORDER="67636" SD_1="140.0" SD_2="400.0" SE="86.50626181573988" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" WEIGHT="6.383646057855454"/>
<CONT_DATA CI_END="-14.727889859916957" CI_START="-185.27211014008304" EFFECT_SIZE="-100.0" ESTIMABLE="YES" MEAN_1="290.0" MEAN_2="390.0" ORDER="67640" SD_1="110.0" SD_2="120.0" SE="43.506978093831606" STUDY_ID="STD-Misfeld-1998" TOTAL_1="14" TOTAL_2="14" WEIGHT="9.92776565019584"/>
<CONT_DATA CI_END="-34.69629930724494" CI_START="-345.30370069275506" EFFECT_SIZE="-190.0" ESTIMABLE="YES" MEAN_1="344.0" MEAN_2="534.0" ORDER="67637" SD_1="106.0" SD_2="288.0" SE="79.23803800364233" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" WEIGHT="6.915640840427509"/>
<CONT_DATA CI_END="34.25742434240581" CI_START="-198.2574243424058" EFFECT_SIZE="-82.0" ESTIMABLE="YES" MEAN_1="270.0" MEAN_2="352.0" ORDER="67638" SD_1="174.0" SD_2="150.0" SE="59.31610236689528" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" WEIGHT="8.54786766479179"/>
<CONT_DATA CI_END="119.60931308492451" CI_START="-247.6093130849245" EFFECT_SIZE="-64.0" ESTIMABLE="YES" MEAN_1="682.0" MEAN_2="746.0" ORDER="67642" SD_1="382.8" SD_2="436.7" SE="93.67994235262042" STUDY_ID="STD-Wong-2000" TOTAL_1="39" TOTAL_2="38" WEIGHT="5.896907311033385"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="183.37917424995706" CI_START="-171.37917424995706" DF="0" EFFECT_SIZE="6.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.07.02" NO="2" P_CHI2="1.0" P_Z="0.9471410269582559" STUDIES="1" TAU2="0.0" TOTAL_1="140" TOTAL_2="70" WEIGHT="6.10784111089139" Z="0.06629743292563091">
<NAME>Cardiac surgery - Total</NAME>
<CONT_DATA CI_END="183.37917424995703" CI_START="-171.37917424995703" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="608.0" MEAN_2="602.0" ORDER="67645" SD_1="717.62" SD_2="562.0" SE="90.50124168051113" STUDY_ID="STD-Isetta-1993" TOTAL_1="140" TOTAL_2="70" WEIGHT="6.10784111089139"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2010-08-23 06:51:53 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Aprotinin versus Epsilon Aminocaproic Acid (Blood Transfusion &amp; Blood Loss)</NAME>
<DICH_OUTCOME CHI2="9.32871822562402" CI_END="0.8850067900287706" CI_START="0.7602841421013966" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.820278384520118" ESTIMABLE="YES" EVENTS_1="522" EVENTS_2="637" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-0.053053397256169255" LOG_CI_START="-0.11902406787137039" LOG_EFFECT_SIZE="-0.08603873256376986" METHOD="MH" MODIFIED="2010-08-23 06:09:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5915785032899235" P_Q="0.0" P_Z="3.181634493187581E-7" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1102" TOTAL_2="1098" WEIGHT="99.99999999999999" Z="5.112357219591625">
<NAME>No. Exposed to Allogeneic Blood</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7386462202749464" CI_START="0.7657457458683129" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.2402112207530636" LOG_CI_START="-0.11591540725537476" LOG_EFFECT_SIZE="0.062147906748844434" MODIFIED="2010-05-17 14:16:06 +0100" MODIFIED_BY="Katharine Ker" ORDER="2605" O_E="0.0" SE="0.2091905441473963" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="25" VAR="0.043760683760683754" WEIGHT="3.4315703168980187"/>
<DICH_DATA CI_END="0.8852021538681629" CI_START="0.7506877794135325" EFFECT_SIZE="0.8151750972762646" ESTIMABLE="YES" EVENTS_1="419" EVENTS_2="514" LOG_CI_END="-0.052957538020965964" LOG_CI_START="-0.12454065403699495" LOG_EFFECT_SIZE="-0.08874909602898043" MODIFIED="2010-01-11 12:48:46 +0000" MODIFIED_BY="Katharine Ker" ORDER="2276" O_E="0.0" SE="0.04204827668995443" STUDY_ID="STD-Fergusson-2008" TOTAL_1="780" TOTAL_2="780" VAR="0.0017680575725949651" WEIGHT="84.93380858629126"/>
<DICH_DATA CI_END="1.3697803938804385" CI_START="0.41064976730065383" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.13665094571788927" LOG_CI_START="-0.3865284189344892" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="67647" O_E="0.0" SE="0.30731814857642953" STUDY_ID="STD-Eberle-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.09444444444444443" WEIGHT="1.590012671721073"/>
<DICH_DATA CI_END="2.3586217117979826" CI_START="0.6251489115625755" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.3726582920289919" LOG_CI_START="-0.2040165206289201" LOG_EFFECT_SIZE="0.08432088570003587" ORDER="67649" O_E="0.0" SE="0.3387416395416184" STUDY_ID="STD-Ray-2001" TOTAL_1="49" TOTAL_2="51" VAR="0.11474589835934375" WEIGHT="1.3086991830422616"/>
<DICH_DATA CI_END="1.0323063713894243" CI_START="0.37319894434005896" EFFECT_SIZE="0.6206896551724138" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.01380860781209295" LOG_CI_START="-0.42805959340339295" LOG_EFFECT_SIZE="-0.20712549279564998" ORDER="67652" O_E="0.0" SE="0.2595555686768485" STUDY_ID="STD-Trinh_x002d_Duc-1992" TOTAL_1="29" TOTAL_2="27" VAR="0.0673690932311622" WEIGHT="2.2290319824412004"/>
<DICH_DATA CI_END="2.5475015595668227" CI_START="0.008011050351928473" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.40611445855130324" LOG_CI_START="-2.0963105385798166" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="67653" O_E="0.0" SE="1.469936830518334" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="2.1607142857142856" WEIGHT="0.06949917646824891"/>
<DICH_DATA CI_END="1.1531481274998097" CI_START="0.3121888605764218" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.061885098121928904" LOG_CI_START="-0.5055825973546417" LOG_EFFECT_SIZE="-0.22184874961635637" MODIFIED="2010-05-17 11:23:23 +0100" MODIFIED_BY="Katharine Ker" ORDER="2575" O_E="0.0" SE="0.3333333333333333" STUDY_ID="STD-Dorman-2008" TOTAL_1="30" TOTAL_2="30" VAR="0.1111111111111111" WEIGHT="1.351510770962912"/>
<DICH_DATA CI_END="3.6287762406689716" CI_START="0.4960541309410133" EFFECT_SIZE="1.3416666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5597601893527253" LOG_CI_START="-0.30447092938427567" LOG_EFFECT_SIZE="0.12764462998422485" ORDER="67648" O_E="0.0" SE="0.507653637159147" STUDY_ID="STD-Greilich-2001" TOTAL_1="24" TOTAL_2="23" VAR="0.25771221532091093" WEIGHT="0.5826959473121212"/>
<DICH_DATA CI_END="2.4772689203208653" CI_START="0.1009175862778834" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3939731540513527" LOG_CI_START="-0.9960331453793151" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="67654" O_E="0.0" SE="0.816496580927726" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.6666666666666667" WEIGHT="0.22525179516048527"/>
<DICH_DATA CI_END="1.346564360926496" CI_START="0.49177073391944337" EFFECT_SIZE="0.8137573004542504" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.12922711595564204" LOG_CI_START="-0.30823732040308555" LOG_EFFECT_SIZE="-0.08950510222372171" ORDER="67646" O_E="0.0" SE="0.25696877540100105" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="66" VAR="0.06603295153109012" WEIGHT="2.274135260629996"/>
<DICH_DATA CI_END="2.3302506070190314" CI_START="0.10728459816595091" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.36740262977830473" LOG_CI_START="-0.9694626211062671" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="67651" O_E="0.0" SE="0.7852812659593165" STUDY_ID="STD-Ray-2005" TOTAL_1="15" TOTAL_2="15" VAR="0.6166666666666667" WEIGHT="0.24351545422755166"/>
<DICH_DATA CI_END="1.5542598037816595" CI_START="0.4946396798386406" EFFECT_SIZE="0.8768115942028986" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.19152361544173646" LOG_CI_START="-0.30571104761130935" LOG_EFFECT_SIZE="-0.057093716084786424" ORDER="67650" O_E="0.0" SE="0.29207810242863735" STUDY_ID="STD-Amar-2003" TOTAL_1="23" TOTAL_2="22" VAR="0.08530961791831358" WEIGHT="1.7602688548448735"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.328718225624018" CI_END="0.8850067900287706" CI_START="0.7602841421013965" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.820278384520118" ESTIMABLE="YES" EVENTS_1="522" EVENTS_2="637" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-0.053053397256169255" LOG_CI_START="-0.11902406787137046" LOG_EFFECT_SIZE="-0.08603873256376986" METHOD="MH" MODIFIED="2010-05-17 14:16:37 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.5915785032899237" P_Q="0.0" P_Z="3.181634493187535E-7" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1102" TOTAL_2="1098" WEIGHT="100.00000000000001" Z="5.112357219591628">
<NAME>No. Exposed to Allogeneic Blood - Type of Surgery</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.873407989032572" CI_END="0.8857199866747966" CI_START="0.7597220253187783" DF="9" EFFECT_SIZE="0.8203054200368896" ESTIMABLE="YES" EVENTS_1="509" EVENTS_2="621" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="-0.05270355515889599" LOG_CI_START="-0.11934528265751772" LOG_EFFECT_SIZE="-0.08602441890820685" MODIFIED="2010-05-17 14:16:37 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="0.4490410930011245" P_Z="4.1917780759470497E-7" STUDIES="10" TAU2="0.0" TOTAL_1="1064" TOTAL_2="1061" WEIGHT="97.99621569092758" Z="5.060035781772283">
<NAME>Cardiac surgery</NAME>
<DICH_DATA CI_END="1.346564360926496" CI_START="0.49177073391944337" EFFECT_SIZE="0.8137573004542504" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.12922711595564204" LOG_CI_START="-0.30823732040308555" LOG_EFFECT_SIZE="-0.08950510222372171" ORDER="67655" O_E="0.0" SE="0.25696877540100105" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="66" VAR="0.06603295153109012" WEIGHT="2.274135260629996"/>
<DICH_DATA CI_END="1.1531481274998097" CI_START="0.3121888605764218" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.061885098121928904" LOG_CI_START="-0.5055825973546417" LOG_EFFECT_SIZE="-0.22184874961635637" MODIFIED="2010-05-17 11:23:41 +0100" MODIFIED_BY="Katharine Ker" ORDER="2576" O_E="0.0" SE="0.3333333333333333" STUDY_ID="STD-Dorman-2008" TOTAL_1="30" TOTAL_2="30" VAR="0.1111111111111111" WEIGHT="1.351510770962912"/>
<DICH_DATA CI_END="1.3697803938804385" CI_START="0.41064976730065383" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.13665094571788927" LOG_CI_START="-0.3865284189344892" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="67656" O_E="0.0" SE="0.30731814857642953" STUDY_ID="STD-Eberle-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.09444444444444443" WEIGHT="1.590012671721073"/>
<DICH_DATA CI_END="0.8852021538681629" CI_START="0.7506877794135325" EFFECT_SIZE="0.8151750972762646" ESTIMABLE="YES" EVENTS_1="419" EVENTS_2="514" LOG_CI_END="-0.052957538020965964" LOG_CI_START="-0.12454065403699495" LOG_EFFECT_SIZE="-0.08874909602898043" MODIFIED="2010-01-11 13:55:36 +0000" MODIFIED_BY="Katharine Ker" ORDER="2291" O_E="0.0" SE="0.04204827668995443" STUDY_ID="STD-Fergusson-2008" TOTAL_1="780" TOTAL_2="780" VAR="0.0017680575725949651" WEIGHT="84.93380858629126"/>
<DICH_DATA CI_END="3.6287762406689716" CI_START="0.4960541309410133" EFFECT_SIZE="1.3416666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5597601893527253" LOG_CI_START="-0.30447092938427567" LOG_EFFECT_SIZE="0.12764462998422485" ORDER="67657" O_E="0.0" SE="0.507653637159147" STUDY_ID="STD-Greilich-2001" TOTAL_1="24" TOTAL_2="23" VAR="0.25771221532091093" WEIGHT="0.5826959473121212"/>
<DICH_DATA CI_END="1.7386462202749464" CI_START="0.7657457458683129" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.2402112207530636" LOG_CI_START="-0.11591540725537476" LOG_EFFECT_SIZE="0.062147906748844434" MODIFIED="2010-05-17 14:16:37 +0100" MODIFIED_BY="Katharine Ker" ORDER="2606" O_E="0.0" SE="0.2091905441473963" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="25" VAR="0.043760683760683754" WEIGHT="3.4315703168980187"/>
<DICH_DATA CI_END="2.4772689203208653" CI_START="0.1009175862778834" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3939731540513527" LOG_CI_START="-0.9960331453793151" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="67661" O_E="0.0" SE="0.816496580927726" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.6666666666666667" WEIGHT="0.22525179516048527"/>
<DICH_DATA CI_END="2.5475015595668227" CI_START="0.008011050351928473" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.40611445855130324" LOG_CI_START="-2.0963105385798166" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="67660" O_E="0.0" SE="1.469936830518334" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="2.1607142857142856" WEIGHT="0.06949917646824891"/>
<DICH_DATA CI_END="2.3586217117979826" CI_START="0.6251489115625755" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.3726582920289919" LOG_CI_START="-0.2040165206289201" LOG_EFFECT_SIZE="0.08432088570003587" ORDER="67658" O_E="0.0" SE="0.3387416395416184" STUDY_ID="STD-Ray-2001" TOTAL_1="49" TOTAL_2="51" VAR="0.11474589835934375" WEIGHT="1.3086991830422616"/>
<DICH_DATA CI_END="1.0323063713894243" CI_START="0.37319894434005896" EFFECT_SIZE="0.6206896551724138" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.01380860781209295" LOG_CI_START="-0.42805959340339295" LOG_EFFECT_SIZE="-0.20712549279564998" ORDER="67659" O_E="0.0" SE="0.2595555686768485" STUDY_ID="STD-Trinh_x002d_Duc-1992" TOTAL_1="29" TOTAL_2="27" VAR="0.0673690932311622" WEIGHT="2.2290319824412004"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.47459535325624785" CI_END="1.4004978318922592" CI_START="0.4788947312954546" DF="1" EFFECT_SIZE="0.8189572839189541" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="0.14628244082973563" LOG_CI_START="-0.319759940952585" LOG_EFFECT_SIZE="-0.08673875006142465" NO="2" P_CHI2="0.49088069064847206" P_Z="0.4656542361726208" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="37" WEIGHT="2.003784309072425" Z="0.7295680943619405">
<NAME>Orthopaedic surgery</NAME>
<DICH_DATA CI_END="1.5542598037816595" CI_START="0.4946396798386406" EFFECT_SIZE="0.8768115942028986" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.19152361544173646" LOG_CI_START="-0.30571104761130935" LOG_EFFECT_SIZE="-0.057093716084786424" ORDER="67662" O_E="0.0" SE="0.29207810242863735" STUDY_ID="STD-Amar-2003" TOTAL_1="23" TOTAL_2="22" VAR="0.08530961791831358" WEIGHT="1.7602688548448735"/>
<DICH_DATA CI_END="2.3302506070190314" CI_START="0.10728459816595091" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.36740262977830473" LOG_CI_START="-0.9694626211062671" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="67663" O_E="0.0" SE="0.7852812659593165" STUDY_ID="STD-Ray-2005" TOTAL_1="15" TOTAL_2="15" VAR="0.6166666666666667" WEIGHT="0.24351545422755166"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.328718225624012" CI_END="0.8850067900287706" CI_START="0.7602841421013966" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.820278384520118" ESTIMABLE="YES" EVENTS_1="522" EVENTS_2="637" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-0.053053397256169255" LOG_CI_START="-0.11902406787137039" LOG_EFFECT_SIZE="-0.08603873256376986" METHOD="MH" MODIFIED="2010-06-24 00:43:31 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5915785032899241" P_Q="0.0" P_Z="3.181634493187581E-7" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1102" TOTAL_2="1098" WEIGHT="99.99999999999999" Z="5.112357219591625">
<NAME>No. Exposed to Allogeneic Blood - Transfusion Protocol</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.446146706823734" CI_END="0.8884247021133553" CI_START="0.7609676134315593" DF="8" EFFECT_SIZE="0.8222301534733715" ESTIMABLE="YES" EVENTS_1="494" EVENTS_2="603" I2="0.0" ID="CMP-005.03.01" LOG_CI_END="-0.05137937465938364" LOG_CI_START="-0.11863382628759421" LOG_EFFECT_SIZE="-0.08500660047348893" MODIFIED="2010-06-24 00:43:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5973871213824875" P_Z="7.247455288407766E-7" STUDIES="9" TAU2="0.0" TOTAL_1="1009" TOTAL_2="1005" WEIGHT="96.21875338028897" Z="4.954612559991128">
<NAME>Transfusion Protocol</NAME>
<DICH_DATA CI_END="1.5542598037816595" CI_START="0.4946396798386406" EFFECT_SIZE="0.8768115942028986" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.19152361544173646" LOG_CI_START="-0.30571104761130935" LOG_EFFECT_SIZE="-0.057093716084786424" ORDER="67664" O_E="0.0" SE="0.29207810242863735" STUDY_ID="STD-Amar-2003" TOTAL_1="23" TOTAL_2="22" VAR="0.08530961791831358" WEIGHT="1.760268854844873"/>
<DICH_DATA CI_END="1.346564360926496" CI_START="0.49177073391944337" EFFECT_SIZE="0.8137573004542504" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.12922711595564204" LOG_CI_START="-0.30823732040308555" LOG_EFFECT_SIZE="-0.08950510222372171" ORDER="67665" O_E="0.0" SE="0.25696877540100105" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="66" VAR="0.06603295153109012" WEIGHT="2.2741352606299956"/>
<DICH_DATA CI_END="1.1531481274998097" CI_START="0.3121888605764218" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.061885098121928904" LOG_CI_START="-0.5055825973546417" LOG_EFFECT_SIZE="-0.22184874961635637" MODIFIED="2010-05-20 14:31:47 +0100" MODIFIED_BY="Katharine Ker" ORDER="5354" O_E="0.0" SE="0.3333333333333333" STUDY_ID="STD-Dorman-2008" TOTAL_1="30" TOTAL_2="30" VAR="0.1111111111111111" WEIGHT="1.3515107709629115"/>
<DICH_DATA CI_END="1.3697803938804385" CI_START="0.41064976730065383" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.13665094571788927" LOG_CI_START="-0.3865284189344892" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="67666" O_E="0.0" SE="0.30731814857642953" STUDY_ID="STD-Eberle-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.09444444444444443" WEIGHT="1.5900126717210727"/>
<DICH_DATA CI_END="0.8852021538681629" CI_START="0.7506877794135325" EFFECT_SIZE="0.8151750972762646" ESTIMABLE="YES" EVENTS_1="419" EVENTS_2="514" LOG_CI_END="-0.052957538020965964" LOG_CI_START="-0.12454065403699495" LOG_EFFECT_SIZE="-0.08874909602898043" MODIFIED="2010-01-11 13:56:12 +0000" MODIFIED_BY="Katharine Ker" ORDER="2292" O_E="0.0" SE="0.04204827668995443" STUDY_ID="STD-Fergusson-2008" TOTAL_1="780" TOTAL_2="780" VAR="0.0017680575725949651" WEIGHT="84.93380858629125"/>
<DICH_DATA CI_END="3.6287762406689716" CI_START="0.4960541309410133" EFFECT_SIZE="1.3416666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5597601893527253" LOG_CI_START="-0.30447092938427567" LOG_EFFECT_SIZE="0.12764462998422485" ORDER="67667" O_E="0.0" SE="0.507653637159147" STUDY_ID="STD-Greilich-2001" TOTAL_1="24" TOTAL_2="23" VAR="0.25771221532091093" WEIGHT="0.582695947312121"/>
<DICH_DATA CI_END="1.7386462202749464" CI_START="0.7657457458683129" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.2402112207530636" LOG_CI_START="-0.11591540725537476" LOG_EFFECT_SIZE="0.062147906748844434" MODIFIED="2010-05-17 14:16:55 +0100" MODIFIED_BY="Katharine Ker" ORDER="2607" O_E="0.0" SE="0.2091905441473963" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="25" VAR="0.043760683760683754" WEIGHT="3.4315703168980183"/>
<DICH_DATA CI_END="2.4772689203208653" CI_START="0.1009175862778834" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3939731540513527" LOG_CI_START="-0.9960331453793151" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="67668" O_E="0.0" SE="0.816496580927726" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.6666666666666667" WEIGHT="0.22525179516048524"/>
<DICH_DATA CI_END="2.5475015595668227" CI_START="0.008011050351928473" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.40611445855130324" LOG_CI_START="-2.0963105385798166" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="67669" O_E="0.0" SE="1.469936830518334" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="2.1607142857142856" WEIGHT="0.0694991764682489"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.856600206186144" CI_END="1.309266805292884" CI_START="0.4700471223251068" DF="2" EFFECT_SIZE="0.7844852415333929" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="34" I2="29.98670252600008" ID="CMP-005.03.02" LOG_CI_END="0.11702815706206726" LOG_CI_START="-0.32785860176656884" LOG_EFFECT_SIZE="-0.10541522235225083" NO="2" P_CHI2="0.23971641225872364" P_Z="0.35298197032297973" STUDIES="3" TAU2="0.0643615423621647" TOTAL_1="93" TOTAL_2="93" WEIGHT="3.7812466197110126" Z="0.9288208072395181">
<NAME>No Transfusion Protocol</NAME>
<DICH_DATA CI_END="2.3586217117979826" CI_START="0.6251489115625755" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.3726582920289919" LOG_CI_START="-0.2040165206289201" LOG_EFFECT_SIZE="0.08432088570003587" ORDER="67670" O_E="0.0" SE="0.3387416395416184" STUDY_ID="STD-Ray-2001" TOTAL_1="49" TOTAL_2="51" VAR="0.11474589835934375" WEIGHT="1.3086991830422612"/>
<DICH_DATA CI_END="2.3302506070190314" CI_START="0.10728459816595091" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.36740262977830473" LOG_CI_START="-0.9694626211062671" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="67671" O_E="0.0" SE="0.7852812659593165" STUDY_ID="STD-Ray-2005" TOTAL_1="15" TOTAL_2="15" VAR="0.6166666666666667" WEIGHT="0.2435154542275516"/>
<DICH_DATA CI_END="1.0323063713894243" CI_START="0.37319894434005896" EFFECT_SIZE="0.6206896551724138" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.01380860781209295" LOG_CI_START="-0.42805959340339295" LOG_EFFECT_SIZE="-0.20712549279564998" ORDER="67672" O_E="0.0" SE="0.2595555686768485" STUDY_ID="STD-Trinh_x002d_Duc-1992" TOTAL_1="29" TOTAL_2="27" VAR="0.0673690932311622" WEIGHT="2.2290319824412"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.328718225624018" CI_END="0.8850067900287706" CI_START="0.7602841421013966" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.820278384520118" ESTIMABLE="YES" EVENTS_1="522" EVENTS_2="637" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="-0.053053397256169255" LOG_CI_START="-0.11902406787137039" LOG_EFFECT_SIZE="-0.08603873256376986" METHOD="MH" MODIFIED="2010-08-23 06:51:53 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5915785032899237" P_Q="0.0" P_Z="3.181634493187581E-7" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1102" TOTAL_2="1098" WEIGHT="99.99999999999999" Z="5.112357219591625">
<NAME>Trial Methodological Quality - Allocation Concealment</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.7511828232926585" CI_END="1.0452255475956256" CI_START="0.7082320145655511" DF="2" EFFECT_SIZE="0.8603849111002768" ESTIMABLE="YES" EVENTS_1="446" EVENTS_2="541" I2="27.303995101046436" ID="CMP-005.04.01" LOG_CI_END="0.01921001629085038" LOG_CI_START="-0.14982444550376828" LOG_EFFECT_SIZE="-0.06530721460645893" MODIFIED="2010-08-23 06:51:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.25269034604844753" P_Z="0.1299037446458748" STUDIES="3" TAU2="0.011745673398208274" TOTAL_1="826" TOTAL_2="825" WEIGHT="89.95539157491034" Z="1.5144815702115324">
<NAME>Allocation concealment - Yes</NAME>
<DICH_DATA CI_END="1.3697803938804385" CI_START="0.41064976730065383" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.13665094571788927" LOG_CI_START="-0.3865284189344892" LOG_EFFECT_SIZE="-0.12493873660829993" MODIFIED="2010-08-23 06:51:18 +0100" MODIFIED_BY="[Empty name]" ORDER="3036" O_E="0.0" SE="0.30731814857642953" STUDY_ID="STD-Eberle-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.09444444444444443" WEIGHT="1.5900126717210727"/>
<DICH_DATA CI_END="0.8852021538681629" CI_START="0.7506877794135325" EFFECT_SIZE="0.8151750972762646" ESTIMABLE="YES" EVENTS_1="419" EVENTS_2="514" LOG_CI_END="-0.052957538020965964" LOG_CI_START="-0.12454065403699495" LOG_EFFECT_SIZE="-0.08874909602898043" MODIFIED="2010-08-23 06:51:18 +0100" MODIFIED_BY="[Empty name]" ORDER="3034" O_E="0.0" SE="0.04204827668995443" STUDY_ID="STD-Fergusson-2008" TOTAL_1="780" TOTAL_2="780" VAR="0.0017680575725949651" WEIGHT="84.93380858629125"/>
<DICH_DATA CI_END="1.7386462202749464" CI_START="0.7657457458683129" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.2402112207530636" LOG_CI_START="-0.11591540725537476" LOG_EFFECT_SIZE="0.062147906748844434" MODIFIED="2010-08-23 06:51:18 +0100" MODIFIED_BY="[Empty name]" ORDER="3035" O_E="0.0" SE="0.2091905441473963" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="25" VAR="0.043760683760683754" WEIGHT="3.4315703168980183"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.189832727569074" CI_END="0.991480370066134" CI_START="0.5848981486439517" DF="7" EFFECT_SIZE="0.7615215248884971" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="84" I2="0.0" ID="CMP-005.04.02" LOG_CI_END="-0.0037158798009385907" LOG_CI_START="-0.23291975329044468" LOG_EFFECT_SIZE="-0.11831781654569164" MODIFIED="2010-08-23 06:51:44 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5177669662966247" P_Z="0.043020149552703314" STUDIES="8" TAU2="0.0" TOTAL_1="253" TOTAL_2="251" WEIGHT="8.284339570244775" Z="2.023514311764807">
<NAME>Allocation concealment - Unclear</NAME>
<DICH_DATA CI_END="1.346564360926496" CI_START="0.49177073391944337" EFFECT_SIZE="0.8137573004542504" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.12922711595564204" LOG_CI_START="-0.30823732040308555" LOG_EFFECT_SIZE="-0.08950510222372171" MODIFIED="2010-08-23 06:51:44 +0100" MODIFIED_BY="[Empty name]" ORDER="3043" O_E="0.0" SE="0.25696877540100105" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="66" VAR="0.06603295153109012" WEIGHT="2.2741352606299956"/>
<DICH_DATA CI_END="1.1531481274998097" CI_START="0.3121888605764218" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.061885098121928904" LOG_CI_START="-0.5055825973546417" LOG_EFFECT_SIZE="-0.22184874961635637" MODIFIED="2010-08-23 06:51:44 +0100" MODIFIED_BY="[Empty name]" ORDER="3039" O_E="0.0" SE="0.3333333333333333" STUDY_ID="STD-Dorman-2008" TOTAL_1="30" TOTAL_2="30" VAR="0.1111111111111111" WEIGHT="1.3515107709629115"/>
<DICH_DATA CI_END="3.6287762406689716" CI_START="0.4960541309410133" EFFECT_SIZE="1.3416666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5597601893527253" LOG_CI_START="-0.30447092938427567" LOG_EFFECT_SIZE="0.12764462998422485" MODIFIED="2010-08-23 06:51:44 +0100" MODIFIED_BY="[Empty name]" ORDER="3044" O_E="0.0" SE="0.507653637159147" STUDY_ID="STD-Greilich-2001" TOTAL_1="24" TOTAL_2="23" VAR="0.25771221532091093" WEIGHT="0.582695947312121"/>
<DICH_DATA CI_END="2.4772689203208653" CI_START="0.1009175862778834" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3939731540513527" LOG_CI_START="-0.9960331453793151" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-08-23 06:51:44 +0100" MODIFIED_BY="[Empty name]" ORDER="3037" O_E="0.0" SE="0.816496580927726" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.6666666666666667" WEIGHT="0.22525179516048524"/>
<DICH_DATA CI_END="2.5475015595668227" CI_START="0.008011050351928473" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.40611445855130324" LOG_CI_START="-2.0963105385798166" LOG_EFFECT_SIZE="-0.8450980400142569" MODIFIED="2010-08-23 06:51:44 +0100" MODIFIED_BY="[Empty name]" ORDER="3042" O_E="0.0" SE="1.469936830518334" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="2.1607142857142856" WEIGHT="0.0694991764682489"/>
<DICH_DATA CI_END="2.3586217117979826" CI_START="0.6251489115625755" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.3726582920289919" LOG_CI_START="-0.2040165206289201" LOG_EFFECT_SIZE="0.08432088570003587" MODIFIED="2010-08-23 06:51:44 +0100" MODIFIED_BY="[Empty name]" ORDER="3038" O_E="0.0" SE="0.3387416395416184" STUDY_ID="STD-Ray-2001" TOTAL_1="49" TOTAL_2="51" VAR="0.11474589835934375" WEIGHT="1.3086991830422612"/>
<DICH_DATA CI_END="2.3302506070190314" CI_START="0.10728459816595091" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.36740262977830473" LOG_CI_START="-0.9694626211062671" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-08-23 06:51:44 +0100" MODIFIED_BY="[Empty name]" ORDER="3041" O_E="0.0" SE="0.7852812659593165" STUDY_ID="STD-Ray-2005" TOTAL_1="15" TOTAL_2="15" VAR="0.6166666666666667" WEIGHT="0.2435154542275516"/>
<DICH_DATA CI_END="1.0323063713894243" CI_START="0.37319894434005896" EFFECT_SIZE="0.6206896551724138" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.01380860781209295" LOG_CI_START="-0.42805959340339295" LOG_EFFECT_SIZE="-0.20712549279564998" MODIFIED="2010-08-23 06:51:44 +0100" MODIFIED_BY="[Empty name]" ORDER="3040" O_E="0.0" SE="0.2595555686768485" STUDY_ID="STD-Trinh_x002d_Duc-1992" TOTAL_1="29" TOTAL_2="27" VAR="0.0673690932311622" WEIGHT="2.2290319824412"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5542598037816595" CI_START="0.4946396798386406" DF="0" EFFECT_SIZE="0.8768115942028986" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" I2="0.0" ID="CMP-005.04.03" LOG_CI_END="0.19152361544173646" LOG_CI_START="-0.30571104761130935" LOG_EFFECT_SIZE="-0.057093716084786424" MODIFIED="2010-08-23 06:51:53 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.652641335896794" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="22" WEIGHT="1.760268854844873" Z="0.4500958424042885">
<NAME>Allocation concealment - No</NAME>
<DICH_DATA CI_END="1.5542598037816595" CI_START="0.4946396798386406" EFFECT_SIZE="0.8768115942028986" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.19152361544173646" LOG_CI_START="-0.30571104761130935" LOG_EFFECT_SIZE="-0.057093716084786424" MODIFIED="2010-08-23 06:51:53 +0100" MODIFIED_BY="[Empty name]" ORDER="3045" O_E="0.0" SE="0.29207810242863735" STUDY_ID="STD-Amar-2003" TOTAL_1="23" TOTAL_2="22" VAR="0.08530961791831358" WEIGHT="1.760268854844873"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.6648890444663611" CI_END="0.27639128231970866" CI_START="-0.6284039110217328" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.17600631435101208" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.05" NO="5" P_CHI2="0.4148395263741248" P_Q="1.0" P_Z="0.4457446774311473" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="35" UNITS="" WEIGHT="100.0" Z="0.7625284478040758">
<NAME>Units of Allogeneic Blood Transfused - Transfused Patients</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.26003815088762194" CI_START="-0.9400381508876225" EFFECT_SIZE="-0.3400000000000003" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="2.24" ORDER="67681" SD_1="1.04" SD_2="0.92" SE="0.3061475392510508" STUDY_ID="STD-Casati-1999" TOTAL_1="19" TOTAL_2="23" WEIGHT="56.843766934476825"/>
<CONT_DATA CI_END="0.7286499561705034" CI_START="-0.6486499561705034" EFFECT_SIZE="0.040000000000000036" ESTIMABLE="YES" MEAN_1="1.29" MEAN_2="1.25" ORDER="67682" SD_1="0.88" SD_2="0.67" SE="0.3513584747487639" STUDY_ID="STD-Eberle-1998" TOTAL_1="9" TOTAL_2="12" WEIGHT="43.156233065523175"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.144454105261596" CI_END="0.13856047186851284" CI_START="-0.5544494848210457" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.20794450647626644" ESTIMABLE="YES" I2="22.246366316905856" I2_Q="0.0" ID="CMP-005.06" MODIFIED="2010-05-20 14:33:07 +0100" MODIFIED_BY="Katharine Ker" NO="6" P_CHI2="0.27279424108159944" P_Q="1.0" P_Z="0.2395096954783732" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.03553388348057781" TOTALS="YES" TOTAL_1="166" TOTAL_2="163" UNITS="" WEIGHT="100.0" Z="1.1762132406389394">
<NAME>Units of Allogeneic Blood Transfused - All Patients</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3112466360074677" CI_START="-1.1112466360074675" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="1.7" ORDER="67685" SD_1="1.5" SD_2="2.5" SE="0.6179943333457281" STUDY_ID="STD-Amar-2003" TOTAL_1="23" TOTAL_2="22" WEIGHT="7.487164840277045"/>
<CONT_DATA CI_END="0.138767997076907" CI_START="-0.618767997076907" EFFECT_SIZE="-0.24" ESTIMABLE="YES" MEAN_1="0.54" MEAN_2="0.78" ORDER="67683" SD_1="1.02" SD_2="1.2" SE="0.1932525291610359" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="66" WEIGHT="42.88563920617145"/>
<CONT_DATA CI_END="-0.019832859334859565" CI_START="-1.7801671406651403" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="0.56" MEAN_2="1.46" MODIFIED="2010-05-20 14:33:07 +0100" MODIFIED_BY="Katharine Ker" ORDER="2579" SD_1="1.1" SD_2="2.2" SE="0.44907311951024936" STUDY_ID="STD-Dorman-2008" TOTAL_1="30" TOTAL_2="30" WEIGHT="13.176712894656594"/>
<CONT_DATA CI_END="0.35095975437843574" CI_START="-0.6909597543784358" EFFECT_SIZE="-0.17000000000000004" ESTIMABLE="YES" MEAN_1="0.58" MEAN_2="0.75" ORDER="67684" SD_1="0.87" SD_2="0.81" SE="0.2658006772000403" STUDY_ID="STD-Eberle-1998" TOTAL_1="20" TOTAL_2="20" WEIGHT="29.435008828967216"/>
<CONT_DATA CI_END="2.0549657434042254" CI_START="-0.45496574340422513" EFFECT_SIZE="0.8" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="1.7" MODIFIED="2010-05-17 14:17:36 +0100" MODIFIED_BY="Katharine Ker" ORDER="2609" SD_1="2.7" SD_2="1.8" SE="0.6403004102642879" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="25" WEIGHT="7.015474229927697"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="26.29543827185073" CI_END="0.4717257946600455" CI_START="-212.50165536175047" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-106.01496478354521" ESTIMABLE="YES" I2="73.37941308438468" I2_Q="0.0" ID="CMP-005.07" MODIFIED="2010-05-20 15:17:30 +0100" MODIFIED_BY="Katharine Ker" NO="7" P_CHI2="4.459641640400802E-4" P_Q="0.4541479522885301" P_Z="0.05102356465931091" Q="0.5602790151140269" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="13708.989482311745" TOTALS="YES" TOTAL_1="253" TOTAL_2="246" UNITS="" WEIGHT="100.00000000000001" Z="1.951281532647785">
<NAME>Blood loss</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="25.735159256736704" CI_END="-2.2107231215116485" CI_START="-220.63965791366226" DF="6" EFFECT_SIZE="-111.42519051758696" ESTIMABLE="YES" I2="76.68559211099742" ID="CMP-005.07.01" MODIFIED="2010-05-20 15:17:30 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="2.494059925695069E-4" P_Z="0.045539405870961044" STUDIES="7" TAU2="14145.969229173419" TOTAL_1="230" TOTAL_2="224" WEIGHT="97.36881748553532" Z="1.9996376450106863">
<NAME>Cardiac surgery - Post-operative</NAME>
<CONT_DATA CI_END="-104.1455744505483" CI_START="-262.8544255494517" EFFECT_SIZE="-183.5" ESTIMABLE="YES" MEAN_1="283.4" MEAN_2="466.9" ORDER="67689" SD_1="232.7" SD_2="234.2" SE="40.487695781855834" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="66" WEIGHT="19.23250313569463"/>
<CONT_DATA CI_END="701.1101156313906" CI_START="-1047.1101156313907" EFFECT_SIZE="-173.0" ESTIMABLE="YES" MEAN_1="423.0" MEAN_2="596.0" MODIFIED="2010-05-17 11:31:14 +0100" MODIFIED_BY="Katharine Ker" ORDER="2580" SD_1="1363.83" SD_2="2026.57" SE="445.98274382910074" STUDY_ID="STD-Dorman-2008" TOTAL_1="30" TOTAL_2="30" WEIGHT="1.3883904360583954"/>
<CONT_DATA CI_END="-36.99870628075428" CI_START="-345.0012937192457" EFFECT_SIZE="-191.0" ESTIMABLE="YES" MEAN_1="391.0" MEAN_2="582.0" ORDER="67690" SD_1="220.0" SD_2="274.0" SE="78.57353243936535" STUDY_ID="STD-Eberle-1998" TOTAL_1="20" TOTAL_2="20" WEIGHT="14.846263485027446"/>
<CONT_DATA CI_END="218.05815426228986" CI_START="-278.05815426228986" EFFECT_SIZE="-30.0" ESTIMABLE="YES" MEAN_1="685.0" MEAN_2="715.0" MODIFIED="2010-05-20 15:17:30 +0100" MODIFIED_BY="Katharine Ker" ORDER="2610" SD_1="505.0" SD_2="394.0" SE="126.56260840451198" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="25" WEIGHT="9.929838329920308"/>
<CONT_DATA CI_END="303.7261961490581" CI_START="40.273803850941874" EFFECT_SIZE="172.0" ESTIMABLE="YES" MEAN_1="515.0" MEAN_2="343.0" ORDER="67686" SD_1="339.48" SD_2="305.13" SE="67.20847790474598" STUDY_ID="STD-Landymore-1997" TOTAL_1="48" TOTAL_2="44" WEIGHT="16.195853933549444"/>
<CONT_DATA CI_END="-99.3658411185487" CI_START="-328.6341588814513" EFFECT_SIZE="-214.0" ESTIMABLE="YES" MEAN_1="298.0" MEAN_2="512.0" ORDER="67687" SD_1="140.0" SD_2="250.0" SE="58.48789048455529" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" WEIGHT="17.23223495354155"/>
<CONT_DATA CI_END="-72.87474276189569" CI_START="-257.1252572381043" EFFECT_SIZE="-165.0" ESTIMABLE="YES" MEAN_1="344.0" MEAN_2="509.0" ORDER="67688" SD_1="106.0" SD_2="148.0" SE="47.00354596552619" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" WEIGHT="18.54373321174354"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="715.0611220553682" CI_START="-515.0611220553682" DF="0" EFFECT_SIZE="100.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.07.02" NO="2" P_CHI2="1.0" P_Z="0.7499830910848766" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="22" WEIGHT="2.6311825144647014" Z="0.3186616604851212">
<NAME>Orthopaedic surgery - Total</NAME>
<CONT_DATA CI_END="715.0611220553682" CI_START="-515.0611220553682" EFFECT_SIZE="100.0" ESTIMABLE="YES" MEAN_1="1700.0" MEAN_2="1600.0" ORDER="67691" SD_1="1000.0" SD_2="1100.0" SE="313.8124613038259" STUDY_ID="STD-Amar-2003" TOTAL_1="23" TOTAL_2="22" WEIGHT="2.6311825144647014"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2010-08-23 06:53:47 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Tranexamic Acid versus Epsilon Aminocaproic Acid (Blood Transfusion &amp; Blood Loss)</NAME>
<DICH_OUTCOME CHI2="14.01005753051979" CI_END="1.2131952469028129" CI_START="0.7697353364558595" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9663535851650711" ESTIMABLE="YES" EVENTS_1="589" EVENTS_2="602" I2="50.03589396580949" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.08393070014841489" LOG_CI_START="-0.11365857570435295" LOG_EFFECT_SIZE="-0.014863937777969004" METHOD="MH" MODIFIED="2010-08-23 06:10:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.051002815733651286" P_Q="0.0" P_Z="0.7680838508002452" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.03628645162553983" TOTALS="YES" TOTAL_1="1000" TOTAL_2="1003" WEIGHT="100.0" Z="0.29488222564236377">
<NAME>No. Exposed to Allogeneic Blood</NAME>
<GROUP_LABEL_1>TXA</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TXA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0714271770893142" CI_START="0.9281536834267589" EFFECT_SIZE="0.9972206781545303" ESTIMABLE="YES" EVENTS_1="506" EVENTS_2="514" LOG_CI_END="0.029962658193486508" LOG_CI_START="-0.03238010746844269" LOG_EFFECT_SIZE="-0.001208724637478083" MODIFIED="2010-01-11 12:51:14 +0000" MODIFIED_BY="Katharine Ker" ORDER="2277" O_E="0.0" SE="0.03662044915148434" STUDY_ID="STD-Fergusson-2008" TOTAL_1="770" TOTAL_2="780" VAR="0.00134105729605645" WEIGHT="35.80110866554023"/>
<DICH_DATA CI_END="3.218204689122558" CI_START="0.7673184255334977" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.5076136632960574" LOG_CI_START="-0.11502437300812099" LOG_EFFECT_SIZE="0.1962946451439682" ORDER="67693" O_E="0.0" SE="0.36574066463306176" STUDY_ID="STD-Pinosky-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.13376623376623376" WEIGHT="7.921701045838468"/>
<DICH_DATA CI_END="1.1828659437077156" CI_START="0.41058060821360803" EFFECT_SIZE="0.6968944099378882" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="23" LOG_CI_END="0.07293552805399836" LOG_CI_START="-0.38660156627741266" LOG_EFFECT_SIZE="-0.1568330191117071" ORDER="67692" O_E="0.0" SE="0.26993436395557435" STUDY_ID="STD-Casati-1999" TOTAL_1="70" TOTAL_2="66" VAR="0.07286456084410048" WEIGHT="12.341676959619061"/>
<DICH_DATA CI_END="7.993224784658692" CI_START="1.1259535722395293" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.9027220263270903" LOG_CI_START="0.05152048311223442" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="67698" O_E="0.0" SE="0.49999999999999994" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.24999999999999997" WEIGHT="4.705449832036259"/>
<DICH_DATA CI_END="1.9698605497043828" CI_START="0.6041456309212826" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.2944354826907784" LOG_CI_START="-0.21885836091197888" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="67695" O_E="0.0" SE="0.3015113445777637" STUDY_ID="STD-Maineri-2000" TOTAL_1="24" TOTAL_2="24" VAR="0.09090909090909094" WEIGHT="10.59083132059352"/>
<DICH_DATA CI_END="2.8531415452949767" CI_START="0.03894342756823292" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45532331768430767" LOG_CI_START="-1.4095658271236327" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67697" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="1.2" WEIGHT="1.0896394876320132"/>
<DICH_DATA CI_END="1.0211571981957106" CI_START="0.6354748849961598" EFFECT_SIZE="0.8055555555555556" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="36" LOG_CI_END="0.009092603060352863" LOG_CI_START="-0.19690160879701507" LOG_EFFECT_SIZE="-0.09390450286833116" ORDER="67694" O_E="0.0" SE="0.12100201973281195" STUDY_ID="STD-Dalmau-2000" TOTAL_1="42" TOTAL_2="42" VAR="0.014641488779419815" WEIGHT="26.45122745989673"/>
<DICH_DATA CI_END="1.939290490630948" CI_START="0.026940212521841325" EFFECT_SIZE="0.22857142857142856" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2876428678867581" LOG_CI_START="-1.5695989826034222" LOG_EFFECT_SIZE="-0.640978057358332" ORDER="67696" O_E="0.0" SE="1.0909530564733625" STUDY_ID="STD-Camarasa-2006" TOTAL_1="35" TOTAL_2="32" VAR="1.1901785714285715" WEIGHT="1.0983652288437245"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.010057530519791" CI_END="1.213195246902813" CI_START="0.7697353364558595" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9663535851650711" ESTIMABLE="YES" EVENTS_1="589" EVENTS_2="602" I2="50.0358939658095" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.08393070014841497" LOG_CI_START="-0.11365857570435295" LOG_EFFECT_SIZE="-0.014863937777969004" METHOD="MH" MODIFIED="2010-01-11 13:57:20 +0000" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.051002815733651286" P_Q="0.0" P_Z="0.7680838508002453" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.036286451625539846" TOTALS="YES" TOTAL_1="1000" TOTAL_2="1003" WEIGHT="99.99999999999999" Z="0.29488222564236366">
<NAME>No. Exposed to Allogeneic Blood - Type of Surgery</NAME>
<GROUP_LABEL_1>TXA</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TXA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.247281035041192" CI_END="1.4630415322940604" CI_START="0.7871348211594018" DF="5" EFFECT_SIZE="1.0731313688785091" ESTIMABLE="YES" EVENTS_1="559" EVENTS_2="562" I2="45.93005250891321" ID="CMP-006.02.01" LOG_CI_END="0.16525665489503838" LOG_CI_START="-0.10395087492065745" LOG_EFFECT_SIZE="0.030652889987190533" MODIFIED="2010-01-11 13:57:20 +0000" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="0.0995982788937172" P_Z="0.6553542649901654" STUDIES="6" TAU2="0.05913277844603159" TOTAL_1="923" TOTAL_2="929" WEIGHT="72.45040731125954" Z="0.446336404023265">
<NAME>Cardiac surgery</NAME>
<DICH_DATA CI_END="1.1828659437077156" CI_START="0.41058060821360803" EFFECT_SIZE="0.6968944099378882" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="23" LOG_CI_END="0.07293552805399836" LOG_CI_START="-0.38660156627741266" LOG_EFFECT_SIZE="-0.1568330191117071" ORDER="67699" O_E="0.0" SE="0.26993436395557435" STUDY_ID="STD-Casati-1999" TOTAL_1="70" TOTAL_2="66" VAR="0.07286456084410048" WEIGHT="12.341676959619063"/>
<DICH_DATA CI_END="1.0714271770893142" CI_START="0.9281536834267589" EFFECT_SIZE="0.9972206781545303" ESTIMABLE="YES" EVENTS_1="506" EVENTS_2="514" LOG_CI_END="0.029962658193486508" LOG_CI_START="-0.03238010746844269" LOG_EFFECT_SIZE="-0.001208724637478083" MODIFIED="2010-01-11 13:57:20 +0000" MODIFIED_BY="Katharine Ker" ORDER="2294" O_E="0.0" SE="0.03662044915148434" STUDY_ID="STD-Fergusson-2008" TOTAL_1="770" TOTAL_2="780" VAR="0.00134105729605645" WEIGHT="35.80110866554022"/>
<DICH_DATA CI_END="1.9698605497043828" CI_START="0.6041456309212826" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.2944354826907784" LOG_CI_START="-0.21885836091197888" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="67700" O_E="0.0" SE="0.3015113445777637" STUDY_ID="STD-Maineri-2000" TOTAL_1="24" TOTAL_2="24" VAR="0.09090909090909094" WEIGHT="10.590831320593521"/>
<DICH_DATA CI_END="7.993224784658692" CI_START="1.1259535722395293" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.9027220263270903" LOG_CI_START="0.05152048311223442" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="67703" O_E="0.0" SE="0.49999999999999994" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.24999999999999997" WEIGHT="4.705449832036259"/>
<DICH_DATA CI_END="2.8531415452949767" CI_START="0.03894342756823292" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45532331768430767" LOG_CI_START="-1.4095658271236327" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67702" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="1.2" WEIGHT="1.0896394876320135"/>
<DICH_DATA CI_END="3.218204689122558" CI_START="0.7673184255334977" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.5076136632960574" LOG_CI_START="-0.11502437300812099" LOG_EFFECT_SIZE="0.1962946451439682" ORDER="67701" O_E="0.0" SE="0.36574066463306176" STUDY_ID="STD-Pinosky-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.13376623376623376" WEIGHT="7.921701045838469"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9392904906309476" CI_START="0.02694021252184131" DF="0" EFFECT_SIZE="0.2285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-006.02.02" LOG_CI_END="0.28764286788675797" LOG_CI_START="-1.5695989826034225" LOG_EFFECT_SIZE="-0.6409780573583321" NO="2" P_CHI2="1.0" P_Z="0.17610042824623465" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="32" WEIGHT="1.0983652288437247" Z="1.3528597871851828">
<NAME>Orthopaedic surgery</NAME>
<DICH_DATA CI_END="1.939290490630948" CI_START="0.026940212521841325" EFFECT_SIZE="0.22857142857142856" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2876428678867581" LOG_CI_START="-1.5695989826034222" LOG_EFFECT_SIZE="-0.640978057358332" ORDER="67704" O_E="0.0" SE="1.0909530564733625" STUDY_ID="STD-Camarasa-2006" TOTAL_1="35" TOTAL_2="32" VAR="1.1901785714285715" WEIGHT="1.0983652288437247"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0211571981957106" CI_START="0.6354748849961598" DF="0" EFFECT_SIZE="0.8055555555555556" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="36" I2="0.0" ID="CMP-006.02.03" LOG_CI_END="0.009092603060352863" LOG_CI_START="-0.19690160879701507" LOG_EFFECT_SIZE="-0.09390450286833116" NO="3" P_CHI2="1.0" P_Z="0.07394750810217901" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="42" WEIGHT="26.451227459896725" Z="1.7869380110107618">
<NAME>Liver surgery</NAME>
<DICH_DATA CI_END="1.0211571981957106" CI_START="0.6354748849961598" EFFECT_SIZE="0.8055555555555556" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="36" LOG_CI_END="0.009092603060352863" LOG_CI_START="-0.19690160879701507" LOG_EFFECT_SIZE="-0.09390450286833116" ORDER="67705" O_E="0.0" SE="0.12100201973281195" STUDY_ID="STD-Dalmau-2000" TOTAL_1="42" TOTAL_2="42" VAR="0.014641488779419815" WEIGHT="26.451227459896725"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.010057530519791" CI_END="1.2131952469028129" CI_START="0.7697353364558595" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9663535851650711" ESTIMABLE="YES" EVENTS_1="589" EVENTS_2="602" I2="50.0358939658095" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.08393070014841489" LOG_CI_START="-0.11365857570435295" LOG_EFFECT_SIZE="-0.014863937777969004" METHOD="MH" MODIFIED="2010-01-11 13:57:55 +0000" MODIFIED_BY="Katharine Ker" NO="3" P_CHI2="0.051002815733651286" P_Q="0.0" P_Z="0.7680838508002452" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.036286451625539846" TOTALS="YES" TOTAL_1="1000" TOTAL_2="1003" WEIGHT="100.0" Z="0.29488222564236377">
<NAME>No. Exposed to Allogeneic Blood - Transfusion Protocol</NAME>
<GROUP_LABEL_1>TXA</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TXA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="14.010057530519791" CI_END="1.2131952469028129" CI_START="0.7697353364558595" DF="7" EFFECT_SIZE="0.9663535851650711" ESTIMABLE="YES" EVENTS_1="589" EVENTS_2="602" I2="50.0358939658095" ID="CMP-006.03.01" LOG_CI_END="0.08393070014841489" LOG_CI_START="-0.11365857570435295" LOG_EFFECT_SIZE="-0.014863937777969004" MODIFIED="2010-01-11 13:57:55 +0000" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="0.051002815733651286" P_Z="0.7680838508002452" STUDIES="8" TAU2="0.036286451625539846" TOTAL_1="1000" TOTAL_2="1003" WEIGHT="100.0" Z="0.29488222564236377">
<NAME>Transfusion Protocol</NAME>
<DICH_DATA CI_END="1.939290490630948" CI_START="0.026940212521841325" EFFECT_SIZE="0.22857142857142856" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2876428678867581" LOG_CI_START="-1.5695989826034222" LOG_EFFECT_SIZE="-0.640978057358332" ORDER="67706" O_E="0.0" SE="1.0909530564733625" STUDY_ID="STD-Camarasa-2006" TOTAL_1="35" TOTAL_2="32" VAR="1.1901785714285715" WEIGHT="1.0983652288437247"/>
<DICH_DATA CI_END="1.1828659437077156" CI_START="0.41058060821360803" EFFECT_SIZE="0.6968944099378882" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="23" LOG_CI_END="0.07293552805399836" LOG_CI_START="-0.38660156627741266" LOG_EFFECT_SIZE="-0.1568330191117071" ORDER="67707" O_E="0.0" SE="0.26993436395557435" STUDY_ID="STD-Casati-1999" TOTAL_1="70" TOTAL_2="66" VAR="0.07286456084410048" WEIGHT="12.341676959619063"/>
<DICH_DATA CI_END="1.0211571981957106" CI_START="0.6354748849961598" EFFECT_SIZE="0.8055555555555556" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="36" LOG_CI_END="0.009092603060352863" LOG_CI_START="-0.19690160879701507" LOG_EFFECT_SIZE="-0.09390450286833116" ORDER="67708" O_E="0.0" SE="0.12100201973281195" STUDY_ID="STD-Dalmau-2000" TOTAL_1="42" TOTAL_2="42" VAR="0.014641488779419815" WEIGHT="26.451227459896725"/>
<DICH_DATA CI_END="1.0714271770893142" CI_START="0.9281536834267589" EFFECT_SIZE="0.9972206781545303" ESTIMABLE="YES" EVENTS_1="506" EVENTS_2="514" LOG_CI_END="0.029962658193486508" LOG_CI_START="-0.03238010746844269" LOG_EFFECT_SIZE="-0.001208724637478083" MODIFIED="2010-01-11 13:57:55 +0000" MODIFIED_BY="Katharine Ker" ORDER="2295" O_E="0.0" SE="0.03662044915148434" STUDY_ID="STD-Fergusson-2008" TOTAL_1="770" TOTAL_2="780" VAR="0.00134105729605645" WEIGHT="35.80110866554022"/>
<DICH_DATA CI_END="1.9698605497043828" CI_START="0.6041456309212826" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.2944354826907784" LOG_CI_START="-0.21885836091197888" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="67709" O_E="0.0" SE="0.3015113445777637" STUDY_ID="STD-Maineri-2000" TOTAL_1="24" TOTAL_2="24" VAR="0.09090909090909094" WEIGHT="10.590831320593521"/>
<DICH_DATA CI_END="7.993224784658692" CI_START="1.1259535722395293" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.9027220263270903" LOG_CI_START="0.05152048311223442" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="67711" O_E="0.0" SE="0.49999999999999994" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.24999999999999997" WEIGHT="4.705449832036259"/>
<DICH_DATA CI_END="2.8531415452949767" CI_START="0.03894342756823292" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45532331768430767" LOG_CI_START="-1.4095658271236327" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67712" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="1.2" WEIGHT="1.0896394876320135"/>
<DICH_DATA CI_END="3.218204689122558" CI_START="0.7673184255334977" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.5076136632960574" LOG_CI_START="-0.11502437300812099" LOG_EFFECT_SIZE="0.1962946451439682" ORDER="67710" O_E="0.0" SE="0.36574066463306176" STUDY_ID="STD-Pinosky-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.13376623376623376" WEIGHT="7.921701045838469"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.01005753051979" CI_END="1.2131952469028129" CI_START="0.7697353364558595" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9663535851650711" ESTIMABLE="YES" EVENTS_1="589" EVENTS_2="602" I2="50.03589396580949" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.08393070014841489" LOG_CI_START="-0.11365857570435295" LOG_EFFECT_SIZE="-0.014863937777969004" METHOD="MH" MODIFIED="2010-08-23 06:53:47 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.051002815733651286" P_Q="0.0" P_Z="0.7680838508002452" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03628645162553983" TOTALS="YES" TOTAL_1="1000" TOTAL_2="1003" WEIGHT="100.0" Z="0.29488222564236377">
<NAME>Trial Methodological Quality - Allocation Concealment</NAME>
<GROUP_LABEL_1>TXA</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0714271770893142" CI_START="0.9281536834267589" DF="0" EFFECT_SIZE="0.9972206781545303" ESTIMABLE="YES" EVENTS_1="506" EVENTS_2="514" I2="0.0" ID="CMP-006.04.01" LOG_CI_END="0.029962658193486508" LOG_CI_START="-0.03238010746844269" LOG_EFFECT_SIZE="-0.001208724637478083" MODIFIED="2010-08-23 06:53:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9394182901069765" STUDIES="1" TAU2="0.0" TOTAL_1="770" TOTAL_2="780" WEIGHT="35.80110866554023" Z="0.07600101572426657">
<NAME>Allocation concealment - Yes</NAME>
<DICH_DATA CI_END="1.0714271770893142" CI_START="0.9281536834267589" EFFECT_SIZE="0.9972206781545303" ESTIMABLE="YES" EVENTS_1="506" EVENTS_2="514" LOG_CI_END="0.029962658193486508" LOG_CI_START="-0.03238010746844269" LOG_EFFECT_SIZE="-0.001208724637478083" MODIFIED="2010-08-23 06:53:11 +0100" MODIFIED_BY="[Empty name]" ORDER="3046" O_E="0.0" SE="0.03662044915148434" STUDY_ID="STD-Fergusson-2008" TOTAL_1="770" TOTAL_2="780" VAR="0.00134105729605645" WEIGHT="35.80110866554023"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.013215658265308" CI_END="1.9816508753888442" CI_START="0.6831056627043871" DF="4" EFFECT_SIZE="1.1634762285845057" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="48" I2="55.620722374129414" ID="CMP-006.04.02" LOG_CI_END="0.29702714346525205" LOG_CI_START="-0.16551211450259096" LOG_EFFECT_SIZE="0.0657575144813305" MODIFIED="2010-08-23 06:53:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.06077006863229617" P_Z="0.5773348964446855" STUDIES="5" TAU2="0.18762092359842064" TOTAL_1="153" TOTAL_2="149" WEIGHT="36.64929864571932" Z="0.5572818214934707">
<NAME>Allocation concealment - Unclear</NAME>
<DICH_DATA CI_END="1.1828659437077156" CI_START="0.41058060821360803" EFFECT_SIZE="0.6968944099378882" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="23" LOG_CI_END="0.07293552805399836" LOG_CI_START="-0.38660156627741266" LOG_EFFECT_SIZE="-0.1568330191117071" MODIFIED="2010-08-23 06:53:31 +0100" MODIFIED_BY="[Empty name]" ORDER="3048" O_E="0.0" SE="0.26993436395557435" STUDY_ID="STD-Casati-1999" TOTAL_1="70" TOTAL_2="66" VAR="0.07286456084410048" WEIGHT="12.341676959619061"/>
<DICH_DATA CI_END="1.9698605497043828" CI_START="0.6041456309212826" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.2944354826907784" LOG_CI_START="-0.21885836091197888" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2010-08-23 06:53:31 +0100" MODIFIED_BY="[Empty name]" ORDER="3051" O_E="0.0" SE="0.3015113445777637" STUDY_ID="STD-Maineri-2000" TOTAL_1="24" TOTAL_2="24" VAR="0.09090909090909094" WEIGHT="10.59083132059352"/>
<DICH_DATA CI_END="7.993224784658692" CI_START="1.1259535722395293" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.9027220263270903" LOG_CI_START="0.05152048311223442" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-08-23 06:53:31 +0100" MODIFIED_BY="[Empty name]" ORDER="3049" O_E="0.0" SE="0.49999999999999994" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.24999999999999997" WEIGHT="4.705449832036259"/>
<DICH_DATA CI_END="2.8531415452949767" CI_START="0.03894342756823292" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45532331768430767" LOG_CI_START="-1.4095658271236327" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2010-08-23 06:53:31 +0100" MODIFIED_BY="[Empty name]" ORDER="3047" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="1.2" WEIGHT="1.0896394876320132"/>
<DICH_DATA CI_END="3.218204689122558" CI_START="0.7673184255334977" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.5076136632960574" LOG_CI_START="-0.11502437300812099" LOG_EFFECT_SIZE="0.1962946451439682" MODIFIED="2010-08-23 06:53:31 +0100" MODIFIED_BY="[Empty name]" ORDER="3050" O_E="0.0" SE="0.36574066463306176" STUDY_ID="STD-Pinosky-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.13376623376623376" WEIGHT="7.921701045838468"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5837776860539852" CI_END="1.837259938659774" CI_START="0.21775822720411353" DF="1" EFFECT_SIZE="0.6325175627250921" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="40" I2="36.859825163244935" ID="CMP-006.04.03" LOG_CI_END="0.2641706053745439" LOG_CI_START="-0.6620254277698965" LOG_EFFECT_SIZE="-0.1989274111976763" MODIFIED="2010-08-23 06:53:47 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.20821743348824795" P_Z="0.3998338557519936" STUDIES="2" TAU2="0.35167353342982344" TOTAL_1="77" TOTAL_2="74" WEIGHT="27.549592688740457" Z="0.8419180120250674">
<NAME>Allocation concealment - No</NAME>
<DICH_DATA CI_END="1.939290490630948" CI_START="0.026940212521841325" EFFECT_SIZE="0.22857142857142856" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2876428678867581" LOG_CI_START="-1.5695989826034222" LOG_EFFECT_SIZE="-0.640978057358332" MODIFIED="2010-08-23 06:53:47 +0100" MODIFIED_BY="[Empty name]" ORDER="3052" O_E="0.0" SE="1.0909530564733625" STUDY_ID="STD-Camarasa-2006" TOTAL_1="35" TOTAL_2="32" VAR="1.1901785714285715" WEIGHT="1.0983652288437245"/>
<DICH_DATA CI_END="1.0211571981957106" CI_START="0.6354748849961598" EFFECT_SIZE="0.8055555555555556" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="36" LOG_CI_END="0.009092603060352863" LOG_CI_START="-0.19690160879701507" LOG_EFFECT_SIZE="-0.09390450286833116" MODIFIED="2010-08-23 06:53:47 +0100" MODIFIED_BY="[Empty name]" ORDER="3053" O_E="0.0" SE="0.12100201973281195" STUDY_ID="STD-Dalmau-2000" TOTAL_1="42" TOTAL_2="42" VAR="0.014641488779419815" WEIGHT="26.45122745989673"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.11963498516172771" CI_END="0.06525856941812497" CI_START="-0.7406553207154396" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.33769837564865735" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.05" NO="5" P_CHI2="0.9419364343561865" P_Q="1.0" P_Z="0.10047621496639583" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="74" UNITS="" WEIGHT="100.0" Z="1.6425493145411683">
<NAME>Units of Allogeneic Blood Transfused - Transfused Patients</NAME>
<GROUP_LABEL_1>TXA</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TXA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="1.0" MEAN_2="1.5" ORDER="67723" SD_1="0.0" SD_2="0.58" SE="0.0" STUDY_ID="STD-Camarasa-2006" TOTAL_1="1" TOTAL_2="4" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.19894802173931042" CI_START="-0.798948021739311" EFFECT_SIZE="-0.30000000000000027" ESTIMABLE="YES" MEAN_1="1.94" MEAN_2="2.24" ORDER="67720" SD_1="0.69" SD_2="0.92" SE="0.2545699949973311" STUDY_ID="STD-Casati-1999" TOTAL_1="17" TOTAL_2="23" WEIGHT="65.22388755595165"/>
<CONT_DATA CI_END="2.621200522311323" CI_START="-2.8012005223113228" EFFECT_SIZE="-0.08999999999999986" ESTIMABLE="YES" MEAN_1="7.72" MEAN_2="7.81" ORDER="67721" SD_1="5.44" SD_2="5.67" SE="1.3832909909043873" STUDY_ID="STD-Dalmau-2000" TOTAL_1="29" TOTAL_2="36" WEIGHT="2.2089913319428125"/>
<CONT_DATA CI_END="0.27610446987475323" CI_START="-1.1361044698747527" EFFECT_SIZE="-0.4299999999999997" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="2.03" ORDER="67722" SD_1="1.19" SD_2="0.36" SE="0.36026400252474783" STUDY_ID="STD-Maineri-2000" TOTAL_1="12" TOTAL_2="11" WEIGHT="32.56712111210553"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.962225601337278" CI_END="0.02621577328771313" CI_START="-0.5913924449458183" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2825883358290526" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.06" NO="6" P_CHI2="0.6180952386960686" P_Q="1.0" P_Z="0.07288122084572109" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="136" TOTAL_2="132" UNITS="" WEIGHT="99.99999999999999" Z="1.7935738039891982">
<NAME>Units of Allogeneic Blood Transfused - All Patients</NAME>
<GROUP_LABEL_1>TXA</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TXA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.04814077309168391" CI_START="-0.668140773091684" EFFECT_SIZE="-0.31000000000000005" ESTIMABLE="YES" MEAN_1="0.47" MEAN_2="0.78" ORDER="67724" SD_1="0.9" SD_2="1.2" SE="0.18272824190477613" STUDY_ID="STD-Casati-1999" TOTAL_1="70" TOTAL_2="66" WEIGHT="74.34617126573954"/>
<CONT_DATA CI_END="1.1401076490397752" CI_START="-3.860107649039776" EFFECT_SIZE="-1.3600000000000003" ESTIMABLE="YES" MEAN_1="5.33" MEAN_2="6.69" ORDER="67725" SD_1="5.77" SD_2="5.92" SE="1.2755885663003532" STUDY_ID="STD-Dalmau-2000" TOTAL_1="42" TOTAL_2="42" WEIGHT="1.5256282561562113"/>
<CONT_DATA CI_END="0.4986669136639429" CI_START="-0.7586669136639429" EFFECT_SIZE="-0.13" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.93" ORDER="67726" SD_1="1.16" SD_2="1.06" SE="0.3207543192746332" STUDY_ID="STD-Maineri-2000" TOTAL_1="24" TOTAL_2="24" WEIGHT="24.128200478104233"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="33.84303993169674" CI_END="138.89038271178788" CI_START="-147.2926750149963" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.2011461516041955" ESTIMABLE="YES" I2="82.27109617779779" I2_Q="0.0" ID="CMP-006.07" MODIFIED="2010-08-19 11:08:50 +0100" MODIFIED_BY="Katharine Ker" NO="7" P_CHI2="7.213535367367463E-6" P_Q="0.8548624252778486" P_Z="0.9541116556235587" Q="0.03345898788646906" RANDOM="YES" SCALE="248.3094195780658" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="28391.90652164707" TOTALS="YES" TOTAL_1="244" TOTAL_2="225" UNITS="" WEIGHT="100.0" Z="0.05754425308289406">
<NAME>Blood loss</NAME>
<GROUP_LABEL_1>TXA</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TXA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="33.80958094381027" CI_END="154.63216420522173" CI_START="-163.35336198869743" DF="5" EFFECT_SIZE="-4.360598891737844" ESTIMABLE="YES" I2="85.21129259688331" ID="CMP-006.07.01" NO="1" P_CHI2="2.5981322674395457E-6" P_Z="0.9571305588866522" STUDIES="6" TAU2="31640.07780695961" TOTAL_1="209" TOTAL_2="193" WEIGHT="88.44982109353727" Z="0.05375475343880533">
<NAME>Cardiac surgery - Post-operative</NAME>
<CONT_DATA CI_END="-77.74820057731712" CI_START="-234.2517994226829" EFFECT_SIZE="-156.0" ESTIMABLE="YES" MEAN_1="310.9" MEAN_2="466.9" ORDER="67730" SD_1="231.1" SD_2="234.2" SE="39.92512109402167" STUDY_ID="STD-Casati-1999" TOTAL_1="70" TOTAL_2="66" WEIGHT="17.775190405000554"/>
<CONT_DATA CI_END="318.1251252915547" CI_START="65.87487470844528" EFFECT_SIZE="192.0" ESTIMABLE="YES" MEAN_1="535.0" MEAN_2="343.0" ORDER="67727" SD_1="336.75" SD_2="305.13" SE="64.35073618005923" STUDY_ID="STD-Landymore-1997" TOTAL_1="56" TOTAL_2="44" WEIGHT="16.383571102953255"/>
<CONT_DATA CI_END="126.72755175080172" CI_START="-206.72755175080172" EFFECT_SIZE="-40.0" ESTIMABLE="YES" MEAN_1="750.0" MEAN_2="790.0" ORDER="67732" SD_1="314.0" SD_2="274.0" SE="85.06664054336068" STUDY_ID="STD-Maineri-2000" TOTAL_1="24" TOTAL_2="24" WEIGHT="14.96019651598636"/>
<CONT_DATA CI_END="413.715459047526" CI_START="36.284540952474" EFFECT_SIZE="225.0" ESTIMABLE="YES" MEAN_1="737.0" MEAN_2="512.0" ORDER="67728" SD_1="400.0" SD_2="250.0" SE="96.2851667357612" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" WEIGHT="14.15206306820828"/>
<CONT_DATA CI_END="188.8636169567318" CI_START="-138.8636169567318" EFFECT_SIZE="25.0" ESTIMABLE="YES" MEAN_1="534.0" MEAN_2="509.0" ORDER="67729" SD_1="288.0" SD_2="148.0" SE="83.60542247167146" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" WEIGHT="15.064408075660008"/>
<CONT_DATA CI_END="-55.4352597653608" CI_START="-666.5647402346392" EFFECT_SIZE="-361.0" ESTIMABLE="YES" MEAN_1="600.0" MEAN_2="961.0" ORDER="67731" SD_1="219.1" SD_2="661.9" SE="155.90324242939914" STUDY_ID="STD-Pinosky-1997" TOTAL_1="20" TOTAL_2="20" WEIGHT="10.114391925728812"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="252.16134638572368" CI_START="-270.1613463857237" DF="0" EFFECT_SIZE="-9.0" ESTIMABLE="YES" I2="0.0" ID="CMP-006.07.02" NO="2" P_CHI2="1.0" P_Z="0.946149263333796" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="32" WEIGHT="11.550178906462731" Z="0.06754321075833127">
<NAME>Orthopaedic surgery - Total</NAME>
<CONT_DATA CI_END="252.16134638572368" CI_START="-270.1613463857237" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="1095.0" MEAN_2="1104.0" ORDER="67733" SD_1="473.0" SD_2="603.0" SE="133.24803335455704" STUDY_ID="STD-Camarasa-2006" TOTAL_1="35" TOTAL_2="32" WEIGHT="11.550178906462731"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.07.03" MODIFIED="2010-08-19 11:08:50 +0100" MODIFIED_BY="Katharine Ker" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Gynaecological surgery - Total</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2011-02-16 14:10:33 +0000" MODIFIED_BY="Emma M Sydenham" NO="7">
<NAME>Aprotinin versus Lysine Analogues (Blood Transfusion)</NAME>
<DICH_OUTCOME CHI2="70.06034068833976" CI_END="0.9885063749263981" CI_START="0.8145951302019362" CI_STUDY="95" CI_TOTAL="95" DF="29" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8973474684806401" ESTIMABLE="YES" EVENTS_1="1043" EVENTS_2="1690" I2="58.60710964994421" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="-0.0050205255547299075" LOG_CI_START="-0.08905819053377852" LOG_EFFECT_SIZE="-0.047039358044254194" METHOD="MH" MODIFIED="2011-02-16 14:10:33 +0000" MODIFIED_BY="Emma M Sydenham" NO="1" P_CHI2="2.9750769981240488E-5" P_Q="0.0" P_Z="0.028224924795041854" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="29" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.021589693492565884" TOTALS="YES" TOTAL_1="2407" TOTAL_2="3159" WEIGHT="99.99999999999999" Z="2.194145866513733">
<NAME>No. Exposed to Allogeneic Blood</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Lysine Analogues</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lysine Analogues</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3697803938804385" CI_START="0.41064976730065383" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.13665094571788927" LOG_CI_START="-0.3865284189344892" LOG_EFFECT_SIZE="-0.12493873660829993" MODIFIED="2010-08-23 04:06:48 +0100" MODIFIED_BY="[Empty name]" ORDER="2733" O_E="0.0" SE="0.30731814857642953" STUDY_ID="STD-Eberle-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.09444444444444443" WEIGHT="2.100087440590795"/>
<DICH_DATA CI_END="1.7386462202749464" CI_START="0.7657457458683129" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.2402112207530636" LOG_CI_START="-0.11591540725537476" LOG_EFFECT_SIZE="0.062147906748844434" MODIFIED="2010-08-23 04:07:14 +0100" MODIFIED_BY="[Empty name]" ORDER="2736" O_E="0.0" SE="0.2091905441473963" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="25" VAR="0.043760683760683754" WEIGHT="3.7288512477436067"/>
<DICH_DATA CI_END="0.8793255509557636" CI_START="0.7577958115542787" EFFECT_SIZE="0.8163021618903972" ESTIMABLE="YES" EVENTS_1="419" EVENTS_2="1020" LOG_CI_END="-0.0558503071695787" LOG_CI_START="-0.12044779946204372" LOG_EFFECT_SIZE="-0.08814905331581117" MODIFIED="2010-08-23 04:24:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2718" O_E="0.0" SE="0.03794488673533784" STUDY_ID="STD-Fergusson-2008" TOTAL_1="780" TOTAL_2="1550" VAR="0.0014398144293576178" WEIGHT="10.581287128993166"/>
<DICH_DATA CI_END="0.9942864949565421" CI_START="0.60582269873457" EFFECT_SIZE="0.7761194029850746" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="67" LOG_CI_END="-0.0024884594142842056" LOG_CI_START="-0.21765445871777034" LOG_EFFECT_SIZE="-0.11007145906602726" MODIFIED="2010-08-23 04:03:45 +0100" MODIFIED_BY="[Empty name]" ORDER="2715" O_E="0.0" SE="0.12638957307974186" STUDY_ID="STD-Dietrich-2008" TOTAL_1="110" TOTAL_2="110" VAR="0.01597432418327941" WEIGHT="6.487107898418158"/>
<DICH_DATA CI_END="3.3417930664224986" CI_START="0.04048385845900427" EFFECT_SIZE="0.367816091954023" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5239795536084553" LOG_CI_START="-1.3927181022058803" LOG_EFFECT_SIZE="-0.4343692742987125" MODIFIED="2010-08-23 04:05:35 +0100" MODIFIED_BY="[Empty name]" ORDER="2729" O_E="0.0" SE="1.1258776908317545" STUDY_ID="STD-Vanek-2005" TOTAL_1="29" TOTAL_2="32" VAR="1.2676005747126435" WEIGHT="0.18901929511191962"/>
<DICH_DATA CI_END="1.0571879058568519" CI_START="0.01930419668276973" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.024152186194750208" LOG_CI_START="-1.714348266223264" LOG_EFFECT_SIZE="-0.8450980400142569" MODIFIED="2010-08-23 04:04:51 +0100" MODIFIED_BY="[Empty name]" ORDER="2723" O_E="0.0" SE="1.0212037714663722" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="1.0428571428571427" WEIGHT="0.22892814130290406"/>
<DICH_DATA CI_END="1.1197841224249232" CI_START="0.3738980690319062" EFFECT_SIZE="0.6470588235294118" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="0.04913430528065808" LOG_CI_START="-0.42724677772075587" LOG_EFFECT_SIZE="-0.18905623622004886" MODIFIED="2010-08-23 04:02:46 +0100" MODIFIED_BY="[Empty name]" ORDER="2709" O_E="0.0" SE="0.27982860627942274" STUDY_ID="STD-Bernet-1999" TOTAL_1="28" TOTAL_2="28" VAR="0.07830404889228418" WEIGHT="2.4394104169457185"/>
<DICH_DATA CI_END="1.435243954367492" CI_START="0.14690857630106668" EFFECT_SIZE="0.45918367346938777" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.15692572617866216" LOG_CI_START="-0.8329528500129644" LOG_EFFECT_SIZE="-0.33801356191715115" MODIFIED="2010-08-23 04:03:02 +0100" MODIFIED_BY="[Empty name]" ORDER="2710" O_E="0.0" SE="0.5814595756329395" STUDY_ID="STD-Blauhut-1994" TOTAL_1="14" TOTAL_2="15" VAR="0.3380952380952381" WEIGHT="0.6774869180245578"/>
<DICH_DATA CI_END="1.1531481274998097" CI_START="0.3121888605764218" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.061885098121928904" LOG_CI_START="-0.5055825973546417" LOG_EFFECT_SIZE="-0.22184874961635637" MODIFIED="2010-08-23 04:06:35 +0100" MODIFIED_BY="[Empty name]" ORDER="2732" O_E="0.0" SE="0.3333333333333333" STUDY_ID="STD-Dorman-2008" TOTAL_1="30" TOTAL_2="30" VAR="0.1111111111111111" WEIGHT="1.8363252317050616"/>
<DICH_DATA CI_END="1.0198361669523746" CI_START="0.33929053749849375" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" LOG_CI_END="0.00853040950370991" LOG_CI_START="-0.46942825226025775" LOG_EFFECT_SIZE="-0.2304489213782739" MODIFIED="2011-02-16 14:10:33 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="2724" O_E="0.0" SE="0.2807552838536876" STUDY_ID="STD-Mengistu-2008" TOTAL_1="25" TOTAL_2="25" VAR="0.07882352941176468" WEIGHT="2.426790304235777"/>
<DICH_DATA CI_END="1.6923197685338265" CI_START="0.5372153021082148" EFFECT_SIZE="0.9534883720930233" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.22848242760880472" LOG_CI_START="-0.2698516253285067" LOG_EFFECT_SIZE="-0.02068459885985102" MODIFIED="2010-08-23 04:03:32 +0100" MODIFIED_BY="[Empty name]" ORDER="2713" O_E="0.0" SE="0.2927238894887227" STUDY_ID="STD-Corbeau-1995" TOTAL_1="43" TOTAL_2="41" VAR="0.08568727547740593" WEIGHT="2.2715205146176802"/>
<DICH_DATA CI_END="2.3302506070190314" CI_START="0.10728459816595091" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.36740262977830473" LOG_CI_START="-0.9694626211062671" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-08-23 04:08:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2740" O_E="0.0" SE="0.7852812659593165" STUDY_ID="STD-Ray-2005" TOTAL_1="15" TOTAL_2="15" VAR="0.6166666666666667" WEIGHT="0.38179303955623944"/>
<DICH_DATA CI_END="1.6825402105470073" CI_START="0.7803284697433366" EFFECT_SIZE="1.1458333333333333" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="24" LOG_CI_END="0.22596545209958277" LOG_CI_START="-0.10772254786226959" LOG_EFFECT_SIZE="0.05912145211865659" MODIFIED="2010-08-23 04:04:31 +0100" MODIFIED_BY="[Empty name]" ORDER="2720" O_E="0.0" SE="0.19600998295983146" STUDY_ID="STD-Isetta-1993" TOTAL_1="140" TOTAL_2="70" VAR="0.038419913419913417" WEIGHT="4.060713747328687"/>
<DICH_DATA CI_END="0.9996095394793454" CI_START="0.06252441331497659" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="16" LOG_CI_END="-1.6960796428367106E-4" LOG_CI_START="-1.2039503746916411" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2010-08-23 04:26:20 +0100" MODIFIED_BY="[Empty name]" ORDER="2725" O_E="0.0" SE="0.7071067811865476" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="48" VAR="0.5" WEIGHT="0.46719066500260215"/>
<DICH_DATA CI_END="2.3586217117979826" CI_START="0.6251489115625755" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.3726582920289919" LOG_CI_START="-0.2040165206289201" LOG_EFFECT_SIZE="0.08432088570003587" MODIFIED="2010-08-23 04:07:58 +0100" MODIFIED_BY="[Empty name]" ORDER="2739" O_E="0.0" SE="0.3387416395416184" STUDY_ID="STD-Ray-2001" TOTAL_1="49" TOTAL_2="51" VAR="0.11474589835934375" WEIGHT="1.7873677185190735"/>
<DICH_DATA CI_END="3.6287762406689716" CI_START="0.4960541309410133" EFFECT_SIZE="1.3416666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5597601893527253" LOG_CI_START="-0.30447092938427567" LOG_EFFECT_SIZE="0.12764462998422485" MODIFIED="2010-08-23 04:07:05 +0100" MODIFIED_BY="[Empty name]" ORDER="2735" O_E="0.0" SE="0.507653637159147" STUDY_ID="STD-Greilich-2001" TOTAL_1="24" TOTAL_2="23" VAR="0.25771221532091093" WEIGHT="0.8724674915273518"/>
<DICH_DATA CI_END="1.0921635201498592" CI_START="0.9156138083267851" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.03828766637439782" LOG_CI_START="-0.03828766637439781" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-23 04:05:19 +0100" MODIFIED_BY="[Empty name]" ORDER="2727" O_E="0.0" SE="0.04498072951065294" STUDY_ID="STD-Pugh-1995" TOTAL_1="21" TOTAL_2="22" VAR="0.0020232660273105246" WEIGHT="10.319834561871588"/>
<DICH_DATA CI_END="1.346564360926496" CI_START="0.49177073391944337" EFFECT_SIZE="0.8137573004542504" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.12922711595564204" LOG_CI_START="-0.30823732040308555" LOG_EFFECT_SIZE="-0.08950510222372171" MODIFIED="2010-08-23 04:06:14 +0100" MODIFIED_BY="[Empty name]" ORDER="2731" O_E="0.0" SE="0.25696877540100105" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="66" VAR="0.06603295153109012" WEIGHT="2.781037204429369"/>
<DICH_DATA CI_END="2.048506537591385" CI_START="0.6656079177641339" EFFECT_SIZE="1.1676909569798068" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.3114373542961579" LOG_CI_START="-0.176781520520187" LOG_EFFECT_SIZE="0.06732791688798542" MODIFIED="2010-08-23 04:03:10 +0100" MODIFIED_BY="[Empty name]" ORDER="2711" O_E="0.0" SE="0.28678218378952774" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="70" VAR="0.08224402093909047" WEIGHT="2.3468469474978413"/>
<DICH_DATA CI_END="1.2365301946437357" CI_START="0.8871155928252136" EFFECT_SIZE="1.0473515248796148" ESTIMABLE="YES" EVENTS_1="185" EVENTS_2="178" LOG_CI_END="0.09220472579804354" LOG_CI_START="-0.05201978709574561" LOG_EFFECT_SIZE="0.02009246935114897" MODIFIED="2010-08-23 04:03:20 +0100" MODIFIED_BY="[Empty name]" ORDER="2712" O_E="0.0" SE="0.08471819279666457" STUDY_ID="STD-Casati-2000" TOTAL_1="518" TOTAL_2="522" VAR="0.007177172190732827" WEIGHT="8.470920622498355"/>
<DICH_DATA CI_END="1.0779225045907352" CI_START="0.9277104761623649" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="27" LOG_CI_END="0.032587539108232075" LOG_CI_START="-0.032587539108232096" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-23 04:04:20 +0100" MODIFIED_BY="[Empty name]" ORDER="2719" O_E="0.0" SE="0.0382841635661914" STUDY_ID="STD-Ickx-2006" TOTAL_1="24" TOTAL_2="27" VAR="0.0014656771799628973" WEIGHT="10.56941739182923"/>
<DICH_DATA CI_END="179.29256051754408" CI_START="0.6748746275401646" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2535622695219755" LOG_CI_START="-0.17077689920552552" LOG_EFFECT_SIZE="1.041392685158225" MODIFIED="2010-08-23 04:04:09 +0100" MODIFIED_BY="[Empty name]" ORDER="2717" O_E="0.0" SE="1.424068828382964" STUDY_ID="STD-Engel-2001" TOTAL_1="12" TOTAL_2="12" VAR="2.0279720279720275" WEIGHT="0.11889460717834009"/>
<DICH_DATA CI_END="1.0323063713894243" CI_START="0.37319894434005896" EFFECT_SIZE="0.6206896551724138" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.01380860781209295" LOG_CI_START="-0.42805959340339295" LOG_EFFECT_SIZE="-0.20712549279564998" MODIFIED="2010-08-23 04:08:14 +0100" MODIFIED_BY="[Empty name]" ORDER="2741" O_E="0.0" SE="0.2595555686768485" STUDY_ID="STD-Trinh_x002d_Duc-1992" TOTAL_1="29" TOTAL_2="27" VAR="0.0673690932311622" WEIGHT="2.739266628243006"/>
<DICH_DATA CI_END="3.754457918288967" CI_START="0.012343864976933615" EFFECT_SIZE="0.2152777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.5745472409165846" LOG_CI_START="-1.9085488374385386" LOG_EFFECT_SIZE="-0.6670007982609769" MODIFIED="2010-08-23 04:26:59 +0100" MODIFIED_BY="[Empty name]" ORDER="2738" O_E="0.0" SE="1.4585829279496223" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="30" VAR="2.1274641577060933" WEIGHT="0.11339028830076966"/>
<DICH_DATA CI_END="1.2732251164306965" CI_START="0.6692225867377" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.10490519719658377" LOG_CI_START="-0.1744294097150076" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2010-08-23 04:05:26 +0100" MODIFIED_BY="[Empty name]" ORDER="2728" O_E="0.0" SE="0.16408253082847335" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.02692307692307691" WEIGHT="5.023045142000813"/>
<DICH_DATA CI_END="1.1284556431965513" CI_START="0.6683072827900095" EFFECT_SIZE="0.868421052631579" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="57" LOG_CI_END="0.05248449270613696" LOG_CI_START="-0.17502380618398225" LOG_EFFECT_SIZE="-0.06126965673892266" MODIFIED="2010-08-23 04:04:44 +0100" MODIFIED_BY="[Empty name]" ORDER="2722" O_E="0.0" SE="0.1336395009522984" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="99" VAR="0.017859516214779367" WEIGHT="6.177103104702321"/>
<DICH_DATA CI_END="1.5542598037816595" CI_START="0.4946396798386406" EFFECT_SIZE="0.8768115942028986" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.19152361544173646" LOG_CI_START="-0.30571104761130935" LOG_EFFECT_SIZE="-0.057093716084786424" MODIFIED="2010-08-23 04:06:07 +0100" MODIFIED_BY="[Empty name]" ORDER="2730" O_E="0.0" SE="0.29207810242863735" STUDY_ID="STD-Amar-2003" TOTAL_1="23" TOTAL_2="22" VAR="0.08530961791831358" WEIGHT="2.2795454203131102"/>
<DICH_DATA CI_END="1.4091078666036987" CI_START="0.8114978976663392" EFFECT_SIZE="1.0693400167084377" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="38" LOG_CI_END="0.14894423943845972" LOG_CI_START="-0.09071260095554438" LOG_EFFECT_SIZE="0.029115819241457678" MODIFIED="2010-08-23 04:03:39 +0100" MODIFIED_BY="[Empty name]" ORDER="2714" O_E="0.0" SE="0.1407756143679307" STUDY_ID="STD-Dalmau-2004" TOTAL_1="63" TOTAL_2="64" VAR="0.01981777360066834" WEIGHT="5.884973239551561"/>
<DICH_DATA CI_END="0.8364512088877062" CI_START="0.19128431915683927" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" LOG_CI_END="-0.07755938683408231" LOG_CI_START="-0.7183206305099928" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2010-08-23 04:03:52 +0100" MODIFIED_BY="[Empty name]" ORDER="2716" O_E="0.0" SE="0.3763863263545405" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.14166666666666666" WEIGHT="1.4926330314091254"/>
<DICH_DATA CI_END="5.1801150354072085" CI_START="0.9343421848583578" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.714339404279566" LOG_CI_START="-0.02949404263515343" LOG_EFFECT_SIZE="0.3424226808222063" MODIFIED="2010-08-23 04:04:37 +0100" MODIFIED_BY="[Empty name]" ORDER="2721" O_E="0.0" SE="0.4369314487526515" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.19090909090909092" WEIGHT="1.1467446105512655"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="75.00752431787856" CI_END="0.979436398982696" CI_START="0.7999332973391347" CI_STUDY="95" CI_TOTAL="95" DF="29" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8851461959316078" ESTIMABLE="YES" EVENTS_1="1025" EVENTS_2="1680" I2="61.33721214807825" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="-0.009023760248786494" LOG_CI_START="-0.09694622526466368" LOG_EFFECT_SIZE="-0.05298499275672508" METHOD="MH" MODIFIED="2010-08-23 04:54:40 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="6.076640009178291E-6" P_Q="0.0" P_Z="0.018162988210723922" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="29" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.024364043915470257" TOTALS="YES" TOTAL_1="2360" TOTAL_2="3109" WEIGHT="99.99999999999997" Z="2.362278571364977">
<NAME>No. Exposed to Allogeneic Blood - Type of Surgery</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Lysine Analogues</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="54.55411338874567" CI_END="0.9610965619432428" CI_START="0.7648188150328474" DF="24" EFFECT_SIZE="0.8573591625669924" ESTIMABLE="YES" EVENTS_1="943" EVENTS_2="1599" I2="56.00698369162549" ID="CMP-007.02.01" LOG_CI_END="-0.017232976314432605" LOG_CI_START="-0.1164414366780436" LOG_EFFECT_SIZE="-0.06683720649623813" MODIFIED="2010-08-23 04:54:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.593757810044229E-4" P_Z="0.008269248738938627" STUDIES="24" TAU2="0.025582004193722717" TOTAL_1="2223" TOTAL_2="2969" WEIGHT="80.65819617994356" Z="2.6408739149820053">
<NAME>Cardiac surgery</NAME>
<DICH_DATA CI_END="1.1197841224249232" CI_START="0.3738980690319062" EFFECT_SIZE="0.6470588235294118" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="0.04913430528065808" LOG_CI_START="-0.42724677772075587" LOG_EFFECT_SIZE="-0.18905623622004886" MODIFIED="2010-08-23 04:48:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2743" O_E="0.0" SE="0.27982860627942274" STUDY_ID="STD-Bernet-1999" TOTAL_1="28" TOTAL_2="28" VAR="0.07830404889228418" WEIGHT="2.598001638640452"/>
<DICH_DATA CI_END="1.435243954367492" CI_START="0.14690857630106668" EFFECT_SIZE="0.45918367346938777" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.15692572617866216" LOG_CI_START="-0.8329528500129644" LOG_EFFECT_SIZE="-0.33801356191715115" MODIFIED="2010-08-23 04:48:49 +0100" MODIFIED_BY="[Empty name]" ORDER="2744" O_E="0.0" SE="0.5814595756329395" STUDY_ID="STD-Blauhut-1994" TOTAL_1="14" TOTAL_2="15" VAR="0.3380952380952381" WEIGHT="0.7358947241493344"/>
<DICH_DATA CI_END="1.346564360926496" CI_START="0.49177073391944337" EFFECT_SIZE="0.8137573004542504" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.12922711595564204" LOG_CI_START="-0.30823732040308555" LOG_EFFECT_SIZE="-0.08950510222372171" MODIFIED="2010-08-23 04:49:01 +0100" MODIFIED_BY="[Empty name]" ORDER="2745" O_E="0.0" SE="0.25696877540100105" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="66" VAR="0.06603295153109012" WEIGHT="2.9506718894027713"/>
<DICH_DATA CI_END="1.2365301946437357" CI_START="0.8871155928252136" EFFECT_SIZE="1.0473515248796148" ESTIMABLE="YES" EVENTS_1="185" EVENTS_2="178" LOG_CI_END="0.09220472579804354" LOG_CI_START="-0.05201978709574561" LOG_EFFECT_SIZE="0.02009246935114897" MODIFIED="2010-08-23 04:49:09 +0100" MODIFIED_BY="[Empty name]" ORDER="2746" O_E="0.0" SE="0.08471819279666457" STUDY_ID="STD-Casati-2000" TOTAL_1="518" TOTAL_2="522" VAR="0.007177172190732827" WEIGHT="8.456613481627265"/>
<DICH_DATA CI_END="1.6923197685338265" CI_START="0.5372153021082148" EFFECT_SIZE="0.9534883720930233" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.22848242760880472" LOG_CI_START="-0.2698516253285067" LOG_EFFECT_SIZE="-0.02068459885985102" MODIFIED="2010-08-23 04:49:19 +0100" MODIFIED_BY="[Empty name]" ORDER="2747" O_E="0.0" SE="0.2927238894887227" STUDY_ID="STD-Corbeau-1995" TOTAL_1="43" TOTAL_2="41" VAR="0.08568727547740593" WEIGHT="2.4237044573579376"/>
<DICH_DATA CI_END="0.9942864949565421" CI_START="0.60582269873457" EFFECT_SIZE="0.7761194029850746" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="67" LOG_CI_END="-0.0024884594142842056" LOG_CI_START="-0.21765445871777034" LOG_EFFECT_SIZE="-0.11007145906602726" MODIFIED="2010-08-23 04:49:48 +0100" MODIFIED_BY="[Empty name]" ORDER="2749" O_E="0.0" SE="0.12638957307974186" STUDY_ID="STD-Dietrich-2008" TOTAL_1="110" TOTAL_2="110" VAR="0.01597432418327941" WEIGHT="6.612361528797286"/>
<DICH_DATA CI_END="0.8364512088877062" CI_START="0.19128431915683927" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" LOG_CI_END="-0.07755938683408231" LOG_CI_START="-0.7183206305099928" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2010-08-23 04:49:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2750" O_E="0.0" SE="0.3763863263545405" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.14166666666666666" WEIGHT="1.6065213020857447"/>
<DICH_DATA CI_END="1.1531481274998097" CI_START="0.3121888605764218" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.061885098121928904" LOG_CI_START="-0.5055825973546417" LOG_EFFECT_SIZE="-0.22184874961635637" MODIFIED="2010-08-23 04:50:15 +0100" MODIFIED_BY="[Empty name]" ORDER="2751" O_E="0.0" SE="0.3333333333333333" STUDY_ID="STD-Dorman-2008" TOTAL_1="30" TOTAL_2="30" VAR="0.1111111111111111" WEIGHT="1.9688619164030556"/>
<DICH_DATA CI_END="1.3697803938804385" CI_START="0.41064976730065383" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.13665094571788927" LOG_CI_START="-0.3865284189344892" LOG_EFFECT_SIZE="-0.12493873660829993" MODIFIED="2010-08-23 04:50:45 +0100" MODIFIED_BY="[Empty name]" ORDER="2752" O_E="0.0" SE="0.30731814857642953" STUDY_ID="STD-Eberle-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.09444444444444443" WEIGHT="2.2450573779089495"/>
<DICH_DATA CI_END="0.8793255509557636" CI_START="0.7577958115542787" EFFECT_SIZE="0.8163021618903972" ESTIMABLE="YES" EVENTS_1="419" EVENTS_2="1020" LOG_CI_END="-0.0558503071695787" LOG_CI_START="-0.12044779946204372" LOG_EFFECT_SIZE="-0.08814905331581117" MODIFIED="2010-08-23 04:51:23 +0100" MODIFIED_BY="[Empty name]" ORDER="2754" O_E="0.0" SE="0.03794488673533784" STUDY_ID="STD-Fergusson-2008" TOTAL_1="780" TOTAL_2="1550" VAR="0.0014398144293576178" WEIGHT="10.336898838390182"/>
<DICH_DATA CI_END="3.6287762406689716" CI_START="0.4960541309410133" EFFECT_SIZE="1.3416666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5597601893527253" LOG_CI_START="-0.30447092938427567" LOG_EFFECT_SIZE="0.12764462998422485" MODIFIED="2010-08-23 04:51:38 +0100" MODIFIED_BY="[Empty name]" ORDER="2755" O_E="0.0" SE="0.507653637159147" STUDY_ID="STD-Greilich-2001" TOTAL_1="24" TOTAL_2="23" VAR="0.25771221532091093" WEIGHT="0.9456019945553572"/>
<DICH_DATA CI_END="1.7386462202749464" CI_START="0.7657457458683129" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.2402112207530636" LOG_CI_START="-0.11591540725537476" LOG_EFFECT_SIZE="0.062147906748844434" MODIFIED="2010-08-23 04:51:46 +0100" MODIFIED_BY="[Empty name]" ORDER="2756" O_E="0.0" SE="0.2091905441473963" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="25" VAR="0.043760683760683754" WEIGHT="3.9153459022780255"/>
<DICH_DATA CI_END="1.6825402105470073" CI_START="0.7803284697433366" EFFECT_SIZE="1.1458333333333333" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="24" LOG_CI_END="0.22596545209958277" LOG_CI_START="-0.10772254786226959" LOG_EFFECT_SIZE="0.05912145211865659" MODIFIED="2010-08-23 04:52:11 +0100" MODIFIED_BY="[Empty name]" ORDER="2758" O_E="0.0" SE="0.19600998295983146" STUDY_ID="STD-Isetta-1993" TOTAL_1="140" TOTAL_2="70" VAR="0.038419913419913417" WEIGHT="4.248408107277936"/>
<DICH_DATA CI_END="5.1801150354072085" CI_START="0.9343421848583578" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.714339404279566" LOG_CI_START="-0.02949404263515343" LOG_EFFECT_SIZE="0.3424226808222063" MODIFIED="2010-08-23 04:52:21 +0100" MODIFIED_BY="[Empty name]" ORDER="2759" O_E="0.0" SE="0.4369314487526515" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.19090909090909092" WEIGHT="1.239039295674361"/>
<DICH_DATA CI_END="1.1284556431965513" CI_START="0.6683072827900095" EFFECT_SIZE="0.868421052631579" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="57" LOG_CI_END="0.05248449270613696" LOG_CI_START="-0.17502380618398225" LOG_EFFECT_SIZE="-0.06126965673892266" MODIFIED="2010-08-23 04:52:30 +0100" MODIFIED_BY="[Empty name]" ORDER="2760" O_E="0.0" SE="0.1336395009522984" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="99" VAR="0.017859516214779367" WEIGHT="6.317133669634482"/>
<DICH_DATA CI_END="1.0571879058568519" CI_START="0.01930419668276973" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.024152186194750208" LOG_CI_START="-1.714348266223264" LOG_EFFECT_SIZE="-0.8450980400142569" MODIFIED="2010-08-23 04:52:37 +0100" MODIFIED_BY="[Empty name]" ORDER="2761" O_E="0.0" SE="1.0212037714663722" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="1.0428571428571427" WEIGHT="0.24993120138221842"/>
<DICH_DATA CI_END="1.0571879058568519" CI_START="0.01930419668276973" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.024152186194750208" LOG_CI_START="-1.714348266223264" LOG_EFFECT_SIZE="-0.8450980400142569" MODIFIED="2010-08-23 04:52:44 +0100" MODIFIED_BY="[Empty name]" ORDER="2762" O_E="0.0" SE="1.0212037714663722" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="1.0428571428571427" WEIGHT="0.24993120138221842"/>
<DICH_DATA CI_END="1.0198361669523746" CI_START="0.33929053749849375" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" LOG_CI_END="0.00853040950370991" LOG_CI_START="-0.46942825226025775" LOG_EFFECT_SIZE="-0.2304489213782739" MODIFIED="2010-08-23 04:52:53 +0100" MODIFIED_BY="[Empty name]" ORDER="2763" O_E="0.0" SE="0.2807552838536876" STUDY_ID="STD-Mengistu-2008" TOTAL_1="25" TOTAL_2="25" VAR="0.07882352941176468" WEIGHT="2.5849224354250397"/>
<DICH_DATA CI_END="0.9996095394793454" CI_START="0.06252441331497659" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="16" LOG_CI_END="-1.6960796428367106E-4" LOG_CI_START="-1.2039503746916411" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2010-08-23 04:53:02 +0100" MODIFIED_BY="[Empty name]" ORDER="2764" O_E="0.0" SE="0.7071067811865476" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="48" VAR="0.5" WEIGHT="0.5086768943174036"/>
<DICH_DATA CI_END="3.754457918288967" CI_START="0.012343864976933615" EFFECT_SIZE="0.2152777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.5745472409165846" LOG_CI_START="-1.9085488374385386" LOG_EFFECT_SIZE="-0.6670007982609769" MODIFIED="2010-08-23 04:53:12 +0100" MODIFIED_BY="[Empty name]" ORDER="2765" O_E="0.0" SE="1.4585829279496223" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="30" VAR="2.1274641577060933" WEIGHT="0.12395593344749065"/>
<DICH_DATA CI_END="1.0921635201498592" CI_START="0.9156138083267851" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.03828766637439782" LOG_CI_START="-0.03828766637439781" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-23 04:53:20 +0100" MODIFIED_BY="[Empty name]" ORDER="2766" O_E="0.0" SE="0.04498072951065294" STUDY_ID="STD-Pugh-1995" TOTAL_1="21" TOTAL_2="22" VAR="0.0020232660273105246" WEIGHT="10.108338967823066"/>
<DICH_DATA CI_END="2.3586217117979826" CI_START="0.6251489115625755" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.3726582920289919" LOG_CI_START="-0.2040165206289201" LOG_EFFECT_SIZE="0.08432088570003587" MODIFIED="2010-08-23 04:53:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2767" O_E="0.0" SE="0.3387416395416184" STUDY_ID="STD-Ray-2001" TOTAL_1="49" TOTAL_2="51" VAR="0.11474589835934375" WEIGHT="1.9174177559768"/>
<DICH_DATA CI_END="1.2732251164306965" CI_START="0.6692225867377" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.10490519719658377" LOG_CI_START="-0.1744294097150076" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2010-08-23 04:54:07 +0100" MODIFIED_BY="[Empty name]" ORDER="2769" O_E="0.0" SE="0.16408253082847335" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.02692307692307691" WEIGHT="5.200757402434679"/>
<DICH_DATA CI_END="1.0323063713894243" CI_START="0.37319894434005896" EFFECT_SIZE="0.6206896551724138" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.01380860781209295" LOG_CI_START="-0.42805959340339295" LOG_EFFECT_SIZE="-0.20712549279564998" MODIFIED="2010-08-23 04:54:26 +0100" MODIFIED_BY="[Empty name]" ORDER="2770" O_E="0.0" SE="0.2595555686768485" STUDY_ID="STD-Trinh_x002d_Duc-1992" TOTAL_1="29" TOTAL_2="27" VAR="0.0673690932311622" WEIGHT="2.9076937914406407"/>
<DICH_DATA CI_END="3.3417930664224986" CI_START="0.04048385845900427" EFFECT_SIZE="0.367816091954023" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5239795536084553" LOG_CI_START="-1.3927181022058803" LOG_EFFECT_SIZE="-0.4343692742987125" MODIFIED="2010-08-23 04:54:40 +0100" MODIFIED_BY="[Empty name]" ORDER="2771" O_E="0.0" SE="1.1258776908317545" STUDY_ID="STD-Vanek-2005" TOTAL_1="29" TOTAL_2="32" VAR="1.2676005747126435" WEIGHT="0.2064544721308762"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.169419822571459" CI_END="3.4769830552249243" CI_START="0.32028475385368343" DF="2" EFFECT_SIZE="1.0552841617290307" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" I2="52.03169541304395" ID="CMP-007.02.02" LOG_CI_END="0.5412025741919602" LOG_CI_START="-0.49446373406426614" LOG_EFFECT_SIZE="0.02336942006384701" MODIFIED="2010-08-23 04:53:53 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.12434323392434687" P_Z="0.9295176733678954" STUDIES="3" TAU2="0.586547474447077" TOTAL_1="50" TOTAL_2="49" WEIGHT="2.9781138413826125" Z="0.08845169780959242">
<NAME>Orthopaedic surgery</NAME>
<DICH_DATA CI_END="1.5542598037816595" CI_START="0.4946396798386406" EFFECT_SIZE="0.8768115942028986" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.19152361544173646" LOG_CI_START="-0.30571104761130935" LOG_EFFECT_SIZE="-0.057093716084786424" MODIFIED="2010-08-23 04:48:16 +0100" MODIFIED_BY="[Empty name]" ORDER="2742" O_E="0.0" SE="0.29207810242863735" STUDY_ID="STD-Amar-2003" TOTAL_1="23" TOTAL_2="22" VAR="0.08530961791831358" WEIGHT="2.432050401990608"/>
<DICH_DATA CI_END="179.29256051754408" CI_START="0.6748746275401646" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2535622695219755" LOG_CI_START="-0.17077689920552552" LOG_EFFECT_SIZE="1.041392685158225" MODIFIED="2010-08-23 04:51:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2753" O_E="0.0" SE="1.424068828382964" STUDY_ID="STD-Engel-2001" TOTAL_1="12" TOTAL_2="12" VAR="2.0279720279720275" WEIGHT="0.12996500768284375"/>
<DICH_DATA CI_END="2.3302506070190314" CI_START="0.10728459816595091" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.36740262977830473" LOG_CI_START="-0.9694626211062671" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-08-23 04:53:53 +0100" MODIFIED_BY="[Empty name]" ORDER="2768" O_E="0.0" SE="0.7852812659593165" STUDY_ID="STD-Ray-2005" TOTAL_1="15" TOTAL_2="15" VAR="0.6166666666666667" WEIGHT="0.41609843170916067"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1417444413788664" CI_END="1.1144241254911798" CI_START="0.9121712955587973" DF="1" EFFECT_SIZE="1.0082389093618978" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="65" I2="12.414725768901835" ID="CMP-007.02.03" LOG_CI_END="0.04705050529519682" LOG_CI_START="-0.039923598370637275" LOG_EFFECT_SIZE="0.003563453462279761" MODIFIED="2010-08-23 04:52:00 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.28528406278555196" P_Z="0.8724044716041558" STUDIES="2" TAU2="0.0015084054207575865" TOTAL_1="87" TOTAL_2="91" WEIGHT="16.363689978673804" Z="0.16060505719006393">
<NAME>Liver surgery</NAME>
<DICH_DATA CI_END="1.4091078666036987" CI_START="0.8114978976663392" EFFECT_SIZE="1.0693400167084377" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="38" LOG_CI_END="0.14894423943845972" LOG_CI_START="-0.09071260095554438" LOG_EFFECT_SIZE="0.029115819241457678" MODIFIED="2010-08-23 04:49:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2748" O_E="0.0" SE="0.1407756143679307" STUDY_ID="STD-Dalmau-2004" TOTAL_1="63" TOTAL_2="64" VAR="0.01981777360066834" WEIGHT="6.037141257332952"/>
<DICH_DATA CI_END="1.0779225045907352" CI_START="0.9277104761623649" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="27" LOG_CI_END="0.032587539108232075" LOG_CI_START="-0.032587539108232096" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-23 04:52:00 +0100" MODIFIED_BY="[Empty name]" ORDER="2757" O_E="0.0" SE="0.0382841635661914" STUDY_ID="STD-Ickx-2006" TOTAL_1="24" TOTAL_2="27" VAR="0.0014656771799628973" WEIGHT="10.326548721340851"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="70.40363632184274" CI_END="0.9836105076543344" CI_START="0.8068808760671926" CI_STUDY="95" CI_TOTAL="95" DF="28" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8908740136096829" ESTIMABLE="YES" EVENTS_1="1024" EVENTS_2="1673" I2="60.229326973963424" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="-0.0071768404539383724" LOG_CI_START="-0.09319057765145357" LOG_EFFECT_SIZE="-0.05018370905269597" METHOD="MH" MODIFIED="2010-08-23 05:08:37 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.634049190968323E-5" P_Q="0.0" P_Z="0.0221937142797814" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="29" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.022469380908359263" TOTALS="YES" TOTAL_1="2340" TOTAL_2="3089" WEIGHT="100.00000000000003" Z="2.287036130706857">
<NAME>No. Exposed to Allogeneic Blood - Transfusion Protocol</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Lysine Analogues</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="66.84443994370535" CI_END="0.9949637750899862" CI_START="0.8046460764689047" DF="24" EFFECT_SIZE="0.8947590166379142" ESTIMABLE="YES" EVENTS_1="984" EVENTS_2="1626" I2="64.09574226336225" ID="CMP-007.03.01" LOG_CI_END="-0.002192730877305167" LOG_CI_START="-0.09439510203664192" LOG_EFFECT_SIZE="-0.048293916456973514" MODIFIED="2010-08-23 05:08:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="6.503030152260614E-6" P_Z="0.04005448256750006" STUDIES="25" TAU2="0.023645645404189168" TOTAL_1="2232" TOTAL_2="2981" WEIGHT="89.73034767203362" Z="2.053186609799445">
<NAME>Transfusion Protocol</NAME>
<DICH_DATA CI_END="1.5542598037816595" CI_START="0.4946396798386406" EFFECT_SIZE="0.8768115942028986" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.19152361544173646" LOG_CI_START="-0.30571104761130935" LOG_EFFECT_SIZE="-0.057093716084786424" MODIFIED="2010-08-23 05:04:47 +0100" MODIFIED_BY="[Empty name]" ORDER="2776" O_E="0.0" SE="0.29207810242863735" STUDY_ID="STD-Amar-2003" TOTAL_1="23" TOTAL_2="22" VAR="0.08530961791831358" WEIGHT="2.3685180257982017"/>
<DICH_DATA CI_END="1.1197841224249232" CI_START="0.3738980690319062" EFFECT_SIZE="0.6470588235294118" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="0.04913430528065808" LOG_CI_START="-0.42724677772075587" LOG_EFFECT_SIZE="-0.18905623622004886" MODIFIED="2010-08-23 05:04:53 +0100" MODIFIED_BY="[Empty name]" ORDER="2777" O_E="0.0" SE="0.27982860627942274" STUDY_ID="STD-Bernet-1999" TOTAL_1="28" TOTAL_2="28" VAR="0.07830404889228418" WEIGHT="2.533172702650515"/>
<DICH_DATA CI_END="1.435243954367492" CI_START="0.14690857630106668" EFFECT_SIZE="0.45918367346938777" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.15692572617866216" LOG_CI_START="-0.8329528500129644" LOG_EFFECT_SIZE="-0.33801356191715115" MODIFIED="2010-08-23 05:05:00 +0100" MODIFIED_BY="[Empty name]" ORDER="2778" O_E="0.0" SE="0.5814595756329395" STUDY_ID="STD-Blauhut-1994" TOTAL_1="14" TOTAL_2="15" VAR="0.3380952380952381" WEIGHT="0.7079909898783247"/>
<DICH_DATA CI_END="1.346564360926496" CI_START="0.49177073391944337" EFFECT_SIZE="0.8137573004542504" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.12922711595564204" LOG_CI_START="-0.30823732040308555" LOG_EFFECT_SIZE="-0.08950510222372171" MODIFIED="2010-08-23 05:05:06 +0100" MODIFIED_BY="[Empty name]" ORDER="2779" O_E="0.0" SE="0.25696877540100105" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="66" VAR="0.06603295153109012" WEIGHT="2.8844042240142125"/>
<DICH_DATA CI_END="1.2365301946437357" CI_START="0.8871155928252136" EFFECT_SIZE="1.0473515248796148" ESTIMABLE="YES" EVENTS_1="185" EVENTS_2="178" LOG_CI_END="0.09220472579804354" LOG_CI_START="-0.05201978709574561" LOG_EFFECT_SIZE="0.02009246935114897" MODIFIED="2010-08-23 05:05:12 +0100" MODIFIED_BY="[Empty name]" ORDER="2780" O_E="0.0" SE="0.08471819279666457" STUDY_ID="STD-Casati-2000" TOTAL_1="518" TOTAL_2="522" VAR="0.007177172190732827" WEIGHT="8.610663798594366"/>
<DICH_DATA CI_END="1.6923197685338265" CI_START="0.5372153021082148" EFFECT_SIZE="0.9534883720930233" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.22848242760880472" LOG_CI_START="-0.2698516253285067" LOG_EFFECT_SIZE="-0.02068459885985102" MODIFIED="2010-08-23 05:05:22 +0100" MODIFIED_BY="[Empty name]" ORDER="2781" O_E="0.0" SE="0.2927238894887227" STUDY_ID="STD-Corbeau-1995" TOTAL_1="43" TOTAL_2="41" VAR="0.08568727547740593" WEIGHT="2.3602477189471953"/>
<DICH_DATA CI_END="1.4091078666036987" CI_START="0.8114978976663392" EFFECT_SIZE="1.0693400167084377" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="38" LOG_CI_END="0.14894423943845972" LOG_CI_START="-0.09071260095554438" LOG_EFFECT_SIZE="0.029115819241457678" MODIFIED="2010-08-23 05:05:30 +0100" MODIFIED_BY="[Empty name]" ORDER="2782" O_E="0.0" SE="0.1407756143679307" STUDY_ID="STD-Dalmau-2004" TOTAL_1="63" TOTAL_2="64" VAR="0.01981777360066834" WEIGHT="6.0367386854786025"/>
<DICH_DATA CI_END="0.9942864949565421" CI_START="0.60582269873457" EFFECT_SIZE="0.7761194029850746" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="67" LOG_CI_END="-0.0024884594142842056" LOG_CI_START="-0.21765445871777034" LOG_EFFECT_SIZE="-0.11007145906602726" MODIFIED="2010-08-23 05:05:36 +0100" MODIFIED_BY="[Empty name]" ORDER="2783" O_E="0.0" SE="0.12638957307974186" STUDY_ID="STD-Dietrich-2008" TOTAL_1="110" TOTAL_2="110" VAR="0.01597432418327941" WEIGHT="6.640267916813754"/>
<DICH_DATA CI_END="0.8364512088877062" CI_START="0.19128431915683927" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" LOG_CI_END="-0.07755938683408231" LOG_CI_START="-0.7183206305099928" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2010-08-23 05:05:53 +0100" MODIFIED_BY="[Empty name]" ORDER="2784" O_E="0.0" SE="0.3763863263545405" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.14166666666666666" WEIGHT="1.5552738432230861"/>
<DICH_DATA CI_END="1.1531481274998097" CI_START="0.3121888605764218" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.061885098121928904" LOG_CI_START="-0.5055825973546417" LOG_EFFECT_SIZE="-0.22184874961635637" MODIFIED="2010-08-23 05:06:02 +0100" MODIFIED_BY="[Empty name]" ORDER="2785" O_E="0.0" SE="0.3333333333333333" STUDY_ID="STD-Dorman-2008" TOTAL_1="30" TOTAL_2="30" VAR="0.1111111111111111" WEIGHT="1.911031301533531"/>
<DICH_DATA CI_END="1.3697803938804385" CI_START="0.41064976730065383" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.13665094571788927" LOG_CI_START="-0.3865284189344892" LOG_EFFECT_SIZE="-0.12493873660829993" MODIFIED="2010-08-23 05:06:11 +0100" MODIFIED_BY="[Empty name]" ORDER="2786" O_E="0.0" SE="0.30731814857642953" STUDY_ID="STD-Eberle-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.09444444444444443" WEIGHT="2.183458635051292"/>
<DICH_DATA CI_END="179.29256051754408" CI_START="0.6748746275401646" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2535622695219755" LOG_CI_START="-0.17077689920552552" LOG_EFFECT_SIZE="1.041392685158225" MODIFIED="2010-08-23 05:06:18 +0100" MODIFIED_BY="[Empty name]" ORDER="2787" O_E="0.0" SE="1.424068828382964" STUDY_ID="STD-Engel-2001" TOTAL_1="12" TOTAL_2="12" VAR="2.0279720279720275" WEIGHT="0.12449831554213873"/>
<DICH_DATA CI_END="0.8793255509557636" CI_START="0.7577958115542787" EFFECT_SIZE="0.8163021618903972" ESTIMABLE="YES" EVENTS_1="419" EVENTS_2="1020" LOG_CI_END="-0.0558503071695787" LOG_CI_START="-0.12044779946204372" LOG_EFFECT_SIZE="-0.08814905331581117" MODIFIED="2010-08-23 05:06:35 +0100" MODIFIED_BY="[Empty name]" ORDER="2788" O_E="0.0" SE="0.03794488673533784" STUDY_ID="STD-Fergusson-2008" TOTAL_1="780" TOTAL_2="1550" VAR="0.0014398144293576178" WEIGHT="10.676917308076774"/>
<DICH_DATA CI_END="3.6287762406689716" CI_START="0.4960541309410133" EFFECT_SIZE="1.3416666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5597601893527253" LOG_CI_START="-0.30447092938427567" LOG_EFFECT_SIZE="0.12764462998422485" MODIFIED="2010-08-23 05:06:43 +0100" MODIFIED_BY="[Empty name]" ORDER="2789" O_E="0.0" SE="0.507653637159147" STUDY_ID="STD-Greilich-2001" TOTAL_1="24" TOTAL_2="23" VAR="0.25771221532091093" WEIGHT="0.9111108829381046"/>
<DICH_DATA CI_END="1.7386462202749464" CI_START="0.7657457458683129" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.2402112207530636" LOG_CI_START="-0.11591540725537476" LOG_EFFECT_SIZE="0.062147906748844434" MODIFIED="2010-08-23 05:06:48 +0100" MODIFIED_BY="[Empty name]" ORDER="2790" O_E="0.0" SE="0.2091905441473963" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="25" VAR="0.043760683760683754" WEIGHT="3.8543900387096883"/>
<DICH_DATA CI_END="1.0779225045907352" CI_START="0.9277104761623649" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="27" LOG_CI_END="0.032587539108232075" LOG_CI_START="-0.032587539108232096" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-23 05:07:06 +0100" MODIFIED_BY="[Empty name]" ORDER="2791" O_E="0.0" SE="0.0382841635661914" STUDY_ID="STD-Ickx-2006" TOTAL_1="24" TOTAL_2="27" VAR="0.0014656771799628973" WEIGHT="10.665380488381036"/>
<DICH_DATA CI_END="1.6825402105470073" CI_START="0.7803284697433366" EFFECT_SIZE="1.1458333333333333" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="24" LOG_CI_END="0.22596545209958277" LOG_CI_START="-0.10772254786226959" LOG_EFFECT_SIZE="0.05912145211865659" MODIFIED="2010-08-23 05:07:13 +0100" MODIFIED_BY="[Empty name]" ORDER="2792" O_E="0.0" SE="0.19600998295983146" STUDY_ID="STD-Isetta-1993" TOTAL_1="140" TOTAL_2="70" VAR="0.038419913419913417" WEIGHT="4.192469371498784"/>
<DICH_DATA CI_END="5.1801150354072085" CI_START="0.9343421848583578" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.714339404279566" LOG_CI_START="-0.02949404263515343" LOG_EFFECT_SIZE="0.3424226808222063" MODIFIED="2010-08-23 05:07:20 +0100" MODIFIED_BY="[Empty name]" ORDER="2793" O_E="0.0" SE="0.4369314487526515" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.19090909090909092" WEIGHT="1.1963554680523363"/>
<DICH_DATA CI_END="1.1284556431965513" CI_START="0.6683072827900095" EFFECT_SIZE="0.868421052631579" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="57" LOG_CI_END="0.05248449270613696" LOG_CI_START="-0.17502380618398225" LOG_EFFECT_SIZE="-0.06126965673892266" MODIFIED="2010-08-23 05:07:29 +0100" MODIFIED_BY="[Empty name]" ORDER="2794" O_E="0.0" SE="0.1336395009522984" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="99" VAR="0.017859516214779367" WEIGHT="6.32986567284513"/>
<DICH_DATA CI_END="1.0571879058568519" CI_START="0.01930419668276973" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.024152186194750208" LOG_CI_START="-1.714348266223264" LOG_EFFECT_SIZE="-0.8450980400142569" MODIFIED="2010-08-23 05:07:37 +0100" MODIFIED_BY="[Empty name]" ORDER="2795" O_E="0.0" SE="1.0212037714663722" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="1.0428571428571427" WEIGHT="0.2396227783958272"/>
<DICH_DATA CI_END="1.0198361669523746" CI_START="0.33929053749849375" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" LOG_CI_END="0.00853040950370991" LOG_CI_START="-0.46942825226025775" LOG_EFFECT_SIZE="-0.2304489213782739" MODIFIED="2010-08-23 05:07:48 +0100" MODIFIED_BY="[Empty name]" ORDER="2796" O_E="0.0" SE="0.2807552838536876" STUDY_ID="STD-Mengistu-2008" TOTAL_1="25" TOTAL_2="25" VAR="0.07882352941176468" WEIGHT="2.520181330723814"/>
<DICH_DATA CI_END="0.9996095394793454" CI_START="0.06252441331497659" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="16" LOG_CI_END="-1.6960796428367106E-4" LOG_CI_START="-1.2039503746916411" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2010-08-23 05:07:55 +0100" MODIFIED_BY="[Empty name]" ORDER="2797" O_E="0.0" SE="0.7071067811865476" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="48" VAR="0.5" WEIGHT="0.4885960993152117"/>
<DICH_DATA CI_END="3.754457918288967" CI_START="0.012343864976933615" EFFECT_SIZE="0.2152777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.5745472409165846" LOG_CI_START="-1.9085488374385386" LOG_EFFECT_SIZE="-0.6670007982609769" MODIFIED="2010-08-23 05:08:03 +0100" MODIFIED_BY="[Empty name]" ORDER="2798" O_E="0.0" SE="1.4585829279496223" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="30" VAR="2.1274641577060933" WEIGHT="0.11873692695076218"/>
<DICH_DATA CI_END="1.0921635201498592" CI_START="0.9156138083267851" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.03828766637439782" LOG_CI_START="-0.03828766637439781" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-23 05:08:10 +0100" MODIFIED_BY="[Empty name]" ORDER="2799" O_E="0.0" SE="0.04498072951065294" STUDY_ID="STD-Pugh-1995" TOTAL_1="21" TOTAL_2="22" VAR="0.0020232660273105246" WEIGHT="10.422577118510077"/>
<DICH_DATA CI_END="3.3417930664224986" CI_START="0.04048385845900427" EFFECT_SIZE="0.367816091954023" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5239795536084553" LOG_CI_START="-1.3927181022058803" LOG_EFFECT_SIZE="-0.4343692742987125" MODIFIED="2010-08-23 05:08:37 +0100" MODIFIED_BY="[Empty name]" ORDER="2800" O_E="0.0" SE="1.1258776908317545" STUDY_ID="STD-Vanek-2005" TOTAL_1="29" TOTAL_2="32" VAR="1.2676005747126435" WEIGHT="0.19787803011083616"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.3069676733698175" CI_END="1.123526976391578" CI_START="0.6487383493972892" DF="3" EFFECT_SIZE="0.8537417854173471" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="47" I2="9.282451589767605" ID="CMP-007.03.02" LOG_CI_END="0.050583504487549384" LOG_CI_START="-0.18793042850826708" LOG_EFFECT_SIZE="-0.06867346201035883" MODIFIED="2010-08-23 05:04:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3466741194854792" P_Z="0.25905212063227456" STUDIES="4" TAU2="0.008673693201435446" TOTAL_1="108" TOTAL_2="108" WEIGHT="10.269652327966414" Z="1.1286343782385557">
<NAME>No Transfusion Protocol</NAME>
<DICH_DATA CI_END="2.3586217117979826" CI_START="0.6251489115625755" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.3726582920289919" LOG_CI_START="-0.2040165206289201" LOG_EFFECT_SIZE="0.08432088570003587" MODIFIED="2010-08-23 05:04:17 +0100" MODIFIED_BY="[Empty name]" ORDER="2773" O_E="0.0" SE="0.3387416395416184" STUDY_ID="STD-Ray-2001" TOTAL_1="49" TOTAL_2="51" VAR="0.11474589835934375" WEIGHT="1.8604087160397118"/>
<DICH_DATA CI_END="2.3302506070190314" CI_START="0.10728459816595091" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.36740262977830473" LOG_CI_START="-0.9694626211062671" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-08-23 05:04:24 +0100" MODIFIED_BY="[Empty name]" ORDER="2774" O_E="0.0" SE="0.7852812659593165" STUDY_ID="STD-Ray-2005" TOTAL_1="15" TOTAL_2="15" VAR="0.6166666666666667" WEIGHT="0.39940870569265124"/>
<DICH_DATA CI_END="1.2732251164306965" CI_START="0.6692225867377" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.10490519719658377" LOG_CI_START="-0.1744294097150076" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2010-08-23 05:04:03 +0100" MODIFIED_BY="[Empty name]" ORDER="2772" O_E="0.0" SE="0.16408253082847335" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.02692307692307691" WEIGHT="5.168329593855226"/>
<DICH_DATA CI_END="1.0323063713894243" CI_START="0.37319894434005896" EFFECT_SIZE="0.6206896551724138" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.01380860781209295" LOG_CI_START="-0.42805959340339295" LOG_EFFECT_SIZE="-0.20712549279564998" MODIFIED="2010-08-23 05:04:34 +0100" MODIFIED_BY="[Empty name]" ORDER="2775" O_E="0.0" SE="0.2595555686768485" STUDY_ID="STD-Trinh_x002d_Duc-1992" TOTAL_1="29" TOTAL_2="27" VAR="0.0673690932311622" WEIGHT="2.8415053123788243"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.2732485483434093" CI_END="0.21081137261618" CI_START="-0.42093753815114054" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.10506308276748028" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.04" MODIFIED="2010-08-23 05:59:22 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.9731123007119606" P_Q="1.0" P_Z="0.5144630320458426" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="106" TOTAL_2="145" UNITS="" WEIGHT="100.0" Z="0.6519041182956768">
<NAME>Units of Allogeneic Blood Transfused - Transfused Patients</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Lysine Analogues</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8589869714360764" CI_START="-0.9189869714360764" EFFECT_SIZE="-0.030000000000000027" ESTIMABLE="YES" MEAN_1="1.68" MEAN_2="1.71" MODIFIED="2010-08-23 05:19:55 +0100" MODIFIED_BY="[Empty name]" ORDER="2801" SD_1="0.48" SD_2="0.95" SE="0.4535731158573791" STUDY_ID="STD-Blauhut-1994" TOTAL_1="3" TOTAL_2="7" WEIGHT="12.625198639897382"/>
<CONT_DATA CI_END="0.32370368413427464" CI_START="-0.7437036841342746" EFFECT_SIZE="-0.20999999999999996" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="2.11" MODIFIED="2010-08-23 05:59:22 +0100" MODIFIED_BY="[Empty name]" ORDER="2817" SD_1="1.04" SD_2="0.83" SE="0.2723028016555718" STUDY_ID="STD-Casati-1999" TOTAL_1="19" TOTAL_2="40" WEIGHT="35.029070289707285"/>
<CONT_DATA CI_END="0.8891461805555804" CI_START="-0.6891461805555802" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.29" MEAN_2="2.19" MODIFIED="2010-08-23 05:20:07 +0100" MODIFIED_BY="[Empty name]" ORDER="2803" SD_1="1.49" SD_2="0.46" SE="0.4026330008001497" STUDY_ID="STD-Corbeau-1995" TOTAL_1="15" TOTAL_2="15" WEIGHT="16.021902867467396"/>
<CONT_DATA CI_END="1.857542465248001" CI_START="-1.6375424652480004" EFFECT_SIZE="0.11000000000000032" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="5.09" MODIFIED="2010-08-23 05:20:12 +0100" MODIFIED_BY="[Empty name]" ORDER="2804" SD_1="4.17" SD_2="3.7" SE="0.8916196823168143" STUDY_ID="STD-Dalmau-2004" TOTAL_1="40" TOTAL_2="38" WEIGHT="3.2671835704134735"/>
<CONT_DATA CI_END="0.6856985140878269" CI_START="-1.7056985140878265" EFFECT_SIZE="-0.5099999999999998" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.61" MODIFIED="2010-08-23 05:20:17 +0100" MODIFIED_BY="[Empty name]" ORDER="2805" SD_1="1.42" SD_2="1.55" SE="0.610061472312422" STUDY_ID="STD-Diprose-2005" TOTAL_1="8" TOTAL_2="20" WEIGHT="6.978878431350926"/>
<CONT_DATA CI_END="0.7286499561705034" CI_START="-0.6486499561705034" EFFECT_SIZE="0.040000000000000036" ESTIMABLE="YES" MEAN_1="1.29" MEAN_2="1.25" MODIFIED="2010-08-23 05:23:23 +0100" MODIFIED_BY="[Empty name]" ORDER="2818" SD_1="0.88" SD_2="0.67" SE="0.3513584747487639" STUDY_ID="STD-Eberle-1998" TOTAL_1="9" TOTAL_2="12" WEIGHT="21.03933282783996"/>
<CONT_DATA CI_END="1.007235382459335" CI_START="-1.8072353824593348" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="2.91" MEAN_2="3.31" MODIFIED="2010-08-23 05:20:23 +0100" MODIFIED_BY="[Empty name]" ORDER="2806" SD_1="1.94" SD_2="1.62" SE="0.7179904291912647" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="12" TOTAL_2="13" WEIGHT="5.038433373323578"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="13.609071708449989" CI_END="-0.08842177957696293" CI_START="-0.41540046794122676" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.25191112375909486" ESTIMABLE="YES" I2="4.4754831299170155" I2_Q="0.0" ID="CMP-007.05" MODIFIED="2010-08-23 06:00:13 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.40193945093245353" P_Q="1.0" P_Z="0.002527802475897763" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0044892601029710875" TOTALS="YES" TOTAL_1="595" TOTAL_2="659" UNITS="" WEIGHT="100.0" Z="3.0199933356072495">
<NAME>Units of Allogeneic Blood Transfused - All Patients</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Lysine Analogues</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3112466360074677" CI_START="-1.1112466360074675" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="1.7" MODIFIED="2010-08-23 05:23:49 +0100" MODIFIED_BY="[Empty name]" ORDER="2819" SD_1="1.5" SD_2="2.5" SE="0.6179943333457281" STUDY_ID="STD-Amar-2003" TOTAL_1="23" TOTAL_2="22" WEIGHT="1.8006884217036712"/>
<CONT_DATA CI_END="0.1594368776521955" CI_START="-1.0394368776521956" EFFECT_SIZE="-0.44000000000000006" ESTIMABLE="YES" MEAN_1="0.36" MEAN_2="0.8" MODIFIED="2010-08-23 05:20:55 +0100" MODIFIED_BY="[Empty name]" ORDER="2807" SD_1="0.47" SD_2="1.08" SE="0.3058407615550475" STUDY_ID="STD-Blauhut-1994" TOTAL_1="14" TOTAL_2="15" WEIGHT="7.097956372726701"/>
<CONT_DATA CI_END="0.22230576824897053" CI_START="-0.38230576824897045" EFFECT_SIZE="-0.07999999999999996" ESTIMABLE="YES" MEAN_1="0.54" MEAN_2="0.62" MODIFIED="2010-08-23 06:00:13 +0100" MODIFIED_BY="[Empty name]" ORDER="2820" SD_1="1.02" SD_2="1.06" SE="0.15424047106657052" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="136" WEIGHT="24.6044007072474"/>
<CONT_DATA CI_END="0.5370930417456575" CI_START="-0.5370930417456575" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.8" MODIFIED="2010-08-23 05:21:17 +0100" MODIFIED_BY="[Empty name]" ORDER="2809" SD_1="1.4" SD_2="1.1" SE="0.27403209751922936" STUDY_ID="STD-Corbeau-1995" TOTAL_1="43" TOTAL_2="41" WEIGHT="8.74305540084931"/>
<CONT_DATA CI_END="1.6646991249456335" CI_START="-1.104699124945634" EFFECT_SIZE="0.2799999999999998" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="3.02" MODIFIED="2010-08-23 05:21:23 +0100" MODIFIED_BY="[Empty name]" ORDER="2810" SD_1="4.16" SD_2="3.79" SE="0.7064921273390551" STUDY_ID="STD-Dalmau-2004" TOTAL_1="63" TOTAL_2="64" WEIGHT="1.3815907591012264"/>
<CONT_DATA CI_END="0.0757066815715326" CI_START="-0.8757066815715324" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="1.7" MODIFIED="2010-08-23 05:21:32 +0100" MODIFIED_BY="[Empty name]" ORDER="2811" SD_1="1.8" SD_2="1.8" SE="0.24271195048676716" STUDY_ID="STD-Dietrich-2008" TOTAL_1="110" TOTAL_2="110" WEIGHT="10.975005822967088"/>
<CONT_DATA CI_END="-0.1468501637761201" CI_START="-1.0331498362238798" EFFECT_SIZE="-0.59" ESTIMABLE="YES" MEAN_1="0.28" MEAN_2="0.87" MODIFIED="2010-08-23 05:21:38 +0100" MODIFIED_BY="[Empty name]" ORDER="2812" SD_1="0.87" SD_2="1.52" SE="0.22610100987537995" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" WEIGHT="12.511880523159713"/>
<CONT_DATA CI_END="-0.019832859334859565" CI_START="-1.7801671406651403" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="0.56" MEAN_2="1.46" MODIFIED="2010-08-23 05:24:04 +0100" MODIFIED_BY="[Empty name]" ORDER="2821" SD_1="1.1" SD_2="2.2" SE="0.44907311951024936" STUDY_ID="STD-Dorman-2008" TOTAL_1="30" TOTAL_2="30" WEIGHT="3.3751019552369583"/>
<CONT_DATA CI_END="0.35095975437843574" CI_START="-0.6909597543784358" EFFECT_SIZE="-0.17000000000000004" ESTIMABLE="YES" MEAN_1="0.58" MEAN_2="0.75" MODIFIED="2010-08-23 05:24:11 +0100" MODIFIED_BY="[Empty name]" ORDER="2822" SD_1="0.87" SD_2="0.81" SE="0.2658006772000403" STUDY_ID="STD-Eberle-1998" TOTAL_1="20" TOTAL_2="20" WEIGHT="9.26010278209246"/>
<CONT_DATA CI_END="2.0549657434042254" CI_START="-0.45496574340422513" EFFECT_SIZE="0.8" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="1.7" MODIFIED="2010-08-23 05:24:18 +0100" MODIFIED_BY="[Empty name]" ORDER="2823" SD_1="2.7" SD_2="1.8" SE="0.6403004102642879" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="25" WEIGHT="1.6787481978335952"/>
<CONT_DATA CI_END="0.35180435354902223" CI_START="-0.5518043535490225" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.8" MODIFIED="2010-08-23 05:21:48 +0100" MODIFIED_BY="[Empty name]" ORDER="2813" SD_1="1.2" SD_2="1.3" SE="0.2305166610778552" STUDY_ID="STD-Hekmat-2004" TOTAL_1="60" TOTAL_2="58" WEIGHT="12.074113934587897"/>
<CONT_DATA CI_END="0.03489067983508409" CI_START="-2.034890679835084" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.8" MODIFIED="2010-08-23 05:21:54 +0100" MODIFIED_BY="[Empty name]" ORDER="2814" SD_1="1.1" SD_2="2.4" SE="0.5280151512977634" STUDY_ID="STD-Mengistu-2008" TOTAL_1="25" TOTAL_2="25" WEIGHT="2.456137134429243"/>
<CONT_DATA CI_END="0.8931433922667307" CI_START="-1.9731433922667307" EFFECT_SIZE="-0.54" ESTIMABLE="YES" MEAN_1="2.33" MEAN_2="2.87" MODIFIED="2010-08-23 05:22:02 +0100" MODIFIED_BY="[Empty name]" ORDER="2815" SD_1="2.1" SD_2="1.9" SE="0.731209044437134" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.2905306924710507"/>
<CONT_DATA CI_END="0.5169682447707552" CI_START="-1.436968244770756" EFFECT_SIZE="-0.4600000000000004" ESTIMABLE="YES" MEAN_1="2.03" MEAN_2="2.49" MODIFIED="2010-08-23 05:22:09 +0100" MODIFIED_BY="[Empty name]" ORDER="2816" SD_1="2.12" SD_2="2.25" SE="0.49846234547009866" STUDY_ID="STD-Wong-2000" TOTAL_1="39" TOTAL_2="38" WEIGHT="2.7506872955936785"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="70.06034068833992" CI_END="0.9885063749263981" CI_START="0.8145951302019361" CI_STUDY="95" CI_TOTAL="95" DF="29" EFFECT_MEASURE="RR" EFFECT_SIZE="0.89734746848064" ESTIMABLE="YES" EVENTS_1="1043" EVENTS_2="1690" I2="58.607109649944306" I2_Q="0.0" ID="CMP-007.06" LOG_CI_END="-0.0050205255547299075" LOG_CI_START="-0.08905819053377859" LOG_EFFECT_SIZE="-0.04703935804425425" METHOD="MH" MODIFIED="2011-02-16 13:51:32 +0000" MODIFIED_BY="Emma M Sydenham" NO="6" P_CHI2="2.97507699817956E-5" P_Q="0.0" P_Z="0.02822492479504188" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="29" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.02158969349256598" TOTALS="YES" TOTAL_1="2407" TOTAL_2="3159" WEIGHT="100.0" Z="2.1941458665137326">
<NAME>Trial Methodological Quality - Allocation Concealment</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Lysine Analogues</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.4436485130738905" CI_END="0.9538035256098457" CI_START="0.7103039735479872" DF="5" EFFECT_SIZE="0.8230980708425655" ESTIMABLE="YES" EVENTS_1="500" EVENTS_2="1124" I2="22.40420951181289" ID="CMP-007.06.01" LOG_CI_END="-0.020541076586496974" LOG_CI_START="-0.1485557558120537" LOG_EFFECT_SIZE="-0.08454841619927529" MODIFIED="2010-08-23 06:57:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2654103340892974" P_Z="0.009626885838769611" STUDIES="6" TAU2="0.008121397103808027" TOTAL_1="985" TOTAL_2="1757" WEIGHT="23.31528115216054" Z="2.588950762568485">
<NAME>Allocation concealment - Yes</NAME>
<DICH_DATA CI_END="0.9942864949565421" CI_START="0.60582269873457" EFFECT_SIZE="0.7761194029850746" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="67" LOG_CI_END="-0.0024884594142842056" LOG_CI_START="-0.21765445871777034" LOG_EFFECT_SIZE="-0.11007145906602726" MODIFIED="2010-08-23 06:57:14 +0100" MODIFIED_BY="[Empty name]" ORDER="3059" O_E="0.0" SE="0.12638957307974186" STUDY_ID="STD-Dietrich-2008" TOTAL_1="110" TOTAL_2="110" VAR="0.01597432418327941" WEIGHT="6.487107898418158"/>
<DICH_DATA CI_END="1.3697803938804385" CI_START="0.41064976730065383" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.13665094571788927" LOG_CI_START="-0.3865284189344892" LOG_EFFECT_SIZE="-0.12493873660829993" MODIFIED="2010-08-23 06:57:14 +0100" MODIFIED_BY="[Empty name]" ORDER="3056" O_E="0.0" SE="0.30731814857642953" STUDY_ID="STD-Eberle-1998" TOTAL_1="20" TOTAL_2="20" VAR="0.09444444444444443" WEIGHT="2.1000874405907988"/>
<DICH_DATA CI_END="0.8793255509557636" CI_START="0.7577958115542787" EFFECT_SIZE="0.8163021618903972" ESTIMABLE="YES" EVENTS_1="419" EVENTS_2="1020" LOG_CI_END="-0.0558503071695787" LOG_CI_START="-0.12044779946204372" LOG_EFFECT_SIZE="-0.08814905331581117" MODIFIED="2010-08-23 06:57:14 +0100" MODIFIED_BY="[Empty name]" ORDER="3054" O_E="0.0" SE="0.03794488673533784" STUDY_ID="STD-Fergusson-2008" TOTAL_1="780" TOTAL_2="1550" VAR="0.0014398144293576178" WEIGHT="10.581287128993148"/>
<DICH_DATA CI_END="1.7386462202749464" CI_START="0.7657457458683129" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.2402112207530636" LOG_CI_START="-0.11591540725537476" LOG_EFFECT_SIZE="0.062147906748844434" MODIFIED="2010-08-23 06:57:14 +0100" MODIFIED_BY="[Empty name]" ORDER="3055" O_E="0.0" SE="0.2091905441473963" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="25" VAR="0.043760683760683754" WEIGHT="3.7288512477436098"/>
<DICH_DATA CI_END="1.0571879058568519" CI_START="0.01930419668276973" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.024152186194750208" LOG_CI_START="-1.714348266223264" LOG_EFFECT_SIZE="-0.8450980400142569" MODIFIED="2010-08-23 06:57:14 +0100" MODIFIED_BY="[Empty name]" ORDER="3057" O_E="0.0" SE="1.0212037714663722" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="1.0428571428571427" WEIGHT="0.22892814130290465"/>
<DICH_DATA CI_END="3.3417930664224986" CI_START="0.04048385845900427" EFFECT_SIZE="0.367816091954023" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5239795536084553" LOG_CI_START="-1.3927181022058803" LOG_EFFECT_SIZE="-0.4343692742987125" MODIFIED="2010-08-23 06:57:14 +0100" MODIFIED_BY="[Empty name]" ORDER="3058" O_E="0.0" SE="1.1258776908317545" STUDY_ID="STD-Vanek-2005" TOTAL_1="29" TOTAL_2="32" VAR="1.2676005747126435" WEIGHT="0.1890192951119201"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="26.77114721557242" CI_END="1.0425364563324575" CI_START="0.8569258016471644" DF="18" EFFECT_SIZE="0.9451859016030049" ESTIMABLE="YES" EVENTS_1="425" EVENTS_2="434" I2="32.763434248609116" ID="CMP-007.06.02" LOG_CI_END="0.018091250703048012" LOG_CI_START="-0.06705678056250103" LOG_EFFECT_SIZE="-0.024482764929726487" MODIFIED="2011-02-16 13:51:32 +0000" MODIFIED_BY="Emma M Sydenham" NO="2" P_CHI2="0.08338917149259573" P_Z="0.2596985885578257" STUDIES="18" TAU2="0.008815362528439334" TOTAL_1="1160" TOTAL_2="1137" WEIGHT="59.70371944131207" Z="1.1271038634956467">
<NAME>Allocation concealment - Unclear</NAME>
<DICH_DATA CI_END="1.1197841224249232" CI_START="0.3738980690319062" EFFECT_SIZE="0.6470588235294118" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="0.04913430528065808" LOG_CI_START="-0.42724677772075587" LOG_EFFECT_SIZE="-0.18905623622004886" MODIFIED="2010-08-23 06:57:48 +0100" MODIFIED_BY="[Empty name]" ORDER="3077" O_E="0.0" SE="0.27982860627942274" STUDY_ID="STD-Bernet-1999" TOTAL_1="28" TOTAL_2="28" VAR="0.07830404889228418" WEIGHT="2.4394104169457225"/>
<DICH_DATA CI_END="1.435243954367492" CI_START="0.14690857630106668" EFFECT_SIZE="0.45918367346938777" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.15692572617866216" LOG_CI_START="-0.8329528500129644" LOG_EFFECT_SIZE="-0.33801356191715115" MODIFIED="2010-08-23 06:57:48 +0100" MODIFIED_BY="[Empty name]" ORDER="3063" O_E="0.0" SE="0.5814595756329395" STUDY_ID="STD-Blauhut-1994" TOTAL_1="14" TOTAL_2="15" VAR="0.3380952380952381" WEIGHT="0.6774869180245593"/>
<DICH_DATA CI_END="1.346564360926496" CI_START="0.49177073391944337" EFFECT_SIZE="0.8137573004542504" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.12922711595564204" LOG_CI_START="-0.30823732040308555" LOG_EFFECT_SIZE="-0.08950510222372171" MODIFIED="2010-08-23 06:57:48 +0100" MODIFIED_BY="[Empty name]" ORDER="3073" O_E="0.0" SE="0.25696877540100105" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="66" VAR="0.06603295153109012" WEIGHT="2.781037204429373"/>
<DICH_DATA CI_END="2.048506537591385" CI_START="0.6656079177641339" EFFECT_SIZE="1.1676909569798068" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.3114373542961579" LOG_CI_START="-0.176781520520187" LOG_EFFECT_SIZE="0.06732791688798542" MODIFIED="2010-08-23 06:57:48 +0100" MODIFIED_BY="[Empty name]" ORDER="3075" O_E="0.0" SE="0.28678218378952774" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="70" VAR="0.08224402093909047" WEIGHT="2.3468469474978453"/>
<DICH_DATA CI_END="1.2365301946437357" CI_START="0.8871155928252136" EFFECT_SIZE="1.0473515248796148" ESTIMABLE="YES" EVENTS_1="185" EVENTS_2="178" LOG_CI_END="0.09220472579804354" LOG_CI_START="-0.05201978709574561" LOG_EFFECT_SIZE="0.02009246935114897" MODIFIED="2010-08-23 06:57:48 +0100" MODIFIED_BY="[Empty name]" ORDER="3069" O_E="0.0" SE="0.08471819279666457" STUDY_ID="STD-Casati-2000" TOTAL_1="518" TOTAL_2="522" VAR="0.007177172190732827" WEIGHT="8.470920622498348"/>
<DICH_DATA CI_END="1.6923197685338265" CI_START="0.5372153021082148" EFFECT_SIZE="0.9534883720930233" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.22848242760880472" LOG_CI_START="-0.2698516253285067" LOG_EFFECT_SIZE="-0.02068459885985102" MODIFIED="2010-08-23 06:57:48 +0100" MODIFIED_BY="[Empty name]" ORDER="3071" O_E="0.0" SE="0.2927238894887227" STUDY_ID="STD-Corbeau-1995" TOTAL_1="43" TOTAL_2="41" VAR="0.08568727547740593" WEIGHT="2.2715205146176842"/>
<DICH_DATA CI_END="1.1531481274998097" CI_START="0.3121888605764218" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.061885098121928904" LOG_CI_START="-0.5055825973546417" LOG_EFFECT_SIZE="-0.22184874961635637" MODIFIED="2010-08-23 06:57:48 +0100" MODIFIED_BY="[Empty name]" ORDER="3074" O_E="0.0" SE="0.3333333333333333" STUDY_ID="STD-Dorman-2008" TOTAL_1="30" TOTAL_2="30" VAR="0.1111111111111111" WEIGHT="1.8363252317050651"/>
<DICH_DATA CI_END="179.29256051754408" CI_START="0.6748746275401646" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2535622695219755" LOG_CI_START="-0.17077689920552552" LOG_EFFECT_SIZE="1.041392685158225" MODIFIED="2010-08-23 06:57:48 +0100" MODIFIED_BY="[Empty name]" ORDER="3060" O_E="0.0" SE="1.424068828382964" STUDY_ID="STD-Engel-2001" TOTAL_1="12" TOTAL_2="12" VAR="2.0279720279720275" WEIGHT="0.11889460717834037"/>
<DICH_DATA CI_END="3.6287762406689716" CI_START="0.4960541309410133" EFFECT_SIZE="1.3416666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5597601893527253" LOG_CI_START="-0.30447092938427567" LOG_EFFECT_SIZE="0.12764462998422485" MODIFIED="2010-08-23 06:57:48 +0100" MODIFIED_BY="[Empty name]" ORDER="3070" O_E="0.0" SE="0.507653637159147" STUDY_ID="STD-Greilich-2001" TOTAL_1="24" TOTAL_2="23" VAR="0.25771221532091093" WEIGHT="0.8724674915273537"/>
<DICH_DATA CI_END="1.0779225045907352" CI_START="0.9277104761623649" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="27" LOG_CI_END="0.032587539108232075" LOG_CI_START="-0.032587539108232096" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-23 06:57:48 +0100" MODIFIED_BY="[Empty name]" ORDER="3067" O_E="0.0" SE="0.0382841635661914" STUDY_ID="STD-Ickx-2006" TOTAL_1="24" TOTAL_2="27" VAR="0.0014656771799628973" WEIGHT="10.569417391829212"/>
<DICH_DATA CI_END="1.6825402105470073" CI_START="0.7803284697433366" EFFECT_SIZE="1.1458333333333333" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="24" LOG_CI_END="0.22596545209958277" LOG_CI_START="-0.10772254786226959" LOG_EFFECT_SIZE="0.05912145211865659" MODIFIED="2010-08-23 06:57:48 +0100" MODIFIED_BY="[Empty name]" ORDER="3062" O_E="0.0" SE="0.19600998295983146" STUDY_ID="STD-Isetta-1993" TOTAL_1="140" TOTAL_2="70" VAR="0.038419913419913417" WEIGHT="4.06071374732869"/>
<DICH_DATA CI_END="1.0198361669523746" CI_START="0.33929053749849375" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" LOG_CI_END="0.00853040950370991" LOG_CI_START="-0.46942825226025775" LOG_EFFECT_SIZE="-0.2304489213782739" MODIFIED="2011-02-16 13:51:32 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="3076" O_E="0.0" SE="0.2807552838536876" STUDY_ID="STD-Mengistu-2008" TOTAL_1="25" TOTAL_2="25" VAR="0.07882352941176468" WEIGHT="2.426790304235781"/>
<DICH_DATA CI_END="0.9996095394793454" CI_START="0.06252441331497659" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="16" LOG_CI_END="-1.6960796428367106E-4" LOG_CI_START="-1.2039503746916411" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2010-08-23 06:57:48 +0100" MODIFIED_BY="[Empty name]" ORDER="3072" O_E="0.0" SE="0.7071067811865476" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="48" VAR="0.5" WEIGHT="0.46719066500260326"/>
<DICH_DATA CI_END="3.754457918288967" CI_START="0.012343864976933615" EFFECT_SIZE="0.2152777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.5745472409165846" LOG_CI_START="-1.9085488374385386" LOG_EFFECT_SIZE="-0.6670007982609769" MODIFIED="2010-08-23 06:57:48 +0100" MODIFIED_BY="[Empty name]" ORDER="3065" O_E="0.0" SE="1.4585829279496223" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="30" VAR="2.1274641577060933" WEIGHT="0.11339028830076993"/>
<DICH_DATA CI_END="1.0921635201498592" CI_START="0.9156138083267851" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.03828766637439782" LOG_CI_START="-0.03828766637439781" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-08-23 06:57:48 +0100" MODIFIED_BY="[Empty name]" ORDER="3066" O_E="0.0" SE="0.04498072951065294" STUDY_ID="STD-Pugh-1995" TOTAL_1="21" TOTAL_2="22" VAR="0.0020232660273105246" WEIGHT="10.31983456187157"/>
<DICH_DATA CI_END="2.3586217117979826" CI_START="0.6251489115625755" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.3726582920289919" LOG_CI_START="-0.2040165206289201" LOG_EFFECT_SIZE="0.08432088570003587" MODIFIED="2010-08-23 06:57:48 +0100" MODIFIED_BY="[Empty name]" ORDER="3061" O_E="0.0" SE="0.3387416395416184" STUDY_ID="STD-Ray-2001" TOTAL_1="49" TOTAL_2="51" VAR="0.11474589835934375" WEIGHT="1.7873677185190764"/>
<DICH_DATA CI_END="2.3302506070190314" CI_START="0.10728459816595091" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.36740262977830473" LOG_CI_START="-0.9694626211062671" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-08-23 06:57:48 +0100" MODIFIED_BY="[Empty name]" ORDER="3078" O_E="0.0" SE="0.7852812659593165" STUDY_ID="STD-Ray-2005" TOTAL_1="15" TOTAL_2="15" VAR="0.6166666666666667" WEIGHT="0.38179303955624033"/>
<DICH_DATA CI_END="1.2732251164306965" CI_START="0.6692225867377" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.10490519719658377" LOG_CI_START="-0.1744294097150076" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2010-08-23 06:57:48 +0100" MODIFIED_BY="[Empty name]" ORDER="3064" O_E="0.0" SE="0.16408253082847335" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.02692307692307691" WEIGHT="5.023045142000815"/>
<DICH_DATA CI_END="1.0323063713894243" CI_START="0.37319894434005896" EFFECT_SIZE="0.6206896551724138" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.01380860781209295" LOG_CI_START="-0.42805959340339295" LOG_EFFECT_SIZE="-0.20712549279564998" MODIFIED="2010-08-23 06:57:48 +0100" MODIFIED_BY="[Empty name]" ORDER="3068" O_E="0.0" SE="0.2595555686768485" STUDY_ID="STD-Trinh_x002d_Duc-1992" TOTAL_1="29" TOTAL_2="27" VAR="0.0673690932311622" WEIGHT="2.7392666282430094"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.337489582064919" CI_END="1.2782176376266556" CI_START="0.6659064699138217" DF="4" EFFECT_SIZE="0.9225905889686665" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="132" I2="61.30588603504064" ID="CMP-007.06.03" LOG_CI_END="0.10660480591405631" LOG_CI_START="-0.17658676550357952" LOG_EFFECT_SIZE="-0.034990979794761574" MODIFIED="2010-08-23 06:58:12 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.035110730122335676" P_Z="0.6281418012771348" STUDIES="5" TAU2="0.07431301050155961" TOTAL_1="262" TOTAL_2="265" WEIGHT="16.980999406527392" Z="0.4843439360726014">
<NAME>Allocation concealment - No</NAME>
<DICH_DATA CI_END="1.5542598037816595" CI_START="0.4946396798386406" EFFECT_SIZE="0.8768115942028986" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.19152361544173646" LOG_CI_START="-0.30571104761130935" LOG_EFFECT_SIZE="-0.057093716084786424" MODIFIED="2010-08-23 06:58:12 +0100" MODIFIED_BY="[Empty name]" ORDER="3081" O_E="0.0" SE="0.29207810242863735" STUDY_ID="STD-Amar-2003" TOTAL_1="23" TOTAL_2="22" VAR="0.08530961791831358" WEIGHT="2.279545420313114"/>
<DICH_DATA CI_END="1.4091078666036987" CI_START="0.8114978976663392" EFFECT_SIZE="1.0693400167084377" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="38" LOG_CI_END="0.14894423943845972" LOG_CI_START="-0.09071260095554438" LOG_EFFECT_SIZE="0.029115819241457678" MODIFIED="2010-08-23 06:58:12 +0100" MODIFIED_BY="[Empty name]" ORDER="3082" O_E="0.0" SE="0.1407756143679307" STUDY_ID="STD-Dalmau-2004" TOTAL_1="63" TOTAL_2="64" VAR="0.01981777360066834" WEIGHT="5.884973239551562"/>
<DICH_DATA CI_END="0.8364512088877062" CI_START="0.19128431915683927" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" LOG_CI_END="-0.07755938683408231" LOG_CI_START="-0.7183206305099928" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2010-08-23 06:58:12 +0100" MODIFIED_BY="[Empty name]" ORDER="3080" O_E="0.0" SE="0.3763863263545405" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.14166666666666666" WEIGHT="1.4926330314091285"/>
<DICH_DATA CI_END="5.1801150354072085" CI_START="0.9343421848583578" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.714339404279566" LOG_CI_START="-0.02949404263515343" LOG_EFFECT_SIZE="0.3424226808222063" MODIFIED="2010-08-23 06:58:12 +0100" MODIFIED_BY="[Empty name]" ORDER="3083" O_E="0.0" SE="0.4369314487526515" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.19090909090909092" WEIGHT="1.146744610551268"/>
<DICH_DATA CI_END="1.1284556431965513" CI_START="0.6683072827900095" EFFECT_SIZE="0.868421052631579" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="57" LOG_CI_END="0.05248449270613696" LOG_CI_START="-0.17502380618398225" LOG_EFFECT_SIZE="-0.06126965673892266" MODIFIED="2010-08-23 06:58:12 +0100" MODIFIED_BY="[Empty name]" ORDER="3079" O_E="0.0" SE="0.1336395009522984" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="99" VAR="0.017859516214779367" WEIGHT="6.177103104702321"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2011-02-10 17:25:45 +0000" MODIFIED_BY="Emma M Sydenham" NO="8">
<NAME>Adverse Events and Other Outcomes (Active versus Control)</NAME>
<DICH_OUTCOME CHI2="56.051150692191925" CI_END="0.7018480105449987" CI_START="0.4414322571054" CI_STUDY="95" CI_TOTAL="95" DF="72" EFFECT_MEASURE="RR" EFFECT_SIZE="0.556613287157083" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="210" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="-0.15375692679944722" LOG_CI_START="-0.35513593449331055" LOG_EFFECT_SIZE="-0.2544464306463789" METHOD="MH" MODIFIED="2011-02-10 17:25:45 +0000" MODIFIED_BY="Emma M Sydenham" NO="1" P_CHI2="0.9170573504596029" P_Q="0.0" P_Z="7.311258064166347E-7" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="85" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="5086" TOTAL_2="4339" WEIGHT="300.0" Z="4.952907910041994">
<NAME>Re-operation for bleeding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="35.442385312781454" CI_END="0.6208852754634404" CI_START="0.33793108842136227" DF="42" EFFECT_SIZE="0.4580572419710857" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="137" I2="0.0" ID="CMP-008.01.01" LOG_CI_END="-0.20698863949497864" LOG_CI_START="-0.4711718528868851" LOG_EFFECT_SIZE="-0.33908024619093186" MODIFIED="2011-02-10 17:25:45 +0000" MODIFIED_BY="Emma M Sydenham" NO="1" P_CHI2="0.7526115977726442" P_Z="4.873081217077398E-7" STUDIES="61" TAU2="0.0" TOTAL_1="3392" TOTAL_2="2725" WEIGHT="100.00000000000009" Z="5.031243748385427">
<NAME>Aprotinin versus Control</NAME>
<DICH_DATA CI_END="1.196542518761225" CI_START="0.27755976630427953" EFFECT_SIZE="0.5762916465475616" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="0.07792813574117179" LOG_CI_START="-0.5566434868425303" LOG_EFFECT_SIZE="-0.23935767555067924" ORDER="67765" O_E="0.0" SE="0.37275051228585876" STUDY_ID="STD-Alderman-1998" TOTAL_1="436" TOTAL_2="434" VAR="0.13894294440937016" WEIGHT="17.332018458108028"/>
<DICH_DATA CI_END="14.733885791800498" CI_START="0.6617186917235279" EFFECT_SIZE="3.122448979591837" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1683172991429276" LOG_CI_START="-0.17932659756475738" LOG_EFFECT_SIZE="0.49449535078908513" ORDER="67734" O_E="0.0" SE="0.7916126958709705" STUDY_ID="STD-Alvarez-1995" TOTAL_1="49" TOTAL_2="51" VAR="0.6266506602641055" WEIGHT="3.842909343001646"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67770" O_E="0.0" SE="0.0" STUDY_ID="STD-Alvarez-2001" TOTAL_1="26" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-21 10:06:56 +0100" MODIFIED_BY="Katharine Ker" ORDER="2345" O_E="0.0" SE="0.0" STUDY_ID="STD-Apostolakis-2008" TOTAL_1="29" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67763" O_E="0.0" SE="0.0" STUDY_ID="STD-Ashraf-1997" TOTAL_1="19" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-11 11:37:56 +0000" MODIFIED_BY="Katharine Ker" ORDER="2262" O_E="0.0" SE="0.0" STUDY_ID="STD-Asimakopoulos-2000" TOTAL_1="8" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.8107039169243295" CI_START="0.014225492643544472" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8926901751653995" LOG_CI_START="-1.8469326846047245" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2010-04-21 10:28:04 +0100" MODIFIED_BY="Katharine Ker" ORDER="2350" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Bert-2008" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="0.929884211959962"/>
<DICH_DATA CI_END="4.038645960707643" CI_START="0.009904309609993965" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6062357833382839" LOG_CI_START="-2.0041757920103214" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="67735" O_E="0.0" SE="1.5333686811054679" STUDY_ID="STD-Bidstrup-1989" TOTAL_1="40" TOTAL_2="40" VAR="2.351219512195122" WEIGHT="1.0242181406868294"/>
<DICH_DATA CI_END="1.423713199648304" CI_START="0.021040488568326122" EFFECT_SIZE="0.17307692307692307" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.15342251152352063" LOG_CI_START="-1.6769441799144693" LOG_EFFECT_SIZE="-0.7617608341954742" ORDER="67736" O_E="0.0" SE="1.075166455011923" STUDY_ID="STD-Bidstrup-1990" TOTAL_1="26" TOTAL_2="18" VAR="1.1559829059829059" WEIGHT="2.0832156467568836"/>
<DICH_DATA CI_END="2.9326796442861944" CI_START="0.008281641316704065" EFFECT_SIZE="0.15584415584415584" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4672646247543525" LOG_CI_START="-2.0818835830040667" LOG_EFFECT_SIZE="-0.8073094791248571" ORDER="67737" O_E="0.0" SE="1.4973822757244322" STUDY_ID="STD-Bidstrup-1993" TOTAL_1="43" TOTAL_2="47" VAR="2.242153679653679" WEIGHT="1.0740395268084584"/>
<DICH_DATA CI_END="15.259760455310136" CI_START="0.0655318281652329" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" ORDER="67766" O_E="0.0" SE="1.390443574307614" STUDY_ID="STD-Bidstrup-2000" TOTAL_1="30" TOTAL_2="30" VAR="1.9333333333333331" WEIGHT="1.245600867479525"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-10 17:25:45 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="67764" O_E="0.0" SE="0.0" STUDY_ID="STD-Boldt-1994" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="77.87685232462876" CI_START="0.13563080279580816" EFFECT_SIZE="3.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8914083896164753" LOG_CI_START="-0.8676416676587266" LOG_EFFECT_SIZE="0.5118833609788743" ORDER="67738" O_E="0.0" SE="1.6206796611615029" STUDY_ID="STD-Casas-1995" TOTAL_1="47" TOTAL_2="51" VAR="2.626602564102564" WEIGHT="0.9168351961728486"/>
<DICH_DATA CI_END="6.518351660109564" CI_START="0.012027580604431858" EFFECT_SIZE="0.28" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8141377866178248" LOG_CI_START="-1.9198217239333863" LOG_EFFECT_SIZE="-0.5528419686577808" MODIFIED="2010-01-12 16:09:49 +0000" MODIFIED_BY="Katharine Ker" ORDER="2335" O_E="0.0" SE="1.605941349815621" STUDY_ID="STD-Cicekcioglu-2006" TOTAL_1="24" TOTAL_2="20" VAR="2.579047619047619" WEIGHT="0.9337406798314015"/>
<DICH_DATA CI_END="82.14351412223073" CI_START="0.2465197674629273" EFFECT_SIZE="4.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9145732781529905" LOG_CI_START="-0.608148250602303" LOG_EFFECT_SIZE="0.6532125137753437" ORDER="67739" O_E="0.0" SE="1.4818591136638255" STUDY_ID="STD-Cosgrove-1992" TOTAL_1="113" TOTAL_2="56" VAR="2.1959064327485383" WEIGHT="1.096659512087166"/>
<DICH_DATA CI_END="1.0125358788407675" CI_START="0.040067111403697356" EFFECT_SIZE="0.20141843971631207" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.005410421226447582" LOG_CI_START="-1.397211966443132" LOG_EFFECT_SIZE="-0.6959007726083422" ORDER="67740" O_E="0.0" SE="0.8239073336099068" STUDY_ID="STD-D_x0027_Ambra-1996" TOTAL_1="141" TOTAL_2="71" VAR="0.6788232943761862" WEIGHT="3.5475530923553444"/>
<DICH_DATA CI_END="1.9774190029426781" CI_START="0.006243329812231785" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.29609870339830113" LOG_CI_START="-2.204583722276951" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="67741" O_E="0.0" SE="1.4689132354192893" STUDY_ID="STD-Deleuze-1991" TOTAL_1="30" TOTAL_2="30" VAR="2.1577060931899643" WEIGHT="1.1160749300971025"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-14 16:05:02 +0100" MODIFIED_BY="Katharine Ker" ORDER="2542" O_E="0.0" SE="0.0" STUDY_ID="STD-Demeyere-2006" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.142666322916847" CI_START="0.04608800582703021" EFFECT_SIZE="0.4868421052631579" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7111883464449171" LOG_CI_START="-1.33641208287251" LOG_EFFECT_SIZE="-0.31261186821379633" MODIFIED="2010-05-17 10:53:29 +0100" MODIFIED_BY="Katharine Ker" ORDER="2557" O_E="0.0" SE="1.2027706279666497" STUDY_ID="STD-Desai-2009" TOTAL_1="38" TOTAL_2="37" VAR="1.4466571834992887" WEIGHT="1.6646387994300278"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67742" O_E="0.0" SE="0.0" STUDY_ID="STD-Dietrich-1990" TOTAL_1="19" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.9834695285518391" CI_START="0.031510441224490204" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2974255329253984" LOG_CI_START="-1.501545515581323" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="67743" O_E="0.0" SE="1.0567244989431572" STUDY_ID="STD-Dietrich-1995" TOTAL_1="15" TOTAL_2="15" VAR="1.1166666666666667" WEIGHT="2.1565626959346997"/>
<DICH_DATA CI_END="6.822750620413927" CI_START="0.14082123346982797" EFFECT_SIZE="0.9801980198019802" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8339594975942212" LOG_CI_START="-0.8513318559644064" LOG_EFFECT_SIZE="-0.008686179185092667" ORDER="67771" O_E="0.0" SE="0.9899484834070812" STUDY_ID="STD-Dignan-2001" TOTAL_1="101" TOTAL_2="99" VAR="0.97999799979998" WEIGHT="2.457312849228869"/>
<DICH_DATA CI_END="1.3197208380365462" CI_START="0.061856000684717444" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.12048207414354972" LOG_CI_START="-1.208618162844101" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="67783" O_E="0.0" SE="0.7807200583588264" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.6095238095238094" WEIGHT="3.950890251536619"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67744" O_E="0.0" SE="0.0" STUDY_ID="STD-Ehrlich-1998" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="17.111978424286665" CI_START="0.07546306347703435" EFFECT_SIZE="1.1363636363636365" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2333002239817072" LOG_CI_START="-1.1222655682820444" LOG_EFFECT_SIZE="0.05551732784983142" ORDER="67775" O_E="0.0" SE="1.3836710066144533" STUDY_ID="STD-Englberger-2002a" TOTAL_1="22" TOTAL_2="25" VAR="1.9145454545454546" WEIGHT="1.2578242378156643"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67776" O_E="0.0" SE="0.0" STUDY_ID="STD-Englberger-2002b" TOTAL_1="15" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.92166985814962" CI_START="0.026879170916340508" EFFECT_SIZE="0.22727272727272727" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2836787781819755" LOG_CI_START="-1.5705841311543505" LOG_EFFECT_SIZE="-0.6434526764861874" ORDER="67773" O_E="0.0" SE="1.0892032116935921" STUDY_ID="STD-Findlay-2001" TOTAL_1="33" TOTAL_2="30" VAR="1.1863636363636363" WEIGHT="2.0298680803370033"/>
<DICH_DATA CI_END="3.9717180977353164" CI_START="0.12367376022739737" EFFECT_SIZE="0.7008547008547008" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5989784158196382" LOG_CI_START="-0.9077224345445281" LOG_EFFECT_SIZE="-0.15437200936244497" ORDER="67745" O_E="0.0" SE="0.8850435377934063" STUDY_ID="STD-Garcia_x002d_Huete-1997" TOTAL_1="39" TOTAL_2="41" VAR="0.7833020637898686" WEIGHT="3.0743716740328972"/>
<DICH_DATA CI_END="60.513113572152186" CI_START="0.11245980588251933" EFFECT_SIZE="2.608695652173913" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7818494991961304" LOG_CI_START="-0.9490026704640289" LOG_EFFECT_SIZE="0.41642341436605074" ORDER="67746" O_E="0.0" SE="1.6041160823946319" STUDY_ID="STD-Hardy-1993" TOTAL_1="22" TOTAL_2="19" VAR="2.5731884057971013" WEIGHT="0.9358668303112848"/>
<DICH_DATA CI_END="15.149704352020958" CI_START="0.06600788878540728" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.180404157621246" LOG_CI_START="-1.180404157621246" LOG_EFFECT_SIZE="0.0" ORDER="67747" O_E="0.0" SE="1.3867504905630728" STUDY_ID="STD-Hardy-1997" TOTAL_1="26" TOTAL_2="26" VAR="1.923076923076923" WEIGHT="1.2522440721060824"/>
<DICH_DATA CI_END="14.553341064518706" CI_START="0.06871274407483083" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1629627073641946" LOG_CI_START="-1.1629627073641946" LOG_EFFECT_SIZE="0.0" ORDER="67777" O_E="0.0" SE="1.3662601021279464" STUDY_ID="STD-Kipfer-2003" TOTAL_1="15" TOTAL_2="15" VAR="1.8666666666666667" WEIGHT="1.2900866127466506"/>
<DICH_DATA CI_END="3.9044944569299305" CI_START="0.11382893466671921" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5915648106131298" LOG_CI_START="-0.9437473287244924" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="67782" O_E="0.0" SE="0.9018499505645788" STUDY_ID="STD-Koster-2004" TOTAL_1="100" TOTAL_2="100" VAR="0.8133333333333332" WEIGHT="2.960854521057887"/>
<DICH_DATA CI_END="2.6624321437406118" CI_START="0.007415974073069934" EFFECT_SIZE="0.1405152224824356" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.42527854791175146" LOG_CI_START="-2.1298317971945115" LOG_EFFECT_SIZE="-0.8522766246413802" ORDER="67778" O_E="0.0" SE="1.5008844647156117" STUDY_ID="STD-Kuepper-2003" TOTAL_1="60" TOTAL_2="59" VAR="2.2526541764246684" WEIGHT="1.0690330110719564"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67784" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67781" O_E="0.0" SE="0.0" STUDY_ID="STD-Kunt-2005" TOTAL_1="40" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.318534659420912" CI_START="0.011315010711186518" EFFECT_SIZE="0.22105263157894736" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6353364094807923" LOG_CI_START="-1.9463450305906491" LOG_EFFECT_SIZE="-0.6555043105549285" ORDER="67774" O_E="0.0" SE="1.5164924574271987" STUDY_ID="STD-Kyriss-2001" TOTAL_1="18" TOTAL_2="20" VAR="2.299749373433584" WEIGHT="1.0471409210698621"/>
<DICH_DATA CI_END="3.7487868945518765" CI_START="0.009091698513516225" EFFECT_SIZE="0.18461538461538463" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5738907529980455" LOG_CI_START="-2.041354974188507" LOG_EFFECT_SIZE="-0.7337321105952308" ORDER="67748" O_E="0.0" SE="1.5362082858245159" STUDY_ID="STD-Lass-1995" TOTAL_1="51" TOTAL_2="47" VAR="2.3599358974358973" WEIGHT="1.0204352074747378"/>
<DICH_DATA CI_END="1.0235676413246815" CI_START="0.1434496103228767" EFFECT_SIZE="0.38318452380952384" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="0.010116547812777458" LOG_CI_START="-0.8433006271660081" LOG_EFFECT_SIZE="-0.4165920396766154" MODIFIED="2010-05-06 16:10:59 +0100" MODIFIED_BY="Katharine Ker" ORDER="2374" O_E="0.0" SE="0.5013014730656864" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="103" VAR="0.2513031668978271" WEIGHT="9.58269530326362"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67749" O_E="0.0" SE="0.0" STUDY_ID="STD-Laub-1994" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.9607551236159635" CI_START="0.05914335603274032" EFFECT_SIZE="0.59375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.775301280754695" LOG_CI_START="-1.228094035488849" LOG_EFFECT_SIZE="-0.226396377367077" MODIFIED="2010-05-07 10:32:06 +0100" MODIFIED_BY="Katharine Ker" ORDER="2410" O_E="0.0" SE="1.176804325728212" STUDY_ID="STD-Leijdekkers-2006" TOTAL_1="16" TOTAL_2="19" VAR="1.3848684210526316" WEIGHT="1.7389100946475835"/>
<DICH_DATA CI_END="0.5477306913790951" CI_START="0.007589869294926794" EFFECT_SIZE="0.06447638603696099" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="-0.2614329232612153" LOG_CI_START="-2.1197657030216233" LOG_EFFECT_SIZE="-1.1905993131414194" ORDER="67750" O_E="0.0" SE="1.0915938737268813" STUDY_ID="STD-Lemmer-1996" TOTAL_1="487" TOTAL_2="157" VAR="1.1915771851580585" WEIGHT="2.0209867284490235"/>
<DICH_DATA CI_END="5.43274760766311" CI_START="0.04601723070060624" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7350195292293191" LOG_CI_START="-1.3370795205572816" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="67751" O_E="0.0" SE="1.2171612389003692" STUDY_ID="STD-Lemmer_x005f_1-1994" TOTAL_1="108" TOTAL_2="108" VAR="1.4814814814814814" WEIGHT="1.62550913206078"/>
<DICH_DATA CI_END="1.2773308213420607" CI_START="0.1264291370138525" EFFECT_SIZE="0.4018604651162791" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.10630339160671308" LOG_CI_START="-0.8981528264801373" LOG_EFFECT_SIZE="-0.395924717436712" ORDER="67752" O_E="0.0" SE="0.5900225546426849" STUDY_ID="STD-Levy-1995" TOTAL_1="215" TOTAL_2="72" VAR="0.34812661498708014" WEIGHT="6.91748798699707"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67753" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Liu-1993" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.9365073188827537"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67780" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.9365073188827537"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67754" O_E="0.0" SE="0.0" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67755" O_E="0.0" SE="0.0" STUDY_ID="STD-Mohr-1992" TOTAL_1="34" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67769" O_E="0.0" SE="0.0" STUDY_ID="STD-Moran-2000" TOTAL_1="28" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.122770474379207" CI_START="0.010462890171214661" EFFECT_SIZE="0.2076923076923077" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6151891571430301" LOG_CI_START="-1.980348333438729" LOG_EFFECT_SIZE="-0.6825795881478495" MODIFIED="2010-05-07 15:03:08 +0100" MODIFIED_BY="Katharine Ker" ORDER="2471" O_E="0.0" SE="1.5246315700855155" STUDY_ID="STD-Nur_x00f6_zler-2008" TOTAL_1="25" TOTAL_2="26" VAR="2.3245014245014244" WEIGHT="1.0359906222228283"/>
<DICH_DATA CI_END="47.84885223959143" CI_START="0.7523691439815274" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6798715247253944" LOG_CI_START="-0.12356902395810711" LOG_EFFECT_SIZE="0.7781512503836436" ORDER="67767" O_E="0.0" SE="1.0593499054713804" STUDY_ID="STD-Nuttall-2000" TOTAL_1="45" TOTAL_2="45" VAR="1.1222222222222225" WEIGHT="2.1458866429845274"/>
<DICH_DATA CI_END="1.6742937483704181" CI_START="0.023890670343201005" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.22383165563129442" LOG_CI_START="-1.6217716643033322" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2010-01-11 16:23:15 +0000" MODIFIED_BY="Katharine Ker" ORDER="2334" O_E="0.0" SE="1.084116526013375" STUDY_ID="STD-Parvizi-2007" TOTAL_1="81" TOTAL_2="81" VAR="1.1753086419753085" WEIGHT="2.048961090832916"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67756" O_E="0.0" SE="0.0" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67757" O_E="0.0" SE="0.0" STUDY_ID="STD-Pugh-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.608296967844409" CI_START="0.05347195824946775" EFFECT_SIZE="0.5476190476190477" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7488310021200593" LOG_CI_START="-1.2718739108806743" LOG_EFFECT_SIZE="-0.26152145438030755" ORDER="67758" O_E="0.0" SE="1.1869720685472709" STUDY_ID="STD-Ray-1997" TOTAL_1="21" TOTAL_2="23" VAR="1.4089026915113871" WEIGHT="1.709246274874916"/>
<DICH_DATA CI_END="0.8140155592489693" CI_START="0.002588686913008042" EFFECT_SIZE="0.04590459045904591" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="-0.08936729384373564" LOG_CI_START="-2.586920471842127" LOG_EFFECT_SIZE="-1.3381438828429313" ORDER="67772" O_E="0.0" SE="1.4670750998438753" STUDY_ID="STD-Ray-1999" TOTAL_1="100" TOTAL_2="50" VAR="2.152309348581917" WEIGHT="1.1188733992693647"/>
<DICH_DATA CI_END="1.1400537876337065" CI_START="0.01868781949795416" EFFECT_SIZE="0.14596273291925466" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.056925341793885816" LOG_CI_START="-1.7284413693141127" LOG_EFFECT_SIZE="-0.8357580137601135" ORDER="67759" O_E="0.0" SE="1.048733243812591" STUDY_ID="STD-Rodrigus-1996" TOTAL_1="46" TOTAL_2="47" VAR="1.0998414166776793" WEIGHT="2.1895535489120608"/>
<DICH_DATA CI_END="2.7278417643535913" CI_START="0.008177019925767694" EFFECT_SIZE="0.14935064935064934" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.43581917431977685" LOG_CI_START="-2.0874049439575173" LOG_EFFECT_SIZE="-0.8257928848188701" ORDER="67760" O_E="0.0" SE="1.4821543372369068" STUDY_ID="STD-Rossi-1997" TOTAL_1="21" TOTAL_2="22" VAR="2.1967814793901748" WEIGHT="1.0962226783683489"/>
<DICH_DATA CI_END="15.765457421379898" CI_START="0.06804141820699317" EFFECT_SIZE="1.0357142857142858" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1977065759528898" LOG_CI_START="-1.1672266428394158" LOG_EFFECT_SIZE="0.015239966556736905" ORDER="67768" O_E="0.0" SE="1.389173479326835" STUDY_ID="STD-Schweizer-2000" TOTAL_1="28" TOTAL_2="29" VAR="1.9298029556650245" WEIGHT="1.24787956721582"/>
<DICH_DATA CI_END="2.5983769423254333" CI_START="0.007854196568971131" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4147021537028376" LOG_CI_START="-2.1048982337313515" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="67761" O_E="0.0" SE="1.4800257398019099" STUDY_ID="STD-Tabuchi-1994" TOTAL_1="20" TOTAL_2="20" VAR="2.1904761904761907" WEIGHT="1.0993781569493197"/>
<DICH_DATA CI_END="14.50846406676568" CI_START="0.061479651087616466" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.161621438444948" LOG_CI_START="-1.2112686058950124" LOG_EFFECT_SIZE="-0.024823583725032152" ORDER="67779" O_E="0.0" SE="1.3938473580404491" STUDY_ID="STD-Taggart-2003" TOTAL_1="36" TOTAL_2="34" VAR="1.94281045751634" WEIGHT="1.2395247656869417"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67762" O_E="0.0" SE="0.0" STUDY_ID="STD-Vedrinne-1992" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.66095512906379" CI_END="1.1680177873542457" CI_START="0.5482585271760654" DF="23" EFFECT_SIZE="0.8002347854288049" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="59" I2="0.0" ID="CMP-008.01.02" LOG_CI_END="0.06744945655290115" LOG_CI_START="-0.26101460492775436" LOG_EFFECT_SIZE="-0.09678257418742661" MODIFIED="2010-05-21 15:03:20 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.9589629124704522" P_Z="0.24808455113278338" STUDIES="27" TAU2="0.0" TOTAL_1="1224" TOTAL_2="1162" WEIGHT="99.99999999999997" Z="1.1550143956897012">
<NAME>Tranexamic Acid versus Control</NAME>
<DICH_DATA CI_END="1.3935915921194053" CI_START="0.023909971823963982" EFFECT_SIZE="0.18253968253968253" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.14413551746614112" LOG_CI_START="-1.6214209356660811" LOG_EFFECT_SIZE="-0.7386427090999701" ORDER="67800" O_E="0.0" SE="1.0370966002152615" STUDY_ID="STD-Andreasen-2004" TOTAL_1="21" TOTAL_2="23" VAR="1.0755693581780539" WEIGHT="3.461086873197408"/>
<DICH_DATA CI_END="2.921261429403705" CI_START="0.21908343894118318" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4655704245760643" LOG_CI_START="-0.659390450592177" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="67794" O_E="0.0" SE="0.660807586719967" STUDY_ID="STD-Armellin-2001" TOTAL_1="150" TOTAL_2="150" VAR="0.4366666666666667" WEIGHT="8.525127450694862"/>
<DICH_DATA CI_END="4.038114968730835" CI_START="0.00710628348875105" EFFECT_SIZE="0.16939890710382513" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6061786795344671" LOG_CI_START="-2.1483574713267806" LOG_EFFECT_SIZE="-0.7710893958961569" ORDER="67785" O_E="0.0" SE="1.6180281701897488" STUDY_ID="STD-Brown-1997" TOTAL_1="60" TOTAL_2="30" VAR="2.618015159527587" WEIGHT="1.4219317918216956"/>
<DICH_DATA CI_END="6.627129539131202" CI_START="0.1508948925919286" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8213254597385298" LOG_CI_START="-0.8213254597385299" LOG_EFFECT_SIZE="0.0" ORDER="67798" O_E="0.0" SE="0.9649012813540154" STUDY_ID="STD-Casati-2002" TOTAL_1="29" TOTAL_2="29" VAR="0.9310344827586208" WEIGHT="3.998390022862936"/>
<DICH_DATA CI_END="2.979618145522277" CI_START="0.034477058165141815" EFFECT_SIZE="0.32051282051282054" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.47416061041229807" LOG_CI_START="-1.4624697984491835" LOG_EFFECT_SIZE="-0.49415459401844275" ORDER="67801" O_E="0.0" SE="1.137586288640367" STUDY_ID="STD-Casati-2004" TOTAL_1="52" TOTAL_2="50" VAR="1.294102564102564" WEIGHT="2.8766181986394597"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-14 16:05:23 +0100" MODIFIED_BY="Katharine Ker" ORDER="2543" O_E="0.0" SE="0.0" STUDY_ID="STD-Demeyere-2006" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.125380959026196" CI_START="0.24005300295266485" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.3274367854801246" LOG_CI_START="-0.6196928568366006" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="67802" O_E="0.0" SE="0.5563486402641868" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.30952380952380953" WEIGHT="12.026987495826447"/>
<DICH_DATA CI_END="29.02955803126674" CI_START="0.33953941963168377" EFFECT_SIZE="3.13953488372093" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4628404238425872" LOG_CI_START="-0.46910979801174824" LOG_EFFECT_SIZE="0.4968653129154196" ORDER="67786" O_E="0.0" SE="1.13483712362507" STUDY_ID="STD-Hardy-1998" TOTAL_1="43" TOTAL_2="45" VAR="1.2878552971576227" WEIGHT="2.890572407489817"/>
<DICH_DATA CI_END="18.302595624998393" CI_START="0.07662052964344189" EFFECT_SIZE="1.1842105263157894" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2625126845761792" LOG_CI_START="-1.1156548502591122" LOG_EFFECT_SIZE="0.07342891715853349" ORDER="67787" O_E="0.0" SE="1.396947382081406" STUDY_ID="STD-Horrow-1991" TOTAL_1="38" TOTAL_2="45" VAR="1.9514619883040936" WEIGHT="1.9076154232645655"/>
<DICH_DATA CI_END="8.802545501889" CI_START="0.01613021795743741" EFFECT_SIZE="0.37681159420289856" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9446082786917515" LOG_CI_START="-1.7923597642246263" LOG_EFFECT_SIZE="-0.42387574276643736" ORDER="67796" O_E="0.0" SE="1.6077085766193955" STUDY_ID="STD-Jares-2003" TOTAL_1="22" TOTAL_2="25" VAR="2.584726867335563" WEIGHT="1.440244628493712"/>
<DICH_DATA CI_END="8.434974839029426" CI_START="0.015364598291429213" EFFECT_SIZE="0.36" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9260837914554372" LOG_CI_START="-1.8134787899208629" LOG_EFFECT_SIZE="-0.44369749923271273" MODIFIED="2010-05-17 14:57:34 +0100" MODIFIED_BY="Katharine Ker" ORDER="2638" O_E="0.0" SE="1.6092326213539263" STUDY_ID="STD-Jimenez-2007" TOTAL_1="24" TOTAL_2="26" VAR="2.5896296296296293" WEIGHT="1.4375179153846176"/>
<DICH_DATA CI_END="2.691330498492686" CI_START="0.023222714577419576" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.42996703290245386" LOG_CI_START="-1.6340870155583787" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="67788" O_E="0.0" SE="1.2124355652982142" STUDY_ID="STD-Karski-1995" TOTAL_1="100" TOTAL_2="50" VAR="1.47" WEIGHT="2.5324074740159346"/>
<DICH_DATA CI_END="1.7152066890871394" CI_START="0.024226383153849028" EFFECT_SIZE="0.20384615384615384" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.23431646170901982" LOG_CI_START="-1.6157114184490775" LOG_EFFECT_SIZE="-0.6906974783700289" ORDER="67789" O_E="0.0" SE="1.0867155345905681" STUDY_ID="STD-Katsaros-1996" TOTAL_1="104" TOTAL_2="106" VAR="1.1809506531204643" WEIGHT="3.152239237911401"/>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="67803" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="1.4476929393124425"/>
<DICH_DATA CI_END="68.25874292736694" CI_START="0.13185124152633107" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.8799157764849103" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-05-20 16:24:45 +0100" MODIFIED_BY="Katharine Ker" ORDER="5388" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Kuitunen-2006" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="1.464644847266921"/>
<DICH_DATA CI_END="2.069128495232804" CI_START="0.5231383985010866" EFFECT_SIZE="1.0404040404040404" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.3157874616844644" LOG_CI_START="-0.28138340146921975" LOG_EFFECT_SIZE="0.017202030107622307" MODIFIED="2010-05-06 16:18:00 +0100" MODIFIED_BY="Katharine Ker" ORDER="2384" O_E="0.0" SE="0.35078112105992115" STUDY_ID="STD-Later-2009" TOTAL_1="99" TOTAL_2="103" VAR="0.12304739489205507" WEIGHT="30.253700129687076"/>
<DICH_DATA CI_END="4.847824441117579" CI_START="0.20627809693732801" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.685546883923407" LOG_CI_START="-0.685546883923407" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-07 12:00:30 +0100" MODIFIED_BY="Katharine Ker" ORDER="2430" O_E="0.0" SE="0.8053872662568291" STUDY_ID="STD-Maddali-2007" TOTAL_1="111" TOTAL_2="111" VAR="0.6486486486486486" WEIGHT="5.739068437988612"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67799" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="1.4476929393124425"/>
<DICH_DATA CI_END="7.897117532359623" CI_START="0.014069831258787349" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8974686016417053" LOG_CI_START="-1.8517111110810305" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2010-05-07 12:17:47 +0100" MODIFIED_BY="Katharine Ker" ORDER="2437" O_E="0.0" SE="1.6148817719123905" STUDY_ID="STD-Mehr_x002d_Aein-2007" TOTAL_1="33" TOTAL_2="33" VAR="2.607843137254902" WEIGHT="1.4274781077216134"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67790" O_E="0.0" SE="0.0" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="71.92321045517915" CI_START="0.12513345751728625" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8568690648743624" LOG_CI_START="-0.9026265554350377" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-05-21 15:03:20 +0100" MODIFIED_BY="Katharine Ker" ORDER="2453" O_E="0.0" SE="1.6209413870933633" STUDY_ID="STD-Murphy-2006" TOTAL_1="50" TOTAL_2="50" VAR="2.627450980392157" WEIGHT="1.4168252860221986"/>
<DICH_DATA CI_END="68.25874292736694" CI_START="0.13185124152633107" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.8799157764849103" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="67791" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="1.464644847266921"/>
<DICH_DATA CI_END="7.74869607009601" CI_START="0.013648380859931773" EFFECT_SIZE="0.3252032520325203" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8892286267377596" LOG_CI_START="-1.8649188669606307" LOG_EFFECT_SIZE="-0.48784512011143555" ORDER="67797" O_E="0.0" SE="1.6177998710484025" STUDY_ID="STD-Pleym-2003" TOTAL_1="40" TOTAL_2="39" VAR="2.6172764227642276" WEIGHT="1.4223331377706645"/>
<DICH_DATA CI_END="6.788528809339318" CI_START="0.16100325082334627" EFFECT_SIZE="1.0454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8317756654124154" LOG_CI_START="-0.7931653550216421" LOG_EFFECT_SIZE="0.019305155195386624" ORDER="67792" O_E="0.0" SE="0.9544983989907418" STUDY_ID="STD-Pugh-1995" TOTAL_1="22" TOTAL_2="23" VAR="0.9110671936758894" WEIGHT="4.086020232803757"/>
<DICH_DATA CI_END="16.31130518173396" CI_START="0.07005492597433315" EFFECT_SIZE="1.0689655172413792" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2124887133729667" LOG_CI_START="-1.1545613215023336" LOG_EFFECT_SIZE="0.028963695935316558" ORDER="67804" O_E="0.0" SE="1.3904169075723947" STUDY_ID="STD-Santos-2006" TOTAL_1="29" TOTAL_2="31" VAR="1.9332591768631813" WEIGHT="1.9255767831624153"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67793" O_E="0.0" SE="0.0" STUDY_ID="STD-Shore_x002d_Lesserson-1996" TOTAL_1="17" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="12.55730570082838" CI_START="0.0796349172206608" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.09889646704573" LOG_CI_START="-1.09889646704573" LOG_EFFECT_SIZE="0.0" ORDER="67795" O_E="0.0" SE="1.2909944487358056" STUDY_ID="STD-Uozaki-2001" TOTAL_1="6" TOTAL_2="6" VAR="1.6666666666666665" WEIGHT="2.2335833920820547"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.836913889641171" CI_END="0.9920815595517547" CI_START="0.10619406844954254" DF="5" EFFECT_SIZE="0.32458154143846196" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="14" I2="0.0" ID="CMP-008.01.03" LOG_CI_END="-0.003452622798190619" LOG_CI_START="-0.9738997404256872" LOG_EFFECT_SIZE="-0.4886761816119388" MODIFIED="2010-05-20 11:22:06 +0100" MODIFIED_BY="Katharine Ker" NO="3" P_CHI2="0.8712194210474383" P_Z="0.04839195849103783" STUDIES="8" TAU2="0.0" TOTAL_1="470" TOTAL_2="452" WEIGHT="99.99999999999999" Z="1.9739101671062906">
<NAME>Epsilon Aminocaproic Acid versus Control</NAME>
<DICH_DATA CI_END="4.108846404950255" CI_START="0.009735092543690317" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6137199069641557" LOG_CI_START="-2.0116599156361934" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2010-05-20 11:22:06 +0100" MODIFIED_BY="Katharine Ker" ORDER="5315" O_E="0.0" SE="1.542161103635161" STUDY_ID="STD-Berenholtz-2009" TOTAL_1="91" TOTAL_2="91" VAR="2.3782608695652177" WEIGHT="13.663421393519119"/>
<DICH_DATA CI_END="1.434362729157795" CI_START="0.004621886033693856" EFFECT_SIZE="0.08142150247413406" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.15665899188360147" LOG_CI_START="-2.3351807675432137" LOG_EFFECT_SIZE="-1.089260887829806" ORDER="67805" O_E="0.0" SE="1.4637190094930537" STUDY_ID="STD-Del-Rossi-1989" TOTAL_1="170" TOTAL_2="180" VAR="2.1424733387513264" WEIGHT="15.167134104700494"/>
<DICH_DATA CI_END="15.168127832299358" CI_START="0.0630924488178857" EFFECT_SIZE="0.9782608695652174" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1809319801092522" LOG_CI_START="-1.200022615921713" LOG_EFFECT_SIZE="-0.009545317906230389" ORDER="67806" O_E="0.0" SE="1.39858451562392" STUDY_ID="STD-Hardy-1998" TOTAL_1="46" TOTAL_2="45" VAR="1.9560386473429952" WEIGHT="16.612749696294056"/>
<DICH_DATA CI_END="7.982820343015618" CI_START="0.0335143010834441" EFFECT_SIZE="0.5172413793103449" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9021563553871819" LOG_CI_START="-1.4747698330737318" LOG_EFFECT_SIZE="-0.2863067388432748" ORDER="67811" O_E="0.0" SE="1.3962182090763327" STUDY_ID="STD-Kluger-2003" TOTAL_1="58" TOTAL_2="30" VAR="1.9494252873563218" WEIGHT="16.669107893154774"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67807" O_E="0.0" SE="0.0" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67808" O_E="0.0" SE="0.0" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67810" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Rao-1999" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="12.784989027378407"/>
<DICH_DATA CI_END="3.160631195382165" CI_START="0.036546854428103924" EFFECT_SIZE="0.33986928104575165" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4997738222695287" LOG_CI_START="-1.4371499966351282" LOG_EFFECT_SIZE="-0.46868808718279964" ORDER="67809" O_E="0.0" SE="1.137758639152131" STUDY_ID="STD-Vander_x002d_Salm-1996" TOTAL_1="51" TOTAL_2="52" VAR="1.2944947209653093" WEIGHT="25.10259788495314"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="42.89284678233436" CI_END="0.9999683989545304" CI_START="0.6309482982717085" CI_STUDY="95" CI_TOTAL="95" DF="67" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7943099896424858" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="140" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="-1.3724376523295265E-5" LOG_CI_START="-0.2000062266437268" LOG_EFFECT_SIZE="-0.10000997551012504" METHOD="MH" MODIFIED="2010-07-08 11:07:50 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.9904438788124242" P_Q="0.0" P_Z="0.049968564500928736" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="92" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="6871" TOTAL_2="5910" WEIGHT="300.0" Z="1.9602329874615734">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="29.540664406118978" CI_END="1.0565616719270494" CI_START="0.6282314039782855" DF="43" EFFECT_SIZE="0.8147178791117664" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="104" I2="0.0" ID="CMP-008.02.01" LOG_CI_END="0.023894852070680293" LOG_CI_START="-0.201880357919062" LOG_EFFECT_SIZE="-0.08899275292419088" MODIFIED="2010-07-08 11:07:50 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="0.9411295871694739" P_Z="0.12232217953179374" STUDIES="63" TAU2="0.0" TOTAL_1="4889" TOTAL_2="3987" WEIGHT="100.00000000000004" Z="1.5450995760288324">
<NAME>Aprotinin versus Control</NAME>
<DICH_DATA CI_END="2.518203954699761" CI_START="0.28908263161831205" EFFECT_SIZE="0.8532110091743119" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.40109090163108607" LOG_CI_START="-0.5389780004044632" LOG_EFFECT_SIZE="-0.06894354938668852" ORDER="67841" O_E="0.0" SE="0.552201126471796" STUDY_ID="STD-Alderman-1998" TOTAL_1="436" TOTAL_2="434" VAR="0.3049260840767204" WEIGHT="5.76810473176948"/>
<DICH_DATA CI_END="74.79945678869373" CI_START="0.1301399825335549" EFFECT_SIZE="3.12" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.873898443926902" LOG_CI_START="-0.8855892558900165" LOG_EFFECT_SIZE="0.4941545940184428" ORDER="67812" O_E="0.0" SE="1.6209367345568726" STUDY_ID="STD-Alvarez-1995" TOTAL_1="49" TOTAL_2="51" VAR="2.6274358974358973" WEIGHT="0.6694152234577134"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67849" O_E="0.0" SE="0.0" STUDY_ID="STD-Alvarez-2001" TOTAL_1="26" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-21 10:07:29 +0100" MODIFIED_BY="Katharine Ker" ORDER="2346" O_E="0.0" SE="0.0" STUDY_ID="STD-Apostolakis-2008" TOTAL_1="29" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67840" O_E="0.0" SE="0.0" STUDY_ID="STD-Ashraf-1997" TOTAL_1="19" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.9453474498525" CI_START="0.01398442444617999" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9001128936458906" LOG_CI_START="-1.8543554030852154" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67813" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Bidstrup-1989" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="0.6718571657563756"/>
<DICH_DATA CI_END="110.51274757531625" CI_START="0.2692184093552281" EFFECT_SIZE="5.454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0434123765035417" LOG_CI_START="-0.5698952460527045" LOG_EFFECT_SIZE="0.7367585652254185" ORDER="67814" O_E="0.0" SE="1.535069833570901" STUDY_ID="STD-Bidstrup-1993" TOTAL_1="43" TOTAL_2="47" VAR="2.3564393939393935" WEIGHT="0.746399671014881"/>
<DICH_DATA CI_END="70.82882080128427" CI_START="0.12706691849706478" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8502100114756685" LOG_CI_START="-0.895967502036344" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="67842" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Bidstrup-2000" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="0.6759199988490364"/>
<DICH_DATA CI_END="67.90969947701805" CI_START="0.13252893282270775" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8319318085736291" LOG_CI_START="-0.8776892991343044" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="67815" O_E="0.0" SE="1.5916448515084427" STUDY_ID="STD-Blauhut-1994" TOTAL_1="14" TOTAL_2="14" VAR="2.5333333333333328" WEIGHT="0.6942811533169221"/>
<DICH_DATA CI_END="23.15802289371009" CI_START="0.20337761436464838" EFFECT_SIZE="2.1702127659574466" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.364701478932597" LOG_CI_START="-0.6916968512801971" LOG_EFFECT_SIZE="0.33650231382620005" ORDER="67816" O_E="0.0" SE="1.2079385585029" STUDY_ID="STD-Casas-1995" TOTAL_1="47" TOTAL_2="51" VAR="1.4591155611180644" WEIGHT="1.2054189779561622"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-12 16:10:15 +0000" MODIFIED_BY="Katharine Ker" ORDER="2336" O_E="0.0" SE="0.0" STUDY_ID="STD-Cicekcioglu-2006" TOTAL_1="24" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="107.27288722482027" CI_START="0.25822770078776697" EFFECT_SIZE="5.2631578947368425" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.030489969714727" LOG_CI_START="-0.5879971716203847" LOG_EFFECT_SIZE="0.721246399047171" ORDER="67843" O_E="0.0" SE="1.5381123085406379" STUDY_ID="STD-Cohen-1998" TOTAL_1="56" TOTAL_2="59" VAR="2.3657894736842104" WEIGHT="0.7434497481569413"/>
<DICH_DATA CI_END="8.265810718802095" CI_START="0.013904416259545962" EFFECT_SIZE="0.3390151515151515" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9172854560242069" LOG_CI_START="-1.856847239132045" LOG_EFFECT_SIZE="-0.4697808915539191" MODIFIED="2010-05-20 12:08:27 +0100" MODIFIED_BY="Katharine Ker" ORDER="5341" O_E="0.0" SE="1.629539277313093" STUDY_ID="STD-Colwell-2007" TOTAL_1="175" TOTAL_2="178" VAR="2.655398256306077" WEIGHT="0.6623660252189809"/>
<DICH_DATA CI_END="3.463558012724104" CI_START="0.3589729607405532" EFFECT_SIZE="1.1150442477876106" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.5395224662315437" LOG_CI_START="-0.4449382629632574" LOG_EFFECT_SIZE="0.04729210163414316" ORDER="67817" O_E="0.0" SE="0.578277105488229" STUDY_ID="STD-Cosgrove-1992" TOTAL_1="113" TOTAL_2="56" VAR="0.33440441073184435" WEIGHT="5.259636332408516"/>
<DICH_DATA CI_END="99.47165719136326" CI_START="0.31273343933241216" EFFECT_SIZE="5.577464788732394" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.9976993533199243" LOG_CI_START="-0.5048256789070502" LOG_EFFECT_SIZE="0.7464368372064369" ORDER="67818" O_E="0.0" SE="1.4699955916288205" STUDY_ID="STD-D_x0027_Ambra-1996" TOTAL_1="141" TOTAL_2="71" VAR="2.160887039408166" WEIGHT="0.8139461046906877"/>
<DICH_DATA CI_END="14.998130825457398" CI_START="0.063211939731786" EFFECT_SIZE="0.9736842105263158" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1760371375375547" LOG_CI_START="-1.199200882637185" LOG_EFFECT_SIZE="-0.011581872549815147" MODIFIED="2010-05-17 10:53:52 +0100" MODIFIED_BY="Katharine Ker" ORDER="2558" O_E="0.0" SE="1.3952265706684663" STUDY_ID="STD-Desai-2009" TOTAL_1="38" TOTAL_2="37" VAR="1.9466571834992887" WEIGHT="0.9035209708784925"/>
<DICH_DATA CI_END="1.2794062399289174" CI_START="0.4479347199245155" EFFECT_SIZE="0.7570273943208641" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="31" LOG_CI_END="0.10700846453074485" LOG_CI_START="-0.34878527359632205" LOG_EFFECT_SIZE="-0.12088840453278861" ORDER="67819" O_E="0.0" SE="0.2677354979912306" STUDY_ID="STD-Dietrich-1992" TOTAL_1="902" TOTAL_2="882" VAR="0.07168229688461225" WEIGHT="24.536680112721577"/>
<DICH_DATA CI_END="3.845086034384406" CI_START="0.010402888164868843" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5849060616512035" LOG_CI_START="-1.982846070323241" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="67820" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Dietrich-1995" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="0.7731189399573051"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67850" O_E="0.0" SE="0.0" STUDY_ID="STD-Dignan-2001" TOTAL_1="101" TOTAL_2="99" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.022569637689829" CI_START="0.013849815723520037" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9043134955566555" LOG_CI_START="-1.8585560049959806" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67862" O_E="0.0" SE="1.6229232210492168" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="2.6338797814207653" WEIGHT="0.6677774744351141"/>
<DICH_DATA CI_END="3.0126911750632708" CI_START="0.1867101429631887" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.47895461529768624" LOG_CI_START="-0.7288320885142859" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="67821" O_E="0.0" SE="0.7094598884597586" STUDY_ID="STD-Ehrlich-1998" TOTAL_1="25" TOTAL_2="25" VAR="0.5033333333333332" WEIGHT="3.4943952087474233"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67855" O_E="0.0" SE="0.0" STUDY_ID="STD-Englberger-2002a" TOTAL_1="22" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67856" O_E="0.0" SE="0.0" STUDY_ID="STD-Englberger-2002b" TOTAL_1="15" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-11 12:09:38 +0000" MODIFIED_BY="Katharine Ker" ORDER="2266" O_E="0.0" SE="0.0" STUDY_ID="STD-Feindt-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.187883568306035" CI_START="0.012850558721381567" EFFECT_SIZE="0.30392156862745096" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8566010336495482" LOG_CI_START="-1.8910779895048382" LOG_EFFECT_SIZE="-0.5172384779276449" ORDER="67851" O_E="0.0" SE="1.614000259431409" STUDY_ID="STD-Findlay-2001" TOTAL_1="33" TOTAL_2="30" VAR="2.6049968374446553" WEIGHT="0.6751814678317194"/>
<DICH_DATA CI_END="3.2274831496672065" CI_START="0.038048015197289314" EFFECT_SIZE="0.3504273504273504" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.508863983540889" LOG_CI_START="-1.4196679935937413" LOG_EFFECT_SIZE="-0.45540200502642614" ORDER="67822" O_E="0.0" SE="1.1328292297561309" STUDY_ID="STD-Garcia_x002d_Huete-1997" TOTAL_1="39" TOTAL_2="41" VAR="1.2833020637898687" WEIGHT="1.3705624248811832"/>
<DICH_DATA CI_END="56.85179657325416" CI_START="0.10295677864895471" EFFECT_SIZE="2.4193548387096775" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7547441933777075" LOG_CI_START="-0.9873450542628527" LOG_EFFECT_SIZE="0.3836995695574274" ORDER="67853" O_E="0.0" SE="1.6107167976247523" STUDY_ID="STD-Golanski-2000" TOTAL_1="30" TOTAL_2="24" VAR="2.5944086021505375" WEIGHT="0.6779370014981219"/>
<DICH_DATA CI_END="2.747722311272708" CI_START="0.09606168891431204" EFFECT_SIZE="0.5137614678899083" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4389728401867553" LOG_CI_START="-1.0174497820556017" LOG_EFFECT_SIZE="-0.2892384709344232" MODIFIED="2010-01-11 14:36:58 +0000" MODIFIED_BY="Katharine Ker" ORDER="2298" O_E="0.0" SE="0.8555098577134124" STUDY_ID="STD-Gott-1998" TOTAL_1="109" TOTAL_2="112" VAR="0.7318971166448232" WEIGHT="2.403132282397563"/>
<DICH_DATA CI_END="11.591049480624264" CI_START="0.04852882398097617" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0641227597780483" LOG_CI_START="-1.314000232994648" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="67823" O_E="0.0" SE="1.396921217853351" STUDY_ID="STD-Green-1995" TOTAL_1="48" TOTAL_2="36" VAR="1.951388888888889" WEIGHT="0.9013301235943527"/>
<DICH_DATA CI_END="73.08526156114004" CI_START="0.13243453110695871" EFFECT_SIZE="3.111111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8638298055758746" LOG_CI_START="-0.8779987617700857" LOG_EFFECT_SIZE="0.49291552190289434" MODIFIED="2010-05-17 14:19:34 +0100" MODIFIED_BY="Katharine Ker" ORDER="2611" O_E="0.0" SE="1.6105636727293162" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="27" VAR="2.5939153439153437" WEIGHT="0.6780659178136508"/>
<DICH_DATA CI_END="3.9409080777837366" CI_START="0.010149944939211815" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5955963050059561" LOG_CI_START="-1.9935363136779936" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="67824" O_E="0.0" SE="1.5208693166281149" STUDY_ID="STD-Hardy-1993" TOTAL_1="22" TOTAL_2="22" VAR="2.313043478260869" WEIGHT="0.7604031679185338"/>
<DICH_DATA CI_END="2.7967897516443347" CI_START="0.024001839657087794" EFFECT_SIZE="0.2590909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.4466598195596907" LOG_CI_START="-1.6197554698591203" LOG_EFFECT_SIZE="-0.5865478251497148" ORDER="67825" O_E="0.0" SE="1.2138225699252623" STUDY_ID="STD-Hayashida-1997" TOTAL_1="110" TOTAL_2="57" VAR="1.473365231259968" WEIGHT="1.1937607533325385"/>
<DICH_DATA CI_END="104.66683659312582" CI_START="0.1883461910350192" EFFECT_SIZE="4.44" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.0198090984305934" LOG_CI_START="-0.7250431582013536" LOG_EFFECT_SIZE="0.6473829701146199" ORDER="67826" O_E="0.0" SE="1.6123398027834082" STUDY_ID="STD-Jamieson-1997" TOTAL_1="24" TOTAL_2="36" VAR="2.5996396396396393" WEIGHT="0.6765728455528088"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67857" O_E="0.0" SE="0.0" STUDY_ID="STD-Kipfer-2003" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67861" O_E="0.0" SE="0.0" STUDY_ID="STD-Koster-2004" TOTAL_1="100" TOTAL_2="100" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67858" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuepper-2003" TOTAL_1="60" TOTAL_2="59" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67863" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67860" O_E="0.0" SE="0.0" STUDY_ID="STD-Kunt-2005" TOTAL_1="40" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="76.5975747998518" CI_START="0.1435353516416592" EFFECT_SIZE="3.3157894736842106" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8842150194013312" LOG_CI_START="-0.8430411223998253" LOG_EFFECT_SIZE="0.5205869485007527" ORDER="67852" O_E="0.0" SE="1.6020037578296284" STUDY_ID="STD-Kyriss-2001" TOTAL_1="18" TOTAL_2="20" VAR="2.5664160401002505" WEIGHT="0.6853314353249461"/>
<DICH_DATA CI_END="3.7487868945518765" CI_START="0.009091698513516225" EFFECT_SIZE="0.18461538461538463" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5738907529980455" LOG_CI_START="-2.041354974188507" LOG_EFFECT_SIZE="-0.7337321105952308" ORDER="67827" O_E="0.0" SE="1.5362082858245159" STUDY_ID="STD-Lass-1995" TOTAL_1="51" TOTAL_2="47" VAR="2.3599358974358973" WEIGHT="0.7452937981552291"/>
<DICH_DATA CI_END="23.285388339548454" CI_START="0.19774635609679242" EFFECT_SIZE="2.1458333333333335" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3670834852284512" LOG_CI_START="-0.703891510569281" LOG_EFFECT_SIZE="0.331595987329585" MODIFIED="2010-05-06 16:11:35 +0100" MODIFIED_BY="Katharine Ker" ORDER="2375" O_E="0.0" SE="1.216500964023151" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="103" VAR="1.4798745954692556" WEIGHT="1.1885098871132078"/>
<DICH_DATA CI_END="17.50864593639377" CI_START="0.08054056579377307" EFFECT_SIZE="1.1875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.243252560412904" LOG_CI_START="-1.0939853238190957" LOG_EFFECT_SIZE="0.07463361829690418" MODIFIED="2010-05-07 10:33:59 +0100" MODIFIED_BY="Katharine Ker" ORDER="2411" O_E="0.0" SE="1.3729051027119943" STUDY_ID="STD-Leijdekkers-2006" TOTAL_1="16" TOTAL_2="19" VAR="1.8848684210526316" WEIGHT="0.9331397188036162"/>
<DICH_DATA CI_END="4.742007900231632" CI_START="0.3863903093400861" EFFECT_SIZE="1.3536121673003803" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="0.6759622731816349" LOG_CI_START="-0.41297377421540027" LOG_EFFECT_SIZE="0.1314942494831173" ORDER="67828" O_E="0.0" SE="0.639646424561387" STUDY_ID="STD-Lemmer-1996" TOTAL_1="526" TOTAL_2="178" VAR="0.40914754845416607" WEIGHT="4.298805149995663"/>
<DICH_DATA CI_END="5.166432555913332" CI_START="0.43550360440198194" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7131907643580054" LOG_CI_START="-0.36100824624664296" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="67829" O_E="0.0" SE="0.6309898162000304" STUDY_ID="STD-Lemmer_x005f_1-1994" TOTAL_1="108" TOTAL_2="108" VAR="0.39814814814814814" WEIGHT="4.417565663895578"/>
<DICH_DATA CI_END="2.6669718764855146" CI_START="0.37845316922755456" EFFECT_SIZE="1.0046511627906978" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.42601843603050193" LOG_CI_START="-0.4219878535598507" LOG_EFFECT_SIZE="0.002015291235325608" ORDER="67830" O_E="0.0" SE="0.4981230922042062" STUDY_ID="STD-Levy-1995" TOTAL_1="215" TOTAL_2="72" VAR="0.2481266149870801" WEIGHT="7.088500314625465"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67831" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Liu-1993" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.6839955066011156"/>
<DICH_DATA CI_END="38.11494103195797" CI_START="0.06689470732866364" EFFECT_SIZE="1.596774193548387" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5810952522048287" LOG_CI_START="-1.1746082420062367" LOG_EFFECT_SIZE="0.20324350509929603" ORDER="67832" O_E="0.0" SE="1.6187138734518747" STUDY_ID="STD-Maccario-1994" TOTAL_1="61" TOTAL_2="32" VAR="2.6202346041055717" WEIGHT="0.6712550035202892"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67844" O_E="0.0" SE="0.0" STUDY_ID="STD-Misfeld-1998" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67833" O_E="0.0" SE="0.0" STUDY_ID="STD-Mohr-1992" TOTAL_1="34" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67847" O_E="0.0" SE="0.0" STUDY_ID="STD-Moran-2000" TOTAL_1="28" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.705388158334567" CI_START="0.0189039550613078" EFFECT_SIZE="0.2982456140350877" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.6725954551956975" LOG_CI_START="-1.7234473237841323" LOG_EFFECT_SIZE="-0.5254259342942175" ORDER="67848" O_E="0.0" SE="1.4074473889757935" STUDY_ID="STD-Murkin-2000" TOTAL_1="228" TOTAL_2="68" VAR="1.9809081527347783" WEIGHT="0.8878986064925137"/>
<DICH_DATA CI_END="0.8307807432743171" CI_START="0.1875551109924871" EFFECT_SIZE="0.39473684210526316" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="-0.08051357856282583" LOG_CI_START="-0.7268710965594319" LOG_EFFECT_SIZE="-0.40369233756112893" MODIFIED="2010-05-21 15:13:26 +0100" MODIFIED_BY="Katharine Ker" ORDER="2455" O_E="0.0" SE="0.3796736055925217" STUDY_ID="STD-Norman-2009" TOTAL_1="11" TOTAL_2="9" VAR="0.14415204678362573" WEIGHT="12.201322337399214"/>
<DICH_DATA CI_END="4.052347097392378" CI_START="0.009870822769781833" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6077066370895764" LOG_CI_START="-2.005646645761614" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="67845" O_E="0.0" SE="1.5350966546541733" STUDY_ID="STD-Nuttall-2000" TOTAL_1="45" TOTAL_2="45" VAR="2.3565217391304345" WEIGHT="0.7463735891746492"/>
<DICH_DATA CI_END="4.312831798130339" CI_START="0.0077932812324565766" EFFECT_SIZE="0.18333333333333332" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6347625208474839" LOG_CI_START="-2.108279651298321" LOG_EFFECT_SIZE="-0.7367585652254186" ORDER="67834" O_E="0.0" SE="1.6112765501961857" STUDY_ID="STD-Okita-1996" TOTAL_1="39" TOTAL_2="21" VAR="2.596212121212121" WEIGHT="0.677466056811143"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67854" O_E="0.0" SE="0.0" STUDY_ID="STD-Palmer-2003" TOTAL_1="30" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67835" O_E="0.0" SE="0.0" STUDY_ID="STD-Rocha-1994" TOTAL_1="28" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.441993153969367" CI_START="0.04795811117017726" EFFECT_SIZE="0.5108695652173914" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7357579911013653" LOG_CI_START="-1.3191379299210408" LOG_EFFECT_SIZE="-0.29168996940983777" ORDER="67836" O_E="0.0" SE="1.2070560359074207" STUDY_ID="STD-Rodrigus-1996" TOTAL_1="46" TOTAL_2="47" VAR="1.4569842738205365" WEIGHT="1.2071822736911122"/>
<DICH_DATA CI_END="7.391737873352934" CI_START="0.015031798071690874" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8687465574849313" LOG_CI_START="-1.8229890669242566" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67837" O_E="0.0" SE="1.5811388300841895" STUDY_ID="STD-Royston-1987" TOTAL_1="11" TOTAL_2="11" VAR="2.4999999999999996" WEIGHT="0.7035382353611478"/>
<DICH_DATA CI_END="73.12440389594961" CI_START="0.1317124063623954" EFFECT_SIZE="3.103448275862069" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8640623387722208" LOG_CI_START="-0.8803733156914835" LOG_EFFECT_SIZE="0.4918445115403688" ORDER="67846" O_E="0.0" SE="1.6120950886075684" STUDY_ID="STD-Schweizer-2000" TOTAL_1="28" TOTAL_2="29" VAR="2.598850574712644" WEIGHT="0.6767782670988483"/>
<DICH_DATA CI_END="94.82568649010662" CI_START="0.19802416911304827" EFFECT_SIZE="4.333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9769259954590463" LOG_CI_START="-0.7032818002846979" LOG_EFFECT_SIZE="0.6368220975871743" ORDER="67838" O_E="0.0" SE="1.5743673264624358" STUDY_ID="STD-Stammers-1997" TOTAL_1="8" TOTAL_2="12" VAR="2.4786324786324783" WEIGHT="0.7096032201487439"/>
<DICH_DATA CI_END="2.6049100552711884" CI_START="0.09597260354310905" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.41579273217535734" LOG_CI_START="-1.0178527235033197" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="67839" O_E="0.0" SE="0.842130437325114" STUDY_ID="STD-Swart-1994" TOTAL_1="49" TOTAL_2="49" VAR="0.7091836734693877" WEIGHT="2.4800988153018877"/>
<DICH_DATA CI_END="28.295943084567533" CI_START="0.33549193252983445" EFFECT_SIZE="3.081081081081081" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.451724173252726" LOG_CI_START="-0.47431791871377055" LOG_EFFECT_SIZE="0.4887031272694776" ORDER="67859" O_E="0.0" SE="1.1313666588832385" STUDY_ID="STD-Van-der-Linden-2005" TOTAL_1="37" TOTAL_2="38" VAR="1.279990516832622" WEIGHT="1.3741082963295617"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-26 12:23:31 +0100" MODIFIED_BY="Katharine Ker" ORDER="2771" O_E="0.0" SE="0.0" STUDY_ID="STD-Wei-2006" TOTAL_1="36" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.0007666903125" CI_END="1.1029764835936962" CI_START="0.3316827261693246" DF="17" EFFECT_SIZE="0.6048456389683342" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="28" I2="0.0" ID="CMP-008.02.02" LOG_CI_END="0.042566253007401265" LOG_CI_START="-0.47927714567885404" LOG_EFFECT_SIZE="-0.21835544633572637" MODIFIED="2010-05-25 13:45:25 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.9035781714921064" P_Z="0.10095957494407007" STUDIES="30" TAU2="0.0" TOTAL_1="1478" TOTAL_2="1439" WEIGHT="100.0" Z="1.6402193137773018">
<NAME>Tranexamic Acid versus Control</NAME>
<DICH_DATA CI_END="76.21167365123344" CI_START="0.14053941198914405" EFFECT_SIZE="3.272727272727273" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8820214990825588" LOG_CI_START="-0.8522018678644345" LOG_EFFECT_SIZE="0.5149098156090622" ORDER="67882" O_E="0.0" SE="1.606096340368614" STUDY_ID="STD-Andreasen-2004" TOTAL_1="21" TOTAL_2="23" VAR="2.5795454545454546" WEIGHT="3.6426077479959376"/>
<DICH_DATA CI_END="3.168362491288542" CI_START="0.03506893905498902" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5008348632458548" LOG_CI_START="-1.45507737268518" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67877" O_E="0.0" SE="1.1489125293076057" STUDY_ID="STD-Armellin-2001" TOTAL_1="150" TOTAL_2="150" VAR="1.32" WEIGHT="7.118388075026496"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67864" O_E="0.0" SE="0.0" STUDY_ID="STD-Blauhut-1994" TOTAL_1="15" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.1114398580419795" CI_START="0.0063054646888222815" EFFECT_SIZE="0.11538461538461539" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.32457871555373485" LOG_CI_START="-2.2002829020560455" LOG_EFFECT_SIZE="-0.9378520932511555" ORDER="67865" O_E="0.0" SE="1.4831162124505617" STUDY_ID="STD-Boylan-1996" TOTAL_1="25" TOTAL_2="20" VAR="2.1996336996337" WEIGHT="4.271744091118315"/>
<DICH_DATA CI_END="36.343034718577506" CI_START="0.0639565513987594" EFFECT_SIZE="1.5245901639344261" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5604211889737918" LOG_CI_START="-1.1941149618874558" LOG_EFFECT_SIZE="0.18315311354316807" ORDER="67866" O_E="0.0" SE="1.6180281701897488" STUDY_ID="STD-Brown-1997" TOTAL_1="60" TOTAL_2="30" VAR="2.618015159527587" WEIGHT="3.5890824485258155"/>
<DICH_DATA CI_END="6.627129539131202" CI_START="0.1508948925919286" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8213254597385298" LOG_CI_START="-0.8213254597385299" LOG_EFFECT_SIZE="0.0" ORDER="67881" O_E="0.0" SE="0.9649012813540154" STUDY_ID="STD-Casati-2002" TOTAL_1="29" TOTAL_2="29" VAR="0.9310344827586208" WEIGHT="10.092292426370898"/>
<DICH_DATA CI_END="6.690017380199802" CI_START="0.012930488128094391" EFFECT_SIZE="0.29411764705882354" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8254272460361436" LOG_CI_START="-1.8883850801206539" LOG_EFFECT_SIZE="-0.5314789170422551" ORDER="67867" O_E="0.0" SE="1.5941067939721714" STUDY_ID="STD-Coffey-1995" TOTAL_1="16" TOTAL_2="14" VAR="2.541176470588235" WEIGHT="3.6976071389720966"/>
<DICH_DATA CI_END="2.9936089991355894" CI_START="0.17043110231829725" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.47619507569744124" LOG_CI_START="-0.7684511470539173" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="67878" O_E="0.0" SE="0.7311113523423155" STUDY_ID="STD-Dalmau-2000" TOTAL_1="42" TOTAL_2="40" VAR="0.5345238095238094" WEIGHT="17.578772154987487"/>
<DICH_DATA CI_END="8.022569637689829" CI_START="0.013849815723520037" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9043134955566555" LOG_CI_START="-1.8585560049959806" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67883" O_E="0.0" SE="1.6229232210492168" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="2.6338797814207653" WEIGHT="3.5674643639074692"/>
<DICH_DATA CI_END="1.769465679824819" CI_START="0.026345091667336132" EFFECT_SIZE="0.2159090909090909" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.24784214357299916" LOG_CI_START="-1.5793002859676784" LOG_EFFECT_SIZE="-0.6657290711973397" ORDER="67868" O_E="0.0" SE="1.073272507613088" STUDY_ID="STD-Dryden-1997" TOTAL_1="22" TOTAL_2="19" VAR="1.1519138755980862" WEIGHT="8.15709616672195"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67869" O_E="0.0" SE="0.0" STUDY_ID="STD-Hardy-1998" TOTAL_1="43" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.737987442424938" CI_START="0.013650190154211364" EFFECT_SIZE="0.325" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8886280205920004" LOG_CI_START="-1.8648612986342514" LOG_EFFECT_SIZE="-0.48811663902112556" ORDER="67870" O_E="0.0" SE="1.6174132561054522" STUDY_ID="STD-Hiipala-1997" TOTAL_1="39" TOTAL_2="38" VAR="2.616025641025641" WEIGHT="3.5918119882613477"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67880" O_E="0.0" SE="0.0" STUDY_ID="STD-Jares-2003" TOTAL_1="22" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-17 14:58:00 +0100" MODIFIED_BY="Katharine Ker" ORDER="2639" O_E="0.0" SE="0.0" STUDY_ID="STD-Jimenez-2007" TOTAL_1="24" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="32.019760174970436" CI_START="0.35412586927944617" EFFECT_SIZE="3.36734693877551" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.5054180747701325" LOG_CI_START="-0.4508423463993473" LOG_EFFECT_SIZE="0.5272878641853926" ORDER="67887" O_E="0.0" SE="1.149117055040213" STUDY_ID="STD-Karski-2005" TOTAL_1="147" TOTAL_2="165" VAR="1.3204700061842918" WEIGHT="7.1158543662699305"/>
<DICH_DATA CI_END="68.56773372198825" CI_START="0.13125707255384883" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8361197955452926" LOG_CI_START="-0.8818772861059678" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="67871" O_E="0.0" SE="1.5965649400644928" STUDY_ID="STD-Kaspar-1997" TOTAL_1="16" TOTAL_2="16" VAR="2.5490196078431375" WEIGHT="3.6862298862367973"/>
<DICH_DATA CI_END="36.35806398729506" CI_START="0.06386466192655374" EFFECT_SIZE="1.5238095238095237" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5606007496318903" LOG_CI_START="-1.1947393824599168" LOG_EFFECT_SIZE="0.18293068358598666" ORDER="67872" O_E="0.0" SE="1.6185004327443508" STUDY_ID="STD-Katoh-1997" TOTAL_1="62" TOTAL_2="31" VAR="2.6195436507936507" WEIGHT="3.586988235980782"/>
<DICH_DATA CI_END="4.194749874738821" CI_START="0.009902455029705713" EFFECT_SIZE="0.2038095238095238" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6227060697512994" LOG_CI_START="-2.004257121192794" LOG_EFFECT_SIZE="-0.6907755257207473" ORDER="67873" O_E="0.0" SE="1.5430911820380762" STUDY_ID="STD-Katsaros-1996" TOTAL_1="104" TOTAL_2="106" VAR="2.381130396083667" WEIGHT="3.94613931034158"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67884" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="16.406136195597867" CI_START="0.06597778748048523" EFFECT_SIZE="1.0404040404040404" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2150063125271002" LOG_CI_START="-1.1806022523118556" LOG_EFFECT_SIZE="0.017202030107622307" MODIFIED="2010-05-06 16:18:28 +0100" MODIFIED_BY="Katharine Ker" ORDER="2385" O_E="0.0" SE="1.4071923294400492" STUDY_ID="STD-Later-2009" TOTAL_1="99" TOTAL_2="103" VAR="1.9801902520349122" WEIGHT="4.745136104664205"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-07 11:57:41 +0100" MODIFIED_BY="Katharine Ker" ORDER="2425" O_E="0.0" SE="0.0" STUDY_ID="STD-Maddali-2007" TOTAL_1="111" TOTAL_2="111" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-07 12:18:33 +0100" MODIFIED_BY="Katharine Ker" ORDER="2438" O_E="0.0" SE="0.0" STUDY_ID="STD-Mehr_x002d_Aein-2007" TOTAL_1="33" TOTAL_2="33" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67875" O_E="0.0" SE="0.0" STUDY_ID="STD-Misfeld-1998" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-11 15:03:59 +0000" MODIFIED_BY="Katharine Ker" ORDER="2305" O_E="0.0" SE="0.0" STUDY_ID="STD-Murphy-2006" TOTAL_1="50" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.052347097392378" CI_START="0.009870822769781833" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6077066370895764" LOG_CI_START="-2.005646645761614" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="67876" O_E="0.0" SE="1.5350966546541733" STUDY_ID="STD-Nuttall-2000" TOTAL_1="45" TOTAL_2="45" VAR="2.3565217391304345" WEIGHT="3.987348006601558"/>
<DICH_DATA CI_END="8.61892084435806" CI_START="0.015341990876414226" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9354528921959627" LOG_CI_START="-1.8141182798564879" LOG_EFFECT_SIZE="-0.43933269383026263" MODIFIED="2010-05-14 11:51:33 +0100" MODIFIED_BY="Katharine Ker" ORDER="2494" O_E="0.0" SE="1.6151117170604201" STUDY_ID="STD-Sadeghi-2007" TOTAL_1="32" TOTAL_2="35" VAR="2.6085858585858586" WEIGHT="3.6020559676455473"/>
<DICH_DATA CI_END="4.264527161761337" CI_START="0.01067201811239352" EFFECT_SIZE="0.21333333333333335" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6298708848770885" LOG_CI_START="-1.971753446348639" LOG_EFFECT_SIZE="-0.6709412807357753" ORDER="67886" O_E="0.0" SE="1.5282070104101297" STUDY_ID="STD-Santos-2006" TOTAL_1="29" TOTAL_2="31" VAR="2.3354166666666667" WEIGHT="4.0233815203718"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67874" O_E="0.0" SE="0.0" STUDY_ID="STD-Shore_x002d_Lesserson-1996" TOTAL_1="17" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67885" O_E="0.0" SE="0.0" STUDY_ID="STD-Wu-2006" TOTAL_1="106" TOTAL_2="108" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67879" O_E="0.0" SE="0.0" STUDY_ID="STD-Zabeeda-2002" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.2966160793014345" CI_END="2.5687046637856996" CI_START="0.44203320902066967" DF="5" EFFECT_SIZE="1.0655762598517071" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="0.0" ID="CMP-008.02.03" LOG_CI_END="0.4097141742307713" LOG_CI_START="-0.35454510179876575" LOG_EFFECT_SIZE="0.027584536216002688" MODIFIED="2010-05-20 11:22:41 +0100" MODIFIED_BY="Katharine Ker" NO="3" P_CHI2="0.8067638745683651" P_Z="0.8874886992257938" STUDIES="8" TAU2="0.0" TOTAL_1="504" TOTAL_2="484" WEIGHT="99.99999999999999" Z="0.1414826073017572">
<NAME>Epsilon Aminocaproic Acid versus Control</NAME>
<DICH_DATA CI_END="8.0762111281345" CI_START="0.013757826454541471" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9072076637368413" LOG_CI_START="-1.8614501731761663" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2010-05-20 11:22:41 +0100" MODIFIED_BY="Katharine Ker" ORDER="5316" O_E="0.0" SE="1.626323318480026" STUDY_ID="STD-Berenholtz-2009" TOTAL_1="91" TOTAL_2="91" VAR="2.6449275362318843" WEIGHT="7.619787556212356"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67888" O_E="0.0" SE="0.0" STUDY_ID="STD-Daily-1994" TOTAL_1="21" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.9936089991355894" CI_START="0.17043110231829725" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.47619507569744124" LOG_CI_START="-0.7684511470539173" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="67892" O_E="0.0" SE="0.7311113523423155" STUDY_ID="STD-Dalmau-2000" TOTAL_1="42" TOTAL_2="40" VAR="0.5345238095238094" WEIGHT="37.70418748159694"/>
<DICH_DATA CI_END="5.174148659988499" CI_START="0.21667473049343697" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7138389024024029" LOG_CI_START="-0.6641917349523386" LOG_EFFECT_SIZE="0.024823583725032145" ORDER="67889" O_E="0.0" SE="0.8094620177438436" STUDY_ID="STD-Del-Rossi-1989" TOTAL_1="170" TOTAL_2="180" VAR="0.6552287581699346" WEIGHT="30.75839647812925"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-17 14:20:42 +0100" MODIFIED_BY="Katharine Ker" ORDER="2612" O_E="0.0" SE="0.0" STUDY_ID="STD-Greilich-2009" TOTAL_1="25" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="99.182453999066" CI_START="0.24144883076953833" EFFECT_SIZE="4.8936170212765955" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9964348495194004" LOG_CI_START="-0.61717489335565" LOG_EFFECT_SIZE="0.6896299780818754" ORDER="67890" O_E="0.0" SE="1.5352473005416867" STUDY_ID="STD-Hardy-1998" TOTAL_1="46" TOTAL_2="45" VAR="2.356984273820536" WEIGHT="8.550666269399834"/>
<DICH_DATA CI_END="37.56235669713492" CI_START="0.06614683080821228" EFFECT_SIZE="1.576271186440678" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5747528324879192" LOG_CI_START="-1.1794909586643374" LOG_EFFECT_SIZE="0.19763093691179093" ORDER="67893" O_E="0.0" SE="1.6178564366494836" STUDY_ID="STD-Kluger-2003" TOTAL_1="58" TOTAL_2="30" VAR="2.6174594496081647" WEIGHT="7.6997509667934505"/>
<DICH_DATA CI_END="73.35586484045308" CI_START="0.12745377985598785" EFFECT_SIZE="3.0576923076923075" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8654348416424724" LOG_CI_START="-0.894647280271168" LOG_EFFECT_SIZE="0.4853937806856523" ORDER="67891" O_E="0.0" SE="1.6212859010389238" STUDY_ID="STD-Vander_x002d_Salm-1996" TOTAL_1="51" TOTAL_2="52" VAR="2.6285679729075953" WEIGHT="7.667211247868159"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="38.81235512018757" CI_END="1.0679588693063793" CI_START="0.7036261186129933" CI_STUDY="95" CI_TOTAL="95" DF="56" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8668585548106269" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="186" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="0.028554526871141683" LOG_CI_START="-0.15265804789711468" LOG_EFFECT_SIZE="-0.06205176051298649" METHOD="MH" MODIFIED="2010-07-08 11:07:50 +0100" MODIFIED_BY="Katharine Ker" NO="3" P_CHI2="0.9610895644674842" P_Q="0.0" P_Z="0.17950448038746364" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="71" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="5605" TOTAL_2="4614" WEIGHT="300.0" Z="1.3422822995400945">
<NAME>Myocardial Infarction (MI)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="27.70640867409754" CI_END="1.1076287544783685" CI_START="0.6909655936244455" DF="38" EFFECT_SIZE="0.8748333326146479" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="140" I2="0.0" ID="CMP-008.03.01" LOG_CI_END="0.04439422167554889" LOG_CI_START="-0.1605435776201106" LOG_EFFECT_SIZE="-0.05807467797228084" MODIFIED="2010-07-08 11:07:50 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="0.8906106513282038" P_Z="0.2666468026785639" STUDIES="49" TAU2="0.0" TOTAL_1="4032" TOTAL_2="3105" WEIGHT="100.00000000000001" Z="1.1108177957470908">
<NAME>Aprotinin versus Control</NAME>
<DICH_DATA CI_END="1.6077071625838795" CI_START="0.3689028907459417" EFFECT_SIZE="0.7701219512195122" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.20620694661662112" LOG_CI_START="-0.4330879416013554" LOG_EFFECT_SIZE="-0.11344049749236712" ORDER="67914" O_E="0.0" SE="0.37552498189997346" STUDY_ID="STD-Alderman-1998" TOTAL_1="410" TOTAL_2="421" VAR="0.1410190120309754" WEIGHT="10.276415910245435"/>
<DICH_DATA CI_END="105.64697314375843" CI_START="0.25594675545702095" EFFECT_SIZE="5.2" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.023857058740018" LOG_CI_START="-0.59185037147042" LOG_EFFECT_SIZE="0.7160033436347992" ORDER="67894" O_E="0.0" SE="1.5364794924662128" STUDY_ID="STD-Alvarez-1995" TOTAL_1="49" TOTAL_2="51" VAR="2.3607692307692307" WEIGHT="0.6138550096275237"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67920" O_E="0.0" SE="0.0" STUDY_ID="STD-Alvarez-2001" TOTAL_1="26" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-11 11:42:53 +0000" MODIFIED_BY="Katharine Ker" ORDER="2258" O_E="0.0" SE="0.0" STUDY_ID="STD-Asimakopoulos-2000" TOTAL_1="8" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.541363678271646" CI_START="0.15664935539787983" EFFECT_SIZE="0.49137931034482757" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.187905120763877" LOG_CI_START="-0.8050713878727311" LOG_EFFECT_SIZE="-0.30858313355442707" ORDER="67895" O_E="0.0" SE="0.5832793164861346" STUDY_ID="STD-Baele-1992" TOTAL_1="58" TOTAL_2="57" VAR="0.3402147610405324" WEIGHT="4.259574200866485"/>
<DICH_DATA CI_END="1.6077071625838795" CI_START="0.3689028907459417" EFFECT_SIZE="0.7701219512195122" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.20620694661662112" LOG_CI_START="-0.4330879416013554" LOG_EFFECT_SIZE="-0.11344049749236712" ORDER="67896" O_E="0.0" SE="0.37552498189997346" STUDY_ID="STD-Bidstrup-1993" TOTAL_1="410" TOTAL_2="421" VAR="0.1410190120309754" WEIGHT="10.276415910245435"/>
<DICH_DATA CI_END="6.64261094358732" CI_START="0.1505432138796847" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8223388166442885" LOG_CI_START="-0.8223388166442885" LOG_EFFECT_SIZE="0.0" ORDER="67915" O_E="0.0" SE="0.9660917830792959" STUDY_ID="STD-Bidstrup-2000" TOTAL_1="30" TOTAL_2="30" VAR="0.9333333333333333" WEIGHT="1.5526821630880798"/>
<DICH_DATA CI_END="8.602503618833898" CI_START="0.2615517644275046" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.93462486398861" LOG_CI_START="-0.5824423458772476" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="67897" O_E="0.0" SE="0.8911327886790068" STUDY_ID="STD-Carrera-1994" TOTAL_1="51" TOTAL_2="51" VAR="0.7941176470588234" WEIGHT="1.8248807645183363"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67899" O_E="0.0" SE="0.0" STUDY_ID="STD-Cicek-1996a" TOTAL_1="50" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67898" O_E="0.0" SE="0.0" STUDY_ID="STD-Cicek-1996b" TOTAL_1="29" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-20 11:56:37 +0100" MODIFIED_BY="Katharine Ker" ORDER="5332" O_E="0.0" SE="0.0" STUDY_ID="STD-Cicekcioglu-2006" TOTAL_1="24" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="107.27288722482027" CI_START="0.25822770078776697" EFFECT_SIZE="5.2631578947368425" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.030489969714727" LOG_CI_START="-0.5879971716203847" LOG_EFFECT_SIZE="0.721246399047171" ORDER="67916" O_E="0.0" SE="1.5381123085406379" STUDY_ID="STD-Cohen-1998" TOTAL_1="56" TOTAL_2="59" VAR="2.3657894736842104" WEIGHT="0.6125523995275184"/>
<DICH_DATA CI_END="16.043206383216464" CI_START="0.06376454498349125" EFFECT_SIZE="1.0114285714285713" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2052911703929732" LOG_CI_START="-1.195420735041949" LOG_EFFECT_SIZE="0.00493521767551215" MODIFIED="2010-05-20 12:09:37 +0100" MODIFIED_BY="Katharine Ker" ORDER="5343" O_E="0.0" SE="1.4101900569680634" STUDY_ID="STD-Colwell-2007" TOTAL_1="175" TOTAL_2="177" VAR="1.9886359967715899" WEIGHT="0.7287256296450598"/>
<DICH_DATA CI_END="5.026670430933967" CI_START="0.5985147306126019" EFFECT_SIZE="1.7345132743362832" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" LOG_CI_END="0.7012804120395381" LOG_CI_START="-0.22292515629342538" LOG_EFFECT_SIZE="0.23917762787305633" ORDER="67900" O_E="0.0" SE="0.5428829257301289" STUDY_ID="STD-Cosgrove-1992" TOTAL_1="113" TOTAL_2="56" VAR="0.29472187104930464" WEIGHT="4.917076610984779"/>
<DICH_DATA CI_END="3.4123328274150158" CI_START="0.20640707865585955" EFFECT_SIZE="0.8392434988179669" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.5330513841778762" LOG_CI_START="-0.6852754128177727" LOG_EFFECT_SIZE="-0.07611201431994824" ORDER="67901" O_E="0.0" SE="0.7156511913701531" STUDY_ID="STD-D_x0027_Ambra-1996" TOTAL_1="141" TOTAL_2="71" VAR="0.5121566277095195" WEIGHT="2.829544597251869"/>
<DICH_DATA CI_END="2.07731834537124" CI_START="0.02852418311150889" EFFECT_SIZE="0.24342105263157895" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.31750305649841715" LOG_CI_START="-1.5447867842539722" LOG_EFFECT_SIZE="-0.6136418638777775" MODIFIED="2010-05-17 10:54:18 +0100" MODIFIED_BY="Katharine Ker" ORDER="2559" O_E="0.0" SE="1.093918270941339" STUDY_ID="STD-Desai-2009" TOTAL_1="38" TOTAL_2="37" VAR="1.1966571834992887" WEIGHT="1.2110151836840324"/>
<DICH_DATA CI_END="2.395116661014344" CI_START="0.14441206247634583" EFFECT_SIZE="0.5881188118811881" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3793266718219245" LOG_CI_START="-0.8403965294248226" LOG_EFFECT_SIZE="-0.23053492880144905" ORDER="67921" O_E="0.0" SE="0.7164714461395606" STUDY_ID="STD-Dignan-2001" TOTAL_1="101" TOTAL_2="99" VAR="0.5133313331333134" WEIGHT="2.8230694784139643"/>
<DICH_DATA CI_END="3.2087008039370097" CI_START="0.1753045965862022" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5063292230920509" LOG_CI_START="-0.7562066963086507" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="67931" O_E="0.0" SE="0.7416198487095662" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.5499999999999998" WEIGHT="2.6348545797858334"/>
<DICH_DATA CI_END="7.8107039169243295" CI_START="0.014225492643544472" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8926901751653995" LOG_CI_START="-1.8469326846047245" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67902" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Ehrlich-1998" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="0.5595805023406545"/>
<DICH_DATA CI_END="17.111978424286665" CI_START="0.07546306347703435" EFFECT_SIZE="1.1363636363636365" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2333002239817072" LOG_CI_START="-1.1222655682820444" LOG_EFFECT_SIZE="0.05551732784983142" ORDER="67925" O_E="0.0" SE="1.3836710066144533" STUDY_ID="STD-Englberger-2002a" TOTAL_1="22" TOTAL_2="25" VAR="1.9145454545454546" WEIGHT="0.7569264106222358"/>
<DICH_DATA CI_END="13.53677361466875" CI_START="0.06435145743791972" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.131515165950651" LOG_CI_START="-1.1914416127055376" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="67926" O_E="0.0" SE="1.3645163106041502" STUDY_ID="STD-Englberger-2002b" TOTAL_1="15" TOTAL_2="14" VAR="1.861904761904762" WEIGHT="0.7783266086068125"/>
<DICH_DATA CI_END="10.83813052319989" CI_START="0.5314569692319404" EFFECT_SIZE="2.4" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.0349543769000427" LOG_CI_START="-0.27453189347683066" LOG_EFFECT_SIZE="0.38021124171160603" ORDER="67924" O_E="0.0" SE="0.7691987172809551" STUDY_ID="STD-Golanski-2000" TOTAL_1="30" TOTAL_2="24" VAR="0.5916666666666667" WEIGHT="2.449301440364295"/>
<DICH_DATA CI_END="2.297323745923574" CI_START="0.3448776507348208" EFFECT_SIZE="0.8901098901098901" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.36122220162110974" LOG_CI_START="-0.46233494850599743" LOG_EFFECT_SIZE="-0.050556373442443875" MODIFIED="2010-05-17 14:22:00 +0100" MODIFIED_BY="Katharine Ker" ORDER="2613" O_E="0.0" SE="0.4837615466583036" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="27" VAR="0.23402523402523406" WEIGHT="6.192366498075798"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67903" O_E="0.0" SE="0.0" STUDY_ID="STD-Harder-1991" TOTAL_1="40" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4839504460692374" CI_START="0.11580436148625915" EFFECT_SIZE="0.41454545454545455" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.1714193986801977" LOG_CI_START="-0.9362750836677779" LOG_EFFECT_SIZE="-0.38242784249379" ORDER="67904" O_E="0.0" SE="0.65066522210732" STUDY_ID="STD-Hayashida-1997" TOTAL_1="110" TOTAL_2="57" VAR="0.4233652312599681" WEIGHT="3.4229783455985845"/>
<DICH_DATA CI_END="7.843592129561627" CI_START="0.03187315146816185" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.8945150020678766" LOG_CI_START="-1.4965749933958392" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="67905" O_E="0.0" SE="1.404538099421754" STUDY_ID="STD-Kalangos-1994" TOTAL_1="110" TOTAL_2="55" VAR="1.9727272727272729" WEIGHT="0.7346023137190915"/>
<DICH_DATA CI_END="14.553341064518706" CI_START="0.06871274407483083" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1629627073641946" LOG_CI_START="-1.1629627073641946" LOG_EFFECT_SIZE="0.0" ORDER="67927" O_E="0.0" SE="1.3662601021279464" STUDY_ID="STD-Kipfer-2003" TOTAL_1="15" TOTAL_2="15" VAR="1.8666666666666667" WEIGHT="0.7763410815440399"/>
<DICH_DATA CI_END="5.281559596881724" CI_START="0.11800845690142829" EFFECT_SIZE="0.7894736842105263" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7227621847129794" LOG_CI_START="-0.9280868685072747" LOG_EFFECT_SIZE="-0.10266234189714772" ORDER="67922" O_E="0.0" SE="0.9697169056961844" STUDY_ID="STD-Klein-1998" TOTAL_1="38" TOTAL_2="30" VAR="0.9403508771929825" WEIGHT="1.541094982766527"/>
<DICH_DATA CI_END="39.05869370178205" CI_START="0.6400623684672634" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5917177144358472" LOG_CI_START="-0.19377770576380962" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="67932" O_E="0.0" SE="1.0488088481701514" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="1.0999999999999999" WEIGHT="1.3174272898929165"/>
<DICH_DATA CI_END="1.8552452689203953" CI_START="0.005670083255838834" EFFECT_SIZE="0.10256410256410256" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2684013327636469" LOG_CI_START="-2.246410564160721" LOG_EFFECT_SIZE="-0.9890046156985368" ORDER="67906" O_E="0.0" SE="1.4772129567730305" STUDY_ID="STD-Lass-1995" TOTAL_1="51" TOTAL_2="47" VAR="2.1821581196581197" WEIGHT="0.6640994554094231"/>
<DICH_DATA CI_END="1.052445490945524" CI_START="0.01709040669319056" EFFECT_SIZE="0.13411458333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="0.022199611781238866" LOG_CI_START="-1.7672476024339185" LOG_EFFECT_SIZE="-0.8725239953263397" MODIFIED="2010-05-06 16:12:14 +0100" MODIFIED_BY="Katharine Ker" ORDER="2376" O_E="0.0" SE="1.0511301515365523" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="103" VAR="1.1048745954692556" WEIGHT="1.3116149333370501"/>
<DICH_DATA CI_END="5.3278061871756135" CI_START="0.650197772680211" EFFECT_SIZE="1.861216730038023" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="4" LOG_CI_END="0.7265484178568543" LOG_CI_START="-0.18695452255805675" LOG_EFFECT_SIZE="0.2697969476493988" ORDER="67907" O_E="0.0" SE="0.5365961491122023" STUDY_ID="STD-Lemmer-1996" TOTAL_1="526" TOTAL_2="178" VAR="0.2879354272420449" WEIGHT="5.032968790130863"/>
<DICH_DATA CI_END="3.6146683029375715" CI_START="0.5645929738206075" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5580684507831964" LOG_CI_START="-0.24826453081171015" LOG_EFFECT_SIZE="0.15490195998574316" ORDER="67908" O_E="0.0" SE="0.4736439848014797" STUDY_ID="STD-Lemmer_x005f_1-1994" TOTAL_1="108" TOTAL_2="108" VAR="0.22433862433862434" WEIGHT="6.459743716243803"/>
<DICH_DATA CI_END="2.0680398044354233" CI_START="0.4603612711326558" EFFECT_SIZE="0.9757281553398058" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="8" LOG_CI_END="0.31555889355164135" LOG_CI_START="-0.33690121944897033" LOG_EFFECT_SIZE="-0.010671162948664523" ORDER="67909" O_E="0.0" SE="0.38325830010620704" STUDY_ID="STD-Levy-1995" TOTAL_1="206" TOTAL_2="67" VAR="0.14688692460029948" WEIGHT="9.865888490930072"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67929" O_E="0.0" SE="0.0" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67918" O_E="0.0" SE="0.0" STUDY_ID="STD-Moran-2000" TOTAL_1="28" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.8955723550096066" CI_START="0.19077117136645608" EFFECT_SIZE="0.8620689655172413" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5905712751949531" LOG_CI_START="-0.7194872536487902" LOG_EFFECT_SIZE="-0.0644579892269185" ORDER="67910" O_E="0.0" SE="0.7695348647371196" STUDY_ID="STD-Murkin-1994" TOTAL_1="29" TOTAL_2="25" VAR="0.592183908045977" WEIGHT="2.4471621048670826"/>
<DICH_DATA CI_END="2.6158531709411212" CI_START="0.004435438911448392" EFFECT_SIZE="0.10771470160116449" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.41761336318447057" LOG_CI_START="-2.353063397841619" LOG_EFFECT_SIZE="-0.9677250173285742" ORDER="67919" O_E="0.0" SE="1.6275092444978858" STUDY_ID="STD-Murkin-2000" TOTAL_1="228" TOTAL_2="73" VAR="2.648786340926079" WEIGHT="0.5471071775368426"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-07 15:03:50 +0100" MODIFIED_BY="Katharine Ker" ORDER="2472" O_E="0.0" SE="0.0" STUDY_ID="STD-Nur_x00f6_zler-2008" TOTAL_1="25" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.405785881208536" CI_START="0.04624674478303774" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7328588396514188" LOG_CI_START="-1.3349188309793814" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-01-11 16:23:40 +0000" MODIFIED_BY="Katharine Ker" ORDER="2335" O_E="0.0" SE="1.2146228393930802" STUDY_ID="STD-Parvizi-2007" TOTAL_1="81" TOTAL_2="81" VAR="1.4753086419753085" WEIGHT="0.9822826069410783"/>
<DICH_DATA CI_END="3.2345221380429106" CI_START="0.03925317174749747" EFFECT_SIZE="0.3563218390804598" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5098101279288101" LOG_CI_START="-1.4061252454975017" LOG_EFFECT_SIZE="-0.4481575587843458" ORDER="67933" O_E="0.0" SE="1.1254299223836706" STUDY_ID="STD-Poston-2006" TOTAL_1="29" TOTAL_2="31" VAR="1.2665925101965145" WEIGHT="1.144148577554249"/>
<DICH_DATA CI_END="2.9309710934368343" CI_START="0.03345349242198305" EFFECT_SIZE="0.31313131313131315" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.46701153525086136" LOG_CI_START="-1.4755585367774158" LOG_EFFECT_SIZE="-0.5042735007632773" ORDER="67911" O_E="0.0" SE="1.1410752761863494" STUDY_ID="STD-Ranaboldo-1997" TOTAL_1="66" TOTAL_2="62" VAR="1.3020527859237536" WEIGHT="1.112988685673047"/>
<DICH_DATA CI_END="4.8033836748969465" CI_START="0.21733655300479887" EFFECT_SIZE="1.0217391304347827" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6815472777144629" LOG_CI_START="-0.662867225206176" LOG_EFFECT_SIZE="0.009340026254143432" ORDER="67912" O_E="0.0" SE="0.7897157339747025" STUDY_ID="STD-Rodrigus-1996" TOTAL_1="46" TOTAL_2="47" VAR="0.6236509404872032" WEIGHT="2.3236876990037088"/>
<DICH_DATA CI_END="3.365562691610729" CI_START="0.07428178373357004" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.5270576847358844" LOG_CI_START="-1.1291176760638466" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="67923" O_E="0.0" SE="0.9728456051340169" STUDY_ID="STD-Santamaria-2000" TOTAL_1="56" TOTAL_2="28" VAR="0.9464285714285714" WEIGHT="1.5311985105170498"/>
<DICH_DATA CI_END="6.855230181218761" CI_START="0.15647965907425473" EFFECT_SIZE="1.0357142857142858" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8360220418760519" LOG_CI_START="-0.805542108762578" LOG_EFFECT_SIZE="0.015239966556736905" ORDER="67917" O_E="0.0" SE="0.9642629079587293" STUDY_ID="STD-Schweizer-2000" TOTAL_1="28" TOTAL_2="29" VAR="0.9298029556650247" WEIGHT="1.5585775567315932"/>
<DICH_DATA CI_END="14.50846406676568" CI_START="0.061479651087616466" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.161621438444948" LOG_CI_START="-1.2112686058950124" LOG_EFFECT_SIZE="-0.024823583725032152" ORDER="67928" O_E="0.0" SE="1.3938473580404491" STUDY_ID="STD-Taggart-2003" TOTAL_1="36" TOTAL_2="34" VAR="1.94281045751634" WEIGHT="0.7459142569856275"/>
<DICH_DATA CI_END="73.24882267849273" CI_START="0.1294207408509027" EFFECT_SIZE="3.0789473684210527" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8648006487074702" LOG_CI_START="-0.8879961184487669" LOG_EFFECT_SIZE="0.4884022651293515" ORDER="67930" O_E="0.0" SE="1.6170064475913375" STUDY_ID="STD-Van-der-Linden-2005" TOTAL_1="37" TOTAL_2="38" VAR="2.614709851551957" WEIGHT="0.5542374110924986"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-26 12:25:22 +0100" MODIFIED_BY="Katharine Ker" ORDER="2774" O_E="0.0" SE="0.0" STUDY_ID="STD-Wei-2006" TOTAL_1="36" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.919915520931636" CI_START="0.0102043015433387" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5932767075335775" LOG_CI_START="-1.991216716205615" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="67913" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Wendel-1995" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="0.6287721156307099"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.835076507950237" CI_END="1.524568969681361" CI_START="0.4144240128681844" DF="12" EFFECT_SIZE="0.7948697945636524" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="25" I2="0.0" ID="CMP-008.03.02" LOG_CI_END="0.18314707611005873" LOG_CI_START="-0.38255508831589097" LOG_EFFECT_SIZE="-0.09970400610291612" MODIFIED="2010-05-25 13:45:25 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.7978821755124106" P_Z="0.48964072624581356" STUDIES="21" TAU2="0.0" TOTAL_1="1117" TOTAL_2="1069" WEIGHT="100.00000000000001" Z="0.6908803726228533">
<NAME>Tranexamic Acid versus Control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67947" O_E="0.0" SE="0.0" STUDY_ID="STD-Andreasen-2004" TOTAL_1="21" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="73.05858468240297" CI_START="0.12318880853118634" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8636712546460013" LOG_CI_START="-0.9094287452066763" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="67942" O_E="0.0" SE="1.6289326669798492" STUDY_ID="STD-Armellin-2001" TOTAL_1="150" TOTAL_2="150" VAR="2.653421633554084" WEIGHT="4.161449408093062"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67934" O_E="0.0" SE="0.0" STUDY_ID="STD-Brown-1997" TOTAL_1="60" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.235048878454709" CI_START="0.06563812219954164" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1828438519035636" LOG_CI_START="-1.1828438519035636" LOG_EFFECT_SIZE="0.0" ORDER="67945" O_E="0.0" SE="1.3896166675593022" STUDY_ID="STD-Casati-2002" TOTAL_1="29" TOTAL_2="29" VAR="1.9310344827586206" WEIGHT="5.718219941158467"/>
<DICH_DATA CI_END="4.429536110874856" CI_START="0.3527457415154469" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6463582465309213" LOG_CI_START="-0.45253822051480863" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="67948" O_E="0.0" SE="0.6454972243679028" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.4166666666666667" WEIGHT="26.500991727299926"/>
<DICH_DATA CI_END="5.562800180520233" CI_START="0.04921921297746887" EFFECT_SIZE="0.5232558139534884" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7452934600745638" LOG_CI_START="-1.3078653350110119" LOG_EFFECT_SIZE="-0.281285937468224" ORDER="67935" O_E="0.0" SE="1.2060356395332144" STUDY_ID="STD-Hardy-1998" TOTAL_1="43" TOTAL_2="45" VAR="1.4545219638242894" WEIGHT="7.59155252447524"/>
<DICH_DATA CI_END="59.399212530180506" CI_START="0.11600532576924143" EFFECT_SIZE="2.625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.773780687471695" LOG_CI_START="-0.935522071987744" LOG_EFFECT_SIZE="0.41912930774197565" ORDER="67936" O_E="0.0" SE="1.591457852171428" STUDY_ID="STD-Hiipala-1995" TOTAL_1="15" TOTAL_2="13" VAR="2.532738095238095" WEIGHT="4.359740119649812"/>
<DICH_DATA CI_END="84.69311383087638" CI_START="0.149022636727436" EFFECT_SIZE="3.5526315789473686" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9278481004507968" LOG_CI_START="-0.8267477566944047" LOG_EFFECT_SIZE="0.550550171878196" ORDER="67937" O_E="0.0" SE="1.6180632419564942" STUDY_ID="STD-Horrow-1991" TOTAL_1="37" TOTAL_2="44" VAR="2.6181286549707603" WEIGHT="4.217546706656511"/>
<DICH_DATA CI_END="17.111978424286665" CI_START="0.07546306347703435" EFFECT_SIZE="1.1363636363636365" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2333002239817072" LOG_CI_START="-1.1222655682820444" LOG_EFFECT_SIZE="0.05551732784983142" ORDER="67944" O_E="0.0" SE="1.3836710066144533" STUDY_ID="STD-Jares-2003" TOTAL_1="22" TOTAL_2="25" VAR="1.9145454545454546" WEIGHT="5.767468126786546"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67938" O_E="0.0" SE="0.0" STUDY_ID="STD-Karski-1995" TOTAL_1="100" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.416639994623157" CI_START="0.12678232153558208" EFFECT_SIZE="0.7482993197278912" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6450920008611732" LOG_CI_START="-0.8969413000410753" LOG_EFFECT_SIZE="-0.12592464958995103" ORDER="67950" O_E="0.0" SE="0.9057979941379268" STUDY_ID="STD-Karski-2005" TOTAL_1="147" TOTAL_2="165" VAR="0.8204700061842918" WEIGHT="13.458237111832615"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67939" O_E="0.0" SE="0.0" STUDY_ID="STD-Katsaros-1996" TOTAL_1="104" TOTAL_2="106" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="14.903914722906746" CI_START="0.06709646549862758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528004" LOG_EFFECT_SIZE="0.0" ORDER="67949" O_E="0.0" SE="1.378404875209022" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="1.9" WEIGHT="5.811620992828931"/>
<DICH_DATA CI_END="1.0459584311055454" CI_START="0.0035781159578946666" EFFECT_SIZE="0.0611764705882353" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="0.019514424970822127" LOG_CI_START="-2.446345589129809" LOG_EFFECT_SIZE="-1.2134155820794936" MODIFIED="2010-05-06 16:19:03 +0100" MODIFIED_BY="Katharine Ker" ORDER="2386" O_E="0.0" SE="1.4484583784866396" STUDY_ID="STD-Later-2009" TOTAL_1="99" TOTAL_2="103" VAR="2.098031674208145" WEIGHT="5.263066340760825"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67946" O_E="0.0" SE="0.0" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-07 12:18:58 +0100" MODIFIED_BY="Katharine Ker" ORDER="2439" O_E="0.0" SE="0.0" STUDY_ID="STD-Mehr_x002d_Aein-2007" TOTAL_1="33" TOTAL_2="33" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.99146782835324" CI_START="0.013903717501920699" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9026265554350377" LOG_CI_START="-1.8568690648743624" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2010-01-11 15:06:41 +0000" MODIFIED_BY="Katharine Ker" ORDER="2309" O_E="0.0" SE="1.6209413870933633" STUDY_ID="STD-Murphy-2006" TOTAL_1="50" TOTAL_2="50" VAR="2.627450980392157" WEIGHT="4.202582643321817"/>
<DICH_DATA CI_END="3.772928267323021" CI_START="0.03874809200388678" EFFECT_SIZE="0.38235294117647056" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5766785482696595" LOG_CI_START="-1.4117496777404963" LOG_EFFECT_SIZE="-0.4175355647354184" ORDER="67940" O_E="0.0" SE="1.1680125828368282" STUDY_ID="STD-Shore_x002d_Lesserson-1996" TOTAL_1="17" TOTAL_2="13" VAR="1.3642533936651584" WEIGHT="8.093862868619794"/>
<DICH_DATA CI_END="3.845086034384406" CI_START="0.010402888164868843" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5849060616512035" LOG_CI_START="-1.982846070323241" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="67941" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="4.85366148851647"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-14 12:19:54 +0100" MODIFIED_BY="Katharine Ker" ORDER="2506" O_E="0.0" SE="0.0" STUDY_ID="STD-Taghaddomi-2009" TOTAL_1="50" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67943" O_E="0.0" SE="0.0" STUDY_ID="STD-Zabeeda-2002" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.4438046063904197" CI_END="1.625757784211423" CI_START="0.47631626856821146" DF="4" EFFECT_SIZE="0.8799857279361459" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" I2="0.0" ID="CMP-008.03.03" LOG_CI_END="0.2110558421091065" LOG_CI_START="-0.3221045849197701" LOG_EFFECT_SIZE="-0.055524371405331785" MODIFIED="2010-05-20 11:23:14 +0100" MODIFIED_BY="Katharine Ker" NO="3" P_CHI2="0.4864745498349088" P_Z="0.6831055761909759" STUDIES="7" TAU2="0.0" TOTAL_1="456" TOTAL_2="440" WEIGHT="100.0" Z="0.4082289783775788">
<NAME>Epsilon aminocaproic Acid versus Control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-20 11:23:14 +0100" MODIFIED_BY="Katharine Ker" ORDER="5317" O_E="0.0" SE="0.0" STUDY_ID="STD-Berenholtz-2009" TOTAL_1="91" TOTAL_2="91" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.3248431352831338" CI_START="0.13539501987261524" EFFECT_SIZE="0.4235294117647059" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.12216445977177443" LOG_CI_START="-0.8683973096657853" LOG_EFFECT_SIZE="-0.3731164249470055" ORDER="67951" O_E="0.0" SE="0.5818608867274617" STUDY_ID="STD-Del-Rossi-1989" TOTAL_1="170" TOTAL_2="180" VAR="0.338562091503268" WEIGHT="28.970279776738906"/>
<DICH_DATA CI_END="2.3817699458924997" CI_START="0.35979416914440665" EFFECT_SIZE="0.9257142857142857" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3768998108602507" LOG_CI_START="-0.44394587914757766" LOG_EFFECT_SIZE="-0.03352303414366349" MODIFIED="2010-05-17 14:22:35 +0100" MODIFIED_BY="Katharine Ker" ORDER="2614" O_E="0.0" SE="0.48216882156229524" STUDY_ID="STD-Greilich-2009" TOTAL_1="25" TOTAL_2="27" VAR="0.23248677248677252" WEIGHT="42.18837230064604"/>
<DICH_DATA CI_END="6.648688139857462" CI_START="0.14393731647383476" EFFECT_SIZE="0.9782608695652174" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8227359626227094" LOG_CI_START="-0.8418265984351703" LOG_EFFECT_SIZE="-0.009545317906230389" ORDER="67952" O_E="0.0" SE="0.9777722880829642" STUDY_ID="STD-Hardy-1998" TOTAL_1="46" TOTAL_2="45" VAR="0.9560386473429952" WEIGHT="10.259248974825889"/>
<DICH_DATA CI_END="37.56235669713492" CI_START="0.06614683080821228" EFFECT_SIZE="1.576271186440678" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5747528324879192" LOG_CI_START="-1.1794909586643374" LOG_EFFECT_SIZE="0.19763093691179093" ORDER="67955" O_E="0.0" SE="1.6178564366494836" STUDY_ID="STD-Kluger-2003" TOTAL_1="58" TOTAL_2="30" VAR="2.6174594496081647" WEIGHT="3.747236089604311"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67954" O_E="0.0" SE="0.0" STUDY_ID="STD-Rao-1999" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="12.545868678250816" CI_START="0.5178996471111383" EFFECT_SIZE="2.549019607843137" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0985007373213926" LOG_CI_START="-0.2857543849035919" LOG_EFFECT_SIZE="0.40637317620890034" ORDER="67953" O_E="0.0" SE="0.8131183109683213" STUDY_ID="STD-Vander_x002d_Salm-1996" TOTAL_1="51" TOTAL_2="52" VAR="0.6611613876319757" WEIGHT="14.834862858184847"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.814695397724975" CI_END="1.4256795811401193" CI_START="0.5468862401756536" CI_STUDY="95" CI_TOTAL="95" DF="32" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8829974778134536" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-008.04" LOG_CI_END="0.15402192959781313" LOG_CI_START="-0.26210300346932114" LOG_EFFECT_SIZE="-0.05404053693575398" METHOD="MH" MODIFIED="2010-07-08 11:07:50 +0100" MODIFIED_BY="Katharine Ker" NO="4" P_CHI2="0.9797097121876833" P_Q="0.0" P_Z="0.6107060371560564" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="45" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3389" TOTAL_2="2696" WEIGHT="300.0" Z="0.5090658967180729">
<NAME>Stroke (CVA)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.973618047530708" CI_END="1.5223967655169917" CI_START="0.4417479460725181" DF="19" EFFECT_SIZE="0.8200705117699185" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="19" I2="0.0" ID="CMP-008.04.01" LOG_CI_END="0.1825278525782188" LOG_CI_START="-0.3548254610887599" LOG_EFFECT_SIZE="-0.08614880425527054" MODIFIED="2010-07-08 11:07:50 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="0.8867499511005286" P_Z="0.529712342631313" STUDIES="23" TAU2="0.0" TOTAL_1="1862" TOTAL_2="1260" WEIGHT="100.0" Z="0.6284451937190958">
<NAME>Aprotinin versus Control</NAME>
<DICH_DATA CI_END="8.837849728013516" CI_START="0.018780676377005198" EFFECT_SIZE="0.4074074074074074" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9463466128803426" LOG_CI_START="-1.726288770881867" LOG_EFFECT_SIZE="-0.3899710790007623" MODIFIED="2010-01-11 11:39:28 +0000" MODIFIED_BY="Katharine Ker" ORDER="2264" O_E="0.0" SE="1.5699192541804385" STUDY_ID="STD-Asimakopoulos-2000" TOTAL_1="8" TOTAL_2="10" VAR="2.4646464646464645" WEIGHT="4.042410702145303"/>
<DICH_DATA CI_END="8.695084862642968" CI_START="0.01520760372642119" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9392738250043677" LOG_CI_START="-1.817939212664893" LOG_EFFECT_SIZE="-0.43933269383026263" ORDER="67956" O_E="0.0" SE="1.6196005867515793" STUDY_ID="STD-Bidstrup-1993" TOTAL_1="43" TOTAL_2="47" VAR="2.62310606060606" WEIGHT="3.7982121254332775"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67957" O_E="0.0" SE="0.0" STUDY_ID="STD-Casas-1995" TOTAL_1="47" TOTAL_2="51" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="22.596047095942403" CI_START="0.1964968032486296" EFFECT_SIZE="2.107142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3540324712460294" LOG_CI_START="-0.7066445106461795" LOG_EFFECT_SIZE="0.32369398029992497" ORDER="67964" O_E="0.0" SE="1.2104518596790557" STUDY_ID="STD-Cohen-1998" TOTAL_1="56" TOTAL_2="59" VAR="1.4651937046004844" WEIGHT="6.799860806396316"/>
<DICH_DATA CI_END="8.219477863126539" CI_START="0.013826998935288172" EFFECT_SIZE="0.3371212121212121" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9148442301476883" LOG_CI_START="-1.8592720705975248" LOG_EFFECT_SIZE="-0.47221392022491826" MODIFIED="2010-05-20 12:10:27 +0100" MODIFIED_BY="Katharine Ker" ORDER="5345" O_E="0.0" SE="1.6295296471548955" STUDY_ID="STD-Colwell-2007" TOTAL_1="175" TOTAL_2="177" VAR="2.655366870956758" WEIGHT="3.7520665617484465"/>
<DICH_DATA CI_END="10.919150695915887" CI_START="0.09288585941241723" EFFECT_SIZE="1.0070921985815602" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0381888597586881" LOG_CI_START="-1.0320503963033352" LOG_EFFECT_SIZE="0.003069231727676536" ORDER="67958" O_E="0.0" SE="1.2160687868604252" STUDY_ID="STD-D_x0027_Ambra-1996" TOTAL_1="141" TOTAL_2="71" VAR="1.4788232943761863" WEIGHT="6.737189820839417"/>
<DICH_DATA CI_END="7.726736792150155" CI_START="0.01365209655845594" EFFECT_SIZE="0.3247863247863248" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.887996118448767" LOG_CI_START="-1.8648006487074702" LOG_EFFECT_SIZE="-0.4884022651293515" MODIFIED="2010-05-17 10:54:45 +0100" MODIFIED_BY="Katharine Ker" ORDER="2560" O_E="0.0" SE="1.6170064475913375" STUDY_ID="STD-Desai-2009" TOTAL_1="38" TOTAL_2="37" VAR="2.614709851551957" WEIGHT="3.8104087303521896"/>
<DICH_DATA CI_END="15.454677816307568" CI_START="0.062168113075117784" EFFECT_SIZE="0.9801980198019802" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1890599557559556" LOG_CI_START="-1.2064323141261408" LOG_EFFECT_SIZE="-0.008686179185092667" ORDER="67966" O_E="0.0" SE="1.4071240172067208" STUDY_ID="STD-Dignan-2001" TOTAL_1="101" TOTAL_2="99" VAR="1.97999799979998" WEIGHT="5.031880459827702"/>
<DICH_DATA CI_END="7.8107039169243295" CI_START="0.014225492643544472" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8926901751653995" LOG_CI_START="-1.8469326846047245" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67959" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Ehrlich-1998" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="3.8471427384353136"/>
<DICH_DATA CI_END="21.54520124544955" CI_START="0.20021207591953577" EFFECT_SIZE="2.076923076923077" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3333505550212796" LOG_CI_START="-0.6985097313169786" LOG_EFFECT_SIZE="0.3174204118521506" MODIFIED="2010-05-17 14:23:05 +0100" MODIFIED_BY="Katharine Ker" ORDER="2615" O_E="0.0" SE="1.1935247900657215" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="27" VAR="1.4245014245014245" WEIGHT="6.994105498475402"/>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="67969" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="3.874544039991121"/>
<DICH_DATA CI_END="16.915109010524368" CI_START="0.0680545524651884" EFFECT_SIZE="1.0729166666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.228274800972161" LOG_CI_START="-1.167142817640953" LOG_EFFECT_SIZE="0.030565991665603823" MODIFIED="2010-05-21 10:37:08 +0100" MODIFIED_BY="Katharine Ker" ORDER="2741" O_E="0.0" SE="1.4070801666817907" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="103" VAR="1.9798745954692556" WEIGHT="5.032194093752726"/>
<DICH_DATA CI_END="9.697573281342368" CI_START="0.10627912144074331" EFFECT_SIZE="1.015209125475285" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="0.9866630701037382" LOG_CI_START="-0.9735520443541036" LOG_EFFECT_SIZE="0.0065555128748173135" ORDER="67971" O_E="0.0" SE="1.1514400614538443" STUDY_ID="STD-Lemmer-1996" TOTAL_1="526" TOTAL_2="178" VAR="1.3258142151208328" WEIGHT="7.514712945496237"/>
<DICH_DATA CI_END="0.5638160191543875" CI_START="0.00795629089874221" EFFECT_SIZE="0.06697674418604652" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="-0.24886258910378742" LOG_CI_START="-2.099289346536924" LOG_EFFECT_SIZE="-1.1740759678203556" ORDER="67960" O_E="0.0" SE="1.0869498370764004" STUDY_ID="STD-Levy-1995" TOTAL_1="215" TOTAL_2="72" VAR="1.1814599483204133" WEIGHT="8.432882773432322"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67965" O_E="0.0" SE="0.0" STUDY_ID="STD-Moran-2000" TOTAL_1="28" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.523159152702815" CI_START="0.011828700177457682" EFFECT_SIZE="0.2777777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8144579746128475" LOG_CI_START="-1.927062976147422" LOG_EFFECT_SIZE="-0.5563025007672873" ORDER="67961" O_E="0.0" SE="1.610382977224155" STUDY_ID="STD-Murkin-1995" TOTAL_1="29" TOTAL_2="24" VAR="2.5933333333333333" WEIGHT="3.841817446924726"/>
<DICH_DATA CI_END="73.06338428845214" CI_START="0.13283837583347674" EFFECT_SIZE="3.1153846153846154" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8636997848175818" LOG_CI_START="-0.8766764430019184" LOG_EFFECT_SIZE="0.49351167090783177" MODIFIED="2010-05-07 15:04:27 +0100" MODIFIED_BY="Katharine Ker" ORDER="2473" O_E="0.0" SE="1.6097105613022769" STUDY_ID="STD-Nur_x00f6_zler-2008" TOTAL_1="25" TOTAL_2="26" VAR="2.591168091168091" WEIGHT="3.84502776166872"/>
<DICH_DATA CI_END="11.19212994966899" CI_START="0.10362311006259958" EFFECT_SIZE="1.0769230769230769" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.048912744022775" LOG_CI_START="-0.9845433772799727" LOG_EFFECT_SIZE="0.032184683371401235" ORDER="67962" O_E="0.0" SE="1.194462191423373" STUDY_ID="STD-Okita-1996" TOTAL_1="39" TOTAL_2="21" VAR="1.4267399267399268" WEIGHT="6.983132005324178"/>
<DICH_DATA CI_END="8.394184190041877" CI_START="0.015060397797369413" EFFECT_SIZE="0.35555555555555557" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9239784945205962" LOG_CI_START="-1.8221635567594336" LOG_EFFECT_SIZE="-0.4490925311194189" ORDER="67970" O_E="0.0" SE="1.6130974345442786" STUDY_ID="STD-Poston-2006" TOTAL_1="29" TOTAL_2="31" VAR="2.6020833333333333" WEIGHT="3.8288986052297025"/>
<DICH_DATA CI_END="67.97404633427536" CI_START="0.1170660270700485" EFFECT_SIZE="2.8208955223880596" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8323431232155192" LOG_CI_START="-0.9315691202706834" LOG_EFFECT_SIZE="0.4503870014724177" ORDER="67963" O_E="0.0" SE="1.6235357334100542" STUDY_ID="STD-Ranaboldo-1997" TOTAL_1="66" TOTAL_2="62" VAR="2.6358682776593225" WEIGHT="3.7798221292525285"/>
<DICH_DATA CI_END="51.262245865436334" CI_START="0.12623758099522608" EFFECT_SIZE="2.543859649122807" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7097976292692112" LOG_CI_START="-0.898811336144244" LOG_EFFECT_SIZE="0.4054931465624835" ORDER="67967" O_E="0.0" SE="1.5323098191064977" STUDY_ID="STD-Santamaria-2000" TOTAL_1="56" TOTAL_2="28" VAR="2.3479733817301875" WEIGHT="4.243282024922182"/>
<DICH_DATA CI_END="73.24882267849273" CI_START="0.1294207408509027" EFFECT_SIZE="3.0789473684210527" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8648006487074702" LOG_CI_START="-0.8879961184487669" LOG_EFFECT_SIZE="0.4884022651293515" ORDER="67968" O_E="0.0" SE="1.6170064475913375" STUDY_ID="STD-Van-der-Linden-2005" TOTAL_1="37" TOTAL_2="38" VAR="2.614709851551957" WEIGHT="3.8104087303521896"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-26 12:26:05 +0100" MODIFIED_BY="Katharine Ker" ORDER="2775" O_E="0.0" SE="0.0" STUDY_ID="STD-Wei-2006" TOTAL_1="36" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.181375734143112" CI_END="3.068715442300026" CI_START="0.49109912551400864" DF="7" EFFECT_SIZE="1.2276169883823198" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" ID="CMP-008.04.02" LOG_CI_END="0.48695661877770385" LOG_CI_START="-0.30883083920331506" LOG_EFFECT_SIZE="0.08906288978719436" MODIFIED="2010-05-25 13:45:25 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.8677318710263906" P_Z="0.6608715021477894" STUDIES="18" TAU2="0.0" TOTAL_1="1050" TOTAL_2="977" WEIGHT="100.00000000000001" Z="0.4387102475448282">
<NAME>Tranexamic Acid versus Control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67981" O_E="0.0" SE="0.0" STUDY_ID="STD-Andreasen-2004" TOTAL_1="21" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67972" O_E="0.0" SE="0.0" STUDY_ID="STD-Brown-1997" TOTAL_1="60" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.214673425796684" CI_START="0.04794164074844354" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.717227115482503" LOG_CI_START="-1.3192871068104655" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="67980" O_E="0.0" SE="1.1962585350828727" STUDY_ID="STD-Casati-2002" TOTAL_1="29" TOTAL_2="29" VAR="1.4310344827586206" WEIGHT="15.269305543037216"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67982" O_E="0.0" SE="0.0" STUDY_ID="STD-Casati-2004" TOTAL_1="52" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="74.95401160728107" CI_START="0.1312374968139608" EFFECT_SIZE="3.1363636363636362" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8747948816443694" LOG_CI_START="-0.8819420618142713" LOG_EFFECT_SIZE="0.49642640991504905" ORDER="67973" O_E="0.0" SE="1.6193209266555566" STUDY_ID="STD-Hardy-1998" TOTAL_1="43" TOTAL_2="45" VAR="2.622200263504611" WEIGHT="8.333041173087038"/>
<DICH_DATA CI_END="4.318534659420912" CI_START="0.011315010711186518" EFFECT_SIZE="0.22105263157894736" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6353364094807923" LOG_CI_START="-1.9463450305906491" LOG_EFFECT_SIZE="-0.6555043105549285" ORDER="67985" O_E="0.0" SE="1.5164924574271987" STUDY_ID="STD-Horrow-1990" TOTAL_1="18" TOTAL_2="20" VAR="2.299749373433584" WEIGHT="9.501427856566671"/>
<DICH_DATA CI_END="84.69311383087638" CI_START="0.149022636727436" EFFECT_SIZE="3.5526315789473686" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9278481004507968" LOG_CI_START="-0.8267477566944047" LOG_EFFECT_SIZE="0.550550171878196" ORDER="67974" O_E="0.0" SE="1.6180632419564942" STUDY_ID="STD-Horrow-1991" TOTAL_1="37" TOTAL_2="44" VAR="2.6181286549707603" WEIGHT="8.346000384044395"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67979" O_E="0.0" SE="0.0" STUDY_ID="STD-Jares-2003" TOTAL_1="22" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="67.12876258952687" CI_START="0.18611657117057434" EFFECT_SIZE="3.5346534653465347" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8269086417403597" LOG_CI_START="-0.7302149570812586" LOG_EFFECT_SIZE="0.5483468423295506" ORDER="67975" O_E="0.0" SE="1.502067059913778" STUDY_ID="STD-Karski-1995" TOTAL_1="100" TOTAL_2="50" VAR="2.256205452478021" WEIGHT="9.68480185874228"/>
<DICH_DATA CI_END="17.78565956134383" CI_START="0.07083750295800453" EFFECT_SIZE="1.1224489795918366" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2500699751468096" LOG_CI_START="-1.1497367562153493" LOG_EFFECT_SIZE="0.05016660946573015" ORDER="67984" O_E="0.0" SE="1.4096583532370384" STUDY_ID="STD-Karski-2005" TOTAL_1="147" TOTAL_2="165" VAR="1.9871366728509585" WEIGHT="10.99617507864417"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67976" O_E="0.0" SE="0.0" STUDY_ID="STD-Katoh-1997" TOTAL_1="62" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.963308734323707" CI_START="0.26077095316147614" EFFECT_SIZE="1.5288461538461537" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9524683556224045" LOG_CI_START="-0.5837407855790622" LOG_EFFECT_SIZE="0.1843637850216711" ORDER="67977" O_E="0.0" SE="0.902376853899632" STUDY_ID="STD-Katsaros-1996" TOTAL_1="104" TOTAL_2="106" VAR="0.8142839864537977" WEIGHT="26.834498925889676"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67983" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="16.406136195597867" CI_START="0.06597778748048523" EFFECT_SIZE="1.0404040404040404" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2150063125271002" LOG_CI_START="-1.1806022523118556" LOG_EFFECT_SIZE="0.017202030107622307" MODIFIED="2010-05-21 10:38:27 +0100" MODIFIED_BY="Katharine Ker" ORDER="2743" O_E="0.0" SE="1.4071923294400492" STUDY_ID="STD-Later-2009" TOTAL_1="99" TOTAL_2="103" VAR="1.9801902520349122" WEIGHT="11.034749179988566"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-07 11:58:07 +0100" MODIFIED_BY="Katharine Ker" ORDER="2426" O_E="0.0" SE="0.0" STUDY_ID="STD-Maddali-2007" TOTAL_1="111" TOTAL_2="111" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-11 15:06:10 +0000" MODIFIED_BY="Katharine Ker" ORDER="2308" O_E="0.0" SE="0.0" STUDY_ID="STD-Murphy-2006" TOTAL_1="50" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-14 12:20:23 +0100" MODIFIED_BY="Katharine Ker" ORDER="2507" O_E="0.0" SE="0.0" STUDY_ID="STD-Taghaddomi-2009" TOTAL_1="50" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67978" O_E="0.0" SE="0.0" STUDY_ID="STD-Zabeeda-2002" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8365602953677065" CI_END="2.362869419942092" CI_START="0.1603936406793357" DF="4" EFFECT_SIZE="0.6156210106180444" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-008.04.03" LOG_CI_END="0.3734397217315799" LOG_CI_START="-0.7948128547091059" LOG_EFFECT_SIZE="-0.21068656648876297" MODIFIED="2010-05-20 11:23:47 +0100" MODIFIED_BY="Katharine Ker" NO="3" P_CHI2="0.765787124889048" P_Z="0.4796081915763877" STUDIES="8" TAU2="0.0" TOTAL_1="477" TOTAL_2="459" WEIGHT="100.00000000000001" Z="0.7069328853568243">
<NAME>Epsilon Aminocaproic Acid versus Control</NAME>
<DICH_DATA CI_END="8.0762111281345" CI_START="0.013757826454541471" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9072076637368413" LOG_CI_START="-1.8614501731761663" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2010-05-20 11:23:47 +0100" MODIFIED_BY="Katharine Ker" ORDER="5318" O_E="0.0" SE="1.626323318480026" STUDY_ID="STD-Berenholtz-2009" TOTAL_1="91" TOTAL_2="91" VAR="2.6449275362318843" WEIGHT="17.80471067987085"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67986" O_E="0.0" SE="0.0" STUDY_ID="STD-Daily-1994" TOTAL_1="21" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.602016847079263" CI_START="0.014471785963776497" EFFECT_SIZE="0.35282651072124754" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9346002887861264" LOG_CI_START="-1.83947786927139" LOG_EFFECT_SIZE="-0.4524387902426318" ORDER="67987" O_E="0.0" SE="1.6295072419513328" STUDY_ID="STD-Del-Rossi-1989" TOTAL_1="170" TOTAL_2="180" VAR="2.655293851571839" WEIGHT="17.735200766557515"/>
<DICH_DATA CI_END="16.360363082235548" CI_START="0.07129426126651824" EFFECT_SIZE="1.08" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2137929376520298" LOG_CI_START="-1.1469454266781303" LOG_EFFECT_SIZE="0.03342375548694973" MODIFIED="2010-05-17 14:23:34 +0100" MODIFIED_BY="Katharine Ker" ORDER="2616" O_E="0.0" SE="1.3867094010509062" STUDY_ID="STD-Greilich-2009" TOTAL_1="25" TOTAL_2="27" VAR="1.922962962962963" WEIGHT="24.489379389435154"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67988" O_E="0.0" SE="0.0" STUDY_ID="STD-Hardy-1998" TOTAL_1="46" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="53.03554378730976" CI_START="0.1301344697753444" EFFECT_SIZE="2.6271186440677967" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7245670261454982" LOG_CI_START="-0.8856076530892038" LOG_EFFECT_SIZE="0.4194796865281473" ORDER="67991" O_E="0.0" SE="1.5332295271555065" STUDY_ID="STD-Kluger-2003" TOTAL_1="58" TOTAL_2="30" VAR="2.350792782941498" WEIGHT="20.032463045469658"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67990" O_E="0.0" SE="0.0" STUDY_ID="STD-Rao-1999" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.144477450772242" CI_START="0.010026174573618974" EFFECT_SIZE="0.20384615384615384" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6174697810739354" LOG_CI_START="-1.998864737813993" LOG_EFFECT_SIZE="-0.6906974783700289" ORDER="67989" O_E="0.0" SE="1.5368478474595098" STUDY_ID="STD-Vander_x002d_Salm-1996" TOTAL_1="51" TOTAL_2="52" VAR="2.3619013062409286" WEIGHT="19.93824611866684"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.974869367953472" CI_END="1.120857703279661" CI_START="0.509817457914037" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7559317594660266" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="49" I2="0.0" I2_Q="0.0" ID="CMP-008.05" LOG_CI_END="0.04955048092410147" LOG_CI_START="-0.29258529686613244" LOG_EFFECT_SIZE="-0.12151740797101546" METHOD="MH" MODIFIED="2010-07-08 10:59:03 +0100" MODIFIED_BY="Katharine Ker" NO="5" P_CHI2="0.976807822835141" P_Q="0.0" P_Z="0.16384586644877153" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="40" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1750" TOTAL_2="1482" WEIGHT="300.0" Z="1.3922527755274665">
<NAME>Deep Vein Thrombosis (DVT)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.219589750386326" CI_END="1.2926801103662844" CI_START="0.46810610653453605" DF="11" EFFECT_SIZE="0.7778891010023188" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="26" I2="0.0" ID="CMP-008.05.01" LOG_CI_END="0.11149106665082219" LOG_CI_START="-0.3296556933802393" LOG_EFFECT_SIZE="-0.10908231336470854" MODIFIED="2010-05-20 12:11:22 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="0.8583180739297406" P_Z="0.3324054276513565" STUDIES="16" TAU2="0.0" TOTAL_1="854" TOTAL_2="602" WEIGHT="99.99999999999997" Z="0.9692801802741895">
<NAME>Aprotinin versus Control</NAME>
<DICH_DATA CI_END="2.7310367005533096" CI_START="0.00810837670981528" EFFECT_SIZE="0.1488095238095238" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4363275363684733" LOG_CI_START="-2.0910660824761242" LOG_EFFECT_SIZE="-0.8273692730538252" ORDER="68001" O_E="0.0" SE="1.4846035225095011" STUDY_ID="STD-Amar-2003" TOTAL_1="23" TOTAL_2="24" VAR="2.204047619047619" WEIGHT="3.046634940886594"/>
<DICH_DATA CI_END="6.8502878048371185" CI_START="0.013820522423330348" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8357088181240913" LOG_CI_START="-1.8594755400818397" LOG_EFFECT_SIZE="-0.5118833609788743" ORDER="67992" O_E="0.0" SE="1.583164633387904" STUDY_ID="STD-Capdevila-1998" TOTAL_1="12" TOTAL_2="11" VAR="2.506410256410256" WEIGHT="2.6791019029684597"/>
<DICH_DATA CI_END="3.9862521275529974" CI_START="0.11405731748555868" EFFECT_SIZE="0.6742857142857143" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6005647640438736" LOG_CI_START="-0.9428768468042117" LOG_EFFECT_SIZE="-0.17115604138016904" MODIFIED="2010-05-20 12:11:22 +0100" MODIFIED_BY="Katharine Ker" ORDER="5347" O_E="0.0" SE="0.9066252423713579" STUDY_ID="STD-Colwell-2007" TOTAL_1="175" TOTAL_2="177" VAR="0.8219693301049233" WEIGHT="8.169317566521892"/>
<DICH_DATA CI_END="36.87276924711144" CI_START="0.06275163674839268" EFFECT_SIZE="1.5211267605633803" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5667057555496076" LOG_CI_START="-1.2023749420138592" LOG_EFFECT_SIZE="0.1821654067678744" ORDER="67993" O_E="0.0" SE="1.6265717089192997" STUDY_ID="STD-D_x0027_Ambra-1996" TOTAL_1="141" TOTAL_2="71" VAR="2.6457355242566507" WEIGHT="2.5380195510868444"/>
<DICH_DATA CI_END="67.05568402675195" CI_START="0.13421680996363317" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8264355970545303" LOG_CI_START="-0.8721930876152056" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="67999" O_E="0.0" SE="1.585187847802434" STUDY_ID="STD-Engel-2001" TOTAL_1="12" TOTAL_2="12" VAR="2.5128205128205123" WEIGHT="2.672267459338438"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="67994" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Hayes-1996" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="2.6113610784988146"/>
<DICH_DATA CI_END="2.0452762263354756" CI_START="0.03055821956723241" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.31075197027588036" LOG_CI_START="-1.514871952931805" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="67997" O_E="0.0" SE="1.0723805294763609" STUDY_ID="STD-Janssens-1994" TOTAL_1="20" TOTAL_2="20" VAR="1.15" WEIGHT="5.839068250059463"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68000" O_E="0.0" SE="0.0" STUDY_ID="STD-Jeserschek-2003" TOTAL_1="9" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68003" O_E="0.0" SE="0.0" STUDY_ID="STD-Llau-1998" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.523159152702815" CI_START="0.011828700177457682" EFFECT_SIZE="0.2777777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8144579746128475" LOG_CI_START="-1.927062976147422" LOG_EFFECT_SIZE="-0.5563025007672873" ORDER="67995" O_E="0.0" SE="1.610382977224155" STUDY_ID="STD-Murkin-1995" TOTAL_1="29" TOTAL_2="24" VAR="2.5933333333333333" WEIGHT="2.5893040440495048"/>
<DICH_DATA CI_END="1.6431945131121413" CI_START="0.42172927190183856" EFFECT_SIZE="0.8324561403508772" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="10" LOG_CI_END="0.21568897607726678" LOG_CI_START="-0.37496625389562654" LOG_EFFECT_SIZE="-0.07963863890917991" ORDER="67998" O_E="0.0" SE="0.3469538058766202" STUDY_ID="STD-Murkin-2000" TOTAL_1="228" TOTAL_2="73" VAR="0.12037694341227145" WEIGHT="55.78251363777235"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68005" O_E="0.0" SE="0.0" STUDY_ID="STD-Petsatodis-2006" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="29.110699242386186" CI_START="0.3532785457274772" EFFECT_SIZE="3.206896551724138" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4640526373681348" LOG_CI_START="-0.4518827360581769" LOG_EFFECT_SIZE="0.506084950654979" ORDER="68006" O_E="0.0" SE="1.1254299223836706" STUDY_ID="STD-Poston-2006" TOTAL_1="29" TOTAL_2="31" VAR="1.2665925101965145" WEIGHT="5.301569710471875"/>
<DICH_DATA CI_END="14.695274109176447" CI_START="0.06005066437100432" EFFECT_SIZE="0.9393939393939394" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1671776913268013" LOG_CI_START="-1.2214821834140308" LOG_EFFECT_SIZE="-0.027152246043614773" ORDER="67996" O_E="0.0" SE="1.4031106344798405" STUDY_ID="STD-Ranaboldo-1997" TOTAL_1="66" TOTAL_2="62" VAR="1.9687194525904204" WEIGHT="3.410810249643721"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68004" O_E="0.0" SE="0.0" STUDY_ID="STD-Ray-2005" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="12.107733462384598" CI_START="0.15052363067472602" EFFECT_SIZE="1.35" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.0830628519038206" LOG_CI_START="-0.8223953149138081" LOG_EFFECT_SIZE="0.13033376849500614" ORDER="68002" O_E="0.0" SE="1.119275559358721" STUDY_ID="STD-Samama-2002" TOTAL_1="40" TOTAL_2="18" VAR="1.2527777777777778" WEIGHT="5.360031608702034"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.70522034672778" CI_END="1.434136922545179" CI_START="0.3525291968172249" DF="11" EFFECT_SIZE="0.7110380703104291" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" I2="0.0" ID="CMP-008.05.02" LOG_CI_END="0.15659061706892735" LOG_CI_START="-0.45280490848390265" LOG_EFFECT_SIZE="-0.1481071457074876" MODIFIED="2010-07-08 10:59:03 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.8922911120135654" P_Z="0.3407435807366007" STUDIES="23" TAU2="0.0" TOTAL_1="746" TOTAL_2="726" WEIGHT="100.00000000000001" Z="0.9526970884020263">
<NAME>Tranexamic Acid versus Control</NAME>
<DICH_DATA CI_END="5.6052899693918485" CI_START="0.31716071558928804" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7485980841655011" LOG_CI_START="-0.4987206109489013" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="68007" O_E="0.0" SE="0.7326811758373191" STUDY_ID="STD-Benoni-1996" TOTAL_1="43" TOTAL_2="43" VAR="0.5368217054263564" WEIGHT="23.869518521943686"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-14 15:57:59 +0100" MODIFIED_BY="Katharine Ker" ORDER="2541" O_E="0.0" SE="0.0" STUDY_ID="STD-Claeys-2007" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="14.903914722906746" CI_START="0.06709646549862758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528004" LOG_EFFECT_SIZE="0.0" ORDER="68013" O_E="0.0" SE="1.378404875209022" STUDY_ID="STD-Ekback-2000" TOTAL_1="20" TOTAL_2="20" VAR="1.9" WEIGHT="6.74403981087148"/>
<DICH_DATA CI_END="94.3366757334742" CI_START="0.2650082781232565" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.974680568368818" LOG_CI_START="-0.5767405596967805" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="68014" O_E="0.0" SE="1.4987174003640065" STUDY_ID="STD-Engel-2001" TOTAL_1="12" TOTAL_2="12" VAR="2.2461538461538457" WEIGHT="5.704718607141287"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68020" O_E="0.0" SE="0.0" STUDY_ID="STD-Garneti-2004" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-20 14:53:36 +0100" MODIFIED_BY="Katharine Ker" ORDER="5367" O_E="0.0" SE="0.0" STUDY_ID="STD-Gill-2009" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.832655227495675" CI_START="0.1354654828671183" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7658663057251534" LOG_CI_START="-0.868171350619916" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="68024" O_E="0.0" SE="0.9598418079539442" STUDY_ID="STD-Good-2003" TOTAL_1="27" TOTAL_2="24" VAR="0.9212962962962964" WEIGHT="13.90831124814902"/>
<DICH_DATA CI_END="3.3449702371300205" CI_START="0.009155537367733415" EFFECT_SIZE="0.175" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.524392257856397" LOG_CI_START="-2.038316160483808" LOG_EFFECT_SIZE="-0.7569619513137056" ORDER="68008" O_E="0.0" SE="1.5053476105442982" STUDY_ID="STD-Hiipala-1995" TOTAL_1="15" TOTAL_2="13" VAR="2.2660714285714283" WEIGHT="5.654577114867815"/>
<DICH_DATA CI_END="6.569203725945863" CI_START="0.14451910011013963" EFFECT_SIZE="0.9743589743589743" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8175127305360728" LOG_CI_START="-0.8400747513554507" LOG_EFFECT_SIZE="-0.011281010409689058" ORDER="68009" O_E="0.0" SE="0.9736750920534478" STUDY_ID="STD-Hiipala-1997" TOTAL_1="39" TOTAL_2="38" VAR="0.9480431848852902" WEIGHT="13.515919786086773"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68022" O_E="0.0" SE="0.0" STUDY_ID="STD-Horrow-1990" TOTAL_1="18" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="9.410345981208485" CI_START="0.01655807074749288" EFFECT_SIZE="0.39473684210526316" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9736055910114718" LOG_CI_START="-1.7809902661337298" LOG_EFFECT_SIZE="-0.40369233756112893" ORDER="68023" O_E="0.0" SE="1.6180632419564942" STUDY_ID="STD-Horrow-1991" TOTAL_1="37" TOTAL_2="44" VAR="2.6181286549707603" WEIGHT="4.894211602752164"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68015" O_E="0.0" SE="0.0" STUDY_ID="STD-Husted-2003" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.930879612644028" CI_START="0.010175839491836992" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5944897432947773" LOG_CI_START="-1.9924297519668148" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="68012" O_E="0.0" SE="1.5195693169746844" STUDY_ID="STD-Jansen-1999" TOTAL_1="21" TOTAL_2="21" VAR="2.309090909090909" WEIGHT="5.549229608158029"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68019" O_E="0.0" SE="0.0" STUDY_ID="STD-Johansson-2005" TOTAL_1="47" TOTAL_2="53" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68010" O_E="0.0" SE="0.0" STUDY_ID="STD-Katoh-1997" TOTAL_1="62" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.244282779363349" CI_START="0.013995665948529062" EFFECT_SIZE="0.3396825396825397" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9161528796878264" LOG_CI_START="-1.854006431896608" LOG_EFFECT_SIZE="-0.4689267761043908" ORDER="68011" O_E="0.0" SE="1.6272052921344415" STUDY_ID="STD-Katsaros-1996" TOTAL_1="104" TOTAL_2="106" VAR="2.6477970627503336" WEIGHT="4.839372254362245"/>
<DICH_DATA CI_END="7.888578229356675" CI_START="0.014085061703212953" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8969987366967316" LOG_CI_START="-1.8512412461360563" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2010-05-20 16:14:03 +0100" MODIFIED_BY="Katharine Ker" ORDER="5381" O_E="0.0" SE="1.6143297699232972" STUDY_ID="STD-Kazemi-2010" TOTAL_1="32" TOTAL_2="32" VAR="2.606060606060606" WEIGHT="4.916875536530719"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68018" O_E="0.0" SE="0.0" STUDY_ID="STD-Lemay-2004" TOTAL_1="20" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68016" O_E="0.0" SE="0.0" STUDY_ID="STD-Niskanen-2005" TOTAL_1="19" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68017" O_E="0.0" SE="0.0" STUDY_ID="STD-Orpen-2006" TOTAL_1="15" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.930879612644028" CI_START="0.010175839491836992" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5944897432947773" LOG_CI_START="-1.9924297519668148" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="68021" O_E="0.0" SE="1.5195693169746844" STUDY_ID="STD-Sorin-1999" TOTAL_1="21" TOTAL_2="21" VAR="2.309090909090909" WEIGHT="5.549229608158029"/>
<DICH_DATA CI_END="8.16018298092523" CI_START="0.013986745755792392" EFFECT_SIZE="0.33783783783783783" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9116998973218928" LOG_CI_START="-1.8542833194397697" LOG_EFFECT_SIZE="-0.47129171105893863" MODIFIED="2010-05-14 15:20:51 +0100" MODIFIED_BY="Katharine Ker" ORDER="2525" O_E="0.0" SE="1.6247522333635427" STUDY_ID="STD-Wong-2008" TOTAL_1="73" TOTAL_2="74" VAR="2.6398198198198197" WEIGHT="4.853996300978757"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-21 16:30:40 +0100" MODIFIED_BY="Katharine Ker" ORDER="2804" O_E="0.0" SE="0.0" STUDY_ID="STD-Zhang-2007" TOTAL_1="51" TOTAL_2="51" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.01874641903972" CI_END="3.034104018879774" CI_START="0.19796328157972656" DF="1" EFFECT_SIZE="0.7750104439500649" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="1.8401457604523916" ID="CMP-008.05.03" LOG_CI_END="0.48203046572266994" LOG_CI_START="-0.7034153556279314" LOG_EFFECT_SIZE="-0.11069244495263073" MODIFIED="2010-05-20 11:24:28 +0100" MODIFIED_BY="Katharine Ker" NO="3" P_CHI2="0.31281683579228603" P_Z="0.714344152875156" STUDIES="4" TAU2="0.02772413839505621" TOTAL_1="150" TOTAL_2="154" WEIGHT="100.00000000000001" Z="0.3660280403547415">
<NAME>Epsilon Aminocaproic Acid versus Control</NAME>
<DICH_DATA CI_END="4.850542055936086" CI_START="0.24535044349768653" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.685790274426512" LOG_CI_START="-0.6102131526477125" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="68026" O_E="0.0" SE="0.7612788283838284" STUDY_ID="STD-Amar-2003" TOTAL_1="22" TOTAL_2="24" VAR="0.5795454545454546" WEIGHT="79.8467214566279"/>
<DICH_DATA CI_END="4.108846404950255" CI_START="0.009735092543690317" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6137199069641557" LOG_CI_START="-2.0116599156361934" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2010-05-20 11:24:28 +0100" MODIFIED_BY="Katharine Ker" ORDER="5319" O_E="0.0" SE="1.542161103635161" STUDY_ID="STD-Berenholtz-2009" TOTAL_1="91" TOTAL_2="91" VAR="2.3782608695652177" WEIGHT="20.153278543372114"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68025" O_E="0.0" SE="0.0" STUDY_ID="STD-Harley-2002" TOTAL_1="22" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68027" O_E="0.0" SE="0.0" STUDY_ID="STD-Ray-2005" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.935053061497478" CI_END="1.6857466763671256" CI_START="0.37537461179073206" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7954787892953694" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-008.06" LOG_CI_END="0.2267923120907271" LOG_CI_START="-0.42553510393643257" LOG_EFFECT_SIZE="-0.09937139592285267" METHOD="MH" MODIFIED="2010-07-08 10:59:03 +0100" MODIFIED_BY="Katharine Ker" NO="6" P_CHI2="0.9601130860397522" P_Q="0.0" P_Z="0.5504160447197417" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="966" TOTAL_2="899" WEIGHT="300.0" Z="0.5971368129471739">
<NAME>Pulmonary Embolism (PE)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.26867832244565903" CI_END="5.290298378116912" CI_START="0.4211028122015434" DF="2" EFFECT_SIZE="1.49256809707641" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-008.06.01" LOG_CI_END="0.7234801673688898" LOG_CI_START="-0.37561185827212584" LOG_EFFECT_SIZE="0.17393415454838193" MODIFIED="2010-05-20 12:13:22 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="0.8742934951407758" P_Z="0.5350348013703715" STUDIES="4" TAU2="0.0" TOTAL_1="304" TOTAL_2="281" WEIGHT="100.0" Z="0.6203387353255136">
<NAME>Aprotinin versus Control</NAME>
<DICH_DATA CI_END="21.478200608048958" CI_START="0.20278176943730142" EFFECT_SIZE="2.0869565217391304" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.331997894405131" LOG_CI_START="-0.6929710916891421" LOG_EFFECT_SIZE="0.31951340135799433" ORDER="68029" O_E="0.0" SE="1.1894768061899181" STUDY_ID="STD-Amar-2003" TOTAL_1="23" TOTAL_2="24" VAR="1.414855072463768" WEIGHT="29.459906332522372"/>
<DICH_DATA CI_END="7.10045882180821" CI_START="0.1440734719790299" EFFECT_SIZE="1.0114285714285713" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8512864131333385" LOG_CI_START="-0.8414159777823143" LOG_EFFECT_SIZE="0.00493521767551215" MODIFIED="2010-05-20 12:13:22 +0100" MODIFIED_BY="Katharine Ker" ORDER="5351" O_E="0.0" SE="0.9943017634358244" STUDY_ID="STD-Colwell-2007" TOTAL_1="175" TOTAL_2="177" VAR="0.9886359967715901" WEIGHT="42.16061123101778"/>
<DICH_DATA CI_END="20.204828378869976" CI_START="0.1747029881813664" EFFECT_SIZE="1.878787878787879" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3054551658686795" LOG_CI_START="-0.7576996666279466" LOG_EFFECT_SIZE="0.27387774962036643" ORDER="68028" O_E="0.0" SE="1.2119073613896487" STUDY_ID="STD-Ranaboldo-1997" TOTAL_1="66" TOTAL_2="62" VAR="1.4687194525904204" WEIGHT="28.379482436459853"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68030" O_E="0.0" SE="0.0" STUDY_ID="STD-Samama-2002" TOTAL_1="40" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.809660004125504" CI_END="1.994135814451903" CI_START="0.2275907399553087" DF="7" EFFECT_SIZE="0.6736815609637026" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-008.06.02" LOG_CI_END="0.2997547334432334" LOG_CI_START="-0.6428454121720638" LOG_EFFECT_SIZE="-0.17154533936441516" MODIFIED="2010-07-08 10:59:03 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.9020342526870766" P_Z="0.47560193396262496" STUDIES="14" TAU2="0.0" TOTAL_1="527" TOTAL_2="479" WEIGHT="100.0" Z="0.7133940906628659">
<NAME>Tranexamic Acid versus Control</NAME>
<DICH_DATA CI_END="7.961364031061661" CI_START="0.013956290740833538" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9009874823623856" LOG_CI_START="-1.8552299918017108" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="68031" O_E="0.0" SE="1.6190157878205267" STUDY_ID="STD-Benoni-1996" TOTAL_1="43" TOTAL_2="43" VAR="2.6212121212121207" WEIGHT="11.695749055510644"/>
<DICH_DATA CI_END="16.49457919273206" CI_START="0.07484688677468962" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.217341240366019" LOG_CI_START="-1.1258262592446688" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="68036" O_E="0.0" SE="1.3763881881375053" STUDY_ID="STD-Benoni-2001" TOTAL_1="18" TOTAL_2="20" VAR="1.8944444444444444" WEIGHT="16.1826013324714"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68039" O_E="0.0" SE="0.0" STUDY_ID="STD-Casati-2002" TOTAL_1="29" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68041" O_E="0.0" SE="0.0" STUDY_ID="STD-Casati-2004" TOTAL_1="52" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="70.29633525231894" CI_START="0.12802943379190027" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.846932684604724" LOG_CI_START="-0.8926901751653996" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="68042" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Garneti-2004" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="11.837866618291372"/>
<DICH_DATA CI_END="6.599912503353391" CI_START="0.012889480641026829" EFFECT_SIZE="0.2916666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8195381780323703" LOG_CI_START="-1.8897645814270687" LOG_EFFECT_SIZE="-0.5351132016973491" ORDER="68032" O_E="0.0" SE="1.591457852171428" STUDY_ID="STD-Hiipala-1995" TOTAL_1="15" TOTAL_2="13" VAR="2.532738095238095" WEIGHT="12.104306895608065"/>
<DICH_DATA CI_END="7.737987442424938" CI_START="0.013650190154211364" EFFECT_SIZE="0.325" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8886280205920004" LOG_CI_START="-1.8648612986342514" LOG_EFFECT_SIZE="-0.48811663902112556" ORDER="68033" O_E="0.0" SE="1.6174132561054522" STUDY_ID="STD-Hiipala-1997" TOTAL_1="39" TOTAL_2="38" VAR="2.616025641025641" WEIGHT="11.71893681399097"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68043" O_E="0.0" SE="0.0" STUDY_ID="STD-Horrow-1990" TOTAL_1="18" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68040" O_E="0.0" SE="0.0" STUDY_ID="STD-Husted-2003" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68037" O_E="0.0" SE="0.0" STUDY_ID="STD-Jares-2003" TOTAL_1="22" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68034" O_E="0.0" SE="0.0" STUDY_ID="STD-Katoh-1997" TOTAL_1="62" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.244282779363349" CI_START="0.013995665948529062" EFFECT_SIZE="0.3396825396825397" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9161528796878264" LOG_CI_START="-1.854006431896608" LOG_EFFECT_SIZE="-0.4689267761043908" ORDER="68035" O_E="0.0" SE="1.6272052921344415" STUDY_ID="STD-Katsaros-1996" TOTAL_1="104" TOTAL_2="106" VAR="2.6477970627503336" WEIGHT="11.578319057094003"/>
<DICH_DATA CI_END="50.95043024524692" CI_START="0.12872503808498176" EFFECT_SIZE="2.5609756097560976" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.707147855709426" LOG_CI_START="-0.8903369710090208" LOG_EFFECT_SIZE="0.4084054423502026" MODIFIED="2010-05-07 11:42:08 +0100" MODIFIED_BY="Katharine Ker" ORDER="2422" O_E="0.0" SE="1.5257754449716752" STUDY_ID="STD-MacGillivray-2010" TOTAL_1="40" TOTAL_2="20" VAR="2.3279907084785134" WEIGHT="13.168883827288122"/>
<DICH_DATA CI_END="7.74869607009601" CI_START="0.013648380859931773" EFFECT_SIZE="0.3252032520325203" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8892286267377596" LOG_CI_START="-1.8649188669606307" LOG_EFFECT_SIZE="-0.48784512011143555" ORDER="68038" O_E="0.0" SE="1.6177998710484025" STUDY_ID="STD-Pleym-2003" TOTAL_1="40" TOTAL_2="39" VAR="2.6172764227642276" WEIGHT="11.71333639974542"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0017852889765800058" CI_END="2.132696616913228" CI_START="0.05510802525792734" DF="1" EFFECT_SIZE="0.34282458930530396" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-008.06.03" LOG_CI_END="0.3289290800291199" LOG_CI_START="-1.2587851512128005" LOG_EFFECT_SIZE="-0.4649280355918404" MODIFIED="2010-05-20 11:26:26 +0100" MODIFIED_BY="Katharine Ker" NO="3" P_CHI2="0.9662972745299958" P_Z="0.25102358643013334" STUDIES="3" TAU2="0.0" TOTAL_1="135" TOTAL_2="139" WEIGHT="100.0" Z="1.1478667725364962">
<NAME>Epsilon Aminocaproic Acid versus Control</NAME>
<DICH_DATA CI_END="8.456051307841562" CI_START="0.01552437863252912" EFFECT_SIZE="0.36231884057971014" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9271676094276654" LOG_CI_START="-1.8089857735581008" LOG_EFFECT_SIZE="-0.44090908206521773" ORDER="68045" O_E="0.0" SE="1.6072300413435225" STUDY_ID="STD-Amar-2003" TOTAL_1="22" TOTAL_2="24" VAR="2.583188405797101" WEIGHT="33.67160331465324"/>
<DICH_DATA CI_END="3.1450480320039014" CI_START="0.035328907533509264" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.49762728249192634" LOG_CI_START="-1.451869791931251" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2010-05-20 11:26:26 +0100" MODIFIED_BY="Katharine Ker" ORDER="5322" O_E="0.0" SE="1.1451442316823288" STUDY_ID="STD-Berenholtz-2009" TOTAL_1="91" TOTAL_2="91" VAR="1.3113553113553114" WEIGHT="66.32839668534676"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68044" O_E="0.0" SE="0.0" STUDY_ID="STD-Harley-2002" TOTAL_1="22" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.281765695717983" CI_END="1.6811973485135074" CI_START="0.4084202094796476" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8286344026508403" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-008.07" LOG_CI_END="0.2256186963899896" LOG_CI_START="-0.38889277626108054" LOG_EFFECT_SIZE="-0.0816370399355454" METHOD="MH" MODIFIED="2010-07-08 10:58:33 +0100" MODIFIED_BY="Katharine Ker" NO="7" P_CHI2="0.6986036872624767" P_Q="0.0" P_Z="0.6025358761212101" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="779" TOTAL_2="705" WEIGHT="300.0" Z="0.520757268819881">
<NAME>Other Thrombosis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.272362563711317" CI_END="2.154978773033343" CI_START="0.24528972061722645" DF="6" EFFECT_SIZE="0.7270447999768667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-008.07.01" LOG_CI_END="0.3334429966313723" LOG_CI_START="-0.6103206514379564" LOG_EFFECT_SIZE="-0.1384388274032921" NO="1" P_CHI2="0.639871244854525" P_Z="0.5652869041860964" STUDIES="9" TAU2="0.0" TOTAL_1="402" TOTAL_2="334" WEIGHT="100.0" Z="0.5750064994079471">
<NAME>Aprotinin versus Control</NAME>
<DICH_DATA CI_END="16.861087354989195" CI_START="0.06983273602652673" EFFECT_SIZE="1.0851063829787233" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2268855784171016" LOG_CI_START="-1.1559409420926636" LOG_EFFECT_SIZE="0.035472318162218866" ORDER="68049" O_E="0.0" SE="1.3996840933289427" STUDY_ID="STD-Casas-1995" TOTAL_1="47" TOTAL_2="51" VAR="1.9591155611180644" WEIGHT="15.687062979548653"/>
<DICH_DATA CI_END="36.87276924711144" CI_START="0.06275163674839268" EFFECT_SIZE="1.5211267605633803" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5667057555496076" LOG_CI_START="-1.2023749420138592" LOG_EFFECT_SIZE="0.1821654067678744" ORDER="68048" O_E="0.0" SE="1.6265717089192997" STUDY_ID="STD-D_x0027_Ambra-1996" TOTAL_1="141" TOTAL_2="71" VAR="2.6457355242566507" WEIGHT="11.615964222314926"/>
<DICH_DATA CI_END="4.761334097402456" CI_START="0.04339363002496523" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6777286564939502" LOG_CI_START="-1.3625740181383628" LOG_EFFECT_SIZE="-0.3424226808222063" ORDER="68053" O_E="0.0" SE="1.1984838907401452" STUDY_ID="STD-Findlay-2001" TOTAL_1="33" TOTAL_2="30" VAR="1.4363636363636363" WEIGHT="21.396231715582385"/>
<DICH_DATA CI_END="75.08221295202115" CI_START="0.1321551351495281" EFFECT_SIZE="3.15" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8755370644113247" LOG_CI_START="-0.8789159568321236" LOG_EFFECT_SIZE="0.4983105537896005" ORDER="68047" O_E="0.0" SE="1.6179793394407553" STUDY_ID="STD-Garcia_x002d_Huete-1997" TOTAL_1="39" TOTAL_2="41" VAR="2.617857142857143" WEIGHT="11.739666266865491"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68051" O_E="0.0" SE="0.0" STUDY_ID="STD-Lentschener-1997" TOTAL_1="48" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.313002635642772" CI_START="0.008384471982887052" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5202217813829129" LOG_CI_START="-2.0765242821502" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="68046" O_E="0.0" SE="1.5253414918196733" STUDY_ID="STD-Murkin-1995" TOTAL_1="29" TOTAL_2="24" VAR="2.3266666666666667" WEIGHT="13.208926586592925"/>
<DICH_DATA CI_END="2.8282345807770137" CI_START="0.008210052591234055" EFFECT_SIZE="0.1523809523809524" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4515154280781609" LOG_CI_START="-2.0856540609061875" LOG_EFFECT_SIZE="-0.8170693164140133" ORDER="68054" O_E="0.0" SE="1.4903459170209286" STUDY_ID="STD-Poston-2006" TOTAL_1="29" TOTAL_2="31" VAR="2.2211309523809524" WEIGHT="13.836540866052374"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68050" O_E="0.0" SE="0.0" STUDY_ID="STD-Rocha-1994" TOTAL_1="28" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="71.90012410628756" CI_START="0.1545353537176922" EFFECT_SIZE="3.3333333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.856729640016114" LOG_CI_START="-0.8109721494554387" LOG_EFFECT_SIZE="0.5228787452803376" ORDER="68052" O_E="0.0" SE="1.567021236472421" STUDY_ID="STD-Thorpe-1994" TOTAL_1="8" TOTAL_2="9" VAR="2.4555555555555553" WEIGHT="12.515607363043253"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.06363089876989286" CI_END="8.987153774184945" CI_START="0.49111210663366706" DF="1" EFFECT_SIZE="2.100880773076064" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-008.07.02" LOG_CI_END="0.9536221727253164" LOG_CI_START="-0.3088193597405429" LOG_EFFECT_SIZE="0.32240140649238674" MODIFIED="2010-07-08 10:58:33 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.8008465550930386" P_Z="0.3167937676404452" STUDIES="9" TAU2="0.0" TOTAL_1="244" TOTAL_2="240" WEIGHT="100.0" Z="1.001068372736263">
<NAME>Tranexamic Acid versus Control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-20 10:48:14 +0100" MODIFIED_BY="Katharine Ker" ORDER="5303" O_E="0.0" SE="0.0" STUDY_ID="STD-Alvarez-2008" TOTAL_1="46" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68056" O_E="0.0" SE="0.0" STUDY_ID="STD-Boylan-1996" TOTAL_1="25" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="9.831331238656524" CI_START="0.3690362806174752" EFFECT_SIZE="1.9047619047619047" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9926123286620322" LOG_CI_START="-0.432930935473946" LOG_EFFECT_SIZE="0.2798406965940431" ORDER="68057" O_E="0.0" SE="0.8373711699064377" STUDY_ID="STD-Dalmau-2000" TOTAL_1="42" TOTAL_2="40" VAR="0.7011904761904761" WEIGHT="78.42630297545946"/>
<DICH_DATA CI_END="68.56773372198825" CI_START="0.13125707255384883" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8361197955452926" LOG_CI_START="-0.8818772861059678" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="68055" O_E="0.0" SE="1.5965649400644928" STUDY_ID="STD-Kaspar-1997" TOTAL_1="16" TOTAL_2="16" VAR="2.5490196078431375" WEIGHT="21.573697024540536"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-21 15:45:54 +0100" MODIFIED_BY="Katharine Ker" ORDER="2794" O_E="0.0" SE="0.0" STUDY_ID="STD-Taghaddomi-2009" TOTAL_1="50" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68058" O_E="0.0" SE="0.0" STUDY_ID="STD-Veien-2002" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68059" O_E="0.0" SE="0.0" STUDY_ID="STD-Yamasaki-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68061" O_E="0.0" SE="0.0" STUDY_ID="STD-Yassen-1993" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68060" O_E="0.0" SE="0.0" STUDY_ID="STD-Zohar-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6941669582504143" CI_END="1.7167464497309024" CI_START="0.15115334824101334" DF="1" EFFECT_SIZE="0.5094035472566896" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" I2="0.0" ID="CMP-008.07.03" LOG_CI_END="0.2347061579367118" LOG_CI_START="-0.820582228198432" LOG_EFFECT_SIZE="-0.2929380351308601" MODIFIED="2010-05-20 11:27:01 +0100" MODIFIED_BY="Katharine Ker" NO="3" P_CHI2="0.40475105757033103" P_Z="0.2765356279694926" STUDIES="2" TAU2="0.0" TOTAL_1="133" TOTAL_2="131" WEIGHT="100.00000000000001" Z="1.0881347811685056">
<NAME>Epsilon Aminocaproic Acid versus Control</NAME>
<DICH_DATA CI_END="1.6081619845155797" CI_START="0.06909198960114746" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.2063297915754598" LOG_CI_START="-1.1605723010147848" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2010-05-20 11:27:01 +0100" MODIFIED_BY="Katharine Ker" ORDER="5323" O_E="0.0" SE="0.8029250554619931" STUDY_ID="STD-Berenholtz-2009" TOTAL_1="91" TOTAL_2="91" VAR="0.6446886446886447" WEIGHT="59.60291501692777"/>
<DICH_DATA CI_END="6.441381281894834" CI_START="0.14081288449846777" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8089790069221077" LOG_CI_START="-0.851357605061984" LOG_EFFECT_SIZE="-0.021189299069938095" ORDER="68062" O_E="0.0" SE="0.9752899446782357" STUDY_ID="STD-Dalmau-2000" TOTAL_1="42" TOTAL_2="40" VAR="0.9511904761904761" WEIGHT="40.39708498307225"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.278050666110175" CI_END="5.672746270274343" CI_START="0.10079665960935036" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7561705329190334" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="39" I2="56.10282006117434" I2_Q="0.0" ID="CMP-008.08" LOG_CI_END="0.7537933589420919" LOG_CI_START="-0.9965538601252606" LOG_EFFECT_SIZE="-0.12138025059158428" METHOD="MH" NO="8" P_CHI2="0.13121682126042478" P_Q="0.0" P_Z="0.7857505604957145" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.445115718523827" TOTALS="YES" TOTAL_1="369" TOTAL_2="359" WEIGHT="100.0" Z="0.2718328306548389">
<NAME>Coronary artery graft occlusion</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.278050666110175" CI_END="5.672746270274343" CI_START="0.10079665960935036" DF="1" EFFECT_SIZE="0.7561705329190334" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="39" I2="56.10282006117434" ID="CMP-008.08.01" LOG_CI_END="0.7537933589420919" LOG_CI_START="-0.9965538601252606" LOG_EFFECT_SIZE="-0.12138025059158428" NO="1" P_CHI2="0.13121682126042478" P_Z="0.7857505604957145" STUDIES="2" TAU2="1.445115718523827" TOTAL_1="369" TOTAL_2="359" WEIGHT="100.0" Z="0.2718328306548389">
<NAME>Aprotinin versus Control</NAME>
<DICH_DATA CI_END="2.1447523003137596" CI_START="0.9763268413084313" EFFECT_SIZE="1.4470588235294117" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="36" LOG_CI_END="0.33137714229294996" LOG_CI_START="-0.010404770842739637" LOG_EFFECT_SIZE="0.16048618572510517" ORDER="68063" O_E="0.0" SE="0.20076438762365992" STUDY_ID="STD-Alderman-1998" TOTAL_1="340" TOTAL_2="328" VAR="0.040306339337903174" WEIGHT="71.16619611879834"/>
<DICH_DATA CI_END="2.8282345807770137" CI_START="0.008210052591234055" EFFECT_SIZE="0.1523809523809524" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4515154280781609" LOG_CI_START="-2.0856540609061875" LOG_EFFECT_SIZE="-0.8170693164140133" ORDER="68064" O_E="0.0" SE="1.4903459170209286" STUDY_ID="STD-Poston-2006" TOTAL_1="29" TOTAL_2="31" VAR="2.2211309523809524" WEIGHT="28.83380388120166"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.519116065979144" CI_END="1.356108481955245" CI_START="0.7389380879143399" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0010395639835754" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="73" I2="0.0" I2_Q="0.0" ID="CMP-008.09" LOG_CI_END="0.13229443232609683" LOG_CI_START="-0.13139194753690023" LOG_EFFECT_SIZE="4.5124239459829564E-4" METHOD="MH" MODIFIED="2010-12-07 17:32:15 +0000" MODIFIED_BY="Emma M Sydenham" NO="9" P_CHI2="0.9694817168876898" P_Q="0.0" P_Z="0.9946477414023026" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="34" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3475" TOTAL_2="2857" WEIGHT="300.0" Z="0.0067081116754673965">
<NAME>Renal Failure / Dysfunction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.642286178807043" CI_END="1.5403825242681122" CI_START="0.7901376052382554" DF="16" EFFECT_SIZE="1.1032289693785533" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="56" I2="0.0" ID="CMP-008.09.01" LOG_CI_END="0.18762858288176448" LOG_CI_START="-0.10229726821393559" LOG_EFFECT_SIZE="0.042665657333914433" MODIFIED="2010-07-08 11:07:50 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="0.9588093190186746" P_Z="0.5640347891050423" STUDIES="27" TAU2="0.0" TOTAL_1="2904" TOTAL_2="2281" WEIGHT="100.00000000000003" Z="0.5768588860577101">
<NAME>Aprotinin versus Control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68079" O_E="0.0" SE="0.0" STUDY_ID="STD-Alvarez-2001" TOTAL_1="26" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-11 11:38:38 +0000" MODIFIED_BY="Katharine Ker" ORDER="2263" O_E="0.0" SE="0.0" STUDY_ID="STD-Asimakopoulos-2000" TOTAL_1="8" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.49541782825278" CI_START="0.2557946746877728" EFFECT_SIZE="1.4741379310344827" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.929184743539629" LOG_CI_START="-0.5921085012091585" LOG_EFFECT_SIZE="0.1685381211652353" ORDER="68065" O_E="0.0" SE="0.89361518248845" STUDY_ID="STD-Baele-1992" TOTAL_1="58" TOTAL_2="57" VAR="0.7985480943738656" WEIGHT="3.6320181311503945"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68066" O_E="0.0" SE="0.0" STUDY_ID="STD-Cicek-1996b" TOTAL_1="29" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="22.596047095942403" CI_START="0.1964968032486296" EFFECT_SIZE="2.107142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3540324712460294" LOG_CI_START="-0.7066445106461795" LOG_EFFECT_SIZE="0.32369398029992497" ORDER="68078" O_E="0.0" SE="1.2104518596790557" STUDY_ID="STD-Cohen-1998" TOTAL_1="56" TOTAL_2="59" VAR="1.4651937046004844" WEIGHT="1.9794933245036805"/>
<DICH_DATA CI_END="7.10045882180821" CI_START="0.1440734719790299" EFFECT_SIZE="1.0114285714285713" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8512864131333385" LOG_CI_START="-0.8414159777823143" LOG_EFFECT_SIZE="0.00493521767551215" MODIFIED="2010-05-20 12:12:20 +0100" MODIFIED_BY="Katharine Ker" ORDER="5349" O_E="0.0" SE="0.9943017634358244" STUDY_ID="STD-Colwell-2007" TOTAL_1="175" TOTAL_2="177" VAR="0.9886359967715901" WEIGHT="2.9336795006783043"/>
<DICH_DATA CI_END="227.02670243555443" CI_START="0.8255414642736488" EFFECT_SIZE="13.690140845070422" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="0" LOG_CI_END="2.3560769410627094" LOG_CI_START="-0.08326110864831064" LOG_EFFECT_SIZE="1.1364079162071994" ORDER="68067" O_E="0.0" SE="1.432879245318341" STUDY_ID="STD-D_x0027_Ambra-1996" TOTAL_1="141" TOTAL_2="71" VAR="2.053142931664058" WEIGHT="1.4126348013242167"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-17 10:55:19 +0100" MODIFIED_BY="Katharine Ker" ORDER="2561" O_E="0.0" SE="0.0" STUDY_ID="STD-Desai-2009" TOTAL_1="38" TOTAL_2="37" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.996214062247193" CI_START="0.5851246200260946" EFFECT_SIZE="1.0807562142607072" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" LOG_CI_END="0.3002071106327127" LOG_CI_START="-0.2327516278907762" LOG_EFFECT_SIZE="0.03372774137096832" ORDER="68068" O_E="0.0" SE="0.3130626011970012" STUDY_ID="STD-Dietrich-1992" TOTAL_1="902" TOTAL_2="882" VAR="0.0980081922682326" WEIGHT="29.59284413106724"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68080" O_E="0.0" SE="0.0" STUDY_ID="STD-Dignan-2001" TOTAL_1="101" TOTAL_2="99" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.022569637689829" CI_START="0.013849815723520037" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9043134955566555" LOG_CI_START="-1.8585560049959806" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="68085" O_E="0.0" SE="1.6229232210492168" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="2.6338797814207653" WEIGHT="1.1011668709484443"/>
<DICH_DATA CI_END="9.948749291495155" CI_START="0.4020605890048373" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9977684867815639" LOG_CI_START="-0.3957084954536016" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="68069" O_E="0.0" SE="0.818535277187245" STUDY_ID="STD-Ehrlich-1998" TOTAL_1="25" TOTAL_2="25" VAR="0.6699999999999999" WEIGHT="4.32886739904698"/>
<DICH_DATA CI_END="17.111978424286665" CI_START="0.07546306347703435" EFFECT_SIZE="1.1363636363636365" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2333002239817072" LOG_CI_START="-1.1222655682820444" LOG_EFFECT_SIZE="0.05551732784983142" ORDER="68081" O_E="0.0" SE="1.3836710066144533" STUDY_ID="STD-Englberger-2002a" TOTAL_1="22" TOTAL_2="25" VAR="1.9145454545454546" WEIGHT="1.5148980404072288"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68082" O_E="0.0" SE="0.0" STUDY_ID="STD-Englberger-2002b" TOTAL_1="15" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68070" O_E="0.0" SE="0.0" STUDY_ID="STD-Gherli-1992" TOTAL_1="18" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.0247417008247117" CI_START="0.4208294843584724" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.3063696275202918" LOG_CI_START="-0.3758938400387156" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2010-05-17 14:24:11 +0100" MODIFIED_BY="Katharine Ker" ORDER="2617" O_E="0.0" SE="0.4007649381027931" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="27" VAR="0.1606125356125356" WEIGHT="18.05799993319518"/>
<DICH_DATA CI_END="14.553341064518706" CI_START="0.06871274407483083" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1629627073641946" LOG_CI_START="-1.1629627073641946" LOG_EFFECT_SIZE="0.0" ORDER="68083" O_E="0.0" SE="1.3662601021279464" STUDY_ID="STD-Kipfer-2003" TOTAL_1="15" TOTAL_2="15" VAR="1.8666666666666667" WEIGHT="1.553754191443648"/>
<DICH_DATA CI_END="5.187980526252747" CI_START="0.22188791337707303" EFFECT_SIZE="1.0729166666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7149983372353179" LOG_CI_START="-0.6538663539041103" LOG_EFFECT_SIZE="0.030565991665603823" MODIFIED="2010-05-06 16:12:49 +0100" MODIFIED_BY="Katharine Ker" ORDER="2377" O_E="0.0" SE="0.804077895564803" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="103" VAR="0.6465412621359223" WEIGHT="4.48593357797439"/>
<DICH_DATA CI_END="5.382078794072228" CI_START="0.021277395426206804" EFFECT_SIZE="0.33840304182509506" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.7309500515808913" LOG_CI_START="-1.6720815352705813" LOG_EFFECT_SIZE="-0.47056574184484506" ORDER="68071" O_E="0.0" SE="1.4115526493147534" STUDY_ID="STD-Lemmer-1996" TOTAL_1="526" TOTAL_2="178" VAR="1.9924808817874995" WEIGHT="1.4556431551601714"/>
<DICH_DATA CI_END="3.3583554802974307" CI_START="0.40529095835636947" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5261266640952466" LOG_CI_START="-0.3922330848340202" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="68072" O_E="0.0" SE="0.5394490624751247" STUDY_ID="STD-Lemmer_x005f_1-1994" TOTAL_1="108" TOTAL_2="108" VAR="0.29100529100529104" WEIGHT="9.9666268862058"/>
<DICH_DATA CI_END="2.5520322561312896" CI_START="0.440663028511081" EFFECT_SIZE="1.0604651162790697" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="6" LOG_CI_END="0.40688615930119987" LOG_CI_START="-0.355893385131503" LOG_EFFECT_SIZE="0.02549638708484843" ORDER="68073" O_E="0.0" SE="0.4480604802194102" STUDY_ID="STD-Levy-1995" TOTAL_1="215" TOTAL_2="72" VAR="0.2007581939344485" WEIGHT="14.44693788343451"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="68084" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="1.1279104500850183"/>
<DICH_DATA CI_END="71.18159445678344" CI_START="0.20823500952903212" EFFECT_SIZE="3.85" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8523677119064768" LOG_CI_START="-0.6814462528894754" LOG_EFFECT_SIZE="0.5854607295085006" ORDER="68074" O_E="0.0" SE="1.4883748655025522" STUDY_ID="STD-Okita-1996" TOTAL_1="39" TOTAL_2="21" VAR="2.2152597402597403" WEIGHT="1.3092555715481968"/>
<DICH_DATA CI_END="7.552671814919479" CI_START="0.013007336341116497" EFFECT_SIZE="0.31343283582089554" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.878100613776194" LOG_CI_START="-1.8858116297100085" LOG_EFFECT_SIZE="-0.5038555079669071" ORDER="68075" O_E="0.0" SE="1.6235357334100542" STUDY_ID="STD-Ranaboldo-1997" TOTAL_1="66" TOTAL_2="62" VAR="2.6358682776593225" WEIGHT="1.1003361518266035"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68076" O_E="0.0" SE="0.0" STUDY_ID="STD-Speekenbrink-1996" TOTAL_1="75" TOTAL_2="37" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68077" O_E="0.0" SE="0.0" STUDY_ID="STD-Stammers-1997" TOTAL_1="8" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-26 12:28:15 +0100" MODIFIED_BY="Katharine Ker" ORDER="2778" O_E="0.0" SE="0.0" STUDY_ID="STD-Wei-2006" TOTAL_1="36" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.517060880363247" CI_END="2.3727069484115244" CI_START="0.3331951116506608" DF="6" EFFECT_SIZE="0.8891424838518721" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" ID="CMP-008.09.02" LOG_CI_END="0.37524410208289866" LOG_CI_START="-0.47730137881001844" LOG_EFFECT_SIZE="-0.05102863836355986" MODIFIED="2010-05-21 10:41:27 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.8665535156655185" P_Z="0.8144997100758656" STUDIES="9" TAU2="0.0" TOTAL_1="454" TOTAL_2="458" WEIGHT="100.0" Z="0.23462512115587278">
<NAME>Tranexamic Acid versus Control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68089" O_E="0.0" SE="0.0" STUDY_ID="STD-Andreasen-2004" TOTAL_1="21" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.022569637689829" CI_START="0.013849815723520037" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9043134955566555" LOG_CI_START="-1.8585560049959806" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="68090" O_E="0.0" SE="1.6229232210492168" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="2.6338797814207653" WEIGHT="9.521697255219754"/>
<DICH_DATA CI_END="74.19854501427012" CI_START="0.12596099353676152" EFFECT_SIZE="3.057142857142857" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8703953891271512" LOG_CI_START="-0.8997639224572833" LOG_EFFECT_SIZE="0.48531573333493394" ORDER="68086" O_E="0.0" SE="1.6272052921344415" STUDY_ID="STD-Katsaros-1996" TOTAL_1="104" TOTAL_2="106" VAR="2.6477970627503336" WEIGHT="9.471649560364234"/>
<DICH_DATA CI_END="5.0327045242656645" CI_START="0.21508128722239936" EFFECT_SIZE="1.0404040404040404" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7018014332288716" LOG_CI_START="-0.667397373013627" LOG_EFFECT_SIZE="0.017202030107622307" MODIFIED="2010-05-21 10:41:27 +0100" MODIFIED_BY="Katharine Ker" ORDER="2387" O_E="0.0" SE="0.8042741564302429" STUDY_ID="STD-Later-2009" TOTAL_1="99" TOTAL_2="103" VAR="0.6468569187015789" WEIGHT="38.77056140278042"/>
<DICH_DATA CI_END="14.903914722906746" CI_START="0.06709646549862758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528004" LOG_EFFECT_SIZE="0.0" ORDER="68088" O_E="0.0" SE="1.378404875209022" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="1.9" WEIGHT="13.19947678175416"/>
<DICH_DATA CI_END="7.897117532359623" CI_START="0.014069831258787349" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8974686016417053" LOG_CI_START="-1.8517111110810305" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2010-05-07 12:20:40 +0100" MODIFIED_BY="Katharine Ker" ORDER="2440" O_E="0.0" SE="1.6148817719123905" STUDY_ID="STD-Mehr_x002d_Aein-2007" TOTAL_1="33" TOTAL_2="33" VAR="2.607843137254902" WEIGHT="9.616761655278031"/>
<DICH_DATA CI_END="71.92321045517915" CI_START="0.12513345751728625" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8568690648743624" LOG_CI_START="-0.9026265554350377" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-01-11 15:05:23 +0000" MODIFIED_BY="Katharine Ker" ORDER="2307" O_E="0.0" SE="1.6209413870933633" STUDY_ID="STD-Murphy-2006" TOTAL_1="50" TOTAL_2="50" VAR="2.627450980392157" WEIGHT="9.544994777253569"/>
<DICH_DATA CI_END="5.89171220973749" CI_START="0.011408460073893293" EFFECT_SIZE="0.25925925925925924" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7702415248685788" LOG_CI_START="-1.9427729731580399" LOG_EFFECT_SIZE="-0.5862657241447304" ORDER="68087" O_E="0.0" SE="1.5936381457791915" STUDY_ID="STD-Shore_x002d_Lesserson-1996" TOTAL_1="17" TOTAL_2="13" VAR="2.5396825396825395" WEIGHT="9.874858567349834"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-14 12:21:00 +0100" MODIFIED_BY="Katharine Ker" ORDER="2508" O_E="0.0" SE="0.0" STUDY_ID="STD-Taghaddomi-2009" TOTAL_1="50" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.47979323470036483" CI_END="1.219969523007787" CI_START="0.13710210031104775" DF="1" EFFECT_SIZE="0.4089747961914459" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" I2="0.0" ID="CMP-008.09.03" LOG_CI_END="0.08634898136747696" LOG_CI_START="-0.8629558920630658" LOG_EFFECT_SIZE="-0.38830345534779437" MODIFIED="2010-12-07 17:32:15 +0000" MODIFIED_BY="Emma M Sydenham" NO="3" P_CHI2="0.488516028271473" P_Z="0.10884494375151013" STUDIES="2" TAU2="0.0" TOTAL_1="117" TOTAL_2="118" WEIGHT="100.0" Z="1.6034064689963234">
<NAME>Epsilon Aminocaproic Acid versus control</NAME>
<DICH_DATA CI_END="15.745204850729616" CI_START="0.0635113997868158" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.197148315335392" LOG_CI_START="-1.197148315335392" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-20 11:25:13 +0100" MODIFIED_BY="Katharine Ker" ORDER="5320" O_E="0.0" SE="1.4064216928154862" STUDY_ID="STD-Berenholtz-2009" TOTAL_1="91" TOTAL_2="91" VAR="1.978021978021978" WEIGHT="15.720107517558311"/>
<DICH_DATA CI_END="1.1384049165564514" CI_START="0.10525471514085721" EFFECT_SIZE="0.34615384615384615" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.056296762716359645" LOG_CI_START="-0.9777584397793457" LOG_EFFECT_SIZE="-0.4607308385314931" MODIFIED="2010-05-17 14:24:51 +0100" MODIFIED_BY="Katharine Ker" ORDER="2618" O_E="0.0" SE="0.6074091446017823" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="27" VAR="0.36894586894586895" WEIGHT="84.2798924824417"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="71.8985634036939" CI_END="0.03695357976774866" CI_START="-0.6164483877392823" CI_STUDY="95" CI_TOTAL="95" DF="34" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2897474039857668" ESTIMABLE="YES" I2="52.71115528540143" I2_Q="0.0" ID="CMP-008.10" MODIFIED="2010-07-08 10:58:07 +0100" MODIFIED_BY="Katharine Ker" NO="10" P_CHI2="1.5805454254136375E-4" P_Q="0.8972666502465447" P_Z="0.08216327284677745" Q="0.21680438887973708" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="31" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.32634431280439763" TOTALS="SUB" TOTAL_1="1503" TOTAL_2="1514" UNITS="" WEIGHT="300.0" Z="1.7382698695959147">
<NAME>Hospital Length of Stay</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="50.1306739716623" CI_END="0.1975427515819384" CI_START="-0.7069281332324733" DF="22" EFFECT_SIZE="-0.2546926908252674" ESTIMABLE="YES" I2="56.11469334636097" ID="CMP-008.10.01" MODIFIED="2010-07-08 10:57:11 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="5.630771951652402E-4" P_Z="0.26966934987225333" STUDIES="23" TAU2="0.5101354152408973" TOTAL_1="1011" TOTAL_2="1006" WEIGHT="100.0" Z="1.1038243674268138">
<NAME>Aprotinin versus Control</NAME>
<CONT_DATA CI_END="0.988027719037168" CI_START="-1.3880277190371684" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="7.6" MEAN_2="7.8" ORDER="68096" SD_1="8.5" SD_2="8.6" SE="0.606147729452265" STUDY_ID="STD-Alderman-1998" TOTAL_1="401" TOTAL_2="395" WEIGHT="6.066817050739219"/>
<CONT_DATA CI_END="4.00363953302444" CI_START="-2.4036395330244384" EFFECT_SIZE="0.8000000000000007" ESTIMABLE="YES" MEAN_1="9.8" MEAN_2="9.0" ORDER="68100" SD_1="5.3" SD_2="5.9" SE="1.634540000884883" STUDY_ID="STD-Amar-2003" TOTAL_1="23" TOTAL_2="24" WEIGHT="1.6732176211687506"/>
<CONT_DATA CI_END="0.05456169447907144" CI_START="-2.7945616944790714" EFFECT_SIZE="-1.37" ESTIMABLE="YES" MEAN_1="5.83" MEAN_2="7.2" MODIFIED="2010-04-21 10:08:15 +0100" MODIFIED_BY="Katharine Ker" ORDER="2347" SD_1="1.65" SD_2="3.61" SE="0.7268305467426097" STUDY_ID="STD-Apostolakis-2008" TOTAL_1="29" TOTAL_2="30" WEIGHT="5.126970010326467"/>
<CONT_DATA CI_END="-0.7252257325004058" CI_START="-1.874774267499594" EFFECT_SIZE="-1.2999999999999998" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="7.6" MODIFIED="2010-01-11 11:40:46 +0000" MODIFIED_BY="Katharine Ker" ORDER="2265" SD_1="0.2" SD_2="0.9" SE="0.2932575659723036" STUDY_ID="STD-Asimakopoulos-2000" TOTAL_1="8" TOTAL_2="10" WEIGHT="8.930753164711811"/>
<CONT_DATA CI_END="0.4686054127706074" CI_START="-1.8686054127706078" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="6.2" MEAN_2="6.9" MODIFIED="2010-01-12 16:17:48 +0000" MODIFIED_BY="Katharine Ker" ORDER="2337" SD_1="1.8" SD_2="2.1" SE="0.5962382074305538" STUDY_ID="STD-Cicekcioglu-2006" TOTAL_1="24" TOTAL_2="20" WEIGHT="6.150323973029496"/>
<CONT_DATA CI_END="3.248603017990621" CI_START="-1.2486030179906211" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="10.9" MEAN_2="9.9" ORDER="68097" SD_1="7.2" SD_2="4.8" SE="1.1472675190602046" STUDY_ID="STD-Cohen-1998" TOTAL_1="56" TOTAL_2="59" WEIGHT="2.9150570340400037"/>
<CONT_DATA CI_END="2.167913022332399" CI_START="-4.367913022332399" EFFECT_SIZE="-1.0999999999999996" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="9.1" ORDER="68099" SD_1="2.2" SD_2="8.0" SE="1.6673332000533068" STUDY_ID="STD-Englberger-2002a" TOTAL_1="22" TOTAL_2="25" WEIGHT="1.6181517093786928"/>
<CONT_DATA CI_END="0.6430366683240476" CI_START="-3.8430366683240504" EFFECT_SIZE="-1.6000000000000014" ESTIMABLE="YES" MEAN_1="9.7" MEAN_2="11.3" ORDER="68101" SD_1="2.4" SD_2="3.6" SE="1.1444274925543714" STUDY_ID="STD-Englberger-2002b" TOTAL_1="15" TOTAL_2="14" WEIGHT="2.925482386520745"/>
<CONT_DATA CI_END="0.9278064534158981" CI_START="-1.227806453415897" EFFECT_SIZE="-0.14999999999999947" ESTIMABLE="YES" MEAN_1="6.65" MEAN_2="6.8" ORDER="68106" SD_1="1.81" SD_2="2.1" SE="0.549911356493026" STUDY_ID="STD-Fauli-2005" TOTAL_1="40" TOTAL_2="20" WEIGHT="6.5522336206071286"/>
<CONT_DATA CI_END="2.473375414467115" CI_START="-2.473375414467115" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="11.8" MEAN_2="11.8" ORDER="68105" SD_1="3.1" SD_2="4.3" SE="1.2619494204877155" STUDY_ID="STD-Harmon-2004" TOTAL_1="17" TOTAL_2="18" WEIGHT="2.5320114152618967"/>
<CONT_DATA CI_END="3.1120301374446506" CI_START="-1.7120301374446485" EFFECT_SIZE="0.7000000000000011" ESTIMABLE="YES" MEAN_1="13.9" MEAN_2="13.2" ORDER="68095" SD_1="5.0" SD_2="2.3" SE="1.2306502346320827" STUDY_ID="STD-Janssens-1994" TOTAL_1="20" TOTAL_2="20" WEIGHT="2.629578741032728"/>
<CONT_DATA CI_END="4.260415688613376" CI_START="-24.660415688613377" EFFECT_SIZE="-10.2" ESTIMABLE="YES" MEAN_1="17.6" MEAN_2="27.8" ORDER="68098" SD_1="7.73" SD_2="20.74" SE="7.3778986770549295" STUDY_ID="STD-Jeserschek-2003" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.09689837544438816"/>
<CONT_DATA CI_END="1.3281327014207394" CI_START="-2.3281327014207394" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="9.7" MEAN_2="10.2" ORDER="68102" SD_1="2.4" SD_2="2.7" SE="0.9327379053088816" STUDY_ID="STD-Kipfer-2003" TOTAL_1="15" TOTAL_2="15" WEIGHT="3.8575477358721066"/>
<CONT_DATA CI_END="1.6558020798754884" CI_START="0.34419792012451167" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="7.0" ORDER="68104" SD_1="1.0" SD_2="2.0" SE="0.3345990462316509" STUDY_ID="STD-Kunt-2005" TOTAL_1="40" TOTAL_2="46" WEIGHT="8.558121283655792"/>
<CONT_DATA CI_END="1.2592334208671665" CI_START="-2.659233420867167" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="7.8" MEAN_2="8.5" MODIFIED="2010-05-06 16:13:30 +0100" MODIFIED_BY="Katharine Ker" ORDER="2378" SD_1="6.7" SD_2="7.4" SE="0.9996272565829525" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="103" WEIGHT="3.5272116608174677"/>
<CONT_DATA CI_END="1.0131758696418367" CI_START="-1.6131758696418363" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="7.3" MEAN_2="7.6" ORDER="68093" SD_1="2.68" SD_2="1.34" SE="0.67" STUDY_ID="STD-Liu-1993" TOTAL_1="20" TOTAL_2="20" WEIGHT="5.551346865456609"/>
<CONT_DATA CI_END="0.9332882306548902" CI_START="-2.133288230654891" EFFECT_SIZE="-0.6000000000000005" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="6.4" ORDER="68103" SD_1="1.8" SD_2="3.0" SE="0.7823042886243179" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="4.744470385614291"/>
<CONT_DATA CI_END="2.2155525515363017" CI_START="-10.815552551536303" EFFECT_SIZE="-4.300000000000001" ESTIMABLE="YES" MEAN_1="11.1" MEAN_2="15.4" ORDER="68092" SD_1="4.85" SD_2="16.0" SE="3.324322591093586" STUDY_ID="STD-Murkin-1994" TOTAL_1="29" TOTAL_2="25" WEIGHT="0.460498253646055"/>
<CONT_DATA CI_END="5.893446770560142" CI_START="-2.4934467705601433" EFFECT_SIZE="1.6999999999999993" ESTIMABLE="YES" MEAN_1="13.1" MEAN_2="11.4" ORDER="68091" SD_1="9.15" SD_2="6.37" SE="2.1395529732370164" STUDY_ID="STD-Murkin-1995" TOTAL_1="29" TOTAL_2="24" WEIGHT="1.0464080484592282"/>
<CONT_DATA CI_END="0.6264092684335909" CI_START="-1.0264092684335913" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="5.3" MEAN_2="5.5" MODIFIED="2010-05-21 15:21:03 +0100" MODIFIED_BY="Katharine Ker" ORDER="2474" SD_1="1.6" SD_2="1.4" SE="0.4216451296820768" STUDY_ID="STD-Nur_x00f6_zler-2008" TOTAL_1="25" TOTAL_2="26" WEIGHT="7.739181895050326"/>
<CONT_DATA CI_END="3.004020403417729" CI_START="-1.0040204034177291" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="7.0" ORDER="68107" SD_1="4.1" SD_2="3.8" SE="1.0224781777752991" STUDY_ID="STD-Poston-2006" TOTAL_1="29" TOTAL_2="31" WEIGHT="3.4224404597517424"/>
<CONT_DATA CI_END="0.3192355011980159" CI_START="-2.7192355011980163" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" MEAN_1="6.1" MEAN_2="7.3" ORDER="68094" SD_1="0.8" SD_2="2.5" SE="0.775134396948899" STUDY_ID="STD-Stammers-1997" TOTAL_1="8" TOTAL_2="12" WEIGHT="4.792158423080708"/>
<CONT_DATA CI_END="1.1403247823048228" CI_START="0.05967521769517825" EFFECT_SIZE="0.6000000000000005" ESTIMABLE="YES" MEAN_1="7.9" MEAN_2="7.3" MODIFIED="2010-05-26 12:28:57 +0100" MODIFIED_BY="Katharine Ker" ORDER="2779" SD_1="1.2" SD_2="1.2" SE="0.27568097504180444" STUDY_ID="STD-Wei-2006" TOTAL_1="36" TOTAL_2="40" WEIGHT="9.083119886334346"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="18.416669628010965" CI_END="0.13364379962863893" CI_START="-0.818896326260947" DF="9" EFFECT_SIZE="-0.34262626331615403" ESTIMABLE="YES" I2="51.131229577407495" ID="CMP-008.10.02" MODIFIED="2010-07-08 10:58:07 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.030635891730664944" P_Z="0.15854318736193243" STUDIES="10" TAU2="0.21112319917536215" TOTAL_1="379" TOTAL_2="393" WEIGHT="100.00000000000001" Z="1.4099881317441538">
<NAME>Tranexamic Acid versus Control</NAME>
<CONT_DATA CI_END="2.2347027692519568" CI_START="-2.2347027692519568" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="10.0" ORDER="68108" SD_1="3.0" SD_2="2.0" SE="1.140175425099138" STUDY_ID="STD-Ellis-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="3.9076037030968074"/>
<CONT_DATA CI_END="2.5126574492385734" CI_START="-1.5126574492385734" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="4.0" MODIFIED="2010-05-17 15:00:25 +0100" MODIFIED_BY="Katharine Ker" ORDER="2640" SD_1="3.55" SD_2="3.71" SE="1.0268849147811687" STUDY_ID="STD-Jimenez-2007" TOTAL_1="24" TOTAL_2="26" WEIGHT="4.665610591449975"/>
<CONT_DATA CI_END="2.510305889012365" CI_START="-7.510305889012365" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="15.5" MODIFIED="2010-05-20 16:14:51 +0100" MODIFIED_BY="Katharine Ker" ORDER="5382" SD_1="12.4" SD_2="7.44" SE="2.5563254878829498" STUDY_ID="STD-Kazemi-2010" TOTAL_1="32" TOTAL_2="32" WEIGHT="0.8753243158260332"/>
<CONT_DATA CI_END="3.1163381520352065" CI_START="-1.3163381520352058" EFFECT_SIZE="0.9000000000000004" ESTIMABLE="YES" MEAN_1="9.4" MEAN_2="8.5" MODIFIED="2010-05-06 16:20:49 +0100" MODIFIED_BY="Katharine Ker" ORDER="2388" SD_1="8.6" SD_2="7.4" SE="1.1308055502638816" STUDY_ID="STD-Later-2009" TOTAL_1="99" TOTAL_2="103" WEIGHT="3.9634143282996566"/>
<CONT_DATA CI_END="1.0304261724838488" CI_START="-2.23042617248385" EFFECT_SIZE="-0.6000000000000005" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="6.4" ORDER="68109" SD_1="2.2" SD_2="3.0" SE="0.8318653737234168" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="6.5382780713914235"/>
<CONT_DATA CI_END="0.33602917694717677" CI_START="-0.33602917694717677" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="4.8" MODIFIED="2010-05-07 12:20:00 +0100" MODIFIED_BY="Katharine Ker" ORDER="2441" SD_1="0.4" SD_2="0.9" SE="0.1714466079977653" STUDY_ID="STD-Mehr_x002d_Aein-2007" TOTAL_1="33" TOTAL_2="33" WEIGHT="24.5507270045612"/>
<CONT_DATA CI_END="-0.7555084756405822" CI_START="-2.2444915243594177" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="5.8" MODIFIED="2010-05-14 11:52:22 +0100" MODIFIED_BY="Katharine Ker" ORDER="2495" SD_1="1.6" SD_2="1.5" SE="0.37984959429452375" STUDY_ID="STD-Sadeghi-2007" TOTAL_1="32" TOTAL_2="35" WEIGHT="16.614300838518016"/>
<CONT_DATA CI_END="0.254516357023345" CI_START="-0.6545163570233454" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="7.1" MEAN_2="7.3" ORDER="68111" SD_1="0.8" SD_2="1.2" SE="0.23190036174568116" STUDY_ID="STD-Wei-2006" TOTAL_1="36" TOTAL_2="40" WEIGHT="22.29086006722312"/>
<CONT_DATA CI_END="2.288900824613061" CI_START="-0.8489008246130632" EFFECT_SIZE="0.7199999999999989" ESTIMABLE="YES" MEAN_1="9.19" MEAN_2="8.47" MODIFIED="2010-05-14 15:19:25 +0100" MODIFIED_BY="Katharine Ker" ORDER="2524" SD_1="5.48" SD_2="4.12" SE="0.8004743132977705" STUDY_ID="STD-Wong-2008" TOTAL_1="73" TOTAL_2="74" WEIGHT="6.931556663049588"/>
<CONT_DATA CI_END="0.23959006460912335" CI_START="-2.239590064609123" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="9.0" ORDER="68110" SD_1="2.0" SD_2="2.0" SE="0.6324555320336759" STUDY_ID="STD-Zohar-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="9.66232441658418"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.1344154151409054" CI_END="4.331297077986287" CI_START="-3.17304048415277" DF="1" EFFECT_SIZE="0.5791282969167585" ESTIMABLE="YES" I2="68.0961242351775" ID="CMP-008.10.03" MODIFIED="2010-05-20 11:25:52 +0100" MODIFIED_BY="Katharine Ker" NO="3" P_CHI2="0.0766561687407954" P_Z="0.7622629002347645" STUDIES="2" TAU2="5.178710248085248" TOTAL_1="113" TOTAL_2="115" WEIGHT="100.0" Z="0.3025105400672626">
<NAME>Epsilon Aminocaproic Acid versus Control</NAME>
<CONT_DATA CI_END="6.757042498100984" CI_START="-0.9570424981009831" EFFECT_SIZE="2.9000000000000004" ESTIMABLE="YES" MEAN_1="11.9" MEAN_2="9.0" ORDER="68112" SD_1="7.3" SD_2="5.9" SE="1.9679149864614056" STUDY_ID="STD-Amar-2003" TOTAL_1="22" TOTAL_2="24" WEIGHT="40.49046915171176"/>
<CONT_DATA CI_END="0.9401565673801429" CI_START="-2.940156567380143" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="8.5" MEAN_2="9.5" MODIFIED="2010-05-20 11:25:52 +0100" MODIFIED_BY="Katharine Ker" ORDER="5321" SD_1="3.9" SD_2="8.6" SE="0.9898939892180929" STUDY_ID="STD-Berenholtz-2009" TOTAL_1="91" TOTAL_2="91" WEIGHT="59.50953084828824"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2010-12-03 14:35:53 +0000" MODIFIED_BY="Katharine Ker" NO="9">
<NAME>Adverse Events and Other Outcomes (Active versus Active)</NAME>
<DICH_OUTCOME CHI2="8.904083109545338" CI_END="0.9276452056403868" CI_START="0.5146437738381836" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6909463288951367" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="104" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="-0.03261809565091096" LOG_CI_START="-0.28849327695222127" LOG_EFFECT_SIZE="-0.16055568630156614" METHOD="MH" MODIFIED="2010-05-21 10:12:03 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="0.780148623958873" P_Q="0.0" P_Z="0.013906751713636725" Q="0.0" RANDOM="YES" SCALE="4.826114826667677" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2005" TOTAL_2="2005" WEIGHT="99.99999999999999" Z="2.459663036202168">
<NAME>Re-operation for bleeding - Aprotinin versus Tranexamic Acid</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Tranexamic Acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.610561210332914" CI_START="0.15127308683518553" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8202383309235528" LOG_CI_START="-0.8202383309235528" LOG_EFFECT_SIZE="0.0" ORDER="68119" O_E="0.0" SE="0.9636241116594315" STUDY_ID="STD-Bernet-1999" TOTAL_1="28" TOTAL_2="28" VAR="0.9285714285714286" WEIGHT="2.4328549370528667"/>
<DICH_DATA CI_END="7.206101557587411" CI_START="0.15147679101544767" EFFECT_SIZE="1.044776119402985" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8577003784622378" LOG_CI_START="-0.8196539038353771" LOG_EFFECT_SIZE="0.019023237313430356" ORDER="68116" O_E="0.0" SE="0.985286208459226" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="70" VAR="0.9707889125799574" WEIGHT="2.3270554032210047"/>
<DICH_DATA CI_END="2.0264001282965136" CI_START="0.3207275422197148" EFFECT_SIZE="0.8061776061776061" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.3067252042787737" LOG_CI_START="-0.4938637437808282" LOG_EFFECT_SIZE="-0.09356926975102729" ORDER="68120" O_E="0.0" SE="0.4702699110694172" STUDY_ID="STD-Casati-2000" TOTAL_1="518" TOTAL_2="522" VAR="0.22115378925723755" WEIGHT="10.21497118359821"/>
<DICH_DATA CI_END="6.99082015435261" CI_START="0.14762187577324476" EFFECT_SIZE="1.0158730158730158" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8445281296247992" LOG_CI_START="-0.8308492805641883" LOG_EFFECT_SIZE="0.006839424530305441" ORDER="68123" O_E="0.0" SE="0.9841249839969435" STUDY_ID="STD-Dalmau-2004" TOTAL_1="63" TOTAL_2="64" VAR="0.9685019841269842" WEIGHT="2.3325502904803925"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-14 16:05:46 +0100" MODIFIED_BY="Katharine Ker" ORDER="2544" O_E="0.0" SE="0.0" STUDY_ID="STD-Demeyere-2006" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.9122118793046785" CI_START="0.11360439008825768" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5924223674655205" LOG_CI_START="-0.9446048855768829" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2010-05-20 14:28:55 +0100" MODIFIED_BY="Katharine Ker" ORDER="5353" O_E="0.0" SE="0.9028574168447171" STUDY_ID="STD-Dietrich-2008" TOTAL_1="110" TOTAL_2="110" VAR="0.8151515151515152" WEIGHT="2.7713615719481672"/>
<DICH_DATA CI_END="1.981815136256692" CI_START="0.08073406902230676" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2970631410432962" LOG_CI_START="-1.0929431583873712" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="68124" O_E="0.0" SE="0.8164965809277259" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.6666666666666665" WEIGHT="3.388619376609351"/>
<DICH_DATA CI_END="0.9971735220781199" CI_START="0.4700835338750489" EFFECT_SIZE="0.6846567411083541" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="62" LOG_CI_END="-0.0012292618249354667" LOG_CI_START="-0.32782496104839626" LOG_EFFECT_SIZE="-0.16452711143666585" MODIFIED="2010-01-11 12:36:17 +0000" MODIFIED_BY="Katharine Ker" ORDER="2269" O_E="0.0" SE="0.19184393039864542" STUDY_ID="STD-Fergusson-2008" TOTAL_1="780" TOTAL_2="770" VAR="0.036804093630800304" WEIGHT="61.38120414180432"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="68125" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.8785309494913129"/>
<DICH_DATA CI_END="0.9830630025247474" CI_START="0.1379845649553128" EFFECT_SIZE="0.36830357142857145" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.007418648218679624" LOG_CI_START="-0.8601694913497957" LOG_EFFECT_SIZE="-0.4337940697842377" MODIFIED="2010-05-21 10:11:48 +0100" MODIFIED_BY="Katharine Ker" ORDER="2403" O_E="0.0" SE="0.5009100664399695" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="99" VAR="0.25091089466089467" WEIGHT="9.00351332874315"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68122" O_E="0.0" SE="0.0" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68115" O_E="0.0" SE="0.0" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="72.48563796148957" CI_START="0.12416252726894049" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.860251965578492" LOG_CI_START="-0.9060094561391671" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="68117" O_E="0.0" SE="1.6249156523318318" STUDY_ID="STD-Mongan-1998" TOTAL_1="75" TOTAL_2="75" VAR="2.6403508771929824" WEIGHT="0.8555982479146532"/>
<DICH_DATA CI_END="224.12628880585987" CI_START="0.7540391664914835" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3504927999251257" LOG_CI_START="-0.12260609531145177" LOG_EFFECT_SIZE="1.1139433523068367" ORDER="68118" O_E="0.0" SE="1.4527105330989338" STUDY_ID="STD-Nuttall-2000" TOTAL_1="45" TOTAL_2="45" VAR="2.1103678929765883" WEIGHT="1.0704671881734769"/>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="68114" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="0.8888181971434362"/>
<DICH_DATA CI_END="5.167657331603573" CI_START="0.04837782073340814" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7132937077873972" LOG_CI_START="-1.3153536991153596" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="68113" O_E="0.0" SE="1.1916375287812984" STUDY_ID="STD-Pugh-1995" TOTAL_1="25" TOTAL_2="25" VAR="1.42" WEIGHT="1.5909011157790378"/>
<DICH_DATA CI_END="69.64188698182446" CI_START="0.12285171138790224" EFFECT_SIZE="2.925" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8428705300313253" LOG_CI_START="-0.9106187891949267" LOG_EFFECT_SIZE="0.4661258704181992" ORDER="68121" O_E="0.0" SE="1.6174132561054522" STUDY_ID="STD-Wong-2000" TOTAL_1="39" TOTAL_2="38" VAR="2.616025641025641" WEIGHT="0.8635540680406087"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9286255306196654" CI_END="0.999172918049802" CI_START="0.49165298974416527" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7008896863491336" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="70" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="-3.593457517384524E-4" LOG_CI_START="-0.3083413155470167" LOG_EFFECT_SIZE="-0.15435033064937762" METHOD="MH" MODIFIED="2010-01-11 12:38:06 +0000" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.6285669652866621" P_Q="0.0" P_Z="0.049467773409114194" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1034" TOTAL_2="1041" WEIGHT="100.0" Z="1.964537659628067">
<NAME>Re-operation for bleeding - Aprotinin versus Epsilon Aminocaproic Acid</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.159981714973729" CI_START="0.3246431615744507" EFFECT_SIZE="1.4141414141414141" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7895794230251727" LOG_CI_START="-0.48859374086379653" LOG_EFFECT_SIZE="0.1504928410806881" ORDER="68128" O_E="0.0" SE="0.7508052435275834" STUDY_ID="STD-Bennett_x002d_Guerrero-1997" TOTAL_1="99" TOTAL_2="105" VAR="0.5637085137085137" WEIGHT="5.805921968670333"/>
<DICH_DATA CI_END="3.804202613499046" CI_START="0.11336842365408308" EFFECT_SIZE="0.6567164179104478" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5802636395958851" LOG_CI_START="-0.9455078920251632" LOG_EFFECT_SIZE="-0.182622126214639" ORDER="68129" O_E="0.0" SE="0.8962457503650936" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="66" VAR="0.8032564450474897" WEIGHT="4.074474178010817"/>
<DICH_DATA CI_END="0.9761161152669228" CI_START="0.4624613901611065" EFFECT_SIZE="0.671875" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="64" LOG_CI_END="-0.01049851714868687" LOG_CI_START="-0.33492451965991443" LOG_EFFECT_SIZE="-0.17271151840430066" MODIFIED="2010-01-11 12:38:06 +0000" MODIFIED_BY="Katharine Ker" ORDER="2270" O_E="0.0" SE="0.1905694398097077" STUDY_ID="STD-Fergusson-2008" TOTAL_1="780" TOTAL_2="780" VAR="0.0363167113893858" WEIGHT="90.11960385331885"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68127" O_E="0.0" SE="0.0" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68126" O_E="0.0" SE="0.0" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68130" O_E="0.0" SE="0.0" STUDY_ID="STD-Ray-2001" TOTAL_1="49" TOTAL_2="51" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8129318006807362" CI_END="1.3863420602746648" CI_START="0.7258101175252593" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0031057240880268" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="68" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="0.1418703995119711" LOG_CI_START="-0.13917698218841737" LOG_EFFECT_SIZE="0.001346708661776869" METHOD="MH" MODIFIED="2010-06-01 16:51:17 +0100" MODIFIED_BY="Katharine Ker" NO="3" P_CHI2="0.6121250358721341" P_Q="0.0" P_Z="0.9850139657393985" Q="0.0" RANDOM="YES" SCALE="10.76233389465076" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="922" TOTAL_2="931" WEIGHT="99.99999999999999" Z="0.01878331303982509">
<NAME>Re-operation for bleeding - Tranexamic Acid versus Epsilon Aminocaproic Acid</NAME>
<GROUP_LABEL_1>Tranexamic Acid</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TXA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6437124540938406" CI_START="0.10843392440926983" EFFECT_SIZE="0.6285714285714286" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5615440970255254" LOG_CI_START="-0.9648348240816641" LOG_EFFECT_SIZE="-0.2016453635280694" ORDER="68134" O_E="0.0" SE="0.8966025339558794" STUDY_ID="STD-Casati-1999" TOTAL_1="70" TOTAL_2="66" VAR="0.8038961038961039" WEIGHT="3.3902706312240123"/>
<DICH_DATA CI_END="1.3715208385610875" CI_START="0.7021481816709964" EFFECT_SIZE="0.9813311688311688" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="64" LOG_CI_END="0.13720241055763788" LOG_CI_START="-0.15357122449290753" LOG_EFFECT_SIZE="-0.00818440696763479" MODIFIED="2010-01-11 12:39:36 +0000" MODIFIED_BY="Katharine Ker" ORDER="2271" O_E="0.0" SE="0.17080187258139748" STUDY_ID="STD-Fergusson-2008" TOTAL_1="770" TOTAL_2="780" VAR="0.029173279677311936" WEIGHT="93.42197318027057"/>
<DICH_DATA CI_END="29.6870401524887" CI_START="0.34693999011278065" EFFECT_SIZE="3.2093023255813953" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4725668998688695" LOG_CI_START="-0.45974563822556946" LOG_EFFECT_SIZE="0.5064106308216499" ORDER="68131" O_E="0.0" SE="1.135049949978001" STUDY_ID="STD-Hardy-1998" TOTAL_1="43" TOTAL_2="46" VAR="1.2883383889450621" WEIGHT="2.11545768951746"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68133" O_E="0.0" SE="0.0" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="68.25874292736694" CI_START="0.13185124152633107" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.8799157764849103" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="68132" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="1.0722984989879483"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.777810387685707" CI_END="1.933743384036748" CI_START="0.9378730201033214" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3467018035524276" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="51" I2="0.0" I2_Q="0.0" ID="CMP-009.04" LOG_CI_END="0.28639884084769646" LOG_CI_START="-0.027855957358102597" LOG_EFFECT_SIZE="0.1292714417447969" METHOD="MH" MODIFIED="2010-05-21 10:36:20 +0100" MODIFIED_BY="Katharine Ker" NO="4" P_CHI2="0.6602399825203524" P_Q="0.0" P_Z="0.10685395624352285" Q="0.0" RANDOM="YES" SCALE="2.7484540670384625" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2060" TOTAL_2="2070" WEIGHT="100.0" Z="1.612496429622975">
<NAME>Mortality - Aprotinin versus Tranexamic Acid</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Tranexamic Acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68141" O_E="0.0" SE="0.0" STUDY_ID="STD-Bernet-1999" TOTAL_1="28" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="72.6230071114122" CI_START="0.14100214804229522" EFFECT_SIZE="3.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8610742278439367" LOG_CI_START="-0.8507742712041246" LOG_EFFECT_SIZE="0.505149978319906" ORDER="68136" O_E="0.0" SE="1.592953232207399" STUDY_ID="STD-Blauhut-1994" TOTAL_1="14" TOTAL_2="15" VAR="2.5374999999999996" WEIGHT="1.34286695830329"/>
<DICH_DATA CI_END="75.57063962633265" CI_START="0.12983395398810435" EFFECT_SIZE="3.1323529411764706" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.878353098081361" LOG_CI_START="-0.8866117166163581" LOG_EFFECT_SIZE="0.4958706907325014" ORDER="68137" O_E="0.0" SE="1.6241540189500108" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="70" VAR="2.637876277271472" WEIGHT="1.2917682819526408"/>
<DICH_DATA CI_END="2.774222942724468" CI_START="0.5271116556854569" EFFECT_SIZE="1.2092664092664092" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.4431413590099643" LOG_CI_START="-0.27809738040065646" LOG_EFFECT_SIZE="0.08252198930465392" ORDER="68142" O_E="0.0" SE="0.423659205719138" STUDY_ID="STD-Casati-2000" TOTAL_1="518" TOTAL_2="522" VAR="0.1794871225905709" WEIGHT="18.984787641102937"/>
<DICH_DATA CI_END="2.209962342898925" CI_START="0.029185960670748645" EFFECT_SIZE="0.25396825396825395" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.34438487349934754" LOG_CI_START="-1.5348260070946613" LOG_EFFECT_SIZE="-0.5952205667976569" ORDER="68144" O_E="0.0" SE="1.1038577735048045" STUDY_ID="STD-Dalmau-2004" TOTAL_1="63" TOTAL_2="64" VAR="1.2185019841269842" WEIGHT="2.7964869578246727"/>
<DICH_DATA CI_END="21.736881949124992" CI_START="0.18401903315121143" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3371972467692281" LOG_CI_START="-0.7351372554412656" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2010-05-17 11:11:12 +0100" MODIFIED_BY="Katharine Ker" ORDER="2572" O_E="0.0" SE="1.2172995448196726" STUDY_ID="STD-Dietrich-2008" TOTAL_1="110" TOTAL_2="110" VAR="1.481818181818182" WEIGHT="2.2995566854994216"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68145" O_E="0.0" SE="0.0" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.418340931341894" CI_START="0.9890390615490491" EFFECT_SIZE="1.5465554129225503" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="30" LOG_CI_END="0.3835175265343159" LOG_CI_START="-0.004786555844472703" LOG_EFFECT_SIZE="0.1893654853449216" MODIFIED="2010-01-11 13:30:24 +0000" MODIFIED_BY="Katharine Ker" ORDER="2272" O_E="0.0" SE="0.228091740125508" STUDY_ID="STD-Fergusson-2008" TOTAL_1="779" TOTAL_2="769" VAR="0.05202584191348228" WEIGHT="65.49677585922068"/>
<DICH_DATA CI_END="3.944898925347026" CI_START="0.009485679882356225" EFFECT_SIZE="0.19344262295081968" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5960358803651128" LOG_CI_START="-2.022931535774396" LOG_EFFECT_SIZE="-0.7134478277046417" ORDER="68146" O_E="0.0" SE="1.5383944243381398" STUDY_ID="STD-Hekmat-2004" TOTAL_1="60" TOTAL_2="58" VAR="2.3666574048346765" WEIGHT="1.4398048909544772"/>
<DICH_DATA CI_END="4.445867821891619" CI_START="0.01128598555110691" EFFECT_SIZE="0.224" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6479565467398456" LOG_CI_START="-1.94746051007152" LOG_EFFECT_SIZE="-0.6497519816658371" ORDER="68148" O_E="0.0" SE="1.5245608266926296" STUDY_ID="STD-Ickx-2006" TOTAL_1="24" TOTAL_2="27" VAR="2.3242857142857143" WEIGHT="1.4660525105631337"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68147" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68135" O_E="0.0" SE="0.0" STUDY_ID="STD-Landymore-1997" TOTAL_1="48" TOTAL_2="56" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="74.99849933654143" CI_START="0.1275400160586429" EFFECT_SIZE="3.0927835051546393" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8750525735733063" LOG_CI_START="-0.8943535326664713" LOG_EFFECT_SIZE="0.4903495204534176" MODIFIED="2010-05-21 10:35:56 +0100" MODIFIED_BY="Katharine Ker" ORDER="2404" O_E="0.0" SE="1.6267628555865639" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="99" VAR="2.6463573883161513" WEIGHT="1.287628391289496"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68138" O_E="0.0" SE="0.0" STUDY_ID="STD-Misfeld-1998" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68139" O_E="0.0" SE="0.0" STUDY_ID="STD-Mongan-1998" TOTAL_1="75" TOTAL_2="75" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68140" O_E="0.0" SE="0.0" STUDY_ID="STD-Nuttall-2000" TOTAL_1="45" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.569203725945863" CI_START="0.14451910011013963" EFFECT_SIZE="0.9743589743589743" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8175127305360728" LOG_CI_START="-0.8400747513554507" LOG_EFFECT_SIZE="-0.011281010409689058" ORDER="68143" O_E="0.0" SE="0.9736750920534478" STUDY_ID="STD-Wong-2000" TOTAL_1="39" TOTAL_2="38" VAR="0.9480431848852902" WEIGHT="3.5942718232892483"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2636463609539029" CI_END="2.3008334023510923" CI_START="0.9942323699861632" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5124691886325665" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-009.05" LOG_CI_END="0.3618851736191058" LOG_CI_START="-0.0025121013081469824" LOG_EFFECT_SIZE="0.17968653615547944" METHOD="MH" MODIFIED="2010-06-01 16:29:42 +0100" MODIFIED_BY="Katharine Ker" NO="5" P_CHI2="0.9667140347652293" P_Q="0.0" P_Z="0.053243518519044616" Q="0.0" RANDOM="YES" SCALE="23.502270613739245" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="949" TOTAL_2="942" WEIGHT="100.0" Z="1.9329405766923036">
<NAME>Mortality - Aprotinin versus Epsilon Aminocaproic Acid</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.422831587313901" CI_START="0.06291788994783064" EFFECT_SIZE="0.9850746268656716" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1881641162473595" LOG_CI_START="-1.201225850565275" LOG_EFFECT_SIZE="-0.00653086715895778" ORDER="68150" O_E="0.0" SE="1.4035394941768315" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="66" VAR="1.9699231117141565" WEIGHT="2.325820368673126"/>
<DICH_DATA CI_END="2.362996535909909" CI_START="0.9752670089360065" EFFECT_SIZE="1.5180752826203983" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="31" LOG_CI_END="0.37346308496867286" LOG_CI_START="-0.010876466729951515" LOG_EFFECT_SIZE="0.1812933091193607" MODIFIED="2010-01-11 13:30:55 +0000" MODIFIED_BY="Katharine Ker" ORDER="2273" O_E="0.0" SE="0.2257629551792362" STUDY_ID="STD-Fergusson-2008" TOTAL_1="779" TOTAL_2="780" VAR="0.05096891193126181" WEIGHT="89.8918011850779"/>
<DICH_DATA CI_END="67.75150586967578" CI_START="0.12318071613639271" EFFECT_SIZE="2.888888888888889" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.830918952441243" LOG_CI_START="-0.909457275378257" LOG_EFFECT_SIZE="0.4607308385314931" MODIFIED="2010-05-17 14:25:43 +0100" MODIFIED_BY="Katharine Ker" ORDER="2619" O_E="0.0" SE="1.6097105613022769" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="25" VAR="2.591168091168091" WEIGHT="1.7681937785361195"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68149" O_E="0.0" SE="0.0" STUDY_ID="STD-Landymore-1997" TOTAL_1="48" TOTAL_2="44" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.72684435116677" CI_START="0.2524130977089139" EFFECT_SIZE="1.396551724137931" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8880021639455309" LOG_CI_START="-0.5978881133141061" LOG_EFFECT_SIZE="0.14505702531571246" ORDER="68151" O_E="0.0" SE="0.8728193041378075" STUDY_ID="STD-Trinh_x002d_Duc-1992" TOTAL_1="29" TOTAL_2="27" VAR="0.7618135376756066" WEIGHT="6.0141846677128665"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4273748610069932" CI_END="1.4657563470587376" CI_START="0.5861277551997065" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9268875214238563" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-009.06" LOG_CI_END="0.16606178345490274" LOG_CI_START="-0.23200771276839943" LOG_EFFECT_SIZE="-0.03297296465674837" METHOD="MH" MODIFIED="2010-10-12 14:41:44 +0100" MODIFIED_BY="Katharine Ker" NO="6" P_CHI2="0.6991306624828073" P_Q="0.0" P_Z="0.7454110235815192" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="980" TOTAL_2="978" WEIGHT="99.99999999999999" Z="0.3246961839773135">
<NAME>Mortality - Tranexamic Acid versus Epsilon Aminocaproic Acid</NAME>
<GROUP_LABEL_1>Tranexamic Acid</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TXA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.587873622928624" CI_START="0.013039781357177392" EFFECT_SIZE="0.3145539906103286" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.880120089042957" LOG_CI_START="-1.8847296905187794" LOG_EFFECT_SIZE="-0.5023048007379113" ORDER="68154" O_E="0.0" SE="1.6240864467417013" STUDY_ID="STD-Casati-1999" TOTAL_1="70" TOTAL_2="66" VAR="2.637656786490085" WEIGHT="2.0728826579502844"/>
<DICH_DATA CI_END="4.6743560803370325" CI_START="0.2139332097968663" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6697217927449455" LOG_CI_START="-0.6697217927449455" LOG_EFFECT_SIZE="0.0" ORDER="68155" O_E="0.0" SE="0.7867957924694431" STUDY_ID="STD-Dalmau-2000" TOTAL_1="42" TOTAL_2="42" VAR="0.619047619047619" WEIGHT="8.832201016703356"/>
<DICH_DATA CI_END="1.6054356470714704" CI_START="0.6001540562909722" EFFECT_SIZE="0.9815847980200512" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="31" LOG_CI_END="0.20559290181663584" LOG_CI_START="-0.22173725426775764" LOG_EFFECT_SIZE="-0.008072176225560886" MODIFIED="2010-01-11 13:31:12 +0000" MODIFIED_BY="Katharine Ker" ORDER="2274" O_E="0.0" SE="0.25101584900236074" STUDY_ID="STD-Fergusson-2008" TOTAL_1="769" TOTAL_2="780" VAR="0.06300895645037596" WEIGHT="86.77421938651307"/>
<DICH_DATA CI_END="4.327191221011991" CI_START="0.010547372079640783" EFFECT_SIZE="0.21363636363636362" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6362060873400173" LOG_CI_START="-1.976855733112995" LOG_EFFECT_SIZE="-0.6703248228864888" ORDER="68152" O_E="0.0" SE="1.5349254481987216" STUDY_ID="STD-Hardy-1998" TOTAL_1="43" TOTAL_2="46" VAR="2.355996131528046" WEIGHT="2.320696938833274"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68153" O_E="0.0" SE="0.0" STUDY_ID="STD-Landymore-1997" TOTAL_1="56" TOTAL_2="44" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.894754029814962" CI_END="1.8914464720904869" CI_START="1.0171490039142477" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3870410574470955" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="85" I2="0.0" I2_Q="0.0" ID="CMP-009.07" LOG_CI_END="0.2767940552747214" LOG_CI_START="0.007384578131842819" LOG_EFFECT_SIZE="0.14208931670328212" METHOD="MH" MODIFIED="2010-10-12 16:04:44 +0100" MODIFIED_BY="Katharine Ker" NO="7" P_CHI2="0.8075414097346705" P_Q="0.0" P_Z="0.0386955229581922" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2115" TOTAL_2="3012" WEIGHT="99.99999999999999" Z="2.067410146664174">
<NAME>Mortality - Aprotinin versus Lysine Analogues</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Lysine Analogues</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lysine Analogues</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-10-12 16:02:58 +0100" MODIFIED_BY="Katharine Ker" ORDER="2851" O_E="0.0" SE="0.0" STUDY_ID="STD-Bernet-1999" TOTAL_1="28" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="72.6230071114122" CI_START="0.14100214804229522" EFFECT_SIZE="3.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8610742278439367" LOG_CI_START="-0.8507742712041246" LOG_EFFECT_SIZE="0.505149978319906" MODIFIED="2010-10-12 16:03:02 +0100" MODIFIED_BY="Katharine Ker" ORDER="2852" O_E="0.0" SE="1.592953232207399" STUDY_ID="STD-Blauhut-1994" TOTAL_1="14" TOTAL_2="15" VAR="2.5374999999999996" WEIGHT="0.986949408689197"/>
<DICH_DATA CI_END="31.953728832921293" CI_START="0.12894564116981438" EFFECT_SIZE="2.029850746268657" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.5045215453447962" LOG_CI_START="-0.8895933340060143" LOG_EFFECT_SIZE="0.3074641056693911" MODIFIED="2010-10-12 15:59:40 +0100" MODIFIED_BY="Katharine Ker" ORDER="2853" O_E="0.0" SE="1.4063149311904504" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="136" VAR="1.977721685689201" WEIGHT="1.2662975496858666"/>
<DICH_DATA CI_END="2.774222942724468" CI_START="0.5271116556854569" EFFECT_SIZE="1.2092664092664092" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.4431413590099643" LOG_CI_START="-0.27809738040065646" LOG_EFFECT_SIZE="0.08252198930465392" MODIFIED="2010-10-12 16:03:08 +0100" MODIFIED_BY="Katharine Ker" ORDER="2854" O_E="0.0" SE="0.423659205719138" STUDY_ID="STD-Casati-2000" TOTAL_1="518" TOTAL_2="522" VAR="0.1794871225905709" WEIGHT="13.953001688380743"/>
<DICH_DATA CI_END="2.209962342898925" CI_START="0.029185960670748645" EFFECT_SIZE="0.25396825396825395" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.34438487349934754" LOG_CI_START="-1.5348260070946613" LOG_EFFECT_SIZE="-0.5952205667976569" MODIFIED="2010-10-12 16:03:16 +0100" MODIFIED_BY="Katharine Ker" ORDER="2855" O_E="0.0" SE="1.1038577735048045" STUDY_ID="STD-Dalmau-2004" TOTAL_1="63" TOTAL_2="64" VAR="1.2185019841269842" WEIGHT="2.0552975351477527"/>
<DICH_DATA CI_END="21.736881949124992" CI_START="0.18401903315121143" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3371972467692281" LOG_CI_START="-0.7351372554412656" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2010-10-12 16:03:21 +0100" MODIFIED_BY="Katharine Ker" ORDER="2856" O_E="0.0" SE="1.2172995448196726" STUDY_ID="STD-Dietrich-2008" TOTAL_1="110" TOTAL_2="110" VAR="1.481818181818182" WEIGHT="1.6900751760759023"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-10-12 16:03:26 +0100" MODIFIED_BY="Katharine Ker" ORDER="2857" O_E="0.0" SE="0.0" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.2192364308675945" CI_START="1.0576948576376777" EFFECT_SIZE="1.5320819040804732" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="61" LOG_CI_END="0.3462035731429183" LOG_CI_START="0.024360392880265733" LOG_EFFECT_SIZE="0.185281983011592" MODIFIED="2010-10-12 16:00:17 +0100" MODIFIED_BY="Katharine Ker" ORDER="2858" O_E="0.0" SE="0.1890522772357184" STUDY_ID="STD-Fergusson-2008" TOTAL_1="779" TOTAL_2="1549" VAR="0.03574076352801093" WEIGHT="70.0708064780454"/>
<DICH_DATA CI_END="67.75150586967578" CI_START="0.12318071613639271" EFFECT_SIZE="2.888888888888889" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.830918952441243" LOG_CI_START="-0.909457275378257" LOG_EFFECT_SIZE="0.4607308385314931" MODIFIED="2010-10-12 16:03:35 +0100" MODIFIED_BY="Katharine Ker" ORDER="2868" O_E="0.0" SE="1.6097105613022769" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="25" VAR="2.591168091168091" WEIGHT="0.9665077819864122"/>
<DICH_DATA CI_END="3.944898925347026" CI_START="0.009485679882356225" EFFECT_SIZE="0.19344262295081968" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5960358803651128" LOG_CI_START="-2.022931535774396" LOG_EFFECT_SIZE="-0.7134478277046417" MODIFIED="2010-10-12 16:03:46 +0100" MODIFIED_BY="Katharine Ker" ORDER="2859" O_E="0.0" SE="1.5383944243381398" STUDY_ID="STD-Hekmat-2004" TOTAL_1="60" TOTAL_2="58" VAR="2.3666574048346765" WEIGHT="1.0581946163533464"/>
<DICH_DATA CI_END="4.445867821891619" CI_START="0.01128598555110691" EFFECT_SIZE="0.224" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6479565467398456" LOG_CI_START="-1.94746051007152" LOG_EFFECT_SIZE="-0.6497519816658371" MODIFIED="2010-10-12 16:03:54 +0100" MODIFIED_BY="Katharine Ker" ORDER="2860" O_E="0.0" SE="1.5245608266926296" STUDY_ID="STD-Ickx-2006" TOTAL_1="24" TOTAL_2="27" VAR="2.3242857142857143" WEIGHT="1.0774854868987005"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-10-12 16:04:00 +0100" MODIFIED_BY="Katharine Ker" ORDER="2861" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-10-12 16:01:38 +0100" MODIFIED_BY="Katharine Ker" ORDER="2862" O_E="0.0" SE="0.0" STUDY_ID="STD-Landymore-1997" TOTAL_1="48" TOTAL_2="100" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="74.99849933654143" CI_START="0.1275400160586429" EFFECT_SIZE="3.0927835051546393" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8750525735733063" LOG_CI_START="-0.8943535326664713" LOG_EFFECT_SIZE="0.4903495204534176" MODIFIED="2010-10-12 16:04:09 +0100" MODIFIED_BY="Katharine Ker" ORDER="2863" O_E="0.0" SE="1.6267628555865639" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="99" VAR="2.6463573883161513" WEIGHT="0.9463514397586147"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-10-12 16:04:18 +0100" MODIFIED_BY="Katharine Ker" ORDER="2864" O_E="0.0" SE="0.0" STUDY_ID="STD-Misfeld-1998" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-10-12 16:04:21 +0100" MODIFIED_BY="Katharine Ker" ORDER="2865" O_E="0.0" SE="0.0" STUDY_ID="STD-Mongan-1998" TOTAL_1="75" TOTAL_2="75" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-10-12 16:04:27 +0100" MODIFIED_BY="Katharine Ker" ORDER="2866" O_E="0.0" SE="0.0" STUDY_ID="STD-Nuttall-2000" TOTAL_1="45" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.72684435116677" CI_START="0.2524130977089139" EFFECT_SIZE="1.396551724137931" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8880021639455309" LOG_CI_START="-0.5978881133141061" LOG_EFFECT_SIZE="0.14505702531571246" MODIFIED="2010-10-12 16:04:37 +0100" MODIFIED_BY="Katharine Ker" ORDER="2870" O_E="0.0" SE="0.8728193041378075" STUDY_ID="STD-Trinh_x002d_Duc-1992" TOTAL_1="29" TOTAL_2="27" VAR="0.7618135376756066" WEIGHT="3.2873977695251293"/>
<DICH_DATA CI_END="6.569203725945863" CI_START="0.14451910011013963" EFFECT_SIZE="0.9743589743589743" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8175127305360728" LOG_CI_START="-0.8400747513554507" LOG_EFFECT_SIZE="-0.011281010409689058" MODIFIED="2010-10-12 16:04:44 +0100" MODIFIED_BY="Katharine Ker" ORDER="2867" O_E="0.0" SE="0.9736750920534478" STUDY_ID="STD-Wong-2000" TOTAL_1="39" TOTAL_2="38" VAR="0.9480431848852902" WEIGHT="2.641635069452937"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.18350733170781" CI_END="1.42168353191687" CI_START="0.7099773332082204" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0046706339175955" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="62" I2="0.0" I2_Q="0.0" ID="CMP-009.08" LOG_CI_END="0.1528029327944217" LOG_CI_START="-0.1487555163791385" LOG_EFFECT_SIZE="0.002023708207641571" METHOD="MH" MODIFIED="2010-12-03 14:35:53 +0000" MODIFIED_BY="Katharine Ker" NO="8" P_CHI2="0.7996172785720588" P_Q="0.0" P_Z="0.9790132855506106" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1778" TOTAL_2="1796" WEIGHT="100.00000000000003" Z="0.02630597957421372">
<NAME>Myocardial Infarction - Aprotinin versus Tranexamic Acid</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Tranexamic Acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68159" O_E="0.0" SE="0.0" STUDY_ID="STD-Bernet-1999" TOTAL_1="28" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.3706504641457387" CI_START="0.18216095011876765" EFFECT_SIZE="0.7835820895522388" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5277137185953252" LOG_CI_START="-0.7395447171850643" LOG_EFFECT_SIZE="-0.10591549929486953" ORDER="68157" O_E="0.0" SE="0.744393878207828" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="70" VAR="0.5541222459132906" WEIGHT="5.662557442377678"/>
<DICH_DATA CI_END="1.9729574707481756" CI_START="0.3445588517133372" EFFECT_SIZE="0.8244998244998245" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.29511772366148753" LOG_CI_START="-0.4627365885852296" LOG_EFFECT_SIZE="-0.08380943246187102" ORDER="68160" O_E="0.0" SE="0.4451673744530697" STUDY_ID="STD-Casati-2000" TOTAL_1="518" TOTAL_2="522" VAR="0.19817399127743957" WEIGHT="15.833303993915898"/>
<DICH_DATA CI_END="8.156669711750888" CI_START="0.014051134117191385" EFFECT_SIZE="0.3385416666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.911512876764905" LOG_CI_START="-1.8522886208862928" LOG_EFFECT_SIZE="-0.470387872060694" ORDER="68163" O_E="0.0" SE="1.6234706807583719" STUDY_ID="STD-Dalmau-2004" TOTAL_1="63" TOTAL_2="64" VAR="2.635657051282051" WEIGHT="1.1904997450472763"/>
<DICH_DATA CI_END="2.399062894750428" CI_START="0.15005859195594384" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.38004163374732225" LOG_CI_START="-0.823739132980035" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="68164" O_E="0.0" SE="0.7071067811865475" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.49999999999999994" WEIGHT="6.275498095166678"/>
<DICH_DATA CI_END="1.9563188370084128" CI_START="0.7299660983868936" EFFECT_SIZE="1.195008965929468" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="28" LOG_CI_END="0.2914396366832041" LOG_CI_START="-0.1366973092293922" LOG_EFFECT_SIZE="0.07737116372690597" MODIFIED="2010-01-11 12:56:13 +0000" MODIFIED_BY="Katharine Ker" ORDER="2279" O_E="0.0" SE="0.25148976134112117" STUDY_ID="STD-Fergusson-2008" TOTAL_1="717" TOTAL_2="727" VAR="0.06324710005941409" WEIGHT="49.61095520009216"/>
<DICH_DATA CI_END="2.53835500603419" CI_START="0.09203248188522475" EFFECT_SIZE="0.48333333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.40455236101315073" LOG_CI_START="-1.0360588659825256" LOG_EFFECT_SIZE="-0.31575325248468755" ORDER="68165" O_E="0.0" SE="0.8462221658778435" STUDY_ID="STD-Hekmat-2004" TOTAL_1="60" TOTAL_2="58" VAR="0.7160919540229884" WEIGHT="4.3817683329012915"/>
<DICH_DATA CI_END="39.05869370178205" CI_START="0.6400623684672634" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5917177144358472" LOG_CI_START="-0.19377770576380962" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="68166" O_E="0.0" SE="1.0488088481701514" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="1.0999999999999999" WEIGHT="2.852499134166671"/>
<DICH_DATA CI_END="74.99849933654143" CI_START="0.1275400160586429" EFFECT_SIZE="3.0927835051546393" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8750525735733063" LOG_CI_START="-0.8943535326664713" LOG_EFFECT_SIZE="0.4903495204534176" MODIFIED="2010-05-06 16:47:33 +0100" MODIFIED_BY="Katharine Ker" ORDER="2405" O_E="0.0" SE="1.6267628555865639" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="99" VAR="2.6463573883161513" WEIGHT="1.1856860533791522"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68162" O_E="0.0" SE="0.0" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.8762538056637834" CI_START="0.11465824136568276" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.588412205631186" LOG_CI_START="-0.9405947237425485" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="68158" O_E="0.0" SE="0.8981462390204986" STUDY_ID="STD-Mongan-1998" TOTAL_1="75" TOTAL_2="75" VAR="0.8066666666666666" WEIGHT="3.8897715465909153"/>
<DICH_DATA CI_END="68.25874292736694" CI_START="0.13185124152633107" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.8799157764849103" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="68156" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="1.234524215442625"/>
<DICH_DATA CI_END="2.6843409694433737" CI_START="0.22634988248563323" EFFECT_SIZE="0.7794871794871795" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.42883767980641796" LOG_CI_START="-0.6452197266419089" LOG_EFFECT_SIZE="-0.10819102341774546" ORDER="68161" O_E="0.0" SE="0.6309066372176553" STUDY_ID="STD-Wong-2000" TOTAL_1="39" TOTAL_2="38" VAR="0.3980431848852901" WEIGHT="7.882936240919659"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.273942697912369" CI_END="2.224534023703321" CI_START="0.9032642218310909" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.417512608006421" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-009.09" LOG_CI_END="0.34723905256264526" LOG_CI_START="-0.04418519177030152" LOG_EFFECT_SIZE="0.15152693039617185" METHOD="MH" MODIFIED="2010-10-12 14:41:12 +0100" MODIFIED_BY="Katharine Ker" NO="9" P_CHI2="0.7353298454396406" P_Q="0.0" P_Z="0.12914799487738382" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="830" TOTAL_2="846" WEIGHT="99.99999999999999" Z="1.5174702669249382">
<NAME>Myocardial Infarction - Aprotinin versus Epsilon Aminocaproic Acid</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.705585869128759" CI_START="0.20621704660852505" EFFECT_SIZE="0.9850746268656716" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6726137029789115" LOG_CI_START="-0.6856754372968271" LOG_EFFECT_SIZE="-0.00653086715895778" ORDER="68167" O_E="0.0" SE="0.7978657646376507" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="66" VAR="0.6365897783808231" WEIGHT="8.30445214373212"/>
<DICH_DATA CI_END="14.903914722906746" CI_START="0.06709646549862758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528004" LOG_EFFECT_SIZE="0.0" ORDER="68168" O_E="0.0" SE="1.378404875209022" STUDY_ID="STD-Eberle-1998" TOTAL_1="20" TOTAL_2="20" VAR="1.9" WEIGHT="2.7823838682908324"/>
<DICH_DATA CI_END="2.91937344005265" CI_START="0.9799741111309606" EFFECT_SIZE="1.6914225941422594" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="20" LOG_CI_END="0.4652896525696162" LOG_CI_START="-0.008785397309014037" LOG_EFFECT_SIZE="0.22825212763030106" MODIFIED="2010-01-11 12:57:35 +0000" MODIFIED_BY="Katharine Ker" ORDER="2280" O_E="0.0" SE="0.2784740310080515" STUDY_ID="STD-Fergusson-2008" TOTAL_1="717" TOTAL_2="735" VAR="0.07754778594587322" WEIGHT="68.1712480281832"/>
<DICH_DATA CI_END="2.586391732449731" CI_START="0.35746952072957927" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.41269430335837154" LOG_CI_START="-0.4467609819559322" LOG_EFFECT_SIZE="-0.017033339298780342" MODIFIED="2010-05-17 14:26:10 +0100" MODIFIED_BY="Katharine Ker" ORDER="2620" O_E="0.0" SE="0.504848288965898" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="25" VAR="0.25487179487179484" WEIGHT="20.741915959793836"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6227942604010961" CI_END="2.2269748537279472" CI_START="0.7967454585380073" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3320405778301518" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-009.10" LOG_CI_END="0.3477153131504054" LOG_CI_START="-0.09868040333274163" LOG_EFFECT_SIZE="0.12451745490883186" METHOD="MH" MODIFIED="2010-10-12 14:40:04 +0100" MODIFIED_BY="Katharine Ker" NO="10" P_CHI2="0.7324229937560638" P_Q="0.0" P_Z="0.27420802797130894" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="840" TOTAL_2="847" WEIGHT="100.0" Z="1.0934232478331334">
<NAME>Myocardial Infarction - Tranexamic Acid versus Epsilon Aminocaproic Acid</NAME>
<GROUP_LABEL_1>Tranexamic Acid</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TXA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.4061058161313085" CI_START="0.29233763026789406" EFFECT_SIZE="1.2571428571428571" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7328845420863781" LOG_CI_START="-0.5341152778145546" LOG_EFFECT_SIZE="0.09938463213591178" ORDER="68170" O_E="0.0" SE="0.7442419659600659" STUDY_ID="STD-Casati-1999" TOTAL_1="70" TOTAL_2="66" VAR="0.5538961038961039" WEIGHT="12.413290837049416"/>
<DICH_DATA CI_END="2.4893019606181834" CI_START="0.8047932897375843" EFFECT_SIZE="1.4154057771664375" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="20" LOG_CI_END="0.3960775811710916" LOG_CI_START="-0.09431565336430146" LOG_EFFECT_SIZE="0.1508809639033951" MODIFIED="2010-01-11 12:58:34 +0000" MODIFIED_BY="Katharine Ker" ORDER="2281" O_E="0.0" SE="0.28805941345175085" STUDY_ID="STD-Fergusson-2008" TOTAL_1="727" TOTAL_2="735" VAR="0.08297822567816673" WEIGHT="82.86117683256282"/>
<DICH_DATA CI_END="5.688650380565166" CI_START="0.05029322875837325" EFFECT_SIZE="0.5348837209302325" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7550092432321541" LOG_CI_START="-1.2984904823561414" LOG_EFFECT_SIZE="-0.2717406195619937" ORDER="68169" O_E="0.0" SE="1.2062359037981454" STUDY_ID="STD-Hardy-1998" TOTAL_1="43" TOTAL_2="46" VAR="1.4550050556117289" WEIGHT="4.725532330387769"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.515719749565829" CI_END="1.5017726623752377" CI_START="0.8159684697520053" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1069774800029664" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="92" I2="0.0" I2_Q="0.0" ID="CMP-009.11" LOG_CI_END="0.1766041943535371" LOG_CI_START="-0.08832662271339467" LOG_EFFECT_SIZE="0.04413878582007125" METHOD="MH" MODIFIED="2010-10-12 16:15:16 +0100" MODIFIED_BY="Katharine Ker" NO="11" P_CHI2="0.821739118246742" P_Q="0.0" P_Z="0.5137050911382472" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1824" TOTAL_2="2642" WEIGHT="100.0" Z="0.6530794075708524">
<NAME>Myocardial infarction - Aprotinin versus Lysine Analogues</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Lysine Analogues</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lysine Analogues</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-10-12 16:14:03 +0100" MODIFIED_BY="Katharine Ker" ORDER="2871" O_E="0.0" SE="0.0" STUDY_ID="STD-Bernet-1999" TOTAL_1="28" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.258122184869758" CI_START="0.2322775698733435" EFFECT_SIZE="0.8699360341151386" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.512967367025805" LOG_CI_START="-0.6339927262762115" LOG_EFFECT_SIZE="-0.06051267962520328" MODIFIED="2010-10-12 16:13:29 +0100" MODIFIED_BY="Katharine Ker" ORDER="2872" O_E="0.0" SE="0.6737300363496326" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="136" VAR="0.45391216187967726" WEIGHT="5.335416685769419"/>
<DICH_DATA CI_END="1.9729574707481756" CI_START="0.3445588517133372" EFFECT_SIZE="0.8244998244998245" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.29511772366148753" LOG_CI_START="-0.4627365885852296" LOG_EFFECT_SIZE="-0.08380943246187102" MODIFIED="2010-10-12 16:14:08 +0100" MODIFIED_BY="Katharine Ker" ORDER="2873" O_E="0.0" SE="0.4451673744530697" STUDY_ID="STD-Casati-2000" TOTAL_1="518" TOTAL_2="522" VAR="0.19817399127743957" WEIGHT="12.220627473642667"/>
<DICH_DATA CI_END="8.156669711750888" CI_START="0.014051134117191385" EFFECT_SIZE="0.3385416666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.911512876764905" LOG_CI_START="-1.8522886208862928" LOG_EFFECT_SIZE="-0.470387872060694" MODIFIED="2010-10-12 16:14:17 +0100" MODIFIED_BY="Katharine Ker" ORDER="2874" O_E="0.0" SE="1.6234706807583719" STUDY_ID="STD-Dalmau-2004" TOTAL_1="63" TOTAL_2="64" VAR="2.635657051282051" WEIGHT="0.9188640537237078"/>
<DICH_DATA CI_END="2.399062894750428" CI_START="0.15005859195594384" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.38004163374732225" LOG_CI_START="-0.823739132980035" LOG_EFFECT_SIZE="-0.22184874961635637" MODIFIED="2010-10-12 16:14:21 +0100" MODIFIED_BY="Katharine Ker" ORDER="2875" O_E="0.0" SE="0.7071067811865475" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.49999999999999994" WEIGHT="4.843621044733001"/>
<DICH_DATA CI_END="14.903914722906746" CI_START="0.06709646549862758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528004" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-10-12 16:14:26 +0100" MODIFIED_BY="Katharine Ker" ORDER="2876" O_E="0.0" SE="1.378404875209022" STUDY_ID="STD-Eberle-1998" TOTAL_1="20" TOTAL_2="20" VAR="1.9" WEIGHT="1.274637117035"/>
<DICH_DATA CI_END="2.1638804283247834" CI_START="0.9081729872016746" EFFECT_SIZE="1.4018479776847979" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="48" LOG_CI_END="0.33523325885899263" LOG_CI_START="-0.04183141994630894" LOG_EFFECT_SIZE="0.1467009194563418" MODIFIED="2010-10-12 16:12:27 +0100" MODIFIED_BY="Katharine Ker" ORDER="2877" O_E="0.0" SE="0.22148965883049676" STUDY_ID="STD-Fergusson-2008" TOTAL_1="717" TOTAL_2="1462" VAR="0.049057668968849846" WEIGHT="49.36660410636872"/>
<DICH_DATA CI_END="2.586391732449731" CI_START="0.35746952072957927" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.41269430335837154" LOG_CI_START="-0.4467609819559322" LOG_EFFECT_SIZE="-0.017033339298780342" MODIFIED="2010-10-12 16:14:34 +0100" MODIFIED_BY="Katharine Ker" ORDER="2878" O_E="0.0" SE="0.504848288965898" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="25" VAR="0.25487179487179484" WEIGHT="9.50207347809794"/>
<DICH_DATA CI_END="2.53835500603419" CI_START="0.09203248188522475" EFFECT_SIZE="0.48333333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.40455236101315073" LOG_CI_START="-1.0360588659825256" LOG_EFFECT_SIZE="-0.31575325248468755" MODIFIED="2010-10-12 16:14:38 +0100" MODIFIED_BY="Katharine Ker" ORDER="2879" O_E="0.0" SE="0.8462221658778435" STUDY_ID="STD-Hekmat-2004" TOTAL_1="60" TOTAL_2="58" VAR="0.7160919540229884" WEIGHT="3.3819825914267345"/>
<DICH_DATA CI_END="39.05869370178205" CI_START="0.6400623684672634" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5917177144358472" LOG_CI_START="-0.19377770576380962" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2010-10-12 16:14:42 +0100" MODIFIED_BY="Katharine Ker" ORDER="2880" O_E="0.0" SE="1.0488088481701514" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="1.0999999999999999" WEIGHT="2.201645929424091"/>
<DICH_DATA CI_END="74.99849933654143" CI_START="0.1275400160586429" EFFECT_SIZE="3.0927835051546393" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8750525735733063" LOG_CI_START="-0.8943535326664713" LOG_EFFECT_SIZE="0.4903495204534176" MODIFIED="2010-10-12 16:14:48 +0100" MODIFIED_BY="Katharine Ker" ORDER="2881" O_E="0.0" SE="1.6267628555865639" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="99" VAR="2.6463573883161513" WEIGHT="0.91514869951389"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-10-12 16:14:59 +0100" MODIFIED_BY="Katharine Ker" ORDER="2882" O_E="0.0" SE="0.0" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.8762538056637834" CI_START="0.11465824136568276" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.588412205631186" LOG_CI_START="-0.9405947237425485" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2010-10-12 16:15:06 +0100" MODIFIED_BY="Katharine Ker" ORDER="2883" O_E="0.0" SE="0.8981462390204986" STUDY_ID="STD-Mongan-1998" TOTAL_1="75" TOTAL_2="75" VAR="0.8066666666666666" WEIGHT="3.0022444492146696"/>
<DICH_DATA CI_END="68.25874292736694" CI_START="0.13185124152633107" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.8799157764849103" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-10-12 16:15:11 +0100" MODIFIED_BY="Katharine Ker" ORDER="2884" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="0.9528434842097706"/>
<DICH_DATA CI_END="2.6843409694433737" CI_START="0.22634988248563323" EFFECT_SIZE="0.7794871794871795" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.42883767980641796" LOG_CI_START="-0.6452197266419089" LOG_EFFECT_SIZE="-0.10819102341774546" MODIFIED="2010-10-12 16:15:16 +0100" MODIFIED_BY="Katharine Ker" ORDER="2885" O_E="0.0" SE="0.6309066372176553" STUDY_ID="STD-Wong-2000" TOTAL_1="39" TOTAL_2="38" VAR="0.3980431848852901" WEIGHT="6.084290886840402"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.9128314773610042" CI_END="1.4687613542317035" CI_START="0.5226067615598546" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8761190643053586" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-009.12" LOG_CI_END="0.1669512369340176" LOG_CI_START="-0.2818249756091957" LOG_EFFECT_SIZE="-0.05743686933758906" METHOD="MH" MODIFIED="2010-10-12 14:40:59 +0100" MODIFIED_BY="Katharine Ker" NO="12" P_CHI2="0.7517875219245722" P_Q="0.0" P_Z="0.6158826976053782" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1017" TOTAL_2="1013" WEIGHT="100.0" Z="0.5016941278970645">
<NAME>Stroke (CVA) - Aprotinin versus Tranexamic Acid</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Tranexamic Acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68172" O_E="0.0" SE="0.0" STUDY_ID="STD-Bernet-1999" TOTAL_1="28" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.350024358809896" CI_START="0.4500845393339413" EFFECT_SIZE="0.7795031055900621" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="28" LOG_CI_END="0.1303416046441055" LOG_CI_START="-0.34670590507369103" LOG_EFFECT_SIZE="-0.10818215021479279" MODIFIED="2010-01-11 12:59:51 +0000" MODIFIED_BY="Katharine Ker" ORDER="2282" O_E="0.0" SE="0.28022006863149135" STUDY_ID="STD-Fergusson-2008" TOTAL_1="759" TOTAL_2="753" VAR="0.07852328686383771" WEIGHT="88.4985982458329"/>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="68174" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="2.7024669844297455"/>
<DICH_DATA CI_END="16.253770153845917" CI_START="0.06542953126775718" EFFECT_SIZE="1.03125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2109541140594726" LOG_CI_START="-1.1842261909435097" LOG_EFFECT_SIZE="0.013363961557981502" MODIFIED="2010-05-21 10:39:32 +0100" MODIFIED_BY="Katharine Ker" ORDER="2745" O_E="0.0" SE="1.406940767492478" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="99" VAR="1.979482323232323" WEIGHT="3.5106152429578747"/>
<DICH_DATA CI_END="72.48563796148957" CI_START="0.12416252726894049" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.860251965578492" LOG_CI_START="-0.9060094561391671" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="68171" O_E="0.0" SE="1.6249156523318318" STUDY_ID="STD-Mongan-1998" TOTAL_1="75" TOTAL_2="75" VAR="2.6403508771929824" WEIGHT="2.6319232330564013"/>
<DICH_DATA CI_END="69.64188698182446" CI_START="0.12285171138790224" EFFECT_SIZE="2.925" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8428705300313253" LOG_CI_START="-0.9106187891949267" LOG_EFFECT_SIZE="0.4661258704181992" ORDER="68173" O_E="0.0" SE="1.6174132561054522" STUDY_ID="STD-Wong-2000" TOTAL_1="39" TOTAL_2="38" VAR="2.616025641025641" WEIGHT="2.656396293723081"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.27314331588943797" CI_END="1.848600156172282" CI_START="0.5970510147386434" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0505753657347365" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-009.13" LOG_CI_END="0.26684298539038054" LOG_CI_START="-0.22398855920072805" LOG_EFFECT_SIZE="0.021427213094826203" METHOD="MH" MODIFIED="2010-10-12 14:40:57 +0100" MODIFIED_BY="Katharine Ker" NO="13" P_CHI2="0.6012310154176421" P_Q="0.0" P_Z="0.8641261453857483" Q="0.0" RANDOM="YES" SCALE="74.5636650490713" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="785" TOTAL_2="793" WEIGHT="100.00000000000001" Z="0.17112415213618745">
<NAME>Stroke (CVA) - Aprotinin versus Epsilon Aminocaproic Acid</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Epsilon Aminocaproic Acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.811513648238779" CI_START="0.5651936551748222" EFFECT_SIZE="1.0118577075098814" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" LOG_CI_END="0.2580416104282208" LOG_CI_START="-0.2478027221561576" LOG_EFFECT_SIZE="0.005119444136031612" MODIFIED="2010-01-11 13:15:36 +0000" MODIFIED_BY="Katharine Ker" ORDER="2284" O_E="0.0" SE="0.29713546492989373" STUDY_ID="STD-Fergusson-2008" TOTAL_1="759" TOTAL_2="768" VAR="0.0882894845191041" WEIGHT="94.15234797119474"/>
<DICH_DATA CI_END="19.900760915747448" CI_START="0.1858333391234606" EFFECT_SIZE="1.9230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2988696821982768" LOG_CI_START="-0.7308763694678753" LOG_EFFECT_SIZE="0.28399665636520083" MODIFIED="2010-05-20 15:24:50 +0100" MODIFIED_BY="Katharine Ker" ORDER="2621" O_E="0.0" SE="1.192282878153696" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="25" VAR="1.4215384615384614" WEIGHT="5.847652028805266"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3026699544566413" CI_END="2.2896356726368468" CI_START="0.7756378823301018" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3326395478266062" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-009.14" LOG_CI_END="0.359766382797886" LOG_CI_START="-0.11034098803433728" LOG_EFFECT_SIZE="0.12471269738177429" METHOD="MH" MODIFIED="2010-10-12 14:40:55 +0100" MODIFIED_BY="Katharine Ker" NO="14" P_CHI2="0.5822135149177636" P_Q="0.0" P_Z="0.2983862433173873" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="820" TOTAL_2="838" WEIGHT="100.0" Z="1.0399002885251758">
<NAME>Stroke (CVA) - Tranexamic Acid versus Epsilon Aminocaproic Acid</NAME>
<GROUP_LABEL_1>Tranexamic Acid</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TXA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.248271721710712" CI_START="0.7494702367428567" EFFECT_SIZE="1.2980804056501267" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="22" LOG_CI_END="0.35184879804836977" LOG_CI_START="-0.12524560934672102" LOG_EFFECT_SIZE="0.11330159435082438" MODIFIED="2010-01-11 13:00:44 +0000" MODIFIED_BY="Katharine Ker" ORDER="2283" O_E="0.0" SE="0.28024761655928115" STUDY_ID="STD-Fergusson-2008" TOTAL_1="753" TOTAL_2="768" VAR="0.07853872658715787" WEIGHT="97.09245216002535"/>
<DICH_DATA CI_END="76.60488571591196" CI_START="0.1340529585584237" EFFECT_SIZE="3.2045454545454546" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8842564690033063" LOG_CI_START="-0.8727235966649216" LOG_EFFECT_SIZE="0.5057664361691925" ORDER="68175" O_E="0.0" SE="1.6194637378449426" STUDY_ID="STD-Hardy-1998" TOTAL_1="43" TOTAL_2="46" VAR="2.6226627981947126" WEIGHT="2.9075478399746606"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68176" O_E="0.0" SE="0.0" STUDY_ID="STD-Maineri-2000" TOTAL_1="24" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.8067649371050125" CI_START="0.052010032375448" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.49999999999999994" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-009.15" LOG_CI_END="0.6818528845554627" LOG_CI_START="-1.2839128758834253" LOG_EFFECT_SIZE="-0.30102999566398125" METHOD="MH" MODIFIED="2010-10-12 14:40:52 +0100" MODIFIED_BY="Katharine Ker" NO="15" P_CHI2="1.0" P_Q="0.0" P_Z="0.5483176049619031" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="127" TOTAL_2="138" WEIGHT="99.99999999999999" Z="0.6002830669264718">
<NAME>Deep Vein Thrombosis (DVT) - Aprotinin versus Tranexamic Acid</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Tranexamic Acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68178" O_E="0.0" SE="0.0" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="70" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.8067649371050125" CI_START="0.052010032375448" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6818528845554627" LOG_CI_START="-1.2839128758834253" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="68179" O_E="0.0" SE="1.1547005383792517" STUDY_ID="STD-Engel-2001" TOTAL_1="12" TOTAL_2="12" VAR="1.3333333333333335" WEIGHT="99.99999999999999"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68177" O_E="0.0" SE="0.0" STUDY_ID="STD-Landymore-1997" TOTAL_1="48" TOTAL_2="56" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.5067893142172926" CI_START="0.007476860430949996" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.13690476190476192" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-009.16" LOG_CI_END="0.39911783474887014" LOG_CI_START="-2.12628072616541" LOG_EFFECT_SIZE="-0.86358144570827" METHOD="MH" MODIFIED="2010-10-12 14:40:49 +0100" MODIFIED_BY="Katharine Ker" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.18009824528276672" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="153" TOTAL_2="147" WEIGHT="100.0" Z="1.340452598256385">
<NAME>Deep Vein Thrombosis (DVT) - Aprotinin versus Epsilon Aminocaproic Acid</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5067893142172926" CI_START="0.007476860430949996" EFFECT_SIZE="0.13690476190476192" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.39911783474887014" LOG_CI_START="-2.12628072616541" LOG_EFFECT_SIZE="-0.86358144570827" ORDER="68182" O_E="0.0" SE="1.483431615605537" STUDY_ID="STD-Amar-2003" TOTAL_1="23" TOTAL_2="22" VAR="2.2005693581780537" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68181" O_E="0.0" SE="0.0" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="66" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68180" O_E="0.0" SE="0.0" STUDY_ID="STD-Landymore-1997" TOTAL_1="48" TOTAL_2="44" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68183" O_E="0.0" SE="0.0" STUDY_ID="STD-Ray-2005" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.17" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-10-12 14:40:46 +0100" MODIFIED_BY="Katharine Ker" NO="17" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="161" TOTAL_2="142" WEIGHT="0.0" Z="0.0">
<NAME>Deep Vein Thrombosis (DVT) - Tranexamic Acid versus Epsilon Aminocaproic Acid</NAME>
<GROUP_LABEL_1>Tranexamic Acid</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TXA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68186" O_E="0.0" SE="0.0" STUDY_ID="STD-Camarasa-2006" TOTAL_1="35" TOTAL_2="32" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68185" O_E="0.0" SE="0.0" STUDY_ID="STD-Casati-1999" TOTAL_1="70" TOTAL_2="66" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68184" O_E="0.0" SE="0.0" STUDY_ID="STD-Landymore-1997" TOTAL_1="56" TOTAL_2="44" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.18" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-10-12 14:40:44 +0100" MODIFIED_BY="Katharine Ker" NO="18" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="115" TOTAL_2="126" WEIGHT="0.0" Z="0.0">
<NAME>Pulmonary Embolism (PE) - Aprotinin versus Tranexamic Acid</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Tranexamic Acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68188" O_E="0.0" SE="0.0" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="70" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68187" O_E="0.0" SE="0.0" STUDY_ID="STD-Landymore-1997" TOTAL_1="48" TOTAL_2="56" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.453843339139822" CI_END="18.42116406422815" CI_START="0.09631792602724823" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3320241430522684" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="31.21679804980515" I2_Q="0.0" ID="CMP-009.19" LOG_CI_END="1.2653170705240961" LOG_CI_START="-1.016292877463109" LOG_EFFECT_SIZE="0.12451209653049349" METHOD="MH" MODIFIED="2010-10-12 14:40:42 +0100" MODIFIED_BY="Katharine Ker" NO="19" P_CHI2="0.22791254755115542" P_Q="0.0" P_Z="0.83061065712922" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.1236912560756611" TOTALS="YES" TOTAL_1="138" TOTAL_2="132" WEIGHT="100.0" Z="0.21391844390810874">
<NAME>Pulmonary Embolism (PE) - Aprotinin versus Epsilon Aminocaproic Acid</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<DICH_DATA CI_END="94.52784694720698" CI_START="0.2428921231779188" EFFECT_SIZE="4.791666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9755597661175481" LOG_CI_START="-0.6145865688335366" LOG_EFFECT_SIZE="0.6804865986420057" ORDER="68191" O_E="0.0" SE="1.5214647785814064" STUDY_ID="STD-Amar-2003" TOTAL_1="23" TOTAL_2="22" VAR="2.314855072463768" WEIGHT="52.23758939898399"/>
<DICH_DATA CI_END="7.919662615327164" CI_START="0.013620171933293509" EFFECT_SIZE="0.3284313725490196" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8987066806522864" LOG_CI_START="-1.8658174101024312" LOG_EFFECT_SIZE="-0.4835553647250723" ORDER="68190" O_E="0.0" SE="1.623895135524273" STUDY_ID="STD-Casati-1999" TOTAL_1="67" TOTAL_2="66" VAR="2.637035411179397" WEIGHT="47.762410601016"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68189" O_E="0.0" SE="0.0" STUDY_ID="STD-Landymore-1997" TOTAL_1="48" TOTAL_2="44" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.587873622928624" CI_START="0.013039781357177392" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3145539906103286" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-009.20" LOG_CI_END="0.880120089042957" LOG_CI_START="-1.8847296905187794" LOG_EFFECT_SIZE="-0.5023048007379113" METHOD="MH" MODIFIED="2010-10-12 14:40:40 +0100" MODIFIED_BY="Katharine Ker" NO="20" P_CHI2="1.0" P_Q="0.0" P_Z="0.47636946667493585" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="134" WEIGHT="100.0" Z="0.7121539303765937">
<NAME>Pulmonary Embolism (PE) - Tranexamic Acid versus Epsilon Aminocaproic Acid</NAME>
<GROUP_LABEL_1>Tranexamic Acid</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TXA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.587873622928624" CI_START="0.013039781357177392" EFFECT_SIZE="0.3145539906103286" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.880120089042957" LOG_CI_START="-1.8847296905187794" LOG_EFFECT_SIZE="-0.5023048007379113" ORDER="68193" O_E="0.0" SE="1.6240864467417013" STUDY_ID="STD-Casati-1999" TOTAL_1="70" TOTAL_2="66" VAR="2.637656786490085" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68192" O_E="0.0" SE="0.0" STUDY_ID="STD-Landymore-1997" TOTAL_1="56" TOTAL_2="44" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68194" O_E="0.0" SE="0.0" STUDY_ID="STD-Maineri-2000" TOTAL_1="24" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.6750144348042593" CI_START="0.0964478893040489" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5079365079365079" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-009.21" LOG_CI_END="0.4273261298858166" LOG_CI_START="-1.0157072721531681" LOG_EFFECT_SIZE="-0.29419057113367575" METHOD="MH" MODIFIED="2010-10-12 14:40:36 +0100" MODIFIED_BY="Katharine Ker" NO="21" P_CHI2="1.0" P_Q="0.0" P_Z="0.42420115537341896" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="139" TOTAL_2="148" WEIGHT="100.0" Z="0.799153953329898">
<NAME>Other Thrombosis - Aprotinin versus Tranexamic Acid</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Tranexamic Acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68196" O_E="0.0" SE="0.0" STUDY_ID="STD-Bernet-1999" TOTAL_1="28" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.6750144348042593" CI_START="0.0964478893040489" EFFECT_SIZE="0.5079365079365079" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4273261298858166" LOG_CI_START="-1.0157072721531681" LOG_EFFECT_SIZE="-0.29419057113367575" ORDER="68197" O_E="0.0" SE="0.8476449634882426" STUDY_ID="STD-Dalmau-2004" TOTAL_1="63" TOTAL_2="64" VAR="0.7185019841269842" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68195" O_E="0.0" SE="0.0" STUDY_ID="STD-Landymore-1997" TOTAL_1="48" TOTAL_2="56" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.22" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-10-12 14:40:34 +0100" MODIFIED_BY="Katharine Ker" NO="22" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="48" TOTAL_2="44" WEIGHT="0.0" Z="0.0">
<NAME>Other Thrombosis - Aprotinin versus Epsilon Aminocaproic Acid</NAME>
<GROUP_LABEL_1>Aproinin</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68198" O_E="0.0" SE="0.0" STUDY_ID="STD-Landymore-1997" TOTAL_1="48" TOTAL_2="44" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.337283820460158" CI_START="0.38694884163700377" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-009.23" LOG_CI_END="1.0144064404263402" LOG_CI_START="-0.41234644909837787" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" MODIFIED="2010-10-12 14:40:32 +0100" MODIFIED_BY="Katharine Ker" NO="23" P_CHI2="1.0" P_Q="0.0" P_Z="0.40820081619158344" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="98" TOTAL_2="86" WEIGHT="100.0" Z="0.8270639633527515">
<NAME>Other Thrombosis - Tranexamic Acid versus Epsilon Aminocaproic Acid</NAME>
<GROUP_LABEL_1>Tranexamic Acid</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TXA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.337283820460158" CI_START="0.38694884163700377" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0144064404263402" LOG_CI_START="-0.41234644909837787" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="68200" O_E="0.0" SE="0.8380817098475257" STUDY_ID="STD-Dalmau-2000" TOTAL_1="42" TOTAL_2="42" VAR="0.7023809523809523" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68199" O_E="0.0" SE="0.0" STUDY_ID="STD-Landymore-1997" TOTAL_1="56" TOTAL_2="44" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2013357100487319" CI_END="1.313634122040952" CI_START="0.7934137590773499" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0209090982162838" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="105" I2="0.0" I2_Q="0.0" ID="CMP-009.24" LOG_CI_END="0.11847442085151574" LOG_CI_START="-0.100500272428094" LOG_EFFECT_SIZE="0.00898707421171085" METHOD="MH" MODIFIED="2010-10-12 14:40:30 +0100" MODIFIED_BY="Katharine Ker" NO="24" P_CHI2="0.7526840354924628" P_Q="0.0" P_Z="0.8721877892868162" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1119" TOTAL_2="1119" WEIGHT="100.0" Z="0.16088015941504433">
<NAME>Renal Failure / Dysfunction - Aprotinin versus Tranexamic Acid</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Tranexamic Acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6750144348042593" CI_START="0.0964478893040489" EFFECT_SIZE="0.5079365079365079" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4273261298858166" LOG_CI_START="-1.0157072721531681" LOG_EFFECT_SIZE="-0.29419057113367575" ORDER="68202" O_E="0.0" SE="0.8476449634882426" STUDY_ID="STD-Dalmau-2004" TOTAL_1="63" TOTAL_2="64" VAR="0.7185019841269842" WEIGHT="2.302687935954841"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-17 11:12:01 +0100" MODIFIED_BY="Katharine Ker" ORDER="2573" O_E="0.0" SE="0.0" STUDY_ID="STD-Dietrich-2008" TOTAL_1="110" TOTAL_2="110" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68203" O_E="0.0" SE="0.0" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.3558100958085664" CI_START="0.8071125502019032" EFFECT_SIZE="1.0460838130941224" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="97" LOG_CI_END="0.13219886348522947" LOG_CI_START="-0.09306589957363992" LOG_EFFECT_SIZE="0.019566481955794763" MODIFIED="2010-01-11 13:22:01 +0000" MODIFIED_BY="Katharine Ker" ORDER="2286" O_E="0.0" SE="0.1323216368993408" STUDY_ID="STD-Fergusson-2008" TOTAL_1="770" TOTAL_2="766" VAR="0.017509015591720987" WEIGHT="94.49336783908826"/>
<DICH_DATA CI_END="4.984121775777423" CI_START="0.21337290907867495" EFFECT_SIZE="1.03125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.697588644787164" LOG_CI_START="-0.670860721671201" LOG_EFFECT_SIZE="0.013363961557981502" MODIFIED="2010-05-06 16:48:07 +0100" MODIFIED_BY="Katharine Ker" ORDER="2406" O_E="0.0" SE="0.8038339317912562" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="99" VAR="0.64614898989899" WEIGHT="2.560533060753469"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="68201" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.643411164203431"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.1168706910236863" CI_END="2.992520144857858" CI_START="0.5915603450260655" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3305097704975961" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="103" I2="52.76045890566819" I2_Q="0.0" ID="CMP-009.25" LOG_CI_END="0.47603708264441624" LOG_CI_START="-0.22800094642899768" LOG_EFFECT_SIZE="0.12401806810770927" METHOD="MH" MODIFIED="2010-10-12 14:40:29 +0100" MODIFIED_BY="Katharine Ker" NO="25" P_CHI2="0.14568400079640353" P_Q="0.0" P_Z="0.48987656914377886" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.2217463134001842" TOTALS="YES" TOTAL_1="796" TOTAL_2="799" WEIGHT="100.0" Z="0.690505162748813">
<NAME>Renal Failure / Dysfunction - Aprotinin versus Epsilon Aminocaproic Acid</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Epsilon Aminocaproic Acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3259506803444958" CI_START="0.7928178947136112" EFFECT_SIZE="1.0252987012987014" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="100" LOG_CI_END="0.12252737048460507" LOG_CI_START="-0.10082655593994846" LOG_EFFECT_SIZE="0.010850407272328317" MODIFIED="2010-01-11 13:21:19 +0000" MODIFIED_BY="Katharine Ker" ORDER="2285" O_E="0.0" SE="0.13119920200154978" STUDY_ID="STD-Fergusson-2008" TOTAL_1="770" TOTAL_2="774" VAR="0.017213230605843465" WEIGHT="71.5719846514554"/>
<DICH_DATA CI_END="8.581490813676588" CI_START="0.7661398353720971" EFFECT_SIZE="2.5641025641025643" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9335627419175793" LOG_CI_START="-0.11569195597057767" LOG_EFFECT_SIZE="0.40893539297350084" MODIFIED="2010-05-20 15:28:05 +0100" MODIFIED_BY="Katharine Ker" ORDER="2622" O_E="0.0" SE="0.616337403434024" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="25" VAR="0.37987179487179484" WEIGHT="28.428015348544605"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.272233084652683" CI_START="0.755094253800785" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.980130548302872" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="100" I2="0.0" I2_Q="0.0" ID="CMP-009.26" LOG_CI_END="0.10456668529433123" LOG_CI_START="-0.12199883466126421" LOG_EFFECT_SIZE="-0.008716074683466492" METHOD="MH" MODIFIED="2010-10-12 14:40:27 +0100" MODIFIED_BY="Katharine Ker" NO="26" P_CHI2="1.0" P_Q="0.0" P_Z="0.88013242601213" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="766" TOTAL_2="774" WEIGHT="100.0" Z="0.15080134408363474">
<NAME>Renal Failure / Dysfunction - Tranexamic Acid versus Epsilon Aminocaproic Acid</NAME>
<GROUP_LABEL_1>Tranexamic Acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Epsilon Aminocaproic Acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.272233084652683" CI_START="0.755094253800785" EFFECT_SIZE="0.980130548302872" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="100" LOG_CI_END="0.10456668529433123" LOG_CI_START="-0.12199883466126421" LOG_EFFECT_SIZE="-0.008716074683466492" MODIFIED="2010-01-11 13:23:35 +0000" MODIFIED_BY="Katharine Ker" ORDER="2287" O_E="0.0" SE="0.13308570793932814" STUDY_ID="STD-Fergusson-2008" TOTAL_1="766" TOTAL_2="774" VAR="0.01771180565771215" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="9.143788291942021" CI_END="0.8273326146020594" CI_START="-0.9177562656396552" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.04521182551879793" ESTIMABLE="YES" I2="45.31806905015224" I2_Q="0.0" ID="CMP-009.27" MODIFIED="2010-10-12 14:40:25 +0100" MODIFIED_BY="Katharine Ker" NO="27" P_CHI2="0.10346459058332014" P_Q="1.0" P_Z="0.9191078079690131" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.4979486974562835" TOTALS="YES" TOTAL_1="1090" TOTAL_2="1084" UNITS="" WEIGHT="100.0" Z="0.10155763490955133">
<NAME>Hospital Length of Stay - Aprotinin versus Tranexamic Acid</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>Tranexamic Acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.546613293983083" CI_START="-1.9466132939830816" EFFECT_SIZE="-0.6999999999999993" ESTIMABLE="YES" MEAN_1="10.4" MEAN_2="11.1" MODIFIED="2010-05-17 11:12:33 +0100" MODIFIED_BY="Katharine Ker" ORDER="2574" SD_1="4.3" SD_2="5.1" SE="0.6360388781713383" STUDY_ID="STD-Dietrich-2008" TOTAL_1="110" TOTAL_2="110" WEIGHT="21.96011108072504"/>
<CONT_DATA CI_END="1.6075733865307054" CI_START="-0.8875733865307065" EFFECT_SIZE="0.35999999999999943" ESTIMABLE="YES" MEAN_1="11.92" MEAN_2="11.56" MODIFIED="2010-06-11 16:59:04 +0100" MODIFIED_BY="Katharine Ker" ORDER="5491" SD_1="14.02" SD_2="10.86" SE="0.6365287303090289" STUDY_ID="STD-Fergusson-2008" TOTAL_1="780" TOTAL_2="770" WEIGHT="21.94495328198119"/>
<CONT_DATA CI_END="2.588750948093388" CI_START="0.011249051906613738" EFFECT_SIZE="1.3000000000000007" ESTIMABLE="YES" MEAN_1="10.3" MEAN_2="9.0" ORDER="68205" SD_1="4.0" SD_2="3.1" SE="0.6575380763416522" STUDY_ID="STD-Hekmat-2004" TOTAL_1="60" TOTAL_2="58" WEIGHT="21.303627752835535"/>
<CONT_DATA CI_END="2.694459410562284" CI_START="-12.694459410562285" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="26.0" MEAN_2="31.0" ORDER="68206" SD_1="7.0" SD_2="19.0" SE="3.9258167350294175" STUDY_ID="STD-Ickx-2006" TOTAL_1="24" TOTAL_2="27" WEIGHT="1.2456875925850148"/>
<CONT_DATA CI_END="0.5601211790068525" CI_START="-3.7601211790068536" EFFECT_SIZE="-1.6000000000000005" ESTIMABLE="YES" MEAN_1="7.8" MEAN_2="9.4" MODIFIED="2010-05-06 16:49:02 +0100" MODIFIED_BY="Katharine Ker" ORDER="2407" SD_1="6.7" SD_2="8.6" SE="1.1021228941172456" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="99" WEIGHT="11.572228807904144"/>
<CONT_DATA CI_END="1.2457725970498899" CI_START="-1.2457725970498899" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="5.8" ORDER="68204" SD_1="1.8" SD_2="2.2" SE="0.6356099432828282" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="21.97339148396909"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8064071013969111" CI_END="0.7718436921512783" CI_START="-1.7430454197922998" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.48560086382051076" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.28" MODIFIED="2010-10-12 14:40:23 +0100" MODIFIED_BY="Katharine Ker" NO="28" P_CHI2="0.36918468381105796" P_Q="1.0" P_Z="0.44910958164235737" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="803" TOTAL_2="802" UNITS="" WEIGHT="100.0" Z="0.7569003336407092">
<NAME>Hospital Length of Stay - Aprotinin versus Epsilon Aminocaproic Acid</NAME>
<GROUP_LABEL_1>Aprotinin</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aprotinin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.641209870351735" CI_START="-5.841209870351735" EFFECT_SIZE="-2.0999999999999996" ESTIMABLE="YES" MEAN_1="9.8" MEAN_2="11.9" ORDER="68207" SD_1="5.3" SD_2="7.3" SE="1.908815621032795" STUDY_ID="STD-Amar-2003" TOTAL_1="23" TOTAL_2="22" WEIGHT="11.296750759368752"/>
<CONT_DATA CI_END="1.0551162465291912" CI_START="-1.61511624652919" EFFECT_SIZE="-0.27999999999999936" ESTIMABLE="YES" MEAN_1="11.92" MEAN_2="12.2" MODIFIED="2010-06-24 05:05:04 +0100" MODIFIED_BY="[Empty name]" ORDER="5492" SD_1="14.02" SD_2="12.86" SE="0.6811942755379268" STUDY_ID="STD-Fergusson-2008" TOTAL_1="780" TOTAL_2="780" WEIGHT="88.70324924063125"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5444304795716326" CI_START="-1.8244304795716302" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6399999999999988" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.29" MODIFIED="2010-10-12 14:40:21 +0100" MODIFIED_BY="Katharine Ker" NO="29" P_CHI2="1.0" P_Q="1.0" P_Z="0.28957477538431753" Q="0.0" RANDOM="YES" SCALE="7.581983867389905" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="770" TOTAL_2="780" UNITS="" WEIGHT="100.00000000000001" Z="1.059054939686539">
<NAME>Hospital Length of Stay - Tranexamic Acid versus Epsilon Aminocaproic Acid</NAME>
<GROUP_LABEL_1>TXA</GROUP_LABEL_1>
<GROUP_LABEL_2>EACA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours TXA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours EACA</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5444304795716326" CI_START="-1.8244304795716302" EFFECT_SIZE="-0.6399999999999988" ESTIMABLE="YES" MEAN_1="11.56" MEAN_2="12.2" MODIFIED="2010-06-11 16:59:45 +0100" MODIFIED_BY="Katharine Ker" ORDER="5493" SD_1="10.86" SD_2="12.86" SE="0.6043123694691677" STUDY_ID="STD-Fergusson-2008" TOTAL_1="770" TOTAL_2="780" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2010-12-07 17:34:06 +0000" MODIFIED_BY="Emma M Sydenham" NO="10">
<NAME>Adverse Events and Other Outcomes (Active versus Control) - Cardiac Surgery</NAME>
<DICH_OUTCOME CHI2="54.09355505642902" CI_END="0.7136688648240902" CI_START="0.44275008164627905" CI_STUDY="95" CI_TOTAL="95" DF="67" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5621182688449764" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="197" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="-0.14650324976127846" LOG_CI_START="-0.35384135005087425" LOG_EFFECT_SIZE="-0.25017229990607637" METHOD="MH" MODIFIED="2010-05-28 14:55:36 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="0.8722798657119142" P_Q="0.0" P_Z="2.247963988654475E-6" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="78" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4822" TOTAL_2="4073" WEIGHT="100.00000000000001" Z="4.7297500754623005">
<NAME>Re-operation for bleeding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="34.55867589461895" CI_END="0.6328995153171939" CI_START="0.33777764994288084" DF="39" EFFECT_SIZE="0.46236274821165047" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="128" I2="0.0" ID="CMP-010.01.01" LOG_CI_END="-0.19866523691377505" LOG_CI_START="-0.4713690901930736" LOG_EFFECT_SIZE="-0.3350171635534243" MODIFIED="2010-05-28 14:55:36 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="0.6725747468802685" P_Z="1.4673001799736714E-6" STUDIES="56" TAU2="0.0" TOTAL_1="3248" TOTAL_2="2579" WEIGHT="57.806367697757054" Z="4.815638406802974">
<NAME>Aprotinin versus Control</NAME>
<DICH_DATA CI_END="1.196542518761225" CI_START="0.27755976630427953" EFFECT_SIZE="0.5762916465475616" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="0.07792813574117179" LOG_CI_START="-0.5566434868425303" LOG_EFFECT_SIZE="-0.23935767555067924" ORDER="68208" O_E="0.0" SE="0.37275051228585876" STUDY_ID="STD-Alderman-1998" TOTAL_1="436" TOTAL_2="434" VAR="0.13894294440937016" WEIGHT="10.67571413564212"/>
<DICH_DATA CI_END="14.733885791800498" CI_START="0.6617186917235279" EFFECT_SIZE="3.122448979591837" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1683172991429276" LOG_CI_START="-0.17932659756475738" LOG_EFFECT_SIZE="0.49449535078908513" ORDER="68209" O_E="0.0" SE="0.7916126958709705" STUDY_ID="STD-Alvarez-1995" TOTAL_1="49" TOTAL_2="51" VAR="0.6266506602641055" WEIGHT="2.3670527292729555"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68210" O_E="0.0" SE="0.0" STUDY_ID="STD-Alvarez-2001" TOTAL_1="26" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68211" O_E="0.0" SE="0.0" STUDY_ID="STD-Ashraf-1997" TOTAL_1="19" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-20 11:10:30 +0100" MODIFIED_BY="Katharine Ker" ORDER="2278" O_E="0.0" SE="0.0" STUDY_ID="STD-Asimakopoulos-2000" TOTAL_1="8" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.8107039169243295" CI_START="0.014225492643544472" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8926901751653995" LOG_CI_START="-1.8469326846047245" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2010-05-20 11:29:30 +0100" MODIFIED_BY="Katharine Ker" ORDER="5324" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Bert-2008" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="0.5727652581334174"/>
<DICH_DATA CI_END="4.038645960707643" CI_START="0.009904309609993965" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6062357833382839" LOG_CI_START="-2.0041757920103214" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="68212" O_E="0.0" SE="1.5333686811054679" STUDY_ID="STD-Bidstrup-1989" TOTAL_1="40" TOTAL_2="40" VAR="2.351219512195122" WEIGHT="0.6308705537638265"/>
<DICH_DATA CI_END="1.423713199648304" CI_START="0.021040488568326122" EFFECT_SIZE="0.17307692307692307" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.15342251152352063" LOG_CI_START="-1.6769441799144693" LOG_EFFECT_SIZE="-0.7617608341954742" ORDER="68213" O_E="0.0" SE="1.075166455011923" STUDY_ID="STD-Bidstrup-1990" TOTAL_1="26" TOTAL_2="18" VAR="1.1559829059829059" WEIGHT="1.2831635727499113"/>
<DICH_DATA CI_END="2.9326796442861944" CI_START="0.008281641316704065" EFFECT_SIZE="0.15584415584415584" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4672646247543525" LOG_CI_START="-2.0818835830040667" LOG_EFFECT_SIZE="-0.8073094791248571" ORDER="68214" O_E="0.0" SE="1.4973822757244322" STUDY_ID="STD-Bidstrup-1993" TOTAL_1="43" TOTAL_2="47" VAR="2.242153679653679" WEIGHT="0.6615582014467277"/>
<DICH_DATA CI_END="15.259760455310136" CI_START="0.0655318281652329" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" ORDER="68215" O_E="0.0" SE="1.390443574307614" STUDY_ID="STD-Bidstrup-2000" TOTAL_1="30" TOTAL_2="30" VAR="1.9333333333333331" WEIGHT="0.7672319770752675"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68216" O_E="0.0" SE="0.0" STUDY_ID="STD-Boldt-1994" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="77.87685232462876" CI_START="0.13563080279580816" EFFECT_SIZE="3.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8914083896164753" LOG_CI_START="-0.8676416676587266" LOG_EFFECT_SIZE="0.5118833609788743" ORDER="68217" O_E="0.0" SE="1.6206796611615029" STUDY_ID="STD-Casas-1995" TOTAL_1="47" TOTAL_2="51" VAR="2.626602564102564" WEIGHT="0.5647276736690682"/>
<DICH_DATA CI_END="6.518351660109564" CI_START="0.012027580604431858" EFFECT_SIZE="0.28" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8141377866178248" LOG_CI_START="-1.9198217239333863" LOG_EFFECT_SIZE="-0.5528419686577808" MODIFIED="2010-01-12 16:18:43 +0000" MODIFIED_BY="Katharine Ker" ORDER="2338" O_E="0.0" SE="1.605941349815621" STUDY_ID="STD-Cicekcioglu-2006" TOTAL_1="24" TOTAL_2="20" VAR="2.579047619047619" WEIGHT="0.5751406622831584"/>
<DICH_DATA CI_END="82.14351412223073" CI_START="0.2465197674629273" EFFECT_SIZE="4.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9145732781529905" LOG_CI_START="-0.608148250602303" LOG_EFFECT_SIZE="0.6532125137753437" ORDER="68218" O_E="0.0" SE="1.4818591136638255" STUDY_ID="STD-Cosgrove-1992" TOTAL_1="113" TOTAL_2="56" VAR="2.1959064327485383" WEIGHT="0.6754910562478919"/>
<DICH_DATA CI_END="1.0125358788407675" CI_START="0.040067111403697356" EFFECT_SIZE="0.20141843971631207" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.005410421226447582" LOG_CI_START="-1.397211966443132" LOG_EFFECT_SIZE="-0.6959007726083422" ORDER="68219" O_E="0.0" SE="0.8239073336099068" STUDY_ID="STD-D_x0027_Ambra-1996" TOTAL_1="141" TOTAL_2="71" VAR="0.6788232943761862" WEIGHT="2.185127069102664"/>
<DICH_DATA CI_END="1.9774190029426781" CI_START="0.006243329812231785" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.29609870339830113" LOG_CI_START="-2.204583722276951" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="68220" O_E="0.0" SE="1.4689132354192893" STUDY_ID="STD-Deleuze-1991" TOTAL_1="30" TOTAL_2="30" VAR="2.1577060931899643" WEIGHT="0.6874500472332213"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-14 16:06:24 +0100" MODIFIED_BY="Katharine Ker" ORDER="2545" O_E="0.0" SE="0.0" STUDY_ID="STD-Demeyere-2006" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.142666322916847" CI_START="0.04608800582703021" EFFECT_SIZE="0.4868421052631579" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7111883464449171" LOG_CI_START="-1.33641208287251" LOG_EFFECT_SIZE="-0.31261186821379633" MODIFIED="2010-05-17 10:55:58 +0100" MODIFIED_BY="Katharine Ker" ORDER="2562" O_E="0.0" SE="1.2027706279666497" STUDY_ID="STD-Desai-2009" TOTAL_1="38" TOTAL_2="37" VAR="1.4466571834992887" WEIGHT="1.0253397782126175"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68221" O_E="0.0" SE="0.0" STUDY_ID="STD-Dietrich-1990" TOTAL_1="19" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.9834695285518391" CI_START="0.031510441224490204" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2974255329253984" LOG_CI_START="-1.501545515581323" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="68222" O_E="0.0" SE="1.0567244989431572" STUDY_ID="STD-Dietrich-1995" TOTAL_1="15" TOTAL_2="15" VAR="1.1166666666666667" WEIGHT="1.328341930458672"/>
<DICH_DATA CI_END="6.822750620413927" CI_START="0.14082123346982797" EFFECT_SIZE="0.9801980198019802" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8339594975942212" LOG_CI_START="-0.8513318559644064" LOG_EFFECT_SIZE="-0.008686179185092667" ORDER="68223" O_E="0.0" SE="0.9899484834070812" STUDY_ID="STD-Dignan-2001" TOTAL_1="101" TOTAL_2="99" VAR="0.97999799979998" WEIGHT="1.513589982817923"/>
<DICH_DATA CI_END="1.3197208380365462" CI_START="0.061856000684717444" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.12048207414354972" LOG_CI_START="-1.208618162844101" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="68224" O_E="0.0" SE="0.7807200583588264" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.6095238095238094" WEIGHT="2.4335639272856144"/>
<DICH_DATA CI_END="17.111978424286665" CI_START="0.07546306347703435" EFFECT_SIZE="1.1363636363636365" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2333002239817072" LOG_CI_START="-1.1222655682820444" LOG_EFFECT_SIZE="0.05551732784983142" ORDER="68225" O_E="0.0" SE="1.3836710066144533" STUDY_ID="STD-Englberger-2002a" TOTAL_1="22" TOTAL_2="25" VAR="1.9145454545454546" WEIGHT="0.7747610024913273"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68226" O_E="0.0" SE="0.0" STUDY_ID="STD-Englberger-2002b" TOTAL_1="15" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="60.513113572152186" CI_START="0.11245980588251933" EFFECT_SIZE="2.608695652173913" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7818494991961304" LOG_CI_START="-0.9490026704640289" LOG_EFFECT_SIZE="0.41642341436605074" ORDER="68227" O_E="0.0" SE="1.6041160823946319" STUDY_ID="STD-Hardy-1993" TOTAL_1="22" TOTAL_2="19" VAR="2.5731884057971013" WEIGHT="0.5764502717084803"/>
<DICH_DATA CI_END="15.149704352020958" CI_START="0.06600788878540728" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.180404157621246" LOG_CI_START="-1.180404157621246" LOG_EFFECT_SIZE="0.0" ORDER="68228" O_E="0.0" SE="1.3867504905630728" STUDY_ID="STD-Hardy-1997" TOTAL_1="26" TOTAL_2="26" VAR="1.923076923076923" WEIGHT="0.7713238809530022"/>
<DICH_DATA CI_END="14.553341064518706" CI_START="0.06871274407483083" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1629627073641946" LOG_CI_START="-1.1629627073641946" LOG_EFFECT_SIZE="0.0" ORDER="68229" O_E="0.0" SE="1.3662601021279464" STUDY_ID="STD-Kipfer-2003" TOTAL_1="15" TOTAL_2="15" VAR="1.8666666666666667" WEIGHT="0.7946331191136699"/>
<DICH_DATA CI_END="3.9044944569299305" CI_START="0.11382893466671921" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5915648106131298" LOG_CI_START="-0.9437473287244924" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="68230" O_E="0.0" SE="0.9018499505645788" STUDY_ID="STD-Koster-2004" TOTAL_1="100" TOTAL_2="100" VAR="0.8133333333333332" WEIGHT="1.8237481422280948"/>
<DICH_DATA CI_END="2.6624321437406118" CI_START="0.007415974073069934" EFFECT_SIZE="0.1405152224824356" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.42527854791175146" LOG_CI_START="-2.1298317971945115" LOG_EFFECT_SIZE="-0.8522766246413802" ORDER="68231" O_E="0.0" SE="1.5008844647156117" STUDY_ID="STD-Kuepper-2003" TOTAL_1="60" TOTAL_2="59" VAR="2.2526541764246684" WEIGHT="0.6584744215080163"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68232" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68233" O_E="0.0" SE="0.0" STUDY_ID="STD-Kunt-2005" TOTAL_1="40" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.7487868945518765" CI_START="0.009091698513516225" EFFECT_SIZE="0.18461538461538463" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5738907529980455" LOG_CI_START="-2.041354974188507" LOG_EFFECT_SIZE="-0.7337321105952308" ORDER="68234" O_E="0.0" SE="1.5362082858245159" STUDY_ID="STD-Lass-1995" TOTAL_1="51" TOTAL_2="47" VAR="2.3599358974358973" WEIGHT="0.6285404435308996"/>
<DICH_DATA CI_END="1.0235676413246815" CI_START="0.1434496103228767" EFFECT_SIZE="0.38318452380952384" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="0.010116547812777458" LOG_CI_START="-0.8433006271660081" LOG_EFFECT_SIZE="-0.4165920396766154" MODIFIED="2010-05-06 16:50:01 +0100" MODIFIED_BY="Katharine Ker" ORDER="2389" O_E="0.0" SE="0.5013014730656864" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="103" VAR="0.2513031668978271" WEIGHT="5.902492889323297"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68235" O_E="0.0" SE="0.0" STUDY_ID="STD-Laub-1994" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.9607551236159635" CI_START="0.05914335603274032" EFFECT_SIZE="0.59375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.775301280754695" LOG_CI_START="-1.228094035488849" LOG_EFFECT_SIZE="-0.226396377367077" MODIFIED="2010-05-07 10:33:09 +0100" MODIFIED_BY="Katharine Ker" ORDER="2412" O_E="0.0" SE="1.176804325728212" STUDY_ID="STD-Leijdekkers-2006" TOTAL_1="16" TOTAL_2="19" VAR="1.3848684210526316" WEIGHT="1.071087428328671"/>
<DICH_DATA CI_END="0.5477306913790951" CI_START="0.007589869294926794" EFFECT_SIZE="0.06447638603696099" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="-0.2614329232612153" LOG_CI_START="-2.1197657030216233" LOG_EFFECT_SIZE="-1.1905993131414194" ORDER="68236" O_E="0.0" SE="1.0915938737268813" STUDY_ID="STD-Lemmer-1996" TOTAL_1="487" TOTAL_2="157" VAR="1.1915771851580585" WEIGHT="1.2448334645498385"/>
<DICH_DATA CI_END="5.43274760766311" CI_START="0.04601723070060624" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7350195292293191" LOG_CI_START="-1.3370795205572816" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="68237" O_E="0.0" SE="1.2171612389003692" STUDY_ID="STD-Lemmer_x005f_1-1994" TOTAL_1="108" TOTAL_2="108" VAR="1.4814814814814814" WEIGHT="1.001237730083224"/>
<DICH_DATA CI_END="1.2773308213420607" CI_START="0.1264291370138525" EFFECT_SIZE="0.4018604651162791" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.10630339160671308" LOG_CI_START="-0.8981528264801373" LOG_EFFECT_SIZE="-0.395924717436712" ORDER="68238" O_E="0.0" SE="0.5900225546426849" STUDY_ID="STD-Levy-1995" TOTAL_1="215" TOTAL_2="72" VAR="0.34812661498708014" WEIGHT="4.260849621434144"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="68239" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Liu-1993" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.5768447827639973"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="68240" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.5768447827639973"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68241" O_E="0.0" SE="0.0" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68242" O_E="0.0" SE="0.0" STUDY_ID="STD-Mohr-1992" TOTAL_1="34" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68243" O_E="0.0" SE="0.0" STUDY_ID="STD-Moran-2000" TOTAL_1="28" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.122770474379207" CI_START="0.010462890171214661" EFFECT_SIZE="0.2076923076923077" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6151891571430301" LOG_CI_START="-1.980348333438729" LOG_EFFECT_SIZE="-0.6825795881478495" MODIFIED="2010-05-07 15:06:18 +0100" MODIFIED_BY="Katharine Ker" ORDER="2475" O_E="0.0" SE="1.5246315700855155" STUDY_ID="STD-Nur_x00f6_zler-2008" TOTAL_1="25" TOTAL_2="26" VAR="2.3245014245014244" WEIGHT="0.6381218527310657"/>
<DICH_DATA CI_END="47.84885223959143" CI_START="0.7523691439815274" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6798715247253944" LOG_CI_START="-0.12356902395810711" LOG_EFFECT_SIZE="0.7781512503836436" ORDER="68244" O_E="0.0" SE="1.0593499054713804" STUDY_ID="STD-Nuttall-2000" TOTAL_1="45" TOTAL_2="45" VAR="1.1222222222222225" WEIGHT="1.3217659803078863"/>
<DICH_DATA CI_END="1.6742937483704181" CI_START="0.023890670343201005" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.22383165563129442" LOG_CI_START="-1.6217716643033322" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2010-05-07 15:34:27 +0100" MODIFIED_BY="Katharine Ker" ORDER="2484" O_E="0.0" SE="1.084116526013375" STUDY_ID="STD-Parvizi-2007" TOTAL_1="81" TOTAL_2="81" VAR="1.1753086419753085" WEIGHT="1.2620643656511228"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68245" O_E="0.0" SE="0.0" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68246" O_E="0.0" SE="0.0" STUDY_ID="STD-Pugh-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.608296967844409" CI_START="0.05347195824946775" EFFECT_SIZE="0.5476190476190477" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7488310021200593" LOG_CI_START="-1.2718739108806743" LOG_EFFECT_SIZE="-0.26152145438030755" ORDER="68247" O_E="0.0" SE="1.1869720685472709" STUDY_ID="STD-Ray-1997" TOTAL_1="21" TOTAL_2="23" VAR="1.4089026915113871" WEIGHT="1.052815900356921"/>
<DICH_DATA CI_END="0.8140155592489693" CI_START="0.002588686913008042" EFFECT_SIZE="0.04590459045904591" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="-0.08936729384373564" LOG_CI_START="-2.586920471842127" LOG_EFFECT_SIZE="-1.3381438828429313" ORDER="68248" O_E="0.0" SE="1.4670750998438753" STUDY_ID="STD-Ray-1999" TOTAL_1="100" TOTAL_2="50" VAR="2.152309348581917" WEIGHT="0.6891737735823877"/>
<DICH_DATA CI_END="1.1400537876337065" CI_START="0.01868781949795416" EFFECT_SIZE="0.14596273291925466" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.056925341793885816" LOG_CI_START="-1.7284413693141127" LOG_EFFECT_SIZE="-0.8357580137601135" ORDER="68249" O_E="0.0" SE="1.048733243812591" STUDY_ID="STD-Rodrigus-1996" TOTAL_1="46" TOTAL_2="47" VAR="1.0998414166776793" WEIGHT="1.3486627555448318"/>
<DICH_DATA CI_END="2.7278417643535913" CI_START="0.008177019925767694" EFFECT_SIZE="0.14935064935064934" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.43581917431977685" LOG_CI_START="-2.0874049439575173" LOG_EFFECT_SIZE="-0.8257928848188701" ORDER="68250" O_E="0.0" SE="1.4821543372369068" STUDY_ID="STD-Rossi-1997" TOTAL_1="21" TOTAL_2="22" VAR="2.1967814793901748" WEIGHT="0.6752219870729326"/>
<DICH_DATA CI_END="15.765457421379898" CI_START="0.06804141820699317" EFFECT_SIZE="1.0357142857142858" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1977065759528898" LOG_CI_START="-1.1672266428394158" LOG_EFFECT_SIZE="0.015239966556736905" ORDER="68251" O_E="0.0" SE="1.389173479326835" STUDY_ID="STD-Schweizer-2000" TOTAL_1="28" TOTAL_2="29" VAR="1.9298029556650245" WEIGHT="0.7686355497199915"/>
<DICH_DATA CI_END="2.5983769423254333" CI_START="0.007854196568971131" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4147021537028376" LOG_CI_START="-2.1048982337313515" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="68252" O_E="0.0" SE="1.4800257398019099" STUDY_ID="STD-Tabuchi-1994" TOTAL_1="20" TOTAL_2="20" VAR="2.1904761904761907" WEIGHT="0.6771656145490403"/>
<DICH_DATA CI_END="14.50846406676568" CI_START="0.061479651087616466" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.161621438444948" LOG_CI_START="-1.2112686058950124" LOG_EFFECT_SIZE="-0.024823583725032152" ORDER="68253" O_E="0.0" SE="1.3938473580404491" STUDY_ID="STD-Taggart-2003" TOTAL_1="36" TOTAL_2="34" VAR="1.94281045751634" WEIGHT="0.7634893820651442"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68254" O_E="0.0" SE="0.0" STUDY_ID="STD-Vedrinne-1992" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.604763001802086" CI_END="1.1662823901749868" CI_START="0.5389758427976196" DF="22" EFFECT_SIZE="0.7928417459900718" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="57" I2="0.0" ID="CMP-010.01.02" LOG_CI_END="0.06680371821558885" LOG_CI_START="-0.26843069970157746" LOG_EFFECT_SIZE="-0.10081349074299435" MODIFIED="2010-05-21 15:03:39 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.9436017252930965" P_Z="0.23846918387729288" STUDIES="26" TAU2="0.0" TOTAL_1="1195" TOTAL_2="1133" WEIGHT="38.25260616284865" Z="1.1788217465239752">
<NAME>Tranexamic Acid versus Control</NAME>
<DICH_DATA CI_END="1.3935915921194053" CI_START="0.023909971823963982" EFFECT_SIZE="0.18253968253968253" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.14413551746614112" LOG_CI_START="-1.6214209356660811" LOG_EFFECT_SIZE="-0.7386427090999701" ORDER="68255" O_E="0.0" SE="1.0370966002152615" STUDY_ID="STD-Andreasen-2004" TOTAL_1="21" TOTAL_2="23" VAR="1.0755693581780539" WEIGHT="1.3790976327100763"/>
<DICH_DATA CI_END="2.921261429403705" CI_START="0.21908343894118318" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4655704245760643" LOG_CI_START="-0.659390450592177" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="68256" O_E="0.0" SE="0.660807586719967" STUDY_ID="STD-Armellin-2001" TOTAL_1="150" TOTAL_2="150" VAR="0.4366666666666667" WEIGHT="3.396904936669123"/>
<DICH_DATA CI_END="4.038114968730835" CI_START="0.00710628348875105" EFFECT_SIZE="0.16939890710382513" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6061786795344671" LOG_CI_START="-2.1483574713267806" LOG_EFFECT_SIZE="-0.7710893958961569" ORDER="68257" O_E="0.0" SE="1.6180281701897488" STUDY_ID="STD-Brown-1997" TOTAL_1="60" TOTAL_2="30" VAR="2.618015159527587" WEIGHT="0.5665800483548423"/>
<DICH_DATA CI_END="2.979618145522277" CI_START="0.034477058165141815" EFFECT_SIZE="0.32051282051282054" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.47416061041229807" LOG_CI_START="-1.4624697984491835" LOG_EFFECT_SIZE="-0.49415459401844275" ORDER="68258" O_E="0.0" SE="1.137586288640367" STUDY_ID="STD-Casati-2004" TOTAL_1="52" TOTAL_2="50" VAR="1.294102564102564" WEIGHT="1.1462114339503697"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-14 16:06:49 +0100" MODIFIED_BY="Katharine Ker" ORDER="2546" O_E="0.0" SE="0.0" STUDY_ID="STD-Demeyere-2006" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.125380959026196" CI_START="0.24005300295266485" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.3274367854801246" LOG_CI_START="-0.6196928568366006" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="68259" O_E="0.0" SE="0.5563486402641868" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.30952380952380953" WEIGHT="4.792248964500901"/>
<DICH_DATA CI_END="29.02955803126674" CI_START="0.33953941963168377" EFFECT_SIZE="3.13953488372093" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4628404238425872" LOG_CI_START="-0.46910979801174824" LOG_EFFECT_SIZE="0.4968653129154196" ORDER="68260" O_E="0.0" SE="1.13483712362507" STUDY_ID="STD-Hardy-1998" TOTAL_1="43" TOTAL_2="45" VAR="1.2878552971576227" WEIGHT="1.1517715996141955"/>
<DICH_DATA CI_END="18.302595624998393" CI_START="0.07662052964344189" EFFECT_SIZE="1.1842105263157894" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2625126845761792" LOG_CI_START="-1.1156548502591122" LOG_EFFECT_SIZE="0.07342891715853349" ORDER="68261" O_E="0.0" SE="1.396947382081406" STUDY_ID="STD-Horrow-1991" TOTAL_1="38" TOTAL_2="45" VAR="1.9514619883040936" WEIGHT="0.7601045598474181"/>
<DICH_DATA CI_END="8.802545501889" CI_START="0.01613021795743741" EFFECT_SIZE="0.37681159420289856" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9446082786917515" LOG_CI_START="-1.7923597642246263" LOG_EFFECT_SIZE="-0.42387574276643736" ORDER="68262" O_E="0.0" SE="1.6077085766193955" STUDY_ID="STD-Jares-2003" TOTAL_1="22" TOTAL_2="25" VAR="2.584726867335563" WEIGHT="0.5738769439913431"/>
<DICH_DATA CI_END="8.434974839029426" CI_START="0.015364598291429213" EFFECT_SIZE="0.36" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9260837914554372" LOG_CI_START="-1.8134787899208629" LOG_EFFECT_SIZE="-0.44369749923271273" MODIFIED="2010-05-17 15:00:58 +0100" MODIFIED_BY="Katharine Ker" ORDER="2641" O_E="0.0" SE="1.6092326213539263" STUDY_ID="STD-Jimenez-2007" TOTAL_1="24" TOTAL_2="26" VAR="2.5896296296296293" WEIGHT="0.5727904634343388"/>
<DICH_DATA CI_END="2.691330498492686" CI_START="0.023222714577419576" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.42996703290245386" LOG_CI_START="-1.6340870155583787" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="68263" O_E="0.0" SE="1.2124355652982142" STUDY_ID="STD-Karski-1995" TOTAL_1="100" TOTAL_2="50" VAR="1.47" WEIGHT="1.0090579290332315"/>
<DICH_DATA CI_END="1.7152066890871394" CI_START="0.024226383153849028" EFFECT_SIZE="0.20384615384615384" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.23431646170901982" LOG_CI_START="-1.6157114184490775" LOG_EFFECT_SIZE="-0.6906974783700289" ORDER="68264" O_E="0.0" SE="1.0867155345905681" STUDY_ID="STD-Katsaros-1996" TOTAL_1="104" TOTAL_2="106" VAR="1.1809506531204643" WEIGHT="1.2560348324118698"/>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="68265" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.5768447827639973"/>
<DICH_DATA CI_END="68.25874292736694" CI_START="0.13185124152633107" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.8799157764849103" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-05-20 16:25:22 +0100" MODIFIED_BY="Katharine Ker" ORDER="5389" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Kuitunen-2006" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="0.5835994055129904"/>
<DICH_DATA CI_END="2.069128495232804" CI_START="0.5231383985010866" EFFECT_SIZE="1.0404040404040404" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.3157874616844644" LOG_CI_START="-0.28138340146921975" LOG_EFFECT_SIZE="0.017202030107622307" MODIFIED="2010-05-21 10:11:08 +0100" MODIFIED_BY="Katharine Ker" ORDER="2390" O_E="0.0" SE="0.35078112105992115" STUDY_ID="STD-Later-2009" TOTAL_1="99" TOTAL_2="103" VAR="0.12304739489205507" WEIGHT="12.054827792007362"/>
<DICH_DATA CI_END="4.847824441117579" CI_START="0.20627809693732801" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.685546883923407" LOG_CI_START="-0.685546883923407" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-07 12:00:04 +0100" MODIFIED_BY="Katharine Ker" ORDER="2429" O_E="0.0" SE="0.8053872662568291" STUDY_ID="STD-Maddali-2007" TOTAL_1="111" TOTAL_2="111" VAR="0.6486486486486486" WEIGHT="2.2867775316715613"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="68266" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.5768447827639973"/>
<DICH_DATA CI_END="7.897117532359623" CI_START="0.014069831258787349" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8974686016417053" LOG_CI_START="-1.8517111110810305" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2010-05-07 12:21:30 +0100" MODIFIED_BY="Katharine Ker" ORDER="2442" O_E="0.0" SE="1.6148817719123905" STUDY_ID="STD-Mehr_x002d_Aein-2007" TOTAL_1="33" TOTAL_2="33" VAR="2.607843137254902" WEIGHT="0.5687900221024162"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68267" O_E="0.0" SE="0.0" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="71.92321045517915" CI_START="0.12513345751728625" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8568690648743624" LOG_CI_START="-0.9026265554350377" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-05-21 15:03:39 +0100" MODIFIED_BY="Katharine Ker" ORDER="2454" O_E="0.0" SE="1.6209413870933633" STUDY_ID="STD-Murphy-2006" TOTAL_1="50" TOTAL_2="50" VAR="2.627450980392157" WEIGHT="0.5645453204449355"/>
<DICH_DATA CI_END="68.25874292736694" CI_START="0.13185124152633107" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.8799157764849103" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="68268" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="0.5835994055129904"/>
<DICH_DATA CI_END="7.74869607009601" CI_START="0.013648380859931773" EFFECT_SIZE="0.3252032520325203" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8892286267377596" LOG_CI_START="-1.8649188669606307" LOG_EFFECT_SIZE="-0.48784512011143555" ORDER="68269" O_E="0.0" SE="1.6177998710484025" STUDY_ID="STD-Pleym-2003" TOTAL_1="40" TOTAL_2="39" VAR="2.6172764227642276" WEIGHT="0.5667399678449906"/>
<DICH_DATA CI_END="6.788528809339318" CI_START="0.16100325082334627" EFFECT_SIZE="1.0454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8317756654124154" LOG_CI_START="-0.7931653550216421" LOG_EFFECT_SIZE="0.019305155195386624" ORDER="68270" O_E="0.0" SE="0.9544983989907418" STUDY_ID="STD-Pugh-1995" TOTAL_1="22" TOTAL_2="23" VAR="0.9110671936758894" WEIGHT="1.6281073075347032"/>
<DICH_DATA CI_END="16.31130518173396" CI_START="0.07005492597433315" EFFECT_SIZE="1.0689655172413792" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2124887133729667" LOG_CI_START="-1.1545613215023336" LOG_EFFECT_SIZE="0.028963695935316558" ORDER="68271" O_E="0.0" SE="1.3904169075723947" STUDY_ID="STD-Santos-2006" TOTAL_1="29" TOTAL_2="31" VAR="1.9332591768631813" WEIGHT="0.767261406763686"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68272" O_E="0.0" SE="0.0" STUDY_ID="STD-Shore_x002d_Lesserson-1996" TOTAL_1="17" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="12.55730570082838" CI_START="0.0796349172206608" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.09889646704573" LOG_CI_START="-1.09889646704573" LOG_EFFECT_SIZE="0.0" ORDER="68273" O_E="0.0" SE="1.2909944487358056" STUDY_ID="STD-Uozaki-2001" TOTAL_1="6" TOTAL_2="6" VAR="1.6666666666666665" WEIGHT="0.8899890934073104"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7391568916057003" CI_END="1.1663087921948723" CI_START="0.1052919785721052" DF="4" EFFECT_SIZE="0.3504325332446182" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" I2="0.0" ID="CMP-010.01.03" LOG_CI_END="0.0668135495582043" LOG_CI_START="-0.9776047132833238" LOG_EFFECT_SIZE="-0.45539558186255963" NO="3" P_CHI2="0.783593074616754" P_Z="0.08741423093890181" STUDIES="7" TAU2="0.0" TOTAL_1="379" TOTAL_2="361" WEIGHT="3.9410261393943147" Z="1.7091982607445249">
<NAME>Epsilon Aminocaproic Acid versus Control</NAME>
<DICH_DATA CI_END="1.434362729157795" CI_START="0.004621886033693856" EFFECT_SIZE="0.08142150247413406" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.15665899188360147" LOG_CI_START="-2.3351807675432137" LOG_EFFECT_SIZE="-1.089260887829806" ORDER="68274" O_E="0.0" SE="1.4637190094930537" STUDY_ID="STD-Del-Rossi-1989" TOTAL_1="170" TOTAL_2="180" VAR="2.1424733387513264" WEIGHT="0.6923377429486961"/>
<DICH_DATA CI_END="15.168127832299358" CI_START="0.0630924488178857" EFFECT_SIZE="0.9782608695652174" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1809319801092522" LOG_CI_START="-1.200022615921713" LOG_EFFECT_SIZE="-0.009545317906230389" ORDER="68275" O_E="0.0" SE="1.39858451562392" STUDY_ID="STD-Hardy-1998" TOTAL_1="46" TOTAL_2="45" VAR="1.9560386473429952" WEIGHT="0.7583260983589085"/>
<DICH_DATA CI_END="7.982820343015618" CI_START="0.0335143010834441" EFFECT_SIZE="0.5172413793103449" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9021563553871819" LOG_CI_START="-1.4747698330737318" LOG_EFFECT_SIZE="-0.2863067388432748" ORDER="68276" O_E="0.0" SE="1.3962182090763327" STUDY_ID="STD-Kluger-2003" TOTAL_1="58" TOTAL_2="30" VAR="1.9494252873563218" WEIGHT="0.7608986942456367"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68277" O_E="0.0" SE="0.0" STUDY_ID="STD-Menichetti-1996" TOTAL_1="24" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68278" O_E="0.0" SE="0.0" STUDY_ID="STD-Penta-de-Peppo-1995" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8799157764849102" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="68279" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Rao-1999" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="0.5835994055129904"/>
<DICH_DATA CI_END="3.160631195382165" CI_START="0.036546854428103924" EFFECT_SIZE="0.33986928104575165" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4997738222695287" LOG_CI_START="-1.4371499966351282" LOG_EFFECT_SIZE="-0.46868808718279964" ORDER="68280" O_E="0.0" SE="1.137758639152131" STUDY_ID="STD-Vander_x002d_Salm-1996" TOTAL_1="51" TOTAL_2="52" VAR="1.2944947209653093" WEIGHT="1.1458641983280835"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="36.51179307062143" CI_END="1.073376150252096" CI_START="0.6504001570303812" CI_STUDY="95" CI_TOTAL="95" DF="53" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8355381599164873" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="114" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="0.030751941305981485" LOG_CI_START="-0.18681936255940673" LOG_EFFECT_SIZE="-0.07803371062671256" METHOD="MH" MODIFIED="2010-07-08 11:07:50 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.9590349949531226" P_Q="0.0" P_Z="0.15974968715771778" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="76" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6004" TOTAL_2="5236" WEIGHT="100.00000000000003" Z="1.4059139205508782">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="26.437008194919986" CI_END="1.1039320189716948" CI_START="0.642425137560716" DF="37" EFFECT_SIZE="0.8421363779968004" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="94" I2="0.0" ID="CMP-010.02.01" LOG_CI_END="0.042942330010482886" LOG_CI_START="-0.19217747381543387" LOG_EFFECT_SIZE="-0.0746175719024755" MODIFIED="2010-07-08 11:07:50 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="0.9014003412320053" P_Z="0.21348945758605187" STUDIES="55" TAU2="0.0" TOTAL_1="4444" TOTAL_2="3730" WEIGHT="85.62977588753454" Z="1.2440275226748834">
<NAME>Aprotinin versus Control</NAME>
<DICH_DATA CI_END="2.518203954699761" CI_START="0.28908263161831205" EFFECT_SIZE="0.8532110091743119" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.40109090163108607" LOG_CI_START="-0.5389780004044632" LOG_EFFECT_SIZE="-0.06894354938668852" ORDER="68325" O_E="0.0" SE="0.552201126471796" STUDY_ID="STD-Alderman-1998" TOTAL_1="436" TOTAL_2="434" VAR="0.3049260840767204" WEIGHT="5.35653388195231"/>
<DICH_DATA CI_END="74.79945678869373" CI_START="0.1301399825335549" EFFECT_SIZE="3.12" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.873898443926902" LOG_CI_START="-0.8855892558900165" LOG_EFFECT_SIZE="0.4941545940184428" ORDER="68324" O_E="0.0" SE="1.6209367345568726" STUDY_ID="STD-Alvarez-1995" TOTAL_1="49" TOTAL_2="51" VAR="2.6274358974358973" WEIGHT="0.6216505234026707"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68323" O_E="0.0" SE="0.0" STUDY_ID="STD-Alvarez-2001" TOTAL_1="26" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68322" O_E="0.0" SE="0.0" STUDY_ID="STD-Ashraf-1997" TOTAL_1="19" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.9453474498525" CI_START="0.01398442444617999" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9001128936458906" LOG_CI_START="-1.8543554030852154" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="68321" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Bidstrup-1989" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="0.6239182261003198"/>
<DICH_DATA CI_END="110.51274757531625" CI_START="0.2692184093552281" EFFECT_SIZE="5.454545454545454" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0434123765035417" LOG_CI_START="-0.5698952460527045" LOG_EFFECT_SIZE="0.7367585652254185" ORDER="68320" O_E="0.0" SE="1.535069833570901" STUDY_ID="STD-Bidstrup-1993" TOTAL_1="43" TOTAL_2="47" VAR="2.3564393939393935" WEIGHT="0.6931419093777043"/>
<DICH_DATA CI_END="70.82882080128427" CI_START="0.12706691849706478" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8502100114756685" LOG_CI_START="-0.895967502036344" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="68319" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Bidstrup-2000" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="0.6276911643754678"/>
<DICH_DATA CI_END="67.90969947701805" CI_START="0.13252893282270775" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8319318085736291" LOG_CI_START="-0.8776892991343044" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="68318" O_E="0.0" SE="1.5916448515084427" STUDY_ID="STD-Blauhut-1994" TOTAL_1="14" TOTAL_2="14" VAR="2.5333333333333328" WEIGHT="0.6447421977031547"/>
<DICH_DATA CI_END="23.15802289371009" CI_START="0.20337761436464838" EFFECT_SIZE="2.1702127659574466" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.364701478932597" LOG_CI_START="-0.6916968512801971" LOG_EFFECT_SIZE="0.33650231382620005" ORDER="68317" O_E="0.0" SE="1.2079385585029" STUDY_ID="STD-Casas-1995" TOTAL_1="47" TOTAL_2="51" VAR="1.4591155611180644" WEIGHT="1.1194088695733053"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-12 16:19:03 +0000" MODIFIED_BY="Katharine Ker" ORDER="2339" O_E="0.0" SE="0.0" STUDY_ID="STD-Cicekcioglu-2006" TOTAL_1="20" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="107.27288722482027" CI_START="0.25822770078776697" EFFECT_SIZE="5.2631578947368425" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.030489969714727" LOG_CI_START="-0.5879971716203847" LOG_EFFECT_SIZE="0.721246399047171" ORDER="68316" O_E="0.0" SE="1.5381123085406379" STUDY_ID="STD-Cohen-1998" TOTAL_1="56" TOTAL_2="59" VAR="2.3657894736842104" WEIGHT="0.6904024719935893"/>
<DICH_DATA CI_END="8.265810718802095" CI_START="0.013904416259545962" EFFECT_SIZE="0.3390151515151515" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9172854560242069" LOG_CI_START="-1.856847239132045" LOG_EFFECT_SIZE="-0.4697808915539191" MODIFIED="2010-05-20 12:08:58 +0100" MODIFIED_BY="Katharine Ker" ORDER="5342" O_E="0.0" SE="1.629539277313093" STUDY_ID="STD-Colwell-2007" TOTAL_1="175" TOTAL_2="178" VAR="2.655398256306077" WEIGHT="0.6151043057172672"/>
<DICH_DATA CI_END="3.463558012724104" CI_START="0.3589729607405532" EFFECT_SIZE="1.1150442477876106" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.5395224662315437" LOG_CI_START="-0.4449382629632574" LOG_EFFECT_SIZE="0.04729210163414316" ORDER="68315" O_E="0.0" SE="0.578277105488229" STUDY_ID="STD-Cosgrove-1992" TOTAL_1="113" TOTAL_2="56" VAR="0.33440441073184435" WEIGHT="4.884346164195055"/>
<DICH_DATA CI_END="99.47165719136326" CI_START="0.31273343933241216" EFFECT_SIZE="5.577464788732394" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.9976993533199243" LOG_CI_START="-0.5048256789070502" LOG_EFFECT_SIZE="0.7464368372064369" ORDER="68314" O_E="0.0" SE="1.4699955916288205" STUDY_ID="STD-D_x0027_Ambra-1996" TOTAL_1="141" TOTAL_2="71" VAR="2.160887039408166" WEIGHT="0.7558687108861278"/>
<DICH_DATA CI_END="14.998130825457398" CI_START="0.063211939731786" EFFECT_SIZE="0.9736842105263158" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1760371375375547" LOG_CI_START="-1.199200882637185" LOG_EFFECT_SIZE="-0.011581872549815147" MODIFIED="2010-05-17 10:56:19 +0100" MODIFIED_BY="Katharine Ker" ORDER="2563" O_E="0.0" SE="1.3952265706684663" STUDY_ID="STD-Desai-2009" TOTAL_1="38" TOTAL_2="37" VAR="1.9466571834992887" WEIGHT="0.8390521529383544"/>
<DICH_DATA CI_END="1.2794062399289174" CI_START="0.4479347199245155" EFFECT_SIZE="0.7570273943208641" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="31" LOG_CI_END="0.10700846453074485" LOG_CI_START="-0.34878527359632205" LOG_EFFECT_SIZE="-0.12088840453278861" ORDER="68313" O_E="0.0" SE="0.2677354979912306" STUDY_ID="STD-Dietrich-1992" TOTAL_1="902" TOTAL_2="882" VAR="0.07168229688461225" WEIGHT="22.785917469653732"/>
<DICH_DATA CI_END="3.845086034384406" CI_START="0.010402888164868843" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5849060616512035" LOG_CI_START="-1.982846070323241" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="68312" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Dietrich-1995" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="0.7179546816914248"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68311" O_E="0.0" SE="0.0" STUDY_ID="STD-Dignan-2001" TOTAL_1="101" TOTAL_2="99" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.022569637689829" CI_START="0.013849815723520037" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9043134955566555" LOG_CI_START="-1.8585560049959806" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="68310" O_E="0.0" SE="1.6229232210492168" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="2.6338797814207653" WEIGHT="0.6201296324796316"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68309" O_E="0.0" SE="0.0" STUDY_ID="STD-Englberger-2002a" TOTAL_1="22" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68308" O_E="0.0" SE="0.0" STUDY_ID="STD-Englberger-2002b" TOTAL_1="15" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-20 14:37:23 +0100" MODIFIED_BY="Katharine Ker" ORDER="5356" O_E="0.0" SE="0.0" STUDY_ID="STD-Feindt-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="56.85179657325416" CI_START="0.10295677864895471" EFFECT_SIZE="2.4193548387096775" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7547441933777075" LOG_CI_START="-0.9873450542628527" LOG_EFFECT_SIZE="0.3836995695574274" ORDER="68307" O_E="0.0" SE="1.6107167976247523" STUDY_ID="STD-Golanski-2000" TOTAL_1="30" TOTAL_2="24" VAR="2.5944086021505375" WEIGHT="0.6295642480887899"/>
<DICH_DATA CI_END="2.747722311272708" CI_START="0.09606168891431204" EFFECT_SIZE="0.5137614678899083" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4389728401867553" LOG_CI_START="-1.0174497820556017" LOG_EFFECT_SIZE="-0.2892384709344232" MODIFIED="2010-01-11 14:35:39 +0000" MODIFIED_BY="Katharine Ker" ORDER="2297" O_E="0.0" SE="0.8555098577134124" STUDY_ID="STD-Gott-1998" TOTAL_1="109" TOTAL_2="112" VAR="0.7318971166448232" WEIGHT="2.2316618875827956"/>
<DICH_DATA CI_END="11.591049480624264" CI_START="0.04852882398097617" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0641227597780483" LOG_CI_START="-1.314000232994648" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="68306" O_E="0.0" SE="1.396921217853351" STUDY_ID="STD-Green-1995" TOTAL_1="48" TOTAL_2="36" VAR="1.951388888888889" WEIGHT="0.8370176289043086"/>
<DICH_DATA CI_END="73.08526156114004" CI_START="0.13243453110695871" EFFECT_SIZE="3.111111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8638298055758746" LOG_CI_START="-0.8779987617700857" LOG_EFFECT_SIZE="0.49291552190289434" MODIFIED="2010-05-17 14:28:19 +0100" MODIFIED_BY="Katharine Ker" ORDER="2623" O_E="0.0" SE="1.6105636727293162" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="27" VAR="2.5939153439153437" WEIGHT="0.6296839658547077"/>
<DICH_DATA CI_END="3.9409080777837366" CI_START="0.010149944939211815" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5955963050059561" LOG_CI_START="-1.9935363136779936" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="68305" O_E="0.0" SE="1.5208693166281149" STUDY_ID="STD-Hardy-1993" TOTAL_1="22" TOTAL_2="22" VAR="2.313043478260869" WEIGHT="0.7061462165320266"/>
<DICH_DATA CI_END="2.7967897516443347" CI_START="0.024001839657087794" EFFECT_SIZE="0.2590909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.4466598195596907" LOG_CI_START="-1.6197554698591203" LOG_EFFECT_SIZE="-0.5865478251497148" ORDER="68304" O_E="0.0" SE="1.2138225699252623" STUDY_ID="STD-Hayashida-1997" TOTAL_1="110" TOTAL_2="57" VAR="1.473365231259968" WEIGHT="1.1085824927816528"/>
<DICH_DATA CI_END="104.66683659312582" CI_START="0.1883461910350192" EFFECT_SIZE="4.44" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.0198090984305934" LOG_CI_START="-0.7250431582013536" LOG_EFFECT_SIZE="0.6473829701146199" ORDER="68303" O_E="0.0" SE="1.6123398027834082" STUDY_ID="STD-Jamieson-1997" TOTAL_1="24" TOTAL_2="36" VAR="2.5996396396396393" WEIGHT="0.6282974285906816"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68302" O_E="0.0" SE="0.0" STUDY_ID="STD-Kipfer-2003" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68301" O_E="0.0" SE="0.0" STUDY_ID="STD-Koster-2004" TOTAL_1="100" TOTAL_2="100" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68300" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuepper-2003" TOTAL_1="60" TOTAL_2="59" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68299" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68298" O_E="0.0" SE="0.0" STUDY_ID="STD-Kunt-2005" TOTAL_1="40" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.7487868945518765" CI_START="0.009091698513516225" EFFECT_SIZE="0.18461538461538463" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5738907529980455" LOG_CI_START="-2.041354974188507" LOG_EFFECT_SIZE="-0.7337321105952308" ORDER="68297" O_E="0.0" SE="1.5362082858245159" STUDY_ID="STD-Lass-1995" TOTAL_1="51" TOTAL_2="47" VAR="2.3599358974358973" WEIGHT="0.6921149437248042"/>
<DICH_DATA CI_END="23.285388339548454" CI_START="0.19774635609679242" EFFECT_SIZE="2.1458333333333335" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3670834852284512" LOG_CI_START="-0.703891510569281" LOG_EFFECT_SIZE="0.331595987329585" MODIFIED="2010-05-06 16:50:47 +0100" MODIFIED_BY="Katharine Ker" ORDER="2391" O_E="0.0" SE="1.216500964023151" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="103" VAR="1.4798745954692556" WEIGHT="1.1037062909577626"/>
<DICH_DATA CI_END="17.50864593639377" CI_START="0.08054056579377307" EFFECT_SIZE="1.1875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.243252560412904" LOG_CI_START="-1.0939853238190957" LOG_EFFECT_SIZE="0.07463361829690418" MODIFIED="2010-05-07 10:33:43 +0100" MODIFIED_BY="Katharine Ker" ORDER="2413" O_E="0.0" SE="1.3729051027119943" STUDY_ID="STD-Leijdekkers-2006" TOTAL_1="16" TOTAL_2="19" VAR="1.8848684210526316" WEIGHT="0.8665575180764212"/>
<DICH_DATA CI_END="4.742007900231632" CI_START="0.3863903093400861" EFFECT_SIZE="1.3536121673003803" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="0.6759622731816349" LOG_CI_START="-0.41297377421540027" LOG_EFFECT_SIZE="0.1314942494831173" ORDER="68296" O_E="0.0" SE="0.639646424561387" STUDY_ID="STD-Lemmer-1996" TOTAL_1="526" TOTAL_2="178" VAR="0.40914754845416607" WEIGHT="3.9920730480216085"/>
<DICH_DATA CI_END="5.166432555913332" CI_START="0.43550360440198194" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7131907643580054" LOG_CI_START="-0.36100824624664296" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="68295" O_E="0.0" SE="0.6309898162000304" STUDY_ID="STD-Lemmer_x005f_1-1994" TOTAL_1="108" TOTAL_2="108" VAR="0.39814814814814814" WEIGHT="4.102359657943793"/>
<DICH_DATA CI_END="2.6669718764855146" CI_START="0.37845316922755456" EFFECT_SIZE="1.0046511627906978" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.42601843603050193" LOG_CI_START="-0.4219878535598507" LOG_EFFECT_SIZE="0.002015291235325608" ORDER="68294" O_E="0.0" SE="0.4981230922042062" STUDY_ID="STD-Levy-1995" TOTAL_1="215" TOTAL_2="72" VAR="0.2481266149870801" WEIGHT="6.582715445229603"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="68293" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Liu-1993" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.6351904614408855"/>
<DICH_DATA CI_END="38.11494103195797" CI_START="0.06689470732866364" EFFECT_SIZE="1.596774193548387" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5810952522048287" LOG_CI_START="-1.1746082420062367" LOG_EFFECT_SIZE="0.20324350509929603" ORDER="68292" O_E="0.0" SE="1.6187138734518747" STUDY_ID="STD-Maccario-1994" TOTAL_1="61" TOTAL_2="32" VAR="2.6202346041055717" WEIGHT="0.6233590298703583"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68291" O_E="0.0" SE="0.0" STUDY_ID="STD-Misfeld-1998" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68290" O_E="0.0" SE="0.0" STUDY_ID="STD-Mohr-1992" TOTAL_1="34" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68289" O_E="0.0" SE="0.0" STUDY_ID="STD-Moran-2000" TOTAL_1="28" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.8307807432743171" CI_START="0.1875551109924871" EFFECT_SIZE="0.39473684210526316" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="-0.08051357856282583" LOG_CI_START="-0.7268710965594319" LOG_EFFECT_SIZE="-0.40369233756112893" MODIFIED="2010-05-28 14:55:21 +0100" MODIFIED_BY="Katharine Ker" ORDER="2456" O_E="0.0" SE="0.3796736055925217" STUDY_ID="STD-Norman-2009" TOTAL_1="11" TOTAL_2="9" VAR="0.14415204678362573" WEIGHT="11.33072292271832"/>
<DICH_DATA CI_END="4.052347097392378" CI_START="0.009870822769781833" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6077066370895764" LOG_CI_START="-2.005646645761614" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="68288" O_E="0.0" SE="1.5350966546541733" STUDY_ID="STD-Nuttall-2000" TOTAL_1="45" TOTAL_2="45" VAR="2.3565217391304345" WEIGHT="0.6931176885517307"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68287" O_E="0.0" SE="0.0" STUDY_ID="STD-Rocha-1994" TOTAL_1="28" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.441993153969367" CI_START="0.04795811117017726" EFFECT_SIZE="0.5108695652173914" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7357579911013653" LOG_CI_START="-1.3191379299210408" LOG_EFFECT_SIZE="-0.29168996940983777" ORDER="68286" O_E="0.0" SE="1.2070560359074207" STUDY_ID="STD-Rodrigus-1996" TOTAL_1="46" TOTAL_2="47" VAR="1.4569842738205365" WEIGHT="1.121046349089955"/>
<DICH_DATA CI_END="7.391737873352934" CI_START="0.015031798071690874" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8687465574849313" LOG_CI_START="-1.8229890669242566" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="68285" O_E="0.0" SE="1.5811388300841895" STUDY_ID="STD-Royston-1987" TOTAL_1="11" TOTAL_2="11" VAR="2.4999999999999996" WEIGHT="0.6533387603391967"/>
<DICH_DATA CI_END="73.12440389594961" CI_START="0.1317124063623954" EFFECT_SIZE="3.103448275862069" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8640623387722208" LOG_CI_START="-0.8803733156914835" LOG_EFFECT_SIZE="0.4918445115403688" ORDER="68284" O_E="0.0" SE="1.6120950886075684" STUDY_ID="STD-Schweizer-2000" TOTAL_1="28" TOTAL_2="29" VAR="2.598850574712644" WEIGHT="0.6284881927190413"/>
<DICH_DATA CI_END="94.82568649010662" CI_START="0.19802416911304827" EFFECT_SIZE="4.333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9769259954590463" LOG_CI_START="-0.7032818002846979" LOG_EFFECT_SIZE="0.6368220975871743" ORDER="68283" O_E="0.0" SE="1.5743673264624358" STUDY_ID="STD-Stammers-1997" TOTAL_1="8" TOTAL_2="12" VAR="2.4786324786324783" WEIGHT="0.658970991031776"/>
<DICH_DATA CI_END="2.6049100552711884" CI_START="0.09597260354310905" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.41579273217535734" LOG_CI_START="-1.0178527235033197" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="68282" O_E="0.0" SE="0.842130437325114" STUDY_ID="STD-Swart-1994" TOTAL_1="49" TOTAL_2="49" VAR="0.7091836734693877" WEIGHT="2.3031366371669524"/>
<DICH_DATA CI_END="28.295943084567533" CI_START="0.33549193252983445" EFFECT_SIZE="3.081081081081081" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.451724173252726" LOG_CI_START="-0.47431791871377055" LOG_EFFECT_SIZE="0.4887031272694776" ORDER="68281" O_E="0.0" SE="1.1313666588832385" STUDY_ID="STD-Van-der-Linden-2005" TOTAL_1="37" TOTAL_2="38" VAR="1.279990516832622" WEIGHT="1.276061720277242"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-26 12:24:03 +0100" MODIFIED_BY="Katharine Ker" ORDER="2772" O_E="0.0" SE="0.0" STUDY_ID="STD-Wei-2006" TOTAL_1="36" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.137047883364928" CI_END="1.2756874485281224" CI_START="0.2603856602751994" DF="11" EFFECT_SIZE="0.5763425358150999" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" I2="0.0" ID="CMP-010.02.02" LOG_CI_END="0.10574428253036969" LOG_CI_START="-0.5843829365202509" LOG_EFFECT_SIZE="-0.2393193269949405" MODIFIED="2010-05-17 15:01:20 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.7878790407657738" P_Z="0.1740402560511463" STUDIES="23" TAU2="0.0" TOTAL_1="1189" TOTAL_2="1153" WEIGHT="9.939050920330837" Z="1.3593356377385335">
<NAME>Tranexamic Acid versus Control</NAME>
<DICH_DATA CI_END="76.21167365123344" CI_START="0.14053941198914405" EFFECT_SIZE="3.272727272727273" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8820214990825588" LOG_CI_START="-0.8522018678644345" LOG_EFFECT_SIZE="0.5149098156090622" ORDER="68326" O_E="0.0" SE="1.606096340368614" STUDY_ID="STD-Andreasen-2004" TOTAL_1="21" TOTAL_2="23" VAR="2.5795454545454546" WEIGHT="0.6331917501084725"/>
<DICH_DATA CI_END="3.168362491288542" CI_START="0.03506893905498902" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5008348632458548" LOG_CI_START="-1.45507737268518" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="68327" O_E="0.0" SE="1.1489125293076057" STUDY_ID="STD-Armellin-2001" TOTAL_1="150" TOTAL_2="150" VAR="1.32" WEIGHT="1.2373840157939329"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68328" O_E="0.0" SE="0.0" STUDY_ID="STD-Blauhut-1994" TOTAL_1="15" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="36.343034718577506" CI_START="0.0639565513987594" EFFECT_SIZE="1.5245901639344261" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5604211889737918" LOG_CI_START="-1.1941149618874558" LOG_EFFECT_SIZE="0.18315311354316807" ORDER="68329" O_E="0.0" SE="1.6180281701897488" STUDY_ID="STD-Brown-1997" TOTAL_1="60" TOTAL_2="30" VAR="2.618015159527587" WEIGHT="0.6238874877801411"/>
<DICH_DATA CI_END="6.690017380199802" CI_START="0.012930488128094391" EFFECT_SIZE="0.29411764705882354" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8254272460361436" LOG_CI_START="-1.8883850801206539" LOG_EFFECT_SIZE="-0.5314789170422551" ORDER="68330" O_E="0.0" SE="1.5941067939721714" STUDY_ID="STD-Coffey-1995" TOTAL_1="16" TOTAL_2="14" VAR="2.541176470588235" WEIGHT="0.6427522526485152"/>
<DICH_DATA CI_END="8.022569637689829" CI_START="0.013849815723520037" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9043134955566555" LOG_CI_START="-1.8585560049959806" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="68331" O_E="0.0" SE="1.6229232210492168" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="2.6338797814207653" WEIGHT="0.6201296324796316"/>
<DICH_DATA CI_END="1.769465679824819" CI_START="0.026345091667336132" EFFECT_SIZE="0.2159090909090909" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.24784214357299916" LOG_CI_START="-1.5793002859676784" LOG_EFFECT_SIZE="-0.6657290711973397" ORDER="68332" O_E="0.0" SE="1.073272507613088" STUDY_ID="STD-Dryden-1997" TOTAL_1="22" TOTAL_2="19" VAR="1.1519138755980862" WEIGHT="1.4179418578493466"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68333" O_E="0.0" SE="0.0" STUDY_ID="STD-Hardy-1998" TOTAL_1="43" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68334" O_E="0.0" SE="0.0" STUDY_ID="STD-Jares-2003" TOTAL_1="22" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-17 15:01:20 +0100" MODIFIED_BY="Katharine Ker" ORDER="2642" O_E="0.0" SE="0.0" STUDY_ID="STD-Jimenez-2007" TOTAL_1="24" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="32.019760174970436" CI_START="0.35412586927944617" EFFECT_SIZE="3.36734693877551" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.5054180747701325" LOG_CI_START="-0.4508423463993473" LOG_EFFECT_SIZE="0.5272878641853926" ORDER="68335" O_E="0.0" SE="1.149117055040213" STUDY_ID="STD-Karski-2005" TOTAL_1="147" TOTAL_2="165" VAR="1.3204700061842918" WEIGHT="1.236943583116899"/>
<DICH_DATA CI_END="36.35806398729506" CI_START="0.06386466192655374" EFFECT_SIZE="1.5238095238095237" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5606007496318903" LOG_CI_START="-1.1947393824599168" LOG_EFFECT_SIZE="0.18293068358598666" ORDER="68336" O_E="0.0" SE="1.6185004327443508" STUDY_ID="STD-Katoh-1997" TOTAL_1="62" TOTAL_2="31" VAR="2.6195436507936507" WEIGHT="0.6235234523971882"/>
<DICH_DATA CI_END="4.194749874738821" CI_START="0.009902455029705713" EFFECT_SIZE="0.2038095238095238" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6227060697512994" LOG_CI_START="-2.004257121192794" LOG_EFFECT_SIZE="-0.6907755257207473" ORDER="68337" O_E="0.0" SE="1.5430911820380762" STUDY_ID="STD-Katsaros-1996" TOTAL_1="104" TOTAL_2="106" VAR="2.381130396083667" WEIGHT="0.6859544120449755"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68338" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="16.406136195597867" CI_START="0.06597778748048523" EFFECT_SIZE="1.0404040404040404" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2150063125271002" LOG_CI_START="-1.1806022523118556" LOG_EFFECT_SIZE="0.017202030107622307" MODIFIED="2010-05-06 16:52:04 +0100" MODIFIED_BY="Katharine Ker" ORDER="2392" O_E="0.0" SE="1.4071923294400492" STUDY_ID="STD-Later-2009" TOTAL_1="99" TOTAL_2="103" VAR="1.9801902520349122" WEIGHT="0.8248434205599727"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-07 11:58:52 +0100" MODIFIED_BY="Katharine Ker" ORDER="2427" O_E="0.0" SE="0.0" STUDY_ID="STD-Maddali-2007" TOTAL_1="111" TOTAL_2="111" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-07 12:21:55 +0100" MODIFIED_BY="Katharine Ker" ORDER="2443" O_E="0.0" SE="0.0" STUDY_ID="STD-Mehr_x002d_Aein-2007" TOTAL_1="33" TOTAL_2="33" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68339" O_E="0.0" SE="0.0" STUDY_ID="STD-Misfeld-1998" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-11 15:07:25 +0000" MODIFIED_BY="Katharine Ker" ORDER="2310" O_E="0.0" SE="0.0" STUDY_ID="STD-Murphy-2006" TOTAL_1="50" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.052347097392378" CI_START="0.009870822769781833" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6077066370895764" LOG_CI_START="-2.005646645761614" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="68340" O_E="0.0" SE="1.5350966546541733" STUDY_ID="STD-Nuttall-2000" TOTAL_1="45" TOTAL_2="45" VAR="2.3565217391304345" WEIGHT="0.6931176885517307"/>
<DICH_DATA CI_END="4.264527161761337" CI_START="0.01067201811239352" EFFECT_SIZE="0.21333333333333335" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6298708848770885" LOG_CI_START="-1.971753446348639" LOG_EFFECT_SIZE="-0.6709412807357753" ORDER="68341" O_E="0.0" SE="1.5282070104101297" STUDY_ID="STD-Santos-2006" TOTAL_1="29" TOTAL_2="31" VAR="2.3354166666666667" WEIGHT="0.6993813670000321"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68342" O_E="0.0" SE="0.0" STUDY_ID="STD-Shore_x002d_Lesserson-1996" TOTAL_1="17" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68343" O_E="0.0" SE="0.0" STUDY_ID="STD-Zabeeda-2002" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9613325950099083" CI_END="5.426256544437944" CI_START="0.5022555142796312" DF="3" EFFECT_SIZE="1.6508686414551264" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-010.02.03" LOG_CI_END="0.7345003226360348" LOG_CI_START="-0.2990752864202925" LOG_EFFECT_SIZE="0.21771251810787118" MODIFIED="2010-05-17 14:28:48 +0100" MODIFIED_BY="Katharine Ker" NO="3" P_CHI2="0.8106071589657309" P_Z="0.4089775893209311" STUDIES="6" TAU2="0.0" TOTAL_1="371" TOTAL_2="353" WEIGHT="4.431173192134661" Z="0.825694203183731">
<NAME>Epsilon Aminocaproic Acid versus Control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68344" O_E="0.0" SE="0.0" STUDY_ID="STD-Daily-1994" TOTAL_1="21" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.174148659988499" CI_START="0.21667473049343697" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7138389024024029" LOG_CI_START="-0.6641917349523386" LOG_EFFECT_SIZE="0.024823583725032145" ORDER="68345" O_E="0.0" SE="0.8094620177438436" STUDY_ID="STD-Del-Rossi-1989" TOTAL_1="170" TOTAL_2="180" VAR="0.6552287581699346" WEIGHT="2.492788786331598"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-17 14:28:48 +0100" MODIFIED_BY="Katharine Ker" ORDER="2624" O_E="0.0" SE="0.0" STUDY_ID="STD-Greilich-2009" TOTAL_1="25" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="99.182453999066" CI_START="0.24144883076953833" EFFECT_SIZE="4.8936170212765955" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9964348495194004" LOG_CI_START="-0.61717489335565" LOG_EFFECT_SIZE="0.6896299780818754" ORDER="68346" O_E="0.0" SE="1.5352473005416867" STUDY_ID="STD-Hardy-1998" TOTAL_1="46" TOTAL_2="45" VAR="2.356984273820536" WEIGHT="0.6929816711082378"/>
<DICH_DATA CI_END="37.56235669713492" CI_START="0.06614683080821228" EFFECT_SIZE="1.576271186440678" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5747528324879192" LOG_CI_START="-1.1794909586643374" LOG_EFFECT_SIZE="0.19763093691179093" ORDER="68347" O_E="0.0" SE="1.6178564366494836" STUDY_ID="STD-Kluger-2003" TOTAL_1="58" TOTAL_2="30" VAR="2.6174594496081647" WEIGHT="0.6240199446423151"/>
<DICH_DATA CI_END="73.35586484045308" CI_START="0.12745377985598785" EFFECT_SIZE="3.0576923076923075" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8654348416424724" LOG_CI_START="-0.894647280271168" LOG_EFFECT_SIZE="0.4853937806856523" ORDER="68348" O_E="0.0" SE="1.6212859010389238" STUDY_ID="STD-Vander_x002d_Salm-1996" TOTAL_1="51" TOTAL_2="52" VAR="2.6285679729075953" WEIGHT="0.6213827900525098"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="35.493129845626825" CI_END="1.0890745638941324" CI_START="0.7133164405732138" CI_STUDY="95" CI_TOTAL="95" DF="51" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8813936642816237" ESTIMABLE="YES" EVENTS_1="193" EVENTS_2="180" I2="0.0" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="0.03705761490655479" LOG_CI_START="-0.1467177662107156" LOG_EFFECT_SIZE="-0.05483007565208041" METHOD="MH" MODIFIED="2010-07-08 11:07:50 +0100" MODIFIED_BY="Katharine Ker" NO="3" P_CHI2="0.9513748134496511" P_Q="0.0" P_Z="0.2421920977396147" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="65" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5151" TOTAL_2="4321" WEIGHT="100.00000000000003" Z="1.1695252421118232">
<NAME>Myocardial Infarction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="24.81738624557587" CI_END="1.1431875836304706" CI_START="0.7093599139992736" DF="35" EFFECT_SIZE="0.9005173213265517" ESTIMABLE="YES" EVENTS_1="162" EVENTS_2="135" I2="0.0" ID="CMP-010.03.01" LOG_CI_END="0.05811749885669311" LOG_CI_START="-0.14913335719591087" LOG_EFFECT_SIZE="-0.045507929169608864" MODIFIED="2010-07-08 11:07:50 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="0.899450913162356" P_Z="0.3893847149365054" STUDIES="46" TAU2="0.0" TOTAL_1="3713" TOTAL_2="2945" WEIGHT="78.62886341748387" Z="0.8607337396067898">
<NAME>Aprotinin versus Control</NAME>
<DICH_DATA CI_END="1.6077071625838795" CI_START="0.3689028907459417" EFFECT_SIZE="0.7701219512195122" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.20620694661662112" LOG_CI_START="-0.4330879416013554" LOG_EFFECT_SIZE="-0.11344049749236712" ORDER="68385" O_E="0.0" SE="0.37552498189997346" STUDY_ID="STD-Alderman-1998" TOTAL_1="410" TOTAL_2="421" VAR="0.1410190120309754" WEIGHT="8.26365543694384"/>
<DICH_DATA CI_END="105.64697314375843" CI_START="0.25594675545702095" EFFECT_SIZE="5.2" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.023857058740018" LOG_CI_START="-0.59185037147042" LOG_EFFECT_SIZE="0.7160033436347992" ORDER="68384" O_E="0.0" SE="1.5364794924662128" STUDY_ID="STD-Alvarez-1995" TOTAL_1="49" TOTAL_2="51" VAR="2.3607692307692307" WEIGHT="0.49362407400680486"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68383" O_E="0.0" SE="0.0" STUDY_ID="STD-Alvarez-2001" TOTAL_1="26" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-20 11:11:46 +0100" MODIFIED_BY="Katharine Ker" ORDER="5304" O_E="0.0" SE="0.0" STUDY_ID="STD-Asimakopoulos-2000" TOTAL_1="8" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.541363678271646" CI_START="0.15664935539787983" EFFECT_SIZE="0.49137931034482757" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.187905120763877" LOG_CI_START="-0.8050713878727311" LOG_EFFECT_SIZE="-0.30858313355442707" ORDER="68382" O_E="0.0" SE="0.5832793164861346" STUDY_ID="STD-Baele-1992" TOTAL_1="58" TOTAL_2="57" VAR="0.3402147610405324" WEIGHT="3.4252850226665603"/>
<DICH_DATA CI_END="1.6077071625838795" CI_START="0.3689028907459417" EFFECT_SIZE="0.7701219512195122" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.20620694661662112" LOG_CI_START="-0.4330879416013554" LOG_EFFECT_SIZE="-0.11344049749236712" ORDER="68381" O_E="0.0" SE="0.37552498189997346" STUDY_ID="STD-Bidstrup-1993" TOTAL_1="410" TOTAL_2="421" VAR="0.1410190120309754" WEIGHT="8.26365543694384"/>
<DICH_DATA CI_END="6.64261094358732" CI_START="0.1505432138796847" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8223388166442885" LOG_CI_START="-0.8223388166442885" LOG_EFFECT_SIZE="0.0" ORDER="68380" O_E="0.0" SE="0.9660917830792959" STUDY_ID="STD-Bidstrup-2000" TOTAL_1="30" TOTAL_2="30" VAR="0.9333333333333333" WEIGHT="1.2485705630166626"/>
<DICH_DATA CI_END="8.602503618833898" CI_START="0.2615517644275046" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.93462486398861" LOG_CI_START="-0.5824423458772476" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="68379" O_E="0.0" SE="0.8911327886790068" STUDY_ID="STD-Carrera-1994" TOTAL_1="51" TOTAL_2="51" VAR="0.7941176470588234" WEIGHT="1.4674557728294606"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68378" O_E="0.0" SE="0.0" STUDY_ID="STD-Cicek-1996a" TOTAL_1="50" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68377" O_E="0.0" SE="0.0" STUDY_ID="STD-Cicek-1996b" TOTAL_1="29" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-20 11:57:02 +0100" MODIFIED_BY="Katharine Ker" ORDER="5333" O_E="0.0" SE="0.0" STUDY_ID="STD-Cicekcioglu-2006" TOTAL_1="24" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="107.27288722482027" CI_START="0.25822770078776697" EFFECT_SIZE="5.2631578947368425" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.030489969714727" LOG_CI_START="-0.5879971716203847" LOG_EFFECT_SIZE="0.721246399047171" ORDER="68376" O_E="0.0" SE="1.5381123085406379" STUDY_ID="STD-Cohen-1998" TOTAL_1="56" TOTAL_2="59" VAR="2.3657894736842104" WEIGHT="0.4925765958656763"/>
<DICH_DATA CI_END="16.043206383216464" CI_START="0.06376454498349125" EFFECT_SIZE="1.0114285714285713" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2052911703929732" LOG_CI_START="-1.195420735041949" LOG_EFFECT_SIZE="0.00493521767551215" MODIFIED="2010-05-20 12:09:59 +0100" MODIFIED_BY="Katharine Ker" ORDER="5344" O_E="0.0" SE="1.4101900569680634" STUDY_ID="STD-Colwell-2007" TOTAL_1="175" TOTAL_2="177" VAR="1.9886359967715899" WEIGHT="0.5859958923473444"/>
<DICH_DATA CI_END="5.026670430933967" CI_START="0.5985147306126019" EFFECT_SIZE="1.7345132743362832" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" LOG_CI_END="0.7012804120395381" LOG_CI_START="-0.22292515629342538" LOG_EFFECT_SIZE="0.23917762787305633" ORDER="68375" O_E="0.0" SE="0.5428829257301289" STUDY_ID="STD-Cosgrove-1992" TOTAL_1="113" TOTAL_2="56" VAR="0.29472187104930464" WEIGHT="3.9540076253359135"/>
<DICH_DATA CI_END="3.4123328274150158" CI_START="0.20640707865585955" EFFECT_SIZE="0.8392434988179669" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.5330513841778762" LOG_CI_START="-0.6852754128177727" LOG_EFFECT_SIZE="-0.07611201431994824" ORDER="68374" O_E="0.0" SE="0.7156511913701531" STUDY_ID="STD-D_x0027_Ambra-1996" TOTAL_1="141" TOTAL_2="71" VAR="0.5121566277095195" WEIGHT="2.2753440303874415"/>
<DICH_DATA CI_END="2.07731834537124" CI_START="0.02852418311150889" EFFECT_SIZE="0.24342105263157895" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.31750305649841715" LOG_CI_START="-1.5447867842539722" LOG_EFFECT_SIZE="-0.6136418638777775" MODIFIED="2010-05-17 10:56:45 +0100" MODIFIED_BY="Katharine Ker" ORDER="2564" O_E="0.0" SE="1.093918270941339" STUDY_ID="STD-Desai-2009" TOTAL_1="38" TOTAL_2="37" VAR="1.1966571834992887" WEIGHT="0.9738231981147097"/>
<DICH_DATA CI_END="2.395116661014344" CI_START="0.14441206247634583" EFFECT_SIZE="0.5881188118811881" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3793266718219245" LOG_CI_START="-0.8403965294248226" LOG_EFFECT_SIZE="-0.23053492880144905" ORDER="68373" O_E="0.0" SE="0.7164714461395606" STUDY_ID="STD-Dignan-2001" TOTAL_1="101" TOTAL_2="99" VAR="0.5133313331333134" WEIGHT="2.270137141968653"/>
<DICH_DATA CI_END="3.2087008039370097" CI_START="0.1753045965862022" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5063292230920509" LOG_CI_START="-0.7562066963086507" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="68372" O_E="0.0" SE="0.7416198487095662" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.5499999999999998" WEIGHT="2.1187864099676705"/>
<DICH_DATA CI_END="17.111978424286665" CI_START="0.07546306347703435" EFFECT_SIZE="1.1363636363636365" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2333002239817072" LOG_CI_START="-1.1222655682820444" LOG_EFFECT_SIZE="0.05551732784983142" ORDER="68371" O_E="0.0" SE="1.3836710066144533" STUDY_ID="STD-Englberger-2002a" TOTAL_1="22" TOTAL_2="25" VAR="1.9145454545454546" WEIGHT="0.6086732089413296"/>
<DICH_DATA CI_END="13.53677361466875" CI_START="0.06435145743791972" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.131515165950651" LOG_CI_START="-1.1914416127055376" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="68370" O_E="0.0" SE="1.3645163106041502" STUDY_ID="STD-Englberger-2002b" TOTAL_1="15" TOTAL_2="14" VAR="1.861904761904762" WEIGHT="0.625881919056946"/>
<DICH_DATA CI_END="10.83813052319989" CI_START="0.5314569692319404" EFFECT_SIZE="2.4" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.0349543769000427" LOG_CI_START="-0.27453189347683066" LOG_EFFECT_SIZE="0.38021124171160603" ORDER="68369" O_E="0.0" SE="0.7691987172809551" STUDY_ID="STD-Golanski-2000" TOTAL_1="30" TOTAL_2="24" VAR="0.5916666666666667" WEIGHT="1.9695760994065663"/>
<DICH_DATA CI_END="2.297323745923574" CI_START="0.3448776507348208" EFFECT_SIZE="0.8901098901098901" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.36122220162110974" LOG_CI_START="-0.46233494850599743" LOG_EFFECT_SIZE="-0.050556373442443875" MODIFIED="2010-05-17 14:29:21 +0100" MODIFIED_BY="Katharine Ker" ORDER="2625" O_E="0.0" SE="0.4837615466583036" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="27" VAR="0.23402523402523406" WEIGHT="4.979516548017061"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68368" O_E="0.0" SE="0.0" STUDY_ID="STD-Harder-1991" TOTAL_1="40" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4839504460692374" CI_START="0.11580436148625915" EFFECT_SIZE="0.41454545454545455" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.1714193986801977" LOG_CI_START="-0.9362750836677779" LOG_EFFECT_SIZE="-0.38242784249379" ORDER="68367" O_E="0.0" SE="0.65066522210732" STUDY_ID="STD-Hayashida-1997" TOTAL_1="110" TOTAL_2="57" VAR="0.4233652312599681" WEIGHT="2.7525465943769105"/>
<DICH_DATA CI_END="7.843592129561627" CI_START="0.03187315146816185" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.8945150020678766" LOG_CI_START="-1.4965749933958392" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="68366" O_E="0.0" SE="1.404538099421754" STUDY_ID="STD-Kalangos-1994" TOTAL_1="110" TOTAL_2="55" VAR="1.9727272727272729" WEIGHT="0.5907215566960553"/>
<DICH_DATA CI_END="14.553341064518706" CI_START="0.06871274407483083" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1629627073641946" LOG_CI_START="-1.1629627073641946" LOG_EFFECT_SIZE="0.0" ORDER="68365" O_E="0.0" SE="1.3662601021279464" STUDY_ID="STD-Kipfer-2003" TOTAL_1="15" TOTAL_2="15" VAR="1.8666666666666667" WEIGHT="0.6242852815083313"/>
<DICH_DATA CI_END="5.281559596881724" CI_START="0.11800845690142829" EFFECT_SIZE="0.7894736842105263" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7227621847129794" LOG_CI_START="-0.9280868685072747" LOG_EFFECT_SIZE="-0.10266234189714772" ORDER="68364" O_E="0.0" SE="0.9697169056961844" STUDY_ID="STD-Klein-1998" TOTAL_1="38" TOTAL_2="30" VAR="0.9403508771929825" WEIGHT="1.2392528722478815"/>
<DICH_DATA CI_END="39.05869370178205" CI_START="0.6400623684672634" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5917177144358472" LOG_CI_START="-0.19377770576380962" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="68363" O_E="0.0" SE="1.0488088481701514" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="1.0999999999999999" WEIGHT="1.059393204983835"/>
<DICH_DATA CI_END="1.8552452689203953" CI_START="0.005670083255838834" EFFECT_SIZE="0.10256410256410256" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2684013327636469" LOG_CI_START="-2.246410564160721" LOG_EFFECT_SIZE="-0.9890046156985368" ORDER="68362" O_E="0.0" SE="1.4772129567730305" STUDY_ID="STD-Lass-1995" TOTAL_1="51" TOTAL_2="47" VAR="2.1821581196581197" WEIGHT="0.5340275367693299"/>
<DICH_DATA CI_END="1.052445490945524" CI_START="0.01709040669319056" EFFECT_SIZE="0.13411458333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="0.022199611781238866" LOG_CI_START="-1.7672476024339185" LOG_EFFECT_SIZE="-0.8725239953263397" MODIFIED="2010-05-06 16:52:30 +0100" MODIFIED_BY="Katharine Ker" ORDER="2393" O_E="0.0" SE="1.0511301515365523" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="103" VAR="1.1048745954692556" WEIGHT="1.054719268830039"/>
<DICH_DATA CI_END="5.3278061871756135" CI_START="0.650197772680211" EFFECT_SIZE="1.861216730038023" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="4" LOG_CI_END="0.7265484178568543" LOG_CI_START="-0.18695452255805675" LOG_EFFECT_SIZE="0.2697969476493988" ORDER="68361" O_E="0.0" SE="0.5365961491122023" STUDY_ID="STD-Lemmer-1996" TOTAL_1="526" TOTAL_2="178" VAR="0.2879354272420449" WEIGHT="4.047200918081588"/>
<DICH_DATA CI_END="3.6146683029375715" CI_START="0.5645929738206075" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5580684507831964" LOG_CI_START="-0.24826453081171015" LOG_EFFECT_SIZE="0.15490195998574316" ORDER="68360" O_E="0.0" SE="0.4736439848014797" STUDY_ID="STD-Lemmer_x005f_1-1994" TOTAL_1="108" TOTAL_2="108" VAR="0.22433862433862434" WEIGHT="5.194524700852341"/>
<DICH_DATA CI_END="2.0680398044354233" CI_START="0.4603612711326558" EFFECT_SIZE="0.9757281553398058" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="8" LOG_CI_END="0.31555889355164135" LOG_CI_START="-0.33690121944897033" LOG_EFFECT_SIZE="-0.010671162948664523" ORDER="68359" O_E="0.0" SE="0.38325830010620704" STUDY_ID="STD-Levy-1995" TOTAL_1="206" TOTAL_2="67" VAR="0.14688692460029948" WEIGHT="7.933534782985323"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68358" O_E="0.0" SE="0.0" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68357" O_E="0.0" SE="0.0" STUDY_ID="STD-Moran-2000" TOTAL_1="28" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.8955723550096066" CI_START="0.19077117136645608" EFFECT_SIZE="0.8620689655172413" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5905712751949531" LOG_CI_START="-0.7194872536487902" LOG_EFFECT_SIZE="-0.0644579892269185" ORDER="68356" O_E="0.0" SE="0.7695348647371196" STUDY_ID="STD-Murkin-1994" TOTAL_1="29" TOTAL_2="25" VAR="0.592183908045977" WEIGHT="1.9678557786675661"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-07 15:06:49 +0100" MODIFIED_BY="Katharine Ker" ORDER="2476" O_E="0.0" SE="0.0" STUDY_ID="STD-Nur_x00f6_zler-2008" TOTAL_1="25" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.405785881208536" CI_START="0.04624674478303774" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7328588396514188" LOG_CI_START="-1.3349188309793814" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-05-07 15:34:55 +0100" MODIFIED_BY="Katharine Ker" ORDER="2485" O_E="0.0" SE="1.2146228393930802" STUDY_ID="STD-Parvizi-2007" TOTAL_1="81" TOTAL_2="81" VAR="1.4753086419753085" WEIGHT="0.789890665808031"/>
<DICH_DATA CI_END="3.2345221380429106" CI_START="0.03925317174749747" EFFECT_SIZE="0.3563218390804598" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5098101279288101" LOG_CI_START="-1.4061252454975017" LOG_EFFECT_SIZE="-0.4481575587843458" ORDER="68355" O_E="0.0" SE="1.1254299223836706" STUDY_ID="STD-Poston-2006" TOTAL_1="29" TOTAL_2="31" VAR="1.2665925101965145" WEIGHT="0.9200532263540817"/>
<DICH_DATA CI_END="4.8033836748969465" CI_START="0.21733655300479887" EFFECT_SIZE="1.0217391304347827" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6815472777144629" LOG_CI_START="-0.662867225206176" LOG_EFFECT_SIZE="0.009340026254143432" ORDER="68354" O_E="0.0" SE="0.7897157339747025" STUDY_ID="STD-Rodrigus-1996" TOTAL_1="46" TOTAL_2="47" VAR="0.6236509404872032" WEIGHT="1.868565330105728"/>
<DICH_DATA CI_END="3.365562691610729" CI_START="0.07428178373357004" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.5270576847358844" LOG_CI_START="-1.1291176760638466" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="68353" O_E="0.0" SE="0.9728456051340169" STUDY_ID="STD-Santamaria-2000" TOTAL_1="56" TOTAL_2="28" VAR="0.9464285714285714" WEIGHT="1.2312947439057402"/>
<DICH_DATA CI_END="6.855230181218761" CI_START="0.15647965907425473" EFFECT_SIZE="1.0357142857142858" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8360220418760519" LOG_CI_START="-0.805542108762578" LOG_EFFECT_SIZE="0.015239966556736905" ORDER="68352" O_E="0.0" SE="0.9642629079587293" STUDY_ID="STD-Schweizer-2000" TOTAL_1="28" TOTAL_2="29" VAR="0.9298029556650247" WEIGHT="1.2533112724391542"/>
<DICH_DATA CI_END="14.50846406676568" CI_START="0.061479651087616466" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.161621438444948" LOG_CI_START="-1.2112686058950124" LOG_EFFECT_SIZE="-0.024823583725032152" ORDER="68351" O_E="0.0" SE="1.3938473580404491" STUDY_ID="STD-Taggart-2003" TOTAL_1="36" TOTAL_2="34" VAR="1.94281045751634" WEIGHT="0.5998179189193589"/>
<DICH_DATA CI_END="73.24882267849273" CI_START="0.1294207408509027" EFFECT_SIZE="3.0789473684210527" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8648006487074702" LOG_CI_START="-0.8879961184487669" LOG_EFFECT_SIZE="0.4884022651293515" ORDER="68350" O_E="0.0" SE="1.6170064475913375" STUDY_ID="STD-Van-der-Linden-2005" TOTAL_1="37" TOTAL_2="38" VAR="2.614709851551957" WEIGHT="0.44568330393926386"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-26 12:24:45 +0100" MODIFIED_BY="Katharine Ker" ORDER="2773" O_E="0.0" SE="0.0" STUDY_ID="STD-Wei-2006" TOTAL_1="36" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.919915520931636" CI_START="0.0102043015433387" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5932767075335775" LOG_CI_START="-1.991216716205615" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="68349" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Wendel-1995" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="0.5056194841968302"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.208633180848671" CI_END="1.4692012298725854" CI_START="0.3719807030759956" DF="10" EFFECT_SIZE="0.7392661945795451" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="24" I2="0.0" ID="CMP-010.03.02" LOG_CI_END="0.1670812832225712" LOG_CI_START="-0.4294795890562323" LOG_EFFECT_SIZE="-0.1311991529168305" MODIFIED="2010-05-17 15:01:45 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.7056128790620487" P_Z="0.38863609652301934" STUDIES="19" TAU2="0.0" TOTAL_1="1073" TOTAL_2="1027" WEIGHT="9.489976433529739" Z="0.8620934642826311">
<NAME>Tranexamic Acid versus Control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68400" O_E="0.0" SE="0.0" STUDY_ID="STD-Andreasen-2004" TOTAL_1="21" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="73.05858468240297" CI_START="0.12318880853118634" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8636712546460013" LOG_CI_START="-0.9094287452066763" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="68399" O_E="0.0" SE="1.6289326669798492" STUDY_ID="STD-Armellin-2001" TOTAL_1="150" TOTAL_2="150" VAR="2.653421633554084" WEIGHT="0.43918105993631024"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68398" O_E="0.0" SE="0.0" STUDY_ID="STD-Brown-1997" TOTAL_1="60" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.429536110874856" CI_START="0.3527457415154469" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6463582465309213" LOG_CI_START="-0.45253822051480863" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="68397" O_E="0.0" SE="0.6454972243679028" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.4166666666666667" WEIGHT="2.796798061157324"/>
<DICH_DATA CI_END="5.562800180520233" CI_START="0.04921921297746887" EFFECT_SIZE="0.5232558139534884" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7452934600745638" LOG_CI_START="-1.3078653350110119" LOG_EFFECT_SIZE="-0.281285937468224" ORDER="68396" O_E="0.0" SE="1.2060356395332144" STUDY_ID="STD-Hardy-1998" TOTAL_1="43" TOTAL_2="45" VAR="1.4545219638242894" WEIGHT="0.8011790502071744"/>
<DICH_DATA CI_END="84.69311383087638" CI_START="0.149022636727436" EFFECT_SIZE="3.5526315789473686" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9278481004507968" LOG_CI_START="-0.8267477566944047" LOG_EFFECT_SIZE="0.550550171878196" ORDER="68395" O_E="0.0" SE="1.6180632419564942" STUDY_ID="STD-Horrow-1991" TOTAL_1="37" TOTAL_2="44" VAR="2.6181286549707603" WEIGHT="0.4451013219956653"/>
<DICH_DATA CI_END="17.111978424286665" CI_START="0.07546306347703435" EFFECT_SIZE="1.1363636363636365" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2333002239817072" LOG_CI_START="-1.1222655682820444" LOG_EFFECT_SIZE="0.05551732784983142" ORDER="68394" O_E="0.0" SE="1.3836710066144533" STUDY_ID="STD-Jares-2003" TOTAL_1="22" TOTAL_2="25" VAR="1.9145454545454546" WEIGHT="0.6086732089413296"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68393" O_E="0.0" SE="0.0" STUDY_ID="STD-Karski-1995" TOTAL_1="100" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.416639994623157" CI_START="0.12678232153558208" EFFECT_SIZE="0.7482993197278912" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6450920008611732" LOG_CI_START="-0.8969413000410753" LOG_EFFECT_SIZE="-0.12592464958995103" ORDER="68392" O_E="0.0" SE="0.9057979941379268" STUDY_ID="STD-Karski-2005" TOTAL_1="147" TOTAL_2="165" VAR="0.8204700061842918" WEIGHT="1.4203231278395625"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68391" O_E="0.0" SE="0.0" STUDY_ID="STD-Katsaros-1996" TOTAL_1="104" TOTAL_2="106" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="14.903914722906746" CI_START="0.06709646549862758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528004" LOG_EFFECT_SIZE="0.0" ORDER="68390" O_E="0.0" SE="1.378404875209022" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="1.9" WEIGHT="0.613332908148536"/>
<DICH_DATA CI_END="1.0459584311055454" CI_START="0.0035781159578946666" EFFECT_SIZE="0.0611764705882353" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="0.019514424970822127" LOG_CI_START="-2.446345589129809" LOG_EFFECT_SIZE="-1.2134155820794936" MODIFIED="2010-05-06 16:52:48 +0100" MODIFIED_BY="Katharine Ker" ORDER="2394" O_E="0.0" SE="1.4484583784866396" STUDY_ID="STD-Later-2009" TOTAL_1="99" TOTAL_2="103" VAR="2.098031674208145" WEIGHT="0.5554408638382674"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68389" O_E="0.0" SE="0.0" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-07 12:22:20 +0100" MODIFIED_BY="Katharine Ker" ORDER="2444" O_E="0.0" SE="0.0" STUDY_ID="STD-Mehr_x002d_Aein-2007" TOTAL_1="33" TOTAL_2="33" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.99146782835324" CI_START="0.013903717501920699" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9026265554350377" LOG_CI_START="-1.8568690648743624" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2010-01-11 15:07:54 +0000" MODIFIED_BY="Katharine Ker" ORDER="2311" O_E="0.0" SE="1.6209413870933633" STUDY_ID="STD-Murphy-2006" TOTAL_1="50" TOTAL_2="50" VAR="2.627450980392157" WEIGHT="0.44352208059397863"/>
<DICH_DATA CI_END="3.772928267323021" CI_START="0.03874809200388678" EFFECT_SIZE="0.38235294117647056" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5766785482696595" LOG_CI_START="-1.4117496777404963" LOG_EFFECT_SIZE="-0.4175355647354184" ORDER="68388" O_E="0.0" SE="1.1680125828368282" STUDY_ID="STD-Shore_x002d_Lesserson-1996" TOTAL_1="17" TOTAL_2="13" VAR="1.3642533936651584" WEIGHT="0.8541906737365514"/>
<DICH_DATA CI_END="3.845086034384406" CI_START="0.010402888164868843" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5849060616512035" LOG_CI_START="-1.982846070323241" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="68387" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Speekenbrink-1995" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="0.5122340771350411"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-14 12:21:41 +0100" MODIFIED_BY="Katharine Ker" ORDER="2509" O_E="0.0" SE="0.0" STUDY_ID="STD-Taghaddomi-2009" TOTAL_1="50" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68386" O_E="0.0" SE="0.0" STUDY_ID="STD-Zabeeda-2002" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.4438046063904193" CI_END="1.625757784211423" CI_START="0.47631626856821146" DF="4" EFFECT_SIZE="0.8799857279361459" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" I2="0.0" ID="CMP-010.03.03" LOG_CI_END="0.2110558421091065" LOG_CI_START="-0.3221045849197701" LOG_EFFECT_SIZE="-0.055524371405331785" MODIFIED="2010-05-17 14:29:42 +0100" MODIFIED_BY="Katharine Ker" NO="3" P_CHI2="0.4864745498349089" P_Z="0.6831055761909759" STUDIES="6" TAU2="0.0" TOTAL_1="365" TOTAL_2="349" WEIGHT="11.88116014898641" Z="0.4082289783775788">
<NAME>Epsilon Aminocaproic Acid versus Control</NAME>
<DICH_DATA CI_END="1.3248431352831338" CI_START="0.13539501987261524" EFFECT_SIZE="0.4235294117647059" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.12216445977177443" LOG_CI_START="-0.8683973096657853" LOG_EFFECT_SIZE="-0.3731164249470055" ORDER="68401" O_E="0.0" SE="0.5818608867274617" STUDY_ID="STD-Del-Rossi-1989" TOTAL_1="170" TOTAL_2="180" VAR="0.338562091503268" WEIGHT="3.4420053358837723"/>
<DICH_DATA CI_END="2.3817699458924997" CI_START="0.35979416914440665" EFFECT_SIZE="0.9257142857142857" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3768998108602507" LOG_CI_START="-0.44394587914757766" LOG_EFFECT_SIZE="-0.03352303414366349" MODIFIED="2010-05-17 14:29:42 +0100" MODIFIED_BY="Katharine Ker" ORDER="2626" O_E="0.0" SE="0.48216882156229524" STUDY_ID="STD-Greilich-2009" TOTAL_1="25" TOTAL_2="27" VAR="0.23248677248677252" WEIGHT="5.012468077290379"/>
<DICH_DATA CI_END="6.648688139857462" CI_START="0.14393731647383476" EFFECT_SIZE="0.9782608695652174" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8227359626227094" LOG_CI_START="-0.8418265984351703" LOG_EFFECT_SIZE="-0.009545317906230389" ORDER="68402" O_E="0.0" SE="0.9777722880829642" STUDY_ID="STD-Hardy-1998" TOTAL_1="46" TOTAL_2="45" VAR="0.9560386473429952" WEIGHT="1.2189178007823105"/>
<DICH_DATA CI_END="37.56235669713492" CI_START="0.06614683080821228" EFFECT_SIZE="1.576271186440678" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5747528324879192" LOG_CI_START="-1.1794909586643374" LOG_EFFECT_SIZE="0.19763093691179093" ORDER="68405" O_E="0.0" SE="1.6178564366494836" STUDY_ID="STD-Kluger-2003" TOTAL_1="58" TOTAL_2="30" VAR="2.6174594496081647" WEIGHT="0.4452151209665041"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68404" O_E="0.0" SE="0.0" STUDY_ID="STD-Rao-1999" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="12.545868678250816" CI_START="0.5178996471111383" EFFECT_SIZE="2.549019607843137" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0985007373213926" LOG_CI_START="-0.2857543849035919" LOG_EFFECT_SIZE="0.40637317620890034" ORDER="68403" O_E="0.0" SE="0.8131183109683213" STUDY_ID="STD-Vander_x002d_Salm-1996" TOTAL_1="51" TOTAL_2="52" VAR="0.6611613876319757" WEIGHT="1.7625538140634445"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.74829135414733" CI_END="1.6277550845910653" CI_START="0.5500498039273984" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9462274383683562" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-010.04" LOG_CI_END="0.21158906061939106" LOG_CI_START="-0.2595979857937589" LOG_EFFECT_SIZE="-0.024004462587183927" METHOD="MH" MODIFIED="2010-07-08 11:07:50 +0100" MODIFIED_BY="Katharine Ker" NO="4" P_CHI2="0.9221186640327819" P_Q="0.0" P_Z="0.8417156934241036" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="38" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2584" TOTAL_2="2266" WEIGHT="100.00000000000003" Z="0.19969938688792707">
<NAME>Stroke</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.546207578384898" CI_END="1.6705553259334662" CI_START="0.3965894275704797" DF="14" EFFECT_SIZE="0.8139561293072063" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" I2="0.0" ID="CMP-010.04.01" LOG_CI_END="0.2228608633023316" LOG_CI_START="-0.40165886756138186" LOG_EFFECT_SIZE="-0.08939900212952513" MODIFIED="2010-07-08 11:07:50 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="0.721259284491512" P_Z="0.5747079468907933" STUDIES="18" TAU2="0.0" TOTAL_1="1177" TOTAL_2="950" WEIGHT="56.92386203738595" Z="0.5611314287392024">
<NAME>Aprotinin versus Control</NAME>
<DICH_DATA CI_END="8.837849728013516" CI_START="0.018780676377005198" EFFECT_SIZE="0.4074074074074074" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9463466128803426" LOG_CI_START="-1.726288770881867" LOG_EFFECT_SIZE="-0.3899710790007623" MODIFIED="2010-05-20 11:12:42 +0100" MODIFIED_BY="Katharine Ker" ORDER="5305" O_E="0.0" SE="1.5699192541804385" STUDY_ID="STD-Asimakopoulos-2000" TOTAL_1="8" TOTAL_2="10" VAR="2.4646464646464645" WEIGHT="3.10818784296627"/>
<DICH_DATA CI_END="8.695084862642968" CI_START="0.01520760372642119" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9392738250043677" LOG_CI_START="-1.817939212664893" LOG_EFFECT_SIZE="-0.43933269383026263" ORDER="68416" O_E="0.0" SE="1.6196005867515793" STUDY_ID="STD-Bidstrup-1993" TOTAL_1="43" TOTAL_2="47" VAR="2.62310606060606" WEIGHT="2.920424870984433"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68415" O_E="0.0" SE="0.0" STUDY_ID="STD-Casas-1995" TOTAL_1="47" TOTAL_2="51" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="22.596047095942403" CI_START="0.1964968032486296" EFFECT_SIZE="2.107142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3540324712460294" LOG_CI_START="-0.7066445106461795" LOG_EFFECT_SIZE="0.32369398029992497" ORDER="68412" O_E="0.0" SE="1.2104518596790557" STUDY_ID="STD-Cohen-1998" TOTAL_1="56" TOTAL_2="59" VAR="1.4651937046004844" WEIGHT="5.228376394582419"/>
<DICH_DATA CI_END="8.219477863126539" CI_START="0.013826998935288172" EFFECT_SIZE="0.3371212121212121" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9148442301476883" LOG_CI_START="-1.8592720705975248" LOG_EFFECT_SIZE="-0.47221392022491826" MODIFIED="2010-05-20 12:10:54 +0100" MODIFIED_BY="Katharine Ker" ORDER="5346" O_E="0.0" SE="1.6295296471548955" STUDY_ID="STD-Colwell-2007" TOTAL_1="175" TOTAL_2="177" VAR="2.655366870956758" WEIGHT="2.8849437953045425"/>
<DICH_DATA CI_END="10.919150695915887" CI_START="0.09288585941241723" EFFECT_SIZE="1.0070921985815602" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0381888597586881" LOG_CI_START="-1.0320503963033352" LOG_EFFECT_SIZE="0.003069231727676536" ORDER="68413" O_E="0.0" SE="1.2160687868604252" STUDY_ID="STD-D_x0027_Ambra-1996" TOTAL_1="141" TOTAL_2="71" VAR="1.4788232943761863" WEIGHT="5.180189010922641"/>
<DICH_DATA CI_END="7.726736792150155" CI_START="0.01365209655845594" EFFECT_SIZE="0.3247863247863248" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.887996118448767" LOG_CI_START="-1.8648006487074702" LOG_EFFECT_SIZE="-0.4884022651293515" MODIFIED="2010-05-17 10:57:05 +0100" MODIFIED_BY="Katharine Ker" ORDER="2565" O_E="0.0" SE="1.6170064475913375" STUDY_ID="STD-Desai-2009" TOTAL_1="38" TOTAL_2="37" VAR="2.614709851551957" WEIGHT="2.929802774895658"/>
<DICH_DATA CI_END="15.454677816307568" CI_START="0.062168113075117784" EFFECT_SIZE="0.9801980198019802" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1890599557559556" LOG_CI_START="-1.2064323141261408" LOG_EFFECT_SIZE="-0.008686179185092667" ORDER="68409" O_E="0.0" SE="1.4071240172067208" STUDY_ID="STD-Dignan-2001" TOTAL_1="101" TOTAL_2="99" VAR="1.97999799979998" WEIGHT="3.8689858168532556"/>
<DICH_DATA CI_END="21.54520124544955" CI_START="0.20021207591953577" EFFECT_SIZE="2.076923076923077" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3333505550212796" LOG_CI_START="-0.6985097313169786" LOG_EFFECT_SIZE="0.3174204118521506" MODIFIED="2010-05-17 14:30:04 +0100" MODIFIED_BY="Katharine Ker" ORDER="2627" O_E="0.0" SE="1.1935247900657215" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="27" VAR="1.4245014245014245" WEIGHT="5.377730093394005"/>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="68408" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="2.9791160694648644"/>
<DICH_DATA CI_END="16.915109010524368" CI_START="0.0680545524651884" EFFECT_SIZE="1.0729166666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.228274800972161" LOG_CI_START="-1.167142817640953" LOG_EFFECT_SIZE="0.030565991665603823" MODIFIED="2010-05-21 10:37:46 +0100" MODIFIED_BY="Katharine Ker" ORDER="2742" O_E="0.0" SE="1.4070801666817907" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="103" VAR="1.9798745954692556" WEIGHT="3.8692269682910307"/>
<DICH_DATA CI_END="0.5638160191543875" CI_START="0.00795629089874221" EFFECT_SIZE="0.06697674418604652" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="-0.24886258910378742" LOG_CI_START="-2.099289346536924" LOG_EFFECT_SIZE="-1.1740759678203556" ORDER="68414" O_E="0.0" SE="1.0869498370764004" STUDY_ID="STD-Levy-1995" TOTAL_1="215" TOTAL_2="72" VAR="1.1814599483204133" WEIGHT="6.483998200289713"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68411" O_E="0.0" SE="0.0" STUDY_ID="STD-Moran-2000" TOTAL_1="28" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="73.06338428845214" CI_START="0.13283837583347674" EFFECT_SIZE="3.1153846153846154" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8636997848175818" LOG_CI_START="-0.8766764430019184" LOG_EFFECT_SIZE="0.49351167090783177" MODIFIED="2010-05-07 15:07:15 +0100" MODIFIED_BY="Katharine Ker" ORDER="2477" O_E="0.0" SE="1.6097105613022769" STUDY_ID="STD-Nur_x00f6_zler-2008" TOTAL_1="25" TOTAL_2="26" VAR="2.591168091168091" WEIGHT="2.956421161843873"/>
<DICH_DATA CI_END="8.394184190041877" CI_START="0.015060397797369413" EFFECT_SIZE="0.35555555555555557" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9239784945205962" LOG_CI_START="-1.8221635567594336" LOG_EFFECT_SIZE="-0.4490925311194189" ORDER="68406" O_E="0.0" SE="1.6130974345442786" STUDY_ID="STD-Poston-2006" TOTAL_1="29" TOTAL_2="31" VAR="2.6020833333333333" WEIGHT="2.944019540223771"/>
<DICH_DATA CI_END="51.262245865436334" CI_START="0.12623758099522608" EFFECT_SIZE="2.543859649122807" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7097976292692112" LOG_CI_START="-0.898811336144244" LOG_EFFECT_SIZE="0.4054931465624835" ORDER="68410" O_E="0.0" SE="1.5323098191064977" STUDY_ID="STD-Santamaria-2000" TOTAL_1="56" TOTAL_2="28" VAR="2.3479733817301875" WEIGHT="3.2626367224738146"/>
<DICH_DATA CI_END="73.24882267849273" CI_START="0.1294207408509027" EFFECT_SIZE="3.0789473684210527" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8648006487074702" LOG_CI_START="-0.8879961184487669" LOG_EFFECT_SIZE="0.4884022651293515" ORDER="68407" O_E="0.0" SE="1.6170064475913375" STUDY_ID="STD-Van-der-Linden-2005" TOTAL_1="37" TOTAL_2="38" VAR="2.614709851551957" WEIGHT="2.929802774895658"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-26 12:26:33 +0100" MODIFIED_BY="Katharine Ker" ORDER="2776" O_E="0.0" SE="0.0" STUDY_ID="STD-Wei-2006" TOTAL_1="36" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.5178603218289237" CI_END="3.905018753548619" CI_START="0.533457486838425" DF="6" EFFECT_SIZE="1.44331614358219" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="0.0" ID="CMP-010.04.02" LOG_CI_END="0.5916231238837736" LOG_CI_START="-0.2729001853625885" LOG_EFFECT_SIZE="0.15936146926059247" MODIFIED="2010-05-21 10:38:55 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.8664635802142573" P_Z="0.4699392245394616" STUDIES="17" TAU2="0.0" TOTAL_1="1021" TOTAL_2="948" WEIGHT="29.705254036143995" Z="0.7225779500298941">
<NAME>Tranexamic Acid versus Control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68421" O_E="0.0" SE="0.0" STUDY_ID="STD-Andreasen-2004" TOTAL_1="21" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68425" O_E="0.0" SE="0.0" STUDY_ID="STD-Brown-1997" TOTAL_1="60" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68420" O_E="0.0" SE="0.0" STUDY_ID="STD-Casati-2004" TOTAL_1="52" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="74.95401160728107" CI_START="0.1312374968139608" EFFECT_SIZE="3.1363636363636362" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8747948816443694" LOG_CI_START="-0.8819420618142713" LOG_EFFECT_SIZE="0.49642640991504905" ORDER="68423" O_E="0.0" SE="1.6193209266555566" STUDY_ID="STD-Hardy-1998" TOTAL_1="43" TOTAL_2="45" VAR="2.622200263504611" WEIGHT="2.9214336850021705"/>
<DICH_DATA CI_END="4.318534659420912" CI_START="0.011315010711186518" EFFECT_SIZE="0.22105263157894736" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6353364094807923" LOG_CI_START="-1.9463450305906491" LOG_EFFECT_SIZE="-0.6555043105549285" ORDER="68429" O_E="0.0" SE="1.5164924574271987" STUDY_ID="STD-Horrow-1990" TOTAL_1="18" TOTAL_2="20" VAR="2.299749373433584" WEIGHT="3.331051751603042"/>
<DICH_DATA CI_END="84.69311383087638" CI_START="0.149022636727436" EFFECT_SIZE="3.5526315789473686" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9278481004507968" LOG_CI_START="-0.8267477566944047" LOG_EFFECT_SIZE="0.550550171878196" ORDER="68428" O_E="0.0" SE="1.6180632419564942" STUDY_ID="STD-Horrow-1991" TOTAL_1="37" TOTAL_2="44" VAR="2.6181286549707603" WEIGHT="2.9259769813372647"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68422" O_E="0.0" SE="0.0" STUDY_ID="STD-Jares-2003" TOTAL_1="22" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="67.12876258952687" CI_START="0.18611657117057434" EFFECT_SIZE="3.5346534653465347" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8269086417403597" LOG_CI_START="-0.7302149570812586" LOG_EFFECT_SIZE="0.5483468423295506" ORDER="68427" O_E="0.0" SE="1.502067059913778" STUDY_ID="STD-Karski-1995" TOTAL_1="100" TOTAL_2="50" VAR="2.256205452478021" WEIGHT="3.395339803921764"/>
<DICH_DATA CI_END="17.78565956134383" CI_START="0.07083750295800453" EFFECT_SIZE="1.1224489795918366" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2500699751468096" LOG_CI_START="-1.1497367562153493" LOG_EFFECT_SIZE="0.05016660946573015" ORDER="68419" O_E="0.0" SE="1.4096583532370384" STUDY_ID="STD-Karski-2005" TOTAL_1="147" TOTAL_2="165" VAR="1.9871366728509585" WEIGHT="3.855086710081821"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68424" O_E="0.0" SE="0.0" STUDY_ID="STD-Katoh-1997" TOTAL_1="62" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.963308734323707" CI_START="0.26077095316147614" EFFECT_SIZE="1.5288461538461537" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9524683556224045" LOG_CI_START="-0.5837407855790622" LOG_EFFECT_SIZE="0.1843637850216711" ORDER="68426" O_E="0.0" SE="0.902376853899632" STUDY_ID="STD-Katsaros-1996" TOTAL_1="104" TOTAL_2="106" VAR="0.8142839864537977" WEIGHT="9.40775491850913"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68418" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuitunen-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="16.406136195597867" CI_START="0.06597778748048523" EFFECT_SIZE="1.0404040404040404" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2150063125271002" LOG_CI_START="-1.1806022523118556" LOG_EFFECT_SIZE="0.017202030107622307" MODIFIED="2010-05-21 10:38:55 +0100" MODIFIED_BY="Katharine Ker" ORDER="2744" O_E="0.0" SE="1.4071923294400492" STUDY_ID="STD-Later-2009" TOTAL_1="99" TOTAL_2="103" VAR="1.9801902520349122" WEIGHT="3.868610185688802"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-07 11:59:09 +0100" MODIFIED_BY="Katharine Ker" ORDER="2428" O_E="0.0" SE="0.0" STUDY_ID="STD-Maddali-2007" TOTAL_1="111" TOTAL_2="111" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-11 15:08:26 +0000" MODIFIED_BY="Katharine Ker" ORDER="2312" O_E="0.0" SE="0.0" STUDY_ID="STD-Murphy-2006" TOTAL_1="50" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-14 12:22:04 +0100" MODIFIED_BY="Katharine Ker" ORDER="2510" O_E="0.0" SE="0.0" STUDY_ID="STD-Taghaddomi-2009" TOTAL_1="50" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68417" O_E="0.0" SE="0.0" STUDY_ID="STD-Zabeeda-2002" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6648078495017506" CI_END="3.099701878548691" CI_START="0.15949030861877334" DF="3" EFFECT_SIZE="0.7031162131795299" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-010.04.03" LOG_CI_END="0.49131992650291495" LOG_CI_START="-0.7972657015802349" LOG_EFFECT_SIZE="-0.15297288753866" MODIFIED="2010-05-17 14:30:28 +0100" MODIFIED_BY="Katharine Ker" NO="3" P_CHI2="0.6447860188280425" P_Z="0.6416811810098815" STUDIES="7" TAU2="0.0" TOTAL_1="386" TOTAL_2="368" WEIGHT="13.370883926470079" Z="0.4653495175681455">
<NAME>Epsilon Aminocaproic Acid versus Control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68435" O_E="0.0" SE="0.0" STUDY_ID="STD-Daily-1994" TOTAL_1="21" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.602016847079263" CI_START="0.014471785963776497" EFFECT_SIZE="0.35282651072124754" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9346002887861264" LOG_CI_START="-1.83947786927139" LOG_EFFECT_SIZE="-0.4524387902426318" ORDER="68434" O_E="0.0" SE="1.6295072419513328" STUDY_ID="STD-Del-Rossi-1989" TOTAL_1="170" TOTAL_2="180" VAR="2.655293851571839" WEIGHT="2.8850231299594755"/>
<DICH_DATA CI_END="16.360363082235548" CI_START="0.07129426126651824" EFFECT_SIZE="1.08" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2137929376520298" LOG_CI_START="-1.1469454266781303" LOG_EFFECT_SIZE="0.03342375548694973" MODIFIED="2010-05-17 14:30:28 +0100" MODIFIED_BY="Katharine Ker" ORDER="2628" O_E="0.0" SE="1.3867094010509062" STUDY_ID="STD-Greilich-2009" TOTAL_1="25" TOTAL_2="27" VAR="1.922962962962963" WEIGHT="3.9837398463568245"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68433" O_E="0.0" SE="0.0" STUDY_ID="STD-Hardy-1998" TOTAL_1="46" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="53.03554378730976" CI_START="0.1301344697753444" EFFECT_SIZE="2.6271186440677967" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7245670261454982" LOG_CI_START="-0.8856076530892038" LOG_EFFECT_SIZE="0.4194796865281473" ORDER="68432" O_E="0.0" SE="1.5332295271555065" STUDY_ID="STD-Kluger-2003" TOTAL_1="58" TOTAL_2="30" VAR="2.350792782941498" WEIGHT="3.258723709810955"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68431" O_E="0.0" SE="0.0" STUDY_ID="STD-Rao-1999" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.144477450772242" CI_START="0.010026174573618974" EFFECT_SIZE="0.20384615384615384" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6174697810739354" LOG_CI_START="-1.998864737813993" LOG_EFFECT_SIZE="-0.6906974783700289" ORDER="68430" O_E="0.0" SE="1.5368478474595098" STUDY_ID="STD-Vander_x002d_Salm-1996" TOTAL_1="51" TOTAL_2="52" VAR="2.3619013062409286" WEIGHT="3.2433972403428237"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.0897138711937218" CI_END="2.867217319812309" CI_START="0.3142713260403589" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9492545439150126" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-010.05" LOG_CI_END="0.4574606114042532" LOG_CI_START="-0.502695241987604" LOG_EFFECT_SIZE="-0.022617315291675277" METHOD="MH" MODIFIED="2010-05-20 12:11:49 +0100" MODIFIED_BY="Katharine Ker" NO="5" P_CHI2="0.7192625154808361" P_Q="0.0" P_Z="0.9264300143527653" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="566" TOTAL_2="480" WEIGHT="99.99999999999999" Z="0.09233734969603749">
<NAME>Deep Vein Thrombosis (DVT)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.179376633790447" CI_END="4.575267832113871" CI_START="0.361290435325646" DF="2" EFFECT_SIZE="1.2856906730609214" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-010.05.01" LOG_CI_END="0.6604165223597322" LOG_CI_START="-0.44214353563728337" LOG_EFFECT_SIZE="0.10913649336122443" MODIFIED="2010-05-20 12:11:49 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="0.5545003011838014" P_Z="0.6980067114570787" STUDIES="3" TAU2="0.0" TOTAL_1="345" TOTAL_2="279" WEIGHT="75.8366179720762" Z="0.38801259819911543">
<NAME>Aprotinin versus Control</NAME>
<DICH_DATA CI_END="3.9862521275529974" CI_START="0.11405731748555868" EFFECT_SIZE="0.6742857142857143" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6005647640438736" LOG_CI_START="-0.9428768468042117" LOG_EFFECT_SIZE="-0.17115604138016904" MODIFIED="2010-05-20 12:11:49 +0100" MODIFIED_BY="Katharine Ker" ORDER="5348" O_E="0.0" SE="0.9066252423713579" STUDY_ID="STD-Colwell-2007" TOTAL_1="175" TOTAL_2="177" VAR="0.8219693301049233" WEIGHT="38.69929546333495"/>
<DICH_DATA CI_END="36.87276924711144" CI_START="0.06275163674839268" EFFECT_SIZE="1.5211267605633803" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5667057555496076" LOG_CI_START="-1.2023749420138592" LOG_EFFECT_SIZE="0.1821654067678744" ORDER="68437" O_E="0.0" SE="1.6265717089192997" STUDY_ID="STD-D_x0027_Ambra-1996" TOTAL_1="141" TOTAL_2="71" VAR="2.6457355242566507" WEIGHT="12.02298327852222"/>
<DICH_DATA CI_END="29.110699242386186" CI_START="0.3532785457274772" EFFECT_SIZE="3.206896551724138" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4640526373681348" LOG_CI_START="-0.4518827360581769" LOG_EFFECT_SIZE="0.506084950654979" ORDER="68436" O_E="0.0" SE="1.1254299223836706" STUDY_ID="STD-Poston-2006" TOTAL_1="29" TOTAL_2="31" VAR="1.2665925101965145" WEIGHT="25.114339230219034"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.004284836548559858" CI_END="3.471447048971809" CI_START="0.03865786581004517" DF="1" EFFECT_SIZE="0.36633145399464334" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-010.05.02" LOG_CI_END="0.5405105452184575" LOG_CI_START="-1.4127621257990612" LOG_EFFECT_SIZE="-0.4361257902903018" NO="2" P_CHI2="0.9478088179804124" P_Z="0.38144353424215427" STUDIES="4" TAU2="0.0" TOTAL_1="221" TOTAL_2="201" WEIGHT="24.163382027923788" Z="0.8752396471638275">
<NAME>Tranexamic Acid versus Control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68441" O_E="0.0" SE="0.0" STUDY_ID="STD-Horrow-1990" TOTAL_1="18" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="9.410345981208485" CI_START="0.01655807074749288" EFFECT_SIZE="0.39473684210526316" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9736055910114718" LOG_CI_START="-1.7809902661337298" LOG_EFFECT_SIZE="-0.40369233756112893" ORDER="68440" O_E="0.0" SE="1.6180632419564942" STUDY_ID="STD-Horrow-1991" TOTAL_1="37" TOTAL_2="44" VAR="2.6181286549707603" WEIGHT="12.149759679355858"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68438" O_E="0.0" SE="0.0" STUDY_ID="STD-Katoh-1997" TOTAL_1="62" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.244282779363349" CI_START="0.013995665948529062" EFFECT_SIZE="0.3396825396825397" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9161528796878264" LOG_CI_START="-1.854006431896608" LOG_EFFECT_SIZE="-0.4689267761043908" ORDER="68439" O_E="0.0" SE="1.6272052921344415" STUDY_ID="STD-Katsaros-1996" TOTAL_1="104" TOTAL_2="106" VAR="2.6477970627503336" WEIGHT="12.01362234856793"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5406792492358711" CI_END="2.7363759805168733" CI_START="0.14388666821664034" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6274775078236791" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-010.06" LOG_CI_END="0.43717576959977" LOG_CI_START="-0.8419794436462339" LOG_EFFECT_SIZE="-0.20240183702323192" METHOD="MH" MODIFIED="2010-05-20 12:14:58 +0100" MODIFIED_BY="Katharine Ker" NO="6" P_CHI2="0.7631202924236318" P_Q="0.0" P_Z="0.5350908435185388" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="473" TOTAL_2="448" WEIGHT="100.0" Z="0.620253596846324">
<NAME>Pulmonary Embolism</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.604191438934906E-4" CI_END="3.1485863887453123" CI_START="0.03507541547486462" DF="1" EFFECT_SIZE="0.3323220963820273" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-010.06.01" LOG_CI_END="0.49811561367450674" LOG_CI_START="-1.4549971759696694" LOG_EFFECT_SIZE="-0.47844078114758126" NO="1" P_CHI2="0.9848533044648285" P_Z="0.33693538559665903" STUDIES="6" TAU2="0.0" TOTAL_1="298" TOTAL_2="271" WEIGHT="42.89353530244797" Z="0.9602381437021947">
<NAME>Tranexamic Acid versus Control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68442" O_E="0.0" SE="0.0" STUDY_ID="STD-Casati-2004" TOTAL_1="52" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68447" O_E="0.0" SE="0.0" STUDY_ID="STD-Horrow-1990" TOTAL_1="18" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68444" O_E="0.0" SE="0.0" STUDY_ID="STD-Jares-2003" TOTAL_1="22" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68445" O_E="0.0" SE="0.0" STUDY_ID="STD-Katoh-1997" TOTAL_1="62" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.244282779363349" CI_START="0.013995665948529062" EFFECT_SIZE="0.3396825396825397" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9161528796878264" LOG_CI_START="-1.854006431896608" LOG_EFFECT_SIZE="-0.4689267761043908" ORDER="68446" O_E="0.0" SE="1.6272052921344415" STUDY_ID="STD-Katsaros-1996" TOTAL_1="104" TOTAL_2="106" VAR="2.6477970627503336" WEIGHT="21.32244477593088"/>
<DICH_DATA CI_END="7.74869607009601" CI_START="0.013648380859931773" EFFECT_SIZE="0.3252032520325203" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8892286267377596" LOG_CI_START="-1.8649188669606307" LOG_EFFECT_SIZE="-0.48784512011143555" ORDER="68443" O_E="0.0" SE="1.6177998710484025" STUDY_ID="STD-Pleym-2003" TOTAL_1="40" TOTAL_2="39" VAR="2.6172764227642276" WEIGHT="21.571090526517096"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.10045882180821" CI_START="0.1440734719790299" DF="0" EFFECT_SIZE="1.0114285714285713" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-010.06.02" LOG_CI_END="0.8512864131333385" LOG_CI_START="-0.8414159777823143" LOG_EFFECT_SIZE="0.00493521767551215" MODIFIED="2010-05-20 12:14:58 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="1.0" P_Z="0.9908812691166072" STUDIES="1" TAU2="0.0" TOTAL_1="175" TOTAL_2="177" WEIGHT="57.106464697552035" Z="0.011428883130054367">
<NAME>Aprotinin versus Control</NAME>
<DICH_DATA CI_END="7.10045882180821" CI_START="0.1440734719790299" EFFECT_SIZE="1.0114285714285713" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8512864131333385" LOG_CI_START="-0.8414159777823143" LOG_EFFECT_SIZE="0.00493521767551215" MODIFIED="2010-05-20 12:14:58 +0100" MODIFIED_BY="Katharine Ker" ORDER="5352" O_E="0.0" SE="0.9943017634358244" STUDY_ID="STD-Colwell-2007" TOTAL_1="175" TOTAL_2="177" VAR="0.9886359967715901" WEIGHT="57.106464697552035"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3971515372102636" CI_END="3.356290377571571" CI_START="0.11335759375461942" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6168152082620015" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-010.07" LOG_CI_END="0.525859527818616" LOG_CI_START="-0.9455493814460418" LOG_EFFECT_SIZE="-0.2098449268137129" METHOD="MH" MODIFIED="2010-12-07 17:33:26 +0000" MODIFIED_BY="Emma M Sydenham" NO="7" P_CHI2="0.4972931184011202" P_Q="0.0" P_Z="0.5761341638648516" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="295" TOTAL_2="231" WEIGHT="100.0" Z="0.5590403813700758">
<NAME>Other Thrombosis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3971515372102636" CI_END="3.356290377571571" CI_START="0.11335759375461942" DF="2" EFFECT_SIZE="0.6168152082620015" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-010.07.01" LOG_CI_END="0.525859527818616" LOG_CI_START="-0.9455493814460418" LOG_EFFECT_SIZE="-0.2098449268137129" NO="1" P_CHI2="0.4972931184011202" P_Z="0.5761341638648516" STUDIES="4" TAU2="0.0" TOTAL_1="245" TOTAL_2="181" WEIGHT="100.0" Z="0.5590403813700758">
<NAME>Aprotinin versus Control</NAME>
<DICH_DATA CI_END="16.861087354989195" CI_START="0.06983273602652673" EFFECT_SIZE="1.0851063829787233" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2268855784171016" LOG_CI_START="-1.1559409420926636" LOG_EFFECT_SIZE="0.035472318162218866" ORDER="68450" O_E="0.0" SE="1.3996840933289427" STUDY_ID="STD-Casas-1995" TOTAL_1="47" TOTAL_2="51" VAR="1.9591155611180644" WEIGHT="38.13132640005213"/>
<DICH_DATA CI_END="36.87276924711144" CI_START="0.06275163674839268" EFFECT_SIZE="1.5211267605633803" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5667057555496076" LOG_CI_START="-1.2023749420138592" LOG_EFFECT_SIZE="0.1821654067678744" ORDER="68449" O_E="0.0" SE="1.6265717089192997" STUDY_ID="STD-D_x0027_Ambra-1996" TOTAL_1="141" TOTAL_2="71" VAR="2.6457355242566507" WEIGHT="28.235503598721586"/>
<DICH_DATA CI_END="2.8282345807770137" CI_START="0.008210052591234055" EFFECT_SIZE="0.1523809523809524" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4515154280781609" LOG_CI_START="-2.0856540609061875" LOG_EFFECT_SIZE="-0.8170693164140133" ORDER="68448" O_E="0.0" SE="1.4903459170209286" STUDY_ID="STD-Poston-2006" TOTAL_1="29" TOTAL_2="31" VAR="2.2211309523809524" WEIGHT="33.63317000122628"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68451" O_E="0.0" SE="0.0" STUDY_ID="STD-Rocha-1994" TOTAL_1="28" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-010.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-12-07 17:33:26 +0000" MODIFIED_BY="Emma M Sydenham" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Tranexamic Acid versus Control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-21 15:46:52 +0100" MODIFIED_BY="Katharine Ker" ORDER="2795" O_E="0.0" SE="0.0" STUDY_ID="STD-Taghaddomi-2009" TOTAL_1="50" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.429960757672783" CI_END="1.329218657428412" CI_START="0.7087274191792122" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="0.970594512968261" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="69" I2="0.0" I2_Q="0.0" ID="CMP-010.08" LOG_CI_END="0.12359642857517959" LOG_CI_START="-0.14952076496971037" LOG_EFFECT_SIZE="-0.012962168197265382" METHOD="MH" MODIFIED="2010-12-07 17:34:06 +0000" MODIFIED_BY="Emma M Sydenham" NO="8" P_CHI2="0.9537459437375233" P_Q="0.0" P_Z="0.8524132701026962" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="30" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3254" TOTAL_2="2658" WEIGHT="99.99999999999999" Z="0.186040157329128">
<NAME>Renal Failure / Dysfunction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.77611455548743" CI_END="1.5122025179089729" CI_START="0.7575175578773181" DF="13" EFFECT_SIZE="1.0702896609714292" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="53" I2="0.0" ID="CMP-010.08.01" LOG_CI_END="0.17960995685347356" LOG_CI_START="-0.12060729655389191" LOG_EFFECT_SIZE="0.029501330149790894" MODIFIED="2010-07-08 11:07:50 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="0.9539227789058219" P_Z="0.7000907169934174" STUDIES="24" TAU2="0.0" TOTAL_1="2774" TOTAL_2="2173" WEIGHT="82.76120158787332" Z="0.38519801199538345">
<NAME>Aprotinin versus Control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68458" O_E="0.0" SE="0.0" STUDY_ID="STD-Alvarez-2001" TOTAL_1="26" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-20 11:13:28 +0100" MODIFIED_BY="Katharine Ker" ORDER="5306" O_E="0.0" SE="0.0" STUDY_ID="STD-Asimakopoulos-2000" TOTAL_1="8" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.49541782825278" CI_START="0.2557946746877728" EFFECT_SIZE="1.4741379310344827" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.929184743539629" LOG_CI_START="-0.5921085012091585" LOG_EFFECT_SIZE="0.1685381211652353" ORDER="68469" O_E="0.0" SE="0.89361518248845" STUDY_ID="STD-Baele-1992" TOTAL_1="58" TOTAL_2="57" VAR="0.7985480943738656" WEIGHT="3.223088337319291"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68464" O_E="0.0" SE="0.0" STUDY_ID="STD-Cicek-1996b" TOTAL_1="29" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="22.596047095942403" CI_START="0.1964968032486296" EFFECT_SIZE="2.107142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3540324712460294" LOG_CI_START="-0.7066445106461795" LOG_EFFECT_SIZE="0.32369398029992497" ORDER="68459" O_E="0.0" SE="1.2104518596790557" STUDY_ID="STD-Cohen-1998" TOTAL_1="56" TOTAL_2="59" VAR="1.4651937046004844" WEIGHT="1.7566216956049157"/>
<DICH_DATA CI_END="7.10045882180821" CI_START="0.1440734719790299" EFFECT_SIZE="1.0114285714285713" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8512864131333385" LOG_CI_START="-0.8414159777823143" LOG_EFFECT_SIZE="0.00493521767551215" MODIFIED="2010-05-20 12:12:46 +0100" MODIFIED_BY="Katharine Ker" ORDER="5350" O_E="0.0" SE="0.9943017634358244" STUDY_ID="STD-Colwell-2007" TOTAL_1="175" TOTAL_2="177" VAR="0.9886359967715901" WEIGHT="2.603375820999554"/>
<DICH_DATA CI_END="227.02670243555443" CI_START="0.8255414642736488" EFFECT_SIZE="13.690140845070422" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="0" LOG_CI_END="2.3560769410627094" LOG_CI_START="-0.08326110864831064" LOG_EFFECT_SIZE="1.1364079162071994" ORDER="68463" O_E="0.0" SE="1.432879245318341" STUDY_ID="STD-D_x0027_Ambra-1996" TOTAL_1="141" TOTAL_2="71" VAR="2.053142931664058" WEIGHT="1.2535859097149709"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-17 10:57:33 +0100" MODIFIED_BY="Katharine Ker" ORDER="2566" O_E="0.0" SE="0.0" STUDY_ID="STD-Desai-2009" TOTAL_1="38" TOTAL_2="37" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.996214062247193" CI_START="0.5851246200260946" EFFECT_SIZE="1.0807562142607072" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" LOG_CI_END="0.3002071106327127" LOG_CI_START="-0.2327516278907762" LOG_EFFECT_SIZE="0.03372774137096832" ORDER="68468" O_E="0.0" SE="0.3130626011970012" STUDY_ID="STD-Dietrich-1992" TOTAL_1="902" TOTAL_2="882" VAR="0.0980081922682326" WEIGHT="26.26097870187117"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68457" O_E="0.0" SE="0.0" STUDY_ID="STD-Dignan-2001" TOTAL_1="101" TOTAL_2="99" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.022569637689829" CI_START="0.013849815723520037" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9043134955566555" LOG_CI_START="-1.8585560049959806" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="68452" O_E="0.0" SE="1.6229232210492168" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="2.6338797814207653" WEIGHT="0.9771862284377302"/>
<DICH_DATA CI_END="17.111978424286665" CI_START="0.07546306347703435" EFFECT_SIZE="1.1363636363636365" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2333002239817072" LOG_CI_START="-1.1222655682820444" LOG_EFFECT_SIZE="0.05551732784983142" ORDER="68456" O_E="0.0" SE="1.3836710066144533" STUDY_ID="STD-Englberger-2002a" TOTAL_1="22" TOTAL_2="25" VAR="1.9145454545454546" WEIGHT="1.3443353061450358"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68455" O_E="0.0" SE="0.0" STUDY_ID="STD-Englberger-2002b" TOTAL_1="15" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68467" O_E="0.0" SE="0.0" STUDY_ID="STD-Gherli-1992" TOTAL_1="18" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.0247417008247117" CI_START="0.4208294843584724" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.3063696275202918" LOG_CI_START="-0.3758938400387156" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2010-05-17 14:31:36 +0100" MODIFIED_BY="Katharine Ker" ORDER="2630" O_E="0.0" SE="0.4007649381027931" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="27" VAR="0.1606125356125356" WEIGHT="16.02484538301548"/>
<DICH_DATA CI_END="14.553341064518706" CI_START="0.06871274407483083" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1629627073641946" LOG_CI_START="-1.1629627073641946" LOG_EFFECT_SIZE="0.0" ORDER="68454" O_E="0.0" SE="1.3662601021279464" STUDY_ID="STD-Kipfer-2003" TOTAL_1="15" TOTAL_2="15" VAR="1.8666666666666667" WEIGHT="1.3788166338026522"/>
<DICH_DATA CI_END="5.187980526252747" CI_START="0.22188791337707303" EFFECT_SIZE="1.0729166666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7149983372353179" LOG_CI_START="-0.6538663539041103" LOG_EFFECT_SIZE="0.030565991665603823" MODIFIED="2010-05-06 16:53:09 +0100" MODIFIED_BY="Katharine Ker" ORDER="2395" O_E="0.0" SE="0.804077895564803" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="103" VAR="0.6465412621359223" WEIGHT="3.980861238866859"/>
<DICH_DATA CI_END="5.382078794072228" CI_START="0.021277395426206804" EFFECT_SIZE="0.33840304182509506" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.7309500515808913" LOG_CI_START="-1.6720815352705813" LOG_EFFECT_SIZE="-0.47056574184484506" ORDER="68462" O_E="0.0" SE="1.4115526493147534" STUDY_ID="STD-Lemmer-1996" TOTAL_1="526" TOTAL_2="178" VAR="1.9924808817874995" WEIGHT="1.291751942661525"/>
<DICH_DATA CI_END="3.3583554802974307" CI_START="0.40529095835636947" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5261266640952466" LOG_CI_START="-0.3922330848340202" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="68466" O_E="0.0" SE="0.5394490624751247" STUDY_ID="STD-Lemmer_x005f_1-1994" TOTAL_1="108" TOTAL_2="108" VAR="0.29100529100529104" WEIGHT="8.844481971010467"/>
<DICH_DATA CI_END="2.5520322561312896" CI_START="0.440663028511081" EFFECT_SIZE="1.0604651162790697" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="6" LOG_CI_END="0.40688615930119987" LOG_CI_START="-0.355893385131503" LOG_EFFECT_SIZE="0.02549638708484843" ORDER="68465" O_E="0.0" SE="0.4480604802194102" STUDY_ID="STD-Levy-1995" TOTAL_1="215" TOTAL_2="72" VAR="0.2007581939344485" WEIGHT="12.820353676848399"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="68453" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="1.0009187415752585"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68461" O_E="0.0" SE="0.0" STUDY_ID="STD-Speekenbrink-1996" TOTAL_1="75" TOTAL_2="37" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68460" O_E="0.0" SE="0.0" STUDY_ID="STD-Stammers-1997" TOTAL_1="8" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-26 12:27:08 +0100" MODIFIED_BY="Katharine Ker" ORDER="2777" O_E="0.0" SE="0.0" STUDY_ID="STD-Wei-2006" TOTAL_1="36" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.517060880363247" CI_END="2.3727069484115244" CI_START="0.3331951116506608" DF="6" EFFECT_SIZE="0.8891424838518721" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" ID="CMP-010.08.02" LOG_CI_END="0.37524410208289866" LOG_CI_START="-0.47730137881001844" LOG_EFFECT_SIZE="-0.05102863836355986" MODIFIED="2010-05-14 12:22:25 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.8665535156655185" P_Z="0.8144997100758656" STUDIES="9" TAU2="0.0" TOTAL_1="454" TOTAL_2="458" WEIGHT="10.262731551373793" Z="0.23462512115587272">
<NAME>Tranexamic Acid versus Control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68474" O_E="0.0" SE="0.0" STUDY_ID="STD-Andreasen-2004" TOTAL_1="21" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.022569637689829" CI_START="0.013849815723520037" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9043134955566555" LOG_CI_START="-1.8585560049959806" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="68473" O_E="0.0" SE="1.6229232210492168" STUDY_ID="STD-Diprose-2005" TOTAL_1="60" TOTAL_2="60" VAR="2.6338797814207653" WEIGHT="0.9771862284377302"/>
<DICH_DATA CI_END="74.19854501427012" CI_START="0.12596099353676152" EFFECT_SIZE="3.057142857142857" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8703953891271512" LOG_CI_START="-0.8997639224572833" LOG_EFFECT_SIZE="0.48531573333493394" ORDER="68472" O_E="0.0" SE="1.6272052921344415" STUDY_ID="STD-Katsaros-1996" TOTAL_1="104" TOTAL_2="106" VAR="2.6477970627503336" WEIGHT="0.9720499678670574"/>
<DICH_DATA CI_END="5.0327045242656645" CI_START="0.21508128722239936" EFFECT_SIZE="1.0404040404040404" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7018014332288716" LOG_CI_START="-0.667397373013627" LOG_EFFECT_SIZE="0.017202030107622307" MODIFIED="2010-05-06 16:53:21 +0100" MODIFIED_BY="Katharine Ker" ORDER="2396" O_E="0.0" SE="0.8042741564302429" STUDY_ID="STD-Later-2009" TOTAL_1="99" TOTAL_2="103" VAR="0.6468569187015789" WEIGHT="3.9789186377278964"/>
<DICH_DATA CI_END="14.903914722906746" CI_START="0.06709646549862758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528004" LOG_EFFECT_SIZE="0.0" ORDER="68471" O_E="0.0" SE="1.378404875209022" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" VAR="1.9" WEIGHT="1.3546268682973424"/>
<DICH_DATA CI_END="7.897117532359623" CI_START="0.014069831258787349" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8974686016417053" LOG_CI_START="-1.8517111110810305" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2010-05-07 12:23:02 +0100" MODIFIED_BY="Katharine Ker" ORDER="2445" O_E="0.0" SE="1.6148817719123905" STUDY_ID="STD-Mehr_x002d_Aein-2007" TOTAL_1="33" TOTAL_2="33" VAR="2.607843137254902" WEIGHT="0.9869424326166352"/>
<DICH_DATA CI_END="71.92321045517915" CI_START="0.12513345751728625" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8568690648743624" LOG_CI_START="-0.9026265554350377" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-01-11 15:08:55 +0000" MODIFIED_BY="Katharine Ker" ORDER="2313" O_E="0.0" SE="1.6209413870933633" STUDY_ID="STD-Murphy-2006" TOTAL_1="50" TOTAL_2="50" VAR="2.627450980392157" WEIGHT="0.9795771905821827"/>
<DICH_DATA CI_END="5.89171220973749" CI_START="0.011408460073893293" EFFECT_SIZE="0.25925925925925924" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7702415248685788" LOG_CI_START="-1.9427729731580399" LOG_EFFECT_SIZE="-0.5862657241447304" ORDER="68470" O_E="0.0" SE="1.5936381457791915" STUDY_ID="STD-Shore_x002d_Lesserson-1996" TOTAL_1="17" TOTAL_2="13" VAR="2.5396825396825395" WEIGHT="1.0134302258449495"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-14 12:22:25 +0100" MODIFIED_BY="Katharine Ker" ORDER="2511" O_E="0.0" SE="0.0" STUDY_ID="STD-Taghaddomi-2009" TOTAL_1="50" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1384049165564514" CI_START="0.10525471514085721" DF="0" EFFECT_SIZE="0.3461538461538462" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" I2="0.0" ID="CMP-010.08.03" LOG_CI_END="0.056296762716359645" LOG_CI_START="-0.9777584397793457" LOG_EFFECT_SIZE="-0.46073083853149305" MODIFIED="2010-12-07 17:34:06 +0000" MODIFIED_BY="Emma M Sydenham" NO="3" P_CHI2="1.0" P_Z="0.0807149925824804" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="27" WEIGHT="6.976066860752878" Z="1.74655250108355">
<NAME>Epsilon Aminocaproic Acid versus control</NAME>
<DICH_DATA CI_END="1.1384049165564514" CI_START="0.10525471514085721" EFFECT_SIZE="0.34615384615384615" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.056296762716359645" LOG_CI_START="-0.9777584397793457" LOG_EFFECT_SIZE="-0.4607308385314931" MODIFIED="2010-05-17 14:31:12 +0100" MODIFIED_BY="Katharine Ker" ORDER="2629" O_E="0.0" SE="0.6074091446017823" STUDY_ID="STD-Greilich-2009" TOTAL_1="26" TOTAL_2="27" VAR="0.36894586894586895" WEIGHT="6.976066860752878"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="44.681059308572564" CI_END="0.12445079311502244" CI_START="-0.3419031478993154" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.10872617739214649" ESTIMABLE="YES" I2="53.00021905261562" I2_Q="0.0" ID="CMP-010.09" MODIFIED="2010-07-08 10:57:11 +0100" MODIFIED_BY="Katharine Ker" NO="9" P_CHI2="0.0019067912626524741" P_Q="0.9094084569345449" P_Z="0.36077175129844863" Q="0.012946961507736887" RANDOM="YES" SCALE="5.89" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.24948255468321884" TOTALS="SUB" TOTAL_1="1089" TOTAL_2="1101" UNITS="" WEIGHT="200.0" Z="0.9138955335161135">
<NAME>Hospital Length of Stay</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="42.90352515898352" CI_END="0.286477226174943" CI_START="-0.7293036377159531" DF="16" EFFECT_SIZE="-0.22141320577050505" ESTIMABLE="YES" I2="62.707027124903334" ID="CMP-010.09.01" MODIFIED="2010-07-08 10:57:11 +0100" MODIFIED_BY="Katharine Ker" NO="1" P_CHI2="2.889514547452787E-4" P_Z="0.3928612403454199" STUDIES="17" TAU2="0.5536289546815384" TOTAL_1="877" TOTAL_2="879" WEIGHT="100.0" Z="0.8544400164214108">
<NAME>Aprotinin versus Control</NAME>
<CONT_DATA CI_END="0.988027719037168" CI_START="-1.3880277190371684" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="7.6" MEAN_2="7.8" ORDER="68484" SD_1="8.5" SD_2="8.6" SE="0.606147729452265" STUDY_ID="STD-Alderman-1998" TOTAL_1="401" TOTAL_2="395" WEIGHT="7.290603692842664"/>
<CONT_DATA CI_END="-0.7252257325004058" CI_START="-1.874774267499594" EFFECT_SIZE="-1.2999999999999998" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="7.6" MODIFIED="2010-05-20 11:14:44 +0100" MODIFIED_BY="Katharine Ker" ORDER="5307" SD_1="0.2" SD_2="0.9" SE="0.2932575659723036" STUDY_ID="STD-Asimakopoulos-2000" TOTAL_1="8" TOTAL_2="10" WEIGHT="10.498222317616813"/>
<CONT_DATA CI_END="3.248603017990621" CI_START="-1.2486030179906211" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="10.9" MEAN_2="9.9" ORDER="68483" SD_1="7.2" SD_2="4.8" SE="1.1472675190602046" STUDY_ID="STD-Cohen-1998" TOTAL_1="56" TOTAL_2="59" WEIGHT="3.591176195023491"/>
<CONT_DATA CI_END="2.167913022332399" CI_START="-4.367913022332399" EFFECT_SIZE="-1.0999999999999996" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="9.1" ORDER="68482" SD_1="2.2" SD_2="8.0" SE="1.6673332000533068" STUDY_ID="STD-Englberger-2002a" TOTAL_1="22" TOTAL_2="25" WEIGHT="2.0143114480696966"/>
<CONT_DATA CI_END="0.6430366683240476" CI_START="-3.8430366683240504" EFFECT_SIZE="-1.6000000000000014" ESTIMABLE="YES" MEAN_1="9.7" MEAN_2="11.3" ORDER="68481" SD_1="2.4" SD_2="3.6" SE="1.1444274925543714" STUDY_ID="STD-Englberger-2002b" TOTAL_1="15" TOTAL_2="14" WEIGHT="3.6037198200827456"/>
<CONT_DATA CI_END="0.9278064534158981" CI_START="-1.227806453415897" EFFECT_SIZE="-0.14999999999999947" ESTIMABLE="YES" MEAN_1="6.65" MEAN_2="6.8" ORDER="68477" SD_1="1.81" SD_2="2.1" SE="0.549911356493026" STUDY_ID="STD-Fauli-2005" TOTAL_1="40" TOTAL_2="20" WEIGHT="7.84429933071764"/>
<CONT_DATA CI_END="2.473375414467115" CI_START="-2.473375414467115" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="11.8" MEAN_2="11.8" ORDER="68479" SD_1="3.1" SD_2="4.3" SE="1.2619494204877155" STUDY_ID="STD-Harmon-2004" TOTAL_1="17" TOTAL_2="18" WEIGHT="3.12885012216149"/>
<CONT_DATA CI_END="1.3281327014207394" CI_START="-2.3281327014207394" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="9.7" MEAN_2="10.2" ORDER="68480" SD_1="2.4" SD_2="2.7" SE="0.9327379053088816" STUDY_ID="STD-Kipfer-2003" TOTAL_1="15" TOTAL_2="15" WEIGHT="4.716795724721514"/>
<CONT_DATA CI_END="1.6558020798754884" CI_START="0.34419792012451167" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="7.0" ORDER="68476" SD_1="1.0" SD_2="2.0" SE="0.3345990462316509" STUDY_ID="STD-Kunt-2005" TOTAL_1="40" TOTAL_2="46" WEIGHT="10.088812338789062"/>
<CONT_DATA CI_END="1.2592334208671665" CI_START="-2.659233420867167" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="7.8" MEAN_2="8.5" MODIFIED="2010-05-06 16:53:58 +0100" MODIFIED_BY="Katharine Ker" ORDER="2397" SD_1="6.7" SD_2="7.4" SE="0.9996272565829525" STUDY_ID="STD-Later-2009" TOTAL_1="96" TOTAL_2="103" WEIGHT="4.324192062876813"/>
<CONT_DATA CI_END="1.0131758696418367" CI_START="-1.6131758696418363" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="7.3" MEAN_2="7.6" ORDER="68487" SD_1="2.68" SD_2="1.34" SE="0.67" STUDY_ID="STD-Liu-1993" TOTAL_1="20" TOTAL_2="20" WEIGHT="6.698027957870506"/>
<CONT_DATA CI_END="0.9332882306548902" CI_START="-2.133288230654891" EFFECT_SIZE="-0.6000000000000005" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="6.4" ORDER="68478" SD_1="1.8" SD_2="3.0" SE="0.7823042886243179" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="5.760810024546993"/>
<CONT_DATA CI_END="2.2155525515363017" CI_START="-10.815552551536303" EFFECT_SIZE="-4.300000000000001" ESTIMABLE="YES" MEAN_1="11.1" MEAN_2="15.4" ORDER="68486" SD_1="4.85" SD_2="16.0" SE="3.324322591093586" STUDY_ID="STD-Murkin-1994" TOTAL_1="29" TOTAL_2="25" WEIGHT="0.5786395375025295"/>
<CONT_DATA CI_END="0.6264092684335909" CI_START="-1.0264092684335913" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="5.3" MEAN_2="5.5" MODIFIED="2010-05-07 15:07:52 +0100" MODIFIED_BY="Katharine Ker" ORDER="2478" SD_1="1.6" SD_2="1.4" SE="0.4216451296820768" STUDY_ID="STD-Nur_x00f6_zler-2008" TOTAL_1="25" TOTAL_2="26" WEIGHT="9.180807195612045"/>
<CONT_DATA CI_END="3.004020403417729" CI_START="-1.0040204034177291" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="7.0" ORDER="68475" SD_1="4.1" SD_2="3.8" SE="1.0224781777752991" STUDY_ID="STD-Poston-2006" TOTAL_1="29" TOTAL_2="31" WEIGHT="4.1992411539664465"/>
<CONT_DATA CI_END="0.3192355011980159" CI_START="-2.7192355011980163" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" MEAN_1="6.1" MEAN_2="7.3" ORDER="68485" SD_1="0.8" SD_2="2.5" SE="0.775134396948899" STUDY_ID="STD-Stammers-1997" TOTAL_1="8" TOTAL_2="12" WEIGHT="5.816532109141653"/>
<CONT_DATA CI_END="1.1403247823048228" CI_START="0.05967521769517825" EFFECT_SIZE="0.6000000000000005" ESTIMABLE="YES" MEAN_1="7.9" MEAN_2="7.3" MODIFIED="2010-05-26 12:29:33 +0100" MODIFIED_BY="Katharine Ker" ORDER="2780" SD_1="1.2" SD_2="1.2" SE="0.27568097504180444" STUDY_ID="STD-Wei-2006" TOTAL_1="36" TOTAL_2="40" WEIGHT="10.66495896845789"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7645871880813069" CI_END="0.18384408532800617" CI_START="-0.34110460532793246" DF="4" EFFECT_SIZE="-0.07863025999996315" ESTIMABLE="YES" I2="0.0" ID="CMP-010.09.02" MODIFIED="2010-05-17 15:02:35 +0100" MODIFIED_BY="Katharine Ker" NO="2" P_CHI2="0.7789545970130844" P_Z="0.5571012688928062" STUDIES="5" TAU2="0.0" TOTAL_1="212" TOTAL_2="222" WEIGHT="99.99999999999999" Z="0.587152536764613">
<NAME>Tranexamic Acid versus Control</NAME>
<CONT_DATA CI_END="1.5126574492385734" CI_START="-2.5126574492385734" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="5.0" MODIFIED="2010-05-17 15:02:35 +0100" MODIFIED_BY="Katharine Ker" ORDER="2644" SD_1="3.55" SD_2="3.71" SE="1.0268849147811687" STUDY_ID="STD-Jimenez-2007" TOTAL_1="24" TOTAL_2="26" WEIGHT="1.7007245949482555"/>
<CONT_DATA CI_END="3.161828580928863" CI_START="-1.3618285809288624" EFFECT_SIZE="0.9000000000000004" ESTIMABLE="YES" MEAN_1="9.4" MEAN_2="8.5" MODIFIED="2010-05-06 16:54:33 +0100" MODIFIED_BY="Katharine Ker" ORDER="2398" SD_1="8.9" SD_2="7.4" SE="1.1540153792466994" STUDY_ID="STD-Later-2009" TOTAL_1="99" TOTAL_2="103" WEIGHT="1.346648795957027"/>
<CONT_DATA CI_END="1.0304261724838488" CI_START="-2.23042617248385" EFFECT_SIZE="-0.6000000000000005" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="6.4" ORDER="68489" SD_1="2.2" SD_2="3.0" SE="0.8318653737234168" STUDY_ID="STD-Mansour-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="2.591620734075271"/>
<CONT_DATA CI_END="0.33602917694717677" CI_START="-0.33602917694717677" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="4.8" MODIFIED="2010-05-07 12:23:33 +0100" MODIFIED_BY="Katharine Ker" ORDER="2446" SD_1="0.4" SD_2="0.9" SE="0.1714466079977653" STUDY_ID="STD-Mehr_x002d_Aein-2007" TOTAL_1="33" TOTAL_2="33" WEIGHT="61.012629982827725"/>
<CONT_DATA CI_END="0.254516357023345" CI_START="-0.6545163570233454" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="7.1" MEAN_2="7.3" ORDER="68488" SD_1="0.8" SD_2="1.2" SE="0.23190036174568116" STUDY_ID="STD-Wei-2006" TOTAL_1="36" TOTAL_2="40" WEIGHT="33.34837589219171"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-02-16 14:10:34 +0000" MODIFIED_BY="Emma M Sydenham">
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-10-19 10:09:38 +0100" MODIFIED_BY="Katharine Ker" NO="1" REF_ID="CMP-001.01" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Aprotinin versus Control (Blood Transfusion &amp; Blood Loss), outcome: 1.1 No. Exposed to Allogeneic Blood.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-12-03 12:34:01 +0000" MODIFIED_BY="Katharine Ker" NO="2" REF_ID="CMP-002.01" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 2 Tranexamic Acid versus Control (Blood Transfusion &amp; Blood Loss), outcome: 2.1 No. Exposed to Allogeneic Blood.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2010-08-23 06:08:59 +0100" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-003.01" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 3 Epsilon Aminocaproic Acid versus Control (Blood Transfusion &amp; Blood Loss), outcome: 3.1 No. Exposed to Allogeneic Blood.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2011-02-16 13:26:14 +0000" MODIFIED_BY="Emma M Sydenham" NO="4" REF_ID="CMP-004.01" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 4 Aprotinin versus Tranexamic Acid (Blood Transfusion &amp; Blood Loss), outcome: 4.1 No. Exposed to Allogeneic Blood.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2010-08-23 06:09:48 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-005.01" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 5 Aprotinin versus Epsilon Aminocaproic Acid (Blood Transfusion &amp; Blood Loss), outcome: 5.1 No. Exposed to Allogeneic Blood.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAAJR0lEQVR42u3dzU5b2RZFYUMh7Q6NK+UZaNT7PwyNPAO9dLZ0pZR/
wT6xD8dmTeP4fENFbIGLhMVg7ekZx35oC6CeRyMAsUAszJunqTfsy7e2uVhfWfTW2x+3ae8f311Z
vU+OI9ZJr9r2l7b/jiG7j/ePK41ZjsIL6L1vLrYrCjjvKNydgIcLa3WxfFv9N/b/WVnEOunGLloN
DDu4wf7HT90QxBpuq/2MNXK7zX5qJ3IYZKzBncLJDvbhFRDr4hRvlvj0KOx/HHnDjLXN421zy9YP
ttN7WN9ecSQSa/++3rF7hG3wruG72+7XthDeiXUBBxVC30v3fy4/C2uGPLSJGwso21h9cA7OjZef
BIltrDlvrv8/EeTb64Z75F8juH54v3PWKeB3d7+2VKxmoOuv/6HpfWs3lh/TNbK7jAVigVgz58UI
iJXg1QiIlUCPVX2vEOue4beygVjFrAuXB7XLxXw6O49ygIwFYoFYs0WPJWNF8HgsGyuCHotYEX4b
AbEiOcEIZCzYWCAWQKxy9FgyVgQ9lo0VQY9FrAh6LGJlcoIRyFiwsUAs4DLcoR5h0vNjzf1JxGSs
85nUYz3/OryEo/AzJvVYb4NLEOsz9FjEyuQEIyBWAs+PRSwQC3NAjzXCtOd598whR/PpTHusvvjx
tli9tZGP//O/N7Unsc4T65PXR1i/f7mx/B28jFWPHotYmXVuBMRKoMciFm4MdcPUMkGKt7GqWP+7
wrbBNIg1bRM99758G/3467Py8+I7Ph7oNzz3Vs3p5oteNe9eEFTGKmBlz6/3F5PTYzkKM+vcCIhV
wo/DSz0Wsc5KUv1Ucvf4dRnra0lqmaMWE/9VTT/vVjK+8P4pq3uFbbKsZ2joKJx3xvJ6hcSq4a1v
8tc2Y3l+LEdhVfharHusLXosGyuCHotYEfRYxDqLbY/lu5/c9v4SusbVg5gG4X2Ml+lnIZ9srOl4
nncZK4Iei1gR9FjEyuQEI5CxYGOBWACxyvF6hTJWBD2WjRVBj0WsCHosYmVyghHIWLCxQCyAWOXo
sWSsCHosGyuCHotYEfRYl7O/7PvBMxCoGfRYNRlrlaa2iao3GetyNq/TM/OfzSeBvZ62+Vf6s37m
macTP3NOQgTE2h6KfeZ568W/sa8Vq+1dzvlYfNVjqRsS6LGKxfJ8hxv0WCVHYeu7cNWE9zV6rC/M
zt8VlqPHIhaEdxDrXvB4LEdhBI/HsrEi6LGIFUGPRaxMTjACGQs2FogFEKscPZaMFUGPZWNF0GMR
K4Iei1iZnGAEMhZsLBALIFY5eiwZK4Iey8aKoMciVgQ9FrEyOcEIZCzYWCAWQKxy9FgyVgQ9lo0V
QY9FrAh6LGJlcoIRyFiwsUAsgFjl6LFkrAh6LBsrgh6LWBH0WMTK5AQjkLFgY12P/tz7+s03+trc
+f2e1StSLt+IZWPdEnosGes4z78OL89Ej2VjHedtcHkmeixiRdBjCe+nDvKv5QR+yFiJjAVH4YmM
te2x3nyjHYWl6LFsrBtEjyVjRTKWHsvGOpGxBpdnosciVgQ9lvB+6iD/Wk7gh4wFRyGIBRCrHD2W
jBVBj2VjRdBjESuCHotYmZxgBDIWbCwQCyBWOXosGSuCHsvGiqDHIlYEPRaxMjnBCGQs2FggFkCs
cvRYMlYEPZaNFUGPRawIeqxysTyLxjonGEFxxuqLJmOhfGORCRGxeIVoeO+r13To831hBz1Wdcba
Owz1WCjfWHNHj0WsCHosYmVyghFUZ6xjaQuwsUAsEGtm6LFkrAh6LBsrgh6LWBH0WMTK5AQjkLFg
Y4FYALHK0WPJWBH0WDZWBD0WsSLosYiVyQlGIGPBxgKxAGKVo8eSsSLosWysCHosYkXQYxErkxOM
QMaCjQViAcQqR48lY0XQY9lYEfRYxIqgxyJWJicYgYwFGwvEAohVjh5Lxoqgx7KxIuixiBVBj0Ws
TE4wAhkLNhaIBRCrHD2WjBVBj2VjRdBjESuCHotYmZxgBDIWbCwQCyBWOXosGSuCHsvGiqDHIlYE
PRaxMjnBCGQs2FggFkCscvRYMlYEPZaNFUGPRawIeixiZXKCEchYsLFALIBY5eixZKwIeiwbK4Ie
i1gR9FjEyuQEI5CxYGNhBhTd7+m7K/YbSjdW23Bfw9FjOQojvBoBsRLosYgVQY9VFN7fq4Uuhq/Q
Y9WI1feyuMks+WkEFUfhRxV6fin6Y3AJG+vYlurn7qy3i5XEDDLWvmMrRfrkvHWfPr04Cy/Pp+1Y
eN+77vFYUDcUo8cqFqubyxo9VmXGWp59rSsc1jnBCGoy1tHtxTDIWCAWiDVXPB5Lxoqgx7KxIuix
iBVBj0WsTE4wAhkLNhaIBRCrHD2WjBVBj2VjRdBjESuCHotYmZxgBDIWbCwQCyBWOXosGSuCHsvG
iqDHIlYEPRaxMjnBCGQs2FggFkCscvRYMlYEPZaNFUGPRawIeixiZXKCEchYsLFALIBY5eixZKwI
eiwbK4Iei1gR9FjEyuQEI5CxYGOBWACxytFjyVgR9Fg2VgQ9FrEi6LGIlckJRiBjwcYCsQBilaPH
krEi6LFsrAh6LGJF0GMRK5MTjEDGgo0FYgHEKkePJWNF0GPZWBH0WMSKoMciViYnGIGMBRsLxAKI
VY4eS8aKoMe6HKMb4d+fZnBq36x/bXtXiDUdPdZp2u44a8fPNRlrLCcYgfCewEkoY+E7Qlbbv0Is
1GSsTbBqx5sDR+EIeqxxt/rwCrGm8WoEwnsCj8e6fGURawQ91ljE2vzaFsfD+3Gxeu/pOxRXvfdy
IQ/X+wL+mplM/ZxH7xX25nFYK/RYxRmLUxDecZOcethMb9c++HEPcX48Y+3fNpC1rhrfEr+ZmXwe
3h9v4OvEbDIWr/BFjtcNq8XGLQTCO1C/sd7jWCs+Gj8+5RVW4sFvVvq71SeFq54Q1ePYzuPwa3ga
vfV2gr3wD9Db4JMn7/rsfotW/o3J/Vmv3wzUzGPwNTx+yw/odQNc8Z/fOKZ8vqdb+7Kzh+JfZ8Ht
j+PE5/q+hyZfd/XffIFyb+OYw98VuuP7DeN4nMFP6F9xPN3bOB5nMMjOq+uPY6Qg7R+ncW2Ptfxs
/Qo7+ePP3yO9TfX3ul3RrMT95MNPq3mH8A5igVgAsUAsEAsgFogFYgHEArFALIBYIBaIBRALN8x/
lwj2F+9hio8AAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2010-08-23 06:10:13 +0100" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-006.01" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 6 Tranexamic Acid versus Epsilon Aminocaproic Acid (Blood Transfusion &amp; Blood Loss), outcome: 6.1 No. Exposed to Allogeneic Blood.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAAJFElEQVR42u3dy24aWRSFYeJGOpMMIuUZolakfv9X8SDPkJ60Jyfq
my+UqSooXAVnYTDfr45BNsH2zu99FsvY/amsgPbcGQGIBWLhtlnPvWF9/FNeLp6vrGqpZec25fXt
3ZWn18lxxJr0qmxelP4rxnRvr9srhVmOwiOotb5cbFYUsOwo7E7A4cJ6unj88/Tfob9nZRFr0o0u
Wo0MG9yg//apG4JY423Vz1gHbveyn8pEDoOMNXpQONvBOr4CYh2d4s0Sbx6FdefIG2esTR4vL7cs
dbCdXsP65oojkVj9x3r7HhGW0avGry7dy7IS3ol1BIMKofbS/e7ys7BukE9l5sYCmm2sOjoHsVp9
+2EGTTaWzTXk77UZnLVuuBW+18/1GaPIhPdb5b/yUAYxAfPFKlWsmswORnB8xhrnLezOw1xkLBAL
xLpR/jACYiW4NwJiJeh6LJM4jB5rIV2PBRurKXqsmXPSY8HGArFALCzgmxEQ63hqfW4VPu+2Cnos
Yp1CKQ/l8c/uG76bDbES/GcExEqgxyJWBD9LQawT+Dq6BLGa8HN0CWKF0WMR6xQ2PdbuG/RYMx/k
+Cb0wo0lvdtYCfRYxMqseCNwFMLGArEAYrV/VGgEMlYCvx/Lxorg+VjEiqDHIlYmOxiBjAUbC8QC
iNUcPZaMFUGPZWNF0GPNw9ff81rurry9nvVYxFpAGQl2IDsYlow1m88Pw0vIWE3w017EArE+JHos
Ys1nwU/Ub3+ucPp3aGG1+u2th4X/3MLjxr/Ww8sD/P5nd+3Lv+tf6/X615dfNNpF3fCyfWbfcttj
/SzDSxBrzAI19FgyVgQ/YU+sy0n8xMJ8tKrEaogei1gRer8fa/J3aME3oZdvLOndxkrg+Vjz0GMt
XfFH/a0FzyR0FGKBWOXWpukoPAu313kR6yzcXudFrKWPCo2AWAn8nndiRfBzhcSKoMeahx5rIUc+
H+vmnr+sx4KjEMQCsbAEPZaMFcHvx7KxIuixiBVBj0WsTHYwAhkLNhaIBRCrOXosGSuCHsvGiqDH
IlYEPdY8+ou9Dn7fuSNwf3a4gI/hGn5KcT1MU12iYtUUF/ET9vP/fweXdRQK7Gh5FO47FIGGYm0O
xSpv7eC3zZwgVuldOhaH3Ouxjs9YmEaPdUp4N5dJ9FiLj8JSu3BVhPdJLuL5WFfwle97hZCxQCwQ
C0vwfCwZK4LnY9lYEfRYxIqgxyJWJjsYgYwFGwvEAojVHD2WjBVBj2VjRdBjESuCHotYmexgBDIW
bCwQCyBWc/RYMlYEPZaNFUGPRawIeixiZbKDEchYsLFALIBYzdFjyVgR9Fg2VgQ9FrEi6LGIlckO
RiBjwcYCsQBiNUePJWNF0GPZWBH0WMSKoMciViY7GIGMBRsLxAKI1Rw9lowVQY9lY0XQYxErgh6L
WJnsYAQyFmwsEAsgVnP0WDJWBD2WjRVBj0WsCHosYmWygxHIWLCxQCyAWM3RY8lYEfRYNlYEPRax
IuixiJXJDkYgY8HGArEAYjVHjyVjRdBj2VgR9FjEiqDHIlYmOxiBjAUbC8QCiNUcPZaMFUGPZWNF
0GMRK4Ie6ySxqslMZQcjOCFj1VWRsdB8Y5EJEbF4hWh4r4+8vECHHuuUjNU7DB2LQ/RYDTYWdtFj
ESuCHotYmexgBKdkrH1pC7CxQCwQC3osGSuDHsvGiqDHIlYEPdY83nuxv34b8lpOXD3WdWSs7u5n
vZv69ed1WWhjXQkPZbjmIGOBWDiAHotYEe6NgFgJ9FjEiqDHupJHhdf2CE+PNXNO1/S9Qj0WsSBj
AcR6d/RYjsIIno9lY0XQYxErgh6LWJnsYAQyFmwsEAsgVnP0WDJWBD2WjRVBj0WsCHosYmWygxHI
WLCxQCyAWM3RY8lYEfRYNlYEPRaxIuixiJXJDkYgY8HGArEAYjVHjyVjRdBj2VgR9FjEiqDHIlYm
OxiBjAUbC8QCiNUcPZaMFUGPZWNF0GMRK4Iei1iZ7GAEMhZsLBALIFZz9FgyVgQ9lo0VQY9FrAh6
LGJlsoMRyFiwsUAsgFjN0WPJWBH0WDZWBD0WsSLosYiVyQ5GIGPBxgKxAGI1R48lY0XQY9lYEfRY
xIqgx5rHeu+xVx//OAL3ZwcjWJyx6qtMvWAlY+HEo3CrEJnQ8Cgc7C4nIdplrL5jT1uryls7fPth
Bksz1uAI7K47FofosRZnLMxBj3WCWNVcJtFjHZuxHs++IrxPZwcjWJ6x9m4vhkHGArFALGzxfCwZ
K4Iey8aKoMciVgQ9FrEy2cEIZCzYWCAWQKzm6LFkrAh6LBsrgh6LWBH0WMTKZAcjkLFgY4FYALGa
o8eSsSLosWysCHosYkXQYxErkx2MQMaCjQViAcRqjh5Lxoqgx7KxIuixiBVBj0WsTHYwAhkLNhaI
BRCrOXosGSuCHsvGiqDHIlYEPRaxMtnBCGQs2FggFkCs5uixZKwIeiwbK4Iei1gR9FjEymQHI5Cx
YGOBWACxmqPHkrEi6LFsrAh6LGJF0GMRK5MdjEDGgo0FYgHEao4eS8aKoMeysSLosYgVQY9FrEx2
MAIZCzYWiAUQqzl6LBkrgh5rHsa0kO8/zOBp3zy/LL0rxDoNPdZqq9LTcVb2n2sy1tLsYATCewIn
oYyFdMgq/SvEQpuM9RKsyv7mwFG4ED3W1q06vkKs47k3AuE9gedjzVtZxFqIHmu1Teuld2WWWLXW
9AOKsz56acinzCdw1TPZd597HxXW4nuEU+ixTshYnILwjotk6mkztZz74MdHiPOHM1b/toGsddb4
lnhnZvJ2eL+7gM8TN5OxeIUT2V83PC02biEQ3oH2G+s1jpXGR+P2Ls+wEgfvrOl7a58UznpCtB7H
Zh7Dz2F98NabCdaGH0AtoztPPvTp3kVp/g+T+1jP3wy0mcfoc7h7ly/Q8wa4xh+/ccy5v/WlfdrZ
Q/HqLLj8cUzc1/s9Nfm8q//iC5SPNo5b+F6hB77vMI67G/gKvYrj6aON4+4GBll5df5xHChI6/Y0
bttjPd5bPcNO3n78NdLbtP63Lmc0K/E4eXi3mncI7yAWiAUQC8QCsQBigVggFkAsEAvEAogFYoFY
ALFwwfwPninYpb/snsoAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2011-02-16 14:10:34 +0000" MODIFIED_BY="Emma M Sydenham" NO="7" REF_ID="CMP-007.01" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 7 Aprotinin versus Lysine Analogues (Blood Transfusion), outcome: 7.1 No. Exposed to Allogeneic Blood.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2011-02-10 17:25:47 +0000" MODIFIED_BY="Emma M Sydenham" NO="8" REF_ID="CMP-008.01" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 7 Adverse Events and Other Outcomes (Active versus Control), outcome: 7.1 Re-operation for bleeding.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2010-08-25 04:03:11 +0100" MODIFIED_BY="[Empty name]" NO="9" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAeAAAACcCAMAAACQnYipAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2010-08-25 04:03:22 +0100" MODIFIED_BY="[Empty name]" NO="10" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAPMAAB5UCAIAAADvbHGtAACAAElEQVR42uydsW4UyfaHRyIhmMCB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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-12-06 16:02:15 +0000" MODIFIED_BY="Karen Blackhall">
<APPENDIX ID="APP-01" MODIFIED="2010-08-20 14:53:13 +0100" MODIFIED_BY="Karen Blackhall" NO="1">
<TITLE MODIFIED="2008-09-08 22:11:45 +0100" MODIFIED_BY="[Empty name]">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-08-20 14:53:13 +0100" MODIFIED_BY="Karen Blackhall">
<P>The original search strategy at the outset of the review included the following terms;</P>
<P>
<B>Exploded MeSH terms:</B> 'aprotinin' 'tranexamic acid' 'Aminocaproic acids' 'Blood transfusion' 'Hemorrhage' 'Anesthesia'.</P>
<P>
<B>Text-word terms</B>:aprotinin, antilysin, contrical, kallikrein-trypsin, bovine pancreatic trypsin, tranexamic, cyklokapron, pharmacia, t-amcha, amcha, ugurol, transamin, kabi, epsilon-aminocaproic acid, aminocaproic, lederle, amicar, transfusion$, bleed$, blood loss$, hemorrhag$.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-12-06 16:02:15 +0000" MODIFIED_BY="Karen Blackhall" NO="2">
<TITLE MODIFIED="2010-08-20 14:59:53 +0100" MODIFIED_BY="Karen Blackhall">Search strategy: 2010 update</TITLE>
<APPENDIX_BODY MODIFIED="2010-12-06 16:02:15 +0000" MODIFIED_BY="Karen Blackhall">
<P>
<B>Cochrane Injuries Group Specialised Register (searched July 2010)</B>
</P>
<P>(Aprotinin* or kallikrein-trypsin inactivator* or bovine kunitz pancreatic trypsin inhibitor* or bovine pancreatic trypsin inhibitor* or basic pancreatic trypsin inhibitor* or BPTI or contrykal or kontrykal or kontrikal or contrical or dilmintal or iniprol or zymofren or traskolan or antilysin or pulmin or amicar or caprocid or epsamon or epsikapron or antilysin or iniprol or kontrikal or kontrykal or pulmin* or Trasylol or Antilysin Spofa or rp?9921 or antagosan or antilysin or antilysine or apronitin* or apronitrine or bayer a?128 or bovine pancreatic secretory trypsin inhibitor* or contrycal or frey inhibitor* or gordox or kallikrein trypsin inhibitor* or kazal type trypsin inhibitor* or (Kunitz adj3 inhibitor*) or midran or (pancrea* adj2 antitrypsin) or (pancrea* adj2 trypsin inhibitor*) or riker?52g or rp?9921or tracylol or trascolan or trasilol or traskolan or trazylol or zymofren or zymophren) or (tranexamic or Cyclohexanecarboxylic Acid* or Methylamine* or amcha or trans-4-aminomethyl-cyclohexanecarboxylic acid* or t-amcha or amca or kabi 2161 or transamin* or exacyl or amchafibrin or anvitoff or spotof or cyklokapron or ugurol oramino methylcyclohexane carboxylate or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or AMCHA or amchafibrin or amikapron or aminomethyl cyclohexane carboxylic acid or aminomethyl cyclohexanecarboxylic acid or aminomethylcyclohexane carbonic acid or aminomethylcyclohexane carboxylic acid or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or aminomethylcyclohexanocarboxylic acid or aminomethylcyclohexanoic acid or amstat or anvitoff or cl?65336 or cl65336 or cyclocapron or cyclokapron or cyklocapron or exacyl or frenolyse or hexacapron or hexakapron or tranex or TXA) or (aminocaproic or amino?caproic or aminohexanoic or amino?hexanoic or epsilon-aminocaproic or E-aminocaproic) adj2 acid*) or epsikapron or cy-116 or cy116 or epsamon or amicar or caprocid or lederle or Aminocaproic or aminohexanoic or amino caproic or amino n hexanoic or acikaprin or afibrin or capracid or capramol or caprogel or caprolest or caprolisine or caprolysin or capromol or cl 10304 or EACA or eaca roche or ecapron or ekaprol or epsamon or epsicapron or epsilcapramin or epsilon amino caproate or epsilon aminocaproate or epsilonaminocaproic or etha?aminocaproic or ethaaminocaproich or emocaprol or hepin or ipsilon or jd?177or neocaprol or nsc?26154 or tachostyptan)</P>
<P>
<B>MEDLINE(Ovid) 1950 to July Week 2 2010</B>
<BR/>1. exp Antifibrinolytic Agents/<BR/>2. (anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or anti-fibrinolysin* or antiplasmin* or anti-plasmin* or ((plasmin or fibrinolysis) adj3 inhibitor*)).ab,ti.<BR/>3. exp Aprotinin/<BR/>4. (Aprotinin* or kallikrein-trypsin inactivator* or bovine kunitz pancreatic trypsin inhibitor* or bovine pancreatic trypsin inhibitor* or basic pancreatic trypsin inhibitor* or BPTI or contrykal or kontrykal or kontrikal or contrical or dilmintal or iniprol or zymofren or traskolan or antilysin or pulmin or amicar or caprocid or epsamon or epsikapron or antilysin or iniprol or kontrikal or kontrykal or pulmin* or Trasylol or Antilysin Spofa or rp?9921 or antagosan or antilysin or antilysine or apronitin* or apronitrine or bayer a?128 or bovine pancreatic secretory trypsin inhibitor* or contrycal or frey inhibitor* or gordox or kallikrein trypsin inhibitor* or kazal type trypsin inhibitor* or (Kunitz adj3 inhibitor*) or midran or (pancrea* adj2 antitrypsin) or (pancrea* adj2 trypsin inhibitor*) or riker?52g or rp?9921or tracylol or trascolan or trasilol or traskolan or trazylol or zymofren or zymophren).ab,ti.<BR/>5. exp Tranexamic Acid/<BR/>6. (tranexamic or Cyclohexanecarboxylic Acid* or Methylamine* or amcha or trans-4-aminomethyl-cyclohexanecarboxylic acid* or t-amcha or amca or kabi 2161 or transamin* or exacyl or amchafibrin or anvitoff or spotof or cyklokapron or ugurol oramino methylcyclohexane carboxylate or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or AMCHA or amchafibrin or amikapron or aminomethyl cyclohexane carboxylic acid or aminomethyl cyclohexanecarboxylic acid or aminomethylcyclohexane carbonic acid or aminomethylcyclohexane carboxylic acid or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or aminomethylcyclohexanocarboxylic acid or aminomethylcyclohexanoic acid or amstat or anvitoff or cl?65336 or cl65336 or cyclocapron or cyclokapron or cyklocapron or exacyl or frenolyse or hexacapron or hexakapron or tranex or TXA).ab,ti.<BR/>7. exp Aminocaproic Acids/ or exp 6-Aminocaproic Acid/<BR/>8. (((aminocaproic or amino?caproic or aminohexanoic or amino?hexanoic or epsilon-aminocaproic or E-aminocaproic) adj2 acid*) or epsikapron or cy-116 or cy116 or epsamon or amicar or caprocid or lederle or Aminocaproic or aminohexanoic or amino caproic or amino n hexanoic or acikaprin or afibrin or capracid or capramol or caprogel or caprolest or caprolisine or caprolysin or capromol or cl 10304 or EACA or eaca roche or ecapron or ekaprol or epsamon or epsicapron or epsilcapramin or epsilon amino caproate or epsilon aminocaproate or epsilonaminocaproic or etha?aminocaproic or ethaaminocaproich or emocaprol or hepin or ipsilon or jd?177or neocaprol or nsc?26154 or tachostyptan).ab,ti.<BR/>9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8<BR/>10. randomi?ed.ab,ti.<BR/>11. randomized controlled trial.pt.<BR/>12. controlled clinical trial.pt.<BR/>13. placebo.ab.<BR/>14. clinical trials as topic.sh.<BR/>15. randomly.ab.<BR/>16. trial.ti.<BR/>17. 10 or 11 or 12 or 13 or 14 or 15 or 16<BR/>18. (animals not (humans and animals)).sh.<BR/>19.17 not 18<BR/>20. 9 and 19<BR/>
<BR/>
<B>EMBASE (Ovid) 1980 to 2010 Week 28</B>
<BR/>1. exp Antifibrinolytic Agent/<BR/>2. (anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or anti-fibrinolysin* or antiplasmin* or anti-plasmin* or ((plasmin or fibrinolysis) adj3 inhibitor*)).ab,ti.<BR/>3. exp Aprotinin/<BR/>4. (Aprotinin* or kallikrein-trypsin inactivator* or bovine kunitz pancreatic trypsin inhibitor* or bovine pancreatic trypsin inhibitor* or basic pancreatic trypsin inhibitor* or BPTI or contrykal or kontrykal or kontrikal or contrical or dilmintal or iniprol or zymofren or traskolan or antilysin or pulmin or amicar or caprocid or epsamon or epsikapron or antilysin or iniprol or kontrikal or kontrykal or pulmin* or Trasylol or Antilysin Spofa or rp?9921 or antagosan or antilysin or antilysine or apronitin* or apronitrine or bayer a?128 or bovine pancreatic secretory trypsin inhibitor* or contrycal or frey inhibitor* or gordox or kallikrein trypsin inhibitor* or kazal type trypsin inhibitor* or (Kunitz adj3 inhibitor*) or midran or (pancrea* adj2 antitrypsin) or (pancrea* adj2 trypsin inhibitor*) or riker?52g or rp?9921or tracylol or trascolan or trasilol or traskolan or trazylol or zymofren or zymophren).ab,ti.<BR/>5. exp Tranexamic Acid/<BR/>6. (tranexamic or Cyclohexanecarboxylic Acid* or Methylamine* or amcha or trans-4-aminomethyl-cyclohexanecarboxylic acid* or t-amcha or amca or kabi 2161 or transamin* or exacyl or amchafibrin or anvitoff or spotof or cyklokapron or ugurol oramino methylcyclohexane carboxylate or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or AMCHA or amchafibrin or amikapron or aminomethyl cyclohexane carboxylic acid or aminomethyl cyclohexanecarboxylic acid or aminomethylcyclohexane carbonic acid or aminomethylcyclohexane carboxylic acid or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or aminomethylcyclohexanocarboxylic acid or aminomethylcyclohexanoic acid or amstat or anvitoff or cl?65336 or cl65336 or cyclocapron or cyclokapron or cyklocapron or exacyl or frenolyse or hexacapron or hexakapron or tranex or TXA).ab,ti.<BR/>7. exp Aminocaproic Acid/<BR/>8. (((aminocaproic or amino?caproic or aminohexanoic or amino?hexanoic or epsilon-aminocaproic or E-aminocaproic) adj2 acid*) or epsikapron or cy-116 or cy116 or epsamon or amicar or caprocid or lederle or Aminocaproic or aminohexanoic or amino caproic or amino n hexanoic or acikaprin or afibrin or capracid or capramol or caprogel or caprolest or caprolisine or caprolysin or capromol or cl 10304 or EACA or eaca roche or ecapron or ekaprol or epsamon or epsicapron or epsilcapramin or epsilon amino caproate or epsilon aminocaproate or epsilonaminocaproic or etha?aminocaproic or ethaaminocaproich or emocaprol or hepin or ipsilon or jd?177or neocaprol or nsc?26154 or tachostyptan).ab,ti.<BR/>9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8<BR/>10. exp Randomized Controlled Trial/<BR/>11. exp controlled clinical trial/<BR/>12. randomi?ed.ab,ti.<BR/>13. placebo.ab.<BR/>14. *Clinical Trial/<BR/>15. randomly.ab.<BR/>16. trial.ti.<BR/>17. 10 or 11 or 12 or 13 or 14 or 15 or 16<BR/>18. exp animal/ not (exp human/ and exp animal/)<BR/>19. 17 not 18<BR/>20. 9 and 19<BR/>
<BR/>
<B>Cochrane Central Register of Controlled Trials (The Cochrane Library 2010, Issue 3)</B>
<BR/>#1 MeSH descriptor Antifibrinolytic Agents explode all trees<BR/>#2 (anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or anti-fibrinolysin* or antiplasmin* or anti-plasmin* ):ab,ti or ((plasmin or fibrinolysis) near3 inhibitor*):ab,ti<BR/>#3 MeSH descriptor Aprotinin explode all trees<BR/>#4 (Aprotinin* or kallikrein-trypsin inactivator* or bovine kunitz pancreatic trypsin inhibitor* or bovine pancreatic trypsin inhibitor* or basic pancreatic trypsin inhibitor* or BPTI or contrykal or kontrykal or kontrikal or contrical or dilmintal or iniprol or zymofren or traskolan or antilysin or pulmin or amicar or caprocid or epsamon or epsikapron or antilysin or iniprol or kontrikal or kontrykal or pulmin* or Trasylol or Antilysin Spofa or rp?9921 or antagosan or antilysin or antilysine or apronitin* or apronitrine or bayer a?128 or bovine pancreatic secretory trypsin inhibitor* or contrycal or frey inhibitor* or gordox or kallikrein trypsin inhibitor* or kazal type trypsin inhibitor or riker?52g or rp?9921or tracylol or trascolan or trasilol or traskolan or trazylol or zymofren or zymophren or midran):ab,ti or ((Kunitz near3 inhibitor*) or (pancrea* near3 antitrypsin) or (pancrea* near3 trypsin next inhibitor*)):ab,ti<BR/>#5 MeSH descriptor Tranexamic Acid explode all trees<BR/>#6 (tranexamic or Cyclohexanecarboxylic Acid* or Methylamine* or amcha or trans-4-aminomethyl-cyclohexanecarboxylic acid* or t-amcha or amca or kabi 2161 or transamin* or exacyl or amchafibrin or anvitoff or spotof or cyklokapron or ugurol oramino methylcyclohexane carboxylate or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or AMCHA or amchafibrin or amikapron or aminomethyl cyclohexane carboxylic acid or aminomethyl cyclohexanecarboxylic acid or aminomethylcyclohexane carbonic acid or aminomethylcyclohexane carboxylic acid or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or aminomethylcyclohexanocarboxylic acid or aminomethylcyclohexanoic acid or amstat or anvitoff or cl?65336 or cl65336 or cyclocapron or cyclokapron or cyklocapron or exacyl or frenolyse or hexacapron or hexakapron or tranex or TXA):ab,ti<BR/>#7 MeSH descriptor Aminocaproic Acids explode all trees<BR/>#8 MeSH descriptor 6-Aminocaproic Acid explode all trees<BR/>#9 (epsikapron or cy-116 or cy116 or epsamon or amicar or caprocid or lederle or Aminocaproic or aminohexanoic or amino caproic or amino n hexanoic or acikaprin or afibrin or capracid or capramol or caprogel or caprolest or caprolisine or caprolysin or capromol or cl 10304 or EACA or eaca roche or ecapron or ekaprol or epsamon or epsicapron or epsilcapramin or epsilon amino caproate or epsilon aminocaproate or epsilonaminocaproic or etha?aminocaproic or ethaaminocaproich or emocaprol or hepin or ipsilon or jd?177or neocaprol or nsc?26154 or tachostyptan):ab,ti<BR/>#10 (aminocaproic or amino?caproic or aminohexanoic or amino?hexanoic or epsilon-aminocaproic or E-aminocaproic):ab,ti<BR/>#11 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>